PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Redfield, RJ				Redfield, Rosemary J.			Comment on "A Bacterium That Can Grow by Using Arsenic Instead of Phosphorus"	SCIENCE			English	Editorial Material									Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Redfield, RJ (corresponding author), Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.	redfield@zoology.ubc.ca	Redfield, Rosemary/K-5633-2012	Redfield, Rosemary/0000-0001-8940-587X				Makino W, 2003, FUNCT ECOL, V17, P121, DOI 10.1046/j.1365-2435.2003.00712.x; Sambrook J., 2001, MOL CLONING LAB MANU; Wolfe-Simon F, 2011, SCIENCE, V332, P1163, DOI 10.1126/science.1197258	3	32	33	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2011	332	6034								10.1126/science.1201482	http://dx.doi.org/10.1126/science.1201482			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	772BO	21622712				2022-12-28	WOS:000291205200027
J	Lebon, G; Warne, T; Edwards, PC; Bennett, K; Langmead, CJ; Leslie, AGW; Tate, CG				Lebon, Guillaume; Warne, Tony; Edwards, Patricia C.; Bennett, Kirstie; Langmead, Christopher J.; Leslie, Andrew G. W.; Tate, Christopher G.			Agonist-bound adenosine A(2A) receptor structures reveal common features of GPCR activation	NATURE			English	Article							PROTEIN-COUPLED RECEPTORS; CRYSTAL-STRUCTURE; BINDING; THERMOSTABILIZATION; STABILITY; RHODOPSIN; MODELS	Adenosine receptors and beta-adrenoceptors are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins on binding the agonists adenosine(1) or noradrenaline(2), respectively. GPCRs have similar structures consisting of seven transmembrane helices that contain well-conserved sequence motifs, indicating that they are probably activated by a common mechanism(3,4). Recent structures of beta-adrenoceptors highlight residues in transmembrane region 5 that initially bind specifically to agonists rather than to antagonists, indicating that these residues have an important role in agonist-induced activation of receptors(5-7). Here we present two crystal structures of the thermostabilized human adenosine A(2A) receptor (A(2A)R-GL31) bound to its endogenous agonist adenosine and the synthetic agonist NECA. The structures represent an intermediate conformation between the inactive and active states, because they share all the features of GPCRs that are thought to be in a fully activated state, except that the cytoplasmic end of transmembrane helix 6 partially occludes the G-protein-binding site. The adenine substituent of the agonists binds in a similar fashion to the chemically related region of the inverse agonist ZM241385 (ref. 8). Both agonists contain a ribose group, not found in ZM241385, which extends deep into the ligand-binding pocket where it makes polar interactions with conserved residues in H7 (Ser 277(7.42) and His 278(7.43); superscripts refer to Ballesteros-Weinstein numbering(9)) and non-polar interactions with residues in H3. In contrast, the inverse agonist ZM241385 does not interact with any of these residues and comparison with the agonist-bound structures indicates that ZM241385 sterically prevents the conformational change in H5 and therefore it acts as an inverse agonist. Comparison of the agonist-bound structures of A(2A)R with the agonist-bound structures of beta-adrenoceptors indicates that the contraction of the ligand-binding pocket caused by the inward motion of helices 3, 5 and 7 may be a common feature in the activation of all GPCRs.	[Lebon, Guillaume; Warne, Tony; Edwards, Patricia C.; Leslie, Andrew G. W.; Tate, Christopher G.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England; [Bennett, Kirstie; Langmead, Christopher J.] BioPark, Heptares Therapeut, Welwyn Garden City AL7 3AX, Herts, England	MRC Laboratory Molecular Biology; Heptares Therapeutics Ltd.	Tate, CG (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 0QH, England.	cgt@mrc-lmb.cam.ac.uk	Lebon, Guillaume/AAZ-4486-2020	Tate, Christopher/0000-0002-2008-9183; Guillaume, Lebon/0000-0003-1162-5148; Langmead, Christopher/0000-0003-3483-1120; Warne, Tony/0000-0001-9646-6080	Medical Research Council; Heptares Therapeutics Ltd; Biotechnology and Biological Sciences Research Council [BB/G003653/1]; Medical Research Council [MC_U105197215, MC_U105184325] Funding Source: researchfish; BBSRC [BB/G003653/1] Funding Source: UKRI; MRC [MC_U105197215, MC_U105184325] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Heptares Therapeutics Ltd; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by core funding from the Medical Research Council, and grants from Heptares Therapeutics Ltd and from the Biotechnology and Biological Sciences Research Council (BB/G003653/1). We would like to thank F. Magnani for technical help at the start of the project and F. Gorrec for developing the crystallization screen. We also thank the beamline staff at the European Synchrotron Radiation Facility, particularly at (beamline ID23-2; D. Flot and A. Popov), the Swiss Light Source (beamline X06SA) and at the Diamond Light Source (beamline I24; G. Evans, D. Axford and R. Owen). F. Marshall, M. Weir, M. Congreve and R. Henderson are thanked for their comments on the manuscript.	Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410; Dal Ben D, 2010, CURR TOP MED CHEM, V10, P993, DOI 10.2174/156802610791293145; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Evans BA, 2010, BRIT J PHARMACOL, V159, P1022, DOI 10.1111/j.1476-5381.2009.00602.x; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285; Gorrec F, 2011, ACTA CRYSTALLOGR D, V67, P463, DOI 10.1107/S0907444911008754; Hofmann KP, 2009, TRENDS BIOCHEM SCI, V34, P540, DOI 10.1016/j.tibs.2009.07.005; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim SK, 2003, J MED CHEM, V46, P4847, DOI 10.1021/jm0300431; Kobilka BK, 2007, TRENDS PHARMACOL SCI, V28, P397, DOI 10.1016/j.tips.2007.06.003; Lebon G, 2011, J MOL BIOL, V409, P298, DOI 10.1016/j.jmb.2011.03.075; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Magnani F, 2008, P NATL ACAD SCI USA, V105, P10744, DOI 10.1073/pnas.0804396105; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Murphree LJ, 2002, MOL PHARMACOL, V61, P455, DOI 10.1124/mol.61.2.455; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Park JH, 2008, NATURE, V454, P183, DOI 10.1038/nature07063; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Rasmussen SGF, 2011, NATURE, V469, P175, DOI 10.1038/nature09648; Robertson N, 2011, NEUROPHARMACOLOGY, V60, P36, DOI 10.1016/j.neuropharm.2010.07.001; Rosenbaum DM, 2011, NATURE, V469, P236, DOI 10.1038/nature09665; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330; Serrano-Vega MJ, 2008, P NATL ACAD SCI USA, V105, P877, DOI 10.1073/pnas.0711253105; Shibata Y, 2009, J MOL BIOL, V390, P262, DOI 10.1016/j.jmb.2009.04.068; Vauquelin G, 2005, FUND CLIN PHARMACOL, V19, P45, DOI 10.1111/j.1472-8206.2005.00319.x; Wacker D, 2010, J AM CHEM SOC, V132, P11443, DOI 10.1021/ja105108q; Warne T, 2003, BBA-BIOMEMBRANES, V1610, P133, DOI 10.1016/S0005-2736(02)00716-2; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101; Warne T, 2011, NATURE, V469, P241, DOI 10.1038/nature09746; Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396; Xu F., 2011, SCIENCE; Yao XJ, 2009, P NATL ACAD SCI USA, V106, P9501, DOI 10.1073/pnas.0811437106	44	644	657	1	130	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2011	474	7352					521	U154		10.1038/nature10136	http://dx.doi.org/10.1038/nature10136			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	781NJ	21593763	Green Accepted			2022-12-28	WOS:000291939700051
J	Fletcher, LN; Hesman, BE; Irwin, PGJ; Baines, KH; Momary, TW; Sanchez-Lavega, A; Flasar, FM; Read, PL; Orton, GS; Simon-Miller, A; Hueso, R; Bjoraker, GL; Mamoutkine, A; del Rio-Gaztelurrutia, T; Gomez, JM; Buratti, B; Clark, RN; Nicholson, PD; Sotin, C				Fletcher, Leigh N.; Hesman, Brigette E.; Irwin, Patrick G. J.; Baines, Kevin H.; Momary, Thomas W.; Sanchez-Lavega, Agustin; Flasar, F. Michael; Read, Peter L.; Orton, Glenn S.; Simon-Miller, Amy; Hueso, Ricardo; Bjoraker, Gordon L.; Mamoutkine, Andrei; del Rio-Gaztelurrutia, Teresa; Gomez, Jose M.; Buratti, Bonnie; Clark, Roger N.; Nicholson, Philip D.; Sotin, Christophe			Thermal Structure and Dynamics of Saturn's Northern Springtime Disturbance	SCIENCE			English	Article							1990 EQUATORIAL DISTURBANCE; SPACE-TELESCOPE OBSERVATIONS; ZONAL WINDS; ATMOSPHERE	Saturn's slow seasonal evolution was disrupted in 2010-2011 by the eruption of a bright storm in its northern spring hemisphere. Thermal infrared spectroscopy showed that within a month, the resulting planetary-scale disturbance had generated intense perturbations of atmospheric temperatures, winds, and composition between 20 degrees and 50 degrees N over an entire hemisphere (140,000 kilometers). The tropospheric storm cell produced effects that penetrated hundreds of kilometers into Saturn's stratosphere (to the 1-millibar region). Stratospheric subsidence at the edges of the disturbance produced "beacons" of infrared emission and longitudinal temperature contrasts of 16 kelvin. The disturbance substantially altered atmospheric circulation, transporting material vertically over great distances, modifying stratospheric zonal jets, exciting wave activity and turbulence, and generating a new cold anticyclonic oval in the center of the disturbance at 41 degrees N.	[Fletcher, Leigh N.; Irwin, Patrick G. J.; Read, Peter L.] Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England; [Hesman, Brigette E.] Univ Maryland, Dept Astron, College Pk, MD 20742 USA; [Baines, Kevin H.] Univ Wisconsin, Ctr Space Sci & Engn, Madison, WI 53706 USA; [Momary, Thomas W.; Orton, Glenn S.; Buratti, Bonnie; Sotin, Christophe] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; [Sanchez-Lavega, Agustin; Hueso, Ricardo; del Rio-Gaztelurrutia, Teresa] Univ Basque Country, Escuela Tecn Super Ingenieros, Dept Fis Aplicada 1, Bilbao 48013, Spain; [Flasar, F. Michael; Simon-Miller, Amy; Bjoraker, Gordon L.; Mamoutkine, Andrei] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Gomez, Jose M.] Fdn Esteve Duran, Barcelona, Spain; [Clark, Roger N.] US Geol Survey, Fed Ctr, Denver, CO 80225 USA; [Nicholson, Philip D.] Cornell Univ, Dept Astron, Ithaca, NY 14853 USA	University of Oxford; University System of Maryland; University of Maryland College Park; University of Wisconsin System; University of Wisconsin Madison; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Basque Country; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; United States Department of the Interior; United States Geological Survey; Cornell University	Fletcher, LN (corresponding author), Univ Oxford, Dept Phys, Clarendon Lab, Parks Rd, Oxford OX1 3PU, England.	fletcher@atm.ox.ac.uk	Flasar, F Michael/C-8509-2012; Fletcher, Leigh/D-6093-2011; Sanchez-Lavega, Agustin/Z-3639-2019; Bjoraker, Gordon L/D-5032-2012; Simon, Amy/C-8020-2012; Hueso, Ricardo/Z-3277-2019; del Río Gaztelurrutia, Teresa/H-8831-2013; Orton, Glenn/AAD-9862-2020; Read, Peter Leonard/AAS-2773-2020	Fletcher, Leigh/0000-0001-5834-9588; Simon, Amy/0000-0003-4641-6186; Hueso, Ricardo/0000-0003-0169-123X; del Río Gaztelurrutia, Teresa/0000-0001-8552-226X; Irwin, Patrick Gerard Joseph/0000-0002-6772-384X; Sanchez-Lavega, Agustin/0000-0001-7234-7634; Sanchez-Lavega, Agustin/0000-0001-7355-1522	Science and Technology Facilities Council; Spanish MICIIN (Spanish Ministry of Science and Innovation) [AYA2009-10701, IT-464-07]; NASA; STFC [ST/I001948/1] Funding Source: UKRI; Science and Technology Facilities Council [ST/I001948/1] Funding Source: researchfish; UK Space Agency [ST/J002755/1] Funding Source: researchfish	Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Spanish MICIIN (Spanish Ministry of Science and Innovation)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); NASA(National Aeronautics & Space Administration (NASA)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); UK Space Agency	L.N.F. is supported by a Glasstone Science Fellowship at the University of Oxford. We thank members of both the Cassini CIRS and VIMS teams for their support in the analysis of Cassini data, and the director and staff of the ESO VLT for their assistance with the execution of these observations. This investigation was partially based on observations acquired at the Paranal UT3/Melipal Observatory under ID 386.C-0096. We are extremely grateful to all those observers contributing to the International Outer Planets Watch Planetary Visual Observatory & Laboratory (IOPW-PVOL), including T. Barry (Australia) for his contribution to Fig. 1. The UK authors acknowledge the support of the Science and Technology Facilities Council. A.S.L., R.H., and T.d.R. are supported by the Spanish MICIIN (Spanish Ministry of Science and Innovation) project AYA2009-10701 with FEDER and Grupos Gobierno Vasco IT-464-07. G.S.O. is supported by grants from NASA to the Jet Propulsion Laboratory, California Institute of Technology. L.N.F. performed the optimal estimation retrievals on both ground-based and space-based data sets and analyzed the results, and wrote the initial draft. B.E.H., G.L.B., and A.S.-M. designed the CIRS mapping observations; calibration assistance was provided by A.M. T.W.M. and K.H.B. provided the VIMS nightside spectra. G.S.O. supported ground-based VLT observations, and A.S.-L., R.H., and T.d.R.-G. provided IOPW-PVOL images. J.M.G. provided cylindrical mapping of IOPW-PVOL images. P.G.J.I. developed the optimal estimation retrieval codes used in this study. All authors discussed the results and commented on the manuscript.	Acarreta JR, 1999, ICARUS, V137, P24, DOI 10.1006/icar.1998.6034; BARNET CD, 1992, ICARUS, V100, P499, DOI 10.1016/0019-1035(92)90113-L; BEEBE RF, 1992, ICARUS, V95, P163, DOI 10.1016/0019-1035(92)90035-6; Brown RH, 2004, SPACE SCI REV, V115, P111, DOI 10.1007/s11214-004-1453-x; Dyudina UA, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL043188; Flasar FM, 2004, SPACE SCI REV, V115, P169, DOI 10.1007/s11214-004-1454-9; Fletcher LN, 2009, ICARUS, V202, P543, DOI 10.1016/j.icarus.2009.03.023; Fletcher LN, 2010, ICARUS, V208, P337, DOI 10.1016/j.icarus.2010.01.022; Guerlet S, 2009, ICARUS, V203, P214, DOI 10.1016/j.icarus.2009.04.002; Hueso R, 2004, ICARUS, V172, P255, DOI 10.1016/j.icarus.2004.06.010; Irwin PGJ, 2008, J QUANT SPECTROSC RA, V109, P1136, DOI 10.1016/j.jqsrt.2007.11.006; Lagage P. O., 2004, MESSENGER, V117, P12; Read PL, 2009, PLANET SPACE SCI, V57, P1682, DOI 10.1016/j.pss.2009.03.004; Sanchez-Lavega A, 1999, PLANET SPACE SCI, V47, P1277, DOI 10.1016/S0032-0633(99)00050-1; SANCHEZ-LAVEGA A, 1982, ICARUS, V49, P1, DOI 10.1016/0019-1035(82)90052-5; Sanchez-Lavega A, 2000, ICARUS, V147, P405, DOI 10.1006/icar.2000.6449; SANCHEZLAVEGA A, 1991, NATURE, V353, P397, DOI 10.1038/353397a0; Sayanagi KM, 2007, ICARUS, V187, P520, DOI 10.1016/j.icarus.2006.10.020; Vasavada AR, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2005JE002563; Vasavada AR, 2005, REP PROG PHYS, V68, P1935, DOI 10.1088/0034-4885/68/8/R06; WESTPHAL JA, 1992, ICARUS, V100, P485, DOI 10.1016/0019-1035(92)90112-K	22	65	65	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2011	332	6036					1413	1417		10.1126/science.1204774	http://dx.doi.org/10.1126/science.1204774			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778FT	21596955	Green Submitted			2022-12-28	WOS:000291689000037
J	Parekh, AK				Parekh, Anand K.			Winning Their Trust	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US Dept HHS, Off Assistant Secretary Hlth, Washington, DC 20201 USA		Parekh, AK (corresponding author), US Dept HHS, Off Assistant Secretary Hlth, Washington, DC 20201 USA.							Delamater AM, 2006, CLIN DIABETES, V24, P71, DOI 10.2337/diaclin.24.2.71.; *DEP HLTH HUM SERV, TOP OBJ IND HLTH PEO; Fiore MC, 2008, CLIN PRACTICE GUIDEL; HAYNES RB, 1985, B NEW YORK ACAD MED, V61, P123; KOCEREK B, 2009, DIABETES SPECTRUM, V22, P80	5	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2011	364	24					E51	U117		10.1056/NEJMp1105645	http://dx.doi.org/10.1056/NEJMp1105645			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	777RZ	21631314				2022-12-28	WOS:000291643800005
J	Kobayashi, T; Tsang, WY; Li, J; Lane, W; Dynlacht, BD				Kobayashi, Tetsuo; Tsang, William Y.; Li, Ji; Lane, William; Dynlacht, Brian David			Centriolar Kinesin Kif24 Interacts with CP110 to Remodel Microtubules and Regulate Ciliogenesis	CELL			English	Article							INTRACELLULAR-TRANSPORT; PROTEIN; CHLAMYDOMONAS; FLAGELLAR; TUBULIN; CELLS; DEPOLYMERIZATION; MECHANISM; DYNAMICS; BINDING	We have identified a protein, Kif24, that shares homology with the kinesin-13 subfamily of motor proteins and specifically interacts with CP110 and Cep97, centrosomal proteins that play a role in regulating centriolar length and ciliogenesis. Kif24 preferentially localizes to mother centrioles. Loss of Kif24 from cycling cells resulted in aberrant cilia assembly but did not promote growth of abnormally long centrioles, unlike CP110 and Cep97 depletion. We found that loss of Kif24 leads to the disappearance of CP110 from mother centrioles, specifically in cycling cells able to form cilia. Kif24 is able to bind and depolymerize microtubules in vitro. Remarkably, ectopically expressed Kif24 specifically remodels centriolar microtubules without significantly altering cytoplasmic microtubules. Thus, our studies have identified a centriolar kinesin that specifically remodels a subset of microtubules, thereby regulating cilia assembly. These studies also suggest mechanistic differences between the regulation of microtubule elongation associated with centrioles and cilia.	[Kobayashi, Tetsuo; Tsang, William Y.; Li, Ji; Dynlacht, Brian David] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Kobayashi, Tetsuo; Tsang, William Y.; Li, Ji; Dynlacht, Brian David] NYU, Sch Med, Inst Canc, Smilow Res Ctr, New York, NY 10016 USA; [Tsang, William Y.] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada; [Tsang, William Y.] McGill Univ, Div Expt Med, Montreal, PQ H3A 1A3, Canada; [Lane, William] Harvard Univ, Mass Spectrometry & Prote Resource Lab, Ctr Syst Biol, Cambridge, MA 02138 USA	New York University; New York University; Universite de Montreal; McGill University; Harvard University	Dynlacht, BD (corresponding author), NYU, Sch Med, Dept Pathol, 522 1st Ave, New York, NY 10016 USA.	brian.dynlacht@med.nyu.edu	Li, Ji/J-6026-2014	Tsang, William/0000-0002-1584-616X	Irma T. Hirschl Career Scientist Award; March of Dimes research grant; DOD	Irma T. Hirschl Career Scientist Award; March of Dimes research grant(March of Dimes); DOD(United States Department of Defense)	We thank all members of the Dynlacht laboratory for constructive advice and encouragement. We thank M. Jelcic and I. Sanchez for assistance with baculoviral expression and thank J. Liu for experimental assistance. We thank J. Salisbury, E. Nigg, K. Lee, C. Janke, T. Katada, and K. Kontani for providing antibodies. B.D.D. was supported, in part, by an Irma T. Hirschl Career Scientist Award and March of Dimes research grant, for which he expresses his gratitude. J.L. was supported by a DOD Prostate Cancer pre-doctoral Training Award.	Bettencourt-Dias M, 2007, NAT REV MOL CELL BIO, V8, P451, DOI 10.1038/nrm2180; Blaineau C, 2007, CURR BIOL, V17, P778, DOI 10.1016/j.cub.2007.03.048; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Dawson SC, 2007, EUKARYOT CELL, V6, P2354, DOI 10.1128/EC.00128-07; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Ems-McClung SC, 2010, SEMIN CELL DEV BIOL, V21, P276, DOI 10.1016/j.semcdb.2010.01.016; Endoh-Yamagami S, 2009, CURR BIOL, V19, P1320, DOI 10.1016/j.cub.2009.06.046; Hammond JW, 2008, CURR OPIN CELL BIOL, V20, P71, DOI 10.1016/j.ceb.2007.11.010; Hirokawa N, 2008, PHYSIOL REV, V88, P1089, DOI 10.1152/physrev.00023.2007; Hsu WB, 2008, EXP CELL RES, V314, P2591, DOI 10.1016/j.yexcr.2008.05.012; Jenkins PM, 2006, CURR BIOL, V16, P1211, DOI 10.1016/j.cub.2006.04.034; Kohlmaier G, 2009, CURR BIOL, V19, P1012, DOI 10.1016/j.cub.2009.05.018; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; Lacroix B, 2010, J CELL BIOL, V189, P945, DOI 10.1083/jcb.201001024; Liem KF, 2009, P NATL ACAD SCI USA, V106, P13377, DOI 10.1073/pnas.0906944106; Moores CA, 2002, MOL CELL, V9, P903, DOI 10.1016/S1097-2765(02)00503-8; Moudjou M, 1996, J CELL SCI, V109, P875; Ogawa T, 2004, CELL, V116, P591, DOI 10.1016/S0092-8674(04)00129-1; Ou GS, 2005, NATURE, V436, P583, DOI 10.1038/nature03818; Ovechkina Y, 2002, J CELL BIOL, V159, P557, DOI 10.1083/jcb.200205089; Paoletti A, 1996, J CELL SCI, V109, P3089; Piao T, 2009, P NATL ACAD SCI USA, V106, P4713, DOI 10.1073/pnas.0808671106; Schmidt TI, 2009, CURR BIOL, V19, P1005, DOI 10.1016/j.cub.2009.05.016; Shipley K, 2004, EMBO J, V23, P1422, DOI 10.1038/sj.emboj.7600165; Spektor A, 2007, CELL, V130, P678, DOI 10.1016/j.cell.2007.06.027; Tang CJC, 2009, NAT CELL BIOL, V11, P825, DOI 10.1038/ncb1889; Tsang WY, 2008, DEV CELL, V15, P187, DOI 10.1016/j.devcel.2008.07.004; Tsang WY, 2007, J CELL BIOL, V178, P621, DOI 10.1083/jcb.200701166; Tsang WY, 2006, MOL BIOL CELL, V17, P3423, DOI 10.1091/mbc.E06-04-0371; Tsang WY, 2009, DEV CELL, V16, P649, DOI 10.1016/j.devcel.2009.03.004; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9	32	139	153	0	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 10	2011	145	6					914	925		10.1016/j.cell.2011.04.028	http://dx.doi.org/10.1016/j.cell.2011.04.028			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	775LS	21620453	Bronze			2022-12-28	WOS:000291461600018
J	Yin, J; Shen, KL				Yin, Ju; Shen, Kunling			Pulmonary Alveolar Microlithiasis in a Child	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Yin, Ju; Shen, Kunling] Capital Med Univ, Beijing Childrens Hosp, Beijing, Peoples R China	Capital Medical University	Yin, J (corresponding author), Capital Med Univ, Beijing Childrens Hosp, Beijing, Peoples R China.	kunlingshen@hotmail.com							0	3	5	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					E49	E49		10.1056/NEJMicm1002094	http://dx.doi.org/10.1056/NEJMicm1002094			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AB	21631318				2022-12-28	WOS:000291200700014
J	Guttmann, A; Schull, MJ; Vermeulen, MJ; Stukel, TA				Guttmann, Astrid; Schull, Michael J.; Vermeulen, Marian J.; Stukel, Therese A.			Association between waiting times and short term mortality and hospital admission after departure from emergency department: population based cohort study from Ontario, Canada	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AMBULANCE DIVERSION; ADVERSE EVENTS; OUTCOMES; IMPACT; CONSEQUENCES; PHYSICIAN	Objective To determine whether patients who are not admitted to hospital after attending an emergency department during shifts with long waiting times are at risk for adverse events. Design Population based retrospective cohort study using health administrative databases. Setting High volume emergency departments in Ontario, Canada, fiscal years 2003-7. Participants All emergency department patients who were not admitted (seen and discharged; left without being seen). Outcome measures Risk of adverse events (admission to hospital or death within seven days) adjusted for important characteristics of patients, shift, and hospital. Results 13 934 542 patients were seen and discharged and 617 011 left without being seen. The risk of adverse events increased with the mean length of stay of similar patients in the same shift in the emergency department. For mean length of stay >= 6 v <1 hour the adjusted odds ratio (95% confidence interval) was 1.79 (1.24 to 2.59) for death and 1.95 (1.79 to 2.13) for admission in high acuity patients and 1.71 (1.25 to 2.35) for death and 1.66 (1.56 to 1.76) for admission in low acuity patients). Leaving without being seen was not associated with an increase in adverse events at the level of the patient or by annual rates of the hospital. Conclusions Presenting to an emergency department during shifts with longer waiting times, reflected in longer mean length of stay, is associated with a greater risk in the short term of death and admission to hospital in patients who are well enough to leave the department. Patients who leave without being seen are not at higher risk of short term adverse events.	[Guttmann, Astrid; Schull, Michael J.; Vermeulen, Marian J.; Stukel, Therese A.] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; [Guttmann, Astrid] Hosp Sick Children, Div Paediat, Toronto, ON M5G 1X8, Canada; [Guttmann, Astrid] Hosp Sick Children, Div Emergency Med, Toronto, ON M5G 1X8, Canada; [Guttmann, Astrid] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; [Guttmann, Astrid; Schull, Michael J.; Stukel, Therese A.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Schull, Michael J.] Sunnybrook Hlth Sci Ctr, Dept Emergency Serv, Toronto, ON M4N 3M5, Canada; [Schull, Michael J.; Vermeulen, Marian J.; Stukel, Therese A.] Sunnybrook Hlth Sci Ctr, Clin Epidemiol Unit, Toronto, ON M4N 3M5, Canada; [Schull, Michael J.] Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Guttmann, A (corresponding author), Inst Clin Evaluat Sci, G-106,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	astrid.guttmann@ices.on.ca	Schull, Michael J/A-7955-2013	Schull, Michael J/0000-0002-1318-6364	Ontario Ministry of Health and Long Term Care; Institute for Clinical Evaluative Sciences; Ministry of Health and Long Term Care	Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario); Institute for Clinical Evaluative Sciences; Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario)	This study was supported by a grant from the Ontario Ministry of Health and Long Term Care and by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ministry of Health and Long Term Care. The funding source had no involvement in the study design, analysis, interpretation or decision to submit this work.	Alberti G., 2004, TRANSFORMING EMERGEN; Asptin BR, 2006, ACAD EMERG MED, V13, P459, DOI 10.1197/j.aem.2006.01.004; Atzema CL, 2009, ANN EMERG MED, V53, P736, DOI 10.1016/j.annemergmed.2008.11.011; Australian Government Department of Health and Ageing, 2008, STAT OUR PUBL HOSP 4; BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; Bell R, 2006, IMPROVING ACCESS EME; Berlin JA, 1999, BIOMETRICS, V55, P470, DOI 10.1111/j.0006-341X.1999.00470.x; Bernstein SL, 2009, ACAD EMERG MED, V16, P1, DOI 10.1111/j.1553-2712.2008.00295.x; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; Bond K, 2006, 674 CAN AG DRUGS TEC; Bond Kenneth, 2007, Healthc Q, V10, P32; Browne GJ, 2001, J PAEDIATR CHILD H, V37, P235, DOI 10.1046/j.1440-1754.2001.00648.x; Canadian Institute for Health Information, 2008, CIHI DAT QUAL STUD E, V2; Diercks DB, 2007, ANN EMERG MED, V50, P489, DOI 10.1016/j.annemergmed.2007.03.033; Fatovich DM, 2005, EMERG MED J, V22, P351, DOI 10.1136/emj.2004.018002; Forster AJ, 2007, QUAL SAF HEALTH CARE, V16, P17, DOI 10.1136/qshc.2005.017384; Holroyd BR, 2007, ACAD EMERG MED, V14, P702, DOI 10.1197/j.aem.2007.04.018; [Institute of Medicine of the National Academies Committee on the Future of Emergency Care in the United States Health System], 2006, HOSP BAS EM CAR BREA; Locker T, 2005, EMERG MED J, V22, P710, DOI 10.1136/emj.2004.019042; McCarthy ML, 2009, ANN EMERG MED, V54, P492, DOI 10.1016/j.annemergmed.2009.03.006; Mills AM, 2010, POSTGRAD MED, V122, P75, DOI 10.3810/pgm.2010.01.2101; Mohsin M, 2007, EMERG MED J, V24, P175, DOI 10.1136/emj.2006.038679; Moskop JC, 2009, ANN EMERG MED, V53, P612, DOI 10.1016/j.annemergmed.2008.09.024; Murray Michael, 2004, CJEM, V6, P421; National Quality Forum, 2008, NQF END MEAS ADDR CA; Niska RW, 2008, NATL HLTH STAT REPOR; Ontario Ministry of Health and Long Term Care, 2009, MCGUINT GOV LAUNCH P; Peatling S, 2010, SUDBURY MORNING 0411; Pines JM, 2007, ANN EMERG MED, V50, P510, DOI 10.1016/j.annemergmed.2007.07.021; Richardson DB, 2006, MED J AUSTRALIA, V184, P213, DOI 10.5694/j.1326-5377.2006.tb00204.x; Schull MJ, 2003, ANN EMERG MED, V41, P467, DOI 10.1067/mem.2003.23; Sprivulis PC, 2006, MED J AUSTRALIA, V184, P208, DOI 10.5694/j.1326-5377.2006.tb00203.x; Topping A, 2010, GUARDIAN        0610; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	34	377	384	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 1	2011	342								d2983	10.1136/bmj.d2983	http://dx.doi.org/10.1136/bmj.d2983			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774MK	21632665	hybrid, Green Published			2022-12-28	WOS:000291390500003
J	Inglis, C; Chedgy, F; Howlett, DC				Inglis, C.; Chedgy, F.; Howlett, D. C.			PICTURE QUIZ A case of recurrent ventricular tachycardia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							NATURAL-HISTORY; CARDIAC-RESYNCHRONIZATION; ANEURYSM; DEFIBRILLATOR; THERAPY; REPAIR		[Inglis, C.; Chedgy, F.; Howlett, D. C.] Eastbourne Dist Gen Hosp, Eastbourne BN21 2UD, England		Inglis, C (corresponding author), Eastbourne Dist Gen Hosp, Eastbourne BN21 2UD, England.	celineinglis@doctors.org.uk						BAALBAKI HA, 1989, CLIN CARDIOL, V12, P5, DOI 10.1002/clc.4960120102; BACIEWICZ PA, 1991, AM J CARDIOL, V68, P193, DOI 10.1016/0002-9149(91)90743-5; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; BENEDIKTSSON R, 1991, J CLIN EPIDEMIOL, V44, P1131, DOI 10.1016/0895-4356(91)90145-Y; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Bristow MR, 2000, J CARD FAIL, V6, P276, DOI 10.1054/jcaf.2000.9501; Buck T, 1997, CIRCULATION, V96, P4286; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; COLTHARP WH, 1994, ANN SURG, V219, P707, DOI 10.1097/00000658-199406000-00015; COOLEY DA, 1992, ANN SURG, V215, P417, DOI 10.1097/00000658-199205000-00003; Dor V, 1997, Semin Thorac Cardiovasc Surg, V9, P123; FAXON DP, 1982, AM J CARDIOL, V50, P157, DOI 10.1016/0002-9149(82)90023-6; Glower DD, 2003, CARDIAC SURG ADULT, P771; GRONDIN P, 1979, J THORAC CARDIOV SUR, V77, P57; KOMEDA M, 1992, ANN THORAC SURG, V53, P22, DOI 10.1016/0003-4975(92)90753-Q; LAPEYRE AC, 1985, J AM COLL CARDIOL, V6, P534, DOI 10.1016/S0735-1097(85)80109-1; Lee DS, 2003, J AM COLL CARDIOL, V41, P1573, DOI 10.1016/S0735-1097(03)00253-5; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MEIZLISH JL, 1984, NEW ENGL J MED, V311, P1001, DOI 10.1056/NEJM198410183111601; MILLS NL, 1993, ANN THORAC SURG, V55, P792, DOI 10.1016/0003-4975(93)90304-Z; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Zipes DP, 2006, CIRCULATION, V114, pE385, DOI 10.1161/CIRCULATIONAHA.106.178233	22	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 1	2011	342								d2654	10.1136/bmj.d2654	http://dx.doi.org/10.1136/bmj.d2654			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774MK	21632667				2022-12-28	WOS:000291390500001
J	Autran, D; Baroux, C; Raissig, MT; Lenormand, T; Wittig, M; Grob, S; Steimer, A; Barann, M; Klostermeier, UC; Leblanc, O; Vielle-Calzada, JP; Rosenstiel, P; Grimanelli, D; Grossniklaus, U				Autran, Daphne; Baroux, Celia; Raissig, Michael T.; Lenormand, Thomas; Wittig, Michael; Grob, Stefan; Steimer, Andrea; Barann, Matthias; Klostermeier, Ulrich C.; Leblanc, Olivier; Vielle-Calzada, Jean-Philippe; Rosenstiel, Phillip; Grimanelli, Daniel; Grossniklaus, Ueli			Maternal Epigenetic Pathways Control Parental Contributions to Arabidopsis Early Embryogenesis	CELL			English	Article							TO-ZYGOTIC TRANSITION; SEED DEVELOPMENT; SMALL-RNA; ENDOSPERM DEVELOPMENT; DNA METHYLATION; PATERNAL GENOME; HYBRID VIGOR; CHROMATIN; EMBRYO; MAINTENANCE	Defining the contributions and interactions of paternal and maternal genomes during embryo development is critical to understand the fundamental processes involved in hybrid vigor, hybrid sterility, and reproductive isolation. To determine the parental contributions and their regulation during Arabidopsis embryogenesis, we combined deep-sequencing-based RNA profiling and genetic analyses. At the 2-4 cell stage there is a strong, genome-wide dominance of maternal transcripts, although transcripts are contributed by both parental genomes. At the globular stage the relative paternal contribution is higher, largely due to a gradual activation of the paternal genome. We identified two antagonistic maternal pathways that control these parental contributions. Paternal alleles are initially downregulated by the chromatin siRNA pathway, linked to DNA and histone methylation, whereas transcriptional activation requires maternal activity of the histone chaperone complex CAF1. Our results define maternal epigenetic pathways controlling the parental contributions in plant embryos, which are distinct from those regulating genomic imprinting.	[Autran, Daphne; Leblanc, Olivier; Grimanelli, Daniel] Univ Montpellier, Inst Rech Dev, UMR 232, F-34394 Montpellier, France; [Baroux, Celia; Raissig, Michael T.; Grob, Stefan; Steimer, Andrea; Grossniklaus, Ueli] Univ Zurich, Inst Plant Biol, CH-8008 Zurich, Switzerland; [Baroux, Celia; Raissig, Michael T.; Grob, Stefan; Steimer, Andrea; Grossniklaus, Ueli] Univ Zurich, Zurich Basel Plant Sci Ctr, CH-8008 Zurich, Switzerland; [Lenormand, Thomas] Univ Montpellier, Ctr Ecol Fonct & Evolut, CNRS, UMR 5175, F-34293 Montpellier, France; [Wittig, Michael; Barann, Matthias; Klostermeier, Ulrich C.; Rosenstiel, Phillip] Univ Kiel, Inst Clin Mol Biol, D-24105 Kiel, Germany; [Vielle-Calzada, Jean-Philippe] CINVESTAV, Natl Lab Genom Biodivers, Guanajuato 36500, Mexico	Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; University of Zurich; University of Zurich; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut Agro; Montpellier SupAgro; CIRAD; Institut de Recherche pour le Developpement (IRD); Universite Paul-Valery; Universite de Montpellier; University of Kiel; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional	Grimanelli, D (corresponding author), Univ Montpellier, Inst Rech Dev, UMR 232, F-34394 Montpellier, France.	daniel.grimanelli@ird.fr; grossnik@botinst.uzh.ch	Vielle-Calzada, Jean-Philippe/AAG-4036-2019; Lenormand, Thomas/A-5328-2012; Raissig, Michael T/AAO-9557-2020; Grob, Stefan/AAJ-3091-2020; Baroux, Célia/J-5359-2013; Grimanelli, Daniel/ABE-4777-2020; Grossniklaus, Ueli/A-2736-2012; Grossniklaus, Ueli/E-9995-2016; Raissig, Michael T/AGF-0291-2022; Autran, Daphné/AAV-4792-2021; Rosenstiel, Philip/A-5137-2009; Autran, Daphné/D-4846-2009	Lenormand, Thomas/0000-0001-8930-5393; Grob, Stefan/0000-0001-6199-7383; Baroux, Célia/0000-0001-6307-2229; Grossniklaus, Ueli/0000-0002-0522-8974; Autran, Daphné/0000-0002-5227-8966; Rosenstiel, Philip/0000-0002-9692-8828; Autran, Daphné/0000-0002-5227-8966; Vielle-Calzada, Jean-Philippe/0000-0002-3017-2490; Grimanelli, Daniel/0000-0001-5424-114X; Raissig, Michael/0000-0003-3179-9372	University of Zurich; Swiss National Science Foundation; European Union; Institut de Recherche pour le Developpement; Agence Nationale de la Recherche; CNRS; European Research Council; Clusters of Excellence; CONACyT	University of Zurich; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Union(European Commission); Institut de Recherche pour le Developpement; Agence Nationale de la Recherche(French National Research Agency (ANR)); CNRS(Centre National de la Recherche Scientifique (CNRS)); European Research Council(European Research Council (ERC)European Commission); Clusters of Excellence; CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	We thank the Arabidopsis Stock Centers (NASC/ABRC), J. Carrington, R. Gross-Hardt, R. Martienssen, F. Meins, T. Lagrange, J. Paszowski, and E. Richards for seeds; C. Michaud, N. Duran-Figueroa, and V. Olmedo-Monfil for technical support; T. Nawy for advice on embryo microdissection; S. Schreiber, L. Bossen, and M. Schilhabel for sequencing support at Kiel; and M. Schmid for help in GEO data submission. We are grateful to M. Arteaga-Vazquez, O. Hamant, and T. Lagrange for helpful comments on earlier versions of the manuscript and to S. Kessler and S. Gillmor for critical reading. C. B., M. R., S. G., and A. S. were supported by the University of Zurich and grants of Swiss National Science Foundation and the European Union (FP5 ApoTool Project) to U. G. D. A., O. L., and D. G. were supported by the Institut de Recherche pour le Developpement and the Agence Nationale de la Recherche, and T. L. by CNRS and a starting grant of the European Research Council. P. R. is supported by the Clusters of Excellence: "The Future Ocean" and "Inflammation at Interfaces." J.-P. V.-C. is supported by CONACyT and is an International Scholar of the Howard Hughes Medical Institute.	ANDEOL Y, 1994, ROUX ARCH DEV BIOL, V204, P3, DOI [10.1007/BF00744867, 10.1007/BF00189062]; Aw SJ, 2010, DEVELOPMENT, V137, P2683, DOI 10.1242/dev.052928; Baroux C, 2008, COLD SH Q B, V73, P89, DOI 10.1101/sqb.2008.73.053; Baroux C, 2001, FEBS LETT, V509, P11, DOI 10.1016/S0014-5793(01)03097-6; Baroux U, 2006, GENE DEV, V20, P1081, DOI 10.1101/gad.378106; Bayer M, 2009, SCIENCE, V323, P1485, DOI 10.1126/science.1167784; Borevitz JO, 2007, P NATL ACAD SCI USA, V104, P12057, DOI 10.1073/pnas.0705323104; Borges F, 2008, PLANT PHYSIOL, V148, P1168, DOI 10.1104/pp.108.125229; Bourc'his D, 2010, SCIENCE, V330, P617, DOI 10.1126/science.1194776; Brodersen P, 2006, TRENDS GENET, V22, P268, DOI 10.1016/j.tig.2006.03.003; Bushell C, 2003, PLANT CELL, V15, P1430, DOI 10.1105/tpc.010496; Chaudhury AM, 2001, SEMIN CELL DEV BIOL, V12, P381, DOI 10.1006/scdb.2001.0267; Chen ZJ, 2010, TRENDS PLANT SCI, V15, P57, DOI 10.1016/j.tplants.2009.12.003; De Renzis S, 2007, PLOS BIOL, V5, P1036, DOI 10.1371/journal.pbio.0050117; Feng SH, 2010, SCIENCE, V330, P622, DOI 10.1126/science.1190614; Gehring M, 2009, SCIENCE, V324, P1447, DOI 10.1126/science.1171609; Grimanelli D, 2005, PLANT CELL, V17, P1061, DOI 10.1105/tpc.104.029819; Groszmann M, 2011, P NATL ACAD SCI USA, V108, P2617, DOI 10.1073/pnas.1019217108; Hennig L, 2003, DEVELOPMENT, V130, P2555, DOI 10.1242/dev.00470; Hennig L, 2005, TRENDS CELL BIOL, V15, P295, DOI 10.1016/j.tcb.2005.04.004; Hsieh TF, 2011, P NATL ACAD SCI USA, V108, P1755, DOI 10.1073/pnas.1019273108; Hsieh TF, 2009, SCIENCE, V324, P1451, DOI [10.1126/science.1172417, 10.1126/science.112417]; Ingouff M, 2010, CURR BIOL, V20, P2137, DOI 10.1016/j.cub.2010.11.012; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jahnke S, 2010, THEOR APPL GENET, V120, P389, DOI 10.1007/s00122-009-1207-y; Jullien PE, 2006, PLANT CELL, V18, P1360, DOI 10.1105/tpc.106.041178; Jullien PE, 2006, CURR BIOL, V16, P486, DOI 10.1016/j.cub.2006.01.020; Kaya H, 2001, CELL, V104, P131, DOI 10.1016/S0092-8674(01)00197-0; Kohler C, 2003, EMBO J, V22, P4804, DOI 10.1093/emboj/cdg444; Lu C, 2005, SCIENCE, V309, P1567, DOI 10.1126/science.1114112; Martienssen RA, 2010, NEW PHYTOL, V186, P46, DOI 10.1111/j.1469-8137.2010.03193.x; Meyer S, 2007, CURR BIOL, V17, P1686, DOI 10.1016/j.cub.2007.08.046; Mosher RA, 2009, NATURE, V460, P283, DOI 10.1038/nature08084; Ngo QA, 2007, DEVELOPMENT, V134, P4107, DOI 10.1242/dev.007310; Okada T, 2005, PLANT J, V44, P557, DOI 10.1111/j.1365-313X.2005.02554.x; Olmedo-Monfil V, 2010, NATURE, V464, P628, DOI 10.1038/nature08828; Ono T, 2006, GENES CELLS, V11, P153, DOI 10.1111/j.1365-2443.2006.00928.x; Ooi SL, 2006, PLOS GENET, V2, P883, DOI 10.1371/journal.pgen.0020097; Pahlavani MH, 2006, J APPL GENET, V47, P331, DOI 10.1007/BF03194642; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Peiffer JA, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-43; Pillot M, 2010, PLANT SIGNAL BEHAV, V5, P1167, DOI 10.4161/psb.5.10.11905; Pillot M, 2010, PLANT CELL, V22, P307, DOI 10.1105/tpc.109.071647; Raissig MT, 2011, PLANT CELL, V23, P16, DOI 10.1105/tpc.110.081018; Ronceret A, 2005, PLANT J, V44, P223, DOI 10.1111/j.1365-313X.2005.02521.x; Ronceret A, 2008, PLANT J, V53, P776, DOI 10.1111/j.1365-313X.2007.03372.x; Scholten S, 2002, PLANT J, V32, P221, DOI 10.1046/j.1365-313X.2002.01418.x; Slotkin RK, 2009, CELL, V136, P461, DOI 10.1016/j.cell.2008.12.038; Tadros W, 2009, DEVELOPMENT, V136, P3033, DOI 10.1242/dev.033183; Tzafrir I, 2004, PLANT PHYSIOL, V135, P1206, DOI 10.1104/pp.104.045179; Vielle-Calzada JP, 2000, NATURE, V404, P91, DOI 10.1038/35003595; Weijers D, 2001, NATURE, V414, P709, DOI 10.1038/414709a; Wuest SE, 2010, CURR BIOL, V20, P506, DOI 10.1016/j.cub.2010.01.051	53	147	154	0	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 27	2011	145	5					707	719		10.1016/j.cell.2011.04.014	http://dx.doi.org/10.1016/j.cell.2011.04.014			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620136	Bronze, Green Submitted			2022-12-28	WOS:000291018600011
J	Elinav, E; Strowig, T; Kau, AL; Henao-Mejia, J; Thaiss, CA; Booth, CJ; Peaper, DR; Bertin, J; Eisenbarth, SC; Gordon, JI; Flavell, RA				Elinav, Eran; Strowig, Till; Kau, Andrew L.; Henao-Mejia, Jorge; Thaiss, Christoph A.; Booth, Carmen J.; Peaper, David R.; Bertin, John; Eisenbarth, Stephanie C.; Gordon, Jeffrey I.; Flavell, Richard A.			NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis	CELL			English	Article							NF-KAPPA-B; INTESTINAL MICROBIOTA; DIVISION TM7; BACTERIA; PREVALENCE; ACTIVATION; RECOGNITION; CASPASE-1; STRAINS; MUCIN	Inflammasomes are multiprotein complexes that function as sensors of endogenous or exogenous damage-associated molecular patterns. Here, we show that deficiency of NLRP6 in mouse colonic epithelial cells results in reduced IL-18 levels and altered fecal microbiota characterized by expanded representation of the bacterial phyla Bacteroidetes (Prevotellaceae) and TM7. NLRP6 inflammasome-deficient mice were characterized by spontaneous intestinal hyperplasia, inflammatory cell recruitment, and exacerbation of chemical colitis induced by exposure to dextran sodium sulfate (DSS). Cross-fostering and cohousing experiments revealed that the colitogenic activity of this microbiota is transferable to neonatal or adult wild-type mice, leading to exacerbation of DSS colitis via induction of the cytokine, CCL5. Antibiotic treatment and electron microscopy studies further supported the role of Prevotellaceae as a key representative of this microbiota-associated phenotype. Altogether, perturbations in this inflammasome pathway, including NLRP6, ASC, caspase-1, and IL-18, may constitute a predisposing or initiating event in some cases of human IBD.	[Elinav, Eran; Strowig, Till; Henao-Mejia, Jorge; Thaiss, Christoph A.; Eisenbarth, Stephanie C.; Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Booth, Carmen J.] Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06520 USA; [Peaper, David R.; Eisenbarth, Stephanie C.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA; [Kau, Andrew L.; Gordon, Jeffrey I.] Washington Univ, Sch Med, Ctr Genome Sci & Syst Biol, St Louis, MO 63108 USA; [Kau, Andrew L.] Washington Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, St Louis, MO 63108 USA; [Bertin, John] GlaxoSmithKline, Pattern Recognit Receptor Discovery Performance U, Collegeville, PA 19426 USA; [Flavell, Richard A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Yale University; Yale University; Yale University; Washington University (WUSTL); Washington University (WUSTL); GlaxoSmithKline; Howard Hughes Medical Institute	Flavell, RA (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, 333 Cedar St, New Haven, CT 06520 USA.	richard.flavell@yale.edu	Kau, Andrew/AGX-9881-2022; Elinav, Eran/ABE-8881-2020	Elinav, Eran/0000-0002-5775-2110; Eisenbarth, Stephanie/0000-0002-1244-208X; Kau, Andrew/0000-0002-9386-3766; Strowig, Till/0000-0003-0185-1459	Cancer Research Institute; Israel-US educational foundation; American Physicians for Medicine in Israel Foundation; W.M Keck Foundation; LLS; Howard Hughes Medical Institute; Crohn's and Colitis Foundation of America; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007974] Funding Source: NIH RePORTER	Cancer Research Institute; Israel-US educational foundation; American Physicians for Medicine in Israel Foundation; W.M Keck Foundation(W.M. Keck Foundation); LLS; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Crohn's and Colitis Foundation of America; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We would like to thank A Hafemann, S. Campton, E. Eynon, J. Alderman, W. Philbrick, C. Zorca, M. Musaheb, J. Stein, A. Ferrandino, F. Manzo, and the members of the Flavell lab for technical help and helpful discussions; K. Fitzgerald for providing AIM2<SUP>-/-</SUP> deficient mice; M. Graham and C. Rahner, CCMI EM Core Facility, Yale School of Medicine; J. Manchester and S. Deng for their assistance with DNA sequencing; V. Nagy for discussion and help with figure preparation; and H. Elinav for important discussions, suggestions, and critique. E. E. is supported by Cancer Research Institute (2010-2012) and the Israel-US educational foundation (2009) and is the recipient of the Claire and Emmanuel G. Rosenblatt award from the American Physicians for Medicine in Israel Foundation. A. L. K. is the recipient of a postdoctoral fellowship from the W.M Keck Foundation. J. H.-M. is supported by a LLS Postdoctoral Fellowship. This work was supported, in part, by Howard Hughes Medical Institute (R. A. F.) and the Crohn's and Colitis Foundation of America (J.I.G.).	Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Arthur JC, 2010, J IMMUNOL, V185, P4515, DOI 10.4049/jimmunol.1002227; Bauer C, 2010, GUT, V59, P1192, DOI 10.1136/gut.2009.197822; Becker C, 2006, NAT PROTOC, V1, P2900, DOI 10.1038/nprot.2006.446; Berube J, 2009, CELL SIGNAL, V21, P448, DOI 10.1016/j.cellsig.2008.12.001; Bjorksten B, 1999, ALLERGY, V54, P17, DOI 10.1111/j.1398-9995.1999.tb04383.x; BREBAN MA, 1993, CLIN EXP RHEUMATOL, V11, P61; Brinig MM, 2003, APPL ENVIRON MICROB, V69, P1687, DOI 10.1128/AEM.69.3.1687-1694.2003; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061; Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012; Geijtenbeek TBH, 2004, ANNU REV IMMUNOL, V22, P33, DOI 10.1146/annurev.immunol.22.012703.104558; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Hirota SA, 2011, INFLAMM BOWEL DIS, V17, P1359, DOI 10.1002/ibd.21478; Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108; Hugenholtz P, 2001, APPL ENVIRON MICROB, V67, P411, DOI 10.1128/AEM.67.1.411-419.2001; Kempster SL, 2011, AM J PHYSIOL-GASTR L, V300, pG253, DOI 10.1152/ajpgi.00397.2010; Kleessen B, 2002, SCAND J GASTROENTERO, V37, P1034, DOI 10.1080/003655202320378220; Kuehbacher T, 2008, J MED MICROBIOL, V57, P1569, DOI 10.1099/jmm.0.47719-0; Kufer TA, 2011, NAT IMMUNOL, V12, P121, DOI 10.1038/ni.1985; Kumar PS, 2003, J DENT RES, V82, P338, DOI 10.1177/154405910308200503; Lee YK, 2011, P NATL ACAD SCI USA, V108, P4615, DOI 10.1073/pnas.1000082107; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Lucke K, 2006, J MED MICROBIOL, V55, P617, DOI 10.1099/jmm.0.46198-0; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Marcy Y, 2007, P NATL ACAD SCI USA, V104, P11889, DOI 10.1073/pnas.0704662104; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Matzinger P, 2007, NAT IMMUNOL, V8, P11, DOI 10.1038/ni0107-11; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Ouverney CC, 2003, APPL ENVIRON MICROB, V69, P6294, DOI 10.1128/AEM.69.10.6294-6298.2003; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Siegmund B, 2001, P NATL ACAD SCI USA, V98, P13249, DOI 10.1073/pnas.231473998; Siegmund B, 2010, IMMUNITY, V32, P300, DOI 10.1016/j.immuni.2010.03.010; Sinkorova Z, 2008, HUM IMMUNOL, V69, P845, DOI 10.1016/j.humimm.2008.08.296; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Suzuki K, 2004, P NATL ACAD SCI USA, V101, P1981, DOI 10.1073/pnas.0307317101; TSAI HH, 1995, GUT, V36, P570, DOI 10.1136/gut.36.4.570; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Vaahtovuo J, 2008, J RHEUMATOL, V35, P1500; Vaishnava S, 2008, P NATL ACAD SCI USA, V105, P20858, DOI 10.1073/pnas.0808723105; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Werts C, 2007, EUR J IMMUNOL, V37, P2499, DOI 10.1002/eji.200737069; Wright DP, 2000, FEMS MICROBIOL LETT, V190, P73, DOI 10.1016/S0378-1097(00)00324-4; Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003	54	1365	1426	10	305	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 27	2011	145	5					745	757		10.1016/j.cell.2011.04.022	http://dx.doi.org/10.1016/j.cell.2011.04.022			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21565393	Green Accepted, Bronze			2022-12-28	WOS:000291018600014
J	Hammerl, G; Spaldin, N				Hammerl, German; Spaldin, Nicola			Shedding Light on Oxide Interfaces	SCIENCE			English	Editorial Material									[Hammerl, German] Univ Augsburg, Ctr Elect Correlat & Magnetism, D-86135 Augsburg, Germany; [Spaldin, Nicola] ETH, Dept Mat, CH-8093 Zurich, Switzerland	University of Augsburg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hammerl, G (corresponding author), Univ Augsburg, Ctr Elect Correlat & Magnetism, Univ Str 1, D-86135 Augsburg, Germany.	german.hammerl@physik.uni-augsburg.de; nicola.spaldin@mat.ethz.ch	Spaldin, Nicola A/A-1017-2010; Hammerl, German/E-9358-2017	Spaldin, Nicola A/0000-0003-0709-9499; Hammerl, German/0000-0002-2010-5163				Boris AV, 2011, SCIENCE, V332, P937, DOI 10.1126/science.1202647; Gozar A, 2008, NATURE, V455, P782, DOI 10.1038/nature07293; Mannhart J, 2010, SCIENCE, V327, P1607, DOI 10.1126/science.1181862; Ohtomo A, 2004, NATURE, V427, P423, DOI 10.1038/nature02308; Schlom DG, 2008, J AM CERAM SOC, V91, P2429, DOI 10.1111/j.1551-2916.2008.02556.x; Spaldin NA, 2010, PHYS TODAY, V63, P38, DOI 10.1063/1.3502547; Stengel M, 2006, NATURE, V443, P679, DOI 10.1038/nature05148	7	24	25	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2011	332	6032					922	923		10.1126/science.1206247	http://dx.doi.org/10.1126/science.1206247			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596980	Green Submitted			2022-12-28	WOS:000290766600028
J	Karkkainen, L; Garaud, JJ				Karkkainen, Leo; Garaud, Jean Jacques		Toyota Motor Corp	Research beyond the recession	NATURE			English	Editorial Material									[Karkkainen, Leo] Nokia Res Ctr, Helsinki, Finland; [Garaud, Jean Jacques] Roche Holding, Basel, Switzerland	Nokia Corporation; Nokia Finland; Siemens AG; Nokia Siemens Networks; Roche Holding	Karkkainen, L (corresponding author), Nokia Res Ctr, Helsinki, Finland.								0	0	0	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 19	2011	473	7347					277	278		10.1038/473277a	http://dx.doi.org/10.1038/473277a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	765QA	21593839	Bronze			2022-12-28	WOS:000290722400014
J	Peedell, C				Peedell, Clive			NHS REFORMS Further privatisation is inevitable under the proposed NHS reforms	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Peedell, Clive] NHS Consultants Assoc, Middlesbrough, Cleveland, England; [Peedell, Clive] James Cook Univ Hosp, Middlesbrough, Cleveland, England	James Cook University Hospital	Peedell, C (corresponding author), NHS Consultants Assoc, Middlesbrough, Cleveland, England.	clive.peedell@stees.nhs.uk							0	13	13	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 17	2011	342								d2996	10.1136/bmj.d2996	http://dx.doi.org/10.1136/bmj.d2996			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QO	21586450				2022-12-28	WOS:000290951700006
J	Wee, CC; Huskey, KW; Ngo, LH; Fowler-Brown, A; Leveille, SG; Mittlemen, MA; McCarthy, EP				Wee, Christina C.; Huskey, Karen W.; Ngo, Long H.; Fowler-Brown, Angela; Leveille, Suzanne G.; Mittlemen, Murray A.; McCarthy, Ellen P.			Obesity, Race, and Risk for Death or Functional Decline Among Medicare Beneficiaries A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-MASS INDEX; OLDER-ADULTS; WEIGHT-LOSS; US ADULTS; MORTALITY; OVERWEIGHT; DISABILITY; AMERICANS; PREVALENCE; MORBIDITY	Background: The adverse effect of obesity on health outcomes may be lower in older and African American adults than in the general U. S. population. Objective: To examine and compare the relationship between obesity and all-cause mortality and functional decline among older U. S. adults. Design: Longitudinal cohort study. Setting: Secondary analysis of data from the 1994 to 2000 Medicare Current Beneficiary Surveys, linked to Medicare enrollment files through 22 April 2008. Participants: 20 975 community-dwelling participants in the 1994 to 2000 Medicare Current Beneficiary Surveys who were aged 65 years or older. Measurements: All-cause mortality through 22 April 2008; new or worsening disability in performing activities of daily living (ADLs) and instrumental activities of daily living (IADLs) in 2 years. Results: 37% of the study sample were overweight (body mass index [BMI] of 25 to <30 kg/m(2)), 18% were obese (BMI >= 30 kg/m(2)), 48% died during the 14-year follow-up, and 27% had ADL and 43% had IADL disability at baseline. Among those without severe disability at baseline, 17% developed new or worsening ADL disability and 26% developed new or worsening IADL disabilor greater were the only group above the normal BMI range who had a higher risk for mortality (hazard ratio, 1.49 [95% CI, 1.20 to 1.85] in men and 1.21 [CI, 1.06 to 1.39] in women, compared with the reference group [BMI of 22.0 to 24.9 kg/m(2)]; P for BMI-sex interaction = 0.003). In contrast, both overweight and obesity were associated with new or progressive ADL and IADL disability in a dose-dependent manner, particularly for white men and women. Significant interactions were detected between BMI and sex but not between BMI and race for any outcome, although risk estimates for ADL disability seemed attenuated in African American relative to white respondents. Limitation: This was an observational study, baseline data were self-reported, and the study had limited power to detect differences between white and African American respondents. Conclusion: Among older U. S. adults, obesity was not associated with mortality, except for those with at least moderately severe obesity. However, lower levels of obesity were associated with new or worsening disability within 2 years. Efforts to prevent disability in older adults should target those who are overweight or obese.	[Wee, Christina C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Univ Massachusetts, Boston, MA 02125 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Massachusetts System; University of Massachusetts Boston	Wee, CC (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave, Boston, MA 02215 USA.	cwee@bidmc.harvard.edu	Leveille, Suzanne G/ACS-6588-2022	Leveille, Suzanne G/0000-0003-0427-1580; Mittleman, Murray/0000-0001-9788-7274	National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK071083]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK087932, R01DK071083] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Grant Support: By the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK071083).	Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; Al Snih S, 2007, ARCH INTERN MED, V167, P774, DOI 10.1001/archinte.167.8.774; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen HL, 2008, J AM GERIATR SOC, V56, P689, DOI 10.1111/j.1532-5415.2007.01624.x; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Doshi JA, 2007, HEALTH AFFAIR, V26, P1111, DOI 10.1377/hlthaff.26.4.1111; Janssen I, 2007, OBES REV, V8, P41, DOI 10.1111/j.1467-789X.2006.00248.x; Jensen GL, 2002, J AM GERIATR SOC, V50, P918, DOI 10.1046/j.1532-5415.2002.50220.x; Jensen GL, 2010, CURR OPIN CLIN NUTR, V13, P46, DOI 10.1097/MCO.0b013e32833309cf; Kuk JL, 2009, J AM GERIATR SOC, V57, P2077, DOI 10.1111/j.1532-5415.2009.02486.x; Lang IA, 2008, J AM GERIATR SOC, V56, P1474, DOI 10.1111/j.1532-5415.2008.01813.x; Lenz M, 2009, DTSCH ARZTEBL INT, V106, P641, DOI 10.3238/arztebl.2009.0641; Liou TH, 2005, NUTR REV, V63, P321, DOI [10.1111/j.1753-4887.2005.tb00110.x, 10.1301/nr.2005.oct.321.331]; Manini TM, 2010, OBESITY, V18, P1168, DOI 10.1038/oby.2009.317; McTigue K, 2006, JAMA-J AM MED ASSOC, V296, P79, DOI 10.1001/jama.296.1.79; McTigue KM, 2006, OBESITY, V14, P1485, DOI 10.1038/oby.2006.171; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Moore SC, 2009, AM J CLIN NUTR, V89, P1003, DOI 10.3945/ajcn.2009.27598; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Peeters A, 2004, OBES RES, V12, P1145, DOI 10.1038/oby.2004.143; Rothman KJ, 2008, INT J OBESITY, V32, pS56, DOI 10.1038/ijo.2008.87; Shea MK, 2010, J GERONTOL A-BIOL, V65, P519, DOI 10.1093/gerona/glp217; Stevens J, 2000, NUTR REV, V58, P346, DOI 10.1111/j.1753-4887.2000.tb01832.x; Villanueva EV, 2001, BMC PUBLIC HEALTH, V1, DOI 10.1186/1471-2458-1-11; Walter S, 2009, INT J OBESITY, V33, P1410, DOI 10.1038/ijo.2009.176; Zamboni M, 2003, AGING CLIN EXP RES, V15, P321, DOI 10.1007/BF03324517; Zamboni M, 2005, INT J OBESITY, V29, P1011, DOI 10.1038/sj.ijo.0803005	28	51	53	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10					645	+		10.7326/0003-4819-154-10-201105170-00003	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-00003			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	764HK	21576532	Green Accepted			2022-12-28	WOS:000290620300013
J	Pusey, PN				Pusey, Peter N.			Brownian Motion Goes Ballistic	SCIENCE			English	Editorial Material							VELOCITY; PARTICLES		Univ Edinburgh, Sch Phys, SUPA, Edinburgh EH9 3JZ, Midlothian, Scotland	University of Edinburgh	Pusey, PN (corresponding author), Univ Edinburgh, Sch Phys, SUPA, Edinburgh EH9 3JZ, Midlothian, Scotland.	p.n.pusey@ed.ac.uk						ALDER BJ, 1970, PHYS REV A-GEN PHYS, V1, P18, DOI 10.1103/PhysRevA.1.18; Chavez I, 2008, REV SCI INSTRUM, V79, DOI 10.1063/1.3002422; CLERCX HJH, 1992, PHYS REV A, V46, P1942, DOI 10.1103/PhysRevA.46.1942; Cunningham E, 1910, P R SOC LOND A-CONTA, V83, P357, DOI 10.1098/rspa.1910.0024; Einstein A, 1907, Z ELKTROCHEM ANGEW P, V13, P41, DOI 10.1002/bbpc.19070130602; Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806; Einstein A, 1956, INVESTIGATIONS THEOR; HINCH EJ, 1975, J FLUID MECH, V72, P499, DOI 10.1017/S0022112075003102; Huang R., 2011, NAT PHYS, DOI [10.1038/nphys1953:arxiv:1003.1980, DOI 10.1038/NPHYS1953:ARXIV:1003.1980]; Li TC, 2011, NAT PHYS, V7, P527, DOI [10.1038/nphys1952, 10.1038/NPHYS1952]; Li TC, 2010, SCIENCE, V328, P1673, DOI 10.1126/science.1189403; Lukic B, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.160601; Uhlenbeck GE, 1930, PHYS REV, V36, P0823, DOI 10.1103/PhysRev.36.823	13	60	62	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2011	332	6031					802	803		10.1126/science.1192222	http://dx.doi.org/10.1126/science.1192222			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566182				2022-12-28	WOS:000290529900035
J	Gardosi, J				Gardosi, Jason			Fetal growth standards: individual and global perspectives	LANCET			English	Editorial Material							WEIGHT; CENTILES; RISK		W Midlands Perinatal Inst, Birmingham B6 5RQ, W Midlands, England		Gardosi, J (corresponding author), W Midlands Perinatal Inst, Birmingham B6 5RQ, W Midlands, England.	jason.gardosi@pi.nhs.uk	Gardosi, Jason/GXN-1375-2022	Gardosi, Jason/0000-0002-3230-1292				Cnattingius S, 1998, NEW ENGL J MED, V338, P147, DOI 10.1056/NEJM199801153380302; Figueras F, 2007, ARCH DIS CHILD-FETAL, V92, P277, DOI 10.1136/adc.2006.108621; Figueras F, 2011, AM J OBSTET GYNECOL, V204, P288, DOI 10.1016/j.ajog.2010.08.055; Gardosi J, 2009, BJOG-INT J OBSTET GY, V116, P1356, DOI 10.1111/j.1471-0528.2009.02245.x; GARDOSI J, 1995, ULTRASOUND OBST GYN, V6, P168, DOI 10.1046/j.1469-0705.1995.06030168.x; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; Gardosi J, 2009, AM J OBSTET GYNECOL, V201; Gardosi J, 2010, CUSTOMISED ANTENATAL; McCowan LME, 2005, BJOG-INT J OBSTET GY, V112, P1026, DOI 10.1111/j.1471-0528.2005.00656.x; Merialdi M, 2005, ULTRASOUND OBST GYN, V26, P123, DOI 10.1002/uog.1954; Mikolajczyk RT, 2011, LANCET, V377, P1855, DOI 10.1016/S0140-6736(11)60364-4; Mongelli M, 1996, OBSTET GYNECOL, V88, P844, DOI 10.1016/0029-7844(96)00285-2; Mullan Z, 2011, LANCET, V377, P1291, DOI 10.1016/S0140-6736(11)60098-6; Olusanya BO, 2010, EARLY HUM DEV, V86, P439, DOI 10.1016/j.earlhumdev.2010.05.023	14	15	16	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2011	377	9780					1812	1814		10.1016/S0140-6736(11)60507-2	http://dx.doi.org/10.1016/S0140-6736(11)60507-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	774UI	21621710				2022-12-28	WOS:000291411700006
J	Mikolajczyk, RT; Zhang, J; Betran, AP; Souza, JP; Mori, R; Gulmezoglu, AM; Merialdi, M				Mikolajczyk, Rafael T.; Zhang, Jun; Betran, Ana Pilar; Souza, Joao Paulo; Mori, Rintaro; Guelmezoglu, A. Metin; Merialdi, Mario			A global reference for fetal-weight and birthweight percentiles	LANCET			English	Article							INTRAUTERINE GROWTH-RETARDATION; STANDARDS; DEFINITION; OUTCOMES; INFANTS; BORN	Background Definition of small for gestational age in various populations worldwide remains a challenge. References based on birthweight are deficient for preterm births, those derived from ultrasound estimates might not be applicable to all populations, and the individualised reference can be too complex to use in developing countries. Our aim was to create a generic reference for fetal weight and birthweight that overcame these deficiencies and could be readily adapted to local populations. Methods We used the fetal-weight reference developed by Hadlock and colleagues and the notion of proportionality proposed by Gardosi and colleagues and made the weight reference easily adjustable according to the mean birthweight at 40 weeks of gestation for any local population. For application and validation, we used data from 24 countries in Africa, Latin America, and Asia that participated in the 2004-08 WHO Global Survey on Maternal and Perinatal Health (237025 births). We compared our reference with that of Hadlock and colleagues (non-customised) and with that of Gardosi and colleagues (individualised). For every reference, the odds ratio (OR) of adverse perinatal outcomes (stillbirths, neonatal deaths, referral to higher-level or special care unit, or Apgar score lower than 7 at 5 min) for infants who were small for gestational age versus those who were not was estimated with multilevel logistic regression. Findings OR of adverse outcomes for infants small for gestational age versus those not small for gestational age was 1.59 (95% CI 1.53-1.66) for the non-customised fetal-weight reference compared with 2.87 (2.73-3.01) for our country-specific reference, and 2.84 (2.71-2.99) for the fully individualised reference. Interpretation Our generic reference for fetal-weight and birthweight percentiles can be easily adapted to local populations. It has a better ability to predict adverse perinatal outcomes than has the non-customised fetal-weight reference, and is simpler to use than the individualised reference without loss of predictive ability.	[Zhang, Jun] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, MOE, Shanghai 200092, Peoples R China; [Zhang, Jun] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai Key Lab Childrens Environm Hlth, Shanghai 200092, Peoples R China; [Mikolajczyk, Rafael T.] Bremen Inst Prevent Res & Social Med, Dept Clin Epidemiol, Bremen, Germany; [Mikolajczyk, Rafael T.] Univ Bielefeld, Sch Publ Hlth, Dept Publ Hlth Med, Bielefeld, Germany; [Zhang, Jun] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, NIH, Bethesda, MD USA; [Betran, Ana Pilar; Souza, Joao Paulo; Guelmezoglu, A. Metin; Merialdi, Mario] WHO, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland; [Mori, Rintaro] Univ Tokyo, Grad Sch Med, Dept Global Hlth Policy, Tokyo, Japan	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Leibniz Institute for Prevention Research & Epidemiology (BIPS); University of Bielefeld; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); World Health Organization; University of Tokyo	Zhang, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, MOE, Shanghai 200092, Peoples R China.	junjimzhang@gmail.com	Mikolajczyk, Rafael/ABB-5259-2021; Souza, João Paulo/G-1982-2010	Souza, João Paulo/0000-0002-2288-4244; Mori, Rintaro/0000-0001-7656-6156; Mikolajczyk, Rafael/0000-0003-1271-7204	UNDP/UNFPA/WHO/World Bank; WHO; United States Agency for International Development (USAID); Ministry of Health, Labour and Welfare of Japan; Ministry of Public Health of the People's Republic of China; Indian Council of Medical Research, India; Eunice Shriver Kennedy National Institute of Child Health and Human Development, National Institutes of Health, USA; Grants-in-Aid for Scientific Research [23406035] Funding Source: KAKEN	UNDP/UNFPA/WHO/World Bank(World Health Organization); WHO(World Health Organization); United States Agency for International Development (USAID)(United States Agency for International Development (USAID)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Public Health of the People's Republic of China; Indian Council of Medical Research, India(Indian Council of Medical Research (ICMR)); Eunice Shriver Kennedy National Institute of Child Health and Human Development, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The 2004-08 WHO Global Survey on Maternal and Perinatal Health (WHOGS) was a research project implemented by the WHO in a global network of health facilities between 2004 and 2008. The authors of this secondary analysis are grateful to all those who contributed to the project design and implementation, including researchers, study coordinators, data collectors, data clerks, and other partners such as the staff from the Ministries of Health and WHO offices. The WHOGS project was financially supported by the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development, and Research Training in Human Reproduction (HRP); WHO; United States Agency for International Development (USAID); Ministry of Health, Labour and Welfare of Japan; Ministry of Public Health of the People's Republic of China; and the Indian Council of Medical Research, India. JZ was supported by the Intramural Programme of Eunice Shriver Kennedy National Institute of Child Health and Human Development, National Institutes of Health, USA. The named authors alone are responsible for the views expressed in this manuscript, which does not necessarily represent the decisions or the stated policy of the WHO.	Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X; [Anonymous], 2004, MEDLINE DATA CHANGES; Chauhan SP, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.11.025; Clausson B, 2001, BRIT J OBSTET GYNAEC, V108, P830, DOI 10.1111/j.1471-0528.2001.00205.x; Doctor BA, 2001, AM J OBSTET GYNECOL, V185, P652, DOI 10.1067/mob.2001.116749; Figueras F, 2008, EUR J OBSTET GYN R B, V136, P20, DOI 10.1016/j.ejogrb.2006.12.015; Figueras F, 2009, FETAL DIAGN THER, V25, P297, DOI 10.1159/000235875; Gardosi J, 2007, BJOG-INT J OBSTET GY, V114, P1301, DOI 10.1111/j.1471-0528.2007.01432.x; Gardosi J, 2006, HORM RES, V65, P15, DOI 10.1159/000091501; Gardosi J, 2005, ULTRASOUND OBST GYN, V26, P112, DOI 10.1002/uog.1971; GARDOSI J, 1995, ULTRASOUND OBST GYN, V6, P73, DOI 10.1046/j.1469-0705.1995.06020073.x; Gardosi J, 2009, BJOG-INT J OBSTET GY, V116, P1356, DOI 10.1111/j.1471-0528.2009.02245.x; GARDOSI J, 1995, ULTRASOUND OBST GYN, V6, P168, DOI 10.1046/j.1469-0705.1995.06030168.x; Gardosi J, 2009, AM J OBSTET GYNECOL, V201; HADLOCK FP, 1991, RADIOLOGY, V181, P129, DOI 10.1148/radiology.181.1.1887021; Hutcheon JA, 2011, AM J EPIDEMIOL, V173, P459, DOI 10.1093/aje/kwq399; McCowan L, 2004, AUST NZ J OBSTET GYN, V44, P428, DOI 10.1111/j.1479-828X.2004.00272.x; Mongelli M, 2007, AUST NZ J OBSTET GYN, V47, P128, DOI 10.1111/j.1479-828X.2007.00698.x; Neta G, 2011, ULTRASOUND OBST GYN, V38, P62, DOI 10.1002/uog.8902; OTT WJ, 1995, AM J PERINAT, V12, P396, DOI 10.1055/s-2007-994506; Shah A, 2008, B WORLD HEALTH ORGAN, V86, P126, DOI 10.2471/BLT.06.039842; SMEDLER AC, 1992, ACTA PAEDIATR, V81, P197, DOI 10.1111/j.1651-2227.1992.tb12203.x; SUNG IK, 1993, J PEDIATR-US, V123, P618, DOI 10.1016/S0022-3476(05)80965-5; Verkauskiene R, 2008, HORM RES, V70, P309, DOI 10.1159/000157878; von Ehrenstein OS, 2009, AM J EPIDEMIOL, V170, P1388, DOI 10.1093/aje/kwp296; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624; Zhang J, 2011, AM J EPIDEMIOL, V173, P539, DOI 10.1093/aje/kwq411; Zhang J, 2010, AM J OBSTET GYNECOL, V202, P522, DOI 10.1016/j.ajog.2009.10.889; Zhang X, 2007, BJOG-INT J OBSTET GY, V114, P474, DOI 10.1111/j.1471-0528.2007.01273.x	29	321	340	0	60	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2011	377	9780					1855	1861		10.1016/S0140-6736(11)60364-4	http://dx.doi.org/10.1016/S0140-6736(11)60364-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774UI	21621717				2022-12-28	WOS:000291411700031
J	Snape, MD; Kelly, DF				Snape, Matthew D.; Kelly, Dominic F.			Fine with five? Shorter antibiotic courses for childhood meningitis	LANCET			English	Editorial Material							INFLUENZAE TYPE-B; CHILDREN		[Snape, Matthew D.] Univ Oxford, Dept Paediat, Oxford, England; Oxford Radcliffe Hosp NHS Trust, Oxford, England	University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford	Snape, MD (corresponding author), Univ Oxford, Dept Paediat, Oxford, England.	matthew.snape@paediatrics.ox.ac.uk		Kelly, Dominic/0000-0002-6063-8896; Snape, Matthew/0000-0003-0531-5426				Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Levine OS, 2010, CURR OPIN INFECT DIS, V23, P236, DOI 10.1097/QCO.0b013e328338c135; MOLYNEUX E, 2011, LANCET, DOI DOI 10.1016/50140-6736(11)60580-1; Morpeth SC, 2009, CLIN INFECT DIS, V49, P606, DOI 10.1086/603553; Ojo LR, 2010, VACCINE, V28, P7117, DOI 10.1016/j.vaccine.2010.07.074; Price EH, 2000, J ANTIMICROB CHEMOTH, V46, P653, DOI 10.1093/jac/46.5.653; Visintin Cristina, 2010, BMJ, V340, pc3209, DOI 10.1136/bmj.c3209	7	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2011	377	9780					1809	1810		10.1016/S0140-6736(11)60762-9	http://dx.doi.org/10.1016/S0140-6736(11)60762-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774UI	21620468				2022-12-28	WOS:000291411700004
J	Hibbs, RE; Gouaux, E				Hibbs, Ryan E.; Gouaux, Eric			Principles of activation and permeation in an anion-selective Cys-loop receptor	NATURE			English	Article							X-RAY-STRUCTURE; NICOTINIC ACETYLCHOLINE-RECEPTOR; GATED CHLORIDE CHANNEL; NEUROMUSCULAR-JUNCTION; CRYSTAL-STRUCTURE; BINDING PROTEIN; LIGAND-BINDING; ION CHANNELS; SUBUNIT; IVERMECTIN	Fast inhibitory neurotransmission is essential for nervous system function and is mediated by binding of inhibitory neurotransmitters to receptors of the Cys-loop family embedded in the membranes of neurons. Neurotransmitter binding triggers a conformational change in the receptor, opening an intrinsic chloride channel and thereby dampening neuronal excitability. Here we present the first three-dimensional structure, to our knowledge, of an inhibitory anion-selective Cys-loop receptor, the homopentameric Caenorhabditis elegans glutamate-gated chloride channel alpha (GluCl), at 3.3 angstrom resolution. The X-ray structure of the GluCl-Fab complex was determined with the allosteric agonist ivermectin and in additional structures with the endogenous neurotransmitter L-glutamate and the open-channel blocker picrotoxin. Ivermectin, used to treat river blindness, binds in the transmembrane domain of the receptor and stabilizes an open-pore conformation. Glutamate binds in the classical agonist site at subunit interfaces, and picrotoxin directly occludes the pore near its cytosolic base. GluCl provides a framework for understanding mechanisms of fast inhibitory neurotransmission and allosteric modulation of Cys-loop receptors.	[Hibbs, Ryan E.; Gouaux, Eric] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; [Gouaux, Eric] Oregon Hlth & Sci Univ, Howard Hughes Med Inst, Portland, OR 97239 USA	Oregon Health & Science University; Howard Hughes Medical Institute; Oregon Health & Science University	Gouaux, E (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	gouauxe@ohsu.edu	Gouaux, Eric/Y-4370-2019	Gouaux, Eric/0000-0002-8549-2360	NIH [F32NS061404]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS061800, F32NS061404] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful to H. Lester for providing the initial GluCl construct, to D. Cawley for monoclonal antibody production, to J. Michel for Fab fragment cloning and sequencing, to C. Alexander and D. C. Dawson for providing Xenopus oocytes, to M. Mayer for advice and equipment related to oocyte experiments, and to L. Vaskalis for help with illustrations. We thank the staff at the Advanced Photon Source beamline 24-ID-C for assistance with X-ray data collection. We are particularly appreciative of discussions with E.G. laboratory members and E. McCleskey. This work was supported by an individual NIH National Research Service Award (F32NS061404) to R.E.H. E.G. is an investigator with the Howard Hughes Medical Institute.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Adelsberger H, 2000, EUR J PHARMACOL, V394, P163, DOI 10.1016/S0014-2999(00)00164-3; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; Alexander C, 2009, BIOCHEMISTRY-US, V48, P10078, DOI 10.1021/bi901314c; ARENA JP, 1991, MOL PHARMACOL, V40, P368; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; AZIZ MA, 1982, LANCET, V2, P171; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Barrantes FJ, 2004, BRAIN RES REV, V47, P71, DOI 10.1016/j.brainresrev.2004.06.008; Bocquet N, 2009, NATURE, V457, P111, DOI 10.1038/nature07462; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CAMPBELL WC, 1983, SCIENCE, V221, P823, DOI 10.1126/science.6308762; CamposCaro A, 1996, P NATL ACAD SCI USA, V93, P6118, DOI 10.1073/pnas.93.12.6118; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; COOMBS JS, 1955, J PHYSIOL-LONDON, V130, P326, DOI 10.1113/jphysiol.1955.sp005412; Corringer PJ, 2010, J PHYSIOL-LONDON, V588, P565, DOI 10.1113/jphysiol.2009.183160; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Cowtan K, 2006, ACTA CRYSTALLOGR D, V62, P1002, DOI 10.1107/S0907444906022116; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; DAMLE VN, 1980, BIOCHEMISTRY-US, V19, P3924, DOI 10.1021/bi00558a006; DeLano W.L, PYMOL MOL GRAPHICS S; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; Etter A, 1996, J BIOL CHEM, V271, P16035, DOI 10.1074/jbc.271.27.16035; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; FATIMASHAD K, 1993, P ROY SOC B-BIOL SCI, V253, P69, DOI 10.1098/rspb.1993.0083; Garcia PS, 2010, CURR NEUROPHARMACOL, V8, P2, DOI 10.2174/157015910790909502; Gensler S, 2001, EUR J BIOCHEM, V268, P2209, DOI 10.1046/j.1432-1327.2001.02093.x; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Harlow E., 1988, ANTIBODIES LAB MANUA; Hilf RJC, 2008, NATURE, V452, P375, DOI 10.1038/nature06717; Hilf RJC, 2009, CURR OPIN STRUC BIOL, V19, P418, DOI 10.1016/j.sbi.2009.07.006; Hilf RJC, 2009, NATURE, V457, P115, DOI 10.1038/nature07461; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; KAO PN, 1984, J BIOL CHEM, V259, P1662; Kawate T, 2006, STRUCTURE, V14, P673, DOI 10.1016/j.str.2006.01.013; Keramidas A, 2004, PROG BIOPHYS MOL BIO, V86, P161, DOI 10.1016/j.pbiomolbio.2003.09.002; Krause RM, 1998, MOL PHARMACOL, V53, P283, DOI 10.1124/mol.53.2.283; KUSAMA T, 1994, NEUROREPORT, V5, P1209, DOI 10.1097/00001756-199406020-00012; Lamla T, 2004, PROTEIN EXPRES PURIF, V33, P39, DOI 10.1016/j.pep.2003.08.014; Lee DJS, 2003, NEUROSCI LETT, V351, P196, DOI 10.1016/j.neulet.2003.08.005; Lee WY, 2005, NATURE, V438, P243, DOI 10.1038/nature04156; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Li P, 2002, FEBS LETT, V528, P77, DOI 10.1016/S0014-5793(02)03245-3; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LYNCH JW, 1995, J BIOL CHEM, V270, P13799, DOI 10.1074/jbc.270.23.13799; Mancinelli R, 2007, J PHYS CHEM B, V111, P13570, DOI 10.1021/jp075913v; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Miller PS, 2010, TRENDS PHARMACOL SCI, V31, P161, DOI 10.1016/j.tips.2009.12.005; Mukhtasimova N, 2005, J GEN PHYSIOL, V126, P23, DOI 10.1085/jgp.200509283; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pei JM, 2008, NUCLEIC ACIDS RES, V36, P2295, DOI 10.1093/nar/gkn072; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; RAJENDRA S, 1995, NEURON, V14, P169, DOI 10.1016/0896-6273(95)90251-1; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; Sauter NK, 2004, J APPL CRYSTALLOGR, V37, P399, DOI 10.1107/S0021889804005874; Shan Q, 2001, J BIOL CHEM, V276, P12556, DOI 10.1074/jbc.M011264200; Sherrington C, 1906, INTEGRATIVE ACTION N; Silberberg SD, 2007, NEURON, V54, P263, DOI 10.1016/j.neuron.2007.03.020; Slimko EM, 2003, J NEUROSCI METH, V124, P75, DOI 10.1016/S0165-0270(02)00362-X; SMART OS, 1993, BIOPHYS J, V65, P2455, DOI 10.1016/S0006-3495(93)81293-1; SPRINGER JP, 1981, J AM CHEM SOC, V103, P4221, DOI 10.1021/ja00404a041; Sunesen M, 2006, J BIOL CHEM, V281, P14875, DOI 10.1074/jbc.M511657200; TAKEUCHI A, 1969, J PHYSIOL-LONDON, V205, P377, DOI 10.1113/jphysiol.1969.sp008972; Thompson AJ, 2010, Q REV BIOPHYS, V43, P449, DOI 10.1017/S0033583510000168; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueno S, 1999, BRIT J PHARMACOL, V127, P377, DOI 10.1038/sj.bjp.0702563; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wada A, 1976, Adv Biophys, P1; Wilson GG, 2000, J GEN PHYSIOL, V115, P93, DOI 10.1085/jgp.115.2.93; Young GT, 2008, P NATL ACAD SCI USA, V105, P14686, DOI 10.1073/pnas.0804372105; Zhang Z, 2006, J APPL CRYSTALLOGR, V39, P112, DOI 10.1107/S0021889805040677	78	768	780	7	204	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2011	474	7349					54	U80		10.1038/nature10139	http://dx.doi.org/10.1038/nature10139			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	771KV	21572436	Green Accepted			2022-12-28	WOS:000291156700035
J	Malayeri, AA; Siegelman, SS				Malayeri, Ashkan A.; Siegelman, Stanley S.			Amyand's Hernia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Malayeri, Ashkan A.; Siegelman, Stanley S.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Malayeri, AA (corresponding author), Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.	sssiegel@jhmi.edu							0	8	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2147	2147		10.1056/NEJMicm1008452	http://dx.doi.org/10.1056/NEJMicm1008452			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AB	21631327				2022-12-28	WOS:000291200700013
J	Fielden, J; Mountford, J				Fielden, Jonathan; Mountford, James			NHS REFORMS A chance to optimise "value" in the NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Fielden, Jonathan] Royal Berkshire NHS Fdn Trust, Reading, Berks, England; [Mountford, James] UCL Partners, London W1T 7NF, England	Royal Berkshire Hospital; University of London; University College London	Fielden, J (corresponding author), Royal Berkshire NHS Fdn Trust, Reading, Berks, England.	jonathan.fielden@royalberkshire.nhs.uk						[Anonymous], 2011, INDEPENDENT     0414; Gaynor Martin Rodrigo Moreno-Serra, 2010, 16164 NAT BUR EC RES; Grint K, 2008, CLIN LEADER, V1, P54; Health Select Committee, 2011, 5 HLTH SEL COMM; James BC, 2011, HEALTH AFFAIR, V30, P1185, DOI 10.1377/hlthaff.2011.0358; Porter ME, 2010, NEW ENGL J MED, V363, P2477, DOI 10.1056/NEJMp1011024; 2010, TRANSPARENCY OUTCOME; 2011, BMJ, V342, pD1804	8	0	0	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 1	2011	342								d3244	10.1136/bmj.d3244	http://dx.doi.org/10.1136/bmj.d3244			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	774MK	21632659				2022-12-28	WOS:000291390500006
J	McCannon, J; Berwick, DM				McCannon, Joseph; Berwick, Donald M.			A New Frontier in Patient Safety	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Berwick, Donald M.] US Dept HHS, Ctr Medicare Serv, Washington, DC 20201 USA; US Dept HHS, Ctr Medicaid Serv, Washington, DC 20201 USA	Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services	Berwick, DM (corresponding author), US Dept HHS, Ctr Medicare Serv, 200 Independence Ave SW,Ste 314, Washington, DC 20201 USA.	donald.berwick@cms.hhs.gov						[Anonymous], 2010, OEI06Y0900090; Berenholtz SM, 2011, INFECT CONT HOSP EP, V32, P305, DOI 10.1086/658938; Haynes Alex B, 2009, N Engl J Med, V360, P491, DOI 10.1056/NEJMsa0810119; Interagency Working Group on Health Care Quality for the National Quality Strategy, NAT QUAL STRAT; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; Pronovost PJ, 2011, HEALTH AFFAIR, V30, P628, DOI 10.1377/hlthaff.2011.0047; Srinivasan A., 2011, Morbidity and Mortality Weekly Report, V60, P243	8	32	32	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2221	2222		10.1001/jama.2011.742	http://dx.doi.org/10.1001/jama.2011.742			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21632485				2022-12-28	WOS:000291106300025
J	Cooper, KL; Hu, JKH; ten Berge, D; Fernandez-Teran, M; Ros, MA; Tabin, CJ				Cooper, Kimberly L.; Hu, Jimmy Kuang-Hsien; ten Berge, Derk; Fernandez-Teran, Marian; Ros, Maria A.; Tabin, Clifford J.			Initiation of Proximal-Distal Patterning in the Vertebrate Limb by Signals and Growth	SCIENCE			English	Article							TISSUE INTERACTIONS; GENE-EXPRESSION; CELL FATE; WING-BUD; CHICK; SPECIFICATION; OUTGROWTH; AXIS; WNT	Two broad classes of models have been proposed to explain the patterning of the proximal-distal axis of the vertebrate limb (from the shoulder to the digit tips). Differentiating between them, we demonstrate that early limb mesenchyme in the chick is initially maintained in a state capable of generating all limb segments through exposure to a combination of proximal and distal signals. As the limb bud grows, the proximal limb is established through continued exposure to flank-derived signal(s), whereas the developmental program determining the medial and distal segments is initiated in domains that grow beyond proximal influence. In addition, the system we have developed, combining in vitro and in vivo culture, opens the door to a new level of analysis of patterning mechanisms in the limb.	[Cooper, Kimberly L.; Hu, Jimmy Kuang-Hsien; Tabin, Clifford J.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [ten Berge, Derk] Erasmus MC, Erasmus MC Stem Cell Inst, Dept Cell Biol, NL-3000 CA Rotterdam, Netherlands; [Fernandez-Teran, Marian; Ros, Maria A.] Univ Cantabria, Inst Biomed & Biotecnol CSIC UC IDICAN, E-39011 Santander, Spain	Harvard University; Harvard Medical School; Erasmus University Rotterdam; Erasmus MC; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC)	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	tabin@genetics.med.harvard.edu	Berge, David/P-2179-2017; Ros, Maria A./K-8160-2014; Berge, Derk ten/C-1967-2012; Berge, Derk ten/ABF-2591-2020	Berge, David/0000-0002-2918-1824; Ros, Maria A./0000-0002-1224-7671; Berge, Derk ten/0000-0002-5863-0860; Fernandez-Teran, M. Angeles/0000-0002-9019-1837; Hu, Jimmy/0000-0003-1035-0779	NIH [R37HD032443]; Spanish Ministry of Science and Innovation [BFU2008-00397]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD032443] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank R. Nusse for generously providing Wnt3a protein, G. Martin for helpful discussions, M. Torres for sharing data before publication, and J. Gros for assistance with confocal live imaging. This work was supported by an NIH grant, R37HD032443, to C. T. and by BFU2008-00397, from the Spanish Ministry of Science and Innovation to M.R.	AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; Cunningham TJ, 2011, DEV DYNAM, V240, P1142, DOI 10.1002/dvdy.22583; Dudley AT, 2002, NATURE, V418, P539, DOI 10.1038/nature00945; Fernandez-Teran M, 1999, CELL TISSUE RES, V296, P121, DOI 10.1007/s004410051273; Galloway JL, 2009, NATURE, V460, P400, DOI 10.1038/nature08117; Hamburger H, 1951, J MORPHOL, V88, P49; Herrmann H, 1967, Natl Cancer Inst Monogr, V26, P303; KRABBENHOFT KM, 1989, DEV BIOL, V131, P373, DOI 10.1016/S0012-1606(89)80011-9; LEWIS JH, 1975, J EMBRYOL EXP MORPH, V33, P419; Mariani FV, 2008, NATURE, V453, P401, DOI 10.1038/nature06876; Mercader N, 2000, DEVELOPMENT, V127, P3961; Mic FA, 2003, P NATL ACAD SCI USA, V100, P7135, DOI 10.1073/pnas.1231422100; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Pascoal S, 2007, J MOL BIOL, V368, P303, DOI 10.1016/j.jmb.2007.01.089; RAWLES ME, 1963, J EMBRYOL EXP MORPH, V11, P765; Ros MA, 2000, METH MOL B, V137, P245; Rosello-Diez A, 2011, SCIENCE, V332, P1086, DOI 10.1126/science.1199489; Sato K, 2007, DEVELOPMENT, V134, P1397, DOI 10.1242/dev.02822; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; Tabin C, 2007, GENE DEV, V21, P1433, DOI 10.1101/gad.1547407; ten Berge D, 2008, DEVELOPMENT, V135, P3247, DOI 10.1242/dev.023176; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Zhao XL, 2009, CURR BIOL, V19, P1050, DOI 10.1016/j.cub.2009.04.059; ZWILLING E, 1964, DEV BIOL, V9, P20, DOI 10.1016/0012-1606(64)90012-0	25	111	113	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2011	332	6033					1083	1086		10.1126/science.1199499	http://dx.doi.org/10.1126/science.1199499			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769FN	21617075	Green Accepted, Green Submitted			2022-12-28	WOS:000290996700044
J	Banerji, JS; Devasia, A				Banerji, John Samuel; Devasia, Antony			Calcified Vasa Deferentia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Banerji, John Samuel; Devasia, Antony] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India	Christian Medical College & Hospital (CMCH) Vellore	Banerji, JS (corresponding author), Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.	johnsbanerji2002@yahoo.co.in	Banerji, John/T-5505-2019						0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					2043	2043		10.1056/NEJMicm1009285	http://dx.doi.org/10.1056/NEJMicm1009285			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QR	21612473				2022-12-28	WOS:000290952000009
J	Brandt, P; Funk, A; Hormann, V; Dengler, M; Greatbatch, RJ; Toole, JM				Brandt, Peter; Funk, Andreas; Hormann, Verena; Dengler, Marcus; Greatbatch, Richard J.; Toole, John M.			Interannual atmospheric variability forced by the deep equatorial Atlantic Ocean	NATURE			English	Article							TROPICAL ATLANTIC; CLIMATE VARIABILITY; JETS; PACIFIC; FLUCTUATIONS; CURRENTS; SECTOR; WAVES; NINO	Climate variability in the tropical Atlantic Ocean is determined by large-scale ocean-atmosphere interactions, which particularly affect deep atmospheric convection over the ocean and surrounding continents(1). Apart from influences from the Pacific El Nino/Southern Oscillation(2) and the North Atlantic Oscillation(3), the tropical Atlantic variability is thought to be dominated by two distinct ocean-atmosphere coupled modes of variability that are characterized by meridional(4,5) and zonal(6,7) sea-surface-temperature gradients and are mainly active on decadal and interannual timescales, respectively(8,9). Here we report evidence that the intrinsic ocean dynamics of the deep equatorial Atlantic can also affect sea surface temperature, wind and rainfall in the tropical Atlantic region and constitutes a 4.5-yr climate cycle. Specifically, vertically alternating deep zonal jets of short vertical wavelength with a period of about 4.5 yr and amplitudes of more than 10 cm s(-1) are observed, in the deep Atlantic, to propagate their energy upwards, towards the surface(10,11). They are linked, at the sea surface, to equatorial zonal current anomalies and eastern Atlantic temperature anomalies that have amplitudes of about 6 cm s(-1) and 0.4 degrees C, respectively, and are associated with distinct wind and rainfall patterns. Although deep jets are also observed in the Pacific(12) and Indian(13) oceans, only the Atlantic deep jets seem to oscillate on interannual timescales. Our knowledge of the persistence and regularity of these jets is limited by the availability of high-quality data. Despite this caveat, the oscillatory behaviour can still be used to improve predictions of sea surface temperature in the tropical Atlantic. Deep-jet generation and upward energy transmission through the Equatorial Undercurrent warrant further theoretical study.	[Brandt, Peter; Funk, Andreas; Hormann, Verena; Dengler, Marcus; Greatbatch, Richard J.] Univ Kiel, Leibniz Inst Meereswissensch, IFM GEOMAR, D-24105 Kiel, Germany; [Toole, John M.] Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; University of Kiel; Woods Hole Oceanographic Institution	Brandt, P (corresponding author), Univ Kiel, Leibniz Inst Meereswissensch, IFM GEOMAR, Dusternbrooker Weg 20, D-24105 Kiel, Germany.	pbrandt@ifm-geomar.de	Dengler, Marcus/A-7327-2014; Brandt, Peter/C-8254-2013; Hormann, Verena/ABB-7179-2020	Dengler, Marcus/0000-0001-5993-9088; Brandt, Peter/0000-0002-9235-955X; Hormann, Verena/0000-0001-5470-5602; Toole, John/0000-0003-2905-0637	German Federal Ministry of Education and Research; German Science Foundation [Sonderforschungsbereich 754]; Woods Hole Oceanographic Institution's Columbus O'Donnell Iselin Chair for Excellence in Oceanography; Directorate For Geosciences [0850175] Funding Source: National Science Foundation	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Science Foundation(German Research Foundation (DFG)); Woods Hole Oceanographic Institution's Columbus O'Donnell Iselin Chair for Excellence in Oceanography; Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	This study was supported by the German Federal Ministry of Education and Research as part of the co-operative project 'North Atlantic' and by the German Science Foundation as part of the Sonderforschungsbereich 754 'Climate-Biogeochemistry Interactions in the Tropical Ocean'. The contribution of J.M.T. was facilitated by support from the Woods Hole Oceanographic Institution's Columbus O'Donnell Iselin Chair for Excellence in Oceanography. We thank J. Fischer for mooring planning and field-work participation, F. Ascani for discussion and S.-H. Didwischus for data processing. This study uses PIRATA velocity and temperature data provided through the TAO project office, Argo float drift data provided by APDRC/IPRC19, rainfall data from the Global Precipitation Climatology Project, Met Office Hadley Centre and microwave optimally interpolated SST data, NCEP/NCAR reanalysis wind data, and AVISO sea level anomaly data (Supplementary Table 1).	Brown GL, 2007, ATMOS OCEAN, V45, P47, DOI 10.3137/ao.v450104; Bunge L, 2008, J PHYS OCEANOGR, V38, P1794, DOI 10.1175/2008JPO3781.1; CANE MA, 1981, J PHYS OCEANOGR, V11, P1578, DOI 10.1175/1520-0485(1981)011<1578:ANOLFE>2.0.CO;2; CARTON JA, 1994, J PHYS OCEANOGR, V24, P888, DOI 10.1175/1520-0485(1994)024<0888:WEITTA>2.0.CO;2; Carton JA, 1996, J PHYS OCEANOGR, V26, P1165, DOI 10.1175/1520-0485(1996)026<1165:DAISVI>2.0.CO;2; Chang P, 2006, J CLIMATE, V19, P5122, DOI 10.1175/JCLI3903.1; Chang P, 1997, NATURE, V385, P516, DOI 10.1038/385516a0; Chang P, 2006, NATURE, V443, P324, DOI 10.1038/nature05053; Czaja A, 2002, J CLIMATE, V15, P3280, DOI 10.1175/1520-0442(2002)015<3280:ADSOTR>2.0.CO;2; d'Orgeville M, 2007, J MAR RES, V65, P1, DOI 10.1357/002224007780388720; Ding H, 2010, J GEOPHYS RES-OCEANS, V115, DOI 10.1029/2010JC006304; Eden C, 2008, J GEOPHYS RES-OCEANS, V113, DOI 10.1029/2007JC004298; Firing E, 1998, J GEOPHYS RES-OCEANS, V103, P21413, DOI 10.1029/98JC01944; Giannini A, 2003, SCIENCE, V302, P1027, DOI 10.1126/science.1089357; Gouretski V, 2004, 35 BUND SEESCH HYDR; Hua BL, 2008, J FLUID MECH, V610, P311, DOI 10.1017/S0022112008002656; Jochum M, 2004, GEOPHYS MONOGR SER, V147, P181; Johnson GC, 2003, J PHYS OCEANOGR, V33, P600, DOI 10.1175/1520-0485(2003)033<0600:SOTAOE>2.0.CO;2; Johnson GC, 2002, J PHYS OCEANOGR, V32, P3396, DOI 10.1175/1520-0485(2002)032<3396:TASSOT>2.0.CO;2; Keenlyside NS, 2007, J CLIMATE, V20, P131, DOI 10.1175/JCLI3992.1; Kushnir Y, 2006, J CLIMATE, V19, P5949, DOI 10.1175/JCLI3943.1; Lebedev K.V., 2007, YOMAHA 07 VELOCITY D, V4; LUYTEN JR, 1976, DEEP-SEA RES, V23, P999, DOI 10.1016/0011-7471(76)90830-5; MCPHADEN MJ, 1986, J PHYS OCEANOGR, V16, P1499, DOI 10.1175/1520-0485(1986)016<1499:TIOEKW>2.0.CO;2; Okumura Y, 2006, J CLIMATE, V19, P5859, DOI 10.1175/JCLI3928.1; PHILANDER SGH, 1981, J GEOPHYS RES-OCEANS, V86, P1903, DOI 10.1029/JC086iC03p01903; PONTE RM, 1990, J PHYS OCEANOGR, V20, P44, DOI 10.1175/1520-0485(1990)020<0044:DVMITW>2.0.CO;2; Ruiz-Barradas A, 2000, J CLIMATE, V13, P3285, DOI 10.1175/1520-0442(2000)013<3285:SOITDC>2.0.CO;2; Wang FM, 2008, J CLIMATE, V21, P2421, DOI 10.1175/2007JCLI2035.1; ZEBIAK SE, 1993, J CLIMATE, V6, P1567, DOI 10.1175/1520-0442(1993)006<1567:AIITEA>2.0.CO;2	30	56	57	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2011	473	7348					497	U237		10.1038/nature10013	http://dx.doi.org/10.1038/nature10013			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21593764	Green Submitted			2022-12-28	WOS:000290951300037
J	Leask, J				Leask, Julie			Target the fence-sitters	NATURE			English	Editorial Material							VACCINATION		Univ Sydney, Sch Publ Hlth, Discipline Paediat & Child Hlth, Natl Ctr Immunisat Res & Surveillance, Sydney, NSW 2006, Australia	University of Sydney	Leask, J (corresponding author), Univ Sydney, Sch Publ Hlth, Discipline Paediat & Child Hlth, Natl Ctr Immunisat Res & Surveillance, Sydney, NSW 2006, Australia.	JulieL3@chw.edu.au	Leask, Julie/ABE-2077-2020	Leask, Julie/0000-0001-5095-1443				[Anonymous], 2010, HLTH PROTECTION REPO, V4; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; Hull BP, 2010, COMMUN DIS INTELL, V34, P241; Leach M., 2007, IDS WORKING PAPER, V276, P51; National Committee for Quality Assurance, 2010, STAT HLTH CAR QUAL; Nicoll A, 1998, BMJ-BRIT MED J, V316, P715, DOI 10.1136/bmj.316.7133.715; Petrovic M, 2001, BRIT MED J, V322, P82, DOI 10.1136/bmj.322.7278.82; *ROYAL COLL GEN PR, 1981, BMJ-BRIT MED J, V282, P23; Stefanoff P, 2010, VACCINE, V28, P5731, DOI 10.1016/j.vaccine.2010.06.009; Wooten K. G., 2010, Morbidity and Mortality Weekly Report, V59, P1171	10	120	122	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2011	473	7348					443	445		10.1038/473443a	http://dx.doi.org/10.1038/473443a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	768QM	21614055	Green Submitted, Bronze			2022-12-28	WOS:000290951300014
J	Vijaykrishna, D; Smith, GJD; Pybus, OG; Zhu, HC; Bhatt, S; Poon, LLM; Riley, S; Bahl, J; Ma, SK; Cheung, CL; Perera, RAPM; Chen, HL; Shortridge, KF; Webby, RJ; Webster, RG; Guan, Y; Peiris, JSM				Vijaykrishna, Dhanasekaran; Smith, Gavin J. D.; Pybus, Oliver G.; Zhu, Huachen; Bhatt, Samir; Poon, Leo L. M.; Riley, Steven; Bahl, Justin; Ma, Siu K.; Cheung, Chung L.; Perera, Ranawaka A. P. M.; Chen, Honglin; Shortridge, Kennedy F.; Webby, Richard J.; Webster, Robert G.; Guan, Yi; Peiris, J. S. Malik			Long-term evolution and transmission dynamics of swine influenza A virus	NATURE			English	Article							PIGS; REASSORTMENT; EMERGENCE; ORIGINS; CHINA; H9N2	Swine influenza A viruses (SwIV) cause significant economic losses in animal husbandry as well as instances of human disease(1) and occasionally give rise to human pandemics(2), including that caused by the H1N1/2009 virus(3,4). The lack of systematic and longitudinal influenza surveillance in pigs has hampered attempts to reconstruct the origins of this pandemic(4). Most existing swine data were derived from opportunistic samples collected from diseased pigs in disparate geographical regions, not from prospective studies in defined locations, hence the evolutionary and transmission dynamics of SwIV are poorly understood. Here we quantify the epidemiological, genetic and antigenic dynamics of SwIV in Hong Kong using a data set of more than 650 SwIV isolates and more than 800 swine sera from 12 years of systematic surveillance in this region, supplemented with data stretching back 34 years. Intercontinental virus movement has led to reassortment and lineage replacement, creating an antigenically and genetically diverse virus population whose dynamics are quantitatively different from those previously observed for human influenza viruses. Our findings indicate that increased antigenic drift is associated with reassortment events and offer insights into the emergence of influenza viruses with epidemic potential in swine and humans.	[Vijaykrishna, Dhanasekaran; Smith, Gavin J. D.; Zhu, Huachen; Poon, Leo L. M.; Bahl, Justin; Ma, Siu K.; Cheung, Chung L.; Perera, Ranawaka A. P. M.; Chen, Honglin; Shortridge, Kennedy F.; Webster, Robert G.; Guan, Yi; Peiris, J. S. Malik] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China; [Vijaykrishna, Dhanasekaran; Smith, Gavin J. D.; Zhu, Huachen; Poon, Leo L. M.; Bahl, Justin; Ma, Siu K.; Cheung, Chung L.; Perera, Ranawaka A. P. M.; Chen, Honglin; Shortridge, Kennedy F.; Webster, Robert G.; Guan, Yi; Peiris, J. S. Malik] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China; [Vijaykrishna, Dhanasekaran; Smith, Gavin J. D.; Zhu, Huachen; Bahl, Justin; Chen, Honglin; Shortridge, Kennedy F.; Guan, Yi] Shantou Univ, Coll Med, Int Inst Infect & Immun, Shantou, Guangdong, Peoples R China; [Vijaykrishna, Dhanasekaran; Smith, Gavin J. D.; Bahl, Justin] Duke NUS Grad Med Sch, Program Emerging Infect Dis, Lab Virus Evolut, Singapore 169857, Singapore; [Pybus, Oliver G.; Bhatt, Samir] Univ Oxford, Dept Zool, Oxford OX1 3PS, England; [Riley, Steven] Univ Hong Kong, Li Ka Shing Fac Med, Dept Community Med, Pokfulam, Hong Kong, Peoples R China; [Riley, Steven] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Pokfulam, Hong Kong, Peoples R China; [Webby, Richard J.; Webster, Robert G.] St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, Memphis, TN 38015 USA; [Peiris, J. S. Malik] Univ Hong Kong, HKU Pasteur Res Ctr, Pokfulam, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Shantou University; National University of Singapore; University of Oxford; University of Hong Kong; University of Hong Kong; St Jude Children's Research Hospital; University of Hong Kong	Guan, Y (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	yguan@hkucc.hku.hk; malik@hkucc.hku.hk	Zhu, Huachen/A-8252-2017; Webby, Richard J/N-5657-2018; Perera, Dr. Ranawaka A.P.M Perera/N-8263-2015; Poon, Leo Lit Man/C-4382-2009; Cheung, Yiu Man/T-2708-2019; Poon, Leo/AAP-6887-2020; Dhanasekaran, Vijaykrishna/D-1011-2010; Chen, Honglin/C-4224-2009; Vijaykrishna, Dhanasekaran/AAG-2077-2020; Bahl, Justin/A-4728-2011; Pybus, Oliver G/B-2640-2012; Bhatt, Samir/ABE-7938-2020	Zhu, Huachen/0000-0003-2711-0501; Perera, Dr. Ranawaka A.P.M Perera/0000-0003-3936-1535; Poon, Leo Lit Man/0000-0002-9101-7953; Dhanasekaran, Vijaykrishna/0000-0003-3293-6279; Chen, Honglin/0000-0001-5108-8338; Vijaykrishna, Dhanasekaran/0000-0003-3293-6279; Bahl, Justin/0000-0001-7572-4300; Pybus, Oliver G/0000-0002-8797-2667; Smith, Gavin JD/0000-0001-5031-468X; Bhatt, Samir/0000-0002-0891-4611; Riley, Steven/0000-0001-7904-4804; Guan, Yi/0000-0001-6057-9243	National Institute of Allergy and Infectious Diseases (NIAID) [HHSN26600700005C]; University Grants Commission of the Hong Kong SAR Government [AoE/M-12/06]; Royal Society of London; UK COSI; Agency for Science, Technology and Research; Ministry of Health, Singapore; BBSRC [BB/H014306/1] Funding Source: UKRI; MRC [MC_G0902096] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/H014306/1] Funding Source: researchfish; Medical Research Council [G0600719B, MC_G0902096] Funding Source: researchfish	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); University Grants Commission of the Hong Kong SAR Government; Royal Society of London(Royal Society of London); UK COSI; Agency for Science, Technology and Research(Agency for Science Technology & Research (A*STAR)); Ministry of Health, Singapore(Ministry of Health-Singapore); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This research was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) contract HHSN26600700005C and the Area of Excellence Scheme of the University Grants Commission (grant AoE/M-12/06) of the Hong Kong SAR Government. We acknowledge the Food and Environmental Hygiene Department of Hong Kong for facilitating the study. We acknowledge support from The Royal Society of London (O.G.P.), UK COSI (S.B.), NIAID (G.J.D.S.), the Agency for Science, Technology and Research and the Ministry of Health, Singapore (D.V., G.J.D.S and J.B.). We thank C. Y. H. Leung for producing some of the ferret antisera used in this study.	Clements ACA, 2002, PREV VET MED, V56, P19, DOI 10.1016/S0167-5877(02)00121-6; Cong YL, 2007, J GEN VIROL, V88, P2035, DOI 10.1099/vir.0.82783-0; Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/mss075; Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088; Dunham EJ, 2009, J VIROL, V83, P5485, DOI 10.1128/JVI.02565-08; Finkelstein DB, 2007, J VIROL, V81, P10292, DOI 10.1128/JVI.00921-07; Garten RJ, 2009, SCIENCE, V325, P197, DOI 10.1126/science.1176225; Guan Y, 1996, J VIROL, V70, P8041, DOI 10.1128/JVI.70.11.8041-8046.1996; [李海燕 Li Haiyan], 2004, [中国预防兽医学报, Chinase Journal of Preventive Veterinary Medicine], V26, P1; Loeffen WLA, 2003, VET IMMUNOL IMMUNOP, V92, P23, DOI 10.1016/S0165-2427(03)00019-9; Lorusso A, 2011, J GEN VIROL, V92, P919, DOI 10.1099/vir.0.027557-0; Moreno A, 2011, VET MICROBIOL, V149, P472, DOI 10.1016/j.vetmic.2010.12.011; Nidom CA, 2010, EMERG INFECT DIS, V16, P1515, DOI 10.3201/eid1610.100508; Obenauer JC, 2006, SCIENCE, V311, P1576, DOI 10.1126/science.1121586; Peiris JSM, 2001, J VIROL, V75, P9679, DOI 10.1128/JVI.75.20.9679-9686.2001; PENSAERT M, 1981, B WORLD HEALTH ORGAN, V59, P75; Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105; Poon LLM, 2010, CLIN CHEM, V56, P1340, DOI 10.1373/clinchem.2010.149179; Rambaut A, 2008, NATURE, V453, P615, DOI 10.1038/nature06945; REED L. J., 1938, AMER JOUR HYG, V27, P493; Russell CA, 2008, SCIENCE, V320, P340, DOI 10.1126/science.1154137; Scholtissek C., 1998, TXB INFLUENZA, P137; Shinde V, 2009, NEW ENGL J MED, V360, P2616, DOI 10.1056/NEJMoa0903812; Smith GJD, 2009, P NATL ACAD SCI USA, V106, P11709, DOI 10.1073/pnas.0904991106; Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Vijaykrishna D, 2010, SCIENCE, V328, P1529, DOI 10.1126/science.1189132; Wang RuoJun, 2006, Banff Pork Seminar Proceedings 2006. The Pork Wars - Internal & External Threats, 17-20 January, 2006, Banff, Alberta, Canada, P33; Webby RJ, 2000, J VIROL, V74, P8243, DOI 10.1128/JVI.74.18.8243-8251.2000; Wolfe ND, 2007, NATURE, V447, P279, DOI 10.1038/nature05775; Yu H, 2008, J CLIN MICROBIOL, V46, P1067, DOI 10.1128/JCM.01257-07; Zhang J., 2008, PEOPLES REPUBLIC CHI	32	170	191	2	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2011	473	7348					519	U263		10.1038/nature10004	http://dx.doi.org/10.1038/nature10004			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21614079	Bronze			2022-12-28	WOS:000290951300042
J	Alam, D				Alam, Daniel			Advances in Surgical Treatment of Facial Nerve Paralysis in Children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VALIDATION; EXPRESSION; EMOTION											Alam D, 2007, ARCH FACIAL PLAST S, V9, P205, DOI 10.1001/archfaci.9.3.205; Boahene KD, 2011, ARCH FACIAL PLAST S, V13, P8, DOI 10.1001/archfacial.2010.100; Brandt MG, 2010, J OTOLARYNGOL-HEAD N, V39, P476, DOI 10.2310/7070.2010.090175; Bray D, 2010, ARCH FACIAL PLAST S, V12, P352, DOI 10.1001/archfacial.2010.69; Coulson SE, 2004, OTOL NEUROTOL, V25, P1014, DOI 10.1097/00129492-200411000-00026; EKMAN P, 1993, AM PSYCHOL, V48, P384, DOI 10.1037/0003-066X.48.4.384; Hadlock TA, 2011, ARCH FACIAL PLAST S, V13, P190, DOI 10.1001/archfacial.2011.29; Kahn JB, 2001, LARYNGOSCOPE, V111, P387, DOI 10.1097/00005537-200103000-00005	8	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2011	305	20					2106	2107		10.1001/jama.2011.689	http://dx.doi.org/10.1001/jama.2011.689			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768AC	21614803				2022-12-28	WOS:000290901700024
J	Hornung, BR; Ravi, S				Hornung, Ben R.; Ravi, Srinivasan			An elusive cause of black stool	BRITISH MEDICAL JOURNAL			English	Editorial Material							MECKELS-DIVERTICULUM; COMPLICATIONS; DIAGNOSIS					benhornung@doctors.net.uk						Chandramohan K, 2007, World J Surg Oncol, V5, P50, DOI 10.1186/1477-7819-5-50; Gosche JR, 2006, SURG CLIN N AM, V86, P285, DOI 10.1016/j.suc.2005.12.014; Kiratli PO, 2009, ANN NUCL MED, V23, P97, DOI 10.1007/s12149-008-0204-6; KUSUMOTO H, 1992, AM J SURG, V164, P382, DOI 10.1016/S0002-9610(05)80909-2; Munroe CA, 2010, DIGEST DIS SCI, V55, P242, DOI 10.1007/s10620-009-1029-4; Park JJ, 2005, ANN SURG, V241, P529, DOI 10.1097/01.sla.0000154270.14308.5f; Prasad TRS, 2007, PEDIATR SURG INT, V23, P141, DOI 10.1007/s00383-006-1844-z; Sagar J, 2006, J ROY SOC MED, V99, P501, DOI 10.1258/jrsm.99.10.501; Thurley PD, 2009, CLIN RADIOL, V64, P109, DOI 10.1016/j.crad.2008.07.012; Zani A, 2008, ANN SURG, V247, P276, DOI 10.1097/SLA.0b013e31815aaaf8	10	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 25	2011	342								d1541	10.1136/bmj.d1541	http://dx.doi.org/10.1136/bmj.d1541			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771KE	21613361				2022-12-28	WOS:000291154800002
J	Carmeliet, P; Jain, RK				Carmeliet, Peter; Jain, Rakesh K.			Molecular mechanisms and clinical applications of angiogenesis	NATURE			English	Review							ENDOTHELIAL GROWTH-FACTOR; TUMOR VASCULATURE; VEGF-A; PROGENITOR CELLS; METASTASIS; PERICYTES; THERAPY; CANCER; PDGF; GLIOBLASTOMA	Blood vessels deliver oxygen and nutrients to every part of the body, but also nourish diseases such as cancer. Over the past decade, our understanding of the molecular mechanisms of angiogenesis (blood vessel growth) has increased at an explosive rate and has led to the approval of anti-angiogenic drugs for cancer and eye diseases. So far, hundreds of thousands of patients have benefited from blockers of the angiogenic protein vascular endothelial growth factor, but limited efficacy and resistance remain outstanding problems. Recent preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.	[Carmeliet, Peter] VIB, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, B-3000 Louvain, Belgium; [Carmeliet, Peter] Katholieke Univ Leuven, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, B-3000 Louvain, Belgium; [Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA; [Jain, Rakesh K.] Harvard Univ, Sch Med, Boston, MA 02114 USA	Flanders Institute for Biotechnology (VIB); Flanders Institute for Biotechnology (VIB); KU Leuven; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Carmeliet, P (corresponding author), VIB, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, B-3000 Louvain, Belgium.	peter.carmeliet@vib-kuleuven.be; jain@steele.mgh.harvard.edu	Carmeliet, Peter/AAQ-5140-2020; Jain, Rakesh K/I-1384-2017	Carmeliet, Peter/0000-0001-7961-1821; Jain, Rakesh K/0000-0001-7571-3548	Federal Government Belgium [IUAP06/30]; Flemish Government [GOA2006/11]; Flanders Research Foundation [FWO G.0673.08]; US National Institutes of Health [P01-CA80124, R01-CA85140, R01-CA115767, R01-CA126642]; Federal Share/NCI; National Foundation for Cancer Research and a Department of Defense [W81XWH-10-1-0016]; NATIONAL CANCER INSTITUTE [R01CA085140, P01CA080124, R01CA126642, R01CA115767, R01CA163815] Funding Source: NIH RePORTER	Federal Government Belgium; Flemish Government(European Commission); Flanders Research Foundation(FWO); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Federal Share/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Foundation for Cancer Research and a Department of Defense; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to acknowledge the late J. Folkman for inspiring us and others to work in the area of tumour angiogenesis. We would like to thank L. Claeson-Welch, H. Augustin, E. Dejana, S. Kozin, D. G. Duda, S. Goel, L. L. Munn, G. Sledge, R. Stupp and H. D. Suit for their comments, and L. Notebaert for help with the illustrations. We apologize to the authors whose work we could not cite because of the limit on the number of references. The work of P.C. is supported by a Federal Government Belgium grant (IUAP06/30), long-term structural Methusalem funding by the Flemish Government, a Concerted Research Activities Belgium grant (GOA2006/11), Leducq Transatlantic Network ARTEMIS and a grant from Flanders Research Foundation (FWO G.0673.08). The research of R.K.J. is supported by US National Institutes of Health grants P01-CA80124, R01-CA85140, R01-CA115767 and R01-CA126642, Federal Share/NCI Proton Beam Program Income, the National Foundation for Cancer Research and a Department of Defense Breast Cancer Research Innovator Award (W81XWH-10-1-0016).	Adams RH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001875; Allegra CJ, 2011, J CLIN ONCOL, V29, P11, DOI 10.1200/JCO.2010.30.0855; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Bais C, 2010, CELL, V141, P166, DOI 10.1016/j.cell.2010.01.033; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Bry M, 2010, CIRCULATION, V122, P1725, DOI 10.1161/CIRCULATIONAHA.110.957332; Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791; Buysschaert I, 2008, J CELL MOL MED, V12, P2533, DOI 10.1111/j.1582-4934.2008.00515.x; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Contois L, 2009, SEMIN CANCER BIOL, V19, P318, DOI 10.1016/j.semcancer.2009.05.002; Corada M, 2010, DEV CELL, V18, P938, DOI 10.1016/j.devcel.2010.05.006; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Dejana E, 2010, CIRC RES, V107, P943, DOI 10.1161/CIRCRESAHA.110.223750; Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004; Deryugina EI, 2010, BBA-MOL CELL RES, V1803, P103, DOI 10.1016/j.bbamcr.2009.09.017; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; di Tomaso E, 2011, CANCER RES, V71, P19, DOI 10.1158/0008-5472.CAN-10-2602; di Tomaso E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005123; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Duda DG, 2010, CANCER RES, V70, P5670, DOI 10.1158/0008-5472.CAN-10-0119; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Escudier B, 2010, J CLIN ONCOL, V28, P2144, DOI 10.1200/JCO.2009.26.7849; Falcon BL, 2009, AM J PATHOL, V175, P2159, DOI 10.2353/ajpath.2009.090391; Ferrara N, 2010, CYTOKINE GROWTH F R, V21, P21, DOI 10.1016/j.cytogfr.2009.11.003; Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Fraisl P, 2009, DEV CELL, V16, P167, DOI 10.1016/j.devcel.2009.01.003; Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521; Gerhardt H, 2008, J MOL MED, V86, P135, DOI 10.1007/s00109-007-0258-2; Hagberg CE, 2010, NATURE, V464, P917, DOI 10.1038/nature08945; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Heissig B, 2010, HISTOL HISTOPATHOL, V25, P765, DOI 10.14670/HH-25.765; Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7; Herbert SP, 2009, SCIENCE, V326, P294, DOI 10.1126/science.1178577; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Hodivala-Dilke K, 2008, CURR OPIN CELL BIOL, V20, P514, DOI 10.1016/j.ceb.2008.06.007; Iruela-Arispe ML, 2009, DEV CELL, V16, P222, DOI 10.1016/j.devcel.2009.01.013; Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Koh YJ, 2010, CANCER CELL, V18, P171, DOI 10.1016/j.ccr.2010.07.001; Kuhnert F, 2010, SCIENCE, V330, P985, DOI 10.1126/science.1196554; Lanahan AA, 2010, DEV CELL, V18, P713, DOI 10.1016/j.devcel.2010.02.016; Lebrin F, 2010, NAT MED, V16, P420, DOI 10.1038/nm.2131; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; McCarty MF, 2007, J CLIN INVEST, V117, P2114, DOI 10.1172/JCI31334; Miles D, 2011, J CLIN ONCOL, V29, P83, DOI 10.1200/JCO.2010.30.2794; Mosch B, 2010, J ONCOL, V2010, DOI 10.1155/2010/135285; Murakami M, 2008, J CLIN INVEST, V118, P3355, DOI 10.1172/JCI35298; Nagengast WB, 2011, CANCER RES, V71, P143, DOI 10.1158/0008-5472.CAN-10-1088; Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Nicoli S, 2010, NATURE, V464, P1196, DOI 10.1038/nature08889; Nisancioglu MH, 2010, CANCER RES, V70, P5109, DOI 10.1158/0008-5472.CAN-09-4245; Ohtani K, 2011, BASIC RES CARDIOL, V106, P5, DOI 10.1007/s00395-010-0139-7; Padera TP, 2008, MOL CANCER THER, V7, P2272, DOI 10.1158/1535-7163.MCT-08-0182; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pardali E, 2010, TRENDS CELL BIOL, V20, P556, DOI 10.1016/j.tcb.2010.06.006; Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015; Phng LK, 2009, DEV CELL, V16, P70, DOI 10.1016/j.devcel.2008.12.009; Plotkin SR, 2009, NEW ENGL J MED, V361, P358, DOI 10.1056/NEJMoa0902579; Pries AR, 2010, NAT REV CANCER, V10, P587, DOI 10.1038/nrc2895; Quaegebeur A, 2010, NEURON, V68, P321, DOI 10.1016/j.neuron.2010.10.024; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Saharinen P, 2008, NAT CELL BIOL, V10, P527, DOI 10.1038/ncb1715; Sawamiphak S, 2010, NATURE, V465, P487, DOI 10.1038/nature08995; Schaper W, 2009, BASIC RES CARDIOL, V104, P5, DOI 10.1007/s00395-008-0760-x; Schwartz JD, 2010, CANCER-AM CANCER SOC, V116, P1027, DOI 10.1002/cncr.24789; Sennino B, 2009, CANCER RES, V69, P4527, DOI 10.1158/0008-5472.CAN-08-3779; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Strilic B, 2009, DEV CELL, V17, P505, DOI 10.1016/j.devcel.2009.08.011; Swift MR, 2009, CIRC RES, V104, P576, DOI 10.1161/CIRCRESAHA.108.188805; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130; Tvorogov D, 2010, CANCER CELL, V18, P630, DOI 10.1016/j.ccr.2010.11.001; Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751	100	3467	3634	32	1376	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					298	307		10.1038/nature10144	http://dx.doi.org/10.1038/nature10144			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593862	Green Accepted			2022-12-28	WOS:000290722400036
J	Chew, EY				Chew, Emily Y.			Fatty Acids and Retinopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Chew, EY (corresponding author), NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.							Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591; SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274; Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571; Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317	4	7	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					1970	1971		10.1056/NEJMcibr1101606	http://dx.doi.org/10.1056/NEJMcibr1101606			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765PJ	21591950				2022-12-28	WOS:000290720700016
J	Hanaway, MJ; Woodle, ES; Mulgaonkar, S; Peddi, VR; Kaufman, DB; First, MR; Croy, R; Holman, J				Hanaway, Michael J.; Woodle, E. Steve; Mulgaonkar, Shamkant; Peddi, V. Ram; Kaufman, Dixon B.; First, M. Roy; Croy, Richard; Holman, John		INTAC Study Grp	Alemtuzumab Induction in Renal Transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RABBIT ANTITHYMOCYTE GLOBULIN; DONOR KIDNEY-TRANSPLANTATION; LONG-TERM; MYCOPHENOLATE-MOFETIL; ALLOGRAFT RECIPIENTS; CORTICOSTEROID CESSATION; MODERN IMMUNOSUPPRESSION; BASILIXIMAB INDUCTION; RANDOMIZED-TRIAL; ACUTE REJECTION	Background There are few comparisons of antibody induction therapy allowing early glucocorticoid withdrawal in renal-transplant recipients. The purpose of the present study was to compare induction therapy involving alemtuzumab with the most commonly used induction regimens in patient populations at either high immunologic risk or low immunologic risk. Methods In this prospective study, we randomly assigned patients to receive alemtuzumab or conventional induction therapy (basiliximab or rabbit antithymocyte globulin). Patients were stratified according to acute rejection risk, with a high risk defined by a repeat transplant, a peak or current value of panel-reactive antibodies of 20% or more, or black race. The 139 high-risk patients received alemtuzumab (one dose of 30 mg, in 70 patients) or rabbit antithymocyte globulin (a total of 6 mg per kilogram of body weight given over 4 days, in 69 patients). The 335 low-risk patients received alemtuzumab (one dose of 30 mg, in 164 patients) or basiliximab (a total of 40 mg over 4 days, in 171 patients). All patients received tacrolimus and mycophenolate mofetil and underwent a 5-day glucocorticoid taper in a regimen of early steroid withdrawal. The primary end point was biopsy-confirmed acute rejection at 6 months and 12 months. Patients were followed for 3 years for safety and efficacy end points. Results The rate of biopsy-confirmed acute rejection was significantly lower in the alemtuzumab group than in the conventional-therapy group at both 6 months (3% vs. 15%, P<0.001) and 12 months (5% vs. 17%, P<0.001). At 3 years, the rate of biopsy-confirmed acute rejection in low-risk patients was lower with alemtuzumab than with basiliximab (10% vs. 22%, P = 0.003), but among high-risk patients, no significant difference was seen between alemtuzumab and rabbit antithymocyte globulin (18% vs. 15%, P = 0.63). Adverse-event rates were similar among all four treatment groups. Conclusions By the first year after transplantation, biopsy-confirmed acute rejection was less frequent with alemtuzumab than with conventional therapy. The apparent superiority of alemtuzumab with respect to early biopsy-confirmed acute rejection was restricted to patients at low risk for transplant rejection; among high-risk patients, alemtuzumab and rabbit antithymocyte globulin had similar efficacy. (Funded by Astellas Pharma Global Development; INTAC ClinicalTrials. gov number, NCT00113269.)	[Hanaway, Michael J.] Univ Alabama, Birmingham, AL USA; [Woodle, E. Steve] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Mulgaonkar, Shamkant] St Barnabas Hlth Syst, W Orange, NJ USA; [Peddi, V. Ram] Calif Pacific Med Ctr, San Francisco, CA USA; [Kaufman, Dixon B.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [First, M. Roy; Croy, Richard; Holman, John] Astellas Pharma, Chicago, IL USA	University of Alabama System; University of Alabama Birmingham; University System of Ohio; University of Cincinnati; California Pacific Medical Center; University of Wisconsin System; University of Wisconsin Madison; Astellas Pharmaceuticals	Hanaway, MJ (corresponding author), Lyons Harrison Res Bldg,Rm 728,1530 3rd Ave, Birmingham, AL 35294 USA.	michael.hanaway@ccc.uab.edu	Kaufman, Dixon B/E-4524-2016; Loss, George/A-6015-2011; Woodle, E. Steve/N-8059-2013	Woodle, E. Steve/0000-0003-4280-0842	Astellas Pharma Global Development	Astellas Pharma Global Development(Astellas Pharmaceuticals)	Supported by Astellas Pharma Global Development.	Ahsan N, 1999, TRANSPLANTATION, V68, P1865; ALMOND PS, 1993, TRANSPLANTATION, V55, P752, DOI 10.1097/00007890-199304000-00013; Boardman RE, 2005, TRANSPL P, V37, P814, DOI 10.1016/j.transproceed.2004.12.071; Brennan DC, 2008, NEW ENGL J MED, V359, P1736, DOI 10.1056/NEJMc0805714; Brennan DC, 2006, NEW ENGL J MED, V355, P1967, DOI 10.1056/NEJMoa060068; Calne R, 1999, TRANSPLANTATION, V68, P1613, DOI 10.1097/00007890-199911270-00032; Ciancio G, 2005, TRANSPLANTATION, V80, P457, DOI 10.1097/01.tp.0000165847.05787.08; FERGUSON R, 1994, CLIN TRANSPLANT, V8, P328; Gallon LG, 2006, CLIN J AM SOC NEPHRO, V1, P1029, DOI 10.2215/CJN.00790306; Huang E, 2007, TRANSPLANTATION, V84, P821, DOI 10.1097/01.tp.0000281942.97406.89; Kaufman DB, 2005, AM J TRANSPLANT, V5, P2539, DOI 10.1111/j.1600-6143.2005.01067.x; Knechtle SJ, 2004, SURGERY, V136, P754, DOI 10.1016/j.surg.2004.06.015; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Margreiter R, 2008, AM J TRANSPLANT, V8, P1480, DOI 10.1111/j.1600-6143.2008.02273.x; Matas AJ, 2001, AM J TRANSPLANT, V1, P278, DOI 10.1034/j.1600-6143.2001.001003278.x; Noel C, 2009, J AM SOC NEPHROL, V20, P1385, DOI 10.1681/ASN.2008101037; Pascual J, 2008, AM J TRANSPLANT, V8, P237; Vanrenterghem Y, 2000, TRANSPLANTATION, V70, P1352, DOI 10.1097/00007890-200011150-00015; Vincenti F, 2001, TRANSPLANTATION, V71, P1282, DOI 10.1097/00007890-200105150-00017; Woodle ES, 2008, ANN SURG, V248, P564, DOI 10.1097/SLA.0b013e318187d1da; Woodle ES, 2005, AM J TRANSPLANT, V5, P2740, DOI 10.1111/j.1600-6143.2005.01090.x; 2008 OPTN SRTR ANN R	22	241	246	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					1909	1919		10.1056/NEJMoa1009546	http://dx.doi.org/10.1056/NEJMoa1009546			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765PJ	21591943				2022-12-28	WOS:000290720700006
J	Sumi, T; Kamiya, K; Bennett, DP; Bond, IA; Abe, F; Botzler, CS; Fukui, A; Furusawa, K; Hearnshaw, JB; Itow, Y; Kilmartin, PM; Korpela, A; Lin, W; Ling, CH; Masuda, K; Matsubara, Y; Miyake, N; Motomura, M; Muraki, Y; Nagaya, M; Nakamura, S; Ohnishi, K; Okumura, T; Perrott, YC; Rattenbury, N; Saito, T; Sako, T; Sullivan, DJ; Sweatman, WL; Tristram, PJ; Yock, PCM; Udalski, A; Szymanski, MK; Kubiak, M; Pietrzynski, G; Poleski, R; Soszynski, I; Wyrzykowski, L; Ulaczyk, K				Sumi, T.; Kamiya, K.; Bennett, D. P.; Bond, I. A.; Abe, F.; Botzler, C. S.; Fukui, A.; Furusawa, K.; Hearnshaw, J. B.; Itow, Y.; Kilmartin, P. M.; Korpela, A.; Lin, W.; Ling, C. H.; Masuda, K.; Matsubara, Y.; Miyake, N.; Motomura, M.; Muraki, Y.; Nagaya, M.; Nakamura, S.; Ohnishi, K.; Okumura, T.; Perrott, Y. C.; Rattenbury, N.; Saito, To; Sako, T.; Sullivan, D. J.; Sweatman, W. L.; Tristram, P. J.; Yock, P. C. M.; Udalski, A.; Szymanski, M. K.; Kubiak, M.; Pietrzynski, G.; Poleski, R.; Soszynski, I.; Wyrzykowski, L.; Ulaczyk, K.		Microlensing Observations Astroph; Optical Gravitational Lensing Expt	Unbound or distant planetary mass population detected by gravitational microlensing	NATURE			English	Article							DIFFERENCE IMAGE-ANALYSIS; GALACTIC BULGE; OPTICAL DEPTH; LENSING EXPERIMENT; MACHO PROJECT; BROWN DWARFS; STAR; NEPTUNES; JUPITERS; SYSTEMS	Since 1995, more than 500 exoplanets have been detected using different techniques(1,2), of which 12 were detected with gravitational microlensing(3,4). Most of these are gravitationally bound to their host stars. There is some evidence of free-floating planetary-mass objects in young star-forming regions(5-8), but these objects are limited to massive objects of 3 to 15 Jupiter masses with large uncertainties in photometric mass estimates and their abundance. Here, we report the discovery of a population of unbound or distant Jupiter-mass objects, which are almost twice (1.8(-0.8)(+1.7)) as common as main-sequence stars, based on two years of gravitational microlensing survey observations towards the Galactic Bulge. These planetary-mass objects have no host stars that can be detected within about ten astronomical units by gravitational microlensing. However, a comparison with constraints from direct imaging(9) suggests that most of these planetary-mass objects are not bound to any host star. An abrupt change in the mass function at about one Jupiter mass favours the idea that their formation process is different from that of stars and brown dwarfs. They may have formed in proto-planetary disks and subsequently scattered into unbound or very distant orbits.	[Sumi, T.] Osaka Univ, Dept Earth & Space Sci, Osaka 5600043, Japan; [Sumi, T.; Kamiya, K.; Abe, F.; Fukui, A.; Furusawa, K.; Itow, Y.; Masuda, K.; Matsubara, Y.; Miyake, N.; Motomura, M.; Nagaya, M.; Nakamura, S.; Okumura, T.; Sako, T.] Nagoya Univ, Solar Terr Environm Lab, Nagoya, Aichi 4648601, Japan; [Bennett, D. P.] Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA; [Bond, I. A.; Lin, W.; Ling, C. H.; Sweatman, W. L.] Massey Univ, N Shore Mail Ctr, Inst Informat & Math Sci, Auckland 0745, New Zealand; [Botzler, C. S.; Rattenbury, N.; Tristram, P. J.; Yock, P. C. M.] Univ Auckland, Dept Phys, Auckland 1142, New Zealand; [Hearnshaw, J. B.] Univ Canterbury, Dept Phys & Astron, Christchurch 8140, New Zealand; [Kilmartin, P. M.] Univ Canterbury, Mt John Univ Observ, Lake Tekapo 8770, New Zealand; [Korpela, A.; Sullivan, D. J.] Victoria Univ, Sch Chem & Phys Sci, Wellington 6140, New Zealand; [Muraki, Y.] Konan Univ, Dept Phys, Kobe, Hyogo 6588501, Japan; [Ohnishi, K.] Nagano Natl Coll Technol, Nagano 3818550, Japan; [Perrott, Y. C.] Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England; [Saito, To] Tokyo Metropolitan Coll Ind Technol, Tokyo 1168523, Japan; [Udalski, A.; Szymanski, M. K.; Kubiak, M.; Pietrzynski, G.; Poleski, R.; Soszynski, I.; Ulaczyk, K.] Univ Warsaw Observ, PL-00478 Warsaw, Poland; [Pietrzynski, G.] Univ Concepcion, Dept Astron, Concepcion, Chile; [Wyrzykowski, L.] Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England	Osaka University; Nagoya University; University of Notre Dame; Massey University; University of Auckland; University of Canterbury; University of Canterbury; Victoria University Wellington; Konan University; University of Cambridge; University of Warsaw; Warsaw University Observatory; Universidad de Concepcion; University of Cambridge	Sumi, T (corresponding author), Osaka Univ, Dept Earth & Space Sci, Osaka 5600043, Japan.	sumi@ess.sci.osaka-u.ac.jp	Fukui, Akihiko/ABE-4506-2020; Poleski, Radoslaw/AAM-7565-2021; Szymański, Michał Krzysztof/X-5627-2019; Rattenbury, Nicholas James/ABB-2102-2021; Szymański, Michał K/H-6951-2018; Sweatman, Winston/S-4931-2019; Bennett, David/O-2136-2013; Fukui, Akihiko/ABF-2092-2021; Fukui, Akihiko/W-2238-2017	Poleski, Radoslaw/0000-0002-9245-6368; Szymański, Michał Krzysztof/0000-0002-0548-8995; Rattenbury, Nicholas James/0000-0001-5069-319X; Szymański, Michał K/0000-0002-0548-8995; Bennett, David/0000-0001-8043-8413; Fukui, Akihiko/0000-0002-4909-5763; Pietrzynski, Grzegorz/0000-0002-9443-4138; Yock, Philip/0000-0001-9716-7752; Wyrzykowski, Lukasz/0000-0002-9658-6151; Udalski, Andrzej/0000-0001-5207-5619; Ulaczyk, Krzysztof/0000-0001-6364-408X; Soszynski, Igor/0000-0002-7777-0842	Marsden Fund of New Zealand; NSF; NASA; European Research Council; Grants-in-Aid for Scientific Research [10J07272, 23340064, 23540339] Funding Source: KAKEN	Marsden Fund of New Zealand(Royal Society of New ZealandMarsden Fund (NZ)); NSF(National Science Foundation (NSF)); NASA(National Aeronautics & Space Administration (NASA)); European Research Council(European Research Council (ERC)European Commission); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The MOA collaboration thanks the JSPS and MEXT of Japan, and the Marsden Fund of New Zealand, for support. D.P.B. acknowledges support by the NSF and NASA. The OGLE collaboration is grateful for funding from the European Research Council Advanced Grants Program.	Alcock C, 2000, ASTROPHYS J, V541, P734, DOI 10.1086/309484; Bennett DP, 1997, ASTR SOC P, V119, P95; Burgess ASM, 2009, ASTRON ASTROPHYS, V508, P823, DOI 10.1051/0004-6361/200912444; Chabrier G, 2003, PUBL ASTRON SOC PAC, V115, P763, DOI 10.1086/376392; Di Stefano R, 1999, ASTROPHYS J, V512, P564, DOI 10.1086/306814; Gaudi B. S., 2011, EXOPLANETS, P79; Gould A, 2000, ASTROPHYS J, V535, P928, DOI 10.1086/308865; Hamadache C, 2006, ASTRON ASTROPHYS, V454, P185, DOI 10.1051/0004-6361:20064893; Han CC, 2003, ASTROPHYS J, V592, P172, DOI 10.1086/375706; Han CG, 2003, ASTROPHYS J, V596, P1320, DOI 10.1086/378191; Howard AW, 2010, SCIENCE, V330, P653, DOI 10.1126/science.1194854; Lafreniere D, 2007, ASTROPHYS J, V670, P1367, DOI 10.1086/522826; LIEBES S, 1964, PHYS REV B, V133, pB835, DOI 10.1103/PhysRev.133.B835; Marsh KA, 2010, ASTROPHYS J, V719, P550, DOI 10.1088/0004-637X/719/1/550; Osorio MRZ, 2000, SCIENCE, V290, P103, DOI 10.1126/science.290.5489.103; PACZYNSKI B, 1986, ASTROPHYS J, V304, P1, DOI 10.1086/164140; Quanz SP, 2010, ASTROPHYS J, V708, P770, DOI 10.1088/0004-637X/708/1/770; Schneider J., 2011, EXTRASOLAR PLANETS E; Sumi T, 2006, ASTROPHYS J, V636, P240, DOI 10.1086/497951; Sumi T, 2003, ASTROPHYS J, V591, P204, DOI 10.1086/375212; Sumi T, 2010, ASTROPHYS J, V710, P1641, DOI 10.1088/0004-637X/710/2/1641; Thies I, 2007, ASTROPHYS J, V671, P767, DOI 10.1086/522512; UDALSKI A, 1994, ACTA ASTRONOM, V44, P165; Veras D, 2009, ASTROPHYS J, V696, P1600, DOI 10.1088/0004-637X/696/2/1600; Winn JN, 2010, ASTROPHYS J LETT, V718, pL145, DOI 10.1088/2041-8205/718/2/L145; Zoccali M, 2000, ASTROPHYS J, V530, P418, DOI 10.1086/308359	29	355	359	4	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					349	352		10.1038/nature10092	http://dx.doi.org/10.1038/nature10092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593867	Green Submitted			2022-12-28	WOS:000290722400042
J	Boly, M; Garrido, MI; Gosseries, O; Bruno, MA; Boveroux, P; Schnakers, C; Massimini, M; Litvak, V; Laureys, S; Friston, KJ				Boly, Melanie; Garrido, Marta Isabel; Gosseries, Olivia; Bruno, Marie-Aurelie; Boveroux, Pierre; Schnakers, Caroline; Massimini, Marcello; Litvak, Vladimir; Laureys, Steven; Friston, Karl J.			Preserved Feedforward But Impaired Top-Down Processes in the Vegetative State	SCIENCE			English	Article							MINIMALLY CONSCIOUS STATE; MISMATCH NEGATIVITY; RESPONSES; MMN; POTENTIALS; EEG	Frontoparietal cortex is involved in the explicit processing (awareness) of stimuli. Frontoparietal activation has also been found in studies of subliminal stimulus processing. We hypothesized that an impairment of top-down processes, involved in recurrent neuronal message-passing and the generation of long-latency electrophysiological responses, might provide a more reliable correlate of consciousness in severely brain-damaged patients, than frontoparietal responses. We measured effective connectivity during a mismatch negativity paradigm and found that the only significant difference between patients in a vegetative state and controls was an impairment of backward connectivity from frontal to temporal cortices. This result emphasizes the importance of top-down projections in recurrent processing that involve high-order associative cortices for conscious perception.	[Boly, Melanie; Gosseries, Olivia; Bruno, Marie-Aurelie; Schnakers, Caroline; Laureys, Steven] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Boly, Melanie; Gosseries, Olivia; Bruno, Marie-Aurelie; Schnakers, Caroline; Laureys, Steven] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [Boly, Melanie; Gosseries, Olivia; Bruno, Marie-Aurelie; Boveroux, Pierre; Schnakers, Caroline; Laureys, Steven] CHU Sart Tilman Hosp, B-4000 Liege, Belgium; [Boly, Melanie; Garrido, Marta Isabel; Litvak, Vladimir; Friston, Karl J.] UCL, Wellcome Trust Ctr Neuroimaging, Inst Neurol, London WC1N 1PJ, England; [Boveroux, Pierre] Univ Liege, Dept Anesthesiol, B-4000 Liege, Belgium; [Massimini, Marcello] Univ Milan, Dept Clin Sci, I-20157 Milan, Italy	University of Liege; University of Liege; University of Liege; University of London; University College London; University of Liege; University of Milan	Boly, M (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium.	mboly@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Gosseries, Olivia/AAB-6469-2020; Litvak, Vladimir/C-1533-2008; Garrido, Marta I/B-7372-2013; Friston, Karl/D-9230-2011; Laureys, Steven/A-3349-2011; Massimini, Marcello/T-8115-2017	Laureys, Steven/0000-0002-3096-3807; Gosseries, Olivia/0000-0001-9011-7496; Litvak, Vladimir/0000-0001-8535-7452; Friston, Karl/0000-0001-7984-8909; Massimini, Marcello/0000-0003-2271-957X; Bekinschtein, Tristan/0000-0001-5501-8628; Garrido, Marta/0000-0003-0679-4959; Boly, Melanie/0000-0001-9584-0907	Belgian Fonds National de la Recherche Scientifique (FNRS); European Commission; Mind Science Foundation; McDonnell Foundation; French-Speaking Community Concerted Research Action [ARC 06/11-340]; Fondation Leon Fredericq; National Institutes of Health; Wellcome Trust	Belgian Fonds National de la Recherche Scientifique (FNRS)(Fonds de la Recherche Scientifique - FNRS); European Commission(European CommissionEuropean Commission Joint Research Centre); Mind Science Foundation; McDonnell Foundation; French-Speaking Community Concerted Research Action; Fondation Leon Fredericq; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by the Belgian Fonds National de la Recherche Scientifique (FNRS), European Commission, Mind Science Foundation, McDonnell Foundation, French-Speaking Community Concerted Research Action (ARC 06/11-340), Fondation Leon Fredericq, and National Institutes of Health. M.-A. B. and O.G. are Research Fellows, M. B. and C. S. Postdoctoral Fellows, and S. L. Senior Research Associate at the FNRS. M. I. G., V. L., and K. F. are supported by the Wellcome Trust.	Balduzzi D, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000091; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; David O, 2005, NEUROIMAGE, V25, P756, DOI 10.1016/j.neuroimage.2004.12.030; David O, 2006, NEUROIMAGE, V30, P1255, DOI 10.1016/j.neuroimage.2005.10.045; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; Del Cul A, 2007, PLOS BIOL, V5, P2408, DOI 10.1371/journal.pbio.0050260; Diaz MT, 2007, J COGNITIVE NEUROSCI, V19, P1768, DOI 10.1162/jocn.2007.19.11.1768; Fischer C, 2010, CLIN NEUROPHYSIOL, V121, P1032, DOI 10.1016/j.clinph.2010.02.005; Friston KJ, 2010, NAT REV NEUROSCI, V11, P127, DOI 10.1038/nrn2787; Friston KJ, 2009, SCIENCE, V326, P399, DOI 10.1126/science.1174521; Friston KJ, 2003, NEUROIMAGE, V19, P1273, DOI 10.1016/S1053-8119(03)00202-7; Garrido MI, 2008, NEUROIMAGE, V42, P936, DOI 10.1016/j.neuroimage.2008.05.018; Garrido MI, 2007, P NATL ACAD SCI USA, V104, P20961, DOI 10.1073/pnas.0706274105; Garrido MI, 2007, NEUROIMAGE, V36, P571, DOI 10.1016/j.neuroimage.2007.03.014; Garrido MI, 2009, NEUROIMAGE, V48, P269, DOI 10.1016/j.neuroimage.2009.06.034; Garrido MI, 2009, CLIN NEUROPHYSIOL, V120, P453, DOI 10.1016/j.clinph.2008.11.029; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Heinke W, 2004, ANESTHESIOLOGY, V100, P617, DOI 10.1097/00000542-200403000-00023; Kiebel SJ, 2009, HUM BRAIN MAPP, V30, P1866, DOI 10.1002/hbm.20775; Lamme VAF, 2006, TRENDS COGN SCI, V10, P494, DOI 10.1016/j.tics.2006.09.001; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Luo Q, 2009, CEREB CORTEX, V19, P1896, DOI 10.1093/cercor/bhn216; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; Rees G, 2002, NAT REV NEUROSCI, V3, P261, DOI 10.1038/nrn783; ROTH M, 1956, ELECTROEN CLIN NEURO, V8, P385, DOI 10.1016/0013-4694(56)90004-9; Ruby P, 2008, J COGNITIVE NEUROSCI, V20, P296, DOI 10.1162/jocn.2008.20023; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020	29	323	336	0	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2011	332	6031					858	862		10.1126/science.1202043	http://dx.doi.org/10.1126/science.1202043			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566197	Green Submitted			2022-12-28	WOS:000290529900051
J	Parsch, J				Parsch, John			The Cost of Being Male	SCIENCE			English	Editorial Material							BIASED GENE-EXPRESSION; DROSOPHILA-MELANOGASTER; EVOLUTION; FITNESS		Univ Munich, Dept Biol 2, D-82152 Planegg Martinsried, Germany	University of Munich	Parsch, J (corresponding author), Univ Munich, Dept Biol 2, D-82152 Planegg Martinsried, Germany.	parsch@zi.biologie.uni-muenchen.de						Ellegren H, 2007, NAT REV GENET, V8, P689, DOI 10.1038/nrg2167; Eyre-Walker A, 2007, NAT REV GENET, V8, P610, DOI 10.1038/nrg2146; Frank SA, 1996, NATURE, V383, P224, DOI 10.1038/383224a0; Gemmell NJ, 2004, TRENDS ECOL EVOL, V19, P238, DOI 10.1016/j.tree.2004.02.002; Gilad Y, 2006, TRENDS GENET, V22, P456, DOI 10.1016/j.tig.2006.06.002; Hutter S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r12; Innocenti P, 2011, SCIENCE, V332, P845, DOI 10.1126/science.1201157; Innocenti P, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000335; Lemos B, 2008, SCIENCE, V319, P91, DOI 10.1126/science.1148861; Lemos B, 2010, P NATL ACAD SCI USA, V107, P15826, DOI 10.1073/pnas.1010383107; Meiklejohn CD, 2003, P NATL ACAD SCI USA, V100, P9894, DOI 10.1073/pnas.1630690100; Muller L, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-81	12	2	2	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					798	799		10.1126/science.1206352	http://dx.doi.org/10.1126/science.1206352			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566179				2022-12-28	WOS:000290529900032
J	Schlacher, K; Christ, N; Siaud, N; Egashira, A; Wu, H; Jasin, M				Schlacher, Katharina; Christ, Nicole; Siaud, Nicolas; Egashira, Akinori; Wu, Hong; Jasin, Maria			Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11	CELL			English	Article							WERNER-SYNDROME PROTEIN; DNA-REPLICATION; HOMOLOGOUS RECOMBINATION; CANCER SUSCEPTIBILITY; GENOMIC STABILITY; ATP HYDROLYSIS; HUMAN RAD51; CELLS; COMPLEX; HYPERSENSITIVITY	Breast cancer suppressor BRCA2 is critical for maintenance of genomic integrity and resistance to agents that damage DNA or collapse replication forks, presumably through homology-directed repair of double-strand breaks (HDR). Using single-molecule DNA fiber analysis, we show here that nascent replication tracts created before fork stalling with hydroxyurea are degraded in the absence of BRCA2 but are stable in wild-type cells. BRCA2 mutational analysis reveals that a conserved C-terminal site involved in stabilizing RAD51 filaments, but not in loading RAD51 onto DNA, is essential for this fork protection but dispensable for HDR. RAD51 filament disruption in wild-type cells phenocopies BRCA2 deficiency. BRCA2 prevents chromosomal aberrations on replication stalling, which are alleviated by inhibition of MRE11, the nuclease responsible for this form of fork instability. Thus, BRCA2 prevents rather than repairs nucleolytic lesions at stalled replication forks to maintain genomic integrity and hence likely suppresses tumorigenesis through this replication-specific function.	[Schlacher, Katharina; Christ, Nicole; Siaud, Nicolas; Egashira, Akinori; Jasin, Maria] Mem Sloan Kettering Canc Ctr, Dev Biol Program, New York, NY 10065 USA; [Schlacher, Katharina; Wu, Hong] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Wu, Hong] Univ Calif Los Angeles, Inst Mol Med, Los Angeles, CA 90095 USA	Memorial Sloan Kettering Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Schlacher, K (corresponding author), Mem Sloan Kettering Canc Ctr, Dev Biol Program, New York, NY 10065 USA.	schlachk@mskcc.org; m-jasin@ski.mskcc.org		SCHLACHER, KATHARINA/0000-0001-7226-6391	Susan G. Komen grant [BCTR122106]; NIH [R01CA121110, R01GM54668, P01CA94060]; NATIONAL CANCER INSTITUTE [P01CA094060, R01CA121110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054668] Funding Source: NIH RePORTER	Susan G. Komen grant(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Francesca Cole, Jeannine LaRocque, Koji Nakanishi, Yu Zhang, and other members of the Jasin lab and for reagents and discussions, Marie-Emilie Terret (MSKCC) and Margaret Leversha (MSKCC) for technical assistance, Julia Sidorova (Seattle) for critical discussions along with Duncan Wright (MSKCC) and Reginald Hill (UCLA), and Toshiyasu Taniguchi (Seattle), Ouathek Ouerfelli (MSKCC), and Berry Sleckman (St. Louis) for reagents. K. S. is the Berger Foundation Fellow of the Damon Runyon Cancer Research Foundation (DRG 1957-07). This work was supported by Susan G. Komen grant BCTR122106 (M.J.) and NIH grants R01CA121110 (H. W.) and R01GM54668 and P01CA94060 (M.J.).	Ayoub Nabieh, 2009, Curr Biol, V19, P1075, DOI 10.1016/j.cub.2009.05.057; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Budzowska M, 2009, CELL BIOCHEM BIOPHYS, V53, P17, DOI 10.1007/s12013-008-9039-y; Cheng WH, 2004, J BIOL CHEM, V279, P21169, DOI 10.1074/jbc.M312770200; Cotta-Ramusino C, 2005, MOL CELL, V17, P153, DOI 10.1016/j.molcel.2004.11.032; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Davies OR, 2007, NAT STRUCT MOL BIOL, V14, P475, DOI 10.1038/nsmb1251; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Dupre A, 2008, NAT CHEM BIOL, V4, P119, DOI 10.1038/nchembio.63; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Esashi F, 2007, NAT STRUCT MOL BIOL, V14, P468, DOI 10.1038/nsmb1245; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Franchitto A, 2004, CELL CYCLE, V3, P1331, DOI 10.4161/cc.3.10.1185; Goggins M, 1996, CANCER RES, V56, P5360; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Hanada K, 2007, NAT STRUCT MOL BIOL, V14, P1096, DOI 10.1038/nsmb1313; Hashimoto Y, 2010, NAT STRUCT MOL BIOL, V17, P1305, DOI 10.1038/nsmb.1927; Hay T, 2005, BIOCHEM SOC T, V33, P715, DOI 10.1042/BST0330715; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Jensen RB, 2010, NATURE, V467, P678, DOI 10.1038/nature09399; Kass EM, 2010, FEBS LETT, V584, P3703, DOI 10.1016/j.febslet.2010.07.057; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Mazloum N, 2009, MOL CELL, V36, P620, DOI 10.1016/j.molcel.2009.09.033; McAllister KA, 2002, CANCER RES, V62, P990; Mimitou EP, 2009, DNA REPAIR, V8, P983, DOI 10.1016/j.dnarep.2009.04.017; Morimatsu M, 1998, CANCER RES, V58, P3441; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Nagaraju G, 2007, DNA REPAIR, V6, P1018, DOI 10.1016/j.dnarep.2007.02.020; Navarro S, 2006, MOL THER, V14, P525, DOI 10.1016/j.ymthe.2006.05.018; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Postow L, 2001, P NATL ACAD SCI USA, V98, P8219, DOI 10.1073/pnas.111006998; Saeki H, 2006, P NATL ACAD SCI USA, V103, P8768, DOI 10.1073/pnas.0600298103; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Schlacher K, 2007, NAT REV MOL CELL BIO, V8, P587, DOI 10.1038/nrm2198; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Stark JM, 2002, J BIOL CHEM, V277, P20185, DOI 10.1074/jbc.M112132200; Su X, 2008, NAT STRUCT MOL BIOL, V15, P1049, DOI 10.1038/nsmb.1490; van Mameren J, 2009, NATURE, V457, P745, DOI 10.1038/nature07581; Wang Y, 2000, GENE DEV, V14, P927; Wiegant WW, 2006, MUTAT RES-FUND MOL M, V600, P79, DOI 10.1016/j.mrfmmm.2006.03.001; Williams RS, 2008, CELL, V135, P97, DOI 10.1016/j.cell.2008.08.017	53	793	803	1	57	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 13	2011	145	4					529	542		10.1016/j.cell.2011.03.041	http://dx.doi.org/10.1016/j.cell.2011.03.041			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565612	Bronze, Green Accepted			2022-12-28	WOS:000290560800007
J	Allison, KR; Brynildsen, MP; Collins, JJ				Allison, Kyle R.; Brynildsen, Mark P.; Collins, James J.			Metabolite-enabled eradication of bacterial persisters by aminoglycosides	NATURE			English	Article							ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; ANTIBIOTIC TOLERANCE; CELLS; RESISTANCE; MECHANISM; BIOFILMS; ROLES; DEATH; ANTIMICROBIALS	Bacterial persistence is a state in which a sub-population of dormant cells, or 'persisters', tolerates antibiotic treatment(1-4). Bacterial persisters have been implicated in biofilms and in chronic and recurrent infections(5-7). Despite this clinical relevance, there are currently no viable means for eradicating persisters. Here we show that specific metabolic stimuli enable the killing of both Gram-negative (Escherichia coli) and Gram-positive (Staphylococcus aureus) persisters with aminoglycosides. This potentiation is aminoglycoside-specific, it does not rely on growth resumption and it is effective in both aerobic and anaerobic conditions. It proceeds by the generation of a proton-motive force which facilitates aminoglycoside uptake. Our results demonstrate that persisters, although dormant, are primed for metabolite uptake, central metabolism and respiration. We show that aminoglycosides can be used in combination with specific metabolites to treat E. coli and S. aureus biofilms. Furthermore, we demonstrate that this approach can improve the treatment of chronic infections in a mouse urinary tract infection model. This work establishes a strategy for eradicating bacterial persisters that is based on metabolism, and highlights the importance of the metabolic environment to antibiotic treatment.	[Allison, Kyle R.; Brynildsen, Mark P.; Collins, James J.] Boston Univ, Howard Hughes Med Inst, Dept Biomed Engn, Ctr Biodynam, Boston, MA 02215 USA; [Collins, James J.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Collins, James J.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02118 USA	Boston University; Howard Hughes Medical Institute; Boston University; Harvard University	Collins, JJ (corresponding author), Boston Univ, Howard Hughes Med Inst, Dept Biomed Engn, Ctr Biodynam, Boston, MA 02215 USA.	jcollins@bu.edu			NIH; Howard Hughes Medical Institute; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD003644] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank A. Slee and T. Murphy from ViviSource Laboratories for assistance with the in vivo mouse studies and T. K. Lu for guidance with the biofilm experiments. This work was supported by the NIH Director's Pioneer Award Program and the Howard Hughes Medical Institute.	Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; BRYAN LE, 1983, ANTIMICROB AGENTS CH, V23, P835, DOI 10.1128/AAC.23.6.835; DAVIS BD, 1987, MICROBIOL REV, V51, P341, DOI 10.1128/MMBR.51.3.341-350.1987; Dhar N, 2007, CURR OPIN MICROBIOL, V10, P30, DOI 10.1016/j.mib.2006.12.007; Dwyer DJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100135; FRAIMOW HS, 1991, J BACTERIOL, V173, P2800, DOI 10.1128/JB.173.9.2800-2808.1991; Gefen O, 2008, P NATL ACAD SCI USA, V105, P6145, DOI 10.1073/pnas.0711712105; Gefen O, 2009, FEMS MICROBIOL REV, V33, P704, DOI 10.1111/j.1574-6976.2008.00156.x; Govantes F, 2000, MOL MICROBIOL, V37, P1456, DOI 10.1046/j.1365-2958.2000.02100.x; Hansen S, 2008, ANTIMICROB AGENTS CH, V52, P2718, DOI 10.1128/AAC.00144-08; HILL S, 1990, J BACTERIOL, V172, P2071, DOI 10.1128/jb.172.4.2071-2078.1990; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Keren I, 2004, J BACTERIOL, V186, P8172, DOI 10.1128/JB.186.24.8172-8180.2004; Keren I, 2004, FEMS MICROBIOL LETT, V230, P13, DOI 10.1016/S0378-1097(03)00856-5; Kohanski MA, 2008, CELL, V135, P679, DOI 10.1016/j.cell.2008.09.038; Kohanski MA, 2007, CELL, V130, P797, DOI 10.1016/j.cell.2007.06.049; Levin BR, 2006, NAT REV MICROBIOL, V4, P556, DOI 10.1038/nrmicro1445; Lewis K, 2007, NAT REV MICROBIOL, V5, P48, DOI 10.1038/nrmicro1557; Lu TK, 2007, P NATL ACAD SCI USA, V104, P11197, DOI 10.1073/pnas.0704624104; Magnet S, 2005, CHEM REV, V105, P477, DOI 10.1021/cr0301088; Majerczyk CD, 2010, J BACTERIOL, V192, P2861, DOI 10.1128/JB.00220-10; MATES SM, 1982, P NATL ACAD SCI-BIOL, V79, P6693, DOI 10.1073/pnas.79.21.6693; Sandoval R, 1998, J AM SOC NEPHROL, V9, P167; Shah D, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-53; Smith PA, 2007, NAT CHEM BIOL, V3, P549, DOI 10.1038/nchembio.2007.27; Spoering AL, 2001, J BACTERIOL, V183, P6746, DOI 10.1128/JB.183.23.6746-6751.2001; TABER HW, 1987, MICROBIOL REV, V51, P439, DOI 10.1128/MMBR.51.4.439-457.1987; Vakulenko SB, 2003, CLIN MICROBIOL REV, V16, P430, DOI 10.1128/CMR.16.3.430-450.2003; Walters MC, 2003, ANTIMICROB AGENTS CH, V47, P317, DOI 10.1128/AAC.47.1.317-323.2003; WEISBLUM B, 1968, BACTERIOL REV, V32, P493, DOI 10.1128/MMBR.32.4_Pt_2.493-528.1968	30	594	625	16	270	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 12	2011	473	7346					216	+		10.1038/nature10069	http://dx.doi.org/10.1038/nature10069			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562562	Green Accepted			2022-12-28	WOS:000290487200039
J	Lucanic, M; Held, JM; Vantipalli, MC; Klang, IM; Graham, JB; Gibson, BW; Lithgow, GJ; Gill, MS				Lucanic, Mark; Held, Jason M.; Vantipalli, Maithili C.; Klang, Ida M.; Graham, Jill B.; Gibson, Bradford W.; Lithgow, Gordon J.; Gill, Matthew S.			N-acylethanolamine signalling mediates the effect of diet on lifespan in Caenorhabditis elegans	NATURE			English	Article							RESTRICTION-INDUCED LONGEVITY; C-ELEGANS; ENDOCANNABINOID SYSTEM; EVOLUTIONARY ORIGINS; DAUER FORMATION; FOOD-INTAKE; EXTENSION; ACID; MECHANISMS; EXPRESSION	Dietary restriction is a robust means of extending adult lifespan and postponing age-related disease in many species, including yeast, nematode worms, flies and rodents(1,2). Studies of the genetic requirements for lifespan extension by dietary restriction in the nematode Caenorhabditis elegans have implicated a number of key molecules in this process(3-5), including the nutrient-sensing target of rapamycin (TOR) pathway(6) and the Foxa transcription factor PHA-4 (ref. 7). However, little is known about the metabolic signals that coordinate the organismal response to dietary restriction and maintain homeostasis when nutrients are limited. The endocannabinoid system is an excellent candidate for such a role given its involvement in regulating nutrient intake and energy balance(8). Despite this, a direct role for endocannabinoid signalling in dietary restriction or lifespan determination has yet to be demonstrated, in part due to the apparent absence of endocannabinoid signalling pathways in model organisms that are amenable to lifespan analysis(9). N-acylethanolamines (NAEs) are lipid-derived signalling molecules, which include the mammalian endocannabinoid arachidonoyl ethanolamide. Here we identify NAEs in C. elegans, show that NAE abundance is reduced under dietary restriction and that NAE deficiency is sufficient to extend lifespan through a dietary restriction mechanism requiring PHA-4. Conversely, dietary supplementation with the nematode NAE eicosapentaenoyl ethanolamide not only inhibits dietary-restriction-induced lifespan extension in wild-type worms, but also suppresses lifespan extension in a TOR pathway mutant. This demonstrates a role for NAE signalling in ageing and indicates that NAEs represent a signal that coordinates nutrient status with metabolic changes that ultimately determine lifespan.	[Lucanic, Mark; Held, Jason M.; Vantipalli, Maithili C.; Klang, Ida M.; Graham, Jill B.; Gibson, Bradford W.; Lithgow, Gordon J.; Gill, Matthew S.] Buck Inst Res Aging, Novato, CA 94945 USA; [Klang, Ida M.] Karolinska Inst, Ctr Biosci, Novum, Dept Biosci & Nutr, S-14183 Huddinge, Sweden	Buck Institute for Research on Aging; Karolinska Institutet	Gill, MS (corresponding author), Scripps Res Inst Scripps Florida, 130 Scripps Way,3B3, Jupiter, FL 33458 USA.	mgill@scripps.edu		Held, Jason/0000-0001-8024-2736; lucanic, mark/0000-0003-1511-1013; Gill, Matthew/0000-0003-0818-8792	NIH National Center for Research Resources (NCRR); NIH [T32 AG000266, R01 AG029631, PL1-AG032118, UL1 DE019608, R21 AG030192, R01 AG036992]; Larry L. Hillblom Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [UL1DE019608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG036992, T32AG000266, R21AG030192, R01AG029631, PL1AG032118] Funding Source: NIH RePORTER	NIH National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Larry L. Hillblom Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Some nematode strains used in this work were provided by the Caenorhabditis Genetics Center, which is funded by the NIH National Center for Research Resources (NCRR). We would like to thank N. J. Harrison, A. Olsen and P. Kapahi. M.L. was supported by NIH training grant T32 AG000266 and NIH grant R01 AG029631. GC-MS analysis was made possible through the Mass Spectrometry and Imaging Technologies Core supported by NIH grant PL1-AG032118. This work was supported by a Larry L. Hillblom Foundation grant and NIH grants to G.J.L. (UL1 DE019608, supporting the Interdisciplinary Research Consortium on Geroscience and R01 AG029631) and by NIH grants R21 AG030192 and R01 AG036992 to M.S.G.	Banni S, 2010, MOL NUTR FOOD RES, V54, P82, DOI 10.1002/mnfr.200900516; Bishop NA, 2007, NAT REV GENET, V8, P835, DOI 10.1038/nrg2188; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Breunig E, 2010, J NEUROSCI, V30, P8965, DOI 10.1523/JNEUROSCI.4030-09.2010; Carrano AC, 2009, NATURE, V460, P396, DOI 10.1038/nature08130; Chen D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000486; De Petrocellis L, 1999, NEUROSCIENCE, V92, P377, DOI 10.1016/S0306-4522(98)00749-0; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2005, NAT NEUROSCI, V8, P585, DOI 10.1038/nn1457; Dupuy D, 2007, NAT BIOTECHNOL, V25, P663, DOI 10.1038/nbt1305; Elphick MR, 2007, GENE, V399, P65, DOI 10.1016/j.gene.2007.04.025; Elphick MR, 2005, HANDB EXP PHARMACOL, V168, P283; FABIAN TJ, 1994, J GERONTOL, V49, pB145, DOI 10.1093/geronj/49.4.B145; Fielenbach N, 2008, GENE DEV, V22, P2149, DOI 10.1101/gad.1701508; Hardison S, 2006, PROSTAG OTH LIPID M, V81, P106, DOI 10.1016/j.prostaglandins.2006.08.002; Held JM, 2006, AGING CELL, V5, P283, DOI 10.1111/j.1474-9726.2006.00218.x; Hobert O, 2002, BIOTECHNIQUES, V32, P728, DOI 10.2144/02324bm01; Honjoh S, 2009, NATURE, V457, P726, DOI 10.1038/nature07583; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Izzo AA, 2010, OBESITY, V18, P55, DOI 10.1038/oby.2009.186; Kaeberlein TL, 2006, AGING CELL, V5, P487, DOI 10.1111/j.1474-9726.2006.00238.x; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Kirkham TC, 2002, BRIT J PHARMACOL, V136, P550, DOI 10.1038/sj.bjp.0704767; Knight CG, 2002, EVOL DEV, V4, P16, DOI 10.1046/j.1525-142x.2002.01058.x; Lehtonen M, 2008, CHEM BIODIVERS, V5, P2431, DOI 10.1002/cbdv.200890208; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; Mair W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004535; McPartland JM, 2006, GENE, V370, P64, DOI 10.1016/j.gene.2005.11.004; McPartland JM, 2003, GENE, V312, P297, DOI 10.1016/S0378-1119(03)00638-3; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Soderstrom K, 2004, J NEUROSCI, V24, P10013, DOI 10.1523/JNEUROSCI.3298-04.2004; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Sultana T, 2006, J CHROMATOGR A, V1101, P278, DOI 10.1016/j.chroma.2005.10.027; Timmons L, 2003, MOL BIOL CELL, V14, P2972, DOI 10.1091/mbc.E03-01-0858; Valenti M, 2005, J NEUROCHEM, V95, P662, DOI 10.1111/j.1471-4159.2005.03406.x; Watts JL, 2002, P NATL ACAD SCI USA, V99, P5854, DOI 10.1073/pnas.092064799	39	104	111	6	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 12	2011	473	7346					226	+		10.1038/nature10007	http://dx.doi.org/10.1038/nature10007			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562563	Green Accepted			2022-12-28	WOS:000290487200041
J	Taljaard, M; McRae, AD; Weijer, C; Bennett, C; Dixon, S; Taleban, J; Skea, Z; Eccles, MP; Brehaut, JC; Donner, A; Saginur, R; Boruch, RF; Grimshaw, JM				Taljaard, Monica; McRae, Andrew D.; Weijer, Charles; Bennett, Carol; Dixon, Stephanie; Taleban, Julia; Skea, Zoe; Eccles, Martin P.; Brehaut, Jamie C.; Donner, Allan; Saginur, Raphael; Boruch, Robert F.; Grimshaw, Jeremy M.			Inadequate reporting of research ethics review and informed consent in cluster randomised trials: review of random sample of published trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							METHODOLOGICAL QUALITY; BOARD APPROVAL; ISSUES; DESIGN; REQUIREMENTS; RATIONALE; IMPROVE	Objectives To investigate the extent to which authors of cluster randomised trials adhered to two basic requirements of the World Medical Association's Declaration of Helsinki and the International Committee of Medical Journal Editors' uniform requirements for manuscripts (namely, reporting of research ethics review and informed consent), to determine whether the adequacy of reporting has improved over time, and to identify characteristics of cluster randomised trials associated with reporting of ethics practices. Design Review of a random sample of published cluster randomised trials from an electronic search in Medline. Setting Cluster randomised trials in health research published in English language journals from 2000 to 2008. Study sample 300 cluster randomised trials published in 150 journals. Results 77 (26%, 95% confidence interval 21% to 31%) trials failed to report ethics review. The proportion reporting ethics review increased significantly over time (P<0.001). Trials with data collection interventions at the individual level were more likely to report ethics review than were trials that used routine data sources only (79% (n=151) v 55% (23); P=0.008). Trials that accounted for clustering in the design and analysis were more likely to report ethics review. The median impact factor of the journal of publication was higher for trials that reported ethics review (3.4 v 2.3; P<0.001). 93 (31%, 26% to 36%) trials failed to report consent. Reporting of consent increased significantly over time (P<0.001). Trials with interventions targeting participants at the individual level were more likely to report consent than were trials with interventions targeting the cluster level (87% (90) v 48% (41); P<0.001). Trials with data collection interventions at the individual level were more likely to report consent than were those that used routine data sources only (78% (146) v 29% (11); P<0.001). Conclusions Reporting of research ethics protections in cluster randomised trials is inadequate. In addition to research ethics approval, authors should report whether informed consent was sought, from whom consent was sought, and what consent was for.	[Taljaard, Monica; Bennett, Carol; Brehaut, Jamie C.; Grimshaw, Jeremy M.] Ottawa Civic Hosp, Clin Epidemiol Program, Res Inst, Ottawa, ON K1Y 4E9, Canada; [McRae, Andrew D.] Univ Calgary, Div Emergency Med, Foothills Med Ctr, Calgary, AB, Canada; [Weijer, Charles] Univ Western Ontario, Rotman Inst Philosophy, Dept Philosophy, London, ON, Canada; [Dixon, Stephanie; Taleban, Julia; Donner, Allan] Univ Western Ontario, Dept Epidemiol & Biostat, Schulich Sch Med & Dens, London, ON, Canada; [Skea, Zoe] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland; [Eccles, Martin P.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England; [Boruch, Robert F.] Univ Penn, Grad Sch Educ, Philadelphia, PA 19104 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Calgary; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Aberdeen; Newcastle University - UK; University of Pennsylvania	Taljaard, M (corresponding author), Ottawa Civic Hosp, Clin Epidemiol Program, Res Inst, Civ Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	mtaljaard@ohri.ca	Grimshaw, Jeremy/D-8726-2013; Eccles, Martin P/AAD-4029-2020; Weijer, Charles/ABC-5433-2020	Weijer, Charles/0000-0002-5510-1074; Grimshaw, Jeremy/0000-0001-8015-8243; Bennett, Carol/0000-0002-3033-9860; Taljaard, Monica/0000-0002-3978-8961	Canadian Institutes of Health Research [MOP85066, MOP89790]; Chief Scientist Office [HSRU2] Funding Source: researchfish	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Chief Scientist Office	This study has been funded by operating grants MOP85066 and MOP89790 from the Canadian Institutes of Health Research. The funding agency had no role in the study design; collection, analysis, or interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication.	Althabe F, 2008, NEW ENGL J MED, V358, P1929, DOI 10.1056/NEJMsa071456; Amdur RJ, 1997, JAMA-J AM MED ASSOC, V277, P909, DOI 10.1001/jama.277.11.909; [Anonymous], SCI AN; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; DiGuiseppi C, 2010, INJURY PREV, V16, P61, DOI 10.1136/ip.2009.023119; Donner A, 2004, AM J PUBLIC HEALTH, V94, P416, DOI 10.2105/AJPH.94.3.416; Edwards SJL, 1999, BMJ-BRIT MED J, V318, P1407, DOI 10.1136/bmj.318.7195.1407; Eldridge SM, 2005, CLIN TRIALS, V2, P91, DOI 10.1191/1740774505cn070oa; Falagas ME, 2008, FASEB J, V22, P2623, DOI 10.1096/fj.08-107938; Finlay KA, 2008, J MED ETHICS, V34, P761, DOI 10.1136/jme.2007.023325; Hutton JL, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-52; Hutton JL, 2001, STAT MED, V20, P473, DOI 10.1002/1097-0258(20010215)20:3<473::AID-SIM805>3.0.CO;2-D; International Committee of Medical Journal Editors, 2010, UN REQ MAN SUB BIOM; International Monetary Fund, 2008, WORLD EC FIN SURV WO; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; *MRC, 2002, CLUST RAND TRIALS ME; Ruiz-Canela M, 2001, J MED ETHICS, V27, P172, DOI 10.1136/jme.27.3.172; Taljaard M, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-15; Taljaard M, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-61; Tuech JJ, 2005, J MED ETHICS, V31, P251, DOI 10.1136/jme.2003.007435; Weijer C, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-100; World Medical Association, 2011, DECL HELS ETH PRINC	22	36	37	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 11	2011	342								d2496	10.1136/bmj.d2496	http://dx.doi.org/10.1136/bmj.d2496			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765OP	21562003	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000290718400001
J	Huang, PY; He, ZY; Ji, SY; Sun, HW; Xiang, D; Liu, CC; Hu, YP; Wang, X; Hui, LJ				Huang, Pengyu; He, Zhiying; Ji, Shuyi; Sun, Huawang; Xiang, Dao; Liu, Changcheng; Hu, Yiping; Wang, Xin; Hui, Lijian			Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors	NATURE			English	Article							ENRICHED TRANSCRIPTION FACTORS; EMBRYONIC STEM-CELLS; TYROSINEMIA TYPE-I; PANCREAS PROGENITORS; HEPATIC-DYSFUNCTION; DIRECT CONVERSION; GENE-EXPRESSION; FACTOR NETWORK; LIVER-FUNCTION; MURINE MODEL	The generation of functional hepatocytes independent of donor liver organs is of great therapeutic interest with regard to regenerative medicine and possible cures for liver disease(1). Induced hepatic differentiation has been achieved previously using embryonic stem cells or induced pluripotent stem cells(2-8). Particularly, hepatocytes generated froma patient's own induced pluripotent stem cells could theoretically avoid immunological rejection. However, the induction of hepatocytes frominduced pluripotent stem cells is a complicated process that would probably be replaced with the arrival of improved technology. Overexpression of lineage-specific transcription factors directly converts terminally differentiated cells into some other lineages(9-12), including neurons(13), cardiomyocytes(14) and blood progenitors(15); however, it remains unclear whether these lineage-converted cells could repair damaged tissues in vivo. Here we demonstrate the direct induction of functional hepatocytelike (iHep) cells from mouse tail-tip fibroblasts by transduction of Gata4, Hnf1 alpha and Foxa3, and inactivation of p19(Arf). iHep cells show typical epithelial morphology, express hepatic genes and acquire hepatocyte functions. Notably, transplanted iHep cells repopulate the livers of fumarylacetoacetate-hydrolase-deficient (Fah(-/-)) mice and rescue almost half of recipients from death by restoring liver functions. Our study provides a novel strategy to generate functional hepatocyte-like cells for the purpose of liver engineering and regenerative medicine.	[Huang, Pengyu; He, Zhiying; Ji, Shuyi; Sun, Huawang; Liu, Changcheng; Hu, Yiping; Wang, Xin; Hui, Lijian] Chinese Acad Sci, Lab Mol Cell Biol, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; [He, Zhiying; Xiang, Dao; Liu, Changcheng; Hu, Yiping] Second Mil Med Univ, Dept Cell Biol, Shanghai 200433, Peoples R China; [Wang, Xin] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Wang, Xin] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Naval Medical University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Hui, LJ (corresponding author), Chinese Acad Sci, Lab Mol Cell Biol, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Yueyang Rd 320, Shanghai 200031, Peoples R China.	ljhui@sibs.ac.cn	Huang, Pengyu/ABF-5330-2021; Huang, Pengyu/ABH-1721-2021	Huang, Pengyu/0000-0001-8394-7280	National Science Foundation of China [91019014, 30801115]; Chinese Academy of Sciences [KSCX2-YW-R-241, XDA01010402]; Chinese National 863 Plan Project [2006AA02Z474]; National Key Basic Research and Development Program of China [2007CB947102, 2009CB941100]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); Chinese National 863 Plan Project(National High Technology Research and Development Program of China); National Key Basic Research and Development Program of China(National Basic Research Program of China)	We would like to thank X. Chen, J. Cen, L. Zhang and J. Yuan for technical support, and F. Tang and D. Li for comments. The laboratory of L. H. is funded by the National Science Foundation of China (91019014) and the Chinese Academy of Sciences (KSCX2-YW-R-241, XDA01010402 and the Hundred Talents Program). The laboratory of X. W. is supported by the National Science Foundation of China (30801115), Chinese National 863 Plan Project (2006AA02Z474) and National Key Basic Research and Development Program of China (2007CB947102 and 2009CB941100).	Basma H, 2009, GASTROENTEROLOGY, V136, P990, DOI 10.1053/j.gastro.2008.10.047; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Duan YY, 2007, STEM CELLS, V25, P3058, DOI 10.1634/stemcells.2007-0291; Feng R, 2008, P NATL ACAD SCI USA, V105, P6057, DOI 10.1073/pnas.0711961105; Gouon-Evans V, 2006, NAT BIOTECHNOL, V24, P1402, DOI 10.1038/nbt1258; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; GROMPE M, 1995, NAT GENET, V10, P453, DOI 10.1038/ng0895-453; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Kyrmizi I, 2006, GENE DEV, V20, P2293, DOI 10.1101/gad.390906; Li FM, 2010, GASTROENTEROLOGY, V139, P2158, DOI 10.1053/j.gastro.2010.08.042; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Mikula M, 2004, HEPATOLOGY, V39, P628, DOI 10.1002/hep.20084; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Schrem H, 2004, PHARMACOL REV, V56, P291, DOI 10.1124/pr.56.2.5; Schrem H, 2002, PHARMACOL REV, V54, P129, DOI 10.1124/pr.54.1.129; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Si-Tayeb K, 2010, HEPATOLOGY, V51, P297, DOI 10.1002/hep.23354; Soto-Gutierrez A, 2006, NAT BIOTECHNOL, V24, P1412, DOI 10.1038/nbt1257; Sullivan GJ, 2010, HEPATOLOGY, V51, P329, DOI 10.1002/hep.23335; Szabo E, 2010, NATURE, V468, P521, DOI 10.1038/nature09591; Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797; Wang X, 2003, P NATL ACAD SCI USA, V100, P11881, DOI 10.1073/pnas.1734199100; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Zaret KS, 2008, COLD SH Q B, V73, P119, DOI 10.1101/sqb.2008.73.040; Zaret KS, 2008, NAT REV GENET, V9, P329, DOI 10.1038/nrg2318; Zern MA, 2009, GASTROENTEROLOGY, V136, P767, DOI 10.1053/j.gastro.2009.01.019; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314	29	611	692	9	213	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 21	2011	475	7356					386	U142		10.1038/nature10116	http://dx.doi.org/10.1038/nature10116			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	794PA	21562492				2022-12-28	WOS:000292911200044
J	Laguette, N; Sobhian, B; Casartelli, N; Ringeard, M; Chable-Bessia, C; Segeral, E; Yatim, A; Emiliani, S; Schwartz, O; Benkirane, M				Laguette, Nadine; Sobhian, Bijan; Casartelli, Nicoletta; Ringeard, Mathieu; Chable-Bessia, Christine; Segeral, Emmanuel; Yatim, Ahmad; Emiliani, Stephane; Schwartz, Olivier; Benkirane, Monsef			SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx	NATURE			English	Article							GAMMA-INDUCED PROTEIN; INNATE IMMUNITY; INFECTION; INHIBITION; TARGET; DOMAIN	The primate lentivirus auxiliary protein Vpx counteracts an unknown restriction factor that renders human dendritic and myeloid cells largely refractory to HIV-1 infection(1-6). Here we identify SAMHD1 as this restriction factor. SAMHD1 is a protein involved in Aicardi-Goutieres syndrome, a genetic encephalopathy with symptoms mimicking congenital viral infection, that has been proposed to act as a negative regulator of the interferon response(7). We show that Vpx induces proteasomal degradation of SAMHD1. Silencing of SAMHD1 in non-permissive cell lines alleviates HIV-1 restriction and is associated with a significant accumulation of viral DNA in infected cells. Concurrently, overexpression of SAMHD1 in sensitive cells inhibits HIV-1 infection. The putative phosphohydrolase activity of SAMHD1 is probably required for HIV-1 restriction. Vpx-mediated relief of restriction is abolished in SAMHD1-negative cells. Finally, silencing of SAMHD1 markedly increases the susceptibility of monocytic-derived dendritic cells to infection. Our results demonstrate that SAMHD1 is an antiretroviral protein expressed in cells of the myeloid lineage that inhibits an early step of the viral life cycle.	[Laguette, Nadine; Sobhian, Bijan; Ringeard, Mathieu; Chable-Bessia, Christine; Yatim, Ahmad; Benkirane, Monsef] CNRS, Inst Genet Humaine, Lab Virol Mol, UPR1142, F-34000 Montpellier, France; [Casartelli, Nicoletta; Schwartz, Olivier] CNRS, Inst Pasteur, Virus & Immun Unit, URA 3015, Paris, France; [Segeral, Emmanuel; Emiliani, Stephane] Univ Paris 05, CNRS, Inst Cochin, UMR 8104,INSERM,U567, Paris, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Benkirane, M (corresponding author), CNRS, Inst Genet Humaine, Lab Virol Mol, UPR1142, F-34000 Montpellier, France.	nadine.laguette@igh.cnrs.fr; monsef.benkirane@igh.cnrs.fr	Schwartz, Olivier/AAZ-3765-2021; Casartelli, Nicoletta/L-4798-2015; Laguette, Nadine/A-2764-2019; Casartelli, Nicoletta/AAD-5583-2021	Schwartz, Olivier/0000-0002-0729-1475; Laguette, Nadine/0000-0001-8072-5607; Sobhian, Bijan/0000-0001-7255-6006	ERC [250333]; Sidaction; ANRS; FRM 'equipe labellisee'; CNRS/region Languedoc Roussillon; European FP7 [201412]; Institut Pasteur	ERC(European Research Council (ERC)European Commission); Sidaction; ANRS(ANRSFrench National Research Agency (ANR)); FRM 'equipe labellisee'; CNRS/region Languedoc Roussillon(Centre National de la Recherche Scientifique (CNRS)Region Occitanie); European FP7; Institut Pasteur(European Commission)	We wish to thank members of the Molecular Virology laboratory for critical reading of the manuscript, N. Manel for SIV3<SUP>+</SUP> molecular clone and J. Luban for SIV delta Vpx and Vpx mutants. This work was supported by grants from the ERC (250333), Sidaction, ANRS and FRM 'equipe labellisee' to M. B. N. L was supported by ANRS and SIDACTION fellowships; B. S. by ANRS fellowship; M. R. by CNRS/region Languedoc Roussillon fellowship. O.S. and N. C. are supported by grants from ANRS, Sidaction, ANR, European FP7 contract 201412 and Institut Pasteur.	Altfeld M, 2011, NAT REV IMMUNOL, V11, P176, DOI 10.1038/nri2935; Ayinde D, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-35; Bergamaschi A, 2009, J VIROL, V83, P4854, DOI 10.1128/JVI.00187-09; Blanchet FP, 2010, IMMUNITY, V32, P654, DOI 10.1016/j.immuni.2010.04.011; Borrow P, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-84; Cobb A, 2011, J IMMUNOL METHODS, V365, P27, DOI 10.1016/j.jim.2010.11.002; Goujon C, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-2; Goujon C, 2008, J VIROL, V82, P12335, DOI 10.1128/JVI.01181-08; Gramberg T, 2010, J VIROL, V84, P1387, DOI 10.1128/JVI.01437-09; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; Kaushik R, 2009, CELL HOST MICROBE, V6, P68, DOI 10.1016/j.chom.2009.05.022; Kumar D, 2009, MOL BIOL CELL, V20, P3170, DOI 10.1091/mbc.E08-12-1185; Lepelley A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001284; Li N, 2000, IMMUNOL LETT, V74, P221, DOI 10.1016/S0165-2478(00)00276-5; Liao WP, 2008, PROTEOMICS, V8, P2640, DOI 10.1002/pmic.200700954; Manel N, 2010, NATURE, V467, P214, DOI 10.1038/nature09337; Nakatani Y, 2003, METHOD ENZYMOL, V370, P430; Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553; Rice GI, 2009, NAT GENET, V41, P829, DOI 10.1038/ng.373; Sharova N, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000057; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Sobhian B, 2010, MOL CELL, V38, P439, DOI 10.1016/j.molcel.2010.04.012; Srivastava S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000059; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Yan N, 2011, CURR OPIN IMMUNOL, V23, P21, DOI 10.1016/j.coi.2010.11.004; Zhao DC, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-114; Zimmerman MD, 2008, J MOL BIOL, V378, P215, DOI 10.1016/j.jmb.2008.02.036	27	1083	1113	2	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2011	474	7353					654	U132		10.1038/nature10117	http://dx.doi.org/10.1038/nature10117			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	785CF	21613998	Green Accepted			2022-12-28	WOS:000292204300042
J	Cymes, GD; Grosman, C				Cymes, Gisela D.; Grosman, Claudio			Tunable pK(a) values and the basis of opposite charge selectivities in nicotinic-type receptors	NATURE			English	Article							CONGENITAL MYASTHENIC SYNDROME; GATED ION CHANNELS; ACETYLCHOLINE-RECEPTOR; SINGLE-CHANNEL; DIELECTRIC-CONSTANTS; CHLORIDE CHANNEL; M2 DOMAIN; MUTATIONS; PORE; SUBUNIT	Among ion channels, only the nicotinic-receptor superfamily has evolved to generate both cation-and anion-selective members. Although other, structurally unrelated, neurotransmitter-gated cation channels exist, no other type of neurotransmitter-gated anion channel, and thus no other source of fast synaptic inhibitory signals, has been described so far. In addition to the seemingly straightforward electrostatic effect of the presence (in the cation-selective members) or absence (in the anion-selective ones) of a ring of pore-facing carboxylates, mutational studies have identified other features of the amino-acid sequence near the intracellular end of the pore-lining transmembrane segments (M2) that are also required to achieve the high charge selectivity shown by native channels(1-10). However, the mechanism underlying this more subtle effect has remained elusive(11) and a subject of speculation. Here we show, using single-channel electrophysiological recordings to estimate the protonation state of native ionizable side chains, that anion-selective-type sequences favour whereas cation-selective-type sequences prevent the protonation of the conserved, buried basic residues at the intracellular entrance of the pore (the M2 0' position). We conclude that the previously unrecognized tunable charge state of the 0' ring of buried basic side chains is an essential feature of these channels' versatile charge-selectivity filter.	[Cymes, Gisela D.; Grosman, Claudio] Univ Illinois, Ctr Biophys & Computat Biol, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; [Cymes, Gisela D.; Grosman, Claudio] Univ Illinois, Neurosci Program, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Grosman, C (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA.	grosman@illinois.edu		Grosman, Claudio/0000-0001-8093-8362; Cymes, Gisela/0000-0002-4155-585X	US National Institutes of Health [R01-NS042169]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042169] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank S. Sine for wild-type muscle AChR cDNA; M. Slaughter and D. Papke for wild-type alpha 1 GlyR cDNA; S. Elenes for critical advice on fast-perfusion experiments; E. Jakobsson and H. Robertson for discussions; and G. Papke, M. Maybaum, J. Pizarek and C. Staehlin for technical assistance. This work was supported by a grant from the US National Institutes of Health (R01-NS042169 to C.G.).	BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; Beg AA, 2003, NAT NEUROSCI, V6, P1145, DOI 10.1038/nn1136; Bocquet N, 2007, NATURE, V445, P116, DOI 10.1038/nature05371; Chimenti MS, 2011, J MOL BIOL, V405, P361, DOI 10.1016/j.jmb.2010.10.001; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Cymes GD, 2005, NATURE, V438, P975, DOI 10.1038/nature04293; Cymes GD, 2008, NAT STRUCT MOL BIOL, V15, P389, DOI 10.1038/nsmb.1407; Elenes S, 2006, J GEN PHYSIOL, V128, P615, DOI 10.1085/jgp.200609570; Engel AG, 1996, HUM MOL GENET, V5, P1217, DOI 10.1093/hmg/5.9.1217; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Grosman C, 2000, J GEN PHYSIOL, V115, P637, DOI 10.1085/jgp.115.5.637; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; Harms MJ, 2009, J MOL BIOL, V389, P34, DOI 10.1016/j.jmb.2009.03.039; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Kamerlin SCL, 2009, J PHYS CHEM B, V113, P1253, DOI 10.1021/jp8071712; Karp DA, 2010, BIOCHEMISTRY-US, V49, P4138, DOI 10.1021/bi902114m; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Keramidas A, 2004, PROG BIOPHYS MOL BIO, V86, P161, DOI 10.1016/j.pbiomolbio.2003.09.002; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; Krishek BJ, 1996, MOL PHARMACOL, V49, P494; Lee DJS, 2003, NEUROSCI LETT, V351, P196, DOI 10.1016/j.neulet.2003.08.005; Menard C, 2005, J BIOL CHEM, V280, P27502, DOI 10.1074/jbc.M501624200; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; Papke D, 2011, J PHYSIOL-LONDON, V589, P1571, DOI 10.1113/jphysiol.2010.203315; Qin F, 2004, BIOPHYS J, V86, P1488, DOI 10.1016/S0006-3495(04)74217-4; Qin F, 1996, BIOPHYS J, V70, P264, DOI 10.1016/S0006-3495(96)79568-1; Schutz CN, 2001, PROTEINS, V44, P400, DOI 10.1002/prot.1106; Sunesen M, 2006, J BIOL CHEM, V281, P14875, DOI 10.1074/jbc.M511657200; Thompson AJ, 2003, BRIT J PHARMACOL, V140, P359, DOI 10.1038/sj.bjp.0705424; van Nierop P, 2005, J NEUROSCI, V25, P10617, DOI 10.1523/JNEUROSCI.2015-05.2005; Wotring VE, 2003, J PHYSIOL-LONDON, V548, P527, DOI 10.1113/jphysiol.2002.032045	32	21	21	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 23	2011	474	7352					526	U160		10.1038/nature10015	http://dx.doi.org/10.1038/nature10015			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	781NJ	21602825	Green Accepted			2022-12-28	WOS:000291939700052
J	Settembre, C; Di Malta, C; Polito, VA; Garcia-Arencibia, M; Vetrini, F; Erdin, S; Erdin, SU; Huynh, T; Medina, D; Colella, P; Sardiello, M; Rubinsztein, DC; Ballabio, A				Settembre, Carmine; Di Malta, Chiara; Polito, Vinicia Assunta; Garcia-Arencibia, Moises; Vetrini, Francesco; Erdin, Serkan; Erdin, Serpil Uckac; Huynh, Tuong; Medina, Diego; Colella, Pasqualina; Sardiello, Marco; Rubinsztein, David C.; Ballabio, Andrea			TFEB Links Autophagy to Lysosomal Biogenesis	SCIENCE			English	Article							IN-VIVO; PHOSPHORYLATION SITES; PROTEIN-DEGRADATION; PREDICTION; PATHWAYS; ULK1	Autophagy is a cellular catabolic process that relies on the cooperation of autophagosomes and lysosomes. During starvation, the cell expands both compartments to enhance degradation processes. We found that starvation activates a transcriptional program that controls major steps of the autophagic pathway, including autophagosome formation, autophagosome-lysosome fusion, and substrate degradation. The transcription factor EB (TFEB), a master gene for lysosomal biogenesis, coordinated this program by driving expression of autophagy and lysosomal genes. Nuclear localization and activity of TFEB were regulated by serine phosphorylation mediated by the extracellular signal-regulated kinase 2, whose activity was tuned by the levels of extracellular nutrients. Thus, a mitogen-activated protein kinase-dependent mechanism regulates autophagy by controlling the biogenesis and partnership of two distinct cellular organelles.	[Settembre, Carmine; Di Malta, Chiara; Polito, Vinicia Assunta; Medina, Diego; Colella, Pasqualina; Ballabio, Andrea] TIGEM, I-80131 Naples, Italy; [Settembre, Carmine; Polito, Vinicia Assunta; Vetrini, Francesco; Erdin, Serkan; Erdin, Serpil Uckac; Huynh, Tuong; Sardiello, Marco; Ballabio, Andrea] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Settembre, Carmine; Polito, Vinicia Assunta; Erdin, Serkan; Erdin, Serpil Uckac; Huynh, Tuong; Sardiello, Marco; Ballabio, Andrea] Texas Childrens Hosp, Jan & Dan Duncan Neurol Res Inst, Houston, TX 77030 USA; [Garcia-Arencibia, Moises; Rubinsztein, David C.] Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 0XY, England; [Ballabio, Andrea] Univ Naples Federico 2, Dept Pediat, I-80131 Naples, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Baylor College of Medicine; Baylor College of Medicine; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Naples Federico II	Ballabio, A (corresponding author), TIGEM, Via Pietro Castellino 111, I-80131 Naples, Italy.	ballabio@tigem.it	Erdin, Serkan/B-4988-2008; Garcia-Arencibia, Moises/K-9920-2013; Polito, Vinicia Assunta/AAA-5219-2020; Di Malta, Chiara/AAX-6395-2020; Medina, Diego/AAC-9622-2020; Rubinsztein, David C/C-3472-2011; COLELLA, PASQUALINA/I-5478-2017; Erdin, Serkan/AAE-4288-2019; Garcia-Arencibia, Moises/B-5538-2012; Settembre, Carmine/AIA-9170-2022; BALLABIO, Andrea/AAL-2672-2020	Erdin, Serkan/0000-0001-6587-2625; Garcia-Arencibia, Moises/0000-0002-1618-4487; Medina, Diego/0000-0002-7347-2645; COLELLA, PASQUALINA/0000-0002-4268-2391; BALLABIO, Andrea/0000-0003-1381-4604; Polito, Vinicia Assunta/0000-0002-5698-7778; SETTEMBRE, Carmine/0000-0002-5829-8589	Italian Telethon Foundation; Beyond Batten Disease Foundation; European Research Council [250154]; European Molecular Biology Organization; Wellcome Trust; U.K. Medical Research Council; Intellectual and Developmental Disabilities Research Center at the Baylor College of Medicine [5 P30 HD024064]; MRC [G0600194] Funding Source: UKRI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS078072] Funding Source: NIH RePORTER; Medical Research Council [G0600194] Funding Source: researchfish	Italian Telethon Foundation(Fondazione Telethon); Beyond Batten Disease Foundation; European Research Council(European Research Council (ERC)European Commission); European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); Wellcome Trust(Wellcome TrustEuropean Commission); U.K. Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Intellectual and Developmental Disabilities Research Center at the Baylor College of Medicine; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank H. Bellen, A. De Matteis, G. Diez-Roux, M. Ferron, G. Karsenty, A. Luini, and H. Zoghbi for critical reading of the manuscript; R. Polishchuck for technical advice with the electron microscopy; K. Moreau, M. Renna, A. Ronza, and M. Palmieri for their contribution; and L. Naldini for the lentivirus production. We acknowledge the support of the Italian Telethon Foundation (C.S., C.D.M., V.P., M.S., and A.B.); the Beyond Batten Disease Foundation (C.S., C.D.M., V.P., S.U.E., T.H., M.S., and A.B.); European Research Council Advanced Investigator grant no. 250154 (A.B.); a European Molecular Biology Organization long-term fellowship (C.S.); a Wellcome Trust Senior Research Fellowship (D.C.R.); and a U.K. Medical Research Council program grant (D.C.R.). We wish to thank Cherie and James C. Flores for their generous donation. We also thank S. Tooze for GFP-LC3 cells, T. Yoshimori for the RFP-GFP, and P. Pandolfi for the HA-ERK2 and ca-MEK; M. Krentz for the CAG-lox-LacZ plasmid and for the useful suggestions during transgene generation; and the TIGEM AAV vector core for virus production. Confocal microscopy was supported by the Intellectual and Developmental Disabilities Research Center at the Baylor College of Medicine (5 P30 HD024064).	Amanchy R, 2007, NAT BIOTECHNOL, V25, P285, DOI 10.1038/nbt0307-285; Bauvy C, 2009, METHOD ENZYMOL, V452, P47, DOI 10.1016/S0076-6879(08)03604-5; Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Dang TH, 2008, BIOINFORMATICS, V24, P2857, DOI 10.1093/bioinformatics/btn546; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Gnad F, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r250; He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hidvegi T, 2010, SCIENCE, V329, P229, DOI 10.1126/science.1190354; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Linding R, 2007, CELL, V129, P1415, DOI 10.1016/j.cell.2007.05.052; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Ravikumar B, 2004, NEUROREPORT, V15, P2443, DOI 10.1097/00001756-200411150-00001; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Settembre C, 2008, GENE DEV, V22, P2645, DOI 10.1101/gad.1711308; Settembre C, 2008, HUM MOL GENET, V17, P119, DOI 10.1093/hmg/ddm289; Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575; Xue Y, 2008, MOL CELL PROTEOMICS, V7, P1598, DOI 10.1074/mcp.M700574-MCP200; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004	29	1901	1953	15	240	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 17	2011	332	6036					1429	1433		10.1126/science.1204592	http://dx.doi.org/10.1126/science.1204592			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778FT	21617040	Green Accepted			2022-12-28	WOS:000291689000041
J	Arora, S; Thornton, K; Murata, G; Deming, P; Kalishman, S; Dion, D; Parish, B; Burke, T; Pak, W; Dunkelberg, J; Kistin, M; Brown, J; Jenkusky, S; Komaromy, M; Qualls, C				Arora, Sanjeev; Thornton, Karla; Murata, Glen; Deming, Paulina; Kalishman, Summers; Dion, Denise; Parish, Brooke; Burke, Thomas; Pak, Wesley; Dunkelberg, Jeffrey; Kistin, Martin; Brown, John; Jenkusky, Steven; Komaromy, Miriam; Qualls, Clifford			Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; PEGINTERFERON ALPHA-2B; RANDOMIZED-TRIAL; PLUS RIBAVIRIN; HEALTH-CENTER; PROJECT ECHO; PREDICTORS; TRANSPLANTATION; MANAGEMENT; MORTALITY	Background The Extension for Community Healthcare Outcomes (ECHO) model was developed to improve access to care for underserved populations with complex health problems such as hepatitis C virus (HCV) infection. With the use of video-conferencing technology, the ECHO program trains primary care providers to treat complex diseases. Methods We conducted a prospective cohort study comparing treatment for HCV infection at the University of New Mexico (UNM) HCV clinic with treatment by primary care clinicians at 21 ECHO sites in rural areas and prisons in New Mexico. A total of 407 patients with chronic HCV infection who had received no previous treatment for the infection were enrolled. The primary end point was a sustained virologic response. Results A total of 57.5% of the patients treated at the UNM HCV clinic (84 of 146 patients) and 58.2% of those treated at ECHO sites (152 of 261 patients) had a sustained viral response (difference in rates between sites, 0.7 percentage points; 95% confidence interval, -9.2 to 10.7; P = 0.89). Among patients with HCV genotype 1 infection, the rate of sustained viral response was 45.8% (38 of 83 patients) at the UNM HCV clinic and 49.7% (73 of 147 patients) at ECHO sites (P = 0.57). Serious adverse events occurred in 13.7% of the patients at the UNM HCV clinic and in 6.9% of the patients at ECHO sites. Conclusions The results of this study show that the ECHO model is an effective way to treat HCV infection in underserved communities. Implementation of this model would allow other states and nations to treat a greater number of patients infected with HCV than they are currently able to treat.	[Arora, Sanjeev] 1 Univ New Mexico, Dept Internal Med, Project ECHO, Albuquerque, NM 87131 USA; [Qualls, Clifford] Univ New Mexico, Clin & Translat Sci Ctr, Albuquerque, NM 87131 USA; [Jenkusky, Steven] Presbyterian Healthcare Serv, Adult & Geriatr Behav Hlth Clin, Albuquerque, NM USA; [Dunkelberg, Jeffrey] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; [Arora, Sanjeev; Thornton, Karla; Murata, Glen; Deming, Paulina; Kalishman, Summers; Dion, Denise; Parish, Brooke; Burke, Thomas; Pak, Wesley; Kistin, Martin; Brown, John; Komaromy, Miriam] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico; University of Iowa; University of New Mexico	Arora, S (corresponding author), 1 Univ New Mexico, Dept Internal Med, Project ECHO, MSC07 4245, Albuquerque, NM 87131 USA.	sarora@salud.unm.edu	Komaromy, Miriam/AAV-4820-2020	Dunkelberg, Jeffrey/0000-0001-9438-8154	Agency for Healthcare Research and Quality [UC1 HS015135, R24HS16510]; Robert Wood Johnson Foundation; New Mexico Department of Health; New Mexico State Legislature; ZymoGenetics; Genentech; Vertex Pharmaceuticals; Tibotec; Human Genome Sciences; Wyeth (now part of Pfizer); Schering-Plough (now part of Merck); Genentech-Roche; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [UC1HS015135, R24HS016510] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000997] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); New Mexico Department of Health; New Mexico State Legislature; ZymoGenetics; Genentech(Roche HoldingGenentech); Vertex Pharmaceuticals(Vertex Pharmaceuticals); Tibotec; Human Genome Sciences(GlaxoSmithKline); Wyeth (now part of Pfizer)(Wyeth); Schering-Plough (now part of Merck)(Merck & CompanySchering Plough Corporation); Genentech-Roche(Roche HoldingGenentech); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by the Agency for Healthcare Research and Quality (Health Information Technology Grant UC1 HS015135 and Minority Research Infrastructure Support Program grant R24HS16510), the Robert Wood Johnson Foundation, the New Mexico Department of Health, and the New Mexico State Legislature.; Dr. Arora reports receiving grant support from ZymoGenetics, Genentech, Vertex Pharmaceuticals, Tibotec, Human Genome Sciences, and Wyeth (now part of Pfizer), speaking fees from Schering-Plough (now part of Merck) and Genentech-Roche, and payment for advisory-board membership from Vertex Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.	Adashi EY, 2010, NEW ENGL J MED, V362, P2047, DOI 10.1056/NEJMp1003729; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Arora S, 2007, PUBLIC HEALTH REP, V122, P74, DOI 10.1177/00333549071220S214; Arora S, 2007, ACAD MED, V82, P154, DOI 10.1097/ACM.0b013e31802d8f68; Bach PB, 2004, NEW ENGL J MED, V351, P575, DOI 10.1056/NEJMsa040609; Backus LI, 2007, HEPATOLOGY, V46, P37, DOI 10.1002/hep.21662; Butt AA, 2007, GUT, V56, P385, DOI 10.1136/gut.2006.099150; Cook NL, 2007, HEALTH AFFAIR, V26, P1459, DOI 10.1377/hlthaff.26.5.1459; *CTR DIS PREV, 2010, HEP C FAQS HLTH PROF; Epstein AM, 2000, NEW ENGL J MED, V343, P1537, DOI 10.1056/NEJM200011233432106; Epstein AM, 2004, NEW ENGL J MED, V351, P603, DOI 10.1056/NEJMe048181; Freeman RB, 2008, AM J TRANSPLANT, V8, P958, DOI 10.1111/j.1600-6143.2008.02174.x; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; Jacobson IM, 2007, HEPATOLOGY, V46, P971, DOI 10.1002/hep.21932; Kanwal F, 2007, HEPATOLOGY, V46, P1741, DOI 10.1002/hep.21927; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Rodriguez-Torres M, 2010, NEW ENGL J MED, V363, P2474; Rousseau CM, 2008, AM J PUBLIC HEALTH, V98, P846, DOI 10.2105/AJPH.2007.113225; Shim M, 2005, HEPATOLOGY, V42, P688, DOI 10.1002/hep.20830; Spaulding AC, 2006, ANN INTERN MED, V144, P762, DOI 10.7326/0003-4819-144-10-200605160-00010; Tan JA, 2008, HEPATOLOGY, V48, P1387, DOI 10.1002/hep.22509; Volk ML, 2010, HEPATOLOGY, V51, P725, DOI 10.1002/hep.23503; WHO, 2020, HEP C; Wise M, 2008, HEPATOLOGY, V47, P1128, DOI 10.1002/hep.22165	25	651	657	2	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2011	364	23					2199	2207		10.1056/NEJMoa1009370	http://dx.doi.org/10.1056/NEJMoa1009370			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774NA	21631316	Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000291392100006
J	Laflamme, MA; Murry, CE				Laflamme, Michael A.; Murry, Charles E.			Heart regeneration	NATURE			English	Review							EMBRYONIC STEM-CELLS; CARDIAC MYOCYTES; FUNCTIONAL CARDIOMYOCYTES; SMOOTH-MUSCLE; PLOIDY LEVEL; DNA-CONTENT; TRANSPLANTATION; THERAPY; DIFFERENTIATION; FIBROBLASTS	Heart failure plagues industrialized nations, killing more people than any other disease. It usually results from a deficiency of specialized cardiac muscle cells known as cardiomyocytes, and a robust therapy to regenerate lost myocardium could help millions of patients every year. Heart regeneration is well documented in amphibia and fish and in developing mammals. After birth, however, human heart regeneration becomes limited to very slow cardiomyocyte replacement. Several experimental strategies to remuscularize the injured heart using adult stem cells and pluripotent stem cells, cellular reprogramming and tissue engineering are in progress. Although many challenges remain, these interventions may eventually lead to better approaches to treat or prevent heart failure.	[Laflamme, Michael A.; Murry, Charles E.] Univ Washington, Inst Stem Cell & Regenerat Med, Ctr Cardiovasc Biol, Dept Pathol, Seattle, WA 98109 USA; [Murry, Charles E.] Univ Washington, Inst Stem Cell & Regenerat Med, Ctr Cardiovasc Biol, Dept Bioengn, Seattle, WA 98109 USA; [Murry, Charles E.] Univ Washington, Inst Stem Cell & Regenerat Med, Ctr Cardiovasc Biol, Dept Med Cardiol, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Murry, CE (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Ctr Cardiovasc Biol, Dept Pathol, Seattle, WA 98109 USA.	murry@u.washington.edu	Laflamme, Michael/AAV-6791-2021	Laflamme, Michael/0000-0001-5908-880X	US National Institutes of Health; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL094374, R01HL084642] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank our many colleagues whose useful discussions and work contributed to the material presented here. This work was supported by grants from the US National Institutes of Health.	Adler C P, 1975, Recent Adv Stud Cardiac Struct Metab, V8, P373; Adler C P, 1975, Recent Adv Stud Cardiac Struct Metab, V6, P343; ADLER CP, 1986, J MOL CELL CARDIOL, V18, P39, DOI 10.1016/S0022-2828(86)80981-6; Ahuja P, 2007, PHYSIOL REV, V87, P521, DOI 10.1152/physrev.00032.2006; Andersen DC, 2009, STEM CELLS, V27, P1571, DOI 10.1002/stem.72; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Bearzi C, 2007, P NATL ACAD SCI USA, V104, P14068, DOI 10.1073/pnas.0706760104; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Bergmann O, 2011, EXP CELL RES, V317, P188, DOI 10.1016/j.yexcr.2010.08.017; Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680; Bersell K, 2009, CELL, V138, P257, DOI 10.1016/j.cell.2009.04.060; Bondue A, 2008, CELL STEM CELL, V3, P69, DOI 10.1016/j.stem.2008.06.009; BRODSKY VY, 1991, VIRCHOWS ARCH B, V61, P289; Carvalho AB, 2010, WORLD J CARDIOL, V2, P107, DOI 10.4330/wjc.v2.i5.107; Caspi O, 2007, J AM COLL CARDIOL, V50, P1884, DOI 10.1016/j.jacc.2007.07.054; Caspi O, 2007, CIRC RES, V100, P263, DOI 10.1161/01.RES.0000257776.05673.ff; Chen SL, 2004, AM J CARDIOL, V94, P92, DOI 10.1016/j.amjcard.2004.03.034; Chimenti I, 2010, CIRC RES, V106, P971, DOI 10.1161/CIRCRESAHA.109.210682; Domian IJ, 2009, SCIENCE, V326, P426, DOI 10.1126/science.1177350; Dvir T, 2009, P NATL ACAD SCI USA, V106, P14990, DOI 10.1073/pnas.0812242106; Efe JA, 2011, NAT CELL BIOL, V13, P215, DOI 10.1038/ncb2164; Engel FB, 2006, P NATL ACAD SCI USA, V103, P15546, DOI 10.1073/pnas.0607382103; Fernandes S, 2010, J MOL CELL CARDIOL, V49, P941, DOI 10.1016/j.yjmcc.2010.09.008; GRAJEK S, 1993, EUR HEART J, V14, P40, DOI 10.1093/eurheartj/14.1.40; Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055; Hassink RJ, 2008, CARDIOVASC RES, V78, P18, DOI 10.1093/cvr/cvm101; Hatzistergos KE, 2010, CIRC RES, V107, P913, DOI 10.1161/CIRCRESAHA.110.222703; He JQ, 2003, CIRC RES, V93, P32, DOI 10.1161/01.RES.0000080317.92718.99; Herget GW, 1997, CARDIOVASC RES, V36, P45, DOI 10.1016/S0008-6363(97)00140-5; Hsieh PCH, 2007, NAT MED, V13, P970, DOI 10.1038/nm1618; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Jopling C, 2010, NATURE, V464, P606, DOI 10.1038/nature08899; Kajstura J, 2010, CIRC RES, V107, P305, DOI 10.1161/CIRCRESAHA.110.223024; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Kikuchi K, 2010, NATURE, V464, P601, DOI 10.1038/nature08804; KINSELLA TJ, 1984, INT J RADIAT ONCOL, V10, P69, DOI 10.1016/0360-3016(84)90414-0; Kubo H, 2008, CIRCULATION, V118, P649, DOI 10.1161/CIRCULATIONAHA.107.761031; Kuhn B, 2007, NAT MED, V13, P962, DOI 10.1038/nm1619; Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327; Laflamme MA, 2007, ANNU REV PATHOL-MECH, V2, P307, DOI 10.1146/annurev.pathol.2.010506.092038; Lepilina A, 2006, CELL, V127, P607, DOI 10.1016/j.cell.2006.08.052; Li FQ, 1996, J MOL CELL CARDIOL, V28, P1737, DOI 10.1006/jmcc.1996.0163; Lorts A, 2009, CIRC RES, V104, pE1, DOI 10.1161/CIRCRESAHA.108.188649; MacMahon HE, 1937, AM J PATHOL, V13, P845; Madden LR, 2010, P NATL ACAD SCI USA, V107, P15211, DOI 10.1073/pnas.1006442107; Messina E, 2004, CIRC RES, V95, P911, DOI 10.1161/01.RES.0000147315.71699.51; Mirotsou M, 2007, P NATL ACAD SCI USA, V104, P1643, DOI 10.1073/pnas.0610024104; Moretti A, 2006, CELL, V127, P1151, DOI 10.1016/j.cell.2006.10.029; Murry CE, 1996, J CLIN INVEST, V98, P2209, DOI 10.1172/JCI119030; Murry CE, 2006, J AM COLL CARDIOL, V47, P1777, DOI 10.1016/j.jacc.2006.02.002; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nussbaum J, 2007, FASEB J, V21, P1345, DOI 10.1096/fj.06-6769com; OBERPRILLER JO, 1974, J EXP ZOOL, V187, P249, DOI 10.1002/jez.1401870208; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P1463, DOI 10.1006/jmcc.1996.0137; OLIVETTI G, 1991, CIRC RES, V68, P1560, DOI 10.1161/01.RES.68.6.1560; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Paige SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011134; Passier R, 2008, NATURE, V453, P322, DOI 10.1038/nature07040; Patella V, 1998, CIRCULATION, V97, P971; Pfister O, 2008, CIRC RES, V103, P825, DOI 10.1161/CIRCRESAHA.108.174615; Porrello ER, 2011, SCIENCE, V331, P1078, DOI 10.1126/science.1200708; Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857; Povsic TJ, 2010, EXPERT REV CARDIOVAS, V8, P1107, DOI 10.1586/ERC.10.99; Radisic M, 2004, P NATL ACAD SCI USA, V101, P18129, DOI 10.1073/pnas.0407817101; Ratner BD, 2004, ANNU REV BIOMED ENG, V6, P41, DOI 10.1146/annurev.bioeng.6.040803.140027; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Rumyantsev P. P., 1979, MUSCLE REGENERATION, P335; Rumyantsev P. P., 1991, GROWTH HYPERPLASIA C, P210; RUMYANTSEV PP, 1990, ACTA HISTOCHEM, P225; Rumyantsev PP., 1991, GROWTH HYPERPLASIA C; Sandstedt J, 2010, BASIC RES CARDIOL, V105, P545, DOI 10.1007/s00395-010-0088-1; Sartiani L, 2007, STEM CELLS, V25, P1136, DOI 10.1634/stemcells.2006-0466; Segers VFM, 2008, NATURE, V451, P937, DOI 10.1038/nature06800; Shi Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004; Smith RR, 2007, CIRCULATION, V115, P896, DOI 10.1161/CIRCULATIONAHA.106.655209; Soonpaa MH, 1997, AM J PHYSIOL-HEART C, V272, pH220, DOI 10.1152/ajpheart.1997.272.1.H220; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Stevens KR, 2009, P NATL ACAD SCI USA, V106, P16568, DOI 10.1073/pnas.0908381106; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tallini YN, 2009, P NATL ACAD SCI USA, V106, P1808, DOI 10.1073/pnas.0808920106; Tang XL, 2010, CIRCULATION, V121, P293, DOI 10.1161/CIRCULATIONAHA.109.871905; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Ueno S, 2007, P NATL ACAD SCI USA, V104, P9685, DOI 10.1073/pnas.0702859104; van Laake LW, 2008, CIRC RES, V102, P1008, DOI 10.1161/CIRCRESAHA.108.175505; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Whelan RS, 2010, ANNU REV PHYSIOL, V72, P19, DOI 10.1146/annurev.physiol.010908.163111; Wu SM, 2006, CELL, V127, P1137, DOI 10.1016/j.cell.2006.10.028; Xu XQ, 2008, DIFFERENTIATION, V76, P958, DOI 10.1111/j.1432-0436.2008.00284.x; Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zakharova L, 2010, CARDIOVASC RES, V87, P40, DOI 10.1093/cvr/cvq027; Zaruba MM, 2010, CIRCULATION, V121, P1992, DOI 10.1161/CIRCULATIONAHA.109.909093; Zhang JH, 2009, CIRC RES, V104, pE30, DOI 10.1161/CIRCRESAHA.108.192237; Zhu WZ, 2010, CIRC RES, V107, P776, DOI 10.1161/CIRCRESAHA.110.223917; Zhu WZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005407; Zimmermann WH, 2006, NAT MED, V12, P452, DOI 10.1038/nm1394; Zwi L, 2009, CIRCULATION, V120, P1513, DOI 10.1161/CIRCULATIONAHA.109.868885	99	851	893	8	398	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					326	335		10.1038/nature10147	http://dx.doi.org/10.1038/nature10147			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593865	Green Accepted			2022-12-28	WOS:000290722400039
J	Pastor, WA; Pape, UJ; Huang, Y; Henderson, HR; Lister, R; Ko, M; McLoughlin, EM; Brudno, Y; Mahapatra, S; Kapranov, P; Tahiliani, M; Daley, GQ; Liu, XS; Ecker, JR; Milos, PM; Agarwal, S; Rao, A				Pastor, William A.; Pape, Utz J.; Huang, Yun; Henderson, Hope R.; Lister, Ryan; Ko, Myunggon; McLoughlin, Erin M.; Brudno, Yevgeny; Mahapatra, Sahasransu; Kapranov, Philipp; Tahiliani, Mamta; Daley, George Q.; Liu, X. Shirley; Ecker, Joseph R.; Milos, Patrice M.; Agarwal, Suneet; Rao, Anjana			Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells	NATURE			English	Article							DEVELOPMENTAL REGULATORS; MYELOID CANCERS; DNA METHYLATION; 5-METHYLCYTOSINE; HYDROXYLATION; TET1; QUANTIFICATION; SPECIFICATION; PLURIPOTENT; CONVERSION	5-hydroxymethylcytosine (5hmC) is a modified base present at low levels in diverse cell types in mammals(1-5). 5hmC is generated by the TET family of Fe(II) and 2-oxoglutarate-dependent enzymes through oxidation of 5-methylcytosine (5mC)(1,2,4-7). 5hmC and TET proteins have been implicated in stem cell biology and cancer(1,4,5,8,9), but information on the genome-wide distribution of 5hmC is limited. Here we describe two novel and specific approaches to profile the genomic localization of 5hmC. The first approach, termed GLIB (glucosylation, periodate oxidation, biotinylation) uses a combination of enzymatic and chemical steps to isolate DNA fragments containing as few as a single 5hmC. The second approach involves conversion of 5hmC to cytosine 5-methylenesulphonate (CMS) by treatment of genomic DNA with sodium bisulphite, followed by immunoprecipitation of CMS-containing DNA with a specific antiserum to CMS5. High-throughput sequencing of 5hmC-containing DNA from mouse embryonic stem (ES) cells showed strong enrichment within exons and near transcriptional start sites. 5hmC was especially enriched at the start sites of genes whose promoters bear dual histone 3 lysine 27 trimethylation (H3K27me3) and histone 3 lysine 4 trimethylation (H3K4me3) marks. Our results indicate that 5hmC has a probable role in transcriptional regulation, and suggest a model in which 5hmC contributes to the 'poised' chromatin signature found at developmentally-regulated genes in ES cells.	[McLoughlin, Erin M.; Daley, George Q.; Agarwal, Suneet] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; [Pape, Utz J.; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [McLoughlin, Erin M.; Daley, George Q.; Agarwal, Suneet] Harvard Stem Cell Inst, Boston, MA 02115 USA; [Pastor, William A.; Pape, Utz J.; Henderson, Hope R.; Tahiliani, Mamta; Rao, Anjana] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA; [Pastor, William A.; Pape, Utz J.; Henderson, Hope R.; Tahiliani, Mamta; Rao, Anjana] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA; [Pastor, William A.; Huang, Yun; Henderson, Hope R.; Ko, Myunggon; Mahapatra, Sahasransu; Rao, Anjana] La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA; [Pape, Utz J.; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Lister, Ryan; Ecker, Joseph R.] Salk Inst Biol Studies, Genom Anal Lab, La Jolla, CA 92037 USA; [Brudno, Yevgeny] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; [Kapranov, Philipp; Milos, Patrice M.] Helicos BioSci Corp, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); La Jolla Institute for Immunology; Harvard University; Harvard T.H. Chan School of Public Health; Salk Institute; Harvard University	Agarwal, S (corresponding author), Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.	Suneet.Agarwal@childrens.harvard.edu; arao@idi.harvard.edu	Ecker, Joseph R/B-9144-2008; Lister, Ryan/B-5168-2012	Ecker, Joseph R/0000-0001-5799-5895; Lister, Ryan/0000-0001-6637-7239; Ko, Myunggon/0000-0002-6007-2570; Kapranov, Philipp/0000-0003-2647-4856; Henderson, Hope/0000-0002-1373-296X; Brudno, Yevgeny/0000-0003-2963-3293; Huang, Yun/0000-0001-5950-9168	National Science Foundation; Leukemia and Lymphoma Society; California Institute for Regenerative Medicine; National Institute of Health [RC1 DA028422, R01 AI44432, 1 R01 HD065812-01A1, NIH K08 HL089150]; Harvard Catalyst, The Harvard Clinical and Translational Science Center (NIH) [1 UL1 RR 025758-02]; Mary. K. Chapman Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD065812] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL089150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [RC1DA028422] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Catalyst, The Harvard Clinical and Translational Science Center (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary. K. Chapman Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank B. Ren for assistance in next generation sequencing using the Illumina platform. We thank M. Guttman for making his RNASeq data set available to us. W. A. P. is supported by a predoctoral graduate research fellowship from the National Science Foundation, and Y.H. by a postdoctoral fellowship from the Leukemia and Lymphoma Society. R. L. is supported by a California Institute for Regenerative Medicine Training Grant. This study was supported by the National Institute of Health grants RC1 DA028422, R01 AI44432 and 1 R01 HD065812-01A1 and a grant from the California Institute of Regenerative Medicine (to A. R.), a pilot grant from Harvard Catalyst, The Harvard Clinical and Translational Science Center (NIH Grant 1 UL1 RR 025758-02) and NIH K08 HL089150 (to S. A.), and a grant from the Mary. K. Chapman Foundation (to J.R.E.).	Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bowers J, 2009, NAT METHODS, V6, P593, DOI 10.1038/nmeth.1354; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Feng SH, 2010, P NATL ACAD SCI USA, V107, P8689, DOI 10.1073/pnas.1002720107; Fouse SD, 2008, CELL STEM CELL, V2, P160, DOI 10.1016/j.stem.2007.12.011; Guttman M, 2010, NAT BIOTECHNOL, V28, P503, DOI 10.1038/nbt.1633; Harris TD, 2008, SCIENCE, V320, P106, DOI 10.1126/science.1150427; HAYATSU H, 1979, BIOCHEMISTRY-US, V18, P632, DOI 10.1021/bi00571a013; Huang Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008888; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Iyer LM, 2009, CELL CYCLE, V8, P1698, DOI 10.4161/cc.8.11.8580; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008; Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Loenarz C, 2009, CHEM BIOL, V16, P580, DOI 10.1016/j.chembiol.2009.06.002; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103; Song CX, 2011, NAT BIOTECHNOL, V29, P68, DOI 10.1038/nbt.1732; Szwagierczak A, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq684; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Zhang H, 2003, NAT BIOTECHNOL, V21, P660, DOI 10.1038/nbt827; Zhang HK, 2010, CELL RES, V20, P1390, DOI 10.1038/cr.2010.156	28	614	659	2	144	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					394	397		10.1038/nature10102	http://dx.doi.org/10.1038/nature10102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21552279	Green Accepted, Green Published			2022-12-28	WOS:000290722400053
J	Gregoire, A; Hornby, SA				Gregoire, Alain; Hornby, Simonetta Agnello			Has child protection become a form of madness? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Gregoire, Alain] S Cent Strateg Hlth Author, Southampton, Hants, England		Gregoire, A (corresponding author), S Cent Strateg Hlth Author, Southampton, Hants, England.			Howard, Louise/0000-0001-9942-744X				*ACT CHILDR, 2009, DEPR RISK CAS EARL I; *BARN, 2009, LOCK GIV WHY CUST TH; *DEP CHILDR SCH FA, 2010, OUTC IND CHILDR LOOK; *DEP ED, CHILDR NEED CENS 200; FUREDI F, 2010, LICENSED HUG CHILD P; Munro E., 2010, MUNRO REV CHILD PR 1; New Economics Foundation, 2009, BACK FUT WHY INV CHI; NSPCC, 2003, IT DOESNT HAPP DIS C; *OFST, 2010, CHILDR CAR MON; Sidebotham P., 2000, CHILD ABUSE REV, V9, P311, DOI [10.1002/1099-0852%28200009/10%299:5%3C311::AID-CAR627%3E3.0.CO;2-U, DOI 10.1002/1099-0852%28200009/10%299:5%3C311::AID-CAR627%3E3.0.CO;2-U]; UNICEF, 2007, CHILD POV PERSP OV C	11	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 18	2011	342								d3040	10.1136/bmj.d3040	http://dx.doi.org/10.1136/bmj.d3040			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QQ	21593097				2022-12-28	WOS:000290951900011
J	Grubina, R; Smith, SA				Grubina, Rozalina; Smith, Steven A.			Intensive glucose control increased mortality and did not prevent CV events compared with standard glucose control in type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Grubina, Rozalina; Smith, Steven A.] Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Grubina, R (corresponding author), Mayo Clin, Rochester, MN 55905 USA.		Smith, Steven/HDM-9496-2022					Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI 10.2337/dc11-S011; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987	3	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-2	10.7326/0003-4819-154-10-201105170-02002	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576520				2022-12-28	WOS:000290620300001
J	Thase, ME				Thase, Michael E.			Cognitive-behavioral therapy reduced risk for recurrence in patients recently hospitalized with cardiovascular disease events	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Thase, ME (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							Miller DB, 1997, ARCH INTERN MED, V157, P2045, DOI 10.1001/archinte.157.18.2045; Rozanski A, 2005, J AM COLL CARDIOL, V45, P637, DOI 10.1016/j.jacc.2004.12.005	2	0	0	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-4	10.7326/0003-4819-154-10-201105170-02004	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576522				2022-12-28	WOS:000290620300003
J	Deslauriers, L; Schelew, E; Wieman, C				Deslauriers, Louis; Schelew, Ellen; Wieman, Carl			Improved Learning in a Large-Enrollment Physics Class	SCIENCE			English	Article							PEER	We compared the amounts of learning achieved using two different instructional approaches under controlled conditions. We measured the learning of a specific set of topics and objectives when taught by 3 hours of traditional lecture given by an experienced highly rated instructor and 3 hours of instruction given by a trained but inexperienced instructor using instruction based on research in cognitive psychology and physics education. The comparison was made between two large sections (N = 267 and N = 271) of an introductory undergraduate physics course. We found increased student attendance, higher engagement, and more than twice the learning in the section taught using research-based instruction.	[Deslauriers, Louis] Univ British Columbia, Carl Wieman Sci Educ Initiat, Vancouver, BC V5Z 1M9, Canada; [Deslauriers, Louis; Schelew, Ellen] Univ British Columbia, Dept Phys & Astron, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia		gilbertwieman@gmail.com			University of British Columbia through the Carl Wieman Science Education Initiative	University of British Columbia through the Carl Wieman Science Education Initiative	This work was supported by the University of British Columbia through the Carl Wieman Science Education Initiative.	Adams WK, 2006, PHYS REV SPEC TOP-PH, V2, DOI 10.1103/PhysRevSTPER.2.010101; Allen G. K., 2001, INN HIGH ED, V26, P103; Bauernfeind R. H., 1973, PHI DELTA KAPPAN, V55, P271; Beichner R.J., 2007, RES BASED REFORM U P, P1; Bloom BS, 1984, EDUC RES, V13, P4, DOI DOI 10.3102/0013189X013006004; Crouch CH, 2001, AM J PHYS, V69, P970, DOI 10.1119/1.1374249; Deslauriers L, 2011, PHYS REV SPEC TOP-PH, V7, DOI 10.1103/PhysRevSTPER.7.010101; Ding L, 2006, PHYS REV SPEC TOP-PH, V2, DOI 10.1103/PhysRevSTPER.2.010105; ERICSSON KA, 1993, PSYCHOL REV, V100, P363, DOI 10.1037/0033-295X.100.3.363; Froyd J. E., 2008, WHITE PAPER PROMISIN; Froyd J. E., 2007, EVIDENCE EFFICACY ST; Hake RR, 1998, AM J PHYS, V66, P64, DOI 10.1119/1.18809; Hestenes D., 1992, PHYS TEACH, V30, P141, DOI [DOI 10.1119/1.2343497, https://doi.org/10.1119/1.2343497]; Knight Jennifer K, 2005, Cell Biol Educ, V4, P298, DOI 10.1187/05-06-0082; Prince M, 2004, J ENG EDUC, V93, P223, DOI 10.1002/j.2168-9830.2004.tb00809.x; Smith MK, 2009, SCIENCE, V323, P122, DOI 10.1126/science.1165919; Springer L, 1999, REV EDUC RES, V69, P21, DOI 10.3102/00346543069001021	17	587	601	6	348	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2011	332	6031					862	864		10.1126/science.1201783	http://dx.doi.org/10.1126/science.1201783			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	763CD	21566198				2022-12-28	WOS:000290529900052
J	Karpac, J; Jasper, H				Karpac, Jason; Jasper, Heinrich			Metabolic Homeostasis: HDACs Take Center Stage	CELL			English	Editorial Material							SIRTUINS; INSIGHTS; KINASE		[Karpac, Jason; Jasper, Heinrich] Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Jasper, H (corresponding author), Univ Rochester, Dept Biol, River Campus Box 270211, Rochester, NY 14627 USA.	henri_jasper@urmc.rochester.edu			NATIONAL EYE INSTITUTE [R01EY018177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM100196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028127] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY018177] Funding Source: Medline; NIA NIH HHS [R01 AG028127] Funding Source: Medline; NIGMS NIH HHS [R01 GM100196] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072; Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573; Biddinger SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI 10.1146/annurev.physiol.68.040104.124723; Guarente L, 2006, NATURE, V444, P868, DOI 10.1038/nature05486; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Mihaylova MM, 2011, CELL, V145, P607, DOI 10.1016/j.cell.2011.03.043; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Rodgers JT, 2008, FEBS LETT, V582, P46, DOI 10.1016/j.febslet.2007.11.034; Viollet B, 2009, ACTA PHYSIOL, V196, P81, DOI 10.1111/j.1748-1716.2009.01970.x; Wang B, 2011, CELL, V145, P596, DOI 10.1016/j.cell.2011.04.013	10	21	22	1	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 13	2011	145	4					497	499		10.1016/j.cell.2011.04.017	http://dx.doi.org/10.1016/j.cell.2011.04.017			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565608	Green Accepted, Bronze			2022-12-28	WOS:000290560800003
J	Slimak, L; Svendsen, JI; Mangerud, J; Plisson, H; Heggen, HP; Brugere, A; Pavlov, PY				Slimak, Ludovic; Svendsen, John Inge; Mangerud, Jan; Plisson, Hugues; Heggen, Herbjorn Presthus; Brugere, Alexis; Pavlov, Pavel Yurievich			Late Mousterian Persistence near the Arctic Circle	SCIENCE			English	Article							NORTHERN EURASIA; LATE QUATERNARY; EASTERN-EUROPE; NEANDERTHALS; SIBERIA; SITE; KOSTENKI; HISTORY; MAMMOTH; CLIMATE	Palaeolithic sites in Russian high latitudes have been considered as Upper Palaeolithic and thus representing an Arctic expansion of modern humans. Here we show that at Byzovaya, in the western foothills of the Polar Urals, the technological structure of the lithic assemblage makes it directly comparable with Mousterian Middle Palaeolithic industries that so far have been exclusively attributed to the Neandertal populations in Europe. Radiocarbon and optical-stimulated luminescence dates on bones and sand grains indicate that the site was occupied during a short period around 28,500 carbon-14 years before the present (about 31,000 to 34,000 calendar years ago), at the time when only Upper Palaeolithic cultures occupied lower latitudes of Eurasia. Byzovaya may thus represent a late northern refuge for Neandertals, about 1000 km north of earlier known Mousterian sites.	[Slimak, Ludovic] Univ Toulouse Le Mirail, CNRS, UMR 5608, TRACES, F-31058 Toulouse 9, France; [Svendsen, John Inge; Mangerud, Jan; Heggen, Herbjorn Presthus] Univ Bergen, Dept Earth Sci, N-5007 Bergen, Norway; [Svendsen, John Inge; Mangerud, Jan; Heggen, Herbjorn Presthus] Univ Bergen, Bjerknes Ctr Climate Res, N-5007 Bergen, Norway; [Plisson, Hugues] Univ Bordeaux 1, CNRS, UMR 5199, PACEA,IPGQ, F-33405 Talence, France; [Brugere, Alexis] CNRS, USR 3225, F-92023 Nanterre, France; [Brugere, Alexis] ArScAn, UMR 7041, F-92023 Nanterre, France; [Pavlov, Pavel Yurievich] Russian Acad Sci, Komi Sci Ctr, Inst Language Literature & Hist, Dept Archaeol, Syktyvkar 167000, Komi, Russia	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Universite de Toulouse; Universite de Toulouse - Jean Jaures; University of Bergen; Bjerknes Centre for Climate Research; University of Bergen; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Humanities & Social Sciences (INSHS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Humanities & Social Sciences (INSHS); Russian Academy of Sciences; Institute of Language, Literature & History, Komi Scientific Centre of the RAS; Komi Science Centre of the Ural Branch of the Russian Academy of Sciences	Slimak, L (corresponding author), Univ Toulouse Le Mirail, CNRS, UMR 5608, TRACES, 5 Allees Antonio Machado, F-31058 Toulouse 9, France.	slimak@univ-tlse2.fr	Pavlov, Pavel Yu/S-3823-2016; Slimak, Ludovic/AAG-7890-2020	Pavlov, Pavel Yu/0000-0001-8827-5719; 	Fondation des Maisons des Sciences de l'Homme; French-Russian Center for Social and Human Sciences in Moscow; French Ministry of Foreign and European Affairs; Research Council of Norway; Russian Foundation for Humanitarian Research [08-01-94952a]	Fondation des Maisons des Sciences de l'Homme; French-Russian Center for Social and Human Sciences in Moscow; French Ministry of Foreign and European Affairs; Research Council of Norway(Research Council of Norway); Russian Foundation for Humanitarian Research	L.S., H. P., and A. B. analyzed the archaeological material; J.I.S, J.M., and H. P. H. performed the stratigraphic, paleoenvironmental, and chronological descriptions and interpretations; and P.Y.P. organized the archaeological field missions. All contributed to the writing of the paper. Supported by the Fondation des Maisons des Sciences de l'Homme, the French-Russian Center for Social and Human Sciences in Moscow, the French Ministry of Foreign and European Affairs, the Research Council of Norway, and Russian Foundation for Humanitarian Research grant 08-01-94952a. Kh. A. Arslanov and S. Gulliksen performed the radiocarbon dating and A. Murray the OSL dating. We thank the Komi Scientific Centre in Syktyvkar; the museums of Pechora and of Syktyvkar; and the Institute of History of Material Culture of St. Petersburg, especially A. A. Sinitsyn and A. E. Matjuhin for access to their collections and N. N. Skakun for her help. We also thank E. Bjorseth for preparing Figs. 1 and 2 and figs. S1 and S2 and J. E. Lewis for improving the English.	Anikovich MV, 2007, SCIENCE, V315, P223, DOI 10.1126/science.1133376; Bader O.N., 1978, SUNGIR UPPER PALAEOL; Barroso Ruiz C, 2003, ARQUEOLOGIA MONOGRAF, V15; Blockley SPE, 2008, J HUM EVOL, V55, P764, DOI 10.1016/j.jhevol.2008.08.009; Bordes F., 1961, TYPOLOGIE PALEOLITHI; BOSINSKI G, 2001, ZEPHYRUS, V53, P77; Bosinski G., 1967, FUNDAMERTA A, V4; Finlayson C, 2006, NATURE, V443, P850, DOI 10.1038/nature05195; Giaccio B, 2008, J VOLCANOL GEOTH RES, V177, P208, DOI 10.1016/j.jvolgeores.2007.10.007; GUENTHER EW, 1991, ALTSTEINZEITLICHE FU, P101; GUSLITSER BI, 1965, SOVETSKAYA ARKHEOLOG, V2, P112; Heggen HP, 2010, BOREAS, V39, P116, DOI 10.1111/j.1502-3885.2009.00109.x; Higham T, 2006, P NATL ACAD SCI USA, V103, P553, DOI 10.1073/pnas.0510005103; Hoffecker JF, 2010, J ARCHAEOL SCI, V37, P1073, DOI 10.1016/j.jas.2009.12.008; Hubberten HW, 2004, QUATERNARY SCI REV, V23, P1333, DOI 10.1016/j.quascirev.2003.12.012; Hublin JJ, 2009, CR PALEVOL, V8, P503, DOI 10.1016/j.crpv.2009.04.001; Hublin JJ, 2007, RETHINKING HUMAN REV, P235; Joris O., 2004, BERICHTE R MISCH GER, V84, P49; Krause J, 2007, NATURE, V449, P902, DOI 10.1038/nature06193; Krause J, 2010, NATURE, V464, P894, DOI 10.1038/nature08976; Mangerud J, 2010, BOREAS, V39, P328, DOI 10.1111/j.1502-3885.2009.00127.x; Pavlov P, 2004, J HUM EVOL, V47, P3, DOI 10.1016/j.jhevol.2004.05.002; Pavlov P, 2001, NATURE, V413, P64, DOI 10.1038/35092552; Pavlov P., 1986, EXCAVATION BYZOVAYA, P7; Pitulko VV, 2004, SCIENCE, V303, P52, DOI 10.1126/science.1085219; Reich D, 2010, NATURE, V468, P1053, DOI 10.1038/nature09710; Reimer PJ, 2009, RADIOCARBON, V51, P1111, DOI 10.1017/S0033822200034202; Simonet P., 1991, Quaternaire, V2, P5; Sinitsyn AA, 2006, QUATERN INT, V152, P164, DOI 10.1016/j.quaint.2005.12.007; Slimak L., 2004, THESIS U PROVENCE AI; Stringer C, 2002, PHILOS T R SOC B, V357, P563, DOI 10.1098/rstb.2001.1057; Svendsen I.G., 2003, CHRONOLOGY AURIGNACI, V33, P109; Svendsen JI, 2004, QUATERNARY SCI REV, V23, P1229, DOI 10.1016/j.quascirev.2003.12.008; Svendsen JI, 2010, QUATERNARY SCI REV, V29, P3138, DOI 10.1016/j.quascirev.2010.06.043; Velichko AA, 2005, QUATERN INT, V126, P137, DOI 10.1016/j.quaint.2004.04.019; Wojtal P, 2005, J ARCHAEOL SCI, V32, P193, DOI 10.1016/j.jas.2004.08.005; ZilhAo J., 2006, FARMING, V2006, P95, DOI DOI 10.3828/BFARM.2006.3.3	38	54	57	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					841	845		10.1126/science.1203866	http://dx.doi.org/10.1126/science.1203866			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	763CD	21566192				2022-12-28	WOS:000290529900046
J	Borden, WB; Redberg, RF; Mushlin, AI; Dai, D; Kaltenbach, LA; Spertus, JA				Borden, William B.; Redberg, Rita F.; Mushlin, Alvin I.; Dai, David; Kaltenbach, Lisa A.; Spertus, John A.			Patterns and Intensity of Medical Therapy in Patients Undergoing Percutaneous Coronary Intervention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR-DATA-REGISTRY; ST-SEGMENT ELEVATION; ARTERY-DISEASE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; PRACTICE GUIDELINES; QUALITY; CARE; PREVALENCE; TRENDS	Context The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) study, which provided optimal medical therapy (OMT) to all patients and demonstrated no incremental advantage of percutaneous coronary intervention (PCI) on outcomes other than angina-related quality of life in stable coronary artery disease (CAD), suggests that a trial of OMT is warranted before PCI. It is unknown to what degree OMT is applied before PCI in routine practice or whether its use increased after the COURAGE trial. Objective To examine the use of OMT in patients with stable angina undergoing PCI before and after the publication of the COURAGE trial. Design, Setting, and Participants An observational study of patients with stable CAD undergoing PCI in the National Cardiovascular Data Registry between September 1, 2005, and June 30, 2009. Analysis compared use of OMT, both before PCI and at the time of discharge, before and after the publication of the COURAGE trial. Optimal medical therapy was defined as either being prescribed or having a documented contraindication to all medicines (antiplatelet agent, beta-blocker, and statin). Main Outcome Measures Rates of OMT before PCI and at discharge (following PCI) between the 2 study periods. Results Among all 467 211 patients (173 416 before [37.1%] and 293 795 after [62.9%] the COURAGE trial) meeting study criteria, OMT was used in 206 569 patients (44.2%; 95% confidence interval [CI], 44.1%-44.4%) before PCI and in 303 864 patients (65.0%; 95% CI, 64.9%-65.2%) at discharge following PCI (P<.001). Before PCI, OMT was applied in 75 381 patients (43.5%; 95% CI, 43.2%-43.7%) before the COURAGE trial and in 131 188 patients (44.7%; 95% CI, 44.5%-44.8%) after the COURAGE trial (P<.001). The use of OMT at discharge following PCI before and after the COURAGE trial was 63.5% (95% CI, 63.3%-63.7%) and 66.0% (95% CI, 65.8%-66.1%), respectively (P<.001). Conclusion Among patients with stable CAD undergoing PCI, less than half were receiving OMT before PCI and approximately two-thirds were receiving OMT at discharge following PCI, with relatively little change in these practice patterns after publication of the COURAGE trial. JAMA. 2011;305(18):1882-1889 www.jama.com	[Borden, William B.] Cornell Univ, Weill Cornell Med Coll, Dept Med, New York, NY 10021 USA; [Borden, William B.; Mushlin, Alvin I.] Cornell Univ, Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10021 USA; [Redberg, Rita F.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Dai, David; Kaltenbach, Lisa A.] Duke Univ, Duke Clin Res Inst, Durham, NC USA; [Spertus, John A.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA	Cornell University; Cornell University; University of California System; University of California San Francisco; Duke University; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City	Borden, WB (corresponding author), Cornell Univ, Weill Cornell Med Coll, Dept Med, 1305 York Ave,8th Floor, New York, NY 10021 USA.	wbb2001@med.cornell.edu	Spertus, John/ABD-3075-2021		NCDR; American College of Cardiology Foundation; Weill Cornell Medical College; Agency for Healthcare Research and Quality [U18 HS016075]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS016075] Funding Source: NIH RePORTER	NCDR; American College of Cardiology Foundation(General Electric); Weill Cornell Medical College; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This work was supported by the NCDR, an initiative of the American College of Cardiology Foundation. Dr Borden is funded through a Nanette Laitman Clinical Scholar in Public Health award at the Weill Cornell Medical College. Dr Mushlin is funded in part by cooperative agreement U18 HS016075 from the Agency for Healthcare Research and Quality.	Ahmed B, 2011, CIRC-CARDIOVASC QUAL, V4, P300, DOI 10.1161/CIRCOUTCOMES.110.957175; Anderson HV, 2007, AM J CARDIOL, V99, P189, DOI 10.1016/j.amjcard.2006.07.083; Association of Amercian Medical Colleges, 2008, IND FUND MED ED; Atwater Brett D, 2009, Clin Cardiol, V32, pE1, DOI 10.1002/clc.20524; Avorn J, 2010, HEALTH AFFAIR, V29, P1891, DOI 10.1377/hlthaff.2010.0696; Boden WE, 2007, NEW ENGL J MED, V356, P1503, DOI 10.1056/NEJMoa070829; Boden WE, 2009, AM J CARDIOL, V104, P1, DOI 10.1016/j.amjcard.2009.02.059; Bonham AC, 2010, HEALTH AFFAIR, V29, P1901, DOI 10.1377/hlthaff.2010.0790; Brindis R G, 2001, J Am Coll Cardiol, V37, P2240, DOI 10.1016/S0735-1097(01)01372-9; Bucher HC, 2000, BMJ-BRIT MED J, V321, P73, DOI 10.1136/bmj.321.7253.73; Butler J, 2002, J AM COLL CARDIOL, V40, P1589, DOI 10.1016/S0735-1097(02)02379-3; Cutler JA, 2008, HYPERTENSION, V52, P818, DOI 10.1161/HYPERTENSIONAHA.108.113357; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Davis DA, 1997, CAN MED ASSOC J, V157, P408; Fraker Theodore D Jr, 2007, Circulation, V116, P2762, DOI 10.1161/CIRCULATIONAHA.107.187930; Gattis WA, 2004, AM J CARDIOL, V93, p74B, DOI 10.1016/j.amjcard.2004.01.019; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Hyre AD, 2007, ANN EPIDEMIOL, V17, P548, DOI 10.1016/j.annepidem.2007.01.032; Katritsis DG, 2005, CIRCULATION, V111, P2906, DOI 10.1161/CIRCULATIONAHA.104.521864; Kereiakes DJ, 2007, J AM COLL CARDIOL, V50, P1598, DOI 10.1016/j.jacc.2007.07.063; Krone RJ, 2006, CATHETER CARDIO INTE, V68, P696, DOI 10.1002/ccd.20910; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Lin GA, 2007, ARCH INTERN MED, V167, P1604, DOI 10.1001/archinte.167.15.1604; Lin GA, 2010, MED CARE, V48, P733, DOI 10.1097/MLR.0b013e3181e35b3a; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Maddox TM, 2010, CIRC-CARDIOVASC QUAL, V3, P632, DOI 10.1161/CIRCOUTCOMES.109.906214; Maron David J, 2011, Curr Treat Options Cardiovasc Med, V13, P16, DOI 10.1007/s11936-010-0104-7; Maron DJ, 2010, J AM COLL CARDIOL, V55, P1348, DOI 10.1016/j.jacc.2009.10.062; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mehta RH, 2006, ARCH INTERN MED, V166, P2027, DOI 10.1001/archinte.166.18.2027; Riley RF, 2011, CIRC-CARDIOVASC QUAL, V4, P193, DOI 10.1161/CIRCOUTCOMES.110.958744; Roe MT, 2005, ARCH INTERN MED, V165, P1630, DOI 10.1001/archinte.165.14.1630; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Smith SC, 2006, CIRCULATION, V113, P2363, DOI 10.1161/CIRCULATIONAHA.106.174516; Stafford RS, 2010, ARCH INTERN MED, V170, P851, DOI 10.1001/archinternmed.2010.130; Stafford RS, 2003, J AM COLL CARDIOL, V41, P56, DOI 10.1016/S0735-1097(02)02670-0; Steinberg BA, 2007, AM J CARDIOL, V99, P1212, DOI 10.1016/j.amjcard.2006.12.039; *VET AFF, VET AFF COOP STUD PR; Weintraub WS, 2008, NEW ENGL J MED, V359, P677, DOI 10.1056/NEJMoa072771; Yan AT, 2007, AM HEART J, V154, P1108, DOI 10.1016/j.ahj.2007.07.040; ISI WEB KNOWLEDGE IT	41	137	142	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2011	305	18					1882	1889		10.1001/jama.2011.601	http://dx.doi.org/10.1001/jama.2011.601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761YH	21558519	Bronze			2022-12-28	WOS:000290438800025
J	Kirby, T				Kirby, Tony			Profile Keryn Christiansen: a household name in microbiology	LANCET			English	Biographical-Item																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2011	377	9780					1827	1827		10.1016/S0140-6736(11)60772-1	http://dx.doi.org/10.1016/S0140-6736(11)60772-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774UI	21621713	Bronze			2022-12-28	WOS:000291411700014
J	Faith, JJ; McNulty, NP; Rey, FE; Gordon, JI				Faith, Jeremiah J.; McNulty, Nathan P.; Rey, Federico E.; Gordon, Jeffrey I.			Predicting a Human Gut Microbiota's Response to Diet in Gnotobiotic Mice	SCIENCE			English	Article							MICROBES	The interrelationships between our diets and the structure and operations of our gut microbial communities are poorly understood. A model community of 10 sequenced human gut bacteria was introduced into gnotobiotic mice, and changes in species abundance and microbial gene expression were measured in response to randomized perturbations of four defined ingredients in the host diet. From the responses, we developed a statistical model that predicted over 60% of the variation in species abundance evoked by diet perturbations, and we were able to identify which factors in the diet best explained changes seen for each community member. The approach is generally applicable, as shown by a follow-up study involving diets containing various mixtures of pureed human baby foods.	[Faith, Jeremiah J.; McNulty, Nathan P.; Rey, Federico E.; Gordon, Jeffrey I.] Washington Univ, Sch Med, Ctr Genome Sci & Syst Biol, St Louis, MO 63108 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Ctr Genome Sci & Syst Biol, St Louis, MO 63108 USA.	jgordon@wustl.edu			NIH [DK30292, DK70977]; Crohn's and Colitis Foundation of America; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070977, R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are indebted to D. O'Donnell, M. Karlsson, and S. Wagoner for their help with various aspects of gnotobiotic mouse husbandry and to B. Mickelson, I. Mogno, A. Goodman, N. Griffin, H. Seedorf, G. Simon, J. Chase, and B. Cohen for their many helpful suggestions during the course of this work. This work was supported by grants from NIH (DK30292 and DK70977) and the Crohn's and Colitis Foundation of America. COPRO-seq and microbial RNA-seq data are available in the Gene Expression Omnibus (accession GSE26687). Processed data can be obtained at http://gordonlab.wustl.edu/modeling_microbiota/.	Chase J.M., 2009, ECOLOGICAL NICHES LI; Clayton TA, 2009, P NATL ACAD SCI USA, V106, P14728, DOI 10.1073/pnas.0904489106; Faith JJ, 2010, ISME J, V4, P1094, DOI 10.1038/ismej.2010.110; Fu X, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-161; Goodman AL, 2009, CELL HOST MICROBE, V6, P279, DOI 10.1016/j.chom.2009.08.003; Handelsman J, 2008, DNA CELL BIOL, V27, P219, DOI 10.1089/dna.2008.1503; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Mahowald MA, 2009, P NATL ACAD SCI USA, V106, P5859, DOI 10.1073/pnas.0901529106; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Muegge BD, 2011, SCIENCE, V332, P970, DOI 10.1126/science.1198719; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rey FE, 2010, J BIOL CHEM, V285, P22082, DOI 10.1074/jbc.M110.117713; Turnbaugh PJ, 2010, P NATL ACAD SCI USA, V107, P7503, DOI 10.1073/pnas.1002355107; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005	15	348	362	8	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2011	333	6038					101	104		10.1126/science.1206025	http://dx.doi.org/10.1126/science.1206025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	785UF	21596954	Green Accepted			2022-12-28	WOS:000292255400059
J	Sato, M; Ishikawa, T; Ujihara, N; Yoshida, S; Fujita, M; Mochizuki, M; Asada, A				Sato, Mariko; Ishikawa, Tadashi; Ujihara, Naoto; Yoshida, Shigeru; Fujita, Masayuki; Mochizuki, Masashi; Asada, Akira			Displacement Above the Hypocenter of the 2011 Tohoku-Oki Earthquake	SCIENCE			English	Article							SEA-FLOOR		[Sato, Mariko; Ishikawa, Tadashi; Ujihara, Naoto; Yoshida, Shigeru; Fujita, Masayuki] Japan Coast Guard, Hydrog & Oceanog Dept, Chuo Ku, Tokyo 1040045, Japan; [Mochizuki, Masashi; Asada, Akira] Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan	University of Tokyo	Sato, M (corresponding author), Japan Coast Guard, Hydrog & Oceanog Dept, Chuo Ku, 5-3-1 Tsukiji, Tokyo 1040045, Japan.	eisei@jodc.go.jp	Ishikawa, Tadashi/AAX-4085-2021	Ishikawa, Tadashi/0000-0001-6385-7915	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Y. Honkura for valuable comments and suggestions, O. L. Colombo for assistance with GPS software, and the GSI for providing us with the GPS data. The installation of MYGW was funded by the Ministry of Education, Culture, Sports, Science and Technology of Japan. Averaged position data for the five stations are available in the supporting online material.	Asada A, 2001, P JPN ACAD B-PHYS, V77, P7, DOI 10.2183/pjab.77.7; Fujita M, 2006, EARTH PLANETS SPACE, V58, P265, DOI 10.1186/BF03351923; Sato M, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL045689	3	322	335	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 17	2011	332	6036					1395	1395		10.1126/science.1207401	http://dx.doi.org/10.1126/science.1207401			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778FT	21596950				2022-12-28	WOS:000291689000031
J	Wise, J				Wise, Jacqui			Trial of niacin alongside statin is stopped early	BRITISH MEDICAL JOURNAL			English	News Item																			0	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2011	342								d3400	10.1136/bmj.d3400	http://dx.doi.org/10.1136/bmj.d3400			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774MG	21628377				2022-12-28	WOS:000291390100019
J	Fuchs, VR; Milstein, A				Fuchs, Victor R.; Milstein, Arnold			The $640 Billion Question - Why Does Cost-Effective Care Diffuse So Slowly?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE		[Fuchs, Victor R.; Milstein, Arnold] Stanford Univ, Stanford, CA 94305 USA; [Milstein, Arnold] Pacific Business Grp Hlth, San Francisco, CA USA	Stanford University	Fuchs, VR (corresponding author), Stanford Univ, Stanford, CA 94305 USA.							Chernew ME, 2010, NEW ENGL J MED, V362, P1166, DOI 10.1056/NEJMp1002873; Emanuel EJ, 2008, JAMA-J AM MED ASSOC, V299, P1057, DOI 10.1001/jama.299.9.1057; McGinnis JM, 2010, I MED HEALTHCARE IMP, P585; Milstein A, 2009, HEALTH AFFAIR, V28, P1317, DOI 10.1377/hlthaff.28.5.1317; Temin P, 2001, HLTH AFF MILLWOOD, V20, P181	5	33	34	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					1985	1987		10.1056/NEJMp1104675	http://dx.doi.org/10.1056/NEJMp1104675			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QR	21591938				2022-12-28	WOS:000290952000001
J	Baker, M				Baker, Monya			THE NEXT STEP FOR THE SYNTHETIC GENOME	NATURE			English	Editorial Material							CHEMICAL-SYNTHESIS; DNA; YEAST; CELL											Caruthers MH, 2011, BIOCHEM SOC T, V39, P575, DOI 10.1042/BST0390575; Danino T, 2010, NATURE, V463, P326, DOI 10.1038/nature08753; Ellis T, 2011, INTEGR BIOL-UK, V3, P109, DOI 10.1039/c0ib00070a; Gibson DG, 2010, NAT METHODS, V7, P901, DOI 10.1038/nmeth.1515; Gibson DG, 2010, SCIENCE, V329, P52, DOI 10.1126/science.1190719; Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/NMETH.1318, 10.1038/nmeth.1318]; Gibson DG, 2008, P NATL ACAD SCI USA, V105, P20404, DOI 10.1073/pnas.0811011106; Itaya M, 2005, P NATL ACAD SCI USA, V102, P15971, DOI 10.1073/pnas.0503868102; Kosuri S, 2010, NAT BIOTECHNOL, V28, P1295, DOI 10.1038/nbt.1716; Parenteau J, 2008, MOL BIOL CELL, V19, P1932, DOI 10.1091/mbc.E07-12-1254; Quan JY, 2011, NAT BIOTECHNOL, V29, P449, DOI 10.1038/nbt.1847; Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640; Wang HH, 2009, NATURE, V460, P894, DOI 10.1038/nature08187	13	24	27	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					403	408		10.1038/473403a	http://dx.doi.org/10.1038/473403a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593873	Bronze			2022-12-28	WOS:000290722400055
J	Shapiro, J; Colin-Thome, D; Mulla, A				Shapiro, Jonathan; Colin-Thome, David; Mulla, Abeda			NHS REFORMS How to lose friends and alienate people	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Shapiro, Jonathan; Mulla, Abeda] Univ Birmingham, CLAHRC, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Shapiro, J (corresponding author), Univ Birmingham, CLAHRC, Birmingham B15 2TT, W Midlands, England.	j.a.shapiro@bham.ac.uk; david@dctconsultingltd.co.uk; A.Mulla@bham.ac.uk		Mulla, Abeda/0000-0002-0364-7972				Checkland K, 2009, J HEALTH SERV RES PO, V14, P20, DOI 10.1258/jhsrp.2008.008043; *DEP HLTH, 2008, HIGH CAR QUAL ALL; *DEP HLTH, 1989, WORK PAT; Department of Health, 2010, EQ EXC LIB NHS; Whitty G, 2000, INT J EDUC DEV, V20, P93, DOI 10.1016/S0738-0593(99)00061-9	5	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 18	2011	342								d3014	10.1136/bmj.d3014	http://dx.doi.org/10.1136/bmj.d3014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QQ	21593091				2022-12-28	WOS:000290951900010
J	Yang, E				Yang, Eugene			Review: Low-dose hydrochlorothiazide is not as effective as other antihypertensive drugs for reducing ambulatory BP in hypertension?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Washington, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Yang, E (corresponding author), Univ Washington, Seattle, WA 98195 USA.		Yang, Eugene/AAY-5639-2021					Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cutler JA, 2008, CIRCULATION, V117, P2691, DOI 10.1161/CIRCULATIONAHA.107.709931; Neff KM, 2010, CARDIOL REV, V18, P51, DOI 10.1097/CRD.0b013e3181c61b52; WRIGHT JM, 2009, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001841.PUB2	4	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-8	10.7326/0003-4819-154-10-201105170-02008	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576526				2022-12-28	WOS:000290620300007
J	Boulton, G; Rawlins, M; Vallance, P; Walport, M				Boulton, Geoffrey; Rawlins, Michael; Vallance, Patrick; Walport, Mark			Science as a public enterprise: the case for open data	LANCET			English	Editorial Material							TRIALS; BIAS		[Boulton, Geoffrey] Univ Edinburgh, Grant Inst, Edinburgh EH9 3JW, Midlothian, Scotland; [Rawlins, Michael] Natl Inst Hlth & Clin Excellence, London, England; [Vallance, Patrick] GlaxoSmithKline Inc, London, England; [Walport, Mark] Wellcome Trust Res Labs, London, England	University of Edinburgh; National Institute for Health & Care Excellence; GlaxoSmithKline	Boulton, G (corresponding author), Univ Edinburgh, Grant Inst, Edinburgh EH9 3JW, Midlothian, Scotland.	G.Boulton@ed.ac.uk		Walport, Mark/0000-0001-7220-5273				[Anonymous], 2010, BBC NEWS        0419; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Dickersin K, 1997, AIDS EDUC PREV, V9, P15; Godlee F, 2011, BMJ-BRIT MED J, V342, pd212; *HUM GEN PROJ, 1997, POL REL HUM GEN SEQ; Kleiner K, 2011, NAT CLIM CHANGE, V1, P10, DOI 10.1038/nclimate1057; Pearce Fred, 2010, CLIMATE FILES; Rising K, 2008, PLOS MED, V5, P1561, DOI 10.1371/journal.pmed.0050217; *ROYAL SOC, 2011, SCI PUBL ENT OP SCI; Russell M, 2010, INDEPENDENT CLIMATE; STEINBROOK R, 2010, BMJ-BRIT MED J, V341, P811; Walport M, 2011, LANCET, V377, P537, DOI 10.1016/S0140-6736(10)62234-9	12	63	64	0	41	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 14	2011	377	9778					1633	1635		10.1016/S0140-6736(11)60647-8	http://dx.doi.org/10.1016/S0140-6736(11)60647-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766JF	21571134				2022-12-28	WOS:000290777700008
J	Wang, B; Moya, N; Niessen, S; Hoover, H; Mihaylova, MM; Shaw, RJ; Yates, JR; Fischer, WH; Thomas, JB; Montminy, M				Wang, Biao; Moya, Noel; Niessen, Sherry; Hoover, Heather; Mihaylova, Maria M.; Shaw, Reuben J.; Yates, John R., III; Fischer, Wolfgang H.; Thomas, John B.; Montminy, Marc			A Hormone-Dependent Module Regulating Energy Balance	CELL			English	Article							CREB COACTIVATOR TORC2; TRANSCRIPTION FACTOR; CLASS IIHDAC; DROSOPHILA; INSULIN; EXPRESSION; KINASE; PHOSPHORYLATION; METABOLISM; PROTEIN	Under fasting conditions, metazoans maintain energy balance by shifting from glucose to fat burning. In the fasted state, SIRT1 promotes catabolic gene expression by deacetylating the forkhead factor FOXO in response to stress and nutrient deprivation. The mechanisms by which hormonal signals regulate FOXO deacetylation remain unclear, however. We identified a hormone-dependent module, consisting of the Ser/Thr kinase SIK3 and the class IIa deacetylase HDAC4, which regulates FOXO activity in Drosophila. During feeding, HDAC4 is phosphorylated and sequestered in the cytoplasm by SIK3, whose activity is upregulated in response to insulin. SIK3 is inactivated during fasting, leading to the dephosphorylation and nuclear translocation of HDAC4 and to FOXO deacetylation. SIK3 mutant flies are starvation sensitive, reflecting FOXO-dependent increases in lipolysis that deplete triglyceride stores; reducing HDAC4 expression restored lipid accumulation. Our results reveal a hormone-regulated pathway that functions in parallel with the nutrient-sensing SIRT1 pathway to maintain energy balance.	[Wang, Biao; Thomas, John B.] Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; [Wang, Biao; Moya, Noel; Fischer, Wolfgang H.; Montminy, Marc] Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA; [Mihaylova, Maria M.; Shaw, Reuben J.] Salk Inst Biol Studies, Mol & Cellular Biol Lab, La Jolla, CA 92037 USA; [Niessen, Sherry; Hoover, Heather; Yates, John R., III] Scripps Res Inst, Ctr Physiol Prote, La Jolla, CA 92037 USA	Salk Institute; Salk Institute; Salk Institute; Scripps Research Institute	Thomas, JB (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jthomas@salk.edu; montminy@salk.edu	Mihaylova, Maria M./ACZ-4949-2022	Mihaylova, Maria M./0000-0002-2725-767X	NIH [R01-DK049777, R01-DK083834, R01-DK077979, R01 DK080425, P01CA120964]; American Diabetes Association [1-08-JF-47]; Keickhefer Foundation; Clayton Foundation for Medical Research; Leona M. and Harry B. Helmsley Charitable Trust; NATIONAL CANCER INSTITUTE [P01CA120964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080425, R01DK083834, R01DK077979, R37DK083834, R56DK077979, R01DK049777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084947, R01GM040613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031249, R01NS040963, R21NS056316] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); Keickhefer Foundation; Clayton Foundation for Medical Research; Leona M. and Harry B. Helmsley Charitable Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by NIH grants (R01-DK049777 and R01-DK083834 to M. M.; R01-DK077979 to J.B.T.; R01 DK080425 and P01CA120964 to R.J.S.), an American Diabetes Association Junior Faculty Award (1-08-JF-47 to R.J.S.), The Keickhefer Foundation, The Clayton Foundation for Medical Research, and The Leona M. and Harry B. Helmsley Charitable Trust. We thank Y. Imai and A. Fukamizu (Tsukuba) for the gift of antisera. We also thank E. Hafen, J. Chung, R. Kulnlein, J. Scott, J. Park, Bloomington Stock Center, VDRC, Exelixis, and TRiP at Harvard Medical School (NIH/NIGMS R01-GM084947) for fly stocks used in this study.	Baker KD, 2007, CELL METAB, V6, P257, DOI 10.1016/j.cmet.2007.09.002; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brent MM, 2008, STRUCTURE, V16, P1407, DOI 10.1016/j.str.2008.06.013; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Fukuoka M, 2003, INT J MOL MED, V12, P503; Gronke S, 2007, PLOS BIOL, V5, P1248, DOI 10.1371/journal.pbio.0050137; Gronke S, 2005, CELL METAB, V1, P323, DOI 10.1016/j.cmet.2005.04.003; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Horike N, 2003, J BIOL CHEM, V278, P18440, DOI 10.1074/jbc.M211770200; Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Kim JK, 2004, J CLIN INVEST, V114, P823, DOI 10.1172/JCI200422230; Kim SK, 2004, NATURE, V431, P316, DOI 10.1038/nature02897; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Mihaylova MM, 2011, CELL, V145, P607, DOI 10.1016/j.cell.2011.03.043; Okamoto M, 2004, TRENDS ENDOCRIN MET, V15, P21, DOI 10.1016/j.tem.2003.11.002; Palanker L, 2009, CELL METAB, V9, P228, DOI 10.1016/j.cmet.2009.01.009; Reiter Lawrence T, 2002, Expert Opin Ther Targets, V6, P387; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Teleman AA, 2008, CELL METAB, V7, P21, DOI 10.1016/j.cmet.2007.11.010; van der Linden AM, 2007, EMBO J, V26, P358, DOI 10.1038/sj.emboj.7601479; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Wagner BL, 2000, J BIOL CHEM, V275, P8263, DOI 10.1074/jbc.275.12.8263; Wang B, 2008, CELL METAB, V7, P434, DOI 10.1016/j.cmet.2008.02.010; Williams SR, 2010, AM J HUM GENET, V87, P219, DOI 10.1016/j.ajhg.2010.07.011	37	166	177	2	34	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 13	2011	145	4					596	606		10.1016/j.cell.2011.04.013	http://dx.doi.org/10.1016/j.cell.2011.04.013			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565616	Green Accepted, Bronze			2022-12-28	WOS:000290560800012
J	Crowley, MA; Mollan, TL; Abdulmalik, OY; Butler, AD; Goodwin, EF; Sarkar, A; Stolle, CA; Gow, AJ; Olson, JS; Weiss, MJ				Crowley, Moira A.; Mollan, Todd L.; Abdulmalik, Osheisa Y.; Butler, Andrew D.; Goodwin, Emily F.; Sarkar, Arindam; Stolle, Catherine A.; Gow, Andrew J.; Olson, John S.; Weiss, Mitchell J.			A Hemoglobin Variant Associated with Neonatal Cyanosis and Anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HB-F; DISTAL HISTIDINE; RATE CONSTANTS; CO BINDING; MYOGLOBIN; BRISTOL; BETA; ALPHA; O-2; AUTOOXIDATION	Globin-gene mutations are a rare but important cause of cyanosis. We identified a missense mutation in the fetal G.-globin gene (HBG2) in a father and daughter with transient neonatal cyanosis and anemia. This new mutation modifies the ligand-binding pocket of fetal hemoglobin by means of two mechanisms. First, the relatively large side chain of methionine decreases both the affinity of oxygen for binding to the mutant hemoglobin subunit and the rate at which it does so. Second, the mutant methionine is converted to aspartic acid post-translationally, probably through oxidative mechanisms. The presence of this polar amino acid in the heme pocket is predicted to enhance hemoglobin denaturation, causing anemia.	[Abdulmalik, Osheisa Y.; Weiss, Mitchell J.] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; [Stolle, Catherine A.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Crowley, Moira A.] Case Western Reserve Univ, Div Neonatol, Cleveland, OH 44106 USA; [Mollan, Todd L.; Sarkar, Arindam; Olson, John S.] Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; [Butler, Andrew D.; Gow, Andrew J.] Rutgers State Univ, Dept Pharmacol, Piscataway, NJ USA; [Goodwin, Emily F.] Univ Alabama, Div Pediat Hematol Oncol, Tuscaloosa, AL 35487 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Case Western Reserve University; Rice University; Rutgers State University New Brunswick; University of Alabama System; University of Alabama Tuscaloosa	Weiss, MJ (corresponding author), Childrens Hosp Philadelphia, Div Hematol, Rm 316B ARC,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	olson@rice.edu; weissmi@email.chop.edu	Gow, Andrew/N-8566-2013; Weiss, Mitchell J/W-9814-2018; Weiss, Mitchell J/A-1245-2013; Gow, Andrew/AAR-2309-2020	Gow, Andrew/0000-0003-0876-5158; Weiss, Mitchell J/0000-0003-2460-3036; Gow, Andrew/0000-0003-0876-5158; abdulmalik, osheiza/0000-0003-2497-4291; Olson, John/0000-0002-0760-5403	National Institutes of Health [DK061692, P30DK090969, HL087427, HL103186, HL47020, GM35649]; Welch Foundation [C-0612]; Abramson Cancer Center [P30CA016520]; University of Pennsylvania [ES013508-04]; NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087427, P01HL064190, P01HL110860, K01HL103186, R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090969, R01DK061692, R56DK061692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508, P30ES005022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); Abramson Cancer Center; University of Pennsylvania; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the National Institutes of Health (DK061692, P30DK090969, and HL087427, to Dr. Weiss; HL103186, to Dr. Abdulmalik; and HL47020 and GM35649, to Dr. Olson), the Welch Foundation (C-0612, to Dr. Olson), the Abramson Cancer Center (P30CA016520), and the Center of Excellence in Environmental Toxicology at the University of Pennsylvania (ES013508-04). Dr. Weiss is a Leukemia and Lymphoma Society Scholar.	Adachi K, 2002, J BIOL CHEM, V277, P13415, DOI 10.1074/jbc.M200857200; Birukou I, 2010, J BIOL CHEM, V285, P8840, DOI 10.1074/jbc.M109.053934; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P623; Dainer E, 2008, HEMOGLOBIN, V32, P596, DOI 10.1080/03630260802507915; Eberle SE, 2007, HEMOGLOBIN, V31, P379, DOI 10.1080/03630260701459408; Forget BG, 2009, DISORDERS OF HEMOGLOBIN: GENETICS, PATHOPHYSIOLOGY, AND CLINICAL MANAGEMENT, 2ND EDITION, P46; FRIER JA, 1977, J MOL BIOL, V112, P97, DOI 10.1016/S0022-2836(77)80158-7; GARROD A, 1928, LANCET, V211, P1055; GLADER BE, 1989, HEMOGLOBIN, V13, P769, DOI 10.3109/03630268908998852; HARGROVE MS, 1994, BIOCHEMISTRY-US, V33, P11767, DOI 10.1021/bi00205a012; Kano G, 2004, INT J HEMATOL, V80, P410, DOI 10.1532/IJH97.04048; KOHLIKUMAR M, 1995, AM J HEMATOL, V49, P43, DOI 10.1002/ajh.2830490108; MAILLETT DH, 2003, ENG HEMOGLOBINS MYOG; MATHEWS AJ, 1994, METHOD ENZYMOL, V232, P363; Miyazaki A, 1996, J MASS SPECTROM, V31, P1311, DOI 10.1002/(SICI)1096-9888(199611)31:11<1311::AID-JMS427>3.0.CO;2-1; MOLCHANOVA TP, 1993, HEMOGLOBIN, V17, P217, DOI 10.3109/03630269308998896; MOLCHANOVA TP, 1992, HEMOGLOBIN, V16, P389, DOI 10.3109/03630269209005690; Nienhaus K, 2003, J BIOL CHEM, V278, P42532, DOI 10.1074/jbc.M306888200; OHBA Y, 1985, HEMOGLOBIN, V9, P79, DOI 10.3109/03630268508996986; PRIEST JR, 1989, PEDIATRICS, V83, P734; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; Rees DC, 1996, BLOOD, V88, P341; Shen TJ, 1997, PROTEIN ENG, V10, P1085, DOI 10.1093/protein/10.9.1085; SMITH L, 2003, THESIS RICE U; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Tingelstad J, 1999, Pediatr Rev, V20, P350, DOI 10.1542/pir.20-10-350; Unzai S, 1998, J BIOL CHEM, V273, P23150, DOI 10.1074/jbc.273.36.23150	28	15	21	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					1837	1843		10.1056/NEJMoa1013579	http://dx.doi.org/10.1056/NEJMoa1013579			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561349	Green Accepted			2022-12-28	WOS:000290483000011
J	Park, E; Rapoport, TA				Park, Eunyong; Rapoport, Tom A.			Preserving the membrane barrier for small molecules during bacterial protein translocation	NATURE			English	Article							ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; SECY PROTEIN; CONDUCTING CHANNEL; TRANSLATION ARREST; SIGNAL SEQUENCE; RIBOSOME; PERMEABILITY; MAINTAINS; COMPLEX	Many proteins are translocated through the SecY channel in bacteria and archaea and through the related Sec61 channel in eukaryotes(1). The channel has an hourglass shape with a narrow constriction approximately halfway across the membrane, formed by a pore ring of amino acids(2). While the cytoplasmic cavity of the channel is empty, the extracellular cavity is filled with a short helix called the plug(2), which moves out of the way during protein translocation(3,4). The mechanism by which the channel transports large polypeptides and yet prevents the passage of small molecules, such as ions or metabolites, has been controversial(2,5-8). Here, we have addressed this issue in intact Escherichia coli cells by testing the permeation of small molecules through wild-type and mutant SecY channels, which are either in the resting state or contain a defined translocating polypeptide chain. We show that in the resting state, the channel is sealed by both the pore ring and the plug domain. During translocation, the pore ring forms a 'gasket-like' seal around the polypeptide chain, preventing the permeation of small molecules. The structural conservation of the channel in all organisms indicates that this may be a universal mechanism by which the membrane barrier is maintained during protein translocation.	[Park, Eunyong; Rapoport, Tom A.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; [Park, Eunyong; Rapoport, Tom A.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Rapoport, TA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 240 Longwood Ave, Boston, MA 02115 USA.	tom_rapoport@hms.harvard.edu			NIH [GM052586]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052586] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank P. Walter, H. Bernstein and G. Phillips for materials, D. Boyd for advice, C. Akey for discussions and C. Akey, A. Osborne and A. Salic for critical reading of the manuscript. The work was supported by a grant from the NIH (GM052586). T.A.R. is a Howard Hughes Medical Institute investigator.	AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Becker T, 2009, SCIENCE, V326, P1369, DOI 10.1126/science.1178535; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; Dalal K, 2009, EMBO REP, V10, P762, DOI 10.1038/embor.2009.87; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Harris CR, 1999, J BACTERIOL, V181, P3438, DOI 10.1128/JB.181.11.3438-3444.1999; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; Heritage D, 2001, J BIOL CHEM, V276, P22655, DOI 10.1074/jbc.M102409200; Junne T, 2010, MOL BIOL CELL, V21, P1662, DOI 10.1091/mbc.E10-01-0060; Le Gall S, 2004, MOL BIOL CELL, V15, P447, DOI 10.1091/mbc.E03-05-0325; Li WK, 2007, MOL CELL, V26, P511, DOI 10.1016/j.molcel.2007.05.002; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Menetret JF, 2008, STRUCTURE, V16, P1126, DOI 10.1016/j.str.2008.05.003; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; Rapoport TA, 2007, NATURE, V450, P663, DOI 10.1038/nature06384; Roy A, 2003, J BIOL CHEM, V278, P4397, DOI 10.1074/jbc.M207295200; Saparov SM, 2007, MOL CELL, V26, P501, DOI 10.1016/j.molcel.2007.03.022; SCHIEBEL E, 1992, J BIOL CHEM, V267, P7505; Schierle CF, 2003, J BACTERIOL, V185, P5706, DOI 10.1128/JB.185.19.5706-5713.2003; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Smith MA, 2005, J BACTERIOL, V187, P6454, DOI 10.1128/JB.187.18.6454-6465.2005; Tam PCK, 2005, EMBO J, V24, P3380, DOI 10.1038/sj.emboj.7600804; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; WADA A, 1990, P NATL ACAD SCI USA, V87, P2657, DOI 10.1073/pnas.87.7.2657; Woolhead CA, 2006, MOL CELL, V22, P587, DOI 10.1016/j.molcel.2006.05.021; Zhang W, 2003, J BIOL CHEM, V278, P50128, DOI 10.1074/jbc.M309840200	30	73	74	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 12	2011	473	7346					239	+		10.1038/nature10014	http://dx.doi.org/10.1038/nature10014			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562565	Green Accepted			2022-12-28	WOS:000290487200044
J	Pearce, F				Pearce, Fred			Dubious assumptions prime population bomb	NATURE			English	Editorial Material												pearcefred@hotmail.com							0	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 12	2011	473	7346					125	125		10.1038/473125a	http://dx.doi.org/10.1038/473125a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	762NT	21562518	Bronze			2022-12-28	WOS:000290487200004
J	Orchard, J; Kountouris, A				Orchard, John; Kountouris, Alex			The management of tennis elbow	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SHOCK-WAVE THERAPY; RANDOMIZED CONTROLLED-TRIAL; PLATELET-RICH PLASMA; DOUBLE-BLIND; CORTICOSTEROID INJECTION; LATERAL EPICONDYLITIS		[Orchard, John] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; [Kountouris, Alex] Australian Cricket Team, Melbourne, Vic, Australia	University of Sydney	Orchard, J (corresponding author), Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.	johnorchard@msn.com.au	Orchard, John W/E-5728-2013; Orchard, John W/AAY-7216-2020	Orchard, John W/0000-0003-3530-1711; Orchard, John W/0000-0003-3530-1711				Alfredson H, 1998, AM J SPORT MED, V26, P360, DOI 10.1177/03635465980260030301; Bisset L, 2006, BMJ-BRIT MED J, V333, P939, DOI 10.1136/bmj.38961.584653.AE; Cook JL, 2009, BRIT J SPORT MED, V43, P409, DOI 10.1136/bjsm.2008.051193; Coombes BK, 2010, LANCET, V376, P1751, DOI 10.1016/S0140-6736(10)61160-9; Croisier JL, 2007, BRIT J SPORT MED, V41, P269, DOI 10.1136/bjsm.2006.033324; Crowther MAA, 2002, J BONE JOINT SURG BR, V84B, P678, DOI 10.1302/0301-620X.84B5.12741; de Wit T, 2009, J ORTHOP RES, V27, P408, DOI 10.1002/jor.20730; Furia JP, 2006, AM J SPORT MED, V34, P733, DOI 10.1177/0363546505281810; Gosens T, 2011, AM J SPORTS MED; Ho C, 2007, Issues Emerg Health Technol, P1; Keizer SB, 2002, CLIN ORTHOP RELAT R, P125; Khan KM, 1999, SPORTS MED, V27, P393, DOI 10.2165/00007256-199927060-00004; Khan KM, 2002, BRIT MED J, V324, P626, DOI 10.1136/bmj.324.7338.626; McCallum SDA, 2011, BRIT J SPORT MED, V45, P416, DOI 10.1136/bjsm.2009.061002; Mishra A, 2009, PM&R, V1, P366, DOI 10.1016/j.pmrj.2009.02.010; NIRSCHL RP, 1994, J BONE JOINT SURG AM, V76A, P951; Osborne H, 2010, J SCI MED SPORT, V13, P380, DOI 10.1016/j.jsams.2009.09.009; Paoloni JA, 2009, BRIT J SPORT MED, V43, P299, DOI 10.1136/bjsm.2008.053108; Paoloni JA, 2003, AM J SPORT MED, V31, P915, DOI 10.1177/03635465030310062901; Peerbooms JC, 2010, AM J SPORT MED, V38, P255, DOI 10.1177/0363546509355445; Petrella R. J., 2010, BMC SPORTS SCI MED R, V2, DOI DOI 10.1186/1758-2555-2-4; Placzek R, 2007, J BONE JOINT SURG AM, V89A, P255, DOI 10.2106/JBJS.F.00401; STANISH WD, 1986, CLIN ORTHOP RELAT R, P65; Staples MP, 2008, J RHEUMATOL, V35, P2038; Tyler TF, 2010, J SHOULDER ELB SURG, V19, P917, DOI 10.1016/j.jse.2010.04.041; Visnes H, 2005, CLIN J SPORT MED, V15, P225; Wong SM, 2005, ANN INTERN MED, V143, P793, DOI 10.7326/0003-4819-143-11-200512060-00007; Yagishita K, 2005, ARTHROSCOPY, V21, P1330, DOI 10.1016/j.arthro.2005.08.020	28	27	28	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2011	342								d2687	10.1136/bmj.d2687	http://dx.doi.org/10.1136/bmj.d2687			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765OM	21558359				2022-12-28	WOS:000290718100004
J	Jenkins, SJ; Ruckerl, D; Cook, PC; Jones, LH; Finkelman, FD; van Rooijen, N; MacDonald, AS; Allen, JE				Jenkins, Stephen J.; Ruckerl, Dominik; Cook, Peter C.; Jones, Lucy H.; Finkelman, Fred D.; van Rooijen, Nico; MacDonald, Andrew S.; Allen, Judith E.			Local Macrophage Proliferation, Rather than Recruitment from the Blood, Is a Signature of T(H)2 Inflammation	SCIENCE			English	Article							CD4(+) T-CELLS; ALTERNATIVE ACTIVATION; HELMINTH INFECTION; IL-4; MONOCYTES; MICE; MECHANISMS; INJURY; REPAIR; LIFE	A defining feature of inflammation is the accumulation of innate immune cells in the tissue that are thought to be recruited from the blood. We reveal that a distinct process exists in which tissue macrophages undergo rapid in situ proliferation in order to increase population density. This inflammatory mechanism occurred during T helper 2 (T(H)2)-related pathologies under the control of the archetypal T(H)2 cytokine interleukin-4 (IL-4) and was a fundamental component of T(H)2 inflammation because exogenous IL-4 was sufficient to drive accumulation of tissue macrophages through self-renewal. Thus, expansion of innate cells necessary for pathogen control or wound repair can occur without recruitment of potentially tissue-destructive inflammatory cells.	[Jenkins, Stephen J.; Ruckerl, Dominik; Cook, Peter C.; Jones, Lucy H.; MacDonald, Andrew S.; Allen, Judith E.] Univ Edinburgh, Sch Biol Sci, Ctr Immun Infect & Evolut, Edinburgh EH9 3JT, Midlothian, Scotland; [Jenkins, Stephen J.; Ruckerl, Dominik; Cook, Peter C.; Jones, Lucy H.; MacDonald, Andrew S.; Allen, Judith E.] Univ Edinburgh, Sch Biol Sci, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH 45220 USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH 45267 USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp, Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA; [van Rooijen, Nico] Free Univ Med Ctr, Dept Mol & Cell Biol, Amsterdam, Netherlands	University of Edinburgh; University of Edinburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Vrije Universiteit Amsterdam	Allen, JE (corresponding author), Univ Edinburgh, Sch Biol Sci, Ctr Immun Infect & Evolut, Edinburgh EH9 3JT, Midlothian, Scotland.	j.allen@ed.ac.uk	Van Rooijen, Nico/Z-1578-2019; Allen, Judith E/C-9198-2011; Cook, Peter/E-6731-2015	Allen, Judith E/0000-0002-3829-066X; Cook, Peter/0000-0002-5208-4985; Jackson-Jones, Lucy/0000-0003-0608-8966; Jenkins, Stephen/0000-0002-0233-5424; Ruckerl, Dominik/0000-0002-0206-1451	Medical Research Council (MRC) UK [G0600818, G0701437]; European Union [INCO-CT-2006-03232]; U.S. Department of Veterans Affairs; National Institutes of Health [RO1 AI070300]; Wellcome Trust; MRC [G0701437, G0600818] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070300] Funding Source: NIH RePORTER; Medical Research Council [G0600818, G0701437] Funding Source: researchfish	Medical Research Council (MRC) UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank R. Zamoyska, F. Brombacher, and D. Gray for critical reading of the manuscript, and A. Fulton and S. Duncan for expert technical assistance. This study was funded by the Medical Research Council (MRC) UK (G0600818 to J.E.A.), with additional support from the European Union ("SCOOTT"; INCO-CT-2006-03232), MRC UK (G0701437 to A. S. M.), the U.S. Department of Veterans Affairs (Merit Award to F. D. F.), and the National Institutes of Health (RO1 AI070300 to F. D. F.). L.H.J. was funded by a Wellcome Trust Ph.D. studentship.	Allen JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002003; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Anthony RM, 2006, NAT MED, V12, P955, DOI 10.1038/nm1451; Ashcroft GS, 2003, J CLIN INVEST, V111, P1309, DOI 10.1172/KCO200316288; Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107; Chorro L, 2009, J EXP MED, V206, P3089, DOI 10.1084/jem.20091586; DAEMS WT, 1982, IMMUNOBIOLOGY, V161, P204, DOI 10.1016/S0171-2985(82)80075-2; Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701; Fine JS, 2003, INFLAMMATION, V27, P161, DOI 10.1023/A:1025076111950; Getts DR, 2008, J EXP MED, V205, P2319, DOI 10.1084/jem.20080421; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; Le Goff L, 2002, INT J PARASITOL, V32, P1277, DOI 10.1016/S0020-7519(02)00125-X; Loke P, 2007, J IMMUNOL, V179, P3926, DOI 10.4049/jimmunol.179.6.3926; Loke P'ng, 2002, BMC Immunol, V3, P7, DOI 10.1186/1471-2172-3-7; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; MacDonald AS, 2003, MED MICROBIOL IMMUN, V192, P33, DOI 10.1007/s00430-002-0156-8; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; Milner JD, 2010, BLOOD, V116, P2476, DOI 10.1182/blood-2009-11-255174; Munder M, 1998, J IMMUNOL, V160, P5347; Murphy J, 2008, AM J RESP CELL MOL, V38, P380, DOI 10.1165/rcmb.2007-0224RC; Ruffell D, 2009, P NATL ACAD SCI USA, V106, P17475, DOI 10.1073/pnas.0908641106; Serbina NV, 2008, ANNU REV IMMUNOL, V26, P421, DOI 10.1146/annurev.immunol.26.021607.090326; Siracusa MC, 2008, J LEUKOCYTE BIOL, V84, P1422, DOI 10.1189/jlb.0308199; Smith P, 2007, J IMMUNOL, V178, P4557, DOI 10.4049/jimmunol.178.7.4557; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410; Vats D, 2006, CELL METAB, V4, P13, DOI 10.1016/j.cmet.2006.05.011; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3	30	959	993	0	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2011	332	6035					1284	1288		10.1126/science.1204351	http://dx.doi.org/10.1126/science.1204351			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775EP	21566158	Green Accepted			2022-12-28	WOS:000291441700035
J	Jones, MDM; Forn, I; Gadelha, C; Egan, MJ; Bass, D; Massana, R; Richards, TA				Jones, Meredith D. M.; Forn, Irene; Gadelha, Catarina; Egan, Martin J.; Bass, David; Massana, Ramon; Richards, Thomas A.			Discovery of novel intermediate forms redefines the fungal tree of life	NATURE			English	Article							OLIGONUCLEOTIDE PROBES; MOLECULAR PHYLOGENY; RIBOSOMAL-RNA; SEQUENCE DATA; LAND PLANTS; DIVERSITY; EVOLUTION; COMMUNITY; EUKARYOTES; ROZELLA	Fungi are the principal degraders of biomass in terrestrial ecosystems and establish important interactions with plants and animals(1-3). However, our current understanding of fungal evolutionary diversity is incomplete(4) and is based upon species amenable to growth in culture(1). These culturable fungi are typically yeast or filamentous forms, bound by a rigid cell wall rich in chitin. Evolution of this body plan was thought critical for the success of the Fungi, enabling them to adapt to heterogeneous habitats and live by osmotrophy: extracellular digestion followed by nutrient uptake(5). Here we investigate the ecology and cell biology of a previously undescribed and highly diverse form of eukaryotic life that branches with the Fungi, using environmental DNA analyses combined with fluorescent detection via DNA probes. This clade is present in numerous ecosystems including soil, freshwater and aquatic sediments. Phylogenetic analyses using multiple ribosomal RNA genes place this clade with Rozella, the putative primary branch of the fungal kingdom(1). Tyramide signal amplification coupled with group-specific fluorescence in situ hybridization reveals that the target cells are small eukaryotes of 3-5 mm in length, capable of forming a microtubule-based flagellum. Co-staining with cell wall markers demonstrates that representatives from the clade do not produce a chitin-rich cell wall during any of the life cycle stages observed and therefore do not conform to the standard fungal body plan(5). We name this highly diverse clade the cryptomycota in anticipation of formal classification.	[Jones, Meredith D. M.; Egan, Martin J.; Richards, Thomas A.] Univ Exeter, Sch Biosci, Exeter EX4 4QD, Devon, England; [Jones, Meredith D. M.; Bass, David; Richards, Thomas A.] Nat Hist Museum, Dept Zool, London SW7 5BD, England; [Forn, Irene; Massana, Ramon] CSIC, Inst Ciencies Mar, Dept Marine Biol & Oceanog, E-08003 Barcelona, Catalonia, Spain; [Gadelha, Catarina] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; [Egan, Martin J.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of Exeter; Natural History Museum London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Mediterraneo de Investigaciones Marinas y Ambientales (CMIMA); CSIC - Instituto de Ciencias del Mar (ICM); University of Cambridge; Harvard University; Harvard Medical School	Richards, TA (corresponding author), Univ Exeter, Sch Biosci, Exeter EX4 4QD, Devon, England.	thomr@nhm.ac.uk	Gadelha, Catarina/ABD-5623-2021; Massana, Ramon/F-4205-2016	Gadelha, Catarina/0000-0001-5016-3682; Richards, Thomas/0000-0002-9692-0973; Massana, Ramon/0000-0001-9172-5418	Leverhulme Trust; Natural Environment Research Council, UK [NE/F011709/1]; Systematics Association; Linnean Society; MICINN [CGL2010-16304]; ERA; Natural Environment Research Council [NE/F011709/1] Funding Source: researchfish; NERC [NE/F011709/1] Funding Source: UKRI	Leverhulme Trust(Leverhulme Trust); Natural Environment Research Council, UK(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Systematics Association; Linnean Society; MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); ERA; Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank: N. J. Talbot for advice, K. Gull for the TAT1 antibody, L. Guillou for access to curated SSU database and the Broad Institute of the Massachusetts Institute of Technology and Harvard for making their Rhizopus and Batrachochytrium genome sequence data publicly available. T.A.R. thanks the Leverhulme Trust for fellowship support. This work was primarily supported by a Natural Environment Research Council grant UK (NE/F011709/1). Additional support came from the Systematic Research Fund (awarded by the Systematics Association and the Linnean Society) to T.A.R., project FLAME (CGL2010-16304, MICINN) to R. M. and the BioMarKs project (European Funding Agencies from the ERA-net program BiodivERsA) to T.A.R. and R.M.	BARTNICKIGARCIA S, 1987, EVOLUTIONARY BIOL FU, P389; Baschien C, 2001, INT REV HYDROBIOL, V86, P371, DOI 10.1002/1522-2632(200107)86:4/5<371::AID-IROH371>3.0.CO;2-P; Bass D, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-162; Bass D, 2007, P ROY SOC B-BIOL SCI, V274, P3069, DOI 10.1098/rspb.2007.1067; Benson DA, 2006, NUCLEIC ACIDS RES, V34, pD16, DOI 10.1093/nar/gkj157; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Foster PG, 1999, J MOL EVOL, V48, P284, DOI 10.1007/PL00006471; Fuchs BM, 2000, APPL ENVIRON MICROB, V66, P3603, DOI 10.1128/AEM.66.8.3603-3607.2000; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hawksworth DL, 2001, MYCOL RES, V105, P1422, DOI 10.1017/S0953756201004725; HELD AA, 1975, CAN J BOT, V53, P2212, DOI 10.1139/b75-245; HELD AA, 1981, BOT REV, V47, P451, DOI 10.1007/BF02860539; James TY, 2006, MYCOLOGIA, V98, P860, DOI 10.3852/mycologia.98.6.860; James TY, 2006, NATURE, V443, P818, DOI 10.1038/nature05110; Keane TM, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-29; Kim E, 2011, P NATL ACAD SCI USA, V108, P1496, DOI 10.1073/pnas.1013337108; LANAVE C, 1984, J MOL EVOL, V20, P86, DOI 10.1007/BF02101990; Lara E, 2010, PROTIST, V161, P116, DOI 10.1016/j.protis.2009.06.005; Lefevre E, 2007, ENVIRON MICROBIOL, V9, P61, DOI 10.1111/j.1462-2920.2006.01111.x; Lepere C, 2008, APPL ENVIRON MICROB, V74, P2940, DOI 10.1128/AEM.01156-07; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293; Mangot JF, 2009, APPL ENVIRON MICROB, V75, P6373, DOI 10.1128/AEM.00607-09; Massana R, 2008, CURR OPIN MICROBIOL, V11, P213, DOI 10.1016/j.mib.2008.04.004; PIROZYNSKI KA, 1975, BIOSYSTEMS, V6, P153, DOI 10.1016/0303-2647(75)90023-4; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; van Hannen EJ, 1999, APPL ENVIRON MICROB, V65, P2478; Vandenkoornhuyse P, 2002, SCIENCE, V295, P2051, DOI 10.1126/science.295.5562.2051; Wang B, 2006, MYCORRHIZA, V16, P299, DOI 10.1007/s00572-005-0033-6; Webster J., 2007, INTRO FUNGI, V3rd; WOODS A, 1989, J CELL SCI, V93, P491; Zettler LAA, 2001, J EUKARYOT MICROBIOL, V48, P293, DOI 10.1111/j.1550-7408.2001.tb00317.x	36	285	307	3	178	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2011	474	7350					200	U234		10.1038/nature09984	http://dx.doi.org/10.1038/nature09984			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	774PE	21562490				2022-12-28	WOS:000291397800047
J	Oehler, S				Oehler, Stefan			Comment on "A Bacterium That Can Grow by Using Arsenic Instead of Phosphorus"	SCIENCE			English	Editorial Material									Biomed Sci Res Ctr Alexander Fleming, Vari 16672, Greece	Alexander Fleming Biomedical Sciences Research Center	Oehler, S (corresponding author), Biomed Sci Res Ctr Alexander Fleming, Vari 16672, Greece.	oehler@fleming.gr						Wolfe-Simon F, 2011, SCIENCE, V332, P1163, DOI 10.1126/science.1197258	1	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2011	332	6034								10.1126/science.1201381	http://dx.doi.org/10.1126/science.1201381			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	772BO	21622709				2022-12-28	WOS:000291205200026
J	Spence, D				Spence, Des			FROM THE FRONTLINE Bad medicine: digital rectal examination	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	6	6	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 1	2011	342								d3421	10.1136/bmj.d3421	http://dx.doi.org/10.1136/bmj.d3421			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774MK	21632663				2022-12-28	WOS:000291390500015
J	Rosello-Diez, A; Ros, MA; Torres, M				Rosello-Diez, Alberto; Ros, Maria A.; Torres, Miguel			Diffusible Signals, Not Autonomous Mechanisms, Determine the Main Proximodistal Limb Subdivision	SCIENCE			English	Article							VERTEBRATE LIMB; RETINOIC ACID; VITAMIN-A; GENE-EXPRESSION; MOUSE LIMB; CELL FATE; BUD; AXIS; FGF; REGENERATION	Vertebrate limbs develop three main proximodistal (PD) segments (upper arm, forearm, and hand) in a proximal-to-distal sequence. Despite extensive research into limb development, whether PD specification occurs through nonautonomous or autonomous mechanisms is not resolved. Heterotopic transplantation of intact and recombinant chicken limb buds identifies signals in the embryo trunk that proximalize distal limb cells to generate a complete PD axis. In these transplants, retinoic acid induces proximalization, which is counteracted by fibroblast growth factors from the distal limb bud; these related actions suggest that the first limb-bud PD regionalization results from the balance between proximal and distal signals. The plasticity of limb progenitor cell identity in response to diffusible signals provides a unifying view of PD patterning during vertebrate limb development and regeneration.	[Rosello-Diez, Alberto; Torres, Miguel] Inst Salud Carlos III, Ctr Nacl Invest Cardiovasc, Dept Desarrollo & Reparac Cardiovasc, E-28029 Madrid, Spain; [Ros, Maria A.] Inst Biomed & Biotecnol Cantabria CSIC UC SODERAN, E-39011 Santander, Spain; [Ros, Maria A.] Univ Cantabria, E-39011 Santander, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Instituto de Salud Carlos III; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Universidad de Cantabria	Torres, M (corresponding author), Inst Salud Carlos III, Ctr Nacl Invest Cardiovasc, Dept Desarrollo & Reparac Cardiovasc, C Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	mtorres@cnic.es	Ros, Maria A./K-8160-2014; Roselló-Díez, Alberto/K-7295-2016; Torres, Miguel/CAG-0003-2022; Torres, Miguel/A-7388-2013	Ros, Maria A./0000-0002-1224-7671; Roselló-Díez, Alberto/0000-0002-5550-9846; Torres, Miguel/0000-0003-0906-4767; Torres, Miguel/0000-0003-0906-4767	Spanish Ministry of Science and Innovation (MICINN) [RD06/0010/0008, BFU2009-08331/BMC, BFU2008-00397]; Madrid's Regional Government (CAM) [CPI/0051/2007]; MICINN; Pro-CNIC Foundation	Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Madrid's Regional Government (CAM); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Pro-CNIC Foundation	We thank K. Storey and R. Diez del Corral for plasmids and C. Tabin for sharing unpublished results. Supported by grants RD06/0010/0008, BFU2009-08331/BMC (M. T.) and BFU2008-00397 (M. A. R.), from the Spanish Ministry of Science and Innovation (MICINN) and fellowship CPI/0051/2007 (A.R.-D.) from Madrid's Regional Government (CAM). The CNIC is supported by the MICINN and the Pro-CNIC Foundation.	Cooper KL, 2011, SCIENCE, V332, P1083, DOI 10.1126/science.1199499; Diez del Corral R, 2003, NEURON, V40, P65; Dudley AT, 2002, NATURE, V418, P539, DOI 10.1038/nature00945; Goldbeter A, 2007, DEV DYNAM, V236, P1495, DOI 10.1002/dvdy.21193; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAYAMIZU TF, 1994, DEV BIOL, V166, P123, DOI 10.1006/dbio.1994.1301; KIENY M, 1977, ROUX ARCH DEV BIOL, V183, P177, DOI 10.1007/BF00867319; MADEN M, 1983, J EMBRYOL EXP MORPH, V77, P273; MADEN M, 1983, DEV BIOL, V98, P409, DOI 10.1016/0012-1606(83)90370-6; Mariani FV, 2008, NATURE, V453, P401, DOI 10.1038/nature06876; Mercader N, 2000, DEVELOPMENT, V127, P3961; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; Mercader N, 2009, INT J DEV BIOL, V53, P1483, DOI 10.1387/ijdb.072430nm; Nelson CE, 1996, DEVELOPMENT, V122, P1449; ROS MA, 1994, DEV BIOL, V166, P59, DOI 10.1006/dbio.1994.1296; SAXENA S, 1977, INDIAN J EXP BIOL, V15, P435; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; SUMMERBELL D, 1977, J EMBRYOL EXP MORPH, V41, P137; SUMMERBELL D, 1975, J EMBRYOL EXP MORPH, V33, P621; Tabin C, 2007, GENE DEV, V21, P1433, DOI 10.1101/gad.1547407; ten Berge D, 2008, DEVELOPMENT, V135, P3247, DOI 10.1242/dev.023176; Vargesson N, 1997, DEVELOPMENT, V124, P1909; Yashiro K, 2004, DEV CELL, V6, P411, DOI 10.1016/S1534-5807(04)00062-0; Zhao XL, 2009, CURR BIOL, V19, P1050, DOI 10.1016/j.cub.2009.04.059	25	97	97	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2011	332	6033					1086	1088		10.1126/science.1199489	http://dx.doi.org/10.1126/science.1199489			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769FN	21617076				2022-12-28	WOS:000290996700045
J	Enthoven, AC				Enthoven, Alain C.			Reforming Medicare by Reforming Incentives	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NATIONAL-HEALTH-INSURANCE; COMPETITION; PLAN		Stanford Univ, Grad Sch Business, Stanford, CA USA	Stanford University	Enthoven, AC (corresponding author), Stanford Univ, Grad Sch Business, Stanford, CA USA.							ENTHOVEN AC, 1978, NEW ENGL J MED, V298, P709, DOI 10.1056/NEJM197803302981304; ENTHOVEN AC, 1978, NEW ENGL J MED, V298, P650, DOI 10.1056/NEJM197803232981204; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; Reid PP, 2005, BUILDING BETTER DELI	4	4	4	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					E44	E44		10.1056/nejmp1104427	http://dx.doi.org/10.1056/nejmp1104427			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768QR	21561341				2022-12-28	WOS:000290952000040
J	Furuya, T; Kamlet, AS; Ritter, T				Furuya, Takeru; Kamlet, Adam S.; Ritter, Tobias			Catalysis for fluorination and trifluoromethylation	NATURE			English	Review							ENANTIOSELECTIVE ALPHA-TRIFLUOROMETHYLATION; FORMING REDUCTIVE ELIMINATION; BOND FORMATION; FUNCTIONALIZED ARYL; COUPLING REACTIONS; PALLADIUM; CARBON; COMPLEXES; REACTIVITY; CHEMISTRY	Recent advances in catalysis have made the incorporation of fluorine into complex organic molecules easier than ever before, but selective, general and practical fluorination reactions remain sought after. Fluorination of molecules often imparts desirable properties, such as metabolic and thermal stability, and fluorinated molecules are therefore frequently used as pharmaceuticals or materials. But the formation of carbon-fluorine bonds in complex molecules is a significant challenge. Here we discuss reactions to make organofluorides that have emerged within the past few years and which exemplify how to overcome some of the intricate challenges associated with fluorination.	[Furuya, Takeru; Kamlet, Adam S.; Ritter, Tobias] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University	Ritter, T (corresponding author), Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA.	ritter@chemistry.harvard.edu	Furuya, Takeru/A-6622-2012; Ritter, Tobias/A-6244-2013; Ritter, Tobias/AAJ-8703-2021	Ritter, Tobias/0000-0002-5478-0036; 	NSF [CHE-0952753]; NIH-NIGMS [GM088237]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088237] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NIH-NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the NSF (CHE-0952753) and the NIH-NIGMS (GM088237) for financial support.	Adams DJ, 1999, CHEM SOC REV, V28, P225, DOI 10.1039/a808707e; Allen AE, 2010, J AM CHEM SOC, V132, P4986, DOI 10.1021/ja100748y; Altman RA, 2008, J AM CHEM SOC, V130, P9613, DOI 10.1021/ja803179s; Ametamey SM, 2008, CHEM REV, V108, P1501, DOI 10.1021/cr0782426; Anbarasan P, 2010, ANGEW CHEM INT EDIT, V49, P2219, DOI 10.1002/anie.200905855; AZIZIAN H, 1981, J ORGANOMET CHEM, V215, P49, DOI 10.1016/S0022-328X(00)84615-X; Ball ND, 2010, J AM CHEM SOC, V132, P2878, DOI 10.1021/ja100955x; Ball ND, 2009, J AM CHEM SOC, V131, P3796, DOI 10.1021/ja8054595; Beeson TD, 2005, J AM CHEM SOC, V127, P8826, DOI 10.1021/ja051805f; Beeson TD, 2007, SCIENCE, V316, P582, DOI 10.1126/science. 1142696; BOTT G, 1980, J AM CHEM SOC, V102, P5618, DOI 10.1021/ja00537a036; CARR GE, 1988, J CHEM SOC PERK T 1, P921, DOI 10.1039/p19880000921; Cho EJ, 2010, SCIENCE, V328, P1679, DOI 10.1126/science.1190524; Chu LL, 2010, ORG LETT, V12, P5060, DOI 10.1021/ol1023135; CLARK HC, 1967, J ORGANOMET CHEM, V7, P515, DOI 10.1016/S0022-328X(00)85373-5; COPE AC, 1965, J AM CHEM SOC, V87, P3272, DOI 10.1021/ja01092a063; Culkin DA, 2004, ORGANOMETALLICS, V23, P3398, DOI 10.1021/om049726k; Curran DP, 1998, ANGEW CHEM INT EDIT, V37, P1175, DOI 10.1002/(SICI)1521-3773(19980518)37:9<1174::AID-ANIE1174>3.0.CO;2-P; de Meijere A., 2004, METAL CATALYZED CROS, V2nd, DOI 10.1002/9783527619535; Dong CJ, 2004, NATURE, V427, P561, DOI 10.1038/nature02280; Dubinina GG, 2008, J AM CHEM SOC, V130, P8600, DOI 10.1021/ja802946s; Dubinina GG, 2008, ORGANOMETALLICS, V27, P6233, DOI 10.1021/om800794m; Eisenberger P, 2006, CHEM-EUR J, V12, P2579, DOI 10.1002/chem.200501052; EMSLEY J, 1980, CHEM SOC REV, V9, P91, DOI 10.1039/cs9800900091; Enders D, 2005, SYNLETT, P991, DOI 10.1055/s-2005-864813; Fors BP, 2008, J AM CHEM SOC, V130, P13552, DOI 10.1021/ja8055358; Fraser SL, 1997, J AM CHEM SOC, V119, P4769, DOI 10.1021/ja963984u; Furuya T, 2008, CURR OPIN DRUG DISC, V11, P803; Furuya T, 2008, J AM CHEM SOC, V130, P10060, DOI 10.1021/ja803187x; Furuya T, 2010, SYNTHESIS-STUTTGART, P1804, DOI 10.1055/s-0029-1218742; Furuya T, 2008, ANGEW CHEM INT EDIT, V47, P5993, DOI 10.1002/anie.200802164; Furuya T, 2010, J AM CHEM SOC, V132, P3793, DOI 10.1021/ja909371t; Furuya T, 2009, ORG LETT, V11, P2860, DOI 10.1021/ol901113t; Furuya T, 2009, J AM CHEM SOC, V131, P1662, DOI 10.1021/ja8086664; Gribble G W, 1996, Fortschr Chem Org Naturst, V68, P1; Gribble G. W., 2009, PROGR CHEM ORGANIC N, V91, P1; Grushin VV, 2007, ORGANOMETALLICS, V26, P4997, DOI 10.1021/om700469k; Grushin VV, 2006, J AM CHEM SOC, V128, P12644, DOI 10.1021/ja064935c; Grushin VV, 2010, ACCOUNTS CHEM RES, V43, P160, DOI 10.1021/ar9001763; Grushin VV, 2006, J AM CHEM SOC, V128, P4632, DOI 10.1021/ja0602389; Grushin VV, 2002, CHEM-EUR J, V8, P1006, DOI 10.1002/1521-3765(20020301)8:5<1006::AID-CHEM1006>3.0.CO;2-M; Hamashima Y, 2002, J AM CHEM SOC, V124, P14530, DOI 10.1021/ja028464f; Hartwig JF, 1998, ACCOUNTS CHEM RES, V31, P852, DOI 10.1021/ar970282g; Hartwig JF, 2008, NATURE, V455, P314, DOI 10.1038/nature07369; Hintermann L, 2000, ANGEW CHEM INT EDIT, V39, P4359, DOI 10.1002/1521-3773(20001201)39:23<4359::AID-ANIE4359>3.0.CO;2-P; Hollingworth C, 2011, ANGEW CHEM INT EDIT, V50, P2613, DOI 10.1002/anie.201007307; Huffman LM, 2008, J AM CHEM SOC, V130, P9196, DOI 10.1021/ja802123p; Hull KL, 2006, J AM CHEM SOC, V128, P7134, DOI 10.1021/ja061943k; Hung M-H, 1999, FLUOROPOLYMERS, V1, P51, DOI DOI 10.1007/0-306-46918-9_4; Ishimaru T, 2008, ANGEW CHEM INT EDIT, V47, P4157, DOI 10.1002/anie.200800717; JENSEN MB, 1995, J PHYS CHEM-US, V99, P8736, DOI 10.1021/j100021a045; Jeschke P, 2004, CHEMBIOCHEM, V5, P570, DOI 10.1002/cbic.200300833; Kaspi AW, 2008, INORG CHEM, V47, P5, DOI 10.1021/ic701722f; Katcher MH, 2010, J AM CHEM SOC, V132, P17402, DOI 10.1021/ja109120n; Kawai H, 2009, ANGEW CHEM INT EDIT, V48, P6324, DOI 10.1002/anie.200902457; Kirk KL, 2008, ORG PROCESS RES DEV, V12, P305, DOI 10.1021/op700134j; Kirsch P., 2013, MODERN FLUOROORGANIC; Knauber T, 2011, CHEM-EUR J, V17, P2689, DOI 10.1002/chem.201002749; KOBAYASHI Y, 1969, TETRAHEDRON LETT, P4095; Kwiatkowski P, 2011, J AM CHEM SOC, V133, P1738, DOI 10.1021/ja111163u; Lectard S, 2010, ADV SYNTH CATAL, V352, P2708, DOI 10.1002/adsc.201000624; LIU ZM, 1993, SURF SCI, V286, P233, DOI 10.1016/0039-6028(93)90408-C; Luo Y.R., 2002, HDB BOND DISSOCIATIO, DOI 10.1201/9781420039863; Ma JA, 2007, J FLUORINE CHEM, V128, P975, DOI 10.1016/j.jfluchem.2007.04.026; Ma JA, 2008, CHEM REV, V108, pPR1, DOI 10.1021/cr800221v; Marigo M, 2005, ANGEW CHEM INT EDIT, V44, P3703, DOI 10.1002/anie.200500395; MCLOUGHL.VC, 1969, TETRAHEDRON, V25, P5921, DOI 10.1016/S0040-4020(01)83100-8; Monnier F, 2009, ANGEW CHEM INT EDIT, V48, P6954, DOI 10.1002/anie.200804497; Morimoto H, 2011, ANGEW CHEM INT EDIT, V50, P3793, DOI 10.1002/anie.201100633; Muci AR, 2002, TOP CURR CHEM, V219, P131, DOI 10.1007/3-540-45313-X_5; Muller K, 2007, SCIENCE, V317, P1881, DOI 10.1126/science.1131943; Nagib DA, 2009, J AM CHEM SOC, V131, P10875, DOI 10.1021/ja9053338; O'Hagan D, 2002, NATURE, V416, P279, DOI 10.1038/416279a; O'Hagan D, 2008, CHEM SOC REV, V37, P308, DOI 10.1039/b711844a; Oishi M, 2009, CHEM COMMUN, P1909, DOI 10.1039/b823249k; Patterson JC, 2005, MOL IMAGING BIOL, V7, P197, DOI 10.1007/s11307-005-4116-8; Pilon MC, 1998, ORGANOMETALLICS, V17, P1774, DOI 10.1021/om9708440; Powers DC, 2010, J AM CHEM SOC, V132, P14092, DOI 10.1021/ja1036644; Powers DC, 2009, NAT CHEM, V1, P302, DOI 10.1038/NCHEM.246; Purser S, 2008, CHEM SOC REV, V37, P320, DOI 10.1039/b610213c; Senecal TD, 2011, J ORG CHEM, V76, P1174, DOI 10.1021/jo1023377; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Shibata N, 2008, TETRAHEDRON-ASYMMETR, V19, P2633, DOI 10.1016/j.tetasy.2008.11.011; Shimizu M, 2005, ANGEW CHEM INT EDIT, V44, P214, DOI 10.1002/anie.200460441; Steiner DD, 2005, ANGEW CHEM INT EDIT, V44, P3706, DOI 10.1002/anie.200500571; Subramanian MA, 2002, SCIENCE, V297, P1665, DOI 10.1126/science.1076397; Tang PP, 2010, J AM CHEM SOC, V132, P12150, DOI 10.1021/ja105834t; Tye JW, 2008, J AM CHEM SOC, V130, P9971, DOI 10.1021/ja076668w; UMEMOTO T, 1994, J ORG CHEM, V59, P5692, DOI 10.1021/jo00098a030; Wang XS, 2010, J AM CHEM SOC, V132, P3648, DOI 10.1021/ja909522s; Wang XS, 2009, J AM CHEM SOC, V131, P7520, DOI 10.1021/ja901352k; Watson DA, 2009, SCIENCE, V325, P1661, DOI 10.1126/science.1178239; WIEMERS DM, 1986, J AM CHEM SOC, V108, P832, DOI 10.1021/ja00264a043; Wu XF, 2010, ANGEW CHEM INT EDIT, V49, P9047, DOI 10.1002/anie.201006374; YAGUPOLSKII LM, 2000, HOUBEN WEYL METHODS, P509; Yamada S, 2010, ANGEW CHEM INT EDIT, V49, P2215, DOI 10.1002/anie.200905052; Yandulov DV, 2007, J AM CHEM SOC, V129, P1342, DOI 10.1021/ja066930l; Ye YD, 2010, J AM CHEM SOC, V132, P14682, DOI 10.1021/ja107780w; Young S., 1881, J CHEM SOC, V39, P489; Zhang CP, 2011, ANGEW CHEM INT EDIT, V50, P1896, DOI 10.1002/anie.201006823	100	1665	1685	18	743	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2011	473	7348					470	477		10.1038/nature10108	http://dx.doi.org/10.1038/nature10108			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21614074	Green Accepted			2022-12-28	WOS:000290951300032
J	Grainge, CL; Lau, LCK; Ward, JA; Dulay, V; Lahiff, G; Wilson, S; Holgate, S; Davies, DE; Howarth, PH				Grainge, Christopher L.; Lau, Laurie C. K.; Ward, Jonathon A.; Dulay, Valdeep; Lahiff, Gemma; Wilson, Susan; Holgate, Stephen; Davies, Donna E.; Howarth, Peter H.			Effect of Bronchoconstriction on Airway Remodeling in Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; ALLERGEN CHALLENGE; EPITHELIAL-CELLS; INFLAMMATION; EXPRESSION; GUIDELINES; MODEL	BACKGROUND Asthma is characterized pathologically by structural changes in the airway, termed airway remodeling. These changes are associated with worse long-term clinical outcomes and have been attributed to eosinophilic inflammation. In vitro studies indicate, however, that the compressive mechanical forces that arise during broncho-constriction may induce remodeling independently of inflammation. We evaluated the influence of repeated experimentally induced bronchoconstriction on airway structural changes in patients with asthma. METHODS We randomly assigned 48 subjects with asthma to one of four inhalation challenge protocols involving a series of three challenges with one type of inhaled agent presented at 48-hour intervals. The two active challenges were with either a dust-mite allergen (which causes bronchoconstriction and eosinophilic inflammation) or methacholine (which causes bronchoconstriction without eosinophilic inflammation); the two control challenges (neither of which causes bronchoconstriction) were either saline alone or albuterol followed by methacholine (to control for non-bronchoconstrictor effects of methacholine). Bronchial-biopsy specimens were obtained before and 4 days after completion of the challenges. RESULTS Allergen and methacholine immediately induced similar levels of bronchoconstriction. Eosinophilic inflammation of the airways increased only in the allergen group, whereas both the allergen and the methacholine groups had significant airway remodeling not seen in the two control groups. Subepithelial collagen-band thickness increased by a median of 2.17 mu m in the allergen group (interquartile range [IQR], 0.70 to 3.67) and 1.94 mu m in the methacholine group (IQR, 0.37 to 3.24) (P<0.001 for the comparison of the two challenge groups with the two control groups); periodic acid-Schiff staining of epithelium (mucus glands) also increased, by a median of 2.17 percentage points in the allergen group (IQR, 1.03 to 4.77) and 2.13 percentage points in the methacholine group (IQR, 1.14 to 7.96) (P=0.003 for the comparison with controls). There were no significant differences between the allergen and methacholine groups. CONCLUSIONS Bronchoconstriction without additional inflammation induces airway remodeling in patients with asthma. These findings have potential implications for management.	[Grainge, Christopher L.; Lau, Laurie C. K.; Ward, Jonathon A.; Dulay, Valdeep; Lahiff, Gemma; Wilson, Susan; Holgate, Stephen; Davies, Donna E.; Howarth, Peter H.] Univ Southampton, Sch Med, Div Infect Inflammat & Immun, Southampton, Hants, England; [Grainge, Christopher L.; Howarth, Peter H.] Wellcome Trust Clin Res Facil, Southampton, Hants, England; [Holgate, Stephen; Howarth, Peter H.] Natl Inst Hlth Res Resp Biomed Res Unit, Southampton, Hants, England	University of Southampton	Howarth, PH (corresponding author), Southampton Gen Hosp, Sir Henry Wellcome Labs, Mailpoint 810,S Block, Southampton SO16 6YD, Hants, England.	p.h.howarth@soton.ac.uk	Davies, Donna E/H-2993-2012	Howarth, Peter/0000-0003-0619-7927; Grainge, Christopher/0000-0002-6565-9928	Defence Postgraduate Medical Deanery; Medical Research Council [G0900453]; Medical Research Council [G0400473, G19/34] Funding Source: researchfish; MRC [G19/34, G0900453, G0400473] Funding Source: UKRI	Defence Postgraduate Medical Deanery; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Defence Postgraduate Medical Deanery and by a grant from the Medical Research Council (G0900453).	Beckett PA, 2003, THORAX, V58, P163, DOI 10.1136/thorax.58.2.163; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Choe MM, 2006, AM J RESP CELL MOL, V35, P306, DOI 10.1165/rcmb.2005-0443OC; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46, DOI 10.1164/ajrccm.164.supplement_2.2106066; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Grainge C, 2010, CLIN RESP J     0607; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hashimoto M, 2005, CHEST, V127, P965, DOI 10.1378/chest.127.3.965; Hatzivlassiou M, 2010, ALLERGY, V65, P355, DOI 10.1111/j.1398-9995.2009.02184.x; Holgate Stephen T, 2009, Proc Am Thorac Soc, V6, P655, DOI 10.1513/pats.200907-072DP; Huang CYC, 2005, STEM CELLS, V23, P1113, DOI 10.1634/stemcells.2004-0202; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Kelly MM, 2010, J ALLERGY CLIN IMMUN, V125, P349, DOI 10.1016/j.jaci.2009.09.011; Labonte I, 2009, AM J PHYSIOL-LUNG C, V297, pL698, DOI 10.1152/ajplung.00142.2009; MCMANUS JFA, 1946, NATURE, V158, P202, DOI 10.1038/158202a0; Miyagawa A, 2009, J DENT RES, V88, P752, DOI 10.1177/0022034509341637; Niimi A, 2005, J ALLERGY CLIN IMMUN, V116, P565, DOI 10.1016/j.jaci.2005.07.010; Nishimura Y, 2008, CIRC J, V72, P647; Park JA, 2010, J BIOL CHEM, V285, P29817, DOI 10.1074/jbc.M110.103416; Park JA, 2009, AM J RESP CELL MOL, V41, P459, DOI 10.1165/rcmb.2008-0195OC; Pascual RM, 2009, J ALLERGY CLIN IMMUN, V124, P883, DOI 10.1016/j.jaci.2009.09.047; Proschan MA, 2000, CONTROL CLIN TRIALS, V21, P527, DOI 10.1016/S0197-2456(00)00106-9; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tamaoka M, 2008, EUR RESPIR J, V32, P1213, DOI 10.1183/09031936.00166907; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; Tschumperlin DJ, 2001, AM J RESP CRIT CARE, V164, pS90, DOI 10.1164/ajrccm.164.supplement_2.2106060; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814, DOI 10.1152/jappl.1997.83.6.1814; Zhang SL, 1999, LAB INVEST, V79, P395	33	388	401	1	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					2006	2015		10.1056/NEJMoa1014350	http://dx.doi.org/10.1056/NEJMoa1014350			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768QR	21612469				2022-12-28	WOS:000290952000005
J	Kelly, RL				Kelly, Robert L.			Lewis R. Binford (1931-2011) RETROSPECTIVE	SCIENCE			English	Biographical-Item									Univ Wyoming, Dept Anthropol, Laramie, WY 82070 USA	University of Wyoming	Kelly, RL (corresponding author), Univ Wyoming, Dept Anthropol, Laramie, WY 82070 USA.	RLKELLY@uwyo.edu						KELLY RM, PUBLICATION LIST	1	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2011	332	6032					928	928		10.1126/science.1207836	http://dx.doi.org/10.1126/science.1207836			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596984				2022-12-28	WOS:000290766600032
J	Lindsay, ME; Dietz, HC				Lindsay, Mark E.; Dietz, Harry C.			Lessons on the pathogenesis of aneurysm from heritable conditions	NATURE			English	Review							EHLERS-DANLOS-SYNDROME; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; THORACIC AORTIC-ANEURYSM; LYSYL HYDROXYLASE 3; MARFAN-SYNDROME; MOUSE MODEL; MISSENSE MUTATION; MICE LACKING; II RECEPTOR	Aortic aneurysm is common, accounting for 1-2% of all deaths in industrialized countries. Early theories of the causes of human aneurysm mostly focused on inherited or acquired defects in components of the extracellular matrix in the aorta. Although several mutations in the genes encoding extracellular matrix proteins have been recognized, more recent discoveries have shown important perturbations in cytokine signalling cascades and intracellular components of the smooth muscle contractile apparatus. The modelling of single-gene heritable aneurysm disorders in mice has shown unexpected involvement of the transforming growth factor-beta cytokine pathway in aortic aneurysm, highlighting the potential for new therapeutic strategies.	[Lindsay, Mark E.] Johns Hopkins Med Inst, Dept Pediat, Div Pediat Cardiol, Baltimore, MD 21205 USA; [Lindsay, Mark E.; Dietz, Harry C.] Johns Hopkins Med Inst, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; [Dietz, Harry C.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University	Dietz, HC (corresponding author), Johns Hopkins Med Inst, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.	hdietz@jhmi.edu			US National Heart, Lung, and Blood Institute; Howard Hughes Medical Institute; US National Marfan Foundation; William S. Smilow Center for Marfan Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL107738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041135] Funding Source: NIH RePORTER	US National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); US National Marfan Foundation; William S. Smilow Center for Marfan Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We would like to thank E. Arbustini for the use of the multidetector computer tomographic image in Fig. 1a. We acknowledge funding support from the US National Heart, Lung, and Blood Institute, the Howard Hughes Medical Institute, the US National Marfan Foundation and the William S. Smilow Center for Marfan Research.	Andersen ND, 2010, J VASC SURG, V51, P468, DOI 10.1016/j.jvs.2009.08.058; ANIDJAR S, 1990, CIRCULATION, V82, P973, DOI 10.1161/01.CIR.82.3.973; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Arteaga-Solis E, 2001, J CELL BIOL, V154, P275, DOI 10.1083/jcb.200105046; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Atsawasuwan P, 2008, J BIOL CHEM, V283, P34229, DOI 10.1074/jbc.M803142200; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109; Bowman MH, 2010, CIRC RES, V106, P145, DOI 10.1161/CIRCRESAHA.109.209486; Brooke BS, 2008, NEW ENGL J MED, V358, P2787, DOI 10.1056/NEJMoa0706585; Bunton TE, 2001, CIRC RES, V88, P37, DOI 10.1161/01.RES.88.1.37; Cao JM, 2010, HUM MOL GENET, V19, P1908, DOI 10.1093/hmg/ddq066; Carta L, 2006, J BIOL CHEM, V281, P8016, DOI 10.1074/jbc.M511599200; Carta L, 2009, J BIOL CHEM, V284, P5630, DOI 10.1074/jbc.M806962200; Cheng CH, 2009, CARDIOVASC RES, V81, P381, DOI 10.1093/cvr/cvn319; Chiou AC, 2001, J SURG RES, V99, P371, DOI 10.1006/jsre.2001.6207; Choudhary B, 2009, GENESIS, V47, P115, DOI 10.1002/dvg.20466; Chung AWY, 2008, CIRC RES, V102, pE73, DOI 10.1161/CIRCRESAHA.108.174367; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Coucke PJ, 2006, NAT GENET, V38, P452, DOI 10.1038/ng1764; Dasouki M, 2007, AM J MED GENET A, V143A, P2635, DOI 10.1002/ajmg.a.31980; Daugherty A, 2000, J CLIN INVEST, V105, P1605, DOI 10.1172/JCI7818; Dietz HC, 2010, J CLIN INVEST, V120, P403, DOI 10.1172/JCI42014; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Distefano G, 2009, MOL CELL BIOL, V29, P2359, DOI 10.1128/MCB.01259-08; Feng YY, 2006, P NATL ACAD SCI USA, V103, P19836, DOI 10.1073/pnas.0609628104; Friedman JM, 2002, GENET MED, V4, P105, DOI 10.1097/00125817-200205000-00002; Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940; Guo DC, 2007, NAT GENET, V39, P1488, DOI 10.1038/ng.2007.6; Habashi JP, 2011, SCIENCE, V332, P361, DOI 10.1126/science.1192152; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; Haldar SM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000502; Hassane S, 2007, ARTERIOSCL THROM VAS, V27, P2177, DOI 10.1161/ATVBAHA.107.149252; Holm TM, 2011, SCIENCE, V332, P358, DOI 10.1126/science.1192149; Horiguchi M, 2009, P NATL ACAD SCI USA, V106, P19029, DOI 10.1073/pnas.0908268106; Hsi DH, 2003, MAYO CLIN PROC, V78, P774, DOI 10.4065/78.6.774; Huang JB, 2010, CIRC RES, V106, P583, DOI 10.1161/CIRCRESAHA.109.207852; Hubchak SC, 2003, J AM SOC NEPHROL, V14, P1969, DOI 10.1097/01.ASN.0000076079.02452.92; Iwasaki Y, 2009, CONGENIT HEART DIS, V4, P38, DOI 10.1111/j.1747-0803.2008.00243.x; Kamath BM, 2004, CIRCULATION, V109, P1354, DOI 10.1161/01.CIR.0000121361.01862.A4; Kashtan CE, 2010, NEPHROL DIAL TRANSPL, V25, P3554, DOI 10.1093/ndt/gfq271; King VL, 2009, CIRCULATION, V119, P426, DOI 10.1161/CIRCULATIONAHA.108.785949; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Lacro RV, 2007, AM HEART J, V154, P624, DOI 10.1016/j.ahj.2007.06.024; Langlois D, 2010, TRANSGENIC RES, V19, P1069, DOI 10.1007/s11248-010-9379-4; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Lee TC, 2000, CIRCULATION, V101, P2345, DOI 10.1161/01.CIR.101.20.2345; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113; Loeys BL, 2006, NEW ENGL J MED, V355, P788, DOI 10.1056/NEJMoa055695; Loeys BL, 2005, NAT GENET, V37, P275, DOI 10.1038/ng1511; Lopez L, 2008, PEDIATRICS, V121, pE1622, DOI 10.1542/peds.2007-2807; Majesky MW, 2007, ARTERIOSCL THROM VAS, V27, P1248, DOI 10.1161/ATVBAHA.107.141069; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Malfait F, 2007, HUM MUTAT, V28, P387, DOI 10.1002/humu.20455; Mizuguchi T, 2004, NAT GENET, V36, P855, DOI 10.1038/ng1392; Morano I, 2000, NAT CELL BIOL, V2, P371, DOI 10.1038/35014065; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Onoda M, 2010, ATHEROSCLEROSIS, V208, P366, DOI 10.1016/j.atherosclerosis.2009.07.036; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Pannu H, 2007, HUM MOL GENET, V16, P2453, DOI 10.1093/hmg/ddm201; Plaisier E, 2007, NEW ENGL J MED, V357, P2687, DOI 10.1056/NEJMoa071906; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; Purnell R, 2005, EUR J CARDIO-THORAC, V28, P346, DOI 10.1016/j.ejcts.2005.05.004; Raben N, 1998, J BIOL CHEM, V273, P19086, DOI 10.1074/jbc.273.30.19086; Rahkonen O, 2004, CIRC RES, V94, P83, DOI 10.1161/01.RES.0000108263.74520.15; Rocha PP, 2010, DEVELOPMENT, V137, P2723, DOI 10.1242/dev.053660; Rodriguez-Vita J, 2005, CIRCULATION, V111, P2509, DOI 10.1161/01.CIR.0000165133.84978.E2; Ruotsalainen H, 2006, J CELL SCI, V119, P625, DOI 10.1242/jcs.02780; Sakalihasan N, 1996, J VASC SURG, V24, P127, DOI 10.1016/S0741-5214(96)70153-2; Salo AM, 2008, AM J HUM GENET, V83, P495, DOI 10.1016/j.ajhg.2008.09.004; Samarakoon R, 2009, CELL SIGNAL, V21, P986, DOI 10.1016/j.cellsig.2009.02.007; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; Schildmeyer LA, 2000, FASEB J, V14, P2213, DOI 10.1096/fj.99-0927com; Schwarze U, 2004, AM J HUM GENET, V74, P917, DOI 10.1086/420794; Sheen VL, 2005, NEUROLOGY, V64, P254, DOI 10.1212/01.WNL.0000149512.79621.DF; SUPERTIFURGA A, 1988, J BIOL CHEM, V263, P6226; Szabo Z, 2006, J MED GENET, V43, P255, DOI 10.1136/jmg.2005.034157; TAKAHASHI H, 1991, J AM SOC NEPHROL, V1, P980; Takaluoma K, 2007, J BIOL CHEM, V282, P6588, DOI 10.1074/jbc.M608830200; Tieu BC, 2009, J CLIN INVEST, V119, P3637, DOI 10.1172/JCI38308; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; van de Laar IMBH, 2011, NAT GENET, V43, P121, DOI 10.1038/ng.744; Waldo KL, 2005, DEV BIOL, V281, P78, DOI 10.1016/j.ydbio.2005.02.012; Wang Y, 2010, J CLIN INVEST, V120, P422, DOI 10.1172/JCI38136; WENSTRUP RJ, 1989, J PEDIATR-US, V115, P405, DOI 10.1016/S0022-3476(89)80839-X; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yoshimura K, 2005, NAT MED, V11, P1330, DOI 10.1038/nm1335; Yu Q, 2004, DEVELOPMENT, V131, P6211, DOI 10.1242/dev.01543; Zacchigna L, 2006, CELL, V124, P929, DOI 10.1016/j.cell.2005.12.035; Zhu LM, 2006, NAT GENET, V38, P343, DOI 10.1038/ng1721; Zhu TN, 2007, J BIOL CHEM, V282, P14816, DOI 10.1074/jbc.M611430200	100	322	329	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					308	316		10.1038/nature10145	http://dx.doi.org/10.1038/nature10145			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593863	Green Accepted			2022-12-28	WOS:000290722400037
J	Roppolo, D; De Rybel, B; Tendon, VD; Pfister, A; Alassimone, J; Vermeer, JEM; Yamazaki, M; Stierhof, YD; Beeckman, T; Geldner, N				Roppolo, Daniele; De Rybel, Bert; Tendon, Valerie Denervaud; Pfister, Alexandre; Alassimone, Julien; Vermeer, Joop E. M.; Yamazaki, Misako; Stierhof, York-Dieter; Beeckman, Tom; Geldner, Niko			A novel protein family mediates Casparian strip formation in the endodermis	NATURE			English	Article							ASYMMETRIC CELL-DIVISION; ARABIDOPSIS ROOT; PLANT; TRANSPORT; MOVEMENT; POLARITY	Polarized epithelia are fundamental to multicellular life. In animal epithelia, conserved junctional complexes establish membrane diffusion barriers, cellular adherence and sealing of the extracellular space(1). Plant cellular barriers are of independent evolutionary origin. The root endodermis strongly resembles a polarized epithelium and functions in nutrient uptake and stress resistance(2). Its defining features are the Casparian strips, belts of specialized cell wall material that generate an extracellular diffusion barrier(2). The mechanisms localizing Casparian strips are unknown. Here we identify and characterize a family of transmembrane proteins of previously unknown function. These 'CASPs' (Casparian strip membrane domain proteins) specifically mark a membrane domain that predicts the formation of Casparian strips. CASP1 displays numerous features required for a constituent of a plant junctional complex: it forms complexes with other CASPs; it becomes immobile upon localization; and it sediments like a large polymer. CASP double mutants display disorganized Casparian strips, demonstrating a role for CASPs in structuring and localizing this cell wall modification. To our knowledge, CASPs are the first molecular factors that are shown to establish a plasma membrane and extracellular diffusion barrier in plants, and represent a novel way of epithelial barrier formation in eukaryotes.	[Roppolo, Daniele; Tendon, Valerie Denervaud; Pfister, Alexandre; Alassimone, Julien; Vermeer, Joop E. M.; Yamazaki, Misako; Geldner, Niko] Univ Lausanne, UNIL Sorge, Dept Plant Mol Biol, CH-1015 Lausanne, Switzerland; [De Rybel, Bert; Beeckman, Tom] Univ Ghent, Dept Plant Biotechnol & Genet, B-9052 Ghent, Belgium; [De Rybel, Bert; Beeckman, Tom] VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium; [Stierhof, York-Dieter] Univ Tubingen, ZMBP, D-72076 Tubingen, Germany	University of Lausanne; Ghent University; Flanders Institute for Biotechnology (VIB); Eberhard Karls University of Tubingen	Geldner, N (corresponding author), Univ Lausanne, UNIL Sorge, Dept Plant Mol Biol, CH-1015 Lausanne, Switzerland.	niko.geldner@unil.ch	Beeckman, Tom/ABI-1703-2020; Vermeer, Joop E.M./J-2232-2014; Beeckman, Tom/ABA-1164-2020; Geldner, Niko/Y-2481-2019	Beeckman, Tom/0000-0001-8656-2060; Vermeer, Joop E.M./0000-0001-8876-5873; Alassimone, Julien/0000-0002-8118-2605; De Rybel, Bert/0000-0002-9551-042X; Geldner, Niko/0000-0002-2300-9644	Swiss National Science Foundation; European Research Council (ERC); Belgian Interuniversity Attraction Poles program [IUAP VI/33]; Ghent University; Roche Research Foundation; Marie-Curie IEF grant	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Research Council (ERC)(European Research Council (ERC)European Commission); Belgian Interuniversity Attraction Poles program(Belgian Federal Science Policy Office); Ghent University(Ghent University); Roche Research Foundation; Marie-Curie IEF grant	We thank the Central Imaging Facility (CIF) and the Protein Analysis Facility (PAF) of the University of Lausanne for technical support, G. Jurgens, W. Michalke, J. Chory for antibodies, T. W. J. Gadella for mTurquoise and J. Takano for mutant BOR1 clone. We thank J. Chory, E. M. N. Dohmann, Y. Lee and G. Jurgens for comments and critical reading of the manuscript. This work was supported by grants of the Swiss National Science Foundation and the European Research Council (ERC) to N.G., the Belgian Interuniversity Attraction Poles program (IUAP VI/33) and the Special Research Fund of Ghent University to B.D.R. and T.B., the Roche Research Foundation to D.R. and a Marie-Curie IEF grant to J.E.M.V.	Alassimone J, 2010, P NATL ACAD SCI USA, V107, P5214, DOI 10.1073/pnas.0910772107; Birnbaum K, 2003, SCIENCE, V302, P1956, DOI 10.1126/science.1090022; BONNETT HT, 1968, J CELL BIOL, V37, P199, DOI 10.1083/jcb.37.1.199; Carlsbecker A, 2010, NATURE, V465, P316, DOI 10.1038/nature08977; Caspary R., 1865, JB WISSENSCHAFTLICHE, V4, P101; Chiba H, 2008, BBA-BIOMEMBRANES, V1778, P588, DOI 10.1016/j.bbamem.2007.08.017; CLARKSON DT, 1984, PLANT CELL ENVIRON, V7, P449, DOI 10.1111/j.1365-3040.1984.tb01435.x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Enstone DE, 2002, J PLANT GROWTH REGUL, V21, P335, DOI 10.1007/s00344-003-0002-2; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; Geldner N, 2009, PLANT J, V59, P169, DOI 10.1111/j.1365-313X.2009.03851.x; Heidstra R, 2004, GENE DEV, V18, P1964, DOI 10.1101/gad.305504; KARAHARA I, 1992, PLANT CELL PHYSIOL, V33, P555; Ma JF, 2007, NATURE, V448, P209, DOI 10.1038/nature05964; Men SZ, 2008, NAT CELL BIOL, V10, P237, DOI 10.1038/ncb1686; NAGAHASHI G, 1974, SCIENCE, V183, P670, DOI 10.1126/science.183.4125.670; Nakajima K, 2001, NATURE, V413, P307, DOI 10.1038/35095061; Reichardt L, 2007, CURR BIOL, V17, P2047, DOI 10.1016/j.cub.2007.10.040; Rufz de Lavison J. d., 1910, REV GEN BOT, V22, P225; Schreiber L, 1996, PLANTA, V199, P596, DOI 10.1007/BF00195192; Sriranganadane D, 2010, J PROTEOME RES, V9, P3511, DOI 10.1021/pr901202z; Steudle E, 2000, PLANT SOIL, V226, P45, DOI 10.1023/A:1026439226716; Takano Junpei, 2010, Proc Natl Acad Sci U S A, V107, P5220, DOI 10.1073/pnas.0910744107; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; VANFLEET DS, 1961, BOT REV, V27, P165, DOI 10.1007/BF02860082; VASSE J, 1995, MOL PLANT MICROBE IN, V8, P241, DOI 10.1094/MPMI-8-0241	27	249	266	5	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					380	U564		10.1038/nature10070	http://dx.doi.org/10.1038/nature10070			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593871				2022-12-28	WOS:000290722400050
J	Gross, JL; Kramer, CK; Leitao, CB; Hawkins, N; Viana, LV; Schaan, BD; Pinto, LC; Rodrigues, TC; Azevedo, MJ				Gross, Jorge L.; Kramer, Caroline K.; Leitao, Cristiane B.; Hawkins, Neil; Viana, Luciana V.; Schaan, Beatriz D.; Pinto, Lana C.; Rodrigues, Ticiana C.; Azevedo, Mirela J.		Diabet Endocrinology Metaanal Grp	Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							BIPHASIC INSULIN ASPART; BEDTIME INSULIN; DOUBLE-BLIND; ROSIGLITAZONE; GLARGINE; EXENATIDE; THERAPY; COMBINATION; MANAGEMENT; STATEMENT	Background: Few studies have examined the effect of adding a third antihyperglycemic drug when blood glucose control is not achieved by using metformin and a sulfonylurea. Purpose: To compare the efficacy of add-on antihyperglycemic drugs in patients with type 2 diabetes that is not controlled with metformin and a sulfonylurea. Data Sources: MEDLINE, EMBASE, Cochrane Library, LILACS, and ClinicalTrials.gov electronic databases. Study Selection: Randomized trials at least 24 weeks in duration. Studies evaluated the effects of adding a third antihyperglycemic drug to treatment of adults aged 18 years or older with type 2 diabetes and a hemoglobin A(1c) (HbA(1c)) level greater than 7.0% who were already receiving a combination of metformin and a sulfonylurea. Data Extraction: Primary end points were change in HbA(1c) level, change in weight, and frequency of severe hypoglycemia. Data Synthesis: Eighteen trials involving 4535 participants that lasted a mean of 31.3 weeks (24 to 52 weeks) were included. Compared with placebo, drug classes did not differ in effect on HbA1c level (reduction ranging from -0.70% [95% credible interval {CrI}, -1.33% to -0.08%] for acarbose to -1.08% [CrI, -1.41% to -0.77%] for insulin). Weight increase was seen with insulins (2.84 kg [CrI, 1.76 to 3.90 kg]) and thiazolidinediones (4.25 kg [CrI, 2.76 to 5.66 kg]), and weight loss was seen with glucagon-like peptide-1 agonists (-1.63 kg [CrI, -2.71 to -0.60 kg]). Insulins caused twice the absolute number of severe hypoglycemic episodes than noninsulin antihyperglycemic agents. Limitations: Most of the trials were short term, and trial quality varied. With so few trials relative to antihyperglycemic agents, investigators relied on indirect comparisons, which increased the uncertainty of the findings and conclusions. Conclusion: There is no clear difference in benefit between drug classes when adding a third agent to treatment of patients with type 2 diabetes who are already receiving metformin and a sulfonylurea. The most appropriate option should depend on each patient's clinical characteristics.	[Gross, Jorge L.; Kramer, Caroline K.; Leitao, Cristiane B.; Hawkins, Neil; Viana, Luciana V.; Schaan, Beatriz D.; Pinto, Lana C.; Rodrigues, Ticiana C.; Azevedo, Mirela J.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Endocrinol, BR-90035003 Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul	Gross, JL (corresponding author), Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Endocrinol, Rua Ramiro Barcelos 2350,Predio 12,4th Floor, BR-90035003 Porto Alegre, RS, Brazil.	jorgeluizgross@gmail.com	Pinto, LC/AAH-9365-2019; Viana, Luciana V/J-5869-2013; Steemburgo, Thais/M-9629-2017; Gerchman, Fernando/K-1936-2017; Kramer, Caroline K/L-9093-2018; Rodrigues, Ticiana C/V-9858-2019; Canani, Luis H/G-9686-2012; Schaan, Beatriz D./I-7518-2017; Camargo, Joiza Lins/G-9301-2011	Pinto, LC/0000-0003-0954-8622; Steemburgo, Thais/0000-0003-3351-9901; Gerchman, Fernando/0000-0001-5873-9498; Canani, Luis H/0000-0002-1813-4491; Schaan, Beatriz D./0000-0002-2128-8387; Camargo, Joiza Lins/0000-0001-8834-4075; Leitao, Cristiane/0000-0002-2106-309X; Hawkins, Neil/0000-0003-3199-221X	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [A576627/2008-9]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Programa Nacional de Pos-Doutorado no Pais [03021/09-2]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Programa Nacional de Pos-Doutorado no Pais	Grant Support: From Conselho Nacional de Desenvolvimento Cientifico e Tecnologico grant A576627/2008-9 and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Programa Nacional de Pos-Doutorado no Pais 03021/09-2.	BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Bergenstal R, 2009, CURR MED RES OPIN, V25, P65, DOI 10.1185/03007990802597951 ; Blickle JF, 2009, DIABETES OBES METAB, V11, P379, DOI 10.1111/j.1463-1326.2008.00980.x; Cook MN, 2007, DIABETIC MED, V24, P350, DOI 10.1111/j.1464-5491.2007.02078.x; Cook MN, 2005, DIABETES CARE, V28, P995, DOI 10.2337/diacare.28.5.995; Dailey GE, 2004, AM J MED, V116, P223, DOI 10.1016/j.amjmed.2003.07.022; Dorkhan M, 2008, DIABETES RES CLIN PR, V82, P340, DOI 10.1016/j.diabres.2008.09.009; Hartemann-Heurtier A, 2009, DIABETES RES CLIN PR, V86, P37, DOI 10.1016/j.diabres.2009.06.028; Heine RJ, 2005, ANN INTERN MED, V143, P559, DOI 10.7326/0003-4819-143-8-200510180-00006; Hermansen K, 2007, DIABETES OBES METAB, V9, P733, DOI 10.1111/j.1463-1326.2007.00744.x; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; International Diabetes Federation, GLOB GUID TYP 2 DIAB; Kadoglou NPE, 2008, DIABETIC MED, V25, P333, DOI 10.1111/j.1464-5491.2007.02375.x; Kendall DM, 2005, DIABETES CARE, V28, P1083, DOI 10.2337/diacare.28.5.1083; Ko GTC, 2006, ADV THER, V23, P799, DOI 10.1007/BF02850321; Ko GTC, 2001, CLIN DRUG INVEST, V21, P401, DOI 10.2165/00044011-200121060-00002; Lam KSL, 1998, DIABETES CARE, V21, P1154, DOI 10.2337/diacare.21.7.1154; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; Nauck MA, 2007, DIABETOLOGIA, V50, P259, DOI 10.1007/s00125-006-0510-2; Phung OJ, 2010, JAMA-J AM MED ASSOC, V303, P1410, DOI 10.1001/jama.2010.405; Reynolds LR, 2007, DIABETES RES CLIN PR, V77, P180, DOI 10.1016/j.diabres.2006.12.011; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150; Rosenstock J, 2006, DIABETES CARE, V29, P554, DOI 10.2337/diacare.29.03.06.dc05-0695; Russell-Jones D, 2009, DIABETOLOGIA, V52, P2046, DOI 10.1007/s00125-009-1472-y; Sherifali D, 2010, DIABETES CARE, V33, P1859, DOI 10.2337/dc09-1727; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Yale JF, 2001, ANN INTERN MED, V134, P737, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00010	32	122	124	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10					672	+		10.7326/0003-4819-154-10-201105170-00007	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576535				2022-12-28	WOS:000290620300016
J	Reverby, SM				Reverby, Susan M.			The art of medicine Listening to narratives from the Tuskegee syphilis study	LANCET			English	Editorial Material									Wellesley Coll, Dept Womens & Gender Studies, Wellesley, MA 02485 USA	Wellesley College	Reverby, SM (corresponding author), Wellesley Coll, Dept Womens & Gender Studies, Wellesley, MA 02485 USA.	sreverby@wellesley.edu						Charon Rita, 2008, NARRATIVE MED HONORI; Katz R, 2011, SEARCH LEGACY US PUB; Reverby SM, 2011, J POLICY HIST, V23, P6, DOI 10.1017/S0898030610000291; Reverby Susan M., 2009, EXAMINING TUSKEGEE I; *US DEP HHS, INF 1946 1948 US PUB	5	24	25	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 14	2011	377	9778					1646	1647		10.1016/S0140-6736(11)60663-6	http://dx.doi.org/10.1016/S0140-6736(11)60663-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766JF	21591285				2022-12-28	WOS:000290777700015
J	Salameh, A; Klein, M; Klein, N; Pfeiffer, D; Dahnert, I; Dhein, S				Salameh, Aida; Klein, Maika; Klein, Norbert; Pfeiffer, Dietrich; Daehnert, Ingo; Dhein, Stefan			Coughing into the darkness	LANCET			English	Editorial Material							CERVICAL ARTERY DISSECTION; INFECTION; RISK		[Salameh, Aida; Daehnert, Ingo] Univ Leipzig, Ctr Heart, Clin Pediat Cardiol, D-04289 Leipzig, Germany; [Klein, Maika; Klein, Norbert; Pfeiffer, Dietrich] Univ Leipzig, Dept Cardiol & Angiol, D-04289 Leipzig, Germany; [Dhein, Stefan] Univ Leipzig, Ctr Heart, Clin Cardiac Surg, D-04289 Leipzig, Germany	Heart Center Leipzig GMBH; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Leipzig University; Heart Center Leipzig GMBH; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Salameh, A (corresponding author), Univ Leipzig, Ctr Heart, Clin Pediat Cardiol, Struempellstr 39, D-04289 Leipzig, Germany.	aida.salameh@med.uni-leipzig.de						Evers S, 2000, NEUROLOGY, V55, P865, DOI 10.1212/WNL.55.6.865; Grau AJ, 1999, ARCH NEUROL-CHICAGO, V56, P851, DOI 10.1001/archneur.56.7.851; Guillon B, 2003, STROKE, V34, pE79, DOI 10.1161/01.STR.0000078309.56307.5C; SCHIEVINK WI, 1993, STROKE, V24, P1678, DOI 10.1161/01.STR.24.11.1678; Touze E, 2003, NEUROLOGY, V61, P1347, DOI 10.1212/01.WNL.0000094325.95097.86	5	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 14	2011	377	9778					1718	1718		10.1016/S0140-6736(11)60206-7	http://dx.doi.org/10.1016/S0140-6736(11)60206-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766JF	21571153				2022-12-28	WOS:000290777700036
J	Alter, H				Alter, Harvey			Baruch Blumberg (1925-2011) OBITUARY	NATURE			English	Biographical-Item											Alter, H (corresponding author), NIH, Dept Transfus Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.	halter@dtm.cc.nih.gov							0	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 12	2011	473	7346					155	155		10.1038/473155a	http://dx.doi.org/10.1038/473155a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562549	Bronze			2022-12-28	WOS:000290487200022
J	Gahl, WA; Tifft, CJ				Gahl, William A.; Tifft, Cynthia J.			The NIH Undiagnosed Diseases Program Lessons Learned	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MUTATIONS		[Tifft, Cynthia J.] NHGRI, NIH, Undiagnosed Dis Program, Bethesda, MD 20892 USA; NHGRI, Off Clin Director, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Tifft, CJ (corresponding author), NHGRI, NIH, Undiagnosed Dis Program, 10 Ctr Dr,MSC 1205,Bldg 10,Room CRC3-2551, Bethesda, MD 20892 USA.	ctifft@nih.gov			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000215] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Amann K, 2008, CLIN J AM SOC NEPHRO, V3, P1599, DOI 10.2215/CJN.02120508; Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109; Markello TC, 2011, MOL GENET METAB, V103, P44, DOI 10.1016/j.ymgme.2011.01.018; *NAT TECHN INF SER, 1989, PUBL NAT TECHN INF S, P17; *NIH OFF RAR DIS R, UND DIS PROGR; St Hilaire C, 2011, NEW ENGL J MED, V364, P432, DOI [10.1056/NEJMoa0912923, 10.1056/NEJMc1102515]	6	84	84	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2011	305	18					1904	1905		10.1001/jama.2011.613	http://dx.doi.org/10.1001/jama.2011.613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761YH	21558523				2022-12-28	WOS:000290438800030
J	Larson, HJ; Ghinai, I				Larson, Heidi J.; Ghinai, Isaac			Lessons from polio eradication	NATURE			English	Editorial Material									[Larson, Heidi J.; Ghinai, Isaac] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Larson, HJ (corresponding author), London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London WC1 7HT, England.	heidi.larson@lshtm.ac.uk	Ghinai, Isaac/AAI-7985-2021; Larson, Heidi J./N-1018-2017	Ghinai, Isaac/0000-0003-1322-1331; Larson, Heidi J./0000-0002-8477-7583				Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P357; Closser S, 2010, CHASING POLIO PAKIST; Donaldson L., 2011, REPORT INDEPENDENT M; Kaufmann JR, 2009, HEALTH AFFAIR, V28, P1091, DOI 10.1377/hlthaff.28.4.1091; Obregon R, 2009, B WORLD HEALTH ORGAN, V87, P624, DOI 10.2471/BLT.08.060863; Taylor S, 2010, J HEALTH COMMUN, V15, P48, DOI 10.1080/10810731003698585; Tebbens RJD, 2010, VACCINE, V29, P334, DOI 10.1016/j.vaccine.2010.10.026; Tool M., 2009, EVALUATION GLOBAL PO; UNICEF Regional Office for South Asia, 2004, EV CHILD COUNTS ENG; Yahya M., 2006, 261 IDS	10	45	47	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2011	473	7348					446	447		10.1038/473446a	http://dx.doi.org/10.1038/473446a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	768QM	21614056	Bronze			2022-12-28	WOS:000290951300015
J	Smith, J; Humes, DJ; Spiller, RC				Smith, Janette; Humes, David J.; Spiller, Robin C.			Should we treat uncomplicated symptomatic diverticular disease with fibre?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							COLON; PATTERNS		[Spiller, Robin C.] Univ Nottingham, Nottingham Digest Dis Ctr, Nottingham NG7 2UH, England; [Smith, Janette; Humes, David J.] Univ Nottingham, Dept Surg, Nottingham NG7 2UH, England; [Spiller, Robin C.] Univ Nottingham, NIHR Biomed Res Ctr, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham; University of Nottingham	Spiller, RC (corresponding author), Univ Nottingham, Nottingham Digest Dis Ctr, Nottingham NG7 2UH, England.	robin.spiller@nottingham.ac.uk	spiller, robin/ABE-6690-2021	spiller, robin/0000-0001-6371-4500; Humes, David/0000-0002-7071-4098	National Institute for Health Research [CL-2006-12-002, NF-SI-0509-10005] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Bijkerk CJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3154; BRODRIBB AJM, 1977, LANCET, V1, P664; Clemens CHM, 2004, GUT, V53, P717, DOI 10.1136/gut.2003.018093; CORTESINI C, 1991, DIS COLON RECTUM, V34, P339, DOI 10.1007/BF02050595; Etzioni DA, 2009, ANN SURG, V249, P210, DOI 10.1097/SLA.0b013e3181952888; Humes D, 2011, CLIN EVID, V3, P405; Kang JY, 2011, ALIMENT PHARM THER, V33, P487, DOI 10.1111/j.1365-2036.2010.04540.x; Longstreth GF, 2006, GASTROENTEROLOGY, V130, P1480, DOI 10.1053/j.gastro.2005.11.061; ORNSTEIN MH, 1981, BRIT MED J, V282, P1353, DOI 10.1136/bmj.282.6273.1353; PAINTER NS, 1982, S AFR MED J, V61, P1016; Rafferty J, 2006, DIS COLON RECTUM, V49, P939, DOI 10.1007/s10350-006-0578-2; Simpson J, 2003, EUR J GASTROEN HEPAT, V15, P1005, DOI 10.1097/00042737-200309000-00011; Simpson J, 2009, NEUROGASTROENT MOTIL, V21, P847, DOI 10.1111/j.1365-2982.2009.01308.x; SNOOK J, 1994, ALIMENT PHARM THERAP, V8, P511; Stollman NH, 1999, AM J GASTROENTEROL, V94, P3110, DOI 10.1111/j.1572-0241.1999.01501.x; Strate LL, 2009, GASTROENTEROLOGY, V136, P115, DOI 10.1053/j.gastro.2008.09.025; Tursi A, 2010, DIGEST LIVER DIS, V42, P458, DOI 10.1016/j.dld.2009.09.003	17	5	5	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	2011	342								d2951	10.1136/bmj.d2951	http://dx.doi.org/10.1136/bmj.d2951			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771KE	21613363				2022-12-28	WOS:000291154800004
J	Spence, D				Spence, Des			FROM THE FRONTLINE Medical stereotypes	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 25	2011	342								d3235	10.1136/bmj.d3235	http://dx.doi.org/10.1136/bmj.d3235			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771KE	21613345				2022-12-28	WOS:000291154800008
J	Heidegger, T				Heidegger, Thomas			Fiberoptic Intubation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ANESTHESIOLOGISTS		Spitalreg Rheintal Werdenberg Sarganserland, Dept Anesthesiol, CH-8880 Walenstadt, Switzerland		Heidegger, T (corresponding author), Spitalreg Rheintal Werdenberg Sarganserland, Dept Anesthesiol, Spitalstr 5, CH-8880 Walenstadt, Switzerland.	thomas.heidegger@srrws.ch						[Anonymous], 2004, ANESTHESIOLOGY; Drolet P, 2009, CAN J ANAESTH, V56, P683, DOI 10.1007/s12630-009-9144-4; Heidegger T, 2003, ANAESTHESIA, V58, P734, DOI 10.1046/j.1365-2044.2003.03200.x; Heidegger T, 2001, ANESTH ANALG, V92, P517; Heidegger T, 2005, BEST PRACT RES-CLIN, V19, P661, DOI 10.1016/j.bpa.2005.07.001; Heidegger T, 2007, ANESTHESIOLOGY, V107, P585, DOI 10.1097/01.anes.0000281925.61143.b5; Kleemann P., 1997, FIBEROPTISCHE INTUBA, P57; Langeron O, 2000, ANESTHESIOLOGY, V92, P1229, DOI 10.1097/00000542-200005000-00009; Ovassapian A, 2001, CLIN CHEST MED, V22, P281, DOI 10.1016/S0272-5231(05)70043-5; Popat M, 2001, PRACTICAL FIBREOPTIC; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; 2003, ANESTHESIOLOGY, V98, P1269	12	13	13	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					E42	U111		10.1056/NEJMvcm0906443	http://dx.doi.org/10.1056/NEJMvcm0906443			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765PJ	21591939				2022-12-28	WOS:000290720700010
J	Smith, DA				Smith, Donald A.			Meta-analysis: More intensive statin therapy prevents major vascular events	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Mt Sinai Sch Med, New York, NY USA	Icahn School of Medicine at Mount Sinai	Smith, DA (corresponding author), Mt Sinai Sch Med, New York, NY USA.							Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1	1	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-3	10.7326/0003-4819-154-10-201105170-02003	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576521				2022-12-28	WOS:000290620300002
J	Fraser, AG; Krucoff, MW; Brindis, RG; Komajda, M; Smith, SC				Fraser, Alan G.; Krucoff, Mitchell W.; Brindis, Ralph G.; Komajda, Michel; Smith, Sidney C., Jr.			Commentary: International collaboration needed on device clinical standards	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Fraser, Alan G.] Cardiff Univ, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales; [Krucoff, Mitchell W.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Brindis, Ralph G.] No Calif Kaiser Permanente, Oakland, CA USA; [Komajda, Michel] CHU Pitie Salpetriere, Inst Cardiol, Paris, France; [Smith, Sidney C., Jr.] Univ N Carolina, Chapel Hill, NC USA	Cardiff University; Duke University; Kaiser Permanente; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of North Carolina; University of North Carolina Chapel Hill	Fraser, AG (corresponding author), Cardiff Univ, Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales.	fraserag@cf.ac.uk						FRASER AG, 2011, EUR HEART J; Global Harmonization Task Force, 2011, STAT CHAIR UPD FUT D; RICHWINE L, 2011, REUTERS         0225; *WHO, 2008, MED TERM STRAT PLAN, P89; *WHO, 2010, PREL RES BAS COUNTR; World Health Organization, 2003, MED DEV REG GLOB OV	6	16	16	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 14	2011	342								d2952	10.1136/bmj.d2952	http://dx.doi.org/10.1136/bmj.d2952			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765OV	21572135				2022-12-28	WOS:000290719100006
J	Brandt, ARML; Schouten, O				Brandt, Alexandra R. M. L.; Schouten, Olaf			Sugar to Reduce a Prolapsed Ileostomy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Brandt, Alexandra R. M. L.; Schouten, Olaf] Reinier de Graaf Hosp, Delft, Netherlands	Reinier de Graaf Hospital	Brandt, ARML (corresponding author), Reinier de Graaf Hosp, Delft, Netherlands.	o.schouten@erasmusmc.nl							0	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					1855	1855		10.1056/NEJMicm1012908	http://dx.doi.org/10.1056/NEJMicm1012908			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561351				2022-12-28	WOS:000290483000013
J	Howard, SC; Jones, DP; Pui, CH				Howard, Scott C.; Jones, Deborah P.; Pui, Ching-Hon			The Tumor Lysis Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE-LYMPHOBLASTIC-LEUKEMIA; RECOMBINANT URATE OXIDASE; ACUTE KIDNEY INJURY; MALIGNANCY-ASSOCIATED HYPERURICEMIA; INFLAMMATORY RESPONSE SYNDROME; ACUTE-RENAL-FAILURE; URIC-ACID; PREDICTIVE MODEL; ADULT PATIENTS; HIGH-RISK	The tumor lysis syndrome is the most common disease-related emergency encountered by physicians caring for children or adults with hematologic cancers. 1-4 Although it develops most often in patients with non-Hodgkin's lymphoma or acute leukemia, its frequency is increasing among patients who have tumors that used to be only rarely associated with this complication. 5-8 The tumor lysis syndrome occurs when tumor cells release their contents into the bloodstream, either spontaneously or in response to therapy, leading to the characteristic findings of hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia.(1-3) These electrolyte and metabolic disturbances can progress to clinical toxic effects, including renal insufficiency, cardiac arrhythmias, seizures, and death due to multiorgan failure. Although optimal methods of risk classification and treatment have been difficult to define, uniform standards for management of the tumor lysis syndrome are beginning to evolve. Indeed, several groups have advocated guidelines for risk stratification and made recommendations for evaluating risk and for prophylactic therapy for the tumor lysis syndrome. 2,9 This review of the tumor lysis syndrome summarizes current strategies for risk assessment, prophylaxis, and therapy. The following case illustrates the clinical challenges.	[Howard, Scott C.; Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Howard, Scott C.; Pui, Ching-Hon] St Jude Childrens Res Hosp, Int Outreach Program, Memphis, TN 38105 USA; [Howard, Scott C.; Jones, Deborah P.; Pui, Ching-Hon] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Howard, SC (corresponding author), St Jude Childrens Res Hosp, Dept Oncol, 262 Danny Thomas Pl,Barry Longinotti Bldg,MS 721, Memphis, TN 38105 USA.	scott.howard@stjude.org			National Institutes of Health [CA21765, U01 GM92666]; American Lebanese Syrian Associated Charities; EnzymeRx; Sanofi-Aventis; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM092666] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Associated Charities(American Lebanese Syrian Associated Charities (ALSAC)); EnzymeRx; Sanofi-Aventis(Sanofi-Aventis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported in part by grants (CA21765 and U01 GM92666) from the National Institutes of Health and by the American Lebanese Syrian Associated Charities.; Dr. Howard reports receiving consulting fees from EnzymeRx and Sanofi-Aventis.	Abu-Alfa AK, 2010, AM J KIDNEY DIS, V55, pS1, DOI 10.1053/j.ajkd.2009.10.056; Bellinghieri G, 2007, EXPERT OPIN EMERG DR, V12, P355, DOI 10.1517/14728214.12.3.355; Beshensky AM, 2001, J AM SOC NEPHROL, V12, P2108, DOI 10.1681/ASN.V12102108; Bouropoulos C, 2004, CRYST RES TECHNOL, V39, P699, DOI 10.1002/crat.200310241; Cairo MS, 2007, BLOOD, V109, P2736, DOI 10.1182/blood-2006-07-036665; Cairo MS, 2010, BRIT J HAEMATOL, V149, P578, DOI 10.1111/j.1365-2141.2010.08143.x; Cairo MS, 2004, BRIT J HAEMATOL, V127, P3, DOI 10.1111/j.1365-2141.2004.05094.x; Cheson Bruce D, 2009, Clin Adv Hematol Oncol, V7, P263; Coiffier, 2010, J CLIN ONCOL, V28, P708, DOI 10.1200/JCO.2009.27.8804; Coiffier B, 2008, J CLIN ONCOL, V26, P2767, DOI 10.1200/JCO.2007.15.0177; CONGER JD, 1977, J CLIN INVEST, V59, P786, DOI 10.1172/JCI108700; Ejaz AA, 2007, CLIN J AM SOC NEPHRO, V2, P16, DOI 10.2215/CJN.00350106; Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885; Feig DI, 2010, NEW ENGL J MED, V362, P2235; Feusner JH, 2008, J CLIN ONCOL, V26, P5657, DOI 10.1200/JCO.2008.19.6030; FINLAYSON B, 1978, KIDNEY INT, V13, P344, DOI 10.1038/ki.1978.53; Gemici C, 2009, J CLIN ONCOL, V27, P2738, DOI 10.1200/JCO.2009.22.4154; Gertz MA, 2010, LEUKEMIA LYMPHOMA, V51, P179, DOI 10.3109/10428190903488788; Giraldez M, 2010, EUR J HAEMATOL, V85, P177, DOI 10.1111/j.1600-0609.2010.01457.x; Godoy H, 2010, INT J GYNECOL OBSTET, V109, P254, DOI 10.1016/j.ijgo.2010.02.005; Goldman SC, 2001, BLOOD, V97, P2998, DOI 10.1182/blood.V97.10.2998; Grases F, 2007, SCAND J UROL NEPHROL, V41, P26, DOI 10.1080/00365590600831571; GREENE ML, 1969, NEW ENGL J MED, V280, P426, DOI 10.1056/NEJM196902202800806; Gutzwiller JP, 2002, NEPHROL DIAL TRANSPL, V17, P1037, DOI 10.1093/ndt/17.6.1037; Hijiya N, 2005, PEDIATR BLOOD CANCER, V44, P63, DOI 10.1002/pbc.20192; Hochberg J, 2008, EXPERT OPIN BIOL TH, V8, P1595, DOI [10.1517/14712598.8.10.1595, 10.1517/14712598.8.10.1595 ]; Howard SC, 2006, LEUKEMIA LYMPHOMA, V47, P782, DOI 10.1080/10428190600765798; Howard SC, 2006, CHILDHOOD LEUKEMIAS, 2ND EDITION, P709; Huang WS, 2009, WORLD J GASTROENTERO, V15, P4464, DOI 10.3748/wjg.15.4464; Jeha S, 2005, LEUKEMIA, V19, P34, DOI 10.1038/sj.leu.2403566; Joshita S, 2010, INTERNAL MED, V49, P991, DOI 10.2169/internalmedicine.49.3153; Keane C, 2009, EUR J HAEMATOL, V82, P244, DOI 10.1111/j.1600-0609.2008.01186.x; Knoebel R, 2010, J ONCOL PHARM P 0323; Krishnan G, 2008, J CLIN ONCOL, V26, P2406, DOI 10.1200/JCO.2007.14.7603; LaRosa C, 2007, PEDIATR NEPHROL, V22, P132, DOI 10.1007/s00467-006-0287-z; Levin A, 2007, AM J KIDNEY DIS, V50, P1, DOI 10.1053/j.ajkd.2007.05.008; MAGRATH IT, 1974, E AFR MED J, V51, P623; Mato AR, 2006, LEUKEMIA LYMPHOMA, V47, P877, DOI 10.1080/10428190500404662; Montesinos P, 2007, HAEMATOLOGICA, V93, P67, DOI 10.3324/haematol.11575; Nakamura M, 2009, TRANSFUS APHER SCI, V40, P41, DOI 10.1016/j.transci.2008.11.004; Noh GY, 2008, J CLIN ONCOL, V26, P6005, DOI 10.1200/JCO.2008.19.4308; Pais VM, 2006, UROLOGY, V67, DOI 10.1016/j.urology.2005.10.057; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Prie D, 2010, NEW ENGL J MED, V362, P2399, DOI 10.1056/NEJMra0904186; Pui CH, 2001, LEUKEMIA, V15, P1505, DOI 10.1038/sj.leu.2402235; Pui CH, 2001, J CLIN ONCOL, V19, P697, DOI 10.1200/JCO.2001.19.3.697; Pui CH, 2009, NEW ENGL J MED, V360, P2730, DOI 10.1056/NEJMoa0900386; Shimada M, 2009, NEPHROL DIAL TRANSPL, V24, P2960, DOI 10.1093/ndt/gfp330; Soares M, 2009, CLINICS, V64, P479, DOI 10.1590/S1807-59322009000500016; St. Jude Leukemia/Lymphoma Board, 2007, TUM LYS SYNDR FOC HY; Sundy JS, 2008, ARTHRITIS RHEUM, V58, P2882, DOI 10.1002/art.23810; Tan HK, 2001, INT J ARTIF ORGANS, V24, P186, DOI 10.1177/039139880102400403; Tonelli M, 2010, NEW ENGL J MED, V362, P1312, DOI 10.1056/NEJMra0912522; Truong TH, 2007, CANCER, V110, P1832, DOI 10.1002/cncr.22990; VA/NIH Acute Renal Failure Trail Network, 2009, NEW ENGL J MED, V361, P2391; Wesson JA, 1998, KIDNEY INT, V53, P952, DOI 10.1111/j.1523-1755.1998.00839.x	56	443	467	4	61	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					1844	1854		10.1056/NEJMra0904569	http://dx.doi.org/10.1056/NEJMra0904569			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561350	Green Accepted			2022-12-28	WOS:000290483000012
J	Kinross, JM; Holmes, E; Darzi, AW; Nicholson, JK				Kinross, James M.; Holmes, Elaine; Darzi, Ara W.; Nicholson, Jeremy K.			Metabolic phenotyping for monitoring surgical patients	LANCET			English	Editorial Material							IDENTIFICATION		[Holmes, Elaine; Nicholson, Jeremy K.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Surg & Canc, Sect Biomol Med, London SW7 2AZ, England; [Kinross, James M.; Darzi, Ara W.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Surg & Canc, Sect Biosurg & Surg Technol, London SW7 2AZ, England	Imperial College London; Imperial College London	Nicholson, JK (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Surg & Canc, Sect Biomol Med, London SW7 2AZ, England.	j.nicholson@imperial.ac.uk	Holmes, Elaine/A-2189-2015; Holmes, Elaine/ABE-6606-2020; Nicholson, Jeremy K/B-3395-2012	Holmes, Elaine/0000-0002-0556-8389; Nicholson, Jeremy K/0000-0002-8123-8349; Kinross, James/0000-0002-0427-7643				[Anonymous], 2010, LANCET, V376, P1025, DOI 10.1016/S0140-6736(10)61466-3; Balog J, 2010, ANAL CHEM, V82, P7343, DOI 10.1021/ac101283x; Can MF, 2008, WORLD J SURG, V32, P589, DOI 10.1007/s00268-007-9321-y; Chan ECY, 2009, J PROTEOME RES, V8, P352, DOI 10.1021/pr8006232; Clayton TA, 2009, P NATL ACAD SCI USA, V106, P14728, DOI 10.1073/pnas.0904489106; Clayton TA, 2006, NATURE, V440, P1073, DOI 10.1038/nature04648; Garcia-Miguel FJ, 2003, LANCET, V362, P1749, DOI 10.1016/S0140-6736(03)14857-X; Holmes E, 2008, CELL, V134, P714, DOI 10.1016/j.cell.2008.08.026; Holmes E, 2008, NATURE, V453, P396, DOI 10.1038/nature06882; Kinross JM, 2011, J PROTEOME RES, V10, P277, DOI 10.1021/pr1003278; Lindon JC, 2008, TRAC-TREND ANAL CHEM, V27, P194, DOI 10.1016/j.trac.2007.08.009; Miura D, 2010, ANAL CHEM, V82, P9789, DOI 10.1021/ac101998z; Nicholson JK, 2008, NATURE, V455, P1054, DOI 10.1038/4551054a	13	64	68	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2011	377	9780					1817	1819		10.1016/S0140-6736(11)60171-2	http://dx.doi.org/10.1016/S0140-6736(11)60171-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774UI	21596428				2022-12-28	WOS:000291411700009
J	Pang, ZPP; Yang, N; Vierbuchen, T; Ostermeier, A; Fuentes, DR; Yang, TQ; Citri, A; Sebastiano, V; Marro, S; Sudhof, TC; Wernig, M				Pang, Zhiping P.; Yang, Nan; Vierbuchen, Thomas; Ostermeier, Austin; Fuentes, Daniel R.; Yang, Troy Q.; Citri, Ami; Sebastiano, Vittorio; Marro, Samuele; Suedhof, Thomas C.; Wernig, Marius			Induction of human neuronal cells by defined transcription factors	NATURE			English	Article							PLURIPOTENT STEM-CELLS; NEURAL DEVELOPMENT; DIFFERENTIATION; FIBROBLASTS; BLASTOCYST; PAX6	Somatic cell nuclear transfer, cell fusion, or expression of lineage-specific factors have been shown to induce cell-fate changes in diverse somatic cell types(1-12). We recently observed that forced expression of a combination of three transcription factors, Brn2 (also known as Pou3f2), Ascl1 and Myt1l, can efficiently convert mouse fibroblasts into functional induced neuronal (iN) cells(13). Here we show that the same three factors can generate functional neurons from human pluripotent stem cells as early as 6 days after transgene activation. When combined with the basic helix-loop-helix transcription factor NeuroD1, these factors could also convert fetal and postnatal human fibroblasts into iN cells showing typical neuronal morphologies and expressing multiple neuronal markers, even after downregulation of the exogenous transcription factors. Importantly, the vast majority of human iN cells were able to generate action potentials and many matured to receive synaptic contacts when co-cultured with primary mouse cortical neurons. Our data demonstrate that non-neural human somatic cells, as well as pluripotent stem cells, can be converted directly into neurons by lineage-determining transcription factors. These methods may facilitate robust generation of patient-specific human neurons for in vitro disease modelling or future applications in regenerative medicine.	[Yang, Nan; Vierbuchen, Thomas; Ostermeier, Austin; Fuentes, Daniel R.; Yang, Troy Q.; Sebastiano, Vittorio; Marro, Samuele; Wernig, Marius] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Dept Pathol, Stanford, CA 94305 USA; [Pang, Zhiping P.; Suedhof, Thomas C.] Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; [Vierbuchen, Thomas; Ostermeier, Austin; Wernig, Marius] Stanford Univ, Sch Med, Program Canc Biol, Stanford, CA 94305 USA; [Citri, Ami] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Suedhof, Thomas C.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Wernig, M (corresponding author), Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Dept Pathol, 265 Campus Dr, Stanford, CA 94305 USA.	wernig@stanford.edu	Yang, Nan/H-3174-2012; Marro, Samuele G./I-4493-2014; Pang, Zhiping/AAF-5757-2020; Citri, Ami/R-8973-2019	Marro, Samuele G./0000-0002-9326-6945; Citri, Ami/0000-0002-9914-0278; Fuentes, Daniel/0000-0002-0412-6933; Pang, Zhiping/0000-0002-6183-1233; Yang, Nan/0000-0003-3663-1288; Vierbuchen, Thomas/0000-0002-5690-5680	Institute for Stem Cell Biology and Regenerative Medicine at Stanford; Ellison Medical Foundation; Stinehard-Reed Foundation; Donald E. and Delia B. Baxter Foundation; NIH [1R01MH092931, RC4NS073015]; New York Stem Cell Foundation; NARSAD Young Investigator Awards; Ruth and Robert Halperin Stanford Graduate Fellowship; AXA research fund; BioX Undergraduate Fellowship; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH092931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [RC4NS073015] Funding Source: NIH RePORTER	Institute for Stem Cell Biology and Regenerative Medicine at Stanford; Ellison Medical Foundation(Lawrence Ellison Foundation); Stinehard-Reed Foundation; Donald E. and Delia B. Baxter Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New York Stem Cell Foundation; NARSAD Young Investigator Awards(NARSAD); Ruth and Robert Halperin Stanford Graduate Fellowship; AXA research fund(AXA Research Fund); BioX Undergraduate Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to thank Y. Kokubu for technical assistance in molecular cloning and Y. Zhang for assistance in iPS cell induced neuron culture. We also thank Y. Sun for providing the microRNAs expression lentiviral vectors and S. Majumder for the REST-VP16 construct. This work was enabled by start-up funds from the Institute for Stem Cell Biology and Regenerative Medicine at Stanford (M. W.), the Ellison Medical Foundation (M. W.), the Stinehard-Reed Foundation (M. W.), the Donald E. and Delia B. Baxter Foundation (M. W.), the NIH grants 1R01MH092931 (M. W. and T. C. S.) and RC4NS073015 (M. W.), and a Robertson Investigator Award from the New York Stem Cell Foundation. Z.P.P. is supported by 2008 and 2010 NARSAD Young Investigator Awards. T. V. is supported by the Ruth and Robert Halperin Stanford Graduate Fellowship. A. C. is supported by the AXA research fund and D. R. F. is supported by BioX Undergraduate Fellowship.	BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Graf T, 2009, NATURE, V462, P587, DOI 10.1038/nature08533; Guo GJ, 2010, DEV CELL, V18, P675, DOI 10.1016/j.devcel.2010.02.012; Gurdon JB, 2006, ANNU REV CELL DEV BI, V22, P1, DOI 10.1146/annurev.cellbio.22.090805.140144; Hansen DV, 2010, NATURE, V464, P554, DOI 10.1038/nature08845; Heins N, 2002, NAT NEUROSCI, V5, P308, DOI 10.1038/nn828; Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Johnson MA, 2007, J NEUROSCI, V27, P3069, DOI 10.1523/JNEUROSCI.4562-06.2007; Koch P, 2009, P NATL ACAD SCI USA, V106, P3225, DOI 10.1073/pnas.0808387106; Kriegstein A, 2006, NAT REV NEUROSCI, V7, P883, DOI 10.1038/nrn2008; Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016; Maximov A, 2007, J NEUROSCI METH, V161, P75, DOI 10.1016/j.jneumeth.2006.10.009; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Somers A, 2010, STEM CELLS, V28, P1728, DOI 10.1002/stem.495; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wong CC, 2010, NAT BIOTECHNOL, V28, P1115, DOI 10.1038/nbt.1686; Wu H, 2007, P NATL ACAD SCI USA, V104, P13821, DOI 10.1073/pnas.0706199104; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Xu Y, 2010, P NATL ACAD SCI USA, V107, P8129, DOI 10.1073/pnas.1002024107; Zhang XQ, 2010, CELL STEM CELL, V7, P90, DOI 10.1016/j.stem.2010.04.017; Zhou Q, 2008, CELL STEM CELL, V3, P382, DOI 10.1016/j.stem.2008.09.015; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314	27	866	924	5	159	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 11	2011	476	7359					220	U122		10.1038/nature10202	http://dx.doi.org/10.1038/nature10202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805MU	21617644	Green Accepted			2022-12-28	WOS:000293731900039
J	Zhou, Y; Cashman, TJ; Nevis, KR; Obregon, P; Carney, SA; Liu, Y; Gu, AH; Mosimann, C; Sondalle, S; Peterson, RE; Heideman, W; Burns, CE; Burns, CG				Zhou, Yong; Cashman, Timothy J.; Nevis, Kathleen R.; Obregon, Pablo; Carney, Sara A.; Liu, Yan; Gu, Aihua; Mosimann, Christian; Sondalle, Samuel; Peterson, Richard E.; Heideman, Warren; Burns, Caroline E.; Burns, C. Geoffrey			Latent TGF-beta binding protein 3 identifies a second heart field in zebrafish	NATURE			English	Article							ARTERIAL POLE; OUTFLOW TRACT; GROWTH; CELLS; DIFFERENTIATION; ORIGIN	The four-chambered mammalian heart develops from two fields of cardiac progenitor cells distinguished by their spatiotemporal patterns of differentiation and contributions to the definitive heart(1-3). The first heart field differentiates earlier in lateral plate mesoderm, generates the linear heart tube and ultimately gives rise to the left ventricle. The second heart field (SHF) differentiates later in pharyngeal mesoderm, elongates the heart tube, and gives rise to the outflow tract and much of the right ventricle. Because hearts in lower vertebrates contain a rudimentary outflow tract but not a right ventricle(4), the existence and function of SHF-like cells in these species has remained a topic of speculation(4-10). Here we provide direct evidence from Cre/Lox-mediated lineage tracing and loss-of-function studies in zebrafish, a lower vertebrate with a single ventricle, that latent TGF-beta binding protein 3 (ltbp3) transcripts mark a field of cardiac progenitor cells with defining characteristics of the anterior SHF in mammals. Specifically, ltbp3(+) cells differentiate in pharyngeal mesoderm after formation of the heart tube, elongate the heart tube at the outflow pole, and give rise to three cardiovascular lineages in the outflow tract and myocardium in the distal ventricle. In addition to expressing Ltbp3, a protein that regulates the bioavailability of TGF-beta ligands(11), zebrafish SHF cells co-express nkx2.5, an evolutionarily conserved marker of cardiac progenitor cells in both fields(4). Embryos devoid of ltbp3 lack the same cardiac structures derived from ltbp3(+) cells due to compromised progenitor proliferation. Furthermore, small-molecule inhibition of TGF-beta signalling phenocopies the ltbp3-morphant phenotype whereas expression of a constitutively active TGF-beta type I receptor rescues it. Taken together, our findings uncover a requirement for ltbp3-TGF-beta signalling during zebrafish SHF development, a process that serves to enlarge the single ventricular chamber in this species.	[Zhou, Yong; Cashman, Timothy J.; Nevis, Kathleen R.; Obregon, Pablo; Gu, Aihua; Sondalle, Samuel; Burns, Caroline E.; Burns, C. Geoffrey] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; [Zhou, Yong; Cashman, Timothy J.; Nevis, Kathleen R.; Obregon, Pablo; Liu, Yan; Gu, Aihua; Mosimann, Christian; Sondalle, Samuel; Burns, Caroline E.; Burns, C. Geoffrey] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Carney, Sara A.; Peterson, Richard E.; Heideman, Warren] Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, Madison, WI 53705 USA; [Liu, Yan] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA; [Gu, Aihua] Nanjing Med Univ, Sch Publ Hlth, Nanjing 210029, Peoples R China; [Mosimann, Christian] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA; [Mosimann, Christian] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; [Sondalle, Samuel; Burns, Caroline E.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Massachusetts General Hospital; Nanjing Medical University; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University	Burns, CE (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.	cburns6@partners.org; gburns@cvrc.mgh.harvard.edu	Cashman, Tim/M-7738-2019; Sondalle, Samuel/C-1283-2014	Sondalle, Samuel/0000-0002-4144-9897; Cashman, Timothy/0000-0001-6238-129X; Mosimann, Christian/0000-0002-0749-2576	NIH, National Institute of Environmental Health Sciences [R01 ES012716]; EMBO long-term fellowship; HFSP long-term fellowship; Cardiovascular Research Center at Massachusetts General Hospital; Claflin Distinguished Scholar Award; Harvard Stem Cell Institute; National Heart Lung and Blood Institute [5R01HL096816]; American Heart Association [10GRNT4270021]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	NIH, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EMBO long-term fellowship(European Molecular Biology Organization (EMBO)); HFSP long-term fellowship; Cardiovascular Research Center at Massachusetts General Hospital; Claflin Distinguished Scholar Award; Harvard Stem Cell Institute; National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M. Whitman for advice on pSmad2 staining, D. Hami and M. Kirby for providing Eln2 antisera and their immunohistochemistry protocol, R. Cornell for providing tfAP2a and tfAP2c morpholinos, M. Whitman, A. Srinivasan, D. Langenau, E. Provost, S. Leach, R. Anderson, D. Stainier, I. Woods, and A. Schier for providing plasmids. J. W. Xiong for providing clo<SUP>m39</SUP> fish, B. Barut and L. Zon for providing bacterial artificial chromosomes (BACs), and the MGH Nephrology Division for access to their confocal microscopy facilities. S. C., R. E. P. and W. H. were supported by NIH grant R01 ES012716 from the National Institute of Environmental Health Sciences. C. M. received support through an EMBO long-term fellowship and an HFSP long-term fellowship. This work was funded by the Cardiovascular Research Center at Massachusetts General Hospital, a Claflin Distinguished Scholar Award and Harvard Stem Cell Institute Seed Grant to C. E. B., and by awards from the National Heart Lung and Blood Institute (5R01HL096816), American Heart Association (Grant in Aid no. 10GRNT4270021), and Harvard Stem Cell Institute (Seed Grant) to C. G. B.	Brade T, 2007, DEV BIOL, V311, P297, DOI 10.1016/j.ydbio.2007.08.004; Cai CL, 2003, DEV CELL, V5, P877, DOI 10.1016/S1534-5807(03)00363-0; Chen JN, 1997, DEVELOPMENT, V124, P4373; de Pater E, 2009, DEVELOPMENT, V136, P1633, DOI 10.1242/dev.030924; Dyer LA, 2009, DEV BIOL, V336, P137, DOI 10.1016/j.ydbio.2009.10.009; Grimes AC, 2006, DEV BIOL, V290, P265, DOI 10.1016/j.ydbio.2005.11.042; Grimes AC, 2010, EVOL DEV, V12, P552, DOI 10.1111/j.1525-142X.2010.00441.x; Ilagan R, 2006, DEVELOPMENT, V133, P2435, DOI 10.1242/dev.02408; Kang J, 2009, DEV BIOL, V334, P513, DOI 10.1016/j.ydbio.2009.06.041; Kelly RG, 2001, DEV CELL, V1, P435, DOI 10.1016/S1534-5807(01)00040-5; Li HY, 2006, J MED CHEM, V49, P2138, DOI 10.1021/jm058209g; Meilhac SM, 2004, DEV CELL, V6, P685, DOI 10.1016/S1534-5807(04)00133-9; Miao M, 2007, MATRIX BIOL, V26, P115, DOI 10.1016/j.matbio.2006.09.011; Mjaatvedt CH, 2001, DEV BIOL, V238, P97, DOI 10.1006/dbio.2001.0409; Mosimann C, 2011, DEVELOPMENT, V138, P169, DOI 10.1242/dev.059345; Olson EN, 2006, SCIENCE, V313, P1922, DOI 10.1126/science.1132292; Prall OWJ, 2007, CELL, V128, P947, DOI 10.1016/j.cell.2007.01.042; Rifkin DB, 2005, J BIOL CHEM, V280, P7409, DOI 10.1074/jbc.R400029200; Rochais F, 2009, CIRC RES, V104, P933, DOI 10.1161/CIRCRESAHA.109.194464; Todorovic V, 2007, DEVELOPMENT, V134, P3723, DOI 10.1242/dev.008599; Vincent SD, 2010, CURR TOP DEV BIOL, V90, P1, DOI 10.1016/S0070-2153(10)90001-X; von Both I, 2004, DEV CELL, V7, P331, DOI 10.1016/j.devcel.2004.07.023; Waldo KL, 2001, DEVELOPMENT, V128, P3179; Zaffran S, 2004, CIRC RES, V95, P261, DOI 10.1161/01.RES.0000136815.73623.BE	24	173	173	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2011	474	7353					645	648		10.1038/nature10094	http://dx.doi.org/10.1038/nature10094			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	785CF	21623370	Green Accepted			2022-12-28	WOS:000292204300040
J	Harkema, S; Gerasimenko, Y; Hodes, J; Burdick, J; Angeli, C; Chen, YS; Ferreira, C; Willhite, A; Rejc, E; Grossman, RG; Edgerton, VR				Harkema, Susan; Gerasimenko, Yury; Hodes, Jonathan; Burdick, Joel; Angeli, Claudia; Chen, Yangsheng; Ferreira, Christie; Willhite, Andrea; Rejc, Enrico; Grossman, Robert G.; Edgerton, V. Reggie			Effect of epidural stimulation of the lumbosacral spinal cord on voluntary movement, standing, and assisted stepping after motor complete paraplegia: a case study	LANCET			English	Article							LUMBAR CORD; LOCOMOTION; INJURY; HUMANS; CAT; SPINALIZATION; VERTEBRATES; PLASTICITY; NETWORKS; GENERATE	Background Repeated periods of stimulation of the spinal cord and training increased the ability to control movement in animal models of spinal cord injury. We hypothesised that tonic epidural spinal cord stimulation can modulate spinal circuitry in human beings into a physiological state that enables sensory input from standing and stepping movements to serve as a source of neural control to undertake these tasks. Methods A 23-year-old man who had paraplegia from a C7-T1 sublimation as a result of a motor vehicle accident in July 2006, presented with complete loss of clinically detectable voluntary motor function and partial preservation of sensation below the T1 cord segment. After 170 locomotor training sessions over 26 months, a 16-electrode array was surgically placed on the dura (L1-S1 cord segments) in December 2009, to allow for chronic electrical stimulation. Spinal cord stimulation was done during sessions that lasted up to 250 min. We did 29 experiments and tested several stimulation combinations and parameters with the aim of the patient achieving standing and stepping. Findings Epidural stimulation enabled the man to achieve full weight-bearing standing with assistance provided only for balance for 4.25 min. The patient achieved this standing during stimulation using parameters identified as specific for standing while providing bilateral load-bearing proprioceptive input. We also noted locomotor-like patterns when stimulation parameters were optimised for stepping. Additionally, 7 months after implantation, the patient recovered supraspinal control of some leg movements, but only during epidural stimulation. Interpretation Task-specific training with epidural stimulation might reactivate previously silent spared neural circuits or promote plasticity. These interventions could be a viable clinical approach for functional recovery after severe paralysis.	[Edgerton, V. Reggie] Univ Calif Los Angeles, Dept Neurobiol, Dept Integrat Biol & Comparat Physiol, Los Angeles, CA 90095 USA; [Harkema, Susan; Hodes, Jonathan; Angeli, Claudia; Chen, Yangsheng; Ferreira, Christie; Willhite, Andrea] Univ Louisville, Kentucky Spinal Cord Res Ctr, Dept Neurol Surg, Louisville, KY 40292 USA; [Harkema, Susan; Angeli, Claudia; Chen, Yangsheng; Ferreira, Christie; Willhite, Andrea] Frazier Rehab Inst, Louisville, KY USA; [Gerasimenko, Yury] IP Pavlov Physiol Inst, St Petersburg 199034, Russia; [Burdick, Joel] CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; [Rejc, Enrico] Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy; [Grossman, Robert G.] Methodist Hosp, Neurol Inst, Dept Neurosurg, Houston, TX 77030 USA	University of California System; University of California Los Angeles; University of Louisville; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Pavlov Institute of Physiology Russian Academy of Sciences; California Institute of Technology; University of Udine; The Methodist Hospital System; The Methodist Hospital - Houston	Edgerton, VR (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, Dept Integrat Biol & Comparat Physiol, Los Angeles, CA 90095 USA.	vre@ucla.edu	Gerasimenko, Yury/A-3655-2017	Angeli, Claudia/0000-0003-4127-7121	National Institutes of Health; Christopher and Dana Reeve Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB007615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062009] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Christopher and Dana Reeve Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Funding National Institutes of Health and Christopher and Dana Reeve Foundation.	BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; Beres-Jones JA, 2003, EXP BRAIN RES, V149, P222, DOI 10.1007/s00221-002-1349-5; Calancie B, 2006, J SPINAL CORD MED, V29, P413, DOI 10.1080/10790268.2006.11753891; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; de Leon RD, 1998, J NEUROPHYSIOL, V79, P1329, DOI 10.1152/jn.1998.79.3.1329; de Leon RD, 1998, J NEUROPHYSIOL, V80, P83; DIETZ V, 1994, LANCET, V344, P1260, DOI 10.1016/S0140-6736(94)90751-X; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; Fuentes R, 2009, SCIENCE, V323, P1578, DOI 10.1126/science.1164901; Gerasimenko Y, 2001, NATO SCI SER I LIFE, V326, P164; Gerasimenko Y, 2008, EXP NEUROL, V209, P417, DOI 10.1016/j.expneurol.2007.07.015; GRILLNER S, 1979, EXP BRAIN RES, V34, P241; GRILLNER S, 1985, SCIENCE, V228, P143, DOI 10.1126/science.3975635; Grillner S, 2003, NAT REV NEUROSCI, V4, P573, DOI 10.1038/nrn1137; GRILLNER S, 1985, ANNU REV NEUROSCI, V8, P233, DOI 10.1146/annurev.ne.08.030185.001313; Harkema S. J., ARCH PHYS M IN PRESS; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797, DOI 10.1152/jn.1997.77.2.797; Harkema SJ, 2008, BRAIN RES REV, V57, P255, DOI 10.1016/j.brainresrev.2007.07.012; Ichiyama RM, 2008, J NEUROSCI, V28, P7370, DOI 10.1523/JNEUROSCI.1881-08.2008; Jankowska E, 2001, J PHYSIOL-LONDON, V533, P31, DOI 10.1111/j.1469-7793.2001.0031b.x; Jilge B, 2004, EXP BRAIN RES, V154, P308, DOI 10.1007/s00221-003-1666-3; KUHN RA, 1950, BRAIN, V73, P1, DOI 10.1093/brain/73.1.1; Maegele M, 2002, J NEUROTRAUM, V19, P1217, DOI 10.1089/08977150260338010; Marino RJ, 2003, J SPINAL CORD MED, V26, pS50, DOI [DOI 10.1080/10790268.2003.11754575, 10.1080/10790268.2003.11754575]; Minassian K, 2007, HUM MOVEMENT SCI, V26, P275, DOI 10.1016/j.humov.2007.01.005; Minassian K, 2004, SPINAL CORD, V42, P401, DOI 10.1038/sj.sc.3101615; Nadeau S, 2010, NEUROREHAB NEURAL RE, V24, P377, DOI 10.1177/1545968309349945; Rossignol S, 2008, BRAIN RES REV, V57, P228, DOI 10.1016/j.brainresrev.2007.06.019; Wernig A, 1998, SPINAL CORD, V36, P744, DOI 10.1038/sj.sc.3100670; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61	30	629	688	11	136	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 4	2011	377	9781					1938	1947		10.1016/S0140-6736(11)60547-3	http://dx.doi.org/10.1016/S0140-6736(11)60547-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777LW	21601270	Green Accepted			2022-12-28	WOS:000291623200030
J	Reichenheim, ME; de Souza, ER; Moraes, CL; Jorge, MHPD; da Silva, CMFP; Minayo, MCD				Reichenheim, Michael Eduardo; de Souza, Edinilsa Ramos; Moraes, Claudia Leite; Prado de Mello Jorge, Maria Helena; Furtado Passos da Silva, Cosme Marcelo; de Souza Minayo, Maria Cecilia			Health in Brazil 5 Violence and injuries in Brazil: the effect, progress made, and challenges ahead	LANCET			English	Article							INTIMATE PARTNER VIOLENCE; SEVERE PHYSICAL PUNISHMENT; DOMESTIC VIOLENCE; MENTAL-HEALTH; ELDER ABUSE; RISK-FACTORS; SAO-PAULO; CHILDREN; POPULATION; PREVALENCE	Although there are signs of decline, homicides and traffic-related injuries and deaths in Brazil account for almost two-thirds of all deaths from external causes. In 2007, the homicide rate was 26.8 per 100 000 people and traffic-related mortality was 23.5 per 100 000. Domestic violence might not lead to as many deaths, but its share of violence-related morbidity is large. These are important public health problems that lead to enormous individual and collective costs. Young, black, and poor men are the main victims and perpetrators of community violence, whereas poor black women and children are the main victims of domestic violence. Regional differentials are also substantial. Besides the sociocultural determinants, much of the violence in Brazil has been associated with the misuse of alcohol and illicit drugs, and the wide availability of firearms. The high traffic-related morbidity and mortality in Brazil have been linked to the chosen model for the transport system that has given priority to roads and private-car use without offering adequate infrastructure. The system is often poorly equipped to deal with violations of traffic rules. In response to the major problems of violence and injuries, Brazil has greatly advanced in terms of legislation and action plans. The main challenge is to assess these advances to identify, extend, integrate, and continue the successful ones.	[Reichenheim, Michael Eduardo; Moraes, Claudia Leite] Univ Estado Rio de Janeiro, Inst Social Med, Dept Epidemiol, BR-20559900 Rio De Janeiro, Brazil; [de Souza, Edinilsa Ramos; de Souza Minayo, Maria Cecilia] Fundacao Oswaldo Cruz, Natl Sch Publ Hlth, Latin Amer Ctr Studies Violence & Hlth CLAVES, Rio De Janeiro, Brazil; [Moraes, Claudia Leite] Estacio de Sa Univ, Rio De Janeiro, Brazil; [Prado de Mello Jorge, Maria Helena] Univ Sao Paulo, Publ Hlth Fac, Dept Epidemiol, Sao Paulo, Brazil; [Furtado Passos da Silva, Cosme Marcelo] Fundacao Oswaldo Cruz, Natl Sch Publ Hlth, Dept Epidemiol & Quantitat Methods Hlth, Rio De Janeiro, Brazil	Universidade do Estado do Rio de Janeiro; Fundacao Oswaldo Cruz; Universidade de Sao Paulo; Fundacao Oswaldo Cruz	Reichenheim, ME (corresponding author), Univ Estado Rio de Janeiro, Inst Social Med, Dept Epidemiol, Rua Sao Francisco Xavier 524,7 Andar, BR-20559900 Rio De Janeiro, Brazil.	michael@ims.uerj.br	Seguranca Publica, Inct/I-2423-2013; Moraes, claudia/AAK-9418-2020	Moraes, claudia/0000-0002-3223-1634	Brazilian National Research Council (CNPq) [PQ-301221/2009-0, PQ-300515/2009-0, PQ-302851/2008-9, PQ-310503/2009-4]; Rio de Janeiro State Research Foundation (FAPERJ) [E-26/101.461/2010]; Health Surveillance Secretariat (Secretaria de Vigilancia em Saude) of the Brazilian Ministry of Health; INCa	Brazilian National Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Rio de Janeiro State Research Foundation (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Health Surveillance Secretariat (Secretaria de Vigilancia em Saude) of the Brazilian Ministry of Health; INCa(Institut National du Cancer (INCA) France)	MER, ERS, CLM and MHPMJ were supported by the Brazilian National Research Council (CNPq), grants PQ-301221/2009-0, PQ-300515/2009-0, PQ-302851/2008-9 and PQ-310503/2009-4, respectively. CLM was also supported by grant E-26/101.461/2010 from the Rio de Janeiro State Research Foundation (FAPERJ). We are grateful to the National Cancer Institute (CONPREV/INCa) for providing data of the Household Survey on Risk Behaviors and Reported Morbidity from Non-Communicable Diseases used in some analyses (intimate-partner violence). This survey was financed by the Health Surveillance Secretariat (Secretaria de Vigilancia em Saude) of the Brazilian Ministry of Health, with counterpart funds from INCa. We thank Tatiana Ribeiro for her collaboration in organising the references and Christopher Peterson for his meticulous Portuguese-to-English translation.	Adorno S., 1993, BIB, V35, P3; ALFONSO R, 2003, PSIKHE, V8, P31; Anacleto AJ, 2009, CAD SAUDE PUBLICA, V25, P800, DOI 10.1590/S0102-311X2009000400011; [Anonymous], 1999, ENDING VIOLENCE WOME; ASSIS SG, 2003, VIOLENCIA SOB OLHAR, P163; Barata Rita Barradas, 2008, Rev. bras. epidemiol., V11, P3, DOI 10.1590/S1415-790X2008000100001; Beato CCFilho, 2007, HOMICIDIOS BRASIL, P177; Bordin IA, 2009, B WORLD HEALTH ORGAN, V87, P336, DOI 10.2471/BLT.07.043125; CAMARA P, 1999, REV ABRAMET, V30, P31; CAMPOS A, 2009, EVOLUCAO OCUPACAO SI; CANO I, 2007, BATITUCCI ECO, P51; CARDIA N, 1999, ATITUDES NORMAS CULT; Cecchetto F. R., 2004, VIOLENCIA ESTILOS MA; CERQUEIRA DRC, 2007, ANALISE CUSTOS CONSE; Comijs HC, 1998, J AM GERIATR SOC, V46, P885, DOI 10.1111/j.1532-5415.1998.tb02724.x; *CONS NAC DES CIEN, DIR GRUP PESQ COL DA; de Assis SG, 2009, CIENC SAUDE COLETIVA, V14, P349, DOI 10.1590/S1413-81232009000200002; De Micheli D, 2004, ADDICTION, V99, P570, DOI 10.1111/j.1360-0443.2003.00671.x; de Moraes CL, 2008, CAD SAUDE PUBLICA, V24, P2289, DOI 10.1590/S0102-311X2008001000010; de Souza ER, 2010, PSYCHOL RES PROG, P1; DUARTE PCA, 2000, ALCOOL VIOLENCIA EST, P61; FARIA L, 2006, CURINGA, V22, P183; Audi CAF, 2008, J PEDIAT-BRAZIL, V84, P60, DOI 10.2223/JPED.1744; FERRAZ SM, 2004, IMPULSO REV CIENCIAS, V15, P79; Galduróz José Carlos F, 2004, Rev. Bras. Psiquiatr., V26, P3, DOI 10.1590/S1516-44462004000500002; Gawryszewski VP, 2008, REV PANAM SALUD PUBL, V24, P400, DOI 10.1590/S1020-49892008001200004; Goncalves HS, 1999, REV SAUDE PUBL, V33, P547, DOI 10.1590/S0034-89101999000600005; *GOV RIO JAN, 2010, UN PAC; Hasselmann MH, 2006, PAEDIATR PERINAT EP, V20, P299, DOI 10.1111/j.1365-3016.2006.00735.x; Hasselmann Maria Helena, 2003, Cad. Saúde Pública, V19, P1083, DOI 10.1590/S0102-311X2003000400030; *I AVON, 2009, PESQ I AVON IBOPE PE; *I BRAS GEOGR EST, PESQ NAC AM DOM; *I NAC CANC COORD, 2003, INQ DOM COMP RISC MO; *I PESQ EC APL, 2006, IMP SOC EC AC TRANS; Silva MAI, 2007, REV LAT-AM ENFERM, V15, P275, DOI 10.1590/S0104-11692007000200013; JARDIM V, 2009, REV ABRAMET, V27, P48; Jewkes R, 2002, SOC SCI MED, V55, P1603, DOI 10.1016/S0277-9536(01)00294-5; JORGE MM, 2007, ACIDENTES TRANSITO B; KOIZUMI M, 2007, REV ABRAMET, V25, P12; Laurenti R, 1972, Rev Saude Publica, V6, P329, DOI 10.1590/S0034-89101972000400003; LIMA D, 2001, REV ABRAMET, V37, P44; Ludermir AB, 2008, SOC SCI MED, V66, P1008, DOI 10.1016/j.socscimed.2007.10.021; Ludermir AB, 2010, LANCET, V376, P903, DOI 10.1016/S0140-6736(10)60887-2; MALTA D, 2009, ATENDIMENTOS SAMU 19; Malta DC, 2010, EPIDEMIOL SERV SAUDE, V19, P77; MATIELO F, 2002, REV ABRAMET, V20, P14; Mello Jorge MHP, 2009, REV ABRAMET, V27, P16; Mello Jorge MHP, 1979, THESIS U SAO PAULO S; Melo Victor Lopes de, 2006, Rev. Bras. Saude Mater. Infant., V6, ps43, DOI 10.1590/S1519-38292006000500006; *MIN SAUD, SERV AT MOV URG SAMU; *MIN SAUD, 2010, PROGR SAUD FAM; *MIN SAUD, SIST VIG VIOL AC; *MIN SAUD, 2001, PORT GM MS 737 DE 16; *MIN SAUD, SIST INF HOSP; Minayo M C, 1993, Cad Saude Publica, V9, P65; Minayo Maria Cecília de Souza, 2003, Cad. Saúde Pública, V19, P783, DOI 10.1590/S0102-311X2003000300010; Ministerio da Saude, SIST INF MORT; Moraes CL, 2006, INT J GYNECOL OBSTET, V95, P254, DOI 10.1016/j.ijgo.2006.08.015; Moraes CL, 2002, INT J GYNECOL OBSTET, V79, P269, DOI 10.1016/S0020-7292(02)00250-3; Moraes CL, 2009, ACTA OBSTET GYN SCAN, V88, P1041, DOI 10.1080/00016340903128439; MORENO C, 2001, REV ABRAMET, V36, P17; Nadanovsky P, 2009, CAD SAUDE PUBLICA, V25, P1859, DOI 10.1590/S0102-311X2009000800022; Neri MC, 2008, NOVA CLASSE MEDIA MO; NETO GHF, 2004, J TROP MED, V50, P292; Nielsen A., 2009, CRIMINALIDADE AVANCA; O'Reilly R, 2007, CONTEMP NURSE, V25, P13, DOI 10.5172/conu.2007.25.1-2.13; OGG J, 1992, BRIT MED J, V305, P998, DOI 10.1136/bmj.305.6860.998; *PAHO, 2009, INF AN SAL SIT SAL A; Paixão Luiz Andrés Ribeiro, 2009, Econ. Apl., V13, P125, DOI 10.1590/S1413-80502009000100006; Paula CS, 2008, REV SAUDE PUBL, V42, P524, DOI 10.1590/S0034-89102008000300019; Peden M., 2004, WORLD REPORT ROAD TR; PERES M, 2006, AVALIACAO RAC REDESC; Peres MFT, 2005, REV SAUDE PUBL, V39, P58, DOI 10.1590/S0034-89102005000100008; PILLEMER K, 1988, GERONTOLOGIST, V28, P51, DOI 10.1093/geront/28.1.51; d'Oliveira AFPL, 2009, REV SAUDE PUBL, V43, P299, DOI 10.1590/S0034-89102009005000013; *PRES REP, 2006, LEI MAR PENH; RAMOS S, 2007, RESPOSTAS BRASILEIRA; Ramos Silvia, 2006, Physis, V16, P185, DOI 10.1590/S0103-73312006000200004; Rede Interagencial de Informacao para a Saude, 2008, IND BAS SAUD BRAS CO, V2a; Reichenheim ME, 2008, PUBLIC HEALTH, V122, P716, DOI 10.1016/j.puhe.2007.09.016; Reichenheim Michael Eduardo, 2006, Cad. Saúde Pública, V22, P425, DOI 10.1590/S0102-311X2006000200020; Reichenheim ME, 2006, REV SAUDE PUBL, V40, P595, DOI 10.1590/S0034-89102006000500007; Rickert VI, 2002, AM J OBSTET GYNECOL, V187, P1002, DOI 10.1067/mob.2002.126649; ROCHA PCX, CIEN SAUDE IN PRESS; Rondon V., 2003, ECONOMIA, V4, P223; Bordin IAS, 2006, REV BRAS PSIQUIATR, V28, P290, DOI 10.1590/S1516-44462006000700008; SANTOS VIM, 1978, REV ASSOC MED BRAS, V24, P255; *SECR ESP DIR HUM, 2010, OBS NAC ID; *SECR ESP POL MULH, 2007, ENFR VIOL MULH BAL A; *SECR ESP POL MULH, 2010, OBS BRAS IG GEN; Silva Iracema Viterbo, 2003, Cad. Saúde Pública, V19, pS263, DOI 10.1590/S0102-311X2003000800008; de Moura ATMS, 2008, CAD SAUDE PUBLICA, V24, P2926, DOI 10.1590/S0102-311X2008001200022; Souza Edinilsa Ramos de, 2005, Ciênc. saúde coletiva, V10, P59, DOI 10.1590/S1413-81232005000100012; SOUZA ER, 2001, CAD SAUDE PUBLICA, V17, P1291; SOUZA ER, 2005, IMPACTO VIOLENCIA SA, P279; SOUZA ER, 2006, AVALIACAO PROJETO LU; SOUZA ER, 2007, EPIDEMIOL SERV SAUDE, V16, P19, DOI DOI 10.5123/S1679-49742007000100003; Stefanello S, 2008, REV BRAS PSIQUIATR, V30, P139, DOI 10.1590/S1516-44462006005000063; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Szwarcwald C L, 1998, Rev Panam Salud Publica, V4, P161; Taft AJ, 2004, AUST NZ J PUBL HEAL, V28, P324, DOI 10.1111/j.1467-842X.2004.tb00438.x; TEIXEIRA PAS, 2010, DOSSIE MULHER 2010; TOLEDO F, 2004, VERIFICACAO USO COCA; Peres MFT, 2008, REV PANAM SALUD PUBL, V23, P268; *UN, 2010, 11 UN SURV CRIM TREN; Vasconcelos MM, 2005, ARQ NEURO-PSIQUIAT, V63, P68, DOI 10.1590/S0004-282X2005000100013; Victora CG, 2011, LANCET, V377, P1863, DOI 10.1016/S0140-6736(11)60138-4; Vitolo YLC, 2005, REV SAUDE PUBL, V39, P716, DOI 10.1590/S0034-89102005000500004; WAISELFISZ JJ, 2010, MAPA VIOLENCIA BRASI; WAISELFISZ JJ, 2004, MAPA VIOLENCIA, V4; Waiselfisz JJ, 2008, MAPA VIOLENCIA MUNIC; *WHO, 2008, AG STAND MORT RAT CA; WONG L, 2009, REDS INTERAGENCIAL I, P36; World Health Organization, WHO MULT STUD WOM HL; World Health Organization, 2007, INT CLASS DIS; World Health Organization, 2002, WORLD REPORT VIOLENC; World Health Organization, 2009, GLOB STAT REP ROAD S; Ximenes LF, 2009, CIENC SAUDE COLETIVA, V14, P417, DOI 10.1590/S1413-81232009000200011; Zaleski M, 2010, J INTERPERS VIOLENCE, V25, P648, DOI 10.1177/0886260509334396; Zaluar Alba, 2007, Estud. av., V21, P31, DOI 10.1590/S0103-40142007000300003; Zaluar Alba, 2004, INTEGRACAO PERVERSA; 2008, LEI SECA 11705 08; 2010, GLOBO           0804; 1997, CODIGO TRANSITO BRAS	124	179	183	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2011	377	9781					1962	1975		10.1016/S0140-6736(11)60053-6	http://dx.doi.org/10.1016/S0140-6736(11)60053-6			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777LW	21561649				2022-12-28	WOS:000291623200033
J	Rich, JD; Wakeman, SE; Dickman, SL				Rich, Josiah D.; Wakeman, Sarah E.; Dickman, Samuel L.			Medicine and the Epidemic of Incarceration in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FORMER INMATES		[Rich, Josiah D.; Dickman, Samuel L.] Miriam Hosp, Dept Med, Div Infect Dis, Providence, RI 02906 USA; [Rich, Josiah D.; Dickman, Samuel L.] Brown Med Sch, Providence, RI USA; [Wakeman, Sarah E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA	Lifespan Health Rhode Island; Miriam Hospital; Brown University; Harvard University; Massachusetts General Hospital	Rich, JD (corresponding author), Miriam Hosp, Dept Med, Div Infect Dis, Providence, RI 02906 USA.				NIDA NIH HHS [K24 DA022112, K24 DA022112-01A2] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K24DA022112] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Binswanger IA, 2007, NEW ENGL J MED, V356, P536; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; James DJ, 2006, MENTAL HLTH PROBLEMS; *PEW CTR STAT, ON 100 BARS AM 2008; Wakeman SE, 2009, J GEN INTERN MED, V24, P860, DOI 10.1007/s11606-009-0977-x	6	90	91	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2081	2083		10.1056/NEJMp1102385	http://dx.doi.org/10.1056/NEJMp1102385			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	772AB	21631319	Green Accepted			2022-12-28	WOS:000291200700001
J	Arendt, AA				Arendt, Anthony A.			Assessing the Status of Alaska's Glaciers	SCIENCE			English	Editorial Material									Univ Alaska Fairbanks, Inst Geophys, Fairbanks, AK 99775 USA	University of Alaska System; University of Alaska Fairbanks	Arendt, AA (corresponding author), Univ Alaska Fairbanks, Inst Geophys, Fairbanks, AK 99775 USA.	anthony.arendt@gi.alaska.edu		Arendt, Anthony/0000-0003-0429-6905	Directorate For Geosciences [0911764] Funding Source: National Science Foundation	Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))		Arendt AA, 2002, SCIENCE, V297, P382, DOI 10.1126/science.1072497; Berthier E, 2010, NAT GEOSCI, V3, P92, DOI 10.1038/NGEO737; Chen JL, 2006, EARTH PLANET SC LETT, V248, P368, DOI 10.1016/j.epsl.2006.05.039; Echelmeyer KA, 1996, J GLACIOL, V42, P538, DOI 10.3189/S002214300000352X; Falk MJ, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007666; Luthcke SB, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024846; Luthcke SB, 2008, J GLACIOL, V54, P767, DOI 10.3189/002214308787779933; MEIER MF, 1984, SCIENCE, V226, P1418, DOI 10.1126/science.226.4681.1418; Schiefer E, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030780; Tamisiea ME, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023961; Van Beusekom A.E., 2010, 20105247 US GEOL SUR; VanLooy J, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL028060; Wu XP, 2010, NAT GEOSCI, V3, P642, DOI 10.1038/NGEO938	13	11	15	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2011	332	6033					1044	1045		10.1126/science.1204400	http://dx.doi.org/10.1126/science.1204400			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617066				2022-12-28	WOS:000290996700033
J	Asaadi, N; Ribe, NM; Sobouti, F				Asaadi, N.; Ribe, N. M.; Sobouti, F.			Inferring nonlinear mantle rheology from the shape of the Hawaiian swell	NATURE			English	Article							GLACIAL-ISOSTATIC-ADJUSTMENT; GEOID HEIGHT; PLUME; LITHOSPHERE; TOPOGRAPHY; CONVECTION; CREEP; TOMOGRAPHY; ANISOTROPY; ANOMALIES	The convective circulation generated within the Earth's mantle by buoyancy forces of thermal and compositional origin is intimately controlled by the rheology of the rocks that compose it. These can deform either by the diffusion of point defects (diffusion creep, with a linear relationship between strain rate and stress) or by the movement of intracrystalline dislocations (nonlinear dislocation creep)(1,2). However, there is still no reliable map showing where in the mantle each of these mechanisms is dominant, and so it is important to identify regions where the operative mechanism can be inferred directly from surface geophysical observations. Here we identify a new observable quantity-the rate of downstream decay of the anomalous seafloor topography (swell) produced by a mantle plume-which depends only on the value of the exponent in the strain rate versus stress relationship that defines the difference between diffusion and dislocation creep. Comparison of the Hawaiian swell topography with the predictions of a simple fluid mechanical model shows that the swell shape is poorly explained by diffusion creep, and requires a dislocation creep rheology. The rheology predicted by the model is reasonably consistent with laboratory deformation data for both olivine(3) and clinopyroxene(4), suggesting that the source of Hawaiian lavas could contain either or both of these components.	[Asaadi, N.; Sobouti, F.] IASBS, Zanjan 4513766731, Iran; [Ribe, N. M.] Univ Paris 11, CNRS, Lab FAST, F-91405 Orsay, France	Institute for Advanced Studies in Basic Sciences (IASBS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Asaadi, N (corresponding author), IASBS, Zanjan 4513766731, Iran.	n_asaadi@iasbs.ac.ir; ribe@fast.u-psud.fr	Asaadi, Nazila/Y-8693-2018		French embassy in Tehran; INSU; ANR in France	French embassy in Tehran; INSU(Centre National de la Recherche Scientifique (CNRS)); ANR in France(French National Research Agency (ANR))	We thank A. Davaille, C. Herzberg, S.-I. Karato and D. Kohlstedt for discussions and advice. This work was supported by the French embassy in Tehran and by the SEDIT programme of INSU and the ANR (grant PTECTO) in France.	BAI Q, 1991, J GEOPHYS RES-SOLID, V96, P2441, DOI 10.1029/90JB01723; BORCH RS, 1989, PHYS EARTH PLANET IN, V55, P269, DOI 10.1016/0031-9201(89)90075-7; Bystricky M, 2001, J GEOPHYS RES-SOL EA, V106, P13443, DOI 10.1029/2001JB000333; CHRISTENSEN U, 1991, GEOPHYS J INT, V104, P213, DOI 10.1111/j.1365-246X.1991.tb02505.x; Cserepes L, 2000, EARTH PLANET SC LETT, V178, P29, DOI 10.1016/S0012-821X(00)00065-0; DAVIES GF, 1992, EARTH PLANET SC LETT, V113, P277, DOI 10.1016/0012-821X(92)90225-K; HAGER BH, 1985, NATURE, V313, P541, DOI 10.1038/313541a0; Herzberg C, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2008GC002057; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; Karato S, 2008, EARTH PLANET SC LETT, V274, P234, DOI 10.1016/j.epsl.2008.07.033; Karato S, 2008, ANNU REV EARTH PL SC, V36, P59, DOI 10.1146/annurev.earth.36.031207.124120; KEEFNER JW, J GEOPHYS R IN PRESS, DOI DOI 10.1029/2010JB00748; KIRBY SH, 1983, REV GEOPHYS, V21, P1458, DOI 10.1029/RG021i006p01458; Long MD, 2009, SURV GEOPHYS, V30, P407, DOI 10.1007/s10712-009-9075-1; MARKS KM, 1991, J GEOPHYS RES-SOLID, V96, P8045, DOI 10.1029/91JB00240; Mitrovica JX, 2004, EARTH PLANET SC LETT, V225, P177, DOI 10.1016/j.epsl.2004.06.005; MONTAGNER JP, 1991, J GEOPHYS RES-SOL EA, V96, P20337, DOI 10.1029/91JB01890; Montelli R, 2004, SCIENCE, V303, P338, DOI 10.1126/science.1092485; MORGAN WJ, 1971, NATURE, V230, P42, DOI 10.1038/230042a0; Olson P., 1990, MAGMA TRANSPORT STOR, P33; PELTIER WR, 1976, GEOPHYS J ROY ASTR S, V46, P669, DOI 10.1111/j.1365-246X.1976.tb01253.x; Ribe NM, 1999, EARTH PLANET SC LETT, V171, P517, DOI 10.1016/S0012-821X(99)00179-X; RIBE NM, 1994, J GEOPHYS RES-SOL EA, V99, P669, DOI 10.1029/93JB02386; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; Smith WHF, 1997, SCIENCE, V277, P1956, DOI 10.1126/science.277.5334.1956; Sobolev AV, 2005, NATURE, V434, P590, DOI 10.1038/nature03411; STEIN CA, 1992, NATURE, V359, P123, DOI 10.1038/359123a0; Tarduno JA, 2003, SCIENCE, V301, P1064, DOI 10.1126/science.1086442; van Hunen J, 2005, EARTH PLANET SC LETT, V238, P146, DOI 10.1016/j.epsl.2005.07.006; WATTS AB, 1974, GEOPHYS J ROY ASTR S, V38, P119, DOI 10.1111/j.1365-246X.1974.tb04112.x; WILSON JT, 1963, CAN J PHYS, V41, P863, DOI 10.1139/p63-094; Wolfe CJ, 2009, SCIENCE, V326, P1388, DOI 10.1126/science.1180165	32	17	17	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2011	473	7348					501	U243		10.1038/nature09993	http://dx.doi.org/10.1038/nature09993			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21562491				2022-12-28	WOS:000290951300038
J	Bridgewater, B				Bridgewater, Ben			Commentary: Unintended consequences of governance	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Bridgewater, Ben] S Manchester Univ Hosp NHS Trust, Manchester M23 9LT, Lancs, England; [Bridgewater, Ben] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; University of Manchester	Bridgewater, B (corresponding author), S Manchester Univ Hosp NHS Trust, Manchester M23 9LT, Lancs, England.	ben.bridgewater@uhsm.nhs.uk						Bridgewater B, 2011, MAINTAINING PATIENTS; Bridgewater B, 2009, DEMONSTRATING QUALIT; Bridgewater B, 2007, HEART, V93, P744, DOI 10.1136/hrt.2006.106393; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; Mid Staffordshire NHS Foundation Trust Inquiry, FIN REP IND INQ CAR; Treasure T, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2466	6	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 26	2011	342								d2865	10.1136/bmj.d2865	http://dx.doi.org/10.1136/bmj.d2865			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771KG	21622510				2022-12-28	WOS:000291155000003
J	Fielding, JE; Teutsch, SM				Fielding, Jonathan E.; Teutsch, Steven M.			An Opportunity Map for Societal Investment in Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Fielding, Jonathan E.; Teutsch, Steven M.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA 90012 USA; [Fielding, Jonathan E.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; [Fielding, Jonathan E.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA	Los Angeles County Department of Public Health; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Teutsch, SM (corresponding author), Los Angeles Cty Dept Publ Hlth, 313 N Figueroa,Room 708, Los Angeles, CA 90012 USA.	steutsch@ph.lacounty.gov						[Anonymous], OV USPSTF STRUCT PRO; Barker DJP, 2000, INFLUENCES DEV DIS L; Dahlgren G, 1991, POLICIES STRATEGIES; Eckenrode J, 2010, ARCH PEDIAT ADOL MED, V164, P9, DOI 10.1001/archpediatrics.2009.240; Petersen M, 2008, DIABETES CARE, V31, P1271, DOI 10.2337/dc08-9017; Secretary's Advisory Committee on National Health Promotion and Disease Prevention, 2008, OBJ 2020 PHAS 1 REP; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805	7	17	17	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2011	305	20					2110	2111		10.1001/jama.2011.698	http://dx.doi.org/10.1001/jama.2011.698			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768AC	21610244				2022-12-28	WOS:000290901700026
J	Paydarfar, D; Schwartz, WJ				Paydarfar, David; Schwartz, William J.			Untitled	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SELF-CONCEPT											Clines FX, 1970, NY TIMES        0225, P51; GECAS V, 1982, ANNU REV SOCIOL, V8, P1, DOI 10.1146/annurev.so.08.080182.000245; KINCH JW, 1963, AM J SOCIOL, V68, P481, DOI 10.1086/223404; MADISON D, 1968, MILBANK FUND Q, V46, P389, DOI 10.2307/3349336; Safire W., 1993, NEW YORK TIMES 0411, V6, P12	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2011	305	20					2046	2047		10.1001/jama.2011.702	http://dx.doi.org/10.1001/jama.2011.702			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768AC	21610229				2022-12-28	WOS:000290901700001
J	Warensjo, E; Byberg, L; Melhus, H; Gedeborg, R; Mallmin, H; Wolk, A; Michaelsson, K				Warensjo, Eva; Byberg, Liisa; Melhus, Hakan; Gedeborg, Rolf; Mallmin, Hans; Wolk, Alicja; Michaelsson, Karl			Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							25-HYDROXYVITAMIN D LEVELS; TOTAL-ENERGY INTAKE; BREAST-CANCER RISK; VITAMIN-D; SUPPLEMENT USE; WOMEN; QUESTIONNAIRE; OLDER; METAANALYSIS; PREVENTION	Objective To investigate associations between long term dietary intake of calcium and risk of fracture of any type, hip fractures, and osteoporosis. Design A longitudinal and prospective cohort study, based on the Swedish Mammography Cohort, including a subcohort, the Swedish Mammography Cohort Clinical. Setting A population based cohort in Sweden established in 1987. Participants 61 433 women (born between 1914 and 1948) were followed up for 19 years. 5022 of these women participated in the subcohort. Main outcome measures Primary outcome measures were incident fractures of any type and hip fractures, which were identified from registry data. Secondary outcome was osteoporosis diagnosed by dual energy x ray absorptiometry in the subcohort. Diet was assessed by repeated food frequency questionnaires. Results During follow-up, 14 738 women (24%) experienced a first fracture of any type and among them 3871 (6%) a first hip fracture. Of the 5022 women in the subcohort, 1012 (20%) were measured as osteoporotic. The risk patterns with dietary calcium were non-linear. The crude rate of a first fracture of any type was 17.2/1000 person years at risk in the lowest quintile of calcium intake, and 14.0/1000 person years at risk in the third quintile, corresponding to a multivariable adjusted hazard ratio of 1.18 (95% confidence interval 1.12 to 1.25). The hazard ratio for a first hip fracture was 1.29 (1.17 to 1.43) and the odds ratio for osteoporosis was 1.47 (1.09 to 2.00). With a low vitamin D intake, the rate of fracture in the first calcium quintile was more pronounced. The highest quintile of calcium intake did not further reduce the risk of fractures of any type, or of osteoporosis, but was associated with a higher rate of hip fracture, hazard ratio 1.19 (1.06 to 1.32). Conclusion Gradual increases in dietary calcium intake above the first quintile in our female population were not associated with further reductions in fracture risk or osteoporosis.	[Warensjo, Eva; Byberg, Liisa; Mallmin, Hans; Michaelsson, Karl] Uppsala Univ, Dept Surg Sci, Sect Orthopaed, Uppsala, Sweden; [Melhus, Hakan] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Warensjo, Eva; Byberg, Liisa; Melhus, Hakan; Gedeborg, Rolf; Michaelsson, Karl] Uppsala Univ, UCR, Uppsala Clin Res Ctr, Uppsala, Sweden; [Wolk, Alicja] Karolinska Inst, Inst Environm Med, Div Nutr Epidemiol, S-10401 Stockholm, Sweden	Uppsala University; Uppsala University; Uppsala University; Karolinska Institutet	Warensjo, E (corresponding author), Uppsala Univ, Dept Surg Sci, Sect Orthopaed, Uppsala, Sweden.	eva.warensjo@surgsci.uu.se	Michaelsson, Karl/AAM-9094-2021; Gedeborg, Rolf/AAV-6702-2020	Gedeborg, Rolf/0000-0002-8850-7863; Michaelsson, Karl/0000-0003-2815-1217	Swedish Research Council [2008-2202, 2009-6281]	Swedish Research Council(Swedish Research CouncilEuropean Commission)	Supported by the Swedish Research Council, grant numbers 2008-2202 and 2009-6281. The funding source was not involved in the design, conduct or interpretation of the study, or in the writing of the submitted work.	[Anonymous], 2005, NORDIC NUTR RECOMMEN; Bergstrom L., 1991, Var Foda, V43, P439; Bischoff-Ferrari HA, 2007, AM J CLIN NUTR, V86, P1780; Bischoff-Ferrari HA, 2009, J BONE MINER RES, V24, P935, DOI [10.1359/JBMR.081242, 10.1359/jbmr.081242]; Bolland MJ, BMJ, V341, pc3691; Burgaz A, 2009, J INTERN MED, V266, P476, DOI 10.1111/j.1365-2796.2009.02125.x; Burgaz A, 2007, AM J CLIN NUTR, V86, P1399, DOI 10.1093/ajcn/86.5.1399; Calltorp J, 1996, LANCET, V347, P587, DOI 10.1016/S0140-6736(96)91278-7; Cashman KD, 2007, J NUTR, V137, p2507S, DOI 10.1093/jn/137.11.2507S; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cleves M., 2009, ANAL MULTIPLE FAILUR; Cumming RG, 1997, J BONE MINER RES, V12, P1321, DOI 10.1359/jbmr.1997.12.9.1321; Cumming RG, 1997, AM J EPIDEMIOL, V145, P926, DOI 10.1093/oxfordjournals.aje.a009052; Feskanich D, 2003, AM J CLIN NUTR, V77, P504, DOI 10.1093/ajcn/77.2.504; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gedeborg R, 2008, EPIDEMIOLOGY, V19, P860, DOI 10.1097/EDE.0b013e318181319e; Griffith JF, 2010, ANN NY ACAD SCI, V1192, P45, DOI 10.1111/j.1749-6632.2009.05378.x; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Kaaks R, 2002, PUBLIC HEALTH NUTR, V5, P969, DOI 10.1079/PHN2002380; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; KANIS JA, 1989, BRIT MED J, V298, P205, DOI 10.1136/bmj.298.6668.205; Key TJ, 2007, PUBLIC HEALTH NUTR, V10, P1314, DOI 10.1017/S1368980007696402; Larsson SC, 2009, EUR J CANCER, V45, P3042, DOI 10.1016/j.ejca.2009.04.035; Larsson SC, 2009, AM J CLIN NUTR, V90, P556, DOI 10.3945/ajcn.2009.27480; Larsson SC, 2009, AM J CLIN NUTR, V89, P277, DOI 10.3945/ajcn.2008.26704; Lin DY, 1997, STAT MED, V16, P901, DOI 10.1002/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M; Melhus H, 2010, J CLIN ENDOCR METAB, V95, P2637, DOI 10.1210/jc.2009-2699; Messerer M, 2004, J NUTR, V134, P1800, DOI 10.1093/jn/134.7.1800; Michaelsson K, 2003, BONE, V32, P694, DOI 10.1016/S8756-3282(03)00048-6; National Health and Medical Research Council, 2006, NUTR REF VAL AUSTR N; NHS Choices, VIT MIN CALC; Orsini N, 2008, EUR J EPIDEMIOL, V23, P661, DOI 10.1007/s10654-008-9273-z; Prentice A, 2004, PUBLIC HEALTH NUTR, V7, P227, DOI 10.1079/PHN2003590; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Reid IR, 2008, OSTEOPOROSIS INT, V19, P1119, DOI 10.1007/s00198-008-0563-9; Reid IR, 2006, AM J MED, V119, P777, DOI 10.1016/j.amjmed.2006.02.038; Sennerby U, 2009, JAMA-J AM MED ASSOC, V302, P1666, DOI 10.1001/jama.2009.1463; Serra-Majem L, 2009, BRIT J NUTR, V102, pS38, DOI 10.1017/S0007114509993138; Snellman G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007747; [STATA Corporation Stata Corporation], 2009, STAT REF MAN REL 11; Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140-6736(07)61342-7; Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S; Xu LZ, 2004, BRIT J NUTR, V91, P625, DOI 10.1079/BJN20031085; Yates AA, 1998, J AM DIET ASSOC, V98, P699, DOI 10.1016/S0002-8223(98)00160-6	44	123	125	1	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	2011	342								d1473	10.1136/bmj.d1473	http://dx.doi.org/10.1136/bmj.d1473			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771KC	21610048	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000291154600007
J	Pincock, S				Pincock, Stephen			Paulo Buss-a leader of public health and health policy in Brazil Profile	LANCET			English	Biographical-Item														Pincock, Stephen/0000-0003-1655-2902					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	2011	377	9779					1738	1738		10.1016/S0140-6736(11)60719-8	http://dx.doi.org/10.1016/S0140-6736(11)60719-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771AS	21601696				2022-12-28	WOS:000291130200015
J	Franke, KJ; Schulze, G; Pascual, JI				Franke, K. J.; Schulze, G.; Pascual, J. I.			Competition of Superconducting Phenomena and Kondo Screening at the Nanoscale	SCIENCE			English	Article							LOCAL ELECTRONIC-STRUCTURE; MAGNETIC-IMPURITIES; STATES; VORTICES; ALLOYS	Magnetic and superconducting interactions couple electrons together to form complex states of matter. We show that, at the atomic scale, both types of interactions can coexist and compete to influence the ground state of a localized magnetic moment. Local spectroscopy at 4.5 kelvin shows that the spin-1 system formed by manganese-phthalocyanine (MnPc) adsorbed on Pb(111) can lie in two different magnetic ground states. These are determined by the balance between Kondo screening and superconducting pair-breaking interactions. Both ground states alternate at nanometer length scales to form a Moire-like superstructure. The quantum phase transition connecting the two (singlet and doublet) ground states is thus tuned by small changes in the molecule-lead interaction.	[Franke, K. J.; Schulze, G.; Pascual, J. I.] Free Univ Berlin, Inst Expt Phys, D-14195 Berlin, Germany	Free University of Berlin	Franke, KJ (corresponding author), Free Univ Berlin, Inst Expt Phys, Arnimallee 14, D-14195 Berlin, Germany.	franke@physik.fu-berlin.de	Pascual, Jose I/F-3489-2011; Franke, Katharina J/G-4470-2011; Pascual, Jose Ignacio/N-3102-2016	Franke, Katharina J/0000-0001-9416-023X; Pascual, Jose Ignacio/0000-0002-7152-4747	Freie Universitat Berlin; Deutsche Forschungsgemeinschaft [Sfb 658, SPP 1243]	Freie Universitat Berlin; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank F. von Oppen and A. Strozecka for stimulating discussions and E. K. U. Gross for motivating us to study this topic. This research was supported by the Focus area "Nanoscale Materials" of the Freie Universitat Berlin and by the Deutsche Forschungsgemeinschaft through the collaborative projects Sfb 658 and SPP 1243.	Balatsky AV, 2006, REV MOD PHYS, V78, P373, DOI 10.1103/RevModPhys.78.373; Bauer J, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/48/486211; Buitelaar MR, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.256801; Eichler A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.126602; Flatte ME, 1997, PHYS REV LETT, V78, P3761, DOI 10.1103/PhysRevLett.78.3761; Flatte ME, 1997, PHYS REV B, V56, P11213, DOI 10.1103/PhysRevB.56.11213; Fu YS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.256601; Gao L, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.106402; Horcas I, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2432410; Ivanov DA, 2001, PHYS REV LETT, V86, P268, DOI 10.1103/PhysRevLett.86.268; Ji SH, 2010, CHINESE PHYS LETT, V27, DOI 10.1088/0256-307X/27/8/087202; Ji SH, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.226801; KONDO J, 1964, PROG THEOR PHYS, V32, P37, DOI 10.1143/PTP.32.37; Li JT, 1998, PHYS REV LETT, V80, P2893, DOI 10.1103/PhysRevLett.80.2893; Liao MS, 2005, INORG CHEM, V44, P1941, DOI 10.1021/ic0401039; Madhavan V, 1998, SCIENCE, V280, P567, DOI 10.1126/science.280.5363.567; MATSUURA T, 1977, PROG THEOR PHYS, V57, P1823, DOI 10.1143/PTP.57.1823; Moca CP, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.174516; Parks JJ, 2010, SCIENCE, V328, P1370, DOI 10.1126/science.1186874; Posazhennikova A, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.036802; Read N, 2000, PHYS REV B, V61, P10267, DOI 10.1103/PhysRevB.61.10267; RUSINOV AI, 1969, SOV PHYS JETP-USSR, V29, P1101; SAKAI O, 1993, J PHYS SOC JPN, V62, P3181, DOI 10.1143/JPSJ.62.3181; Salkola MI, 1997, PHYS REV B, V55, P12648, DOI 10.1103/PhysRevB.55.12648; Sand-Jespersen T, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.126603; SHIBA H, 1968, PROG THEOR PHYS, V40, P435, DOI 10.1143/PTP.40.435; Ternes M, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.132501; Volovik GE, 1999, JETP LETT+, V70, P609, DOI 10.1134/1.568223; Yazdani A, 1997, SCIENCE, V275, P1767, DOI 10.1126/science.275.5307.1767; Yu L., 1965, ACTA PHYS SINICA, V21, P75, DOI DOI 10.7498/APS.21.75	30	292	294	1	156	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2011	332	6032					940	944		10.1126/science.1202204	http://dx.doi.org/10.1126/science.1202204			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596987				2022-12-28	WOS:000290766600036
J	Li, L; Richter, C; Paetel, S; Kopp, T; Mannhart, J; Ashoori, RC				Li, Lu; Richter, C.; Paetel, S.; Kopp, T.; Mannhart, J.; Ashoori, R. C.			Very Large Capacitance Enhancement in a Two-Dimensional Electron System	SCIENCE			English	Article							OXIDE INTERFACES; GAS; COMPRESSIBILITY; ENERGY	Increases in the gate capacitance of field-effect transistor structures allow the production of lower-power devices that are compatible with higher clock rates, driving the race for developing high-k dielectrics. However, many-body effects in an electronic system can also enhance capacitance. Onto the electron system that forms at the LaAlO3/SrTiO3 interface, we fabricated top-gate electrodes that can fully deplete the interface of all mobile electrons. Near depletion, we found a greater than 40% enhancement of the gate capacitance. Using an electric-field penetration measurement method, we show that this capacitance originates from a negative compressibility of the interface electron system. Capacitance enhancement exists at room temperature and arises at low electron densities, in which disorder is strong and the in-plane conductance is much smaller than the quantum conductance.	[Li, Lu; Ashoori, R. C.] MIT, Dept Phys, Cambridge, MA 02139 USA; [Richter, C.; Paetel, S.; Kopp, T.; Mannhart, J.] Univ Augsburg, Ctr Elect Correlat & Magnetism, D-86135 Augsburg, Germany	Massachusetts Institute of Technology (MIT); University of Augsburg	Ashoori, RC (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.	ashoori@mit.edu	Richter, Christoph/A-6172-2013; Li, Lu/AAF-9416-2019	Richter, Christoph/0000-0002-6591-1118; Li, Lu/0000-0002-8054-7406; /0000-0001-5031-1673; Mannhart, Jochen/0000-0001-6331-2640; Paetel, Stefan/0000-0002-7051-5208	National Science Foundation through the Nanoscale Science and Engineering Center; Deutsche Forschungsgemeinschaft [TRR 80]; European Commission; Nanoscale Research Initiative; MIT;  [ARO-54173PH]	National Science Foundation through the Nanoscale Science and Engineering Center(National Science Foundation (NSF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Commission(European CommissionEuropean Commission Joint Research Centre); Nanoscale Research Initiative; MIT; 	The authors gratefully acknowledge helpful discussions and interactions with O. E. Dial, M. M. Fogler, R. Jany, P. A. Lee, L. S. Levitov, A. J. Millis, B. Shklovskii, P. Solomon, and J.-M. Triscone. This work was supported by ARO-54173PH, by the National Science Foundation through the Nanoscale Science and Engineering Center program, by the Deutsche Forschungsgemeinschaft (TRR 80), the European Commission (OxIDes), and by the Nanoscale Research Initiative. L. Li thanks the MIT Pappalardo Fellowships in Physics for support.	Allison G, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.216407; ASHOORI RC, 1992, SOLID STATE COMMUN, V81, P821, DOI 10.1016/0038-1098(92)90545-K; Bello B. I., 1981, SOV PHYS JETP, V80, P1596; Edge A. F., 2006, APPL PHYS LETT, V88; KRAVCHENKO SV, 1990, PHYS REV B, V42, P3741, DOI 10.1103/PhysRevB.42.3741; Loth MS, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.056102; Mannhart J, 2010, SCIENCE, V327, P1607, DOI 10.1126/science.1181862; Mannhart J, 2008, MRS BULL, V33, P1027, DOI 10.1557/mrs2008.222; MULLER KA, 1979, PHYS REV B, V19, P3593, DOI 10.1103/PhysRevB.19.3593; Ohtomo A, 2004, NATURE, V427, P423, DOI 10.1038/nature02308; Okamoto S, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.056802; Shapira S, 1996, PHYS REV LETT, V77, P3181, DOI 10.1103/PhysRevLett.77.3181; Solomon P. M., 2010, FUTURE TRENDS MICROE, P127; Thiel S, 2006, SCIENCE, V313, P1942, DOI 10.1126/science.1131091	18	167	167	6	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2011	332	6031					825	828		10.1126/science.1204168	http://dx.doi.org/10.1126/science.1204168			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566188	Green Submitted			2022-12-28	WOS:000290529900041
J	Prokesch, A; Lazar, MA				Prokesch, Andreas; Lazar, Mitchell A.			A Hormone Sends Instant Messages to the Genome	CELL			English	Editorial Material							TRANSCRIPTION; ELONGATION; PROMOTERS		[Prokesch, Andreas; Lazar, Mitchell A.] Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med,Inst Diabet Obest & Metab, Philadelphia, PA 19104 USA; [Prokesch, Andreas] Graz Univ Technol, Inst Genom & Bioinformat, A-8010 Graz, Austria	University of Pennsylvania; Graz University of Technology	Lazar, MA (corresponding author), Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med,Inst Diabet Obest & Metab, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019; PROKESCH, ANDREAS/B-6786-2019	PROKESCH, ANDREAS/0000-0002-8487-7103				Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Larschan E, 2011, NATURE, V471, P115, DOI 10.1038/nature09757; Lupien M, 2009, ENDOCR-RELAT CANCER, V16, P381, DOI 10.1677/ERC-09-0038; Min IM, 2011, GENE DEV, V25, P742, DOI 10.1101/gad.2005511; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Seila AC, 2009, CELL CYCLE, V8, P2557, DOI 10.4161/cc.8.16.9305; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88	10	3	4	1	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 13	2011	145	4					499	501		10.1016/j.cell.2011.04.016	http://dx.doi.org/10.1016/j.cell.2011.04.016			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565609	Bronze			2022-12-28	WOS:000290560800004
J	O'Neill, D				O'Neill, Desmond			The art of medicine The art of the demographic dividend	LANCET			English	Editorial Material									Adelaide & Meath Hosp, Trinity Ctr Hlth Sci, Ctr Ageing Neurosci & Humanities, Dublin 24, Ireland	Trinity College Dublin	O'Neill, D (corresponding author), Adelaide & Meath Hosp, Trinity Ctr Hlth Sci, Ctr Ageing Neurosci & Humanities, Dublin 24, Ireland.	doneill@tcd.ie	O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				Clarfield A.M., 2007, BMJ, V334, P1225, DOI [10.1136/bmj.39237.488356.94, DOI 10.1136/BMJ.39237.488356.94]; Crutch SJ, 2001, LANCET, V357, P2129, DOI 10.1016/S0140-6736(00)05187-4; DORMANDY T, 2001, OLD MASTERS GREAT AR; HAKAMIESBLOMQVI.L, 2002, BEHAVIOUR, V5, P271; Murphy KM, 2006, J POLIT ECON, V114, P871, DOI 10.1086/508033; ONEILL D, 2010, BRIT MED J, V341, pE5975; Said Edward, 2006, LATE STYLE MUSIC LIT; SHAINBERG L, 1987, PARIS REV, P100; Sontag S., 1987, ILLNESS METAPHOR	9	18	18	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2011	377	9780					1828	1829		10.1016/S0140-6736(11)60612-0	http://dx.doi.org/10.1016/S0140-6736(11)60612-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	774UI	21630498				2022-12-28	WOS:000291411700015
J	Perla, RJ				Perla, Rocco J.			The Physics of Health Care Improvement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							QUALITY IMPROVEMENT		[Perla, Rocco J.] UMass Mem Healthcare, Worcester, MA 01605 USA; [Perla, Rocco J.] Univ Massachusetts, Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Perla, RJ (corresponding author), UMass Mem Healthcare, 22 Shattuck St, Worcester, MA 01605 USA.	rocco.perla2@umassmemorial.org						Berwick DM, 2011, NEW ENGL J MED, V364, DOI 10.1056/NEJMp1103602; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; Deming WE, 1994, NEW EC IND GOVT ED; Langley GJ, 2009, IMPROVEMENT GUIDE; Leviton L, 2011, BMJ QUAL SAF, V20, pI28, DOI 10.1136/bmjqs.2010.046375; Lloyd RC, 2009, JAMA-J AM MED ASSOC, V302, P894, DOI 10.1001/jama.2009.1251; Maeda J., 2006, LAWS SIMPLICITY; Newton I., 1729, MATH PRINCIPLES NATU; Provost LP., 2011, HEALTHCARE DATA GUID; Shewhart WA., 1931, EC CONTROL QUALITY M	10	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2223	2224		10.1001/jama.2011.735	http://dx.doi.org/10.1001/jama.2011.735			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21632486				2022-12-28	WOS:000291106300026
J	Norenzayan, A				Norenzayan, Ara			Explaining Human Behavioral Diversity	SCIENCE			English	Editorial Material							CULTURAL VARIATION		Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Norenzayan, A (corresponding author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	ara@psych.ubc.ca						ALESINA A, NBER WORKING PAPER; Bang M, 2007, P NATL ACAD SCI USA, V104, P13868, DOI 10.1073/pnas.0706627104; Brown GR, 2011, PHILOS T R SOC B, V366, P313, DOI 10.1098/rstb.2010.0267; Cohen D, 2001, PSYCHOL BULL, V127, P451, DOI 10.1037//0033-2909.127.4.451; Gangestad SW, 2006, PSYCHOL INQ, V17, P75, DOI 10.1207/s15327965pli1702_1; Gelfand MJ, 2011, SCIENCE, V332, P1100, DOI 10.1126/science.1197754; Henrich J, 2010, BEHAV BRAIN SCI, V33, P61, DOI 10.1017/S0140525X0999152X; Laland KN, 2010, NAT REV GENET, V11, P137, DOI 10.1038/nrg2734; Norris Pippa, 2004, SACRED SECULAR RELIG; Richerson J., 2005, NOT GENES ALONE CULT; Sperber Dan, 1996, EXPLAINING CULTURE N	11	15	16	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2011	332	6033					1041	1042		10.1126/science.1207050	http://dx.doi.org/10.1126/science.1207050			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617064				2022-12-28	WOS:000290996700031
J	Hartvigsen, J; Foster, NE; Croft, PR				Hartvigsen, Jan; Foster, Nadine E.; Croft, Peter R.			PERSONAL VIEW We need to rethink front line care for back pain	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Hartvigsen, Jan] Inst Sports Sci & Clin Biomech, Odense, Denmark; [Foster, Nadine E.; Croft, Peter R.] Keele Univ, Arthrit Res UK Primary Care Ctr, Keele, Staffs, England	University of Southern Denmark; Keele University	Hartvigsen, J (corresponding author), Inst Sports Sci & Clin Biomech, Odense, Denmark.	jhartvigsen@health.sdu.dk		Foster, Nadine/0000-0003-4429-9756; Hartvigsen, Jan/0000-0002-5876-7410	National Institute for Health Research [NF-SI-0509-10183] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))			0	12	12	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 25	2011	342								d3260	10.1136/bmj.d3260	http://dx.doi.org/10.1136/bmj.d3260			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771KE	21613346				2022-12-28	WOS:000291154800010
J	Boutitie, F; Pinede, L; Schulman, S; Agnelli, G; Raskob, G; Julian, J; Hirsh, J; Kearon, C				Boutitie, Florent; Pinede, Laurent; Schulman, Sam; Agnelli, Giancarlo; Raskob, Gary; Julian, Jim; Hirsh, Jack; Kearon, Clive			Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTENSITY WARFARIN THERAPY; DEEP-VEIN THROMBOSIS; 1ST EPISODE; LONG-TERM; PULMONARY-EMBOLISM; D-DIMER; DURATION; METAANALYSIS; PREVENTION	Objective To determine how length of anticoagulation and clinical presentation of venous thromboembolism influence the risk of recurrence after anticoagulant treatment is stopped and to identify the shortest length of anticoagulation that reduces the risk of recurrence to its lowest level. Design Pooled analysis of individual participants' data from seven randomised trials. Setting Outpatient anticoagulant clinics in academic centres. Population 2925 men or women with a first venous thromboembolism who did not have cancer and received different durations of anticoagulant treatment. Main outcome measure First recurrent venous thromboembolism after stopping anticoagulant treatment during up to 24 months of follow-up. Results Recurrence was lower after isolated distal deep vein thrombosis than after proximal deep vein thrombosis (hazard ratio 0.49, 95% confidence interval 0.34 to 0.71), similar after pulmonary embolism and proximal deep vein thrombosis (1.19, 0.87 to 1.63), and lower after thrombosis provoked by a temporary risk factor than after unprovoked thrombosis (0.55, 0.41 to 0.74). Recurrence was higher if anticoagulation was stopped at 1.0 or 1. 5 months compared with at 3 months or later (hazard ratio 1.52, 1.14 to 2.02) and similar if treatment was stopped at 3 months compared with at 6 months or later (1.19, 0.86 to 1.65). High rates of recurrence associated with shorter durations of anticoagulation were confined to the first 6 months after stopping treatment. Conclusion Three months of treatment achieves a similar risk of recurrent venous thromboembolism after stopping anticoagulation to a longer course of treatment. Unprovoked proximal deep vein thrombosis and pulmonary embolism have a high risk of recurrence whenever treatment is stopped.	[Boutitie, Florent] CHU Lyon, Hosp Civils Lyon, Serv Biostat, UMR 5558, Lyon, France; [Pinede, Laurent] Infirm Protestante, Dept Internal Med, Lyon, France; [Schulman, Sam] Karolinska Hosp, S-10401 Stockholm, Sweden; [Schulman, Sam; Hirsh, Jack; Kearon, Clive] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Schulman, Sam; Hirsh, Jack; Kearon, Clive] Henderson Res Ctr, Hamilton, ON, Canada; [Agnelli, Giancarlo] Univ Perugia, Med Interna Cardiovasc Stroke Unit E, I-06100 Perugia, Italy; [Raskob, Gary] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK USA; [Julian, Jim] McMaster Univ, Dept Oncol, Hamilton, ON, Canada; [Julian, Jim] Henderson Res Ctr, Hamilton, ON, Canada	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); CHU Lyon; VetAgro Sup; Karolinska Institutet; Karolinska University Hospital; McMaster University; University of Perugia; University of Oklahoma System; University of Oklahoma Health Sciences Center; McMaster University	Kearon, C (corresponding author), Hamilton Hlth Sci, Henderson Div, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	kearonc@mcmaster.ca	Schulman, Sam/I-7559-2019	Schulman, Sam/0000-0002-8512-9043	French Ministry of Health [00.010]; Heart and Stroke Foundation of Ontario; Canadian Institutes of Health Research [FRN 79846]	French Ministry of Health; Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This study was supported by a grant from the French Ministry of Health (HCL-PHRC No 00.010). CK was supported by the Heart and Stroke Foundation of Ontario and by a Canadian Institutes of Health Research Team Grant in Venous Thromboembolism (FRN 79846). Sponsors of the analysis had no role in study design; the collection, analysis, and interpretation of data; or writing, review, or approval of the manuscript. The authors are independent of the sponsors.	Agnelli G, 2003, ANN INTERN MED, V139, P19, DOI 10.7326/0003-4819-139-1-200307010-00008; Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302; Baglin T, 2003, LANCET, V362, P523, DOI 10.1016/S0140-6736(03)14111-6; Campbell A, 2007, BMJ-BRIT MED J, V334, P674, DOI 10.1136/bmj.39098.583356.55; Douketis J, 2010, ANN INTERN MED, V153, P523, DOI 10.7326/0003-4819-153-8-201010190-00009; Eichinger S, 2004, ARCH INTERN MED, V164, P92, DOI 10.1001/archinte.164.1.92; Farraj RS, 2004, SAUDI MED J, V25, P848; FENNERTY AG, 1987, CLIN LAB HAEMATOL, V9, P17; Hansson PO, 2000, ARCH INTERN MED, V160, P769, DOI 10.1001/archinte.160.6.769; HOLMGREN KAJ, 1985, ACTA MED SCAND, V218, P279; Hutten BA, 2000, COCHRANE DB SYST REV, V3; Iorio A, 2010, ARCH INTERN MED, V170, P1710, DOI 10.1001/archinternmed.2010.367; Kearon C, 2004, J THROMB HAEMOST, V2, P743, DOI 10.1046/j.1538-7836.2004.00698.x; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Kearon C, 2008, CHEST, V133, p454S, DOI 10.1378/chest.08-0658; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; Ost D, 2005, JAMA-J AM MED ASSOC, V294, P706, DOI 10.1001/jama.294.6.706; OSULLIVAN EF, 1972, MED J AUSTRALIA, V2, P1104, DOI 10.5694/j.1326-5377.1972.tb103752.x; Pinede L, 2001, CIRCULATION, V103, P2453; Pinede L, 2000, J INTERN MED, V247, P553, DOI 10.1046/j.1365-2796.2000.00631.x; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Rodger MA, 2008, CAN MED ASSOC J, V179, P417, DOI 10.1503/cmaj.080493; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SUDLOW MF, 1992, LANCET, V340, P873; van Dongen CJ, 2003, ARCH INTERN MED, V163, P2793, DOI 10.1001/archinte.163.22.2793-a; Verhovsek M, 2008, ANN INTERN MED, V149, P481, DOI 10.7326/0003-4819-149-7-200810070-00008	30	242	256	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	2011	342								d3036	10.1136/bmj.d3036	http://dx.doi.org/10.1136/bmj.d3036			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771KC	21610040	Green Published, hybrid			2022-12-28	WOS:000291154600011
J	Muegge, BD; Kuczynski, J; Knights, D; Clemente, JC; Gonzalez, A; Fontana, L; Henrissat, B; Knight, R; Gordon, JI				Muegge, Brian D.; Kuczynski, Justin; Knights, Dan; Clemente, Jose C.; Gonzalez, Antonio; Fontana, Luigi; Henrissat, Bernard; Knight, Rob; Gordon, Jeffrey I.			Diet Drives Convergence in Gut Microbiome Functions Across Mammalian Phylogeny and Within Humans	SCIENCE			English	Article								Coevolution of mammals and their gut microbiota has profoundly affected their radiation into myriad habitats. We used shotgun sequencing of microbial community DNA and targeted sequencing of bacterial 16S ribosomal RNA genes to gain an understanding of how microbial communities adapt to extremes of diet. We sampled fecal DNA from 33 mammalian species and 18 humans who kept detailed diet records, and we found that the adaptation of the microbiota to diet is similar across different mammalian lineages. Functional repertoires of microbiome genes, such as those encoding carbohydrate-active enzymes and proteases, can be predicted from bacterial species assemblages. These results illustrate the value of characterizing vertebrate gut microbiomes to understand host evolutionary histories at a supraorganismal level.	[Muegge, Brian D.; Gordon, Jeffrey I.] Washington Univ, Sch Med, Ctr Genome Sci & Syst Biol, St Louis, MO 63108 USA; [Kuczynski, Justin; Knight, Rob] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; [Knights, Dan; Clemente, Jose C.; Gonzalez, Antonio] Univ Colorado, Dept Comp Sci, Boulder, CO 80309 USA; [Fontana, Luigi] Washington Univ, Sch Med, Dept Med, St Louis, MO 63108 USA; [Fontana, Luigi] Ist Super Sanita, Div Nutr & Aging, I-00161 Rome, Italy; [Henrissat, Bernard] CNRS, Marseille, France; [Henrissat, Bernard] Aix Marseille Univ, Marseille, France; [Knight, Rob] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	Washington University (WUSTL); University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Washington University (WUSTL); Istituto Superiore di Sanita (ISS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Gordon, JI (corresponding author), Washington Univ, Sch Med, Ctr Genome Sci & Syst Biol, St Louis, MO 63108 USA.	jgordon@wustl.edu	Gonzalez, Antonio/A-6421-2018; Fontana, Luigi/K-4773-2013; Knight, Rob/D-1299-2010; Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588; Fontana, Luigi/0000-0001-8500-5537; Knight, Rob/0000-0002-0975-9019; Muegge, Brian/0000-0002-0044-3704	NIH [DK30292, DK70977, DK078669, UL1 RR024992, T32-A1007172]; Crohn's and Colitis Foundation of America; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292, R01DK070977, P01DK078669, P30DK056341] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank J. Manchester and S. Wagoner for technical assistance; B. Cantarel, V. Lombard, C. Rancurel, and P. Coutinho for CAZyme annotation; R. Ley and members of the Gordon lab for their suggestions; and S. Bircher, R. Ramey, M. Schlegel, M. Schrenzel, T. Tucker, and P. Turnbaugh for past help in procuring mammalian fecal samples. This work was supported by grants from NIH (DK30292, DK70977, DK078669, and UL1 RR024992), the Crohn's and Colitis Foundation of America, and NIH Institutional Training Grant T32-A1007172 (to B.D.M.). The National Center for Biotechnology Information Sequence Read Archive accession number for the bacterial 16S rRNA and shotgun data sets related to our studies of mammalian and Calorie Restriction Society member human fecal microbiomes is SRA030940. Sequence data have also been deposited in MG-Rast with project accession numbers qiime:625, qiime:626, qiime:627, and qiime:628.	Cantarel BL, 2009, NUCLEIC ACIDS RES, V37, pD233, DOI 10.1093/nar/gkn663; Cerling TE, 1998, PHILOS T R SOC B, V353, P159, DOI 10.1098/rstb.1998.0198; Flint HJ, 2004, ADV APPL MICROBIOL, V56, P89, DOI 10.1016/S0065-2164(04)56003-3; Fontana L, 2007, JAMA-J AM MED ASSOC, V297, P986, DOI 10.1001/jama.297.9.986; GOWER JC, 1975, PSYCHOMETRIKA, V40, P33, DOI 10.1007/BF02291478; Haussler D, 2009, J HERED, V100, P659, DOI 10.1093/jhered/esp086; Heilbronn LK, 2006, JAMA-J AM MED ASSOC, V295, P1539, DOI 10.1001/jama.295.13.1539; HURLEY JR, 1962, BEHAV SCI, V7, P258, DOI 10.1002/bs.3830070216; Huson DH, 2007, GENOME RES, V17, P377, DOI 10.1101/gr.5969107; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kristiansson E, 2009, BIOINFORMATICS, V25, P2737, DOI 10.1093/bioinformatics/btp508; Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Poslusna K, 2009, BRIT J NUTR, V101, pS73, DOI 10.1017/S0007114509990602; Rawlings ND, 2010, NUCLEIC ACIDS RES, V38, pD227, DOI 10.1093/nar/gkp971; SCHAKEL SF, 1988, J AM DIET ASSOC, V88, P1268	17	1182	1221	13	504	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2011	332	6032					970	974		10.1126/science.1198719	http://dx.doi.org/10.1126/science.1198719			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596990	Green Accepted			2022-12-28	WOS:000290766600045
J	Najjar, SS; Rao, SV; Melloni, C; Raman, SV; Povsic, TJ; Melton, L; Barsness, GW; Prather, K; Heitner, JF; Kilaru, R; Gruberg, L; Hasselblad, V; Greenbaum, AB; Patel, M; Kim, RJ; Talan, M; Ferrucci, L; Longo, DL; Lakatta, EG; Harrington, RA				Najjar, Samer S.; Rao, Sunil V.; Melloni, Chiara; Raman, Subha V.; Povsic, Thomas J.; Melton, Laura; Barsness, Gregory W.; Prather, Kristi; Heitner, John F.; Kilaru, Rakhi; Gruberg, Luis; Hasselblad, Vic; Greenbaum, Adam B.; Patel, Manesh; Kim, Raymond J.; Talan, Mark; Ferrucci, Luigi; Longo, Dan L.; Lakatta, Edward G.; Harrington, Robert A.		REVEAL Investigators	Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction REVEAL: A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; ISCHEMIA; MORTALITY; AGE; ENHANCEMENT; EXPRESSION; EXPANSION; PROTECTS; CONTRAST; HYPOXIA	Context Acute ST-segment elevation myocardial infarction (STEMI) is a leading cause of morbidity and mortality. In experimental models of MI, erythropoietin reduces infarct size and improves left ventricular (LV) function. Objective To evaluate the safety and efficacy of a single intravenous bolus of epoetin alfa in patients with STEMI. Design, Setting, and Patients A prospective, randomized, double-blind, placebo-controlled trial with a dose-escalation safety phase and a single dose (60 000 U of epoetin alfa) efficacy phase; the Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (REVEAL) trial was conducted at 28 US sites between October 2006 and February 2010, and included 222 patients with STEMI who underwent successful percutaneous coronary intervention (PCI) as a primary or rescue reperfusion strategy. Intervention Participants were randomly assigned to treatment with intravenous epoetin alfa or matching saline placebo administered within 4 hours of reperfusion. Main Outcome Measure Infarct size, expressed as percentage of LV mass, assessed by cardiac magnetic resonance (CMR) imaging performed 2 to 6 days after study medication administration (first CMR) and again 12 +/- 2 weeks later (second CMR). Results In the efficacy cohort, the infarct size did not differ between groups on either the first CMR scan (n=136; 15.8% LV mass [95% confidence interval {CI}, 13.3-18.2% LV mass] for the epoetin alfa group vs 15.0% LV mass [95% CI, 12.6-17.3% LV mass] for the placebo group; P=.67) or on the second CMR scan (n=124; 10.6% LV mass [95% CI, 8.4-12.8% LV mass] vs 10.4% LV mass [95% CI, 8.5-12.3% LV mass], respectively; P=.89). In a prespecified analysis of patients aged 70 years or older (n=21), the mean infarct size within the first week (first CMR) was larger in the epoetin alfa group (19.9% LV mass; 95% CI, 14.0-25.7% LV mass) than in the placebo group (11.7% LV mass; 95% CI, 7.2-16.1% LV mass) (P=.03). In the safety cohort, of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke, or stent thrombosis occurred in 5 (4.0%; 95% CI, 1.31%-9.09%) but in none of the 97 who received placebo (P=.04). Conclusions In patients with STEMI who had successful reperfusion with primary or rescue PCI, a single intravenous bolus of epoetin alfa within 4 hours of PCI did not reduce infarct size and was associated with higher rates of adverse cardiovascular events. Subgroup analyses raised concerns about an increase in infarct size among older patients.	[Najjar, Samer S.] Washington Hosp Ctr, MedStar Hlth Res Inst, Washington, DC 20010 USA; [Najjar, Samer S.; Talan, Mark; Ferrucci, Luigi; Longo, Dan L.; Lakatta, Edward G.] NIA, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Rao, Sunil V.; Melloni, Chiara; Povsic, Thomas J.; Patel, Manesh; Kim, Raymond J.; Harrington, Robert A.] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC 27706 USA; [Rao, Sunil V.; Melloni, Chiara; Povsic, Thomas J.; Melton, Laura; Prather, Kristi; Kilaru, Rakhi; Hasselblad, Vic; Patel, Manesh; Harrington, Robert A.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Raman, Subha V.] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA; [Barsness, Gregory W.] Mayo Clin, Rochester, MN USA; [Heitner, John F.] New York Methodist Hosp, Brooklyn, NY USA; [Gruberg, Luis] SUNY Stony Brook, Med Ctr, Div Cardiol, Stony Brook, NY 11794 USA; [Greenbaum, Adam B.] Henry Ford Hlth Syst, Div Cardiol, W Bloomfield, MI USA	MedStar Health Research Institute; MedStar Washington Hospital Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Duke University; Duke University; University System of Ohio; Ohio State University; Mayo Clinic; NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Henry Ford Health System	Najjar, SS (corresponding author), Washington Hosp Ctr, MedStar Hlth Res Inst, 110 Irving St NW, Washington, DC 20010 USA.	Samer.S.Najjar@medstar.net	Lakatta, Edward G/AAL-1447-2020; Kim, Raymond J/B-1426-2008; Gruberg, Luis/ABF-8926-2021; Longo, Dan L./F-6022-2011; Patel, Manesh/AAC-5385-2019	Lakatta, Edward/0000-0002-4772-0035	Novartis; Cordis Corporation; Ikaria; National Institutes of Health; Siemens Corporation; Baxter International; Regado Biosciences; Theragen; Empire Clinical Research Investigator Program; Eli Lilly; Medicure Inc; National Institute on Aging [HHS-N-260-2005-00010-C]; Centocor Ortho Biotech nor Florida Biologix; NATIONAL INSTITUTE ON AGING [ZIAAG000243, ZIAAG000866] Funding Source: NIH RePORTER	Novartis(Novartis); Cordis Corporation; Ikaria; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Siemens Corporation; Baxter International; Regado Biosciences; Theragen; Empire Clinical Research Investigator Program; Eli Lilly(Eli Lilly); Medicure Inc; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Centocor Ortho Biotech nor Florida Biologix; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Najjar reported receiving research funding from HeartWare. Dr Rao reported receiving research funding from Novartis, Cordis Corporation, and Ikaria; and being a consultant for sanofi-aventis, Bristol-Meyers Squibb, Astra-Zeneca, Daiichi Sankyo-Lilly, and Terumo USA. Dr Raman reported receiving grant support from the National Institutes of Health and from Siemens Corporation. Dr Povsic reported receiving grants from Baxter International, Regado Biosciences, and Theragen. Dr Barsness reported being a consultant for Gilead Sciences Inc and receiving travel compensation from Novartis Pharmaceuticals Corporation. Dr Heitner reported that New York Methodist Hospital received compensation for his work as a principal investigator for a study; receiving compensation for his expert testimony in an individual malpractice case; receiving grant support from the Empire Clinical Research Investigator Program; and receiving compensation for serving on a steering committee for a trial. Dr Hasselblad reported receiving salary support via grants from Eli Lilly and Medicure Inc administered through Duke University. Dr Greenbaum reported receiving compensation from various law firms for expert testimony; compensation for serving on speakers bureaus for various companies; and owning stock or stock options in various other device and health care companies. Dr Patel reported being a board member for Genzyme's advisory board and Bayer Healthcare; and serving as a consultant for Ikaria. Dr Kim reported being an inventor on a US patent for Delayed Enhancement MRI, which is owned by Northwestern University. Dr Harrington reported that a complete listing of disclosure information is available at https://dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf. None of the other authors reported disclosures.; This study was supported by Intramural Research Program contract HHS-N-260-2005-00010-C from the National Institute on Aging.; The Duke Clinical Research Institute served as the coordinating center under contract from the National Institute on Aging. Investigators from the National Institute on Aging and the Duke Clinical Research Institute collaborated in designing and supervising the conduct of the study. Neither Centocor Ortho Biotech nor Florida Biologix provided funding or had input into the design or conduct of the study nor any input into data collection, data analysis, or the writing of the manuscript.	ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Antman EM, 2008, J AM COLL CARDIOL, V51, P2028, DOI [10.1016/j.jacc.2008.04.002, 10.1016/j.jacc.2007.10.001]; Bahlmann FH, 2004, BLOOD, V103, P921, DOI 10.1182/blood-2003-04-1284; Bennett CL, 2008, JAMA-J AM MED ASSOC, V299, P914, DOI 10.1001/jama.299.8.914; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Binbrek AS, 2009, AM J CARDIOL, V104, P1035, DOI 10.1016/j.amjcard.2009.05.050; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Chong ZZ, 2002, J HEMATOTH STEM CELL, V11, P863, DOI 10.1089/152581602321080529; DUDLEY RA, 1993, J CLIN EPIDEMIOL, V46, P261; EATON LW, 1979, NEW ENGL J MED, V300, P57, DOI 10.1056/NEJM197901113000202; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Ezekowitz JA, 2010, AM HEART J, V160, P272, DOI 10.1016/j.ahj.2010.05.035; Ferrario M, 2011, INT J CARDIOL, V147, P124, DOI 10.1016/j.ijcard.2009.10.028; Jennison C, 2000, GROUP SEQUENTIAL MET; Kim RJ, 2008, CIRCULATION, V117, P629, DOI 10.1161/CIRCULATIONAHA.107.723262; Kim RJ, 1999, CIRCULATION, V100, P1992, DOI 10.1161/01.CIR.100.19.1992; Kristensen J, 2005, CLIN PHYSIOL FUNCT I, V25, P305, DOI 10.1111/j.1475-097X.2005.00626.x; Liem A, 2009, INT J CARDIOL, V131, P285, DOI 10.1016/j.ijcard.2007.07.076; Lipsic E, 2006, J AM COLL CARDIOL, V48, P2161, DOI 10.1016/j.jacc.2006.08.031; Lipsic E, 2006, CARDIOVASC DRUG THER, V20, P135, DOI 10.1007/s10557-006-7680-5; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; Melloni C, 2010, AM HEART J, V160, P795, DOI 10.1016/j.ahj.2010.09.007; Moon C, 2005, CARDIOVASC DRUG THER, V19, P243, DOI 10.1007/s10557-005-3189-6; Moon C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/pnas.1930406100; Ott I, 2010, CIRC-CARDIOVASC INTE, V3, P408, DOI 10.1161/CIRCINTERVENTIONS.109.904425; Ozawa T, 2010, CIRC J, V74, P1415, DOI 10.1253/circj.CJ-10-0109; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Smith KJ, 2003, CARDIOVASC RES, V59, P538, DOI 10.1016/S0008-6363(03)00468-1; Suh JW, 2011, INT J CARDIOL, V149, P216, DOI 10.1016/j.ijcard.2010.02.002; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; Voors AA, 2010, EUR HEART J, V31, P2593, DOI 10.1093/eurheartj/ehq304; WEISMAN HF, 1987, PROG CARDIOVASC DIS, V30, P73, DOI 10.1016/0033-0620(87)90004-1; WEISS JL, 1991, AM J CARDIOL, V68, pD35; Wright GL, 2004, FASEB J, V18, P1031, DOI 10.1096/fj.03-1289fje; Yang YN, 2008, AM J PHYSIOL-HEART C, V294, pH1815, DOI 10.1152/ajpheart.00831.2007; Young John J, 2003, Rev Cardiovasc Med, V4, P216	40	177	187	2	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2011	305	18					1863	1872		10.1001/jama.2011.592	http://dx.doi.org/10.1001/jama.2011.592			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761YH	21558517	Green Accepted, Bronze			2022-12-28	WOS:000290438800023
J	Bland, JM; Altman, DG				Bland, J. Martin; Altman, Douglas G.			Comparisons within randomised groups can be very misleading	BMJ-BRITISH MEDICAL JOURNAL			English	Article									[Bland, J. Martin] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Altman, Douglas G.] Univ Oxford, Ctr Stat Med, Oxford OX2 6UD, England	University of York - UK; University of Oxford	Bland, JM (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	martin.bland@york.ac.uk						Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Bland JM, 2009, BRIT J DERMATOL, V161, P1207, DOI 10.1111/j.1365-2133.2009.09433.x; BLAND JM, 1993, BRIT MED J, V306, P928, DOI 10.1136/bmj.306.6882.928-b; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Watson REB, 2009, BRIT J DERMATOL, V161, P419, DOI 10.1111/j.1365-2133.2009.09216.x	5	25	25	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 6	2011	342								d561	10.1136/bmj.d561	http://dx.doi.org/10.1136/bmj.d561			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V41KN	21551184	Bronze			2022-12-28	WOS:000209545200001
J	Stefater, JA; Lewkowich, I; Rao, S; Mariggi, G; Carpenter, AC; Burr, AR; Fan, JQ; Ajima, R; Molkentin, JD; Williams, BO; Wills-Karp, M; Pollard, JW; Yamaguchi, T; Ferrara, N; Gerhardt, H; Lang, RA				Stefater, James A., III; Lewkowich, Ian; Rao, Sujata; Mariggi, Giovanni; Carpenter, April C.; Burr, Adam R.; Fan, Jieqing; Ajima, Rieko; Molkentin, Jeffery D.; Williams, Bart O.; Wills-Karp, Marsha; Pollard, Jeffrey W.; Yamaguchi, Terry; Ferrara, Napoleone; Gerhardt, Holger; Lang, Richard A.			Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RETINAL NEOVASCULARIZATION; MOUSE; MECHANISM; VASCULATURE; MACROPHAGES; TUMORIGENESIS; HETEROGENEITY; INHIBITION; RECEPTOR-1	Myeloid cells are a feature of most tissues. Here we show that during development, retinal myeloid cells (RMCs) produce Wnt ligands to regulate blood vessel branching. In the mouse retina, where angiogenesis occurs postnatally(1), somatic deletion in RMCs of the Wnt ligand transporter Wntless(2,3) results in increased angiogenesis in the deeper layers. We also show that mutation of Wnt5a and Wnt11 results in increased angiogenesis and that these ligands elicit RMC responses via a non-canonical Wnt pathway. Using cultured myeloid-like cells and RMC somatic deletion of Flt1, we show that an effector of Wnt-dependent suppression of angiogenesis by RMCs is Flt1, a naturally occurring inhibitor of vascular endothelial growth factor (VEGF)(4-6). These findings indicate that resident myeloid cells can use a non-canonical, Wnt-Flt1 pathway to suppress angiogenic branching.	[Stefater, James A., III; Rao, Sujata; Carpenter, April C.; Fan, Jieqing; Lang, Richard A.] Cincinnati Childrens Hosp, Visual Syst Grp, Div Pediat Ophthalmol, Med Ctr, Cincinnati, OH 45229 USA; [Stefater, James A., III; Rao, Sujata; Carpenter, April C.; Fan, Jieqing; Lang, Richard A.] Cincinnati Childrens Hosp, Div Dev Biol, Med Ctr, Cincinnati, OH 45229 USA; [Stefater, James A., III; Rao, Sujata] Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH 45229 USA; [Lewkowich, Ian; Wills-Karp, Marsha] Cincinnati Childrens Hosp, Div Immunobiol, Med Ctr, Cincinnati, OH 45229 USA; [Mariggi, Giovanni; Gerhardt, Holger] Canc Res UK, Vasc Biol Lab, London Res Inst, London WC2 3PX, England; [Burr, Adam R.; Molkentin, Jeffery D.] Univ Cincinnati, Div Mol Cardiovasc Biol, Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; [Ajima, Rieko; Yamaguchi, Terry] NCI, Canc & Dev Biol Lab, Frederick, MD 21701 USA; [Molkentin, Jeffery D.] Univ Cincinnati, Med Ctr, Howard Hughes Med Inst, Cincinnati Childrens Hosp, Cincinnati, OH 45229 USA; [Williams, Bart O.] Van Andel Res Inst, Ctr Skeletal Dis Res, Grand Rapids, MI 49503 USA; [Pollard, Jeffrey W.] Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Ferrara, Napoleone] Genentech Inc, San Francisco, CA 94080 USA; [Gerhardt, Holger] VIB, Vasc Patterning Lab, Vesalius Res Ctr, B-3000 Louvain, Belgium	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cancer Research UK; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cincinnati Children's Hospital Medical Center; Howard Hughes Medical Institute; University System of Ohio; University of Cincinnati; Van Andel Institute; Yeshiva University; Albert Einstein College of Medicine; Roche Holding; Genentech; Flanders Institute for Biotechnology (VIB)	Lang, RA (corresponding author), Cincinnati Childrens Hosp, Visual Syst Grp, Div Pediat Ophthalmol, Med Ctr, Cincinnati, OH 45229 USA.	richard.lang@cchmc.org	Williams, Bart/A-3539-2013; Lang, Richard/E-5578-2011; Burr, Adam/AAU-2980-2020; Gerhardt, Holger/G-4610-2011; Gerhardt, Holger/G-4610-2011	Williams, Bart/0000-0002-5261-5301; Gerhardt, Holger/0000-0002-3030-0384; Lang, Richard/0000-0002-5212-254X; Gerhardt, Holger/0000-0001-9228-7472; Molkentin, Jeffery/0000-0002-3558-6529	NIH; HHMI; Cancer Research UK; MRC [G1002033] Funding Source: UKRI; Medical Research Council [G1002033] Funding Source: researchfish; NATIONAL EYE INSTITUTE [R01EY015766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053293] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HHMI(Howard Hughes Medical Institute); Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank P. Speeg for technical assistance and A. P. McMahon for the Wnt11 mice. This work was supported by the NIH (J.A.S., M.W-K., J.W.P., J.D.M., T.Y., B.O.W., R.A.L.) by the HHMI (J.D.M.) and Cancer Research UK (H.G.).	Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249; Behringer R, 2003, MANIPULATING MOUSE E, P371; Blumenthal A, 2006, BLOOD, V108, P965, DOI 10.1182/blood-2005-12-5046; Bryja V, 2009, MOL BIOL CELL, V20, P924, DOI 10.1091/mbc.E08-07-0711; Carpenter AC, 2010, GENESIS, V48, P554, DOI 10.1002/dvg.20651; Chan CK, 2005, LAB INVEST, V85, P721, DOI 10.1038/labinvest.3700277; Chan CK, 2004, INVEST OPHTH VIS SCI, V45, P441, DOI 10.1167/iovs.03-0869; Chappell JC, 2009, DEV CELL, V17, P377, DOI 10.1016/j.devcel.2009.07.011; Ching W, 2006, CELL, V125, P432, DOI 10.1016/j.cell.2006.04.018; Deng L, 2010, AM J PATHOL, V176, P952, DOI 10.2353/ajpath.2010.090622; Fantin A, 2010, BLOOD, V116, P829, DOI 10.1182/blood-2009-12-257832; Gao GQ, 2002, DIABETES, V51, P1218, DOI 10.2337/diabetes.51.4.1218; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Haigh JJ, 2003, DEV BIOL, V262, P225, DOI 10.1016/S0012-1606(03)00356-7; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Lin SL, 2010, P NATL ACAD SCI USA, V107, P4194, DOI 10.1073/pnas.0912228107; Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928; Machnik A, 2009, NAT MED, V15, P545, DOI 10.1038/nm.1960; Majumdar A, 2003, DEVELOPMENT, V130, P3175, DOI 10.1242/dev.00520; Martin P, 2003, CURR BIOL, V13, P1122, DOI 10.1016/S0960-9822(03)00396-8; Mendes-Jorge L, 2009, INVEST OPHTH VIS SCI, V50, P5997, DOI 10.1167/iovs.09-3515; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms; Seifert JRK, 2007, NAT REV GENET, V8, P126, DOI 10.1038/nrg2042; Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Tauber AI, 2003, NAT REV MOL CELL BIO, V4, P897, DOI 10.1038/nrm1244; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211	35	196	199	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 23	2011	474	7352					511	515		10.1038/nature10085	http://dx.doi.org/10.1038/nature10085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	781NJ	21623369	Green Accepted			2022-12-28	WOS:000291939700049
J	Purdy, KS; Langley, RG; Webb, AN; Walsh, N; Haldane, D				Purdy, Kerri S.; Langley, Richard G.; Webb, Amanda N.; Walsh, Noreen; Haldane, David			Cutaneous larva migrans	LANCET			English	Editorial Material									[Purdy, Kerri S.; Langley, Richard G.] Dalhousie Univ, Div Dermatol, Halifax, NS, Canada; [Webb, Amanda N.] Dalhousie Univ, Dept Med, Halifax, NS, Canada; [Walsh, Noreen] Dalhousie Univ, Div Anat Pathol, Halifax, NS, Canada; [Haldane, David] Dalhousie Univ, Dept Pathol & Lab Med, Div Infect Dis, Halifax, NS, Canada	Dalhousie University; Dalhousie University; Dalhousie University; Dalhousie University	Langley, RG (corresponding author), 4-195 Dickson Bldg,QE11 Hlth Sci Ctr,5820 Univ Av, Halifax, NS B3H 1V7, Canada.	richard.langley@dal.ca							0	11	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 4	2011	377	9781					1948	1948		10.1016/S0140-6736(10)61149-X	http://dx.doi.org/10.1016/S0140-6736(10)61149-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777LW	21601273	Bronze			2022-12-28	WOS:000291623200031
J	Mac Donald, CL; Johnson, AM; Cooper, D; Nelson, EC; Werner, NJ; Shimony, JS; Snyder, AZ; Raichle, ME; Witherow, JR; Fang, R; Flaherty, SF; Brody, DL				Mac Donald, Christine L.; Johnson, Ann M.; Cooper, Dana; Nelson, Elliot C.; Werner, Nicole J.; Shimony, Joshua S.; Snyder, Abraham Z.; Raichle, Marcus E.; Witherow, John R.; Fang, Raymond; Flaherty, Stephen F.; Brody, David L.			Detection of Blast-Related Traumatic Brain Injury in U.S. Military Personnel	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; WHITE-MATTER INJURY; CLOSED-HEAD INJURY; MILD; VETERANS; MEMORY; MODEL; TIME; IRAQ	Background Blast-related traumatic brain injuries have been common in the Iraq and Afghanistan wars, but fundamental questions about the nature of these injuries remain unanswered. Methods We tested the hypothesis that blast-related traumatic brain injury causes traumatic axonal injury, using diffusion tensor imaging (DTI), an advanced form of magnetic resonance imaging that is sensitive to axonal injury. The subjects were 63 U. S. military personnel who had a clinical diagnosis of mild, uncomplicated traumatic brain injury. They were evacuated from the field to the Landstuhl Regional Medical Center in Landstuhl, Germany, where they underwent DTI scanning within 90 days after the injury. All the subjects had primary blast exposure plus another, blast-related mechanism of injury (e. g., being struck by a blunt object or injured in a fall or motor vehicle crash). Controls consisted of 21 military personnel who had blast exposure and other injuries but no clinical diagnosis of traumatic brain injury. Results Abnormalities revealed on DTI were consistent with traumatic axonal injury in many of the subjects with traumatic brain injury. None had detectible intracranial injury on computed tomography. As compared with DTI scans in controls, the scans in the subjects with traumatic brain injury showed marked abnormalities in the middle cerebellar peduncles (P<0.001), in cingulum bundles (P=0.002), and in the right orbitofrontal white matter (P=0.007). In 18 of the 63 subjects with traumatic brain injury, a significantly greater number of abnormalities were found on DTI than would be expected by chance (P<0.001). Follow-up DTI scans in 47 subjects with traumatic brain injury 6 to 12 months after enrollment showed persistent abnormalities that were consistent with evolving injuries. Conclusions DTI findings in U. S. military personnel support the hypothesis that blast-related mild traumatic brain injury can involve axonal injury. However, the contribution of primary blast exposure as compared with that of other types of injury could not be determined directly, since none of the subjects with traumatic brain injury had isolated primary blast injury. Furthermore, many of these subjects did not have abnormalities on DTI. Thus, traumatic brain injury remains a clinical diagnosis. (Funded by the Congressionally Directed Medical Research Program and the National Institutes of Health; ClinicalTrials.gov number, NCT00785304.)	[Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Witherow, John R.; Fang, Raymond; Flaherty, Stephen F.] Landstuhl Reg Med Ctr, Landstuhl, Germany; [Flaherty, Stephen F.] Walter Reed Army Med Ctr, Washington, DC 20307 USA	Washington University (WUSTL); Landstuhl Regional Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, Biotech Bldg,Rm 201,660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			Congressionally Directed Medical Research Program [W81XWH-08-2-0061]; National Institutes of Health [F32NS062529, 5K23HD053212, P30NS048056, P50NS06833, 5K08NS49237]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K23HD053212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS048056, F32NS062529, K08NS049237, P50NS006833] Funding Source: NIH RePORTER	Congressionally Directed Medical Research Program(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by a grant from the Congressionally Directed Medical Research Program (W81XWH-08-2-0061, to Dr. Brody) and the National Institutes of Health (F32NS062529, to Dr. Mac Donald; 5K23HD053212, to Dr. Shimony; P30NS048056, to Dr. Snyder; P50NS06833, to Drs. Raichle and Snyder; and 5K08NS49237, to Dr. Brody.)	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI [10.1089/neu.2009.0885, 10.1089/neu.2009-0885]; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; Dempsey Kenneth E, 2009, J Trauma Nurs, V16, P6, DOI 10.1097/01.JTN.0000348063.41099.a7; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mori S., 2005, MRI ATLAS HUMAN WHIT; Mott FW, 1917, J ROY ARMY MED CORPS, V29, P662; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P441, DOI 10.1023/A:1007781107513; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110	43	446	449	2	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2091	2100		10.1056/NEJMoa1008069	http://dx.doi.org/10.1056/NEJMoa1008069			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AB	21631321	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000291200700007
J	Smith, TJ; Hillner, BE				Smith, Thomas J.; Hillner, Bruce E.			Bending the Cost Curve in Cancer Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CELL LUNG-CANCER; 2006 UPDATE; FEBRILE NEUTROPENIA; PALLIATIVE CARE; ONCOLOGY; LIFE; CHEMOTHERAPY; END; GUIDELINES; HEALTH		[Smith, Thomas J.] Virginia Commonwealth Univ, Div Hematol Oncol & Palliat Care, Richmond, VA 23284 USA; [Hillner, Bruce E.] Virginia Commonwealth Univ, Div Gen Internal Med, Richmond, VA 23284 USA; [Smith, Thomas J.; Hillner, Bruce E.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23284 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Smith, TJ (corresponding author), Virginia Commonwealth Univ, Div Hematol Oncol & Palliat Care, Richmond, VA 23284 USA.			Smith, Thomas/0000-0003-3040-6434	NCI NIH HHS [P30 CA006973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaron HJ, 2009, HEALTH AFFAIR, V28, P1260, DOI 10.1377/hlthaff.28.5.1260; [Anonymous], 1996, J CLIN ONCOL, V14, P671; Azzoli CG, 2009, J CLIN ONCOL, V27, P6251, DOI 10.1200/JCO.2009.23.5622; Bach PB, 2009, NEW ENGL J MED, V360, P626, DOI 10.1056/NEJMhpr0807774; Blayney DW, 2009, J CLIN ONCOL, V27, P3802, DOI 10.1200/JCO.2008.21.6770; Bodenheimer T, 2007, ANN INTERN MED, V146, P301, DOI 10.7326/0003-4819-146-4-200702200-00011; Bohlius J., 2008, COCHRANE DB SYST REV, V4; Brickates Kennedy V, 2010, MARKETWATCH     1025; Brody H, 2010, NEW ENGL J MED, V362, P283, DOI 10.1056/NEJMp0911423; Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Cardoso F, 2009, JNCI-J NATL CANCER I, V101, P1174, DOI 10.1093/jnci/djp235; Carlson RW, 2009, J NATL COMPR CANC NE, V7, P122, DOI 10.6004/jnccn.2009.0012; Carrick S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003372.pub3; Chiew KS, 2008, HEALTH EXPECT, V11, P35, DOI 10.1111/j.1369-7625.2007.00470.x; Clement FM, 2009, JAMA-J AM MED ASSOC, V302, P1437, DOI 10.1001/jama.2009.1409; Connor SR, 2007, J PAIN SYMPTOM MANAG, V33, P238, DOI 10.1016/j.jpainsymman.2006.10.010; Donovan RJ, 2006, LANCET ONCOL, V7, P668, DOI 10.1016/S1470-2045(06)70794-X; Dow LA, 2010, J CLIN ONCOL, V28, P299, DOI 10.1200/JCO.2009.24.6397; Eastern Cooperative Oncology Group, ECOG PERF STAT; Elkin EB, 2010, JAMA-J AM MED ASSOC, V303, P1086, DOI 10.1001/jama.2010.283; Ettinger DS, 2010, J NATL COMPR CANC NE, V8, P740, DOI 10.6004/jnccn.2010.0056; Finn JW, 2002, P AN M AM SOC CLIN, V21, P1452; Fojo T, 2009, JNCI-J NATL CANCER I, V101, P1044, DOI 10.1093/jnci/djp177; Gade G, 2008, J PALLIAT MED, V11, P180, DOI 10.1089/jpm.2007.0055; Harrington SE, 2008, JAMA-J AM MED ASSOC, V299, P2667, DOI 10.1001/jama.299.22.2667; Hillner BE, 2009, J CLIN ONCOL, V27, P2111, DOI 10.1200/JCO.2008.21.0534; Hortobagyi GN, 2007, J CLIN ONCOL, V25, P1468, DOI 10.1200/JCO.2007.10.9397; Huskamp HA, 2009, ARCH INTERN MED, V169, P954, DOI 10.1001/archinternmed.2009.127; Jackson VA, 2008, J PALLIAT MED, V11, P893, DOI 10.1089/jpm.2007.2480; Jacobson JO, 2008, J CLIN ONCOL, V26, P1893, DOI 10.1200/JCO.2007.14.2992; Jacobson M, 2006, HEALTH AFFAIR, V25, P437, DOI 10.1377/hlthaff.25.2.437; Jacobson M, 2010, HEALTH AFFAIR, V29, P1391, DOI 10.1377/hlthaff.2009.0563; Johnson A, 2010, WALL STREET J   1019; Keating NL, 2010, CANCER-AM CANCER SOC, V116, P998, DOI 10.1002/cncr.24761; Kelly K, 2011, 1 LINE CHEMOTHERAPY; Khatcheressian JL, 2006, J CLIN ONCOL, V24, P5091, DOI 10.1200/JCO.2006.08.8575; Kuderer NM, 2007, J CLIN ONCOL, V25, P3158, DOI 10.1200/JCO.2006.08.8823; Levy AR, 2010, PHARMACOECONOMICS, V28, P813, DOI 10.2165/11536150-000000000-00000; Locker GY, 2006, J CLIN ONCOL, V24, P5313, DOI 10.1200/JCO.2006.08.2644; Loprinzi Charles L, 2003, J Clin Oncol, V21, p108s, DOI 10.1200/JCO.2003.01.190; Mariotto AB, 2011, JNCI-J NATL CANCER I, V103, P117, DOI 10.1093/jnci/djq495; Matsuyama R, 2006, J CLIN ONCOL, V24, P3490, DOI 10.1200/JCO.2005.03.6236; National Cancer Institute, CANC TRENDS PROGR RE; Neubauer MA, 2010, J ONCOL PRACT, V6, P12, DOI 10.1200/JOP.091058; Pearson SD, 2010, HEALTH AFFAIR, V29, P1796, DOI 10.1377/hlthaff.2010.0623; Peppercorn JM, 2011, J CLIN ONCOL, V29, P755, DOI 10.1200/JCO.2010.33.1744; Pyenson B, 2004, J PAIN SYMPTOM MANAG, V28, P200, DOI 10.1016/j.jpainsymman.2004.05.003; Rustin GJS, 2010, LANCET, V376, P1155, DOI 10.1016/S0140-6736(10)61268-8; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V265, P380, DOI 10.1001/jama.265.3.380; Sepucha KR, 2009, MED DECIS MAKING, V29, P475, DOI 10.1177/0272989X09333124; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Smith Thomas J, 2011, J Support Oncol, V9, P79; Smith TJ, 2010, ONCOLOGY-NY, V24, P521; Smith TJ, 2010, ONCOLOGIST, V15, P65, DOI 10.1634/theoncologist.2010-S1-65; Smith TJ, 2010, J CLIN ONCOL, V28, pE128, DOI 10.1200/JCO.2009.26.8243; SMITH TJ, 1995, J CLIN ONCOL, V13, P2464, DOI 10.1200/JCO.1995.13.9.2464; Smith TJ, 2005, J CLIN ONCOL, V23, P6807, DOI 10.1200/JCO.2005.01.5545; Spettell CM, 2009, J PALLIAT MED, V12, P827, DOI 10.1089/jpm.2009.0089; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Timmer-Bonte JNH, 2008, J CLIN ONCOL, V26, P290, DOI 10.1200/JCO.2007.13.0898; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Yabroff KR, 2008, JNCI-J NATL CANCER I, V100, P630, DOI 10.1093/jnci/djn103; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	63	306	308	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					2060	2065		10.1056/NEJMsb1013826	http://dx.doi.org/10.1056/NEJMsb1013826			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QR	21612477	Green Accepted			2022-12-28	WOS:000290952000015
J	Alehagen, U; Dahlstrom, U; Rehfeld, JF; Goetze, JP				Alehagen, Urban; Dahlstroem, Ulf; Rehfeld, Jens F.; Goetze, Jens P.			Association of Copeptin and N-Terminal proBNP Concentrations With Risk of Cardiovascular Death in Older Patients With Symptoms of Heart Failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ARGININE-VASOPRESSIN INCREASES; LEFT-VENTRICULAR DYSFUNCTION; NATRIURETIC PEPTIDE; PROVASOPRESSIN COPEPTIN; PROGNOSTIC MARKER; DIAGNOSIS; PLASMA; BNP	Context Measurement of plasma concentrations of the biomarker copeptin may help identify patients with heart failure at high and low risk of mortality, although the value of copeptin measurement in elderly patients is not fully known. Objective To evaluate the association between plasma concentrations of copeptin, a surrogate marker of vasopressin, combined with concentrations of the N-terminal fragment of the precursor to B-type natriuretic peptide (NT-proBNP), and mortality in a cohort of elderly patients with symptoms of heart failure. Design, Setting, and Participants Primary health care population in Sweden enrolling 470 elderly patients with heart failure symptoms between January and December 1996. Clinical examination, echocardiography, and measurement of peptide concentrations were performed, with follow-up through December 2009. Main Outcome Measures All-cause mortality and cardiovascular mortality. Results After a median follow-up of 13 years, there were 226 deaths from all causes, including 146 deaths from cardiovascular causes. Increased concentration of copeptin was associated with increased risk of all-cause mortality (fourth quartile vs first quartile: 69.5% vs 38.5%, respectively; hazard ratio [HR], 2.04 [95% confidence interval {CI}, 1.38-3.02]) and cardiovascular mortality (fourth quartile vs first quartile: 46.6% vs 26.5%; HR, 1.94 [95% CI, 1.20-3.13]). The combination of elevated NT-proBNP concentrations and elevated copeptin concentrations also was associated with increased risk of all-cause mortality (copeptin fourth quartile: HR, 1.63 [95% CI, 1.08-2.47]; P=.01; NT-proBNP fourth quartile: HR, 3.17 [95% CI, 2.02-4.98]; P<.001). Using the 2 biomarkers simultaneously in the evaluation of cardiovascular mortality, there was a significant association for copeptin in the presence of NT-proBNP (log likelihood trend test, P=.048) and a significant association for NT-proBNP (fourth quartile: HR, 4.68 [95% CI 2.63-8.34]; P<.001). Conclusion Among elderly patients with symptoms of heart failure, elevated concentrations of copeptin and the combination of elevated concentrations of copeptin and NT-proBNP were associated with increased risk of all-cause mortality. JAMA. 2011; 305(20): 2088-2095	[Alehagen, Urban; Dahlstroem, Ulf] Linkoping Univ, Div Cardiovasc Med, Dept Med & Hlth Sci,Cty Council Ostergotland, Fac Hlth Sci,Dept Cardiol UHL, SE-58185 Linkoping, Sweden; [Rehfeld, Jens F.; Goetze, Jens P.] Univ Copenhagen, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark	City Council Ostergotland; Linkoping University; Rigshospitalet; University of Copenhagen	Alehagen, U (corresponding author), Linkoping Univ, Dept Cardiol, Ctr Heart, SE-58185 Linkoping, Sweden.	urban.alehagen@liu.se		Goetze, Jens Peter/0000-0001-6356-3829	County Council of Ostergotland; Swedish Heart and Lung Foundation; University of Linkoping	County Council of Ostergotland; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); University of Linkoping	This study was supported by grants from the County Council of Ostergotland, the Swedish Heart and Lung Foundation, and the University of Linkoping.	Alehagen U., 2002, HeartDrug, V2, P211, DOI 10.1159/000067723; Alehagen U, 2003, CLIN CHEM, V49, P1337, DOI 10.1373/49.8.1337; Apple FS, 2003, CLIN CHIM ACTA, V328, P191, DOI 10.1016/S0009-8981(02)00374-1; Chatterjee K, 2005, AM J CARDIOL, V95, p8B, DOI 10.1016/j.amjcard.2005.03.003; CHOY AMJ, 1994, BRIT HEART J, V72, P16; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Dieplinger B, 2009, HEART, V95, P1508, DOI 10.1136/hrt.2009.170696; EBERT TJ, 1986, J CLIN INVEST, V77, P1136, DOI 10.1172/JCI112413; Fan YH, 2007, LIFE SCI, V81, P327, DOI 10.1016/j.lfs.2007.05.018; Fukuzawa J, 1999, MOL CELL BIOCHEM, V195, P93, DOI 10.1023/A:1006980517557; Gegenhuber A, 2004, CLIN CHEM, V50, P454, DOI 10.1373/clinchem.2003.028712; Jensen-Urstad K, 1998, AM J CARDIOL, V81, P538, DOI 10.1016/S0002-9149(97)00964-8; Jochberger S, 2009, CRIT CARE MED, V37, P476, DOI 10.1097/CCM.0b013e3181957532; Keller T, 2010, J AM COLL CARDIOL, V55, P2096, DOI 10.1016/j.jacc.2010.01.029; Khan SQ, 2007, CIRCULATION, V115, P2103, DOI 10.1161/CIRCULATIONAHA.106.685503; McCullough PA, 2002, CIRCULATION, V106, P416, DOI 10.1161/01.CIR.0000025242.79963.4C; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X; Mebazaa A, 2007, JAMA-J AM MED ASSOC, V297, P1883, DOI 10.1001/jama.297.17.1883; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Mosterd A, 1999, EUR HEART J, V20, P447, DOI 10.1053/euhj.1998.1239; MOYE LA, 1991, AM J CARDIOL, V68, pD70; Nakamura T, 2006, INT J CARDIOL, V106, P191, DOI 10.1016/j.ijcard.2005.01.043; Neuhold S, 2008, J AM COLL CARDIOL, V52, P266, DOI 10.1016/j.jacc.2008.03.050; Swedberg K, 1999, J Card Fail, V5, P276, DOI 10.1016/S1071-9164(99)90013-1; URETSKY BF, 1985, AM J PHYSIOL, V248, pH396, DOI 10.1152/ajpheart.1985.248.3.H396; vanRoyen N, 1996, AM J CARDIOL, V77, P843, DOI 10.1016/S0002-9149(97)89179-5; Voors AA, 2009, EUR HEART J, V30, P1187, DOI 10.1093/eurheartj/ehp098	27	110	130	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2011	305	20					2088	2095		10.1001/jama.2011.666	http://dx.doi.org/10.1001/jama.2011.666			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768AC	21610241				2022-12-28	WOS:000290901700022
J	Northcutt, RG				Northcutt, R. Glenn			Evolving Large and Complex Brains	SCIENCE			English	Editorial Material							EVOLUTION		[Northcutt, R. Glenn] Univ Calif San Diego, Scripps Inst Oceanog, Lab Comparat Neurobiol, La Jolla, CA 92093 USA; [Northcutt, R. Glenn] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of California System; University of California San Diego	Northcutt, RG (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Lab Comparat Neurobiol, La Jolla, CA 92093 USA.	rgnorthcutt@ucsd.edu						Alonso PD, 2004, NATURE, V430, P666, DOI 10.1038/nature02706; Bruce L.L., 2007, P125; Burish MJ, 2004, BRAIN BEHAV EVOLUT, V63, P107, DOI 10.1159/000075674; Hopson J.A., 1979, P39; HOPSON JA, 1977, ANNU REV ECOL SYST, V8, P429, DOI 10.1146/annurev.es.08.110177.002241; Karten HJ, 1997, P NATL ACAD SCI USA, V94, P2800, DOI 10.1073/pnas.94.7.2800; Kenward B, 2005, NATURE, V433, P121, DOI 10.1038/433121a; Kundrat M, 2007, NATURWISSENSCHAFTEN, V94, P499, DOI 10.1007/s00114-007-0219-1; NORTHCUTT RG, 1995, TRENDS NEUROSCI, V18, P373; Reiner A, 2005, ANAT REC PART A, V287A, P1080, DOI 10.1002/ar.a.20253; Rowe TB, 2011, SCIENCE, V332, P955, DOI 10.1126/science.1203117; Striedter GF, 1997, BRAIN BEHAV EVOLUT, V49, P179, DOI 10.1159/000112991; van Dongen P.A.M., 1998, P2099	13	16	16	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2011	332	6032					926	927		10.1126/science.1206915	http://dx.doi.org/10.1126/science.1206915			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596983				2022-12-28	WOS:000290766600031
J	Cohen, MS; Shaw, GM; McMichael, AJ; Haynes, BF				Cohen, Myron S.; Shaw, George M.; McMichael, Andrew J.; Haynes, Barton F.			MEDICAL PROGRESS Acute HIV-1 Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; ANTIRETROVIRAL THERAPY; SEXUAL TRANSMISSION; INTEGRIN ALPHA(4)BETA(7); PARTNER NOTIFICATION; RESPONSES; STAGE; SIV; VIREMIA	IN 2009, THE UNITED NATIONS ESTIMATED THAT 33.2 MILLION PEOPLE worldwide were living with human immunodeficiency virus type 1 (HIV-1) infection and that 2.6 million people had been newly infected.(1) The need for effective HIV-1 prevention has never been greater. In this review, we address recent critical advances in our understanding of HIV-1 transmission and acute HIV-1 infection. Fourth-generation HIV-1 testing, now available worldwide,(2,3) will allow the diagnosis of infection in many patients and may lead to new treatments and opportunities for prevention.	[Cohen, Myron S.] Univ N Carolina, Inst Global Hlth & Infect Dis, Chapel Hill, NC USA; [Haynes, Barton F.] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC USA; [Shaw, George M.] Univ Alabama Birmingham, Birmingham, AL USA; [McMichael, Andrew J.] Univ Oxford, Weatherall Inst Mol Med, Oxford, England; [McMichael, Andrew J.] Univ Oxford, Natl Inst Hlth Res, Biomed Res Ctr, Oxford, England	University of North Carolina; University of North Carolina Chapel Hill; Duke University; University of Alabama System; University of Alabama Birmingham; University of Oxford; University of Oxford	Cohen, MS (corresponding author), 2031 Bioinformat Bldg,130 Mason Farm Rd, Chapel Hill, NC 27517 USA.	mscohen@med.unc.edu			National Institutes of Health; Center for HIV-AIDS Vaccine Immunology; GlaxoSmith-Kline; Merck; Peregrine Pharmaceuticals; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067854] Funding Source: NIH RePORTER; MRC [MC_U137884177] Funding Source: UKRI; Medical Research Council [MC_U137884177] Funding Source: researchfish	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for HIV-AIDS Vaccine Immunology; GlaxoSmith-Kline(GlaxoSmithKline); Merck(Merck & Company); Peregrine Pharmaceuticals; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the National Institutes of Health and the Center for HIV-AIDS Vaccine Immunology.; Dr. Cohen reports receiving consulting fees from GlaxoSmith-Kline and Merck; Dr. McMichael, receiving payment for the development of educational presentations from Henry Stewart Talks; and Dr. Haynes, receiving a research grant from Peregrine Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.	Abrahams MR, 2009, J VIROL, V83, P3556, DOI 10.1128/JVI.02132-08; Abu-Raddad LJ, 2008, AIDS, V22, P1055, DOI 10.1097/QAD.0b013e3282f8af84; Alter G, 2007, J EXP MED, V204, P3027, DOI 10.1084/jem.20070695; [Anonymous], 2010, PREEXP PROPH PREEP H; Archin N, 2010, 17 C RETR OPP INF SA; Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566; Bar KJ, 2010, J VIROL, V84, P6241, DOI 10.1128/JVI.00077-10; Bell SK, 2010, J INFECT DIS, V202, pS278, DOI 10.1086/655655; Boggiano C, 2007, IMMUNITY, V26, P145, DOI 10.1016/j.immuni.2007.02.001; Bonsignori M, 2009, J IMMUNOL, V183, P2708, DOI 10.4049/jimmunol.0901068; Borrow P, 2008, CURR OPIN HIV AIDS, V3, P36, DOI 10.1097/COH.0b013e3282f2bce7; Branson BM, 2007, CLIN INFECT DIS, V45, pS221, DOI 10.1086/522541; Brenchley JM, 2008, CURR OPIN HIV AIDS, V3, P356, DOI 10.1097/COH.0b013e3282f9ae9c; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Brenner BG, 2007, J INFECT DIS, V195, P951, DOI 10.1086/512088; Brown LB, 2011, JAIDS-J ACQ IMM DEF, V56, P437, DOI 10.1097/QAI.0b013e318202bf7d; Burns DN, 2010, CLIN INFECT DIS, V51, P725, DOI 10.1086/655889; Chun TW, 2007, J INFECT DIS, V195, P1762, DOI 10.1086/518250; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Cicala C, 2009, P NATL ACAD SCI USA, V106, P20877, DOI 10.1073/pnas.0911796106; Cohen MS, 2007, ANN INTERN MED, V146, P591, DOI 10.7326/0003-4819-146-8-200704170-00010; Coutinho FAB, 2001, B MATH BIOL, V63, P1041, DOI 10.1006/bulm.2001.0257; Daar ES, 2008, CURR OPIN HIV AIDS, V3, P10, DOI 10.1097/COH.0b013e3282f2e295; Damond F, 2010, J CLIN MICROBIOL, V48, P1413, DOI 10.1128/JCM.01409-09; Emau Peter, 2006, AIDS Res Ther, V3, P29, DOI 10.1186/1742-6405-3-29; Eshleman SH, 2009, JAIDS-J ACQ IMM DEF, V52, P121, DOI 10.1097/QAI.0b013e3181ab61e1; Ferrari G, 2010, AIDS RES HUM RETROV, V26, pA5; Fidler S, 2008, CURR OPIN INFECT DIS, V21, P4, DOI 10.1097/QCO.0b013e3282f428bf; Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005; Fischer W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012303; Garcia-Lerma JG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000391; Gasper-Smith N, 2008, J VIROL, V82, P7700, DOI 10.1128/JVI.00605-08; Gay Cynthia L, 2008, Curr Infect Dis Rep, V10, P323, DOI 10.1007/s11908-008-0052-5; Golden MR, 2009, AIDS, V23, P133, DOI 10.1097/QAD.0b013e32831fb52f; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Haaland RE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000274; Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757; Hansasuta P, 2004, EUR J IMMUNOL, V34, P1673, DOI 10.1002/eji.200425089; Hayes RJ, 2006, J INFECT DIS, V193, P604, DOI 10.1086/499606; Haynes BF, 2010, CURR OPIN HIV AIDS, V5, P362, DOI 10.1097/COH.0b013e32833d2e90; Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917; Hightow LB, 2005, JAIDS-J ACQ IMM DEF, V38, P531, DOI 10.1097/01.qai.0000155037.10628.cb; Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302; Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007; Hollingsworth TD, 2008, J INFECT DIS, V198, P687, DOI 10.1086/590501; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; Kader M, 2009, MUCOSAL IMMUNOL, V2, P439, DOI 10.1038/mi.2009.90; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Keele BF, 2009, J EXP MED, V206, P1117, DOI 10.1084/jem.20082831; Koopman JS, 1997, J ACQ IMMUN DEF SYND, V14, P249, DOI 10.1097/00042560-199703010-00009; Kramer HB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000893; Kretzschmar M, 1998, MATH BIOSCI, V148, P83, DOI 10.1016/S0025-5564(97)10008-6; Lackner AA, 2007, ANNU REV MED, V58, P461, DOI 10.1146/annurev.med.58.082405.094316; Lee HY, 2009, J THEOR BIOL, V261, P341, DOI 10.1016/j.jtbi.2009.07.038; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Li H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000890; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Lichterfeld M, 2004, AIDS, V18, P1383, DOI 10.1097/01.aids.0000131329.51633.a3; Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469; Ma ZM, 2009, J VIROL, V83, P3288, DOI 10.1128/JVI.02423-08; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Masharsky AE, 2010, J INFECT DIS, V201, P1697, DOI 10.1086/652702; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mayer KH, 2010, AM J PUBLIC HEALTH, V100, P1867, DOI 10.2105/AJPH.2009.184796; McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Miller WC, 2010, CURR OPIN HIV AIDS, V5, P277, DOI 10.1097/COH.0b013e32833a0d3a; Moir S, 2010, BLOOD, V116, P5571, DOI 10.1182/blood-2010-05-285528; Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006; Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233; Murray JM, 2007, AIDS, V21, P2315, DOI 10.1097/QAD.0b013e3282f12377; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Pettifor A, 2010, AIDS BEHAV      1027; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; Pinkerton SD, 1996, EVALUATION REV, V20, P516, DOI 10.1177/0193841X9602000502; Pinkerton SD, 2008, AIDS BEHAV, V12, P677, DOI 10.1007/s10461-007-9329-1; Pinkerton SD, 2007, AIDS, V21, P1625, DOI 10.1097/QAD.0b013e32826fb6a6; Pollara J, 2010, AIDS RES HUM RETROV, V26, pA12; Powers K, 2010, 18 INT AIDS C VIENN; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Ribeiro RM, 2010, J VIROL, V84, P6096, DOI 10.1128/JVI.00127-10; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706; Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378; Salomon JA, 2008, AIDS, V22, pS149, DOI 10.1097/01.aids.0000327636.82542.87; Schacker T, 2001, J INFECT DIS, V183, P555, DOI 10.1086/318524; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Sickinger E, 2008, TRANSFUSION, V48, P584, DOI 10.1111/j.1537-2995.2007.01583.x; Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08; Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; UNAIDS, 2010, GLOB REP 2010; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Weiss HA, 2010, AIDS, V24, pS61, DOI 10.1097/01.aids.0000390708.66136.f4; Xiridou M, 2004, AIDS, V18, P1311, DOI 10.1097/00002030-200406180-00010; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zhang ZQ, 1999, SCIENCE, V286, P2273; Zhang ZQ, 2004, P NATL ACAD SCI USA, V101, P5640, DOI 10.1073/pnas.0308425101	103	405	421	0	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					1943	1954		10.1056/NEJMra1011874	http://dx.doi.org/10.1056/NEJMra1011874			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765PJ	21591946	Green Accepted			2022-12-28	WOS:000290720700009
J	Grimes, RN				Grimes, Russell N.			William Nunn Lipscomb Jr (1919-2011) OBITUARY	NATURE			English	Biographical-Item									[Grimes, Russell N.] Univ Virginia, Charlottesville, VA 22903 USA	University of Virginia	Grimes, RN (corresponding author), Univ Virginia, Charlottesville, VA 22903 USA.	rng@virginia.edu							0	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 19	2011	473	7347					286	286		10.1038/473286a	http://dx.doi.org/10.1038/473286a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593854	Bronze			2022-12-28	WOS:000290722400028
J	Dyrbye, LN; Shanafelt, TD				Dyrbye, Liselotte N.; Shanafelt, Tait D.			Physician Burnout A Potential Threat to Successful Health Care Reform	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AMERICAN SURGEONS		[Dyrbye, Liselotte N.; Shanafelt, Tait D.] Mayo Clin, Coll Med, Dept Med, Rochester, MN 55905 USA	Mayo Clinic	Dyrbye, LN (corresponding author), Mayo Clin, Coll Med, Dept Med, 200 1st St SW, Rochester, MN 55905 USA.	dyrbye.liselotte@mayo.edu						[Anonymous], REP PRES REAL FULL P; Association of American Medical Colleges, 2018, COMPL PHYS SUPPL DEM; Campbell DA, 2001, SURGERY, V130, P696, DOI 10.1067/msy.2001.116676; Dyrbye LN, 2011, ARCH SURG-CHICAGO, V146, P211, DOI 10.1001/archsurg.2010.310; Shanafelt TD, 2009, ANN SURG, V250, P463, DOI 10.1097/SLA.0b013e3181ac4dfd; SteelFisher GK, 2009, NEW ENGL J MED, V361, DOI 10.1056/NEJMp0909851; Taylor C, 2005, LANCET, V366, P742, DOI 10.1016/S0140-6736(05)67178-4; Wallace JE, 2009, LANCET, V374, P1714, DOI 10.1016/S0140-6736(09)61424-0; West CP, 2006, JAMA-J AM MED ASSOC, V296, P1071, DOI 10.1001/jama.296.9.1071; Wilson JF, 2008, ANN INTERN MED, V148, P489, DOI 10.7326/0003-4819-148-6-200803180-00029	10	230	233	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2011	305	19					2009	2010		10.1001/jama.2011.652	http://dx.doi.org/10.1001/jama.2011.652			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764WO	21586718				2022-12-28	WOS:000290665500027
J	Woolf, SH				Woolf, Steven H.			Public Health Implications of Government Spending Reductions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Woolf, Steven H.] Virginia Commonwealth Univ, Ctr Human Needs, Richmond, VA 23298 USA	Virginia Commonwealth University	Woolf, SH (corresponding author), Virginia Commonwealth Univ, West Hosp, Ctr Human Needs, 1200 E Broad St,POB 980251, Richmond, VA 23298 USA.	swoolf@vcu.edu						Braveman P, 2008, OVERCOMING OBSTACLES; Miller WD, 2011, AM J PREV MED, V40, pS48, DOI 10.1016/j.amepre.2010.09.024; National Center forHealth Statistics, 2011, HLTH US 2010 SPEC FE; OFFICE OF MANAGEMENT AND BUDGET, 2011, FISC YEAR 2012 BUDG; PLEIS JR, 2007, VITAL HLTH STAT, V10, P1; Singh GK, 2003, NCI CANC SURVEILLANC, V4; *VA COMM U CTR HUM, VCU PROJ SOC DISTR; Woolf SH, 2007, AM J PUBLIC HEALTH, V97, P679, DOI 10.2105/AJPH.2005.084848; Woolf SH, 2010, AM J PUBLIC HEALTH, V100, P750, DOI 10.2105/AJPH.2009.165142; Woolf SH, 2009, JAMA-J AM MED ASSOC, V301, P1166, DOI 10.1001/jama.2009.320	10	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2011	305	18					1902	1903		10.1001/jama.2011.617	http://dx.doi.org/10.1001/jama.2011.617			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	761YH	21558522				2022-12-28	WOS:000290438800029
J	Mummery, C				Mummery, Christine			Induced Pluripotent Stem Cells - A Cautionary Note	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Leiden Univ, Dept Anat & Embryol, Med Ctr, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Mummery, C (corresponding author), Leiden Univ, Dept Anat & Embryol, Med Ctr, Leiden, Netherlands.			Mummery, Christine/0000-0002-4549-6535				Dambrot C, 2011, BIOCHEM J, V434, P25, DOI 10.1042/BJ20101707; Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805; Hussein SM, 2011, NATURE, V471, P58, DOI 10.1038/nature09871; Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798; Pera MF, 2011, NATURE, V471, P46, DOI 10.1038/471046a	5	42	45	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2160	2162		10.1056/NEJMcibr1103052	http://dx.doi.org/10.1056/NEJMcibr1103052			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	772AB	21631331				2022-12-28	WOS:000291200700018
J	Lilly, CM; Cody, S; Zhao, HF; Landry, K; Baker, SP; McIlwaine, J; Chandler, MW; Irwin, RS				Lilly, Craig M.; Cody, Shawn; Zhao, Huifang; Landry, Karen; Baker, Stephen P.; McIlwaine, John; Chandler, M. Willis; Irwin, Richard S.		Univ Massachusetts	Hospital Mortality, Length of Stay, and Preventable Complications Among Critically Ill Patients Before and After Tele-ICU Reengineering of Critical Care Processes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; MULTIPLE IMPUTATION; UNIT TELEMEDICINE; ECONOMIC OUTCOMES; ASSOCIATION; PARADIGM; THERAPY; HEALTH	Context The association of an adult tele-intensive care unit (ICU) intervention with hospital mortality, length of stay, best practice adherence, and preventable complications for an academic medical center has not been reported. Objective To quantify the association of a tele-ICU intervention with hospital mortality, length of stay, and complications that are preventable by adherence to best practices. Design, Setting, and Patients Prospective stepped-wedge clinical practice study of 6290 adults admitted to any of 7 ICUs (3 medical, 3 surgical, and 1 mixed cardiovascular) on 2 campuses of an 834-bed academic medical center that was performed from April 26, 2005, through September 30, 2007. Electronically supported and monitored processes for best practice adherence, care plan creation, and clinician response times to alarms were evaluated. Main Outcome Measures Case-mix and severity-adjusted hospital mortality. Other outcomes included hospital and ICU length of stay, best practice adherence, and complication rates. Results The hospital mortality rate was 13.6% (95% confidence interval [CI], 11.9%-15.4%) during the preintervention period compared with 11.8% (95% CI, 10.9%-12.8%) during the tele-ICU intervention period (adjusted odds ratio [OR], 0.40 [95% CI, 0.31-0.52]). The tele-ICU intervention period compared with the preintervention period was associated with higher rates of best clinical practice adherence for the prevention of deep vein thrombosis (99% vs 85%, respectively; OR, 15.4 [95% CI, 11.3-21.1]) and prevention of stress ulcers (96% vs 83%, respectively; OR, 4.57 [95% CI, 3.91-5.77], best practice adherence for cardiovascular protection (99% vs 80%, respectively; OR, 30.7 [95% CI, 19.3-49.2]), prevention of ventilator-associated pneumonia (52% vs 33%, respectively; OR, 2.20 [95% CI, 1.79-2.70]), lower rates of preventable complications (1.6% vs 13%, respectively, for ventilator-associated pneumonia [OR, 0.15; 95% CI, 0.09-0.23] and 0.6% vs 1.0%, respectively, for catheter-related bloodstream infection [OR, 0.50; 95% CI, 0.27-0.93]), and shorter hospital length of stay (9.8 vs 13.3 days, respectively; hazard ratio for discharge, 1.44 [95% CI, 1.33-1.56]). The results for medical, surgical, and cardiovascular ICUs were similar. Conclusion In a single academic medical center study, implementation of a tele-ICU intervention was associated with reduced adjusted odds of mortality and reduced hospital length of stay, as well as with changes in best practice adherence and lower rates of preventable complications. JAMA. 2011;305(21):2175-2183 Published online May 16, 2011. doi:10.1001/jama.2011.697 www.jama.com	[Lilly, Craig M.] Univ Massachusetts, Mem Med Ctr, Sch Med, Dept Med, Worcester, MA 01605 USA; [Lilly, Craig M.; McIlwaine, John] Univ Massachusetts, Sch Med, Dept Anesthesiol & Surg, Worcester, MA 01605 USA; [Lilly, Craig M.; Zhao, Huifang] Univ Massachusetts, Dept Nursing, Clin & Populat Hlth Res Program, Worcester, MA 01605 USA; [Lilly, Craig M.; Zhao, Huifang; Baker, Stephen P.] Univ Massachusetts, Dept Nursing, Grad Sch Biomed Sci, Worcester, MA 01605 USA; [Cody, Shawn] Univ Massachusetts Mem Hlth Care, Mem Med Ctr, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University Massachusetts Worcester Hospital	Lilly, CM (corresponding author), Univ Massachusetts, Mem Med Ctr, Sch Med, Dept Med, 281 Lincoln St, Worcester, MA 01605 USA.	craig.lilly@umassmed.edu			University of Massachusetts	University of Massachusetts	This project was funded in its entirety by the University of Massachusetts.	Alsarraf AA, 2005, J CRIT CARE, V20, P194, DOI 10.1016/j.jcrc.2005.05.004; Angus DC, 2006, CRIT CARE MED, V34, P1016, DOI 10.1097/01.CCM.0000206105.05626.15; Bhonagiri D, 2011, MED J AUSTRALIA, V194, P287, DOI 10.5694/j.1326-5377.2011.tb02976.x; Breslow MJ, 2004, CRIT CARE MED, V32, P31, DOI 10.1097/01.CCM.0000104204.61296.41; Cannon C, 2003, J INVASIVE CARDIO SB, V15, p27B; Cannon Christopher, 2003, J Invasive Cardiol, V15 Suppl B, p22B; Collard HR, 2003, ANN INTERN MED, V138, P494, DOI 10.7326/0003-4819-138-6-200303180-00015; Fleiss J. L., 1981, STAT METHODS RATES P, V2; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; Harel O, 2007, STAT MED, V26, P3057, DOI 10.1002/sim.2787; Harty Richard F, 2006, Curr Treat Options Gastroenterol, V9, P157, DOI 10.1007/s11938-006-0034-3; Hirsh J, 2001, CHEST, V119, p1S, DOI 10.1378/chest.119.1_suppl.1S; HOSMER DW, 1989, APPL LOGISTIC REGRES; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Isakow W, 2006, SEMIN RESP CRIT CARE, V27, P5, DOI 10.1055/s-2006-933668; Kohl BA, 2007, CRIT CARE MED, V35, pA22; Kumar A, 2009, CHEST, V136, P1237, DOI 10.1378/chest.09-0087; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Kuperman GJ, 1999, J AM MED INFORM ASSN, V6, P512, DOI 10.1136/jamia.1999.0060512; Lilly Craig M, 2010, J Intensive Care Med, V25, P16, DOI 10.1177/0885066609349216; MACKINNON DP, 1993, EVALUATION REV, V17, P144, DOI 10.1177/0193841X9301700202; McCambridge M, 2010, ARCH INTERN MED, V170, P648, DOI 10.1001/archinternmed.2010.74; McCauley K, 2006, CHEST, V130, P1571, DOI 10.1378/chest.130.5.1571; MCLEAN RA, 1991, AM STAT, V45, P54, DOI 10.2307/2685241; Milbrandt EB, 2008, CRIT CARE MED, V36, P2504, DOI 10.1097/CCM.0b013e318183ef84; Morrison JL, 2010, CRIT CARE MED, V38, P2, DOI 10.1097/CCM.0b013e3181b78fa8; Moser DK, 2007, J CARDIOVASC NURS, V22, P326, DOI 10.1097/01.JCN.0000278963.28619.4a; Phillips JoAnne, 2006, Crit Care Nurs Clin North Am, V18, P145, DOI 10.1016/j.ccell.2006.01.002; Pronovost P, 2003, J CRIT CARE, V18, P71, DOI 10.1053/jcrc.2003.50008; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Robinson GK, 1991, STAT SCI, V45, P15; Rosenfeld BA, 2000, CRIT CARE MED, V28, P3925, DOI 10.1097/00003246-200012000-00034; Schafer JL, 1998, MULTIVAR BEHAV RES, V33, P545, DOI 10.1207/s15327906mbr3304_5; Thomas EJ, 2009, JAMA-J AM MED ASSOC, V302, P2671, DOI 10.1001/jama.2009.1902; Yoo EJ, 2009, JAMA-J AM MED ASSOC, V302, P2705, DOI 10.1001/jama.2009.1924	38	283	291	0	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2175	2183		10.1001/jama.2011.697	http://dx.doi.org/10.1001/jama.2011.697			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21576622	Bronze			2022-12-28	WOS:000291106300020
J	Tung, N				Tung, Nadine			Management of Women With BRCA Mutations A 41-Year-Old Woman With a BRCA Mutation and a Recent History of Breast Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BILATERAL PROPHYLACTIC MASTECTOMY; REDUCING SALPINGO-OOPHORECTOMY; PREIMPLANTATION GENETIC DIAGNOSIS; POLICY STATEMENT UPDATE; ORAL-CONTRACEPTIVE USE; HIGH FAMILIAL RISK; PROSE-STUDY-GROUP; QUALITY-OF-LIFE; TERM-FOLLOW-UP; OVARIAN-CANCER	Ms E, a 41-year-old BRCA1 mutation carrier, was diagnosed 4 years ago as having breast cancer and opted for breast-conserving therapy. Prior to receiving chemotherapy, she harvested her eggs through in vitro fertilization and subsequently used preimplantation genetic diagnosis; 3 months ago she delivered a healthy boy. This review examines the prevalence of BRCA mutations in women with breast cancer, as well as current recommendations for surgery and systemic therapy in these women. In particular, the risk of a contralateral breast cancer is reviewed to help guide the choice of prophylactic mastectomies vs breast-conserving therapy. The technology of preimplantation genetic diagnosis and genetic testing in relatives of mutation carriers is discussed. JAMA. 2011;305(21):2211-2220 www.jama.com	[Tung, Nadine] Beth Israel Deaconess Med Ctr, Canc Risk & Prevent Program, Boston, MA 02215 USA; [Tung, Nadine] Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University	Tung, N (corresponding author), Beth Israel Deaconess Med Ctr, Canc Risk & Prevent Program, Shapiro Bldg,Room 913,330 Brookline Ave, Boston, MA 02215 USA.	ntung@bidmc.harvard.edu						*AM COLL MED GEN F, 1999, GEN SUSC BREAST OV C; Amir E, 2010, JNCI-J NATL CANCER I, V102, P680, DOI 10.1093/jnci/djq088; Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008; Begg CB, 2008, JAMA-J AM MED ASSOC, V299, P194, DOI 10.1001/jama.2007.55-a; Beiner ME, 2007, GYNECOL ONCOL, V104, P7, DOI 10.1016/j.ygyno.2006.08.004; Berg AO, 2005, ANN INTERN MED, V143, P355, DOI 10.7326/0003-4819-143-5-200509060-00011; de Gonzalez A, 2009, JNCI-J NATL CANCER I, V101, P205, DOI 10.1093/jnci/djn440; Brandberg Y, 2008, J CLIN ONCOL, V26, P3943, DOI 10.1200/JCO.2007.13.9568; Brandt AC, 2010, FAM CANCER, V9, P479, DOI 10.1007/s10689-010-9343-8; Brekelmans CTM, 2007, EUR J CANCER, V43, P867, DOI 10.1016/j.ejca.2006.12.009; Brekelmans CTM, 2006, ANN ONCOL, V17, P391, DOI 10.1093/annonc/mdj095; Brohet RM, 2007, J CLIN ONCOL, V25, P3831, DOI 10.1200/JCO.2007.11.1179; Broome DR, 2007, AM J ROENTGENOL, V188, P586, DOI 10.2214/AJR.06.1094; Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365; Bruinooge SS, 2003, J CLIN ONCOL, V21, P2397, DOI 10.1200/JCO.2003.03.189; Byrski T, 2009, BREAST CANCER RES TR, V115, P359, DOI 10.1007/s10549-008-0128-9; Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019; Callahan MJ, 2007, J CLIN ONCOL, V25, P3985, DOI 10.1200/JCO.2007.12.2622; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; Domchek SM, 2010, BREAST CANCER RES TR, V124, P195, DOI 10.1007/s10549-010-0799-x; Domchek SM, 2010, JAMA-J AM MED ASSOC, V304, P967, DOI 10.1001/jama.2010.1237; Eisen A, 2005, J CLIN ONCOL, V23, P7491, DOI 10.1200/JCO.2004.00.7138; Eisen A, 2008, J NATL CANCER I, V100, P1361, DOI 10.1093/jnci/djn313; Evans DGR, 2009, J MED GENET, V46, P811, DOI 10.1136/jmg.2009.067850; Ferla R, 2007, ANN ONCOL, V18, P93, DOI 10.1093/annonc/mdm234; Finch A, 2006, JAMA-J AM MED ASSOC, V296, P185, DOI 10.1001/jama.296.2.185; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Fortuny D, 2009, HUM REPROD, V24, P1000, DOI 10.1093/humrep/den471; Foulkes WD, 2006, FAM CANCER, V5, P135, DOI 10.1007/s10689-005-2832-5; Gallagher DJ, 2010, CLIN CANCER RES, V16, P2115, DOI 10.1158/1078-0432.CCR-09-2871; Geiger AM, 2007, ANN SURG ONCOL, V14, P686, DOI 10.1245/s10434-006-9206-6; Gelmon KA, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3002; Graeser MK, 2009, J CLIN ONCOL, V27, P5887, DOI 10.1200/JCO.2008.19.9430; Gronwald J, 2006, INT J CANCER, V118, P2281, DOI 10.1002/ijc.21536; Gronwald J, 2009, J CLIN ONCOL, V27; Haile RW, 2006, CANCER EPIDEM BIOMAR, V15, P1863, DOI 10.1158/1055-9965.EPI-06-0258; Hamel N, 2011, EUR J HUM GENET, V19, P300, DOI 10.1038/ejhg.2010.203; Heemskerk-Gerritsen BAM, 2010, EJC SUPPL, V8, P206, DOI 10.1016/S1359-6349(10)70521-8; Hermsen BBJ, 2007, BRIT J CANCER, V96, P1335, DOI 10.1038/sj.bjc.6603725; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Iodice S, 2010, EUR J CANCER, V46, P2275, DOI 10.1016/j.ejca.2010.04.018; Isakoff SJ, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.1019; James PA, 2006, J CLIN ONCOL, V24, P707, DOI 10.1200/JCO.2005.01.9737; Kauff ND, 2008, J CLIN ONCOL, V26, P1331, DOI 10.1200/JCO.2007.13.9626; Keating NL, 2008, J CLIN ONCOL, V26, P5789, DOI 10.1200/JCO.2008.17.8053; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kramer JL, 2005, J CLIN ONCOL, V23, P8629, DOI 10.1200/JCO.2005.02.9199; Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759; Kriege M, 2009, J CLIN ONCOL, V27, P3764, DOI 10.1200/JCO.2008.19.9067; Kuhl CK, 2007, LANCET, V370, P485, DOI 10.1016/S0140-6736(07)61232-X; Kuhl CK, 2005, J CLIN ONCOL, V23, P8469, DOI 10.1200/JCO.2004.00.4960; Kurian AW, 2010, J CLIN ONCOL, V28, P222, DOI 10.1200/JCO.2009.22.7991; Kwon JS, 2010, J CLIN ONCOL, V28, P4214, DOI 10.1200/JCO.2010.28.0719; Leach MO, 2005, LANCET, V365, P1769, DOI 10.1016/S0140-6736(05)66481-1; Levine DA, 2001, GYNECOL ONCOL, V80, P395, DOI 10.1006/gyno.2000.6082; Liede A, 2004, J CLIN ONCOL, V22, P735, DOI 10.1200/JCO.2004.05.055; Lu KH, 2007, GYNECOL ONCOL, V104, P3, DOI 10.1016/j.ygyno.2006.11.015; Malone KE, 2010, J CLIN ONCOL, V28, P2404, DOI 10.1200/JCO.2009.24.2495; Mavaddat N, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2576; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Menon U, 2007, HUM REPROD, V22, P1573, DOI 10.1093/humrep/dem055; Metcalfe K, 2004, J CLIN ONCOL, V22, P2328, DOI 10.1200/JCO.2004.04.033; Narod SA, 2002, JNCI-J NATL CANCER I, V94, P1773, DOI 10.1093/jnci/94.23.1773; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; National Comprehensive Cancer Network, 2010, CLIN PRACT GUID ONC; National Human Genome Research Institute, GEN INF NOND ACT GIN; O'Neill SC, 2010, FAM CANCER, V9, P43, DOI 10.1007/s10689-009-9243-y; Phelan CM, 2002, HUM MUTAT, V20, P352, DOI 10.1002/humu.10123; Pierce LJ, 2006, J CLIN ONCOL, V24, P2437, DOI 10.1200/JCO.2005.02.7888; Pierce LJ, 2010, BREAST CANCER RES TR, V121, P389, DOI 10.1007/s10549-010-0894-z; Rebbeck TR, 2009, JNCI-J NATL CANCER I, V101, P80, DOI 10.1093/jnci/djn442; Rebbeck TR, 2005, J CLIN ONCOL, V23, P7804, DOI 10.1200/JCO.2004.00.8151; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rebbeck TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188; Reding KW, 2010, BREAST CANCER RES TR, V123, P491, DOI 10.1007/s10549-010-0769-3; Rennert G, 2007, NEW ENGL J MED, V357, P115, DOI 10.1056/NEJMoa070608; Rijnsburger AJ, 2010, J CLIN ONCOL, V28, P5265, DOI 10.1200/JCO.2009.27.2294; Risch HA, 2006, JNCI-J NATL CANCER I, V98, P1694, DOI 10.1093/jnci/djj465; Robson M, 2005, CANCER, V103, P44, DOI 10.1002/cncr.20728; Robson M, 2007, NEW ENGL J MED, V357, P154, DOI 10.1056/NEJMcp071286; Robson ME, 2010, J CLIN ONCOL, V28, P893, DOI 10.1200/JCO.2009.27.0660; Robson ME, 2004, BREAST CANCER RES, V6, pR8, DOI 10.1186/bcr658; Sardanelli F, 2007, RADIOLOGY, V242, P698, DOI 10.1148/radiol.2423051965; Shah P, 2009, BREAST CANCER RES TR, V118, P539, DOI 10.1007/s10549-009-0475-1; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tai YC, 2007, J NATL CANCER I, V99, P1811, DOI 10.1093/jnci/djm203; Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Tryggvadottir L, 2007, JNCI-J NATL CANCER I, V99, P929, DOI 10.1093/jnci/djm005; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; van der Kolk DM, 2010, BREAST CANCER RES TR, V124, P643, DOI 10.1007/s10549-010-0805-3; van Sprundel TC, 2005, BRIT J CANCER, V93, P287, DOI 10.1038/sj.bjc.6602703; Verhoog LC, 2000, BRIT J CANCER, V83, P384, DOI 10.1054/bjoc.2000.1239; Warner E, 1999, J NATL CANCER I, V91, P1241, DOI 10.1093/jnci/91.14.1241; Warner E, 2004, JAMA-J AM MED ASSOC, V292, P1317, DOI 10.1001/jama.292.11.1317; Warner E, 2008, ANN INTERN MED, V148, P671, DOI 10.7326/0003-4819-148-9-200805060-00007; Weitzel JN, 2007, JAMA-J AM MED ASSOC, V297, P2587, DOI 10.1001/jama.297.23.2587; Wideroff L, 2005, J MED GENET, V42, P749, DOI 10.1136/jmg.2004.030296; Yap TA, 2011, CA-CANCER J CLIN, V61, P31, DOI 10.3322/caac.20095	103	24	24	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2211	2220		10.1001/jama.2011.678	http://dx.doi.org/10.1001/jama.2011.678			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21558506				2022-12-28	WOS:000291106300024
J	Barbui, C; Baschirotto, C; Cipriani, A				Barbui, Corrado; Baschirotto, Cinzia; Cipriani, Andrea			EMA must improve the quality of its clinical trial reports	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DRUG; INFORMATION; PAROXETINE		[Barbui, Corrado; Baschirotto, Cinzia; Cipriani, Andrea] Univ Verona, WHO Collaborating Ctr Res & Training Mental Hlth, I-37100 Verona, Italy	University of Verona	Barbui, C (corresponding author), Policlin GB Rossi, Sect Psychiat & Clin Psychol, Piazzale LA Scuro 10, I-37134 Verona, Italy.	corrado.barbui@univr.it	Cipriani, Andrea/P-6944-2015	Cipriani, Andrea/0000-0001-5179-8321				[Anonymous], 2010, LANCET, V375, P1753, DOI [10.1016/S0140-6736(10)60760-X, 10.1016/S0140-6736(10)60785-4]; Asamoah AK, 2010, NEW ENGL J MED, V362, P2341, DOI 10.1056/NEJMp1005202; Aursnes I, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-14; Barbui C, 2008, CAN MED ASSOC J, V178, P296, DOI 10.1503/cmaj.070693; Barbui C, 2007, PSYCHOPHARMACOLOGY, V190, P265, DOI 10.1007/s00213-006-0629-3; Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; European Medicines Agency, ASS REP CIRC; Garattini S, 2005, PHARMACOECONOMICS, V23, P207, DOI 10.2165/00019053-200523030-00001; Garattini S, 2003, LANCET, V361, P635, DOI 10.1016/S0140-6736(03)12615-3; Garattini S, 2001, LANCET, V358, P64, DOI 10.1016/S0140-6736(00)05258-2; Garattini S, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1578; Nuesch E, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3244; Rosenbaum SE, 2010, J CLIN EPIDEMIOL, V63, P620, DOI 10.1016/j.jclinepi.2009.12.014; Schulz KF, 2010, BMC MED, V8, DOI [10.1186/1741-7015-8-18, 10.1136/bmj.c332]; Schwartz LM, 2009, NEW ENGL J MED, V361, P1717, DOI 10.1056/NEJMp0907708; Schwartz LM, 2009, ANN INTERN MED, V150, P516, DOI 10.7326/0003-4819-150-8-200904210-00106; Turner Erick H, 2008, N Engl J Med, V358, P252, DOI 10.1056/NEJMsa065779; Vitry A, 2008, INTERN MED J, V38, P559, DOI 10.1111/j.1445-5994.2007.01588.x	18	20	21	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	2011	342								d2291	10.1136/bmj.d2291	http://dx.doi.org/10.1136/bmj.d2291			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771KE	21613341				2022-12-28	WOS:000291154800003
J	Buss, P				Buss, Paulo			Brazil: structuring cooperation for health	LANCET			English	Editorial Material									Fiocruz MS, Ctr Global Hlth, Oswaldo Cruz Fdn, BR-21040360 Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz	Buss, P (corresponding author), Fiocruz MS, Ctr Global Hlth, Oswaldo Cruz Fdn, BR-21040360 Rio De Janeiro, Brazil.	buss@fiocruz.br						ALMEIDA C, 2010, RECIIS REV ELECT COM; BUSS PM, 2010, RECIIS REV ELECT COM; *CPLP, STRAT PLAN COOP HLTH; FCTC, WHO FRAM CONV TOB CO; *PAHO, 1992, PROS NOV MUND HIST P, P296; 2010 15 QUINQUENNIAL	6	25	28	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	2011	377	9779					1722	1723		10.1016/S0140-6736(11)60354-1	http://dx.doi.org/10.1016/S0140-6736(11)60354-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771AS	21561654				2022-12-28	WOS:000291130200005
J	Naoz, S; Farr, WM; Lithwick, Y; Rasio, FA; Teyssandier, J				Naoz, Smadar; Farr, Will M.; Lithwick, Yoram; Rasio, Frederic A.; Teyssandier, Jean			Hot Jupiters from secular planet-planet interactions	NATURE			English	Article							TIDAL FRICTION; STAR SYSTEMS; EVOLUTION; ECCENTRICITY; BINARY; PERTURBATIONS; SCATTERING; MIGRATION; ORBITS; CYGNI	About 25 per cent of 'hot Jupiters' (extrasolar Jovian-mass planets with close-in orbits) are actually orbiting counter to the spin direction of the star(1). Perturbations from a distant binary star companion(2,3) can produce high inclinations, but cannot explain orbits that are retrograde with respect to the total angular momentum of the system. Such orbits in a stellar context can be produced through secular (that is, long term) perturbations in hierarchical triple-star systems. Here we report a similar analysis of planetary bodies, including both octupole-order effects and tidal friction, and find that we can produce hot Jupiters in orbits that are retrograde with respect to the total angular momentum. With distant stellar mass perturbers, such an outcome is not possible(2,3). With planetary perturbers, the inner orbit's angular momentum component parallel to the total angular momentum need not be constant(4). In fact, as we show here, it can even change sign, leading to a retrograde orbit. A brief excursion to very high eccentricity during the chaotic evolution of the inner orbit allows planet-star tidal interactions to rapidly circularize that orbit, decoupling the planets and forming a retrograde hot Jupiter.	[Naoz, Smadar; Farr, Will M.; Lithwick, Yoram; Rasio, Frederic A.; Teyssandier, Jean] Northwestern Univ, CIERA, Evanston, IL 60208 USA	Northwestern University	Naoz, S (corresponding author), Northwestern Univ, CIERA, Evanston, IL 60208 USA.	snaoz@northwestern.edu		Teyssandier, Jean/0000-0002-6277-2933; Naoz, Smadar/0000-0002-9802-9279; Rasio, Frederic/0000-0002-7132-418X	Gruber Foundation; Weizmann Institute of Science; NSF MRI	Gruber Foundation; Weizmann Institute of Science; NSF MRI(National Science Foundation (NSF)NSF - Office of the Director (OD))	We thank D. Fabrycky and H. Perets for discussions. S.N. acknowledges support from a Gruber Foundation Fellowship and from the National Post Doctoral Award Program for Advancing Women in Science (Weizmann Institute of Science). Simulations for this project were performed on the HPC cluster fugu funded by an NSF MRI award.	Eggleton PP, 1998, ASTROPHYS J, V499, P853, DOI 10.1086/305670; Fabrycky D, 2007, ASTROPHYS J, V669, P1298, DOI 10.1086/521702; Ford EB, 2006, ASTROPHYS J, V638, pL45, DOI 10.1086/500734; Ford EB, 2000, ASTROPHYS J, V535, P385, DOI 10.1086/308815; Gaudi BS, 2007, ASTROPHYS J, V655, P550, DOI 10.1086/509910; Harrington R. S., 1969, Celestial Mechanics, V1, P200, DOI 10.1007/BF01228839; Holman M, 1997, NATURE, V386, P254, DOI 10.1038/386254a0; Kalas P, 2008, SCIENCE, V322, P1345, DOI 10.1126/science.1166609; Kiseleva LG, 1998, MON NOT R ASTRON SOC, V300, P292, DOI 10.1046/j.1365-8711.1998.01903.x; KOZAI Y, 1962, ASTRON J, V67, P591, DOI 10.1086/108790; Krymolowski K, 1999, MON NOT R ASTRON SOC, V304, P720, DOI 10.1046/j.1365-8711.1999.02349.x; Lai D., 2011, MON NOT R ASTR UNPUB; LIDOV ML, 1962, PLANET SPACE SCI, V9, P719, DOI 10.1016/0032-0633(62)90129-0; Masset FS, 2003, ASTROPHYS J, V588, P494, DOI 10.1086/373892; Matsumura S, 2010, ASTROPHYS J, V725, P1995, DOI 10.1088/0004-637X/725/2/1995; MAZEH T, 1979, ASTRON ASTROPHYS, V77, P145; Mikkola S, 1998, ASTRON J, V116, P444, DOI 10.1086/300404; Nagasawa M, 2008, ASTROPHYS J, V678, P498, DOI 10.1086/529369; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; Schlaufman KC, 2010, ASTROPHYS J, V719, P602, DOI 10.1088/0004-637X/719/1/602; Takeda G, 2008, ASTROPHYS J, V683, P1063, DOI 10.1086/589852; Triaud AHMJ, 2010, ASTRON ASTROPHYS, V524, DOI 10.1051/0004-6361/201014525; Winn JN, 2010, ASTROPHYS J LETT, V718, pL145, DOI 10.1088/2041-8205/718/2/L145; Wu Y., 2010, SECULAR CHAOS PRODUC; Wu YQ, 2007, ASTROPHYS J, V670, P820, DOI 10.1086/521996; Zdziarski AA, 2007, MON NOT R ASTRON SOC, V377, P1006, DOI 10.1111/j.1365-2966.2007.11686.x	29	327	331	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 12	2011	473	7346					187	189		10.1038/nature10076	http://dx.doi.org/10.1038/nature10076			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562558	Green Submitted			2022-12-28	WOS:000290487200032
J	Reisch, CR; Stoudemayer, MJ; Varaljay, VA; Amster, IJ; Moran, MA; Whitman, WB				Reisch, Chris R.; Stoudemayer, Melissa J.; Varaljay, Vanessa A.; Amster, I. Jonathan; Moran, Mary Ann; Whitman, William B.			Novel pathway for assimilation of dimethylsulphoniopropionate widespread in marine bacteria	NATURE			English	Article							ACYL-COENZYME-A; DIMETHYL SULFIDE; DIMETHYLSULFONIOPROPIONATE; SULFUR; DMSP; METHANETHIOL; DEGRADATION; METHIONINE; ABUNDANT; ENZYME	Dimethylsulphoniopropionate (DMSP) accounts for up to 10% of carbon fixed by marine phytoplankton in ocean surface waters(1,2), producing an estimated 11.7-103 T mol S per year(3), most of which is processed by marine bacteria through the demethylation/demethiolation pathway(4). This pathway releases methanethiol (MeSH) instead of the climatically active gas dimethylsulphide (DMS) and enables marine microorganisms to assimilate the reduced sulphur(5-7). Despite recognition of this critical microbial transformation for over two decades, the biochemical pathway and enzymes responsible have remained unidentified. Here we show that three new enzymes related to fatty acid beta-oxidation constitute the pathway that assimilates methylmercaptopropionate (MMPA), the first product of DMSP demethylation/demethiolation, and that two previously unknown coenzyme A (CoA) derivatives, 3-methylmercaptopropionyl-CoA (MMPA-CoA) and methylthioacryloyl-CoA (MTA-CoA), are formed as novel intermediates. A member of the marine roseobacters, Ruegeria pomeroyi DSS-3, requires the MMPA-CoA pathway for MMPA assimilation and MeSH production. This pathway and the ability to produce MeSH from MMPA are present in diverse bacteria, and the ubiquitous SAR11 clade bacterium Pelagibacter ubique possesses enzymes for at least the first two steps. Analysis of marine metagenomic data indicates that the pathway is widespread among bacterioplankton in the ocean surface waters, making it one of the most important known routes for acquisition of reduced carbon and sulphur by surface ocean heterotrophs.	[Reisch, Chris R.; Varaljay, Vanessa A.; Whitman, William B.] Univ Georgia, Dept Microbiol, Athens, GA 30602 USA; [Moran, Mary Ann] Univ Georgia, Dept Marine Sci, Athens, GA 30602 USA; [Stoudemayer, Melissa J.; Amster, I. Jonathan] Univ Georgia, Dept Chem, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Whitman, WB (corresponding author), Univ Georgia, Dept Microbiol, Athens, GA 30602 USA.	whitman@uga.edu	Whitman, William/AAC-5896-2020; Moran, Mary Ann/B-6939-2012; Amster, Jon/D-6957-2011	Amster, Jon/0000-0001-7523-5144; Whitman, William/0000-0003-1229-0423; Moran, Mary Ann/0000-0002-0702-8167; Stoudemayer, Melissa/0000-0002-2967-9948	National Science Foundation [MCB-0702125, OCE-0724017]; Gordon and Betty Moore Foundation	National Science Foundation(National Science Foundation (NSF)); Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation)	We thank G. Wylie for assistance with NMR spectroscopy, S. Sharma, S. Sun and H. Luo for bioinformatics assistance, S. Gifford for technical advice, C. Smith and W. Crabb for technical assistance, and C. English for assistance with graphics. Funding for this research was provided by the National Science Foundation (MCB-0702125 and OCE-0724017) and the Gordon and Betty Moore Foundation.	ANDREAE MO, 1990, MAR CHEM, V30, P1, DOI 10.1016/0304-4203(90)90059-L; Archer SD, 2001, AQUAT MICROB ECOL, V24, P225, DOI 10.3354/ame024225; BELL RP, 1949, PROC R SOC LON SER-A, V197, P141, DOI 10.1098/rspa.1949.0055; Bentley R, 2004, CHEMOSPHERE, V55, P291, DOI 10.1016/j.chemosphere.2003.12.017; BRETSCHER AP, 1978, J BACTERIOL, V133, P763, DOI 10.1128/JB.133.2.763-768.1978; CHAMBERS ST, 1987, J BACTERIOL, V169, P4845, DOI 10.1128/jb.169.10.4845-4847.1987; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; Curson ARJ, 2008, ENVIRON MICROBIOL, V10, P1099, DOI 10.1111/j.1462-2920.2008.01592.x; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; Gonzalez JM, 2003, INT J SYST EVOL MICR, V53, P1261, DOI 10.1099/ijs.0.02491-0; Gonzalez JM, 1999, APPL ENVIRON MICROB, V65, P3810; GUPTA N K, 1970, Archives of Biochemistry and Biophysics, V141, P632, DOI 10.1016/0003-9861(70)90183-9; HENRIKSEN JR, 2008, THESIS U GEORGIA; Howard EC, 2008, ENVIRON MICROBIOL, V10, P2397, DOI 10.1111/j.1462-2920.2008.01665.x; Howard EC, 2006, SCIENCE, V314, P649, DOI 10.1126/science.1130657; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kiene RP, 2000, J SEA RES, V43, P209, DOI 10.1016/S1385-1101(00)00023-X; KIENE RP, 1988, APPL ENVIRON MICROB, V54, P2208, DOI 10.1128/AEM.54.9.2208-2212.1988; Kiene RP, 1999, APPL ENVIRON MICROB, V65, P4549; Kiene RP, 1996, MAR CHEM, V54, P69, DOI 10.1016/0304-4203(96)00006-0; Koch Arthur L., 1994, P248; Ledyard KM, 1996, LIMNOL OCEANOGR, V41, P33, DOI 10.4319/lo.1996.41.1.0033; Li MZ, 2007, NAT METHODS, V4, P251, DOI 10.1038/NMETH1010; MYERS RW, 1993, J BIOL CHEM, V268, P24785; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; Reisch CR, 2008, J BACTERIOL, V190, P8018, DOI 10.1128/JB.00770-08; Rusch DB, 2007, PLOS BIOL, V5, P398, DOI 10.1371/journal.pbio.0050077; Simo R, 2002, LIMNOL OCEANOGR, V47, P53, DOI 10.4319/lo.2002.47.1.0053; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; Taylor BF, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P265; TAYLOR BF, 1991, APPL ENVIRON MICROB, V57, P3581, DOI 10.1128/AEM.57.12.3581-3584.1991; Todd JD, 2009, ENVIRON MICROBIOL, V11, P1376, DOI 10.1111/j.1462-2920.2009.01864.x; Todd JD, 2007, SCIENCE, V315, P666, DOI 10.1126/science.1135370; Todd JD, 2011, ENVIRON MICROBIOL, V13, P427, DOI 10.1111/j.1462-2920.2010.02348.x; Todd JD, 2010, ENVIRON MICROBIOL, V12, P327, DOI 10.1111/j.1462-2920.2009.02071.x; Tripp HJ, 2008, NATURE, V452, P741, DOI 10.1038/nature06776; van Duyl FC, 1998, J SEA RES, V40, P221, DOI 10.1016/S1385-1101(98)00024-0; Venkateswaran A, 2000, APPL ENVIRON MICROB, V66, P2620, DOI 10.1128/AEM.66.6.2620-2626.2000	38	94	104	1	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 12	2011	473	7346					208	+		10.1038/nature10078	http://dx.doi.org/10.1038/nature10078			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562561				2022-12-28	WOS:000290487200037
J	van Meerbeeck, JP; Fennell, DA; De Ruysscher, DKM				van Meerbeeck, Jan P.; Fennell, Dean A.; De Ruysscher, Dirk K. M.			Small-cell lung cancer	LANCET			English	Article							PHASE-III TRIAL; PROPHYLACTIC CRANIAL IRRADIATION; EATON MYASTHENIC SYNDROME; WHOLE-BRAIN RADIOTHERAPY; DAILY THORACIC RADIOTHERAPY; RANDOMIZED CONTROLLED-TRIALS; RADIATION-THERAPY; PROGNOSTIC-FACTORS; GROWTH-FACTOR; COMBINATION CHEMOTHERAPY	The incidence and mortality of small-cell lung cancer worldwide make this disease a notable health-care issue. Diagnosis relies on histology, with the use of immunohistochemical studies to confirm difficult cases. Typical patients are men older than 70 years who are current or past heavy smokers and who have pulmonary and cardiovascular comorbidities. Patients often present with rapid-onset symptoms due to local intrathoracic tumour growth, extrapulmonary distant spread, paraneoplastic syndromes, or a combination of these features. Staging aims ultimately to define disease as metastatic or non-metastatic. Combination chemotherapy, generally platinum-based plus etoposide or irinotecan, is the mainstay first-line treatment for metastatic small-cell lung cancer. For non-metastatic disease, evidence supports early concurrent thoracic radiotherapy. Prophylactic cranial irradiation should be considered for patients with or without metastases whose disease does not progress after induction chemotherapy and radiotherapy. Despite high initial response rates, most patients eventually relapse. Except for topotecan, few treatment options then remain. Signalling pathways have been identified that might yield new drug targets.	[van Meerbeeck, Jan P.] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium; [van Meerbeeck, Jan P.] Ghent Univ Hosp, Lung Oncol Network, Ghent, Belgium; [Fennell, Dean A.] Queens Univ Belfast, Belfast Canc Res UK Ctr, Belfast, Antrim, North Ireland; [De Ruysscher, Dirk K. M.] Maastricht Univ Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol, Maastro Clin, Maastricht, Netherlands	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Queens University Belfast; Maastricht University; Maastricht University Medical Centre (MUMC)	van Meerbeeck, JP (corresponding author), Ghent Univ Hosp LONG, Dept Resp Med, De Pintelaan 185, B-9000 Ghent, Belgium.	jan.vanmeerbeeck@ugent.be	van Meerbeeck, Jan/ABA-5109-2020	van Meerbeeck, Jan/0000-0001-7872-8622	AstraZeneca; Amgen; Pfizer; Hospira; Eli Lilly; Sanofi-Aventis; GlaxoSmithKline; Merck; Astellas; Genentech; Boehringer Ingelheim; Daiichi Sankyo; Roche	AstraZeneca(AstraZeneca); Amgen(Amgen); Pfizer(Pfizer); Hospira; Eli Lilly(Eli Lilly); Sanofi-Aventis(Sanofi-Aventis); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Astellas(Astellas Pharmaceuticals); Genentech(Roche HoldingGenentech); Boehringer Ingelheim(Boehringer Ingelheim); Daiichi Sankyo(Daiichi Sankyo Company Limited); Roche(Roche Holding)	JvM has received money for consultancy from AstraZeneca, Amgen, Pfizer, Hospira, Eli Lilly, Sanofi-Aventis, and GlaxoSmithKline, and for speaking from Eli Lilly, and his institution has received educational grants from Eli Lilly. DAF has received money for consultancy from Merck, Astellas, Genentech, Boehringer Ingelheim, AstraZeneca, Amgen, and Daiichi Sankyo, and for speaking from Merck, Genentech, and Roche. DDR declares that he has no conflicts of interest.	Akl EA, 2007, COCHRANE DB SYST REV, V2; Akl EA, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-4; ALBAIN KS, 1990, J CLIN ONCOL, V8, P1563, DOI 10.1200/JCO.1990.8.9.1563; Amarasena IU, 2008, COCHRANE DB SYST REV, V4; Ando Y, 2002, THER DRUG MONIT, V24, P111, DOI 10.1097/00007691-200202000-00018; [Anonymous], 1966, Lancet, V2, P979; Antony GK, 2010, J THORAC ONCOL, V5, P747, DOI 10.1097/JTO.0b013e3181d6e124; ARRIAGADA R, 1995, JNCI-J NATL CANCER I, V87, P183, DOI 10.1093/jnci/87.3.183; Barnard WG, 1926, J PATHOL BACTERIOL, V29, P241, DOI 10.1002/path.1700290304; Boscaro M, 2009, J CLIN ENDOCR METAB, V94, P3121, DOI 10.1210/jc.2009-0612; Brunelli A, 2009, EUR RESPIR J, V34, P17, DOI 10.1183/09031936.00184308; CERNY T, 1987, INT J CANCER, V39, P146, DOI 10.1002/ijc.2910390204; Chute JP, 2006, CLIN CANCER RES, V12, P888, DOI 10.1158/1078-0432.CCR-05-1536; Ciuleanu T, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.7002; Coe BR, 2006, GENE CHROMOSOME CANC, V45, P11, DOI 10.1002/gcc.20260; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; De Ruysscher D, 2006, J CLIN ONCOL, V24, P1057, DOI 10.1200/JCO.2005.02.9793; De Ruysscher D, 2000, RADIOTHER ONCOL, V55, P1, DOI 10.1016/S0167-8140(00)00156-0; De Ruysscher D, 2006, RADIOTHER ONCOL, V80, P307, DOI 10.1016/j.radonc.2006.07.029; Dehing-Oberije C, 2009, RADIOTHER ONCOL, V91, P421, DOI 10.1016/j.radonc.2008.12.002; Demedts IK, 2010, EUR RESPIR J, V35, P202, DOI 10.1183/09031936.00105009; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Eckardt JR, 2007, J CLIN ONCOL, V25, P2086, DOI 10.1200/JCO.2006.08.3998; Eckardt JR, 2009, J CLIN ONCOL, V27, P2046, DOI 10.1200/JCO.2008.19.3235; Edelman MJ, 2004, J CLIN ONCOL, V22, P127, DOI 10.1200/JCO.2004.06.070; Ellison DH, 2007, NEW ENGL J MED, V356, P2064, DOI 10.1056/NEJMcp066837; Ettinger DS, 2005, J CLIN ONCOL, V23, P4991, DOI 10.1200/JCO.2005.00.414; EVANS WK, 1985, J CLIN ONCOL, V3, P1471, DOI 10.1200/JCO.1985.3.11.1471; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; Field JK, 2008, BRIT J CANCER, V99, P557, DOI 10.1038/sj.bjc.6604509; Foster NR, 2009, CANCER-AM CANCER SOC, V115, P2721, DOI 10.1002/cncr.24314; Franklin WA, 2010, PRINCIPLES PRACTICE, P287; Fried DB, 2004, J CLIN ONCOL, V22, P4837, DOI 10.1200/JCO.2004.01.178; Furuse K, 1997, BRIT J CANCER, V75, P614, DOI 10.1038/bjc.1997.108; Gandhi Leena, 2006, J Natl Compr Canc Netw, V4, P631; Garces YI, 2004, CHEST, V126, P1733, DOI 10.1378/chest.126.6.1733; Giordano KF, 2005, LUNG CANCER, V49, P209, DOI 10.1016/j.lungcan.2005.01.009; Goldstraw P, 2009, IASLC STAGING HDB TH; Graus F, 1997, J CLIN ONCOL, V15, P2866, DOI 10.1200/JCO.1997.15.8.2866; GREEN RA, 1969, AM J MED, V46, P516, DOI 10.1016/0002-9343(69)90071-0; Gregor A, 1997, EUR J CANCER, V33, P1752, DOI 10.1016/S0959-8049(97)00135-4; Gritz ER, 2003, EVIDENCE-BASED CANCER CARE AND PREVENTION: BEHAVIORAL INTERVENTIONS, P107; Grosshans DR, 2008, CANCER, V112, P589, DOI 10.1002/cncr.23222; Gultekin SH, 2000, BRAIN, V123, P1481, DOI 10.1093/brain/123.7.1481; Han JY, 2005, J CLIN ONCOL, V23, P3488, DOI 10.1200/JCO.2005.01.082; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanna N, 2002, LUNG CANCER, V35, P293, DOI 10.1016/S0169-5002(01)00429-9; Hanna N, 2006, J CLIN ONCOL, V24, P2038, DOI 10.1200/JCO.2005.04.8595; Harting FH, 1879, VJSCHR GERICHTL MED, V30, P296; Hermes A, 2008, J CLIN ONCOL, V26, P4261, DOI 10.1200/JCO.2007.15.7545; HIRSCH FR, 1987, J CLIN ONCOL, V5, P585, DOI 10.1200/JCO.1987.5.4.585; Hodkinson PS, 2006, CELL DEATH DIFFER, V13, P1776, DOI 10.1038/sj.cdd.4401849; IKEGAKI N, 1994, CANCER RES, V54, P6; Inoue A, 2010, ANN ONCOL, V21, P800, DOI 10.1093/annonc/mdp384; Inoue A, 2008, J CLIN ONCOL, V26, P5401, DOI 10.1200/JCO.2008.18.1974; Ioannou M, 2009, LUNG, V187, P321, DOI 10.1007/s00408-009-9169-z; Jacoby JJ, 2010, J THORAC ONCOL, V5, P940, DOI 10.1097/JTO.0b013e3181dc211f; Jeremic B, 1999, J CLIN ONCOL, V17, P2092, DOI 10.1200/JCO.1999.17.7.2092; Jiang JW, 2010, J THORAC ONCOL, V5, P867, DOI 10.1097/JTO.0b013e3181d95c87; JIANG SX, 1995, J PATHOL, V177, P135, DOI 10.1002/path.1711770206; Kaiser U, 1996, LUNG CANCER-J IASLC, V15, P31, DOI 10.1016/0169-5002(96)00568-5; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KATO Y, 1969, CANCER, V23, P517, DOI 10.1002/1097-0142(196903)23:3<517::AID-CNCR2820230301>3.0.CO;2-L; Khanzada UK, 2006, ONCOGENE, V25, P877, DOI 10.1038/sj.onc.1209117; Kiaris H, 1999, P NATL ACAD SCI USA, V96, P14894, DOI 10.1073/pnas.96.26.14894; Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027; Konrad Muller-HermelinkH., 2004, WHO CLASSIFICATION T, V10; KOSMIDIS PA, 1994, SEMIN ONCOL, V21, P23; LAD T, 1994, CHEST, V106, pS320, DOI 10.1378/chest.106.6.320S; Lally BE, 2007, ONCOLOGIST, V12, P1096, DOI 10.1634/theoncologist.12-9-1096; Lara PN, 2009, J CLIN ONCOL, V27, P2530, DOI 10.1200/JCO.2008.20.1061; Le Pechoux C, 2009, LANCET ONCOL, V10, P467, DOI 10.1016/S1470-2045(09)70101-9; Lee ST, 2007, SEMIN NUCL MED, V37, P451, DOI 10.1053/j.semnuclmed.2007.07.001; Lim E, 2008, J THORAC ONCOL, V3, P1267, DOI 10.1097/JTO.0b013e318189a860; LOWENBRAUN S, 1979, CANCER, V44, P406, DOI 10.1002/1097-0142(197908)44:2<406::AID-CNCR2820440206>3.0.CO;2-1; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; Maddison P, 1999, LANCET, V353, P117, DOI 10.1016/S0140-6736(05)76153-5; Maddison P, 2008, J NEUROIMMUNOL, V201, P159, DOI 10.1016/j.jneuroim.2008.05.024; Mascaux C, 2000, LUNG CANCER-J IASLC, V30, P23, DOI 10.1016/S0169-5002(00)00127-6; Masters GA, 2010, PRINCIPLES PRACTICE, P341; Mazza R, 2010, ANN ONCOL, V21, P1404, DOI 10.1093/annonc/mdp599; Meyerson M, 2004, SEMIN ONCOL, V31, P4, DOI 10.1053/j.seminoncol.2003.12.009; Miller AA, 2010, J THORAC ONCOL, V5, P380, DOI 10.1097/JTO.0b013e3181cee36e; Monson JM, 1998, CANCER-AM CANCER SOC, V82, P842, DOI 10.1002/(SICI)1097-0142(19980301)82:5<842::AID-CNCR7>3.3.CO;2-O; Monstad SE, 2004, J CLIN ONCOL, V22, P795, DOI 10.1200/JCO.2004.01.028; National Cancer Institute, 1975, SEER CANC STAT REV; National Comprehensive Cancer Network, NCCN CLIN PRACT GUID; Neuhaus T, 2009, BRIT J CANCER, V100, P291, DOI 10.1038/sj.bjc.6604835; Nicholson SA, 2002, AM J SURG PATHOL, V26, P1184, DOI 10.1097/00000478-200209000-00009; Noda K, 2001, NEW ENGL J MED, V346, P85; O'Brien MER, 2006, J CLIN ONCOL, V24, P5441, DOI 10.1200/JCO.2006.06.5821; Okamoto H, 2007, BRIT J CANCER, V97, P162, DOI 10.1038/sj.bjc.6603810; Olejniczak ET, 2007, MOL CANCER RES, V5, P331, DOI 10.1158/1541-7786.MCR-06-0367; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Oze I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007835; Paesmans M, 2000, CANCER, V89, P523, DOI 10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6; Paesmans MN, 2010, J THORAC ONCOL, V5, pS104; Paik PK, 2010, CANCER CHEMOTH PHARM, V66, P1079, DOI 10.1007/s00280-010-1265-5; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2006, EMBO J, V25, P3078, DOI 10.1038/sj.emboj.7601198; Pardo OE, 2009, CANCER RES, V69, P8645, DOI 10.1158/0008-5472.CAN-09-1576; Payne M, 2010, J THORAC ONCOL, V5, P34, DOI 10.1097/JTO.0b013e3181c3f4f1; Pelayo Alvarez M, 2009, COCHRANE DB SYST REV, V4; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; Pijls-Johannesma M, 2007, CANCER TREAT REV, V33, P461, DOI 10.1016/j.ctrv.2007.03.002; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Postmus PE, 1998, RADIOTHER ONCOL, V46, P29, DOI 10.1016/S0167-8140(97)00149-7; Postmus PE, 2000, J CLIN ONCOL, V18, P3400, DOI 10.1200/JCO.2000.18.19.3400; Prophylactic Cranial Irradiation Overview Collaborative Group, 2000, COCHRANE DB SYST REV, V4; Puglisi M, 2010, BRIT J CANCER, V102, P629, DOI 10.1038/sj.bjc.6605527; Pujol JL, 2000, BRIT J CANCER, V83, P8; Robinet G, 2001, ANN ONCOL, V12, P59, DOI 10.1023/A:1008338312647; Rossi A, 2008, CLIN LUNG CANCER, V9, P271, DOI 10.3816/CLC.2008.n.042; Rothschild SI, 2010, CLIN LUNG CANCER, V11, P238, DOI 10.3816/CLC.2010.n.030; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rudin CM, 2008, J CLIN ONCOL, V26, P870, DOI 10.1200/JCO.2007.14.3461; Rudin CM, 2009, CLIN CANCER RES, V15, P5646, DOI 10.1158/1078-0432.CCR-09-0377; De Ruysscher D, 2009, ANN ONCOL, V20, P98, DOI 10.1093/annonc/mdn559; SAGMAN U, 1992, J CLIN ONCOL, V10, P1525, DOI 10.1200/JCO.1992.10.10.1525; SAGMAN U, 1991, J CLIN ONCOL, V9, P1639, DOI 10.1200/JCO.1991.9.9.1639; Saito H, 2006, J CLIN ONCOL, V24, P5247, DOI 10.1200/JCO.2006.07.1605; Sculier JP, 2008, J THORAC ONCOL, V3, P457, DOI 10.1097/JTO.0b013e31816de2b8; SEIFTER EJ, 1988, SEMIN ONCOL, V15, P278; Seute T, 2008, CANCER, V112, P1827, DOI 10.1002/cncr.23361; Shepherd FA, 2007, J THORAC ONCOL, V2, P1067, DOI 10.1097/JTO.0b013e31815bdc0d; Shepherd FA, 2010, J THORAC ONCOL, V5, P147, DOI 10.1097/JTO.0b013e3181c8cbf5; Simon GR, 2007, CHEST, V132, p324S, DOI 10.1378/chest.07-1385; Slotman B, 2007, NEW ENGL J MED, V357, P664, DOI 10.1056/NEJMoa071780; Smythe WR, 2001, ANN THORAC SURG, V71, P962, DOI 10.1016/S0003-4975(00)02459-0; Sorensen M, 2010, ANN ONCOL, V21, pv120, DOI 10.1093/annonc/mdq172; Soussain C, 2009, LANCET, V374, P1639, DOI 10.1016/S0140-6736(09)61299-X; Sundstrom S, 2005, LUNG CANCER, V48, P251, DOI 10.1016/j.lungcan.2004.10.016; Sundstrom S, 2002, J CLIN ONCOL, V20, P4665, DOI 10.1200/JCO.2002.12.111; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Tahir SK, 2010, MOL CANCER THER, V9, P545, DOI 10.1158/1535-7163.MCT-09-0651; Terzolo M, 2001, ANN ONCOL, V12, pS83, DOI 10.1093/annonc/12.suppl_2.S83; Titulaer MJ, 2009, J CLIN ONCOL, V27, P4260, DOI 10.1200/JCO.2008.20.6169; Tucker MA, 1997, J NATL CANCER I, V89, P1782, DOI 10.1093/jnci/89.23.1782; Turrisi AT, 1999, NEW ENGL J MED, V340, P265, DOI 10.1056/NEJM199901283400403; van Loon J, 2010, INT J RADIAT ONCOL, V77, P329, DOI 10.1016/j.ijrobp.2009.04.075; von Pawel J, 1999, J CLIN ONCOL, V17, P658, DOI 10.1200/JCO.1999.17.2.658; WARDE P, 1992, J CLIN ONCOL, V10, P890, DOI 10.1200/JCO.1992.10.6.890; Warshamana-Greene GS, 2005, CLIN CANCER RES, V11, P1563, DOI 10.1158/1078-0432.CCR-04-1544; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; WATSON WL, 1962, CANCER, V15, P759, DOI 10.1002/1097-0142(196207/08)15:4<759::AID-CNCR2820150410>3.0.CO;2-6; Weiss RH, 1999, J AM SOC NEPHROL, V10, P1880; Wilson LD, 2007, NEW ENGL J MED, V356, P1862, DOI 10.1056/NEJMcp067190; Wirtz PW, 2005, J NEUROIMMUNOL, V164, P161, DOI 10.1016/j.jneuroim.2005.04.001; Wolfson AH, 2011, INT J RADIAT ONCOL, V81, P77, DOI 10.1016/j.ijrobp.2010.05.013; Yu JB, 2010, J THORAC ONCOL, V5, P215, DOI 10.1097/JTO.0b013e3181cd3208; ZELEN M, 1973, CANCER CHEMOTH REP 3, V4, P31	152	683	690	4	94	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2011	378	9804					1741	1755		10.1016/S0140-6736(11)60165-7	http://dx.doi.org/10.1016/S0140-6736(11)60165-7			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	846LB	21565397				2022-12-28	WOS:000296899800031
J	Anderson, E; Siegel, EH; Bliss-Moreau, E; Barrett, LF				Anderson, Eric; Siegel, Erika H.; Bliss-Moreau, Eliza; Barrett, Lisa Feldman			The Visual Impact of Gossip	SCIENCE			English	Article							BINOCULAR-RIVALRY; DOMINANCE DURATIONS; FACIAL EXPRESSIONS; PERCEPTION; ATTENTION; CONTRAST; EMOTION; FACES; RECOGNITION; PREDOMINATE	Gossip is a form of affective information about who is friend and who is foe. We show that gossip does not influence only how a face is evaluated-it affects whether a face is seen in the first place. In two experiments, neutral faces were paired with negative, positive, or neutral gossip and were then presented alone in a binocular rivalry paradigm (faces were presented to one eye, houses to the other). In both studies, faces previously paired with negative (but not positive or neutral) gossip dominated longer in visual consciousness. These findings demonstrate that gossip, as a potent form of social affective learning, can influence vision in a completely top-down manner, independent of the basic structural features of a face.	[Anderson, Eric; Siegel, Erika H.; Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA; [Bliss-Moreau, Eliza] Univ Calif Davis, Dept Psychiat & Behav Sci, Davis, CA 95616 USA; [Barrett, Lisa Feldman] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA; [Barrett, Lisa Feldman] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA	Northeastern University; University of California System; University of California Davis; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Barrett, LF (corresponding author), Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.	l.barrett@neu.edu	Barrett, Lisa Feldman/ABC-8157-2020	Anderson, Eric/0000-0002-4215-6308	NIH [DP1OD003312]; U.S. Army Research Institute for the Behavioral and Social Sciences [W91WAW-08-C-0018]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD003312] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Army Research Institute for the Behavioral and Social Sciences; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Preparation of this manuscript was supported by the NIH Director's Pioneer Award (DP1OD003312) and by the U.S. Army Research Institute for the Behavioral and Social Sciences (contract W91WAW-08-C-0018) to L.F.B. The views, opinions, and/or findings contained in this article are solely those of the author(s) and should not be construed as an official Department of the Army or Department of Defense position, policy, or decision. We thank J. Shang and M. Norton for their help with data collection.	Abelson RP, 1997, PSYCHOL METHODS, V2, P315, DOI 10.1037/1082-989X.2.4.315; Alpers GW, 2007, EMOTION, V7, P495, DOI 10.1037/1528-3542.7.3.495; Alpers GW, 2006, COGNITION EMOTION, V20, P596, DOI 10.1080/02699930500282249; Alpers GW, 2005, INT J PSYCHOPHYSIOL, V57, P25, DOI 10.1016/j.ijpsycho.2005.01.008; Andrews TJ, 1997, P NATL ACAD SCI USA, V94, P9905, DOI 10.1073/pnas.94.18.9905; Bannerman RL, 2008, OPHTHAL PHYSL OPT, V28, P317, DOI 10.1111/j.1475-1313.2008.00568.x; Bar M, 2006, P NATL ACAD SCI USA, V103, P449, DOI 10.1073/pnas.0507062103; Barrett LF, 2009, PHILOS T R SOC B, V364, P1325, DOI 10.1098/rstb.2008.0312; Baumeister RF, 2004, REV GEN PSYCHOL, V8, P111, DOI 10.1037/1089-2680.8.2.111; Blake R., 2001, BRAIN MIND, V2, P5, DOI [https://doi.org/10.1023/A:1017925416289, DOI 10.1023/A:1017925416289, 10.1023/A:1017925416289]; Bliss-Moreau E, 2008, EMOTION, V8, P479, DOI 10.1037/1528-3542.8.4.479; Carmel D, 2010, CURR BIOL, V20, pR799, DOI 10.1016/j.cub.2010.07.036; Carter OL, 2005, CURR BIOL, V15, pR412, DOI 10.1016/j.cub.2005.05.043; Chong SC, 2005, J VISION, V5, P1004, DOI 10.1167/5.11.6; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Delplanque S, 2007, J NEUROSCI METH, V165, P144, DOI 10.1016/j.jneumeth.2007.05.030; Dunbar RIM, 2004, REV GEN PSYCHOL, V8, P100, DOI 10.1037/1089-2680.8.2.100; Duncan S, 2007, COGNITION EMOTION, V21, P1184, DOI 10.1080/02699930701437931; HOLLINS M, 1980, PERCEPT PSYCHOPHYS, V27, P550, DOI 10.3758/BF03198684; Kakizaki S., 1960, JPN PSYCHOL RES, V2, P94, DOI [10.4992/psycholres1954.2.94, DOI 10.4992/PSYCHOLRES1954.2.94]; Knebel JF, 2008, BRAIN TOPOGR, V20, P284, DOI 10.1007/s10548-008-0046-5; Levelt WJM, 1965, BINOCULAR RIVALRY; Meng M, 2004, J VISION, V4, P539, DOI 10.1167/4.7.2; Nagamine M, 2007, PHYSIOL BEHAV, V91, P161, DOI 10.1016/j.physbeh.2007.02.016; Ohman A, 2001, J EXP PSYCHOL GEN, V130, P466, DOI 10.1037/0096-3445.130.3.466; Oliva A, 2007, TRENDS COGN SCI, V11, P520, DOI 10.1016/j.tics.2007.09.009; Olsson A, 2004, PSYCHOL SCI, V15, P822, DOI 10.1111/j.0956-7976.2004.00762.x; Phelps EA, 2006, PSYCHOL SCI, V17, P292, DOI 10.1111/j.1467-9280.2006.01701.x; PRATTO F, 1991, J PERS SOC PSYCHOL, V61, P380, DOI 10.1037/0022-3514.61.3.380; Schyns PG, 1999, COGNITION, V69, P243, DOI 10.1016/S0010-0277(98)00069-9; Tong F, 2006, TRENDS COGN SCI, V10, P502, DOI 10.1016/j.tics.2006.09.003; WHITTLE P, 1965, Q J EXP PSYCHOL, V17, P217, DOI 10.1080/17470216508416435; Yoon KL, 2009, EMOTION, V9, P172, DOI 10.1037/a0014714; YU K, 1992, J EXP PSYCHOL HUMAN, V18, P1158, DOI 10.1037/0096-1523.18.4.1158	34	99	104	6	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 17	2011	332	6036					1446	1448		10.1126/science.1201574	http://dx.doi.org/10.1126/science.1201574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	778FT	21596956	Green Accepted			2022-12-28	WOS:000291689000046
J	Johansson, K; Hemmingsson, E; Harlid, R; Trolle, Y; Granath, F; Rossner, S; Neovius, M				Johansson, Kari; Hemmingsson, Erik; Harlid, Richard; Trolle, Ylva; Granath, Fredrik; Rossner, Stephan; Neovius, Martin			Longer term effects of very low energy diet on obstructive sleep apnoea in cohort derived from randomised controlled trial: prospective observational follow-up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WEIGHT-REDUCTION PROGRAM; LIFE-STYLE INTERVENTION; BARIATRIC SURGERY; EPIDEMIOLOGY; RELIABILITY; MORTALITY; MODERATE; DEVICE	Objective To determine whether initial improvements in obstructive sleep apnoea after a very low energy diet were maintained after one year in patients with moderate to severe obstructive sleep apnoea. Design Single centre, prospective observational follow-up study. Setting Outpatient obesity clinic in a university hospital in Stockholm, Sweden. Participants 63 men aged 30-65 with body mass index (BMI) 30-40 and moderate to severe obstructive sleep apnoea defined as an apnoea-hypopnoea index >= 15 (events/hour), all treated with continuous positive airway pressure. Intervention A one year weight loss programme, consisting of an initial very low energy diet for nine weeks (seven weeks of 2.3 MJ/day and two weeks of gradual introduction of normal food) followed by a weight loss maintenance programme. Main outcome measure Apnoea-hypopnoea index, the main index for severity of obstructive sleep apnoea. Data from all patients were analysed (baseline carried forward for missing data). Results Of 63 eligible patients, 58 completed the very low energy diet period and started the weight maintenance programme and 44 completed the full programme; 49 had complete measurements at one year. At baseline the mean apnoea-hypopnoea index was 36 events/hour. After the very low energy diet period, apnoea-hypopnoea index was improved by -21 events/hour (95% confidence interval -17 to -25) and weight by -18 kg (-16 to -19; both P<0.001). After one year the apnoea-hypopnoea index had improved by -17 events/hour (-13 to -21) and body weight by -12 kg (-10 to -14) compared with baseline (both P<0.001). Patients with severe obstructive sleep apnoea at baseline had greater improvements in apnoea-hypopnoea index (-25 events/hour) compared with patients with moderate disease (-7 events/hour, P<0.001). At one year, 30/63 (48%, 95% confidence interval 35% to 60%) no longer required continuous positive airway pressure and 6/63 (10%, 2% to 17%) had total remission of obstructive sleep apnoea (apnoeahypopnoea index <5 events/hour). There was a dose-response association between weight loss and apnoeahypopnoea index at follow-up (beta=0.50 events/kg, 0.11 to 0.88; P=0.013). Conclusion Initial improvements in obstructive sleep apnoea after treatment with a very low energy diet can be maintained after one year in obese men with moderate to severe disease. Those who lose the most weight or have severe sleep apnoea at baseline benefit most.	[Johansson, Kari; Hemmingsson, Erik; Trolle, Ylva; Rossner, Stephan] Karolinska Inst, Dept Med Huddinge, Obes Unit, SE-14186 Stockholm, Sweden; [Harlid, Richard] Aleris Fysiologlab, Stockholm, Sweden; [Trolle, Ylva; Granath, Fredrik; Neovius, Martin] Karolinska Inst, Dept Med Solna, Clin Epidemiol Unit, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Johansson, K (corresponding author), Karolinska Inst, Dept Med Huddinge, Obes Unit, SE-14186 Stockholm, Sweden.	kari.johansson@ki.se	Lagerros, Ylva Trolle/AAH-7683-2020; Johanson, Kari/AAZ-4397-2020	Lagerros, Ylva Trolle/0000-0001-6816-7577; Hemmingsson, Erik/0000-0001-7335-3796; Neovius, Martin/0000-0003-2300-3055	Cambridge Weight Plan, Northants, UK; Novo Nordisk AS, Bagsvaerd, Denmark	Cambridge Weight Plan, Northants, UK; Novo Nordisk AS, Bagsvaerd, Denmark(Novo Nordisk)	This study was partly supported by research grants from Cambridge Weight Plan, Northants, UK, and Novo Nordisk AS, Bagsvaerd, Denmark. No one representing the funding sources read or commented on any version of the manuscript.	Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Ascaso Juan F, 2003, Eur J Intern Med, V14, P101, DOI 10.1016/S0953-6205(03)00022-0; Banno K, 2007, SLEEP MED, V8, P400, DOI 10.1016/j.sleep.2007.03.003; Bar A, 2003, CHEST, V123, P695, DOI 10.1378/chest.123.3.695; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Foster GD, 2009, ARCH INTERN MED, V169, P1619, DOI 10.1001/archinternmed.2009.266; Franz MJ, 2007, J AM DIET ASSOC, V107, P1755, DOI 10.1016/j.jada.2007.07.017; Fritscher LG, 2007, RESPIRATION, V74, P647, DOI 10.1159/000107736; Grunstein RR, 2007, SLEEP, V30, P703, DOI 10.1093/sleep/30.6.703; Guardiano SA, 2003, CHEST, V124, P1615, DOI 10.1378/chest.124.4.1615; Johansson K, 2009, OBES REV, V10, P564, DOI 10.1111/j.1467-789X.2009.00581.x; Johansson K, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4609; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kajaste S, 2004, SLEEP MED, V5, P125, DOI 10.1016/j.sleep.2003.07.007; Levendowski DJ, 2009, SLEEP BREATH, V13, P163, DOI 10.1007/s11325-008-0214-6; Lindberg E, 2000, SLEEP MED REV, V4, P411, DOI 10.1053/smrv.2000.0118; Lojander J, 1998, J INTERN MED, V244, P251; Marshall NS, 2008, SLEEP, V31, P1079; Marshall NS, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4363; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Melin I, 2006, Eat Weight Disord, V11, P22; Melin I, 2003, INT J OBESITY, V27, P1127, DOI 10.1038/sj.ijo.0802372; Neovius M, 2007, MED SCI SPORT EXER, V39, P2199, DOI 10.1249/mss.0b013e3181579.38a; Piliar G, 2008, DIABETES CARE, V31, pS303, DOI 10.2337/dc08-s272; PILLAR G, 1994, CHEST, V106, P1702, DOI 10.1378/chest.106.6.1702; Punjabi Naresh M, 2008, Proc Am Thorac Soc, V5, P136, DOI 10.1513/pats.200709-155MG; Punjabi NM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000132; SCOOP-VLCD, 2002, SCOOP VLCD TASK 7 3; Sullivan M., 1997, SF 12 HLTH SURVEY SW; Tuomilehto H, 2010, AM J CLIN NUTR, V92, P688, DOI 10.3945/ajcn.2010.29485; Tuomilehto HPI, 2009, AM J RESP CRIT CARE, V179, P320, DOI 10.1164/rccm.200805-669OC; Valencia-Flores M, 2004, OBES SURG, V14, P755, DOI 10.1381/0960892041590773; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; Young T, 2008, SLEEP, V31, P1071; Zou D, 2006, SLEEP, V29, P367, DOI 10.1093/sleep/29.3.367	36	81	82	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 1	2011	342								d3017	10.1136/bmj.d3017	http://dx.doi.org/10.1136/bmj.d3017			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774MK	21632666	Green Published, hybrid			2022-12-28	WOS:000291390500004
J	Nilsson, J; Payne, DN				Nilsson, Johan; Payne, David N.			High-Power Fiber Lasers	SCIENCE			English	Editorial Material							BEAM		[Nilsson, Johan; Payne, David N.] Univ Southampton, Optoelect Res Ctr, Southampton SO17 1BJ, Hants, England	University of Southampton	Nilsson, J (corresponding author), Univ Southampton, Optoelect Res Ctr, Southampton SO17 1BJ, Hants, England.	jn@orc.soton.ac.uk		Nilsson, Johan/0000-0003-1691-7959				Daniault L, 2011, OPT LETT, V36, P621, DOI 10.1364/OL.36.000621; Fan TY, 2005, IEEE J SEL TOP QUANT, V11, P567, DOI 10.1109/JSTQE.2005.850241; Jeong Y, 2004, OPT EXPRESS, V12, P6088, DOI 10.1364/OPEX.12.006088; KAFKA JD, 1989, Patent No. 4829529; Maurer R., 1974, U.S. Patent, Patent No. [3,808,549, 3808549]; MEARS RJ, 1987, ELECTRON LETT, V23, P1026, DOI 10.1049/el:19870719; Mourou GA, 2006, AIP CONF PROC, V827, P152, DOI 10.1063/1.2195207; PASK HM, 1995, IEEE J SEL TOP QUANT, V1, P2, DOI 10.1109/2944.468377; Paurisse M, 2009, OPT EXPRESS, V17, P13000, DOI 10.1364/OE.17.013000; Richardson DJ, 2010, J OPT SOC AM B, V27, pB63, DOI 10.1364/JOSAB.27.000B63; Shay TM, 2009, PROC SPIE, V7195, DOI 10.1117/12.809416; SNITZER E, 1988, OSA TECHNICAL DIGEST; Stiles E., 2009, 5 INT WORKSH FIB LAS	13	190	199	15	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2011	332	6032					921	922		10.1126/science.1194863	http://dx.doi.org/10.1126/science.1194863			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596979				2022-12-28	WOS:000290766600027
J	West, KP; Christian, P; Labrique, AB; Rashid, M; Shamim, AA; Klemm, RDW; Massie, AB; Mehra, S; Schulze, KJ; Ali, H; Ullah, B; Wu, LSF; Katz, J; Banu, H; Akhter, HH; Sommer, A				West, Keith P., Jr.; Christian, Parul; Labrique, Alain B.; Rashid, Mahbubur; Shamim, Abu Ahmed; Klemm, Rolf D. W.; Massie, Allan B.; Mehra, Sucheta; Schulze, Kerry J.; Ali, Hasmot; Ullah, Barkat; Wu, Lee S. F.; Katz, Joanne; Banu, Hashina; Akhter, Halida H.; Sommer, Alfred			Effects of Vitamin A or Beta Carotene Supplementation on Pregnancy-Related Mortality and Infant Mortality in Rural Bangladesh A Cluster Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MATERNAL NIGHT BLINDNESS; NEPAL; WOMEN; HEALTH; SURVIVAL; RISK	Context Maternal vitamin A deficiency is a public health concern in the developing world. Its prevention may improve maternal and infant survival. Objective To assess efficacy of maternal vitamin A or beta carotene supplementation in reducing pregnancy-related and infant mortality. Design, Setting, and Participants Cluster randomized, double-masked, placebo-controlled trial among pregnant women 13 to 45 years of age and their live-born infants to 12 weeks (84 days) postpartum in rural northern Bangladesh between 2001 and 2007. Interventions Five hundred ninety-six community clusters (study sectors) were randomized for pregnant women to receive weekly, from the first trimester through 12 weeks postpartum, 7000 mu g of retinol equivalents as retinyl palmitate, 42 mg of all-trans beta carotene, or placebo. Married women (n=125 257) underwent 5-week surveillance for pregnancy, ascertained by a history of amenorrhea and confirmed by urine test. Blood samples were obtained from participants in 32 sectors (5%) for biochemical studies. Main Outcome Measures All-cause mortality of women related to pregnancy, stillbirth, and infant mortality to 12 weeks (84 days) following pregnancy outcome. Results Groups were comparable across risk factors. For the mortality outcomes, neither of the supplement group outcomes was significantly different from the placebo group outcomes. The numbers of deaths and all-cause, pregnancy-related mortality rates (per 100 000 pregnancies) were 41 and 206 (95% confidence interval [CI], 140-273) in the placebo group, 47 and 237(95% CI, 166-309) in the vitamin A group, and 50 and 250(95% CI, 177-323) in the beta carotene group. Relative risks for mortality in the vitamin A and beta carotene groups were 1.15 (95% CI, 0.75-1.76) and 1.21 (95% CI, 0.81-1.81), respectively. In the placebo, vitamin A, and beta carotene groups the rates of stillbirth and infant mortality were 47.9(95% CI, 44.3-51.5), 45.6(95% CI, 42.1-49.2), and 51.8(95% CI, 48.0-55.6) per 1000 births and 68.1 (95% CI, 63.7-72.5), 65.0 (95% CI, 60.7-69.4), and 69.8(95% CI, 65.4-72.3) per 1000 live births, respectively. Vitamin A compared with either placebo or beta carotene supplementation increased plasma retinol concentrations by end of study (1.46 [95% CI, 1.42-1.50] mu mol/L vs 1.13 [95% CI, 1.09-1.17] mu mol/L and 1.18 [95% CI, 1.14-1.22] mu mol/L, respectively; P<.001) and reduced, but did not eliminate, gestational night blindness (7.1% for vitamin A vs 9.2% for placebo and 8.9% for beta carotene [P<.001 for both]). Conclusion Use of weekly vitamin A or beta carotene in pregnant women in Bangladesh, compared with placebo, did not reduce all-cause maternal, fetal, or infant mortality.	[West, Keith P., Jr.; Christian, Parul; Labrique, Alain B.; Klemm, Rolf D. W.; Massie, Allan B.; Mehra, Sucheta; Schulze, Kerry J.; Wu, Lee S. F.; Katz, Joanne; Sommer, Alfred] Johns Hopkins Univ, Ctr Human Nutr, Dept Int Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Rashid, Mahbubur] Partners Populat & Dev, Secretariat, Dhaka, Bangladesh; [Shamim, Abu Ahmed; Ali, Hasmot; Ullah, Barkat; Banu, Hashina] JiVitA Project, Gaibandha, Bangladesh; [Akhter, Halida H.] Ctr Hlth Serv, Arlington, VA USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	West, KP (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	kwest@jhsph.edu	Ali, Hasmot/I-8700-2019	Ali, Hasmot/0000-0003-0044-1992; Katz, Joanne/0000-0002-5997-7823; Abu Ahmed, Shamim/0000-0002-7071-8558; Labrique, Alain/0000-0003-2502-7819	Office of Health, Infectious Diseases and Nutrition, US Agency for International Development (USAID), Washington, DC [HRN-A-00-97-00015-00, GHS-A-00-03-00019-00]; Johns Hopkins University, Baltimore, Maryland [HRN-A-00-97-00015-00, GHS-A-00-03-00019-00]; Bill and Melinda Gates Foundation, Seattle, Washington [614]; USAID Mission, Dhaka, Bangladesh; Ministry of Health and Family Welfare, Government of Bangladesh, Dhaka; Micronutrient Initiative/Canadian International Development Agency, Ottawa, Ontario; Nutrilite Health Institute, Access Business Group LLC, Buena Park, California; Sight and Life Research Institute, Baltimore, Maryland	Office of Health, Infectious Diseases and Nutrition, US Agency for International Development (USAID), Washington, DC(United States Agency for International Development (USAID)); Johns Hopkins University, Baltimore, Maryland(Johns Hopkins University); Bill and Melinda Gates Foundation, Seattle, Washington(Bill & Melinda Gates Foundation); USAID Mission, Dhaka, Bangladesh(United States Agency for International Development (USAID)); Ministry of Health and Family Welfare, Government of Bangladesh, Dhaka; Micronutrient Initiative/Canadian International Development Agency, Ottawa, Ontario; Nutrilite Health Institute, Access Business Group LLC, Buena Park, California; Sight and Life Research Institute, Baltimore, Maryland	The conduct of this trial was financially supported by Micronutrients for Health Cooperative Agreement HRN-A-00-97-00015-00 and Global Research Activity GHS-A-00-03-00019-00 between the Office of Health, Infectious Diseases and Nutrition, US Agency for International Development (USAID), Washington, DC, and Johns Hopkins University, Baltimore, Maryland, and Global Control of Micronutrient Deficiency grant 614 from the Bill and Melinda Gates Foundation, Seattle, Washington, with additional support from the USAID Mission, Dhaka, Bangladesh; the Ministry of Health and Family Welfare, Government of Bangladesh, Dhaka; the Micronutrient Initiative/Canadian International Development Agency, Ottawa, Ontario; the Nutrilite Health Institute, Access Business Group LLC, Buena Park, California; and the Sight and Life Research Institute, Baltimore, Maryland.	Christian P, 2000, J NUTR, V130, P2675, DOI 10.1093/jn/130.11.2675; Christian P, 2000, AM J EPIDEMIOL, V152, P542, DOI 10.1093/aje/152.6.542; Christian P, 2001, J NUTR, V131, P1510, DOI 10.1093/jn/131.5.1510; Christian P, 1998, INT J EPIDEMIOL, V27, P231, DOI 10.1093/ije/27.2.231; Christian P, 2008, PUBLIC HEALTH, V122, P161, DOI 10.1016/j.puhe.2007.06.003; DIXIT DT, 1966, INDIAN J MED RES, V54, P791; Faisel H, 2000, PUBLIC HEALTH NUTR, V3, P321, DOI 10.1017/S1368980000000367; Green HN, 1928, BRIT MED J, V1928, P691, DOI 10.1136/bmj.2.3537.691; Gunnsteinsson S, 2010, J HEALTH POPUL NUTR, V28, P509; Hill K, 2007, LANCET, V370, P1311, DOI 10.1016/S0140-6736(07)61572-4; Iwata M, 2011, VITAM HORM, V86, P127, DOI 10.1016/B978-0-12-386960-9.00006-X; KATZ J, 1995, J NUTR, V125, P2122, DOI 10.1093/jn/125.8.2122; Katz J, 2000, AM J CLIN NUTR, V71, P1570; Kim CH, 2011, VITAM HORM, V86, P83, DOI 10.1016/B978-0-12-386960-9.00004-6; Kirkwood BR, 2010, LANCET, V375, P1640, DOI 10.1016/S0140-6736(10)60311-X; Koblinsky M, 2008, J HEALTH POPUL NUTR, V26, P280; Labrique AB, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-102; Mandal GS, 1969, J OBSTET GYN INDIA, V19, P453; Nti Christina A, 2008, Nutr Res Pract, V2, P35, DOI 10.4162/nrp.2008.2.1.35; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Ross AC, 2011, VITAM HORM, V86, P103, DOI 10.1016/B978-0-12-386960-9.00005-8; Ross DA, 2002, J NUTR, V132, p2902S, DOI 10.1093/jn/132.9.2902S; Schurmann AT, 2009, J HEALTH POPUL NUTR, V27, P505; Sommer A, 1996, VITAMIN A HLTH SURVI; Sugimoto JD, 2007, J HEALTH POPUL NUTR, V25, P436; Tielsch JM, 2008, J NUTR, V138, P787, DOI 10.1093/jn/138.4.787; UNICEF, 1998, PROG PATH ROAD PROGR; West KP, 1999, BMJ-BRIT MED J, V318, P570, DOI 10.1136/bmj.318.7183.570; WHO, 2010, TRENDS MAT MORT 1990; World Health Organization, 2009, GLOB PREV VIT DEF PO; Yamini S, 2001, EUR J CLIN NUTR, V55, P252, DOI 10.1038/sj.ejcn.1601152; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	32	95	98	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2011	305	19					1986	1995		10.1001/jama.2011.656	http://dx.doi.org/10.1001/jama.2011.656			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764WO	21586714	Bronze			2022-12-28	WOS:000290665500022
J	Bender, BS				Bender, Bradley S.			Quadrivalent HPV vaccine prevented HPV infection and external genital lesions in boys and men 16 to 26 years of age	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA		Bender, BS (corresponding author), N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA.							Kim JJ, 2011, NEW ENGL J MED, V364, P393, DOI 10.1056/NEJMp1012246; Workowski Kimberly A., 2006, Morbidity and Mortality Weekly Report, V55, P1; Zimet GD, 2010, BMC WOMENS HEALTH, V10, DOI 10.1186/1472-6874-10-27	3	0	1	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-10	10.7326/0003-4819-154-10-201105170-02010	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576528				2022-12-28	WOS:000290620300009
J	Wang, WC; Ware, RE; Miller, ST; Iyer, RV; Casella, JF; Minniti, CP; Rana, S; Thornburg, CD; Rogers, ZR; Kalpatthi, RV; Barredo, JC; Brown, RC; Sarnaik, SA; Howard, TH; Wynn, LW; Kutlar, A; Armstrong, FD; Files, BA; Goldsmith, JC; Waclawiw, MA; Huang, XK; Thompson, BW				Wang, Winfred C.; Ware, Russell E.; Miller, Scott T.; Iyer, Rathi V.; Casella, James F.; Minniti, Caterina P.; Rana, Sohail; Thornburg, Courtney D.; Rogers, Zora R.; Kalpatthi, Ram V.; Barredo, Julio C.; Brown, R. Clark; Sarnaik, Sharada A.; Howard, Thomas H.; Wynn, Lynn W.; Kutlar, Abdullah; Armstrong, F. Daniel; Files, Beatrice A.; Goldsmith, Jonathan C.; Waclawiw, Myron A.; Huang, Xiangke; Thompson, Bruce W.		BABY HUG Investigators	Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)	LANCET			English	Article							HYDROXYUREA THERAPY; ADVERSE OUTCOMES; SPLENIC FUNCTION; DISEASE; PREDICTION; MORTALITY; EFFICACY	Background Sickle-cell anaemia is associated with substantial morbidity from acute complications and organ dysfunction beginning in the first year of life. Hydroxycarbamide substantially reduces episodes of pain and acute chest syndrome, admissions to hospital, and transfusions in adults with sickle-cell anaemia. We assessed the effect of hydroxycarbamide therapy on organ dysfunction and clinical complications, and examined laboratory findings and toxic effects. Methods This randomised trial was undertaken in 13 centres in the USA between October, 2003, and September, 2009. Eligible participants had haemoglobin SS (HbSS) or haemoglobin S beta(0)thalassaemia, were aged 9-18 months at randomisation, and were not selected for clinical severity. Participants received liquid hydroxycarbamide, 20 mg/kg per day, or placebo for 2 years. Randomisation assignments were generated by the medical coordinating centre by a pre-decided schedule. Identical appearing and tasting formulations were used for hydroxycarbamide and placebo. Patients, caregivers, and coordinating centre staff were masked to treatment allocation. Primary study endpoints were splenic function (qualitative uptake on Tc-99 spleen scan) and renal function (glomerular filtration rate by Tc-99m-DTPA clearance). Additional assessments included blood counts, fetal haemoglobin concentration, chemistry profiles, spleen function biomarkers, urine osmolality, neurodevelopment, transcranial Doppler ultrasonography, growth, and mutagenicity. Study visits occurred every 2-4 weeks. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00006400. Findings 96 patients received hydroxycarbamide and 97 placebo, of whom 83 patients in the hydroxycarbamide group and 84 in the placebo group completed the study. Significant differences were not seen between groups for the primary endpoints (19 of 70 patients with decreased spleen function at exit in the hydroxycarbamide group vs 28 of 74 patients in the placebo group, p=0.21; and a difference in the mean increase in DTPA glomerular filtration rate in the hydroxycarbamide group versus the placebo group of 2 ml/min per 1.73 m(2), p=0.84). Hydroxycarbamide significantly decreased pain (177 events in 62 patients vs 375 events in 75 patients in the placebo group, p=0.002) and dactylitis (24 events in 14 patients vs 123 events in 42 patients in the placebo group, p<0.0001), with some evidence for decreased acute chest syndrome, hospitalisation rates, and transfusion. Hydroxyurea increased haemoglobin and fetal haemoglobin, and decreased white blood-cell count. Toxicity was limited to mild-to-moderate neutropenia. Interpretation On the basis of the safety and efficacy data from this trial, hydroxycarbamide can now be considered for all very young children with sickle-cell anaemia.	[Wang, Winfred C.] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN 38105 USA; [Miller, Scott T.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; [Iyer, Rathi V.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Casella, James F.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Minniti, Caterina P.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Rana, Sohail] Howard Univ, Coll Med, Washington, DC USA; [Thornburg, Courtney D.] Duke Univ, Med Ctr, Raleigh, NC USA; [Rogers, Zora R.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Kalpatthi, Ram V.] Med Univ S Carolina, Charleston, SC 29425 USA; [Barredo, Julio C.; Armstrong, F. Daniel] Univ Miami, Miami, FL USA; [Brown, R. Clark; Files, Beatrice A.] Emory Univ, Sch Med, Atlanta, GA USA; [Howard, Thomas H.] Childrens Hosp Michigan, Detroit, MI 48201 USA; [Kutlar, Abdullah] Med Coll Georgia, Augusta, GA 30912 USA; [Goldsmith, Jonathan C.; Waclawiw, Myron A.] NHLBI, Bethesda, MD 20892 USA; [Huang, Xiangke; Thompson, Bruce W.] Clinical Trials & Surveys Corp, Owings Mills, MD USA	St Jude Children's Research Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Mississippi; University of Mississippi Medical Center; Johns Hopkins University; Children's National Health System; Howard University; Duke University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Medical University of South Carolina; University of Miami; Emory University; Children's Hospital of Michigan; University System of Georgia; Augusta University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wang, WC (corresponding author), St Jude Childrens Res Hosp, Dept Hematol, 262 Danny Thomas Pl, Memphis, TN 38105 USA.	winfred.wang@stjude.org	Minniti, Caterina/AAX-3187-2021; Mattison, Donald/L-4661-2013	Mattison, Donald/0000-0001-5623-0874; Faughnan, Lane/0000-0002-8463-8217	National Heart, Lung and Blood Institute; National Institutes of Health [N01-HB-07150, N01-HB-07160]; Children's National Medical Center; Duke University Medical Center; Howard University College of Medicine; Johns Hopkins University School of Medicine; Sinai Hospital, Baltimore; Medical University of South Carolina; St Jude Children's Research Hospital; SUNY Downstate Medical Center/Kings County Hospital Center; University of Miami; University of Mississippi Medical Center; University of Texas Southwestern Medical Center, Dallas; University of Alabama at Birmingham; Drexel University; Emory University School of Medicine; Children's Hospital of Michigan; Clinical Trials and Surveys Corp; National Institute of Child Health and Human Development; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB007156, N01HB007154, N01HB007153, N01HB007160, N01HB007157, N01HB007152, N01HB007155, N01HB007158, N01HB007150, N01HB007151, N01HB007159] Funding Source: NIH RePORTER	National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's National Medical Center; Duke University Medical Center; Howard University College of Medicine; Johns Hopkins University School of Medicine(Johns Hopkins University); Sinai Hospital, Baltimore; Medical University of South Carolina; St Jude Children's Research Hospital; SUNY Downstate Medical Center/Kings County Hospital Center; University of Miami; University of Mississippi Medical Center; University of Texas Southwestern Medical Center, Dallas; University of Alabama at Birmingham; Drexel University; Emory University School of Medicine; Children's Hospital of Michigan; Clinical Trials and Surveys Corp; National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The National Heart, Lung and Blood Institute and National Institutes of Health (contracts N01-HB-07150 to N01-HB-07160) funded the study, with partial support from the Best Pharmaceuticals for Children Act and the National Institute of Child Health and Human Development. We thank the following people at the participating Clinical Centers, the Medical Coordinating Center, and the sponsoring institutes: Children's National Medical Center (Catherine Driscoll, Lori Luchtman-Jones, Brenda Martin, Barbara Speller-Brown, Romuladus Azuine); Duke University Medical Center (Sherri Zimmerman, William Schultz, Tracy Kelly, Shelly Burgett); Howard University College of Medicine (Caroline K Reed, Erin Yeagley, Patricia Houston-Yu); Johns Hopkins University School of Medicine (Phillip Seaman, Jeffrey Keefer, Sue Dixon, Patrice Sharp); Sinai Hospital, Baltimore (Jason Fixler, Joan Marasciulo); Medical University of South Carolina (Miguel Abboud, Mary Ellen Cavalier, Sherron Jackson, Betsy Rackoff, Lisa Kuisel, Deborah Disco); St Jude Children's Research Hospital (Lane Faughnan); SUNY Downstate Medical Center/Kings County Hospital Center (Kathy Rey, Sreedhar P Rao); University of Miami (Stuart Toledano, Tally Hustace, Noeline Lewis, Ofelia Alvarez); University of Mississippi Medical Center (Glenda Thomas, Tobi Breland, Amy Forsythe, Torn Hogan); University of Texas Southwestern Medical Center, Dallas (Cindy Cochran, Nicole Corrigan, Jennifer Marshall, Roxanna Mars, Leah Adix); University of Alabama at Birmingham (Jennifer McDuffie, Kimberly Whelan, Roy McDonald); Drexel University (Canton Dampier, Lori Luck, Mary Lou MacDermott, Maureen Meier, Michele Cahill); Emory University School of Medicine (Peter Lane, Ifeyinwa Osunkwo, Ellen Debenham, Leann Hassen, Terrell Faircloth); Children's Hospital of Michigan (Wanda Whitten-Shurney, Mary Murphy, Kristin Stone-Kennedy); Clinical Trials and Surveys Corp (Zhibao Mi, Zhaoyu Luo, Billie Fish, Joulia Haziminas, Renee Rees, Franka Barton); the National Heart, Lung and Blood Institute (Charles Peterson); and the National Institute of Child Health and Human Development (Donald Mattison). We thank the following consultants: Robert Adams (Medical University of South Carolina); Steven Pavlakis (Maimonides Medical Center); Michael Jeng (Stanford University Medical Center); Stephen Dertinger (Litron Corporation); Beth McCarville and Barry Shulkin (St Jude Children's Research Hospital); Eglal Rana (Howard University); and Niren Patel (Medical College of Georgia). Additionally, we appreciate the contributions of Charles Pegelow, who led the University of Miami Center until his untimely death. We acknowledge the efforts of the BABY HUG participants and their families, and the contributions of all who participated in BABY HUG.	ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Brawley OW, 2008, ANN INTERN MED, V148, P932, DOI 10.7326/0003-4819-148-12-200806170-00220; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Ferster A, 1996, BLOOD, V88, P1960, DOI 10.1182/blood.V88.6.1960.bloodjournal8861960; Fitzhugh CD, 2005, PEDIATR BLOOD CANCER, V45, P982, DOI 10.1002/pbc.20296; Flanagan JM, 2010, MUTAT RES-GEN TOX EN, V698, P38, DOI 10.1016/j.mrgentox.2010.03.001; Hanft VN, 2000, BLOOD, V95, P3589, DOI 10.1182/blood.V95.11.3589.011k38_3589_3593; Hankins JS, 2008, PEDIATR BLOOD CANCER, V50, P293, DOI 10.1002/pbc.21271; Hankins JS, 2005, BLOOD, V106, P2269, DOI 10.1182/Blood-2004-12-4973; Heeney MM, 2004, J PEDIAT HEMATOL ONC, V26, P179, DOI 10.1097/00043426-200403000-00007; Jones A. C., 2009, CHEM VAPOUR DEPOSITI, P1, DOI DOI 10.1039/9781847558794-00001; Lanzkron S, 2008, ANN INTERN MED, V148, P939, DOI 10.7326/0003-4819-148-12-200806170-00221; Miller ST, 2010, PEDIATR BLOOD CANCER, V54, P265, DOI 10.1002/pbc.22189; Miller ST, 2000, NEW ENGL J MED, V342, P83, DOI 10.1056/NEJM200001133420203; Olivieri NF, 1998, J PEDIAT HEMATOL ONC, V20, P26, DOI 10.1097/00043426-199801000-00004; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Quinn CT, 2008, BLOOD, V111, P544, DOI 10.1182/blood-2007-07-100719; Rogers ZR, 2011, BLOOD, V117, P2614, DOI 10.1182/blood-2010-04-278747; Santos A, 2002, EUR J NUCL MED MOL I, V29, P536, DOI 10.1007/s00259-001-0738-5; Steinberg MH, 2010, AM J HEMATOL, V85, P403, DOI 10.1002/ajh.21699; Strouse JJ, 2008, PEDIATRICS, V122, P1332, DOI 10.1542/peds.2008-0441; Thompson BW, 2010, PEDIATR BLOOD CANCER, V54, P250, DOI 10.1002/pbc.22269; Thornburg CD, 2009, PEDIATR BLOOD CANCER, V52, P609, DOI 10.1002/pbc.21738; Voskaridou E, 2010, BLOOD, V115, P2354, DOI 10.1182/blood-2009-05-221333; Wang WC, 2001, J PEDIATR-US, V139, P790, DOI 10.1067/mpd.2001.119590; Ware RE, 2010, BLOOD, V115, P5300, DOI 10.1182/blood-2009-04-146852; Ware RE, 2010, J PEDIATR-US, V156, P66, DOI 10.1016/j.jpeds.2009.06.060; Wigfall DR, 2000, J PEDIATR-US, V136, P749, DOI 10.1016/S0022-3476(00)48828-1; Zimmerman SA, 2004, BLOOD, V103, P2039, DOI 10.1182/blood-2003-07-2475	30	507	512	0	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	2011	377	9778					1663	1672		10.1016/S0140-6736(11)60355-3	http://dx.doi.org/10.1016/S0140-6736(11)60355-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766JF	21571150	Green Accepted			2022-12-28	WOS:000290777700031
J	Mihaylova, MM; Vasquez, DS; Ravnskjaer, K; Denechaud, PD; Yu, RT; Alvarez, JG; Downes, M; Evans, RM; Montminy, M; Shaw, RJ				Mihaylova, Maria M.; Vasquez, Debbie S.; Ravnskjaer, Kim; Denechaud, Pierre-Damien; Yu, Ruth T.; Alvarez, Jacqueline G.; Downes, Michael; Evans, Ronald M.; Montminy, Marc; Shaw, Reuben J.			Class IIa Histone Deacetylases Are Hormone-Activated Regulators of FOXO and Mammalian Glucose Homeostasis	CELL			English	Article							CREB COACTIVATOR TORC2; STEM-CELL HOMEOSTASIS; PROTEIN-KINASE; TRANSCRIPTION FACTOR; METABOLIC SYNDROME; GENE-EXPRESSION; CLASS IIHDAC; PHOSPHORYLATION; ACETYLATION; DISEASE	Class IIa histone deacetylases (HDACs) are signal-dependent modulators of transcription with established roles in muscle differentiation and neuronal survival. We show here that in liver, class IIa HDACs (HDAC4, 5, and 7) are phosphorylated and excluded from the nucleus by AMPK family kinases. In response to the fasting hormone glucagon, class IIa HDACs are rapidly dephosphorylated and translocated to the nucleus where they associate with the promoters of gluconeogenic enzymes such as G6Pase. In turn, HDAC4/5 recruit HDAC3, which results in the acute transcriptional induction of these genes via deacetylation and activation of FOXO family transcription factors. Loss of class IIa HDACs in murine liver results in inhibition of FOXO target genes and lowers blood glucose, resulting in increased glycogen storage. Finally, suppression of class IIa HDACs in mouse models of type 2 diabetes ameliorates hyperglycemia, suggesting that inhibitors of class I/II HDACs may be potential therapeutics for metabolic syndrome.	[Mihaylova, Maria M.; Vasquez, Debbie S.; Denechaud, Pierre-Damien; Shaw, Reuben J.] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; [Ravnskjaer, Kim; Montminy, Marc] Salk Inst Biol Studies, Clayton Labs Peptide Biol, La Jolla, CA 92037 USA; [Yu, Ruth T.; Alvarez, Jacqueline G.; Downes, Michael; Evans, Ronald M.] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; [Evans, Ronald M.; Shaw, Reuben J.] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; [Mihaylova, Maria M.; Vasquez, Debbie S.; Ravnskjaer, Kim; Denechaud, Pierre-Damien; Yu, Ruth T.; Alvarez, Jacqueline G.; Downes, Michael; Evans, Ronald M.; Montminy, Marc; Shaw, Reuben J.] Salk Inst Biol Studies, Leona & Harry Helmsley Ctr Nutr Genom, La Jolla, CA 92037 USA	Salk Institute; Salk Institute; Salk Institute; Howard Hughes Medical Institute; Salk Institute; Salk Institute	Shaw, RJ (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shaw@salk.edu	Evans, Ronald/AAF-4001-2019; Pierre-Damien, Denechaud/M-5650-2016; Mihaylova, Maria M./ACZ-4949-2022; Ravnskjaer, Kim/GRJ-3065-2022	Evans, Ronald/0000-0002-9986-5965; Pierre-Damien, Denechaud/0000-0003-3502-4814; Mihaylova, Maria M./0000-0002-2725-767X; Ravnskjaer, Kim/0000-0002-5322-3887; Yu, Ruth/0000-0002-9527-9627	NIH [HD027183, DK062434, R01 DK049777, R01DK083834, R01 DK080425, P01CA120964]; American Diabetes Association [1-08-JF-47];  [T32 CMG]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA120964, P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK090962, R01DK049777, R01DK080425, R37DK083834, R01DK083834, U19DK062434] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	M.M.M. performed all cell and biochemistry experiments, designed shRNAs, generated and large-scale purified all adenoviruses utilized, characterized all antisera utilized, and with assistance from D. S. V. performed all mouse experiments. M. M. M. and R.J.S. designed the study, analyzed the data, and wrote the paper. In addition, K. R. in the lab of M. M. performed ChIP in Figure 3, Figure 5, and Figure S3; P.-D.D. in the lab of R.J.S. assisted with hepatocyte generation for Figure S2. R.T.Y. in the lab of R. M. E. performed microarray analysis in Figure 3A. J.G.A. and M. D. in the lab of R. M. E. performed qPCR in Figure 3B and Figure 6D. We thank A. Fukamizu (U. of Tsukuba) and A. Brunet (Stanford) for Foxo1 antibodies; M. Karin (UCSD) and P. Chambon (IGBMC) for the Albumin-creERT2 mice; B. Wang and S. Hedrick for sharing reagents and assistance; H. Juguilon for technical assistance; D. Shackelford for assistance with the in vivo mouse imaging studies; R. Dentin for initial help with hepatocytes; L. Gerken for genotyping; R. Kohnz for initial characterization of Alb-creERT2 LKB1 mice; J. Fitzpatrick for confocal imaging assistance; and K. Lamia for comments on the manuscript. We apologize to many investigators whose primary studies in the HDAC and FOXO fields could not be cited due to space limitations. M. M. M. was supported through the T32 CMG training grant to UCSD/Salk. R. M. E. is funded by the NIH HD027183 and DK062434. M. M. is funded by the NIH R01 DK049777 and R01DK083834. R. J. S. is funded by the NIH R01 DK080425 and P01CA120964 and the American Diabetes Association Junior Faculty Award 1-08-JF-47. We thank the Leona M. and Harry B. Helmsley Charitable Trust for their generous support.	Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573; Biddinger SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI 10.1146/annurev.physiol.68.040104.124723; Brent MM, 2008, STRUCTURE, V16, P1407, DOI 10.1016/j.str.2008.06.013; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Canto C, 2010, CELL MOL LIFE SCI, V67, P3407, DOI 10.1007/s00018-010-0454-z; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005; Creemers EE, 2006, DEVELOPMENT, V133, P4245, DOI 10.1242/dev.02610; Dansen TB, 2004, J LIPID RES, V45, P81, DOI 10.1194/jlr.M300111-JLR200; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Dequiedt F, 2006, MOL CELL BIOL, V26, P7086, DOI 10.1128/MCB.00231-06; Djouder N, 2010, EMBO J, V29, P469, DOI 10.1038/emboj.2009.339; Dong XC, 2006, J CLIN INVEST, V116, P101, DOI 10.1172/JCI25735; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Gross DN, 2009, CURR DIABETES REP, V9, P208, DOI 10.1007/s11892-009-0034-5; Guarente L, 2006, NATURE, V444, P868, DOI 10.1038/nature05486; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Haeusler RA, 2010, J BIOL CHEM, V285, P35245, DOI 10.1074/jbc.C110.175851; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Houtkooper RH, 2010, ENDOCR REV, V31, P194, DOI 10.1210/er.2009-0026; Hurley RL, 2006, J BIOL CHEM, V281, P36662, DOI 10.1074/jbc.M606676200; Hutton JC, 2009, J BIOL CHEM, V284, P29241, DOI 10.1074/jbc.R109.025544; Imai T, 2000, GENESIS, V26, P147, DOI 10.1002/(SICI)1526-968X(200002)26:2<147::AID-GENE15>3.0.CO;2-3; Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Lahm A, 2007, P NATL ACAD SCI USA, V104, P17335, DOI 10.1073/pnas.0706487104; Matsumoto M, 2007, CELL METAB, V6, P208, DOI 10.1016/j.cmet.2007.08.006; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Mcgee SL, 2008, DIABETES, V57, P860, DOI 10.2337/db07-0843; Montminy M, 2004, ANN ENDOCRINOL-PARIS, V65, P73, DOI 10.1016/S0003-4266(04)95634-X; Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013; Peng WT, 2009, GENESIS, V47, P590, DOI 10.1002/dvg.20538; Qiang L, 2010, J BIOL CHEM, V285, P27396, DOI 10.1074/jbc.M110.140228; Renault VM, 2009, CELL STEM CELL, V5, P527, DOI 10.1016/j.stem.2009.09.014; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Salganik SV, 2009, LAB INVEST, V89, P1032, DOI 10.1038/labinvest.2009.64; Schuetz A, 2008, J BIOL CHEM, V283, P11355, DOI 10.1074/jbc.M707362200; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; van der Linden AM, 2007, EMBO J, V26, P358, DOI 10.1038/sj.emboj.7601479; Vander Kooi BT, 2003, J BIOL CHEM, V278, P11782, DOI 10.1074/jbc.M212570200; Viollet B, 2009, ACTA PHYSIOL, V196, P81, DOI 10.1111/j.1748-1716.2009.01970.x; Wang B, 2011, CELL, V145, P596, DOI 10.1016/j.cell.2011.04.013; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102	54	406	423	1	53	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 13	2011	145	4					607	621		10.1016/j.cell.2011.03.043	http://dx.doi.org/10.1016/j.cell.2011.03.043			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565617	Bronze, Green Accepted			2022-12-28	WOS:000290560800013
J	Conroy, T; Desseigne, F; Ychou, M; Bouche, O; Guimbaud, R; Becouarn, Y; Adenis, A; Raoul, JL; Gourgou-Bourgade, S; de la Fouchardiere, C; Bennouna, J; Bachet, JB; Khemissa-Akouz, F; Pere-Verge, D; Delbaldo, C; Assenat, E; Chauffert, B; Michel, P; Montoto-Grillot, C; Ducreux, M				Conroy, Thierry; Desseigne, Francoise; Ychou, Marc; Bouche, Olivier; Guimbaud, Rosine; Becouarn, Yves; Adenis, Antoine; Raoul, Jean-Luc; Gourgou-Bourgade, Sophie; de la Fouchardiere, Christelle; Bennouna, Jaafar; Bachet, Jean-Baptiste; Khemissa-Akouz, Faiza; Pere-Verge, Denis; Delbaldo, Catherine; Assenat, Eric; Chauffert, Bruno; Michel, Pierre; Montoto-Grillot, Christine; Ducreux, Michel		Grp Tumeurs Digestives Unicanc; PRODIGE Intergrp	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III TRIAL; CLINICAL-TRIALS; 1ST-LINE THERAPY; COMBINATION; IRINOTECAN; OXALIPLATIN; 5-FLUOROURACIL; CARCINOMA; CISPLATIN; SURVIVAL	BACKGROUND Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. METHODS We randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks. Six months of chemotherapy were recommended in both groups in patients who had a response. The primary end point was overall survival. RESULTS The median overall survival was 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001). The objective response rate was 31.6% in the FOLFIRINOX group versus 9.4% in the gemcitabine group (P<0.001). More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P<0.001). CONCLUSIONS As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. (Funded by the French government and others; ClinicalTrials. gov number, NCT00112658.)	[Conroy, Thierry] Ctr Alexis Vautrin, Nancy, France; [Conroy, Thierry] Nancy Univ, Nancy, France; [Desseigne, Francoise; de la Fouchardiere, Christelle] Ctr Leon Berard, F-69373 Lyon, France; [Ychou, Marc; Gourgou-Bourgade, Sophie] Ctr Val Aurelle, Montpellier, France; [Assenat, Eric] Ctr Hosp Univ St Eloi, Montpellier, France; [Bouche, Olivier] Ctr Hosp Univ Robert Debre, Reims, France; [Guimbaud, Rosine] Inst Claudius Regaud, Toulouse, France; [Becouarn, Yves] Inst Bergonie, Bordeaux, France; [Adenis, Antoine] Ctr Oscar Lambret, F-59020 Lille, France; [Raoul, Jean-Luc] Ctr Eugene Marquis, Rennes, France; [Bennouna, Jaafar] Ctr Rene Gauducheau, F-44035 Nantes, France; [Bachet, Jean-Baptiste] Hop Ambroise Pare, Boulogne, France; [Khemissa-Akouz, Faiza] Ctr Hosp, Perpignan, France; [Pere-Verge, Denis] Hop Croix Rousse, F-69317 Lyon, France; [Delbaldo, Catherine] Ctr Hosp Henri Mondor, Creteil, France; [Chauffert, Bruno] Ctr Georges Francois Leclerc, Dijon, France; [Michel, Pierre] Rouen Univ Hosp, Rouen, France; [Michel, Pierre] Univ Rouen, Rouen, France; [Montoto-Grillot, Christine] Uni Canc Bur Etud Clin & Therapeut, Paris, France; [Ducreux, Michel] Inst Gustave Roussy, Villejuif, France; [Ducreux, Michel] Univ Paris 11, Le Kremlin Bicetre, France	UNICANCER; Institut de cancerologie de Lorraine (ICL); Universite de Lorraine; UNICANCER; Centre Leon Berard; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU de Montpellier; CHU de Reims; UNICANCER; Institut Claudius Regaud; UNICANCER; Institut Bergonie; UNICANCER; Centre Oscar Lambret; UNICANCER; Centre Eugene Marquis; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UNICANCER; Centre Georges-Francois Leclerc; CHU de Rouen; Universite de Rouen Normandie; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Conroy, T (corresponding author), Ctr Alexis Vautrin, Dept Med Oncol, F-54511 Vandoeuvre Les Nancy, France.	t.conroy@nancy.fnclcc.fr	Conroy, Thierry/X-8127-2019; ADENIS, ANTOINE/AFL-9835-2022; Ducreux, Michel/AAG-9415-2019; de la Fouchardiere, Christelle/AAW-7887-2021; ADENIS, ANTOINE/AAH-2034-2022; Sperduti, Isabella/K-8902-2016; BACHET, Jean-Baptiste/N-6943-2017	Ducreux, Michel/0000-0001-8649-7449; ghiringhelli, francois/0000-0002-5465-8305; Raoul, Jean-Luc/0000-0001-6305-8953; Sperduti, Isabella/0000-0001-5115-3099; DE LA FOUCHARDIERE, CHRISTELLE/0000-0003-2291-5693; Bennouna, Jaafar/0000-0002-5034-1108; Ychou, Marc/0000-0001-7378-9469; BACHET, Jean-Baptiste/0000-0003-4337-286X; LECOMTE, Thierry/0000-0001-5093-0212	French government; French Ministry of Health; Amgen; French National League against Cancer; Pfizer; Roche; AstraZeneca; Boehringer	French government; French Ministry of Health; Amgen(Amgen); French National League against Cancer; Pfizer(Pfizer); Roche(Roche Holding); AstraZeneca(AstraZeneca); Boehringer(Boehringer Ingelheim)	Funded by the French government and others; ClinicalTrials. gov number, NCT00112658.); Supported by Clinical Research Hospital Program grants (PHRC 2004 and 2007) from the French Ministry of Health, and grants from Amgen and the French National League against Cancer.; Dr. Ducreux reports receiving consulting fees from Pfizer, serving on an advisory board for Sanofi-Aventis, receiving payment for the development of educational presentations from Pfizer and Sanofi-Aventis, and receiving grant support to his institution from Pfizer; Dr. Bennouna, serving on advisory boards for Roche, Boehringer, and Bayer, receiving lecture fees from Roche, AstraZeneca, and Amgen, and receiving travel fees from Boehringer and Roche; Dr. Bouche, serving on advisory boards for Roche and Pfizer; Dr. Ychou, serving on advisory boards for Amgen, Bayer, Merck, Novartis, and Roche; and Dr. Bachet, receiving payment for the development of an educational presentation from Janssen-Cilag. No other potential conflict of interest relevant to this article was reported.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Azrak RG, 2004, CLIN CANCER RES, V10, P1121, DOI 10.1158/1078-0432.CCR-0913-3; Bonnetain F, 2010, EUR J CANCER, V46, P2753, DOI 10.1016/j.ejca.2010.07.023; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Colucci G, 2002, CANCER, V94, P902, DOI 10.1002/cncr.10323.abs; Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006, COMMON TERMINOLOGY C; Conroy T, 2005, J CLIN ONCOL, V23, P1228, DOI 10.1200/JCO.2005.06.050; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Di Marco M, 2010, ONCOL REP, V23, P1183, DOI 10.3892/or_00000749; Ducreux M, 2004, ANN ONCOL, V15, P467, DOI 10.1093/annonc/mdh098; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; Fayers P, 2001, QLQC30 EORTC; Fayers P, 1998, QLQC30 EORTC; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; Heinemann V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-82; Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; Hidalgo M, 2010, NEW ENGL J MED, V363, P298; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lima CMR, 2004, J CLIN ONCOL, V22, P3776, DOI 10.1200/JCO.2004.12.082; Louvet C, 2005, J CLIN ONCOL, V23, P3509, DOI 10.1200/JCO.2005.06.023; Mans DRA, 1999, EUR J CANCER, V35, P1851, DOI 10.1016/S0959-8049(99)00222-1; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Mullany S, 1998, CANCER CHEMOTH PHARM, V42, P391, DOI 10.1007/s002800050835; Oettle H, 2006, ANN ONCOL, V17, P535, DOI 10.1093/annonc/mdl032; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Pavillard V, 1998, BIOCHEM PHARMACOL, V56, P1315, DOI 10.1016/S0006-2952(98)00205-6; Sant M, 2009, EUR J CANCER, V45, P931, DOI 10.1016/j.ejca.2008.11.018; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Ueno H, 2007, CANCER CHEMOTH PHARM, V59, P447, DOI 10.1007/s00280-006-0283-9; WAGENER DJT, 1995, ANN ONCOL, V6, P129, DOI 10.1093/oxfordjournals.annonc.a059107; Ychou M, 2003, ANN ONCOL, V14, P481, DOI 10.1093/annonc/mdg119; Zeghari-Squalli N, 1999, CLIN CANCER RES, V5, P1189	36	4785	4913	8	267	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					1817	1825		10.1056/NEJMoa1011923	http://dx.doi.org/10.1056/NEJMoa1011923			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561347	Bronze			2022-12-28	WOS:000290483000009
J	Reich, ES				Reich, Eugenie Samuel			BEST FACE FORWARD	NATURE			English	News Item																			0	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 12	2011	473	7346					138	139		10.1038/473138a	http://dx.doi.org/10.1038/473138a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562536	Bronze			2022-12-28	WOS:000290487200011
J	Hickie, IB; Rogers, NL				Hickie, Ian B.; Rogers, Naomi L.			Novel melatonin-based therapies: potential advances in the treatment of major depression	LANCET			English	Article							PROLONGED-RELEASE MELATONIN; CHRONIC SLEEP RESTRICTION; DOUBLE-BLIND; LIGHT THERAPY; CIRCADIAN GENES; ANTIDEPRESSANT AGOMELATINE; AGONIST AGOMELATINE; RAMELTEON TAK-375; BODY-TEMPERATURE; MOOD DISORDERS	Major depression is one of the leading causes of premature death and disability. Although available drugs are effective, they also have substantial limitations. Recent advances in our understanding of the fundamental links between chronobiology and major mood disorders, as well as the development of new drugs that target the circadian system, have led to a renewed focus on this area. In this review, we summarise the associations between disrupted chronobiology and major depression and outline new antidepressant treatment strategies that target the circadian system. In particular, we highlight agomelatine, a melatonin-receptor agonist and selective serotonergic receptor subtype (ie, 5-HT2C) antagonist that has chronobiotic, antidepressant, and anxiolytic effects. In the short-term, agomelatine has similar antidepressant efficacy to venlafaxine, fluoxetine, and sertraline and, in the longer term, fewer patients on agomelatine relapse (23.9%) than do those receiving placebo (50.0%). Patients with depression treated with agomelatine report improved sleep quality and reduced waking after sleep onset. As agomelatine does not raise serotonin levels, it has less potential for the common gastrointestinal, sexual, or metabolic side-effects that characterise many other antidepressant compounds.	[Hickie, Ian B.; Rogers, Naomi L.] Univ Sydney, Brain & Mind Res Inst, Camperdown, NSW 2050, Australia; [Rogers, Naomi L.] Cent Queensland Univ, Sch Management & Mkt, Inst Hlth & Social Sci Res, Mackay, Qld, Australia	University of Sydney; Central Queensland University	Hickie, IB (corresponding author), Univ Sydney, Brain & Mind Res Inst, 94 Mallett St,Bldg F,Level 4, Camperdown, NSW 2050, Australia.	ian.hickie@sydney.edu.au	Hickie, Ian B/K-8975-2015; Rogers, Naomi/G-3538-2013	Hickie, Ian B/0000-0001-8832-9895; Rogers, Naomi/0000-0002-0536-9814	Wyeth; Eli Lily; Servier; Pfizer; AstraZeneca; National Health and Medical Research Council Australian Medical Research; Vanda Pharmaceuticals; Cephalon; CSL Biotherapies	Wyeth(Wyeth); Eli Lily; Servier(Servier); Pfizer(Pfizer); AstraZeneca(AstraZeneca); National Health and Medical Research Council Australian Medical Research; Vanda Pharmaceuticals; Cephalon; CSL Biotherapies	IBH was previously chief executive officer and clinical adviser of beyondblue, an Australian National Depression Initiative. He has led projects for health professionals and the community supported by governmental, community agency, and drug industry partners (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) for the identification and management of depression and anxiety. He has served on advisory boards convened by the drug industry in relation to specific antidepressants, including nefazodone, duloxetine, and desvenlafaxine, and has participated in a multicentre clinical trial of agomelatine effects on sleep architecture in depression. IBH is also supported by a National Health and Medical Research Council Australian Medical Research Fellowship. He is a participant in a family-practice-based audit of sleep disturbance and major depression, supported by Servier, the manufacturers of agomelatine. NLR has received grant support from Vanda Pharmaceuticals, Servier, Pfizer, and Cephalon, and has received honoraria for lectures from Pfizer, CSL Biotherapies, and Servier. She has previously received research funding from Vanda Pharmaceuticals, manufacturers of tasimelteon. She has also received an unrestricted educational grant from Servier. Research studies done by IBH and NLR are mainly funded by NHMRC project and program grants.	[Anonymous], NOV CLIN TRIAL RES D; [Anonymous], AG SEARCH; [Anonymous], VALDOXAN PRODUCT INF; [Anonymous], AG SEARCH; Brunner P, 2006, EUR J HISTOCHEM, V50, P311; Cajochen C, 1997, AM J PHYSIOL-REG I, V272, pR1189, DOI 10.1152/ajpregu.1997.272.4.R1189; CARMAN JS, 1976, AM J PSYCHIAT, V133, P1181; Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; Czeisler C.A., 2005, PRIN PRACT SLEEP MED, V4th Edn, P375, DOI 10.1016/b0-72-160797-7/50038-0; Dalton EJ, 2000, J PSYCHIATR NEUROSCI, V25, P48; De Berardis D, 2011, CNS NEUROL DISORD-DR, V10, P119, DOI 10.2174/187152711794488674; de Bodinat C, 2010, NAT REV DRUG DISCOV, V9, P628, DOI 10.1038/nrd3140; DIJK DJ, 1995, J NEUROSCI, V15, P3526; Dinges D.F., 2005, PRINCIPLES PRACTICE, V4th ed., P67, DOI DOI 10.1016/B0-72-160797-7/50013-6; Dubovsky SL, 2009, EXPERT OPIN INV DRUG, V18, P1533, DOI 10.1517/13543780903292634; Duffy JF, 2005, J BIOL RHYTHM, V20, P326, DOI 10.1177/0748730405277983; Dumont GJH, 2005, BRIT J CLIN PHARMACO, V59, P495, DOI 10.1111/j.1365-2125.2005.02342.x; Erman M, 2006, SLEEP MED, V7, P17, DOI 10.1016/j.sleep.2005.09.004; European Medicines Agency, EV MED HUM US CHMP A; Even C, 2008, J AFFECT DISORDERS, V108, P11, DOI 10.1016/j.jad.2007.09.008; Frank E, 2007, J CLIN PSYCHOL, V63, P463, DOI 10.1002/jclp.20371; Germain A, 2008, HUM PSYCHOPHARM CLIN, V23, P571, DOI 10.1002/hup.964; Golden RN, 2005, AM J PSYCHIAT, V162, P656, DOI 10.1176/appi.ajp.162.4.656; Goodwin GM, 2008, EUR NEUROPSYCHOPHARM, V18, pS338, DOI 10.1016/S0924-977X(08)70471-1; Goodwin GM, 2009, J CLIN PSYCHIAT, V70, P1128, DOI 10.4088/JCP.08m04548; Hale A, 2010, INT CLIN PSYCHOPHARM, V25, P305, DOI 10.1097/YIC.0b013e32833a86aa; Hall WD, 2003, BRIT MED J, V326, P1008, DOI 10.1136/bmj.326.7397.1008; Hickie I, 1999, COGN BEHAV PRACT, V6, P442; Hickie I, 2007, BRIT MED J, V335, P329, DOI 10.1136/bmj.39268.497350.AD; Hickie I, 2006, BRIT MED J, V333, P575, DOI 10.1136/bmj.38933.585764.AE; Hirsch-Rodriguez E, 2007, MED HYPOTHESES, V69, P120, DOI 10.1016/j.mehy.2006.11.012; Iitaka C, 2005, J BIOL CHEM, V280, P29397, DOI 10.1074/jbc.M503526200; JOHNSSON A, 1979, PHARMAKOPSYCH NEURO, V12, P423, DOI 10.1055/s-0028-1094638; Kaplan KA, 2009, SLEEP MED REV, V13, P275, DOI 10.1016/j.smrv.2008.09.001; Kasper S, 2010, J CLIN PSYCHIAT, V71, P109, DOI 10.4088/JCP.09m05347blu; Kasper S, 2009, WORLD J BIOL PSYCHIA, V10, P117, DOI 10.1080/15622970902717024; Kato K, 2005, NEUROPHARMACOLOGY, V48, P301, DOI 10.1016/j.neuropharm.2004.09.007; Kennedy SH, 2006, EUR NEUROPSYCHOPHARM, V16, P93, DOI 10.1016/j.euroneuro.2005.09.002; Kennedy SH, 2008, J CLIN PSYCHOPHARM, V28, P329, DOI 10.1097/JCP.0b013e318172b48c; Kennedy SH, 2010, CNS DRUGS, V24, P479, DOI 10.2165/11534420-000000000-00000; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; KLEMFUSS H, 1992, PHARMACOL THERAPEUT, V56, P53, DOI 10.1016/0163-7258(92)90037-Z; Kopp C, 1999, BEHAV PHARMACOL, V10, P73, DOI 10.1097/00008877-199902000-00007; Krauchi K, 1997, AM J PHYSIOL-REG I, V272, pR1178, DOI 10.1152/ajpregu.1997.272.4.R1178; Lemoine P, 2007, J SLEEP RES, V16, P372, DOI 10.1111/j.1365-2869.2007.00613.x; Lemoine P, 2007, J CLIN PSYCHIAT, V68, P1723, DOI 10.4088/JCP.v68n1112; Leproult R, 2005, CLIN ENDOCRINOL, V63, P298, DOI 10.1111/j.1365-2265.2005.02341.x; Llorca PM, 2010, J PSYCHOPHARMACOL, V24, P21, DOI 10.1177/1359786810372978; Lockley SW, 2003, J CLIN ENDOCR METAB, V88, P4502, DOI 10.1210/jc.2003-030570; Loo H, 2002, INT CLIN PSYCHOPHARM, V17, P239; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Mansour HA, 2005, ANN MED, V37, P196, DOI 10.1080/07853890510007377; Mansour HA, 2009, BIPOLAR DISORD, V11, P701, DOI 10.1111/j.1399-5618.2009.00756.x; McClung CA, 2007, PHARMACOL THERAPEUT, V114, P222, DOI 10.1016/j.pharmthera.2007.02.003; Millan MJ, 2003, J PHARMACOL EXP THER, V306, P954, DOI 10.1124/jpet.103.051797; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; Montejo AL, 2010, J PSYCHOPHARMACOL, V24, P111, DOI 10.1177/0269881108096507; Monteleone P, 2008, EUR NEUROPSYCHOPHARM, V18, P701, DOI 10.1016/j.euroneuro.2008.06.007; Montgomery SA, 2004, INT CLIN PSYCHOPHARM, V19, P271, DOI 10.1097/01.yic.0000137184.64610.c8; MOORE RY, 1983, FED PROC, V42, P2783; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nickelsen T, 2002, CHRONOBIOL INT, V19, P915, DOI 10.1081/CBI-120014108; Olie JP, 2007, INT J NEUROPSYCHOPH, V10, P661, DOI 10.1017/S1461145707007766; Paizanis E, 2010, INT J NEUROPSYCHOPH, V13, P759, DOI 10.1017/S1461145709990514; Pandi-Perumal SR, 2008, PROG NEUROBIOL, V85, P335, DOI 10.1016/j.pneurobio.2008.04.001; Partonen T, 2007, ANN MED, V39, P229, DOI 10.1080/07853890701278795; Quera-Salva M-A, 2010, INT J NEUROPSYCHIAT, V13, pP03; Quiroz JA, 2004, MOL INTERV, V4, P259, DOI 10.1124/mi.4.5.6; Racagni G, 2010, INT CLIN PSYCHOPHARM, V25, P117, DOI 10.1097/YIC.0b013e3283311acd; Rajaratnam SMW, 2009, SLEEP MED CLIN, V4, P179, DOI 10.1016/j.jsmc.2009.02.007; Rajaratnam SMW, 2009, LANCET, V373, P482, DOI 10.1016/S0140-6736(08)61812-7; Roberts RE, 2000, AM J PSYCHIAT, V157, P81, DOI 10.1176/ajp.157.1.81; Rogers NL, 2008, J SLEEP RES, V17, P406, DOI 10.1111/j.1365-2869.2008.00681.x; Rogers NL, 2003, SLEEP, V26, P1058; Rogers NL, 2001, SLEEP, V24, pA172; Rogers NL, 2000, SLEEP, V23, pA70; Roth T, 2005, SLEEP, V28, P303; Roth T, 2007, CURR MED RES OPIN, V23, P1005, DOI 10.1185/030079907X178874; Roth T, 2006, SLEEP MED, V7, P312, DOI 10.1016/j.sleep.2006.01.003; SOUETRE E, 1989, PSYCHIAT RES, V28, P263, DOI 10.1016/0165-1781(89)90207-2; Spadoni G, 2007, MELATONIN MOL THERAP, P33; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; Srinivasan V, 2009, PSYCHIAT RES, V165, P201, DOI 10.1016/j.psychres.2007.11.020; Stahl SM, 2010, J CLIN PSYCHIAT, V71, P616, DOI 10.4088/JCP.09m05471blu; Therapeutic Goods Administration Department of Health and Ageing, AUSTR PUBL ASS REP A; Touitou Y, 2007, PHYSIOL BEHAV, V90, P294, DOI 10.1016/j.physbeh.2006.09.001; Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779; Tuunainen A, 2004, Cochrane Database Syst Rev, pCD004050, DOI 10.1002/14651858.CD004050.pub2; Vachharajani NN, 2003, J PHARM SCI, V92, P760, DOI 10.1002/jps.10348; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; VOGEL GW, 1990, NEUROSCI BIOBEHAV R, V14, P49, DOI 10.1016/S0149-7634(05)80159-9; von Gall C, 2002, CELL TISSUE RES, V309, P151, DOI 10.1007/s00441-002-0581-4; Wade AG, 2007, CURR MED RES OPIN, V23, P2597, DOI 10.1185/030079907X233098; Weaver DR, 1999, LUNG BIOL HEALTH DIS, V133, P197; Wirz-Justice A, 2005, PSYCHOL MED, V35, P939, DOI 10.1017/S003329170500437X; Wirz-Justice Anna, 2008, Dialogues Clin Neurosci, V10, P337; Wirz-Justice A, 2009, J AFFECT DISORDERS, V116, P159, DOI 10.1016/j.jad.2009.04.024; Wright Jr KP, 2007, MELATONIN MOL THERAP, P547; Wu JC, 2009, BIOL PSYCHIAT, V66, P298, DOI 10.1016/j.biopsych.2009.02.018; Wulff K, 2010, NAT REV NEUROSCI, V11, P589, DOI 10.1038/nrn2868; Zajecka J, 2010, J CLIN PSYCHOPHARM, V30, P135, DOI 10.1097/JCP.0b013e3181d420a7; Zammit G, 2007, J CLIN SLEEP MED, V3, P495; Zammit G, 2009, SLEEP MED, V10, P55, DOI 10.1016/j.sleep.2008.04.010; Zupancic M, 2006, CNS DRUGS, V20, P981, DOI 10.2165/00023210-200620120-00003	105	200	218	1	60	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2011	378	9791					621	631		10.1016/S0140-6736(11)60095-0	http://dx.doi.org/10.1016/S0140-6736(11)60095-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	812UX	21596429				2022-12-28	WOS:000294319500034
J	Williams, BA; Sudore, RL; Greifinger, R; Morrison, RS				Williams, Brie A.; Sudore, Rebecca L.; Greifinger, Robert; Morrison, R. Sean			Balancing Punishment and Compassion for Seriously III Prisoners	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PALLIATIVE CARE; LIFE; DISABILITY; END	Compassionate release is a program that allows some eligible, seriously ill prisoners to die outside of prison before sentence completion. It became a matter of federal statute in 1984 and has been adopted by most U. S. prison jurisdictions. Incarceration is justified on 4 principles: retribution, rehabilitation, deterrence, and incapacitation. Compassionate release derives from the theory that changes in health status may affect these principles and thus alter justification for incarceration and sentence completion. The medical profession is intricately involved in this process because eligibility for consideration for compassionate release is generally based on medical evidence. Many policy experts are calling for broader use of compassionate release because of many factors, such as an aging prison population, overcrowding, the increasing deaths in custody, and the soaring medical costs of the criminal justice system. Even so, the medical eligibility criteria of many compassionate-release guidelines-which often assume a definitive prognosis-are clinically flawed, and procedural barriers may further limit their rational application. We propose changes to address these flaws.	[Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA; San Francisco VA Med Ctr, San Francisco, CA USA; CUNY, Mt Sinai Sch Med, John Jay Coll Criminal Justice, New York, NY 10021 USA; Natl Palliat Care Res Ctr, New York, NY USA; James J Peters Vet Affairs Med Ctr, Bronx, NY USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center	Williams, BA (corresponding author), Univ Calif San Francisco, Div Geriatr, 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA.	brie.williams@ucsf.edu	Sudore, Rebecca/AAF-1635-2021		Brookdale Leadership in Aging Fellowship; National Institute on Aging [K23AG033102, K24 AG022345]; National Palliative Care Research Center; Pfizer; NATIONAL INSTITUTE ON AGING [K23AG033102, K24AG022345] Funding Source: NIH RePORTER	Brookdale Leadership in Aging Fellowship; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Palliative Care Research Center; Pfizer(Pfizer); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By a grant from the Brookdale Leadership in Aging Fellowship and the National Institute on Aging (K23AG033102) (Dr. Williams), from Mid-Career-Investigator Award in Patient-Oriented Research from the National Institute on Aging (K24 AG022345) and the National Palliative Care Research Center (Dr. Morrison), and a Pfizer Fellowship in Clear Health Communication (Dr. Sudore).		0	35	35	1	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 19	2011	155	2					122	126		10.7326/0003-4819-155-2-201107190-00348	http://dx.doi.org/10.7326/0003-4819-155-2-201107190-00348			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	793KW	21628351	Green Accepted			2022-12-28	WOS:000292822000019
J	Noudoost, B; Moore, T				Noudoost, Behrad; Moore, Tirin			Control of visual cortical signals by prefrontal dopamine	NATURE			English	Article							FRONTAL EYE FIELD; ATTENTIONAL MODULATION; RECEPTOR ACTIONS; MESSENGER-RNAS; NEURONS; CORTEX; SELECTION; EXPRESSION	The prefrontal cortex is thought to modulate sensory signals in posterior cortices during top-down attention(1,2), but little is known about the underlying neural circuitry. Experimental and clinical evidence indicate that prefrontal dopamine has an important role in cognitive functions(3), acting predominantly through D1 receptors. Here we show that dopamine D1 receptors mediate prefrontal control of signals in the visual cortex of macaques (Macaca mulatta). We pharmacologically altered D1-receptor-mediated activity in the frontal eye field of the prefrontal cortex and measured the effect on the responses of neurons in area V4 of the visual cortex. This manipulation was sufficient to enhance the magnitude, the orientation selectivity and the reliability of V4 visual responses to an extent comparable with the known effects of top-down attention. The enhancement of V4 signals was restricted to neurons with response fields overlapping the part of visual space affected by the D1 receptor manipulation. Altering either D1- or D2-receptor-mediated frontal eye field activity increased saccadic target selection but the D2 receptor manipulation did not enhance V4 signals. Our results identify a role for D1 receptors in mediating the control of visual cortical signals by the prefrontal cortex and suggest how processing in sensory areas could be altered in mental disorders involving prefrontal dopamine.	[Noudoost, Behrad; Moore, Tirin] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Noudoost, Behrad; Moore, Tirin] Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Noudoost, B (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Fairchild Bldg,299 Campus Dr W, Stanford, CA 94305 USA.	behrad@stanford.edu			NATIONAL EYE INSTITUTE [R01EY014924, R56EY014924] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NEI NIH HHS [R01 EY014924-04, R01 EY014924, R01 EY014924-05, EY014924, R01 EY014924-06A2, R56 EY014924] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Armstrong KM, 2009, J NEUROSCI, V29, P15621, DOI 10.1523/JNEUROSCI.4465-09.2009; Awh E, 2006, TRENDS COGN SCI, V10, P124, DOI 10.1016/j.tics.2006.01.001; Bourne JA, 2001, CNS DRUG REV, V7, P399; Castellanos FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/nrn896; Durstewitz D, 2000, NAT NEUROSCI, V3, P1184, DOI 10.1038/81460; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; Gregoriou GG, 2009, SCIENCE, V324, P1207, DOI 10.1126/science.1171402; Herrero JL, 2008, NATURE, V454, P1110, DOI 10.1038/nature07141; HUNTSMAN MM, 1994, J NEUROSCI, V14, P2236; LIDOW MS, 1991, NEUROSCIENCE, V40, P657, DOI 10.1016/0306-4522(91)90003-7; Lidow MS, 1998, SYNAPSE, V28, P10, DOI 10.1002/(SICI)1098-2396(199801)28:1<10::AID-SYN2>3.0.CO;2-F; McAdams CJ, 1999, J NEUROSCI, V19, P431, DOI 10.1523/JNEUROSCI.19-01-00431.1999; McAlonan K, 2008, NATURE, V456, P391, DOI 10.1038/nature07382; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mitchell JF, 2007, NEURON, V55, P131, DOI 10.1016/j.neuron.2007.06.018; Monosov IE, 2009, J NEUROPHYSIOL, V102, P3656, DOI 10.1152/jn.00750.2009; Moore T, 2003, NATURE, V421, P370, DOI 10.1038/nature01341; Munoz DP, 2003, J NEUROPHYSIOL, V90, P503, DOI 10.1152/jn.00192.2003; Noudoost B, 2011, J NEUROSCI METH, V194, P218, DOI 10.1016/j.jneumeth.2010.10.009; Noudoost B, 2010, CURR OPIN NEUROBIOL, V20, P183, DOI 10.1016/j.conb.2010.02.003; Pouget P, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.002.2009; Reynolds JH, 2004, ANNU REV NEUROSCI, V27, P611, DOI 10.1146/annurev.neuro.26.041002.131039; Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535; Santana N, 2009, CEREB CORTEX, V19, P849, DOI 10.1093/cercor/bhn134; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; Schiller PH, 2003, EUR J NEUROSCI, V18, P3127, DOI 10.1111/j.1460-9568.2003.03036.x; Thompson KG, 2005, J NEUROSCI, V25, P9479, DOI 10.1523/JNEUROSCI.0741-05.2005; Vijayraghavan S, 2007, NAT NEUROSCI, V10, P376, DOI 10.1038/nn1846; Wang M, 2004, SCIENCE, V303, P853, DOI 10.1126/science.1091162; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0	30	230	230	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2011	474	7351					372	375		10.1038/nature09995	http://dx.doi.org/10.1038/nature09995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777TD	21572439	Green Accepted			2022-12-28	WOS:000291647100044
J	Dieffenbach, CW; Fauci, AS				Dieffenbach, Carl W.; Fauci, Anthony S.			Thirty Years of HIV and AIDS: Future Challenges and Opportunities	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; NEUTRALIZING ANTIBODIES; POTENT NEUTRALIZATION; DISEASE PROGRESSION; DOUBLE-BLIND; T-CELLS; INFECTION; VACCINE; PREVENTION; TRANSMISSION	As the third decade since AIDS was first recognized comes to an end, extraordinary advances have occurred in the understanding, treatment, and prevention of HIV infection and AIDS. As a result of these successes, it is now time to focus on future challenges. Paramount among these is reaching the goal of truly controlling and ultimately ending the HIV and AIDS pandemic. To that end, AIDS researchers and public health personnel worldwide are aggressively pursuing 3 key areas of scientific research. Given the availability of highly effective therapeutic regimens for HIV infection, the first challenge is efficiently identifying a maximum number of HIV-infected persons through voluntary HIV testing and initiating antiretroviral therapy (ART). Second, scientists are trying to develop a cure for HIV infection, which would alleviate the need for lifelong ART. Finally, preventing new cases of HIV infection, which currently number approximately 2.6 million per year globally, is critical to any attempt to end this pandemic. This article addresses each of these challenges and provides directions for the future.	[Dieffenbach, Carl W.] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dieffenbach, CW (corresponding author), NIAID, Div Aids, NIH, 6700 Rockledge Dr,MSC 7620, Bethesda, MD 20892 USA.	cdieffenba@niaid.nih.gov						Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591; [Anonymous], 2010, NAT HIV AIDS STRAT U; [Anonymous], SAF EFF TEN 1 GEL TE; [Anonymous], 2009, AIDS EP UPD 2009; [Anonymous], STRAT TIM ANT TREATM; [Anonymous], US PRESIDENTS EMERGE; Bailey R. C., 2010, 18 INT AIDS C VIENN; Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Centers for Disease Control (CDC), 1982, MMWR Morb Mortal Wkly Rep, V31, P305; Centers for Disease Control (CDC), 1981, MMWR Morb Mortal Wkly Rep, V30, P305; Centers for Disease Control (CDC), 1981, MMWR Morb Mortal Wkly Rep, V30, P250; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Costello C, 1999, AIDS, V13, P1990, DOI 10.1097/00002030-199910010-00031; Derdeyn CA, 2004, SCIENCE, V303, P2019, DOI 10.1126/science.1093137; DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, 2011, GUID US ANT AG HIV 1; Dieffenbach CW, 2009, JAMA-J AM MED ASSOC, V301, P2380, DOI 10.1001/jama.2009.828; Fauci AS, 2008, SCIENCE, V321, P530, DOI 10.1126/science.1161000; Fauci AS, 2009, HEALTH AFFAIR, V28, P1629, DOI 10.1377/hlthaff.28.6.1629; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Folkers GK, 2010, JAMA-J AM MED ASSOC, V304, P350, DOI 10.1001/jama.2010.957; Gallo RC, 2003, NEW ENGL J MED, V349, P2283, DOI 10.1056/NEJMp038194; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Gray G, 2009, AIDS VACC 2009 PAR F; Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; HYMES KB, 1981, LANCET, V2, P598; Joint United Nations Programme on HIV/AIDS, 2010, GLOB REP UNAIDS REP; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Lima VD, 2008, J INFECT DIS, V198, P59, DOI 10.1086/588673; Margolis DM, 2011, AIDS RES HUM RETROV, V27, P347, DOI 10.1089/aid.2011.0017; Mofenson LM, 2010, CLIN INFECT DIS, V50, pS130, DOI 10.1086/651484; Montero M, 2008, MICROBIOL MOL BIOL R, V72, P54, DOI 10.1128/MMBR.00020-07; Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385; Padian NS, 2008, LANCET, V372, P585, DOI 10.1016/S0140-6736(08)60885-5; Pejchal R, 2010, P NATL ACAD SCI USA, V107, P11483, DOI 10.1073/pnas.1004600107; Pietzsch J, 2010, J EXP MED, V207, P1995, DOI 10.1084/jem.20101176; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706; Rodes B, 2004, AIDS, V18, P1109, DOI [10.1097/00002030-200405210-00004, 10.1097/01.aids.0000125962.16506.f9]; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; Rotheram-Borus MJ, 2009, ANNU REV CLIN PSYCHO, V5, P143, DOI 10.1146/annurev.clinpsy.032408.153530; Stover J, 2002, LANCET, V360, P73, DOI 10.1016/S0140-6736(02)09339-X; Strain MC, 2005, J INFECT DIS, V191, P1410, DOI 10.1086/428777; Wagner BG, 2010, AIDS, V24, P775, DOI 10.1097/QAD.0b013e3283366782; Walker Bruce D, 2007, Top HIV Med, V15, P134; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; WHO, 2010, ANT THER HIV INF AD; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	58	113	117	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 7	2011	154	11					766	771		10.7326/0003-4819-154-11-201106070-00345	http://dx.doi.org/10.7326/0003-4819-154-11-201106070-00345			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773MV	21628350				2022-12-28	WOS:000291312300008
J	Schmidt, MI; Duncan, BB; Silva, GAE; Menezes, AM; Monteiro, CA; Barreto, SM; Chor, D; Menezes, PR				Schmidt, Maria Ines; Duncan, Bruce Bartholow; Azevedo e Silva, Gulnar; Menezes, Ana Maria; Monteiro, Carlos Augusta; Barreto, Sandhi Maria; Chor, Dora; Menezes, Paulo Rossi			Health in Brazil 4 Chronic non-communicable diseases in Brazil: burden and current challenges	LANCET			English	Article							MIDDLE-INCOME COUNTRIES; PREVENTING CHRONIC DISEASES; LATIN-AMERICAN CITIES; CANCER MORTALITY DATA; SAO-PAULO; PHYSICAL-ACTIVITY; MENTAL-DISORDERS; TELEPHONE SURVEY; HIGH PREVALENCE; POPULATION	Non-communicable diseases (NCDs) have become a major health priority in Brazil-72% of all deaths were attributable to NCDs in 2007. They are also the main source of disease burden, with neuropsychiatric disorders being the single largest contributor. Morbidity and mortality due to NCDs are greatest in the poor population. Although the crude NCD mortality increased 5% between 1996 and 2007, age-standardised mortality declined by 20%. Declines were primarily for cardiovascular and chronic respiratory diseases, in association with the successful implementation of health policies that lead to decreases in smoking and the expansion of access to primary health care. Of note, however, the prevalence of diabetes and hypertension is rising in parallel with that of excess weight; these increases are associated with unfavourable changes of diet and physical activity. Brazil has implemented major policies for the prevention of NCDs, and its age-adjusted NCD mortality is falling by 1.8% per year. However, the unfavourable trends for most major risk factors pose an enormous challenge and call for additional and timely action and policies, especially those of a legislative and regulatory nature and those providing cost-effective chronic care for individuals affected by NCDs.	[Schmidt, Maria Ines; Duncan, Bruce Bartholow] Univ Fed Rio Grande do Sul, Fac Med, Porto Alegre, RS, Brazil; [Azevedo e Silva, Gulnar] Univ Estado Rio De Janeiro, Inst Social Med, Rio De Janeiro, Brazil; [Menezes, Ana Maria] Univ Fed Pelotas, Fac Med, Pelotas, Brazil; [Monteiro, Carlos Augusta] Univ Sao Paulo, Sch Publ Hlth, Sao Paulo, Brazil; [Barreto, Sandhi Maria] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil; [Chor, Dora] Osvaldo Cruz Fdn, Natl Sch Publ Hlth, Rio De Janeiro, Brazil; [Menezes, Paulo Rossi] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil	Universidade Federal do Rio Grande do Sul; Universidade do Estado do Rio de Janeiro; Universidade Federal de Pelotas; Universidade de Sao Paulo; Universidade Federal de Minas Gerais; Universidade de Sao Paulo	Schmidt, MI (corresponding author), Univ Fed Rio Grande do Sul, Fac Med, Rua Ramiro Barcelos 2600,Sala 414, Porto Alegre, RS, Brazil.	maria.schmidt@ufrgs.br	Barreto, Sandhi M/D-2855-2014; Menezes, Paulo R/C-9985-2010; Schmidt, Maria/V-3196-2019; Duncan, Bruce B/L-4140-2016; Barreto, Sandhi Maria M/A-5140-2012; Schmidt, Maria Inês/AGP-6441-2022; Monteiro, Carlos Augusto/F-9892-2012; Iats, Inct/K-2300-2013; Schmidt, Maria Inês/AGT-5691-2022; Menezes, Ana MB/G-7266-2012; Oliveira, Claudia DL/G-8618-2011; Menezes, Paulo/AAM-3529-2021	Barreto, Sandhi M/0000-0001-7383-7811; Menezes, Paulo R/0000-0001-6330-3314; Duncan, Bruce B/0000-0002-7491-2630; Barreto, Sandhi Maria M/0000-0003-4392-5428; Schmidt, Maria Inês/0000-0002-3837-0731; Monteiro, Carlos Augusto/0000-0002-3777-1533; Menezes, Ana MB/0000-0002-2996-9427; Menezes, Paulo/0000-0001-6330-3314				Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Ahmad OB, GPE DISCUSSION PAPER, V31; Alwan A, 2010, LANCET, V376, P1861, DOI 10.1016/S0140-6736(10)61853-3; Andrade L, 2002, SOC PSYCH PSYCH EPID, V37, P316, DOI 10.1007/s00127-002-0551-x; [Anonymous], 2005, PREV CHRON DIS VIT I; [Anonymous], 1966, CANC INCIDENCE 5 CON, DOI DOI 10.1001/jamaoncol.2019.2996; Antunes JLF, 2006, BRAZ J MED BIOL RES, V39, P1091, DOI 10.1590/S0100-879X2006000800012; AYRES A, REV SAUDE P IN PRESS; Barros M. B. de A., 2006, Ciencia & Saude Coletiva, V11, P911, DOI 10.1590/S1413-81232006000400014; Bassanesi SL, 2008, ARQ BRAS CARDIOL, V90, P403; Beaglehole R, 2008, LANCET, V372, P940, DOI 10.1016/S0140-6736(08)61404-X; Beaglehole R, 2007, LANCET, V370, P2152, DOI 10.1016/S0140-6736(07)61700-0; Beaglehole R, 2010, LANCET, V376, P1619, DOI 10.1016/S0140-6736(10)61929-0; Bialous SA, 2009, TOB CONTROL, V18, P341, DOI 10.1136/tc.2009.033167; Bottino CMC, 2008, DEMENT GERIATR COGN, V26, P291, DOI 10.1159/000161053; *BRAS MIN SAUD I N, 2002, VIV MULH CANC COL UT; Brownell KD, 2010, HEALTH AFFAIR, V29, P379, DOI 10.1377/hlthaff.2009.0739; CARLINI EA, 2005, LEVANTAMENTO DOMICIL; Cecchini M, 2010, LANCET, V376, P1775, DOI 10.1016/S0140-6736(10)61514-0; Chiara Vera Lúcia, 2003, Rev. Nutr., V16, P227, DOI 10.1590/S1415-52732003000200010; Chor Dóra, 2005, Cad. Saúde Pública, V21, P1586, DOI 10.1590/S0102-311X2005000500033; Coimbra Carlos E. A. Jr., 2001, Ethnicity and Disease, V11, P232; COIMBRA CEA, 2005, XAVANTE TRANSITION; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; COLEMAN M, 1993, TRENDS CANC INCIDENC; Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI 10.1016/S1470-2045(08)70179-7; Conde W, 2010, CHILDHOOD OBESITY PR, P144; Cooper PJ, 2009, ALLERGY, V64, P5, DOI 10.1111/j.1398-9995.2008.01902.x; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Correa PCRP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-206; Curado MP, 2007, CANC INCIDENCE 5 CON; De Lima MS, 1999, SOC PSYCH PSYCH EPID, V34, P316, DOI 10.1007/s001270050150; DOLL R, 1990, EUR J CANCER, V26, P500; Chrestani MAD, 2009, CAD SAUDE PUBLICA, V25, P2395, DOI 10.1590/S0102-311X2009001100010; Epping-Jordan JE, 2005, LANCET, V366, P1667, DOI 10.1016/S0140-6736(05)67342-4; FAO, 2004, FAO STAT DAT; Farmer P, 2010, LANCET, V376, P1186, DOI 10.1016/S0140-6736(10)61152-X; Galduroz JCF, 2007, BRAZ J MED BIOL RES, V40, P367, DOI 10.1590/S0100-879X2007000300012; Gamarra CJ, 2010, REV SAUDE PUBL, V44, P629, DOI 10.1590/S0034-89102010000400006; Gaziano TA, 2007, LANCET, V370, P1939, DOI 10.1016/S0140-6736(07)61697-3; Geneau R, 2010, LANCET, V376, P1689, DOI 10.1016/S0140-6736(10)61414-6; Gugelmin Silvia Angela, 2006, Cad. Saúde Pública, V22, P1865, DOI 10.1590/S0102-311X2006000900017; Herrera E, 2002, ALZ DIS ASSOC DIS, V16, P103, DOI 10.1097/00002093-200204000-00007; *I BRAS GEOGR EST, 2009, GLOB AD TOB SURV GAT; Iglesias R, 2008, EPIDEMIOL SERV SAUDE, V17, P301; Instituto Brasileiro de Geografia e Estatistica, 2009, PESQ NAC SAUD ESC 20; Instituto Brasileiro de Geografia e Estatistica, 2002, PERF ID RESP PEL DOM; Instituto Brasileiro de Geografia e Estatistica, 2009, IND SOC SAUD BRAS 20; Instituto Brasileiro de Geografia e Estatistica-IBGE, 2010, PAN SAUD BRAS AC UT; Kessler RC, 2010, DEPRESS ANXIETY, V27, P351, DOI 10.1002/da.20634; KICKBUSCH I, 1996, PUBLICACION CIENTIFI, V557, P15; Laranjeira R, 2010, REV BRAS PSIQUIATR, V32, P231, DOI 10.1590/S1516-44462009005000012; Latorre, 1997, Cad Saude Publica, V13 Suppl 1, P67; Martins LFL, 2005, REV BRAS GINECOL OBS, V27, P485, DOI 10.1590/S0100-72032005000800009; Levy RB, 2009, PUBLIC HEALTH NUTR, V12, P2084, DOI 10.1017/S1368980009005588; Lim SS, 2007, LANCET, V370, P2054, DOI 10.1016/S0140-6736(07)61699-7; Lloyd-Sherlock P, 1998, J DEV AREAS, V32, P491; Ludermir A B, 2000, Cad Saude Publica, V16, P647, DOI 10.1590/S0102-311X2000000300013; MALERBI DA, 1992, DIABETES CARE, V15, P1509, DOI 10.2337/diacare.15.11.1509; Malta Deborah Carvalho, 2007, J. bras. pneumol., V33, P536, DOI 10.1590/S1806-37132007000500008; Maragno Luciana, 2006, Cad. Saúde Pública, V22, P1639, DOI 10.1590/S0102-311X2006000800012; Mendonca, 1997, Cad Saude Publica, V13 Suppl 1, P79; Menezes AMB, 2007, EUR RESPIR J, V30, P1180, DOI 10.1183/09031936.00083507; Menezes AMB, 2005, LANCET, V366, P1875, DOI 10.1016/S0140-6736(05)67632-5; Menezes PR, 2007, BRIT J PSYCHIAT, V191, pS102, DOI 10.1192/bjp.191.51.s102; Menezes PR, 1996, REV SAUDE PUBL, V30, P304, DOI 10.1590/S0034-89101996000400003; *MIN SAUD, 2008, POL NAC AL NUTR; *MIN SAUD, 2010, NUCL AP SAUD FAM NAS; *MIN SAUD, VIG BRAS 2006 2009; *MIN SAUD I NAC CA, 2007, PLAN IMPL AB TRAT TA; *MIN SAUD I NAC CA, 2010, CANC BRAS DAD REG CA; Ministerio do Planejamento Orcamento e Gestao (BR); Instituto Brasileiro de Geografia e Estatistica, 2010, PESQ ORC FAM 2008 20; Monteiro CA, 2002, PUBLIC HEALTH NUTR, V5, P105, DOI 10.1079/PHN2001281; MONTEIRO CA, 2000, VELHOS NOVOS MALES S, P247; MONTEIRO CA, 2009, PESQUISA NACL DEMOGR, P211; Monteiro CA, 2007, AM J PUBLIC HEALTH, V97, P1808, DOI 10.2105/AJPH.2006.099630; Monteiro Carlos A., 2003, Rev Panam Salud Publica, V14, P246, DOI 10.1590/S1020-49892003000900005; Monteiro CA, 2008, REV SAUDE PUBL, V42, P575, DOI 10.1590/S0034-89102008000400002; Monteiro CA, 2008, REV SAUDE PUBL, V42, P582, DOI 10.1590/S0034-89102008000400002; Monteiro CA, 2007, B WORLD HEALTH ORGAN, V85, P527, DOI 10.2471/BLT.06.039073; Monteiro CA, 2010, B WORLD HEALTH ORGAN, V88, P305, DOI 10.2471/BLT.09.069195; Moreira Gisela C, 2009, J Hypertens, V27, P1900, DOI 10.1097/HJH.0b013e32832dd10f; *NAT I HLTH CLIN E, 2010, PUBL HLTH GUID 25 PR; National Commission on Social Determinants of Health, 2008, SOC CAUS HLTH IN BRA; NETO RMN, 2010, ATLAS CORACOES BRASI; Neves Fabrícia Junqueira das, 2006, Rev. bras. epidemiol., V9, P112, DOI 10.1590/S1415-790X2006000100014; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Lima MCP, 2008, REV SAUDE PUBL, V42, P717, DOI 10.1590/S0034-89102008005000034; Pereira MR, 2007, CAD SAUDE PUBLICA, V23, P2363, DOI 10.1590/S0102-311X2007001000011; Pratt M, 2010, J PHYS ACT HEALTH, V7, pS131, DOI 10.1123/jpah.7.s2.s131; Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0; Rocha R., 2009, 4119 IZA I STUD LAB; Rosa RD, 2008, EPIDEMIOL SERV SAUDE, V17, P131; ROSE G, 1992, CORONARY HEART DIS E, P311; Samb B, 2010, LANCET, V376, P1785, DOI 10.1016/S0140-6736(10)61353-0; Sarno F, 2009, REV SAUDE PUBL, V43, P219, DOI 10.1590/S0034-89102009005000002; Sassi F, 2009, IMPROVING LIFESTYLES; Scazufca M, 2008, INT J EPIDEMIOL, V37, P879, DOI 10.1093/ije/dyn125; Scazufca M, 2008, INT PSYCHOGERIATR, V20, P394, DOI 10.1017/S1041610207005625; Schei MA, 2004, J EXPO ANAL ENV EPID, V14, pS110, DOI 10.1038/sj.jea.7500365; SCHMIDT MI, 2010, SAUDE BRASIL 2009 AN; Schramm Joyce Mendes de Andrade, 2004, Ciênc. saúde coletiva, V9, P897, DOI 10.1590/S1413-81232004000400011; Sembajwe G, 2010, EUR RESPIR J, V35, P279, DOI 10.1183/09031936.00027509; SILVA JB, 2009, SAUDE BRASIL 2008 20; Strong K, 2005, LANCET, V366, P1578, DOI 10.1016/S0140-6736(05)67341-2; Talamo C, 2007, CHEST, V131, P60, DOI 10.1378/chest.06-1149; Toscano CM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-189; United Nations Department of Economic and Social Affairs, 2002, WORLD POP AG 1950 20; Viacava F., 2010, ACESSO USO SERVICOS; Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X; Victora CG, 2011, LANCET, V377, P1863, DOI 10.1016/S0140-6736(11)60138-4; Vorcaro CMR, 2001, ACTA PSYCHIAT SCAND, V104, P257, DOI 10.1034/j.1600-0447.2001.00440.x; W.H. Organization, 2009, WORLD HLTH STAT 2009; Wagner E H, 1998, Eff Clin Pract, V1, P2; Warren Charles W., 2008, Morbidity and Mortality Weekly Report, V57, P1; Welch JR, 2009, HUM ECOL, V37, P13, DOI 10.1007/s10745-009-9216-7; *WHO, 2011, INNOVATIVE CARE CHRO; *WHO, WORLD HLTH SURV RES; *WHO, 2011, STEPWISE APPR CHR DI; *WHO, 1995, TECHN REP SER WHO, V854; World Health Organization, 2008, 2008 2013 ACT PLAN G; World Health Organization, 2019, WHO REP GLOB TOB EP; World Health Organization, 2009, INT DIET PHYS ACT WH; World Health Organization, 2004, GLOB STRAT DIET PHYS; World Health Organization, 2006, WHO CHILD GROWTH STA; World Health Organization. Noncommunicable Diseases and Mental Health Cluster, 2002, AG LIF COURS ACT AG	126	676	715	0	79	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2011	377	9781					1949	1961		10.1016/S0140-6736(11)60135-9	http://dx.doi.org/10.1016/S0140-6736(11)60135-9			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777LW	21561658				2022-12-28	WOS:000291623200032
J	Boppana, SB; Ross, SA; Shimamura, M; Palmer, AL; Ahmed, A; Michaels, MG; Sanchez, PJ; Bernstein, DI; Tolan, RW; Novak, Z; Chowdhury, N; Britt, WJ; Fowler, KB				Boppana, Suresh B.; Ross, Shannon A.; Shimamura, Masako; Palmer, April L.; Ahmed, Amina; Michaels, Marian G.; Sanchez, Pablo J.; Bernstein, David I.; Tolan, Robert W., Jr.; Novak, Zdenek; Chowdhury, Nazma; Britt, William J.; Fowler, Karen B.		Natl Inst Deafness Other Commun	Saliva Polymerase-Chain-Reaction Assay for Cytomegalovirus Screening in Newborns	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRIED BLOOD SPOTS; SENSORINEURAL HEARING-LOSS; CONGENITAL CMV INFECTION; DNA DETECTION; LIKELIHOOD RATIOS; FILTER-PAPER; CHILDREN; TRANSMISSION; VIRUS; URINE	Background Congenital cytomegalovirus (CMV) infection is an important cause of hearing loss, and most infants at risk for CMV-associated hearing loss are not identified early in life because of failure to test for the infection. The standard assay for newborn CMV screening is rapid culture performed on saliva specimens obtained at birth, but this assay cannot be automated. Two alternatives - real-time polymerase-chain-reaction (PCR)-based testing of a liquid-saliva or dried-saliva specimen obtained at birth - have been developed. Methods In our prospective, multicenter screening study of newborns, we compared real-time PCR assays of liquid-saliva and dried-saliva specimens with rapid culture of saliva specimens obtained at birth. Results A total of 177 of 34,989 infants (0.5%; 95% confidence interval [CI], 0.4 to 0.6) were positive for CMV, according to at least one of the three methods. Of 17,662 newborns screened with the use of the liquid-saliva PCR assay, 17,569 were negative for CMV, and the remaining 85 infants (0.5%; 95% CI, 0.4 to 0.6) had positive results on both culture and PCR assay. The sensitivity and specificity of the liquid-saliva PCR assay were 100% (95% CI, 95.8 to 100) and 99.9% (95% CI, 99.9 to 100), respectively, and the positive and negative predictive values were 91.4% (95% CI, 83.8 to 96.2) and 100% (95% CI, 99.9 to 100), respectively. Of 17,327 newborns screened by means of the dried-saliva PCR assay, 74 were positive for CMV, whereas 76 (0.4%; 95% CI, 0.3 to 0.5) were found to be CMV-positive on rapid culture. Sensitivity and specificity of the dried-saliva PCR assay were 97.4% (95% CI, 90.8 to 99.7) and 99.9% (95% CI, 99.9 to 100), respectively. The positive and negative predictive values were 90.2% (95% CI, 81.7 to 95.7) and 99.9% (95% CI, 99.9 to 100), respectively. Conclusions Real-time PCR assays of both liquid-and dried-saliva specimens showed high sensitivity and specificity for detecting CMV infection and should be considered potential screening tools for CMV in newborns. (Funded by the National Institute on Deafness and Other Communication Disorders.)	[Boppana, Suresh B.; Ross, Shannon A.; Shimamura, Masako; Novak, Zdenek; Chowdhury, Nazma; Britt, William J.; Fowler, Karen B.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35233 USA; [Boppana, Suresh B.; Britt, William J.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35233 USA; [Britt, William J.] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35233 USA; [Fowler, Karen B.] Univ Alabama Birmingham, Dept Epidemiol & Int Hlth, Birmingham, AL 35233 USA; [Palmer, April L.] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA; [Ahmed, Amina] Carolinas Med Ctr, Dept Pediat, Charlotte, NC 28203 USA; [Michaels, Marian G.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Michaels, Marian G.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [Sanchez, Pablo J.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Bernstein, David I.] Univ Cincinnati, Cincinnati, OH USA; [Bernstein, David I.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Tolan, Robert W., Jr.] St Peters Univ Hosp, New Brunswick, NJ USA; [Tolan, Robert W., Jr.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Mississippi; University of Mississippi Medical Center; Carolinas Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Southwestern Medical Center Dallas; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Saint Peter's University Hospital; Drexel University	Boppana, SB (corresponding author), Univ Alabama Birmingham, Dept Pediat, Childrens Harbor Bldg 114,1600 6th Ave S, Birmingham, AL 35233 USA.	sboppana@peds.uab.edu	Mejias, Maria Asuncion/E-3659-2011; Mejias, Asuncion/AAC-5998-2019	Mejias, Asuncion/0000-0002-5983-8006; Arora, Nitin/0000-0001-6840-4333	National Institute on Deafness and Other Communication Disorders [N01 DC50008]; GlaxoSmithKline; Roche; Mead Johnson; Vical; Merck; Novartis	National Institute on Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); GlaxoSmithKline(GlaxoSmithKline); Roche(Roche Holding); Mead Johnson; Vical; Merck(Merck & Company); Novartis(Novartis)	Supported by a grant (N01 DC50008) from the National Institute on Deafness and Other Communication Disorders.; Dr. Boppana reports receiving consulting fees from GlaxoSmithKline; Dr. Palmer, grant support from Roche; Dr. Ahmed, manuscript preparation fees from Mead Johnson; Dr. Berstein, consulting fees from Vical and Novartis; and Dr. Fowler, consulting fees from GlaxoSmithKline and Merck. No other potential conflict of interest relevant to this article was reported.	BALCAREK KB, 1993, J INFECT DIS, V167, P1433, DOI 10.1093/infdis/167.6.1433; Bale JF, 2010, JAMA-J AM MED ASSOC, V303, P1425, DOI 10.1001/jama.2010.424; Barbi M, 2000, J CLIN VIROL, V17, P159, DOI 10.1016/S1386-6532(00)00089-5; Barbi M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-2; BOPPANA SB, 1992, J CLIN MICROBIOL, V30, P721, DOI 10.1128/JCM.30.3.721-723.1992; Boppana SB, 2010, JAMA-J AM MED ASSOC, V303, P1375, DOI 10.1001/jama.2010.423; Busa J, 2007, PEDIATRICS, V120, P898, DOI 10.1542/peds.2007-2333; Dahle A J, 2000, J Am Acad Audiol, V11, P283; DAHLE AJ, 1979, J SPEECH HEAR DISORD, V44, P220, DOI 10.1044/jshd.4402.220; de Vries JJC, 2009, J CLIN VIROL, V46, pS37, DOI 10.1016/j.jcv.2009.09.001; Deeks JJ, 2004, BRIT MED J, V329, P168, DOI 10.1136/bmj.329.7458.168; DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315; DWORSKY M, 1983, PEDIATRICS, V72, P295; Foulon I, 2008, J PEDIATR-US, V153, P84, DOI 10.1016/j.jpeds.2007.12.049; Fowler KB, 1997, J PEDIATR-US, V130, P624, DOI 10.1016/S0022-3476(97)70248-8; Gohring K, 2010, J CLIN VIROL, V48, P278, DOI 10.1016/j.jcv.2010.04.011; Halwachs-Baumann G, 2002, J CLIN VIROL, V25, pS81; Hamprecht K, 2001, LANCET, V357, P513, DOI 10.1016/S0140-6736(00)04043-5; HICKS T, 1993, J PEDIATR-US, V123, P779, DOI 10.1016/S0022-3476(05)80859-5; Inoue N, 2008, PEDIATR INFECT DIS J, V27, P182, DOI 10.1097/INF.0b013e318161a2d5; Johansson PJH, 1997, SCAND J INFECT DIS, V29, P465, DOI 10.3109/00365549709011855; KNOX GE, 1979, J INFECT DIS, V140, P419, DOI 10.1093/infdis/140.3.419; Korver AMH, 2010, JAMA-J AM MED ASSOC, V304, P1701, DOI 10.1001/jama.2010.1501; Morton CC, 2006, NEW ENGL J MED, V354, P2151, DOI 10.1056/NEJMra050700; Mosca F, 2001, LANCET, V357, P1800, DOI 10.1016/S0140-6736(00)04914-X; Nozawa N, 2007, J CLIN MICROBIOL, V45, P1305, DOI 10.1128/JCM.02502-06; PASS RF, 1982, J INFECT DIS, V146, P1, DOI 10.1093/infdis/146.1.1; Revello MG, 2002, CLIN MICROBIOL REV, V15, P680, DOI 10.1128/CMR.15.4.680-715.2002; REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101; Scanga L, 2006, J MOL DIAGN, V8, P240, DOI 10.2353/jmoldx.2006.050075; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Soetens O, 2008, J CLIN MICROBIOL, V46, P943, DOI 10.1128/JCM.01391-07; Stagno SBW, 2006, INFECT DIS FETUS NEW, P389; Stehel EK, 2008, PEDIATRICS, V121, P970, DOI 10.1542/peds.2006-3441; WILLIAMSON WD, 1992, PEDIATRICS, V90, P862; Yamagishi Y, 2006, J MED VIROL, V78, P923, DOI 10.1002/jmv.20642; Yamamoto AY, 2006, J CLIN VIROL, V36, P228, DOI 10.1016/j.jcv.2006.03.011; Yamamoto AY, 2001, J VIROL METHODS, V97, P159, DOI 10.1016/S0166-0934(01)00347-0	38	299	313	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2111	2118		10.1056/NEJMoa1006561	http://dx.doi.org/10.1056/NEJMoa1006561			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AB	21631323	Green Accepted			2022-12-28	WOS:000291200700009
J	Kwon, HB; Sabatini, BL				Kwon, Hyung-Bae; Sabatini, Bernardo L.			Glutamate induces de novo growth of functional spines in developing cortex	NATURE			English	Article							HIPPOCAMPAL SLICE CULTURES; SINGLE DENDRITIC SPINES; SYNAPSE FORMATION; PYRAMIDAL NEURONS; ADULT CORTEX; IN-VIVO; PLASTICITY; SYNAPTOGENESIS; ACTIVATION; MATURATION	Mature cortical pyramidal neurons receive excitatory inputs onto small protrusions emanating from their dendrites called spines. Spines undergo activity-dependent remodelling, stabilization and pruning during development, and similar structural changes can be triggered by learning and changes in sensory experiences(1-4). However, the biochemical triggers and mechanisms of de novo spine formation in the developing brain and the functional significance of new spines to neuronal connectivity are largely unknown. Here we develop an approach to induce and monitor de novo spine formation in real time using combined two-photon laser-scanning microscopy and two-photon laser uncaging of glutamate. Our data demonstrate that, in mouse cortical layer 2/3 pyramidal neurons, glutamate is sufficient to trigger de novo spine growth from the dendrite shaft in a location-specific manner. We find that glutamate-induced spinogenesis requires opening of NMDARs (N-methyl-D-aspartate-type glutamate receptors) and activation of protein kinase A (PKA) but is independent of calcium-calmodulin-dependent kinase II (CaMKII) and tyrosine kinase receptor B (TrkB) receptors. Furthermore, newly formed spines express glutamate receptors and are rapidly functional such that they transduce presynaptic activity into postsynaptic signals. Together, our data demonstrate that early neural connectivity is shaped by activity in a spatially precise manner and that nascent dendrite spines are rapidly functionally incorporated into cortical circuits.	[Kwon, Hyung-Bae; Sabatini, Bernardo L.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Sabatini, BL (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02115 USA.	bsabatini@hms.harvard.edu			Simons Foundation; National Institute of Neurological Disorders and Stroke [NS046579]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046579] Funding Source: NIH RePORTER	Simons Foundation; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank members of the Sabatini laboratory for their comments on the manuscript and assistance with data analysis. We are grateful to S. Nazia for technical support and for acting as the blind evaluator. This work was supported by a SFARI grant from the Simons Foundation and the National Institute of Neurological Disorders and Stroke (NS046579).	Busetto G, 2008, J PHYSIOL-LONDON, V586, P1519, DOI 10.1113/jphysiol.2007.149336; Chalifoux JR, 2010, NEURON, V66, P101, DOI 10.1016/j.neuron.2010.03.012; Dalva MB, 2007, NAT REV NEUROSCI, V8, P206, DOI 10.1038/nrn2075; De Roo M, 2008, CEREB CORTEX, V18, P151, DOI 10.1093/cercor/bhm041; Di Cristo G, 2001, SCIENCE, V292, P2337, DOI 10.1126/science.1059075; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fiala JC, 1998, J NEUROSCI, V18, P8900; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; HAMORI J, 1973, BRAIN RES, V62, P337, DOI 10.1016/0006-8993(73)90694-X; Harvey CD, 2008, SCIENCE, V321, P136, DOI 10.1126/science.1159675; Harvey CD, 2007, NATURE, V450, P1195, DOI 10.1038/nature06416; Hofer SB, 2009, NATURE, V457, P313, DOI 10.1038/nature07487; Knott GW, 2006, NAT NEUROSCI, V9, P1117, DOI 10.1038/nn1747; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; MILLER M, 1981, J COMP NEUROL, V203, P555, DOI 10.1002/cne.902030402; Nagerl UV, 2007, J NEUROSCI, V27, P8149, DOI 10.1523/JNEUROSCI.0511-07.2007; RAKIC P, 1986, SCIENCE, V232, P232, DOI 10.1126/science.3952506; Richards DA, 2005, P NATL ACAD SCI USA, V102, P6166, DOI 10.1073/pnas.0501881102; Scheiffele P, 2003, ANNU REV NEUROSCI, V26, P485, DOI 10.1146/annurev.neuro.26.043002.094940; Skeberdis VA, 2006, NAT NEUROSCI, V9, P501, DOI 10.1038/nn1664; Sorra KE, 1998, J COMP NEUROL, V398, P225; Sudhof TC, 2008, NATURE, V455, P903, DOI 10.1038/nature07456; Tanaka JI, 2008, SCIENCE, V319, P1683, DOI 10.1126/science.1152864; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; Yasuda H, 2003, NAT NEUROSCI, V6, P15, DOI 10.1038/nn985; Yuste R, 2004, NAT REV NEUROSCI, V5, P24, DOI 10.1038/nrn1300; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zito K, 2009, NEURON, V61, P247, DOI 10.1016/j.neuron.2008.10.054; Zuo Y, 2005, NATURE, V436, P261, DOI 10.1038/nature03715	30	249	251	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 2	2011	474	7349					100	104		10.1038/nature09986	http://dx.doi.org/10.1038/nature09986			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	771KV	21552280	Green Accepted			2022-12-28	WOS:000291156700046
J	Appleby, J				Appleby, John			DATA BRIEFING What's happening to NHS spending across the UK?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Fund, London, England		Appleby, J (corresponding author), Kings Fund, London, England.	j.appleby@kingsfund.org.uk						*HM TREAS, 2011, GDP DEFL LAT FIG; *HM TREAS, CMND7942; HM Treasury, 2011, PUBL EXP STAT AN PES; *NO IR EX, BUDG 2011 2015; *SCOTT GOV, SCOTL SPEND PLANS DR; *WELSH ASS, 2011, FIN BUD	6	4	4	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2011	342								d2982	10.1136/bmj.d2982	http://dx.doi.org/10.1136/bmj.d2982			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771KC	21610050	Green Submitted			2022-12-28	WOS:000291154600009
J	Kuper, M; Gold, SJ; Callow, C; Quraishi, T; King, S; Mulreany, A; Bianchi, M; Conway, DH				Kuper, Martin; Gold, Stuart J.; Callow, Colin; Quraishi, Tanviha; King, Sarah; Mulreany, Aundrea; Bianchi, Michele; Conway, Daniel H.			QUALITY IMPROVEMENT REPORT Intraoperative fluid management guided by oesophageal Doppler monitoring	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; MAJOR ABDOMINAL-SURGERY; OF-THE-LITERATURE; HOSPITAL STAY; LAPAROSCOPIC COLECTOMY; CARDIAC-SURGERY; BOWEL SURGERY; OPTIMIZATION; METAANALYSIS; MORBIDITY	Problem Fluid management during major surgery poses a challenge to the surgical team as postoperative complications are often related to giving the wrong amount of intravenous fluid. Postoperative morbidity can be reduced by using the oesophageal Doppler cardiac output monitor to individualise fluid administration, but this technology has not been widely adopted. Design A campaign for adopting this technology in major surgical specialties explored clinical and managerial barriers throughout the procurement and implementation process. We compared patient outcomes 12 months before implementation and after implementation. Setting Three large hospitals in England with different size, geographical location, and case mix. Strategies for change Project leads at each site included a consultant anaesthetist, a divisional manager, and an audit facilitator. A business case was prepared by each team with support from NHS Technology Adoption Centre, allowing senior management to overcome the unequal spread of costs versus benefits. A survey of anaesthetists revealed concerns about familiarity with the device, which we dealt with by clinicians volunteering to "champion" the technique, supported by standard training provided by the manufacturer. We encouraged appropriate use of the technology by collecting intraoperative patient related data and postoperative patient outcomes and by giving regular, timely feedback. Key measures for improvement The key outcome measure was length of hospital stay. In-hospital mortality, readmission, and reoperation rates were also recorded. Process measures were use of monitors and change in stroke volume during surgery. Effects of the change We compared 649 patients after implementation across all sites with 658 matched cases before implementation. Use of Doppler increased from 11% to 65% of eligible operations, with a 3.7 day reduction in total length of stay. Length of stay was reduced at each site, and in most specialties. Concurrent improvements in patient care could have contributed to these findings. The only sign of harm from the intervention was one episode of pulmonary oedema. Mortality, readmission, and reoperation rates all fell non-significantly. Lessons learnt Managerial barriers consisted of silo budgeting, difficulties with preparing a business case, and fears about uncontrolled implementation. By collecting outcome data, we convinced senior managers to support and sustain investment. Clinical barriers consisted mainly of scepticism regarding clinical effectiveness and worries about training. Clinicians "championing" the technology took on responsibility for data collection, education, advocacy, and spanning boundaries. When barriers to adoption of oesophageal Doppler monitoring are overcome, outcome improvements suggested by research can be replicated in the real world. The project generated a web based guide (www.howtowhyto.nhs.uk) to provide tools and resources to support implementation.	[Quraishi, Tanviha; Conway, Daniel H.] Manchester Royal Infirm, Manchester Acad Hlth Sci Ctr, Manchester M13 9WL, Lancs, England; [Kuper, Martin; Mulreany, Aundrea; Bianchi, Michele] Whittington Hosp NHS Trust, London N19 5NF, England; [Gold, Stuart J.; King, Sarah] Royal Derby Hosp NHS Fdn Trust, Derby DE22 3NE, England; [Callow, Colin] NHS Technol Adopt Ctr, Manchester M13 9WL, Lancs, England	University of Manchester	Conway, DH (corresponding author), Manchester Royal Infirm, Manchester Acad Hlth Sci Ctr, Oxford Rd, Manchester M13 9WL, Lancs, England.	daniel.conway@cmft.nhs.uk		Conway, Daniel/0000-0002-4755-2203; Callow, Colin/0000-0003-4941-8152	NHS Technology Adoption Centre	NHS Technology Adoption Centre	This project was supported by the NHS Technology Adoption Centre.	Abbas SM, 2008, ANAESTHESIA, V63, P44, DOI 10.1111/j.1365-2044.2007.05233.x; Bundgaard-Nielsen M, 2010, ACTA ANAESTH SCAND, V54, P464, DOI 10.1111/j.1399-6576.2009.02175.x; Conway DH, 2002, ANAESTHESIA, V57, P845, DOI 10.1046/j.1365-2044.2002.02708.x; Copeland G P, 1991, Br J Surg, V78, P355, DOI 10.1002/bjs.1800780327; Enhanced Recovery Partnership Programme, 2010, DEL ENH REC HELP PAT; Gan TJ, 2002, ANESTHESIOLOGY, V97, P820, DOI 10.1097/00000542-200210000-00012; Grocott MPW, 2007, J CLIN EPIDEMIOL, V60, P919, DOI 10.1016/j.jclinepi.2006.12.003; HamiltonDavies C, 1997, INTENS CARE MED, V23, P276, DOI 10.1007/s001340050328; Khuri SF, 2005, ANN SURG, V242, P326, DOI 10.1097/01.sla.0000179621.33268.83; Levy BF, 2009, DIS COLON RECTUM, V52, P1239, DOI 10.1007/DCR.0b013e3181a0b32d; Marik PE, 2008, CHEST, V134, P172, DOI 10.1378/chest.07-2331; McKendry M, 2004, BMJ-BRIT MED J, V329, P258, DOI 10.1136/bmj.38156.767118.7C; Mowatt G, 2008, EVIDENCE REV OESOPHA; MYTHEN MG, 1995, ARCH SURG-CHICAGO, V130, P423; Noblett SE, 2006, BRIT J SURG, V93, P1069, DOI 10.1002/bjs.5454; Senagore AJ, 2009, DIS COLON RECTUM, V52, P1935, DOI 10.1007/DCR.0b013e3181b4c35e; Sinclair S, 1997, BMJ-BRIT MED J, V315, P909; Varadhan KK, 2010, P NUTR SOC, V69, P488, DOI 10.1017/S0029665110001734; Venn R, 2002, BRIT J ANAESTH, V88, P65, DOI 10.1093/bja/88.1.65; Wakeling HG, 2005, BRIT J ANAESTH, V95, P634, DOI 10.1093/bja/aei223; Walsh SR, 2008, INT J CLIN PRACT, V62, P466, DOI 10.1111/j.1742-1241.2007.01516.x	21	43	47	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2011	342								d3016	10.1136/bmj.d3016	http://dx.doi.org/10.1136/bmj.d3016			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771KC	21610051				2022-12-28	WOS:000291154600010
J	Pilling, S; Whittington, C; Taylor, C; Kendrick, T				Pilling, Stephen; Whittington, Craig; Taylor, Clare; Kendrick, Tony			GUIDELINES Identification and care pathways for common mental health disorders: summary of NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material							ANXIETY		[Pilling, Stephen] UCL, Ctr Outcomes Res & Effectiveness, London WC1E 7HB, England; [Pilling, Stephen; Whittington, Craig] UCL, Natl Collaborating Ctr Mental Hlth, London WC1E 7HB, England; [Taylor, Clare] Royal Coll Psychiatrists, Natl Collaborating Ctr Mental Hlth, London E1 8AA, England; [Kendrick, Tony] Hull York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England	University of London; University College London; University of London; University College London; University of London; University College London; University of Hull; University of York - UK	Pilling, S (corresponding author), UCL, Ctr Outcomes Res & Effectiveness, London WC1E 7HB, England.	s.pilling@ucl.ac.uk	Kendrick, Tony/H-8558-2014; Whittington, Craig/B-1380-2008	Kendrick, Tony/0000-0003-1618-9381; Whittington, Craig/0000-0002-1950-0334				[Anonymous], 2005, OBS COMP DIS COR INT; Campbell SM, 2009, NEW ENGL J MED, V361, P368, DOI 10.1056/NEJMsa0807651; Clark DM, 2009, BEHAV RES THER, V47, P910, DOI 10.1016/j.brat.2009.07.010; Department of Health, 2007, IMPR ACC PSYCH THER; Goldberg DP., 1992, COMMON MENTAL DISORD; *IMPR ACC PSYCH TH, 2010, IAPT DAT HDB; KISELY S, 1995, MENTAL ILLNESS GEN H, P175; Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004; MCMANUS S, 2009, ADULT PSYCHIAT MORBI, P2007; *NAT I HLTH CLIN E, 2011, GEN AN DIS PAN DIS A; National Collaborating Centre for Mental Health (Great Britain) and Royal College of Psychiatrists, 2011, COMM MENT HLTH DIS I; National Institute for Health and Care Excellence (NICE), 2011, ALCOHOL USE DISORDER; National Institute for Health and Clinical Excellence, 2010, ALC US DIS DIAGN CLI; National Institute for Health and Clinical Excellence, 2009, DEPR AD CHRON PHYS H; National Institute for Health and Clinical Excellence, 2009, GUID MAN; National Institute for Health and Clinical Excellence, 2005, POSTTR STRESS DIS PT; National Institute for Health and Clinical Excellence, 2009, DEPR TREATM MAN DEPR; National Institute for Health and Clinical Excellence, 2007, ANT POSTN MENT HLTH; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Tylee A, 2007, J CLIN PSYCHIAT, V68, P27; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	19	20	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2011	342								d2868	10.1136/bmj.d2868	http://dx.doi.org/10.1136/bmj.d2868			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771KC	21610049				2022-12-28	WOS:000291154600008
J	Kleinert, S; Horton, R				Kleinert, Sabine; Horton, Richard			Brazil: towards sustainability and equity in health	LANCET			English	Editorial Material									[Kleinert, Sabine; Horton, Richard] The Lancet, London NW1 7BY, England		Kleinert, S (corresponding author), The Lancet, London NW1 7BY, England.							*FIOCRUZ, GETT KNOW FIOCR; Leahy J., 2011, FINANCIAL TIMES 0303; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Rousseff D., 2011, COMMUNICATION   0101; VICTORA CG, 2011, LANCET, DOI DOI 10.1016/S)140-6736(11)60055-X; *WORLD BANK, 2010, BRAZ COUNTR BRIEF; YOKOTA RTD, 2011, GLOBAL HLTH METRICS; ZITKOMELO P, 2011, GLOBAL HLTH METRICS	8	22	25	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	2011	377	9779					1721	1722		10.1016/S0140-6736(11)60433-9	http://dx.doi.org/10.1016/S0140-6736(11)60433-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771AS	21561652				2022-12-28	WOS:000291130200004
J	Seymour, MT; Thompson, LC; Wasan, HS; Middleton, G; Brewster, AE; Shepherd, SF; O'Mahony, MS; Maughan, TS; Parmar, M; Langley, RE				Seymour, Matthew T.; Thompson, Lindsay C.; Wasan, Harpreet S.; Middleton, Gary; Brewster, Alison E.; Shepherd, Stephen F.; O'Mahony, M. Sinend; Maughan, Timothy S.; Parmar, Mahesh; Langley, Ruth E.		FOCUS2 Investigators; Natl Canc Res Inst	Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial	LANCET			English	Article							COMBINATION CHEMOTHERAPY; 1ST-LINE TREATMENT; CLINICAL-TRIALS; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; OLDER; CAPECITABINE; ONCOLOGY; COIN	Background Elderly and frail patients with cancer, although often treated with chemotherapy, are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose chemotherapy options and to seek objective predictors of outcome in frail patients with advanced colorectal cancer. Methods We undertook an open, 2 x 2 factorial trial in 61 UK centres for patients with previously untreated advanced colorectal cancer who were considered unfit for full-dose chemotherapy. After comprehensive health assessment (CHA), patients were randomly assigned by minimisation to: 48-h intravenous fluorouracil with levofolinate (group A); oxaliplatin and fluorouracil (group B); capecitabine (group C); or oxaliplatin and capecitabine (group D). Treatment allocation was not masked. Starting doses were 80% of standard doses, with discretionary escalation to full dose after 6 weeks. The two primary outcome measures were: addition of oxaliplatin ([A vs B] + [C vs D]), assessed with progression-free survival (PFS); and substitution of fluorouracil with capecitabine ([A vs C] + [B vs D]), assessed by change from baseline to 12 weeks in global quality of life (QoL). Analysis was by intention to treat. Baseline clinical and CHA data were modelled against outcomes with a novel composite measure, overall treatment utility (OTU). This study is registered, number ISRCTN21221452. Findings 459 patients were randomly assigned (115 to each of groups A C, 114 to group D). Factorial comparison of addition of oxaliplatin versus no addition suggested some improvement in PFS, but the finding was not significant (median 5.8 months [IQR 3.3-7.5] vs 4.5 months [2.8-6.4]; hazard ratio 0.84, 95% CI 0-69-1.01, p=0.07). Replacement of fluorouracil with capecitabine did not improve global QoL: 69 of 124 (56%) patients receiving fluorouracil reported improvement in global QoL compared with 69 of 123 (56%) receiving capecitabine. The risk of having any grade 3 or worse toxic effect was not significantly increased with oxaliplatin (83/219 [38%] vs 70/221 [32%]; p=0.17), but was higher with capecitabine than with fluorouracil (88/222 [40 4] vs 65/218 [30%]; p=0.03). In multivariable analysis, fewer baseline symptoms (odds ratio 1.32, 95% CI 1.14-1.52), less widespread disease (1.51, 1.05-2-19), and use of oxaliplatin (0.57, 0.39-0.82) were predictive of better OTU. Interpretation FOCUS2 shows that with an appropriate design, including reduced starting doses of chemotherapy, frail and elderly patients can participate in a randomised controlled trial. On balance, a combination including oxaliplatin was preferable to single-agent fluoropyrimidines, although the primary endpoint of PFS was not met. Capecitabine did not improve QoL compared with fluorouracil. Comprehensive baseline assessment holds promise as an objective predictor of treatment benefit.	[Seymour, Matthew T.] St James Univ Hosp, St Jamess Inst Oncol, Leeds LS9 7TF, W Yorkshire, England; [Seymour, Matthew T.] Univ Leeds, Leeds, W Yorkshire, England; [Thompson, Lindsay C.; Parmar, Mahesh; Langley, Ruth E.] MRC, Clin Trials Unit, London, England; [Wasan, Harpreet S.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England; [Middleton, Gary] Royal Surrey Cty Hosp, Guildford, Surrey, England; [Brewster, Alison E.; O'Mahony, M. Sinend; Maughan, Timothy S.] Velindre Hosp NHS Trust, Cardiff, S Glam, Wales; [Brewster, Alison E.; O'Mahony, M. Sinend; Maughan, Timothy S.] Univ Cardiff, Cardiff, S Glam, Wales; [Shepherd, Stephen F.] Cheltenham Gen Hosp, Cheltenham, Glos, England	Saint James's University Hospital; University of Leeds; Medical Research Council Clinical Trials Unit; Imperial College London; Royal Surrey County Hospital; Velindre Hospital; Cardiff University; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital	Seymour, MT (corresponding author), St James Univ Hosp, St Jamess Inst Oncol, Leeds LS9 7TF, W Yorkshire, England.	m.seymour@ncrn.org.uk	Maughan, Tim/AAV-7636-2021	Sebag-Montefiore, David/0000-0002-5978-9259; Hickish, Tamas/0000-0001-6770-7279; Naderi, Ali/0000-0001-7142-7616; Astras, George/0000-0003-4931-8397; Quirke, Philip/0000-0002-3597-5444; Seymour, Matthew/0000-0002-2441-9629; Wasan, Harpreet/0000-0002-6268-2030; Samuel, Leslie/0000-0002-8402-8670; Middleton, Gary/0000-0001-5695-3474	UK MRC; Cancer Research UK [C6003/A3830]; National Institute of Health Research (NIHR) National Cancer Research Network	UK MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); National Institute of Health Research (NIHR) National Cancer Research Network(National Institute for Health Research (NIHR))	MTS has received travel and accommodation and departmental research funding (unconnected with FOCUS2) from Roche. HSW has received travel support, honoraria, and educational support from Roche and Sanofi-Aventis. LCT, MP, and REL are employed by the UK MRC, which is also the trial sponsor. MSO'M is the Chair the Academic and Research Committee of the British Geriatrics Society and chairs the Drugs and Prescribing section of the British Geriatrics Society. The British Geriatrics Society has a mission statement that clinical trials be inclusive of older people and frail people. GM, AEB, SFS, and TSM declare that they have no conflicts of interest.; This trial was developed by the UK National Cancer Research Institute Colorectal Clinical Studies Group, funded by Cancer Research UK (C6003/A3830), and ran within the National Health Service supported by the National Institute of Health Research (NIHR) National Cancer Research Network. Discounted levofolinate and infusors were provided, respectively, by Wyeth and Baxter; these companies did not have access to data, and were not involved in any aspect of the research. We thank the 459 participating patients and the large number of clinicians, research nurses, data managers, and other clinical and support staff at the participating centres.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Adams R, 2009, EJC SUPPL, V7, P10, DOI 10.1016/S1359-6349(09)72050-6; American Cancer Society, 2006, CANC FACTS FIG 2006; [Anonymous], 2006, MRC GOOD RES PRACT; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cheeseman SL, 2002, BRIT J CANCER, V87, P393, DOI 10.1038/sj.bjc.6600467; Cort MC, 1994, JAMA-J AM MED ASSOC, V272, P1035; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Folprecht G, 2008, J CLIN ONCOL, V26, P1443, DOI 10.1200/JCO.2007.14.0509; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Kind P, 1996, QUALITY LIFE PHARMAC; Maas HAAM, 2007, EUR J CANCER, V43, P2161, DOI 10.1016/j.ejca.2007.08.002; Maughan T, 2009, EJC SUPPL, V7, P4, DOI 10.1016/S1359-6349(09)72034-8; Nonni F, 1998, CLIN REHABIL, V1, P233; Rosati G, 2010, ANN ONCOL, V21, P781, DOI 10.1093/annonc/mdp359; Saif MW, 2009, CRIT REV ONCOL HEMAT, V72, P155, DOI 10.1016/j.critrevonc.2009.02.006; Sargent DJ, 2009, J CLIN ONCOL, V27, P1948, DOI 10.1200/JCO.2008.20.2879; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Seymour MT, 1996, J CLIN ONCOL, V14, P2280, DOI 10.1200/JCO.1996.14.8.2280; Simonsick EM, 2000, AGING-CLIN EXP RES, V12, P274, DOI 10.1007/BF03339847; TEBBUTT NC, 2009, J CLIN ONCOL S, V27, P4023; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Townsley CA, 2005, J CLIN ONCOL, V23, P3112, DOI 10.1200/JCO.2005.00.141; Twelves C, 2001, EUR J CANCER, V37, P597, DOI 10.1016/S0959-8049(00)00444-5; Twelves C, 2001, EJC SUPPL, V37, P272; UK Office of National Statistics, MORT STAT 2007 REG; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	278	280	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2011	377	9779					1749	1759		10.1016/S0140-6736(11)60399-1	http://dx.doi.org/10.1016/S0140-6736(11)60399-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771AS	21570111	Green Published, Bronze			2022-12-28	WOS:000291130200033
J	Feldstein, SB				Feldstein, Steven B.			Subtropical Rainfall and the Antarctic Ozone Hole	SCIENCE			English	Editorial Material							HEMISPHERE CLIMATE-CHANGE; TROPOSPHERE; EDDIES; FLOW		Penn State Univ, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Feldstein, SB (corresponding author), Penn State Univ, University Pk, PA 16802 USA.	sbf1@meteo.psu.edu						Arblaster JM, 2006, J CLIMATE, V19, P2896, DOI 10.1175/JCLI3774.1; Chen G, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031200; FARMAN JC, 1985, NATURE, V315, P207, DOI 10.1038/315207a0; Gillett NP, 2003, SCIENCE, V302, P273, DOI 10.1126/science.1087440; Kang SM, 2011, SCIENCE, V332, P951, DOI 10.1126/science.1202131; Kim HK, 2001, J ATMOS SCI, V58, P2859, DOI 10.1175/1520-0469(2001)058<2859:HCDIAP>2.0.CO;2; Kushner PJ, 2004, J CLIMATE, V17, P629, DOI 10.1175/1520-0442(2004)017<0629:SCIARS>2.0.CO;2; PFEFFER RL, 1981, J ATMOS SCI, V38, P1340, DOI 10.1175/1520-0469(1981)038<1340:WMFIIT>2.0.CO;2; Polvani LM, 2011, J CLIMATE, V24, P795, DOI 10.1175/2010JCLI3772.1; Simpson IR, 2009, J ATMOS SCI, V66, P1347, DOI 10.1175/2008JAS2758.1; Solomon S, 1999, REV GEOPHYS, V37, P275, DOI 10.1029/1999RG900008; Son SW, 2008, SCIENCE, V320, P1486, DOI 10.1126/science.1155939; Son SW, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL038671; Song YC, 2004, J ATMOS SCI, V61, P1711, DOI 10.1175/1520-0469(2004)061<1711:DMFSIO>2.0.CO;2; Thompson DWJ, 2002, SCIENCE, V296, P895, DOI 10.1126/science.1069270; Wittman MAH, 2007, J ATMOS SCI, V64, P479, DOI 10.1175/JAS3828.1	16	20	23	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2011	332	6032					925	926		10.1126/science.1206834	http://dx.doi.org/10.1126/science.1206834			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	766FO	21596982				2022-12-28	WOS:000290766600030
J	Copertino, MD				Copertino, Margareth da Silva			Add coastal vegetation to the climate critical list	NATURE			English	Editorial Material									Fundacao Univ Fed Rio Grande, Inst Oceanog, Rio Grande, Brazil	Universidade Federal do Rio Grande	Copertino, MD (corresponding author), Fundacao Univ Fed Rio Grande, Inst Oceanog, Rio Grande, Brazil.	doccoper@furg.br	Copertino, Margareth/T-6873-2019; Fapesp, Biota/F-8655-2017; Copertino, Margareth S/C-9893-2013; da Silva Oliveira, Margareth/K-9670-2015	Copertino, Margareth/0000-0001-5771-829X; Fapesp, Biota/0000-0002-9887-8449; Copertino, Margareth S/0000-0001-5771-829X; da Silva Oliveira, Margareth/0000-0002-6490-5170					0	21	23	5	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 19	2011	473	7347					255	255		10.1038/473255a	http://dx.doi.org/10.1038/473255a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	765QA	21593818	Bronze			2022-12-28	WOS:000290722400004
J	Muller, J; Hipsley, CA; Head, JJ; Kardjilov, N; Hilger, A; Wuttke, M; Reisz, RR				Mueller, Johannes; Hipsley, Christy A.; Head, Jason J.; Kardjilov, Nikolay; Hilger, Andre; Wuttke, Michael; Reisz, Robert R.			Eocene lizard from Germany reveals amphisbaenian origins	NATURE			English	Article							SQUAMATE REPTILES; BODY-FORM; PHYLOGENETIC ANALYSIS; MIDDLE-EOCENE; EVOLUTION; SNAKES; SYSTEMATICS; RESOLUTION; POSITION	Amphisbaenia is a speciose clade of fossorial lizards characterized by a snake-like body and a strongly reinforced skull adapted for head-first burrowing(1,2). The evolutionary origins of amphisbaenians are controversial, with molecular data uniting them with lacertids(3,4), a clade of Old World terrestrial lizards, whereas morphology supports a grouping with snakes and other limbless squamates(5-9). Reports of fossil stem amphisbaenians(10) have been falsified(11), and no fossils have previously tested these competing phylogenetic hypotheses or shed light on ancestral amphisbaenian ecology. Here we report the discovery of a new lacertid-like lizard from the Eocene Messel locality of Germany that provides the first morphological evidence for lacertid-amphisbaenian monophyly on the basis of a reinforced, akinetic skull roof and braincase, supporting the view that body elongation and limblessness in amphisbaenians and snakes evolved independently. Morphometric analysis of body shape and ecology in squamates indicates that the postcranial anatomy of the new taxon is most consistent with opportunistically burrowing habits, which in combination with cranial reinforcement indicates that head-first burrowing evolved before body elongation and may have been a crucial first step in the evolution of amphisbaenian fossoriality.	[Mueller, Johannes; Hipsley, Christy A.] Humboldt Univ, Leibniz Inst Evolut & Biodiversitatsforsch, Museum Nat Kunde, D-10115 Berlin, Germany; [Hipsley, Christy A.] Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA; [Head, Jason J.; Reisz, Robert R.] Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada; [Kardjilov, Nikolay; Hilger, Andre] Helmholtz Zentrum Berlin Mat & Energie, D-14109 Berlin, Germany; [Wuttke, Michael] Gen Direkt Kulturelles Erbe RLP, Direkt Landesarchaol, D-55116 Mainz, Germany	Humboldt University of Berlin; Leibniz Institut fur Evolutions und Biodiversitatsforschung; University of California System; University of California Santa Cruz; University of Toronto; University Toronto Mississauga; Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB)	Muller, J (corresponding author), Humboldt Univ, Leibniz Inst Evolut & Biodiversitatsforsch, Museum Nat Kunde, Invalidenstr 43, D-10115 Berlin, Germany.	johannes.mueller@mfn-berlin.de	Kardjilov, Nikolay/AAX-9855-2021; Müller, Johannes/A-6293-2017	Müller, Johannes/0000-0001-5801-856X; Hipsley, Christy/0000-0002-5740-9363; Kardjilov, Nikolay/0000-0002-0980-1440; Hilger, Andre/0000-0002-6454-7967	Natural Sciences and Engineering Research Council of Canada; Alexander von Humboldt-Stiftung	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Alexander von Humboldt-Stiftung(Alexander von Humboldt Foundation)	We thank S. Schaal for making the specimen available for study, J. J. Wiens for providing his morphometric data set of extant squamates, J. L. Conrad for providing his morphological data set of fossil and extant squamates, I. Manke for technical and administrative support, H. Mewis, H. Stohr and A. Paulke for technical support, C. Bell and D. Evans for discussion, and P. Holroyd, M. Kroniger, M. Cunningham, M.-O. Rodel, K. Seymour, H.-D. Sues and F. Tillack for access to specimens. J.J.H. was funded by Natural Sciences and Engineering Research Council of Canada Discovery and Research Tools and Instruments grants, R.R.R. was funded by a Natural Sciences and Engineering Research Council of Canada Discovery grant and the Alexander von Humboldt-Stiftung.	BERMAN DS, 1977, J PALEONTOL, V51, P986; BERMAN DS, 1973, COPEIA, P704; Brandley MC, 2008, EVOLUTION, V62, P2042, DOI 10.1111/j.1558-5646.2008.00430.x; Conrad JL, 2008, B AM MUS NAT HIST, P1, DOI 10.1206/310.1; Estes R., 1988, P119; Estes R., 1983, HDB PALAOHERPETOL 10; Evans SE, 1998, ZOOL J LINN SOC-LOND, V124, P235, DOI 10.1006/zjls.1997.0139; Franzen J. L., 1982, COUR FORSCH I SENCKE, V54, P12; GANS C, 1975, AM ZOOL, V15, P455; Gans C., 2008, BIOL REPTILIA MORPHO, P621; GREER AE, 1991, J HERPETOL, V25, P166, DOI 10.2307/1564644; Hallermann J, 1998, ZOOL J LINN SOC-LOND, V122, P385, DOI 10.1006/zjls.1996.0109; Hipsley CA, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-151; Kearney M, 2005, J MORPHOL, V264, P1, DOI 10.1002/jmor.10210; Kearney M, 2003, HERPETOL MONOGR, V17, P1, DOI 10.1655/0733-1347(2003)017[0001:SOTALB]2.0.CO;2; Kearney M, 2003, J VERTEBR PALEONTOL, V23, P394, DOI 10.1671/0272-4634(2003)023[0394:TPPOSH]2.0.CO;2; Lee MSY, 2009, J EVOLUTION BIOL, V22, P1308, DOI 10.1111/j.1420-9101.2009.01751.x; Lee MSY, 1998, BIOL J LINN SOC, V65, P369, DOI 10.1111/j.1095-8312.1998.tb01148.x; Muller J, 2001, J VERTEBR PALEONTOL, V21, P261, DOI 10.1671/0272-4634(2001)021[0261:OAROER]2.0.CO;2; Popov SV., 2004, COUR FORSCH I SENCKE, V250, P1; RIEPPEL O, 1988, EVOL BIOL, V22, P37; Rieppel O, 2007, J PALEONTOL, V81, P760, DOI 10.1666/pleo0022-3360(2007)081[0760:NMDFEK]2.0.CO;2; The Deep Scaly Project, 2008, RHIN FLOR FLOR WORM; Townsend TM, 2004, SYST BIOL, V53, P735, DOI 10.1080/10635150490522340; Vidal N, 2005, CR BIOL, V328, P1000, DOI 10.1016/j.crvi.2005.10.001; Weber Sinje, 2004, Abhandlungen der Senckenbergischen Naturforschenden Gesellschaft, V561, P1; Wiens JJ, 2006, EVOLUTION, V60, P123, DOI 10.1111/j.0014-3820.2006.tb01088.x; Wiens JJ, 2001, EVOLUTION, V55, P2303; Wiens JJ, 2010, SYST BIOL, V59, P674, DOI 10.1093/sysbio/syq048; WU XC, 1993, NATURE, V366, P57, DOI 10.1038/366057a0	30	73	77	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					364	367		10.1038/nature09919	http://dx.doi.org/10.1038/nature09919			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593869				2022-12-28	WOS:000290722400046
J	Cohen-Bearak, A				Cohen-Bearak, Adena			Entering Data	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												adenacb@verizon.net							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2011	305	19					1944	1944		10.1001/jama.2011.621	http://dx.doi.org/10.1001/jama.2011.621			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764WO	21586704				2022-12-28	WOS:000290665500001
J	Zinberg, JM				Zinberg, Joel M.			When Patients Call, Will Physicians Respond?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICAID PATIENTS		[Zinberg, Joel M.] Mt Sinai Med Ctr, New York Cty Med Soc, New York, NY 10029 USA; [Zinberg, Joel M.] Mt Sinai Med Ctr, Dept Surg, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Zinberg, JM (corresponding author), 111 E 88th St,1A, New York, NY 10128 USA.	jmzinberg@hotmail.com						Ackerman T, 2010, HOUSTON CHRONIC 0517; [Anonymous], 2010, 2010 ANN REPORT BOAR; Berman S, 2002, PEDIATRICS, V110, P239, DOI 10.1542/peds.110.2.239; Cunningham PJ, 2008, MILBANK Q, V86, P91, DOI 10.1111/j.1468-0009.2007.00514.x; Foster RS, 2010, FOST CAR IND ACT 199; Issacs SL, 2007, HLTH AFF MILLWOOD, V26, P871; Jost TS, 2010, NEW ENGL J MED, V363, P103, DOI 10.1056/NEJMp1005402; SACK K, 2011, NY TIMES        0909, pA1	8	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2011	305	19					2011	2012		10.1001/jama.2011.661	http://dx.doi.org/10.1001/jama.2011.661			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764WO	21586719				2022-12-28	WOS:000290665500028
J	Douketis, J				Douketis, James			Rivaroxaban was noninferior to enoxaparin for preventing short-term recurrent VTE and superior to placebo in continued treatment	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PHARMACOKINETICS; PHARMACODYNAMICS		St Josephs Hosp, Hamilton, ON, Canada	McGill University; McMaster University	Douketis, J (corresponding author), St Josephs Hosp, Hamilton, ON, Canada.		Douketis, James/AAO-5659-2021					Douketis JD, 2010, CURR PHARM DESIGN, V16, P3436; Eriksson BI, 2009, CLIN PHARMACOKINET, V48, P1, DOI 10.2165/0003088-200948010-00001; Frydman A, 1996, HAEMOSTASIS, V26, P24; Kearon C, 2008, CHEST, V133, p454S, DOI 10.1378/chest.08-0658; Lassen MR, 2009, NEW ENGL J MED, V361, P594, DOI 10.1056/NEJMoa0810773	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-6	10.7326/0003-4819-154-10-201105170-02006	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576524				2022-12-28	WOS:000290620300005
J	Hussain, AA				Hussain, Anwar A.			Meaningful Use of Information Technology: A Local Perspective	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CLINICAL-PRACTICE GUIDELINES; ELECTRONIC HEALTH RECORDS; ORDER ENTRY SYSTEM; CARE; MORTALITY; QUALITY; IMPLEMENTATION; PERFORMANCE; IMPACT	To reduce costs of care and improve quality, the federal government is stimulating adoption of health information technology through meaningful use policy. The legislation, however, is built on several assumptions that are unrealistic from a provider's perspective-the group that is expected to purchase, use, and sustain the information technology infrastructure. A viable meaningful use policy may do better to account for the realities of patient care by using a bottom-up approach for adoption rather than the current top-down strategy.	[Hussain, Anwar A.] UHS Hosp, Johnson City, NY USA		Hussain, AA (corresponding author), 33-57 Harrison St, Johnson City, NY 13790 USA.	hussain.a.anwar@gmail.com						Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Centers for Medicare & Medicaid Services, EHR INC PROGR OV; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; Congressional Budget Office, 2008, EV COSTS BEN HLTH IN; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Greenhalgh T, 2009, MILBANK Q, V87, P729, DOI 10.1111/j.1468-0009.2009.00578.x; Hammond WE, 2005, HEALTH AFFAIR, V24, P1205, DOI 10.1377/hlthaff.24.5.1205; Han YY, 2005, PEDIATRICS, V116, P1506, DOI 10.1542/peds.2005-1287; Holdsworth MT, 2007, PEDIATRICS, V120, P1058, DOI 10.1542/peds.2006-3160; Jha AK, 2009, NEW ENGL J MED, V360, P1628, DOI 10.1056/NEJMsa0900592; Longhurst CA, 2010, PEDIATRICS, V126, P14, DOI 10.1542/peds.2009-3271; Mitiku Tezeta F, 2008, Healthc Q, V11, P23; Plsek PE, 2001, BRIT MED J, V323, P625, DOI 10.1136/bmj.323.7313.625; Shekelle P, 2006, EVIDENCE REPORTS TEC, V132; Tricoci P, 2009, JAMA-J AM MED ASSOC, V301, P831, DOI 10.1001/jama.2009.205; U.S. Department of Health and Human Services, 2010, GET FACTS STR HLTH I; Varkey P, 2007, MAYO CLIN PROC, V82, P735, DOI 10.4065/82.6.735; Walsh SH, 2004, BMJ-BRIT MED J, V328, P1184, DOI 10.1136/bmj.328.7449.1184; Wears RL, 2005, JAMA-J AM MED ASSOC, V293, P1261, DOI 10.1001/jama.293.10.1261; Weingart SN, 2003, ARCH INTERN MED, V163, P2625, DOI 10.1001/archinte.163.21.2625; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694	21	7	7	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10					690	692		10.7326/0003-4819-154-10-201105170-00010	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-00010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576537				2022-12-28	WOS:000290620300018
J	Caballero, A; Despagnet-Ayoub, E; Diaz-Requejo, MM; Diaz-Rodriguez, A; Gonzalez-Nunez, ME; Mello, R; Munoz, BK; Ojo, WS; Asensio, G; Etienne, M; Perez, PJ				Caballero, Ana; Despagnet-Ayoub, Emmanuelle; Mar Diaz-Requejo, M.; Diaz-Rodriguez, Alba; Elena Gonzalez-Nunez, Maria; Mello, Rossella; Munoz, Bianca K.; Ojo, Wilfried-Solo; Asensio, Gregorio; Etienne, Michel; Perez, Pedro J.			Silver-Catalyzed C-C Bond Formation Between Methane and Ethyl Diazoacetate in Supercritical CO2	SCIENCE			English	Article							H ACTIVATION; CARBENE INSERTION; METAL-COMPLEXES; FUNCTIONALIZATION; OXIDATION; HYDROCARBONS; ALKANES; METATHESIS; CONVERSION; MECHANISM	Even in the context of hydrocarbons' general resistance to selective functionalization, methane's volatility and strong bonds pose a particular challenge. We report here that silver complexes bearing perfluorinated indazolylborate ligands catalyze the reaction of methane (CH4) with ethyl diazoacetate (N2CHCO2Et) to yield ethyl propionate (CH3CH2CO2Et). The use of supercritical carbon dioxide (scCO(2)) as the solvent is key to the reaction's success. Although the catalyst is only sparingly soluble in CH4/CO2 mixtures, optimized conditions presently result in a 19% yield of ethyl propionate (based on starting quantity of the diazoester) at 40 degrees C over 14 hours.	[Diaz-Rodriguez, Alba; Elena Gonzalez-Nunez, Maria; Mello, Rossella; Asensio, Gregorio] Univ Valencia, Fac Farm, Dept Quim Organ, Valencia 46100, Spain; [Caballero, Ana; Mar Diaz-Requejo, M.; Diaz-Rodriguez, Alba; Perez, Pedro J.] Univ Huelva, Ctr Invest Quim Sostenible, Dept Quim & Ciencia Mat, Lab Catalisis Homogenea,Unidad Asociada,CSIC, Huelva 21007, Spain; [Despagnet-Ayoub, Emmanuelle; Munoz, Bianca K.; Ojo, Wilfried-Solo; Etienne, Michel] CNRS, LCC, F-31077 Toulouse, France; [Despagnet-Ayoub, Emmanuelle; Munoz, Bianca K.; Ojo, Wilfried-Solo; Etienne, Michel] Univ Toulouse 3, Univ Toulouse, Inst Natl Polytech Toulouse, LCC, F-31077 Toulouse, France	University of Valencia; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Huelva; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National Polytechnique de Toulouse	Asensio, G (corresponding author), Univ Valencia, Fac Farm, Dept Quim Organ, Valencia 46100, Spain.	gregorio.asensio@uv.es; michel.etienne@lcc-toulouse.fr; perez@dqcm.uhu.es	González-Núñez, María Elena/K-7857-2012; Díaz-Requejo, M Mar/D-2431-2012; Caballero, Ana/J-6996-2012; ASENSIO, GREGORIO/L-2026-2014; Perez, Pedro J./E-5851-2011; Munoz, Bianca K/E-5114-2011; Mello, Rossella C.C./K-8576-2012	González-Núñez, María Elena/0000-0003-4170-4568; Díaz-Requejo, M Mar/0000-0001-8295-4059; Caballero, Ana/0000-0001-7846-6183; ASENSIO, GREGORIO/0000-0001-5060-4417; Perez, Pedro J./0000-0002-6899-4641; Munoz, Bianca K/0000-0001-7943-188X; Mello, Rossella C.C./0000-0002-0293-2018; Etienne, Michel/0000-0002-1099-3232	Ministerio de Ciencia e Innovacion [CTQ2008-00042-BQU, CTQ2007-65251-BQU, CTQ2007-30762-E]; European Research Area Chemistry Programme [1736154]; Consolider Ingenio 2010 [CSD2006-003, CSD2007-00006]; Institut de Chimie of the CNRS; Junta de Andalucia [P07-FQM-2870]; Generalitat Velenciana [ACOMP/2010/155]	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); European Research Area Chemistry Programme; Consolider Ingenio 2010(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Institut de Chimie of the CNRS; Junta de Andalucia(Junta de Andalucia); Generalitat Velenciana	We dedicate this work to Professor Ernesto Carmona. Support for this work was provided by the Ministerio de Ciencia e Innovacion (grants CTQ2008-00042-BQU, CTQ2007-65251-BQU, and CTQ2007-30762-E), the European Research Area Chemistry Programme (2nd call "Chemical activation of carbon dioxide and methane" contract no. 1736154), the Consolider Ingenio 2010 (grants CSD2006-003 and CSD2007-00006), the Institut de Chimie of the CNRS, the Junta de Andalucia (P07-FQM-2870), and the Generalitat Velenciana (ACOMP/2010/155). We thank the Servicio Central de Soporte a la Investigacion Experimental (Universidad de Valencia) for access to the instrumental facilities and J. de la Rosa and A. Sanchez de la Campa (Universidad de Huelva) for ICP-MS analyses.	ARNDTSEN BA, 1995, ACCOUNTS CHEM RES, V28, P154, DOI 10.1021/ar00051a009; Asensio G, 1997, TETRAHEDRON LETT, V38, P2373, DOI 10.1016/S0040-4039(97)00353-5; Bergman RG, 2007, NATURE, V446, P391, DOI 10.1038/446391a; Blanksby SJ, 2003, ACCOUNTS CHEM RES, V36, P255, DOI 10.1021/ar020230d; Braga AAC, 2006, ORGANOMETALLICS, V25, P5292, DOI 10.1021/om060445h; Caballero A, 2009, EUR J INORG CHEM, P1137, DOI 10.1002/ejic.200800944; Crabtree RH, 2010, CHEM REV, V110, P575, DOI 10.1021/cr900388d; Davies HML, 2000, J AM CHEM SOC, V122, P3063, DOI 10.1021/ja994136c; DESIMONE JM, 2003, CHEM USING LIQUID SU, P14515; Despagnet-Ayoub E, 2008, ORGANOMETALLICS, V27, P4779, DOI 10.1021/om800531a; Diaz-Requejo MM, 2008, CHEM REV, V108, P3379, DOI 10.1021/cr078364y; Diaz-Requejo MM, 2006, DALTON T, P5559, DOI 10.1039/b610183f; Doyle M.P., 1998, MODERN CATALYTIC MET; Doyle MP, 2010, CHEM REV, V110, P704, DOI 10.1021/cr900239n; Golden JT, 2001, J AM CHEM SOC, V123, P5837, DOI 10.1021/ja0155480; Goldman A. S, 2004, ACS S SERIES; Goldman AS, 2006, SCIENCE, V312, P257, DOI 10.1126/science.1123787; Hartwig J, 2009, ORGANOTRANSITION MET; Jensen CM, 1999, CHEM COMMUN, P2443, DOI 10.1039/a903573g; Jones CJ, 2004, ANGEW CHEM INT EDIT, V43, P4626, DOI 10.1002/anie.200461055; Kirillova MV, 2007, J AM CHEM SOC, V129, P10531, DOI 10.1021/ja072531u; Labinger JA, 2002, NATURE, V417, P507, DOI 10.1038/417507a; Mkhalid IAI, 2010, CHEM REV, V110, P890, DOI 10.1021/cr900206p; Nakamura E, 2002, J AM CHEM SOC, V124, P7181, DOI 10.1021/ja017823o; OLAH GA, 1987, ACCOUNTS CHEM RES, V20, P422, DOI 10.1021/ar00143a006; OLAH GA, 2003, HYDROCARBON CHEM, P427; Periana RA, 2003, SCIENCE, V301, P814, DOI 10.1126/science.1086466; Periana RA, 1998, SCIENCE, V280, P560, DOI 10.1126/science.280.5363.560; PERIANA RA, 1993, SCIENCE, V259, P340, DOI 10.1126/science.259.5093.340; Sadow AD, 2005, J AM CHEM SOC, V127, P643, DOI 10.1021/ja040141r; Shilov AE, 1997, CHEM REV, V97, P2879, DOI 10.1021/cr9411886; Thu HY, 2008, ANGEW CHEM INT EDIT, V47, P9747, DOI 10.1002/anie.200803157; Urbano J, 2005, ORGANOMETALLICS, V24, P1528, DOI 10.1021/om050024k; Urbano J, 2009, ORGANOMETALLICS, V28, P5968, DOI 10.1021/om9006888	34	180	186	2	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					835	838		10.1126/science.1204131	http://dx.doi.org/10.1126/science.1204131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566191	Green Submitted			2022-12-28	WOS:000290529900044
J	Liu, YY; Slotine, JJ; Barabasi, AL				Liu, Yang-Yu; Slotine, Jean-Jacques; Barabasi, Albert-Laszlo			Controllability of complex networks	NATURE			English	Article							CONTRACTION ANALYSIS; PERCOLATION	The ultimate proof of our understanding of natural or technological systems is reflected in our ability to control them. Although control theory offers mathematical tools for steering engineered and natural systems towards a desired state, a framework to control complex self-organized systems is lacking. Here we develop analytical tools to study the controllability of an arbitrary complex directed network, identifying the set of driver nodes with time-dependent control that can guide the system's entire dynamics. We apply these tools to several real networks, finding that the number of driver nodes is determined mainly by the network's degree distribution. We show that sparse inhomogeneous networks, which emerge in many real complex systems, are the most difficult to control, but that dense and homogeneous networks can be controlled using a few driver nodes. Counterintuitively, we find that in both model and real systems the driver nodes tend to avoid the high-degree nodes.	[Liu, Yang-Yu; Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA; [Liu, Yang-Yu; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Phys, Boston, MA 02115 USA; [Liu, Yang-Yu; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Comp Sci & Biol, Boston, MA 02115 USA; [Liu, Yang-Yu; Barabasi, Albert-Laszlo] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA; [Slotine, Jean-Jacques] MIT, Nonlinear Syst Lab, Cambridge, MA 02139 USA; [Slotine, Jean-Jacques] MIT, Dept Mech Engn, Cambridge, MA 02139 USA; [Slotine, Jean-Jacques] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; [Barabasi, Albert-Laszlo] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Northeastern University; Northeastern University; Northeastern University; Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Barabasi, AL (corresponding author), Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA.	alb@neu.edu	Liu, Yang-Yu/G-8885-2011; Barabasi, Albert-Laszlo/S-6474-2017	Liu, Yang-Yu/0000-0003-2728-4907; Barabasi, Albert/0000-0002-4028-3522	US Army Research Laboratory [W911NF-09-2-0053]; Office of Naval Research [N000141010968]; Defense Threat Reduction Agency [WMD BRBAA07-J-2-0035, BRBAA08-Per4-C-2-0033]; James S. McDonnell Foundation 21st Century Initiative in Studying Complex Systems	US Army Research Laboratory(United States Department of DefenseUS Army Research Laboratory (ARL)); Office of Naval Research(Office of Naval Research); Defense Threat Reduction Agency(United States Department of DefenseDefense Threat Reduction Agency); James S. McDonnell Foundation 21st Century Initiative in Studying Complex Systems	We thank C. Song, G. Bianconi, H. Zhou, L. Vepstas, N. Gulbahce, H. Jeong, Y.-Y. Ahn, B. Barzel, N. Blumm, D. Wang, Z. Qu and Y. Li for discussions. This work was supported by the Network Science Collaborative Technology Alliance sponsored by the US Army Research Laboratory under Agreement Number W911NF-09-2-0053; the Office of Naval Research under Agreement Number N000141010968; the Defense Threat Reduction Agency awards WMD BRBAA07-J-2-0035 and BRBAA08-Per4-C-2-0033; and the James S. McDonnell Foundation 21st Century Initiative in Studying Complex Systems.	Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; [Anonymous], [No title captured]; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bauer M, 2001, EUR PHYS J B, V24, P339, DOI 10.1007/s10051-001-8683-4; Boguna M, 2004, EUR PHYS J B, V38, P205, DOI 10.1140/epjb/e2004-00038-8; Bollobas B., 2001, RANDOM GRAPHS; Caldarelli G., 2007, SCALE FREE NETWORKS; Callaway DS, 2000, PHYS REV LETT, V85, P5468, DOI 10.1103/PhysRevLett.85.5468; Chiang M, 2007, P IEEE, V95, P255, DOI 10.1109/JPROC.2006.887322; Chung F., 2002, ANN COMB, V6, P125, DOI [10.1007/PL00012580, 10.1007/PL00012580.pdf, DOI 10.1007/PL00012580.PDF]; Cohen R, 2000, PHYS REV LETT, V85, P4626, DOI 10.1103/PhysRevLett.85.4626; Dorogovtsev SN, 2003, EVOLUTION NETWORKS B; ERDOS P, 1960, B INT STATIST INST, V38, P343; Goh KI, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.278701; Hopcroft J. E., 1973, SIAM Journal on Computing, V2, P225, DOI 10.1137/0202019; Kalman R. E., 1963, SIAM J CONTROL     A, V1, P152, DOI [DOI 10.1137/0301010, 10.1137/0301010]; Kelly FP, 1998, J OPER RES SOC, V49, P237, DOI 10.2307/3010473; Kim DH, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/113047; Lezon TR, 2006, P NATL ACAD SCI USA, V103, P19033, DOI 10.1073/pnas.0609152103; LIN CT, 1974, IEEE T AUTOMAT CONTR, VAC19, P201, DOI 10.1109/TAC.1974.1100557; Liu B, 2008, IEEE T AUTOMAT CONTR, V53, P1009, DOI 10.1109/TAC.2008.919548; Lohmiller W, 1998, AUTOMATICA, V34, P683, DOI 10.1016/S0005-1098(98)00019-3; Lombardi A, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.056110; Lovasz Laszlo, 2009, MATCHING THEORY, V367; Luenberger D. G., 1979, INTRO DYNAMIC SYSTEM; Marucci L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008083; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Mesbahi M, 2010, GRAPH THEORETIC METHODS IN MULTIAGENT NETWORKS, P1; Mezard M, 2001, EUR PHYS J B, V20, P217, DOI 10.1007/PL00011099; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Motter AE, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.1; Newman MEJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.208701; Nishikawa T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.014101; Ou-Yang Zhong-can, 2003, MAXIMUM MATCHING RAN; Pastor-Satorras R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.258701; Pastor-Satorras R, 2001, PHYS REV LETT, V86, P3200, DOI 10.1103/PhysRevLett.86.3200; Pastor-Satorras R, 2004, EVOLUTION STRUCTURE; Rahman A, 2009, SIAM J CONTROL OPTIM, V48, P162, DOI 10.1137/060674909; SHIELDS RW, 1976, IEEE T AUTOMAT CONTR, V21, P203, DOI 10.1109/TAC.1976.1101198; Slotine J.J.E., 1991, APPL NONLINEAR CONTR; Srikant R., 2004, MATH INTERNET CONGES; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Tanner HG, 2004, IEEE DECIS CONTR P, P2467, DOI 10.1109/CDC.2004.1428782; Wang W, 2005, BIOL CYBERN, V92, P38, DOI 10.1007/s00422-004-0527-x; Wang XF, 2002, PHYSICA A, V310, P521, DOI 10.1016/S0378-4371(02)00772-0; Yu WW, 2010, IEEE T SYST MAN CY B, V40, P881, DOI 10.1109/TSMCB.2009.2031624; Yu WW, 2009, AUTOMATICA, V45, P429, DOI 10.1016/j.automatica.2008.07.016; Zdeborova L, 2006, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2006/05/P05003	50	1981	2072	28	721	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 12	2011	473	7346					167	173		10.1038/nature10011	http://dx.doi.org/10.1038/nature10011			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562557				2022-12-28	WOS:000290487200029
J	Sagiya, T; Kanamori, H; Yagi, Y; Yamada, M; Mori, J				Sagiya, Takeshi; Kanamori, Hiroo; Yagi, Yuji; Yamada, Masumi; Mori, Jim			Rebuilding seismology	NATURE			English	Editorial Material							JAPAN TRENCH		[Sagiya, Takeshi] Nagoya Univ, Nagoya, Aichi, Japan; [Kanamori, Hiroo] CALTECH, Pasadena, CA USA; [Yagi, Yuji] Univ Tsukuba, Tsukuba, Ibaraki, Japan; [Yamada, Masumi; Mori, Jim] Kyoto Univ, Disaster Prevent Res Inst, Kyoto, Japan	Nagoya University; California Institute of Technology; University of Tsukuba; Kyoto University	Sagiya, T (corresponding author), Nagoya Univ, Nagoya, Aichi, Japan.		Yagi, Yuji/D-8301-2014; Sagiya, Takeshi/N-8417-2018	Yagi, Yuji/0000-0001-5327-9277; Sagiya, Takeshi/0000-0001-7949-8048				Hashimoto C, 2009, NAT GEOSCI, V2, P141, DOI 10.1038/NGEO421; IKEDA Y, 1996, ACTIVE FAULT RES; Kawasaki I, 2001, TECTONOPHYSICS, V330, P267, DOI 10.1016/S0040-1951(00)00245-6; Nishimura T, 2004, GEOPHYS J INT, V157, P901, DOI 10.1111/j.1365-246X.2004.02159.x; NISHIMURA T, 2000, SPATIOTEMPORAL CHANG	5	31	32	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 12	2011	473	7346					146	148		10.1038/473146a	http://dx.doi.org/10.1038/473146a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562539				2022-12-28	WOS:000290487200046
J	Theron, BT; Pearson, L; Gillson, J				Theron, Byron Temba; Pearson, Laura; Gillson, John			PICTURE QUIZ An odd cause of dysphagia	BRITISH MEDICAL JOURNAL			English	Editorial Material							SUPERIOR VENA-CAVA; PRIMARY MEDIASTINAL TUMORS; LYMPHOMA		[Theron, Byron Temba; Pearson, Laura; Gillson, John] Sandwell & Birmingham NHS Trust, W Bromwich B74 4HJ, England		Theron, BT (corresponding author), Sandwell & Birmingham NHS Trust, W Bromwich B74 4HJ, England.	byrontheron@nhs.net						ANDERSON T, 1982, CANCER, V50, P2699, DOI 10.1002/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A; ATKINS CD, 1993, NEW ENGL J MED, V329, P987; Herth FJF, 2005, CURR OPIN PULM MED, V11, P278, DOI 10.1097/01.mcp.0000166492.69788.e3; KAWASHIMA A, 1991, RADIOGRAPHICS, V11, P1045, DOI 10.1148/radiographics.11.6.1749849; Markman M, 1999, CLEV CLIN J MED, V66, P59, DOI 10.3949/ccjm.66.1.59; MOORMEIER JA, 1990, SEMIN ONCOL, V17, P43; Nagata T, 2007, CARDIOVASC INTER RAD, V30, P959, DOI 10.1007/s00270-007-9088-4; PARISH JM, 1981, MAYO CLIN PROC, V56, P407; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Rice TW, 2006, MEDICINE, V85, P37, DOI 10.1097/01.md.0000198474.99876.f0; SKAIRLEVY M, 2000, EUR RADIOL, V10, P714; Strollo DC, 1997, CHEST, V112, P1344, DOI 10.1378/chest.112.5.1344; Strollo DC, 1997, CHEST, V112, P511, DOI 10.1378/chest.112.2.511; YELLIN A, 1990, AM REV RESPIR DIS, V141, P1114, DOI 10.1164/ajrccm/141.5_Pt_1.1114	14	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 11	2011	342								d737	10.1136/bmj.d737	http://dx.doi.org/10.1136/bmj.d737			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765OP	21562015				2022-12-28	WOS:000290718400017
J	Maitland, K; Kiguli, S; Opoka, RO; Engoru, C; Olupot-Olupot, P; Akech, SO; Nyeko, R; Mtove, G; Reyburn, H; Lang, T; Brent, B; Evans, JA; Tibenderana, JK; Crawley, J; Russell, EC; Levin, M; Babiker, AG; Gibb, DM				Maitland, Kathryn; Kiguli, Sarah; Opoka, Robert O.; Engoru, Charles; Olupot-Olupot, Peter; Akech, Samuel O.; Nyeko, Richard; Mtove, George; Reyburn, Hugh; Lang, Trudie; Brent, Bernadette; Evans, Jennifer A.; Tibenderana, James K.; Crawley, Jane; Russell, Elizabeth C.; Levin, Michael; Babiker, Abdel G.; Gibb, Diana M.		FEAST Trial Grp	Mortality after Fluid Bolus in African Children with Severe Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEONATAL SEPTIC SHOCK; VOLUME EXPANSION; CAPILLARY REFILL; SEVERE MALARIA; ALBUMIN; CARE; RESUSCITATION; SEPSIS; SALINE	BACKGROUND The role of fluid resuscitation in the treatment of children with shock and life-threatening infections who live in resource-limited settings is not established. METHODS We randomly assigned children with severe febrile illness and impaired perfusion to receive boluses of 20 to 40 ml of 5% albumin solution (albumin-bolus group) or 0.9% saline solution (saline-bolus group) per kilogram of body weight or no bolus (control group) at the time of admission to a hospital in Uganda, Kenya, or Tanzania (stratum A); children with severe hypotension were randomly assigned to one of the bolus groups only (stratum B). All children received appropriate antimicrobial treatment, intravenous maintenance fluids, and supportive care, according to guidelines. Children with malnutrition or gastroenteritis were excluded. The primary end point was 48-hour mortality; secondary end points included pulmonary edema, increased intracranial pressure, and mortality or neurologic sequelae at 4 weeks. RESULTS The data and safety monitoring committee recommended halting recruitment after 3141 of the projected 3600 children in stratum A were enrolled. Malaria status (57% overall) and clinical severity were similar across groups. The 48-hour mortality was 10.6% (111 of 1050 children), 10.5% (110 of 1047 children), and 7.3% (76 of 1044 children) in the albumin-bolus, saline-bolus, and control groups, respectively (relative risk for saline bolus vs. control, 1.44; 95% confidence interval [CI], 1.09 to 1.90; P = 0.01; relative risk for albumin bolus vs. saline bolus, 1.01; 95% CI, 0.78 to 1.29; P = 0.96; and relative risk for any bolus vs. control, 1.45; 95% CI, 1.13 to 1.86; P = 0.003). The 4-week mortality was 12.2%, 12.0%, and 8.7% in the three groups, respectively (P = 0.004 for the comparison of bolus with control). Neurologic sequelae occurred in 2.2%, 1.9%, and 2.0% of the children in the respective groups (P = 0.92), and pulmonary edema or increased intracranial pressure occurred in 2.6%, 2.2%, and 1.7% (P = 0.17), respectively. In stratum B, 69% of the children (9 of 13) in the albuminbolus group and 56% (9 of 16) in the saline-bolus group died (P = 0.45). The results were consistent across centers and across subgroups according to the severity of shock and status with respect to malaria, coma, sepsis, acidosis, and severe anemia. CONCLUSIONS Fluid boluses significantly increased 48-hour mortality in critically ill children with impaired perfusion in these resource-limited settings in Africa. (Funded by the Medical Research Council, United Kingdom; FEAST Current Controlled Trials number, ISRCTN69856593.)	[Maitland, Kathryn; Akech, Samuel O.; Lang, Trudie; Brent, Bernadette] KEMRI, Wellcome Trust Programme, Kilifi Clin Trials Facil, Kilifi, Kenya; [Maitland, Kathryn; Brent, Bernadette; Levin, Michael] Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Ctr Clin Trop Med, Dept Paediat, Fac Med, London SW7 2AZ, England; [Crawley, Jane; Russell, Elizabeth C.; Babiker, Abdel G.; Gibb, Diana M.] MRC, Clin Trials Unit, London, England; [Kiguli, Sarah; Opoka, Robert O.] Makerere Univ, Dept Paediat, Mulago Hosp, Kampala, Uganda; [Engoru, Charles] Soroti Reg Referral Hosp, Soroti, Uganda; [Olupot-Olupot, Peter] Mbale Reg Referral Hosp, Mbale, Uganda; [Nyeko, Richard] St Marys Hosp, Lacor, Uganda; [Mtove, George; Reyburn, Hugh] Hosp Teule, Joint Malaria Programme, Muheza, Tanzania; [Evans, Jennifer A.] Univ Wales Hosp, Dept Paediat, Cardiff, Wales	Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Medical Research Council Clinical Trials Unit; Makerere University; Mulago National Referral Hospital; Cardiff University	Maitland, K (corresponding author), KEMRI, Wellcome Trust Programme, Kilifi Clin Trials Facil, POB 230, Kilifi, Kenya.	kathryn.maitland@gmail.com	George, Elizabeth/C-7329-2013; Angus, Brian/L-9246-2019; Tibenderana, James Kananura/M-2272-2018; George, Elizabeth/V-3381-2017	Angus, Brian/0000-0003-3598-7784; Tibenderana, James Kananura/0000-0002-0755-4597; George, Elizabeth/0000-0002-2928-3580; Gibb, Diana/0000-0002-9738-5490; Waithira, Naomi/0000-0002-2267-9347; Maitland, Kathryn/0000-0002-0007-0645; Ddungu, Ahmed/0000-0001-5653-0885; Mtove, George/0000-0001-5173-0829; Thomason, Margaret/0000-0003-3590-0140; Chebet, Martin/0000-0001-7013-7297; Levin, Michael/0000-0003-2767-6919; Kiprono, Julie/0000-0002-6396-2026	Medical Research Council, United Kingdom [G0801439]; Medical Research Council [MC_U122886353, G0601027, G0801439] Funding Source: researchfish; MRC [G0601027, G0801439, MC_U122886353] Funding Source: UKRI	Medical Research Council, United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a grant (G0801439) from the Medical Research Council, United Kingdom; Baxter Healthcare donated the resuscitation fluids.	Akech S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010021; Akech S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4416; [Anonymous], 2005, HOSP CAR CHILDR GUID; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Brierley J, 2009, CRIT CARE MED, V37, P666, DOI 10.1097/CCM.0b013e31819323c6; Crawley J, 2010, LANCET, V375, P1468, DOI 10.1016/S0140-6736(10)60447-3; Delaney AP, 2011, CRIT CARE MED, V39, P386, DOI 10.1097/CCM.0b013e3181ffe217; Dellinger RP, 2008, CRIT CARE MED, V36, P1394; English M, 2004, LANCET, V363, P1948, DOI 10.1016/S0140-6736(04)16408-8; English M, 2000, T ROY SOC TROP MED H, V94, P585, DOI 10.1016/S0035-9203(00)90197-4; Evans JA, 2004, QJM-INT J MED, V97, P591, DOI 10.1093/qjmed/hch093; Evans JA, 2006, J PEDIATR-US, V149, P676, DOI 10.1016/j.jpeds.2006.07.040; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Han YY, 2003, PEDIATRICS, V112, P793, DOI 10.1542/peds.112.4.793; Inwald DP, 2009, ARCH DIS CHILD, V94, P348, DOI 10.1136/adc.2008.153064; Maitland K, 2005, CLIN INFECT DIS, V40, P538, DOI 10.1086/427505; Maitland K, 2003, QJM-INT J MED, V96, P427, DOI 10.1093/qjmed/hcg077; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nadjm B, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1350; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Otieno H, 2004, ARCH DIS CHILD, V89, P977, DOI 10.1136/adc.2003.043901; Pamba A, 2004, ARCH DIS CHILD, V89, P950, DOI 10.1136/adc.2003.032516; Parker Margaret M, 2004, Crit Care Med, V32, pS591, DOI 10.1097/01.CCM.0000145904.97821.0D; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Planche T, 2005, TRENDS PARASITOL, V21, P562, DOI 10.1016/j.pt.2005.09.010; Planche T, 2004, PLOS MED, V1, P56, DOI 10.1371/journal.pmed.0010018; Reddy EA, 2010, LANCET INFECT DIS, V10, P417, DOI 10.1016/S1473-3099(10)70072-4; Robertson MA, 2001, ARCH DIS CHILD, V85, P208, DOI 10.1136/adc.85.3.208; Rothman KJ., 1982, EPIDEMIOLOGIC ANAL P; Van den Bruel A, 2010, LANCET, V375, P834, DOI 10.1016/S0140-6736(09)62000-6	33	984	1019	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2011	364	26					2483	2495		10.1056/NEJMoa1101549	http://dx.doi.org/10.1056/NEJMoa1101549			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	785AM	21615299	Green Submitted, Green Published			2022-12-28	WOS:000292199800004
J	Tada, K; Susumu, H; Sakuno, T; Watanabe, Y				Tada, Kenji; Susumu, Hiroaki; Sakuno, Takeshi; Watanabe, Yoshinori			Condensin association with histone H2A shapes mitotic chromosomes	NATURE			English	Article							AURORA-B KINASE; FISSION YEAST; MEIOSIS-I; BUDDING YEAST; SCHIZOSACCHAROMYCES-POMBE; MONOPOLAR ATTACHMENT; GENE-TRANSCRIPTION; H3 PHOSPHORYLATION; MITOSIS; KINETOCHORES	Chromosome structure is dynamically regulated during cell division, and this regulation is dependent, in part, on condensin. The localization of condensin at chromosome arms is crucial for chromosome partitioning during anaphase. Condensin is also enriched at kinetochores but its precise role and loading machinery remain unclear. Here we show that fission yeast (Schizosaccharomyces pombe) kinetochore proteins Pcs1 and Mde4-homologues of budding yeast (Saccharomyces cerevisiae) monopolin subunits and known to prevent merotelic kinetochore orientation-act as a condensin 'recruiter' at kinetochores, and that condensin itself may act to clamp microtubule binding sites during metaphase. In addition to the regional recruitment factors, overall condensin association with chromatin is governed by the chromosomal passenger kinase Aurora B. Aurora-B-dependent phosphorylation of condensin promotes its association with histone H2A and H2A.Z, which we identify as conserved chromatin 'receptors' of condensin. Condensin phosphorylation and its deposition onto chromosome arms reach a peak during anaphase, when Aurora B kinase relocates from centromeres to the spindle midzone, where the separating chromosome arms are positioned. Our results elucidate the molecular basis for the spatiotemporal regulation of mitotic chromosome architecture, which is crucial for chromosome partitioning.	[Tada, Kenji; Susumu, Hiroaki; Sakuno, Takeshi; Watanabe, Yoshinori] Univ Tokyo, Lab Chromosome Dynam, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; [Tada, Kenji; Susumu, Hiroaki; Watanabe, Yoshinori] Univ Tokyo, Grad Sch Sci, Grad Program Biophys & Biochem, Tokyo 1130032, Japan	University of Tokyo; University of Tokyo	Watanabe, Y (corresponding author), Univ Tokyo, Lab Chromosome Dynam, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.	ywatanab@iam.u-tokyo.ac.jp	Sakuno, Takeshi/Y-9478-2019	Watanabe, Yoshinori/0000-0002-5488-4812	Global COE Program(Integrative Life Science Based on the Study of Biosignaling Mechanisms); Special Coordination Funds for Promoting Science and Technology; MEXT, Japan; Grants-in-Aid for Scientific Research [21000010] Funding Source: KAKEN	Global COE Program(Integrative Life Science Based on the Study of Biosignaling Mechanisms)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Special Coordination Funds for Promoting Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank S. Hauf for critically reading the manuscript and K.-i. Noma, T. Hirano and the Yeast Genetic Resource Center (YGRC) for yeast strains or reagents. We also thank S. Hauf and M. Yanagida for communicating unpublished results, and all the members of our laboratory for their support and discussion. This work was supported in part by Global COE Program(Integrative Life Science Based on the Study of Biosignaling Mechanisms) (to K.T. and H.S.), Special Coordination Funds for Promoting Science and Technology (to T.S.) and a Grant-in-Aid for Specially Promoted Research, MEXT, Japan (to Y.W.).	Aono N, 2002, NATURE, V417, P197, DOI 10.1038/417197a; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bazile F, 2010, CELL CYCLE, V9, P3243, DOI 10.4161/cc.9.16.12620; Brito IL, 2010, GENETICS, V185, P55, DOI 10.1534/genetics.110.115139; Buchanan L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000726; Corbett KD, 2010, CELL, V142, P556, DOI 10.1016/j.cell.2010.07.017; D'Ambrosio C, 2008, GENE DEV, V22, P2215, DOI 10.1101/gad.1675708; DOUGHERTY WG, 1989, VIROLOGY, V171, P356, DOI 10.1016/0042-6822(89)90603-X; Fuller BG, 2008, NATURE, V453, P1132, DOI 10.1038/nature06923; Gerlich D, 2006, CURR BIOL, V16, P333, DOI 10.1016/j.cub.2005.12.040; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Gregan J, 2007, CURR BIOL, V17, P1190, DOI 10.1016/j.cub.2007.06.044; Haeusler RA, 2008, GENE DEV, V22, P2204, DOI 10.1101/gad.1675908; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hauf S, 2007, EMBO J, V26, P4475, DOI 10.1038/sj.emboj.7601880; Hirano T, 2005, CURR BIOL, V15, pR265, DOI 10.1016/j.cub.2005.03.037; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Hudson DF, 2008, MOL BIOL CELL, V19, P3070, DOI 10.1091/mbc.E08-01-0057; Hudson DF, 2009, CHROMOSOME RES, V17, P131, DOI 10.1007/s10577-008-9009-7; Iwasaki O, 2010, MOL BIOL CELL, V21, P254, DOI 10.1091/mbc.E09-09-0790; Johzuka K, 2009, MOL CELL, V34, P26, DOI 10.1016/j.molcel.2009.02.021; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Kawashima SA, 2007, GENE DEV, V21, P420, DOI 10.1101/gad.1497307; Kim HS, 2009, NAT STRUCT MOL BIOL, V16, P1286, DOI 10.1038/nsmb.1688; Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663; Koch A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001588; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lavoie BD, 2004, GENE DEV, V18, P76, DOI 10.1101/gad.1150404; Lipp JJ, 2007, J CELL SCI, V120, P1245, DOI 10.1242/jcs.03425; Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272; Miller KM, 2003, MOL CELL, V11, P303, DOI 10.1016/S1097-2765(03)00041-8; Mora-Bermudez F, 2007, NAT CELL BIOL, V9, P822, DOI 10.1038/ncb1606; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nakazawa N, 2008, J CELL BIOL, V180, P1115, DOI 10.1083/jcb.200708170; Nasmyth K, 2009, ANNU REV GENET, V43, P525, DOI 10.1146/annurev-genet-102108-134233; Neurohr G, 2011, SCIENCE, V332, P465, DOI 10.1126/science.1201578; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Oliveira RA, 2005, MOL CELL BIOL, V25, P8971, DOI 10.1128/MCB.25.20.8971-8984.2005; Ono T, 2004, MOL BIOL CELL, V15, P3296, DOI 10.1091/mbc.E04-03-0242; Parra MA, 2007, MOL CELL BIOL, V27, P7641, DOI 10.1128/MCB.00742-07; Petersen J, 2003, CURR BIOL, V13, P590, DOI 10.1016/S0960-9822(03)00205-7; Petronczki M, 2006, CELL, V126, P1049, DOI 10.1016/j.cell.2006.07.029; Rabitsch KP, 2003, DEV CELL, V4, P535, DOI 10.1016/S1534-5807(03)00086-8; Rangasamy D, 2004, NAT STRUCT MOL BIOL, V11, P650, DOI 10.1038/nsmb786; Renshaw MJ, 2010, DEV CELL, V19, P232, DOI 10.1016/j.devcel.2010.07.013; Ribeiro SA, 2009, MOL BIOL CELL, V20, P2371, DOI 10.1091/mbc.E08-11-1127; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Sakuno T, 2009, NATURE, V458, P852, DOI 10.1038/nature07876; Samoshkin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006831; Takayama Y, 2008, MOL BIOL CELL, V19, P682, DOI 10.1091/mbc.E07-05-0504; Takemoto A, 2007, NUCLEIC ACIDS RES, V35, P2403, DOI 10.1093/nar/gkm157; Takemoto A, 2009, NAT STRUCT MOL BIOL, V16, P1302, DOI 10.1038/nsmb.1708; Talbert PB, 2010, NAT REV MOL CELL BIO, V11, P264, DOI 10.1038/nrm2861; Tanaka TU, 2010, EMBO J, V29, P4070, DOI 10.1038/emboj.2010.294; Yokobayashi S, 2003, MOL CELL BIOL, V23, P3965, DOI 10.1128/MCB.23.11.3965-3973.2003; Yokobayashi S, 2005, CELL, V123, P803, DOI 10.1016/j.cell.2005.09.013	58	142	142	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2011	474	7352					477	U105		10.1038/nature10179	http://dx.doi.org/10.1038/nature10179			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	781NJ	21633354				2022-12-28	WOS:000291939700041
J	Ide, S; Baltay, A; Beroza, GC				Ide, Satoshi; Baltay, Annemarie; Beroza, Gregory C.			Shallow Dynamic Overshoot and Energetic Deep Rupture in the 2011 M-w 9.0 Tohoku-Oki Earthquake	SCIENCE			English	Article							DIPPING FAULTS; STRESS; JAPAN; AFTERSHOCKS; PARAMETERS; INVERSION; SEQUENCE	Strong spatial variation of rupture characteristics in the moment magnitude (M-w) 9.0 Tohoku-Oki megathrust earthquake controlled both the strength of shaking and the size of the tsunami that followed. Finite-source imaging reveals that the rupture consisted of a small initial phase, deep rupture for up to 40 seconds, extensive shallow rupture at 60 to 70 seconds, and continuing deep rupture lasting more than 100 seconds. A combination of a shallow dipping fault and a compliant hanging wall may have enabled large shallow slip near the trench. Normal faulting aftershocks in the area of high slip suggest dynamic overshoot on the fault. Despite prodigious total slip, shallower parts of the rupture weakly radiated at high frequencies, whereas deeper parts of the rupture radiated strongly at high frequencies.	[Ide, Satoshi] Univ Tokyo, Dept Earth & Planetary Sci, Bunkyo Ku, Tokyo 1130033, Japan; [Baltay, Annemarie; Beroza, Gregory C.] Stanford Univ, Dept Geophys, Stanford, CA 94305 USA	University of Tokyo; Stanford University	Ide, S (corresponding author), Univ Tokyo, Dept Earth & Planetary Sci, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	ide@eps.s.u-tokyo.ac.jp	IDE, SATOSHI/G-4887-2014	IDE, SATOSHI/0000-0003-0063-548X	Ministry of Education, Culture, Sports, Science and Technology of Japan [21107007]; Japan Society for the Promotion of Science [23244090]; Stanford University; Grants-in-Aid for Scientific Research [23244090] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Stanford University(Stanford University); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan KAKENHI (grant 21107007) and the Japan Society for the Promotion of Science KAKENHI (grant 23244090). GMT software (31) was used to draw figures. A. B. was supported at Stanford University by the Gabilan Stanford Graduate Fellowship. GSN data are available online (www.iris.edu/hq/programs/gsn/data) through a cooperative scientific facility operated jointly by the Incorporated Research Institutions for Seismology, the USGS, and the NSF. KiK-net data are also available online (www.kik.bosai.go.jp/kik/) through National Research Institute for Earth Science and Disaster Prevention.	Baltay A, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL046698; Baltay A, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB006736; BEROZA GC, 1993, SCIENCE, V259, P210, DOI 10.1126/science.259.5092.210; Bizzarri A, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003862; BOATWRIGHT J, 1986, J GEOPHYS RES-SOLID, V91, P2095, DOI 10.1029/JB091iB02p02095; FUKUYAMA E, 1986, B SEISMOL SOC AM, V76, P1623; HARTZELL SH, 1978, GEOPHYS RES LETT, V5, P1, DOI 10.1029/GL005i001p00001; HAUKSSON E, 1994, B SEISMOL SOC AM, V84, P917; Ide S, 2001, TECTONOPHYSICS, V334, P35, DOI 10.1016/S0040-1951(01)00027-0; Ide S, 2001, GEOPHYS RES LETT, V28, P3349, DOI 10.1029/2001GL013106; Kanamori H., 1972, Physics of the Earth and Planetary Interiors, V6, P346, DOI 10.1016/0031-9201(72)90058-1; KANAMORI H, 1981, PHYS EARTH PLANET IN, V27, P8, DOI 10.1016/0031-9201(81)90083-2; KANAMORI H, 1993, NATURE, V361, P714, DOI 10.1038/361714a0; Ma S, 2008, B SEISMOL SOC AM, V98, P1642, DOI 10.1785/0120070201; Mai PM, 2000, B SEISMOL SOC AM, V90, P604, DOI 10.1785/0119990126; MENDOZA C, 1988, B SEISMOL SOC AM, V78, P1438; MORI J, 1990, B SEISMOL SOC AM, V80, P507; Nakayama W, 1997, B SEISMOL SOC AM, V87, P918; Oglesby DD, 1998, SCIENCE, V280, P1055, DOI 10.1126/science.280.5366.1055; Oglesby DD, 2001, B SEISMOL SOC AM, V91, P1099, DOI 10.1785/0120000714; Ratchkovski NA, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017905; Sato T, 1996, GEOPHYS RES LETT, V23, P33, DOI 10.1029/95GL03584; Schmitt SV, 2011, J GEOPHYS RES-SOL EA, V116, DOI 10.1029/2010JB008035; Scholz C. H., 2008, MECH EARTHQUAKES FAU; Tanioka Y, 1996, GEOPHYS RES LETT, V23, P1549, DOI 10.1029/96GL01479; Uchida N., 2010, 2010 AM GEOPH UN FAL; Venkataraman A, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002549; WELLS DL, 1994, B SEISMOL SOC AM, V84, P974; Wessel P, 1991, EOS T AM GEOPHYS UN, V72, P445, DOI [10.1029/90EO00319, DOI 10.1029/90EO00319, DOI 10.1029/90E000319]	29	447	457	4	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 17	2011	332	6036					1426	1429		10.1126/science.1207020	http://dx.doi.org/10.1126/science.1207020			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778FT	21596957				2022-12-28	WOS:000291689000040
J	Sander, LE; Davis, MJ; Boekschoten, MV; Amsen, D; Dascher, CC; Ryffel, B; Swanson, JA; Muller, M; Blander, JM				Sander, Leif E.; Davis, Michael J.; Boekschoten, Mark V.; Amsen, Derk; Dascher, Christopher C.; Ryffel, Bernard; Swanson, Joel A.; Mueller, Michael; Blander, J. Magarian			Detection of prokaryotic mRNA signifies microbial viability and promotes immunity	NATURE			English	Article							TOLL-LIKE RECEPTORS; T-CELL RESPONSES; TRANSCRIPTION FACTORS; PROTECTIVE IMMUNITY; INNATE; INFLAMMASOME; RECOGNITION; ACTIVATION; REGULATORS; PHAGOSOME	Live vaccines have long been known to trigger far more vigorous immune responses than their killed counterparts(1-6). This has been attributed to the ability of live microorganisms to replicate and express specialized virulence factors that facilitate invasion and infection of their hosts(7). However, protective immunization can often be achieved with a single injection of live, but not dead, attenuated microorganisms stripped of their virulence factors. Pathogen-associated molecular patterns (PAMPs), which are detected by the immune system(8,9), are present in both live and killed vaccines, indicating that certain poorly characterized aspects of live microorganisms, not incorporated in dead vaccines, are particularly effective at inducing protective immunity. Here we show that the mammalian innate immune system can directly sense microbial viability through detection of a special class of viability-associated PAMPs (vita-PAMPs). We identify prokaryotic messenger RNA as a vita-PAMP present only in viable bacteria, the recognition of which elicits a unique innate response and a robust adaptive antibody response. Notably, the innate response evoked by viability and prokaryotic mRNA was thus far considered to be reserved for pathogenic bacteria, but we show that even non-pathogenic bacteria in sterile tissues can trigger similar responses, provided that they are alive. Thus, the immune system actively gauges the infectious risk by searching PAMPs for signatures of microbial life and thus infectivity. Detection of vita-PAMPs triggers a state of alert not warranted for dead bacteria. Vaccine formulations that incorporate vita-PAMPs could thus combine the superior protection of live vaccines with the safety of dead vaccines.	[Sander, Leif E.; Dascher, Christopher C.; Blander, J. Magarian] Mt Sinai Sch Med, Inst Immunol, Dept Med, New York, NY 10029 USA; [Davis, Michael J.; Swanson, Joel A.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; [Boekschoten, Mark V.; Mueller, Michael] Wageningen Univ, Div Human Nutr, Nutr Metab & Genom Grp, NL-6703 HD Wageningen, Netherlands; [Amsen, Derk] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands; [Ryffel, Bernard] Univ Orleans, Lab Mol Immunol & Embryol, F-45071 Orleans, France; [Ryffel, Bernard] CNRS, F-45071 Orleans, France	Icahn School of Medicine at Mount Sinai; University of Michigan System; University of Michigan; Wageningen University & Research; University of Amsterdam; Academic Medical Center Amsterdam; Universite de Orleans; Centre National de la Recherche Scientifique (CNRS)	Blander, JM (corresponding author), Mt Sinai Sch Med, Inst Immunol, Dept Med, 1425 Madison Ave, New York, NY 10029 USA.	julie.blander@mssm.edu	Sander, Leif Erik/AAI-8619-2020; Boekschoten, Mark V/A-2458-2011; Boekschoten, Mark/AAS-4597-2021; Muller, Michael/M-5724-2019; Muller, Michael/B-5795-2008; Swanson, Joel A/P-4362-2014	Boekschoten, Mark V/0000-0002-2139-0795; Boekschoten, Mark/0000-0002-2139-0795; Muller, Michael/0000-0002-5930-9905; Muller, Michael/0000-0002-5930-9905; Swanson, Joel A/0000-0003-0900-8212; Blander, Julie Magarian/0000-0001-9207-1700; Sander, Leif Erik/0000-0002-0476-9947; Davis, Michael/0000-0002-3970-2208	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI095245, R21AI080959, R01AI064668] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI064668, R21 AI080959-01A1, R21 AI080959, AI080959A, R01 AI095245] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson BR, 2010, NUCLEIC ACIDS RES, V38, P5884, DOI 10.1093/nar/gkq347; Belasco JG, 2010, NAT REV MOL CELL BIO, V11, P467, DOI 10.1038/nrm2917; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brockstedt DG, 2005, NAT MED, V11, P853, DOI 10.1038/nm1276; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; Cheers C, 1996, TRENDS MICROBIOL, V4, P453, DOI 10.1016/0966-842X(96)10067-6; Coll RC, 2010, J INNATE IMMUN, V2, P406, DOI 10.1159/000315469; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Davis MJ, 2010, J LEUKOCYTE BIOL, V88, P813, DOI 10.1189/jlb.0310159; Detmer A, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-23; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gripenland J, 2010, NAT REV MICROBIOL, V8, P857, DOI 10.1038/nrmicro2457; Haraga A, 2008, NAT REV MICROBIOL, V6, P53, DOI 10.1038/nrmicro1788; Herskovits AA, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030051; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; KAWAMURA I, 1994, INFECT IMMUN, V62, P4396, DOI 10.1128/IAI.62.10.4396-4403.1994; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lauvau G, 2001, SCIENCE, V294, P1735, DOI 10.1126/science.1064571; Lim So-Yon, 2006, J Immune Based Ther Vaccines, V4, P5, DOI 10.1186/1476-8518-4-5; Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997; MAURELLI AT, 1985, INFECT IMMUN, V49, P164, DOI 10.1128/IAI.49.1.164-171.1985; Medzhitov R, 2009, IMMUNITY, V30, P766, DOI 10.1016/j.immuni.2009.06.004; Monroe KM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000665; Nallagatla SR, 2008, RNA BIOL, V5, P140, DOI 10.4161/rna.5.3.6839; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pang IK, 2011, TRENDS IMMUNOL, V32, P34, DOI 10.1016/j.it.2010.11.004; Piekna-Przybylska D, 2008, NUCLEIC ACIDS RES, V36, pD178, DOI 10.1093/nar/gkm855; Raskin DM, 2006, CELL, V124, P703, DOI 10.1016/j.cell.2006.02.002; Rehwinkel J, 2010, SCIENCE, V327, P284, DOI 10.1126/science.1185068; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Samarajiwa SA, 2009, NUCLEIC ACIDS RES, V37, pD852, DOI 10.1093/nar/gkn732; Sartor MA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-538; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Schnupf P, 2007, MICROBES INFECT, V9, P1176, DOI 10.1016/j.micinf.2007.05.005; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Shimada T, 2010, CELL HOST MICROBE, V7, P38, DOI 10.1016/j.chom.2009.12.008; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Torchinsky MB, 2009, NATURE, V458, P78, DOI 10.1038/nature07781; Vance RE, 2009, CELL HOST MICROBE, V6, P10, DOI 10.1016/j.chom.2009.06.007; VONKOENIG CHW, 1982, NATURE, V297, P233, DOI 10.1038/297233a0; Wing HJ, 2004, J BACTERIOL, V186, P699, DOI 10.1128/JB.186.3.699-705.2004; Woodward JJ, 2010, SCIENCE, V328, P1703, DOI 10.1126/science.1189801; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	51	296	300	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2011	474	7351					385	+		10.1038/nature10072	http://dx.doi.org/10.1038/nature10072			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777TD	21602824	Green Accepted			2022-12-28	WOS:000291647100047
J	Fowkes, FGR; Price, JF				Fowkes, F. Gerry R.; Price, Jackie F.			Gene therapy for critical limb ischaemia: the TAMARIS trial	LANCET			English	Editorial Material							CELL THERAPY; STEM-CELL; ANGIOGENESIS; DISEASE		[Fowkes, F. Gerry R.] Univ Edinburgh, Ctr Populat Hlth Sci, Wolfson Unit Prevent Peripheral Vasc Dis, Edinburgh EH8 9AG, Midlothian, Scotland; [Price, Jackie F.] Univ Edinburgh, Ctr Populat Hlth Sci, Mol Epidemiol Res Grp, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Fowkes, FGR (corresponding author), Univ Edinburgh, Ctr Populat Hlth Sci, Wolfson Unit Prevent Peripheral Vasc Dis, Edinburgh EH8 9AG, Midlothian, Scotland.	gerry.fowkes@ed.ac.uk		Price, Jackie/0000-0003-3251-3970				Aboyans V., 2009, PERIPHERAL ARTERIAL, P1; Belch J, 2011, LANCET, V377, P1929, DOI 10.1016/S0140-6736(11)60394-2; Collinson DJ, 2004, EUR J VASC ENDOVASC, V28, P9, DOI 10.1016/j.ejvs.2004.03.021; De Haro J, 2009, HEART VESSELS, V24, P321, DOI 10.1007/s00380-008-1140-z; FUFFOLO AJ, 2010, COCHRANE DB SYST REV, V1; Gupta R, 2009, CIRC RES, V105, P724, DOI 10.1161/CIRCRESAHA.109.200386; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Kalka C, 2008, VASC MED, V13, P157, DOI 10.1177/1358863x08088616; Lawall H, 2010, THROMB HAEMOSTASIS, V103, P696, DOI 10.1160/TH09-10-0688; Nikol S, 2008, MOL THER, V16, P972, DOI 10.1038/mt.2008.33; Norgren L, 2007, J VASC SURG, V45, pS5, DOI 10.1016/j.jvs.2006.12.037	11	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2011	377	9781					1894	1896		10.1016/S0140-6736(11)60441-8	http://dx.doi.org/10.1016/S0140-6736(11)60441-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777LW	21621833				2022-12-28	WOS:000291623200005
J	Debiec, H; Lefeu, F; Kemper, MJ; Niaudet, P; Deschenes, G; Remuzzi, G; Ulinski, T; Ronco, P				Debiec, Hanna; Lefeu, Florence; Kemper, Markus J.; Niaudet, Patrick; Deschenes, Georges; Remuzzi, Giuseppe; Ulinski, Tim; Ronco, Pierre			Early-Childhood Membranous Nephropathy Due to Cationic Bovine Serum Albumin	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-RESPONSES; DIETARY ANTIGENS; IGG4 ANTIBODIES; PREVALENCE; COMPLEXES; PROTEINS; INFANTS; DISEASE; TARGET; CELLS	Background The M-type phospholipase A(2) receptor (PLA(2)R) was recently identified as a candidate antigen in 70% of cases of idiopathic membranous nephropathy, a common form of the nephrotic syndrome. The nature of antigens involved in other idiopathic and secondary membranous nephropathies remains unclear. Methods We searched for antibodies against bovine serum albumin and circulating bovine serum albumin by means of enzyme-linked immunosorbent assay and Western blotting in serum specimens obtained from 50 patients with membranous nephropathy and 172 controls. The properties of immunopurified circulating bovine serum albumin obtained from serum specimens were analyzed with the use of two-dimensional sodium dodecyl sulfate-polyacrylamide-gel electrophoresis. We detected bovine serum albumin in glomerular deposits and analyzed the reactivity of eluted IgG. Results Eleven patients, including four children, had high levels of circulating anti-bovine serum albumin antibodies, of both the IgG1 and IgG4 subclasses. These patients also had elevated levels of circulating bovine serum albumin, without an increase in circulating immune complex levels. Bovine serum albumin immunopurified from the serum specimens of these four children migrated in the basic range of pH, whereas the bovine serum albumin from adult patients migrated in neutral regions as native bovine serum albumin. Bovine serum albumin was detected in subepithelial immune deposits only in the children with both high levels of cationic circulating bovine serum albumin and bovine serum albumin-specific antibodies, and it colocalized with IgG in the absence of PLA(2)R. IgG eluted from such deposits was specific for bovine serum albumin. Conclusions Some patients with childhood membranous nephropathy have both circulating cationic bovine serum albumin and anti-bovine serum albumin antibodies. Bovine serum albumin is present in immune deposits, suggesting that cationic bovine serum albumin is pathogenic through binding to the anionic glomerular capillary wall and in situ formation of immune complexes, as shown in experimental models.	[Debiec, Hanna] Univ Paris 06, Tenon Hosp, AP HP, INSERM,Unite Mixte Rech Sci 702, F-75020 Paris, France; [Niaudet, Patrick] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Dept Pediat Nephrol, Paris, France; [Deschenes, Georges] Univ Paris 07, Hop Robert Debre, AP HP, Dept Pediat Nephrol, Paris, France; [Ulinski, Tim] Armand Trousseau Childrens Hosp, AP HP, Pediat Nephrol Unit, Paris, France; [Kemper, Markus J.] Univ Med Ctr, Dept Pediat Nephrol, Hamburg, Germany; [Remuzzi, Giuseppe] Mario Negri Inst Pharmacol Res, Nephrol Unit, I-24100 Bergamo, Italy; [Remuzzi, Giuseppe] Mario Negri Inst Pharmacol Res, Unit Dialysis, I-24100 Bergamo, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Hamburg; University Medical Center Hamburg-Eppendorf; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Debiec, H (corresponding author), Univ Paris 06, Tenon Hosp, AP HP, INSERM,Unite Mixte Rech Sci 702, 4 Rue Chine, F-75020 Paris, France.	hanna.debiec@upmc.fr	Debiec, Hanna/AAL-8144-2021; Ronco, Pierre/AAC-8390-2022; Remuzzi, Giuseppe/V-9766-2017	Debiec, Hanna/0000-0002-8946-8245; Remuzzi, Giuseppe/0000-0002-6194-3446; deschenes, georges/0000-0002-5158-2915	Agence Nationale pour la Recherche [ANR-07-Physio-016-01]; European Community [HEALTH-F2-2007-201590]; Association pour l'Utilisation du Rein Artificiel; Amgen France; Fondation pour la Recherche Medicale; Assistance Publique-Hopitaux de Paris	Agence Nationale pour la Recherche(French National Research Agency (ANR)); European Community(European Commission); Association pour l'Utilisation du Rein Artificiel; Amgen France(Amgen); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Assistance Publique-Hopitaux de Paris	Supported by grants from Agence Nationale pour la Recherche (ANR-07-Physio-016-01), Coordination Theme 1 (Health) of the European Community's 7th Framework Program (HEALTH-F2-2007-201590), Association pour l'Utilisation du Rein Artificiel, Amgen France, and Fondation pour la Recherche Medicale, and by a Translational Research Contract from Assistance Publique-Hopitaux de Paris (to Dr. Debiec).	Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; Alting AC, 1997, DIABETES CARE, V20, P875, DOI 10.2337/diacare.20.5.875; Beck LH, 2009, NEW ENGL J MED, V361, P11, DOI 10.1056/NEJMoa0810457; BORDER WA, 1982, J CLIN INVEST, V69, P451, DOI 10.1172/JCI110469; Briani C, 2008, AUTOIMMUN REV, V7, P644, DOI 10.1016/j.autrev.2008.05.006; Chen Ashton, 2007, BMC Nephrol, V8, P11, DOI 10.1186/1471-2369-8-11; Chen JS, 2004, NEPHROL DIAL TRANSPL, V19, P2721, DOI 10.1093/ndt/gfh419; Davis PJ, 1998, ALLERGY, V53, P102, DOI 10.1111/j.1398-9995.1998.tb04975.x; Debiec H, 2004, LANCET, V364, P1252, DOI 10.1016/S0140-6736(04)17142-0; FIOCCHI A, 1995, J AM COLL NUTR, V14, P239; Glassock RJ, 2010, AM J KIDNEY DIS, V56, P157, DOI 10.1053/j.ajkd.2010.01.008; Husby S, 2000, J PEDIATR GASTR NUTR, V30, pS13, DOI 10.1097/00005176-200001001-00003; KLETTER B, 1971, INT ARCH ALLER A IMM, V40, P656, DOI 10.1159/000230447; KOYAMA A, 1986, IMMUNOLOGY, V58, P535; Kuroki A, 2005, KIDNEY INT, V68, P302, DOI 10.1111/j.1523-1755.2005.00415.x; Kuroki A, 2002, INTERNAL MED, V41, P936, DOI 10.2169/internalmedicine.41.936; Lempainen J, 2009, J AUTOIMMUN, V33, P155, DOI 10.1016/j.jaut.2009.04.003; MALOSSE D, 1992, NEUROEPIDEMIOLOGY, V11, P304, DOI 10.1159/000110946; Menon S, 2010, PEDIATR NEPHROL, V25, P1419, DOI 10.1007/s00467-009-1324-5; Mogues T, 2005, J IMMUNOL METHODS, V300, P1, DOI 10.1016/j.jim.2005.01.022; Oliveira DBG, 1998, LANCET, V351, P670, DOI 10.1016/S0140-6736(97)04122-6; PEREZMACEDA B, 1991, CLIN CHIM ACTA, V203, P153, DOI 10.1016/0009-8981(91)90287-M; Ponticelli C, 2007, J NEPHROL, V20, P268; Ronco P, 2010, J AM SOC NEPHROL, V21, P564, DOI 10.1681/ASN.2009121220; Sanchez C, 2003, REV FR ALLERGOL, V43, P13, DOI 10.1016/S0335-7457(02)00003-5; Sathe SK, 2005, BIOTECHNOL ADV, V23, P423, DOI 10.1016/j.biotechadv.2005.05.008; SCHMIDT DG, 1995, CLIN EXP ALLERGY, V25, P1007, DOI 10.1111/j.1365-2222.1995.tb00404.x; Sreedharan R, 2004, PEDIATRICS, V113, P1044; Strobel S, 1998, IMMUNOL TODAY, V19, P173, DOI 10.1016/S0167-5699(97)01239-5; Tipping PG, 2005, CLIN EXP IMMUNOL, V142, P207, DOI 10.1111/j.1365-2249.2005.02842.x; Torente F, 2004, PEDIAT GASTROINTESTI, P944; van Elburg RM, 2003, ARCH DIS CHILD-FETAL, V88, P52; VANDERZEE JS, 1986, J IMMUNOL, V137, P3566; VANDERZEE JS, 1986, CLIN EXP IMMUNOL, V64, P415; Winer S, 2001, J IMMUNOL, V166, P4751, DOI 10.4049/jimmunol.166.7.4751	35	139	156	3	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2101	2110		10.1056/NEJMoa1013792	http://dx.doi.org/10.1056/NEJMoa1013792			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AB	21631322	Bronze			2022-12-28	WOS:000291200700008
J	Wechsler, LR				Wechsler, Lawrence R.			Intravenous Thrombolytic Therapy for Acute Ischemic Stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; ULTRASOUND-ENHANCED THROMBOLYSIS; COOPERATIVE ACUTE STROKE; QUALITY-OF-CARE; INTRACEREBRAL HEMORRHAGE; CEREBRAL-ISCHEMIA; OROLINGUAL ANGIOEDEMA; CLINICAL-PRACTICE; EARLY REPERFUSION; DOSE-ESCALATION		Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wechsler, LR (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 811 Lillian Kaufmann Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA.	wechslerlr@upmc.edu	Wechsler, Lawrence/AAB-9176-2020		Abbott Vascular; Lundbeck; Ferrer; NMT Medical	Abbott Vascular(Abbott Laboratories); Lundbeck(Lundbeck Corporation); Ferrer; NMT Medical	Dr. Wechsler reports receiving consulting fees from Abbott Vascular, Lundbeck, and Ferrer and grant support from NMT Medical and holding stock in NeuroInterventions. No other potential conflict of interest relevant to this article was reported.	Adams, 2007, STROKE, V38, pE38, DOI 10.1161/STROKEAHA.106.110011; Adams, 2007, STROKE, V38, pE96; Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Adams Harold P Jr, 2009, Handb Clin Neurol, V94, P971, DOI 10.1016/S0072-9752(08)94048-3; Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Alexandrov AV, 2000, STROKE, V31, P610, DOI 10.1161/01.STR.31.3.610; Alexandrov AV, 2004, NEW ENGL J MED, V351, P2170, DOI 10.1056/NEJMoa041175; Alexandrov AV, 2004, J NEUROIMAGING, V14, P113, DOI 10.1177/1051228403261462; *AM COLL EM PHYS, US INTR TPA MAN AC S; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Brott T, 2000, NEW ENGL J MED, V343, P710, DOI 10.1056/NEJM200009073431007; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Chen CI, 2005, EUR NEUROL, V54, P140, DOI 10.1159/000089086; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Daffertshofer M, 2005, STROKE, V36, P1441, DOI 10.1161/01.STR.0000170707.86793.1a; Darby DG, 1999, STROKE, V30, P2043, DOI 10.1161/01.STR.30.10.2043; del Zoppo GJ, 2009, STROKE, V40, P2945, DOI 10.1161/STROKEAHA.109.192535; DELZOPPO GJ, 2010, STROKE, V4, pE562; Demchuk AM, 1999, STROKE, V30, P34, DOI 10.1161/01.STR.30.1.34; Eggers J, 2008, STROKE, V39, P1470, DOI 10.1161/STROKEAHA.107.503870; Engelter ST, 2005, J NEUROL, V252, P1167, DOI 10.1007/s00415-005-0789-9; European Stroke Organisation [ESO] Executive Committee and the ESO Writing Committee, GUID MAN ISCH STROK; Fisher M, 1997, STROKE, V28, P866, DOI 10.1161/01.STR.28.4.866; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Furlan AJ, 2006, STROKE, V37, P1227, DOI 10.1161/01.STR.0000217403.66996.6d; Goldstein JN, 2010, ARCH NEUROL-CHICAGO, V67, P965, DOI 10.1001/archneurol.2010.175; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hacke W, 2009, LANCET NEUROL, V8, P141, DOI 10.1016/S1474-4422(08)70267-9; Haley EC, 2010, STROKE, V41, P707, DOI 10.1161/STROKEAHA.109.572040; Haley EC, 2005, STROKE, V36, P607, DOI 10.1161/01.STR.0000154872.73240.e9; Hill MD, 2005, CAN MED ASSOC J, V172, P1307, DOI 10.1503/cmaj.1041561; Hill MD, 2003, NEUROLOGY, V60, P1525, DOI 10.1212/01.WNL.0000058840.66596.1A; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; Jauch EC, 2010, CIRCULATION, V122, pS818, DOI 10.1161/CIRCULATIONAHA.110.971044; Johnston SC, 2003, ANN NEUROL, V54, P439, DOI 10.1002/ana.10678; Johnston SC, 2003, STROKE, V34, P2446, DOI 10.1161/01.STR.0000090842.81076.68; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; Kelly-Hayes Margaret, 2003, J Stroke Cerebrovasc Dis, V12, P119, DOI 10.1016/S1052-3057(03)00042-9; Kidwell CS, 2010, CURR NEUROL NEUROSCI, V10, P21, DOI 10.1007/s11910-009-0075-9; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Larrue V, 1997, STROKE, V28, P957, DOI 10.1161/01.STR.28.5.957; Larrue V, 2001, STROKE, V32, P438, DOI 10.1161/01.STR.32.2.438; Lev MH, 2001, STROKE, V32, P2021, DOI 10.1161/hs0901.095680; LEVY DE, 1994, STROKE, V25, P291, DOI 10.1161/01.STR.25.2.291; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Marder VJ, 2010, J THROMB HAEMOST, V8, P433, DOI 10.1111/j.1538-7836.2009.03701.x; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mishra NK, 2010, STROKE, V41, pE25, DOI 10.1161/STROKEAHA.109.566869; Molina CA, 2002, STROKE, V33, P1551, DOI 10.1161/01.STR.0000016323.13456.E5; Moodie ML, 2004, STROKE, V35, P1041, DOI 10.1161/01.STR.0000125012.36134.89; Nakagawara J, 2010, STROKE, V41, P1984, DOI 10.1161/STROKEAHA.110.589606; Rasler F, 2007, ANN EMERG MED, V50, P485, DOI 10.1016/j.annemergmed.2007.04.030; Roger, 2011, CIRCULATION, V123, pE240, DOI 10.1161/CIR.0b013e3182117650; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736; Sandercock P, 2004, STROKE, V35, P1490, DOI 10.1161/01.STR.0000126871.98801.6E; Saqqur M, 2008, NEUROLOGY, V71, P1304, DOI 10.1212/01.wnl.0000313936.15842.0d; Selim M, 2002, STROKE, V33, P2047, DOI 10.1161/01.STR.0000023577.65990.4E; Stahl JE, 2003, RADIOLOGY, V228, P659, DOI 10.1148/radiol.2283021557; Sylaja PN, 2006, J NEUROL NEUROSUR PS, V77, P826, DOI 10.1136/jnnp.2005.086595; Tanne D, 2002, CIRCULATION, V105, P1679, DOI 10.1161/01.CIR.0000012747.53592.6A; Tanswell P, 2002, CLIN PHARMACOKINET, V41, P1229, DOI 10.2165/00003088-200241150-00001; Tsivgoulis G, 2010, STROKE, V41, P280, DOI 10.1161/STROKEAHA.109.563304; von Kummer R, 2009, STROKE, V40, P2268, DOI 10.1161/STROKEAHA.108.539353; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; *WORK GROUP THROMB, POS STAT AM AC EM ME; Yamaguchi T, 2006, STROKE, V37, P1810, DOI 10.1161/01.STR.0000227191.01792.e3; CLIN PRACTICE STATEM	75	65	70	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2138	2146		10.1056/NEJMct1007370	http://dx.doi.org/10.1056/NEJMct1007370			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AB	21631326				2022-12-28	WOS:000291200700012
J	Cohen, NM; Kenigsberg, E; Tanay, A				Cohen, Netta Mendelson; Kenigsberg, Ephraim; Tanay, Amos			Primate CpG Islands Are Maintained by Heterogeneous Evolutionary Regimes Involving Minimal Selection	CELL			English	Article							BIASED GENE CONVERSION; DIFFERENTIALLY METHYLATED REGIONS; PLURIPOTENT STEM-CELLS; DNA METHYLATION; HUMAN GENOME; BINDING SITES; HYPERMETHYLATION; PATTERNS; FREQUENCIES; SEQUENCES	Mammalian CpG islands are key epigenomic elements that were first characterized experimentally as genomic fractions with low levels of DNA methylation. Currently, CpG islands are defined based on their genomic sequences alone. Here, we develop evolutionary models to show that several distinct evolutionary processes generate and maintain CpG islands. One central evolutionary regime resulting in enriched CpG content is driven by low levels of DNA methylation and consequentially low rates of CpG deamination. Another major force forming CpG islands is biased gene conversion that stabilizes constitutively methylated CpG islands by balancing rapid deamination with CpG fixation. Importantly, evolutionary analysis and population genetics data suggest that selection for high CpG content is not a significant factor contributing to conservation of CpGs in differentially methylated regions. The heterogeneous, but not selective, origins of CpG islands have direct implications for the understanding of DNA methylation patterns in healthy and diseased cells.	[Cohen, Netta Mendelson; Kenigsberg, Ephraim; Tanay, Amos] Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Tanay, A (corresponding author), Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel.	amos.tanay@weizmann.ac.il	Kenigsberg, Ephraim/AAM-5690-2020		Israeli Science foundation [1372/08]; EU EPIGENESYS NoE	Israeli Science foundation(Israel Science Foundation); EU EPIGENESYS NoE	We'd like to thank members of the Tanay group for discussions and critical reading of the manuscript. A. T. wishes to thank Tim Bestor, Peter Jones, and Einav Nili Gal-Yam for discussions. Research in A.T.'s lab was supported by the Israeli Science foundation (1372/08) and the EU EPIGENESYS NoE program.	Arndt PF, 2007, GENE, V390, P75, DOI 10.1016/j.gene.2006.11.022; Baele G, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-244; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; Cohen NM, 2009, GENOME RES, V19, P2193, DOI 10.1101/gr.096685.109; Cohn I, 2010, J MACH LEARN RES, V11, P2745; Dindot SV, 2009, GENOME RES, V19, P1374, DOI 10.1101/gr.089185.108; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Dreszer TR, 2007, GENOME RES, V17, P1420, DOI 10.1101/gr.6395807; Edwards JR, 2010, GENOME RES, V20, P972, DOI 10.1101/gr.101535.109; EYREWALKER A, 1993, P ROY SOC B-BIOL SCI, V252, P237, DOI 10.1098/rspb.1993.0071; Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105; Galtier N, 2001, GENETICS, V159, P907; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hwang DG, 2004, P NATL ACAD SCI USA, V101, P13994, DOI 10.1073/pnas.0404142101; Illingworth RS, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001134; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; Jorgensen HF, 2002, MENT RETARD DEV D R, V8, P87, DOI 10.1002/mrdd.10021; Kenigsberg E, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001039; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; KSCHISCHANG FR, 2001, IEEE T INFORM THEORY, V47, P21; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Rakyan VK, 2008, GENOME RES, V18, P1518, DOI 10.1101/gr.077479.108; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Schulz R, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001214; Straussman R, 2009, NAT STRUCT MOL BIOL, V16, P564, DOI 10.1038/nsmb.1594; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tanay A, 2007, P NATL ACAD SCI USA, V104, P5521, DOI 10.1073/pnas.0609746104; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990	39	104	104	0	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 27	2011	145	5					773	786		10.1016/j.cell.2011.04.024	http://dx.doi.org/10.1016/j.cell.2011.04.024			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620139	Bronze			2022-12-28	WOS:000291018600016
J	Rios, AC; Serralbo, O; Salgado, D; Marcelle, C				Rios, Anne C.; Serralbo, Olivier; Salgado, David; Marcelle, Christophe			Neural crest regulates myogenesis through the transient activation of NOTCH	NATURE			English	Article							DERMOMYOTOME DORSOMEDIAL LIP; PROGENITOR CELLS; GENE-EXPRESSION; MUSCLE; DIFFERENTIATION; MAINTENANCE; POPULATION; INHIBITION; MOVEMENTS; MECHANISM	How dynamic signalling and extensive tissue rearrangements interact to generate complex patterns and shapes during embryogenesis is poorly understood(1-3). Here we characterize the signalling events taking place during early morphogenesis of chick skeletal muscles. We show that muscle progenitors present in somites require the transient activation of NOTCH signalling to undergo terminal differentiation. The NOTCH ligand Delta1 is expressed in a mosaic pattern in neural crest cells that migrate past the somites. Gain and loss of Delta1 function in neural crest modifies NOTCH signalling in somites, which results in delayed or premature myogenesis. Our results indicate that the neural crest regulates early muscle formation by a unique mechanism that relies on the migration of Delta1-expressing neural crest cells to trigger the transient activation of NOTCH signalling in selected muscle progenitors. This dynamic signalling guarantees a balanced and progressive differentiation of the muscle progenitor pool.	[Rios, Anne C.; Serralbo, Olivier; Salgado, David; Marcelle, Christophe] Monash Univ, EMBL Australia, Clayton, Vic 3800, Australia; [Rios, Anne C.; Serralbo, Olivier; Salgado, David; Marcelle, Christophe] Monash Univ, ARMI, Clayton, Vic 3800, Australia	European Molecular Biology Laboratory (EMBL); Monash University; Australian Regenerative Medicine Institute; Monash University	Marcelle, C (corresponding author), Monash Univ, EMBL Australia, Bldg 75, Clayton, Vic 3800, Australia.	christophe.marcelle@monash.edu	SALGADO, David/A-1417-2014	Serralbo, Olivier/0000-0003-0808-3464; Rios, Anne/0000-0002-9082-8068; Salgado, David/0000-0002-5905-3591	Agence Nationale pour le Recherche (ANR); EU	Agence Nationale pour le Recherche (ANR)(French National Research Agency (ANR)); EU(European Commission)	We thank N. Rosenthal and P. Currie for critical reading of the manuscript. This study was funded by grants from the Agence Nationale pour le Recherche (ANR), and by the EU 6th Framework Programme Network of Excellence MYORES. The help of P. Weber, S. Firth, C. Johnson and I. Harper from Imaging Facilities (IBDML, Marseille and MMI, Monash University) is acknowledged.	Ben-Yair R, 2005, DEVELOPMENT, V132, P689, DOI 10.1242/dev.01617; Cinnamon Y, 1999, DEVELOPMENT, V126, P4305; Das RM, 2006, DEV BIOL, V294, P554, DOI 10.1016/j.ydbio.2006.02.020; Daudet N, 2005, DEVELOPMENT, V132, P541, DOI 10.1242/dev.01589; De Calisto J, 2005, DEVELOPMENT, V132, P2587, DOI 10.1242/dev.01857; Denetclaw WF, 2001, DEVELOPMENT, V128, P1745; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Gros J, 2005, NATURE, V435, P954, DOI 10.1038/nature03572; Gros J, 2004, DEV CELL, V6, P875, DOI 10.1016/j.devcel.2004.05.006; Gros J, 2009, NATURE, V457, P589, DOI 10.1038/nature07564; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Henrique D, 1997, GENE DEV, V11, P603, DOI 10.1101/gad.11.5.603; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; Hirsinger E, 2001, DEVELOPMENT, V128, P107; Iimura T, 2006, NATURE, V442, P568, DOI 10.1038/nature04838; Joubin K, 1999, CELL, V98, P559, DOI 10.1016/S0092-8674(00)80044-6; Jouve C, 2000, DEVELOPMENT, V127, P1421; Kahane N, 2002, DEVELOPMENT, V129, P2675; Kahane N, 1998, DEVELOPMENT, V125, P4259; Kahane N, 2001, DEVELOPMENT, V128, P2187; Kassar-Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505; Manceau M, 2008, GENE DEV, V22, P668, DOI 10.1101/gad.454408; Marcelle C, 1997, DEVELOPMENT, V124, P3955; MAXWELL IH, 1986, CANCER RES, V46, P4660; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/S0092-8674(04)01054-2; Ohtsuka T, 2006, MOL CELL NEUROSCI, V31, P109, DOI 10.1016/j.mcn.2005.09.006; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594; Rios AC, 2010, DEV DYNAM, V239, P346, DOI 10.1002/dvdy.22174; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Schuster-Gossler K, 2007, P NATL ACAD SCI USA, V104, P537, DOI 10.1073/pnas.0608281104; Shimojo H, 2008, NEURON, V58, P52, DOI 10.1016/j.neuron.2008.02.014; Tobiume M, 2002, J VIROL, V76, P5959, DOI 10.1128/JVI.76.12.5959-5965.2002; Uchikawa M, 2003, DEV CELL, V4, P509, DOI 10.1016/S1534-5807(03)00088-1; Vasyutina E, 2007, CELL CYCLE, V6, P1451; Vasyutina E, 2007, P NATL ACAD SCI USA, V104, P4443, DOI 10.1073/pnas.0610647104; Venters SJ, 2002, DEVELOPMENT, V129, P3873; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Werner T, 2007, NUCLEIC ACIDS RES, V35, P6526, DOI 10.1093/nar/gkm727	41	111	112	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2011	473	7348					532	U279		10.1038/nature09970	http://dx.doi.org/10.1038/nature09970			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21572437				2022-12-28	WOS:000290951300045
J	Treasure, T; Hasan, A; Yacoub, M				Treasure, Tom; Hasan, Asif; Yacoub, Magdi			Is there a risk in avoiding risk for younger patients with aortic valve disease?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ROOT REPLACEMENT; ROSS PROCEDURE; HEART-VALVES; OUTCOMES; DURABILITY; AUTOGRAFT; SURVIVAL; MODELS; AGE		[Treasure, Tom] UCL, Dept Math, Clin Operat Res Unit, London WC1H 0BT, England; [Hasan, Asif] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Yacoub, Magdi] Harefield Hosp, Heart Sci Ctr, Harefield UB9 6JH, Middx, England	University of London; University College London; Newcastle Freeman Hospital; Newcastle University - UK; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Treasure, T (corresponding author), UCL, Dept Math, Clin Operat Res Unit, London WC1H 0BT, England.	tom.treasure@gmail.com						Banbury MK, 2001, ANN THORAC SURG, V72, P753, DOI 10.1016/S0003-4975(01)02992-7; Berwick DM, 2008, JAMA-J AM MED ASSOC, V299, P1182, DOI 10.1001/jama.299.10.1182; Bridgewater B, 2009, 6 NATL ADULT CARDIAC; El-Hamamsy I, 2010, LANCET, V376, P524, DOI 10.1016/S0140-6736(10)60828-8; El-Hamamsy I, 2010, J AM COLL CARDIOL, V55, P368, DOI 10.1016/j.jacc.2009.09.030; Hasan A, 2000, BRIT MED J, V320, P171, DOI 10.1136/bmj.320.7228.171; Hirsh J, 2009, LANCET, V374, P273, DOI 10.1016/S0140-6736(09)60787-X; Kvidal P, 2000, J AM COLL CARDIOL, V35, P747, DOI 10.1016/S0735-1097(99)00584-7; Mokhles MM, 2011, CIRCULATION, V123, P31, DOI 10.1161/CIRCULATIONAHA.110.947341; Murday AJ, 2003, ANN THORAC SURG, V76, P66, DOI 10.1016/S0003-4975(03)00118-8; ROSS DN, 1967, LANCET, V2, P956; Royston G, 1999, BMJ-BRIT MED J, V318, P360; Society for Cardiothoracic Surgery in Great Britain and Ireland, 2011, CARD SURG DAT; Stoica S, 2010, HEART, V96, P1730, DOI 10.1136/hrt.2010.201939; Takkenberg JJM, 2004, J AM COLL CARDIOL, V44, P1142, DOI 10.1016/j.jacc.2004.06.010; Takkenberg JJM, 2003, ANN THORAC SURG, V75, P1372, DOI 10.1016/S0003-4975(02)04996-2; Takkenberg JJM, 2010, HEART, V96, P1691, DOI 10.1136/hrt.2010.207050; Takkenberg JJM, 2009, CIRCULATION, V119, P222, DOI 10.1161/CIRCULATIONAHA.107.726349; TREASURE T, 1990, LANCET, V336, P1115, DOI 10.1016/0140-6736(90)92583-4; TREASURE T, 1994, LANCET, V343, P1308, DOI 10.1016/S0140-6736(94)92463-5; Vink R, 2003, J AM COLL CARDIOL, V42, P2042, DOI 10.1016/j.jacc.2003.07.029	21	24	24	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 26	2011	342								d2466	10.1136/bmj.d2466	http://dx.doi.org/10.1136/bmj.d2466			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771KG	21622509				2022-12-28	WOS:000291155000001
J	Gostin, LO; Record, KL				Gostin, Lawrence O.; Record, Katherine L.			Dangerous People or Dangerous Weapons Access to Firearms for Persons With Mental Illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gostin, Lawrence O.; Record, Katherine L.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				Bureau of Alcohol Tobacco Firearms and Explosives, 2008, STAT LAWS PUBL ORD F, pi; Gostin LO, 2010, JAMA-J AM MED ASSOC, V304, P1485, DOI 10.1001/jama.2010.1419; Obama Barack, 2011, COMMUNICATION   0112; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI 10.1001/archpsyc.55.5.393; US General Accounting Office, 2000, GUN CONTR OPT IMPR N; Wiebe DJ, 2003, ANN EMERG MED, V41, P771, DOI 10.1067/mem.2003.187	6	16	16	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2011	305	20					2108	2109		10.1001/jama.2011.688	http://dx.doi.org/10.1001/jama.2011.688			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768AC	21610243				2022-12-28	WOS:000290901700025
J	Sims, H; Erber, WN				Sims, Hannah; Erber, Wendy N.			RATIONAL TESTING Investigation of an incidental finding of eosinophilia	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Sims, Hannah; Erber, Wendy N.] Addenbrookes Hosp, Dept Haematol, Cambridge CB2 0QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Erber, WN (corresponding author), Univ Western Australia, M504,35 Stirling Highway, Nedlands, WA 6009, Australia.	werber@meddent.uwa.edu.au	Erber, Wendy/A-1955-2012	Erber, Wendy/0000-0002-1028-9376				Brito-Babapulle F, 2003, BRIT J HAEMATOL, V121, P203, DOI 10.1046/j.1365-2141.2003.04195.x; Erber WN, 2010, DIAGNOSTIC TECHNIQUE; Gleich GJ, 2009, BRIT J HAEMATOL, V145, P271, DOI 10.1111/j.1365-2141.2009.07599.x; Klco JM, 2010, AM J CLIN PATHOL, V133, P602, DOI 10.1309/AJCPPPZ1WFVGNE4A; Swerdlow SH, 2008, WHO CLASSIFICATION T; Tefferi A, 2006, BRIT J HAEMATOL, V133, P468, DOI 10.1111/j.1365-2141.2006.06038.x	6	13	13	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 18	2011	342								d2670	10.1136/bmj.d2670	http://dx.doi.org/10.1136/bmj.d2670			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QQ	21593088				2022-12-28	WOS:000290951900002
J	Mustafa, R; Garg, AX				Mustafa, Reem; Garg, Amit X.			In hemodialysis patients with CHF, adding telmisartan to standard ACE inhibitors reduced CHD mortality and admissions	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TRIAL		[Mustafa, Reem] McMaster Univ, Hamilton, ON, Canada; [Garg, Amit X.] Univ Western Ontario, London, ON, Canada	McMaster University; Western University (University of Western Ontario)	Mustafa, R (corresponding author), McMaster Univ, Hamilton, ON, Canada.			Mustafa, Reem/0000-0002-2091-0875				Coca SG, 2006, JAMA-J AM MED ASSOC, V296, P1377, DOI 10.1001/jama.296.11.1377; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317	4	1	1	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-5	10.7326/0003-4819-154-10-201105170-02005	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576523				2022-12-28	WOS:000290620300004
J	Innocenti, P; Morrow, EH; Dowling, DK				Innocenti, Paolo; Morrow, Edward H.; Dowling, Damian K.			Experimental Evidence Supports a Sex-Specific Selective Sieve in Mitochondrial Genome Evolution	SCIENCE			English	Article							POPULATION VIABILITY; MALE-STERILITY; MOTHERS CURSE; NUCLEAR; GENES; CONSEQUENCES; INHERITANCE; MUTATIONS; WOLBACHIA; CONFLICT	Mitochondria are maternally transmitted; hence, their genome can only make a direct and adaptive response to selection through females, whereas males represent an evolutionary dead end. In theory, this creates a sex-specific selective sieve, enabling deleterious mutations to accumulate in mitochondrial genomes if they exert male-specific effects. We tested this hypothesis, expressing five mitochondrial variants alongside a standard nuclear genome in Drosophila melanogaster, and found striking sexual asymmetry in patterns of nuclear gene expression. Mitochondrial polymorphism had few effects on nuclear gene expression in females but major effects in males, modifying nearly 10% of transcripts. These were mostly male-biased in expression, with enrichment hotspots in the testes and accessory glands. Our results suggest an evolutionary mechanism that results in mitochondrial genomes harboring male-specific mutation loads.	[Dowling, Damian K.] Monash Univ, Sch Biol Sci, Clayton, Vic 3800, Australia; [Innocenti, Paolo; Morrow, Edward H.] Uppsala Univ, Evolutionary Biol Ctr, Dept Ecol & Genet, S-75236 Uppsala, Sweden	Monash University; Uppsala University	Dowling, DK (corresponding author), Monash Univ, Sch Biol Sci, Clayton, Vic 3800, Australia.	damian.dowling@monash.edu	Morrow, Edward/C-2358-2011; Morrow, Edward H/Q-6730-2019; Dowling, Damian/C-9016-2009	Morrow, Edward/0000-0002-1853-7469; Morrow, Edward H/0000-0002-1853-7469; Dowling, Damian/0000-0003-2209-3458; Innocenti, Paolo/0000-0003-2082-0586	Australian Research Council [DP1092897]; Monash University; Swedish Research Council [2008-5533]	Australian Research Council(Australian Research Council); Monash University(Monash University); Swedish Research Council(Swedish Research CouncilEuropean Commission)	Funded by grants from the Australian Research Council (Discovery Project and Australian Research Fellowship, number DP1092897) and Monash University to D. K. D.; P. I. and E. H. M. were supported by the Swedish Research Council (grant 2008-5533 to E. H. M.). We thank D. Clancy for fly strains; U. Friberg for discussion; M. Norgate for sequencing; G. Arnqvist, U. Friberg, and J. Abbott for comments on the manuscript; and the Uppsala Array Platform. Microarray data have been deposited on the Gene Expression Omnibus database, accession no. GSE24729.	ADAMS MD, 2000, Insect Mol Biol, V287, P263; Charlat S, 2003, TRENDS GENET, V19, P217, DOI 10.1016/S0168-9525(03)00024-6; Chintapalli VR, 2007, NAT GENET, V39, P715, DOI 10.1038/ng2049; Clancy DJ, 2008, AGING CELL, V7, P795, DOI 10.1111/j.1474-9726.2008.00428.x; Dowling DK, 2007, J EVOLUTION BIOL, V20, P358, DOI 10.1111/j.1420-9101.2006.01189.x; Dowling DK, 2008, TRENDS ECOL EVOL, V23, P546, DOI 10.1016/j.tree.2008.05.011; Dowling DK, 2010, AM NAT, V176, P131, DOI 10.1086/653671; Frank SA, 1996, NATURE, V383, P224, DOI 10.1038/383224a0; Gemmell NJ, 2004, TRENDS ECOL EVOL, V19, P238, DOI 10.1016/j.tree.2004.02.002; Gemmell NJ, 2001, TRENDS ECOL EVOL, V16, P115, DOI 10.1016/S0169-5347(00)02087-5; Innocenti P, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000335; Lee HY, 2008, CELL, V135, P1065, DOI 10.1016/j.cell.2008.10.047; Lemos B, 2008, SCIENCE, V319, P91, DOI 10.1126/science.1148861; Lemos B, 2010, P NATL ACAD SCI USA, V107, P15826, DOI 10.1073/pnas.1010383107; Lynch M, 1997, MOL BIOL EVOL, V14, P914, DOI 10.1093/oxfordjournals.molbev.a025834; Michaud J, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-363; Moran NA, 1996, P NATL ACAD SCI USA, V93, P2873, DOI 10.1073/pnas.93.7.2873; Rand DM, 2004, TRENDS ECOL EVOL, V19, P645, DOI 10.1016/j.tree.2004.10.003; Rhoades MM, 1931, SCIENCE, V73, P340, DOI 10.1126/science.73.1891.340; Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040; Schnable PS, 1998, TRENDS PLANT SCI, V3, P175, DOI 10.1016/S1360-1385(98)01235-7; Smith S, 2010, MOL ECOL, V19, P36, DOI 10.1111/j.1365-294X.2009.04444.x; de Moraes VCS, 2009, BIOCHEM BIOPH RES CO, V381, P210, DOI 10.1016/j.bbrc.2009.02.014; Wade MJ, 2009, EVOLUTION, V63, P1084, DOI 10.1111/j.1558-5646.2009.00614.x; Werren John H, 2008, Nat Rev Microbiol, V6, P741, DOI 10.1038/nrmicro1969; Woodson JD, 2008, NAT REV GENET, V9, P383, DOI 10.1038/nrg2348; Zeh JA, 2005, TRENDS GENET, V21, P281, DOI 10.1016/j.tig.2005.03.006	27	198	201	5	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					845	848		10.1126/science.1201157	http://dx.doi.org/10.1126/science.1201157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566193				2022-12-28	WOS:000290529900047
J	Wagner, DE; Wang, IE; Reddien, PW				Wagner, Daniel E.; Wang, Irving E.; Reddien, Peter W.			Clonogenic Neoblasts Are Pluripotent Adult Stem Cells That Underlie Planarian Regeneration	SCIENCE			English	Article							SCHMIDTEA-MEDITERRANEA; SELF-RENEWAL; MARROW-CELLS; GENE; PLASTICITY; PROTEIN; DIFFERENTIATION; IDENTIFICATION; REPOPULATION; CULTURE	Pluripotent cells in the embryo can generate all cell types, but lineage-restricted cells are generally thought to replenish adult tissues. Planarians are flatworms and regenerate from tiny body fragments, a process requiring a population of proliferating cells (neoblasts). Whether regeneration is accomplished by pluripotent cells or by the collective activity of multiple lineage-restricted cell types is unknown. We used ionizing radiation and single-cell transplantation to identify neoblasts that can form large descendant-cell colonies in vivo. These clonogenic neoblasts (cNeoblasts) produce cells that differentiate into neuronal, intestinal, and other known postmitotic cell types and are distributed throughout the body. Single transplanted cNeoblasts restored regeneration in lethally irradiated hosts. We conclude that broadly distributed, adult pluripotent stem cells underlie the remarkable regenerative abilities of planarians.	[Wagner, Daniel E.; Wang, Irving E.; Reddien, Peter W.] MIT, Dept Biol, Howard Hughes Med Inst, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Wagner, DE (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	reddien@wi.mit.edu		/0000-0002-5569-333X; Wagner, Daniel/0000-0002-2983-635X	NIH [R01GM080639]; Keck Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080639] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Keck Foundation(W.M. Keck Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D. Kim for manuscript comments; S. Lapan for neuronal and intestinal markers; M. Srivastava for phylogenetics advice; D. Wenemoser for SMEDWI-1 antibody purification; J. Owen for Illumina data; M. Griffin for flow cytometry assistance; and P. Hsu, G. Bell, R. Young, and all members of the Reddien Lab for extensive comments and discussion. P. W. R. is an early career scientist of the Howard Hughes Medical Institute and an associate member of the Broad Institute of Harvard and MIT. We acknowledge support from the NIH (grant R01GM080639) and the Keck Foundation.	BAGUNA J, 1976, J EXP ZOOL, V195, P53, DOI 10.1002/jez.1401950106; BAGUNA J, 1989, DEVELOPMENT, V107, P77; Bardeen CR, 1904, J EXP ZOOL, V1, P191, DOI 10.1002/jez.1400010107; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Dubois F, 1949, B BIOL FR BELG, V83, P213; Eisenhoffer GT, 2008, CELL STEM CELL, V3, P327, DOI 10.1016/j.stem.2008.07.002; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; EVANS MJ, 1972, J EMBRYOL EXP MORPH, V28, P163; Guo TX, 2006, DEV CELL, V11, P159, DOI 10.1016/j.devcel.2006.06.004; Hayashi T, 2006, DEV GROWTH DIFFER, V48, P371, DOI 10.1111/j.1440-169x.2006.00876.x; Hewitson Tim D, 2006, Methods Mol Biol, V326, P219; Keller J., 1894, JENA F R MED NAT, V28, P370; LANGE CS, 1968, INT J RADIAT BIOL RE, V14, P373, DOI 10.1080/09553006814551221; LENDER T, 1965, CR HEBD ACAD SCI, V260, P4095; Morgan TH, 1898, ARCH ENTW MECH ORG, V7, P364; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Newmark PA, 2000, DEV BIOL, V220, P142, DOI 10.1006/dbio.2000.9645; Nishimura K, 2010, NEUROSCIENCE, V168, P18, DOI 10.1016/j.neuroscience.2010.03.038; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; Pearson BJ, 2010, DEVELOPMENT, V137, P213, DOI 10.1242/dev.044297; Reddien PW, 2005, SCIENCE, V310, P1327, DOI 10.1126/science.1116110; Reddien PW, 2005, DEV CELL, V8, P635, DOI 10.1016/j.devcel.2005.02.014; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P725, DOI 10.1146/annurev.cellbio.20.010403.095114; Salvetti A, 2009, DEV BIOL, V328, P305, DOI 10.1016/j.ydbio.2009.01.029; Scimone ML, 2010, DEVELOPMENT, V137, P1231, DOI 10.1242/dev.042051; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wenemoser D, 2010, DEV BIOL, V344, P979, DOI 10.1016/j.ydbio.2010.06.017; WOLFF ETIENNE, 1948, REV SUISSE ZOOL, V55, P218	37	409	425	0	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					811	816		10.1126/science.1203983	http://dx.doi.org/10.1126/science.1203983			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566185	Green Accepted, Green Published			2022-12-28	WOS:000290529900038
J	Vikram, HR; Dhaliwal, G; Saint, S; Simpson, CB				Vikram, Holenarasipur R.; Dhaliwal, Gurpreet; Saint, Sanjay; Simpson, C. Blake			A Recurrent Problem	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY COCCIDIOIDOMYCOSIS; PARALYSIS		[Vikram, Holenarasipur R.] Mayo Clin, Div Infect Dis, Phoenix, AZ 85054 USA; [Dhaliwal, Gurpreet] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Dhaliwal, Gurpreet] San Francisco Vet Affairs VA Med Ctr, Dept Med, San Francisco, CA USA; [Saint, Sanjay] Univ Michigan, Ann Arbor VA Med Ctr, Ann Arbor, MI 48109 USA; [Saint, Sanjay] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Simpson, C. Blake] Univ Texas Hlth Sci Ctr San Antonio, Dept Otolaryngol Head & Neck Surg, San Antonio, TX 78229 USA	Mayo Clinic; Mayo Clinic Phoenix; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Texas System; University of Texas Health San Antonio	Vikram, HR (corresponding author), Mayo Clin, Div Infect Dis, 5777 E Mayo Blvd, Phoenix, AZ 85054 USA.	vikram.HR@mayo.edu	Saint, Sanjay/AAF-5126-2019					Bando H, 2006, WORLD J SURG, V30, P293, DOI 10.1007/s00268-005-7959-x; BATRA P, 1992, J THORAC IMAG, V7, P29, DOI 10.1097/00005382-199209000-00006; Blair JE, 2006, MYCOPATHOLOGIA, V162, P317, DOI 10.1007/s11046-006-0062-5; Capone D, 2008, BRIT J RADIOL, V81, P721, DOI 10.1259/bjr/12054884; Feierabend RH, 2009, AM FAM PHYSICIAN, V80, P363; Galgiani JN, 2005, CLIN INFECT DIS, V41, P1217, DOI 10.1086/496991; GALGIANI JN, 1993, WESTERN J MED, V159, P153; Gould MK, 2007, CHEST, V132, p108S, DOI 10.1378/chest.07-1353; Jaroszewski DE, 2009, ANN THORAC SURG, V88, P1765, DOI 10.1016/j.athoracsur.2009.07.075; Myssiorek D, 2004, OTOLARYNG CLIN N AM, V37, P25, DOI 10.1016/S0030-6665(03)00172-5; Nguyen BD, 2006, CLIN NUCL MED, V31, P568, DOI 10.1097/01.rlu.0000233349.46383.06; Rafay MA, 2000, ANN THORAC SURG, V70, P2142, DOI 10.1016/S0003-4975(00)01193-0; Rubin AD, 2007, OTOLARYNG CLIN N AM, V40, P1109, DOI 10.1016/j.otc.2007.05.012	13	1	1	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2148	2154		10.1056/NEJMcps1000691	http://dx.doi.org/10.1056/NEJMcps1000691			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AB	21631328				2022-12-28	WOS:000291200700015
J	Gelfand, MJ; Raver, JL; Nishii, L; Leslie, LM; Lun, J; Lim, BC; Duan, LL; Almaliach, A; Ang, S; Arnadottir, J; Aycan, Z; Boehnke, K; Boski, P; Cabecinhas, R; Chan, D; Chhokar, J; D'Amato, A; Ferrer, M; Fischlmayr, IC; Fischer, R; Fulop, M; Georgas, J; Kashima, ES; Kashima, Y; Kim, K; Lempereur, A; Marquez, P; Othman, R; Overlaet, B; Panagiotopoulou, P; Peltzer, K; Perez-Florizno, LR; Ponomarenko, L; Realo, A; Schei, V; Schmitt, M; Smith, PB; Soomro, N; Szabo, E; Taveesin, N; Toyama, M; Van de Vliert, E; Vohra, N; Ward, C; Yamaguchi, S				Gelfand, Michele J.; Raver, Jana L.; Nishii, Lisa; Leslie, Lisa M.; Lun, Janetta; Lim, Beng Chong; Duan, Lili; Almaliach, Assaf; Ang, Soon; Arnadottir, Jakobina; Aycan, Zeynep; Boehnke, Klaus; Boski, Pawel; Cabecinhas, Rosa; Chan, Darius; Chhokar, Jagdeep; D'Amato, Alessia; Ferrer, Montse; Fischlmayr, Iris C.; Fischer, Ronald; Fueloep, Marta; Georgas, James; Kashima, Emiko S.; Kashima, Yoshishima; Kim, Kibum; Lempereur, Alain; Marquez, Patricia; Othman, Rozhan; Overlaet, Bert; Panagiotopoulou, Penny; Peltzer, Karl; Perez-Florizno, Lorena R.; Ponomarenko, Larisa; Realo, Anu; Schei, Vidar; Schmitt, Manfred; Smith, Peter B.; Soomro, Nazar; Szabo, Erna; Taveesin, Nalinee; Toyama, Midori; Van de Vliert, Evert; Vohra, Naharika; Ward, Colleen; Yamaguchi, Susumu			Differences Between Tight and Loose Cultures: A 33-Nation Study	SCIENCE			English	Article							SELF; BEHAVIOR	With data from 33 nations, we illustrate the differences between cultures that are tight (have many strong norms and a low tolerance of deviant behavior) versus loose (have weak social norms and a high tolerance of deviant behavior). Tightness-looseness is part of a complex, loosely integrated multilevel system that comprises distal ecological and historical threats (e. g., high population density, resource scarcity, a history of territorial conflict, and disease and environmental threats), broad versus narrow socialization in societal institutions (e. g., autocracy, media regulations), the strength of everyday recurring situations, and micro-level psychological affordances (e. g., prevention self-guides, high regulatory strength, need for structure). This research advances knowledge that can foster cross-cultural understanding in a world of increasing global interdependence and has implications for modeling cultural change.	[Gelfand, Michele J.; Lun, Janetta] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA; [Raver, Jana L.] Queens Sch Business, Kingston, ON K7L 3N6, Canada; [Nishii, Lisa] Cornell Univ, Ind Labor Relat Sch, Ithaca, NY 14853 USA; [Leslie, Lisa M.] Univ Minnesota, Carlson Sch Management, Minneapolis, MN 55455 USA; [Lim, Beng Chong] Minist Def, Singapore, Singapore; [Lim, Beng Chong] Nanyang Technol Univ, Nanyang Business Sch, Singapore, Singapore; [Duan, Lili] McKinsey & Co Inc, Washington, DC 20036 USA; [Almaliach, Assaf] BIP Inst Psychol Ltd, IL-51260 Bney Brak, Israel; [Ang, Soon] Nanyang Technol Univ, Singapore 639798, Singapore; [Aycan, Zeynep] Koc Univ, Dept Psychol, TR-34450 Sariyer, Turkey; [Boehnke, Klaus] Jacobs Univ Bremen, Bremen Int Grad Sch Social Sci, D-28759 Bremen, Germany; [Boski, Pawel] Warsaw Sch Social Sci & Humanities, PL-03815 Warsaw, Poland; [Cabecinhas, Rosa] Univ Minho, P-4710057 Braga, Portugal; [Chan, Darius] Chinese Univ Hong Kong, Dept Psychol, Shatin, Hong Kong, Peoples R China; [Chhokar, Jagdeep] Indian Inst Management, Ahmadabad 380015, Gujarat, India; [D'Amato, Alessia] Pontificia Univ Catolica Peru, CTR Catolica, Lima 33, Peru; [Ferrer, Montse] Univ Valencia, Social Psychol Dept, Valencia 46010, Spain; [Fischlmayr, Iris C.; Szabo, Erna] Johannes Kepler Univ Linz, Inst Int Management, A-4040 Linz, Austria; [Fischer, Ronald] Victoria Univ Wellington, Ctr Appl Cross Cultural Psychol, Sch Psychol, Wellington, New Zealand; [Fueloep, Marta] Hungarian Acad Sci, Inst Psychol, H-1132 Budapest, Hungary; [Georgas, James] Univ Athens, Athens 10674, Greece; [Kashima, Emiko S.] La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3086, Australia; [Kashima, Yoshishima] Psychol Sci Univ Melbourne, Melbourne, Vic 3010, Australia; [Kim, Kibum] Sungkyunkwan Univ, Sch Social Sci, Seoul 110745, South Korea; [Lempereur, Alain] ESSEC Business Sch, F-95021 Cergy Pontoise, France; [Marquez, Patricia] Univ San Diego, San Diego, CA 92131 USA; [Overlaet, Bert] Katholieke Univ Leuven, B-3000 Louvain, Belgium; [Panagiotopoulou, Penny] Univ Patras, Patras 26500, Greece; [Peltzer, Karl] Human Sci Res Council, ZA-0001 Pretoria, South Africa; [Perez-Florizno, Lorena R.] Invest Colegio Fontera Norte, Tijuana 22560, Baja California, Mexico; [Ponomarenko, Larisa] Odessa Natl Univ, Dept Psychol, UA-67027 Odessa, Ukraine; [Realo, Anu] Univ Tartu, Dept Psychol, EE-50410 Tartu, Estonia; [Schei, Vidar] Norwegian Sch Econ & Business Adm, Dept Strategy & Management, N-5045 Bergen, Norway; [Schmitt, Manfred] Univ Koblenz Landau, D-76829 Landau, Germany; [Smith, Peter B.] Univ Sussex, Dept Psychol, Brighton BN1 9QH, E Sussex, England; [Soomro, Nazar] Univ Sindh, Dept Psychol Testing Guidance & Res, Hyderabad 71000, Pakistan; [Toyama, Midori] Gakushuin Univ, Dept Psychol, Toshima Ku, Tokyo 1718588, Japan; [Van de Vliert, Evert] Univ Groningen, NL-9712 TS Groningen, Netherlands; [Vohra, Naharika] Indian Inst Management, Ahmadabad 380015, Gujarat, India; [Ward, Colleen] Victoria Univ Wellington, Sch Psychol, Wellington 6140, New Zealand; Univ Tokyo, Grad Sch Humanities & Sociol, Dept Social Psychol, Bunkyo Ku, Tokyo 1130033, Japan	University System of Maryland; University of Maryland College Park; Cornell University; University of Minnesota System; University of Minnesota Twin Cities; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Koc University; Jacobs University; SWPS University of Social Sciences & Humanities; Universidade do Minho; Chinese University of Hong Kong; Indian Institute of Management (IIM System); Indian Institute of Management Ahmedabad; Pontificia Universidad Catolica del Peru; University of Valencia; Johannes Kepler University Linz; Victoria University Wellington; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; National & Kapodistrian University of Athens; La Trobe University; Sungkyunkwan University (SKKU); ESSEC Business School; University of San Diego; KU Leuven; University of Patras; Human Sciences Research Council-South Africa; Ministry of Education & Science of Ukraine; Odesa I. I. Mechnikov National University; University of Tartu; Norwegian School of Economics (NHH); University of Koblenz & Landau; University of Sussex; University of Sindh; Gakushuin University; University of Groningen; Indian Institute of Management (IIM System); Indian Institute of Management Ahmedabad; Victoria University Wellington; University of Tokyo	Gelfand, MJ (corresponding author), Univ Maryland, Dept Psychol, College Pk, MD 20742 USA.		Boehnke, Klaus/D-1980-2013; Fischer, Ronald/G-6447-2017; Fulop, Marta/AAB-7446-2019; Peltzer, Karl/D-1518-2019; Cabecinhas, Rosa/W-4198-2017; Lim, Beng-Chong/AAH-7116-2021; Fülöp, Márta/B-3699-2013; Kashima, Emiko/G-2976-2011; Aycan, Zeynep/Y-8845-2018; Peltzer, Karl/Q-7334-2019; Realo, Anu/M-9524-2016	Boehnke, Klaus/0000-0002-5435-4037; Fischer, Ronald/0000-0002-3055-3955; Peltzer, Karl/0000-0002-5980-0876; Cabecinhas, Rosa/0000-0002-1491-3420; Lim, Beng-Chong/0000-0002-1055-1653; Fülöp, Márta/0000-0003-0348-7806; Aycan, Zeynep/0000-0003-4784-334X; Peltzer, Karl/0000-0002-5980-0876; Lun, Janetta/0000-0002-0255-0423; Chan, Darius/0000-0002-2959-8064; Raver, Jana/0000-0002-5855-7181; PEREZ-FLORIANO, LORENA R./0000-0001-6898-7794; Van de Vliert, Evert/0000-0003-3322-7829; Kashima, Yoshihisa/0000-0003-3627-3273; Ward, Colleen/0000-0003-4010-8932	NSF [9910760]; U.S. Army Research Lab and Research Office [W911NF-08-1-0144]; Turkish Academy of Sciences; Polish Academy of Sciences; Australian Research Council; Estonian Ministry of Science	NSF(National Science Foundation (NSF)); U.S. Army Research Lab and Research Office; Turkish Academy of Sciences(Turkish Academy of Sciences); Polish Academy of Sciences; Australian Research Council(Australian Research Council); Estonian Ministry of Science	Supported by NSF grant 9910760 and U.S. Army Research Lab and Research Office grant W911NF-08-1-0144 (M.J.G.), Turkish Academy of Sciences (Z.A.), Polish Academy of Sciences (P. B.), Australian Research Council (Y.K.), and Estonian Ministry of Science (A. R.). We thank C. B. Bruss and R. Mohr for their help in preparing this manuscript.	ARNETT JJ, 1995, J MARRIAGE FAM, V57, P617, DOI 10.2307/353917; BARRY H, 1959, AM ANTHROPOL, V61, P51; Baumeister RF, 1996, PSYCHOL INQ, V7, P1, DOI 10.1207/s15327965pli0701_1; Berry J. W., 1979, ADV EXP SOC PSYCHOL, V12, P177, DOI DOI 10.1016/S0065-2601(08)60262-2; BOLDT ED, 1978, CAN J SOCIOL, V3, P349, DOI 10.2307/3340310; Cohen D, 2001, PSYCHOL BULL, V127, P451, DOI 10.1037//0033-2909.127.4.451; Erving Goffman, 1963, BEHAV PUBLIC PLACES; Fiske A. P., 1998, HDB SOCIAL PSYCHOL, V2, P915; Herodotus Robin, 1998, HISTORIES; HIGGINS ET, 1987, PSYCHOL REV, V94, P319, DOI 10.1037/0033-295X.94.3.319; Kitayama S, 1997, J PERS SOC PSYCHOL, V72, P1245, DOI 10.1037/0022-3514.72.6.1245; Kitayama S, 2002, PSYCHOL BULL, V128, P89, DOI 10.1037/0033-2909.128.1.89; MISCHEL W, 1977, PERSONALITY CROSSROA; NEUBERG SL, 1993, J PERS SOC PSYCHOL, V65, P113, DOI 10.1037/0022-3514.65.1.113; Norenzayan A, 2008, SCIENCE, V322, P58, DOI 10.1126/science.1158757; Ostroff C, 2002, J APPL PSYCHOL, V87, P355, DOI 10.1037//0021-9010.87.2.355; PELTO PJ, 1968, TRANS-ACT-SOC SCI MO, V5, P37; PRICE RH, 1974, J PERS SOC PSYCHOL, V30, P579, DOI 10.1037/h0037037; SNYDER M, 1974, J PERS SOC PSYCHOL, V30, P526, DOI 10.1037/h0037039; Triandis H. C., 1972, ANAL SUBJECTIVE CULT	20	1247	1268	37	509	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2011	332	6033					1100	1104		10.1126/science.1197754	http://dx.doi.org/10.1126/science.1197754			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617077	Green Submitted			2022-12-28	WOS:000290996700049
J	Luo, WB; Hu, HX; Chang, R; Zhong, J; Knabel, M; O'Meally, R; Cole, RN; Pandey, A; Semenza, GL				Luo, Weibo; Hu, Hongxia; Chang, Ryan; Zhong, Jun; Knabel, Matthew; O'Meally, Robert; Cole, Robert N.; Pandey, Akhilesh; Semenza, Gregg L.			Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1	CELL			English	Article							TUMOR-GROWTH; CANCER-THERAPY; OXYGEN SENSOR; HIF; HYDROXYLATION; GENE; TRANSACTIVATION; HIF-1-ALPHA; METABOLISM; TENSION	The pyruvate kinase isoforms PKM1 and PKM2 are alternatively spliced products of the PKM2 gene. PKM2, but not PKM1, alters glucose metabolism in cancer cells and contributes to tumorigenesis by mechanisms that are not explained by its known biochemical activity. We show that PKM2 gene transcription is activated by hypoxia-inducible factor 1 (HIF-1). PKM2 interacts directly with the HIF-1 alpha subunit and promotes transactivation of HIF-1 target genes by enhancing HIF-1 binding and p300 recruitment to hypoxia response elements, whereas PKM1 fails to regulate HIF-1 activity. Interaction of PKM2 with prolyl hydroxylase 3 (PHD3) enhances PKM2 binding to HIF-1 alpha and PKM2 coactivator function. Mass spectrometry and anti-hydroxyproline antibody assays demonstrate PKM2 hydroxylation on proline-403/408. PHD3 knockdown inhibits PKM2 coactivator function, reduces glucose uptake and lactate production, and increases O(2) consumption in cancer cells. Thus, PKM2 participates in a positive feedback loop that promotes HIF-1 transactivation and reprograms glucose metabolism in cancer cells.	[Luo, Weibo; Hu, Hongxia; Chang, Ryan; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn, Baltimore, MD 21205 USA; [Luo, Weibo; Hu, Hongxia; Knabel, Matthew; Pandey, Akhilesh; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; [Zhong, Jun; O'Meally, Robert; Cole, Robert N.; Pandey, Akhilesh; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Pandey, Akhilesh; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Pandey, Akhilesh] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu	Pandey, Akhilesh/B-4127-2009; Hu, Hongxia/Q-7765-2016; Zhong, Jun/D-1662-2010	Pandey, Akhilesh/0000-0001-9943-6127; Zhong, Jun/0000-0003-3148-4143; Luo, Weibo/0000-0002-1992-0320	NHLBI [N01-HV28180, HHS-N268201000032C]; Japan Science and Technology Agency; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028180] Funding Source: NIH RePORTER	NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Karen Padgett (Novus Biologicals) for providing antibodies against HIF-1 beta, HIF-2 alpha, PKM2, PHD2, PHD3, GLUT1, PDK1, LDHA, histone H3, p300, and rabbit IgG; Vickram Srinivas (Thomas Jefferson University) for FLAG-PHD1 vector; Frank S. Lee (University of Pennsylvania) for FLAG-PHD2 vector; Ted Dawson (The Johns Hopkins University) for shNT vector; and Kevin Bittman (Seahorse Bioscience, Inc) for assistance with OCR assays. G. L. S. is the C. Michael Armstrong Professor at The Johns Hopkins University School of Medicine. This work was supported, in part, by contracts N01-HV28180 and HHS-N268201000032C from NHLBI and an International Cooperative Research Project award from the Japan Science and Technology Agency.	Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Dombrauckas JD, 2005, BIOCHEMISTRY-US, V44, P9417, DOI 10.1021/bi0474923; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Koditz J, 2007, BLOOD, V110, P3610, DOI 10.1182/blood-2007-06-094441; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Li DX, 2004, J BIOL CHEM, V279, P55051, DOI 10.1074/jbc.M410287200; Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577; Melillo G, 2007, CANCER METAST REV, V26, P341, DOI 10.1007/s10555-007-9059-x; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wheaton WW, 2011, AM J PHYSIOL-CELL PH, V300, pC385, DOI 10.1152/ajpcell.00485.2010; Xie L, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000444; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105	28	936	982	10	178	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 27	2011	145	5					732	744		10.1016/j.cell.2011.03.054	http://dx.doi.org/10.1016/j.cell.2011.03.054			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620138	Bronze, Green Accepted			2022-12-28	WOS:000291018600013
J	Kropf, SP				Kropf, Simone Petraglia			The art of medicine Carlos Chagas: science, health, and national debate in Brazil	LANCET			English	Editorial Material									Fundacao Oswaldo Cruz, Dept Hist Sci & Hlth, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz	Kropf, SP (corresponding author), Fundacao Oswaldo Cruz, Dept Hist Sci & Hlth, Rio De Janeiro, Brazil.	simonek@coc.fiocruz.br						Kropf S.P., 2009, DOENCA CHAGAS DOENCA; Kropf SP, 2009, HIST CIENC SAUDE-MAN, V16, P13, DOI 10.1590/S0104-59702009000500002; KROPF SP, 2009, C CHAGAS SCI BRAZIL; LIMA NT, 2005, AVATARES MED AM LATI, P145	4	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	2011	377	9779					1740	1741		10.1016/S0140-6736(11)60721-6	http://dx.doi.org/10.1016/S0140-6736(11)60721-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771AS	21608153				2022-12-28	WOS:000291130200017
J	Morris, K				Morris, Kelly			Sonia Fleury-promoting social inclusion for better health in Brazil Profile	LANCET			English	Biographical-Item																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	2011	377	9779					1739	1739		10.1016/S0140-6736(11)60720-4	http://dx.doi.org/10.1016/S0140-6736(11)60720-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771AS	21601697				2022-12-28	WOS:000291130200016
J	Su, ZX; Huang, W; Gu, X				Su, Zhixi; Huang, Wei; Gu, Xun			Comment on "Positive Selection of Tyrosine Loss in Metazoan Evolution"	SCIENCE			English	Editorial Material							MONOSIGA-BREVICOLLIS; GENOME; PRESSURE; NETWORK; ORIGIN		[Su, Zhixi; Huang, Wei; Gu, Xun] Fudan Univ, MOE Key Lab Contemporary Anthropol, Sch Life Sci, Inst Biomed Sci, Shanghai 200433, Peoples R China; [Su, Zhixi; Huang, Wei; Gu, Xun] Fudan Univ, Ctr Evolutionary Biol, Sch Life Sci, Inst Biomed Sci, Shanghai 200433, Peoples R China; [Gu, Xun] Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50011 USA	Fudan University; Fudan University; Iowa State University	Gu, X (corresponding author), Fudan Univ, MOE Key Lab Contemporary Anthropol, Sch Life Sci, Inst Biomed Sci, Shanghai 200433, Peoples R China.	xgu@iastate.edu	Su, Zhixi/B-6487-2012					BERNARDI G, 1986, J MOL EVOL, V24, P1, DOI 10.1007/BF02099946; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; Costantini M, 2008, GENE, V410, P241, DOI 10.1016/j.gene.2007.12.016; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Gu X, 1998, GENETICA, V102-3, P383, DOI 10.1023/A:1017028102013; Gu X, 2009, J EXP ZOOL PART B, V312B, P75, DOI 10.1002/jez.b.21249; Hedges SB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-2; King N, 2008, NATURE, V451, P783, DOI 10.1038/nature06617; Lynch M, 2007, P NATL ACAD SCI USA, V104, P8597, DOI 10.1073/pnas.0702207104; Manning G, 2008, P NATL ACAD SCI USA, V105, P9674, DOI 10.1073/pnas.0801314105; SUEOKA N, 1988, P NATL ACAD SCI USA, V85, P2653, DOI 10.1073/pnas.85.8.2653; Tan CSH, 2009, SCIENCE, V325, P1686, DOI 10.1126/science.1174301	13	9	9	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2011	332	6032					917	917		10.1126/science.1187374	http://dx.doi.org/10.1126/science.1187374			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596977				2022-12-28	WOS:000290766600024
J	Queiroz, AB; de Miranda, JS				Queiroz, Andre Brito; de Miranda, Jocielle Santos			Hydropic Gallbladder	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Queiroz, Andre Brito; de Miranda, Jocielle Santos] Univ Sao Paulo, Hosp Clin, Sao Paulo, Brazil	Universidade de Sao Paulo	Queiroz, AB (corresponding author), Univ Sao Paulo, Hosp Clin, Sao Paulo, Brazil.		Miranda, Jocielle/B-4338-2013	Miranda, Jocielle/0000-0001-5837-3975					0	1	1	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					E43	E43		10.1056/NEJMicm1000943	http://dx.doi.org/10.1056/NEJMicm1000943			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765PJ	21591940				2022-12-28	WOS:000290720700012
J	Carpenter, D; Joffe, S				Carpenter, Daniel; Joffe, Steven			A Unique Researcher Identifier for the Physician Payments Sunshine Act	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Carpenter, Daniel] Harvard Univ, Dept Govt, Cambridge, MA 02138 USA; [Joffe, Steven] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Harvard University; Dana-Farber Cancer Institute	Carpenter, D (corresponding author), Harvard Univ, Dept Govt, 1737 Cambridge St, Cambridge, MA 02138 USA.	dcarpenter@gov.harvard.edu	Joffe, Steven/H-3941-2019	Joffe, Steven/0000-0002-0667-7384	NCRR NIH HHS [UL1 RR025758, 1UL1RR025758-01, UL1 RR025758-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 2009, NATURE, V462, P825; Bohne-Lang Andreas, 2005, Biomed Digit Libr, V2, P1, DOI 10.1186/1742-5581-2-1; Cals JWL, 2008, LANCET, V371, P2152, DOI 10.1016/S0140-6736(08)60931-9; Chimonas S, 2011, ARCH INTERN MED, V171, P81, DOI 10.1001/archinternmed.2010.341; Enserink M, 2009, SCIENCE, V323, P1662, DOI 10.1126/science.323.5922.1662; Friedberg EC, 2010, DNA REPAIR, V9, P102, DOI 10.1016/j.dnarep.2009.12.005; US Institute of Medicine, 2009, CONFL INT MED RES ED; 2009, FED REG, V74, P21610	8	12	12	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2011	305	19					2007	2008		10.1001/jama.2011.651	http://dx.doi.org/10.1001/jama.2011.651			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764WO	21586717	Green Accepted, Green Published			2022-12-28	WOS:000290665500026
J	Hsia, RY; Kellermann, AL; Shen, YC				Hsia, Renee Y.; Kellermann, Arthur L.; Shen, Yu-Chu			Factors Associated With Closures of Emergency Departments in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SAFETY-NET HOSPITALS; HEALTH-CARE; INTENSIVE-CARE; FOR-PROFIT; COMPETITION; RELOCATIONS; SURVIVAL; OUTCOMES; ACCESS; CRISIS	Context Between 1998 and 2008, the number of hospital-based emergency departments (EDs) in the United States declined, while the number of ED visits increased, particularly visits by patients who were publicly insured and uninsured. Little is known about the hospital, community, and market factors associated with ED closures. Federal law requiring EDs to treat all in need regardless of a patient's ability to pay may make EDs more vulnerable to the market forces that govern US health care. Objective To determine hospital, community, and market factors associated with ED closures. Design Emergency department and hospital organizational information from 1990 through 2009 was acquired from the American Hospital Association (AHA) Annual Surveys (annual response rates ranging from 84%-92%) and merged with hospital financial and payer mix information available through 2007 from Medicare hospital cost reports. We evaluated 3 sets of risk factors: hospital characteristics (safety net [as defined by hospitals caring for more than double their Medicaid share of discharges compared with other hospitals within a 15-mile radius], ownership, teaching status, system membership, ED size, case mix), county population demographics (race, poverty, uninsurance, elderly), and market factors (ownership mix, profit margin, location in a competitive market, presence of other EDs). Setting All general, acute, nonrural, short-stay hospitals in the United States with an operating ED anytime from 1990-2009. Main Outcome Measure Closure of an ED during the study period. Results From 1990 to 2009, the number of hospitals with EDs in nonrural areas declined from 2446 to 1779, with 1041 EDs closing and 374 hospitals opening EDs. Based on analysis of 2814 urban acute-care hospitals, constituting 36 335 hospital-year observations over an 18-year study interval (1990-2007), for-profit hospitals and those with low profit margins were more likely to close than their counterparts (cumulative hazard rate based on bivariate model, 26% vs16%; hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.5-2.1, and 36% vs 18%; HR, 1.9; 95% CI, 1.6-2.3, respectively). Hospitals in more competitive markets had a significantly higher risk of closing their EDs (34% vs 17%; HR, 1.3; 95% CI, 1.1-1.6), as did safety-net hospitals(10% vs6%; HR, 1.4; 95% CI, 1.1-1.7) and those serving a higher share of populations in poverty (37% vs 31%; HR, 1.4; 95% CI, 1.1-1.7). Conclusion From 1990 to 2009, the number of hospital EDs in nonrural areas declined by 27%, with for-profit ownership, location in a competitive market, safety-net status, and low profit margin associated with increased risk of ED closure. JAMA. 2011; 305(19): 1978-1985	[Hsia, Renee Y.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA; [Kellermann, Arthur L.] RAND Hlth, Hlth Res Div, Washington, DC USA; [Shen, Yu-Chu] USN, Grad Sch Business & Publ Policy, Postgrad Sch, Monterey, CA USA; [Shen, Yu-Chu] Natl Bur Econ Res, Cambridge, MA 02138 USA	University of California System; University of California San Francisco; RAND Corporation; United States Department of Defense; United States Navy; Naval Postgraduate School; National Bureau of Economic Research	Hsia, RY (corresponding author), San Francisco Gen Hosp, 1001 Potrero Ave,1E21, San Francisco, CA 94110 USA.	renee.hsia@ucsf.edu			NIH/NCRR/OD UCSF-CTSI [KL2 RR024130]; Robert Wood Johnson Foundation; Robert Wood Johnson Foundation Changes in Health Care Financing and Organization initiative [63974]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000143] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024130] Funding Source: NIH RePORTER	NIH/NCRR/OD UCSF-CTSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Robert Wood Johnson Foundation Changes in Health Care Financing and Organization initiative; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This publication was supported by NIH/NCRR/OD UCSF-CTSI grant KL2 RR024130 (R.Y.H.), the Robert Wood Johnson Foundation Physician Faculty Scholars (R.Y.H.), and the Robert Wood Johnson Foundation Changes in Health Care Financing and Organization initiative (grant 63974) (Y.S.).	American Hospital Association, TRENDWATCH CHARTB 20; [Anonymous], COST REP OV; [Anonymous], 2010, NY TIMES        0406, pA23; [Anonymous], 2008, US TODAY        0530; [Anonymous], 1992, AHA ANN SURV DAT FIS; Asplin BR, 2001, ANN EMERG MED, V37, P500, DOI 10.1067/mem.2001.115174; Baker LC, 2002, RAND J ECON, V33, P524, DOI 10.2307/3087471; Baxter RJ, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.4.7; Bazzoll GJ, 2005, HEALTH AFFAIR, V24, P1047, DOI 10.1377/hlthaff.24.4.1047; Bernstein SL, 2009, ACAD EMERG MED, V16, P1, DOI 10.1111/j.1553-2712.2008.00295.x; Burt Catharine W, 2004, Vital Health Stat 13, P1; Carr BG, 2007, J TRAUMA, V63, P9, DOI 10.1097/TA.0b013e31805d8f6b; Centers for Medicare and Medicaid Services, HIST IMP FIL FY 1994; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Chang DC, 2011, J AM COLL SURGEONS, V212, P12, DOI 10.1016/j.jamcollsurg.2010.09.014; DeNavas-Walt Carmen, 2010, US CENSUS BUREAU CUR, VP60-238; GARNICK DW, 1987, HEALTH SERV RES, V22, P69; Gaskin DJ, 2001, HEALTH SERV RES, V36, P25; Gautam K, 1996, Health Serv Manage Res, V9, P156; Gresenz CR, 2004, HEALTH SERV RES, V39, P417, DOI 10.1111/j.1475-6773.2004.00235.x; Hadley J, 2004, HEALTH SERV RES, V39, P1527, DOI 10.1111/j.1475-6773.2004.00302.x; Horwitz JR, 2009, J HEALTH ECON, V28, P924, DOI 10.1016/j.jhealeco.2009.06.008; Horwitz JR, 2005, HEALTH AFFAIR, V24, P790, DOI 10.1377/hlthaff.24.3.790; Institute of Medicine, HOSP BAS EM CAR BREA; Institute of Medicine, 2000, AM HLTH CAR SAF NET; Institute of Medicine (US) Committee on the Consequences of Uninsurance, 2003, SHAR DEST COMM EFF U; Johnson LA, 2001, ANN EMERG MED, V37, P495, DOI 10.1067/mem.2001.115173; Lutfiyya MN, 2007, INT J QUAL HEALTH C, V19, P141, DOI 10.1093/intqhc/mzm010; Malone R E, 2000, J Emerg Nurs, V26, P380, DOI 10.1067/men.2000.108629; McConnell KJ, 2007, ANN EMERG MED, V49, P727, DOI 10.1016/j.annemergmed.2006.10.017; Miro O, 1999, Eur J Emerg Med, V6, P105; Mullner R, 2002, J CONSUM MARK, V19, P614, DOI 10.1108/07363760210451438; Nichols LM, 2004, HEALTH AFFAIR, V23, P8, DOI 10.1377/hlthaff.23.2.8; Pines JM, 2009, ACAD EMERG MED, V16, P617, DOI 10.1111/j.1553-2712.2009.00456.x; Pitts SR, 2010, HEALTH AFFAIR, V29, P1620, DOI 10.1377/hlthaff.2009.1026; Pitts Stephen R, 2008, Natl Health Stat Report, P1; Porter ME, 2007, JAMA-J AM MED ASSOC, V297, P1103, DOI 10.1001/jama.297.10.1103; Pottenger BC, 2008, ANN EMERG MED, V52, P677, DOI 10.1016/j.annemergmed.2008.06.004; PRENTICE RL, 1978, BIOMETRICS, V34, P57, DOI 10.2307/2529588; RICE MF, 1987, SOC SCI MED, V24, P889, DOI 10.1016/0277-9536(87)90282-6; ROBINSON JC, 1988, JAMA-J AM MED ASSOC, V260, P2676, DOI 10.1001/jama.260.18.2676; ROSE MG, 1983, HEALTH SERV RES, V18, P551; Saha S, 2006, J GEN INTERN MED, V21, P1211, DOI 10.1111/j.1525-1497.2006.00618.x; Shen YC, 2009, MED CARE, V47, P968, DOI 10.1097/MLR.0b013e31819c9415; Shen YC, 2009, HEALTH ECON, V18, P305, DOI 10.1002/hec.1366; Singer J.D., 2003, APPL LONGITUDINAL DA; Slifkin RT, 2000, J HEALTH CARE POOR U, V11, P231; Succi MJ, 1997, HEALTH SERV RES, V31, P679; Sun BC, 2006, ANN EMERG MED, V47, P309, DOI 10.1016/j.annemergmed.2005.12.003; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112; US Dept of Health and Human Services. Health Resource and Services Administration (HRSA). National Center for Health Workforce Analysis, AR RES FIL; Weber T, 2004, LOS ANGELES TIM 1205, pA1; Zuckerman S, 2001, HEALTH AFFAIR, V20, P159, DOI 10.1377/hlthaff.20.4.159	53	147	149	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2011	305	19					1978	1985		10.1001/jama.2011.620	http://dx.doi.org/10.1001/jama.2011.620			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	764WO	21586713	Green Accepted, Bronze			2022-12-28	WOS:000290665500021
J	Weaver, AJ				Weaver, Andrew J.			Toward the Second Commitment Period of the Kyoto Protocol	SCIENCE			English	Editorial Material							CLIMATE; EMISSIONS; TARGETS		Univ Victoria, Sch Earth & Ocean Sci, Victoria, BC V8W 3V6, Canada	University of Victoria	Weaver, AJ (corresponding author), Univ Victoria, Sch Earth & Ocean Sci, Victoria, BC V8W 3V6, Canada.	weaver@uvic.ca	Weaver, Andrew J/E-7590-2011	Weaver, Andrew J/0000-0001-8919-3598				Davis SJ, 2010, SCIENCE, V329, P1330, DOI 10.1126/science.1188566; Forster P, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P129; Hansen J, 2004, P NATL ACAD SCI USA, V101, P16109, DOI 10.1073/pnas.0406982101; Jackson SC, 2009, SCIENCE, V326, P526, DOI 10.1126/science.1177042; Meinshausen M, 2009, NATURE, V458, P1158, DOI 10.1038/nature08017; Monni S., 2006, VTT PUBLICATIONS, V603; Ramanathan V, 2008, NAT GEOSCI, V1, P221, DOI 10.1038/ngeo156; Reddy MS, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028904; SCHIMEL D, 1996, CLIMATE CHANGE 1995, P407; Shindell DT, 2009, SCIENCE, V326, P716, DOI 10.1126/science.1174760; UNEP, 2011, INT ASS BLACK CARB T; Weaver Andrew, 2008, KEEPING OUR COOL CAN; Zickfeld K, 2009, P NATL ACAD SCI USA, V106, P16129, DOI 10.1073/pnas.0805800106; REPRESENTATIVE CONCE	14	12	12	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2011	332	6031					795	796		10.1126/science.1202087	http://dx.doi.org/10.1126/science.1202087			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	763CD	21566178				2022-12-28	WOS:000290529900030
J	Chad, DA; Stone, JH; Gupta, R				Chad, David A.; Stone, John H.; Gupta, Rajiv			Case 14-2011: A Woman with Asymmetric Sensory Loss and Paresthesias	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DORSAL-ROOT GANGLIONITIS; PARANEOPLASTIC SYNDROMES; SJOGRENS-SYNDROME; NEUROPATHY; NEURONOPATHY; PYRIDOXINE		[Chad, David A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Stone, John H.] Massachusetts Gen Hosp, Dept Rheumatol, Boston, MA 02114 USA; [Gupta, Rajiv] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Chad, David A.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Stone, John H.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Gupta, Rajiv] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Chad, DA (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.							ASBURY AK, 1987, SEMIN NEUROL, V7, P58, DOI 10.1055/s-2008-1041406; BROWN MJ, 1987, SEMIN NEUROL, V7, P1, DOI 10.1055/s-2008-1041400; Camdessanche JP, 2009, BRAIN, V132, P1723, DOI 10.1093/brain/awp136; Chai J, 2005, NEUROLOGY, V65, P925, DOI 10.1212/01.wnl.0000176034.38198.f9; Chartrand-Lefebvre C, 1998, AM J ROENTGENOL, V170, P1513, DOI 10.2214/ajr.170.6.9609164; DALAKAS MC, 1986, ANN NEUROL, V19, P545, DOI 10.1002/ana.410190605; Dalmau J, 2008, LANCET NEUROL, V7, P327, DOI 10.1016/S1474-4422(08)70060-7; Darnell RB, 2006, SEMIN ONCOL, V33, P270, DOI 10.1053/j.seminoncol.2006.03.008; Defendenti C, 2011, AUTOIMMUN REV, V10, P150, DOI 10.1016/j.autrev.2010.09.005; GRIFFIN JW, 1990, ANN NEUROL, V27, P304, DOI 10.1002/ana.410270313; HORWICH MS, 1977, ANN NEUROL, V2, P7, DOI 10.1002/ana.410020103; KISSEL JT, 1992, NEUROL CLIN, V10, P761, DOI 10.1016/S0733-8619(18)30207-X; LEWIS RA, 1982, NEUROLOGY, V32, P958, DOI 10.1212/WNL.32.9.958; MALINOW K, 1986, ANN NEUROL, V20, P535, DOI 10.1002/ana.410200416; Molinuevo JL, 1998, ANN NEUROL, V44, P976, DOI 10.1002/ana.410440620; Mori K, 2005, BRAIN, V128, P2518, DOI 10.1093/brain/awh605; PARRY GJ, 1985, NEUROLOGY, V35, P1466, DOI 10.1212/WNL.35.10.1466; Rudnicki SA, 2000, MUSCLE NERVE, V23, P1800, DOI 10.1002/1097-4598(200012)23:12<1800::AID-MUS3>3.0.CO;2-X; SCHAUMBURG H, 1983, NEW ENGL J MED, V309, P445, DOI 10.1056/NEJM198308253090801; Schaumburg H. H., 1992, DISORDERS PERIPHERAL; STERMAN AB, 1980, ANN NEUROL, V7, P354, DOI 10.1002/ana.410070413; Titulaer MJ, 2011, EUR J NEUROL, V18, P19, DOI 10.1111/j.1468-1331.2010.03220.x; WINDEBANK AJ, 1990, NEUROLOGY, V40, P584, DOI 10.1212/WNL.40.4.584	23	2	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					1856	1865		10.1056/NEJMcpc1012550	http://dx.doi.org/10.1056/NEJMcpc1012550			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561352				2022-12-28	WOS:000290483000015
J	Ornetti, P; Vinit, J				Ornetti, Paul; Vinit, Julien			Sjogren's Syndrome and MALT Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ornetti, Paul; Vinit, Julien] Dijon Univ Hosp, Dijon, France	CHU Dijon Bourgogne	Ornetti, P (corresponding author), Dijon Univ Hosp, Dijon, France.								0	2	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					E41	E41		10.1056/NEJMicm1011193	http://dx.doi.org/10.1056/NEJMicm1011193			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561343				2022-12-28	WOS:000290483000014
J	Molyneux, E; Nizami, SQ; Saha, S; Huu, KT; Azam, M; Bhutta, ZA; Zaki, R; Weber, MW; Qazi, SA				Molyneux, Elizabeth; Nizami, Shaikh Qamaruddin; Saha, Samir; Huu, Khanh Truong; Azam, Matloob; Bhutta, Zulfiqar Ahmad; Zaki, Ramadan; Weber, Martin Willi; Qazi, Shamim Ahmad		CSF 5 Study Grp	5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study	LANCET			English	Article							INFLUENZAE TYPE-B; MENINGOCOCCAL MENINGITIS; STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; ANTIBIOTIC-THERAPY; DISEASE; BURDEN; CHLORAMPHENICOL; SURVEILLANCE; IMMUNIZATION	Background Bacterial meningitis is an important cause of morbidity and mortality in developing countries, but the duration of treatment is not well established. We aimed to compare the efficacy of 5 and 10 days of parenteral ceftriaxone for the treatment of bacterial meningitis in children. Methods We did a multicountry, double-blind, placebo-controlled, randomised equivalence study of 5 versus 10 days of treatment with ceftriaxone in children aged 2 months to 12 years with purulent meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae type B, or Neisseria meningitidis. Our study was done in ten paediatric referral hospitals in Bangladesh, Egypt, Malawi, Pakistan, and Vietnam. We randomly assigned children who were stable after 5 days of treatment, through site-balanced computer-generated allocation lists, to receive a further 5 days of ceftriaxone or placebo. Patients, their guardians, and staff were masked to study-group allocation. Our primary outcomes were bacteriological failure or relapse. Our analysis was per protocol. This study is registered with the International Standard Randomised Controlled Trial Number Register, number ISRCTN38717320. Findings We included 1004 of 1027 children randomly assigned to study groups in our analyses; 496 received treatment with ceftriaxone for 5 days, and 508 for 10 days. In the 5-day treatment group, two children (one infected with HIV) had a relapse; there were no relapses in the 10-day treatment group and there were no bacteriological failures in either study group. Side-effects of antibiotic treatment were minor and similar in both groups. Interpretation In children beyond the neonatal age-group with purulent meningitis caused by S pneumoniae, H influenzae type b, or N meningitidis who are stable by day 5 of ceftriaxone treatment, the antibiotic can be safely discontinued.	[Weber, Martin Willi; Qazi, Shamim Ahmad] WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland; [Molyneux, Elizabeth] Univ Malawi, Sch Med, Dept Paediat, Queen Elizabeth Cent Hosp, Blantyre, Malawi; [Nizami, Shaikh Qamaruddin; Bhutta, Zulfiqar Ahmad] Aga Khan Univ, Div Maternal & Child Hlth, Karachi, Pakistan; [Saha, Samir] Dhaka Shishu Hosp, Dept Microbiol, Dhaka, Bangladesh; [Huu, Khanh Truong] Children Hosp 1, Ho Chi Minh City, Vietnam; [Azam, Matloob] Wah Med Coll, Dept Paediat, Islamabad, Pakistan; [Zaki, Ramadan] Abbasia Fever Hosp, Dept Paediat, Cairo, Egypt	University of Geneva; World Health Organization; University of Malawi; Aga Khan University; Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt; Abbassia Fever Hospital	Qazi, SA (corresponding author), WHO, Dept Child & Adolescent Hlth & Dev, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	qazis@who.int	Weber, Martin/GPW-6095-2022; Asturias, Edwin/D-9842-2016	Asturias, Edwin/0000-0002-1275-0787	United States Agency for International Development	United States Agency for International Development(United States Agency for International Development (USAID))	Funding United States Agency for International Development.	AUVERGNAT JC, 1988, PATHOL BIOL, V36, P735; Daza P, 2006, VACCINE, V24, P6232, DOI 10.1016/j.vaccine.2006.05.076; Eisenhut M., 2002, AUDIOL MED, V11, P86; ELFILALI KM, 1993, EUR J CLIN MICROBIOL, V12, P766, DOI 10.1007/BF02098465; Feigin RD, 1992, TXB PEDIAT INFECT DI, P400; Forsyth H., 2004, AUDIOL MED, V2, P100; FORTNUM HM, 1992, ARCH DIS CHILD, V67, P1128, DOI 10.1136/adc.67.9.1128; GIRGIS NI, 1988, SCAND J INFECT DIS, V20, P613, DOI 10.3109/00365548809035661; Goetghebuer T, 2000, TROP MED INT HEALTH, V5, P207, DOI 10.1046/j.1365-3156.2000.00535.x; Goto H, 2009, J INFECT CHEMOTHER, V15, P347, DOI 10.1007/s10156-009-0719-3; Hussey G, 1997, S AFR MED J, V87, P51; JADAVJI T, 1986, PEDIATRICS, V78, P21; Karageorgopoulos DE, 2009, ARCH DIS CHILD, V94, P607, DOI 10.1136/adc.2008.151563; Kisakye A, 2009, CLIN INFECT DIS, V48, pS153, DOI 10.1086/596495; KLUGMAN KP, 1994, INT J ANTIMICROB AG, V4, P63, DOI 10.1016/0924-8579(94)90063-9; Kutz JW, 2006, ARCH OTOLARYNGOL, V132, P941, DOI 10.1001/archotol.132.9.941; Lambert HP, 1999, LANCET, V354, P943, DOI 10.1016/S0140-6736(99)01139-3; Lehmann D, 1999, ANN TROP PAEDIATR, V19, P21, DOI 10.1080/02724939992608; LIN TY, 1985, JAMA-J AM MED ASSOC, V253, P3559, DOI 10.1001/jama.253.24.3559; LUTSAR I, 1995, INFECTION, V23, P113, DOI 10.1007/BF01833878; MARTIN E, 1984, J PEDIATR-US, V105, P475, DOI 10.1016/S0022-3476(84)80032-3; MARTIN E, 1990, INFECTION, V18, P70, DOI 10.1007/BF01641418; Molyneux E, 1998, TROP MED INT HEALTH, V3, P610, DOI 10.1046/j.1365-3156.1998.00278.x; Mudhune S, 2009, CLIN INFECT DIS, V48, pS147, DOI 10.1086/596494; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nathan N, 2005, LANCET, V366, P308, DOI 10.1016/S0140-6736(05)66792-X; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; O'Neill E, 2006, J ANTIMICROB CHEMOTH, V57, P356, DOI 10.1093/jac/dki462; Palmer A, 1999, J TROP PEDIATRICS, V45, P51, DOI 10.1093/tropej/45.1.51; Peter G, 2000, REPORT COMMITTE INFE; Price EH, 2000, J ANTIMICROB CHEMOTH, V46, P653, DOI 10.1093/jac/46.5.653; Qazi SA, 1996, ARCH DIS CHILD, V75, P482, DOI 10.1136/adc.75.6.482; RADETSKY M, 1990, PEDIATR INFECT DIS J, V9, P2, DOI 10.1097/00006454-199001000-00002; Ramakrishnan M, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-47; Roine I, 2000, PEDIATR INFECT DIS J, V19, P219, DOI 10.1097/00006454-200003000-00009; Sholtz H, 1998, CHEMOTHERAPY, V44, P142; Simeonsson RJ, 2000, J CLIN EPIDEMIOL, V53, P113, DOI 10.1016/S0895-4356(99)00133-X; Singhi P, 2002, J TROP PEDIATRICS, V48, P273, DOI 10.1093/tropej/48.5.273; Squires J, 1997, J PEDIATR PSYCHOL, V22, P313, DOI 10.1093/jpepsy/22.3.313; Trunkel AR, 1993, CLIN MICROBIOL REV, V6, P118, DOI DOI 10.1128/CMR.6.2.118; Velasquez PAG, 2009, J PEDIAT-BRAZIL, V85, P516, DOI [10.2223/JPED.1949, 10.1590/S0021-75572009000600008]; VILADRICH PF, 1986, ARCH INTERN MED, V146, P2380, DOI 10.1001/archinte.146.12.2380; Visintin Cristina, 2010, BMJ, V340, pc3209, DOI 10.1136/bmj.c3209; Watt JP, 2009, LANCET, V374, P903, DOI 10.1016/S0140-6736(09)61203-4; WHO, 2006, BACT MED GUID STAND; WHO, 1998, ANT SUPP THER MEN CH; Wikler M. A., 2009, PERFORMANCE STANDARD; World Health Organization, 2006, WORLD HLTH STAT 2006	48	57	60	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2011	377	9780					1837	1845		10.1016/S0140-6736(11)60580-1	http://dx.doi.org/10.1016/S0140-6736(11)60580-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774UI	21620467				2022-12-28	WOS:000291411700029
J	Hauri, EH; Weinreich, T; Saal, AE; Rutherford, MC; Van Orman, JA				Hauri, Erik H.; Weinreich, Thomas; Saal, Alberto E.; Rutherford, Malcolm C.; Van Orman, James A.			High Pre-Eruptive Water Contents Preserved in Lunar Melt Inclusions	SCIENCE			English	Article							OCEAN-RIDGE BASALT; VOLATILE CONTENT; SNC METEORITES; GLASSES; MANTLE; MOON; DEHYDRATION; CONSTRAINTS; ABUNDANCES; ISOTOPES	The Moon has long been thought to be highly depleted in volatiles such as water, and indeed published direct measurements of water in lunar volcanic glasses have never exceeded 50 parts per million (ppm). Here, we report in situ measurements of water in lunar melt inclusions; these samples of primitive lunar magma, by virtue of being trapped within olivine crystals before volcanic eruption, did not experience posteruptive degassing. The lunar melt inclusions contain 615 to 1410 ppm water and high correlated amounts of fluorine (50 to 78 ppm), sulfur (612 to 877 ppm), and chlorine (1.5 to 3.0 ppm). These volatile contents are very similar to primitive terrestrial mid-ocean ridge basalts and indicate that some parts of the lunar interior contain as much water as Earth's upper mantle.	[Hauri, Erik H.] Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA; [Weinreich, Thomas; Saal, Alberto E.; Rutherford, Malcolm C.] Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; [Van Orman, James A.] Case Western Reserve Univ, Dept Geol Sci, Cleveland, OH 44106 USA	Carnegie Institution for Science; Brown University; Case Western Reserve University	Hauri, EH (corresponding author), Carnegie Inst Sci, Dept Terr Magnetism, 5241 Broad Branch Rd NW, Washington, DC 20015 USA.	ehauri@ciw.edu		Van Orman, James/0000-0001-8741-0288	Carnegie Institution of Washington; NASA; NASA Lunar Science Institute; NASA Astrobiology Institute	Carnegie Institution of Washington; NASA(National Aeronautics & Space Administration (NASA)); NASA Lunar Science Institute; NASA Astrobiology Institute	This work was supported by the Carnegie Institution of Washington, the NASA LASER and Cosmochemistry programs, the NASA Lunar Science Institute, and the NASA Astrobiology Institute. We thank J. Wang for NanoSIMS assistance, and L. Nittler and Z. Peeters for help with image processing software.	Albarede F, 2009, NATURE, V461, P1227, DOI 10.1038/nature08477; Bombardieri DJ, 2005, METEORIT PLANET SCI, V40, P679, DOI 10.1111/j.1945-5100.2005.tb00973.x; Boyce JW, 2010, NATURE, V466, P466, DOI 10.1038/nature09274; Canup RM, 2004, ANNU REV ASTRON ASTR, V42, P441, DOI 10.1146/annurev.astro.41.082201.113457; Crotts APS, 2008, ASTROPHYS J, V687, P692, DOI 10.1086/591634; DELANO JW, 1986, J GEOPHYS RES-SOLID, V91, pD201, DOI 10.1029/JB091iB04p0D201; Dixon JE, 2002, NATURE, V420, P385, DOI 10.1038/nature01215; Feldman WC, 2001, J GEOPHYS RES-PLANET, V106, P23231, DOI 10.1029/2000JE001444; Greenwood JP, 2011, NAT GEOSCI, V4, P79, DOI 10.1038/NGEO1050; Hauri E, 2002, CHEM GEOL, V183, P115, DOI 10.1016/S0009-2541(01)00374-6; JAMBON A, 1990, EARTH PLANET SC LETT, V101, P323, DOI 10.1016/0012-821X(90)90163-R; Kelley KA, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003732; KLEIN N, 1998, LUNAR PLANET SCI, V29, P1448; Lassiter JC, 2002, EARTH PLANET SC LETT, V202, P525, DOI 10.1016/S0012-821X(02)00826-9; McCubbin FM, 2010, P NATL ACAD SCI USA, V107, P11223, DOI 10.1073/pnas.1006677107; MCSWEEN HY, 1993, SCIENCE, V259, P1890, DOI 10.1126/science.259.5103.1890; MICHAEL P, 1995, EARTH PLANET SC LETT, V131, P301, DOI 10.1016/0012-821X(95)00023-6; Pahlevan K, 2007, EARTH PLANET SC LETT, V262, P438, DOI 10.1016/j.epsl.2007.07.055; ROEDDER E, 1972, EARTH PLANET SC LETT, V13, P272, DOI 10.1016/0012-821X(72)90103-3; Roedder E., 1970, P APOLLO 11 LUNAR SC, P801; Roedder E., 1971, P LUNAR PLANET SCI C, V2, P507; Saal AE, 2002, NATURE, V419, P451, DOI 10.1038/nature01073; Saal AE, 2008, NATURE, V454, P192, DOI 10.1038/nature07047; Sharp ZD, 2010, SCIENCE, V329, P1050, DOI 10.1126/science.1192606; Shaw AM, 2008, EARTH PLANET SC LETT, V275, P138, DOI 10.1016/j.epsl.2008.08.015; Shaw AM, 2010, EARTH PLANET SC LETT, V289, P311, DOI 10.1016/j.epsl.2009.11.018; Shimizu N, 1998, PHYS EARTH PLANET IN, V107, P183, DOI 10.1016/S0031-9201(97)00133-7; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; Weitz CM, 1999, METEORIT PLANET SCI, V34, P527, DOI 10.1111/j.1945-5100.1999.tb01361.x; [No title captured]	30	246	256	4	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 8	2011	333	6039					213	215		10.1126/science.1204626	http://dx.doi.org/10.1126/science.1204626			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	789GG	21617039				2022-12-28	WOS:000292502700047
J	Borgia, MB; Borgia, A; Best, RB; Steward, A; Nettels, D; Wunderlich, B; Schuler, B; Clarke, J				Borgia, Madeleine B.; Borgia, Alessandro; Best, Robert B.; Steward, Annette; Nettels, Daniel; Wunderlich, Bengt; Schuler, Benjamin; Clarke, Jane			Single-molecule fluorescence reveals sequence-specific misfolding in multidomain proteins	NATURE			English	Article							FOLDING MECHANISM; DOMAIN; AGGREGATION; ENERGY; TITIN; INTERMEDIATE; SPECTROSCOPY; COLLAPSE	A large range of debilitating medical conditions(1) is linked to protein misfolding, which may compete with productive folding particularly in proteins containing multiple domains(2). Seventy-five per cent of the eukaryotic proteome consists of multidomain proteins, yet it is not understood how interdomain misfolding is avoided. It has been proposed that maintaining low sequence identity between covalently linked domains is a mechanism to avoid misfolding(3). Here we use single-molecule Forster resonance energy transfer(4,5) to detect and quantify rare misfolding events in tandem immunoglobulin domains from the I band of titin under native conditions. About 5.5 per cent of molecules with identical domains misfold during refolding in vitro and form an unexpectedly stable state with an unfolding half-time of several days. Tandem arrays of immunoglobulin-like domains in humans show significantly lower sequence identity between neighbouring domains than between non-adjacent domains(3). In particular, the sequence identity of neighbouring domains has been found to be preferentially below 40 per cent(3). We observe no misfolding for a tandem of naturally neighbouring domains with low sequence identity (24 per cent), whereas misfolding occurs between domains that are 42 per cent identical. Coarse-grained molecular simulations predict the formation of domain-swapped structures that are in excellent agreement with the observed transfer efficiency of the misfolded species. We infer that the interactions underlying misfolding are very specific and result in a sequence-specific domain-swapping mechanism. Diversifying the sequence between neighbouring domains seems to be a successful evolutionary strategy to avoid misfolding in multidomain proteins.	[Borgia, Madeleine B.; Best, Robert B.; Steward, Annette; Clarke, Jane] Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England; [Borgia, Madeleine B.; Borgia, Alessandro; Nettels, Daniel; Wunderlich, Bengt; Schuler, Benjamin] Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Cambridge; University of Zurich	Clarke, J (corresponding author), Univ Cambridge, Chem Lab, Lensfield Rd, Cambridge CB2 1EW, England.	schuler@bioc.uzh.ch; jc162@cam.ac.uk	Schuler, Benjamin/E-7342-2011; Borgia, Alessandro/AAF-9203-2019; Best, Robert/H-7588-2016	Schuler, Benjamin/0000-0002-5970-4251; Borgia, Alessandro/0000-0002-4701-8967; Best, Robert/0000-0002-7893-3543	Wellcome Trust [064417]; Swiss National Science Foundation; Swiss National Center of Competence in Research in Structural Biology; UK Medical Research Council; Marie Curie Intra-European Fellowship; Royal Society; MRC [MC_U105485808] Funding Source: UKRI; Medical Research Council [MC_U105485808] Funding Source: researchfish	Wellcome Trust(Wellcome Trust); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss National Center of Competence in Research in Structural Biology(Swiss National Science Foundation (SNSF)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Marie Curie Intra-European Fellowship(European Commission); Royal Society(Royal Society of London); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Wellcome Trust (grant number, 064417), the Swiss National Science Foundation (to B. S.) and the Swiss National Center of Competence in Research in Structural Biology (to B. S.). M. B. B. was supported by a UK Medical Research Council studentship. A. B. is supported by a Marie Curie Intra-European Fellowship. R. B. B. is supported by a Royal Society University Research Fellowship. J.C. is a Wellcome Trust Senior Research Fellow. We thank H. Hofmann, A. Soranno and A. Hoffmann for discussions and contributions to data analysis.	Arora P, 2006, BIOCHEMISTRY-US, V45, P12312, DOI 10.1021/bi060923s; Balamurali MM, 2008, PROTEIN SCI, V17, P1815, DOI 10.1110/ps.036376.108; Bennett MJ, 2006, STRUCTURE, V14, P811, DOI 10.1016/j.str.2006.03.011; Borgia A, 2008, ANGEW CHEM INT EDIT, V47, P6900, DOI 10.1002/anie.200801761; Borgia A, 2008, ANNU REV BIOCHEM, V77, P101, DOI 10.1146/annurev.biochem.77.060706.093102; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Capaldi AP, 2002, NAT STRUCT BIOL, V9, P209, DOI 10.1038/nsb757; Dahan M, 1999, CHEM PHYS, V247, P85, DOI 10.1016/S0301-0104(99)00132-9; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; Fowler SB, 2001, STRUCTURE, V9, P355, DOI 10.1016/S0969-2126(01)00596-2; Gambin Y, 2009, P NATL ACAD SCI USA, V106, P10153, DOI 10.1073/pnas.0904461106; Gianni S, 2010, NAT STRUCT MOL BIOL, V17, P1431, DOI 10.1038/nsmb.1956; Gregersen N, 2006, ANNU REV GENOM HUM G, V7, P103, DOI 10.1146/annurev.genom.7.080505.115737; Hillger F, 2007, J FLUORESC, V17, P759, DOI 10.1007/s10895-007-0187-z; Hoffmann A, 2007, P NATL ACAD SCI USA, V104, P105, DOI 10.1073/pnas.0604353104; Hofmann H, 2010, P NATL ACAD SCI USA, V107, P11793, DOI 10.1073/pnas.1002356107; Improta S, 1996, STRUCTURE, V4, P323, DOI 10.1016/S0969-2126(96)00036-6; Ivarsson Y, 2008, J BIOL CHEM, V283, P8954, DOI 10.1074/jbc.M707424200; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; Joo C, 2008, ANNU REV BIOCHEM, V77, P51, DOI 10.1146/annurev.biochem.77.070606.101543; Karanicolas J, 2003, J MOL BIOL, V334, P309, DOI 10.1016/j.jmb.2003.09.047; Korzhnev DM, 2010, SCIENCE, V329, P1312, DOI 10.1126/science.1191723; Li HB, 2002, NATURE, V418, P998, DOI 10.1038/nature00938; Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3; Mitraki A, 2010, ADV PROTEIN CHEM STR, V79, P89, DOI 10.1016/S1876-1623(10)79003-9; Nettels D, 2009, P NATL ACAD SCI USA, V106, P20740, DOI 10.1073/pnas.0900622106; Oberhauser AF, 1999, NAT STRUCT BIOL, V6, P1025; Schuler B, 2002, NATURE, V419, P743, DOI 10.1038/nature01060; Schuler B, 2008, CURR OPIN STRUC BIOL, V18, P16, DOI 10.1016/j.sbi.2007.12.003; Schuler Benjamin, 2007, V350, P115; Scott KA, 2002, J MOL BIOL, V315, P819, DOI 10.1006/jmbi.2001.5260; Steward A, 2002, PROTEIN SCI, V11, P2179, DOI 10.1110/ps.0212702; Straub JE, 2010, CURR OPIN STRUC BIOL, V20, P187, DOI 10.1016/j.sbi.2009.12.017; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Wright CF, 2005, NATURE, V438, P878, DOI 10.1038/nature04195; Yang SC, 2004, P NATL ACAD SCI USA, V101, P13786, DOI 10.1073/pnas.0403724101	37	140	140	2	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	2011	474	7353					662	U142		10.1038/nature10099	http://dx.doi.org/10.1038/nature10099			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	785CF	21623368	Green Accepted			2022-12-28	WOS:000292204300044
J	Confalonieri, M; Meduri, GU				Confalonieri, Marco; Meduri, G. Umberto			Glucocorticoid treatment in community-acquired pneumonia	LANCET			English	Editorial Material							INFLAMMATORY MARKERS; SEPSIS; MORTALITY		[Confalonieri, Marco] Univ Hosp Trieste, Dept Pneumol, I-34149 Trieste, Italy; [Meduri, G. Umberto] Univ Tennessee, Ctr Hlth Sci, Memphis Vet Affairs Med Ctr, Memphis, TN 38163 USA; [Meduri, G. Umberto] Univ Tennessee, Ctr Hlth Sci, Div Pulm Crit Care & Sleep Med, Memphis, TN 38163 USA	University of Trieste; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center	Confalonieri, M (corresponding author), Univ Hosp Trieste, Dept Pneumol, I-34149 Trieste, Italy.	marco.confalonieri@aots.sanita.fvg.it	Confalonieri, Marco/AAA-3665-2019	Confalonieri, Marco/0000-0002-4791-768X				Annane D, 2009, JAMA-J AM MED ASSOC, V301, P2362, DOI 10.1001/jama.2009.815; Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61; Cesari M, 2003, CIRCULATION, V108, P2317, DOI 10.1161/01.CIR.0000097109.90783.FC; Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC; Kaplan V, 2003, ARCH INTERN MED, V163, P317, DOI 10.1001/archinte.163.3.317; Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655; Meduri GU, 2009, CHEST, V136, P1631, DOI 10.1378/chest.08-2408; MEDURI GU, 1999, SEPSIS, V3, P21, DOI DOI 10.1023/A:1009870524359; Meijvis SCA, 2011, LANCET, V377, P2023, DOI 10.1016/S0140-6736(11)60607-7; Niederman MS, 1998, CLIN THER, V20, P820, DOI 10.1016/S0149-2918(98)80144-6; Yende S, 2008, AM J RESP CRIT CARE, V177, P1242, DOI 10.1164/rccm.200712-1777OC; Yende S, 2011, CRIT CARE MED, V39, P1871, DOI 10.1097/CCM.0b013e31821b8290	12	9	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 11	2011	377	9782					1982	1984		10.1016/S0140-6736(11)60777-0	http://dx.doi.org/10.1016/S0140-6736(11)60777-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	782LR	21636121				2022-12-28	WOS:000292011700006
J	Heinrich, A; Loth, S				Heinrich, Andreas; Loth, Sebastian			A Logical Use for Atoms	SCIENCE			English	Editorial Material									[Heinrich, Andreas; Loth, Sebastian] IBM Res Div, Almaden Res Ctr, San Jose, CA 95120 USA	International Business Machines (IBM)	Heinrich, A (corresponding author), IBM Res Div, Almaden Res Ctr, 650 Harry Rd, San Jose, CA 95120 USA.	heinrich@almaden.ibm.com	Loth, Sebastian/ABG-5237-2020	Loth, Sebastian/0000-0002-1587-3678				Allwood DA, 2005, SCIENCE, V309, P1688, DOI 10.1126/science.1108813; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Gross L, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/32/325301; Heinrich AJ, 2002, SCIENCE, V298, P1381, DOI 10.1126/science.1076768; Imre A, 2006, SCIENCE, V311, P205, DOI 10.1126/science.1120506; Khajetoorians AA, 2011, SCIENCE, V332, P1062, DOI 10.1126/science.1201725	6	9	9	1	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2011	332	6033					1039	1040		10.1126/science.1206086	http://dx.doi.org/10.1126/science.1206086			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617062				2022-12-28	WOS:000290996700029
J	Malovannaya, A; Lanz, RB; Jung, SY; Bulynko, Y; Le, NT; Chan, DW; Ding, C; Shi, Y; Yucer, N; Krenciute, G; Kim, BJ; Li, CS; Chen, R; Li, W; Wang, Y; O'Malley, BW; Qin, J				Malovannaya, Anna; Lanz, Rainer B.; Jung, Sung Yun; Bulynko, Yaroslava; Le, Nguyen T.; Chan, Doug W.; Ding, Chen; Shi, Yi; Yucer, Nur; Krenciute, Giedre; Kim, Beom-Jun; Li, Chunshu; Chen, Rui; Li, Wei; Wang, Yi; O'Malley, Bert W.; Qin, Jun			Analysis of the Human Endogenous Coregulator Complexome	CELL			English	Article							NUCLEAR RECEPTOR COREGULATORS; CUL3-BASED E3 LIGASE; COFACTOR COMPLEX; PROTEIN; COACTIVATOR; BRCA1; SRC-3/AIB1; DEGRADATION; ADAPTER; BREAST	Elucidation of endogenous cellular protein-protein interactions and their networks is most desirable for biological studies. Here we report our study of endogenous human coregulator protein complex networks obtained from integrative mass spectrometry-based analysis of 3290 affinity purifications. By preserving weak protein interactions during complex isolation and utilizing high levels of reciprocity in the large dataset, we identified many unreported protein associations, such as a transcriptional network formed by ZMYND8, ZNF687, and ZNF592. Furthermore, our work revealed a tiered interplay within networks that share common proteins, providing a conceptual organization of a cellular proteome composed of minimal endogenous modules (MEMOs), complex isoforms (uniCOREs), and regulatory complex-complex interaction networks (CCIs). This resource will effectively fill a void in linking correlative genomic studies with an understanding of transcriptional regulatory protein functions within the proteome for formulation and testing of future hypotheses.	[Malovannaya, Anna; Lanz, Rainer B.; Jung, Sung Yun; Bulynko, Yaroslava; Chan, Doug W.; Li, Wei; Wang, Yi; O'Malley, Bert W.; Qin, Jun] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Malovannaya, Anna; Jung, Sung Yun; Le, Nguyen T.; Chan, Doug W.; Ding, Chen; Shi, Yi; Yucer, Nur; Krenciute, Giedre; Kim, Beom-Jun; Li, Chunshu; Wang, Yi; Qin, Jun] Baylor Coll Med, Ctr Mol Discovery, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Chen, Rui] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	berto@bcm.edu; jqin@bcm.edu	Krenciute, Giedre/N-8094-2018; Shi, Yi/P-7972-2018	Krenciute, Giedre/0000-0003-4335-0644; Shi, Yi/0000-0002-2761-8324; Li, Wei/0000-0001-9931-5990; Jung, Sung Yun/0000-0003-1521-7977	NURSA [U19-DK62434]; Proteomics Strand; Collaborative Bridging Project; Center for Molecular Discovery; McLean Foundation at Baylor College of Medicine.; NIH [HD08188, DK059820, CA84199, GM080703]; CPRIT [RP101499]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007857, R01HD008188] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008188] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA084199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059820, U19DK062434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080703] Funding Source: NIH RePORTER	NURSA; Proteomics Strand; Collaborative Bridging Project; Center for Molecular Discovery; McLean Foundation at Baylor College of Medicine.; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is supported partially by the NURSA grant U19-DK62434 including the Proteomics Strand funding to B.W.O. and J.Q. and the Collaborative Bridging Project funding to R. B. L. We acknowledge the significant financial support of the Center for Molecular Discovery and the McLean Foundation at Baylor College of Medicine. NIH grants HD08188 and DK059820 to B.W.O., CA84199 to J.Q., GM080703 to Y.W., and CPRIT RP101499 fellowship to N.Y. are also acknowledged.	Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Brown LA, 2010, BREAST CANCER RES TR, V121, P347, DOI 10.1007/s10549-009-0479-x; Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981; Coste A, 2008, P NATL ACAD SCI USA, V105, P17187, DOI 10.1073/pnas.0808207105; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Feng L, 2009, GENE DEV, V23, P719, DOI 10.1101/gad.1770609; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Gianni M, 2006, EMBO J, V25, P739, DOI 10.1038/sj.emboj.7600981; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Guenther MG, 2000, GENE DEV, V14, P1048; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Ishikawa H, 2006, FEBS LETT, V580, P4784, DOI 10.1016/j.febslet.2006.07.066; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kaeser MD, 2008, J BIOL CHEM, V283, P32254, DOI 10.1074/jbc.M806061200; Kim HT, 2008, MOL CELLS, V25, P457; Kim H, 2007, SCIENCE, V316, P1202, DOI 10.1126/science.1139621; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kocher T, 2007, NAT METHODS, V4, P807, DOI 10.1038/NMETH1093; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Lanz RB, 2006, NUCLEIC ACIDS RES, V34, pD221, DOI 10.1093/nar/gkj029; Lanz RB, 2010, MOL ENDOCRINOL, V24, P859, DOI 10.1210/me.2009-0499; Li C, 2008, MOL CELL, V31, P835, DOI 10.1016/j.molcel.2008.07.019; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012; Lonard DM, 2007, ENDOCR REV, V28, P575, DOI 10.1210/er.2007-0012; Louet JF, 2006, P NATL ACAD SCI USA, V103, P17868, DOI 10.1073/pnas.0608711103; Malovannaya A, 2010, P NATL ACAD SCI USA, V107, P2431, DOI 10.1073/pnas.0912599106; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; O'Malley BW, 2008, CURR OPIN CELL BIOL, V20, P310, DOI 10.1016/j.ceb.2008.04.005; Poleshko A, 2010, J BIOL CHEM, V285, P422, DOI 10.1074/jbc.M109.064667; Raouf A, 2005, JNCI-J NATL CANCER I, V97, P1302, DOI 10.1093/jnci/dji254; Ruepp A, 2010, NUCLEIC ACIDS RES, V38, pD497, DOI 10.1093/nar/gkp914; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Shao G, 2009, GENE DEV, V23, P740, DOI 10.1101/gad.1739609; Shao G, 2009, P NATL ACAD SCI USA, V106, P3166, DOI 10.1073/pnas.0807485106; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang B, 2009, GENE DEV, V23, P729, DOI 10.1101/gad.1770309; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang Y, 2000, GENE DEV, V14, P927; Weake VM, 2010, NAT REV GENET, V11, P426, DOI 10.1038/nrg2781; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yan J, 2006, ACTA PHARMACOL SIN, V27, P387, DOI 10.1111/j.1745-7254.2006.00315.x; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yan J, 2007, CANCER RES, V67, P6647, DOI 10.1158/0008-5472.CAN-07-0924; Yi P, 2008, MOL CELL, V29, P465, DOI 10.1016/j.molcel.2007.12.030; York B, 2010, P NATL ACAD SCI USA, V107, P11122, DOI 10.1073/pnas.1005262107; Yu CD, 2007, MOL CELL, V25, P765, DOI 10.1016/j.molcel.2007.01.025; Zeng WL, 2010, BIOCHEM BIOPH RES CO, V394, P1024, DOI 10.1016/j.bbrc.2010.03.115; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123	63	303	312	0	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 27	2011	145	5					787	799		10.1016/j.cell.2011.05.006	http://dx.doi.org/10.1016/j.cell.2011.05.006			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620140	Bronze, Green Accepted			2022-12-28	WOS:000291018600017
J	Russell, HC; McDougall, V; Dutton, GN				Russell, Heather C.; McDougall, Valerie; Dutton, Gordon N.			EASILY MISSED? Congenital cataract	BRITISH MEDICAL JOURNAL			English	Editorial Material							SURGICAL-TREATMENT; PERIOD		[Russell, Heather C.] Princess Alexandra Eye Pavil, Edinburgh EH3 9HA, Midlothian, Scotland; [McDougall, Valerie] MacLean Med Practice, Glasgow G44 3QG, Lanark, Scotland; [Dutton, Gordon N.] Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland	University of Glasgow	Russell, HC (corresponding author), Princess Alexandra Eye Pavil, Edinburgh EH3 9HA, Midlothian, Scotland.	heatherrussell74@gmail.com		Dutton, Gordon N/0000-0003-2516-5795				Birch EE, 1996, INVEST OPHTH VIS SCI, V37, P1532; Birch EE, 2009, J AAPOS, V13, P67, DOI 10.1016/j.jaapos.2008.07.010; HALL DMB, 1996, HLTH ALL CHILDREN RE; Lambert SR, 2006, J AAPOS, V10, P30, DOI 10.1016/j.jaapos.2005.10.002; McLaughlin C, 2006, PEDIATR EMERG CARE, V22, P137, DOI 10.1097/01.pec.0000199567.87134.81; Morgan S, 1999, BRIT MED J, V319, P122, DOI 10.1136/bmj.319.7202.122; Rahi JS, 1999, BRIT MED J, V318, P362, DOI 10.1136/bmj.318.7180.362; Rahi JS, 2001, INVEST OPHTH VIS SCI, V42, P1444; *ROYAL COLL OPHTH, 1994, OPHTH SERV CHILDR RE; RUSSELL HC, 2010, J PEDIATR OPHTHALMOL, V46, pE1; Sotomi O, 2007, Ir Med J, V100, P398	11	3	3	1	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 27	2011	342								d3075	10.1136/bmj.d3075	http://dx.doi.org/10.1136/bmj.d3075			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771KI	21622506				2022-12-28	WOS:000291155200003
J	Hellum, C; Johnsen, LG; Storheim, K; Nygaard, OP; Brox, JI; Rossvoll, I; Ro, M; Sandvik, L; Grundnes, O				Hellum, Christian; Johnsen, Lars Gunnar; Storheim, Kjersti; Nygaard, Oystein P.; Brox, Jens Ivar; Rossvoll, Ivar; Ro, Magne; Sandvik, Leiv; Grundnes, Oliver		Norwegian Spine Study Grp	Surgery with disc prosthesis versus rehabilitation in patients with lowback pain and degenerative disc: two year follow-up of randomised study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BACK-PAIN; OSWESTRY DISABILITY INDEX; CHARITE ARTIFICIAL DISC; OSTEOPOROTIC VERTEBRAL FRACTURES; INVESTIGATIONAL DEVICE EXEMPTION; LUMBAR INSTRUMENTED FUSION; COGNITIVE INTERVENTION; NONSURGICAL TREATMENT; CLINICAL-OUTCOMES; CONTROLLED-TRIAL	Objective To compare the efficacy of surgery with disc prosthesis versus non-surgical treatment for patients with chronic low back pain. Design A prospective randomised multicentre study. Setting Five university hospitals in Norway. Participants 173 patients with a history of low back pain for at least one year, Oswestry disability index of at least 30 points, and degenerative changes in one or two lower lumbar spine levels (86 patients randomised to surgery). Patients were treated from April 2004 to September 2007. Interventions Surgery with disc prosthesis or outpatient multidisciplinary rehabilitation for 12-15 days. Main outcome measures The primary outcome measure was the score on the Oswestry disability index after two years. Secondary outcome measures were low back pain, satisfaction with life (SF-36 and EuroQol EQ-5D), Hopkins symptom check list (HSCL-25), fear avoidance beliefs (FABQ), self efficacy beliefs for pain, work status, and patients' satisfaction and drug use. A blinded independent observer evaluated scores on the back performance scale and Prolo scale at two year follow-up. Results The study was powered to detect a difference of 10 points on the Oswestry disability index between the groups at two years. At two years there was a mean difference of -8.4 points (95% confidence interval -13.2 to -3.6) in favour of surgery. In the analysis of prespecified secondary outcomes, there were significant differences in favour of surgery for low back pain (mean difference -12.2, -21.3 to -3.1), patients' satisfaction (63% (n=46) v 39% (n=26)), SF-36 physical component score (mean difference 5.8, 2.5 to 9.1), self efficacy for pain (mean difference 1.0, 0.2 to 1.9), and the Prolo scale (mean difference 0.9, 0.1 to 1.6). There were no significant differences in return to work, SF-36 mental component score, EQ-5D, fear avoidance beliefs, Hopkins symptom check list, drug use, and the back performance scale. One serious complication of leg amputation occurred during surgical revision of a polyethylene dislodgement. The drop-out rate was 20% (34) and the crossover rate was 6% (5). Conclusions Surgical intervention with disc prosthesis for chronic low back pain resulted in a significantly greater improvement in the Oswestry score compared with rehabilitation, but this improvement did not clearly exceed the prespecified minimally important clinical difference between groups of 10 points, and the data are consistent with a wide range of differences between the groups, including values well below 10 points. The potential risks of surgery and the substantial amount of improvement experienced by a sizeable proportion of the rehabilitation group also have to be incorporated into overall decision making.	[Hellum, Christian; Storheim, Kjersti] Oslo Univ Hosp, Dept Orthopaed, Norwegian Res Ctr Act Rehabil NAR, N-0407 Oslo, Norway; [Hellum, Christian; Brox, Jens Ivar] Univ Oslo, N-0407 Oslo, Norway; [Johnsen, Lars Gunnar; Nygaard, Oystein P.; Rossvoll, Ivar] Univ Trondheim Hosp, Natl Ctr Dis Spine, N-7030 Trondheim, Norway; [Johnsen, Lars Gunnar; Rossvoll, Ivar] Univ Trondheim Hosp, Dept Orthopaed, N-7030 Trondheim, Norway; [Storheim, Kjersti] Norwegian Univ Sci & Technol, Fac Med, N-7491 Trondheim, MR, Norway; [Storheim, Kjersti] Oslo Univ Hosp, FORMI, N-0407 Oslo, Norway; [Ro, Magne] Univ Trondheim Hosp, Dept Phys Med & Rehabil, Multidiscipline Spinal Unit, N-7030 Trondheim, Norway; [Sandvik, Leiv] Oslo Univ Hosp, Sect Biostat & Epidemiol, N-0407 Oslo, Norway	University of Oslo; University of Oslo; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); University of Oslo; Norwegian University of Science & Technology (NTNU); University of Oslo	Hellum, C (corresponding author), Oslo Univ Hosp, Dept Orthopaed, Norwegian Res Ctr Act Rehabil NAR, Kirkevn 166, N-0407 Oslo, Norway.	christian.hellum@medisin.uio.no	Brox, Jens Ivar/N-1601-2018		South Eastern Norway Regional Health Authority; Norwegian Foundation for Health and Rehabilitation through the Norwegian Back Pain Association	South Eastern Norway Regional Health Authority; Norwegian Foundation for Health and Rehabilitation through the Norwegian Back Pain Association	The study was funded by the South Eastern Norway Regional Health Authority and EXTRA funds from the Norwegian Foundation for Health and Rehabilitation, through the Norwegian Back Pain Association.	Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; APRILL C, 1992, BRIT J RADIOL, V65, P361, DOI 10.1259/0007-1285-65-773-361; Berg S, 2009, EUR SPINE J, V18, P1512, DOI 10.1007/s00586-009-1047-0; Blumenthal S, 2005, SPINE, V30, P1565, DOI 10.1097/01.brs.0000170587.32676.0e; Brox JI, 2006, PAIN, V122, P145, DOI 10.1016/j.pain.2006.01.027; Brox JI, 2010, ANN RHEUM DIS, V69, P1643, DOI 10.1136/ard.2009.108902; Brox JI, 2003, SPINE, V28, P1913; Buchbinder R, 2009, NEW ENGL J MED, V361, P557, DOI 10.1056/NEJMoa0900429; David T, 2007, SPINE, V32, P661, DOI 10.1097/01.brs.0000257554.67505.45; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Fairbank J, 2005, BMJ-BRIT MED J, V330, P1233, DOI 10.1136/bmj.38441.620417.8F; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Fairbank JCT, 2007, SPINE, V32, P2787, DOI 10.1097/BRS.0b013e31815b9e9d; Freeman BJ, SPINE, V30, P2369; Fritzell P, 2001, SPINE, V26, P2521, DOI 10.1097/00007632-200112010-00002; Gibson JN, 2005, COCHRANE DB SYST REV, V4; Grotle M, 2003, J REHABIL MED, V35, P241, DOI 10.1080/16501970306094; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Guyer RD, 2008, SPINE, V33, P2566, DOI 10.1097/BRS.0b013e318185941a; Guyer RD, 2009, SPINE J, V9, P374, DOI 10.1016/j.spinee.2008.08.007; Hagg O, 2003, EUR SPINE J, V12, P12, DOI 10.1007/s00586-002-0464-0; Inamasu J, 2006, ACTA NEUROCHIR, V148, P375, DOI 10.1007/s00701-005-0669-1; Kurtz SM, 2010, SPINE PHILA PA 1976; Lemaire JP, 2005, J SPINAL DISORD TECH, V18, P353, DOI 10.1097/01.bsd.0000172361.07479.6b; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; Luoma K, 2000, SPINE, V25, P487, DOI 10.1097/00007632-200002150-00016; Mannion AF, 2009, SPINE, V34, P1590, DOI 10.1097/BRS.0b013e31819fcd52; Masharawi Y, 2008, SPINE, V33, P2094, DOI 10.1097/BRS.0b013e31817f19f7; McAfee PC, 2006, SPINE, V31, P1217, DOI 10.1097/01.brs.0000217689.08487.a8; MODIC MT, 1988, RADIOLOGY, V166, P193, DOI 10.1148/radiology.166.1.3336678; NACHEMSON A, 1994, QUAL LIFE RES, V3, pS11, DOI 10.1007/BF00433370; Ostelo RWJG, 2005, BEST PRACT RES CL RH, V19, P593, DOI 10.1016/j.berh.2005.03.003; Pauza Kevin J, 2004, Spine J, V4, P27, DOI 10.1016/j.spinee.2003.07.001; Peul WC, 2007, NEW ENGL J MED, V356, P2245, DOI 10.1056/NEJMoa064039; PROLO DJ, 1986, SPINE, V11, P601, DOI 10.1097/00007632-198607000-00012; Putzier M, 2006, EUR SPINE J, V15, P183, DOI 10.1007/s00586-005-1022-3; Rousing R, 2010, SPINE, V35, P478, DOI 10.1097/BRS.0b013e3181b71bd1; Siepe CJ, 2006, SPINE, V31, P1923, DOI 10.1097/01.brs.0000228780.06569.e8; Siepe CJ, 2010, SPINE, V35, P1991, DOI 10.1097/BRS.0b013e3181d6f878; Strand LI, 2002, PHYS THER, V82, P1213, DOI 10.1093/ptj/82.12.1213; Thomas E, 1999, BRIT MED J, V318, P1662, DOI 10.1136/bmj.318.7199.1662; Tripiano P, 2005, J BONE JOINT SURG AM, V87A, P490, DOI 10.2106/JBJS.C.01345; van den Eerenbeemt KD, 2010, EUR SPINE J, V19, P1262, DOI 10.1007/s00586-010-1445-3; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; Waddell G, 2004, BACK PAIN REVOLUTION; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Weinstein JN, 2007, NEW ENGL J MED, V356, P2257, DOI 10.1056/NEJMoa070302; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2451, DOI 10.1001/jama.296.20.2451; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Zigler J, 2007, SPINE, V32, P1155, DOI 10.1097/BRS.0b013e318054e377	51	78	78	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 19	2011	342								d2786	10.1136/bmj.d2786	http://dx.doi.org/10.1136/bmj.d2786			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768QS	21596740	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000290952100003
J	White, PM; Lewis, SC; Gholkar, A; Sellar, RJ; Nahser, H; Cognard, C; Forrester, L; Wardlaw, JM				White, Philip M.; Lewis, Stephanie C.; Gholkar, Anil; Sellar, Robin J.; Nahser, Hans; Cognard, Christophe; Forrester, Lynn; Wardlaw, Joanna M.		HELPS Trial Collaborators	Hydrogel-coated coils versus bare platinum coils for the endovascular treatment of intracranial aneurysms (HELPS): a randomised controlled trial	LANCET			English	Article							CEREBRAL ANEURYSMS; EMBOLIZATION; MENINGITIS; AGREEMENT; OCCLUSION; PACKING; EDEMA; ISAT	Background Coated coils for endovascular treatment of cerebral aneurysm were developed to reduce recurrence and retreatment rates, and have been in clinical use for 8-9 years without robust evidence to determine their efficacy. We assessed the efficacy and safety of hydrogel-coated coils. Methods This randomised trial was undertaken in 24 centres in seven countries. Patients aged 18-75 years with a previously untreated ruptured or unruptured cerebral aneurysm of 2-25 mm in maximum diameter were randomly allocated (1:1) to aneurysm coiling with either hydrogel-coated coils or standard bare platinum coils (control). Randomisation was done with a computer-generated sequence, stratified by aneurysm size, shape, and dome-to-neck ratio; intention to use assist device; and by region. Participants and those assessing outcomes were masked to allocation. Analysis was by modified intention to treat (excluding missing data). Primary outcome was a composite of angiographic and clinical outcomes at 18-month follow-up. We also did prespecified subgroup analyses of characteristics likely to be relevant to angiographic outcome. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN30531382. Findings 249 patients were allocated to the hydrogel coil group and 250 to the control group. In 44 of 467 patients for whom an 18-month composite primary outcome was unavailable, 6-month angiographic results were used. 70 (28%) patients in the hydrogel group and 90 (36%) control patients had an adverse composite primary outcome, giving an absolute reduction in the proportion of adverse composite primary outcomes with hydrogel of 7.0% (95% CI -1.6 to 15.5), odds ratio (OR) 0.73 (0.49-1.1, p=0.13). In a prespecified subgroup analysis in recently ruptured aneurysms, there were more adverse composite primary outcomes in the control group than in the hydrogel group OR 2.08 (1.24-3.46, p=0.014). There were 8.6% fewer major angiographic recurrences in patients allocated to hydrogel coils OR 0.7 (0.4-1.0, p=0.049). There were five cases of unexplained hydrocephalus in not-recently-ruptured aneurysms in the hydrogel coil group and one case in the control group. Interpretation Whether use of hydrogel coils reduces late aneurysm rupture or improves long-term clinical outcome is not dear, but our results indicate that their use lowers major recurrence.	[White, Philip M.; Sellar, Robin J.; Forrester, Lynn; Wardlaw, Joanna M.] Western Gen Hosp, Dept Neuroradiol, Edinburgh EH4 2XU, Midlothian, Scotland; [White, Philip M.; Sellar, Robin J.; Forrester, Lynn; Wardlaw, Joanna M.] Western Gen Hosp, Univ Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; [White, Philip M.; Sellar, Robin J.; Forrester, Lynn; Wardlaw, Joanna M.] Univ Edinburgh, SINAPSE Collaborat, Edinburgh, Midlothian, Scotland; [Lewis, Stephanie C.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Gholkar, Anil] Newcastle Gen Hosp, Dept Neuroradiol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Nahser, Hans] Walton Ctr Neurosurg & Neurol, Liverpool, Merseyside, England; [Cognard, Christophe] Purpan Hosp, Dept Neuroradiol, Toulouse, France	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; Newcastle General Hospital; Walton Centre; CHU de Toulouse	White, PM (corresponding author), Western Gen Hosp, Dept Neuroradiol, Edinburgh EH4 2XU, Midlothian, Scotland.	pwhite1@staffmail.ed.ac.uk	Hernandez, María/GYU-3543-2022; Wardlaw, Joanna M/Y-3456-2019	Wardlaw, Joanna M/0000-0002-9812-6642; cognard, christophe/0000-0003-4287-2627; White, Philip/0000-0001-6007-6013	MicroVention Inc; Lothian University Hospitals Division (Edinburgh, UK); Scottish Funding Council [SC005336]; Micrus; Codman; Siemens Medical; MicroVention Terumo; MicroVention Terumo Inc.; Medical Research Council [G0800803] Funding Source: researchfish; MRC [G0800803] Funding Source: UKRI	MicroVention Inc; Lothian University Hospitals Division (Edinburgh, UK); Scottish Funding Council; Micrus; Codman; Siemens Medical; MicroVention Terumo; MicroVention Terumo Inc.; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The trial was funded by MicroVention Inc (the manufacturers of the hydrogel coils used in this trial) and sponsored by Lothian University Hospitals Division (Edinburgh, UK). (MW was supported by the Scottish Funding Council through the SINAPSE Collaboration (grant number SC005336). We are very grateful to all the trial participants and collaborators, and to the data monitoring committee (RB, PS, and NA). Preliminary findings from this study have been presented at the World Federation of Interventional and Therapeutic Neuroradiology Congress; Montreal, Canada; June 29 July 3, 2009.; PMW has done consultancy work for MicroVention Inc and Micrus (both companies manufacture coils for aneurysm treatment); holds an unrestricted research grant front MicroVention for HELPS as the Chief Investigator, has received financial support to attend conferences during the past 5 years from Micrus, Codman (a manufacturer of coils for aneurysm treatment), and MicroVention; had MicroVention stock options from 2001-02, which were bought out when Terumo took over Microvention in 2006; and is the co-organiser of an educational meeting (Brainstorm), which is sponsored by Siemens Medical and MicroVention Terumo. SCL had some of her salary paid from the grant from Microvention Terumo for HELPS. AG has received travel support to conferences from MicroVention Inc and Codman, and has done consultancy work for Codman. RJS has done consultancy work for MicroVention and Micrus and is the co-organiser of an annual educational meeting (Brainstorm), which is sponsored by Siemens Medical and Microvention Terumo. HN has done consultancy work for Boston Scientific (a manufacturer of coils for aneurysm treatment) and has received support to attend conferences during the past 5 years from Boston, Codman, and Microvention. CC has done consultancy work for Boston Scientific, Codman, eV3 (a manufacturer of coils for aneurysm treatment), and MicroVention Terumo Inc. LF was employed as the trial manager of HELPS, funded by MicroVention Terumo Inc. JMW declares that she has no conflicts of interest.	Adams WM, 2000, NEUROINTERVENTIONIST, V1, P74; BREIG A, 1967, LANCET, V1, P874; Brilstra EH, 1999, STROKE, V30, P470, DOI 10.1161/01.STR.30.2.470; Byrne JV, 1999, J NEUROSURG, V90, P656, DOI 10.3171/jns.1999.90.4.0656; Campi A, 2007, STROKE, V38, P1538, DOI 10.1161/STROKEAHA.106.466987; Cloft HJ, 2007, AM J NEURORADIOL, V28, P497; Cloft HJ, 2004, AM J NEURORADIOL, V25, P60; Cognard C, 1998, RADIOLOGY, V206, P499, DOI 10.1148/radiology.206.2.9457205; DRAKE CG, 1988, J NEUROSURG, V68, P985; Fanning NF, 2008, J NEUROSURG, V108, P1074, DOI 10.3171/JNS/2008/108/6/1074; Horie N, 2007, J NEUROSURG, V106, P916, DOI 10.3171/jns.2007.106.5.916; Im SH, 2007, AM J NEURORADIOL, V28, P511; Kallmes DF, 2002, AM J NEURORADIOL, V23, P1580; Meyers PM, 2004, NEUROSURGERY, V55, P1222, DOI 10.1227/01.NEU.0000140987.71791.DF; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8; Naggara ON, 2010, RADIOLOGY, V256, P887, DOI 10.1148/radiol.10091982; Plowman RS, 2011, J NEUROSURG, V114, P863, DOI 10.3171/2010.6.JNS091058; Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9; Raymond J, 2007, AM J NEURORADIOL, V28, P501; ROTHWELL P, 1995, LANCET, V346, P1623, DOI 10.1016/S0140-6736(95)91953-8; White PM, 2008, AM J NEURORADIOL, V29, P217, DOI 10.3174/ajnr.A0936; White PM, 2009, AM J NEURORADIOL, V30, P219, DOI 10.3174/ajnr.A1324; Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3	25	200	209	1	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	2011	377	9778					1655	1662		10.1016/S0140-6736(11)60408-X	http://dx.doi.org/10.1016/S0140-6736(11)60408-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766JF	21571149				2022-12-28	WOS:000290777700030
J	Davidoff, F; Miglus, J				Davidoff, Frank; Miglus, Jennifer			Delivering Clinical Evidence Where It's Needed Building an Information System Worthy of the Profession	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PATIENT-CARE; IMPACT		[Davidoff, Frank] Inst Healthcare Improvement, Cambridge, MA USA; [Miglus, Jennifer] Hartford Med Soc, Farmington, CT USA; [Miglus, Jennifer] Univ Connecticut, Ctr Hlth, Farmington, CT USA	Institute for Healthcare Improvement; University of Connecticut	Davidoff, F (corresponding author), 143 Garden St, Wethersfield, CT 06109 USA.	fdavidoff@cox.net		Miglus, Jennifer/0000-0003-4052-6851				Bastian H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000326; Cochrane AL, 2000, MED YEAR 2000, V1979, P1; Davidoff F, 2000, ANN INTERN MED, V132, P996, DOI 10.7326/0003-4819-132-12-200006200-00012; Ely JW, 2007, J AM MED INFORM ASSN, V14, P407, DOI 10.1197/jamia.M2398; Marchildon G, 2004, ROMANOW PAPERS, P21; Mulvaney SA, 2008, J AM MED INFORM ASSN, V15, P203, DOI 10.1197/jamia.M2461; Polger M. A., 2010, J HOSP LIBRARIANSHIP, V10, P363, DOI [DOI 10.1080/15323269.2010.514556, 10.1080/15323269.2010.514556]; Rankin JA, 2008, J MED LIBR ASSOC, V96, P194, DOI 10.3163/1536-5050.96.3.005; SMITH R, 2010, BMJ-BRIT MED J, V341, P1281; Weightman AL, 2005, HEALTH INFO LIBR J, V22, P4, DOI 10.1111/j.1471-1842.2005.00549.x	10	17	18	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2011	305	18					1906	1907		10.1001/jama.2011.619	http://dx.doi.org/10.1001/jama.2011.619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	761YH	21558524				2022-12-28	WOS:000290438800031
J	Denniston, CR				Denniston, Clark R.			Miles Together	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												cdennist@med.unc.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2011	305	18					1840	1841		10.1001/jama.2011.591	http://dx.doi.org/10.1001/jama.2011.591			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761YH	21558508				2022-12-28	WOS:000290438800001
J	Charleston, B; Bankowski, BM; Gubbins, S; Chase-Topping, ME; Schley, D; Howey, R; Barnett, PV; Gibson, D; Juleff, ND; Woolhouse, MEJ				Charleston, Bryan; Bankowski, Bartlomies M.; Gubbins, Simon; Chase-Topping, Margo E.; Schley, David; Howey, Richard; Barnett, Paul V.; Gibson, Debi; Juleff, Nicholas D.; Woolhouse, Mark E. J.			Relationship Between Clinical Signs and Transmission of an Infectious Disease and the Implications for Control	SCIENCE			English	Article							MOUTH-DISEASE; VIRUS TRANSMISSION; INFLUENZA; DYNAMICS; OUTBREAK	Control of many infectious diseases relies on the detection of clinical cases and the isolation, removal, or treatment of cases and their contacts. The success of such "reactive" strategies is influenced by the fraction of transmission occurring before signs appear. We performed experimental studies of foot-and-mouth disease transmission in cattle and estimated this fraction at less than half the value expected from detecting virus in body fluids, the standard proxy measure of infectiousness. This is because the infectious period is shorter (mean 1.7 days) than currently realized, and animals are not infectious until, on average, 0.5 days after clinical signs appear. These results imply that controversial preemptive control measures may be unnecessary; instead, efforts should be directed at early detection of infection and rapid intervention.	[Charleston, Bryan; Bankowski, Bartlomies M.; Gubbins, Simon; Schley, David; Barnett, Paul V.; Gibson, Debi; Juleff, Nicholas D.] AFRC, Inst Anim Hlth, Pirbright Lab, Woking GU24 0NF, Surrey, England; [Chase-Topping, Margo E.; Howey, Richard; Woolhouse, Mark E. J.] Univ Edinburgh, Ashworth Labs, Ctr Immun Infect & Evolut, Edinburgh EH9 3JT, Midlothian, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; University of Edinburgh	Charleston, B (corresponding author), AFRC, Inst Anim Hlth, Pirbright Lab, Ash Rd, Woking GU24 0NF, Surrey, England.	bryan.charleston@bbsrc.ac.uk		Charleston, Bryan/0000-0002-6952-9338; Gubbins, Simon/0000-0003-0538-4173	Biotechnology and Biological Sciences Research Council, UK [BBSB00549]; Biotechnology and Biological Sciences Research Council [BBSEI00001444]; Wellcome Trust; Biotechnology and Biological Sciences Research Council [BBS/B/00549, BBS/B/01480, BBS/E/I/00001444] Funding Source: researchfish; BBSRC [BBS/E/I/00001444] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council, UK(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank L. Fitzpatrick, C. Randal, and M. Jenkins for their assistance with the handling and management of experimental animals; P. Hamblin and P. Keel for help and advice with serology assays; L. Reid, M. Windsor, and S. Cox for assistance with laboratory assays; S. Alexandersen, D. Paton, and N. Savill for valuable advice on study design; and B. Grenfell, M. Keeling, M. de Jong, A. Graham, C. Dye, and four anonymous referees fur insightful comments. The work was funded by the Biotechnology and Biological Sciences Research Council (grant BBSB00549), UK. B.C. and P.V.B. are Jenner Investigators. S.G. and D.S. acknowledge funding from the Biotechnology and Biological Sciences Research Council (grant BBSEI00001444). M.E.C.T. is partly supported by the Wellcome Trust.	Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375; Chinsangaram J, 1999, J VIROL, V73, P9891, DOI 10.1128/JVI.73.12.9891-9898.1999; Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101; Howey R, 2009, J R SOC INTERFACE, V6, P835, DOI 10.1098/rsif.2008.0434; King DA, 2006, SCIENCE, V313, P1392, DOI 10.1126/science.1129134; Lau LLH, 2010, J INFECT DIS, V201, P1509, DOI 10.1086/652241; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; Mardones F, 2010, VET RES, V41, DOI 10.1051/vetres/2010017; Orsel K, 2009, PREV VET MED, V88, P158, DOI 10.1016/j.prevetmed.2008.09.001; Orsel K, 2007, VACCINE, V25, P327, DOI 10.1016/j.vaccine.2006.07.030; Paton DJ, 2010, VET REC, V166, P569, DOI 10.1136/vr.c2300; Paton DJ, 2009, PHILOS T R SOC B, V364, P2657, DOI 10.1098/rstb.2009.0100; Patrozou E, 2009, PUBLIC HEALTH REP, V124, P193, DOI 10.1177/003335490912400205; SCOTT GR, 1981, VIRUS DISEASES FOOD, V2, P401; Tildesley MJ, 2009, P ROY SOC B-BIOL SCI, V276, P3239, DOI 10.1098/rspb.2009.0427; Tracy CS, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-470; *WHO, WHO FACTSH; WILLIAMS GC, 1991, Q REV BIOL, V66, P1, DOI 10.1086/417048; Yamagishi T, 2010, JPN J INFECT DIS, V63, P327; Zinsstag J, 2001, SCIENCE, V294, P477, DOI 10.1126/science.294.5542.477	20	107	112	3	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 6	2011	332	6030					726	729		10.1126/science.1199884	http://dx.doi.org/10.1126/science.1199884			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	759RK	21551063	Green Accepted			2022-12-28	WOS:000290265800045
J	Colgrove, J; Bayer, R; Bachynski, KE				Colgrove, James; Bayer, Ronald; Bachynski, Kathleen E.			Nowhere Left to Hide? The Banishment of Smoking from Public Spaces	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Colgrove, James; Bayer, Ronald; Bachynski, Kathleen E.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA	Columbia University	Colgrove, J (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA.							Bayer R, 2006, AM J PUBLIC HEALTH, V96, P47, DOI 10.2105/AJPH.2005.071886; Chapman S, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2804; Klepeis NE, 2007, J AIR WASTE MANAGE, V57, P522, DOI 10.3155/1047-3289.57.5.522; *NY CIT COUNC, 2010, TRANSCR MIN JOINT CO; Rabin RL, 2008, LOYOLA LOS ANGELES L, V41, P1721	5	25	25	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2011	364	25					2375	2377		10.1056/NEJMp1104637	http://dx.doi.org/10.1056/NEJMp1104637			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	781MG	21612464				2022-12-28	WOS:000291936100002
J	Finks, JF; Osborne, NH; Birkmeyer, JD				Finks, Jonathan F.; Osborne, Nicholas H.; Birkmeyer, John D.			Trends in Hospital Volume and Operative Mortality for High-Risk Surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATIONAL TRENDS; CARDIAC-SURGERY; CANCER-SURGERY; LUNG-CANCER; HEALTH-CARE; REGIONALIZATION; CENTERS; CALIFORNIA; RESECTION; OUTCOMES	Background There were numerous efforts in the United States during the previous decade to concentrate selected surgical procedures in high-volume hospitals. It remains unknown whether referral patterns for high-risk surgery have changed as a result and how operative mortality has been affected. Methods We used national Medicare data to study patients undergoing one of eight different cancer and cardiovascular operations from 1999 through 2008. For each procedure, we examined trends in hospital volume and market concentration, defined as the proportion of Medicare patients undergoing surgery in the top decile of hospitals by volume per year. We used regression-based techniques to assess the effects of volume and market concentration on mortality over time, adjusting for case mix. Results Median hospital volumes of four cancer resections (lung, esophagus, pancreas, and bladder) and of repair of abdominal aortic aneurysm (AAA) rose substantially. Depending on the procedure, higher hospital volumes were attributable to an increasing number of cases nationwide, an increasing market concentration, or both. Hospital volumes rose slightly for aortic-valve replacement but fell for coronary-artery bypass grafting and carotid endarterectomy. Operative mortality declined for all eight procedures, ranging from a relative decline of 8% for carotid endarterectomy (1.3% mortality in 1999 and 1.2% in 2008) to 36% for AAA repair (4.4% in 1999 and 2.8% in 2008). Higher hospital volumes explained a large portion of the decline in mortality for pancreatectomy (67% of the decline), cystectomy (37%), and esophagectomy (32%), but not for the other procedures. Conclusions Operative mortality with high-risk surgery fell substantially during the previous decade. Although increased market concentration and hospital volume have contributed to declining mortality with some high-risk cancer operations, declines in mortality with other procedures are largely attributable to other factors. (Funded by the National Institute on Aging.)	Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Surg, Sect Gen Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Finks, JF (corresponding author), 2210F Taubman Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	jfinks@umich.edu			National Institute on Aging [P01AG019783-07S1]; NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by a grant (P01AG019783-07S1) from the National Institute on Aging.	Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; BLINDER AS, 1973, J HUM RESOUR, V8, P436, DOI 10.2307/144855; Chappel AR, 2006, J AM COLL SURGEONS, V203, P599, DOI 10.1016/j.jamcollsurg.2006.07.009; Cheung MC, 2009, ANN SURG ONCOL, V16, P3, DOI 10.1245/s10434-008-0025-9; *COMM QUAL HLTH CA, 2000, INT VOL OUTC REL CON; DIMICK JB, 2004, HLTH AFF MILLWOOD S, pVAR45; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; FAIRLIE RW, 2003, 873 YAL U EC GROWTH; Ferguson TB, 2002, ANN THORAC SURG, V73, P480, DOI 10.1016/S0003-4975(01)03339-2; Finlayson E V, 2001, Eff Clin Pract, V4, P172; FINLAYSON EVA, 2001, EFF CLIN PRACT, V4, P235; Finlayson SRG, 1999, MED CARE, V37, P204, DOI 10.1097/00005650-199902000-00010; Gasper WJ, 2009, ANN SURG, V250, P472, DOI 10.1097/SLA.0b013e3181b47c79; Giles KA, 2009, J VASC SURG, V49, P543, DOI 10.1016/j.jvs.2008.09.067; Goodney PP, 2002, J AM COLL SURGEONS, V195, P219, DOI 10.1016/S1072-7515(02)01228-0; Hall BL, 2009, ANN SURG, V250, P363, DOI 10.1097/SLA.0b013e3181b4148f; Hill JS, 2008, J VASC SURG, V48, P29, DOI 10.1016/j.jvs.2008.02.048; Ho V, 2006, ANN SURG ONCOL, V13, P851, DOI 10.1245/ASO.2006.07.021; Hollenbeck BK, 2005, J UROLOGY, V174, P1385, DOI 10.1097/01.ju.0000173632.58991.a7; Holmes JS, 2007, HEALTH AFFAIR, V26, P169, DOI 10.1377/hlthaff.26.1.169; Kirby JB, 2006, MED CARE, V44, P64; Kohn KT, 1999, ERR IS HUMAN BUILDIN; *LEAPFR GROUP, EV BAS HOSP REF; Matsen SL, 2006, J VASC SURG, V44, P488, DOI 10.1016/j.jvs.2006.05.017; Milstein A, 2000, Eff Clin Pract, V3, P313; MILSTEIN A, 2001, EFF CLIN PRACT, V4, P94; Oaxaca R., 1973, INT ECON REV, V14, P693, DOI DOI 10.2307/2525981; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Peterson ED, 2004, JAMA-J AM MED ASSOC, V291, P195, DOI 10.1001/jama.291.2.195; Roux AVD, 2001, NEW ENGL J MED, V345, P99, DOI 10.1056/NEJM200107123450205; Rowe JW, 2007, ANN INTERN MED, V146, P151, DOI 10.7326/0003-4819-146-11-200706050-00022; Rowe JW, 2006, ANN INTERN MED, V145, P695, DOI 10.7326/0003-4819-145-9-200611070-00013; Shahian DM, 2009, ANN THORAC SURG, V88, pS2, DOI 10.1016/j.athoracsur.2009.05.053; Steinbrook R, 2006, NEW ENGL J MED, V355, P1847, DOI 10.1056/NEJMp068222; Ward MM, 2004, J RURAL HEALTH, V20, P344, DOI 10.1111/j.1748-0361.2004.tb00048.x	37	954	973	0	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2128	2137		10.1056/NEJMsa1010705	http://dx.doi.org/10.1056/NEJMsa1010705			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	772AB	21631325	Green Accepted			2022-12-28	WOS:000291200700011
J	Chen, CY; Samuel, TK; Sinclair, J; Dailey, HA; Hamza, I				Chen, Caiyong; Samuel, Tamika K.; Sinclair, Jason; Dailey, Harry A.; Hamza, Iqbal			An Intercellular Heme-Trafficking Protein Delivers Maternal Heme to the Embryo during Development in C. elegans	CELL			English	Article							CAENORHABDITIS-ELEGANS; GENE FAMILY; HEMOPEXIN; EXPRESSION; FERROCHELATASE; PROTOPORPHYRIA; IDENTIFICATION; BIOSYNTHESIS; HOMEOSTASIS; INFECTIONS	Extracellular free heme can intercalate into membranes and promote damage to cellular macromolecules. Thus it is likely that specific intercellular pathways exist for the directed transport, trafficking, and delivery of heme to cellular destinations, although none have been found to date. Here we show that Caenorhabditis elegans HRG-3 is required for the delivery of maternal heme to developing embryos. HRG-3 binds heme and is exclusively secreted by maternal intestinal cells into the interstitial fluid for transport of heme to extraintestinal cells, including oocytes. HRG-3 deficiency results either in death during embryogenesis or in developmental arrest immediately post-hatching-phenotypes that are fully suppressed by maternal but not zygotic hrg-3 expression. Our results establish a role for HRG-3 as an intercellular heme-trafficking protein.	[Chen, Caiyong; Samuel, Tamika K.; Sinclair, Jason; Hamza, Iqbal] Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA; [Chen, Caiyong; Samuel, Tamika K.; Sinclair, Jason; Hamza, Iqbal] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; [Dailey, Harry A.] Univ Georgia, Biomed & Hlth Sci Inst, Dept Microbiol, Athens, GA 30602 USA; [Dailey, Harry A.] Univ Georgia, Biomed & Hlth Sci Inst, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Hamza, I (corresponding author), Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA.	hamza@umd.edu		Hamza, Iqbal/0000-0003-0045-0610	National Institutes of Health [R01DK74797]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074797, R01DK032303] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank A. Golden and M. Krause for critical discussions and reading of the manuscript; B. Grant, D. Hall, and J. McGhee for insights into intestinal regulation in C. elegans; J. Lippincott-Schwartz for the FPP assay; B. Grant for RNAi clones and C. elegans strain RT1315; J. Hanover for use of the COPAS BioSort; T. Blumenthal for the SL2 ICS sequence; and National Bioresource Project and S. Mitani for the hrg-3 strain. This work was supported by funding from the National Institutes of Health R01DK74797 (I. H.). C. C., T. K. S., J. S., and I. H. designed studies and interpreted data. H. A. D. conducted the biochemical heme-binding studies. C. C. and I. H. wrote the manuscript. All authors discussed the results and commented on the manuscript.	Balklava Z, 2007, NAT CELL BIOL, V9, P1066, DOI 10.1038/ncb1627; BALLA G, 1991, LAB INVEST, V64, P648; Banci L, 2010, NATURE, V465, P645, DOI 10.1038/nature09018; BLUMENTHAL T, 1984, J MOL BIOL, V174, P1, DOI 10.1016/0022-2836(84)90361-9; BONKOVSKY HL, 1991, AM J GASTROENTEROL, V86, P1050; Brodigan TM, 2003, DEV BIOL, V254, P102, DOI 10.1016/S0012-1606(02)00032-5; CHAN MS, 1994, PARASITOLOGY, V109, P373, DOI 10.1017/S0031182000078410; Childs S, 2000, CURR BIOL, V10, P1001, DOI 10.1016/S0960-9822(00)00653-9; Chotard L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015662; Dailey HA, 2002, BIOCHEM SOC T, V30, P590, DOI 10.1042/bst0300590; Dooley KA, 2008, EXP HEMATOL, V36, P1132, DOI 10.1016/j.exphem.2008.04.008; Faller M, 2007, NAT STRUCT MOL BIOL, V14, P23, DOI 10.1038/nsmb1182; Fay DS, 2000, DEVELOPMENT, V127, P4049; Fuller VL, 2008, NEW PHYTOL, V180, P27, DOI 10.1111/j.1469-8137.2008.02508.x; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; Held MR, 2006, INFECT IMMUN, V74, P289, DOI 10.1128/IAI.74.1.289-295.2006; Hotez PJ, 2008, J CLIN INVEST, V118, P1311, DOI 10.1172/JCI34261; HRKAL Z, 1974, EUR J BIOCHEM, V43, P73, DOI 10.1111/j.1432-1033.1974.tb03386.x; Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185; Jasmer DP, 2003, ANNU REV PHYTOPATHOL, V41, P245, DOI 10.1146/annurev.phyto.41.052102.104023; Johnston WL, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-35; Kaasik K, 2004, NATURE, V430, P467, DOI 10.1038/nature02724; Keel SB, 2008, SCIENCE, V319, P825, DOI 10.1126/science.1151133; Kim AM, 2010, NAT CHEM BIOL, V6, P674, DOI [10.1038/NCHEMBIO.419, 10.1038/nchembio.419]; Kim BE, 2008, NAT CHEM BIOL, V4, P176, DOI 10.1038/nchembio.72; KIMBLE J, 1983, DEV BIOL, V96, P189, DOI 10.1016/0012-1606(83)90322-6; Knutson MD, 2005, P NATL ACAD SCI USA, V102, P1324, DOI 10.1073/pnas.0409409102; LI JM, 1988, J BACTERIOL, V170, P1021, DOI 10.1128/jb.170.2.1021-1025.1988; Lorenz H, 2006, NAT METHODS, V3, P205, DOI 10.1038/nmeth857; Magness ST, 2002, BLOOD, V100, P1470, DOI 10.1182/blood-2001-12-0283; McGhee James D, 2007, WormBook, P1; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; Okano S, 2010, GENES CELLS, V15, P77, DOI 10.1111/j.1365-2443.2009.01366.x; Puy H, 2010, LANCET, V375, P924, DOI 10.1016/S0140-6736(09)61925-5; Quigley JG, 2004, CELL, V118, P757, DOI 10.1016/j.cell.2004.08.014; Rajagopal A, 2008, NATURE, V453, P1127, DOI 10.1038/nature06934; Rao AU, 2005, P NATL ACAD SCI USA, V102, P4270, DOI 10.1073/pnas.0500877102; Rolls MM, 2002, MOL BIOL CELL, V13, P1778, DOI 10.1091/mbc.01-10-0514; Severance S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001044; Severance S, 2009, CHEM REV, V109, P4596, DOI 10.1021/cr9001116; Sinclair J, 2010, J BIOL CHEM, V285, P39536, DOI 10.1074/jbc.M110.167619; SPIETH J, 1985, MOL CELL BIOL, V5, P2495, DOI 10.1128/MCB.5.10.2495; Tolosano E, 1999, BLOOD, V94, P3906, DOI 10.1182/blood.V94.11.3906; Tolosano E, 2010, ANTIOXID REDOX SIGN, V12, P305, DOI 10.1089/ars.2009.2787; Uc A, 2004, AM J PHYSIOL-GASTR L, V287, pG1150, DOI 10.1152/ajpgi.00157.2004; Worthington MT, 2001, AM J PHYSIOL-GASTR L, V280, pG1172, DOI 10.1152/ajpgi.2001.280.6.G1172; Wu B, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000475; Yang ZT, 2010, J BIOL CHEM, V285, P28874, DOI 10.1074/jbc.M110.119131	49	42	44	1	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 27	2011	145	5					720	731		10.1016/j.cell.2011.04.025	http://dx.doi.org/10.1016/j.cell.2011.04.025			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620137	Green Accepted, Bronze			2022-12-28	WOS:000291018600012
J	Macilwain, C				Macilwain, Colin			Can Europe build a framework for success?	NATURE			English	Editorial Material												colinmacilwain@googlemail.com							0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2011	473	7348					421	421		10.1038/473421a	http://dx.doi.org/10.1038/473421a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	768QM	21614034	Bronze			2022-12-28	WOS:000290951300004
J	Bouros, D				Bouros, Demosthenes			Pirfenidone for idiopathic pulmonary fibrosis	LANCET			English	Editorial Material									Democritus Univ Thrace, Sch Med, Dept Pneumonol, Alexandroupolis 68100, Greece	Democritus University of Thrace	Bouros, D (corresponding author), Democritus Univ Thrace, Sch Med, Dept Pneumonol, Alexandroupolis 68100, Greece.	bouros@med.duth.gr	Bouros, Demosthenes/AAP-9138-2020	Bouros, Demosthenes/0000-0002-0685-0765; Bouros, Demosthenes/0000-0003-4245-2227				Bouros D, 2005, EUR RESPIR J, V26, P693, DOI 10.1183/09031936.05.00145004; Bouros D, 2009, LANCET, V374, P180, DOI 10.1016/S0140-6736(09)60689-9; Collard HR, 2010, EUR RESPIR J, V35, P728, DOI 10.1183/09031936.00006610; du Bois RM, 2011, AM J RESP CRIT CARE, V183, P1231, DOI [10.1164/rccm.201007.1179OC, 10.1164/rccm.201007-1179OC]; Karakatsani A, 2009, RESP MED, V103, P1122, DOI 10.1016/j.rmed.2009.03.001; Latsi PI, 2003, AM J RESP CRIT CARE, V168, P531, DOI 10.1164/rccm.200210-1245OC; Martinez FJ, 2005, ANN INTERN MED, V142, P963, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00005; Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4; Raghu G, 1999, AM J RESP CRIT CARE, V159, P1061, DOI 10.1164/ajrccm.159.4.9805017; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; SEYMOUR S, 2010, DIVISION SUMMARY OVE; Taniguchi H, 2010, EUR RESPIR J, V35, P821, DOI 10.1183/09031936.00005209	12	51	52	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2011	377	9779					1727	1729		10.1016/S0140-6736(11)60546-1	http://dx.doi.org/10.1016/S0140-6736(11)60546-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771AS	21571363				2022-12-28	WOS:000291130200008
J	Berenson, RA; Basch, P; Sussex, A				Berenson, Robert A.; Basch, Peter; Sussex, Amanda			Revisiting E&M Visit Guidelines - A Missing Piece of Payment Reform	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SERVICES		[Berenson, Robert A.] Urban Inst, Washington, DC 20037 USA; [Basch, Peter] Med Star Hlth, Washington, DC 20037 USA; [Sussex, Amanda] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA	Urban Institute; Columbia University	Berenson, RA (corresponding author), Urban Inst, Washington, DC 20037 USA.							BRAUN P, 1992, MED CARE, V30, pNS13, DOI 10.1097/00005650-199211001-00002; Brett AS, 1998, NEW ENGL J MED, V339, P1705, DOI 10.1056/NEJM199812033392312; Centers for Medicare Medicaid Services, DOC GUID EV MAN E M; Hartzband P, 2008, NEW ENGL J MED, V358, P1656, DOI 10.1056/NEJMp0802221; Park Todd, 2009, HIST OPPORTUNITY WED	5	23	23	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					1892	1895		10.1056/NEJMp1102099	http://dx.doi.org/10.1056/NEJMp1102099			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765PJ	21591942				2022-12-28	WOS:000290720700004
J	Thomas, C				Thomas, Clare			Cardiovascular Biology	NATURE			English	Editorial Material																			0	1	1	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 19	2011	473	7347					297	297		10.1038/473297a	http://dx.doi.org/10.1038/473297a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	765QA	21593861	Bronze			2022-12-28	WOS:000290722400035
J	Djulbegovic, B; Paul, A				Djulbegovic, Benjamin; Paul, Ash			From Efficacy to Effectiveness in the Face of Uncertainty Indication Creep and Prevention Creep	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Djulbegovic, Benjamin] Univ S Florida, Ctr Evidence Based Med & Hlth Outcomes Res, Tampa, FL 33612 USA; [Djulbegovic, Benjamin] Univ S Florida, Dept Med, Div Evidence Based Med & Hlth Outcomes Res, Tampa, FL 33612 USA; [Djulbegovic, Benjamin] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, Tampa, FL 33612 USA; [Djulbegovic, Benjamin] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL 33612 USA; [Paul, Ash] Natl Hlth Serv, Bedford, England	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; NHS Blood & Transplant (NHSBT)	Djulbegovic, B (corresponding author), Univ S Florida, Ctr Evidence Based Med & Hlth Outcomes Res, 12901 Bruce B Downs Blvd,MDC27,Room 3127-3126, Tampa, FL 33612 USA.	bdjulbeg@health.usf.edu	Djulbegovic, Benjamin/I-3661-2012	Djulbegovic, Benjamin/0000-0003-0671-1447				Abernethy AP, 2009, ANN INTERN MED, V150, P336, DOI 10.7326/0003-4819-150-5-200903030-00107; Brody H, 2011, AM J PUBLIC HEALTH, V101, P399, DOI 10.2105/AJPH.2010.199844; Djulbegovic B, 2007, PLOS MED, V4, P211, DOI 10.1371/journal.pmed.0040026; Djulbegovic B, 2011, HBK PHILOS SCI, V16, P299; Djulbegovic M, 2011, JAMA-J AM MED ASSOC, V305, P298, DOI 10.1001/jama.2010.2013; Hammond K. R, 1996, HUMAN JUDGMENT SOCIA; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hebert PC, 2007, CAN MED ASSOC J, V177, P697, DOI 10.1503/cmaj.071223; Stafford RS, 2008, NEW ENGL J MED, V358, P1427, DOI 10.1056/NEJMp0802107	9	74	74	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2011	305	19					2005	2006		10.1001/jama.2011.650	http://dx.doi.org/10.1001/jama.2011.650			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764WO	21586716				2022-12-28	WOS:000290665500025
J	James, S; Daubert, JC; Van de Werf, F				James, Stefan; Daubert, Jean-Claude; Van de Werf, Frans			Commentary: Use of registries to investigate the past and develop the future	BRITISH MEDICAL JOURNAL			English	Editorial Material									[James, Stefan] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Daubert, Jean-Claude] Univ Rennes 1, CHU Rennes, F-35014 Rennes, France; [Van de Werf, Frans] Univ Hosp Leuven, Dept Cardiovasc Med, Louvain, Belgium	Uppsala University; CHU Rennes; Universite de Rennes; KU Leuven; University Hospital Leuven	James, S (corresponding author), Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden.	stefan.james@ucr.uu.se	James, Stefan K/J-4554-2014	Van de Werf, Frans/0000-0001-9479-7767				FRASER AG, 2011, EUR HEART J; Frobert O, 2010, AM HEART J, V160, P1042, DOI 10.1016/j.ahj.2010.08.040; Herrett E, 2010, HEART, V96, P1264, DOI 10.1136/hrt.2009.192328; Jernberg T, 2010, HEART, V96, P1617, DOI 10.1136/hrt.2010.198804	4	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 14	2011	342								d2826	10.1136/bmj.d2826	http://dx.doi.org/10.1136/bmj.d2826			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765OV	21572132	Green Submitted			2022-12-28	WOS:000290719100003
J	Skinner, J; Kay, P				Skinner, John; Kay, Peter			Commentary: Metal on metal hips	BRITISH MEDICAL JOURNAL			English	Editorial Material							RESURFACINGS; ARTHROPLASTY; FAILURE; BEARING		[Skinner, John] Royal Natl Orthopaed Hosp, Stanmore HA7 4LP, Middx, England; [Skinner, John] British Orthopaed Assoc, Joint Expert Advisory Grp Met Bearing Hips, British Hip Soc, London, England; [Kay, Peter] Wrightington Hosp, Wigan, England	University of London; University College London; Royal National Orthopaedic Hospital NHS Trust	Skinner, J (corresponding author), Royal Natl Orthopaed Hosp, Stanmore HA7 4LP, Middx, England.	john.skinner@ucl.ac.uk		Skinner, John/0000-0002-1901-9057				Berton C, 2010, J BONE JOINT SURG BR, V92B, P202, DOI 10.1302/0301-620X.92B2.22653; Bolland BJRF, 2011, J BONE JOINT SURG BR, V93B, P608, DOI 10.1302/0301-620X.93B5.26309; Bozic KJ, 2009, J BONE JOINT SURG AM, V91A, P1614, DOI 10.2106/JBJS.H.01220; Brodner W, 2003, J BONE JOINT SURG AM, V85A, P2168, DOI 10.2106/00004623-200311000-00017; Carrothers AD, 2010, J BONE JOINT SURG BR, V92B, P1344, DOI 10.1302/0301-620X.92B10.23504; CLOHISY JC, 2004, CLIN ORTHOP RELAT R, V429, P66; Grammatopoulos G, 2009, J BONE JOINT SURG BR, V91B, P1019, DOI 10.1302/0301-620X.91B8.22562; HADDAD FS, J BONE JOINT SURG BR, V93, P572; Hart AJ, 2009, J BONE JOINT SURG BR, V91B, P738, DOI 10.1302/0301-620X.91B6.21682; McMinn D, 2006, P I MECH ENG H, V220, P239, DOI 10.1243/095441105X68944; Medicines and Healthcare Products Regulatory Agency, 2010, MED DEV AL MDA 2010; Morlock MM, 2008, J BONE JOINT SURG AM, V90A, P89, DOI 10.2106/JBJS.H.00621; National Joint Registry for England and Wales, 2010, 7 NAT JOINT REG ENGL; Pandit H, 2008, J BONE JOINT SURG BR, V90B, P847, DOI 10.1302/0301-620X.90B7.20213; Sandiford NA, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749-799X-5-88; Shimmin AJ, 2005, J BONE JOINT SURG BR, V87B, P463, DOI 10.1302/0301-620X.87B4	16	19	19	1	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 14	2011	342								d3009	10.1136/bmj.d3009	http://dx.doi.org/10.1136/bmj.d3009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765OV	21572137				2022-12-28	WOS:000290719100008
J	Thompson, M; Heneghan, C; Billingsley, M; Cohen, D				Thompson, Matthew; Heneghan, Carl; Billingsley, Matthew; Cohen, Deborah			Medical device recalls and transparency in the UK	BRITISH MEDICAL JOURNAL			English	Editorial Material							FDA		[Thompson, Matthew; Heneghan, Carl] Univ Oxford, Dept Primary Hlth Care, Oxford, England; [Thompson, Matthew] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA; [Billingsley, Matthew; Cohen, Deborah] BMJ, London WC1H 9JR, England	University of Oxford; Oregon Health & Science University	Heneghan, C (corresponding author), Univ Oxford, Dept Primary Hlth Care, Oxford, England.	carl.heneghan@phc.ox.ac.uk						Avorn J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c5730; Dhruva SS, 2009, JAMA-J AM MED ASSOC, V302, P2679, DOI 10.1001/jama.2009.1899; Heneghan C, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000155; Hines JZ, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000280; Lenzer J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4753; MAXWELL A, 2010, CLINICA         0726; *MHRA, 2010, DEV B MHRA; *MHRA, MED DEV DIR; *MHRA, 2011, REP ADV INC DISS MED; SORREL S, APPL CLIN TRIALS ONL; Zuckerman DM, 2011, ARCH INTERN MED 0214	11	26	26	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 14	2011	342								d2973	10.1136/bmj.d2973	http://dx.doi.org/10.1136/bmj.d2973			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765OV	21572136				2022-12-28	WOS:000290719100007
J	[Anonymous]				[Anonymous]			Stroke care-a work in progress	LANCET			English	Editorial Material																			0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 14	2011	377	9778					1625	1625						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766JF	21571128				2022-12-28	WOS:000290777700001
J	Dutko, JA; Mullins, MC				Dutko, James A.; Mullins, Mary C.			SnapShot: BMP Signaling in Development	CELL			English	Editorial Material									[Dutko, James A.; Mullins, Mary C.] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Dutko, JA (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.				NICHD NIH HHS [5T32HD007516] Funding Source: Medline; NIGMS NIH HHS [R01-GM56326] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056326] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blair SS, 2007, ANNU REV CELL DEV BI, V23, P293, DOI 10.1146/annurev.cellbio.23.090506.123606; Little SC, 2009, NAT CELL BIOL, V11, P637, DOI 10.1038/ncb1870; Liu AM, 2005, NAT REV NEUROSCI, V6, P945, DOI 10.1038/nrn1805; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Umulis D, 2009, DEVELOPMENT, V136, P3715, DOI 10.1242/dev.031534; Vuilleumier R, 2010, NAT CELL BIOL, V12, P611, DOI 10.1038/ncb2064; Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012; Zakin L, 2010, DEV BIOL, V347, P204, DOI 10.1016/j.ydbio.2010.08.025	8	28	29	0	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 13	2011	145	4					636	U157		10.1016/j.cell.2011.05.001	http://dx.doi.org/10.1016/j.cell.2011.05.001			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565618	Bronze			2022-12-28	WOS:000290560800016
J	Short, PM; Lipworth, SIW; Elder, DHJ; Schembri, S; Lipworth, BJ				Short, Philip M.; Lipworth, Samuel I. W.; Elder, Douglas H. J.; Schembri, Stuart; Lipworth, Brian J.			Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INHALED CORTICOSTEROIDS; MORTALITY; COPD; RISK; SELECTIVITY; REDUCTION; BLOCKADE; AIRWAYS; ASTHMA	Objective To examine the effect of beta blockers in the management of chronic obstructive pulmonary disease (COPD), assessing their effect on mortality, hospital admissions, and exacerbations of COPD when added to established treatment for COPD. Design Retrospective cohort study using a disease specific database of COPD patients (TARDIS) linked to the Scottish morbidity records of acute hospital admissions, the Tayside community pharmacy prescription records, and the General Register Office for Scotland death registry. Setting Tayside, Scotland (2001-2010) Population 5977 patients aged >50 years with a diagnosis of COPD. Main outcome measures Hazard ratios for all cause mortality, emergency oral corticosteroid use, and respiratory related hospital admissions calculated through Cox proportional hazard regression after correction for influential covariates. Results Mean follow-up was 4.35 years, mean age at diagnosis was 69.1 years, and 88% of beta blockers used were cardioselective. There was a 22% overall reduction in all cause mortality with beta blocker use. Furthermore, there were additive benefits of beta blockers on all cause mortality at all treatment steps for COPD. Compared with controls (given only inhaled therapy with either short acting beta agonists or short acting antimuscarinics), the adjusted hazard ratio for all cause mortality was 0.28 (95% CI 0.21 to 0.39) for treatment with inhaled corticosteroid, long acting beta agonist, and long acting antimuscarinic plus beta blocker versus 0.43 (0.38 to 0.48) without beta blocker. There were similar trends showing additive benefits of beta blockers in reducing oral corticosteroid use and hospital admissions due to respiratory disease. beta blockers had no deleterious impact on lung function at all treatment steps when given in conjunction with either a long acting beta agonist or antimuscarinic agent Conclusions beta blockers may reduce mortality and COPD exacerbations when added to established inhaled stepwise therapy for COPD, independently of overt cardiovascular disease and cardiac drugs, and without adverse effects on pulmonary function.	[Short, Philip M.; Lipworth, Brian J.] Univ Dundee, Ctr Cardiovasc & Lung Biol, Div Med Sci, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland; [Lipworth, Samuel I. W.] Univ St Andrews, Bute Med Sch, St Andrews KY16 9UY, Fife, Scotland; [Schembri, Stuart] Perth Royal Infirm, Dept Resp Med, Perth PH1 1NX, Scotland	University of Dundee; University of St Andrews	Lipworth, BJ (corresponding author), Univ Dundee, Ctr Cardiovasc & Lung Biol, Div Med Sci, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland.	brianlipworth@gmail.com	Hug, Balthasar L./G-1568-2010	Lipworth, Sam/0000-0001-5872-9214	University of Dundee	University of Dundee	This study was funded by the University of Dundee. The university had no influence over the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.	Agusti A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-122; [Anonymous], 2009, GLOB STRAT DIAGN MAN; Chang CL, 2010, INTERN MED J, V40, P193, DOI 10.1111/j.1445-5994.2009.01943.x; Crim C, 2009, EUR RESPIR J, V34, P641, DOI 10.1183/09031936.00193908; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GAULD DR, 1979, MED J AUSTRALIA, V2, P88; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; IND PW, 1989, AM REV RESPIR DIS, V139, P1390, DOI 10.1164/ajrccm/139.6.1390; LIPWORTH BJ, 1991, EUR J CLIN PHARMACOL, V40, P135; LIPWORTH BJ, 1989, BRIT J CLIN PHARMACO, V28, P95, DOI 10.1111/j.1365-2125.1989.tb03510.x; LIPWORTH BJ, 1991, EUR J CLIN PHARMACOL, V40, P467, DOI 10.1007/BF00315224; Lipworth BJ, 2009, LANCET, V373, P104, DOI 10.1016/S0140-6736(09)60018-0; Mancini GBJ, 2006, J AM COLL CARDIOL, V47, P2554, DOI 10.1016/j.jacc.2006.04.039; Olenchock BA, 2009, AM J CARDIOL, V103, P295, DOI 10.1016/j.amjcard.2008.09.081; RAINE JM, 1981, BRIT MED J, V282, P548, DOI 10.1136/bmj.282.6263.548; Rodrigo GJ, 2009, CHEST, V136, P1029, DOI 10.1378/chest.09-0821; Rutten FH, 2010, ARCH INTERN MED, V170, P880, DOI 10.1001/archinternmed.2010.112; Salpeter S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003566.pub2; Salpeter SR, 2003, RESP MED, V97, P1094, DOI 10.1016/S0954-6111(03)00168-9; Schembri S, 2009, RESP MED, V103, P1461, DOI 10.1016/j.rmed.2009.04.021; Scottish Government, 2009, SCOTT IND MULT DEPR; Shah SM, 2008, BRIT J GEN PRACT, V58, P862, DOI 10.3399/bjgp08X376195; Sin DD, 2003, CIRCULATION, V107, P1514, DOI 10.1161/01.CIR.0000056767.69054.B3; Soyseth V, 2007, EUR RESPIR J, V29, P279, DOI 10.1183/09031936.00106406; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; van der Woude HJ, 2005, CHEST, V127, P818, DOI 10.1378/chest.127.3.818; van Gestel YRBM, 2008, AM J RESP CRIT CARE, V178, P695, DOI 10.1164/rccm.200803-384OC; van Gestel Yvette R B M, 2009, Int J Chron Obstruct Pulmon Dis, V4, P177; WHEELDON NM, 1992, BRIT J CLIN PHARMACO, V34, P337, DOI 10.1111/j.1365-2125.1992.tb05640.x; WILLIAMS IP, 1980, THORAX, V35, P160, DOI 10.1136/thx.35.2.160; Zvezdin B, 2009, CHEST, V136, P376, DOI 10.1378/chest.08-2918	32	165	180	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2011	342								d2549	10.1136/bmj.d2549	http://dx.doi.org/10.1136/bmj.d2549			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765OM	21558357	Green Published, hybrid			2022-12-28	WOS:000290718100001
J	Pelet, S; Rudolf, F; Nadal-Ribelles, M; de Nadal, E; Posas, F; Peter, M				Pelet, Serge; Rudolf, Fabian; Nadal-Ribelles, Mariona; de Nadal, Eulalia; Posas, Francesc; Peter, Matthias			Transient Activation of the HOG MAPK Pathway Regulates Bimodal Gene Expression	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SINGLE-CELL; TRANSCRIPTION; ADAPTATION; KINASE; OSMOREGULATION; NOISE	Mitogen-activated protein kinase (MAPK) cascades are conserved signaling modules that control many cellular processes by integrating intra- and extracellular cues. The p38/Hog1 MAPK is transiently activated in response to osmotic stress, leading to rapid translocation into the nucleus and induction of a specific transcriptional program. When investigating the dynamic interplay between Hog1 activation and Hog1-driven gene expression, we found that Hog1 activation increases linearly with stimulus, whereas the transcriptional output is bimodal. Modeling predictions, corroborated by single-cell experiments, established that a slow stochastic transition from a repressed to an activated transcriptional state in conjunction with transient Hog1 activation generates this behavior. Together, these findings provide a molecular mechanism by which a cell can impose a transcriptional threshold in response to a linear signaling behavior.	[Pelet, Serge; Rudolf, Fabian; Peter, Matthias] ETH, Dept Biol, Inst Biochem, CH-8093 Zurich, Switzerland; [Nadal-Ribelles, Mariona; de Nadal, Eulalia; Posas, Francesc] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signaling Unit, E-08003 Barcelona, Spain	Swiss Federal Institutes of Technology Domain; ETH Zurich; Pompeu Fabra University	Pelet, S (corresponding author), ETH, Dept Biol, Inst Biochem, Schafmattstr 18, CH-8093 Zurich, Switzerland.	serge.pelet@bc.biol.ethz.ch; matthias.peter@bc.biol.ethz.ch	Nadal-Ribelles, Mariona/T-7540-2017; Posas, Francesc/K-1364-2013; de Nadal, Eulàlia/J-8178-2014; Nadal-Ribelles, Mariona/ABE-4295-2021	Nadal-Ribelles, Mariona/0000-0003-3314-6711; Posas, Francesc/0000-0002-4164-7076; de Nadal, Eulàlia/0000-0003-0039-5607; Nadal-Ribelles, Mariona/0000-0003-3314-6711; Peter, Matthias/0000-0002-2160-6824; Pelet, Serge/0000-0002-0245-049X	ICREA Academia (Generalitat de Catalunya); Fundacion Marcelino Botin (FMB); Ministerio de Ciencia y Innovacion [BFU2008-00530, BIO2009-07762]; Swiss National Science Foundation; ETHZ;  [155111]	ICREA Academia (Generalitat de Catalunya)(ICREAGeneralitat de Catalunya); Fundacion Marcelino Botin (FMB); Ministerio de Ciencia y Innovacion(Spanish Government); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); ETHZ(ETH Zurich); 	We thank R. Dechant, C. Schuller, G. Ammerer, A Colman-Lerner, and A. Smith for strains, plasmids, and helpful discussions, and S.-S. Lee and H. Koeppl fur help with flow chamber experiments and model design, respectively. We are grateful to C. Rupp and D. Conde for technical assistance. This work was supported by QUASI, UNICELLSYS, the SystemsX.ch organization, and the Competence Centre "Systems Physiology and Metabolic Disease" (CC-SPMD). M.N.-R. is supported by 155111, and F.P is recipient of an ICREA Academia (Generalitat de Catalunya) award. Work in the Posas and de Nadal laboratories is funded by the Fundacion Marcelino Botin (FMB) and the Ministerio de Ciencia y Innovacion (BFU2008-00530 to E.N. and BIO2009-07762 to F.P.). The Peter Laboratory is supported by the Swiss National Science Foundation and ETHZ. The authors declare that they have no competing financial interests.	Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; Bar-Even A, 2006, NAT GENET, V38, P636, DOI 10.1038/ng1807; Capaldi AP, 2008, NAT GENET, V40, P1300, DOI 10.1038/ng.235; Chen RE, 2007, BBA-MOL CELL RES, V1773, P1311, DOI 10.1016/j.bbamcr.2007.05.003; Colman-Lerner A, 2005, NATURE, V437, P699, DOI 10.1038/nature03998; de Nadal E, 2003, MOL CELL BIOL, V23, P229, DOI 10.1128/MCB.23.1.229-237.2003; de Nadal E, 2010, EMBO J, V29, P4, DOI 10.1038/emboj.2009.346; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Hersen P, 2008, P NATL ACAD SCI USA, V105, P7165, DOI 10.1073/pnas.0710770105; Hohmann S, 2007, METHOD ENZYMOL, V428, P29, DOI 10.1016/S0076-6879(07)28002-4; Klopf E, 2009, MOL CELL BIOL, V29, P4994, DOI 10.1128/MCB.01858-08; Loewer A, 2010, CELL, V142, P89, DOI 10.1016/j.cell.2010.05.031; Lopez-Maury L, 2008, NAT REV GENET, V9, P583, DOI 10.1038/nrg2398; Macia J, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000056; Mas G, 2009, EMBO J, V28, P326, DOI 10.1038/emboj.2008.299; Muzzey D, 2009, CELL, V138, P160, DOI 10.1016/j.cell.2009.04.047; Newman JRS, 2006, NATURE, V441, P840, DOI 10.1038/nature04785; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Strickfaden SC, 2007, CELL, V128, P519, DOI 10.1016/j.cell.2006.12.032; Weake VM, 2010, NAT REV GENET, V11, P426, DOI 10.1038/nrg2781; Westfall PJ, 2008, P NATL ACAD SCI USA, V105, P12212, DOI 10.1073/pnas.0805797105; Yu RC, 2008, NATURE, V456, P755, DOI 10.1038/nature07513; Zapater M, 2007, MOL CELL BIOL, V27, P3900, DOI 10.1128/MCB.00089-07	25	104	105	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 6	2011	332	6030					732	735		10.1126/science.1198851	http://dx.doi.org/10.1126/science.1198851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	759RK	21551064	Green Accepted			2022-12-28	WOS:000290265800047
J	Li, MY; Wang, IX; Li, Y; Bruzel, A; Richards, AL; Toung, JM; Cheung, VG				Li, Mingyao; Wang, Isabel X.; Li, Yun; Bruzel, Alan; Richards, Allison L.; Toung, Jonathan M.; Cheung, Vivian G.			Widespread RNA and DNA Sequence Differences in the Human Transcriptome	SCIENCE			English	Article							MESSENGER-RNA; EDITING SITES; IDENTIFICATION; POLYMERASE; CONVERSION; CEPH	The transmission of information from DNA to RNA is a critical process. We compared RNA sequences from human B cells of 27 individuals to the corresponding DNA sequences from the same individuals and uncovered more than 10,000 exonic sites where the RNA sequences do not match that of the DNA. All 12 possible categories of discordances were observed. These differences were nonrandom as many sites were found in multiple individuals and in different cell types, including primary skin cells and brain tissues. Using mass spectrometry, we detected peptides that are translated from the discordant RNA sequences and thus do not correspond exactly to the DNA sequences. These widespread RNA-DNA differences in the human transcriptome provide a yet unexplored aspect of genome variation.	[Wang, Isabel X.; Bruzel, Alan; Cheung, Vivian G.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [Li, Mingyao] Univ Penn, Sch Med, Dept Biostat, Philadelphia, PA 19104 USA; [Li, Mingyao] Univ Penn, Sch Med, Dept Epidemiol, Philadelphia, PA 19104 USA; [Li, Yun] Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC 27599 USA; [Li, Yun] Univ N Carolina, Sch Med, Dept Biostat, Chapel Hill, NC 27599 USA; [Richards, Allison L.] Univ Penn, Sch Med, Cell & Mol Biol Grad Program, Philadelphia, PA 19104 USA; [Toung, Jonathan M.] Univ Penn, Sch Med, Genom & Computat Biol Grad Program, Philadelphia, PA 19104 USA; [Cheung, Vivian G.] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; [Cheung, Vivian G.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Cheung, VG (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.	vcheung@mail.med.upenn.edu	Cheung, Vivian G./AAT-3115-2020	wang, isabel/0000-0003-3264-7071	National Institutes of Health; Howard Hughes Medical Institute; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG005854] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Dedicated to the memory of Dr. Tom Kadesch who gave us important suggestions, taught us salient and subtle points on gene expression, and inspired us with his enthusiasm. Dr. Kadesch died during the preparation of this manuscript. We thank D. Epstein, H. Kazazian, D. Puppione, and L. Simpson for suggestions and discussions. We thank C. Gunter, R. Nussbaum, and J. Puck for comments on the manuscript, M. Morley for help with data analysis, W. Ankener for sample processing, and J. Devlin and CHOP NAP core for results on Sanger sequencing. The mass spectrometry analysis was carried out at the Wistar Proteomic Facility; we thank K. Speicher for help and suggestions. Funded by grants from the National Institutes of Health (to V. G. C. and M. L.) and support from the Howard Hughes Medical Institute. The RNA-Seq data have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus under the accession no. GSE25840.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Athanasiadis A, 2004, PLOS BIOL, V2, P2144, DOI 10.1371/journal.pbio.0020391; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Cann HM, 1992, CURR OPIN GENET DEV, V2, P393, DOI 10.1016/S0959-437X(05)80148-0; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Chester A, 2000, BBA-GENE STRUCT EXPR, V1494, P1, DOI 10.1016/S0167-4781(00)00219-0; Conticello SG, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-229; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; de Godoy LMF, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-6-r50; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Harrow J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s4; Hundley HA, 2008, RNA, V14, P2050, DOI 10.1261/rna.1165008; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; LIBBY RT, 1991, MOL MICROBIOL, V5, P999, DOI 10.1111/j.1365-2958.1991.tb01872.x; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; Matise TC, 2003, AM J HUM GENET, V73, P271, DOI 10.1086/377137; Michalski A, 2011, J PROTEOME RES, V10, P1785, DOI 10.1021/pr101060v; Montgomery SB, 2010, NATURE, V464, P773, DOI 10.1038/nature08903; Nishikura K, 2010, ANNU REV BIOCHEM, V79, P321, DOI 10.1146/annurev-biochem-060208-105251; Phreaner CG, 1996, PLANT CELL, V8, P107, DOI 10.1105/tpc.8.1.107; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Rosenberg BR, 2011, NAT STRUCT MOL BIOL, V18, P230, DOI 10.1038/nsmb.1975; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; Sakurai M, 2010, NAT CHEM BIOL, V6, P733, DOI 10.1038/nchembio.434; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sodek KL, 2008, MOL BIOSYST, V4, P762, DOI 10.1039/b717542f; Sydow JF, 2009, CURR OPIN STRUC BIOL, V19, P732, DOI 10.1016/j.sbi.2009.10.009; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Wang D, 2009, SCIENCE, V324, P1203, DOI 10.1126/science.1168729; Zenkin N, 2006, SCIENCE, V313, P518, DOI 10.1126/science.1127422	38	310	327	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2011	333	6038					53	58		10.1126/science.1207018	http://dx.doi.org/10.1126/science.1207018			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	785UF	21596952	Green Accepted, Green Published			2022-12-28	WOS:000292255400045
J	Lee, JM; Lee, YK; Mamrosh, JL; Busby, SA; Griffin, PR; Pathak, MC; Ortlund, EA; Moore, DD				Lee, Jae Man; Lee, Yoon Kwang; Mamrosh, Jennifer L.; Busby, Scott A.; Griffin, Patrick R.; Pathak, Manish C.; Ortlund, Eric A.; Moore, David D.			A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects	NATURE			English	Article							ORPHAN RECEPTORS; LIVER; IDENTIFICATION; LRH-1; PHOSPHOLIPIDS; HOMOLOG-1; BINDING; DEFICIENCY; ACTIVATION; PROMOTER	Nuclear hormone receptors regulate diverse metabolic pathways and the orphan nuclear receptor LRH-1 (also known as NR5A2) regulates bile acid biosynthesis(1,2). Structural studies have identified phospholipids as potential LRH-1 ligands(3-5), but their functional relevance is unclear. Here we show that an unusual phosphatidylcholine species with two saturated 12 carbon fatty acid acyl side chains (dilauroyl phosphatidylcholine (DLPC)) is an LRH-1 agonist ligand in vitro. DLPC treatment induces bile acid biosynthetic enzymes in mouse liver, increases bile acid levels, and lowers hepatic triglycerides and serum glucose. DLPC treatment also decreases hepatic steatosis and improves glucose homeostasis in two mouse models of insulin resistance. Both the antidiabetic and lipotropic effects are lost in liver-specific Lrh-1 knockouts. These findings identify an LRH-1 dependent phosphatidylcholine signalling pathway that regulates bile acid metabolism and glucose homeostasis.	[Lee, Jae Man; Moore, David D.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Lee, Yoon Kwang; Mamrosh, Jennifer L.; Moore, David D.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Lee, Yoon Kwang] Northeastern Ohio Univ Coll Med & Pharm, Dept Integrat Med Sci, Coll Med, Rootstown, OH 44272 USA; [Lee, Yoon Kwang] Northeastern Ohio Univ Coll Med & Pharm, Coll Pharm, Rootstown, OH 44272 USA; [Busby, Scott A.; Griffin, Patrick R.] Scripps Res Inst, Scripps Res Mol Screening Ctr, Jupiter, FL 33458 USA; [Pathak, Manish C.; Ortlund, Eric A.] Emory Univ, Dept Biochem, Sch Med, Atlanta, GA 30322 USA	Baylor College of Medicine; Baylor College of Medicine; Northeast Ohio Medical University (NEOMED); Northeast Ohio Medical University (NEOMED); Scripps Research Institute; Emory University	Moore, DD (corresponding author), Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA.	moore@bcm.edu	Ortlund, Eric Anthony/P-3121-2019; Ortlund, Eric Anthony/F-4672-2014	Ortlund, Eric Anthony/0000-0001-8855-3029; Ortlund, Eric Anthony/0000-0001-8855-3029	NIH [DK-079638, DK068804, R01 CA134873]; USDA [ARS 6250-52000-055]; Alkek Foundation; Robert R. P. Doherty Jr-Welch Chair in Science; NATIONAL CANCER INSTITUTE [R01CA134873] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007696, R01DK068804, P30DK079638, R01DK083572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U54MH084512] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USDA(United States Department of Agriculture (USDA)); Alkek Foundation; Robert R. P. Doherty Jr-Welch Chair in Science; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank S. A. Kliewer and D. J. Mangelsdorf (UT Southwestern Medical Center) for the gift of Lrh-1<SUP>f/f</SUP> mice, A. J. Cooney for the OCT4 promoter constructs, C. Mills and D. Kuruvilla for experimental assistance, the Baylor College of Medicine Diabetes Endocrine Research Center (supported by NIH DK-079638 and USDA ARS 6250-52000-055) and the services of the Mouse Metabolism Core for hyperinsulinaemic clamp studies, and the current and previous members of the D.D.M. laboratory for discussions and technical support. Supported by NIH R01 DK068804, the Alkek Foundation and the Robert R. P. Doherty Jr-Welch Chair in Science to D.D.M., and NIH R01 CA134873 to P.R.G.	Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Chakravarthy MV, 2009, CELL, V138, P476, DOI 10.1016/j.cell.2009.05.036; Chalkiadaki A, 2005, MOL CELL BIOL, V25, P5095, DOI 10.1128/MCB.25.12.5095-5105.2005; Cusi K, 2009, CURR OPIN ENDOCRINOL, V16, P141, DOI 10.1097/MED.0b013e3283293015; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Dong B, 2009, P NATL ACAD SCI USA, V106, P18831, DOI 10.1073/pnas.0909731106; Gu PL, 2005, MOL CELL BIOL, V25, P3492, DOI 10.1128/MCB.25.9.3492-3505.2005; Hunt AN, 2006, J CELL BIOCHEM, V97, P244, DOI 10.1002/jcb.20691; Kanayama T, 2007, J BIOL CHEM, V282, P10290, DOI 10.1074/jbc.M700270200; Kang HW, 2010, TRENDS ENDOCRIN MET, V21, P449, DOI 10.1016/j.tem.2010.02.001; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Lee H, 2000, CIRC RES, V87, P516; Lee YK, 2006, J BIOL CHEM, V281, P7850, DOI 10.1074/jbc.M509115200; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lee YK, 2008, MOL ENDOCRINOL, V22, P1345, DOI 10.1210/me.2007-0565; Li DH, 2007, MOL CELL BIOL, V27, P6669, DOI 10.1128/MCB.00355-07; Li SJ, 2010, P NATL ACAD SCI USA, V107, P3441, DOI 10.1073/pnas.0914798107; Li Y, 2005, MOL CELL, V17, P491, DOI 10.1016/j.molcel.2005.02.002; Ma K, 2006, J CLIN INVEST, V116, P1102, DOI 10.1172/JCI25604; Mataki C, 2007, MOL CELL BIOL, V27, P8330, DOI 10.1128/MCB.00852-07; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Ortlund EA, 2005, NAT STRUCT MOL BIOL, V12, P357, DOI 10.1038/nsmb910; Sablin EP, 2009, MOL ENDOCRINOL, V23, P25, DOI 10.1210/me.2007-0508; Savage DB, 2006, J CLIN INVEST, V116, P817, DOI 10.1172/JCI27300; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Urs AN, 2006, ENDOCRINOLOGY, V147, P5249, DOI 10.1210/en.2006-0355; Vidovic D, 2011, CHEMMEDCHEM, V6, P94, DOI 10.1002/cmdc.201000428; Wang W, 2005, P NATL ACAD SCI USA, V102, P7505, DOI 10.1073/pnas.0409482102; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Whitby RJ, 2006, J MED CHEM, V49, P6652, DOI 10.1021/jm060990k	32	162	167	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2011	474	7352					506	U135		10.1038/nature10111	http://dx.doi.org/10.1038/nature10111			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	781NJ	21614002	Green Accepted			2022-12-28	WOS:000291939700048
J	Edlin, BR				Edlin, Brian R.			Test and treat this silent killer	NATURE			English	Editorial Material							HEPATITIS-C VIRUS; INJECTION-DRUG USERS; UNITED-STATES; INFECTION		SUNY Downstate Coll Med, New York, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Edlin, BR (corresponding author), SUNY Downstate Coll Med, New York, NY USA.	brian.edlin@downstate.edu	Edlin, Brian R/F-2966-2018	Edlin, Brian R/0000-0001-8172-8797	NIDA NIH HHS [R01 DA029512, R01 DA016159, R01 DA021550] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA029512, R01DA016159, R01DA021550] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004; Edlin BR, 2006, CLIN INFECT DIS, V42, P673, DOI 10.1086/499960; Edlin BR, 2005, HEPATOLOGY, V42, p213A; *I MED, 2009, IN NAT PRIOR COMP EF, P126; Institute of Medicine, 2010, HEP LIV CANC NAT STR; McQuillan GM, 1997, J ACQ IMMUN DEF SYND, V14, P355, DOI 10.1097/00042560-199704010-00008; Onofrey Shauna, 2011, Morbidity and Mortality Weekly Report, V60, P537; Pyenson B., 2009, CONSEQUENCES HEPATIT; Tseng FC, 2007, HEPATOLOGY, V46, P666, DOI 10.1002/hep.21765	9	62	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2011	474	7350					S18	S19		10.1038/474S18a	http://dx.doi.org/10.1038/474S18a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	774PE	21613999	Bronze, Green Accepted			2022-12-28	WOS:000291397800011
J	Farrell, HM				Farrell, Helen M.			A House Built Out of Madness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Hosp Cincinnati, Cincinnati, OH USA	University of Cincinnati	Farrell, HM (corresponding author), Univ Hosp Cincinnati, Cincinnati, OH USA.	helen.farrell@yahoo.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2153	2154		10.1001/jama.2011.701	http://dx.doi.org/10.1001/jama.2011.701			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21632475				2022-12-28	WOS:000291106300001
J	Leproult, R; Van Cauter, E				Leproult, Rachel; Van Cauter, Eve			Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy Men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							OLDER MEN		[Leproult, Rachel; Van Cauter, Eve] Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Leproult, R (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	evcauter@medicine.bsd.uchicago.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000055] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000055, MO1-RR-00055] Funding Source: Medline; NHLBI NIH HHS [R01 HL072694, 5R01HL72694-5] Funding Source: Medline; NIDDK NIH HHS [P60DK-020595, P60 DK020595] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen ML, 2008, SLEEP MED REV, V12, P365, DOI 10.1016/j.smrv.2007.12.003; Axelsson J, 2005, J CLIN ENDOCR METAB, V90, P4530, DOI 10.1210/jc.2005-0520; Bremner WJ, 2010, NEW ENGL J MED, V363, P189, DOI 10.1056/NEJMe1006197; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; MONK TH, 1989, PSYCHIAT RES, V27, P89, DOI 10.1016/0165-1781(89)90013-9; Penev PD, 2007, SLEEP, V30, P427, DOI 10.1093/sleep/30.4.427	6	150	157	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2173	2174		10.1001/jama.2011.710	http://dx.doi.org/10.1001/jama.2011.710			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21632481	Green Accepted			2022-12-28	WOS:000291106300017
J	Ruthenburg, AJ; Li, HT; Milne, TA; Dewell, S; McGinty, RK; Yuen, M; Ueberheide, B; Dou, YL; Muir, TW; Patel, DJ; Allis, CD				Ruthenburg, Alexander J.; Li, Haitao; Milne, Thomas A.; Dewell, Scott; McGinty, Robert K.; Yuen, Melanie; Ueberheide, Beatrix; Dou, Yali; Muir, Tom W.; Patel, Dinshaw J.; Allis, C. David			Recognition of a Mononucleosomal Histone Modification Pattern by BPTF via Multivalent Interactions	CELL			English	Article							CHROMATIN REMODELING COMPLEX; PHD FINGER; MASS-SPECTROMETRY; NATIVE CHROMATIN; BINDING MODULES; HUMAN-CELLS; FACTOR NURF; BROMODOMAIN; METHYLATION; LYSINE-4	Little is known about how combinations of histone marks are interpreted at the level of nucleosomes. The second PHD finger of human BPTF is known to specifically recognize histone H3 when methylated on lysine 4 (H3K4me2/3). Here, we examine how additional heterotypic modifications influence BPTF binding. Using peptide surrogates, three acetyllysine ligands are indentified for a PHD-adjacent bromodomain in BPTF via systematic screening and biophysical characterization. Although the bromodomain displays limited discrimination among the three possible acetyllysines at the peptide level, marked selectivity is observed for only one of these sites, H4K16ac, in combination with H3K4me3 at the mononucleosome level. In support, these two histone marks constitute a unique trans-histone modification pattern that unambiguously resides within a single nucleosomal unit in human cells, and this module colocalizes with these marks in the genome. Together, our data call attention to nucleosomal patterning of covalent marks in dictating critical chromatin associations.	[Ruthenburg, Alexander J.; Milne, Thomas A.; Allis, C. David] Rockefeller Univ, Lab Chromatin Biol & Epigenet, New York, NY 10065 USA; [Dewell, Scott] Rockefeller Univ, Genom Resource Ctr, New York, NY 10065 USA; [McGinty, Robert K.; Yuen, Melanie; Muir, Tom W.] Rockefeller Univ, Lab Synthet Prot Chem, New York, NY 10065 USA; [Ueberheide, Beatrix] Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10065 USA; [Li, Haitao; Patel, Dinshaw J.] Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA; [Dou, Yali] Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA	Rockefeller University; Rockefeller University; Rockefeller University; Rockefeller University; Memorial Sloan Kettering Cancer Center; University of Michigan System; University of Michigan	Allis, CD (corresponding author), Rockefeller Univ, Lab Chromatin Biol & Epigenet, 1230 York Ave, New York, NY 10065 USA.	alliscd@rockefeller.edu	Milne, Tom/E-1872-2016; Li, Haitao/B-2668-2012; Muir, Tom/AHD-0860-2022; Ruthenburg, Alexander/F-3992-2015	Milne, Tom/0000-0002-0413-4271; Li, Haitao/0000-0001-6741-293X; Muir, Tom/0000-0001-9635-0344; Ruthenburg, Alexander/0000-0003-2709-4564; Ueberheide, Beatrix/0000-0003-2512-0204	National Center for Research Resources at the National Institutes of Health; Irvington Institute of the Cancer Research Institute; MSTP; NIH; Rockefeller University; Leukemia and Lymphoma Society; Starr Foundation; Abby Rockefeller Mauze Trust; Dewitt Wallace and Maloris Foundations; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P30EB009998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040922, T32GM007739, R37GM053512, R01GM053512] Funding Source: NIH RePORTER	National Center for Research Resources at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Irvington Institute of the Cancer Research Institute; MSTP; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rockefeller University; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Starr Foundation; Abby Rockefeller Mauze Trust; Dewitt Wallace and Maloris Foundations; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank the staff at beamline 24ID-C of the Advanced Photon Source at the Argonne National Laboratory and the staff at beamline X29 of the National Synchrotron Light Source at Brookhaven National Laboratory, supported by the US Department of Energy, for assistance with data collection. This work is based upon research conducted at the Northeastern Collaborative Access Team (NE-CAT) beamlines of the Advanced Photon Source and the Macromolecular Crystallography Research Resource (PXRR) at the National Synchrotron Light Source, which are supported by the National Center for Research Resources at the National Institutes of Health. We would like to thank L. Liang for assistance in protein production and crystallization of BPTF H4 peptide complexes; H. A. Zebrowski for assistance in the preparation of the SPOT membrane; S. S. Yi of the Microchemistry and Proteomics Core at Memorial-Sloan Kettering Cancer Center for synthesis of peptides; Y. Wei of the Rockefeller Chemical Biology Spectroscopy center for use of their Biacore instrument; S. Yokoyama and H. Kurumizaka for an expression construct bearing codon optimized histone H4; K. Chiang for his 3_601_3_x32 repeat plasmid; M. Vila-Perello for HF cleavage of Boc-peptides; H. Dormann for HP1-chromodomain recombinantly produced protein; H. Yu of the Rockefeller Proteomics Core for MS assistance; C. Wu for the human BPTF cDNA; and L. Baker, F. Casadio, J. Denu, P. W. Lewis, K-M. Noh, R. G. Roeder, R. Sadeh, D. Shechter, T. Swigut, G. G. Wang, and J. Wysocka for valuable discussions and scientific input. A. J. R. is supported by Irvington Institute Fellowship Program of the Cancer Research Institute, and R. K. M. is supported by an MSTP grant. This work was supported by a MERIT grant from the NIH and funds from The Rockefeller University to C. D. A., as well as funds from the Leukemia and Lymphoma Society and Starr Foundation to C. D. A. and D. J. P. D. J. P. is supported by funds from the Abby Rockefeller Mauze Trust and the Dewitt Wallace and Maloris Foundations, and T. W. M. is supported by an award from the NIH. D. J. P. is a consultant in GlaxoSmithKline's epigenetic programs.	Badenhorst P, 2002, GENE DEV, V16, P3186, DOI 10.1101/gad.1032202; Badenhorst P, 2005, GENE DEV, V19, P2540, DOI 10.1101/gad.1342605; Bai X, 2007, GENETICS, V176, P1491, DOI 10.1534/genetics.107.071571; Barak O, 2003, EMBO J, V22, P6089, DOI 10.1093/emboj/cdg582; Basu A, 2009, P NATL ACAD SCI USA, V106, P13785, DOI 10.1073/pnas.0906801106; Becker PB, 2006, NATURE, V442, P31, DOI 10.1038/442031a; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Brand M, 2008, NAT PROTOC, V3, P398, DOI 10.1038/nprot.2008.8; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Changeux JP, 2005, SCIENCE, V308, P1424, DOI 10.1126/science.1108595; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Clapier CR, 2001, MOL CELL BIOL, V21, P875, DOI 10.1128/MCB.21.3.875-883.2001; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Eberharter A, 2004, EMBO J, V23, P4029, DOI 10.1038/sj.emboj.7600382; Grune T, 2003, MOL CELL, V12, P449, DOI 10.1016/S1097-2765(03)00273-9; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hamiche A, 2001, P NATL ACAD SCI USA, V98, P14316, DOI 10.1073/pnas.251421398; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Krishnamurthy V.M., 2006, FRAGMENT BASED APPRO, P11, DOI DOI 10.1002/3527608761.CH2; Kwon SY, 2008, DEV BIOL, V316, P538, DOI 10.1016/j.ydbio.2008.01.033; Kwon SY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000574; Landry J, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000241; Li B, 2007, SCIENCE, V316, P1050, DOI 10.1126/science.1139004; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; McGinty RK, 2008, NATURE, V453, P812, DOI 10.1038/nature06906; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mizzen CA, 1999, METHOD ENZYMOL, V304, P675; Moriniere J, 2009, NATURE, V461, P664, DOI 10.1038/nature08397; Muir TW, 2003, ANNU REV BIOCHEM, V72, P249, DOI 10.1146/annurev.biochem.72.121801.161900; Mujtaba S, 2007, ONCOGENE, V26, P5521, DOI 10.1038/sj.onc.1210618; Nady N, 2008, TRENDS BIOCHEM SCI, V33, P305, DOI 10.1016/j.tibs.2008.04.014; O'Neill LP, 2003, METHODS, V31, P76, DOI 10.1016/S1046-2023(03)00090-2; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Pesavento JJ, 2008, J BIOL CHEM, V283, P14927, DOI 10.1074/jbc.M709796200; Pesavento JJ, 2006, ANAL CHEM, V78, P4271, DOI 10.1021/ac0600050; Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051; Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schwanbeck R, 2004, J BIOL CHEM, V279, P39933, DOI 10.1074/jbc.M406060200; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shin HJ, 2009, BIOINFORMATICS, V25, P2605, DOI 10.1093/bioinformatics/btp479; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Shogren-Knaak MA, 2004, METHOD ENZYMOL, V375, P62; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8; Zeng L, 2008, STRUCTURE, V16, P643, DOI 10.1016/j.str.2008.01.010; Zheng CY, 2004, METHOD ENZYMOL, V375, P179; Zhou YG, 2005, CURR BIOL, V15, P1434, DOI 10.1016/j.cub.2005.06.057	58	240	245	1	73	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 27	2011	145	5					692	706		10.1016/j.cell.2011.03.053	http://dx.doi.org/10.1016/j.cell.2011.03.053			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21596426	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000291018600010
J	Noble, PW; Albera, C; Bradford, WZ; Costabel, U; Glassberg, MK; Kardatzke, D; King, TE; Lancaster, L; Sahn, SA; Szwarcberg, J; Valeyre, D; du Bois, RM				Noble, Paul W.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; Glassberg, Marilyn K.; Kardatzke, David; King, Talmadge E., Jr.; Lancaster, Lisa; Sahn, Steven A.; Szwarcberg, Javier; Valeyre, Dominique; du Bois, Roland M.		CAPACITY Study Grp	Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials	LANCET			English	Article							PLACEBO-CONTROLLED TRIAL; BLEOMYCIN HAMSTER MODEL; NECROSIS-FACTOR-ALPHA; TRANSCRIPTIONAL LEVEL; GENE-EXPRESSION; LUNG FIBROSIS; SURVIVAL	Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis. Methods In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a minimum of 72 weeks in 110 centres in Australia, Europe, and North America. In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo. The randomisation code (permuted block design) was computer generated and stratified by region. All study personnel were masked to treatment group assignment until after final database lock. Treatments were administered orally, 801 mg or 399 mg three times a day. The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72. Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, numbers NCT00287729 and NCT00287716. Findings In study 004,174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo. In study 006,171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo. All patients in both studies were analysed. In study 004, pirfenidone reduced decline in FVC (p=0.001). Mean FVC change at week 72 was -8.0% (SD 16.5) in the pirfenidone 2403 mg/day group and -12-4% (18.5) in the placebo group (difference 4.4%, 95% CI 0.7 to 9-1); 35 (20%) of 174 versus 60 (35%) of 174 patients, respectively, had a decline of at least 10%. A significant treatment effect was noted at all timepoints from week 24 and in an analysis over all study timepoints (p=0.0007). Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups. In study 006, the difference between groups in FVC change at week 72 was not significant (p=0.501). Mean change in FVC at week 72 was -9.0% (SD 19.6) in the pirfenidone group and -9.6% (19.1) in the placebo group, and the difference between groups in predicted FVC change at week 72 was not significant (0.6%, -3.5 to 4.7); however, a consistent pirfenidone effect was apparent until week 48 (p=0.005) and in an analysis of all study timepoints (p=0.007). Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12%] vs 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the placebo group. Fewer overall deaths (19 [6%] vs 29 [8%]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3%] vs 25 [7%]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups. Interpretation The data show pirfenidone has a favourable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.	[Noble, Paul W.] Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Sch Med, Durham, NC 27710 USA; [Albera, Carlo] Univ Turin, Dept Clin & Biol Sci, Turin, Italy; [Bradford, Williamson Z.; Kardatzke, David; Szwarcberg, Javier] InterMune, Brisbane, CA USA; [Costabel, Ulrich] Univ Duisburg Essen, Ruhrlandklin, Essen, Germany; [Costabel, Ulrich] Univ Duisburg Essen, Fac Med, Essen, Germany; [Glassberg, Marilyn K.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [King, Talmadge E., Jr.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Lancaster, Lisa] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Sahn, Steven A.] Med Univ S Carolina, Charleston, SC 29425 USA; [Valeyre, Dominique] Hop Avicenne, AP HP, F-93009 Bobigny, France; [du Bois, Roland M.] Univ London Imperial Coll Sci Technol & Med, London, England	Duke University; University of Turin; University of Duisburg Essen; University of Duisburg Essen; University of Miami; University of California System; University of California San Francisco; Vanderbilt University; Medical University of South Carolina; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Imperial College London	Noble, PW (corresponding author), Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Sch Med, 106 Res Dr,Box 103000, Durham, NC 27710 USA.	paul.noble@duke.edu	Agostini, Carlo/J-3103-2012; Poletti, Venerino/K-8821-2016	Agostini, Carlo/0000-0001-7786-3574; Poletti, Venerino/0000-0002-8634-2284; Morell Brotad, Ferran/0000-0002-7206-4543; Valeyre, dominique/0000-0003-4470-1776; Hollingsworth, Helen/0000-0001-9007-9012	InterMune (Brisbane, CA, USA)	InterMune (Brisbane, CA, USA)	This study was funded by InterMune (Brisbane, CA, USA). We are indebted to Alan Cohen, Kenneth Glasscock, and Sharon Safrin for medical writing and editorial assistance, and to the participating staff members and patients at all study centres.	Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646; Azuma A, 2005, AM J RESP CRIT CARE, V171, P1040, DOI 10.1164/rccm.200404-571OC; Bjoraker JA, 1998, AM J RESP CRIT CARE, V157, P199, DOI 10.1164/ajrccm.157.1.9704130; Collard HR, 2003, AM J RESP CRIT CARE, V168, P538, DOI 10.1164/rccm.200211-1311OC; Daniels CE, 2010, AM J RESP CRIT CARE, V181, P604, DOI 10.1164/rccm.200906-0964OC; Demedts M, 2005, NEW ENGL J MED, V353, P2229, DOI 10.1056/NEJMoa042976; du Bois R, 2009, AM J RESP CRIT CARE, V179; du Bois RM, 2011, AM J RESP CRIT CARE, V183, P1231, DOI [10.1164/rccm.201007.1179OC, 10.1164/rccm.201007-1179OC]; Eakin EG, 1998, CHEST, V113, P619, DOI 10.1378/chest.113.3.619; Flaherty KR, 2003, AM J RESP CRIT CARE, V168, P543, DOI 10.1164/rccm.200209-1112OC; Hirano A, 2006, AM J RESP CELL MOL, V35, P366, DOI 10.1165/rcmb.2005-0452OC; Holland AE, 2009, RESP MED, V103, P1430, DOI 10.1016/j.rmed.2009.04.024; Iyer SN, 1999, J PHARMACOL EXP THER, V289, P211; Iyer SN, 1998, EXP LUNG RES, V24, P119, DOI 10.3109/01902149809046058; Iyer SN, 1999, J PHARMACOL EXP THER, V291, P367; IYER SN, 1995, J LAB CLIN MED, V125, P779; Jegal Y, 2005, AM J RESP CRIT CARE, V171, P639, DOI 10.1164/rccm.200403-331OC; King TE, 2008, AM J RESP CRIT CARE, V177, P75, DOI 10.1164/rccm.200705-732OC; King TE, 2009, LANCET, V374, P222, DOI 10.1016/S0140-6736(09)60551-1; King TE, 2005, CHEST, V127, P171, DOI 10.1378/chest.127.1.171; King TE, 2001, AM J RESP CRIT CARE, V164, P1171, DOI 10.1164/ajrccm.164.7.2003140; Nakazato H, 2002, EUR J PHARMACOL, V446, P177, DOI 10.1016/S0014-2999(02)01758-2; Oku H, 2002, EUR J PHARMACOL, V446, P167, DOI 10.1016/S0014-2999(02)01757-0; Oku H, 2008, EUR J PHARMACOL, V590, P400, DOI 10.1016/j.ejphar.2008.06.046; Raghu G, 2004, NEW ENGL J MED, V350, P125, DOI 10.1056/NEJMoa030511; SCHWARTZ DA, 1994, AM J RESP CRIT CARE, V149, P450, DOI 10.1164/ajrccm.149.2.8306044; Spagnolo P, 2010, COCHRANE DB SYST REV, V9; Swigris JJ, 2010, THORAX, V65, P173, DOI 10.1136/thx.2009.113498; Taniguchi H, 2010, EUR RESPIR J, V35, P821, DOI 10.1183/09031936.00005209; Zappala CJ, 2010, EUR RESPIR J, V35, P830, DOI 10.1183/09031936.00155108	30	1336	1373	3	114	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2011	377	9779					1760	1769		10.1016/S0140-6736(11)60405-4	http://dx.doi.org/10.1016/S0140-6736(11)60405-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771AS	21571362				2022-12-28	WOS:000291130200034
J	Paim, J; Travassos, C; Almeida, C; Bahia, L; Macinko, J				Paim, Jairnilson; Travassos, Claudia; Almeida, Celia; Bahia, Ligia; Macinko, James			Health in Brazil 1 The Brazilian health system: history, advances, and challenges	LANCET			English	Article							PRIMARY-CARE; PROGRAM; HOSPITALS; EVENTS	Brazil is a country of continental dimensions with widespread regional and social inequalities. In this report, we examine the historical development and components of the Brazilian health system, focusing on the reform process during the past 40 years, including the creation of the Unified Health System. A defining characteristic of the contemporary health sector reform in Brazil is that it was driven by civil society rather than by governments, political parties, or international organisations. The advent of the Unified Health System increased access to health care for a substantial proportion of the Brazilian population, at a time when the system was becoming increasingly privatised. Much is still to be done if universal health care is to be achieved. Over the past 20 years, there have been other advances, including investments in human resources, science and technology, and primary care, and a substantial decentralisation process, widespread social participation, and growing public awareness of a right to health care. If the Brazilian health system is to overcome the challenges with which it is presently faced, strengthened political support is needed so that financing can be restructured and the roles of both the public and private sector can be redefined.	[Paim, Jairnilson] Univ Fed Bahia, Salvador, BA, Brazil; [Travassos, Claudia] Fundacao Oswaldo Cruz, Ctr Comunicacao & Informacao Cient & Tecnol, Rio De Janeiro, Brazil; [Almeida, Celia] Fundacao Oswaldo Cruz, Sergio Arouca Natl Sch Publ Hlth, Rio De Janeiro, Brazil; [Bahia, Ligia] Univ Rio de Janeiro Fed Univ, Rio De Janeiro, Brazil; [Macinko, James] NYU, New York, NY USA	Universidade Federal da Bahia; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; New York University	Paim, J (corresponding author), Inst Saude Colet, Rua Basilio Gama S-N, BR-40110040 Salvador, BA, Brazil.	jairnil@ufba.br	Velasco, Sofia RM Maito/C-3251-2014; Oliveira, Claudia DL/G-8618-2011	Almeida, Cecilia M V B/0000-0002-0473-906X; Macinko, James/0000-0001-8055-5441	Brazilian National Research Council (CNPq)	Brazilian National Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	JP, CT, and CA are partly supported by the Brazilian National Research Council (CNPq). We thank David Sanders for comments on an early version of this report, and Evangelina Xavier Gouveia for the production of figure 1.	AFONSO JR, 2010, CADERNO PESQUISA, V83; Alfradique ME, 2009, CAD SAUDE PUBLICA, V25, P1337, DOI 10.1590/S0102-311X2009000600016; ALMEIDA C, 2006, VALIDACAO METODOLOGI, P215; ALMEIDA C, 2008, GESTION LOCAL SALUD, P65; ALMEIDA CM, 1995, THESIS ESCOLA NACL S; ALMEIDA CM, 1981, THESIS U ESTADUL RIO; ALMEIDA M, 2009, SISTEMA INFORM NAS B; ALMEIDA MHT, 1996, FEDERALISMO BRASIL D, P13; ALMEIDA PF, 2010, CAD SAUDE PUBLICA, V2, P286; [Anonymous], SAUDE BRASIL ALGUMAS; Aquino R, 2009, AM J PUBLIC HEALTH, V99, P87, DOI 10.2105/AJPH.2007.127480; BAHIA L, 1999, THESIS NACL SAUDE PU; Barriga-Carrasco MD, 2011, LASER PART BEAMS, V29, P81, DOI 10.1017/S0263034610000789; BIRMAN J, 1991, PHYSIS-REV SAUDE COL, V1, P16; Braga JCS, 1981, SAUDE PREVIDENCIA ES; Cano FG, 2009, CAD SAUDE PUBLICA, V25, pS360, DOI 10.1590/S0102-311X2009001500003; CARVALHO AI, 1995, CONSELHOS SAUDE BRAS, P136; *COM NAC DET SOC S, 2008, ASC SOC IN SAUD BRAS; *CONASS, 2006, SUS AV DES; *CONS FED MED, COD ET MED; *CONS REG MED, 2009, PROGR CONTR INF HOSO; Cortes SV, 2009, CAD SAUDE PUBLICA, V25, P1626, DOI 10.1590/S0102-311X2009000700022; DACHS JNW, 2002, CIENC SAUDE COLETIVA, V41, P641; *DATSUS, INF SAUD ASS SAUD; DELGADO PG, 2010, RADIS, V97, P18; DONNANGELO MCF, 1975, MED SOC MED SEU MERC; DRAIBE SM, 1990, DESENVOLVINENT UNPUB; ESCOREL S, 2008, ORG POLITICAS SISTEM, P979; ESCOREL S, 1998, REVIRAVOLTA SUADE OR; Escorel S, 2007, REV PANAM SALUD PUBL, V21, P164; FARIAS SF, 2009, INTERESSES ESTRUTURA; Fonseca CM, 2007, SAUDE GOVERNO VARGAS; GIRARDI SN, 2010, DIVULG SAUDE DEBATE, V45, P11; Guanais F, 2009, J AMBUL CARE MANAG, V32, P115, DOI 10.1097/JAC.0b013e31819942e51; Guanais FC, 2009, HEALTH AFFAIR, V28, P1127, DOI 10.1377/hlthaff.28.4.1127; Guizardi Francini Lube, 2004, Physis, V14, P15, DOI 10.1590/S0103-73312004000100003; Hartz Zulmira M. de Araújo, 2004, Cad. Saúde Pública, V20, pS331, DOI 10.1590/S0102-311X2004000800026; Heimann L, 2005, PUBLICO PRIVADO SAUD; HICKMANN C, 2007, 62007 DEP EST TECN U; *I BRAS GEOGR EST, 2005, PESQ ORC FAM 2002 20; *I BRAS GEOGR EST, 1983, AN EST BRAS; *I BRAS GEOGR EST, ASS MED SAN AMS; *I BRAS GEOGR EST, SER EST SER HIST; *I BRAS GEOGR EST, 1970, AN EST BRAS; *I BRAS GEOGR EST, 2008, MICR PNAD; *I BRAS GEOGR EST, 2008, PAN SAUD BRAS AC UT; Instituto Brasileiro de Geografia e Estatistica, 2010, PESQ ORC FAM 2008 20; Instituto Brasileiro de Geografia e Estatistica, 2007, DIR PESQ COORD CONT; Labra Maria Eliana, 2002, Cad. Saúde Pública, V18, pS47, DOI 10.1590/S0102-311X2002000700006; LAFORGIA B, 2009, DESEMPENHO HOSP BRAS; LAMOUNIER B, 2002, ORGANIZADOR ERA FHC; LOPES CMN, 2010, REGIONALIZACAO SAUDE; LUZ Madel Therezinha, 1991, PHYSIS REV SAUDE COL, V1, DOI [10.1590/S0103-73311991000100004, DOI 10.1590/S0103-73311991000100004]; MACHADO CV, 2010, REV POLITICA PLANEJ, V1, P11; MACHADO Roberto, 1978, DANACAO NORMA MED SO; Macinko J, 2007, SOC SCI MED, V65, P2070, DOI 10.1016/j.socscimed.2007.06.028; Maio MC, 2009, CAD SAUDE PUBLICA, V25, P1611, DOI 10.1590/S0102-311X2009000700019; Marinho A, 2010, CAD SAUDE PUBLICA, V26, P786, DOI 10.1590/S0102-311X2010000400020; MEDICI AC, 1990, PLANEJ POLIT PUBLICA, V4, P83; Mendes A, 2009, CIENC SAUDE COLETIVA, V14, P841, DOI 10.1590/S1413-81232009000300019; MENDES E, 2009, REDES ATENCAO SAUDE; Mendes W, 2009, INT J QUAL HEALTH C, V21, P279, DOI 10.1093/intqhc/mzp022; *MIN ED ARTS SPORT, 2006, PHYS WORK, P14; *MIN OUTR PROV, 2009, DIARIO OFICIAL UNIAO, V245, P65; *MIN PREV SOC, AEPS INF; *MIN SAUD, 2009, 3252 MIN SAUD; *MIN SAUD, SIT MON PROGR TEL BR; *MIN SAUD, 2008, SIST INF ORC SUAD; *MIN SAUD, 2010, CAD NAC EST SAUD; *MIN SAUD, 2010, SER CAD PLAN, V9; *MIN SAUD, 2004, POL NACL AT CARD ALT; *MIN SAUD, BRAS DF; *MIN SAUD, POL NACL HUM; *MIN SAUD, 2008, DAT VIG VIG FAT RISC; *MIN SAUD, DECR PRES I U ALB SU; *MIN SAUD, 2009, CAD NACL EST SAUD CN; *MIN SAUD, 2010, DEP AT BAS; *MIN SAUD, 1993, DESC AC SERV SAUD OU, P67; *MIN SAUD, 2010, SAUD DEST; *MIN SAUD, 2008, RED INT INF SAUD RIP; *MIN SAUD AG NACL, 2010, CAD INF SAUD S; *MIN SAUD AG NACL, 2009, CAD INF SAUD S; *MIN SAUD SECR EX, 2006, DIR OP PACT PEL VID; *MIN SAUD SECR GES, 2010, POL NACL SUAD INT B; Miranda AS, 2007, HEALTH POLICY PLANN, V22, P186, DOI 10.1093/heapol/czm004; Moreira MR, 2009, CIENC SAUDE COLETIVA, V14, P795, DOI 10.1590/S1413-81232009000300015; NETO FCB, 2008, ORG POLITICAS SISTEM, P665; NETO GV, 2007, CIENC SAUDE COLETIVA, V4, P825; NETO JSM, 2006, SAUDE DEBATE, V30, P248; NOGUEIRA R, 2007, COMPOSICAO PUBLICO V; NORONHA J, 2011, ORG GESTAO PUBLICA R, P152; *OECD, OECD HLTH DAT 2009 F; Oliveira Evangelina X. G. de, 2004, Cad. Saúde Pública, V20, pS298, DOI 10.1590/S0102-311X2004000800023; PAIM J. S., 2009, QUE SUS; PAIM J. S., 2008, REFORMA SANITARIA BR; PEGO RA, 2002, CAD SAUDE PUBLICA, V4, P971; PEREIRA AP, 2008, CONSUMO RESIDENCIAL; POCHMANN M, 2009, POBREZA CRISE EC QUE, P115; Rasella D, 2010, PEDIATRICS, V126, pE534, DOI 10.1542/peds.2009-3197; Rasella D, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-380; Reichenheim ME, 2011, LANCET, V377, P1962, DOI 10.1016/S0140-6736(11)60053-6; SANTOS RV, 2008, ORG POLITICAS SISTEM, P1035; Schmidt M. I., 2011, Lancet (British edition), V377, P1949, DOI 10.1016/S0140-6736(11)60135-9; Silva SF., 2008, REDES ATENCAO SAUDE; SINGER P, 1978, PREVENIR CURAR CONTR; *SOC BRAS END MET, 2009, DIV RES VIG 2008; SOLLA J, 2008, ORG POLITICAS SISTEM, P627; Szwarcwald CL, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-217; Tatagiba L. T., 2002, SOC CIVIL ESPACOS PU; TEIXEIRA S, 1988, REFORMA SANITARIA IT; TEIXEIRA SMF, 1987, REV ADM PUBLICA, V4, P94; VANDOORSLAER E, 2006, CMAJ, V17, P174; VIACAVA F, 2009, INTRO EXPERIENCIA  B; Victora CG, 2011, LANCET, V377, P85, DOI 10.1016/S0140-6736(10)60810-0; *WHO, STAT INF SYST WHOS	115	1134	1310	3	146	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2011	377	9779					1778	1797		10.1016/S0140-6736(11)60054-8	http://dx.doi.org/10.1016/S0140-6736(11)60054-8			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771AS	21561655	Green Published			2022-12-28	WOS:000291130200037
J	Sheffield, VC; Stone, EM				Sheffield, Val C.; Stone, Edwin M.			Genomics and the Eye	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COMPLEMENT FACTOR-H; GENE-THERAPY; DISEASE; MUTATIONS; GENERATION; PHOTORECEPTORS; SUSCEPTIBILITY; POLYMORPHISM; CELLS; DIFFERENTIATION	THE EYE HAS HAD A PIVOTAL ROLE IN THE EVOLUTION OF HUMAN GENOMICS. At least 90% of the genes in the human genome are expressed in one or more of the eye's many tissues and cell types at some point during a person's life. Consistent with this impressive genomic footprint is the observation that about a third of entries in the Online Mendelian Inheritance in Man database for which a clinical synopsis is provided include a term that refers to the structure or function of the eye.(1) Moreover, the phenotypic effects of even small genetic variations are made readily apparent by the many layers of amplification in the human visual system. For example, a single-nucleotide change in PAX6 can cause an anatomic abnormality of the macula less than a millimeter in diameter that results in noticeably reduced visual acuity and nystagmus.(2) The heritable inability to correctly perceive the color green, known as Daltonism (after the English chemist John Dalton, who himself was affected), was the first human trait mapped to the X chromosome.(3) (See Fig. 1 for a timeline of historic discoveries.) The Coppock cataract was the first human trait mapped to an autosome,(4) and Leber's hereditary optic neuropathy was the first human disease shown to be caused by a mutation in mitochondrial DNA.(5) More recently, age-related macular degeneration (AMD) and glaucoma(6,7) - two common causes of human blindness - have been shown to be largely genetic, as has Fuchs' endothelial dystrophy,(8) the most common cause of corneal transplantation in developed countries. Here, we review discoveries in mendelian and complex ophthalmic disorders and their implications for genetic testing and therapeutic intervention.	[Sheffield, Val C.] Univ Iowa, Carver Coll Med, Howard Hughes Med Inst, Dept Pediat, Iowa City, IA 52242 USA; [Sheffield, Val C.; Stone, Edwin M.] Univ Iowa, Carver Coll Med, Howard Hughes Med Inst, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Stone, EM (corresponding author), Univ Iowa, Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA.	edwin-stone@uiowa.edu		Stone, Edwin M./0000-0003-3343-4414; Sheffield, Val/0000-0002-6282-0835	Howard Hughes Medical Institute Funding Source: Medline; NEI NIH HHS [R01 EY011298, R01 EY017168] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY017168, R01EY011298] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b; Alward WLM, 1998, NEW ENGL J MED, V338, P1022, DOI 10.1056/NEJM199804093381503; Azuma N, 1996, NAT GENET, V13, P141, DOI 10.1038/ng0696-141; Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Baratz KH, 2010, NEW ENGL J MED, V363, P1016, DOI 10.1056/NEJMoa1007064; Boatright JH, 2006, MOL VIS, V12, P1706; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; Cideciyan AV, 2009, HUM MOL GENET, V18, P931, DOI 10.1093/hmg/ddn421; den Hollander AI, 2011, J CLIN INVEST, V121, P456, DOI 10.1172/JCI45855; den Hollander AI, 2010, J CLIN INVEST, V120, P3042, DOI 10.1172/JCI42258; Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807; Dowling J, 2009, EYE, V23, P1999, DOI 10.1038/eye.2008.385; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941; Fan BJ, 2010, J CLIN INVEST, V120, P3064, DOI 10.1172/JCI43085; Gorbatyuk M, 2007, EXP EYE RES, V84, P44, DOI 10.1016/j.exer.2006.08.014; Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Hamosh A, 1998, J PEDIATR-US, V132, P255, DOI 10.1016/S0022-3476(98)70441-X; Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107; Hussein SM, 2011, NATURE, V471, P58, DOI 10.1038/nature09871; Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102; Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630; Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103; Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763; Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798; MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161; Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315; Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673; Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079; Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106; NEWMAN NJ, 1991, AM J OPHTHALMOL, V111, P750, DOI 10.1016/S0002-9394(14)76784-4; Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384; Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393; Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224; Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820; Radu RA, 2006, INVEST OPHTH VIS SCI, V47, P3735; RENWICK JH, 1963, ANN HUM GENET, V27, P67, DOI 10.1111/j.1469-1809.1963.tb00782.x; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353; Schindler EI, 2010, HUM MOL GENET, V19, P3693, DOI 10.1093/hmg/ddq284; Senju S, 2009, STEM CELLS, V27, P1021, DOI 10.1002/stem.33; Shah AS, 2008, P NATL ACAD SCI USA, V105, P3380, DOI 10.1073/pnas.0712327105; Sheffield Val C, 2010, Trans Am Clin Climatol Assoc, V121, P172; Shepard AR, 2007, HUM MOL GENET, V16, P609, DOI 10.1093/hmg/ddm001; Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103; Stone Edwin M, 2003, Trans Am Ophthalmol Soc, V101, P437; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sunden SLF, 1996, GENOME RES, V6, P862, DOI 10.1101/gr.6.9.862; Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thorleifsson G, 2010, NAT GENET, V42, P906, DOI 10.1038/ng.661; Tucker B, PLOS ONE IN PRESS; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Wilson EB, 1911, ARCH MIKROSK ANAT, V77, P249; Zweier C, 2007, AM J HUM GENET, V80, P994, DOI 10.1086/515583	63	55	59	0	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					1932	1942		10.1056/NEJMra1012354	http://dx.doi.org/10.1056/NEJMra1012354			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765PJ	21591945				2022-12-28	WOS:000290720700008
J	Sambasivan, K; Osman, E				Sambasivan, K.; Osman, E.			A young man becomes short of breath and yellow Congestive cardiac failure	BRITISH MEDICAL JOURNAL			English	Editorial Material							IDIOPATHIC DILATED CARDIOMYOPATHY; CHRONIC HEART-FAILURE; ALCOHOL; DISEASE; MUSCLE		[Sambasivan, K.; Osman, E.] Basildon & Thurrock Univ Hosp, Basildon SS16 5NL, Essex, England		Sambasivan, K (corresponding author), 107 Brim Hill, London N2 0EZ, England.	k.sambasivan@doctors.org.uk						Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Fauchier L, 2000, EUR HEART J, V21, P306, DOI 10.1053/euhj.1999.1761; Giallourakis Cosmas C, 2002, Clin Liver Dis, V6, P947, DOI 10.1016/S1089-3261(02)00056-9; JACOB AJ, 1991, AM J CARDIOL, V68, P805, DOI 10.1016/0002-9149(91)90662-5; Klatsky AL, 2010, PHYSIOL BEHAV, V100, P76, DOI 10.1016/j.physbeh.2009.12.019; Krum H, 2003, JAMA-J AM MED ASSOC, V289, P712, DOI 10.1001/jama.289.6.712; Lowe MD, 1999, BRIT MED J, V318, P585, DOI 10.1136/bmj.318.7183.585; McKenna CJ, 1998, AM HEART J, V135, P833, DOI 10.1016/S0002-8703(98)70042-0; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; RICHMAN SM, 1961, AM J MED, V30, P211, DOI 10.1016/0002-9343(61)90093-6; SHERLOCK S, 1951, BRIT HEART J, V13, P273; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701	12	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 18	2011	342								d2637	10.1136/bmj.d2637	http://dx.doi.org/10.1136/bmj.d2637			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QQ	21593100				2022-12-28	WOS:000290951900001
J	Spinelli, M; Howard, LM				Spinelli, Margaret; Howard, Louise M.			Has child protection become a form of madness? No	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Spinelli, Margaret] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Howard, Louise M.] Kings Coll London, London WC2R 2LS, England	Columbia University; University of London; King's College London	Spinelli, M (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	Mgs8@columbia.edu	Howard, Louise/E-3495-2010	Howard, Louise/0000-0001-9942-744X				Bakermans-Kranenburg MJ, 2003, PSYCHOL BULL, V129, P195, DOI 10.1037/0033-2909.129.2.195; *CHILDH, 2007, PREV TREATM CHILD AB; Department for Children Schools and Families, 2010, WORK TOG SAF CHILDR; Gilbert R, 2009, LANCET, V373, P167, DOI 10.1016/S0140-6736(08)61707-9; Howard LM, 2010, INT REV PSYCHIATR, V22, P525, DOI 10.3109/09540261.2010.512283; Laming Lord, 2009, PROTECTION CHILDREN; MacMillan HL, 2009, LANCET, V373, P250, DOI 10.1016/S0140-6736(08)61708-0; *NSPCC, CHILD CRUELT UK 2011; Spinelli M, 2002, INFANTICIDE PSYCHOSO	9	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 18	2011	342								d3063	10.1136/bmj.d3063	http://dx.doi.org/10.1136/bmj.d3063			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QQ	21593098				2022-12-28	WOS:000290951900012
J	Batchelor, JM; Handfield-Jones, SE				Batchelor, J. M.; Handfield-Jones, S. E.			LESSON OF THE WEEK When a cyst is not a cyst	BMJ-BRITISH MEDICAL JOURNAL			English	Article									[Batchelor, J. M.] Addenbrookes Hosp, Dept Dermatol, Cambridge CB2 0QQ, England; [Handfield-Jones, S. E.] W Suffolk Hosp NHS Trust, Dept Dermatol, Bury St Edmunds IP33 2QZ, Suffolk, England	Addenbrooke's Hospital; University of Cambridge	Batchelor, JM (corresponding author), Addenbrookes Hosp, Dept Dermatol, Cambridge CB2 0QQ, England.	jmb@doctors.org.uk						Al-Khateeb TH, 2009, J ORAL MAXIL SURG, V67, P52, DOI 10.1016/j.joms.2007.05.023; BROWNSTEIN M H, 1973, Archives of Dermatology, V107, P80, DOI 10.1001/archderm.107.1.80; Goodwin N, 2008, INT J INTEG CARE, V8, P1; PARK HK, 1987, J AM ACAD DERMATOL, V17, P285, DOI 10.1016/S0190-9622(87)70204-7; TAYLOR HB, 1962, CANCER, V15, P717, DOI 10.1002/1097-0142(196207/08)15:4<717::AID-CNCR2820150405>3.0.CO;2-2	5	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 17	2011	342								d2844	10.1136/bmj.d2844	http://dx.doi.org/10.1136/bmj.d2844			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768QO	21586479				2022-12-28	WOS:000290951700003
J	VanderWeele, TJ; Knol, MJ				VanderWeele, Tyler J.; Knol, Mirjam J.			Interpretation of Subgroup Analyses in Randomized Trials: Heterogeneity Versus Secondary Interventions	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; SYNERGISM	In randomized trials with subgroup analyses, the primary treatment or intervention of interest is randomized, but the secondary factors defining subgroups are not. This article clarifies when confounding is an issue in subgroup analyses. If investigators are interested simply in targeting subpopulations for intervention, control for confounding is not needed. If investigators are interested in intervening on the secondary factors that define the subgroups to increase the treatment effect or in attributing the subgroup differences to the secondary factors themselves, then confounding is relevant and must be controlled for. The authors demonstrate this point by using examples from published randomized trials.	[VanderWeele, Tyler J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Med Ctr Utrecht, Utrecht, Netherlands	Harvard University; Harvard T.H. Chan School of Public Health; Utrecht University; Utrecht University Medical Center	VanderWeele, TJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.	tvanderw@hsph.harvard.edu			National Institutes of Health [R01 ES017876]; Escher Project [T6-202]; Top Institute Pharma; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES017876] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Escher Project; Top Institute Pharma; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Grant Support: By grant R01 ES017876 from the National Institutes of Health and by the Escher Project (T6-202).r Dr. Knol: Grants received (money to institution): Top Institute Pharma. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-2468.	Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Greenland S., 2008, MODERN EPIDEMIOLOGY; Groenwold RHH, 2009, ARCH INTERN MED, V169, P1532, DOI 10.1001/archinternmed.2009.250; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; Lagakos SW, 2006, NEW ENGL J MED, V354, P1667, DOI 10.1056/NEJMp068070; Li RL, 2007, ANN EPIDEMIOL, V17, P227, DOI 10.1016/j.annepidem.2006.10.009; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; Pocock SJ, 1983, CLIN TRIALS PRACITCA; ROTHMAN KJ, 1980, AM J EPIDEMIOL, V112, P467, DOI 10.1093/oxfordjournals.aje.a113015; Rothwell PM, 2005, LANCET, V365, P176, DOI 10.1016/S0140-6736(05)17709-5; Sadowski LS, 2009, JAMA-J AM MED ASSOC, V301, P1771, DOI 10.1001/jama.2009.561; SARACCI R, 1980, AM J EPIDEMIOL, V112, P465, DOI 10.1093/oxfordjournals.aje.a113014; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; VanderWeele TJ, 2007, EPIDEMIOLOGY, V18, P329, DOI 10.1097/01.ede.0000260218.66432.88; VanderWeele TJ, 2009, EPIDEMIOLOGY, V20, P863, DOI 10.1097/EDE.0b013e3181ba333c; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	18	79	79	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10					680	+		10.7326/0003-4819-154-10-201105170-00008	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576536	Green Accepted			2022-12-28	WOS:000290620300017
J	Levine, M				Levine, Michael			Paused RNA Polymerase II as a Developmental Checkpoint	CELL			English	Review							NEGATIVE ELONGATION-FACTOR; C-TERMINAL DOMAIN; TRANSCRIPTION ELONGATION; DROSOPHILA-MELANOGASTER; SINGLE-MOLECULE; GENE-EXPRESSION; GAGA FACTOR; HSP70 GENE; HIV-1 TAT; IN-VIVO	The textbook view of gene activation is that the rate-limiting step is the interaction of RNA polymerase II (Pol II) with the gene's promoter. However, studies in a variety of systems, including human embryonic stem cells and the early Drosophila embryo, have begun to challenge this view. There is increasing evidence that differential gene expression often depends on the regulation of transcription elongation via the release of Pol II from the proximal promoter. I review the implications of this mechanism of gene activation with respect to the orderly unfolding of complex gene networks governing animal development.	Univ Calif Berkeley, Div Genet Genom & Dev, Dept Mol & Cell Biol, Ctr Integrat Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, M (corresponding author), Univ Calif Berkeley, Div Genet Genom & Dev, Dept Mol & Cell Biol, Ctr Integrat Biol, Berkeley, CA 94720 USA.	mlevine@berkeley.edu		Levine, Michael/0000-0001-7629-0081	NIGMS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034431] Funding Source: NIH RePORTER	NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	I thank the NIGMS for grant support, members of my lab for their enthusiasm and insights, and the anonymous referees for their guidance in polishing this Review.	Akhtar MS, 2009, MOL CELL, V34, P387, DOI 10.1016/j.molcel.2009.04.016; Arndt KM, 2003, TRENDS GENET, V19, P543, DOI 10.1016/j.tig.2003.08.008; Bartkowiak B, 2010, GENE DEV, V24, P2303, DOI 10.1101/gad.1968210; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bilodeau S, 2009, GENE DEV, V23, P2484, DOI 10.1101/gad.1837309; Boehm AK, 2003, MOL CELL BIOL, V23, P7628, DOI 10.1128/MCB.23.21.7628-7637.2003; Boeing S, 2010, J BIOL CHEM, V285, P188, DOI 10.1074/jbc.M109.046565; Boettiger AN, 2009, SCIENCE, V325, P471, DOI 10.1126/science.1173976; Canduri F, 2008, MED CHEM, V4, P210, DOI 10.2174/157340608784325205; Chopra VS, 2009, GENE DEV, V23, P1505, DOI 10.1101/gad.1807309; Chopra VS, 2009, CURR BIOL, V19, P688, DOI 10.1016/j.cub.2009.02.055; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Cowden J, 2002, DEVELOPMENT, V129, P1785; Fuda NJ, 2009, NATURE, V461, P186, DOI 10.1038/nature08449; Galburt EA, 2009, METHODS, V48, P323, DOI 10.1016/j.ymeth.2009.04.021; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; Gilchrist DA, 2008, GENE DEV, V22, P1921, DOI 10.1101/gad.1643208; Gilchrist DA, 2010, CELL, V143, P540, DOI 10.1016/j.cell.2010.10.004; Gilchrist DA, 2009, METHODS, V48, P398, DOI 10.1016/j.ymeth.2009.02.024; Gilmour DS, 2009, METHODS, V48, P368, DOI 10.1016/j.ymeth.2009.02.020; Gilmour DS, 2009, CHROMOSOMA, V118, P1, DOI 10.1007/s00412-008-0182-4; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; Glover-Cutter K, 2009, MOL CELL BIOL, V29, P5455, DOI 10.1128/MCB.00637-09; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Guenther MG, 2010, SCIENCE, V329, P150, DOI 10.1126/science.1193995; He NH, 2010, MOL CELL, V38, P428, DOI 10.1016/j.molcel.2010.04.013; Hendrix DA, 2008, P NATL ACAD SCI USA, V105, P7762, DOI 10.1073/pnas.0802406105; Herbert KM, 2008, ANNU REV BIOCHEM, V77, P149, DOI 10.1146/annurev.biochem.77.073106.100741; Hirose Y, 2007, J BIOCHEM, V141, P601, DOI 10.1093/jb/mvm090; Juven-Gershon T, 2008, CURR OPIN CELL BIOL, V20, P253, DOI 10.1016/j.ceb.2008.03.003; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Keogh MC, 2003, MOL CELL BIOL, V23, P7005, DOI 10.1128/MCB.23.19.7005-7018.2003; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kornberg RD, 2007, P NATL ACAD SCI USA, V104, P12955, DOI 10.1073/pnas.0704138104; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; Leptin M, 2004, CURR BIOL, V14, pR480, DOI 10.1016/j.cub.2004.06.016; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Li BY, 1996, MOL CELL BIOL, V16, P5433; Liang HL, 2008, NATURE, V456, P400, DOI 10.1038/nature07388; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Lis JT, 2007, NATURE, V450, P198, DOI 10.1038/nature06324; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Missra A, 2010, P NATL ACAD SCI USA, V107, P11301, DOI 10.1073/pnas.1000681107; Mohan M, 2010, NAT REV CANCER, V10, P720, DOI 10.1038/nrc2915; Morel V, 2000, GENE DEV, V14, P377; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Nechaev S, 2010, SCIENCE, V327, P335, DOI 10.1126/science.1181421; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; Okada M, 1998, MOL CELL BIOL, V18, P2455, DOI 10.1128/MCB.18.5.2455; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; Petesch SJ, 2008, CELL, V134, P74, DOI 10.1016/j.cell.2008.05.029; Preker P, 2008, SCIENCE, V322, P1851, DOI 10.1126/science.1164096; Price DH, 2008, MOL CELL, V30, P7, DOI 10.1016/j.molcel.2008.03.001; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981; Seila AC, 2008, SCIENCE, V322, P1849, DOI 10.1126/science.1162253; Sikorski TW, 2009, CURR OPIN CELL BIOL, V21, P344, DOI 10.1016/j.ceb.2009.03.006; Smith ER, 2008, P NATL ACAD SCI USA, V105, P8575, DOI 10.1073/pnas.0804379105; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; ten Bosch JR, 2006, DEVELOPMENT, V133, P1967, DOI 10.1242/dev.02373; Thomas MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI 10.1080/10409230600648736; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VanderZwan-Butler CJ, 2007, DEV BIOL, V301, P350, DOI 10.1016/j.ydbio.2006.10.027; Wang XL, 2007, GENE DEV, V21, P1031, DOI 10.1101/gad.1521207; Wang YC, 2005, NATURE, V434, P229, DOI 10.1038/nature03318; Wheeler SR, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-56; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963; Winston F, 2001, GENOME BIOL, V2; Wittwer F, 2001, DEVELOPMENT, V128, P791; Wu CH, 2005, NUCLEIC ACIDS RES, V33, P1269, DOI 10.1093/nar/gki274; Yao J, 2007, MOL CELL, V28, P978, DOI 10.1016/j.molcel.2007.10.017; Zaffran S, 2005, BIOCHEM BIOPH RES CO, V334, P361, DOI 10.1016/j.bbrc.2005.06.090; Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26; Zhang ZQ, 2007, J BIOL CHEM, V282, P16981, DOI 10.1074/jbc.M610688200; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	87	205	210	0	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 13	2011	145	4					502	511		10.1016/j.cell.2011.04.021	http://dx.doi.org/10.1016/j.cell.2011.04.021			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565610	Green Accepted, Bronze			2022-12-28	WOS:000290560800005
J	Simons, M; Minson, SE; Sladen, A; Ortega, F; Jiang, JL; Owen, SE; Meng, LS; Ampuero, JP; Wei, SJ; Chu, RS; Helmberger, DV; Kanamori, H; Hetland, E; Moore, AW; Webb, FH				Simons, Mark; Minson, Sarah E.; Sladen, Anthony; Ortega, Francisco; Jiang, Junle; Owen, Susan E.; Meng, Lingsen; Ampuero, Jean-Paul; Wei, Shengji; Chu, Risheng; Helmberger, Donald V.; Kanamori, Hiroo; Hetland, Eric; Moore, Angelyn W.; Webb, Frank H.			The 2011 Magnitude 9.0 Tohoku-Oki Earthquake: Mosaicking the Megathrust from Seconds to Centuries	SCIENCE			English	Article							SUBDUCTION-ZONE EARTHQUAKES; SANRIKU TSUNAMI EARTHQUAKE; STRONG GROUND MOTIONS; ENERGY RADIATION; FAULT; SUMATRA; INVERSION; MODEL	Geophysical observations from the 2011 moment magnitude (M(w)) 9.0 Tohoku-Oki, Japan earthquake allow exploration of a rare large event along a subduction megathrust. Models for this event indicate that the distribution of coseismic fault slip exceeded 50 meters in places. Sources of high-frequency seismic waves delineate the edges of the deepest portions of coseismic slip and do not simply correlate with the locations of peak slip. Relative to the M(w) 8.8 2010 Maule, Chile earthquake, the Tohoku-Oki earthquake was deficient in high-frequency seismic radiation-a difference that we attribute to its relatively shallow depth. Estimates of total fault slip and surface secular strain accumulation on millennial time scales suggest the need to consider the potential for a future large earthquake just south of this event.	[Simons, Mark; Minson, Sarah E.; Sladen, Anthony; Ortega, Francisco; Jiang, Junle; Meng, Lingsen; Ampuero, Jean-Paul; Wei, Shengji; Chu, Risheng; Helmberger, Donald V.; Kanamori, Hiroo] CALTECH, Seismol Lab, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; [Sladen, Anthony] Univ Nice Sophia Antipolis, CNRS, IRD, Observ Cote Azur, F-06103 Nice 2, France; [Owen, Susan E.; Moore, Angelyn W.; Webb, Frank H.] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; [Hetland, Eric] Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA	California Institute of Technology; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Michigan System; University of Michigan	Simons, M (corresponding author), CALTECH, Seismol Lab, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.	simons@caltech.edu	Wei, Shengji/M-2137-2015; Ampuero, Jean Paul/N-3348-2013; Jiang, Junle/B-3974-2008; Simons, Mark/N-4397-2015; Sladen, Anthony/A-2532-2017; Ortega Culaciati, Francisco Hernán/A-2587-2014	Wei, Shengji/0000-0002-0319-0714; Ampuero, Jean Paul/0000-0002-4827-7987; Jiang, Junle/0000-0002-8796-5846; Simons, Mark/0000-0003-1412-6395; Sladen, Anthony/0000-0003-4126-0020; Ortega Culaciati, Francisco Hernán/0000-0002-2983-8646; Hetland, Eric A/0000-0002-8439-6465; Chu, Risheng/0000-0002-1062-5982	Gordon and Betty Moore Foundation; NSF [CDI-0941374, EAR-1015704, EAR-0106924, 02HQAG0008]; National Aeronautics and Space Administration; Directorate For Geosciences [0941374] Funding Source: National Science Foundation; Division Of Earth Sciences [1015704] Funding Source: National Science Foundation	Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); NSF(National Science Foundation (NSF)); National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Division Of Earth Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	Supported in part by the Gordon and Betty Moore Foundation. M.S. and S.E.M. are supported by NSF grant CDI-0941374; J.P.A. and L.S.M. are supported by NSF grant EAR-1015704 and the Southern California Earthquake Center, which is funded by NSF Cooperative Agreement EAR-0106924 and USGS Cooperative Agreement 02HQAG0008. A portion of the research was carried out at the Jet Propulsion Laboratory (JPL), California Institute of Technology, under a contract with the National Aeronautics and Space Administration and funded through the internal Research and Technology Development program. We acknowledge the Geospatial Information Authority (GSI) of Japan for kindly providing all the GEONET RINEX data. Raw RINEX data are available directly from GSI. Processed GPS time series are provided through the ARIA project. We thank T. Ito for providing the interseismic velocity estimates used in Fig. 4. This paper is Caltech Tectonics Observatory contribution 165 and Caltech Seismological Laboratory contribution 10059.	ABE K, 1977, TECTONOPHYSICS, V41, P269, DOI 10.1016/0040-1951(77)90136-6; Borcea L, 2006, INVERSE PROBL, V22, P1405, DOI 10.1088/0266-5611/22/4/016; CLOOS M, 1992, GEOLOGY, V20, P601, DOI 10.1130/0091-7613(1992)020<0601:TTSZEA>2.3.CO;2; Delouis B, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL043899; DeMets C, 2010, GEOPHYS J INT, V181, P1, DOI 10.1111/j.1365-246X.2009.04491.x; *EARTHQ RES COMM H, 1998, SEISM ACT JAP REG PE; Gusev AA, 2006, PURE APPL GEOPHYS, V163, P1305, DOI 10.1007/s00024-006-0068-4; Hashimoto C, 2009, NAT GEOSCI, V2, P141, DOI 10.1038/NGEO421; HEATON TH, 1989, PURE APPL GEOPHYS, V129, P131, DOI 10.1007/BF00874626; Hetland EA, 2010, GEOPHYS J INT, V181, P99, DOI 10.1111/j.1365-246X.2009.04482.x; Hsu YJ, 2006, SCIENCE, V312, P1921, DOI 10.1126/science.1126960; Ishii M, 2005, NATURE, V435, P933, DOI 10.1038/nature03675; Ito Y, 2007, SCIENCE, V315, P503, DOI 10.1126/science.1134454; Ji C, 2002, B SEISMOL SOC AM, V92, P1208, DOI 10.1785/0120000917; Kanamori H, 2006, EARTH PLANETS SPACE, V58, P1533, DOI 10.1186/BF03352657; Koji M., 2001, J NAT DISASTER SCI, V23, P83; Loveless JP, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2008JB006248; MADARIAGA R, 1983, ANN GEOPHYS, V1, P17; MINSON SE, 2010, AGU 2010 FALL M SAN; Mochizuki K, 2008, SCIENCE, V321, P1194, DOI 10.1126/science.1160250; Nakahara H, 2008, ADV GEOPHYS, V50, P401, DOI 10.1016/S0065-2687(08)00015-0; Ni S, 2005, NATURE, V434, P582, DOI 10.1038/434582a; Polet J, 2000, GEOPHYS J INT, V142, P684, DOI 10.1046/j.1365-246x.2000.00205.x; SCHMIDT RO, 1986, IEEE T ANTENN PROPAG, V34, P276, DOI 10.1109/TAP.1986.1143830; Schwartz SY, 1999, J GEOPHYS RES-SOL EA, V104, P23111, DOI 10.1029/1999JB900226; Sladen A, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB006429; Tanioka Y, 1996, GEOPHYS RES LETT, V23, P1549, DOI 10.1029/96GL01479; Tanioka Y, 2001, GEOPHYS RES LETT, V28, P3389, DOI 10.1029/2001GL013149; Venkataraman A, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002549; Vigny C, 2011, SCIENCE, V332, P1417, DOI 10.1126/science.1204132; Yamada M, 2009, B SEISMOL SOC AM, V99, P3264, DOI 10.1785/0120090067; ZENG YH, 1994, GEOPHYS RES LETT, V21, P725, DOI 10.1029/94GL00367	32	545	563	3	392	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 17	2011	332	6036					1421	1425		10.1126/science.1206731	http://dx.doi.org/10.1126/science.1206731			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778FT	21596953				2022-12-28	WOS:000291689000039
J	Belch, J; Hiatt, WR; Baumgartner, I; Driver, IV; Nikol, S; Norgren, L; Van Belle, E				Belch, Jill; Hiatt, William R.; Baumgartner, Iris; Driver, I. Vickie; Nikol, Sigrid; Norgren, Lars; Van Belle, Eric		TAMARIS Comm Investigators	Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia	LANCET			English	Article							QUALITY-OF-LIFE; PLASMID DNA; ANGIOGENESIS	Background Patients with critical limb ischaemia have a high rate of amputation and mortality. We tested the hypothesis that non-viral 1 fibroblast growth factor (NV1FGF) would improve amputation-free survival. Methods In this phase 3 trial (EFC6145/TAMARIS), 525 patients with critical limb ischaemia unsuitable for revascularisation were enrolled from 171 sites in 30 countries. All had ischaemic ulcer in legs or minor skin gangrene and met haemodynamic criteria (ankle pressure <70 mm Hg or a toe pressure <50 mm Hg, or both, or a transcutaneous oxygen pressure <30 mm Hg on the treated leg). Patients were randomly assigned to either NV1FGF at 0.2 mg/mL or matching placebo (visually identical) in a 1:1 ratio. Randomisation was done with a central interactive voice response system by block size 4 and was stratified by diabetes status and country. Investigators, patients, and study teams were masked to treatment. Patients received eight intramuscular injections of their assigned treatment in the index leg on days 1, 15, 29, and 43. The primary endpoint was time to major amputation or death at 1 year analysed by intention to treat with a log-rank test using a multivariate Cox proportional hazard model. This trial is registered with ClinicalTrials.gov, number NCT00566657. Findings 259 patients were assigned to NV1FGF and 266 to placebo. All 525 patients were analysed. The mean age was 70 years (range 50-92), 365 (70%) were men, 280 (53%) had diabetes, and 248 (47%) had a history of coronary artery disease. The primary endpoint or components of the primary did not differ between treatment groups, with major amputation or death in 86 patients (33%) in the placebo group, and 96 (36%) in the active group (hazard ratio 1.11, 95% CI 0.83-1.49; p=0.48). No significant safety issues were recorded. Interpretation TAMARIS provided no evidence that NV1FGF is effective in reduction of amputation or death in patients with critical limb ischaemia. Thus, this group of patients remains a major therapeutic challenge for the clinician.	[Belch, Jill] Univ Dundee, Ninewells Hosp & Med Sch, Inst Cardiovasc Res, Vasc & Inflammatory Dis Res Unit, Dundee DD1 9SY, Scotland; [Hiatt, William R.] Univ Colorado, Sch Med, Div Cardiol, Aurora, CO USA; [Hiatt, William R.] CPC Clin Res, Aurora, CO USA; [Baumgartner, Iris] Univ Hosp Bern, Inselspital, Div Angiol, Ctr Cardiovasc, CH-3010 Bern, Switzerland; [Driver, I. Vickie] Boston Univ, Sch Med, Clin Res Foot Care Serv, Boston, MA 02118 USA; [Driver, I. Vickie] Boston Univ, Sch Med, Endovasc Serv, Boston, MA 02118 USA; [Driver, I. Vickie] Boston Univ, Sch Med, Vasc Serv, Boston, MA 02118 USA; [Nikol, Sigrid] Askleplios Klin St Georg, Dept Angiol, Hamburg, Germany; [Norgren, Lars] Orebro Univ Hosp, Dept Surg, Orebro, Sweden; [Van Belle, Eric] Ctr Hosp Reg Univ Lille, Dept Cardiol, Lille, France; [Van Belle, Eric] Univ Lille Nord France, EA 2693, Lille, France	University of Dundee; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Bern; University Hospital of Bern; Boston University; Boston University; Boston University; Asklepios Klinik St. Georg; Orebro University; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille	Belch, J (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Inst Cardiovasc Res, Vasc & Inflammatory Dis Res Unit, Dundee DD1 9SY, Scotland.	j.j.f.belch@dundee.ac.uk	Belch, Jill/AAE-9189-2019	Belch, Jill/0000-0001-8280-6689; VAN BELLE, ERIC/0000-0001-6509-443X	Sanofi-Aventis, Paris, France	Sanofi-Aventis, Paris, France(Sanofi-Aventis)	Funding Sanofi-Aventis, Paris, France.	ALBERS M, 1992, J VASC SURG, V16, P54, DOI 10.1016/0741-5214(92)90417-7; Baumgartner I, 2005, ANNU REV MED, V56, P249, DOI 10.1146/annurev.med.56.082103.104649; Baumgartner I, 2009, MOL THER, V17, P914, DOI 10.1038/mt.2009.24; Caron A, 2004, J GENE MED, V6, P1033, DOI 10.1002/jgm.594; Comerota AJ, 2002, J VASC SURG, V35, P930, DOI 10.1067/mva.2002.123677; De Haro J, 2009, HEART VESSELS, V24, P321, DOI 10.1007/s00380-008-1140-z; Dormandy J, 1999, Semin Vasc Surg, V12, P142; Germani A, 2009, CARDIOVASC THER, V27, P289, DOI 10.1111/j.1755-5922.2009.00105.x; Ghosh R, 2008, INT J CLIN PRACT, V62, P1383, DOI 10.1111/j.1742-1241.2008.01842.x; Gupta R, 2009, CIRC RES, V105, P724, DOI 10.1161/CIRCRESAHA.109.200386; Halperin JL, 2002, THROMB RES, V106, pV303, DOI 10.1016/S0049-3848(01)00366-8; Hershey JC, 2003, CARDIOVASC RES, V59, P997, DOI 10.1016/S0008-6363(03)00522-4; ISCHEMIA EWG, 1991, CIRCULATION S, V84, P1; Katz J, 1999, SURG CLIN N AM, V79, P231, DOI 10.1016/S0039-6109(05)70381-9; Mac Gabhann F, 2010, CURR OPIN MOL THER, V12, P570; Nikol S, 2008, MOL THER, V16, P972, DOI 10.1038/mt.2008.33; Norgren L, 2007, J VASC SURG, V45, pS5, DOI 10.1016/j.jvs.2006.12.037; Patterson DBJ, 2006, VASCULAR MED COMPANI, P248; Ruffolo AJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006544.pub2; TASC Working Group, 2000, EUR J VASC ENDOVASC, V19, pS1; Treat-Jacobson D, 2002, J NURS SCHOLARSHIP, V34, P55, DOI 10.1111/j.1547-5069.2002.00055.x; VANBELLE E, EUR J ENDOV IN PRESS	22	230	239	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2011	377	9781					1929	1937		10.1016/S0140-6736(11)60394-2	http://dx.doi.org/10.1016/S0140-6736(11)60394-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777LW	21621834	Green Submitted			2022-12-28	WOS:000291623200029
J	Cohen, IG; Adashi, EY				Cohen, I. Glenn; Adashi, Eli Y.			Human Embryonic Stem-Cell Research under Siege - Battle Won but Not the War	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Cohen, I. Glenn] Harvard Univ, Sch Law, Petrie Flom Ctr Hlth Law Policy Biotechnol & Bioe, Cambridge, MA 02138 USA; [Adashi, Eli Y.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA	Harvard University; Brown University	Cohen, IG (corresponding author), Harvard Univ, Sch Law, Petrie Flom Ctr Hlth Law Policy Biotechnol & Bioe, Cambridge, MA 02138 USA.							Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	1	29	30	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22								10.1056/NEJMp1105088	http://dx.doi.org/10.1056/NEJMp1105088			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	772AB	21591937				2022-12-28	WOS:000291200700006
J	Drife, JO				Drife, James Owen			IN AND OUT OF HOSPITAL No news is good news: Confidential Enquiries into Maternal Deaths	BRITISH MEDICAL JOURNAL			English	Editorial Material												J.O.Drife@leeds.ac.uk							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 1	2011	342								d3390	10.1136/bmj.d3390	http://dx.doi.org/10.1136/bmj.d3390			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	774MK	21632661				2022-12-28	WOS:000291390500012
J	Hawkes, N				Hawkes, Nigel			BODY POLITIC Keep GPs in the driving seat	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 1	2011	342								d3382	10.1136/bmj.d3382	http://dx.doi.org/10.1136/bmj.d3382			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774MK	21632660				2022-12-28	WOS:000291390500011
J	Dyson, C; Austin, T; Lees, C				Dyson, Charlotte; Austin, Topun; Lees, Christoph			Could routine cardiotocography reduce long term cognitive impairment?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							NEONATAL ENCEPHALOPATHY; SCHOOL-AGE; ASPHYXIA; SURVIVORS; SEIZURES; OUTCOMES		[Dyson, Charlotte; Lees, Christoph] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Div Maternal Fetal Med, Cambridge CB2 2QQ, England; [Austin, Topun] Addenbrookes Hosp, Div Neonatol, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Lees, C (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Div Maternal Fetal Med, Cambridge CB2 2QQ, England.	christoph.lees@addenbrookes.nhs.uk	Austin, Topun/ABG-1960-2021	Austin, Topun/0000-0002-8428-8624				Al-Macki N, 2009, PEDIATR NEUROL, V41, P399, DOI 10.1016/j.pediatrneurol.2009.06.001; Alfirevic Z, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006066; Chen HY, 2011, AM J OBSTET GYNECOL, V204, pS43, DOI 10.1016/j.ajog.2010.10.091; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Glass HC, 2009, J PEDIATR-US, V155, P318, DOI 10.1016/j.jpeds.2009.03.040; Graham EM, 2006, OBSTET GYNECOL, V108, P656, DOI 10.1097/01.AOG.0000230533.62760.ef; Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094; Ingemarsson Ingemar, 2009, Neonatology, V95, P342, DOI 10.1159/000209299; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Lindstrom K, 2006, PEDIATR NEUROL, V35, P268, DOI 10.1016/j.pediatrneurol.2006.05.003; Marlow N, 2005, ARCH DIS CHILD-FETAL, V90, pF380, DOI 10.1136/adc.2004.067520; Morris JK, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3794; Moster D, 2002, ARCH DIS CHILD-FETAL, V86, pF16, DOI 10.1136/fn.86.1.F16; National Institute for Health and Clinical Excellence, 2007, NICE CLIN GUID INTR; Office for National Statistics, 2005, LIV BIRTHS MULT GEST; Office for National Statistics, FERT; ROBERTSON CMT, 1989, J PEDIATR-US, V114, P753, DOI 10.1016/S0022-3476(89)80132-5; Silverstein FS, 2007, ANN NEUROL, V62, P112, DOI 10.1002/ana.21167; Tekgul H, 2006, PEDIATRICS, V117, P1270, DOI 10.1542/peds.2005-1178; TEMPLE CM, 1995, DEV MED CHILD NEUROL, V37, P109; van Handel M, 2007, EUR J PEDIATR, V166, P645, DOI 10.1007/s00431-007-0437-8	21	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2011	342								d3120	10.1136/bmj.d3120	http://dx.doi.org/10.1136/bmj.d3120			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774MG	21628365	Green Submitted			2022-12-28	WOS:000291390100003
J	Bangash, MA; Park, JM; Melnikova, T; Wang, DH; Jeon, SK; Lee, D; Syeda, S; Kim, J; Kouser, M; Schwartz, J; Cui, YY; Zhao, X; Speed, HE; Kee, SE; Tu, JC; Hu, JH; Petralia, RS; Linden, DJ; Powell, CM; Savonenko, A; Xiao, B; Worley, PF				Bangash, M. Ali; Park, Joo Min; Melnikova, Tatiana; Wang, Dehua; Jeon, Soo Kyeong; Lee, Deidre; Syeda, Sbaa; Kim, Juno; Kouser, Mehreen; Schwartz, Joshua; Cui, Yiyuan; Zhao, Xia; Speed, Haley E.; Kee, Sara E.; Tu, Jian Cheng; Hu, Jia-Hua; Petralia, Ronald S.; Linden, David J.; Powell, Craig M.; Savonenko, Alena; Xiao, Bo; Worley, Paul F.			RETRACTED: Enhanced Polyubiquitination of Shank3 and NMDA Receptor in a Mouse Model of Autism (Retracted article. See vol. 152, pg. 367, 2013)	CELL			English	Article; Retracted Publication							SCAFFOLDING PROTEIN SHANK3; X MENTAL-RETARDATION; SPECTRUM DISORDERS; SCHIZOPHRENIA; MUTATIONS; HOMER; GENE; MICE; RECOGNITION; EXPRESSION	We have created a mouse genetic model that mimics a human mutation of Shank3 that deletes the C terminus and is associated with autism. Expressed as a single copy [Shank3(+/Delta C) mice], Shank3 Delta C protein interacts with the wild-type (WT) gene product and results in >90% reduction of Shank3 at synapses. This "gain-of-function" phenotype is linked to increased polyubiquitination of WT Shank3 and its redistribution into proteasomes. Similarly, the NR1 subunit of the NMDA receptor is reduced at synapses with increased polyubiquitination. Assays of postsynaptic density proteins, spine morphology, and synapse number are unchanged in Shank3(+/Delta C) mice, but the amplitude of NMDAR responses is reduced together with reduced NMDAR-dependent LTP and LTD. Reciprocally, mGluR-dependent LTD is markedly enhanced. Shank3(+/Delta C) mice show behavioral deficits suggestive of autism and reduced NMDA receptor function. These studies reveal a mechanism distinct from haploinsufficiency by which mutations of Shank3 can evoke an autism-like disorder.	[Bangash, M. Ali; Park, Joo Min; Jeon, Soo Kyeong; Kim, Juno; Schwartz, Joshua; Tu, Jian Cheng; Hu, Jia-Hua; Linden, David J.; Xiao, Bo; Worley, Paul F.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Melnikova, Tatiana; Lee, Deidre; Syeda, Sbaa; Savonenko, Alena] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Melnikova, Tatiana; Lee, Deidre; Syeda, Sbaa; Savonenko, Alena] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Kouser, Mehreen; Speed, Haley E.; Kee, Sara E.; Powell, Craig M.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Kouser, Mehreen; Speed, Haley E.; Kee, Sara E.; Powell, Craig M.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Wang, Dehua; Cui, Yiyuan; Zhao, Xia; Xiao, Bo] Sichuan Univ, State Key Lab Biotherapy, W China Hosp, Chengdu 610065, Peoples R China; [Petralia, Ronald S.] Natl Inst Deafness & Other Commun Disorders, Neurochem Lab, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Sichuan University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Worley, PF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	pworley@jhmi.edu	Savonenko, Alena/AAT-2274-2021		National Institute of Neurological Disorders and Stroke [5R01NS070301-02]; National Institute of Mental Health [5P50MH084020-03]; National 973 Basic Research Program of China [20009CB941400, R21HD065290, R01MH081164]; Autism Speaks; Autism Science Foundation; Hartwell Foundation; NIDCD; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD069560] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD065290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH084020, R01MH081164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZICDC000081, ZIADC000003] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National 973 Basic Research Program of China(National Basic Research Program of China); Autism Speaks; Autism Science Foundation; Hartwell Foundation; NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	M.A.B., A. S., B. X., and P. F. W. designed the study. M. A. B. executed and analyzed all the biochemistry, immunocytochemistry, and DiI experiments. B. X., M. A. B., D. W., Y.C., and X.Z. created the Shank3 mouse. J.M.P., S.K.J., and J.K. did the electrophysiology experiments and analysis supervised by P. F. W. and D.J.L. R. S. P. did the electron microscopy. T. M., D. L., S. S., M. K., H. E. S., and S. E. K. did the behavior experiments and analysis supervised by A. S. and C. M. P. J.C.T. and J.-H.H. provided reagents. M. A. B., A. S., and P. F. W. wrote the manuscript and P. F. W. supervised the overall project. We thank Maria Papapavlou for administrative assistance; Holly Wellington, Ann Lawler, Johnisha Witherspoon, and Charles Hawkins for assistance in generating the Shank3(+/Delta C) mice; Uejin Kim, Jasmin Harpe, Matt Jo, Pennson Wang, Dakim Gaines, Olivia Tong, Julia Wynne, and Eugenia Cho for help with behavioral testing and data handling; Ya-Xian Wang for help with the electron microscopy preparation. This work was supported by National Institute of Neurological Disorders and Stroke grant 5R01NS070301-02 (P. F. W.), National Institute of Mental Health Core grant 5P50MH084020-03 (P. F. W.), National 973 Basic Research Program of China 20009CB941400 (B. X.), R21HD065290 (C. M. P.), R01MH081164 (C. M. P.), Autism Speaks (C. M. P. and M. K.), The Autism Science Foundation (C. M. P. and H. S.), The Hartwell Foundation (C. M. P.), NIDCD Intramural Program (R. S. P.), and Weatherstone predoctoral fellowship from Autism Speaks (M.A.B.).	Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Bonaglia MC, 2001, AM J HUM GENET, V69, P261, DOI 10.1086/321293; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Condra JA, 2007, PSYCHIAT GENET, V17, P292, DOI 10.1097/YPG.0b013e3281ac2345; DeLisi LE, 2002, AM J PSYCHIAT, V159, P803, DOI 10.1176/appi.ajp.159.5.803; Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Ferguson JN, 2002, FRONT NEUROENDOCRIN, V23, P200, DOI 10.1006/frne.2002.0229; Gauthier J, 2010, P NATL ACAD SCI USA, V107, P7863, DOI 10.1073/pnas.0906232107; Geschwind DH, 2008, CELL, V135, P391, DOI 10.1016/j.cell.2008.10.016; Hayashi MK, 2009, CELL, V137, P159, DOI 10.1016/j.cell.2009.01.050; Huber KM, 2002, P NATL ACAD SCI USA, V99, P7746, DOI 10.1073/pnas.122205699; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Kato A, 2005, P NATL ACAD SCI USA, V102, P5600, DOI 10.1073/pnas.0501769102; Marshall CR, 2008, AM J HUM GENET, V82, P477, DOI 10.1016/j.ajhg.2007.12.009; Moessner R, 2007, AM J HUM GENET, V81, P1289, DOI 10.1086/522590; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; NESSLINGER NJ, 1994, AM J HUM GENET, V54, P464; Powell CM, 2006, BIOL PSYCHIAT, V59, P1198, DOI 10.1016/j.biopsych.2006.05.008; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Rapoport J, 2009, J AM ACAD CHILD PSY, V48, P10, DOI 10.1097/CHI.0b013e31818b1c63; Roussignol G, 2005, J NEUROSCI, V25, P3560, DOI 10.1523/JNEUROSCI.4354-04.2005; Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659; Szumlinski KK, 2005, GENES BRAIN BEHAV, V4, P273, DOI 10.1111/j.1601-183X.2005.00120.x	25	92	96	0	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 27	2011	145	5					758	772		10.1016/j.cell.2011.03.052	http://dx.doi.org/10.1016/j.cell.2011.03.052			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21565394	Green Accepted, Bronze			2022-12-28	WOS:000291018600015
J	Grigoryan, G; Kim, YH; Acharya, R; Axelrod, K; Jain, RM; Willis, L; Drndic, M; Kikkawa, JM; DeGrado, WF				Grigoryan, Gevorg; Kim, Yong Ho; Acharya, Rudresh; Axelrod, Kevin; Jain, Rishabh M.; Willis, Lauren; Drndic, Marija; Kikkawa, James M.; DeGrado, William F.			Computational Design of Virus-Like Protein Assemblies on Carbon Nanotube Surfaces	SCIENCE			English	Article							DE-NOVO DESIGN; PEPTIDES; DNA; BINDING; INDUCTION; DOMAIN; MODEL	There is a general need for the engineering of protein-like molecules that organize into geometrically specific superstructures on molecular surfaces, directing further functionalization to create richly textured, multilayered assemblies. Here we describe a computational approach whereby the surface properties and symmetry of a targeted surface define the sequence and superstructure of surface-organizing peptides. Computational design proceeds in a series of steps that encode both surface recognition and favorable intersubunit packing interactions. This procedure is exemplified in the design of peptides that assemble into a tubular structure surrounding single-walled carbon nanotubes (SWNTs). The geometrically defined, virus-like coating created by these peptides converts the smooth surfaces of SWNTs into highly textured assemblies with long-scale order, capable of directing the assembly of gold nanoparticles into helical arrays along the SWNT axis.	[Grigoryan, Gevorg; Acharya, Rudresh; DeGrado, William F.] Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; [Kim, Yong Ho; DeGrado, William F.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; [Axelrod, Kevin; Jain, Rishabh M.; Willis, Lauren; Drndic, Marija; Kikkawa, James M.] Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	DeGrado, WF (corresponding author), Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.	wdegrado@mail.med.upenn.edu	Jain, Rishabh/D-7797-2013; Acharya, Rudresh/AAD-1247-2021	Acharya, Rudresh/0000-0002-9012-9849	NSF Materials Research Science and Engineering Center [DMR05-20020]; NIH [GM54616, 5F32GM084631-02]; NSF National Science and Engineering Center [DMR-0425780]; NSF [DMR-0907226, DGE-0221664]; Roy and Diana Vagelos Program in the Molecular Life Sciences; Direct For Mathematical & Physical Scien [0907266] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM084631, R01GM054616, R37GM054616] Funding Source: NIH RePORTER	NSF Materials Research Science and Engineering Center(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF National Science and Engineering Center; NSF(National Science Foundation (NSF)); Roy and Diana Vagelos Program in the Molecular Life Sciences; Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the NSF Materials Research Science and Engineering Center DMR05-20020 grant (to J.M.K., M. D., and W. F. D.), NIH grant no. GM54616 (to W. F. D.), a NSF National Science and Engineering Center grant no. DMR-0425780 (to W. F. D. and M. D.), NSF grant no. DMR-0907226 (to J.M.K.), and NIH grant no. 5F32GM084631-02 (to G. G.). K. A. acknowledges support from the Roy and Diana Vagelos Program in the Molecular Life Sciences, and L. W. acknowledges funding from the NSF-Integrative Graduate Education and Research Traineeship program (grant DGE-0221664). We would like to thank K. A. McAllister for training Y.H.K. in peptide synthesis, and A. E. Keating for comments on the manuscript.	Ashworth J, 2006, NATURE, V441, P656, DOI 10.1038/nature04818; Calhoun JR, 2005, BIOPOLYMERS, V80, P264, DOI 10.1002/bip.20230; Capriotti LA, 2007, J AM CHEM SOC, V129, P5281, DOI 10.1021/ja070356b; Chakraborty AK, 2001, ANNU REV PHYS CHEM, V52, P537, DOI 10.1146/annurev.physchem.52.1.537; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; DEGRADO WF, 1985, J AM CHEM SOC, V107, P7684, DOI 10.1021/ja00311a076; Dieckmann GR, 2003, J AM CHEM SOC, V125, P1770, DOI 10.1021/ja029084x; Fairman R, 2005, CURR OPIN STRUC BIOL, V15, P453, DOI 10.1016/j.sbi.2005.07.005; Ghirlanda G, 2002, J MOL BIOL, V319, P243, DOI 10.1016/S0022-2836(02)00233-4; Ghirlanda G, 1998, J MOL BIOL, V281, P379, DOI 10.1006/jmbi.1998.1912; Ghosh D, 2005, CURR OPIN CHEM BIOL, V9, P97, DOI 10.1016/j.cbpa.2005.02.005; Golberg D, 2007, ADV MATER, V19, P2413, DOI 10.1002/adma.200700179; Grigoryan G, 2011, J MOL BIOL, V405, P1079, DOI 10.1016/j.jmb.2010.08.058; Grigoryan G, 2009, NATURE, V458, P859, DOI 10.1038/nature07885; Haring D, 2001, BIOCONJUGATE CHEM, V12, P385, DOI 10.1021/bc000117c; Jiang L, 2008, SCIENCE, V319, P1387, DOI 10.1126/science.1152692; Kaplan J, 2004, P NATL ACAD SCI USA, V101, P11566, DOI 10.1073/pnas.0404387101; Katz E, 2004, CHEMPHYSCHEM, V5, P1085, DOI 10.1002/cphc.200400193; Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; Masica DL, 2010, J AM CHEM SOC, V132, P12252, DOI 10.1021/ja1001086; Nygren P, 2008, NANO LETT, V8, P1844, DOI 10.1021/nl080386s; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Ortiz-Acevedo A, 2005, J AM CHEM SOC, V127, P9512, DOI 10.1021/ja050507f; Rapaport H, 2006, SUPRAMOL CHEM, V18, P445, DOI 10.1080/10610270600665905; Reina J, 2002, NAT STRUCT BIOL, V9, P621, DOI 10.1038/nsb815; Rothlisberger D, 2008, NATURE, V453, P190, DOI 10.1038/nature06879; Segman S, 2010, ANGEW CHEM INT EDIT, V49, P716, DOI 10.1002/anie.200904566; Torrens ON, 2006, NANO LETT, V6, P2864, DOI 10.1021/nl062071n; Tu XM, 2009, NATURE, V460, P250, DOI 10.1038/nature08116; Wang SQ, 2003, NAT MATER, V2, P196, DOI 10.1038/nmat833; Zheng M, 2003, SCIENCE, V302, P1545, DOI 10.1126/science.1091911	34	161	171	0	178	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2011	332	6033					1071	1076		10.1126/science.1198841	http://dx.doi.org/10.1126/science.1198841			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769FN	21617073	Green Accepted			2022-12-28	WOS:000290996700041
J	Mackem, S; Lewandoski, M				Mackem, Susan; Lewandoski, Mark			Limb Cells Don't Tell Time	SCIENCE			English	Editorial Material							VERTEBRATE LIMB; REGENERATION; AXIS; WNT		[Mackem, Susan; Lewandoski, Mark] NCI, Canc & Dev Biol Lab, Ctr Canc Res, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mackem, S (corresponding author), NCI, Canc & Dev Biol Lab, Ctr Canc Res, Frederick, MD 21702 USA.	mackems@mail.nih.gov; lewandom@mail.nih.gov		Lewandoski, Mark/0000-0002-1066-3735	NATIONAL CANCER INSTITUTE [ZIABC010518] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cooper KL, 2011, SCIENCE, V332, P1083, DOI 10.1126/science.1199499; Galloway JL, 2009, NATURE, V460, P400, DOI 10.1038/nature08117; Kawakami Y, 2006, GENE DEV, V20, P3232, DOI 10.1101/gad.1475106; Lin G, 2008, DEV BIOL, V316, P323, DOI 10.1016/j.ydbio.2008.01.032; MADEN M, 1982, NATURE, V295, P672, DOI 10.1038/295672a0; Mariani FV, 2008, NATURE, V453, P401, DOI 10.1038/nature06876; Rosello-Diez A, 2011, SCIENCE, V332, P1086, DOI 10.1126/science.1199489; Schlueter J, 2007, CYTOGENET GENOME RES, V117, P256, DOI 10.1159/000103187; Tabin C, 2007, GENE DEV, V21, P1433, DOI 10.1101/gad.1547407; ten Berge D, 2008, DEVELOPMENT, V135, P3247, DOI 10.1242/dev.023176; Zhao XL, 2009, CURR BIOL, V19, P1050, DOI 10.1016/j.cub.2009.04.059	11	1	1	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2011	332	6033					1038	1039		10.1126/science.1207554	http://dx.doi.org/10.1126/science.1207554			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617061				2022-12-28	WOS:000290996700028
J	Shi, FM; Lemmon, MA				Shi, Fumin; Lemmon, Mark A.			KSR Plays CRAF-ty	SCIENCE			English	Editorial Material							SCAFFOLD; KINASE; INHIBITORS; BINDING; BRAF; RAS; ATP		[Shi, Fumin] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Grad Grp Biochem & Mol Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Shi, FM (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, 422 Curie Blvd, Philadelphia, PA 19104 USA.	mlemmon@mail.med.upenn.edu	Shi, Fumin/H-3472-2013	Lemmon, Mark/0000-0002-3379-5319				Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Brennan DF, 2011, NATURE, V472, P366, DOI 10.1038/nature09860; Cichowski K, 2010, NATURE, V464, P358, DOI 10.1038/464358a; Good MC, 2011, SCIENCE, V332, P680, DOI 10.1126/science.1198701; Hu JC, 2011, P NATL ACAD SCI USA, V108, P6067, DOI 10.1073/pnas.1102554108; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; McKay MM, 2011, CURR BIOL, V21, P563, DOI 10.1016/j.cub.2011.02.033; McKay MM, 2009, P NATL ACAD SCI USA, V106, P11022, DOI 10.1073/pnas.0901590106; Morrison DK, 2001, J CELL SCI, V114, P1609; Mukherjee K, 2008, CELL, V133, P328, DOI 10.1016/j.cell.2008.02.036; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Udell CM, 2011, CELL MOL LIFE SCI, V68, P553, DOI 10.1007/s00018-010-0520-6; Zeqiraj E, 2010, CURR OPIN STRUC BIOL, V20, P772, DOI 10.1016/j.sbi.2010.10.001	15	4	4	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2011	332	6033					1043	1044		10.1126/science.1208063	http://dx.doi.org/10.1126/science.1208063			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617065				2022-12-28	WOS:000290996700032
J	Blazeby, JM; McNair, AGK				Blazeby, Jane M.; McNair, Angus G. K.			Commentary: Talking to patients about surgical innovations	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Blazeby, Jane M.; McNair, Angus G. K.] Univ Bristol, Sch Social & Community Med, Surg Res Unit, Bristol BS8 2PS, Avon, England; [Blazeby, Jane M.] Univ Hosp Bristol NHS Fdn Trust, Div Surg Head & Neck, Bristol BS2 8HW, Avon, England; [McNair, Angus G. K.] Severn Deanery, Severn Sch Surg, Bristol, Avon, England	University of Bristol; University of Bristol	Blazeby, JM (corresponding author), Univ Bristol, Sch Social & Community Med, Surg Res Unit, Bristol BS8 2PS, Avon, England.	j.m.blazeby@bris.ac.uk	Blazeby, Jane/H-6703-2019; McNair, Angus/K-6544-2012	Blazeby, Jane/0000-0002-3354-3330; McNair, Angus/0000-0002-2601-9258				*DEP HLTH, 2004, BETT INF BETT CHOIC; Donovan J, 2002, BMJ-BRIT MED J, V325, P766, DOI 10.1136/bmj.325.7367.766; McCulloch P, 2009, LANCET, V374, P1105, DOI 10.1016/S0140-6736(09)61116-8; Treasure T, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2466	4	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 26	2011	342								d2871	10.1136/bmj.d2871	http://dx.doi.org/10.1136/bmj.d2871			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771KG	21622511				2022-12-28	WOS:000291155000004
J	Hansen, SG; Ford, JC; Lewis, MS; Ventura, AB; Hughes, CM; Coyne-Johnson, L; Whizin, N; Oswald, K; Shoemaker, R; Swanson, T; Legasse, AW; Chiuchiolo, MJ; Parks, CL; Axthelm, MK; Nelson, JA; Jarvis, MA; Piatak, M; Lifson, JD; Picker, LJ				Hansen, Scott G.; Ford, Julia C.; Lewis, Matthew S.; Ventura, Abigail B.; Hughes, Colette M.; Coyne-Johnson, Lia; Whizin, Nathan; Oswald, Kelli; Shoemaker, Rebecca; Swanson, Tonya; Legasse, Alfred W.; Chiuchiolo, Maria J.; Parks, Christopher L.; Axthelm, Michael K.; Nelson, Jay A.; Jarvis, Michael A.; Piatak, Michael, Jr.; Lifson, Jeffrey D.; Picker, Louis J.			Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine	NATURE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY VIRUS SIVMAC239; PRIMARY HIV-1 INFECTION; IMMUNE-RESPONSES; RHESUS-MONKEYS; MACAQUE MODEL; REPLICATION; CHALLENGE; PROTECTION; AIDS	The acquired immunodeficiency syndrome (AIDS)-causing lentiviruses human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) effectively evade host immunity and, once established, infections with these viruses are only rarely controlled by immunological mechanisms(1-3). However, the initial establishment of infection in the first few days after mucosal exposure, before viral dissemination and massive replication, may be more vulnerable to immune control(4). Here we report that SIV vaccines that include rhesus cytomegalovirus (RhCMV) vectors(5) establish indefinitely persistent, high-frequency, SIV-specific effector memory T-cell (T(EM)) responses at potential sites of SIV replication in rhesus macaques and stringently control highly pathogenic SIV(MAC239) infection early after mucosal challenge. Thirteen of twenty-four rhesus macaques receiving either RhCMV vectors alone or RhCMV vectors followed by adenovirus 5 (Ad5) vectors (versus 0 of 9 DNA/Ad5-vaccinated rhesus macaques) manifested early complete control of SIV (undetectable plasma virus), and in twelve of these thirteen animals we observed long-term (>= 1 year) protection. This was characterized by: occasional blips of plasma viraemia that ultimately waned; predominantly undetectable cell-associated viral load in blood and lymph node mononuclear cells; no depletion of effector-site CD4(+) memory T cells; no induction or boosting of SIV Env-specific antibodies; and induction and then loss of T-cell responses to an SIV protein (Vif) not included in the RhCMV vectors. Protection correlated with the magnitude of the peak SIV-specific CD8(+) T-cell responses in the vaccine phase, and occurred without anamnestic T-cell responses. Remarkably, long-term RhCMV vector-associated SIV control was insensitive to either CD8(+) or CD4(+) lymphocyte depletion and, at necropsy, cell-associated SIV was only occasionally measurable at the limit of detection with ultrasensitive assays, observations that indicate the possibility of eventual viral clearance. Thus, persistent vectors such as CMV and their associated TEM responses might significantly contribute to an efficacious HIV/AIDS vaccine.	[Hansen, Scott G.; Ford, Julia C.; Lewis, Matthew S.; Ventura, Abigail B.; Hughes, Colette M.; Coyne-Johnson, Lia; Whizin, Nathan; Swanson, Tonya; Legasse, Alfred W.; Axthelm, Michael K.; Nelson, Jay A.; Jarvis, Michael A.; Picker, Louis J.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Dept Mol Microbiol & Immunol, Beaverton, OR 97006 USA; [Hansen, Scott G.; Ford, Julia C.; Lewis, Matthew S.; Ventura, Abigail B.; Hughes, Colette M.; Coyne-Johnson, Lia; Whizin, Nathan; Swanson, Tonya; Legasse, Alfred W.; Axthelm, Michael K.; Nelson, Jay A.; Jarvis, Michael A.; Picker, Louis J.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Dept Pathol, Beaverton, OR 97006 USA; [Hansen, Scott G.; Ford, Julia C.; Lewis, Matthew S.; Ventura, Abigail B.; Hughes, Colette M.; Coyne-Johnson, Lia; Whizin, Nathan; Swanson, Tonya; Legasse, Alfred W.; Axthelm, Michael K.; Nelson, Jay A.; Jarvis, Michael A.; Picker, Louis J.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA; [Oswald, Kelli; Shoemaker, Rebecca; Piatak, Michael, Jr.; Lifson, Jeffrey D.] NCI, AIDS & Canc Virus Program, SAIC Frederick Inc, Frederick, MD 21702 USA; [Chiuchiolo, Maria J.; Parks, Christopher L.] Int AIDS Vaccine Initiat, Vaccine Design & Dev Lab, Brooklyn, NY 11220 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon National Primate Research Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; International AIDS Vaccine Initiative	Picker, LJ (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Dept Mol Microbiol & Immunol, Beaverton, OR 97006 USA.	pickerl@ohsu.edu		Jarvis, Michael A/0000-0002-0124-4061	National Institute of Allergy and Infectious Diseases [RO1 AI060392, HHSN272200900037C]; International AIDS Vaccine Initiative (IAVI); United States Agency for International Development (USAID); Bill & Melinda Gates Foundation; National Center for Research Resources [P51 RR00163, R24 RR016001]; National Cancer Institute [HHSN261200800001E]; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR016001, P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI060392, R01AI060392] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [U24OD010850] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); International AIDS Vaccine Initiative (IAVI); United States Agency for International Development (USAID)(United States Agency for International Development (USAID)CGIAR); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institute of Allergy and Infectious Diseases (RO1 AI060392; contract #HHSN272200900037C); the International AIDS Vaccine Initiative (IAVI) and its donors, particularly the United States Agency for International Development (USAID); the Bill & Melinda Gates Foundation-supported Collaboration for AIDS Vaccine Discovery; the National Center for Research Resources (P51 RR00163; R24 RR016001); and the National Cancer Institute (contract HHSN261200800001E). We thank A. Sylwester, D. Seiss, R. Lum, H. Park and A. Okoye for specialized technical assistance; P. Barry, G. Pavlakis, G. Franchini, C. Miller, N. Wilson, and K. Reimann and Nonhuman Primate Reagent Resource for provision of crucial constructs or reagents; D. Watkins for MHC typing; D. Montefiori for neutralizing antibody assays; N. Letvin and L. Shen for TRIM5a typing; S. Mongoue-Tchokote and M. Mori for statistical assistance; A. Townsend and T. Schroyer for figure preparation; and K. Fruh, D. Watkins, B. Beresford, A. McDermott, R. King and W. Koff for discussion and advice.	Anton PA, 2003, AIDS, V17, P53, DOI 10.1097/00002030-200301030-00008; Bachmann MF, 1997, P NATL ACAD SCI USA, V94, P640, DOI 10.1073/pnas.94.2.640; Blankson JN, 2007, J VIROL, V81, P2508, DOI 10.1128/JVI.02165-06; Casimiro DR, 2005, J VIROL, V79, P15547, DOI 10.1128/JVI.79.24.15547-15555.2005; Chang WLW, 2003, J VIROL, V77, P5073, DOI 10.1128/JVI.77.9.5073-5083.2003; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Cline AN, 2005, J MED PRIMATOL, V34, P303; Dinoso JB, 2009, J VIROL, V83, P9247, DOI 10.1128/JVI.00840-09; Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357; Grovit-Ferbas K, 1999, PERSISTENT VIRAL INF, P3; Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757; Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706; Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Kulkarni V, 2011, VACCINE, V29, P6742, DOI 10.1016/j.vaccine.2010.12.056; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; MONTEFIORI DC, 2005, CURR PROTOC IMMUNOL, V12; North TW, 2010, J VIROL, V84, P2913, DOI 10.1128/JVI.02356-09; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P9293, DOI 10.1073/pnas.96.16.9293; Okoye A, 2009, J EXP MED, V206, P1575, DOI 10.1084/jem.20090356; Pitcher CJ, 2002, J IMMUNOL, V168, P29, DOI 10.4049/jimmunol.168.1.29; Reynolds MR, 2008, J EXP MED, V205, P2537, DOI 10.1084/jem.20081524; Robinson HL, 2005, NAT MED, V11, pS25, DOI 10.1038/nm1212; Rosati M, 2005, J VIROL, V79, P8480, DOI 10.1128/JVI.79.13.8480-8492.2005; Rosati M, 2009, P NATL ACAD SCI USA, V106, P15831, DOI 10.1073/pnas.0902628106; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; Ruiz L, 1999, AIDS, V13, pF1, DOI 10.1097/00002030-199901140-00001; Schmitz JE, 2000, J IMMUNOL, V164, P6015, DOI 10.4049/jimmunol.164.11.6015; Shen AD, 2003, J VIROL, V77, P4938, DOI 10.1128/JVI.77.8.4938-4949.2003; Shen AD, 2007, J VIROL, V81, P1660, DOI 10.1128/JVI.01396-06; Vaccari M, 2008, J VIROL, V82, P9629, DOI 10.1128/JVI.00893-08; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Venneti S, 2008, AM J PATHOL, V172, P1603, DOI 10.2353/ajpath.2008.070967; Wilson NA, 2006, J VIROL, V80, P5875, DOI 10.1128/JVI.00171-06	36	757	785	1	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2011	473	7348					523	U270		10.1038/nature10003	http://dx.doi.org/10.1038/nature10003			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21562493	Green Submitted, Green Accepted			2022-12-28	WOS:000290951300043
J	Hudson, JJ; Kara, DM; Smallman, IJ; Sauer, BE; Tarbutt, MR; Hinds, EA				Hudson, J. J.; Kara, D. M.; Smallman, I. J.; Sauer, B. E.; Tarbutt, M. R.; Hinds, E. A.			Improved measurement of the shape of the electron	NATURE			English	Article							YBF MOLECULE; DIPOLE MOMENT; ENHANCEMENT	The electron is predicted to be slightly aspheric(1), with a distortion characterized by the electric dipole moment (EDM), de. No experiment has ever detected this deviation. The standard model of particle physics predicts that de is far too small to detect(2), being some eleven orders of magnitude smaller than the current experimental sensitivity. However, many extensions to the standard model naturally predict much larger values of de that should be detectable(3). This makes the search for the electron EDM a powerful way to search for new physics and constrain the possible extensions. In particular, the popular idea that new supersymmetric particles may exist at masses of a few hundred GeV/c(2) (where c is the speed of light) is difficult to reconcile with the absence of an electron EDM at the present limit of sensitivity(2,4). The size of the EDM is also intimately related to the question of why the Universe has so little antimatter. If the reason is that some undiscovered particle interaction(5) breaks the symmetry between matter and antimatter, this should result in a measurable EDM in most models of particle physics(2). Here we use cold polar molecules to measure the electron EDM at the highest level of precision reported so far, providing a constraint on any possible new interactions. We obtain d(e) = (-2.4 +/- 5.7(stat) +/- 1.5(syst)) x 10(-28) e cm, where e is the charge on the electron, which sets a new upper limit of vertical bar d(e)vertical bar < 10.5 x 10(-28) e cm with 90 per cent confidence. This result, consistent with zero, indicates that the electron is spherical at this improved level of precision. Our measurement of atto-electronvolt energy shifts in a molecule probes new physics at the tera-electronvolt energy scale(2).	[Hudson, J. J.; Kara, D. M.; Smallman, I. J.; Sauer, B. E.; Tarbutt, M. R.; Hinds, E. A.] Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Ctr Cold Matter, London SW7 2AZ, England	Imperial College London	Hinds, EA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Ctr Cold Matter, Prince Consort Rd, London SW7 2AZ, England.	ed.hinds@imperial.ac.uk	Tarbutt, Michael/N-3370-2017	Tarbutt, Michael/0000-0003-2713-9531; Kara, Dhiren/0000-0003-1052-5495	UK research council STFC; UK research council EPSRC; Royal Society; STFC; EPSRC [EP/E036112/1, EP/F035160/1] Funding Source: UKRI; STFC [ST/H000968/1, PP/D00425X/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/E036112/1, EP/F035160/1] Funding Source: researchfish; Science and Technology Facilities Council [PP/D00425X/1, ST/H000968/1] Funding Source: researchfish	UK research council STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); UK research council EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Royal Society(Royal Society of London); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	We acknowledge the contributions of P. Condylis and H. Ashworth. We are grateful for technical assistance from J. Dyne and V. Gerulis. This work was supported by the UK research councils STFC and EPSRC, and by the Royal Society. J.J.H. is supported by an STFC Advanced Fellowship.	BARRY JF, 2011, BRIGHT SLOW CRYOGENI; Commins E. D., 1999, ADV ATOM MOL OPT PHY, V40, P1; Commins E D, 2010, LEPTON DIPOLE MOMENT; EDMONDS AR, 1996, ANGULAR MOMENTUM QUA, P73; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; HARRISON GE, 1971, J PHYS E SCI INSTRUM, V4, P750, DOI 10.1088/0022-3735/4/10/010; Hinds EA, 1997, PHYS SCRIPTA, VT70, P34, DOI 10.1088/0031-8949/1997/T70/005; Hudson JJ, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.033410; Hudson JJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.023003; HUTZLER NR, 2011, CRYOGENIC BEAM REFRA; Khriplovich I. B., 1997, CP VIOLATION STRANGE; Kozlov MG, 1997, J PHYS B-AT MOL OPT, V30, pL607, DOI 10.1088/0953-4075/30/18/003; KOZLOV MG, 1994, PHYS REV A, V49, P4502, DOI 10.1103/PhysRevA.49.4502; Ma TM, 2009, J PHYS CHEM A, V113, P8038, DOI 10.1021/jp903596g; Maronna R A, 2006, ROBUST STAT THEORY M, P31; Mosyagin NS, 1998, J PHYS B-AT MOL OPT, V31, pL763, DOI 10.1088/0953-4075/31/19/002; Parpia FA, 1998, J PHYS B-AT MOL OPT, V31, P1409, DOI 10.1088/0953-4075/31/7/008; Pospelov M, 2005, ANN PHYS-NEW YORK, V318, P119, DOI 10.1016/j.aop.2005.04.002; Quiney HM, 1998, J PHYS B-AT MOL OPT, V31, pL85, DOI 10.1088/0953-4075/31/3/003; Regan BC, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.071805; SAKHAROV AD, 1967, JETP LETT-USSR, V5, P24; Sauer BE, 2008, REV SCI INSTRUM, V79, DOI 10.1063/1.3036985; Skoff SM, 2011, PHYS REV A, V83, DOI 10.1103/PhysRevA.83.023418; Tarbutt MR, 2009, FARADAY DISCUSS, V142, P37, DOI 10.1039/b820625b; Tarbutt M. R., 2009, COLD MOL THEORY EXPT; Tarbutt MR, 2002, J PHYS B-AT MOL OPT, V35, P5013, DOI 10.1088/0953-4075/35/24/306; Titov AV, 1996, PHYS REV LETT, V77, P5346, DOI 10.1103/PhysRevLett.77.5346; VANDEMEERAKKER SYT, 2009, COLD MOL THEORY EXPT, pCH14	29	513	514	2	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2011	473	7348					493	U232		10.1038/nature10104	http://dx.doi.org/10.1038/nature10104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21614077	Green Submitted			2022-12-28	WOS:000290951300036
J	Conen, D; Chae, CU; Glynn, RJ; Tedrow, UB; Everett, BM; Buring, JE; Albert, CM				Conen, David; Chae, Claudia U.; Glynn, Robert J.; Tedrow, Usha B.; Everett, Brendan M.; Buring, Julie E.; Albert, Christine M.			Risk of Death and Cardiovascular Events in Initially Healthy Women With New-Onset Atrial Fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGESTIVE-HEART-FAILURE; FOLLOW-UP; ALCOHOL-CONSUMPTION; PREDICTING STROKE; NATURAL-HISTORY; SECULAR TRENDS; BLOOD-PRESSURE; MORTALITY; COMMUNITY; PREVALENCE	Context The risks associated with new-onset atrial fibrillation (AF) among middle-aged women and populations with a low comorbidity burden are poorly defined. Objectives To examine the association between incident AF and mortality in initially healthy women and to evaluate the influence of associated cardiovascular comorbidities on risk. Design, Setting, and Participants Between 1993 and March 16, 2010, 34 722 women participating in the Women's Health Study underwent prospective follow-up. Participants were 95% white, older than 45 years (median, 53 [interquartile range {IQR}, 49-59] years), and free of AF and cardiovascular disease at baseline. Cox proportional hazards models with time-varying covariates were used to determine the risk of events among women with incident AF. Secondary analyses were performed among women with paroxysmal AF. Main Outcome Measures Primary outcomes included all-cause, cardiovascular, and noncardiovascular mortality. Secondary outcomes included stroke, congestive heart failure, and myocardial infarction. Results During a median follow-up of 15.4 (IQR, 14.7-15.8) years, 1011 women developed AF. Incidence rates per 1000 person-years among women with and without AF were 10.8 (95% confidence interval [CI], 8.1-13.5) and 3.1 (95% CI, 2.9-3.2) for all-cause mortality, 4.3 (95% CI, 2.6-6.0) and 0.57 (95% CI, 0.5-0.6) for cardiovascular mortality, and 6.5 (95% CI, 4.4-8.6) and 2.5 (95% CI, 2.4-2.6) for noncardiovascular mortality, respectively. In multivariable models, hazard ratios (HRs) of new-onset AF for all-cause, cardiovascular, and noncardiovascular mortality were 2.14 (95% CI, 1.64-2.77), 4.18 (95% CI, 2.69-6.51), and 1.66 (95% CI, 1.19-2.30), respectively. Adjustment for nonfatal cardiovascular events potentially on the causal pathway to death attenuated these risks, but incident AF remained associated with all mortality components (all-cause: HR, 1.70 [95% CI, 1.30-2.22]; cardiovascular: HR, 2.57 [95% CI, 1.63-4.07]; and noncardiovascular: HR, 1.42 [95% CI, 1.02-1.98]). Among women with paroxysmal AF (n=656), the increase in mortality risk was limited to cardiovascular causes (HR, 2.94; 95% CI, 1.55-5.59). Conclusion Among a group of healthy women, new-onset AF was independently associated with all-cause, cardiovascular, and noncardiovascular mortality, with some of the risk potentially explained by nonfatal cardiovascular events. JAMA. 2011; 305(20): 2080-2087	[Conen, David] Univ Basel Hosp, Dept Med, CH-4031 Basel, Switzerland; [Conen, David; Tedrow, Usha B.; Albert, Christine M.] Harvard Univ, Sch Med, Dept Med, Ctr Arrhythmia Prevent,Brigham & Womens Hosp, Boston, MA USA; [Conen, David; Chae, Claudia U.; Glynn, Robert J.; Everett, Brendan M.; Buring, Julie E.; Albert, Christine M.] Harvard Univ, Sch Med, Dept Med, Div Prevent Med,Brigham & Womens Hosp, Boston, MA USA; [Tedrow, Usha B.; Everett, Brendan M.; Albert, Christine M.] Harvard Univ, Sch Med, Dept Med, Cardiovasc Div,Brigham & Womens Hosp, Boston, MA USA	University of Basel; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Conen, D (corresponding author), Univ Basel Hosp, Dept Med, Petersgraben 4, CH-4031 Basel, Switzerland.	conend@uhbs.ch	Tedrow, Usha/AFV-2528-2022	Albert, Christine/0000-0002-2081-1121	Boehringer Ingelheim; Sanofi-Aventis; Novartis; Swiss National Science Foundation [PP00P3_133681]; University of Basel; AstraZeneca; St Jude Medical; Biosense Webster; Medtronic Inc; National Institutes of Health/National Heart, Lung, and Blood Institute (NHLBI); American Heart Association; Siemens Healthcare Diagnostics; Boston Scientific; NHLBI [HL-093613, HL-043851, HL-080467, HL-099355]; National Cancer Institute [CA-047988]; NATIONAL CANCER INSTITUTE [R01CA047988] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851, R01HL080467, RC1HL099355, R21HL093613] Funding Source: NIH RePORTER	Boehringer Ingelheim(Boehringer Ingelheim); Sanofi-Aventis(Sanofi-Aventis); Novartis(Novartis); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); University of Basel; AstraZeneca(AstraZeneca); St Jude Medical(St. Jude Medical); Biosense Webster; Medtronic Inc(Medtronic); National Institutes of Health/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); Siemens Healthcare Diagnostics; Boston Scientific(Boston Scientific); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Conen reports receiving research grants from Boehringer Ingelheim, Sanofi-Aventis, Novartis, the Swiss National Science Foundation (PP00P3_133681), and the University of Basel. Dr Glynn reports receiving an honorarium for an invited talk from Merck and research grants for data monitoring and analysis of clinical trials from AstraZeneca. Dr Tedrow reports receiving consultancy fees from St Jude Medical, research grants from Biosense Webster, and grants from Biosense Webster, St Jude Medical, and Medtronic Inc to support the fellows' program at Brigham and Women's Hospital that she directs. Dr Albert reports receiving grant and administrative support from the National Institutes of Health/National Heart, Lung, and Blood Institute (NHLBI), American Heart Association, Siemens Healthcare Diagnostics, and St Jude Medical, consultancy fees from Novartis, and speaker honorarium from Boston Scientific and St Jude Medical. No other conflict of interest disclosures were reported.; This study was supported by grant HL-093613 from the NHLBI to Dr Albert. The WHS was supported by grants HL-043851, HL-080467, and HL-099355 from the NHLBI and grant CA-047988 from the National Cancer Institute.	Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Conen D, 2008, JAMA-J AM MED ASSOC, V300, P2489, DOI 10.1001/jama.2008.755; Conen D, 2009, CIRCULATION, V119, P2146, DOI 10.1161/CIRCULATIONAHA.108.830042; Dagenais GR, 2006, LANCET, V368, P581, DOI 10.1016/S0140-6736(06)69201-5; Di Pasquale G, 2005, J THROMB HAEMOST, V3, P428, DOI 10.1111/j.1538-7836.2005.01182.x; Friberg J, 2004, AM J CARDIOL, V94, P889, DOI 10.1016/j.amjcard.2004.06.023; Friberg L, 2007, EUR HEART J, V28, P2346, DOI 10.1093/eurheartj/ehm308; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; Jahangir A, 2007, CIRCULATION, V115, P3050, DOI 10.1161/CIRCULATIONAHA.106.644484; Keating RJ, 2005, AM J CARDIOL, V96, P1420, DOI 10.1016/j.amjcard.2005.07.050; KRAHN AD, 1995, AM J MED, V98, P476, DOI 10.1016/S0002-9343(99)80348-9; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; Miyasaka Y, 2007, J AM COLL CARDIOL, V49, P986, DOI 10.1016/j.jacc.2006.10.062; Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140; Mukamal KJ, 2005, CIRCULATION, V112, P1736, DOI 10.1161/CIRCULATIONAHA.105.547844; Nieuwlaat R, 2005, EUR HEART J, V26, P2422, DOI 10.1093/eurheartj/ehi505; Ott A, 1997, STROKE, V28, P316, DOI 10.1161/01.STR.28.2.316; Psaty BM, 1997, CIRCULATION, V96, P2455; Rexrode KM, 2000, J WOMEN HEALTH GEN-B, V9, P19, DOI 10.1089/152460900318911; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Stewart S, 2002, AM J MED, V113, P359, DOI 10.1016/S0002-9343(02)01236-6; Tedrow UB, 2010, J AM COLL CARDIOL, V55, P2319, DOI 10.1016/j.jacc.2010.02.029; Turnbull F, 2003, LANCET, V362, P1527; Vidaillet H, 2002, AM J MED, V113, P365, DOI 10.1016/S0002-9343(02)01253-6; Wang TJ, 2004, JAMA-J AM MED ASSOC, V292, P2471, DOI 10.1001/jama.292.20.2471; Wang TJ, 2003, CIRCULATION, V107, P2920, DOI 10.1161/01.CIR.0000072767.89944.6E; Wang TJ, 2003, JAMA-J AM MED ASSOC, V290, P1049, DOI 10.1001/jama.290.8.1049; Wolf PA, 1996, AM HEART J, V131, P790, DOI 10.1016/S0002-8703(96)90288-4; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	34	263	271	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2011	305	20					2080	2087		10.1001/jama.2011.659	http://dx.doi.org/10.1001/jama.2011.659			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768AC	21610240	Green Accepted, Bronze			2022-12-28	WOS:000290901700021
J	Rauch, SD; Halpin, CF; Antonelli, PJ; Babu, S; Carey, JP; Gantz, BJ; Goebel, JA; Hammerschlag, PE; Harris, JP; Isaacson, B; Lee, D; Linstrom, CJ; Parnes, LS; Shi, HL; Slattery, WH; Telian, SA; Vrabec, JT; Reda, DJ				Rauch, Steven D.; Halpin, Christopher F.; Antonelli, Patrick J.; Babu, Seilesh; Carey, John P.; Gantz, Bruce J.; Goebel, Joel A.; Hammerschlag, Paul E.; Harris, Jeffrey P.; Isaacson, Brandon; Lee, Daniel; Linstrom, Christopher J.; Parnes, Lorne S.; Shi, Helen; Slattery, William H.; Telian, Steven A.; Vrabec, Jeffrey T.; Reda, Domenic J.			Oral vs Intratympanic Corticosteroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLIND CLINICAL-TRIAL; DEXAMETHASONE; METHYLPREDNISOLONE; STEROIDS; DEAFNESS; PHARMACOKINETICS; IMPAIRMENT; PERFUSION; FLUIDS; JAPAN	Context Idiopathic sudden sensorineural hearing loss has been treated with oral corticosteroids for more than 30 years. Recently, many patients' symptoms have been managed with intratympanic steroid therapy. No satisfactory comparative effectiveness study to support this practice exists. Objective To compare the effectiveness of oral vs intratympanic steroid to treat sudden sensorineural hearing loss. Design, Setting, and Patients Prospective, randomized, noninferiority trial involving 250 patients with unilateral sensorineural hearing loss presenting within 14 days of onset of 50 dB or higher of pure tone average (PTA) hearing threshold. The study was conducted from December 2004 through October 2009 at 16 academic community-based otology practices. Participants were followed up for 6 months. Intervention One hundred twenty-one patients received either 60 mg/d of oral prednisone for 14 days with a 5-day taper and 129 patients received 4 doses over 14 days of 40 mg/mL of methylprednisolone injected into the middle ear. Main Outcome Measures Primary end point was change in hearing at 2 months after treatment. Noninferiority was defined as less than a 10-dB difference in hearing outcome between treatments. Results In the oral prednisone group, PTA improved by 30.7 dB compared with a 28.7-dB improvement in the intratympanic treatment group. Mean pure tone average at 2 months was 56.0 for the oral steroid treatment group and 57.6 dB for the intratympanic treatment group. Recovery of hearing on oral treatment at 2 months by intention-to-treat analysis was 2.0 dB greater than intratympanic treatment (95.21% upper confidence interval, 6.6 dB). Per-protocol analysis confirmed the intention-to-treat result. Thus, the hypothesis of inferiority of intratympanic methylprednisolone to oral prednisone for primary treatment of sudden sensorineural hearing loss was rejected. Conclusion Among patients with idiopathic sudden sensorineural hearing loss, hearing level 2 months after treatment showed that intratympanic treatment was not inferior to oral prednisone treatment.	[Rauch, Steven D.] Harvard Univ, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA; [Rauch, Steven D.; Halpin, Christopher F.; Lee, Daniel] Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA 02114 USA; [Antonelli, Patrick J.] Univ Florida, Dept Otolaryngol, Gainesville, FL USA; [Babu, Seilesh] Michigan Ear Inst, Farmington, CT USA; [Carey, John P.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA; [Gantz, Bruce J.] Univ Iowa, Dept Otolaryngol Head & Neck Surg, Iowa City, IA 52242 USA; [Goebel, Joel A.] Washington Univ, Dept Otolaryngol Head & Neck Surg, St Louis, MO USA; [Hammerschlag, Paul E.] NYU, Dept Otolaryngol, New York, NY 10016 USA; [Harris, Jeffrey P.] Univ Calif San Diego, Dept Otolaryngol Head & Neck Surg, La Jolla, CA 92093 USA; [Isaacson, Brandon] Univ Texas SW Med Ctr Dallas, Dept Otolaryngol Head & Neck Surg, Dallas, TX 75390 USA; [Linstrom, Christopher J.] New York Eye & Ear Infirm, Dept Otolaryngol, New York, NY 10003 USA; [Parnes, Lorne S.] Univ Western Ontario, Dept Otolaryngol Head & Neck Surg, London, ON, Canada; [Shi, Helen; Reda, Domenic J.] Hines VA Hosp, Cooperat Studies Program, Coordinating Ctr, Hines, IL USA; [Slattery, William H.] House Ear Res Inst, Los Angeles, CA USA; [Telian, Steven A.] Univ Michigan, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA; [Vrabec, Jeffrey T.] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts Eye & Ear Infirmary; State University System of Florida; University of Florida; Johns Hopkins University; University of Iowa; Washington University (WUSTL); New York University; University of California System; University of California San Diego; University of Texas System; University of Texas Southwestern Medical Center Dallas; New York Eye & Ear Infirmary of Mount Sinai; Western University (University of Western Ontario); US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; House Research Institute; University of Michigan System; University of Michigan; Baylor College of Medicine	Rauch, SD (corresponding author), Harvard Univ, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.	steven_rauch@meei.harvard.edu	Isaacson, Brandon/A-6358-2013; Lee, Daniel/N-5422-2019	, Domenic/0000-0003-1831-4270; Isaacson, Brandon/0000-0003-4725-1555; Hammerschlag, Paul/0000-0003-3251-077X; Gantz, Bruce/0000-0002-9916-6048	Otonomy Inc.; National Institute on Deafness and Communication Disorders [U01-DC006296]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [U01DC006296] Funding Source: NIH RePORTER	Otonomy Inc.; National Institute on Deafness and Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Harris reported that he has a financial interest in Otonomy Inc. Drs Rauch, Carey, Gantz, and Harris reported that they have served as paid consultants of Otonomy, and Drs Rauch, Gantz, and Linstrom reported that they have been investigators in a clinical trial supported by Otonomy Inc; otherwise, no other conflicts were reported.; This study was funded by grant U01-DC006296 from the National Institute on Deafness and Communication Disorders.	Alexander TH, 2009, OTOL NEUROTOL, V30, P443, DOI 10.1097/MAO.0b013e3181a52773; Alexiou C, 2001, ARCH OTOLARYNGOL, V127, P253, DOI 10.1001/archotol.127.3.253; [Anonymous], 2004, S3 21 AM NAT STAND M; Banerjee A, 2005, OTOL NEUROTOL, V26, P878, DOI 10.1097/01.mao.0000185052.07513.5a; Battaglia A, 2008, OTOL NEUROTOL, V29, P453, DOI 10.1097/MAO.0b013e318168da7a; BYL FM, 1984, LARYNGOSCOPE, V94, P647; Chandrasekhar SS, 2001, OTOL NEUROTOL, V22, P18, DOI 10.1097/00129492-200101000-00005; Chen CY, 2003, OTOL NEUROTOL, V24, P728, DOI 10.1097/00129492-200309000-00006; Chia EM, 2007, EAR HEARING, V28, P187, DOI 10.1097/AUD.0b013e31803126b6; Choung YH, 2006, LARYNGOSCOPE, V116, P747, DOI 10.1097/01.mlg.0000205183.29986.f6; Dallan I, 2010, OTOL NEUROTOL, V31, P25, DOI 10.1097/MAO.0b013e3181c34f18; DARMSTADT GL, 1989, AM J OTOLARYNG, V10, P410, DOI 10.1016/0196-0709(89)90037-9; DIRKS D, 1964, ARCHIV OTOLARYNGOL, V79, P551, DOI 10.1001/archotol.79.6.551; Fetterman BL, 1996, AM J OTOL, V17, P529; Fitzgerald DC, 2007, ANN OTO RHINOL LARYN, V116, P253, DOI 10.1177/000348940711600405; GATES GA, 1990, EAR HEARING, V11, P247, DOI 10.1097/00003446-199008000-00001; Haynes DS, 2007, LARYNGOSCOPE, V117, P3, DOI 10.1097/01.mlg.0000245058.11866.15; Herr BD, 2005, OTOLARYNG HEAD NECK, V132, P527, DOI 10.1016/j.otohns.2004.09.138; Ho GM, 2004, LARYNGOSCOPE, V114, P1184; Jerger J, 1997, J Am Acad Audiol, V8, P269; Kallinen J, 1997, ANN OTO RHINOL LARYN, V106, P22, DOI 10.1177/000348949710600104; MATTOX DE, 1977, ANN OTO RHINOL LARYN, V86, P463, DOI 10.1177/000348947708600406; MEGIGHIAN D, 1986, ARCH OTO-RHINO-LARYN, V243, P250, DOI 10.1007/BF00464440; Minoda R, 2000, AM J OTOL, V21, P819; Nakashima T, 2000, OTOLARYNG HEAD NECK, V123, P593, DOI 10.1067/mhn.2000.109486; Parnes LS, 1999, LARYNGOSCOPE, V109, P1, DOI 10.1097/00005537-199907001-00001; Plontke SKR, 2003, HEARING RES, V182, P34, DOI 10.1016/S0378-5955(03)00138-2; Plontke SK, 2008, OTOL NEUROTOL, V29, P732, DOI 10.1097/MAO.0b013e318173fcea; Plontke SK, 2008, OTOL NEUROTOL, V29, P401, DOI 10.1097/MAO.0b013e318161aaae; SHAIA FT, 1976, LARYNGOSCOPE, V86, P389, DOI 10.1288/00005537-197603000-00008; She WD, 2010, OTOLARYNG HEAD NECK, V142, P266, DOI 10.1016/j.otohns.2009.10.046; SIMMONS FB, 1973, LARYNGOSCOPE, V83, P1221, DOI 10.1288/00005537-197308000-00005; Stokroos RJ, 1998, ACTA OTO-LARYNGOL, V118, P488, DOI 10.1080/00016489850154603; Tucci DL, 2002, OTOL NEUROTOL, V23, P301, DOI 10.1097/00129492-200205000-00012; Westerlaken BO, 2003, ANN OTO RHINOL LARYN, V112, P993, DOI 10.1177/000348940311201113; WILSON WR, 1980, ARCH OTOLARYNGOL, V106, P772; YANAGITA N, 1994, ACTA OTO-LARYNGOL, P9	37	215	242	2	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2011	305	20					2071	2079		10.1001/jama.2011.679	http://dx.doi.org/10.1001/jama.2011.679			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768AC	21610239	Bronze			2022-12-28	WOS:000290901700020
J	Bennell, KL; Bowles, KA; Payne, C; Cicuttini, FM; Williamson, E; Forbes, A; Hanna, F; Davies-Tuck, M; Harris, A; Hinman, RS				Bennell, Kim L.; Bowles, Kelly-Ann; Payne, Craig; Cicuttini, Flavia M.; Williamson, Elizabeth; Forbes, Andrew; Hanna, Fahad; Davies-Tuck, Miranda; Harris, Anthony; Hinman, Rana S.			Lateral wedge insoles for medial knee osteoarthritis: 12 month randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VARUS DEFORMITY OSTEOARTHRITIS; TIBIAL CARTILAGE VOLUME; BONE-MARROW LESIONS; CLINICAL-TRIALS; CONSENSUS DEVELOPMENT; DISEASE PROGRESSION; NATURAL-HISTORY; DOUBLE-BLIND; BASE-LINE; FOLLOW-UP	Objective To assess the effect of lateral wedge insoles compared with flat control insoles on improving symptoms and slowing structural disease progression in medial knee osteoarthritis. Design Randomised controlled trial. Setting Community in Melbourne, Australia. Participants 200 people aged 50 or more with clinical and radiographic diagnosis of mild to moderately severe medial knee osteoarthritis. Interventions Full length 5 degree lateral wedged insoles or flat control insoles worn inside the shoes daily for 12 months. Main outcome measures Primary symptomatic outcome was change in overall knee pain (past week) measured on an 11 point numerical rating scale. Primary structural outcome was change in volume of medial tibial cartilage from magnetic resonance imaging scans. Secondary clinical outcomes included changes in measures of pain, function, stiffness, and health related quality of life. Secondary structural outcomes included progression of medial cartilage defects and bone marrow lesions. Results Between group differences did not differ significantly for the primary outcomes of change in overall pain (-0.3 points, 95% confidence intervals -1.0 to 0.3) and change in medial tibial cartilage volume (-0.4 mm(3), 95% confidence interval -15.4 to 14.6), and confidence intervals did not include minimal clinically important differences. None of the changes in secondary outcomes showed differences between groups. Conclusion Lateral wedge insoles worn for 12 months provided no symptomatic or structural benefits compared with flat control insoles.	[Bennell, Kim L.; Bowles, Kelly-Ann; Hinman, Rana S.] Univ Melbourne, Dept Physiotherapy, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; [Payne, Craig] La Trobe Univ, Sch Human Biosci, Dept Podiatry, Melbourne, Vic, Australia; [Cicuttini, Flavia M.; Williamson, Elizabeth; Forbes, Andrew; Hanna, Fahad; Davies-Tuck, Miranda] Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Melbourne, Vic 3181, Australia; [Williamson, Elizabeth] Univ Melbourne, Sch Populat Hlth, MEGA Epidemiol, Parkville, Vic 3010, Australia; [Hanna, Fahad] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia; [Harris, Anthony] Monash Univ, Hlth Econ Unit, Melbourne, Vic 3004, Australia	University of Melbourne; La Trobe University; Florey Institute of Neuroscience & Mental Health; Monash University; University of Melbourne; Baker Heart and Diabetes Institute; Monash University	Bennell, KL (corresponding author), Univ Melbourne, Dept Physiotherapy, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia.	k.bennell@unimelb.edu.au	Williamson, Elizabeth/H-3876-2019; Bowles, Kelly-Ann/I-2226-2014; Hanna, Fahad/J-2602-2019; Cicuttini, Flavia/H-4978-2014; Bennell, Kim/C-7022-2014	Williamson, Elizabeth/0000-0001-6905-876X; Bowles, Kelly-Ann/0000-0002-5965-5971; Hanna, Fahad/0000-0002-0494-9585; Cicuttini, Flavia/0000-0002-8200-1618; Forbes, Andrew/0000-0003-4269-914X; Harris, Anthony/0000-0003-1641-3320; Davies-Tuck, Miranda/0000-0003-1918-5538; Bennell, Kim/0000-0003-4982-5639; Hinman, Rana/0000-0001-6368-9456	National Health and Medical Research Council [350297]; Australian Research Council	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council)	This study was supported by a project grant from the National Health and Medical Research Council (No 350297). KLB is funded in part by an Australian Research Council future fellowship. The study sponsor had no role in the design of the study; the collection, analysis, and interpretation of the data; or the writing of the article and the decision to submit it for publication.	ALTMAN RD, 1995, OSTEOARTHR CARTILAGE, V3, P3; Baker K, 2007, ARTHRITIS RHEUM, V56, P1198, DOI 10.1002/art.22516; Barrios JA, 2009, KNEE, V16, P136, DOI 10.1016/j.knee.2008.10.002; Bellamy N, 1997, J RHEUMATOL, V24, P768; Bellamy N, 1997, J RHEUMATOL, V24, P799; BELLAMY N, 1992, J RHEUMATOL, V19, P451; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bennell K, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-96; Bennell KL, 2005, ANN RHEUM DIS, V64, P906, DOI 10.1136/ard.2004.026526; Briem K, 2009, J ORTHOP RES, V27, P1420, DOI 10.1002/jor.20899; Cicuttini FM, 2003, ARTHRITIS RHEUM-US, V48, P682, DOI 10.1002/art.10840; Cicuttini FM, 2005, ARTHRITIS RHEUM-US, V52, P2033, DOI 10.1002/art.21148; Cicuttini FM, 2004, ANN RHEUM DIS, V63, P1124, DOI 10.1136/ard.2004.021253; Cicuttini FM, 2004, RHEUMATOLOGY, V43, P321, DOI 10.1093/rheumatology/keh017; Davies-Tuck ML, 2008, OSTEOARTHR CARTILAGE, V16, P337, DOI 10.1016/j.joca.2007.07.005; Ding CH, 2005, OSTEOARTHR CARTILAGE, V13, P198, DOI 10.1016/j.joca.2004.11.007; Eckstein F, 2006, OSTEOARTHR CARTILAGE, V14, pA46, DOI 10.1016/j.joca.2006.02.026; Eckstein F, 2010, ARTHRITIS CARE RES H; Hawthorne G, 1999, QUAL LIFE RES, V8, P209, DOI 10.1023/A:1008815005736; Hinman RS, 2008, ARTHRIT RHEUM-ARTHR, V59, P408, DOI 10.1002/art.23326; Hinman RS, 2008, ARTHRIT RHEUM-ARTHR, V59, P144, DOI 10.1002/art.23249; Hinman RS, 2003, BRIT MED J, V327, P135, DOI 10.1136/bmj.327.7407.135; Hunter DJ, 2011, OSTEO CART; Hurwitz DE, 2002, J ORTHOPAED RES, V20, P101, DOI 10.1016/S0736-0266(01)00081-X; Hurwitz DE, 2000, J ORTHOPAED RES, V18, P572, DOI 10.1002/jor.1100180409; Keating E M, 1993, Orthop Rev, V22, P921; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kerrigan DC, 2002, ARCH PHYS MED REHAB, V83, P889, DOI 10.1053/apmr.2002.33225; Kito N, 2010, CLIN BIOMECH, V25, P914, DOI 10.1016/j.clinbiomech.2010.06.008; Kraus VB, 2005, ARTHRITIS RHEUM, V52, P1730, DOI 10.1002/art.21100; Lachance L, 2002, OSTEOARTHR CARTILAGE, V10, P849, DOI 10.1053/joca.2002.0840; Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176; Little R. J. A., 1987, STAT ANAL MISSING DA; Maillefert JF, 2001, OSTEOARTHR CARTILAGE, V9, P738, DOI 10.1053/joca.2001.0470; Maly MR, 2008, CLIN BIOMECH, V23, P796, DOI 10.1016/j.clinbiomech.2008.01.014; Miyazaki T, 2002, ANN RHEUM DIS, V61, P617, DOI 10.1136/ard.61.7.617; Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P46, DOI 10.1016/j.joca.2003.08.011; Reichmann WM, 2011, OSTEO CART; Salaffi F, 2004, EUR J PAIN, V8, P283, DOI 10.1016/j.ejpain.2003.09.004; Somers TJ, 2009, CURR OPIN RHEUMATOL, V21, P501, DOI 10.1097/BOR.0b013e32832ed704; Stuart E, 2008, PREV SCI, V9, P288, DOI 10.1007/s11121-008-0104-y; Tanamas SK, 2010, RHEUMATOLOGY, V49, P2413, DOI 10.1093/rheumatology/keq286; Thorp LE, 2007, ARTHRIT RHEUM-ARTHR, V57, P1254, DOI 10.1002/art.22991; Toda Y, 2008, OSTEOARTHR CARTILAGE, V16, P244, DOI 10.1016/j.joca.2007.06.010; Toda Y, 2006, OSTEOARTHR CARTILAGE, V14, P231, DOI 10.1016/j.joca.2005.09.006; Toda Y, 2005, OSTEOARTHR CARTILAGE, V13, P353, DOI 10.1016/j.joca.2004.12.012; Toda Y, 2004, ARTHRITIS RHEUM-US, V50, P3129, DOI 10.1002/art.20569; Wandel S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4675; Washburn RA, 1999, J SPORT MED PHYS FIT, V39, P336; White IR, 2005, STAT MED, V24, P993, DOI 10.1002/sim.1981; Wluka A, 2001, ANN RHEUM DIS, V60, P332, DOI 10.1136/ard.60.4.332; Wluka A, 2002, ARTHRITIS RHEUM-US, V46, P2065, DOI 10.1002/art.10460; Wluka A, 2009, ANN RHEUM DIS, V68, P850, DOI 10.1136/ard.2008.092221; Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013	54	123	125	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 18	2011	342								d2912	10.1136/bmj.d2912	http://dx.doi.org/10.1136/bmj.d2912			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768QQ	21593096	Green Published, Green Accepted, hybrid, Green Submitted			2022-12-28	WOS:000290951900004
J	Altman, D; Vayrynen, T; Engh, ME; Axelsen, S; Falconer, C				Altman, Daniel; Vayrynen, Tapio; Engh, Marie Ellstrom; Axelsen, Susanne; Falconer, Christian		Nordic Transvaginal Mesh Grp	Anterior Colporrhaphy versus Transvaginal Mesh for Pelvic-Organ Prolapse	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VAGINAL WALL PROLAPSE; RANDOMIZED TRIAL; REPAIR; MULTICENTER; RECURRENCE; COLLAGEN; SURGERY; QUALITY; WOMEN	BACKGROUND The use of standardized mesh kits for repair of pelvic-organ prolapse has spread rapidly in recent years, but it is unclear whether this approach results in better outcomes than traditional colporrhaphy. METHODS In this multicenter, parallel-group, randomized, controlled trial, we compared the use of a trocar-guided, transvaginal polypropylene-mesh repair kit with traditional colporrhaphy in women with prolapse of the anterior vaginal wall (cystocele). The primary outcome was a composite of the objective anatomical designation of stage 0 (no prolapse) or 1 (position of the anterior vaginal wall more than 1 cm above the hymen), according to the Pelvic Organ Prolapse Quantification system, and the subjective absence of symptoms of vaginal bulging 12 months after the surgery. RESULTS Of 389 women who were randomly assigned to a study treatment, 200 underwent prolapse repair with the transvaginal mesh kit and 189 underwent traditional colporrhaphy. At 1 year, the primary outcome was significantly more common in the women treated with transvaginal mesh repair (60.8%) than in those who underwent colporrhaphy (34.5%) (absolute difference, 26.3 percentage points; 95% confidence interval, 15.6 to 37.0). The surgery lasted longer and the rates of intraoperative hemorrhage were higher in the mesh-repair group than in the colporrhaphy group (P<0.001 for both comparisons). Rates of bladder perforation were 3.5% in the mesh-repair group and 0.5% in the colporrhaphy group (P = 0.07), and the respective rates of new stress urinary incontinence after surgery were 12.3% and 6.3% (P = 0.05). Surgical reintervention to correct mesh exposure during follow-up occurred in 3.2% of 186 patients in the mesh-repair group. CONCLUSIONS As compared with anterior colporrhaphy, use of a standardized, trocar-guided mesh kit for cystocele repair resulted in higher short-term rates of successful treatment but also in higher rates of surgical complications and postoperative adverse events. (Funded by the Karolinska Institutet and Ethicon; ClinicalTrials.gov number, NCT00566917.)	[Altman, Daniel; Falconer, Christian] Danderyd Hosp, Dept Clin Sci, Div Obstet & Gynecol, S-18288 Danderyd, Sweden; [Altman, Daniel] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Vayrynen, Tapio] Hyvinkaa Hosp, Hosp Dist Helsinki & Uusimaa, Dept Obstet & Gynecol, Hyvinkaa, Finland; [Engh, Marie Ellstrom] Univ Oslo, Akershus Univ Hosp, Dept Obstet & Gynaecol, Lorenskog, Norway; [Axelsen, Susanne] Aarhus Univ Hosp, Dept Obstet & Gynecol, Skejby, Denmark	Danderyds Hospital; Karolinska Institutet; University of Helsinki; Helsinki University Central Hospital; University of Oslo; Aarhus University	Altman, D (corresponding author), Danderyd Hosp, Dept Obstet & Gynecol, S-18288 Danderyd, Sweden.	daniel.altman@ds.se		Uustal, Eva/0000-0003-3299-8437	Karolinska Institutet and Ethicon; Swedish Society of Medicine; Karolinska Institutet research foundations; Stockholm County Council; Karolinska Institutet; Ethicon	Karolinska Institutet and Ethicon; Swedish Society of Medicine; Karolinska Institutet research foundations(Karolinska Institutet); Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet); Ethicon	Funded by the Karolinska Institutet and Ethicon; ClinicalTrials.gov number, NCT00566917.); Supported by grants from the Swedish Society of Medicine, the Karolinska Institutet research foundations, the regional agreement on clinical research (ALF) between the Stockholm County Council and the Karolinska Institutet, and Ethicon.	Abdel-Fattah M, 2008, BJOG-INT J OBSTET GY, V115, P22, DOI 10.1111/j.1471-0528.2007.01558.x; Altman D, 2007, OBSTET GYNECOL, V109, P303, DOI 10.1097/01.AOG.0000250970.23128.63; Altman D, 2009, OBSTET GYNECOL, V113, P127, DOI 10.1097/AOG.0b013e3181922362; Brincat M, 1986, BMJ-BRIT MED J, V287, P1337; Bump RC, 1996, AM J OBSTET GYNECOL, V175, P10, DOI 10.1016/S0002-9378(96)70243-0; de Tayrac R, 2006, INT UROGYNECOL J, V17, P483, DOI 10.1007/s00192-005-0046-x; DELANCEY JOL, 1992, AM J OBSTET GYNECOL, V166, P1717, DOI 10.1016/0002-9378(92)91562-O; Ek M, 2010, NEUROUROL URODYNAM, V29, P527, DOI 10.1002/nau.20811; Elmer C, 2009, OBSTET GYNECOL, V113, P117, DOI 10.1097/AOG.0b013e3181922164; Fatton B, 2007, INT UROGYNECOL J, V18, P743, DOI 10.1007/s00192-006-0234-3; Feiner B, 2009, BJOG-INT J OBSTET GY, V116, P15, DOI 10.1111/j.1471-0528.2008.02023.x; FitzGerald MP, 2001, AM J OBSTET GYNECOL, V185, P20, DOI 10.1067/mob.2001.116364; Gunasekera P, 2007, LANCET, V369, P1789, DOI 10.1016/S0140-6736(07)60814-9; Hiltunen R, 2007, OBSTET GYNECOL, V110, P455, DOI 10.1097/01.AOG.0000261899.87638.0a; Hinoul P, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.09.036; Jackson SR, 1996, LANCET, V347, P1658, DOI 10.1016/S0140-6736(96)91489-0; Jelovsek JE, 2007, LANCET, V369, P1027, DOI 10.1016/S0140-6736(07)60462-0; Kenton K, 2007, AM J OBSTET GYNECOL, V197; Kenton K, 2006, BJU INT, V98, P1, DOI 10.1111/j.1464-410X.2006.06299.x; Maher C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004014.pub4; McCulloch P, 2009, LANCET, V374, P1105, DOI 10.1016/S0140-6736(09)61116-8; Meschia M, 2007, J UROLOGY, V177, P192, DOI 10.1016/j.juro.2006.08.100; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Nguyen JN, 2008, OBSTET GYNECOL, V111, P891, DOI 10.1097/AOG.0b013e31816a2489; Richter HE, 2010, NEW ENGL J MED, V362, P2066, DOI 10.1056/NEJMoa0912658; Rogers RG, 2004, INT UROGYNECOL J, V15, P219, DOI 10.1007/s00192-004-1167-3; Rooney K, 2006, AM J OBSTET GYNECOL, V195, P1837, DOI 10.1016/j.ajog.2006.06.065; Sand PK, 2001, AM J OBSTET GYNECOL, V184, P1357, DOI 10.1067/mob.2001.115118; Sentilhes L, 2008, INT UROGYNECOL J, V19, P763, DOI 10.1007/s00192-007-0521-7; Shah AD, 2008, INT UROGYNECOL J, V19, P421, DOI 10.1007/s00192-007-0457-y; SHUMAKER SA, 1994, QUAL LIFE RES, V3, P291, DOI 10.1007/BF00451721; Sung VW, 2008, OBSTET GYNECOL, V112, P1131, DOI 10.1097/AOG.0b013e3181898ba9; Weber AM, 2001, AM J OBSTET GYNECOL, V185, P1299, DOI 10.1067/mob.2001.119081	33	419	453	1	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					1826	1836		10.1056/NEJMoa1009521	http://dx.doi.org/10.1056/NEJMoa1009521			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561348	Green Submitted			2022-12-28	WOS:000290483000010
J	Meersseman, W; Verschueren, P; Tousseyn, T; De Vos, R; Cassiman, D				Meersseman, Wouter; Verschueren, Patrick; Tousseyn, Thomas; De Vos, Rita; Cassiman, David			PAS-positive macrophages-not always infection	LANCET			English	Editorial Material									[Meersseman, Wouter] Univ Hosp Gasthuisberg, Dept Gen Internal Med, B-3000 Louvain, Belgium; [Verschueren, Patrick] Univ Hosp Gasthuisberg, Dept Rheumatol, B-3000 Louvain, Belgium; [Tousseyn, Thomas; De Vos, Rita] Univ Hosp Gasthuisberg, Dept Morphol & Mol Pathol, B-3000 Louvain, Belgium; [Cassiman, David] Univ Hosp Gasthuisberg, Dept Hepatol, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven	Meersseman, W (corresponding author), Univ Hosp Gasthuisberg, Dept Gen Internal Med, B-3000 Louvain, Belgium.	wouter.meersseman@uzleuven.be	Cassiman, David/H-6813-2014; Verschueren, Patrick/L-6397-2019	Cassiman, David/0000-0002-6154-0970; Verschueren, Patrick/0000-0002-0340-3580; Tousseyn, Thomas/0000-0002-0397-1086				Beck M, 2010, EXPERT OPIN EMERG DR, V15, P495, DOI 10.1517/14728214.2010.498580; McGovern MM, 2008, PEDIATRICS, V122, pE341, DOI 10.1542/peds.2007-3016; Simpson WL, 2010, AM J ROENTGENOL, V194, pW12, DOI 10.2214/AJR.09.2871; Venmans BJ, 1997, LANCET, V349, P433, DOI 10.1016/S0140-6736(97)80059-1; Vom Dahl S, 2010, BEST PRACT RES CL GA, V24, P619, DOI 10.1016/j.bpg.2010.09.001	5	7	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2011	377	9780					1890	1890		10.1016/S0140-6736(11)60285-7	http://dx.doi.org/10.1016/S0140-6736(11)60285-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774UI	21621718				2022-12-28	WOS:000291411700035
J	Vincent, A; Herman, J; Schulick, R; Hruban, RH; Goggins, M				Vincent, Audrey; Herman, Joseph; Schulick, Rich; Hruban, Ralph H.; Goggins, Michael			Pancreatic cancer	LANCET			English	Article							PHASE-III TRIAL; GEMCITABINE-BASED CHEMORADIATION; PAPILLARY MUCINOUS NEOPLASMS; DNA METHYLATION ALTERATIONS; GENOME-WIDE ASSOCIATION; FINE-NEEDLE-ASPIRATION; HIGH-RISK INDIVIDUALS; DUCTAL ADENOCARCINOMA; FAMILY-HISTORY; RESECTABLE ADENOCARCINOMA	Substantial progress has been made in our understanding of the biology of pancreatic cancer, and advances in patients' management have also taken place. Evidence is beginning to show that screening first-degree relatives of individuals with several family members affected by pancreatic cancer can identify non-invasive precursors of this malignant disease. The incidence of and number of deaths caused by pancreatic tumours have been gradually rising, even as incidence and mortality of other common cancers have been declining. Despite developments in detection and management of pancreatic cancer, only about 4% of patients will live 5 years after diagnosis. Survival is better for those with malignant disease localised to the pancreas, because surgical resection at present offers the only chance of cure. Unfortunately, 80-85% of patients present with advanced unresectable disease. Furthermore, pancreatic cancer responds poorly to most chemotherapeutic agents. Hence, we need to understand the biological mechanisms that contribute to development and progression of pancreatic tumours. In this Seminar we will discuss the most common and deadly form of pancreatic cancer, pancreatic ductal adenocarcinoma.	[Vincent, Audrey; Hruban, Ralph H.; Goggins, Michael] Johns Hopkins Univ, Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD 21231 USA; [Hruban, Ralph H.; Goggins, Michael] Johns Hopkins Univ, Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Oncol, Baltimore, MD 21231 USA; [Schulick, Rich] Johns Hopkins Univ, Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Surg, Baltimore, MD 21231 USA; [Goggins, Michael] Johns Hopkins Univ, Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Med, Baltimore, MD 21231 USA; [Herman, Joseph] Johns Hopkins Univ, Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Radiat Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Univ, Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, CRBII Room 342,1550 Orleans St, Baltimore, MD 21231 USA.	mgoggins@jhmi.edu	Vincent, Audrey/I-2934-2016; Franzeck, Fabian C/B-5055-2011; Hug, Balthasar L./G-1568-2010	Vincent, Audrey/0000-0003-0058-2058; 	National Cancer Institute [CA62924, CA120432, RC2CA148346]; Michael Rolfe Foundation; NATIONAL CANCER INSTITUTE [P50CA062924, RC2CA148346, R01CA120432] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Michael Rolfe Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute grants (CA62924, CA120432, RC2CA148346), and the Michael Rolfe Foundation.	Abrams RA, 2009, ANN SURG ONCOL, V16, P1751, DOI 10.1245/s10434-009-0413-9; Amundadottir L, 2009, NAT GENET, V41, P986, DOI 10.1038/ng.429; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Bilimoria KY, 2007, ANN SURG, V246, P173, DOI 10.1097/SLA.0b013e3180691579; Bilimoria KY, 2009, JNCI-J NATL CANCER I, V101, P848, DOI 10.1093/jnci/djp107; Blackford A, 2009, CLIN CANCER RES, V15, P4674, DOI 10.1158/1078-0432.CCR-09-0227; Blackford A, 2009, CANCER RES, V69, P3681, DOI 10.1158/0008-5472.CAN-09-0015; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Brentnall TA, 1999, ANN INTERN MED, V131, P247, DOI 10.7326/0003-4819-131-4-199908170-00003; Brody JR, 2009, CANCER RES, V69, P984, DOI 10.1158/0008-5472.CAN-08-3610; Brune K, 2006, AM J SURG PATHOL, V30, P1067; Brune KA, 2010, JNCI-J NATL CANCER I, V102, P119, DOI 10.1093/jnci/djp466; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Caldwell ME, 2009, GASTROENTEROLOGY, V137, P782, DOI 10.1053/j.gastro.2009.07.035; Callery MP, 2009, ANN SURG ONCOL, V16, P1727, DOI 10.1245/s10434-009-0408-6; Cameron JL, 2006, ANN SURG, V244, P10, DOI 10.1097/01.sla.0000217673.04165.ea; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Canto MI, 2006, CLIN GASTROENTEROL H, V4, P766, DOI 10.1016/j.cgh.2006.02.005; Canto MI, 2004, CLIN GASTROENTEROL H, V2, P606, DOI 10.1016/S1542-3565(04)00244-7; Canto MI, 2010, DIG DIS WEEK DDW 201; Carter H, 2010, CANCER BIOL THER, V10, P582, DOI 10.4161/cbt.10.6.12537; Chari ST, 2005, GASTROENTEROLOGY, V129, P504, DOI 10.1053/j.gastro.2005.05.007; Chari ST, 2008, GASTROENTEROLOGY, V134, P95, DOI 10.1053/j.gastro.2007.10.040; Conroy T, 2010, 2010 ASCO ANN M CHIC; Corsini MM, 2008, J CLIN ONCOL, V26, P3511, DOI 10.1200/JCO.2007.15.8782; Couch FJ, 2007, CANCER EPIDEM BIOMAR, V16, P342, DOI 10.1158/1055-9965.EPI-06-0783; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; de Jong K, 2010, CLIN GASTROENTEROL H, V8, P806, DOI 10.1016/j.cgh.2010.05.017; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Disis ML, 2009, LANCET, V373, P673, DOI 10.1016/S0140-6736(09)60404-9; Evans DB, 2008, J CLIN ONCOL, V26, P3496, DOI 10.1200/JCO.2007.15.8634; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Farrell JJ, 2009, GASTROENTEROLOGY, V136, P187, DOI 10.1053/j.gastro.2008.09.067; Feudtner C, 2009, NEW ENGL J MED, V361, P2306, DOI 10.1056/NEJMp0906516; Gillen S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000267; Goggins M, 1996, CANCER RES, V56, P5360; Goggins M, 2010, PANCREATIC CANC, P1176; Gold DV, 2010, CANCER EPIDEM BIOMAR, V19, P2786, DOI 10.1158/1055-9965.EPI-10-0667; Grover S, 2004, CLIN GASTROENTEROL H, V2, P813, DOI 10.1016/S1542-3565(04)00352-0; Hahn SA, 2003, JNCI-J NATL CANCER I, V95, P214, DOI 10.1093/jnci/95.3.214; Harewood GC, 2002, AM J GASTROENTEROL, V97, P1386, DOI 10.1016/S0002-9270(02)04133-3; Harsha HC, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000046; Hattangadi JA, 2009, CANCER-AM CANCER SOC, V115, P3640, DOI 10.1002/cncr.24410; Heinemann V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-82; Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490; Herman JM, 2008, J CLIN ONCOL, V26, P3503, DOI 10.1200/JCO.2007.15.8469; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hidalgo M, 2009, NEW ENGL J MED, V361, P2094, DOI 10.1056/NEJMcibr0905857; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hong SM, 2011, MODERN PATHOL, V24, P256, DOI 10.1038/modpathol.2010.181; Hristov B, 2010, INT J RADIAT ONCOL, V76, P176, DOI 10.1016/j.ijrobp.2009.01.047; Hruban RH, 2008, INT J CLIN EXP PATHO, V1, P306; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; Hruban RH, 2006, TUMORS PANCREAS; Hsu CC, 2010, ANN SURG ONCOL, V17, P981, DOI 10.1245/s10434-009-0743-7; Huguet F, 2007, J CLIN ONCOL, V25, P326, DOI 10.1200/JCO.2006.07.5663; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202; KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899; Kastrinos F, 2009, JAMA-J AM MED ASSOC, V302, P1790, DOI 10.1001/jama.2009.1529; Katz MHG, 2008, J AM COLL SURGEONS, V206, P833, DOI 10.1016/j.jamcollsurg.2007.12.020; Katz MHG, 2009, ANN SURG ONCOL, V16, P836, DOI 10.1245/s10434-008-0295-2; Kelly KA, 2008, PLOS MED, V5, P657, DOI 10.1371/journal.pmed.0050085; Kelsen DP, 1997, SURGERY, V122, P53, DOI 10.1016/S0039-6060(97)90264-6; Kent OA, 2009, CANCER BIOL THER, V8, P2013, DOI 10.4161/cbt.8.21.9685; Kern SE, 2007, CANCER RES, V67, P8985, DOI 10.1158/0008-5472.CAN-07-1971; Khorana AA, 2004, LANCET ONCOL, V5, P655, DOI 10.1016/S1470-2045(04)01606-7; Klein AP, 2004, CANCER RES, V64, P2634, DOI 10.1158/0008-5472.CAN-03-3823; Kooby DA, 2010, J AM COLL SURGEONS, V210, P779, DOI 10.1016/j.jamcollsurg.2009.12.033; Koopmann J, 2006, CLIN CANCER RES, V12, P442, DOI 10.1158/1078-0432.CCR-05-0564; Koshy MC, 2005, INT J RADIAT ONCOL, V61, P965, DOI 10.1016/j.ijrobp.2004.11.018; Laffan TA, 2008, AM J ROENTGENOL, V191, P802, DOI 10.2214/AJR.07.3340; Leary RJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000702; Lee CJ, 2008, J CLIN ONCOL, V26, P2806, DOI 10.1200/JCO.2008.16.6702; Lennon AM, 2010, PANCREATIC CANC, P675; Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227; Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013; Lutz E, 2011, ANN SURG, V253, P328, DOI 10.1097/SLA.0b013e3181fd271c; Maithel SK, 2008, ANN SURG ONCOL, V15, P3512, DOI 10.1245/s10434-008-0134-5; Matsubayashi H, 2006, CANCER RES, V66, P1208, DOI 10.1158/0008-5472.CAN-05-2664; McCarthy DM, 2003, APPL IMMUNOHISTO M M, V11, P238; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Moss AC, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004200.pub2; Murphy KM, 2002, CANCER RES, V62, P3789; National Comprehensive Cancer Network, NCCN GUID; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Neuhaus P, 2008, 2008 ASCO ANN M CHIC; Newman NA, 2010, SURGERY, V148, P371, DOI 10.1016/j.surg.2010.04.008; NIEDERHUBER JE, 1995, CANCER, V76, P1671, DOI 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R; O'Reilly EM, 2010, JAMA-J AM MED ASSOC, V304, P1124, DOI 10.1001/jama.2010.1302; Ojajarvi IA, 2000, OCCUP ENVIRON MED, V57, P316, DOI 10.1136/oem.57.5.316; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Omura N, 2010, MOL CANCER RES, V8, P821, DOI 10.1158/1541-7786.MCR-09-0336; Omura N, 2009, INT J CLIN EXP PATHO, V2, P310; Pannala R, 2008, GASTROENTEROLOGY, V134, P981, DOI 10.1053/j.gastro.2008.01.039; Pannala R, 2009, LANCET ONCOL, V10, P88, DOI 10.1016/S1470-2045(08)70337-1; Parsi MA, 2008, CLIN GASTROENTEROL H, V6, P1270, DOI 10.1016/j.cgh.2008.07.007; Pawlik TM, 2008, ANN SURG ONCOL, V15, P2081, DOI 10.1245/s10434-008-9929-7; Pelaez-Luna M, 2007, AM J GASTROENTEROL, V102, P2157, DOI 10.1111/j.1572-0241.2007.01480.x; Pelzer U, 2008, 2008 ASCO ANN M CHIC; Petersen GM, 2010, NAT GENET, V42, P224, DOI 10.1038/ng.522; Petersen GM, 2006, CANCER EPIDEM BIOMAR, V15, P704, DOI 10.1158/1055-9965.EPI-05-0734; Philip PA, 2009, J CLIN ONCOL, V27, P5660, DOI 10.1200/JCO.2009.21.9022; Picozzi VJ, 2011, ANN ONCOL, V22, P348, DOI 10.1093/annonc/mdq384; Raimondi S, 2009, NAT REV GASTRO HEPAT, V6, P699, DOI 10.1038/nrgastro.2009.177; Redmond KJ, 2010, ANN SURG ONCOL, V17, P3112, DOI 10.1245/s10434-010-1200-3; Regine WF, 2008, JAMA-J AM MED ASSOC, V299, P1019, DOI 10.1001/jama.299.9.1019; Rothenberg ML, 1996, ANN ONCOL, V7, P347; Rozenblum E, 1997, CANCER RES, V57, P1731; Sato N, 2003, CANCER RES, V63, P4158; Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008; Sato N, 2005, CLIN CANCER RES, V11, P4681, DOI 10.1158/1078-0432.CCR-04-2471; Sato N, 2003, CANCER RES, V63, P3735; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; Sato N, 2008, MODERN PATHOL, V21, P238, DOI 10.1038/modpathol.3800991; Sato N, 2006, J HEPATO-BILIARY-PAN, V13, P280, DOI 10.1007/s00534-005-1056-2; Scharpf RB, 2010, CANCER INFORM, V9, P257, DOI 10.4137/CIN.S5755; Schutte M, 1997, CANCER RES, V57, P3126; Shi CJ, 2009, CLIN CANCER RES, V15, P7737, DOI 10.1158/1078-0432.CCR-09-0004; Shi C, 2009, ARCH PATHOL LAB MED, V133, P365, DOI 10.1043/1543-2165-133.3.365; Slater EP, 2010, CLIN GENET, V78, P490, DOI 10.1111/j.1399-0004.2010.01425.x; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Storniolo AM, 1999, CANCER, V85, P1261, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T; Szafranska AE, 2008, CLIN CHEM, V54, P1716, DOI 10.1373/clinchem.2008.109603; Tanaka M, 2006, PANCREATOLOGY, V6, P17, DOI 10.1159/000090023; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Tempero M, 2003, J CLIN ONCOL, V21, P3402, DOI 10.1200/JCO.2003.09.140; Tischkowitz MD, 2009, GASTROENTEROLOGY, V137, P1183, DOI 10.1053/j.gastro.2009.06.055; Van Cutsem E, 2009, J CLIN ONCOL, V27, P2231, DOI 10.1200/JCO.2008.20.0238; van der Gaag NA, 2010, NEW ENGL J MED, V362, P129, DOI 10.1056/NEJMoa0903230; van der Heijden MS, 2005, CLIN CANCER RES, V11, P7508, DOI 10.1158/1078-0432.CCR-05-1048; van Heek NT, 2002, AM J PATHOL, V161, P1541, DOI 10.1016/S0002-9440(10)64432-X; Varadhachary GR, 2008, J CLIN ONCOL, V26, P3487, DOI 10.1200/JCO.2007.15.8642; Varadhachary GR, 2006, ANN SURG ONCOL, V13, P1035, DOI 10.1245/ASO.2006.08.011; Villarroel MC, 2011, MOL CANCER THER, V10, P3, DOI 10.1158/1535-7163.MCT-10-0893; Vincent A, 2008, FASEB J, V22, P3035, DOI 10.1096/fj.07-103390; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Walter K, 2010, CLIN CANCER RES, V16, P1781, DOI 10.1158/1078-0432.CCR-09-1913; Wang L, 2009, CANCER EPIDEM BIOMAR, V18, P2829, DOI 10.1158/1055-9965.EPI-09-0557; Wang WY, 2007, J CLIN ONCOL, V25, P1417, DOI 10.1200/JCO.2006.09.2452; White R, 2008, J AM COLL SURGEONS, V206, P445, DOI 10.1016/j.jamcollsurg.2007.09.021; Wolpin BM, 2009, J NATL CANCER I, V101, P424, DOI 10.1093/jnci/djp020; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	150	1748	1835	7	322	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2011	378	9791					607	620		10.1016/S0140-6736(10)62307-0	http://dx.doi.org/10.1016/S0140-6736(10)62307-0			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	812UX	21620466	Green Accepted			2022-12-28	WOS:000294319500033
J	Zafonte, R				Zafonte, Ross			Diagnosis and Management of Sports-Related Concussion A 15-Year-Old Athlete With a Concussion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMATIC-BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; MILD HEAD-INJURY; HIGH-SCHOOL; RECURRENT CONCUSSION; NEUROCOGNITIVE PERFORMANCE; POSTTRAUMATIC MIGRAINE; INTELLECTUAL ABILITY; MAGNETIC-RESONANCE; POSTURAL STABILITY	Concussion in youth athletes is a growing problem worldwide. During the past decade, significant progress has been made in standardization of the assessment of young athletes, and a growing appreciation of metabolic vulnerability, activity, and cognitive challenges has led to guidelines and suggestions for rest from the field as well as cognitive rest from school. Outcome data have begun to establish groups linked to symptom class, genetics, and sex who are at risk of worse outcomes from concussions. Decisions regarding return to activity are now based on at-rest symptoms, graded increases in activity, and neuropsychological testing. Using the case of Ms X, a 15-year-old otherwise healthy high school student who fell while skiing, evaluation, prognosis, and management of concussion are discussed.	[Zafonte, Ross] Spaulding Rehabil Hosp Network, Boston, MA 02114 USA; [Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Zafonte, Ross] Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Spaulding Rehabilitation Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Zafonte, R (corresponding author), Spaulding Rehabil Hosp Network, 125 Nashua St, Boston, MA 02114 USA.	rzafonte@partners.org			National Institutes of Health; National Institute on Disability and Rehabilitation Research; Department of Defense; US Food and Drug Administration	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Disability and Rehabilitation Research; Department of Defense(United States Department of Defense); US Food and Drug Administration	The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Zafonte reports receiving research funding from the National Institutes of Health, the National Institute on Disability and Rehabilitation Research, and the Department of Defense. He is principal investigator on a study funded by the US Food and Drug Administration orphan drug program in collaboration with Neurohealing. He is a member of Neurohealing's scientific advisory board but receives no compensation.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Barth JT, 2009, PM&R, V1, P769, DOI 10.1016/j.pmrj.2009.07.001; Bey T, 2009, WEST J EMERG MED, V10, P6; Bouma G J, 1995, New Horiz, V3, P384; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Centers for Disease Control and Prevention, WHAT SHOULD I DO IF; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Collins M. W., 2007, BRAIN INJURY MED PRI, P407; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Congeni Joseph, 2009, Adolesc Med State Art Rev, V20, P41; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hagel B, 2005, MED SPORT SCI, V48, P74, DOI 10.1159/000084284; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jung CS, 2011, ACTA NEUROCHIR, V153, P101, DOI 10.1007/s00701-010-0704-8; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mathew NT, 1997, NEUROL CLIN, V15, P167, DOI 10.1016/S0733-8619(05)70302-9; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Runkle D, 2010, NCAA COMMITTEE COMPE; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; SHEFTELL FD, 1994, HEADACHE, V34, P67, DOI 10.1111/j.1526-4610.1994.hed3402067.x; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weir DR., 2009, NATL FOOTBALL LEAGUE; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x	81	13	13	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2011	306	1					79	86		10.1001/jama.2011.819	http://dx.doi.org/10.1001/jama.2011.819			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	787LV	21632470				2022-12-28	WOS:000292378700023
J	Courtine, G; van den Brand, R; Musienko, P				Courtine, Gregoire; van den Brand, Rubio; Musienko, Pavel			Spinal cord injury: time to move	LANCET			English	Editorial Material									[Courtine, Gregoire; van den Brand, Rubio; Musienko, Pavel] Univ Zurich, Dept Neurol, Expt Neurorehabil Lab, CH-8008 Zurich, Switzerland; [Musienko, Pavel] Pavlov Inst Physiol, Motor Physiol Lab, St Petersburg, Russia	University of Zurich; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Pavlov Institute of Physiology Russian Academy of Sciences	Courtine, G (corresponding author), Univ Zurich, Dept Neurol, Expt Neurorehabil Lab, CH-8008 Zurich, Switzerland.	gregoire.courtine@uzh.ch	Musienko, Pavel/L-6677-2015	Musienko, Pavel/0000-0002-7324-9021; courtine, gregoire/0000-0002-5744-4142				Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Capaday C, 2002, TRENDS NEUROSCI, V25, P370, DOI 10.1016/S0166-2236(02)02173-2; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; DIETZ V, 1994, LANCET, V344, P1260, DOI 10.1016/S0140-6736(94)90751-X; Dietz V, 2008, BRAIN, V131, P2240, DOI 10.1093/brain/awn185; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Harkema SJ, 2008, BRAIN RES REV, V57, P255, DOI 10.1016/j.brainresrev.2007.07.012; Musienko P E, 2007, Neurosci Behav Physiol, V37, P181, DOI 10.1007/s11055-007-0166-5; Musienko PE, 2010, J NEUROPHYSIOL, V103, P1080, DOI 10.1152/jn.00575.2009; Musienko P, 2009, IEEE T BIO-MED ENG, V56, P2707, DOI 10.1109/TBME.2009.2027226; MUSIENKO PE, J NEUROSCI IN PRESS; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; VANDENBRAND R, 2010, NEUR M PLANN SAN DIE	13	31	31	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2011	377	9781					1896	1898		10.1016/S0140-6736(11)60711-3	http://dx.doi.org/10.1016/S0140-6736(11)60711-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777LW	21601272				2022-12-28	WOS:000291623200006
J	Annas, GJ				Annas, George J.			Sudden Death for a Challenge to Federal Funding of Stem-Cell Research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				Annas GJ, 2010, NEW ENGL J MED, V363, P1687, DOI 10.1056/NEJMp1010466; [Anonymous], 2009, FED REGISTER, V74, P32170	2	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22								10.1056/NEJMp1105498	http://dx.doi.org/10.1056/NEJMp1105498			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	772AB	21591936				2022-12-28	WOS:000291200700005
J	Griffith, M; Townend, J				Griffith, Michael; Townend, Jonathan			PERSONAL VIEW How we took control and became more efficient	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Griffith, Michael; Townend, Jonathan] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Dept Cardiol, Birmingham, W Midlands, England	University of Birmingham	Griffith, M (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Dept Cardiol, Birmingham, W Midlands, England.	michael.griffith@uhb.nhs.uk		Townend, Jonathan/0000-0002-5881-5806				Casalino L, 2001, HEALTH AFFAIR, V20, P97, DOI 10.1377/hlthaff.20.4.97; DUNBAR RIM, 1993, BEHAV BRAIN SCI, V16, P681, DOI 10.1017/S0140525X00032325; Hall MA, 2002, HEALTH AFFAIR, V21, P197, DOI 10.1377/hlthaff.21.2.197; MARX K, 1932, ERSTE ABTEILUNG, V3; von Hayek F., 1944, ROAD SERFDOM	5	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2011	342								c5072	10.1136/bmj.c5072	http://dx.doi.org/10.1136/bmj.c5072			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774MG	21628363				2022-12-28	WOS:000291390100001
J	Cao, Q; van der Hilst, RD; de Hoop, MV; Shim, SH				Cao, Q.; van der Hilst, R. D.; de Hoop, M. V.; Shim, S-H			Seismic Imaging of Transition Zone Discontinuities Suggests Hot Mantle West of Hawaii	SCIENCE			English	Article							PHASE-BOUNDARY; STRUCTURE BENEATH; PLUME CONDUIT; TOMOGRAPHY; CONVECTION; PRESSURES; DYNAMICS; HOTSPOTS; ORIGIN; FLOW	The Hawaiian hotspot is often attributed to hot material rising from depth in the mantle, but efforts to detect a thermal plume seismically have been inconclusive. To investigate pertinent thermal anomalies, we imaged with inverse scattering of SS waves the depths to seismic discontinuities below the Central Pacific, which we explain with olivine and garnet transitions in a pyrolitic mantle. The presence of an 800- to 2000-kilometer-wide thermal anomaly (Delta T-max similar to 300 to 400 kelvin) deep in the transition zone west of Hawaii suggests that hot material does not rise from the lower mantle through a narrow vertical plume but accumulates near the base of the transition zone before being entrained in flow toward Hawaii and, perhaps, other islands. This implies that geochemical trends in Hawaiian lavas cannot constrain lower mantle domains directly.	[Cao, Q.; van der Hilst, R. D.; Shim, S-H] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; [de Hoop, M. V.] Purdue Univ, Ctr Computat & Appl Math, W Lafayette, IN 47907 USA	Massachusetts Institute of Technology (MIT); Purdue University System; Purdue University; Purdue University West Lafayette Campus	Cao, Q (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA.	qinc@mit.edu; hilst@mit.edu		Cao, Qin/0000-0001-7304-7916; Shim, Sang-Heon/0000-0001-5203-6038	U.S. National Science Foundation [EAR-0757871, DMS-0724778]; Shell research fellowship; Directorate For Geosciences [0757814] Funding Source: National Science Foundation; Division Of Earth Sciences [0757871] Funding Source: National Science Foundation	U.S. National Science Foundation(National Science Foundation (NSF)); Shell research fellowship; Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Division Of Earth Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	This research was supported by the CSEDI (Collaborative Studies of Earth's Deep Interior, grant EAR-0757871) and CMG (Collaborative Mathematical Geosciences, grant DMS-0724778) programs of the U.S. National Science Foundation and a Shell research fellowship awarded to Q. C. The seismic waveforms used here were all retrieved from the Data Management Center of IRIS (Incorporated Research Institutions for Seismology).	Akaogi M, 1999, PHYS EARTH PLANET IN, V114, P129, DOI 10.1016/S0031-9201(99)00039-4; Allegre CJ, 2002, PHILOS T ROY SOC A, V360, P2411, DOI 10.1098/rsta.2002.1075; Anderson DL, 2000, GEOPHYS RES LETT, V27, P3623, DOI 10.1029/2000GL011533; Blichert-Toft J, 2009, EARTH PLANET SC LETT, V282, P190, DOI 10.1016/j.epsl.2009.03.015; Cao Q, 2010, PHYS EARTH PLANET IN, V180, P80, DOI 10.1016/j.pepi.2010.02.006; Collins JA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013302; Courtillot V, 2003, EARTH PLANET SC LETT, V205, P295, DOI 10.1016/S0012-821X(02)01048-8; Cserepes L, 2000, EARTH PLANET SC LETT, V183, P61, DOI 10.1016/S0012-821X(00)00265-X; DAVIES GF, 1988, J GEOPHYS RES-SOLID, V93, P10467, DOI 10.1029/JB093iB09p10467; DePaolo DJ, 1996, J GEOPHYS RES-SOL EA, V101, P11643, DOI 10.1029/96JB00070; Deuss A, 2006, SCIENCE, V311, P198, DOI 10.1126/science.1120020; Deuss A, 2009, SURV GEOPHYS, V30, P301, DOI 10.1007/s10712-009-9078-y; Farnetani CG, 2009, EARTH PLANET SC LETT, V282, P314, DOI 10.1016/j.epsl.2009.03.035; Grand SP, 2002, PHILOS T R SOC A, V360, P2475, DOI 10.1098/rsta.2002.1077; Hanano D, 2010, GEOCHEM GEOPHY GEOSY, V11, DOI 10.1029/2009GC002782; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; Helffrich G, 2000, REV GEOPHYS, V38, P141, DOI 10.1029/1999RG000060; Hirose K, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000597; Houser C, 2010, EARTH PLANET SC LETT, V296, P255, DOI 10.1016/j.epsl.2010.05.006; Irifune T, 1998, SCIENCE, V279, P1698, DOI 10.1126/science.279.5357.1698; KATSURA T, 1989, J GEOPHYS RES-SOLID, V94, P15663, DOI 10.1029/JB094iB11p15663; Lawrence JF, 2008, GEOPHYS J INT, V174, P143, DOI 10.1111/J.1365-246X.2007.03673.X; Li C., 2008, GEOCHEM GEOPHY GEOSY, V9, P5, DOI [10.1029/2007GC001806, DOI 10.1029/2007GC001806]; Li X, 2000, NATURE, V405, P938, DOI 10.1038/35016054; Montelli R, 2004, SCIENCE, V303, P338, DOI 10.1126/science.1092485; MORGAN WJ, 1971, NATURE, V230, P42, DOI 10.1038/230042a0; MORISHIMA H, 1994, SCIENCE, V265, P1202, DOI 10.1126/science.265.5176.1202; Nishiyama N, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002216; Ribe NM, 1999, EARTH PLANET SC LETT, V171, P517, DOI 10.1016/S0012-821X(99)00179-X; Schmerr N, 2010, EARTH PLANET SC LETT, V294, P143, DOI 10.1016/j.epsl.2010.03.014; Shen Y, 2003, EARTH PLANET SC LETT, V214, P143, DOI 10.1016/S0012-821X(03)00349-2; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; Steinberger B, 1998, GEOPHYS J INT, V132, P412, DOI 10.1046/j.1365-246x.1998.00447.x; Suzuki A, 2000, GEOPHYS RES LETT, V27, P803, DOI 10.1029/1999GL008425; Tarduno J, 2009, SCIENCE, V324, P50, DOI 10.1126/science.1161256; Weidner DJ, 1998, J GEOPHYS RES-SOL EA, V103, P7431, DOI 10.1029/97JB03511; WILSON JT, 1963, CAN J PHYS, V41, P863, DOI 10.1139/p63-094; Wolbern I, 2006, GEOPHYS J INT, V166, P767, DOI 10.1111/j.1365-246X.2006.03036.x; Wolfe CJ, 2011, EARTH PLANET SC LETT, V303, P267, DOI 10.1016/j.epsl.2011.01.004; Wolfe CJ, 2009, SCIENCE, V326, P1388, DOI 10.1126/science.1180165	40	63	65	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2011	332	6033					1068	1071		10.1126/science.1202731	http://dx.doi.org/10.1126/science.1202731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769FN	21617072				2022-12-28	WOS:000290996700040
J	Tennant, DA				Tennant, Daniel A.			PK-M2 Makes Cells Sweeter on HIF1	CELL			English	Editorial Material							INDUCIBLE FACTOR-I; PYRUVATE-KINASE; M2	The transcription factor hypoxia-inducible factor 1 (HIF1) facilitates the induction of enzymes necessary for anaerobic glycolysis. Luo et al. (2011) now identify pyruvate kinase (PK)-M2 as an intriguing new interacting partner for HIF1, revealing a potential mechanism for the Warburg effect, an elevation in aerobic glycolytic metabolism frequently observed in cancer.	Univ Birmingham, Sch Canc Sci, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Tennant, DA (corresponding author), Univ Birmingham, Sch Canc Sci, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.	d.tennant@bham.ac.uk	Tennant, Daniel/ABE-8145-2021	Tennant, Daniel/0000-0003-0499-2732				CHEN N, 2011, CELL RES IN PRESS, DOI DOI 10.1038/CR.2011.66P; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Lee JW, 2008, INT J BIOCHEM CELL B, V40, P1043, DOI 10.1016/j.biocel.2007.11.009; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; REINACHER M, 1981, VIRCHOWS ARCH B, V37, P79, DOI 10.1007/BF02892557; Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	10	15	15	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 27	2011	145	5					647	649		10.1016/j.cell.2011.05.009	http://dx.doi.org/10.1016/j.cell.2011.05.009			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620132	Bronze			2022-12-28	WOS:000291018600006
J	Paxton, A; Wardlaw, T				Paxton, Anne; Wardlaw, Tessa			Are We Making Progress in Maternal Mortality?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Paxton, Anne] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA; [Paxton, Anne] Columbia Univ, Mailman Sch Publ Hlth, Dept Populat & Family Hlth, New York, NY USA; [Wardlaw, Tessa] UNICEF, Div Policy & Practice, Stat & Monitoring Sect, New York, NY USA	Columbia University; Columbia University; UNICEF	Paxton, A (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.							Abdool Karim Q, 2010, LANCET, V375, P1948, DOI 10.1016/S0140-6736(10)60747-7; Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1; Lobis S, 2005, INT J GYNECOL OBSTET, V88, P203, DOI 10.1016/j.ijgo.2004.11.025; Nanda G, 2005, ACCELERATING PROGR T, P4; World Health Organization, 2012, TRENDS MAT MORT 1900	5	36	36	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					1990	1993		10.1056/NEJMp1012860	http://dx.doi.org/10.1056/NEJMp1012860			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QR	21612467				2022-12-28	WOS:000290952000003
J	Boris, AV; Matiks, Y; Benckiser, E; Frano, A; Popovich, P; Hinkov, V; Wochner, P; Castro-Colin, M; Detemple, E; Malik, VK; Bernhard, C; Prokscha, T; Suter, A; Salman, Z; Morenzoni, E; Cristiani, G; Habermeier, HU; Keimer, B				Boris, A. V.; Matiks, Y.; Benckiser, E.; Frano, A.; Popovich, P.; Hinkov, V.; Wochner, P.; Castro-Colin, M.; Detemple, E.; Malik, V. K.; Bernhard, C.; Prokscha, T.; Suter, A.; Salman, Z.; Morenzoni, E.; Cristiani, G.; Habermeier, H. -U.; Keimer, B.			Dimensionality Control of Electronic Phase Transitions in Nickel-Oxide Superlattices	SCIENCE			English	Article							METAL-INSULATOR-TRANSITION; ORDER	The competition between collective quantum phases in materials with strongly correlated electrons depends sensitively on the dimensionality of the electron system, which is difficult to control by standard solid-state chemistry. We have fabricated superlattices of the paramagnetic metal lanthanum nickelate (LaNiO(3)) and the wide-gap insulator lanthanum aluminate (LaAlO(3)) with atomically precise layer sequences. We used optical ellipsometry and low-energy muon spin rotation to show that superlattices with LaNiO(3) as thin as two unit cells undergo a sequence of collective metal-insulator and antiferromagnetic transitions as a function of decreasing temperature, whereas samples with thicker LaNiO(3) layers remain metallic and paramagnetic at all temperatures. Metal-oxide superlattices thus allow control of the dimensionality and collective phase behavior of correlated-electron systems.	[Boris, A. V.; Matiks, Y.; Benckiser, E.; Frano, A.; Popovich, P.; Hinkov, V.; Cristiani, G.; Habermeier, H. -U.; Keimer, B.] Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; [Wochner, P.; Castro-Colin, M.; Detemple, E.] Max Planck Inst Met Res, D-70569 Stuttgart, Germany; [Malik, V. K.; Bernhard, C.] Univ Fribourg, Dept Phys, CH-1700 Fribourg, Switzerland; [Malik, V. K.; Bernhard, C.] Fribourg Ctr Nano Mat, CH-1700 Fribourg, Switzerland; [Prokscha, T.; Suter, A.; Salman, Z.; Morenzoni, E.] Paul Scherrer Inst, Lab Muon Spin Spect, CH-5232 Villigen, Switzerland	Max Planck Society; Max Planck Society; University of Fribourg; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Boris, AV (corresponding author), Max Planck Inst Festkorperforsch, Heisenbergstr 1, D-70569 Stuttgart, Germany.	A.Boris@fkf.mpg.de; B.Keimer@fkf.mpg.de	Castro-Colin, Miguel/U-8367-2019; Popovich, Paul/A-9199-2010; Benckiser, Eva/R-6973-2019; Hinkov, Vladimir/D-1495-2016; Salman, Zaher/A-5696-2008; Boris, Alexander/AAG-5662-2019; Morenzoni, Elvezio/R-3541-2019; Salman, Zaher/AAC-3300-2020	Benckiser, Eva/0000-0002-7638-2282; Salman, Zaher/0000-0002-3431-8135; Morenzoni, Elvezio/0000-0002-9663-4213; Salman, Zaher/0000-0002-3431-8135; Keimer, Bernhard/0000-0001-5220-9023; Bernhard, Christian/0000-0002-9957-3487; Detemple, Eric/0000-0002-8414-8218	Deutsche Forschungsgemeinschaft [TRR80, C1]; Schweizerische Nationalfonds [200020-129484]; NCCR-MaNEP	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Schweizerische Nationalfonds(Swiss National Science Foundation (SNSF)); NCCR-MaNEP(Swiss National Science Foundation (SNSF))	We thank Y.-L. Mathis and R. Weigel for support at the infrared IR1 and Max-Planck-Institut fur Metallforschung x-ray beamlines of the synchrotron facility Angstrom Quelle Karlsruhe (ANKA) at the Karlsruhe Institute of Technology. We thank G. Khaliullin and O. K. Andersen for discussions, W. Sigle and P. A. van Aken for support and discussions of transmission EM results, A. Szokefalvi-Nagy for x-ray software support, and G. Logvenov for support in sample growth and characterization. This work was supported by the Deutsche Forschungsgemeinschaft, grant TRR80, project C1. V.K.M. and C.B. were supported by the Schweizerische Nationalfonds via grants 200020-129484 and NCCR-MaNEP.	Benckiser E, 2011, NAT MATER, V10, P189, DOI [10.1038/nmat2958, 10.1038/NMAT2958]; Chaloupka J, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.016404; Dagotto E, 2005, SCIENCE, V309, P257, DOI 10.1126/science.1107559; Eguchi R, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.115122; Freeland JW, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.094414; Garcia-Munoz JL, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.134432; Garcia-Munoz JL, 2006, PHYSICA B, V374, P87, DOI 10.1016/j.physb.2005.11.022; GARCIAMUNOZ JL, 1995, PHYS REV B, V51, P15197, DOI 10.1103/PhysRevB.51.15197; Giovannetti G, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.156401; Habermeier HU, 2007, MATER TODAY, V10, P34, DOI 10.1016/S1369-7021(07)70243-2; Hansmann P, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.016401; Imada M, 1998, REV MOD PHYS, V70, P1039, DOI 10.1103/RevModPhys.70.1039; KATSUFUJI T, 1995, PHYS REV B, V51, P4830, DOI 10.1103/PhysRevB.51.4830; Mannhart J, 2010, SCIENCE, V327, P1607, DOI 10.1126/science.1181862; Mazin II, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.176406; Prokscha T, 2008, NUCL INSTRUM METH A, V595, P317, DOI 10.1016/j.nima.2008.07.081; Scagnoli V, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.100409; Scagnoli V, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.115138; XU XQ, 1993, PHYS REV B, V48, P1112, DOI 10.1103/PhysRevB.48.1112	19	280	282	4	257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2011	332	6032					937	940		10.1126/science.1202647	http://dx.doi.org/10.1126/science.1202647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596986	Green Submitted			2022-12-28	WOS:000290766600035
J	Rowe, TB; Macrini, TE; Luo, ZX				Rowe, Timothy B.; Macrini, Thomas E.; Luo, Zhe-Xi			Fossil Evidence on Origin of the Mammalian Brain	SCIENCE			English	Article							EVOLUTION; DIVERSIFICATION; CYNODONTIA; THERAPSIDA; EAR	Many hypotheses have been postulated regarding the early evolution of the mammalian brain. Here, x-ray tomography of the Early Jurassic mammaliaforms Morganucodon and Hadrocodium sheds light on this history. We found that relative brain size expanded to mammalian levels, with enlarged olfactory bulbs, neocortex, olfactory (pyriform) cortex, and cerebellum, in two evolutionary pulses. The initial pulse was probably driven by increased resolution in olfaction and improvements in tactile sensitivity (from body hair) and neuromuscular coordination. A second pulse of olfactory enhancement then enlarged the brain to mammalian levels. The origin of crown Mammalia saw a third pulse of olfactory enhancement, with ossified ethmoid turbinals supporting an expansive olfactory epithelium in the nasal cavity, allowing full expression of a huge odorant receptor genome.	[Rowe, Timothy B.] Univ Texas Austin, Jackson Sch Geosci, Austin, TX 78712 USA; [Macrini, Thomas E.] St Marys Univ, Dept Biol Sci, San Antonio, TX 78228 USA; [Luo, Zhe-Xi] Carnegie Museum Nat Hist, Sect Vertebrate Paleontol, Pittsburgh, PA 15213 USA	University of Texas System; University of Texas Austin	Rowe, TB (corresponding author), Univ Texas Austin, Jackson Sch Geosci, C1100, Austin, TX 78712 USA.	rowe@mail.utexas.edu	Luo, Zhe-XI/AAU-2263-2021; Macrini, Thomas E./H-4577-2019	Macrini, Thomas E./0000-0001-9488-1512	NSF [DEB 0309369, EAR-0948842, AToL 0531767, DEB 0316558, EF0129959]; University of Texas Jackson School of Geosciences; NSF of China; Humboldt Foundation (Germany); National Geographic Society	NSF(National Science Foundation (NSF)); University of Texas Jackson School of Geosciences; NSF of China(National Natural Science Foundation of China (NSFC)); Humboldt Foundation (Germany)(Alexander von Humboldt Foundation); National Geographic Society(National Geographic Society)	This research was funded by NSF DEB 0309369 (T.E.M. and T.R.), NSF EAR-0948842 (T.R.), AToL 0531767 (T.R.), the University of Texas Jackson School of Geosciences (T.R. and T.E.M.), and funded by NSF DEB 0316558 and EF0129959, NSF of China, Humboldt Foundation (Germany), and National Geographic Society to Z.-X.L. Endocasts and computed tomography imagery are online at www.DigiMorph.org.	Aboitiz F, 2007, ADV ANAT EMBRYOL CEL, V193, P1; Allman J., 1990, Seminars in the Neurosciences, V2, P257; Bottorff W., 1995, THRINAXODON DIGITAL; CATANIA KC, 2009, EVOLUTIONARY NEUROSC, P697; GAUTHIER J, 1988, CLADISTICS, V4, P105, DOI 10.1111/j.1096-0031.1988.tb00514.x; Hopson J.A., 1979, P39; Hulbert A.J., 1988, P148; Jerison H.J., 2009, EVOLUTIONARY NEUROSC, P497; Jerison HJ., 1973, EVOLUTION BRAIN INTE; Ji Q, 2006, SCIENCE, V311, P1123, DOI 10.1126/science.1123026; Kemp TS, 2009, J VERTEBR PALEONTOL, V29, P1188, DOI 10.1671/039.029.0430; KIELAN-JAWOROWSKA Z, 2004, MAMMALS AGE DINOSAUR; Krubitzer L, 2009, EVOLUTIONARY NEUROSC, P545; Luo ZX, 2007, NATURE, V450, P1011, DOI 10.1038/nature06277; Luo ZX, 2011, P ROY SOC B-BIOL SCI, V278, P28, DOI 10.1098/rspb.2010.1148; Luo ZX, 2001, SCIENCE, V292, P1535, DOI 10.1126/science.1058476; Macrini TE, 2006, THESIS U TEXAS AUSTI; Macrini TE, 2007, J MORPHOL, V268, P844, DOI 10.1002/jmor.10556; Nieuwenhuys R., 1998, CENTRAL NERVOUS SYST; Niimura Y, 2009, GENOME BIOL EVOL, V1, P34, DOI 10.1093/gbe/evp003; NORTHCUTT RG, 1995, TRENDS NEUROSCI, V18, P373; QUIROGA JC, 1984, J HIRNFORSCH, V25, P285; QUIROGA JC, 1980, J HIRNFORSCH, V21, P299; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; Rowe T, 1996, SCIENCE, V273, P651, DOI 10.1126/science.273.5275.651; ROWE T, 1996, CALIFORNIA ACAD SCI, V20, P71; Rowe T, 2008, P NATL ACAD SCI USA, V105, P1238, DOI 10.1073/pnas.0706385105; Rowe Timothy B., 2005, Journal of Mammalian Evolution, V12, P303, DOI 10.1007/s10914-005-5731-5; Zelena J, 1994, NERVES MECHANORECEPT; [No title captured]	30	214	216	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2011	332	6032					955	957		10.1126/science.1203117	http://dx.doi.org/10.1126/science.1203117			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596988				2022-12-28	WOS:000290766600040
J	Gubbins, D; Sreenivasan, B; Mound, J; Rost, S				Gubbins, David; Sreenivasan, Binod; Mound, Jon; Rost, Sebastian			Melting of the Earth's inner core	NATURE			English	Article							BOUNDARY HEAT-FLOW; LATERAL VARIATIONS; MAGNETIC-FIELD; GEOMAGNETIC REVERSALS; NUMERICAL DYNAMOS; SECULAR VARIATION; OUTER-CORE; MANTLE; CONVECTION; LAYER	The Earth's magnetic field is generated by a dynamo in the liquid iron core, which convects in response to cooling of the overlying rocky mantle. The core freezes from the innermost surface outward, growing the solid inner core and releasing light elements that drive compositional convection(1-3). Mantle convection extracts heat from the core at a rate that has enormous lateral variations(4). Here we use geodynamo simulations to show that these variations are transferred to the inner-core boundary and can be large enough to cause heat to flow into the inner core. If this were to occur in the Earth, it would cause localized melting. Melting releases heavy liquid that could form the variable-composition layer suggested by an anomaly in seismic velocity in the 150 kilometres immediately above the inner-core boundary(5-7). This provides a very simple explanation of the existence of this layer, which otherwise requires additional assumptions such as locking of the inner core to the mantle, translation from its geopotential centre(7,8) or convection with temperature equal to the solidus but with composition varying from the outer to the inner core(9). The predominantly narrow downwellings associated with freezing and broad upwellings associated with melting mean that the area of melting could be quite large despite the average dominance of freezing necessary to keep the dynamo going. Localized melting and freezing also provides a strong mechanism for creating seismic anomalies in the inner core itself, much stronger than the effects of variations in heat flow so far considered(10).	[Sreenivasan, Binod] Indian Inst Technol, Dept Mech Engn, Kanpur 208016, Uttar Pradesh, India; [Gubbins, David] SIO, IGPP, La Jolla, CA 92093 USA; [Gubbins, David; Mound, Jon; Rost, Sebastian] Univ Leeds, Sch Earth & Environm, Leeds LS2 9JT, W Yorkshire, England	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kanpur; University of Leeds	Sreenivasan, B (corresponding author), Indian Inst Technol, Dept Mech Engn, Kanpur 208016, Uttar Pradesh, India.	bsreeni@iitk.ac.in	Rost, Sebastian/GOH-2868-2022	Mound, Jon/0000-0002-1243-6915; Gubbins, David/0000-0002-8125-4752				Alboussiere T, 2010, NATURE, V466, P744, DOI 10.1038/nature09257; Aubert J, 2008, NATURE, V454, P758, DOI 10.1038/nature07109; Aubert J, 2007, PHYS EARTH PLANET IN, V160, P143, DOI 10.1016/j.pepi.2006.11.003; Bloxham J, 2000, PHILOS T R SOC A, V358, P1171, DOI 10.1098/rsta.2000.0579; BRAGINSKII SI, 1963, DOKL AKAD NAUK SSSR+, V149, P1311; Buffett BA, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB006751; Christensen U, 1998, GEOPHYS RES LETT, V25, P1565, DOI 10.1029/98GL00911; Christensen UR, 2003, PHYS EARTH PLANET IN, V138, P39, DOI 10.1016/S0031-9201(03)00064-5; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Gibbons SJ, 2000, GEOPHYS J INT, V142, P631, DOI 10.1046/j.1365-246x.2000.00192.x; Glatzmaier GA, 1999, NATURE, V401, P885, DOI 10.1038/44776; Gubbins D, 2004, GEOPHYS J INT, V157, P1407, DOI 10.1111/j.1365-246X.2004.02219.x; Gubbins D, 2008, GEOPHYS J INT, V174, P1007, DOI 10.1111/j.1365-246X.2008.03879.x; Gubbins D, 2007, PHYS EARTH PLANET IN, V162, P256, DOI 10.1016/j.pepi.2007.04.014; Helffrich G, 2010, NATURE, V468, P807, DOI 10.1038/nature09636; Kutzner C, 2004, GEOPHYS J INT, V157, P1105, DOI 10.1111/j.1365-246X.2004.02309.x; Labrosse S, 1997, PHYS EARTH PLANET IN, V99, P1, DOI 10.1016/S0031-9201(96)03207-4; Masters T. G., 1996, PHILOS T R SOC LON A, V354, P1385; MOFFATT HK, 1994, GEOPHYS J INT, V117, P394, DOI 10.1111/j.1365-246X.1994.tb03939.x; Monnereau M, 2010, SCIENCE, V328, P1014, DOI 10.1126/science.1186212; Nakagawa T, 2008, EARTH PLANET SC LETT, V271, P348, DOI 10.1016/j.epsl.2008.04.013; Nimmo F, 2004, GEOPHYS J INT, V156, P363, DOI 10.1111/j.1365-246X.2003.02157.x; Olson P, 2002, GEOPHYS J INT, V151, P809, DOI 10.1046/j.1365-246X.2002.01818.x; SONG XD, 1992, J GEOPHYS RES-SOL EA, V97, P6573, DOI 10.1029/92JB00330; SOURIAU A, 1991, GEOPHYS RES LETT, V18, P2023, DOI 10.1029/91GL02417; Sreenivasan B, 2006, GEOPHYS J INT, V164, P467, DOI 10.1111/j.1365-246X.2005.02845.x; Sreenivasan B, 2008, GEOPHYS ASTRO FLUID, V102, P395, DOI 10.1080/03091920801900047; Sreenivasan B, 2008, PHYS LETT A, V372, P5471, DOI 10.1016/j.physleta.2008.06.075; Sreenivasan B, 2009, PHYS EARTH PLANET IN, V177, P130, DOI 10.1016/j.pepi.2009.08.007; Zhang K, 2000, PHILOS T R SOC A, V358, P899, DOI 10.1098/rsta.2000.0566; Zhang K, 1996, PHYS FLUIDS, V8, P1141, DOI 10.1063/1.868914	31	103	105	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					361	U53		10.1038/nature10068	http://dx.doi.org/10.1038/nature10068			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593868				2022-12-28	WOS:000290722400045
J	Molgaard-Nielsen, D; Hviid, A				Molgaard-Nielsen, Ditte; Hviid, Anders			Newer-Generation Antiepileptic Drugs and the Risk of Major Birth Defects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY-REGISTER; UK-EPILEPSY; PRELIMINARY EXPERIENCE; LAMOTRIGINE; WOMEN; MALFORMATIONS; REGISTRATION; METAANALYSIS; FREQUENCY; EXPOSURE	Context Epilepsy during pregnancy is a therapeutic challenge. Since the 1990s, the number of licensed antiepileptic drugs has substantially increased, but safety data on first-trimester use of newer-generation antiepileptic drugs and birth defects are limited. Objective To study the association between fetal exposure to newer-generation antiepileptic drugs during the first trimester of pregnancy and the risk of major birth defects. Design, Setting, and Participants Population-based cohort study of 837 795 live-born infants in Denmark from January 1, 1996, through September 30, 2008. Individual-level information on dispensed antiepileptic drugs to mothers, birth defect diagnoses, and potential confounders were ascertained from nationwide health registries. Main Outcome Measures Prevalence odds ratios (PORs) of any major birth defect diagnosed within the first year of life by fetal exposure to antiepileptic drugs. Results Of the 1532 infants exposed to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam during the first trimester, 49 were diagnosed with a major birth defect compared with 19 911 of the 836 263 who were not exposed to an antiepileptic drug (3.2% vs 2.4%, respectively; adjusted POR [APOR], 0.99; 95% confidence interval [CI], 0.72-1.36). A major birth defect was diagnosed in 38 of 1019 infants (3.7%) exposed to lamotrigine during the first trimester (APOR, 1.18; 95% CI, 0.83-1.68), in 11 of 393 infants (2.8%) exposed to oxcarbazepine (APOR, 0.86; 95% CI, 0.46-1.59), and in 5 of 108 infants (4.6%) exposed to topiramate (APOR, 1.44; 95% CI, 0.58-3.58). Gabapentin (n=59) and levetiracetam (n=58) exposure during the first trimester was uncommon, with only 1 (1.7%) and 0 infants diagnosed with birth defects, respectively. Conclusion Among live-born infants in Denmark, first-trimester exposure to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam compared with no exposure was not associated with an increased risk of major birth defects. JAMA. 2011; 305(19): 1996-2002	[Molgaard-Nielsen, Ditte; Hviid, Anders] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark	Statens Serum Institut	Molgaard-Nielsen, D (corresponding author), Artillerivej 5, DK-2300 Copenhagen S, Denmark.	dnl@ssi.dk	Hviid, Anders/AAH-4319-2020	Hviid, Anders/0000-0002-7509-9127	Danish Medical Research Council; Lundbeck Foundation	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden)	The study was supported by the Danish Medical Research Council and the Lundbeck Foundation.	Agergaard Peter, 2011, Clin Epidemiol, V3, P61, DOI 10.2147/CLEP.S15627; Andersen TF, 1999, DAN MED BULL, V46, P263; Artama M, 2005, NEUROLOGY, V64, P1874, DOI 10.1212/01.WNL.0000163771.96962.1F; Clayton D, 2001, STAT MODELS EPIDEMIO, P227; Cunnington M, 2007, EPILEPSIA, V48, P1207, DOI 10.1111/j.1528-1167.2007.01021.x; CZEIZEL AE, 1992, EUR J EPIDEMIOL, V8, P122; *DAN MED AG, REG MED PROD STAT; Dolk H, 2010, ADV EXP MED BIOL, V686, P349, DOI 10.1007/978-90-481-9485-8_20; EUROCAT, MIN AN EXCL; EUROCAT, COD EUROCAT SUBGR CO; Fried S, 2004, DRUG SAFETY, V27, P197, DOI 10.2165/00002018-200427030-00004; Holmes LB, 2008, NEUROLOGY, V70, P2152, DOI 10.1212/01.wnl.0000304343.45104.d6; Honein MA, 1999, TERATOLOGY, V60, P356, DOI 10.1002/(SICI)1096-9926(199912)60:6<356::AID-TERA8>3.0.CO;2-B; Hunt S, 2008, NEUROLOGY, V71, P272, DOI 10.1212/01.wnl.0000318293.28278.33; Hunt S, 2006, NEUROLOGY, V67, P1876, DOI 10.1212/01.wnl.0000244491.48937.55; Jorgensen Finn Stener, 2003, Ugeskr Laeger, V165, P4409; Knudsen LB, 1998, DAN MED BULL, V45, P320; Kristensen J, 1996, J CLIN EPIDEMIOL, V49, P893, DOI 10.1016/0895-4356(96)00018-2; Larsen H, 2003, SCAND J PUBLIC HEALT, V31, P12, DOI 10.1080/14034940210134194; Malm H, 2003, EUR J CLIN PHARMACOL, V59, P127, DOI 10.1007/s00228-003-0584-4; Meador K, 2008, EPILEPSY RES, V81, P1, DOI 10.1016/j.eplepsyres.2008.04.022; Meador Kimford J, 2004, Cleve Clin J Med, V71 Suppl 2, pS38; Meador Kimford J, 2009, Epilepsy Behav, V15, P339, DOI 10.1016/j.yebeh.2009.04.026; Morrow J, 2006, J NEUROL NEUROSUR PS, V77, P193, DOI 10.1136/jnnp.2005.074203; Perucca E, 2005, LANCET NEUROL, V4, P781, DOI 10.1016/S1474-4422(05)70224-6; Sabers A, 2004, ACTA NEUROL SCAND, V109, P9, DOI 10.1034/j.1600-0404.2003.00200.x; Tomson T, 2007, CLIN PHARMACOKINET, V46, P209, DOI 10.2165/00003088-200746030-00002; Tomson T, 2009, NEUROL CLIN, V27, P993, DOI 10.1016/j.ncl.2009.06.006; Tsiropoulos I, 2006, ACTA NEUROL SCAND, V113, P405, DOI 10.1111/j.1600-0404.2006.00639.x; Vajda FJE, 2010, SEIZURE-EUR J EPILEP, V19, P558, DOI 10.1016/j.seizure.2010.07.019; WHO Collaborating Centre for Drug Statistics Methodology, ATC DDD IND 2011; Wide K, 2004, ACTA PAEDIATR, V93, P174, DOI 10.1080/08035250310021118	32	161	167	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2011	305	19					1996	2002		10.1001/jama.2011.624	http://dx.doi.org/10.1001/jama.2011.624			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764WO	21586715				2022-12-28	WOS:000290665500023
J	Freemantle, N				Freemantle, Nick			Commentary: Evaluating and regulating device therapy	BRITISH MEDICAL JOURNAL			English	Editorial Material							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; HEART-FAILURE		UCL, Dept Primary Care & Populat Hlth, London NW3 2PF, England	University of London; University College London	Freemantle, N (corresponding author), UCL, Dept Primary Care & Populat Hlth, London NW3 2PF, England.	nicholas.freemantle@ucl.ac.uk		Freemantle, Nick/0000-0001-5807-5740				[Anonymous], 1998, ICH HARM TRIP GUID S; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Bradley DJ, 2003, JAMA-J AM MED ASSOC, V289, P730, DOI 10.1001/jama.289.6.730; *FDA, 1996, STAT GUID CLIN TRIAL; Food and Drug Administration, MED DEV PREM APPR PM; Gould PA, 2006, JAMA-J AM MED ASSOC, V295, P1907, DOI 10.1001/jama.295.16.1907; Maisel WH, 2006, JAMA-J AM MED ASSOC, V295, P1901, DOI 10.1001/jama.295.16.1901; *MHRA, 2011, CE MARK; *MHRA, GUID NOT MAN STAT CO	9	12	12	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 14	2011	342								d2839	10.1136/bmj.d2839	http://dx.doi.org/10.1136/bmj.d2839			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765OV	21572133				2022-12-28	WOS:000290719100004
J	Atchley, WR				Atchley, William R.			Walter M. Fitch (1929-2011)	SCIENCE			English	Biographical-Item									N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Atchley, WR (corresponding author), N Carolina State Univ, Dept Genet, Box 7614, Raleigh, NC 27695 USA.	bill@atchleylab.org						FITCH W, PUBLICATION LIST	1	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					804	804		10.1126/science.1207426	http://dx.doi.org/10.1126/science.1207426			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566183				2022-12-28	WOS:000290529900036
J	Fleishman, SJ; Whitehead, TA; Ekiert, DC; Dreyfus, C; Corn, JE; Strauch, EM; Wilson, IA; Baker, D				Fleishman, Sarel J.; Whitehead, Timothy A.; Ekiert, Damian C.; Dreyfus, Cyrille; Corn, Jacob E.; Strauch, Eva-Maria; Wilson, Ian A.; Baker, David			Computational Design of Proteins Targeting the Conserved Stem Region of Influenza Hemagglutinin	SCIENCE			English	Article							RECOGNITION; ANTIBODIES; INTERFACE; DOCKING; SURFACE; PAIR	We describe a general computational method for designing proteins that bind a surface patch of interest on a target macromolecule. Favorable interactions between disembodied amino acid residues and the target surface are identified and used to anchor de novo designed interfaces. The method was used to design proteins that bind a conserved surface patch on the stem of the influenza hemagglutinin (HA) from the 1918 H1N1 pandemic virus. After affinity maturation, two of the designed proteins, HB36 and HB80, bind H1 and H5 HAs with low nanomolar affinity. Further, HB80 inhibits the HA fusogenic conformational changes induced at low pH. The crystal structure of HB36 in complex with 1918/H1 HA revealed that the actual binding interface is nearly identical to that in the computational design model. Such designed binding proteins may be useful for both diagnostics and therapeutics.	[Fleishman, Sarel J.; Whitehead, Timothy A.; Corn, Jacob E.; Strauch, Eva-Maria; Baker, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA; [Ekiert, Damian C.; Dreyfus, Cyrille; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Ekiert, Damian C.; Dreyfus, Cyrille; Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Baker, David] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Scripps Research Institute; Scripps Research Institute; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Baker, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.	dabaker@uw.edu	Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217; Ekiert, Damian/0000-0002-2570-0404; Fleishman, Sarel/0000-0003-3177-7560	Human Frontier Science Program; Jane Coffin Childs Memorial Fund; National Institute of Allergy and Infectious Diseases, NIH [AI057141]; Defense Advanced Research Projects Agency; NIH yeast resource center; Defense Threat Reduction Agency; Howard Hughes Medical Institute; NIH [AI058113, GM080209]; Achievement Rewards for College Scientists Foundation; Skaggs Institute for Chemical Biology; National Cancer Institute [Y1-CO-1020]; National Institute of General Medical Science, NIH [Y1-GM-1104]; U.S. Department of Energy, Basic Energy Sciences, Office of Science [DE-AC02-06CH11357]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI058113, U54AI057141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM080209] Funding Source: NIH RePORTER	Human Frontier Science Program(Human Frontier Science Program); Jane Coffin Childs Memorial Fund; National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NIH yeast resource center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Defense Threat Reduction Agency(United States Department of DefenseDefense Threat Reduction Agency); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Achievement Rewards for College Scientists Foundation(General Electric); Skaggs Institute for Chemical Biology; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Science, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); U.S. Department of Energy, Basic Energy Sciences, Office of Science(United States Department of Energy (DOE)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Computational designs were generated on resources generously provided by participants of Rosetta @ Home and the Argonne National Leadership Computing Facility. We thank J. L. Gallaher for protein preparation. S. J. F. was supported by a long-term fellowship from the Human Frontier Science Program, J. E. C. was supported by the Jane Coffin Childs Memorial Fund, and E. M. S. by a career development award from the National Institute of Allergy and Infectious Diseases, NIH, AI057141. Research in the Baker laboratory was supported by grants from the Defense Advanced Research Projects Agency, the NIH yeast resource center, the Defense Threat Reduction Agency, and the Howard Hughes Medical Institute and in the Wilson laboratory by NIH AI058113, predoctoral fellowships from the Achievement Rewards for College Scientists Foundation and the NIH Molecular Evolution Training Program GM080209 (D. C. E.), and the Skaggs Institute for Chemical Biology. X-ray diffraction data sets were collected at the Stanford Synchrotron Radiation Lightsource beamline 9-2 and at the Advanced Photon Source (APS) beamline 23ID-B (GM/CA-CAT). The GM/CA CAT 23-ID-B beamline has been funded in whole or in part with federal funds from National Cancer Institute (Y1-CO-1020) and the National Institute of General Medical Science, NIH (Y1-GM-1104). Use of the APS was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Science, under contract no. DE-AC02-06CH11357. Coordinates and structure factors were deposited in the Protein Data Bank as entry 3R2X.	[Anonymous], 2010, NEW ENGL J MED, V362, P1708; Chao G, 2006, NAT PROTOC, V1, P755, DOI 10.1038/nprot.2006.94; Chen J, 1999, P NATL ACAD SCI USA, V96, P8967, DOI 10.1073/pnas.96.16.8967; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Das R, 2008, ANNU REV BIOCHEM, V77, P363, DOI 10.1146/annurev.biochem.77.062906.171838; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Gray JJ, 2003, J MOL BIOL, V331, P281, DOI 10.1016/S0022-2836(03)00670-3; Huang PS, 2007, PROTEIN SCI, V16, P2770, DOI 10.1110/ps.073125207; Jha RK, 2010, J MOL BIOL, V400, P257, DOI 10.1016/j.jmb.2010.05.006; Karanicolas J, 2011, MOL CELL, V42, P250, DOI 10.1016/j.molcel.2011.03.010; Kortemme T, 2004, NAT STRUCT MOL BIOL, V11, P371, DOI 10.1038/nsmb749; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; Ledford H, 2008, NATURE, V455, P437, DOI 10.1038/455437a; Lerner RA, 2006, ANGEW CHEM INT EDIT, V45, P8106, DOI 10.1002/anie.200603381; Lo Conte L, 1999, J MOL BIOL, V285, P2177; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Liu S, 2007, P NATL ACAD SCI USA, V104, P5330, DOI 10.1073/pnas.0606198104; Stevenson CEM, 2006, PROTEINS, V65, P1041, DOI 10.1002/prot.21136; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566	20	414	442	4	176	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					816	821		10.1126/science.1202617	http://dx.doi.org/10.1126/science.1202617			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566186	Green Accepted			2022-12-28	WOS:000290529900039
J	Liu, HH; Schmidt, S; Poulsen, HF; Godfrey, A; Liu, ZQ; Sharon, JA; Huang, X				Liu, H. H.; Schmidt, S.; Poulsen, H. F.; Godfrey, A.; Liu, Z. Q.; Sharon, J. A.; Huang, X.			Three-Dimensional Orientation Mapping in the Transmission Electron Microscope	SCIENCE			English	Article							DIFFRACTION; MAPS; TEM	Over the past decade, efforts have been made to develop nondestructive techniques for three-dimensional (3D) grain-orientation mapping in crystalline materials. 3D x-ray diffraction microscopy and differential-aperture x-ray microscopy can now be used to generate 3D orientation maps with a spatial resolution of 200 nanometers (nm). We describe here a nondestructive technique that enables 3D orientation mapping in the transmission electron microscope of mono-and multiphase nanocrystalline materials with a spatial resolution reaching 1 nm. We demonstrate the technique by an experimental study of a nanocrystalline aluminum sample and use simulations to validate the principles involved.	[Liu, H. H.; Schmidt, S.; Poulsen, H. F.; Huang, X.] Tech Univ Denmark, Riso Natl Lab Sustainable Energy, Mat Res Div, Ctr Fundamental Res Met Struct Dimens 4, DK-4000 Roskilde, Denmark; [Godfrey, A.] Tsinghua Univ, Dept Mat Sci & Engn, Adv Mat Lab, Beijing 100084, Peoples R China; [Liu, Z. Q.] Chinese Acad Sci, Inst Met Res, Shenyang Natl Lab Mat Sci, Shenyang 110016, Peoples R China; [Sharon, J. A.] Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA; [Huang, X.] Tech Univ Denmark, Riso Natl Lab Sustainable Energy, Mat Res Div, Danish Chinese Ctr Nanomet, DK-4000 Roskilde, Denmark	Technical University of Denmark; Tsinghua University; Chinese Academy of Sciences; Institute of Metal Research, CAS; Johns Hopkins University; Technical University of Denmark	Huang, X (corresponding author), Tech Univ Denmark, Riso Natl Lab Sustainable Energy, Mat Res Div, Ctr Fundamental Res Met Struct Dimens 4, DK-4000 Roskilde, Denmark.	xihu@risoe.dtu.dk	Godfrey, Andy/G-4458-2010; Liu, Haihua/N-4063-2017; Liu, Zhi-Quan/G-4635-2017; Poulsen, Henning F/A-4131-2012; Schmidt, Søren/B-1483-2010; Huang, Xiaoxu/N-2856-2017; Huang, Xiaoxu/AFV-2572-2022	Godfrey, Andy/0000-0002-5496-0424; Liu, Zhi-Quan/0000-0001-7097-8977; Poulsen, Henning F/0000-0001-7876-4113; Schmidt, Søren/0000-0002-8694-2044; Huang, Xiaoxu/0000-0002-4635-6112; 	Danish National Research Foundation; National Natural Science Foundation of China [50571049, 50911130230]; National Basic Research Program of China [2010CB631006]; U.S. Department of Energy [DE-FG02-07ER46437]	Danish National Research Foundation(Danmarks Grundforskningsfond); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); U.S. Department of Energy(United States Department of Energy (DOE))	We thank K. Sugio for the development of software simulating electron diffraction; E. Johnson, B. Ralph, R. Gardner, H. O. Sorensen, R. Dunin-Borkowski, D. Juul Jensen, N. Hansen, and K. J. Hemker for helpful discussions; and J. R. Bowen and N. Saowadee for providing the 3D-EBSD data. Financial support was provided by the Danish National Research Foundation. A. G. acknowledges support from the National Natural Science Foundation of China under contract numbers 50571049 and 50911130230, Z.Q.L. acknowledges support from the National Basic Research Program of China (grant no. 2010CB631006), and J. A. S. acknowledges support for the thin-film deposition from the U.S. Department of Energy under grant number DE-FG02-07ER46437.	Dingley DJ, 2006, MICROCHIM ACTA, V155, P19, DOI 10.1007/s00604-006-0502-4; Fundenberger JJ, 2003, ULTRAMICROSCOPY, V96, P127, DOI 10.1016/S0304-3991(02)00435-7; Ganesh KJ, 2009, MICROSC MICROANAL, V15, P752, DOI 10.1017/S1431927609096354; Larson BC, 2002, NATURE, V415, P887, DOI 10.1038/415887a; Midgley PA, 2009, NAT MATER, V8, P271, DOI 10.1038/nmat2406; Poulsen H. H., 2004, 3 DIMENSIONAL XRAY D; Rauch ER, 2005, MATER SCI FORUM, V495-497, P197, DOI 10.4028/www.scientific.net/MSF.495-497.197; Rollett AD, 2007, ANNU REV MATER RES, V37, P627, DOI 10.1146/annurev.matsci.37.052506.084401; Schmidt S, 2008, SCRIPTA MATER, V59, P491, DOI 10.1016/j.scriptamat.2008.04.049; Sugio K, 2009, RISO MAT SCI, P337; Wu GL, 2009, ULTRAMICROSCOPY, V109, P1317, DOI 10.1016/j.ultramic.2009.06.002	11	90	91	6	187	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					833	834		10.1126/science.1202202	http://dx.doi.org/10.1126/science.1202202			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566190				2022-12-28	WOS:000290529900043
J	Johnson, MW; Amin, MHS; Gildert, S; Lanting, T; Hamze, F; Dickson, N; Harris, R; Berkley, AJ; Johansson, J; Bunyk, P; Chapple, EM; Enderud, C; Hilton, JP; Karimi, K; Ladizinsky, E; Ladizinsky, N; Oh, T; Perminov, I; Rich, C; Thom, MC; Tolkacheva, E; Truncik, CJS; Uchaikin, S; Wang, J; Wilson, B; Rose, G				Johnson, M. W.; Amin, M. H. S.; Gildert, S.; Lanting, T.; Hamze, F.; Dickson, N.; Harris, R.; Berkley, A. J.; Johansson, J.; Bunyk, P.; Chapple, E. M.; Enderud, C.; Hilton, J. P.; Karimi, K.; Ladizinsky, E.; Ladizinsky, N.; Oh, T.; Perminov, I.; Rich, C.; Thom, M. C.; Tolkacheva, E.; Truncik, C. J. S.; Uchaikin, S.; Wang, J.; Wilson, B.; Rose, G.			Quantum annealing with manufactured spins	NATURE			English	Article							STATE	Many interesting but practically intractable problems can be reduced to that of finding the ground state of a system of interacting spins; however, finding such a ground state remains computationally difficult(1). It is believed that the ground state of some naturally occurring spin systems can be effectively attained through a process called quantum annealing(2,3). If it could be harnessed, quantum annealing might improve on known methods for solving certain types of problem(4,5). However, physical investigation of quantum annealing has been largely confined to microscopic spins in condensed-matter systems(6-12). Here we use quantum annealing to find the ground state of an artificial Ising spin system comprising an array of eight superconducting flux quantum bits with programmable spin-spin couplings. We observe a clear signature of quantum annealing, distinguishable from classical thermal annealing through the temperature dependence of the time at which the system dynamics freezes. Our implementation can be configured in situ to realize a wide variety of different spin networks, each of which can be monitored as it moves towards a low-energy configuration(13,14). This programmable artificial spin network bridges the gap between the theoretical study of ideal isolated spin networks and the experimental investigation of bulk magnetic samples. Moreover, with an increased number of spins, such a system may provide a practical physical means to implement a quantum algorithm, possibly allowing more-effective approaches to solving certain classes of hard combinatorial optimization problems.	[Johnson, M. W.; Amin, M. H. S.; Gildert, S.; Lanting, T.; Hamze, F.; Dickson, N.; Harris, R.; Berkley, A. J.; Bunyk, P.; Chapple, E. M.; Enderud, C.; Hilton, J. P.; Karimi, K.; Ladizinsky, E.; Ladizinsky, N.; Oh, T.; Perminov, I.; Rich, C.; Thom, M. C.; Tolkacheva, E.; Uchaikin, S.; Wang, J.; Wilson, B.; Rose, G.] D Wave Syst Inc, Burnaby, BC V5C 6G9, Canada; [Johansson, J.] Univ Agder, Dept Nat Sci, NO-4604 Kristiansand, Norway; [Truncik, C. J. S.] Simon Fraser Univ, Dept Phys, Burnaby, BC V5A 1S6, Canada	University of Agder; Simon Fraser University	Johnson, MW (corresponding author), D Wave Syst Inc, 100-4401 Still Creek Dr, Burnaby, BC V5C 6G9, Canada.	mwjohnson@dwavesys.com	Uchaikin, Sergey/A-7642-2014; Amin, Mohammad/AAM-9571-2020; Johansson, Jan/G-9005-2012; Karimi, Kamran/B-2815-2013	Uchaikin, Sergey/0000-0003-2955-3306; Karimi, Kamran/0000-0001-5733-9409; Berkley, Andrew/0000-0002-4235-8452				Aharonov D, 2007, SIAM J COMPUT, V37, P166, DOI 10.1137/S0097539705447323; BARAHONA F, 1982, J PHYS A-MATH GEN, V15, P3241, DOI 10.1088/0305-4470/15/10/028; Bennett DA, 2009, QUANTUM INF PROCESS, V8, P217, DOI 10.1007/s11128-009-0099-8; Berns DM, 2008, NATURE, V455, P51, DOI 10.1038/nature07262; Biamonte JD, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.012352; Brooke J, 1999, SCIENCE, V284, P779, DOI 10.1126/science.284.5415.779; Burkard G, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.064503; Caciuffo R, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.174407; Carretta S, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.207205; Chen XY, 2010, NAT BIOTECHNOL, V28, P567, DOI 10.1038/nbt.1637; DEVORET MH, 1985, PHYS REV LETT, V55, P1908, DOI 10.1103/PhysRevLett.55.1908; DiCarlo L, 2009, NATURE, V460, P240, DOI 10.1038/nature08121; Farhi E, 2001, SCIENCE, V292, P472, DOI 10.1126/science.1057726; FINNILA AB, 1994, CHEM PHYS LETT, V219, P343, DOI 10.1016/0009-2614(94)00117-0; Ghosh S, 2003, NATURE, V425, P48, DOI 10.1038/nature01888; Guidi T, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.104432; Harris R, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.024511; Harris R, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.134510; Harris R, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.117003; Hinton GE, 2006, SCIENCE, V313, P504, DOI 10.1126/science.1127647; Hogg T, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.052311; Il'ichev E, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.012506; Kadowaki T, 1998, PHYS REV E, V58, P5355, DOI 10.1103/PhysRevE.58.5355; Kim K, 2010, NATURE, V465, P590, DOI 10.1038/nature09071; Lupascu A, 2007, NAT PHYS, V3, P119, DOI 10.1038/nphys509; Poletto S, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/1/013009; Steffen M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.067903; Vion D, 2002, SCIENCE, V296, P886, DOI 10.1126/science.1069372; VOSS RF, 1981, PHYS REV LETT, V47, P265, DOI 10.1103/PhysRevLett.47.265; Waldmann O, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.237202; Wernsdorfer W, 2010, INT J NANOTECHNOL, V7, P497, DOI 10.1504/IJNT.2010.031732; Yoshihara F, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.132502	33	920	934	2	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 12	2011	473	7346					194	198		10.1038/nature10012	http://dx.doi.org/10.1038/nature10012			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562559				2022-12-28	WOS:000290487200034
J	Hatzis, C; Pusztai, L; Valero, V; Booser, DJ; Esserman, L; Lluch, A; Vidaurre, T; Holmes, F; Souchon, E; Wang, HK; Martin, M; Cotrina, J; Gomez, H; Hubbard, R; Chacon, JI; Ferrer-Lozano, J; Dyer, R; Buxton, M; Gong, Y; Wu, Y; Ibrahim, N; Andreopoulou, E; Ueno, NT; Hunt, K; Yang, W; Nazario, A; DeMichele, A; O'Shaughnessy, J; Hortobagyi, GN; Symmans, WF				Hatzis, Christos; Pusztai, Lajos; Valero, Vicente; Booser, Daniel J.; Esserman, Laura; Lluch, Ana; Vidaurre, Tatiana; Holmes, Frankie; Souchon, Eduardo; Wang, Hongkun; Martin, Miguel; Cotrina, Jose; Gomez, Henry; Hubbard, Rebekah; Ignacio Chacon, J.; Ferrer-Lozano, Jaime; Dyer, Richard; Buxton, Meredith; Gong, Yun; Wu, Yun; Ibrahim, Nuhad; Andreopoulou, Eleni; Ueno, Naoto T.; Hunt, Kelly; Yang, Wei; Nazario, Arlene; DeMichele, Angela; O'Shaughnessy, Joyce; Hortobagyi, Gabriel N.; Symmans, W. Fraser			A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENE-EXPRESSION PROFILES; ADJUVANT BREAST; PACLITAXEL; CYCLOPHOSPHAMIDE; SENSITIVITY; DOXORUBICIN; ACCURACY; THERAPY; BIOPSY; INDEX	Context Prediction of high probability of survival from standard cancer treatments is fundamental for individualized cancer treatment strategies. Objective To develop a predictor of response and survival from chemotherapy for newly diagnosed invasive breast cancer. Design, Setting, and Patients Prospective multicenter study conducted from June 2000 to March 2010 at the M. D. Anderson Cancer Center to develop and test genomic predictors for neoadjuvant chemotherapy. Patients were those with newly diagnosed ERBB2 (HER2 or HER2/neu)-negative breast cancer treated with chemotherapy containing sequential taxane and anthracycline-based regimens (then endocrine therapy if estrogen receptor [ER]-positive). Different predictive signatures for resistance and response to preoperative (neoadjuvant) chemotherapy (stratified according to ER status) were developed from gene expression microarrays of newly diagnosed breast cancer (310 patients). Breast cancer treatment sensitivity was then predicted using the combination of signatures for (1) sensitivity to endocrine therapy, (2) chemoresistance, and (3) chemosensitivity, with independent validation (198 patients) and comparison with other reported genomic predictors of chemotherapy response. Main Outcome Measures Distant relapse-free survival (DRFS) if predicted treatment sensitive and absolute risk reduction ([ARR], difference in DRFS between 2 predicted groups) at median follow-up (3 years). Results Patients in the independent validation cohort (99% clinical stage II-III) who were predicted to be treatment sensitive (28%) had 56% (95% CI, 31%-78%) probability of excellent pathologic response and DRFS of 92% (95% CI, 85%-100%), with an ARR of 18% (95% CI, 6%-28%). Survival was predicted in ER-positive (30% predicted sensitive; DRFS, 97% [95% CI, 91%-100%]; ARR, 11% [95% CI, 0.1%21%]) and ER-negative (26% predicted sensitive; DRFS, 83% [95% CI, 68%100%]; ARR, 26% [95% CI, 4%-48%]) subsets and was significant in multivariate analysis. Other genomic predictors showed paradoxically worse survival for patients predicted to be responsive to chemotherapy. Conclusion A genomic predictor combining ER status, predicted chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy. JAMA. 2011;305(18):1873-1881 www.jama.com	[Symmans, W. Fraser] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Hatzis, Christos] Nuvera Biosci Inc, Woburn, MA USA; [Esserman, Laura; Buxton, Meredith] Univ Calif San Francisco, I SPY Clin Trial Investigators Canc & Leukemia Gr, San Francisco, CA 94143 USA; [DeMichele, Angela] Univ Penn, Philadelphia, PA 19104 USA; [Lluch, Ana; Martin, Miguel; Ignacio Chacon, J.; Ferrer-Lozano, Jaime] Grp Espanol Invest Canc Mama GEICAM, Madrid, Spain; [Vidaurre, Tatiana; Cotrina, Jose; Gomez, Henry; Dyer, Richard] Inst Nacl Enfermedades Neoplas, Lima, Peru; [Holmes, Frankie; O'Shaughnessy, Joyce] US Oncol, The Woodlands, TX USA; [Souchon, Eduardo] Univ Texas Hlth Sci Ctr, Lyndon B Johnson Hosp, Houston, TX USA; [Wang, Hongkun] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Francisco; University of Pennsylvania; GEICAM; Instituto Nacional de Enfermedades Neoplasicas; US Oncology Network; University of Texas System; University of Texas Health Science Center Houston; Georgetown University	Symmans, WF (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	fsymmans@mdanderson.org	Pusztai, Lajos/AAB-2901-2019; Ferrer-Lozano, Jaime/ABE-9951-2021; Lluch, Ana/R-5493-2019; Martin, Miguel/AAJ-9242-2020; Chacon, Jose-Ignacio/GZL-0643-2022; Martin, Miguel/V-6589-2019; Hatzis, Christos/M-3867-2015	Lluch, Ana/0000-0003-2766-407X; Martin, Miguel/0000-0001-9237-3231; Chacon, Jose-Ignacio/0000-0002-1286-6157; Ferrer-Lozano, Jaime/0000-0001-5773-1611; Gomez, Henry/0000-0003-2660-1843; Hatzis, Christos/0000-0002-8120-2290	Novartis; National Cancer Institute [1 R01 CA106290, CA31946, CA33601]; Breast Cancer Research Foundation; Safeway Foundation; M. D. Anderson Cancer Center (MDACC); Georgetown University Medical Center, Washington, DC [CA77597]; Memorial Sloan-Kettering Cancer Center, New York, NY [CA77651]; University of California at San Francisco [CA60138]; University of Chicago, Chicago, Illinois [CA41287]; University of Minnesota, Minneapolis [CA16450]; University of North Carolina at Chapel Hill [CA47559]; University of Texas Southwestern Medical Center, Dallas [CA37347];  [KG081680]; NATIONAL CANCER INSTITUTE [U10CA016450, U10CA031946, U10CA077651, U10CA077597, U10CA033601, U10CA060138, R01CA106290, U10CA047559, P30CA016672, U10CA041287, R43CA130188] Funding Source: NIH RePORTER	Novartis(Novartis); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; Safeway Foundation; M. D. Anderson Cancer Center (MDACC); Georgetown University Medical Center, Washington, DC; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California at San Francisco(University of California System); University of Chicago, Chicago, Illinois(University of Chicago); University of Minnesota, Minneapolis(University of Minnesota System); University of North Carolina at Chapel Hill; University of Texas Southwestern Medical Center, Dallas; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Hatzis reported holding equity in his employer, Nuvera Biosciences, and holding joint patents with Nuera Biosciences. Dr Pusztai reported serving as an unpaid scientific advisor for Nuvera Biosciences and holding joint patents with Nuera Biosciences. Dr Holmes reported receiving honoraria from Novartis, Genentech, and Philips (with relevance outside the submitted work). Dr Gomez reporting receiving honoraria from GlaxoSmithKline and Bristol-Meyers Squibb (with relevance outside the submitted work). Dr Hortobagyi reported serving as a paid consultant to Allergan, Genentech, Novartis, and sanofi-aventis and receiving research funding from Novartis (with relevance outside the submitted work). Dr Symmans reported serving as an unpaid scientific advisor to Nuvera Biosciences; holding equity in Nuvera Biosciences; holding joint patents with Nuera Biosciences with royalty; and receiving honoraria from Agendia BV.; This study was supported by grants from Susan G. Komen for The Cure (KG081680) to Dr Symmans; the National Cancer Institute (1 R01 CA106290) to Dr Pusztai; the Breast Cancer Research Foundation to Dr Pusztai and Dr Symmans; the Safeway Foundation to Dr Pusztai and Dr Symmans; faculty funds from Dr Gong, Dr Wu, and Dr Symmans; and generally by the Nellie B. Connally Breast Cancer Research Fund at the M. D. Anderson Cancer Center (MDACC). Additionally, the I-SPY-1 (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis) trial was supported in part by grants from the National Cancer Institute to the Cancer and Leukemia Group B (Monica M. Bertagnolli, MD, chair [CA31946]) and to the Cancer and Leukemia Group B Statistical Center (Daniel J. Sargent, PhD [CA33601]) and by grants to participating sites: Georgetown University Medical Center, Washington, DC (Minetta C. Liu, MD [CA77597]), Memorial Sloan-Kettering Cancer Center, New York, NY (Clifford A. Hudis, MD[CA77651]), University of California at San Francisco (Charles J. Ryan, MD [CA60138]), University of Chicago, Chicago, Illinois (Hedy L. Kindler, MD [CA41287]), University of Minnesota, Minneapolis (Bruce A. Peterson, MD[CA16450]), University of North Carolina at Chapel Hill (Thomas C. Shea, MD [CA47559]), and University of Texas Southwestern Medical Center, Dallas (Debasish Tripathy, MD [CA37347]).	Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6; Bear HD, 2006, J CLIN ONCOL, V24, P2019, DOI 10.1200/JCO.2005.04.1665; Committee on Cancer Clinical Trials the NCI Cooperative Group Program Institute of Medicine, 2010, NAT CANC CLIN TRIALS; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; FRIEDMAN JH, 2004, GRADIENT DIRECTED RE; Gianni L, 2005, J CLIN ONCOL, V23, P7265, DOI 10.1200/JCO.2005.02.0818; Goldstein LJ, 2008, J CLIN ONCOL, V26, P4063, DOI 10.1200/JCO.2007.14.4501; Gong Y, 2007, LANCET ONCOL, V8, P203, DOI 10.1016/S1470-2045(07)70042-6; Hayes DF, 2007, NEW ENGL J MED, V357, P1496, DOI 10.1056/NEJMoa071167; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Lee JK, 2010, CLIN CANCER RES, V16, P711, DOI 10.1158/1078-0432.CCR-09-2247; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Liedtke C, 2009, J CLIN ONCOL, V27, P3185, DOI 10.1200/JCO.2008.18.5934; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Moskowitz CS, 2004, STAT MED, V23, P1555, DOI 10.1002/sim.1747; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Popovici V, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2468; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056; Straver ME, 2010, BREAST CANCER RES TR, V119, P551, DOI 10.1007/s10549-009-0333-1; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; Symmans WF, 2007, SEMIN ONCOL, V34, pS4, DOI 10.1053/j.seminoncol.2007.03.016; Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273; Symmans WF, 2003, CANCER, V97, P2960, DOI 10.1002/cncr.11435; Therneau TM, 2000, MODELING SURVIVAL DA; Tibshirani RJ, 2009, STAT APPL GENET MOL, V8, DOI 10.2202/1544-6115.1438; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Wolmark N, 2001, J Natl Cancer Inst Monogr, P96	30	427	439	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2011	305	18					1873	1881		10.1001/jama.2011.593	http://dx.doi.org/10.1001/jama.2011.593			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761YH	21558518	Green Accepted			2022-12-28	WOS:000290438800024
J	Rieselbach, RE; Kellermann, AL				Rieselbach, Richard E.; Kellermann, Arthur L.			A Model Health Care Delivery System for Medicaid	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Rieselbach, Richard E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Kellermann, Arthur L.] RAND Corp, Santa Monica, CA USA	University of Wisconsin System; University of Wisconsin Madison; RAND Corporation	Rieselbach, RE (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.							Berwick DM, 2011, NEW ENGL J MED, V364, DOI 10.1056/NEJMp1103602; *COMM HLTH CTR, 2010, OPP CHALL HLTH REF I; Hackbarth G, 2011, NEW ENGL J MED, V364, P693, DOI 10.1056/NEJMp1012691; *MACPAC, C MARCH 15 201 UNPUB; Rieselbach RE, 2010, ANN INTERN MED, V152, P118, DOI 10.7326/0003-4819-152-2-201001190-00186	5	9	9	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2011	364	26					2476	2478		10.1056/NEJMp1104873	http://dx.doi.org/10.1056/NEJMp1104873			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	785AM	21631315				2022-12-28	WOS:000292199800002
J	Aaron, HJ				Aaron, Henry J.			The Independent Payment Advisory Board - Congress's "Good Deed"	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brookings Inst, Washington, DC 20036 USA	Brookings Institution	Aaron, HJ (corresponding author), Brookings Inst, Washington, DC 20036 USA.							Ebeler J, 2011, INDEPENDENT PAYMENT; JOST TS, 2010, IND PAYM ADV BOARD P; Pear R, 2011, NY TIMES        0419; POLLACK H, 2011, REAL PROBLEM INDEPEN	4	12	12	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2011	364	25					2377	2379		10.1056/NEJMp1105144	http://dx.doi.org/10.1056/NEJMp1105144			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	781MG	21561342				2022-12-28	WOS:000291936100003
J	Kozlov, AS; Baumgart, J; Risler, T; Versteegh, CPC; Hudspeth, AJ				Kozlov, Andrei S.; Baumgart, Johannes; Risler, Thomas; Versteegh, Corstiaen P. C.; Hudspeth, A. J.			Forces between clustered stereocilia minimize friction in the ear on a subnanometre scale	NATURE			English	Article							HAIR CELL STEREOCILIA; TRANSDUCTION CHANNELS; MECHANICAL AMPLIFICATION; COHERENT MOTION; BUNDLE; MEMBRANE	The detection of sound begins when energy derived from an acoustic stimulus deflects the hair bundles on top of hair cells(1). As hair bundles move, the viscous friction between stereocilia and the surrounding liquid poses a fundamental physical challenge to the ear's high sensitivity and sharp frequency selectivity. Part of the solution to this problem lies in the active process that uses energy for frequency-selective sound amplification(2,3). Here we demonstrate that a complementary part of the solution involves the fluid-structure interaction between the liquid within the hair bundle and the stereocilia. Using force measurement on a dynamically scaled model, finite-element analysis, analytical estimation of hydrodynamic forces, stochastic simulation and high-resolution interferometric measurement of hair bundles, we characterize the origin and magnitude of the forces between individual stereocilia during small hair-bundle deflections. We find that the close apposition of stereocilia effectively immobilizes the liquid between them, which reduces the drag and suppresses the relative squeezing but not the sliding mode of stereociliary motion. The obliquely oriented tip links couple the mechanotransduction channels to this least dissipative coherent mode, whereas the elastic horizontal top connectors that stabilize the structure further reduce the drag. As measured from the distortion products associated with channel gating at physiological stimulation amplitudes of tens of nanometres, the balance of viscous and elastic forces in a hair bundle permits a relative mode of motion between adjacent stereocilia that encompasses only a fraction of a nanometre. A combination of high-resolution experiments and detailed numerical modelling of fluid-structure interactions reveals the physical principles behind the basic structural features of hair bundles and shows quantitatively how these organelles are adapted to the needs of sensitive mechanotransduction.	[Kozlov, Andrei S.; Versteegh, Corstiaen P. C.; Hudspeth, A. J.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA; [Kozlov, Andrei S.; Versteegh, Corstiaen P. C.; Hudspeth, A. J.] Rockefeller Univ, Lab Sensory Neurosci, New York, NY 10065 USA; [Baumgart, Johannes] Tech Univ Dresden, Dept Math, Inst Comp Sci, D-01062 Dresden, Germany; [Risler, Thomas] Inst Curie, Ctr Rech, F-75005 Paris, France; [Risler, Thomas] Univ Paris 06, UMR 168, F-75005 Paris, France; [Risler, Thomas] CNRS, UMR 168, F-75005 Paris, France; [Versteegh, Corstiaen P. C.] Wageningen Univ, Expt Zool Grp, NL-6709 PG Wageningen, Netherlands	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Technische Universitat Dresden; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Wageningen University & Research	Hudspeth, AJ (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10065 USA.	hudspaj@rockefeller.edu	Risler, Thomas/E-6943-2011; Baumgart, Johannes/A-8547-2011	Risler, Thomas/0000-0003-1677-4636; Baumgart, Johannes/0000-0001-7384-5715	Howard Hughes Medical Institute Funding Source: Medline; NIDCD NIH HHS [DC000241, R01 DC000241-30, R01 DC000241, F32 DC000241] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F32DC000241, R01DC000241] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Batchelor G. K., 2000, INTRO FLUID DYNAMICS, P353; BROERSMA S, 1981, J CHEM PHYS, V74, P6989, DOI 10.1063/1.441071; Cotton J, 2004, HEARING RES, V197, P105, DOI 10.1016/j.heares.2004.06.005; DENK W, 1989, P NATL ACAD SCI USA, V86, P5371, DOI 10.1073/pnas.86.14.5371; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; Hudspeth AJ, 2008, NEURON, V59, P530, DOI 10.1016/j.neuron.2008.07.012; Hudspeth AJ, 2010, J NEUROPHYSIOL, V104, P1219, DOI 10.1152/jn.00437.2010; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; JARAMILLO F, 1993, NATURE, V364, P527, DOI 10.1038/364527a0; Karavitaki KD, 2010, J NEUROSCI, V30, P9051, DOI 10.1523/JNEUROSCI.4864-09.2010; Kozlov AS, 2007, NAT NEUROSCI, V10, P87, DOI 10.1038/nn1818; Martin P, 2000, P NATL ACAD SCI USA, V97, P12026, DOI 10.1073/pnas.210389497; NEUGEBAUER DC, 1987, CELL TISSUE RES, V249, P199, DOI 10.1007/BF00215434; Perrin F, 1934, J PHYS-PARIS, V5, P497, DOI 10.1051/jphysrad:01934005010049700; PICKLES JO, 1993, HEARING RES, V68, P159, DOI 10.1016/0378-5955(93)90120-P; Stokes G. G., 1850, T CAMBRIDGE PHILOS S, V9, P1; Tamada K., 1957, Q J MECH APPL MATH, V10, P425, DOI DOI 10.1093/QJMAM/10.4.425; Verpy E, 2011, J COMP NEUROL, V519, P194, DOI 10.1002/cne.22509; Yeom J, 2009, J MICROMECH MICROENG, V19, DOI 10.1088/0960-1317/19/6/065025	19	51	51	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2011	474	7351					376	379		10.1038/nature10073	http://dx.doi.org/10.1038/nature10073			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777TD	21602823	Green Submitted, Green Accepted			2022-12-28	WOS:000291647100045
J	Che, H; Drake, JF; Swisdak, M				Che, H.; Drake, J. F.; Swisdak, M.			A current filamentation mechanism for breaking magnetic field lines during reconnection	NATURE			English	Article							ELECTROSTATIC SOLITARY WAVES; PARTICLE SIMULATIONS; TURBULENCE; HOLES	During magnetic reconnection, the field lines must break and reconnect to release the energy that drives solar and stellar flares(1,2) and other explosive events in space(3) and in the laboratory(4). Exactly how this happens has been unclear, because dissipation is needed to break magnetic field lines and classical collisions are typically weak. Ion-electron drag arising from turbulence(5), dubbed 'anomalous resistivity', and thermal momentum transport(6) are two mechanisms that have been widely invoked. Measurements of enhanced turbulence near reconnection sites in space(7,8) and in the laboratory(9,10) support the anomalous resistivity idea but there has been no demonstration from measurements that this turbulence produces the necessary enhanced drag(11). Here we report computer simulations that show that neither of the two previously favoured mechanisms controls how magnetic field lines reconnect in the plasmas of greatest interest, those in which the magnetic field dominates the energy budget. Rather, we find that when the current layers that form during magnetic reconnection become too intense, they disintegrate and spread into a complex web of filaments that causes the rate of reconnection to increase abruptly. This filamentary web can be explored in the laboratory or in space with satellites that can measure the resulting electromagnetic turbulence.	[Che, H.] Univ Colorado, Dept Phys, Ctr Integrated Plasma Studies, Boulder, CO 80309 USA; [Drake, J. F.; Swisdak, M.] Univ Maryland, Dept Phys, College Pk, MD 20742 USA; [Drake, J. F.] Univ Maryland, Inst Phys Sci & Technol, College Pk, MD 20742 USA	University of Colorado System; University of Colorado Boulder; University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Che, H (corresponding author), Univ Colorado, Dept Phys, Ctr Integrated Plasma Studies, Boulder, CO 80309 USA.	haihong.che@colorado.edu	Swisdak, Michael/R-1352-2017; MMS, Science Team NASA/J-5393-2013; Drake, James/P-9477-2017; Che, Haihong/AAX-9286-2021	Swisdak, Michael/0000-0002-5435-3544; Drake, James/0000-0002-9150-1841; 	NSF/DOE; NASA; NASA through Magnetospheric Multiscale Mission Science Team	NSF/DOE(National Science Foundation (NSF)United States Department of Energy (DOE)); NASA(National Aeronautics & Space Administration (NASA)); NASA through Magnetospheric Multiscale Mission Science Team	This work has been supported by the NSF/DOE programme in plasma science and by NASA through the Supporting Research and Technology Program and the Magnetospheric Multiscale Mission Science Team. Computations were carried out in part at the National Energy Research Scientific Computing Center.	Baker DN, 1996, J GEOPHYS RES-SPACE, V101, P12975, DOI 10.1029/95JA03753; Cattell C, 2005, J GEOPHYS RES-SPACE, V110, DOI 10.1029/2004JA010519; Che H, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL043608; Che H, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.145004; Drake JF, 2003, SCIENCE, V299, P873, DOI 10.1126/science.1080333; DRAKE JF, 1994, PHYS REV LETT, V73, P1251, DOI 10.1103/PhysRevLett.73.1251; Eastwood JP, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.035001; Ferraro NM, 2004, PHYS PLASMAS, V11, P4382, DOI 10.1063/1.1776565; Fox W, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.255003; Galeev A. A., 1983, BASIC PLASMA PHYSICS, V1, P677; Goldman MV, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035608; Hesse M, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014714; Ji HT, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.115001; KAW PK, 1979, PHYS REV LETT, V43, P1398, DOI 10.1103/PhysRevLett.43.1398; KINGSEP AS, 1990, REV PLASMA PHYS, V16, P243; Kowal G, 2009, ASTROPHYS J, V700, P63, DOI 10.1088/0004-637X/700/1/63; Lazarian A, 1999, ASTROPHYS J, V517, P700, DOI 10.1086/307233; Matsumoto H, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016319; McMillan BF, 2006, PHYS PLASMAS, V13, DOI 10.1063/1.2198212; Omura Y, 1996, J GEOPHYS RES-SPACE, V101, P2685, DOI 10.1029/95JA03145; Oppenheim MM, 2001, GEOPHYS RES LETT, V28, P1891, DOI 10.1029/2000GL012383; Priest E. R., 2000, MAGNETIC RECONNECTIO; Pritchett PL, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2003JA009999; Ricci P, 2004, PHYS PLASMAS, V11, P4102, DOI 10.1063/1.1768552; TSUNETA S, 1985, ASTROPHYS J, V290, P353, DOI 10.1086/162992; VASYLIUNAS VM, 1975, REV GEOPHYS, V13, P303, DOI 10.1029/RG013i001p00303; YAMADA M, 1994, PHYS PLASMAS, V1, P3269, DOI 10.1063/1.870479; Zeiler A, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2001JA000287	28	121	121	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2011	474	7350					184	187		10.1038/nature10091	http://dx.doi.org/10.1038/nature10091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	774PE	21633355				2022-12-28	WOS:000291397800043
J	Weng, CS; Yang, YC				Weng, Chia-Sui; Yang, Yuh-Cheng			Villar's Nodule - Umbilical Endometriosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Weng, Chia-Sui; Yang, Yuh-Cheng] Mackay Mem Hosp, Taipei, Taiwan	Mackay Memorial Hospital	Weng, CS (corresponding author), Mackay Mem Hosp, Taipei, Taiwan.								0	7	9	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					E45	E45		10.1056/NEJMicm1009351	http://dx.doi.org/10.1056/NEJMicm1009351			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QR	21612465				2022-12-28	WOS:000290952000010
J	Zwar, NA; Torda, A				Zwar, Nicholas A.; Torda, Adrienne			RATIONAL TESTING Investigation of diarrhoea in a traveller just returned from India	BRITISH MEDICAL JOURNAL			English	Editorial Material							IRRITABLE-BOWEL-SYNDROME; EPIDEMIOLOGY		[Zwar, Nicholas A.] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia; [Torda, Adrienne] Prince Wales Hosp, Randwick, NSW 2031, Australia	University of New South Wales Sydney	Zwar, NA (corresponding author), Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia.	n.zwar@unsw.edu.au	Torda, Adrienne/AAY-2196-2020	Torda, Adrienne/0000-0003-4154-6459; Zwar, Nicholas/0000-0001-6462-9121				Connor BA, 2005, CLIN INFECT DIS, V41, pS577, DOI 10.1086/432956; De Bruyn G, 2000, COCHRANE DB SYST REV, DOI 10.1002/; Ericsson CD, 1998, INFECT DIS CLIN N AM, V12, P285, DOI 10.1016/S0891-5520(05)70006-4; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; Nield VF, 2010, HLTH INFORM OVERSEAS; Okhuysen PC, 2004, AM J GASTROENTEROL, V99, P1774, DOI 10.1111/j.1572-0241.2004.30435.x; Ostrosky-Zeichner L, 2001, PRINCIPLES PRACTICE, P154; Patel U, 2004, J NATL MED ASSOC, V96, P1212; Rohner P, 1997, J CLIN MICROBIOL, V35, P1427, DOI 10.1128/JCM.35.6.1427-1432.1997; Ryan ET, 2002, NEW ENGL J MED, V347, P505, DOI 10.1056/NEJMra020118; Shlim DR, 2005, CLIN INFECT DIS, V41, pS531, DOI 10.1086/432947; Steffen R, 2005, CLIN INFECT DIS, V41, pS536, DOI 10.1086/432948; van Gool T, 2003, EUR J CLIN MICROBIOL, V22, P284, DOI 10.1007/s10096-003-0919-1	13	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAY 26	2011	342								d2978	10.1136/bmj.d2978	http://dx.doi.org/10.1136/bmj.d2978			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771KG	21622512	Green Submitted			2022-12-28	WOS:000291155000005
J	Black, ME				Black, Mary E.			THE BIGGER PICTURE Four burials and a funeral	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 25	2011	342								d3241	10.1136/bmj.d3241	http://dx.doi.org/10.1136/bmj.d3241			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771KE	21613364				2022-12-28	WOS:000291154800009
J	Jain, SH; Rother, J				Jain, Sachin H.; Rother, John			Are Patients Knights, Knaves, or Pawns?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Jain, Sachin H.] Adm Off, Ctr Medicare, Washington, DC 20201 USA; [Jain, Sachin H.] Ctr Medicaid Serv, Washington, DC 20201 USA; [Rother, John] AARP, Washington, DC USA	Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services; American Association of Retired Persons (AARP)	Jain, SH (corresponding author), Adm Off, Ctr Medicare, 200 Independence Ave SW,Ste 310, Washington, DC 20201 USA.	shjain@post.harvard.edu						Berwick DM, 2009, HEALTH AFFAIR, V28, pW555, DOI 10.1377/hlthaff.28.4.w555; Coleman K, 2009, HEALTH AFFAIR, V28, P75, DOI 10.1377/hlthaff.28.1.75; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Jain SH, 2010, JAMA-J AM MED ASSOC, V304, P1009, DOI 10.1001/jama.2010.1250; Kullgren JT, 2010, ARCH INTERN MED, V170, P1918, DOI 10.1001/archinternmed.2010.428; Le Grand J., 2003, MOTIVATION AGENCY PU	6	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2011	305	20					2112	2113		10.1001/jama.2011.694	http://dx.doi.org/10.1001/jama.2011.694			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768AC	21610245				2022-12-28	WOS:000290901700027
J	Zoncu, R; Sabatini, DM				Zoncu, Roberto; Sabatini, David M.			The TASCC of Secretion	SCIENCE			English	Editorial Material							SENESCENCE; PATHWAYS; P53		[Zoncu, Roberto; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Zoncu, Roberto; Sabatini, David M.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Zoncu, Roberto; Sabatini, David M.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Sabatini, David M.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute	Zoncu, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	sabatini@wi.mit.edu		/0000-0002-1446-7256	NATIONAL CANCER INSTITUTE [R01CA103866] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [R01 CA103866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032	13	10	10	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2011	332	6032					923	925		10.1126/science.1207552	http://dx.doi.org/10.1126/science.1207552			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596981	Green Accepted, Green Submitted			2022-12-28	WOS:000290766600029
J	Duy, C; Hurtz, C; Shojaee, S; Cerchietti, L; Geng, HM; Swaminathan, S; Klemm, L; Kweon, SM; Nahar, R; Braig, M; Park, E; Kim, YM; Hofmann, WK; Herzog, S; Jumaa, H; Koeffler, HP; Yu, JJ; Heisterkamp, N; Graeber, TG; Wu, H; Ye, BH; Melnick, A; Muschen, M				Duy, Cihangir; Hurtz, Christian; Shojaee, Seyedmehdi; Cerchietti, Leandro; Geng, Huimin; Swaminathan, Srividya; Klemm, Lars; Kweon, Soo-mi; Nahar, Rahul; Braig, Melanie; Park, Eugene; Kim, Yong-mi; Hofmann, Wolf-Karsten; Herzog, Sebastian; Jumaa, Hassan; Koeffler, H. Phillip; Yu, J. Jessica; Heisterkamp, Nora; Graeber, Thomas G.; Wu, Hong; Ye, B. Hilda; Melnick, Ari; Mueschen, Markus			BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition	NATURE			English	Article							CHRONIC MYELOID-LEUKEMIA; GERMINAL-CENTER FORMATION; IMATINIB RESISTANCE; INITIATING CELLS; IN-VITRO; B-CELLS; EXPRESSION; STAT5; PROLIFERATION; INFLAMMATION	Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with leukaemia driven by BCR-ABL1 (ref. 1) and other oncogenic tyrosine kinases(2,3). Recent efforts have focused on developing more potent TKIs that also inhibit mutant tyrosine kinases(4,5). However, even effective TKIs typically fail to eradicate leukaemia-initiating cells (LICs)(6-8), which often cause recurrence of leukaemia after initially successful treatment. Here we report the discovery of a novel mechanism of drug resistance, which is based on protective feedback signalling of leukaemia cells in response to treatment with TKI. We identify BCL6 as a central component of this drug-resistance pathway and demonstrate that targeted inhibition of BCL6 leads to eradication of drug-resistant and leukaemia-initiating subclones.	[Duy, Cihangir; Hurtz, Christian; Shojaee, Seyedmehdi; Swaminathan, Srividya; Klemm, Lars; Nahar, Rahul; Mueschen, Markus] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Duy, Cihangir; Kweon, Soo-mi; Nahar, Rahul; Park, Eugene; Kim, Yong-mi; Heisterkamp, Nora; Mueschen, Markus] Univ So Calif, Dept Pediat, Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; [Cerchietti, Leandro; Geng, Huimin; Melnick, Ari] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA; [Cerchietti, Leandro; Geng, Huimin; Melnick, Ari] Weill Cornell Med Coll, Dept Pharmacol, New York, NY 10065 USA; [Braig, Melanie] Univ Klinikum Hamburg Eppendorf, Dept Hematol & Oncol, Hamburg, Germany; [Hofmann, Wolf-Karsten] Heidelberg Univ, Klinikum Mannheim, Dept Hematol & Oncol, Mannheim, Germany; [Hurtz, Christian; Herzog, Sebastian; Jumaa, Hassan] Univ Freiburg, Fac Biol, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany; [Hurtz, Christian; Herzog, Sebastian; Jumaa, Hassan] Max Planck Inst Immunobiol, Freiburg, Germany; [Koeffler, H. Phillip] Cedars Sinai Med Ctr, Div Hematol & Oncol, Los Angeles, CA 90095 USA; [Yu, J. Jessica; Ye, B. Hilda] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; [Graeber, Thomas G.; Wu, Hong] Univ Calif Los Angeles, Dept Mol Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California San Francisco; Children's Hospital Los Angeles; University of Southern California; Cornell University; Cornell University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Freiburg; Max Planck Society; Cedars Sinai Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California Los Angeles	Muschen, M (corresponding author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.	markus.muschen@ucsf.edu	kim, y/AAR-6095-2020; Heisterkamp, Nora/C-1698-2012; Melnick, Ari/AAA-5763-2020; Duy, Cihangir/AAD-7735-2022	Heisterkamp, Nora/0000-0003-2769-2273; Duy, Cihangir/0000-0001-9150-9379; Herzog, Sebastian/0000-0001-7167-3489; Kim, Yong-Mi/0000-0003-3793-6438; Graeber, Thomas/0000-0001-8574-9181; Cerchietti, Leandro/0000-0003-0608-1350	National Institutes of Health/National Cancer Institute [R01CA104348, R01CA085573, R01CA026038, R01CA090321, R01CA137060, R01CA139032, R01CA157664, R21CA152497]; Leukemia and Lymphoma Society [SCOR 7005-11]; Alex's Lemonade Stand Foundation for Pediatric Cancer Research; California Institute for Regenerative Medicine [TR02-1816]; William Laurence and Blanche Hughes Foundation; Stand Up To Cancer-American Association for Cancer Research [IRG00909]; NATIONAL CANCER INSTITUTE [R01CA090321, R21CA152497, R01CA085573, R01CA157644, R01CA026038, R01CA104348, R01CA137060, R01CA157664, R01CA139032] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Alex's Lemonade Stand Foundation for Pediatric Cancer Research; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); William Laurence and Blanche Hughes Foundation; Stand Up To Cancer-American Association for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank R. Dalla-Favera and L. Hennighausen for sharing BCL6<SUP>-/-</SUP> and STAT5<SUP>fl/fl</SUP> mice and wild-type controls with us. We thank A. L. Shaffer and L. M. Staudt for sharing their inducible BCL6 constructs. This work was supported by grants from the National Institutes of Health/National Cancer Institute through R01CA104348 (to A. M.), R01CA085573 (to B.H.Y.), R01CA026038 (to H. P. K.), R01CA090321 (to N.H.), R01CA137060 (to M. M.), R01CA139032 (to M. M.), R01CA157664 (to M. M.) and R21CA152497 (to M. M.), grants from the Leukemia and Lymphoma Society (to M. M.) Leukemia and Lymphoma Society SCOR 7005-11 (PI B. J. Druker), a grant from the Alex's Lemonade Stand Foundation for Pediatric Cancer Research (to M. M.), the California Institute for Regenerative Medicine through TR02-1816 (to M. M.), the William Laurence and Blanche Hughes Foundation and a Stand Up To Cancer-American Association for Cancer Research Innovative Research Grant IRG00909 (to M. M.). A. M. and M. M. are Scholars of the Leukemia and Lymphoma Society.	Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Cerchietti LC, 2010, CANCER CELL, V17, P400, DOI 10.1016/j.ccr.2009.12.050; Cerchietti LC, 2009, BLOOD, V113, P3397, DOI 10.1182/blood-2008-07-168773; Chakravarti Laha, 1967, HDB METHODS APPL STA, V1, P392; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Ci WM, 2009, BLOOD, V113, P5536, DOI 10.1182/blood-2008-12-193037; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Duy C, 2010, J EXP MED, V207, P1209, DOI 10.1084/jem.20091299; Ghetu AF, 2008, MOL CELL, V29, P384, DOI 10.1016/j.molcel.2007.12.026; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Goldberg Z, 2004, CELL CYCLE, V3, P1188; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gruber TA, 2010, CANCER RES, V70, P7411, DOI 10.1158/0008-5472.CAN-10-1438; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Krause DS, 2006, NAT MED, V12, P1175, DOI 10.1038/nm1489; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016/j.ccr.2009.09.028; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Oravecz-Wilson KI, 2009, CANCER CELL, V16, P137, DOI 10.1016/j.ccr.2009.06.007; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Saito M, 2007, CANCER CELL, V12, P280, DOI 10.1016/j.ccr.2007.08.011; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Skorta I, 2009, CANCER RES, V69, P9337, DOI 10.1158/0008-5472.CAN-09-0548; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Trageser D, 2009, J EXP MED, V206, P1739, DOI 10.1084/jem.20090004; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Wendel HG, 2006, P NATL ACAD SCI USA, V103, P7444, DOI 10.1073/pnas.0602402103; Williams RT, 2007, GENE DEV, V21, P2283, DOI 10.1101/gad.1588607; Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161	45	147	153	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					384	U572		10.1038/nature09883	http://dx.doi.org/10.1038/nature09883			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593872	Green Accepted, Green Submitted			2022-12-28	WOS:000290722400051
J	Thien, F				Thien, Francis			Review: Omalizumab added to corticosteroids reduces exacerbations and corticosteroid use in adults and children with asthma	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Thien, Francis] Eastern Hlth, Melbourne, Vic, Australia; [Thien, Francis] Monash Univ, Melbourne, Vic 3004, Australia	Monash University	Thien, F (corresponding author), Eastern Hlth, Melbourne, Vic, Australia.							Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Nopp A, 2010, ALLERGY, V65, P56, DOI 10.1111/j.1398-9995.2009.02144.x; PACE E, 2011, J ASTHMA        0311	3	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-11	10.7326/0003-4819-154-10-201105170-02011	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576529				2022-12-28	WOS:000290620300010
J	Kajstura, J; Rota, M; Hall, SR; Hosoda, T; D'Amario, D; Sanada, F; Zheng, HQ; Ogorek, B; Rondon-Clavo, C; Ferreira-Martins, J; Matsuda, A; Arranto, C; Goichberg, P; Giordano, G; Haley, KJ; Bardelli, S; Rayatzadeh, H; Liu, XL; Quaini, F; Liao, RL; Leri, A; Perrella, MA; Loscalzo, J; Anversa, P				Kajstura, Jan; Rota, Marcello; Hall, Sean R.; Hosoda, Toru; D'Amario, Domenico; Sanada, Fumihiro; Zheng, Hanqiao; Ogorek, Barbara; Rondon-Clavo, Carlos; Ferreira-Martins, Joao; Matsuda, Alex; Arranto, Christian; Goichberg, Polina; Giordano, Giovanna; Haley, Kathleen J.; Bardelli, Silvana; Rayatzadeh, Hussein; Liu, Xiaoli; Quaini, Federico; Liao, Ronglih; Leri, Annarosa; Perrella, Mark A.; Loscalzo, Joseph; Anversa, Piero			Evidence for Human Lung Stem Cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGENITOR CELLS; AIRWAY EPITHELIUM; BASAL-CELLS; BETA-CELLS; IN-VIVO; MOUSE; IDENTIFICATION; MAINTENANCE; MULTIPOTENT; POPULATION	Background Although progenitor cells have been described in distinct anatomical regions of the lung, description of resident stem cells has remained elusive. Methods Surgical lung-tissue specimens were studied in situ to identify and characterize human lung stem cells. We defined their phenotype and functional properties in vitro and in vivo. Results Human lungs contain undifferentiated human lung stem cells nested in niches in the distal airways. These cells are self-renewing, clonogenic, and multipotent in vitro. After injection into damaged mouse lung in vivo, human lung stem cells form human bronchioles, alveoli, and pulmonary vessels integrated structurally and functionally with the damaged organ. The formation of a chimeric lung was confirmed by detection of human transcripts for epithelial and vascular genes. In addition, the self-renewal and long-term proliferation of human lung stem cells was shown in serial-transplantation assays. Conclusions Human lungs contain identifiable stem cells. In animal models, these cells participate in tissue homeostasis and regeneration. They have the undemonstrated potential to promote tissue restoration in patients with lung disease. (Funded by the National Institutes of Health.)	[Kajstura, Jan; Rota, Marcello; Hosoda, Toru; D'Amario, Domenico; Sanada, Fumihiro; Zheng, Hanqiao; Ogorek, Barbara; Rondon-Clavo, Carlos; Ferreira-Martins, Joao; Matsuda, Alex; Arranto, Christian; Goichberg, Polina; Bardelli, Silvana; Rayatzadeh, Hussein; Leri, Annarosa; Anversa, Piero] Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA; [Kajstura, Jan; Rota, Marcello; Hall, Sean R.; Hosoda, Toru; D'Amario, Domenico; Sanada, Fumihiro; Zheng, Hanqiao; Ogorek, Barbara; Rondon-Clavo, Carlos; Ferreira-Martins, Joao; Matsuda, Alex; Arranto, Christian; Goichberg, Polina; Haley, Kathleen J.; Bardelli, Silvana; Rayatzadeh, Hussein; Liu, Xiaoli; Liao, Ronglih; Leri, Annarosa; Perrella, Mark A.; Loscalzo, Joseph; Anversa, Piero] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Perrella, Mark A.] Brigham & Womens Hosp, Dept Newborn Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; [Giordano, Giovanna; Quaini, Federico] Univ Parma, I-43100 Parma, Italy	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Parma	Anversa, P (corresponding author), Harvard Univ, Sch Med, Dept Anesthesia & Med, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	panversa@partners.org	Liu, Xiaoli/HGE-7614-2022; Giordano, Giovanna/AAH-6784-2019; D'Amario, Domenico/L-3603-2018; Ferreira-Martins, Joao/AAS-9477-2020; Matsuda, Alex/AAO-3595-2021; Loscalzo, Joseph/ABD-8980-2021; Hosoda, Toru/G-1873-2010	Giordano, Giovanna/0000-0003-4357-1287; Ferreira-Martins, Joao/0000-0002-5491-9421; Liao, Ronglih/0000-0002-9598-9020; /0000-0003-3774-8330; Hosoda, Toru/0000-0002-7273-0630; Quaini, Federico/0000-0003-2377-4810	National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL102897, U54HL070819, R37HL061795, P01HL048743] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funded by the National Institutes of Health.	Bearzi C, 2007, P NATL ACAD SCI USA, V104, P14068, DOI 10.1073/pnas.0706760104; Bearzi C, 2009, P NATL ACAD SCI USA, V106, P15885, DOI 10.1073/pnas.0907622106; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bonner-Weir S, 2005, NAT BIOTECHNOL, V23, P857, DOI 10.1038/nbt1115; BRODY JS, 1992, ANNU REV PHYSIOL, V54, P351, DOI 10.1146/annurev.physiol.54.1.351; Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398; Chen Huaiyong, 2009, Proc Am Thorac Soc, V6, P602, DOI 10.1513/pats.200907-078RM; Chen XP, 2005, MOL BIOL CELL, V16, P3140, DOI 10.1091/mbc.E05-03-0218; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; Domian IJ, 2009, SCIENCE, V326, P426, DOI 10.1126/science.1177350; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908; Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7; Giangreco A, 2009, P NATL ACAD SCI USA, V106, P9286, DOI 10.1073/pnas.0900668106; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Hosoda T, 2009, P NATL ACAD SCI USA, V106, P17169, DOI 10.1073/pnas.0903089106; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kotton DN, 2008, CELL TISSUE RES, V331, P145, DOI 10.1007/s00441-007-0479-2; Laugwitz KL, 2007, NATURE, V446, P934, DOI 10.1038/nature05790; Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215; Leri A, 2009, CIRCULATION, V120, P2515, DOI 10.1161/CIRCULATIONAHA.109.911107; LOUD AV, 1984, LAB INVEST, V50, P250; Morrisey EE, 2010, DEV CELL, V18, P8, DOI 10.1016/j.devcel.2009.12.010; Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269; ORLIC D, 1993, BLOOD, V82, P762, DOI 10.1182/blood.V82.3.762.bloodjournal823762; Rawlins EL, 2009, CELL STEM CELL, V4, P525, DOI 10.1016/j.stem.2009.04.002; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Snyder JC, 2009, J PATHOL, V217, P254, DOI 10.1002/path.2473; Stripp Barry R, 2008, Proc Am Thorac Soc, V5, P328, DOI 10.1513/pats.200711-167DR; Tillmanns J, 2008, P NATL ACAD SCI USA, V105, P1668, DOI 10.1073/pnas.0706315105; Wong AP, 2009, J CLIN INVEST, V119, P336, DOI 10.1172/JCI36882; Xie T, 2007, DEVELOPMENT, V134, P2001, DOI 10.1242/dev.002022; Yamanaka S, 2010, NATURE, V465, P704, DOI 10.1038/nature09229; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314	35	288	314	0	99	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					1795	1806		10.1056/NEJMoa1101324	http://dx.doi.org/10.1056/NEJMoa1101324			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561345	Green Accepted, Bronze			2022-12-28	WOS:000290483000007
J	Victora, CG; Aquino, EML; Leal, MD; Monteiro, CA; Barros, FC; Szwarcwald, CL				Victora, Cesar G.; Aquino, Estela M. L.; Leal, Maria do Carmo; Monteiro, Carlos Augusto; Barros, Fernando C.; Szwarcwald, Celia L.			Health in Brazil 2 Maternal and child health in Brazil: progress and challenges	LANCET			English	Article							LOW-BIRTH-WEIGHT; INFANT-MORTALITY; CESAREAN-SECTIONS; SOUTHERN BRAZIL; DIARRHEA MORTALITY; PRETERM BIRTHS; RISK-FACTORS; COHORTS; RATES; CARE	In the past three decades, Brazil has undergone rapid changes in major social determinants of health and in the organisation of health services. In this report, we examine how these changes have affected indicators of maternal health, child health, and child nutrition. We use data from vital statistics, population censuses, demographic and health surveys, and published reports. In the past three decades, infant mortality rates have reduced substantially, decreasing by 5.5% a year in the 1980s and 1990s, and by 4.4% a year since 2000 to reach 20 deaths per 1000 livebirths in 2008. Neonatal deaths account for 68% of infant deaths. Stunting prevalence among children younger than 5 years decreased from 37% in 1974-75 to 7% in 2006-07. Regional differences in stunting and child mortality also decreased. Access to most maternal-health and child-health interventions increased sharply to almost universal coverage, and regional and socioeconomic inequalities in access to such interventions were notably reduced. The median duration of breastfeeding increased from 2.5 months in the 1970s to 14 months by 2006-07. Official statistics show stable maternal mortality ratios during the past 10 years, but modelled data indicate a yearly decrease of 4%, a trend which might not have been noticeable in official reports because of improvements in death registration and the increased number of investigations into deaths of women of reproductive age. The reasons behind Brazil's progress include: socioeconomic and demographic changes (economic growth, reduction in income disparities between the poorest and wealthiest populations, urbanisation, improved education of women, and decreased fertility rates), interventions outside the health sector (a conditional cash transfer programme and improvements in water and sanitation), vertical health programmes in the 1980s (promotion of breastfeeding, oral rehydration, and immunisations), creation of a tax-funded national health service in 1988 (coverage of which expanded to reach the poorest areas of the country through the Family Health Program in the mid-1990s); and implementation of many national and state-wide programmes to improve child health and child nutrition and, to a lesser extent, to promote women's health. Nevertheless, substantial challenges remain, including overmedicalisation of childbirth (nearly 50% of babies are delivered by caesarean section), maternal deaths caused by illegal abortions, and a high frequency of preterm deliveries.	[Victora, Cesar G.] Univ Fed Pelotas, Postgrad Programme Epidemiol, BR-96001970 Pelotas, RS, Brazil; [Aquino, Estela M. L.] Univ Fed Bahia, Inst Collect Hlth, Salvador, BA, Brazil; [Aquino, Estela M. L.] Brazilian Natl Council Womens Rights, Brasilia, DF, Brazil; [Leal, Maria do Carmo] Fundacao Oswaldo Cruz, Natl Sch Publ Hlth, Rio De Janeiro, Brazil; [Szwarcwald, Celia L.] Fundacao Oswaldo Cruz, Inst Commun Informat Sci & Technol Hlth, Rio De Janeiro, Brazil; [Monteiro, Carlos Augusto] Univ Sao Paulo, Fac Publ Hlth, Sao Paulo, Brazil; [Barros, Fernando C.] Univ Catolica Pelotas, Pelotas, Brazil	Universidade Federal de Pelotas; Universidade Federal da Bahia; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade de Sao Paulo; Universidade Catolica de Pelotas; Universidade Federal de Pelotas	Victora, CG (corresponding author), Univ Fed Pelotas, Postgrad Programme Epidemiol, CP 464, BR-96001970 Pelotas, RS, Brazil.	cvictora@gmail.com	Monteiro, Carlos Augusto/F-9892-2012; Victora, Cesar Gomes/Y-2455-2019; Aquino, Estela M. L./G-2599-2012; Barros, Fernando C/D-4857-2013; Victora, Cesar G/D-4476-2013	Monteiro, Carlos Augusto/0000-0002-3777-1533; Victora, Cesar Gomes/0000-0002-2465-2180; Aquino, Estela M. L./0000-0002-8204-1249; Victora, Cesar G/0000-0002-2465-2180				[Anonymous], 2007, LANCET, V370, P1283; [Anonymous], GAPM WORLD; [Anonymous], GAPM DAT; [Anonymous], 2008, IND BAS SAUD BRAS CO; Aquino R, 2009, AM J PUBLIC HEALTH, V99, P87, DOI 10.2105/AJPH.2007.127480; Arruda J.M., 1987, PESQUISA NACL SAUDE; Barreto ML, 2011, LANCET, V377, P1877, DOI 10.1016/S0140-6736(11)60202-X; Barros A. J. D., 2005, Reaching the poor with health, nutrition, and population services: what works, what doesn't and why, P281; Barros FC, 2005, LANCET, V365, P847, DOI 10.1016/S0140-6736(05)71042-4; BARROS FC, 1991, LANCET, V338, P167, DOI 10.1016/0140-6736(91)90149-J; Barros FC, 2008, CAD SAUDE PUBLICA, V24, pS390, DOI 10.1590/S0102-311X2008001500004; Barros FC, 2010, AM J PUBLIC HEALTH, V100, P1877, DOI 10.2105/AJPH.2010.196816; Dias MAB, 2008, CIENC SAUDE COLETIVA, V13, P1521, DOI 10.1590/S1413-81232008000500017; Batista Filho Malaquias, 2003, Cad. Saúde Pública, V19, pS181, DOI 10.1590/S0102-311X2003000700019; Behague DP, 2002, BMJ-BRIT MED J, V324, P942, DOI 10.1136/bmj.324.7343.942; Betran AP, 2007, PAEDIATR PERINAT EP, V21, P98, DOI 10.1111/j.1365-3016.2007.00786.x; Bettiol H, 2000, PAEDIATR PERINAT EP, V14, P30, DOI 10.1046/j.1365-3016.2000.00222.x; Bhutta ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; COHN J, 1985, LANCET, V2, P437; Comissao Nacional sobre Determinantes Sociais da Saude, 2008, CAUS SOC IN SAUD BRA; Cook RJ, 2004, LANCET, V363, P73, DOI 10.1016/S0140-6736(03)15178-1; Costa AM, 2009, CIENC SAUDE COLETIVA, V14, P1073, DOI 10.1590/S1413-81232009000400014; Datasus, 2006, PACT AT BAS 2006; Datasus, MORT GER; Datasus, RED ASS; Datasus, OB FET; Datasus, NASC VIV; Datasus, RAZ ENTR OB INF EST; Datasus, MORB HOSP; Datasus, OB MAT; Datasus, OB INF; Succi RCD, 2007, CAD SAUDE PUBLICA, V23, pS379, DOI 10.1590/S0102-311X2007001500006; de Onis M, 2006, ACTA PAEDIATR, V95, P76, DOI 10.1080/08035320500495548; Diniz D, CIEN SAUDE COLET S1, V15, P959; Diniz SG, 2004, REPROD HEALTH MATTER, V12, P100, DOI 10.1016/S0968-8080(04)23112-3; Dubos R, 1959, MIR HLTH UT PROGR BI; Fathalla MF, 2006, LANCET, V368, P2095, DOI 10.1016/S0140-6736(06)69483-X; FIOCRUZ, RED BRAS BANC LEIT H; Assuncao MCF, 2007, REV SAUDE PUBL, V41, P539, DOI 10.1590/S0034-89102006005000031; Freitas PF, 2005, REV SAUDE PUBL, V39, P761, DOI 10.1590/S0034-89102005000500010; Frias PG, 2009, SAUDE BRASIL 2008 20; Glasier A, 2006, LANCET, V368, P1595, DOI 10.1016/S0140-6736(06)69478-6; Goldani MZ, 2004, J BIOSOC SCI, V36, P177, DOI 10.1017/S0021932003006175; Gomes UA, 1999, INT J EPIDEMIOL, V28, P687, DOI 10.1093/ije/28.4.687; Hall MH, 1999, LANCET, V354, P776, DOI 10.1016/S0140-6736(05)76016-5; Harper S, 2010, MILBANK Q, V88, P4, DOI 10.1111/j.1468-0009.2010.00587.x; Hill K, 2007, LANCET, V370, P1311, DOI 10.1016/S0140-6736(07)61572-4; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; [IBGE UNICEF], 1992, PERF EST CRIANC MAES; [IBGE UNICEF], 1982, PERF EST CRIANC MAES; IBGE, EST PROJ POP; IBGE. Instituto Brasileiro de Geografia e Estatistica, PESQ NAC AM DOM; Instituto Brasileiro de Geografia e Estat o A stica (IBGE), CENS DEM; Instituto de Pesquisa Economica, 2009, DES POBR BRAS METR D; Lago TDG, 2009, PESQUISA NACL DEMOGR, P151; Lansky Sônia, 2002, Cad. Saúde Pública, V18, P1389, DOI 10.1590/S0102-311X2002000500032; Laurenti Ruy, 2004, Rev. bras. epidemiol., V7, P449, DOI 10.1590/S1415-790X2004000400008; Leal Maria do Carmo, 2004, Cad Saude Publica, V20 Suppl 1, pS20, DOI 10.1590/S0102-311X2004000700003; Leal MC, 2002, RADIS, V2, P8; Leal MD, 2005, REV SAUDE PUBL, V39, P100, DOI 10.1590/S0034-89102005000100013; Leser W, 1975, CIENCIA CULTURA, V27, P224; Macinko J, 2006, J EPIDEMIOL COMMUN H, V60, P13, DOI 10.1136/jech.2005.038323; Macinko J, 2007, SOC SCI MED, V65, P2070, DOI 10.1016/j.socscimed.2007.06.028; Martins I R, 1991, Cad Saude Publica, V7, P251; Matijasevich A, 2008, CAD SAUDE PUBLICA, V24, pS399, DOI 10.1590/S0102-311X2008001500005; Matijasevich A, 2008, AM J PUBLIC HEALTH, V98, P692, DOI 10.2105/AJPH.2006.093492; Mello CG, 1971, REV BRAS HOSP, V3, P29; Menezes G, 2009, CAD SAUDE PUBLICA, V25, pS193, DOI 10.1590/S0102-311X2009001400002; Ministerio da Saude, 2009, MAN COM MORT MAT; Ministerio da Saude, 2009, SAUD BRAS 2008 20 AN; Ministerio da Saude, 2008, PNDS 2006 PESQ NAC D; Monteiro CA, 2002, PUBLIC HEALTH NUTR, V5, P105, DOI 10.1079/PHN2001281; Monteiro CA, 2000, VELHOS NOVOS MALES S, P375; Monteiro CA, 2009, B WORLD HEALTH ORGAN, V88, P305; Monteiro CA, 2009, REV SAUDE PUBL, V43, P35, DOI 10.1590/S0034-89102009000100005; Monteiro MFG, 2006, REV SAUDE SEX REPROD, V26, P1; Oliveira Maria Inês Couto de, 2008, Rev. Saúde Pública, V42, P895; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Potter JE, 2008, BIRTH-ISS PERINAT C, V35, P33, DOI 10.1111/j.1523-536X.2007.00209.x; Ramos AN, 2007, CAD SAUDE PUBLICA, V23, pS370, DOI 10.1590/S0102-311X2007001500005; Rasella D, 2010, PEDIATRICS, V126, pE534, DOI 10.1542/peds.2009-3197; Rattner D, 1996, REV SAUDE PUBL, V30, P19, DOI 10.1590/S0034-89101996000100004; Rea Marina Ferreira, 2003, Cad. Saúde Pública, V19, pS37, DOI 10.1590/S0102-311X2003000700005; Reichenheim ME, 2011, LANCET, V5, P69, DOI [DOI 10.1016/S0140-6736(11)60053-6, 10.1016/S0140-6736(11)60053-6]; Saraceni Valéria, 2005, Cad. Saúde Pública, V21, P1244, DOI 10.1590/S0102-311X2005000400027; Say Lale, 2004, Reprod Health, V1, P3, DOI 10.1186/1742-4755-1-3; Schmidt MI., 2011, LANCET, V377, P1949, DOI [10.1016/S0140-6736%2811%2960135-9, DOI 10.1016/S0140-6736%2811%2960135-9]; Serruya Suzanne Jacob, 2004, Cad. Saúde Pública, V20, P1281, DOI 10.1590/S0102-311X2004000500022; Silva AAM, 2004, INT J EPIDEMIOL, V33, P821, DOI 10.1093/ije/dyh101; Silva AAM, 2001, PAEDIATR PERINAT EP, V15, P257, DOI 10.1046/j.1365-3016.2001.00358.x; Silveira Mariângela F, 2008, Rev. Saúde Pública, V42, P957, DOI 10.1590/S0034-89102008000500023; Singh S, 2006, LANCET, V368, P1887, DOI 10.1016/S0140-6736(06)69778-X; [Sociedade Civil de Bem-Estar Familiar ORT Macro], 1996, BRAZ DHS 1996 RIN RE; Sousa Maria H, 2008, Reprod Health, V5, P6, DOI 10.1186/1742-4755-5-6; Szwarcwald CL, 2008, BRAZ J INFECT DIS, V12, P167, DOI 10.1590/S1413-86702008000300002; Szwarcwald CL, 2008, INT J EPIDEMIOL, V37, P738, DOI 10.1093/ije/dyn130; Szwarcwald CL, 2002, SOC SCI MED, V55, P2083, DOI 10.1016/S0277-9536(01)00353-7; Travassos Claudia, 2008, Rev. bras. epidemiol., V11, P98, DOI 10.1590/S1415-790X2008000500010; UNICEF, 2009, STATE WORLDS CHILDRE; Unicef Brasil, IN HISP AM CRIANC; [UNIFEM UNICEF], 2010, DES RAC GEN ENTR CRI; United Nations Population Division, 1982, MOD LIF TABL DEV COU; United Nations U, MILL DEV GOALS; VENANCIO SI, 1998, REV BRAS EPIDEMIOL, V1, P40, DOI DOI 10.1590/S1415-790X1998000100005; Victora CG, 2010, HEALTH POLICY PLANN, V25, P253, DOI 10.1093/heapol/czp065; Victora C G, 2001, Sao Paulo Med J, V119, P33; Victora CG, 2009, J PEDIAT-BRAZIL, V85, P3, DOI 10.2223/JPED.1860; Victora CG, 1996, HEALTH POLICY PLANN, V11, P132, DOI 10.1093/heapol/11.2.132; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; Victora CG, 2011, LANCET, DOI [10.1016/S0140-6736(11)60055-X, DOI 10.1016/S0140-6736(11)60055-X]; Villar J, 2006, LANCET, V367, P1819, DOI 10.1016/S0140-6736(06)68704-7; Walker GJA, 2007, SEMIN FETAL NEONAT M, V12, P198, DOI 10.1016/j.siny.2007.01.019; WHO, 2010, TRENDS MAT MORT 1990; World Health Organization, 2006, WHO CHILD GROWTH STA; World Health Organization Expert Committee on Nutrition, 1995, PHYS STAT US INT ANT	117	436	457	3	127	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2011	377	9780					1863	1876		10.1016/S0140-6736(11)60138-4	http://dx.doi.org/10.1016/S0140-6736(11)60138-4			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	774UI	21561656	Green Published			2022-12-28	WOS:000291411700033
J	Almeida, N				Almeida-Filho, Naomar			Higher education and health care in Brazil	LANCET			English	Editorial Material									Univ Fed Bahia, Inst Saude Colet, BR-40110040 Salvador, BA, Brazil	Universidade Federal da Bahia	Almeida, N (corresponding author), Univ Fed Bahia, Inst Saude Colet, Campus Univ Canela, BR-40110040 Salvador, BA, Brazil.	naomarf@ufba.br	Almeida-Filho, Naomar M/C-1788-2013	Almeida-Filho, Naomar M/0000-0002-4435-755X				Barriga-Carrasco MD, 2011, LASER PART BEAMS, V29, P81, DOI 10.1017/S0263034610000789; *FED REP BRAZ, 2008, 1998 CONST 1996 REF; Instituto Brasileiro de Geografia e Estatistica, 2010 POP CENS; *MIN ED I NAC EST, 2009 HIGH ED CENS; Ministerio da Saude, SECR AT SAUD; Ministerio da Saude (BR), 2007, NAT PROGR REOR PROF; Morita M.C., 2010, CURRENT PROFILE TREN; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Santos B. S., 2008, U 21 CENTURY NEW U; SPINK M. J. P., 2007, PSYCHOL DIALOGUE SUS, P53; Victora CG, 2011, LANCET, V377, P1863, DOI 10.1016/S0140-6736(11)60138-4	11	39	55	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 4	2011	377	9781					1898	1900		10.1016/S0140-6736(11)60326-7	http://dx.doi.org/10.1016/S0140-6736(11)60326-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	777LW	21561653	Green Published			2022-12-28	WOS:000291623200007
J	Siva, N				Siva, Nayanah			Major African clinical trial ends early due to high mortality in children	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2011	342								d3414	10.1136/bmj.d3414	http://dx.doi.org/10.1136/bmj.d3414			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774MG	21628381				2022-12-28	WOS:000291390100021
J	Roeling, D; Morelli, LG; Ares, S; Julicher, F; Oates, AC				Roeling, Daniela; Morelli, Luis G.; Ares, Saul; Juelicher, Frank; Oates, Andrew C.			SnapShpt: The Segmentation Clock	CELL			English	Editorial Material							SOMITOGENESIS; NUMBER		[Roeling, Daniela; Morelli, Luis G.; Oates, Andrew C.] Max Planck Inst Cell Biol & Genet, D-01307 Dresden, Germany; [Ares, Saul; Juelicher, Frank] Max Planck Inst Phys Komplexer Syst, D-01187 Dresden, Germany	Max Planck Society; Max Planck Society	Roeling, D (corresponding author), Max Planck Inst Cell Biol & Genet, D-01307 Dresden, Germany.		Morelli, Luis G/A-6345-2009; Ares, Saúl/B-4082-2008; Julicher, Frank/B-1828-2009	Morelli, Luis G/0000-0001-5614-073X; Ares, Saúl/0000-0001-6214-4083; Julicher, Frank/0000-0003-4731-9185				Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Gomez C, 2008, NATURE, V454, P335, DOI 10.1038/nature07020; Herrgen L, 2010, CURR BIOL, V20, P1244, DOI 10.1016/j.cub.2010.06.034; Horikawa K, 2006, NATURE, V441, P719, DOI 10.1038/nature04861; KROL AJ, 2011, IN PRESS; Lewis J, 2003, CURR BIOL, V13, P1398, DOI 10.1016/S0960-9822(03)00534-7; Masamizu Y, 2006, P NATL ACAD SCI USA, V103, P1313, DOI 10.1073/pnas.0508658103; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Riedel-Kruse IH, 2007, SCIENCE, V317, P1911, DOI 10.1126/science.1142538; Schroter C, 2010, CURR BIOL, V20, P1254, DOI 10.1016/j.cub.2010.05.071	12	5	5	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 27	2011	145	5					800	+		10.1016/j.cell.2011.05.007	http://dx.doi.org/10.1016/j.cell.2011.05.007			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620141	Bronze			2022-12-28	WOS:000291018600018
J	Rappuoli, R; Aderem, A				Rappuoli, Rino; Aderem, Alan			A 2020 vision for vaccines against HIV, tuberculosis and malaria	NATURE			English	Article							CELL-MEDIATED-IMMUNITY; YELLOW-FEVER VACCINE; DOUBLE-BLIND; SYSTEMS BIOLOGY; EFFICACY; DESIGN; ANTIBODIES; TRIAL; IMMUNOGENICITY; IMMUNIZATION	Acquired immune deficiency syndrome (AIDS), malaria and tuberculosis collectively cause more than five million deaths per year, but have nonetheless eluded conventional vaccine development; for this reason they represent one of the major global public health challenges as we enter the second decade of the twenty-first century. Recent trials have provided evidence that it is possible to develop vaccines that can prevent infection by human immunodeficiency virus (HIV) and malaria. Furthermore, advances in vaccinology, including novel adjuvants, prime-boost regimes and strategies for intracellular antigen presentation, have led to progress in developing a vaccine against tuberculosis. Here we discuss these advances and suggest that new tools such as systems biology and structure-based antigen design will lead to a deeper understanding of mechanisms of protection which, in turn, will lead to rational vaccine development. We also argue that new and innovative approaches to clinical trials will accelerate the availability of these vaccines.	[Rappuoli, Rino] Novartis Vaccines & Diagnost, I-53100 Siena, Italy; [Aderem, Alan] Seattle Biomed Res Inst, Seattle, WA 98109 USA	Novartis; Center for Infectious Disease Research	Rappuoli, R (corresponding author), Novartis Vaccines & Diagnost, I-53100 Siena, Italy.	rino.rappuoli@novartis.com	Rivet, Catherine A/M-7978-2014					Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; [Anonymous], 1927, VACCINATION PREVENTI; [Anonymous], 2010, MILL DEV GOALS REP; Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Bertholet S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001094; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Burton DR, 2004, SCIENCE, V303, P316, DOI 10.1126/science.1094620; Campbell H, 2009, VACCINE, V27, pB20, DOI 10.1016/j.vaccine.2009.04.067; Corey L, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001863; Dormitzer PR, 2008, TRENDS BIOTECHNOL, V26, P659, DOI 10.1016/j.tibtech.2008.08.002; Dutta S, 2007, P NATL ACAD SCI USA, V104, P12488, DOI 10.1073/pnas.0701464104; Fitzgerald DW, 2011, J INFECT DIS, V203, P765, DOI 10.1093/infdis/jiq114; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Freidlin B, 2005, CLIN CANCER RES, V11, P7872, DOI 10.1158/1078-0432.CCR-05-0605; Galli G, 2009, P NATL ACAD SCI USA, V106, P3877, DOI 10.1073/pnas.0813390106; Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6.5.723; Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292; Good MF, 2010, IMMUNITY, V33, P555, DOI 10.1016/j.immuni.2010.10.005; GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; Hoffman SL, 2010, HUM VACCINES, V6, P97, DOI 10.4161/hv.6.1.10396; HORWITZ MA, 2010, NEW GENERATION VACCI; Johnston MI, 2007, NEW ENGL J MED, V356, P2073, DOI 10.1056/NEJMra066267; Kaufmann SHE, 2010, IMMUNITY, V33, P567, DOI 10.1016/j.immuni.2010.09.015; Kaufmann SHE, 2010, LANCET, V375, P2110, DOI 10.1016/S0140-6736(10)60393-5; Koup RA, 2011, NAT REV IMMUNOL, V11, P65, DOI 10.1038/nri2890; Kusi KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008110; Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205; Maertzdorf J, 2011, GENES IMMUN, V12, P15, DOI 10.1038/gene.2010.51; Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256; Masignani V, 2003, VACCINE, V21, pS110, DOI 10.1016/S0264-410X(03)00209-3; McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011; NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0; O'Hallahan J, 2009, NEW ZEAL MED J, V122, P48; Olotu A, 2011, LANCET INFECT DIS, V11, P102, DOI 10.1016/S1473-3099(10)70262-0; Palermo RE, 2011, J VIROL, V85, P1099, DOI 10.1128/JVI.01522-10; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; Pulendran B, 2010, IMMUNITY, V33, P516, DOI 10.1016/j.immuni.2010.10.006; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Remarque EJ, 2008, INFECT IMMUN, V76, P2660, DOI 10.1128/IAI.00170-08; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a; Sauerwein RW, 2011, NAT REV IMMUNOL, V11, P57, DOI 10.1038/nri2902; SCARSELLI M, SCI TRANSL IN PRESS; Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Struik SS, 2004, IMMUNOL REV, V201, P268, DOI 10.1111/j.0105-2896.2004.00181.x; UNAIDS, 2010, REP GLOB AIDS EP; Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517; WHO, 2010, WORLD MALARIA REPORT 2010, P1; *WHO, 2010, MDG6 COMB HIV AIDS M; WHO, 2010, GLOB TUB CONTR 2010; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Zak DE, 2009, IMMUNOL REV, V227, P264, DOI 10.1111/j.1600-065X.2008.00721.x	58	193	201	0	57	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 26	2011	473	7348					463	469		10.1038/nature10124	http://dx.doi.org/10.1038/nature10124			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21614073	Bronze			2022-12-28	WOS:000290951300031
J	Astrow, AB; Popp, B				Astrow, Alan B.; Popp, Beth			The Palliative Care Information Act in Real Life	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Astrow, Alan B.; Popp, Beth] Maimonides Hosp, Brooklyn, NY 11219 USA	Maimonides Medical Center	Astrow, AB (corresponding author), Maimonides Hosp, Brooklyn, NY 11219 USA.								0	28	28	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					1885	1887		10.1056/NEJMp1102392	http://dx.doi.org/10.1056/NEJMp1102392			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765PJ	21591941				2022-12-28	WOS:000290720700001
J	Schwanhausser, B; Busse, D; Li, N; Dittmar, G; Schuchhardt, J; Wolf, J; Chen, W; Selbach, M				Schwanhaeusser, Bjoern; Busse, Dorothea; Li, Na; Dittmar, Gunnar; Schuchhardt, Johannes; Wolf, Jana; Chen, Wei; Selbach, Matthias			Global quantification of mammalian gene expression control	NATURE			English	Article							QUANTITATIVE PROTEOMICS; NUCLEOTIDE RESOLUTION; REGULATORY NETWORKS; IN-VIVO; PROTEIN; DYNAMICS; TRANSLATION; TRANSCRIPTION; STABILITY; CELLS	Gene expression is a multistep process that involves the transcription, translation and turnover of messenger RNAs and proteins. Although it is one of the most fundamental processes of life, the entire cascade has never been quantified on a genome-wide scale. Here we simultaneously measured absolute mRNA and protein abundance and turnover by parallel metabolic pulse labelling for more than 5,000 genes in mammalian cells. Whereas mRNA and protein levels correlated better than previously thought, corresponding half-lives showed no correlation. Using a quantitative model we have obtained the first genome-scale prediction of synthesis rates of mRNAs and proteins. We find that the cellular abundance of proteins is predominantly controlled at the level of translation. Genes with similar combinations of mRNA and protein stability shared functional properties, indicating that half-lives evolved under energetic and dynamic constraints. Quantitative information about all stages of gene expression provides a rich resource and helps to provide a greater understanding of the underlying design principles.	[Schwanhaeusser, Bjoern; Busse, Dorothea; Li, Na; Dittmar, Gunnar; Wolf, Jana; Chen, Wei; Selbach, Matthias] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; [Schuchhardt, Johannes] MicroDiscovery GmbH, D-10405 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Wolf, J (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	jana.wolf@mdc-berlin.de; wei.chen@mdc-berlin.de; matthias.selbach@mdc-berlin.de	Dittmar, Gunnar/B-6383-2016; Dittmar, Gunnar/C-6333-2019; Selbach, Matthias/C-5988-2008; Chen, Wei/C-1273-2011	Dittmar, Gunnar/0000-0003-3647-8623; Dittmar, Gunnar/0000-0003-3647-8623; Li, Na/0000-0001-6163-1648; Chen, Wei/0000-0003-3263-1627	Helmholtz Association; German Ministry of Education and Research (BMBF); Senate of Berlin by Berlin Institute of Medical Systems Biology (BIMSB) [315362A]; German Ministry of Education and Research [315289]; Helmholtz Alliance on Systems Biology/MSBN; China Scholarship Council CSC	Helmholtz Association(Helmholtz Association); German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Senate of Berlin by Berlin Institute of Medical Systems Biology (BIMSB); German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Helmholtz Alliance on Systems Biology/MSBN; China Scholarship Council CSC(China Scholarship Council)	We thank N. Rajewsky and L. Dolken for fruitful discussions and C. Sommer for technical assistance. M.S. and W.C. are supported by the Helmholtz Association, the German Ministry of Education and Research (BMBF) and the Senate of Berlin by funds aimed at establishing the Berlin Institute of Medical Systems Biology (BIMSB) (grant number 315362A). J.W. is supported by the ForSys-programme of the German Ministry of Education and Research (grant number 315289); D.B. by the Helmholtz Alliance on Systems Biology/MSBN; and N.L. by the China Scholarship Council CSC.	Abreu RD, 2009, MOL BIOSYST, V5, P1512, DOI 10.1039/b908315d; Arava Y, 2005, NUCLEIC ACIDS RES, V33, P2421, DOI 10.1093/nar/gki331; Belle A, 2006, P NATL ACAD SCI USA, V103, P13004, DOI 10.1073/pnas.0605420103; Beynon RJ, 2005, MOL CELL PROTEOMICS, V4, P857, DOI 10.1074/mcp.R400010-MCP200; Churchman LS, 2011, NATURE, V469, P368, DOI 10.1038/nature09652; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Darzacq X, 2007, NAT STRUCT MOL BIOL, V14, P796, DOI 10.1038/nsmb1280; de-Leon SBT, 2009, DEV BIOL, V325, P317, DOI 10.1016/j.ydbio.2008.10.043; Doherty MK, 2009, J PROTEOME RES, V8, P104, DOI 10.1021/pr800641v; Friedel CC, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp542; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Gouw JW, 2010, MOL CELL PROTEOMICS, V9, P11, DOI 10.1074/mcp.R900001-MCP200; Hao SL, 2009, NAT IMMUNOL, V10, P281, DOI 10.1038/ni.1699; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hogan DJ, 2008, PLOS BIOL, V6, P2297, DOI 10.1371/journal.pbio.0060255; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kirkpatrick DS, 2005, NAT CELL BIOL, V7, P750, DOI 10.1038/ncb0805-750; Komili S, 2008, NAT REV GENET, V9, P38, DOI 10.1038/nrg2223; Lam YW, 2007, CURR BIOL, V17, P749, DOI 10.1016/j.cub.2007.03.064; Legewie S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.29; Lu P, 2007, NAT BIOTECHNOL, V25, P117, DOI 10.1038/nbt1270; Lu R, 2009, NATURE, V462, P358, DOI 10.1038/nature08575; Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036; Malmstrom J, 2009, NATURE, V460, P762, DOI 10.1038/nature08184; Mann M, 2006, NAT REV MOL CELL BIO, V7, P952, DOI 10.1038/nrm2067; Milner E, 2006, MOL CELL PROTEOMICS, V5, P357, DOI 10.1074/mcp.M500241-MCP200; Mittal N, 2009, P NATL ACAD SCI USA, V106, P20300, DOI 10.1073/pnas.0906940106; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Pedraza JM, 2008, SCIENCE, V319, P339, DOI 10.1126/science.1144331; Price JC, 2010, P NATL ACAD SCI USA, V107, P14508, DOI 10.1073/pnas.1006551107; Rabani M, 2011, NAT BIOTECHNOL, V29, P436, DOI 10.1038/nbt.1861; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; Schwanhausser B, 2009, PROTEOMICS, V9, P205, DOI 10.1002/pmic.200800275; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Vogel C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.59; Wagner A, 2005, MOL BIOL EVOL, V22, P1365, DOI 10.1093/molbev/msi126; Wu CC, 2004, ANAL CHEM, V76, P4951, DOI 10.1021/ac049208j; Wu G, 2008, CURR MICROBIOL, V57, P18, DOI 10.1007/s00284-008-9145-5; Yang E, 2003, GENOME RES, V13, P1863, DOI 10.1101/gr.1272403; Yen HCS, 2008, SCIENCE, V322, P918, DOI 10.1126/science.1160489	44	3891	3970	15	674	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					337	342		10.1038/nature10098	http://dx.doi.org/10.1038/nature10098			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593866	Green Accepted			2022-12-28	WOS:000290722400040
J	Johnson, WL; Kaltenboeck, G; Demetriou, MD; Schramm, JP; Liu, X; Samwer, K; Kim, CP; Hofmann, DC				Johnson, William L.; Kaltenboeck, Georg; Demetriou, Marios D.; Schramm, Joseph P.; Liu, Xiao; Samwer, Konrad; Kim, C. Paul; Hofmann, Douglas C.			Beating Crystallization in Glass-Forming Metals by Millisecond Heating and Processing	SCIENCE			English	Article							VISCOUS-FLOW; SUPERCOOLED LIQUID; BEHAVIOR; ALLOY; RELAXATION; KINETICS; SILICON; FLASH	The development of metal alloys that form glasses at modest cooling rates has stimulated broad scientific and technological interest. However, intervening crystallization of the liquid in even the most robust bulk metallic glass-formers is orders of magnitude faster than in many common polymers and silicate glass-forming liquids. Crystallization limits experimental studies of the undercooled liquid and hampers efforts to plastically process metallic glasses. We have developed a method to rapidly and uniformly heat a metallic glass at rates of 10(6) kelvin per second to temperatures spanning the undercooled liquid region. Liquid properties are subsequently measured on millisecond time scales at previously inaccessible temperatures under near-adiabatic conditions. Rapid thermoplastic forming of the undercooled liquid into complex net shapes is implemented under rheological conditions typically used in molding of plastics. By operating in the millisecond regime, we are able to "beat" the intervening crystallization and successfully process even marginal glass-forming alloys with very limited stability against crystallization that are not processable by conventional heating.	[Johnson, William L.; Kaltenboeck, Georg; Demetriou, Marios D.; Schramm, Joseph P.; Liu, Xiao; Samwer, Konrad; Kim, C. Paul; Hofmann, Douglas C.] CALTECH, Keck Lab Engn, Pasadena, CA 91125 USA	California Institute of Technology	Johnson, WL (corresponding author), CALTECH, Keck Lab Engn, Pasadena, CA 91125 USA.	wlj@caltech.edu			II-VI Foundation	II-VI Foundation	The authors acknowledge partial support by the II-VI Foundation, the assistance of R. Overstreet with the thermal imaging unit, and useful discussions with M. A. Nicolet. A patent filed by the California Institute of Technology is currently pending. The U. S. patent application number is US2009/0236017 A1.	Ballard D. E., 1991, U.S. Patent, Patent No. [5,005,456, 5005456]; BUSCH R, 1995, J APPL PHYS, V77, P4039, DOI 10.1063/1.359485; Choi-Yim H, 1998, J APPL PHYS, V83, P7993, DOI 10.1063/1.367981; de Oliveira MF, 2002, APPL PHYS LETT, V81, P1606, DOI 10.1063/1.1502008; DIENES GJ, 1946, J APPL PHYS, V17, P458, DOI 10.1063/1.1707739; Duan G, 2007, ADV MATER, V19, P4272, DOI 10.1002/adma.200700969; Fan GJ, 2004, APPL PHYS LETT, V84, P487, DOI 10.1063/1.1644052; GIBBS MRJ, 1984, IEEE T MAGN, V20, P1373, DOI 10.1109/TMAG.1984.1063448; Guntherodt H. J., 1977, ADV SOLID STATE PHYS, V17, P25, DOI DOI 10.1007/BFB0107754; Han C.D., 2007, RHEOLOGY PROCESSING, V1 and 2; HERLACH DM, 1993, INT MATER REV, V38, P273, DOI 10.1179/095066093790326267; Inoue A, 2000, ACTA MATER, V48, P279, DOI 10.1016/S1359-6454(99)00300-6; Johnson WL, 1999, MRS BULL, V24, P42, DOI 10.1557/S0883769400053252; Kim YJ, 1996, APPL PHYS LETT, V68, P1057, DOI 10.1063/1.116247; KLEMENT W, 1960, NATURE, V187, P869, DOI 10.1038/187869b0; KUI HW, 1984, APPL PHYS LETT, V45, P615, DOI 10.1063/1.95330; KULIK T, 1991, MAT SCI ENG A-STRUCT, V133, P232, DOI 10.1016/0921-5093(91)90058-U; Kumar G, 2011, ADV MATER, V23, P461, DOI 10.1002/adma.201002148; Kumar G, 2009, NATURE, V457, P868, DOI 10.1038/nature07718; Lin XH, 1997, MATER T JIM, V38, P473, DOI 10.2320/matertrans1989.38.473; Lohofer G, 2005, INT J THERMOPHYS, V26, P1239, DOI 10.1007/s10765-005-6721-9; Lu J, 2003, ACTA MATER, V51, P3429, DOI 10.1016/S1359-6454(03)00164-2; Masuhr A, 1999, PHYS REV LETT, V82, P2290, DOI 10.1103/PhysRevLett.82.2290; NAGEL SR, 1977, PHYS REV B, V16, P1694, DOI 10.1103/PhysRevB.16.1694; PEKER A, 1993, APPL PHYS LETT, V63, P2342, DOI 10.1063/1.110520; Saotome Y, 2004, MAT SCI ENG A-STRUCT, V375, P389, DOI 10.1016/j.msea.2003.10.173; Schroers J, 2000, APPL PHYS LETT, V77, P1158, DOI 10.1063/1.1289033; Schroers J, 1999, PHYS REV B, V60, P11855, DOI 10.1103/PhysRevB.60.11855; Schroers J, 2007, SCRIPTA MATER, V57, P341, DOI 10.1016/j.scriptamat.2007.04.033; Schroers J, 2010, ADV MATER, V22, P1566, DOI 10.1002/adma.200902776; Wang WH, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.052204; Waniuk TA, 1998, ACTA MATER, V46, P5229, DOI 10.1016/S1359-6454(98)00242-0; Wiest A, 2009, SCRIPTA MATER, V60, P160, DOI 10.1016/j.scriptamat.2008.09.021; Yavari AR, 2004, MAT SCI ENG A-STRUCT, V375, P227, DOI 10.1016/j.msea.2003.10.267; ZALUSKA A, 1986, INT J RAPID SOLIDIF, V2, P205	35	173	186	7	281	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2011	332	6031					828	833		10.1126/science.1201362	http://dx.doi.org/10.1126/science.1201362			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566189				2022-12-28	WOS:000290529900042
J	Wilson, A; Lissauer, D; Thangaratinam, S; Khan, KS; MacArthur, C; Coomarasamy, A				Wilson, Amie; Lissauer, David; Thangaratinam, Shakila; Khan, Khalid S.; MacArthur, Christine; Coomarasamy, Arri			A comparison of clinical officers with medical doctors on outcomes of caesarean section in the developing world: meta-analysis of controlled studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OBSTETRICIANS; DELIVERIES; SURGERY; MALAWI; CARE	Objective To review the effectiveness and safety of clinical officers (healthcare providers trained to perform tasks usually undertaken by doctors) carrying out caesarean section in developing countries compared with doctors. Design Systematic review with meta-analysis. Data sources Medline, Embase, Cochrane Central Register of Controlled Trials, CINAHL, BioMed Central, the Reproductive Health Library, and the Science Citation Index (inception-2010) without language restriction. Study selection Controlled studies. Data extraction Information was extracted from each selected article on study characteristics, quality, and outcome data. Two independent reviewers extracted data. Results Six non-randomised controlled studies (16 018 women) evaluated the effectiveness of clinical officers carrying out caesarean section. Meta-analysis found no significant differences between the clinical officers and doctors for maternal death (odds ratio 1.46, 95% confidence interval 0.78 to 2.75; P=0.24) or for perinatal death (1.31, 0.87 to 1.95; P=0.19). The results were heterogeneous, with some studies reporting a higher incidence of both outcomes with clinical officers. Clinical officers were associated with a higher incidence of wound infection (1.58, 1.01 to 2.47; P=0.05) and wound dehiscence (1.89, 1.21 to 2.95; P=0.005). Two studies accounted for confounding factors. Conclusion Clinical officers and doctors did not differ significantly in key outcomes for caesarean section, but the conclusions are tentative owing to the non-randomised nature of the studies. The increase in wound infection and dehiscence may highlight a particular training need for clinical officers.	[Wilson, Amie; Lissauer, David; Coomarasamy, Arri] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England; [Thangaratinam, Shakila; Khan, Khalid S.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Hlth Sci, London, England; [MacArthur, Christine] Univ Birmingham, Coll Med & Dent Sci, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of London; Queen Mary University London; University of Birmingham	Coomarasamy, A (corresponding author), Univ Birmingham, Birmingham Womens Fdn Trust, Acad Unit, Birmingham B15 2TG, W Midlands, England.	a.coomarasamy@bham.ac.uk	MacArthur, Christine/ABA-8601-2021; Khan, Khalid S/AAT-8824-2020; Wilson, Amie/HHS-0117-2022; Thangaratinam, Shakila/AAP-3724-2021	MacArthur, Christine/0000-0003-0434-2158; Khan, Khalid S/0000-0001-5084-7312; Wilson, Amie/0000-0002-1015-3786; Thangaratinam, Shakila/0000-0002-4254-460X; Lissauer, David/0000-0002-7878-2327	Ammalife; Birmingham Women's NHS foundation Trust RD department	Ammalife; Birmingham Women's NHS foundation Trust RD department	This study was funded by the registered charity Ammalife (www.ammalife.org) and Birmingham Women's NHS foundation Trust R&D department.	Bradley S, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-14; Brown SR, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005199.pub2; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Chilopora Garvey, 2007, Hum Resour Health, V5, P17, DOI 10.1186/1478-4491-5-17; Dovlo Delanyo, 2004, Hum Resour Health, V2, P7, DOI 10.1186/1478-4491-2-7; Fenton P, 1997, E CENT AFR J SURG, V3, P33; Fenton PM, 2003, BRIT MED J, V327, P587, DOI 10.1136/bmj.327.7415.587; Hounton SH, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-34; Lewis G, 2007, 7 CEMACH; MCCARTHY J, 1992, STUD FAMILY PLANN, V23, P23, DOI 10.2307/1966825; McCord C, 2009, HEALTH AFFAIR, V28, pW876, DOI 10.1377/hlthaff.28.5.w876; Mullan F, 2007, LANCET, V370, P2158, DOI 10.1016/S0140-6736(07)60785-5; Pereira C, 1996, BRIT J OBSTET GYNAEC, V103, P508, DOI 10.1111/j.1471-0528.1996.tb09797.x; Record R, 2006, GLOBALIZATION HEALTH, V2, DOI 10.1186/1744-8603-2-12; Vaz F, 1999, B WORLD HEALTH ORGAN, V77, P688; Wells G., 2000, NEWCASTLEOTTAWA SCAL; WHITE SM, 1987, LANCET, V2, P612	17	62	62	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	2011	342								d2600	10.1136/bmj.d2600	http://dx.doi.org/10.1136/bmj.d2600			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765OR	21571914	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000290718700002
J	Boeckxstaens, GE; Annese, V; des Varannes, SB; Chaussade, S; Costantini, M; Cuttitta, A; Elizalde, JI; Fumagalli, U; Gaudric, M; Rohof, WO; Smout, AJ; Tack, J; Zwinderman, AH; Zaninotto, G; Busch, OR				Boeckxstaens, Guy E.; Annese, Vito; des Varannes, Stanislas Bruley; Chaussade, Stanislas; Costantini, Mario; Cuttitta, Antonello; Ignasi Elizalde, J.; Fumagalli, Uberto; Gaudric, Marianne; Rohof, Wout O.; Smout, Andre J.; Tack, Jan; Zwinderman, Aeilko H.; Zaninotto, Giovanni; Busch, Olivier R.		European Achalasia Trial Investiga	Pneumatic Dilation versus Laparoscopic Heller's Myotomy for Idiopathic Achalasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESOPHAGEAL ACHALASIA; FOLLOW-UP; DILATATION; ESOPHAGOMYOTOMY; FUNDOPLICATION; QUESTIONNAIRE	Background Many experts consider laparoscopic Heller's myotomy (LHM) to be superior to pneumatic dilation for the treatment of achalasia, and LHM is increasingly considered to be the treatment of choice for this disorder. Methods We randomly assigned patients with newly diagnosed achalasia to pneumatic dilation or LHM with Dor's fundoplication. Symptoms, including weight loss, dysphagia, retrosternal pain, and regurgitation, were assessed with the use of the Eckardt score (which ranges from 0 to 12, with higher scores indicating more pronounced symptoms). The primary outcome was therapeutic success (a drop in the Eckardt score to <= 3) at the yearly follow-up assessment. The secondary outcomes included the need for retreatment, pressure at the lower esophageal sphincter, esophageal emptying on a timed barium esophagogram, quality of life, and the rate of complications. Results A total of 201 patients were randomly assigned to pneumatic dilation (95 patients) or LHM (106). The mean follow-up time was 43 months (95% confidence interval [CI], 40 to 47). In an intention-to-treat analysis, there was no significant difference between the two groups in the primary outcome; the rate of therapeutic success with pneumatic dilation was 90% after 1 year of follow-up and 86% after 2 years, as compared with a rate with LHM of 93% after 1 year and 90% after 2 years (P = 0.46). After 2 years of follow-up, there was no significant between-group difference in the pressure at the lower esophageal sphincter (LHM, 10 mm Hg [95% CI, 8.7 to 12]; pneumatic dilation, 12 mm Hg [95% CI, 9.7 to 14]; P = 0.27); esophageal emptying, as assessed by the height of barium-contrast column (LHM, 1.9 cm [95% CI, 0 to 6.8]; pneumatic dilation, 3.7 cm [95% CI, 0 to 8.8]; P = 0.21); or quality of life. Similar results were obtained in the per-protocol analysis. Perforation of the esophagus occurred in 4% of the patients during pneumatic dilation, whereas mucosal tears occurred in 12% during LHM. Abnormal exposure to esophageal acid was observed in 15% and 23% of the patients in the pneumatic-dilation and LHM groups, respectively (P = 0.28). Conclusions After 2 years of follow-up, LHM, as compared with pneumatic dilation, was not associated with superior rates of therapeutic success. (European Achalasia Trial Netherlands Trial Register number, NTR37, and Current Controlled Trials number, ISRCTN56304564.)	[Boeckxstaens, Guy E.] Katholieke Univ Leuven, Katholieke Univ Leuven Hosp, Dept Gastroenterol, B-3000 Louvain, Belgium; [Boeckxstaens, Guy E.; Rohof, Wout O.; Zwinderman, Aeilko H.; Busch, Olivier R.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Annese, Vito; Cuttitta, Antonello] Osped Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy; [Costantini, Mario; Zaninotto, Giovanni] Padova Univ Hosp, Padua, Italy; [des Varannes, Stanislas Bruley] CHU Nantes, F-44035 Nantes 01, France; [Chaussade, Stanislas; Gaudric, Marianne] Cochin Univ Hosp, Paris, France; [Ignasi Elizalde, J.] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer, Hosp Clin, Inst Clin Malalties Digest & Metab, Barcelona, Spain; [Fumagalli, Uberto] Ist Clin Humanitas, Milan, Italy; [Smout, Andre J.] Univ Med Ctr Utrecht, Utrecht, Netherlands	Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; University of Amsterdam; Academic Medical Center Amsterdam; IRCCS Casa Sollievo Della Sofferenza; University of Padua; Azienda Ospedaliera - Universita di Padova; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; IRCCS Humanitas Research Hospital; Utrecht University; Utrecht University Medical Center	Boeckxstaens, GE (corresponding author), Katholieke Univ Leuven, Katholieke Univ Leuven Hosp, Dept Gastroenterol, Herestr 49, B-3000 Louvain, Belgium.	guy.boeckxstaens@med.kuleuven.be	Annese, Vito/AGW-4200-2022; Boeckxstaens, Guy/AAP-2502-2020; Busch, Olivier/AAC-3650-2020; Coriat, Romain/O-7902-2017	Annese, Vito/0000-0002-0082-892X; Zaninotto, Giovanni/0000-0003-0333-9491; Dousset, Bertrand/0000-0003-2526-7345; Tack, Jan/0000-0002-3206-6704	Flemish Government [G.0905.08]; Given Imaging; Novartis; Danone; AstraZeneca; Takeda Pharmaceuticals; Nycomed; Rome Foundation; XenoPort, Movetis; Abbott	Flemish Government(European Commission); Given Imaging; Novartis(Novartis); Danone(Danone Nutricia); AstraZeneca(AstraZeneca); Takeda Pharmaceuticals(Takeda Pharmaceutical Company Ltd); Nycomed; Rome Foundation; XenoPort, Movetis; Abbott(Abbott Laboratories)	Dr. Boeckxstaens is supported by a grant (G.0905.08) from the Odysseus program, Fonds Wetenschappelijk Onderzoek, of the Flemish Government.; Dr. Bruley des Varannes reports receiving payment for board membership from Janssen Cilag, IPRAD Laboratories, Cephalon, and Mayoly Spindler Laboratories, consulting fees from Given Imaging, Novartis, and Danone, and lecture fees from AstraZeneca, Takeda Pharmaceuticals, and Nycomed; Dr. Elizalde, consulting fees from AstraZeneca; and Dr. Tack, payment for board membership from the Rome Foundation, consulting fees from XenoPort, Movetis (now part of Shire), Almirall, AstraZeneca, Danone, Menarini, Nycomed, SK Life Sciences, Theravance, Zeria Pharmaceuticals, ARYx Therapeutics, Ipsen, Ocera Therapeutics, Rose Pharma, Tranzyme Pharma, Norgine, Pfizer, Cargill, Forest Laboratories, and Ironwood Pharmaceuticals, grant support from Novartis, AstraZeneca, and Movetis, lecture fees from Abbott, AstraZeneca, Movetis, Nycomed, Novartis, Menarini, and Ipsen, and payment for the development of educational presentationsfrom Menarini and the Rome Foundation. No other potential conflict of interest relevant to this article was reported.	Blazeby JM, 1996, EUR J CANCER, V32A, P1912, DOI 10.1016/0959-8049(96)00199-2; Boeckxstaens GEE, 2007, BEST PRACT RES CL GA, V21, P595, DOI 10.1016/j.bpg.2007.03.004; Bravi I, 2010, ALIMENT PHARM THER, V31, P658, DOI 10.1111/j.1365-2036.2009.04217.x; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Campos GM, 2009, ANN SURG, V249, P45, DOI 10.1097/SLA.0b013e31818e43ab; Costantini M, 2005, SURG ENDOSC, V19, P345, DOI 10.1007/s00464-004-8941-7; CSENDES A, 1981, GASTROENTEROLOGY, V80, P789; Csendes A, 2006, ANN SURG, V243, P196, DOI 10.1097/01.sla.0000197469.12632.e0; deOliveira JM, 1997, AM J ROENTGENOL, V169, P473, DOI 10.2214/ajr.169.2.9242756; Eckardt V F, 2001, Gastrointest Endosc Clin N Am, V11, P281; Eckardt VF, 1999, GASTROENTEROLOGY, V116, P1300, DOI 10.1016/S0016-5085(99)70493-2; Eckardt VF, 2004, GUT, V53, P629, DOI 10.1136/gut.2003.029298; FERGUSON MK, 1991, ANN THORAC SURG, V52, P336, DOI 10.1016/0003-4975(91)91373-4; Hulselmans M, 2010, CLIN GASTROENTEROL H, V8, P30, DOI 10.1016/j.cgh.2009.09.020; Kostic S, 2007, WORLD J SURG, V31, P470, DOI 10.1007/s00268-006-0600-9; Leeuwenburgh I, 2006, ALIMENT PHARM THERAP, V23, P1197, DOI 10.1111/j.1365-2036.2006.02871.x; Leeuwenburgh I, 2006, SCAND J GASTROENTERO, V41, P7, DOI 10.1080/00365520600664201; Lopushinsky SR, 2006, JAMA-J AM MED ASSOC, V296, P2227, DOI 10.1001/jama.296.18.2227; Lundell LR, 1999, GUT, V45, P172, DOI 10.1136/gut.45.2.172; Oelschlager BK, 2003, ARCH SURG-CHICAGO, V138, P490, DOI 10.1001/archsurg.138.5.490; Pandolfino JE, 2008, GASTROENTEROLOGY, V135, P1526, DOI 10.1053/j.gastro.2008.07.022; Patti MG, 2001, ARCH SURG-CHICAGO, V136, P870, DOI 10.1001/archsurg.136.8.870; Richter JE, 2008, CLIN GASTROENTEROL H, V6, P859, DOI 10.1016/j.cgh.2008.02.061; Schuchert MJ, 2008, ANN THORAC SURG, V85, P1729, DOI 10.1016/j.athoracsur.2007.11.017; Sharp KW, 2002, ANN SURG, V235, P631, DOI 10.1097/00000658-200205000-00004; Vaezi MF, 2002, GUT, V50, P765, DOI 10.1136/gut.50.6.765; Vela MF, 2006, CLIN GASTROENTEROL H, V4, P580, DOI 10.1016/S1542-3565(05)00986-9; Zaninotto G, 2000, J GASTROINTEST SURG, V4, P282, DOI 10.1016/S1091-255X(00)80077-3; Zaninotto G, 2008, ANN SURG, V248, P986, DOI 10.1097/SLA.0b013e3181907bdd; Zerbib F, 2006, AM J GASTROENTEROL, V101, P692, DOI 10.1111/j.1572-0241.2006.00385.x	30	535	553	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					1807	1816		10.1056/NEJMoa1010502	http://dx.doi.org/10.1056/NEJMoa1010502			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561346	Bronze			2022-12-28	WOS:000290483000008
J	Iheanacho, I				Iheanacho, Ike			DRUG TALES AND OTHER STORIES Take it like a man: pseudodrugs for man flu	BRITISH MEDICAL JOURNAL			English	Editorial Material												iiheanacho@bmjgroup.com							0	1	1	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 11	2011	342								d2863	10.1136/bmj.d2863	http://dx.doi.org/10.1136/bmj.d2863			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765OP	21562005				2022-12-28	WOS:000290718400004
J	Barreto, ML; Teixeira, MG; Bastos, FI; Ximenes, RAA; Barata, RB; Rodrigues, LC				Barreto, Mauricio L.; Teixeira, M. Gloria; Bastos, Francisco I.; Ximenes, Ricardo A. A.; Barata, Rita B.; Rodrigues, Laura C.			Health in Brazil 3 Successes and failures in the control of infectious diseases in Brazil: social and environmental context, policies, interventions, and research needs	LANCET			English	Article							DENGUE HEMORRHAGIC-FEVER; RIO-DE-JANEIRO; HEPATITIS-A; CHAGAS-DISEASE; LATIN-AMERICA; RISK-FACTORS; DRUG-USERS; SAO-PAULO; IMMUNODEFICIENCY-SYNDROME; VISCERAL LEISHMANIASIS	Despite pronounced reductions in the number of deaths due to infectious diseases over the past six decades, infectious diseases are still a public health problem in Brazil. In this report, we discuss the major successes and failures in the control of infectious diseases in Brazil, and identify research needs and policies to further improve control or interrupt transmission. Control of diseases such as cholera, Chagas disease, and those preventable by vaccination has been successful through efficient public policies and concerted efforts from different levels of government and civil society. For these diseases, policies dealt with key determinants (eg, the quality of water and basic sanitation, vector control), provided access to preventive resources (such as vaccines), and successfully integrated health policies with broader social policies. Diseases for which control has failed (such as dengue fever and visceral leishmaniasis) are vector-borne diseases with changing epidemiological profiles and major difficulties in treatment (in the case of dengue fever, no treatment is available). Diseases for which control has been partly successful have complex transmission patterns related to adverse environmental, social, economic, or unknown determinants; are sometimes transmitted by insect vectors that are difficult to control; and are mostly chronic diseases with long infectious periods that require lengthy periods of treatment.	[Barreto, Mauricio L.; Teixeira, M. Gloria] Univ Fed Bahia, Inst Saude Colet, BR-40110040 Salvador, BA, Brazil; [Bastos, Francisco I.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil; [Bastos, Francisco I.] Brown Univ, Providence, RI 02912 USA; [Ximenes, Ricardo A. A.] Univ Fed Pernambuco, Recife, PE, Brazil; [Barata, Rita B.] Santa Casa Sao Paulo, Fac Med Sci, Sao Paulo, Brazil; [Rodrigues, Laura C.] London Sch Hyg & Trop Med, London WC1, England	Universidade Federal da Bahia; Fundacao Oswaldo Cruz; Brown University; Universidade Federal de Pernambuco; University of London; London School of Hygiene & Tropical Medicine	Barreto, ML (corresponding author), Univ Fed Bahia, Inst Saude Colet, BR-40110040 Salvador, BA, Brazil.	mauricio@ufba.br	Teixeira, Maria Gloria L C/G-4808-2012; RODRIGUES, LAURA CUNHA/AAO-4130-2021; Barata, Rita B/F-9077-2012; Iats, Inct/K-2300-2013; Barreto, Mauricio L/B-1752-2008	Teixeira, Maria Gloria L C/0000-0003-3318-3408; Barata, Rita B/0000-0002-7215-9788; Barreto, Mauricio L/0000-0002-0215-4930; Rodrigues, Laura Cunha/0000-0001-9008-660X; Bastos, Francisco/0000-0001-5970-8896				Aguiar F, 2009, INT J TUBERC LUNG D, V13, P54; [Anonymous], SINAN SVS MS; [Anonymous], 2010, WORLD HLTH STAT 2010; Antunes JLF, 2007, INT J EPIDEMIOL, V36, P1319, DOI 10.1093/ije/dym208; Baggaley RF, 2010, ANTIMICROBIAL RESISTANCE IN DEVELOPING COUNTRIES, P75, DOI 10.1007/978-0-387-89370-9_6; Baliza M, 2008, REV SOC BRAS MED TRO, V41, P11, DOI 10.1590/S0037-86822008000100003; Barata R B, 1998, Rev Panam Salud Publica, V3, P102; Barata R.B., 2000, CIENC SAUDE COLETIVA, V5, P333, DOI DOI 10.1590/S1413-81232000000200008; Barata R C, 1995, Cad Saude Publica, V11, P128, DOI 10.1590/S0102-311X1995000100019; BARATA RDB, 1988, REV SAUDE PUBL, V22, P16; Barata RDB, 1997, REV SAUDE PUBL, V31, P531, DOI 10.1590/S0034-89101997000600015; Barata Rita Barradas, 2004, Cad. Saúde Pública, V20, P1762, DOI 10.1590/S0102-311X2004000600039; Barcellos Christovam, 2009, Rev. Saúde Pública, V43, P1006, DOI 10.1590/S0034-89102009005000070; Barreto ML, 2007, LANCET, V370, P1622, DOI 10.1016/S0140-6736(07)61638-9; Barreto ML, 2006, REV SAUDE PUBL, V40, P79, DOI 10.1590/S0034-89102006000400012; Barreto ML, 2006, T ROY SOC TROP MED H, V100, P234, DOI 10.1016/j.trstmh.2005.03.010; Barreto ML, 1996, INF EPIDEMIOL SUS, V3, P7; Bastos FI, 2005, MEM I OSWALDO CRUZ, V100, P91, DOI 10.1590/S0074-02762005000100017; Nemes MIB, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-51; Benicio MHD, 2000, REV SAUDE PUBL, V34, P83, DOI 10.1590/S0034-89102000000700011; Bierrenbach Ana Luiza, 2007, Rev. Saúde Pública, V41, P24, DOI 10.1590/S0034-89102007000800005; Blanton RE, 2008, EUR J HUM GENET, V16, P762, DOI 10.1038/ejhg.2008.4; Brasil, 2021, TAX LET LEISHM VISC; Brasil Ministerio da Saude, DENG; Brazilian Ministry of Health, B EP AIDS DST; Brazilian Ministry of Health, NAT MAL CONTR PROGR; Carmo Eduardo Hage, 2008, Estud. av., V22, P19, DOI 10.1590/S0103-40142008000300003; Carmo EH, PREVENCAO CONTROLE M; Carmo EH, 1994, CAD SAUDE PUBLICA, V10, P4225; Miranzi SDC, 2007, CAD SAUDE PUBLICA, V23, P1689, DOI 10.1590/S0102-311X2007000700021; Conselho Regional de Medicina do Estado de Sao Paulo, 2010, CONTR INF HOSP EST S; [Coordenadoria de Controle de doencas Divisao de doencas de transmissao respiratoria], 2005, REV SAUDE PUBL, V39, P857; Correia JB, 2010, J INFECT DIS, V201, P363, DOI 10.1086/649843; Costa MFFLE, 2001, INT J EPIDEMIOL, V30, P887, DOI 10.1093/ije/30.4.887; Costa ZB, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-116; [Datasus Ministerio da Saude], MORT BRAS; Ximenes RAD, 2008, INT J EPIDEMIOL, V37, P852, DOI 10.1093/ije/dyn114; Ximenes RAD, 2010, CAD SAUDE PUBLICA, V26, P1693, DOI 10.1590/S0102-311X2010000900003; Ximenes RAD, 2009, INT J EPIDEMIOL, V38, P1285, DOI 10.1093/ije/dyp224; de Araujo JA, 2008, BRAZ J INFECT DIS, V12, P447, DOI 10.1590/S1413-86702008000500019; Moraes José Cássio de, 2005, Cad. Saúde Pública, V21, P1458, DOI 10.1590/S0102-311X2005000500019; de Quadros CA, 2000, INFECT DIS CLIN N AM, V14, P241, DOI 10.1016/S0891-5520(05)70226-9; Souza Márcia Beatriz de, 2006, J. bras. pneumol., V32, P430, DOI 10.1590/S1806-37132006000500010; Degallier N, 2009, REV SAUDE PUBL, V43, P1, DOI 10.1590/S0034-89102009000100001; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; do Amaral RS, 2006, MEM I OSWALDO CRUZ, V101, P79, DOI 10.1590/S0074-02762006000900012; Donalisio Maria Rita, 2007, Cad. Saúde Pública, V23, P494, DOI 10.1590/S0102-311X2007000300001; Donalisio MR, 2008, CAD SAUDE PUBLICA, V24, P1141, DOI 10.1590/S0102-311X2008000500021; Dourado I, 2007, CAD SAUDE PUBLICA, V23, P25, DOI 10.1590/S0102-311X2007000100004; Drumond João Augusto Guimarães, 2006, Cad. Saúde Pública, V22, P2131, DOI 10.1590/S0102-311X2006001000019; Dujardin JC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000780; Echevarría José M., 2003, Cad. Saúde Pública, V19, P1583, DOI 10.1590/S0102-311X2003000600003; Penna MLF, 2009, LEPROSY REV, V80, P332; Ferrer SR, 2008, INT J EPIDEMIOL, V37, P805, DOI 10.1093/ije/dyn093; Figueiredo MAA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000699; Fl Bastos, 2008, PUBLIC HLTH ASPECTS, P629, DOI DOI 10.1007/978-0-387-72711-0_29; Francisco PMSB, 2005, REV SAUDE PUBL, V39, P75, DOI 10.1590/S0034-89102005000100010; FUNDACAO IBGE, SER EST SER HIST; Gerolomo M., 1999, INFORME EPID SUS, V8, P49; Gontijo Célia Maria Ferreira, 2004, Rev. bras. epidemiol., V7, P338; Grangeiro A, 2010, REV SAUDE PUBL, V44, P430, DOI 10.1590/S0034-89102010005000013; Guimarães Jorge A., 2004, Ciênc. saúde coletiva, V9, P303, DOI 10.1590/S1413-81232004000200009; Guthmann JP, 1995, J TROP MED HYG, V98, P419; Hacker MA, 2009, HEALTH PLACE, V15, P514, DOI 10.1016/j.healthplace.2008.09.011; Hill DL, 2004, LATIN AM SHOWS RAPID; Hoffmann R NM, 2008, ECONOMICA, V10, P7; Inciardi JA, 2006, J PSYCHOACTIVE DRUGS, V38, P305, DOI 10.1080/02791072.2006.10399856; Katsuragawa Tony Hiroshi, 2008, Estud. av., V22, P111, DOI 10.1590/S0103-40142008000300008; Katz N, 2000, Rev Soc Bras Med Trop, V33, P303, DOI 10.1590/S0037-86822000000300009; Kerr-Pontes LRS, 2004, INT J EPIDEMIOL, V33, P262, DOI 10.1093/ije/dyh002; KERRPONTES LRS, 1991, REV SAUDE PUBL, V25, P375, DOI 10.1590/S0034-89101991000500009; Loiola Carlos Catão Prates, 2002, Rev Panam Salud Publica, V11, P235, DOI 10.1590/S1020-49892002000400005; Luna EJA, 2009, VACCINE, V27, P5326, DOI 10.1016/j.vaccine.2009.06.096; Maia-Elkhoury ANS, 2008, CAD SAUDE PUBLICA, V24, P2941, DOI 10.1590/S0102-311X2008001200024; Malta M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-317; Martelli Celina Maria Turchi, 2002, Rev. bras. epidemiol., V5, P273; Massad E, 2008, EPIDEMIOL INFECT, V136, P1153, DOI 10.1017/S0950268807009879; Mast Eric E., 2006, Morbidity and Mortality Weekly Report, V55, P1; Matida LH, 2009, PEDIATR INFECT DIS J, V28, P920, DOI 10.1097/INF.0b013e3181a81b5d; de Farias LMM, 2007, CAD SAUDE PUBLICA, V23, P235, DOI 10.1590/S0102-311X2007000100025; Ministerio da Saude, NOT TECN CGPNCD DEVE; Ministerio da Saude, SER HIST CAS COL; [Ministerio da Saude (Brasil) Secretaria de Vigilancia em Saude], 2009, FEBR AM ASP EP; Ministerio da Saude (Brasil), 2009, PROT CLIN DIR TER TR; Ministerio da Saude (Brasil), 2008, VIG SAUD SIT EP HANS; Ministerio da Saude (Brasil), SER HIST TAX MORT TU; Ministerio da Saude Brasil, COINF HIV TB RESP NA; Ministerio da Saude Brasil, 1999, PORT 1 399 15 DEZ 19; Ministerio da Saude Brasil. Secretaria de Vigilancia em Sande. Departamento de Vigilancia Epidemiologica, 2009, GUI VIG EP; Ministerio da Saude (Brasil) Secretaria de Vigilancia em Saude, 2009, INFL H1N1 INF EP 2; Ministerio da Saude Brasil. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Epidemiologica. Programa Nacional de Controle da Tuberculose, NOT TECN MUD TRAT TU; Ministerio da Saude Brasil. Secretaria de Vigilancia em Saude. Programs Nacional de Controle da Tuberculose, 2010, PROGR NAC CONTR TUB; Ministerio da Saude (Brasil) SINAN (Sistema Nacional de Agravos de Notificacao), TAX IC TUB; Ministerio da Saude (Brazil), PROGR NAC IM; Ministerio da Saude Hanseniase (Brasil), INF TECN; Ministerio da Saude. Secretaria de Vigilancia em Saude, SECR VIG SAUD; Ministry of Health Brazil, 2006, FLOWS FIN RES HLTH R; Moncayo A, 2009, MEM I OSWALDO CRUZ, V104, P17, DOI 10.1590/S0074-02762009000900005; MONTEIRO CA, 1982, REV SAUDE PUBL, V16, P7, DOI 10.1590/S0034-89101982000100002; Lemos ACM, 2009, J BRAS PNEUMOL, V35, P63, DOI 10.1590/S1806-37132009000100009; Morel CM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000501; NEWTON EAC, 1992, AM J TROP MED HYG, V47, P709, DOI 10.4269/ajtmh.1992.47.709; Nunn AS, 2007, PLOS MED, V4, P1804, DOI 10.1371/journal.pmed.0040305; Olive JM, 1997, J INFECT DIS, V175, pS189, DOI 10.1093/infdis/175.Supplement_1.S189; OLIVEIRA LHS, 1991, REV MICROBIOL, V22, P226; Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115; Ooi EE, 2006, EMERG INFECT DIS, V12, P887, DOI 10.3201/eid1206.051210; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16; Penna G, 2009, EMERG INFECT DIS, V15, P626, DOI 10.3201/eid1504.081329; Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240; Dias JCP, 2009, MEM I OSWALDO CRUZ, V104, P41, DOI 10.1590/S0074-02762009000900007; Prade SS., 1995, REV CONTROLE INFECCA, V2, P11; Prata A, 2001, Lancet Infect Dis, V1, P92, DOI 10.1016/S1473-3099(01)00065-2; Programa Nacional de DST/AIDS Programa Nacional de Controls da Tuberculose, IMPL TEST RAP COM DI; Moreno ACR, 2010, DIAGN MICR INFEC DIS, V66, P50, DOI 10.1016/j.diagmicrobio.2008.03.017; Rasella D, 2010, PEDIATRICS, V126, pE534, DOI 10.1542/peds.2009-3197; Regalado A, 2010, SCIENCE, V330, P1306, DOI 10.1126/science.330.6009.1306; Reis CT, 2008, CAD SAUDE PUBLICA, V24, P1219, DOI 10.1590/S0102-311X2008000600003; Ribeiro GS, 2007, VACCINE, V25, P4420, DOI 10.1016/j.vaccine.2007.03.024; Riley Lee W, 2007, BMC Int Health Hum Rights, V7, P2, DOI 10.1186/1472-698X-7-2; Salomao R, 2008, REV PANAM SALUD PUBL, V24, P195, DOI 10.1590/S1020-49892008000900006; Sanchez A, 2009, INT J TUBERC LUNG D, V13, P1247; Sanchez AR, 2007, CAD SAUDE PUBLICA, V23, P545, DOI 10.1590/S0102-311X2007000300013; Santo AH, 2009, REV PANAM SALUD PUBL, V26, P299; Santos Joseney, 2007, Rev. Saúde Pública, V41, P89, DOI [10.1590/S0034-89102007000800012, 10.1590/s0034-89102007000800012]; Sastry N, 2005, SOC SCI MED, V60, P923, DOI 10.1016/j.socscimed.2004.06.051; Scatena Lúcia Marina, 2009, Rev. Saúde Pública, V43, P389, DOI 10.1590/S0034-89102009005000022; Schramm Joyce Mendes de Andrade, 2004, Ciênc. saúde coletiva, V9, P897, DOI 10.1590/S1413-81232004000400011; Secretaria Nacional de Seguranca Pnblica, RED INFOSEG BRAS OIT; Silva L. J., 1986, Cadernos de Saude Publica, V2, P124, DOI 10.1590/S0102-311X1986000200002; Silva LJ, 2001, CAD SAUDE PUBLICA S1, V17, pS141; Silva LK, 2010, EUR J HUM GENET, V18, P1221, DOI 10.1038/ejhg.2010.98; Silveira Antonio Carlos, 1998, Revista da Sociedade Brasileira de Medicina Tropical, V31, P15; Situacao da Tuberculose no Brasil, PROGR NAC CONTR TUB; Sociedade Brasileira de Pneumologia e Tisiologia, 2007, J Bras Pneumol, V33 Suppl 1, pS1; Stoddard ST, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000481; Tatem AJ, 2006, P NATL ACAD SCI USA, V103, P6242, DOI 10.1073/pnas.0508391103; Tauil PL, 2006, REV SOC BRAS MED TRO, V39, P275, DOI 10.1590/S0037-86822006000300010; Teixeira Maria da Glória, 2005, Cad. Saúde Pública, V21, P1307, DOI 10.1590/S0102-311X2005000500002; Teixeira MG, 2009, CAD SAUDE PUBLICA, V25, pS7, DOI 10.1590/S0102-311X2009001300002; Teixeira MD, 2002, TROP MED INT HEALTH, V7, P757, DOI 10.1046/j.1365-3156.2002.00930.x; Teixeira-Rocha ES, 2005, REV PANAM SALUD PUBL, V18, P21, DOI 10.1590/S1020-49892005000600004; Toledo LM, 1993, INFORM EPIDEMIOLOGIC, V2, P8; Transparencia Publica, EX ORC; Veloso VG, 2010, REV SAUDE PUBL, V44, P803, DOI 10.1590/S0034-89102010005000034; Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808; Victora CG, 2011, LANCET, V377, P1863, DOI 10.1016/S0140-6736(11)60138-4; Victora CG, 1996, HEALTH POLICY PLANN, V11, P132, DOI 10.1093/heapol/11.2.132; Vitral CL, 2008, J VIRAL HEPATITIS, V15, P22, DOI 10.1111/j.1365-2893.2008.01024.x; Vitral CL, 1998, MEM I OSWALDO CRUZ, V93, P1, DOI 10.1590/S0074-02761998000100001; WALDMAN E., 2001, REV USP, V51, P128; Wasley A, 2006, EPIDEMIOL REV, V28, P101, DOI 10.1093/epirev/mxj012; Werneck GL, 2008, CAD SAUDE PUBLICA, V24, P2937, DOI 10.1590/S0102-311X2008001200023	154	200	225	3	56	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2011	377	9780					1877	1889		10.1016/S0140-6736(11)60202-X	http://dx.doi.org/10.1016/S0140-6736(11)60202-X			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	774UI	21561657	Green Published			2022-12-28	WOS:000291411700034
J	Zhao, TB; Zhang, ZN; Rong, ZL; Xu, Y				Zhao, Tongbiao; Zhang, Zhen-Ning; Rong, Zhili; Xu, Yang			Immunogenicity of induced pluripotent stem cells	NATURE			English	Article							GENERATION; FIBROBLASTS; EXPRESSION	Induced pluripotent stem cells (iPSCs), reprogrammed from somatic cells with defined factors, hold great promise for regenerative medicine as the renewable source of autologous cells(1-5). Whereas it has been generally assumed that these autologous cells should be immune-tolerated by the recipient from whom the iPSCs are derived, their immunogenicity has not been vigorously examined. We show here that, whereas embryonic stem cells (ESCs) derived from inbred C57BL/6 (B6) mice can efficiently form teratomas in B6 mice without any evident immune rejection, the allogeneic ESCs from 129/SvJ mice fail to form teratomas in B6 mice due to rapid rejection by recipients. B6 mouse embryonic fibroblasts (MEFs) were reprogrammed into iPSCs by either retroviral approach (ViPSCs) or a novel episomal approach (EiPSCs) that causes no genomic integration. In contrast to B6 ESCs, teratomas formed by B6 ViPSCs were mostly immune-rejected by B6 recipients. In addition, the majority of teratomas formed by B6 EiPSCs were immunogenic in B6 mice with T cell infiltration, and apparent tissue damage and regression were observed in a small fraction of teratomas. Global gene expression analysis of teratomas formed by B6 ESCs and EiPSCs revealed a number of genes frequently over-expressed in teratomas derived from EiPSCs, and several such gene products were shown to contribute directly to the immunogenicity of the B6 EiPSC-derived cells in B6 mice. These findings indicate that, in contrast to derivatives of ESCs, abnormal gene expression in some cells differentiated from iPSCs can induce T-cell-dependent immune response in syngeneic recipients. Therefore, the immunogenicity of therapeutically valuable cells derived from patient-specific iPSCs should be evaluated before any clinical application of these autologous cells into the patients.	[Zhao, Tongbiao; Zhang, Zhen-Ning; Rong, Zhili; Xu, Yang] Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu	liang, yan/H-3894-2011; Rong, Zhili/H-7561-2014; Zhao, Tongbiao/C-5761-2011	Rong, Zhili/0000-0002-1699-7074; Zhao, Tongbiao/0000-0003-1429-5818; Zhang, Zhen-Ning/0000-0003-3798-7104; Xu, Yang/0000-0001-5574-921X	NIH; California Institute for Regenerative Medicine [ET-01277]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine)	We thank M. Abe, S. Ding and K. Hochedlinger for their generous supply of integration-free mouse iPSCs. We thank N. Shastri for his advice on how to identify antigen-specific T cells. We thank J. Fink and Blue Lake of Xu laboratory as well as UCSD Cancer Center pathologic core for technical support. This work was supported by a NIH grant and an Early Translational Award from California Institute for Regenerative Medicine to Y.X. (ET-01277).	Chen Yao-Tseng, 2005, Cancer Immun, V5, P9; Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008; Dhodapkar KM, 2010, P NATL ACAD SCI USA, V107, P8718, DOI 10.1073/pnas.0915086107; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Jincho Y, 2010, J BIOL CHEM, V285, P26384, DOI 10.1074/jbc.M110.115915; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; Kont V, 2008, MOL IMMUNOL, V45, P25, DOI 10.1016/j.molimm.2007.05.014; Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798; Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Song H, 2010, CELL STEM CELL, V6, P80, DOI 10.1016/j.stem.2009.11.016; Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhao TBA, 2010, TRENDS CELL BIOL, V20, P170, DOI 10.1016/j.tcb.2009.12.004; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005	23	1002	1053	3	256	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2011	474	7350					212	U251		10.1038/nature10135	http://dx.doi.org/10.1038/nature10135			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	774PE	21572395	Green Published			2022-12-28	WOS:000291397800050
J	Borhani, DW				Borhani, David W.			Comment on "A Bacterium That Can Grow by Using Arsenic Instead of Phosphorus"	SCIENCE			English	Editorial Material												david.borhani@alum.mit.edu	Borhani, David/O-2692-2019	Borhani, David/0000-0002-8486-8792				WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; Wolfe-Simon F, 2011, SCIENCE, V332, P1163, DOI 10.1126/science.1197258	2	12	13	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2011	332	6034								10.1126/science.1201255	http://dx.doi.org/10.1126/science.1201255			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	772BO	21622711				2022-12-28	WOS:000291205200024
J	Ioannidis, JPA; Panagiotou, OA				Ioannidis, John P. A.; Panagiotou, Orestis A.			Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-HEART-DISEASE; HELICOBACTER-PYLORI INFECTION; PROSTATE-CANCER RISK; C-REACTIVE PROTEIN; GROWTH-FACTOR-I; PLATELET GLYCOPROTEIN RECEPTOR; TYPE-2 DIABETES-MELLITUS; LYMPHOTOXIN-ALPHA GENE; BREAST-CANCER; MYOCARDIAL-INFARCTION	Context Many biomarkers are proposed in highly cited studies as determinants of disease risk, prognosis, or response to treatment, but few eventually transform clinical practice. Objective To examine whether the magnitude of the effect sizes of biomarkers proposed in highly cited studies is accurate or overestimated. Data Sources We searched ISI Web of Science and MEDLINE until December 2010. Study Selection We included biomarker studies that had a relative risk presented in their abstract. Eligible articles were those that had received more than 400 citations in the ISI Web of Science and that had been published in any of 24 highly cited biomedical journals. We also searched MEDLINE for subsequent meta-analyses on the same associations (same biomarker and same outcome). Data Extraction In the highly cited studies, data extraction was focused on the disease/outcome, biomarker under study, and first reported relative risk in the abstract. From each meta-analysis, we extracted the overall relative risk and the relative risk in the largest study. Data extraction was performed independently by 2 investigators. Results We evaluated 35 highly cited associations. For 30 of the 35 (86%), the highly cited studies had a stronger effect estimate than the largest study; for 3 the largest study was also the highly cited study; and only twice was the effect size estimate stronger in the largest than in the highly cited study. For 29 of the 35 (83%) highly cited studies, the corresponding meta-analysis found a smaller effect estimate. Only 15 of the associations were nominally statistically significant based on the largest studies, and of those only 7 had a relative risk point estimate greater than 1.37. Conclusion Highly cited biomarker studies often report larger effect estimates for postulated associations than are reported in subsequent meta-analyses evaluating the same associations. JAMA. 2011;305(21):2200-2210 www.jama.com	[Ioannidis, John P. A.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; [Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; [Ioannidis, John P. A.; Panagiotou, Orestis A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece	Stanford University; Stanford University; University of Ioannina	Ioannidis, JPA (corresponding author), Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Med Sch Off Bldg,Room X306,251 Campus Dr, Stanford, CA 94305 USA.	jioannid@stanford.edu	Panagiotou, Orestis A/I-5934-2015; Panagiotou, Orestis/AAI-1268-2021; Ioannidis, John P. A./G-9836-2011	Panagiotou, Orestis A/0000-0001-9604-8380; 				Adamu MA, 2010, EUR J EPIDEMIOL, V25, P439, DOI 10.1007/s10654-010-9482-0; Agerholm-Larsen B, 2000, ARTERIOSCL THROM VAS, V20, P484, DOI 10.1161/01.ATV.20.2.484; AgerholmLarsen B, 1997, CIRCULATION, V95, P2358, DOI 10.1161/01.CIR.95.10.2358; Altman DG, 2001, BMJ-BRIT MED J, V323, P224, DOI 10.1136/bmj.323.7306.224; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159; BLASER MJ, 1995, CANCER RES, V55, P2111; Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; Clarke R, 2006, PLOS GENET, V2, P990, DOI 10.1371/journal.pgen.0020107; Cleophas TJ, 2000, AM J CARDIOL, V86, P1005, DOI 10.1016/S0002-9149(00)01137-1; Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Den Heijer M, 2005, J THROMB HAEMOST, V3, P292, DOI 10.1111/j.1538-7836.2005.01141.x; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Di Castelnuovo A, 2001, THROMB HAEMOSTASIS, V85, P626; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Eckman MH, 2009, ANN INTERN MED, V150, P73, DOI 10.7326/0003-4819-150-2-200901200-00005; Edwards SM, 1999, INT J CANCER, V84, P458, DOI 10.1002/(SICI)1097-0215(19991022)84:5<458::AID-IJC2>3.0.CO;2-Y; Egger M, 1998, BRIT MED J, V316, P140; Emmerich J, 2001, THROMB HAEMOSTASIS, V86, P809; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Eslick GD, 1999, AM J GASTROENTEROL, V94, P2373, DOI 10.1111/j.1572-0241.1999.01360.x; Evans HS, 2001, BRIT J CANCER, V84, P435, DOI 10.1054/bjoc.2000.1603; Fock KM, 2009, J GASTROEN HEPATOL, V24, P1587, DOI 10.1111/j.1440-1746.2009.05982.x; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; Friedenson Bernard, 2005, MedGenMed, V7, P60; Garcia-Closas M, 2005, LANCET, V366, P649, DOI 10.1016/S0140-6736(05)67137-1; Gardemann A, 1998, THROMB HAEMOSTASIS, V80, P214; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Gohil R, 2009, THROMB HAEMOSTASIS, V102, P360, DOI 10.1160/TH09-01-0013; Gouda HN, 2010, AM J EPIDEMIOL, V171, P645, DOI 10.1093/aje/kwp450; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; Greenberg Steven A, 2009, BMJ, V339, pb2680, DOI 10.1136/bmj.b2680; Greenland S, 2005, J R STAT SOC A STAT, V168, P267, DOI 10.1111/j.1467-985X.2004.00349.x; Hackam DG, 2003, JAMA-J AM MED ASSOC, V290, P932, DOI 10.1001/jama.290.7.932; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010; Higashi MK, 2002, JAMA-J AM MED ASSOC, V287, P1690, DOI 10.1001/jama.287.13.1690; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; Hlatky Mark A, 2009, Circulation, V119, P2408, DOI 10.1161/CIRCULATIONAHA.109.192278; Huang JQ, 2003, GASTROENTEROLOGY, V125, P1636, DOI 10.1053/j.gastro.2003.08.033; Humphrey LL, 2008, MAYO CLIN PROC, V83, P1203, DOI 10.4065/83.11.1203; Ioannidis JPA, 2008, EPIDEMIOLOGY, V19, P640, DOI 10.1097/EDE.0b013e31818131e7; Ioannidis JPA, 2010, JAMA-J AM MED ASSOC, V303, P1646, DOI 10.1001/jama.2010.503; Ioannidis JPA, 2009, ANN INTERN MED, V150, P139, DOI 10.7326/0003-4819-150-2-200901200-00012; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304; Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7; Kavvoura FK, 2007, PLOS MED, V4, P456, DOI 10.1371/journal.pmed.0040079; Key TJ, 2010, LANCET ONCOL, V11, P530, DOI 10.1016/S1470-2045(10)70095-4; Kimber CH, 2007, DIABETOLOGIA, V50, P1186, DOI 10.1007/s00125-007-0661-9; Kjaergard LL, 2002, J CLIN EPIDEMIOL, V55, P407, DOI 10.1016/S0895-4356(01)00513-3; KUIPERS EJ, 1995, LANCET, V345, P1525, DOI 10.1016/S0140-6736(95)91084-0; Kyzas PA, 2005, JNCI-J NATL CANCER I, V97, P1043, DOI 10.1093/jnci/dji184; Kyzas PA, 2007, EUR J CANCER, V43, P2559, DOI 10.1016/j.ejca.2007.08.030; Kyzas PA, 2007, JNCI-J NATL CANCER I, V99, P236, DOI 10.1093/jnci/djk032; Leitich H, 2007, BEST PRACT RES CL OB, V21, P375, DOI 10.1016/j.bpobgyn.2006.12.005; Li WL, 2010, ATHEROSCLEROSIS, V208, P433, DOI 10.1016/j.atherosclerosis.2009.08.014; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; Lopez-Cervantes M, 2004, ENVIRON HEALTH PERSP, V112, P207, DOI [10.1289/ehp.6492, 10.1289/ehp.112-1241830]; Ma J, 1997, CANCER RES, V57, P1098; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Margaglione M, 2000, THROMB HAEMOSTASIS, V84, P775; MEIS PJ, 1995, AM J OBSTET GYNECOL, V173, P1231, DOI 10.1016/0002-9378(95)91360-2; Millikan R, 2000, CANCER EPIDEM BIOMAR, V9, P1233; Moller L F, 1995, J Cardiovasc Risk, V2, P235; Moons KGM, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b606; Moons KGM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b375; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Ozasa K, 1999, DIGEST DIS SCI, V44, P253, DOI 10.1023/A:1026633913154; Pallares R, 2002, AM J MED, V113, P120, DOI 10.1016/S0002-9343(02)01162-2; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Pischon T, 2004, JAMA-J AM MED ASSOC, V291, P1730, DOI 10.1001/jama.291.14.1730; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Rifai N, 2008, CLIN CHEM, V54, P1101, DOI 10.1373/clinchem.2008.108993; Riley R D, 2003, Health Technol Assess, V7, P1; Rinaldi S, 2006, ENDOCR-RELAT CANCER, V13, P593, DOI 10.1677/erc.1.01150; Rinaldi S, 2010, INT J CANCER, V126, P1702, DOI 10.1002/ijc.24927; Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353; Ross D, 1996, BRIT MED J, V313, P686; Rowlands MA, 2009, INT J CANCER, V124, P2416, DOI 10.1002/ijc.24202; Ruige JB, 1998, CIRCULATION, V97, P996; Salanti G, 2009, J CLIN EPIDEMIOL, V62, P115, DOI 10.1016/j.jclinepi.2008.05.014; Sanderson S, 2005, GENET MED, V7, P97, DOI 10.1097/01.GIM.0000153664.65759.CF; Sattar N, 2006, CIRCULATION, V114, P623, DOI 10.1161/CIRCULATIONAHA.106.618918; Schinkel J, 2004, ANTIVIR THER, V9, P275; Severi G, 2006, CANCER EPIDEM BIOMAR, V15, P1137, DOI 10.1158/1055-9965.EPI-05-0823; SIPPONEN P, 1994, SCAND J GASTROENTERO, V29, P336, DOI 10.3109/00365529409094845; Siris ES, 2001, JAMA-J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Stehouwer CDA, 1998, ARTERIOSCL THROM VAS, V18, P1895, DOI 10.1161/01.ATV.18.12.1895; Taioli E, 2009, AM J EPIDEMIOL, V170, P1207, DOI 10.1093/aje/kwp275; Thompson S, 2011, INT J EPIDEMIOL, V40, P765, DOI 10.1093/ije/dyq248; Tleyjeh IM, 2006, CLIN INFECT DIS, V42, P788, DOI 10.1086/500140; Tong Y, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-15; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; Tsai AW, 2003, AM J HEMATOL, V72, P192, DOI 10.1002/ajh.10287; Tzoulaki I, 2009, JAMA-J AM MED ASSOC, V302, P2345, DOI 10.1001/jama.2009.1757; Ulvik A, 2004, CANCER EPIDEM BIOMAR, V13, P2175; Vasan RS, 2006, CIRCULATION, V113, P2335, DOI 10.1161/CIRCULATIONAHA.104.482570; Vergouwe Yvonne, 2002, Semin Urol Oncol, V20, P96, DOI 10.1053/suro.2002.32521; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; Wu AH, 2003, INT J CANCER, V103, P815, DOI 10.1002/ijc.10887; Zeegers MP, 2004, CANCER EPIDEM BIOMAR, V13, P1765; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364	123	186	190	1	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2200	2210		10.1001/jama.2011.713	http://dx.doi.org/10.1001/jama.2011.713			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21632484				2022-12-28	WOS:000291106300023
J	Schindler, P; Barreiro, JT; Monz, T; Nebendahl, V; Nigg, D; Chwalla, M; Hennrich, M; Blatt, R				Schindler, Philipp; Barreiro, Julio T.; Monz, Thomas; Nebendahl, Volckmar; Nigg, Daniel; Chwalla, Michael; Hennrich, Markus; Blatt, Rainer			Experimental Repetitive Quantum Error Correction	SCIENCE			English	Article							COMPUTATION; COMPUTERS; CODES; IONS	The computational potential of a quantum processor can only be unleashed if errors during a quantum computation can be controlled and corrected for. Quantum error correction works if imperfections of quantum gate operations and measurements are below a certain threshold and corrections can be applied repeatedly. We implement multiple quantum error correction cycles for phase-flip errors on qubits encoded with trapped ions. Errors are corrected by a quantum-feedback algorithm using high-fidelity gate operations and a reset technique for the auxiliary qubits. Up to three consecutive correction cycles are realized, and the behavior of the algorithm for different noise environments is analyzed.	[Schindler, Philipp; Barreiro, Julio T.; Monz, Thomas; Nigg, Daniel; Chwalla, Michael; Hennrich, Markus; Blatt, Rainer] Univ Innsbruck, Inst Expt Phys, A-6020 Innsbruck, Austria; [Nebendahl, Volckmar] Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria; [Chwalla, Michael; Blatt, Rainer] Austrian Acad Sci, Inst Quantenopt & Quanteninformat, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck; Austrian Academy of Sciences	Hennrich, M (corresponding author), Univ Innsbruck, Inst Expt Phys, Technikerstr 25, A-6020 Innsbruck, Austria.	markus.hennrich@uibk.ac.at	Barreiro, Julio T/P-2540-2018; Monz, Thomas/E-1285-2017; Schindler, Philipp/E-1485-2017; Hennrich, Markus/D-2475-2009; Schindler, Philipp/AAB-4803-2019; Blatt, Rainer/H-9527-2014	Barreiro, Julio T/0000-0002-1957-8211; Schindler, Philipp/0000-0002-9461-9650; Hennrich, Markus/0000-0003-2955-7980; Schindler, Philipp/0000-0002-9461-9650; Monz, Thomas/0000-0001-7410-4804	Austrian Science Fund (FWF); European Commission; Institut fur Quanteninformation GmbH; European Research Council; Intelligence Advanced Research Projects Activity; European Community; Austrian Science Fund (FWF) [P 20748] Funding Source: researchfish	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); European Commission(European CommissionEuropean Commission Joint Research Centre); Institut fur Quanteninformation GmbH; European Research Council(European Research Council (ERC)European Commission); Intelligence Advanced Research Projects Activity; European Community(European Commission); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank C. F. Roos for helpful discussions and R. Gerritsma, G. Paz-Silva, G. Brennen, and J. Twamley for carefully reading the manuscript. We gratefully acknowledge support by the Austrian Science Fund (FWF), by the European Commission [Scalable Quantum Computing with Light and Atoms (SCALA) and Atomic Quantum Technologies (AQUTE) projects], by the Institut fur Quanteninformation GmbH, and by the European Research Council. This material is based on work supported in part by the Intelligence Advanced Research Projects Activity. J. T. B. acknowledges support by a Marie Curie International Incoming Fellowship within the 7th European Community Framework Programme.	Aoki T, 2009, NAT PHYS, V5, P541, DOI 10.1038/NPHYS1309; Benhelm J, 2008, NAT PHYS, V4, P463, DOI 10.1038/nphys961; Boulant N, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.130501; Calderbank AR, 1996, PHYS REV A, V54, P1098, DOI 10.1103/PhysRevA.54.1098; Chiaverini J, 2004, NATURE, V432, P602, DOI 10.1038/nature03074; Cory DG, 1998, PHYS REV LETT, V81, P2152, DOI 10.1103/PhysRevLett.81.2152; DiVincenzo DP, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.020501; Khodjasteh K, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.090501; Knill E, 2001, PHYS REV LETT, V86, P5811, DOI 10.1103/PhysRevLett.86.5811; Lidar DA, 1998, PHYS REV LETT, V81, P2594, DOI 10.1103/PhysRevLett.81.2594; Monz T, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.040501; Monz T, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.130506; Nebendahl V, 2009, PHYS REV A, V79, DOI 10.1103/PhysRevA.79.012312; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Paz-Silva GA, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.100501; Pittman TB, 2005, PHYS REV A, V71, DOI 10.1103/PhysRevA.71.052332; Preskill J, 1998, P ROY SOC A-MATH PHY, V454, P385, DOI 10.1098/rspa.1998.0167; Riebe M, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.220407; Riebe M, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/7/211; Schmidt-Kaler F, 2004, EUROPHYS LETT, V65, P587, DOI 10.1209/epl/i2003-10174-3; Steane A, 1996, P ROY SOC A-MATH PHY, V452, P2551, DOI 10.1098/rspa.1996.0136; Zanardi P, 1997, PHYS REV LETT, V79, P3306, DOI 10.1103/PhysRevLett.79.3306	25	215	219	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2011	332	6033					1059	1061		10.1126/science.1203329	http://dx.doi.org/10.1126/science.1203329			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769FN	21617070				2022-12-28	WOS:000290996700037
J	Duncan, PW; Sullivan, KJ; Behrman, AL; Azen, SP; Wu, SS; Nadeau, SE; Dobkin, BH; Rose, DK; Tilson, JK; Cen, S; Hayden, SK				Duncan, Pamela W.; Sullivan, Katherine J.; Behrman, Andrea L.; Azen, Stanley P.; Wu, Samuel S.; Nadeau, Stephen E.; Dobkin, Bruce H.; Rose, Dorian K.; Tilson, Julie K.; Cen, Steven; Hayden, Sarah K.		LEAPS Investigative Team	Body-Weight-Supported Treadmill Rehabilitation after Stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBACUTE-STROKE; MOTOR RECOVERY; 6-MINUTE WALK; EXERCISE; INDIVIDUALS; LOCOMOTOR; BALANCE; FALLS; SPEED; GAIT	BACKGROUND Locomotor training, including the use of body-weight support in treadmill stepping, is a physical therapy intervention used to improve recovery of the ability to walk after stroke. The effectiveness and appropriate timing of this intervention have not been established. METHODS We stratified 408 participants who had had a stroke 2 months earlier according to the extent of walking impairment - moderate (able to walk 0.4 to <0.8 m per second) or severe (able to walk <0.4 m per second) - and randomly assigned them to one of three training groups. One group received training on a treadmill with the use of body-weight support 2 months after the stroke had occurred (early locomotor training), the second group received this training 6 months after the stroke had occurred (late locomotor training), and the third group participated in an exercise program at home managed by a physical therapist 2 months after the stroke (home-exercise program). Each intervention included 36 sessions of 90 minutes each for 12 to 16 weeks. The primary outcome was the proportion of participants in each group who had an improvement in functional walking ability 1 year after the stroke. RESULTS At 1 year, 52.0% of all participants had increased functional walking ability. No significant differences in improvement were found between early locomotor training and home exercise (adjusted odds ratio for the primary outcome, 0.83; 95% confidence interval [CI], 0.50 to 1.39) or between late locomotor training and home exercise (adjusted odds ratio, 1.19; 95% CI, 0.72 to 1.99). All groups had similar improvements in walking speed, motor recovery, balance, functional status, and quality of life. Neither the delay in initiating the late locomotor training nor the severity of the initial impairment affected the outcome at 1 year. Ten related serious adverse events were reported (occurring in 2.2% of participants undergoing early locomotor training, 3.5% of those undergoing late locomotor training, and 1.6% of those engaging in home exercise). As compared with the home-exercise group, each of the groups receiving locomotor training had a higher frequency of dizziness or faintness during treatment (P=0.008). Among patients with severe walking impairment, multiple falls were more common in the group receiving early locomotor training than in the other two groups (P=0.02). CONCLUSIONS Locomotor training, including the use of body-weight support in stepping on a treadmill, was not shown to be superior to progressive exercise at home managed by a physical therapist. (Funded by the National Institute of Neurological Disorders and Stroke and the National Center for Medical Rehabilitation Research; LEAPS ClinicalTrials.gov number, NCT00243919.)	[Duncan, Pamela W.; Hayden, Sarah K.] Duke Univ, Div Phys Therapy, Dept Community & Family Med, Durham, NC 27705 USA; [Sullivan, Katherine J.; Tilson, Julie K.; Cen, Steven] Univ So Calif, Div Biokinesiol & Phys Therapy, Los Angeles, CA 90089 USA; [Azen, Stanley P.] Univ So Calif, Dept Prevent Med, Div Biostat, Los Angeles, CA 90089 USA; [Dobkin, Bruce H.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Behrman, Andrea L.; Rose, Dorian K.] Univ Florida, Dept Phys Therapy, Gainesville, FL 32611 USA; [Wu, Samuel S.] Univ Florida, Dept Biostat, Gainesville, FL 32611 USA; [Nadeau, Stephen E.] Univ Florida, Dept Neurol, Gainesville, FL 32611 USA; [Nadeau, Stephen E.] Dept Vet Affairs, Gainesville, FL USA	Duke University; University of Southern California; University of Southern California; University of California System; University of California Los Angeles; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Duncan, PW (corresponding author), Duke Univ, Div Phys Therapy, Dept Community & Family Med, 2200 W Main St,Suite B-230, Durham, NC 27705 USA.	pamela.duke@duke.edu		Duncan, Pamela/0000-0002-4838-3253	National Institute of Neurological Disorders and Stroke [RO1 NS050506]; National Center for Medical Rehabilitation Research; National Institutes of Health; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028740] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Center for Medical Rehabilitation Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by the National Institute of Neurological Disorders and Stroke (RO1 NS050506) and the National Center for Medical Rehabilitation Research. The body-weight support treadmill systems and the cost of all study screenings and interventions were supported by funding from the National Institutes of Health.	American Heart Association, 2010, HEART DIS STROK STAT; Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; Batchelor F, 2010, STROKE, V41, P1715, DOI 10.1161/STROKEAHA.109.570390; BERG K, 1995, SCAND J REHABIL MED, V27, P27; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Duncan PW, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-39; DUNCAN PW, 1994, STROKE, V25, P1181, DOI 10.1161/01.STR.25.6.1181; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Eich HJ, 2004, CLIN REHABIL, V18, P640, DOI 10.1191/0269215504cr779oa; Eng JJ, 2002, STROKE, V33, P756, DOI 10.1161/hs0302.104195; FOLSTEIN MF, 1983, ARCH GEN PSYCHIAT, V40, P812; Fulk George D., 2008, Physiotherapy Theory and Practice, V24, P195, DOI 10.1080/09593980701588284; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; Hesse S, 2008, NEUROREHABILITATION, V23, P55; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; Lin KC, 2010, NEUROREHAB NEURAL RE, V24, P486, DOI 10.1177/1545968309356295; Lundebjerg N, 2001, J AM GERIATR SOC, V49, P664, DOI 10.1046/j.1532-5415.2001.49115.x; Macko RF, 2005, STROKE, V36, P2206, DOI 10.1161/01.STR.0000181076.91805.89; Michael KM, 2005, ARCH PHYS MED REHAB, V86, P1552, DOI 10.1016/j.apmr.2004.12.026; MOSELEY AM, 2005, COCHRANE DB SYST REV, V4; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Pohl M, 2002, STROKE, V33, P553, DOI 10.1161/hs0202.102365; Pouwels S, 2009, STROKE, V40, P3281, DOI 10.1161/STROKEAHA.109.554055; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Resnick B, 2001, J Nurs Meas, V9, P275; Rigler SK, 2002, CLIN REHABIL, V16, P420, DOI 10.1191/0269215502cr515oa; Schmid A, 2007, STROKE, V38, P2096, DOI 10.1161/STROKEAHA.106.475921; Sherrington C, 2008, J AM GERIATR SOC, V56, P2234, DOI 10.1111/j.1532-5415.2008.02014.x; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Sullivan KJ, 2002, ARCH PHYS MED REHAB, V83, P683, DOI 10.1053/apmr.2002.32488; Tilson JK, 2010, PHYS THER, V90, P196, DOI 10.2522/ptj.20090079; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Weerdesteyn V, 2008, J REHABIL RES DEV, V45, P1195, DOI 10.1682/JRRD.2007.09.0145; Weinrich M, 2004, NEUROREHAB NEURAL RE, V18, P12, DOI 10.1177/0888439003262041; Williams LS, 2005, STROKE, V36, P635, DOI 10.1161/01.STR.0000155688.18207.33; Yates JS, 2004, J AGING PHYS ACTIV, V12, P64, DOI 10.1123/japa.12.1.64	40	392	400	1	93	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					2026	2036		10.1056/NEJMoa1010790	http://dx.doi.org/10.1056/NEJMoa1010790			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QR	21612471	Green Accepted, Bronze			2022-12-28	WOS:000290952000007
J	Moskovitz, C; Kellogg, D				Moskovitz, Cary; Kellogg, David			Inquiry-Based Writing in the Laboratory Course	SCIENCE			English	Editorial Material							CHEMISTRY; SCIENCE; STUDENTS		[Moskovitz, Cary] Duke Univ, Thompson Writing Program, Durham, NC 27708 USA; [Kellogg, David] Coastal Carolina Univ, Dept English, Conway, SC 29528 USA; [Kellogg, David] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Duke University; Coastal Carolina University; National University of Singapore	Moskovitz, C (corresponding author), Duke Univ, Thompson Writing Program, Durham, NC 27708 USA.	cmosk@duke.edu						Adams DJ, 2009, BIOSCI ED, V13, P1; Alaimo P. J., 2009, WAC J, V20, P17; Braine G., 1989, ENGL SPECIF PURP, V8, P3, DOI [10.1016/0889-4906(89)90003-3, DOI 10.1016/0889-4906(89)90003-3]; Burke KA, 2006, J CHEM EDUC, V83, P1032, DOI 10.1021/ed083p1032; BURKE KA, 2005, PROCESS USING INQUIR; Dunstan M, 1997, J CHEM EDUC, V74, P1067, DOI 10.1021/ed074p1067; Elliott MJ, 2008, J CHEM EDUC, V85, P145, DOI 10.1021/ed085p145; Gragson DE, 2010, J CHEM EDUC, V87, P62, DOI 10.1021/ed800015t; Jackson L, 2006, ENGL SPECIF PURP, V25, P260, DOI 10.1016/j.esp.2005.04.003; Lerner N, 2007, WRIT COMMUN, V24, P191, DOI 10.1177/0741088307302765; *NAT RES COUNC, 1997, INQ NAT SCI ED STAND; National Research Council, 1999, TRANSF UND ED SCI MA; Osborne J, 2010, SCIENCE, V328, P463, DOI 10.1126/science.1183944; Poock JR, 2007, J CHEM EDUC, V84, P1371; Russell D., 1995, RECONCEIVING WRITING, P51; SARKIS VD, 1974, J CHEM EDUC, V51, P745, DOI 10.1021/ed051p745; SWALES J, 1990, GENRE ANAL ENGLISH A, P137	17	45	45	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2011	332	6032					919	920		10.1126/science.1200353	http://dx.doi.org/10.1126/science.1200353			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	766FO	21596978				2022-12-28	WOS:000290766600026
J	Douketis, J				Douketis, James			Apixaban reduced VTE and did not increase major bleeding compared with enoxaparin in hip replacement	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									St Josephs Hosp, Hamilton, ON, Canada	McGill University; McMaster University	Douketis, J (corresponding author), St Josephs Hosp, Hamilton, ON, Canada.		Douketis, James/AAO-5659-2021					Douketis JD, 2010, CURR PHARM DESIGN, V16, P3436; Eriksson BI, 2009, CLIN PHARMACOKINET, V48, P1, DOI 10.2165/0003088-200948010-00001; Frydman A, 1996, HAEMOSTASIS, V26, P24; KEAR, 2008, CHEST, V133, pS454	4	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-7	10.7326/0003-4819-154-10-201105170-02007	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576525				2022-12-28	WOS:000290620300006
J	Langhorne, P; Bernhardt, J; Kwakkel, G				Langhorne, Peter; Bernhardt, Julie; Kwakkel, Gert			Stroke Care 2 Stroke rehabilitation	LANCET			English	Article							WALKING COMPETENCE; RECOVERY; THERAPY; INTERVENTIONS; METAANALYSIS; IMPROVEMENT; INTENSITY; STRENGTH; PROGRAMS; TIME	Stroke is a common, serious, and disabling global health-care problem, and rehabilitation is a major part of patient care. There is evidence to support rehabilitation in well coordinated multidisciplinary stroke units or through provision of early supported provision of discharge teams. Potentially beneficial treatment options for motor recovery of the arm include constraint-induced movement therapy and robotics. Promising interventions that could be beneficial to improve aspects of gait include fitness training, high-intensity therapy, and repetitive-task training. Repetitive-task training might also improve transfer functions. Occupational therapy can improve activities of daily living; however, information about the clinical effect of various strategies of cognitive rehabilitation and strategies for aphasia and dysarthria is scarce. Several large trials of rehabilitation practice and of novel therapies (eg, stem-cell therapy, repetitive transcranial magnetic stimulation, virtual reality, robotic therapies, and drug augmentation) are underway to inform future practice.	[Langhorne, Peter] Univ Glasgow, Royal Infirm, Acad Sect Geriatr Med, Inst Cardiovasc & Med Sci, Glasgow G4 0SF, Lanark, Scotland; [Bernhardt, Julie] Florey Neurosci Inst, Stroke Div, Melbourne, Vic, Australia; [Bernhardt, Julie] La Trobe Univ, Bundoora, Vic, Australia; [Kwakkel, Gert] Vrije Univ Amsterdam Med Ctr, Res Inst MOVE, Dept Rehabil Med, Amsterdam, Netherlands; [Kwakkel, Gert] Univ Med Ctr Utrecht, Rudolf Magnus Inst, Utrecht, Netherlands	Royal Infirmary of Edinburgh; University of Glasgow; Florey Institute of Neuroscience & Mental Health; La Trobe University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Utrecht University; Utrecht University Medical Center	Langhorne, P (corresponding author), Univ Glasgow, Royal Infirm, Acad Sect Geriatr Med, Inst Cardiovasc & Med Sci, Level 4,Walton Bldg, Glasgow G4 0SF, Lanark, Scotland.	peter.langhorne@glasgow.ac.uk	; Bernhardt, Julie/F-9538-2015	Kwakkel, Gert/0000-0002-4041-4043; Bernhardt, Julie/0000-0002-2787-8484	Stroke Association; Chest, Heart and Stroke, Scotland; Wiley	Stroke Association; Chest, Heart and Stroke, Scotland; Wiley	PL has received honoraria and travel expenses for educational conference sessions run by Sanofi-Aventis and Boehringer Ingelheim, grant support from The Stroke Association and Chest, Heart and Stroke, Scotland, and royalties from Wiley. JB and GK declare that they have no conflicts of interest.	Ada L, 2006, AUST J PHYSIOTHER, V52, P241, DOI 10.1016/S0004-9514(06)70003-4; Anderson C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub2; [Anonymous], [No title captured], DOI DOI 10.1002/14651858.CD004129.PUB2; [Anonymous], 2008, NAT CLIN GUID STROK; Aziz NA, 2008, COCHRANE DB SYST REV, V2; BARCLAYGODDARD RE, 2010, COCHRANE DB SYST REV, V1; BATH PM, 1999, COCHRANE DB SYST REV, V2; Beaglehole R., 2003, WORLD HLTH REPORT 20; Bernhardt J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006187.pub2; Boncoraglio GB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007231.pub2; Bonita R, 2004, LANCET NEUROL, V3, P391, DOI 10.1016/S1474-4422(04)00800-2; Borisova Y, 2009, CLIN REHABIL, V23, P681, DOI 10.1177/0269215509334841; BOWEN A, 2008, COCHRANE DB SYST REV, V2; Bowen A, 2007, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003586.PUB2; BRADT J, 2010, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD006787.PUB2; Brady M., 2006, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003864.PUB2; Cherney LR, 2008, J SPEECH LANG HEAR R, V51, P1282, DOI 10.1044/1092-4388(2008/07-0206); COUPAR F, 2007, COCHRANE DB SYST REV, V4; Coupar F., 2010, COCHRANE DB SYST REV, V4; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Doyle S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006331.pub2; Ellis G, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005066.pub2; English C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007513.pub2; Foley N, 2008, AGE AGEING, V37, P258, DOI 10.1093/ageing/afn064; Forster A., 2009, COCHRANE DB SYST REV, V1; Forster A, 2008, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001730.PUB2; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; Govender Paran, 2007, Expert Rev Neurother, V7, P1013, DOI 10.1586/14737175.7.8.1013; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Henderson A, 2007, TOP STROKE REHABIL, V14, P52, DOI 10.1310/tsr1402-52; Hoffmann T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006430.pub2; Hurn J, 2006, CLIN REHABIL, V20, P756, DOI 10.1177/0269215506070793; Kelly H, 2010, COCHRANE DB SYST REV, V5; Kottink AIR, 2004, ARTIF ORGANS, V28, P577, DOI 10.1111/j.1525-1594.2004.07310.x; Kwakkel G, 2004, RESTOR NEUROL NEUROS, V22, P281; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; KWAN J, 2004, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD002924.PUB2; Langhorne P, 2007, J REHABIL MED, V39, P103, DOI 10.2340/16501977-0042; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Langhorne P, 2009, LANCET NEUROL, V8, P308, DOI 10.1016/S1474-4422(09)70060-2; Legg L, 2000, BRIT J THERAPY REHAB, V7, P319; Legg LA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003585.pub2; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Lincoln NB, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002842, DOI 10.1002/14651858.CD002842]; MARTINSSON L, 2007, COCHRANE DB SYST REV, V1; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Mehrholz J, 2008, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD006876.PUB2; Morris SL, 2004, CLIN REHABIL, V18, P27, DOI 10.1191/0269215504cr699oa; MOSELEY AM, 2005, COCHRANE DB SYST REV, V4; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nair RD, 2007, COCHRANE DB SYST REV, V3; National Stroke Foundation, 2010, CLIN GUID STROK MAN; Nijland R, 2010, J REHABIL MED, V42, P694, DOI 10.2340/16501977-0560; Outpatient Service Trialists, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002925; Patterson CJ, 1999, CLIN REHABIL, V13, P101, DOI 10.1191/026921599677096598; Pohl M, 2002, STROKE, V33, P553, DOI 10.1161/hs0202.102365; POLLOCK A, 2007, COCHRANE DB SYST REV, V1; POLLOCK A, 2010, COCHRANE DB SYST REV, V3; Pomeroy V, 2006, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003241.PUB2; Richards LG, 2008, NEUROPSYCHOLOGIA, V46, P3, DOI 10.1016/j.neuropsychologia.2007.08.013; Sackley C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003908.pub3; Saposnik G, 2009, STROKE, V40, P3321, DOI 10.1161/STROKEAHA.109.554907; Saunders DH, 2009, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003316.PUB2; Scottish Intercollegiate Guideline Network, 2010, MAN PAT STROK 591 RE; SELLARS C, 2005, COCHRANE DB SYST REV, V3; Sirtori V, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004433.pub2; Smith J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001919.pub2; States RA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006075.pub2; THIEME H, 2010, COCHRANE DB SYST REV, V4; Thomas LH, 2008, COCHRANE DB SYST REV, V1; TYSON SF, 2009, COCHRANE DB SYST REV, V3; van de Port IGL, 2007, AM J PHYS MED REHAB, V86, P935, DOI 10.1097/PHM.0b013e31802ee464; Van Peppen RPS, 2006, J REHABIL MED, V38, P3, DOI 10.1080/16501970500344902; Wade DT., 1992, MEASUREMENT NEUROLOG; Walker MF, 2004, STROKE, V35, P2226, DOI 10.1161/01.STR.0000137766.17092.fb; Warlow C, 2008, STROKE PRACTICAL MAN; Warsi A, 2004, ARCH INTERN MED, V164, P1641, DOI 10.1001/archinte.164.15.1641; WEST C, 2008, COCHRANE DB SYST REV, V1; West C, 2005, COCHRANE DB SYST REV, V4; Wevers L, 2009, STROKE, V40, P2450, DOI 10.1161/STROKEAHA.108.541946; WHO, 2001, WHO INT CLASS FUNCT; Woodford H, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004585.pub2; WU HM, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004131.PUB2; Zimmermann-Schlatter A, 2008, J NEUROENG REHABIL, V5, DOI 10.1186/1743-0003-5-8	87	1350	1402	37	1095	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	2011	377	9778					1693	1702		10.1016/S0140-6736(11)60325-5	http://dx.doi.org/10.1016/S0140-6736(11)60325-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766JF	21571152				2022-12-28	WOS:000290777700034
J	Wittner, M; Hamperl, S; Stockl, U; Seufert, W; Tschochner, H; Milkereit, P; Griesenbeck, J				Wittner, Manuel; Hamperl, Stephan; Stoeckl, Ulrike; Seufert, Wolfgang; Tschochner, Herbert; Milkereit, Philipp; Griesenbeck, Joachim			Establishment and Maintenance of Alternative Chromatin States at a Multicopy Gene Locus	CELL			English	Article							RIBOSOMAL-RNA GENES; POLYMERASE-I TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; ACTIVE GENES; PROTEIN HMO1; BOX PROTEIN; YEAST; RDNA; UBF	In eukaryotes, each of the more than 100 copies of ribosomal RNA (rRNA) genes exists in either an RNA polymerase I transcribed open chromatin state or a nucleosomal, closed chromatin state. Open rRNA genes guarantee the cell's supply with structural components of the ribosome, whereas closed rRNA genes ensure genomic integrity. We report that the observed balance between open and closed rRNA gene chromatin states in proliferating yeast cells is due to a dynamic equilibrium of transcription-dependent removal and replication-dependent assembly of nucleosomes. Pol I transcription is required for the association of the HMG box protein Hmo1 with open rRNA genes, counteracting replication-independent nucleosome deposition and maintaining the open rRNA gene chromatin state outside of S phase. The findings indicate that the opposing effects of replication and transcription lead to a de novo establishment of chromatin states for rRNA genes during each cell cycle.	[Wittner, Manuel; Hamperl, Stephan; Stoeckl, Ulrike; Tschochner, Herbert; Milkereit, Philipp; Griesenbeck, Joachim] Univ Regensburg, Inst Biochem Genet & Mikrobiol, Lehrstuhl Biochem 3, D-93053 Regensburg, Germany; [Seufert, Wolfgang] Univ Regensburg, Inst Biochem Genet & Mikrobiol, Lehrstuhl Genet, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg	Milkereit, P (corresponding author), Univ Regensburg, Inst Biochem Genet & Mikrobiol, Lehrstuhl Biochem 3, D-93053 Regensburg, Germany.	philipp.milkereit@vkl.uni-regensburg.de; joachim.griesenbeck@vkl.uni-regensburg.de	Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064; Griesenbeck, Joachim/0000-0002-7817-6095; Hamperl, Stephan/0000-0002-1658-7948	DFG research unit [FOR 1068]; Elitenetzwerk Bayern	DFG research unit(German Research Foundation (DFG)); Elitenetzwerk Bayern	We would like to thank Drs. M. Nomura and K. Yankulov for providing yeast strains and plasmids. We are grateful to colleagues at the department of Biochemistry III at the University of Regensburg for discussions. We thank Dr. H. Richter for help with flow cytometric analyses. We acknowledge Drs. A. Conconi and A. Ehrensberger for comments on the manuscript. This work was supported by a grant in the context of the DFG research unit FOR 1068 (J.G.). M. W. received a fellowship of the Elitenetzwerk Bayern.	Bermejo R, 2009, CELL, V138, P870, DOI 10.1016/j.cell.2009.06.022; Birch JL, 2008, BIOCHEM SOC T, V36, P619, DOI 10.1042/BST0360619; Birch JL, 2009, EMBO J, V28, P854, DOI 10.1038/emboj.2009.33; Brown SE, 2008, CELL CYCLE, V7, P382, DOI 10.4161/cc.7.3.5283; Cioci F, 2003, MOL CELL, V12, P135, DOI 10.1016/S1097-2765(03)00262-4; Claypool JA, 2004, MOL BIOL CELL, V15, P946, DOI 10.1091/mbc.E03-08-0594; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; DAMMANN R, 1995, MOL CELL BIOL, V15, P5294; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; DAVIS AH, 1983, J MOL BIOL, V167, P133, DOI 10.1016/S0022-2836(83)80038-2; Fahy D, 2005, EXP CELL RES, V305, P365, DOI 10.1016/j.yexcr.2005.01.016; French SL, 2003, MOL CELL BIOL, V23, P1558, DOI 10.1128/MCB.23.5.1558-1568.2003; Gadal O, 2002, EMBO J, V21, P5498, DOI 10.1093/emboj/cdf539; Gagnon-Kugler T, 2009, MOL CELL, V35, P414, DOI 10.1016/j.molcel.2009.07.008; GebraneYounes J, 1997, J CELL SCI, V110, P2429; Geil C, 2008, CURR BIOL, V18, P1001, DOI 10.1016/j.cub.2008.06.025; Goetze H, 2010, MOL CELL BIOL, V30, P2028, DOI 10.1128/MCB.01512-09; Ide S, 2010, SCIENCE, V327, P693, DOI 10.1126/science.1179044; Kamau E, 2004, J BIOL CHEM, V279, P55234, DOI 10.1074/jbc.M409459200; Kasahara K, 2007, MOL CELL BIOL, V27, P6686, DOI 10.1128/MCB.00876-07; Keener J, 1998, J BIOL CHEM, V273, P33795, DOI 10.1074/jbc.273.50.33795; Lu J, 1996, J BIOL CHEM, V271, P33678, DOI 10.1074/jbc.271.52.33678; Lucchini R, 2001, EMBO J, V20, P7294, DOI 10.1093/emboj/20.24.7294; LUCCHINI R, 1995, NATURE, V374, P276, DOI 10.1038/374276a0; McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259; Merz K, 2008, GENE DEV, V22, P1190, DOI 10.1101/gad.466908; MILLER OL, 1969, SCIENCE, V164, P955, DOI 10.1126/science.164.3882.955; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Nemeth A, 2008, EPIGENETICS-US, V3, P243, DOI 10.4161/epi.3.5.6913; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Philippi A, 2010, NUCL ACIDS RES; Raska I, 2004, BIOL CELL, V96, P579, DOI 10.1016/j.biolcel.2004.04.015; Raska I, 2006, CURR OPIN CELL BIOL, V18, P325, DOI 10.1016/j.ceb.2006.04.008; Sanij E, 2008, J CELL BIOL, V183, P1259, DOI 10.1083/jcb.200805146; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Stancheva I, 1997, NUCLEIC ACIDS RES, V25, P1727, DOI 10.1093/nar/25.9.1727; Stefanovsky V, 2006, MOL CELL, V21, P629, DOI 10.1016/j.molcel.2006.01.023; Tan RZ, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.14; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Yamamoto RT, 1996, EMBO J, V15, P3964, DOI 10.1002/j.1460-2075.1996.tb00770.x	41	55	55	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 13	2011	145	4					543	554		10.1016/j.cell.2011.03.051	http://dx.doi.org/10.1016/j.cell.2011.03.051			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565613	Bronze			2022-12-28	WOS:000290560800008
J	Kraemer, JD; Gostin, LO				Kraemer, John D.; Gostin, Lawrence O.			Vaccine Liability in the Supreme Court Forging a Social Compact	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FDA		[Gostin, Lawrence O.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA; [Kraemer, John D.] Georgetown Univ, Sch Nursing & Hlth Studies, Dept Hlth Syst Adm, Washington, DC 20001 USA	Georgetown University; Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						CDC, 1999, MMWR MORB MORTAL WKL, V48, P243; Gerber JS, 2009, CLIN INFECT DIS, V48, P456, DOI 10.1086/596476; Gostin L., 2008, PUBLIC HLTH LAW POWE; Gostin LO, 2008, JAMA-J AM MED ASSOC, V299, P2313, DOI 10.1001/jama.299.19.2313; Gostin LO, 2009, JAMA-J AM MED ASSOC, V301, P2036, DOI 10.1001/jama.2009.680; Institute of Medicine, 2010, PRIOR NAT VACC PLAN; Offit Paul A., 2011, DEADLY CHOICES ANTIV	7	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2011	305	18					1900	1901		10.1001/jama.2011.615	http://dx.doi.org/10.1001/jama.2011.615			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761YH	21558521				2022-12-28	WOS:000290438800028
J	Herbst, RS; Ansari, R; Bustin, F; Flynn, P; Hart, L; Otterson, GA; Vlahovic, G; Soh, CH; O'Connor, P; Hainsworth, J				Herbst, Roy S.; Ansari, Rafat; Bustin, Frederique; Flynn, Patrick; Hart, Lowell; Otterson, Gregory A.; Vlahovic, Gordana; Soh, Chang-Heok; O'Connor, Paula; Hainsworth, John			Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial	LANCET			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; COMBINATION; MUTATIONS; CARBOPLATIN; PACLITAXEL; GEFITINIB; VANDETANIB	Background Bevacizumab and erlotinib target different tumour growth pathways with little overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial assessing safety and activity of erlotinib plus bevacizumab for recurrent or refractory non-small-cell lung cancer (NSCLC), we aimed to assess efficacy and safety of this combination in a phase 3 trial. Methods In our double-blind, placebo-controlled, randomised phase 3 trial (BeTa), we enrolled patients with recurrent or refractory NSCLC who presented to 177 study sites in 12 countries after failure of first-line treatment. Patients were randomly allocated in a one-to-one ratio to receive erlotinib plus bevacizumab (bevacizumab group) or erlotinib plus placebo (control group) according to a computer-generated randomisation sequence by use of an interactive voice response system. The primary endpoint was overall survival in all enrolled patients. Patients, study staff, and investigators were masked to treatment assignment. We assessed safety by calculation of incidence of adverse events and tissue was collected for biomarker analyses. This trial is registered with ClinicalTrials.gov, number NCT00130728. Findings Overall survival did not differ between 317 controls and 319 patients in the bevacizumab group (hazard ratio [HR] 0.97, 95% CI 0.80-1.18, p=0.7583). Median overall survival was 9.3 months (IQR 4.1-21.6) for patients in the bevacizumab group compared with 9.2 months (3.8-20.2) for controls. Progression-free survival seemed to be longer in the bevacizumab group (3.4 months [1.4-8.4]) than in the control group (1.7 months [1.3-4-1]; HR 0.62, 95% CI 0.52-0.75) and objective response rate suggested some clinical activity of bevacizumab and erlotinib. However, these secondary endpoint differences could not be defined as significant because the study prespecified that the primary endpoint had to be significant before testing of secondary endpoints could be done, to control type I error rate. In the bevacizumab group, 130 (42%) of 313 patients with safety data had a serious adverse event, compared with 114 (36%) controls. There were 20 (6%) grade 5 adverse events, including two arterial thromboembolic events, in the bevacizumab group, and 14 (4%) in the control group. Interpretation Addition of bevacizumab to erlotinib does not improve survival in patients with recurrent or refractory NSCLC.	[Herbst, Roy S.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Ansari, Rafat] Michiana Hematol Oncol, South Bend, IN USA; [Bustin, Frederique] Ctr Hosp Reg Citadelle, Liege, Belgium; [Flynn, Patrick] Minnesota Oncol Hematol PA, Maplewood, MN USA; [Hart, Lowell] Florida Canc Specialists, Ft Myers, FL USA; [Otterson, Gregory A.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA; [Vlahovic, Gordana] Duke Univ, Med Ctr, Durham, NC USA; [Soh, Chang-Heok; O'Connor, Paula] Genentech Inc, San Francisco, CA 94080 USA; [Hainsworth, John] Sarah Cannon Res Inst, Nashville, TN USA	University of Texas System; UTMD Anderson Cancer Center; Florida Cancer Specialists; University System of Ohio; Ohio State University; Duke University; Roche Holding; Genentech; Sarah Cannon Research Institute	Herbst, RS (corresponding author), Yale Canc Ctr, 333 Cedar St,POB 208028, New Haven, CT 06520 USA.	roy.herbst@yale.edu			Genentech; Metro Minnesota Community; NCI; NATIONAL CANCER INSTITUTE [P30CA016672, P30CA016058] Funding Source: NIH RePORTER	Genentech(Roche HoldingGenentech); Metro Minnesota Community; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Genentech funded this clinical trial. RSH, LH, PF, and GAO have received funding from Genentech. RSH has consulted for Genentech, OSI, and Roche. GAO has consulted for Genentech and Abraxis. PP has consulted for Genentech, participated in speakers' bureaux for Genentech and 051 Pharmaceuticals, and grant funding from the Metro Minnesota Community Clinical Oncology Program, a non-profit research program sponsored by NCI. CV has consulted for Genentech and participated in speakers' bureaux for Genentech and Sanofi-Aventis. C-HS and PO'C have been employed by Genentech and were stockholders with Roche.	Andratschke Nicolaus H, 2004, Clin Lung Cancer, V5, P340, DOI 10.3816/CLC.2004.n.012; [Anonymous], 2007, BEV AV PACK INS; [Anonymous], 2017, ANAL CLIN TRIALS USI; [Anonymous], 2007, ERL TARC PACK INS; Bozec A, 2008, BRIT J CANCER, V99, P93, DOI 10.1038/sj.bjc.6604429; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Ciardiello F, 2000, CLIN CANCER RES, V6, P3739; Ciardiello F, 2004, CLIN CANCER RES, V10, P784, DOI 10.1158/1078-0432.CCR-1100-03; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Herbst RS, 2007, J CLIN ONCOL, V25, P4743, DOI 10.1200/JCO.2007.12.3026; Herbst RS, 2010, LANCET ONCOL, V11, P619, DOI 10.1016/S1470-2045(10)70132-7; Herbst RS, 2005, J CLIN ONCOL, V23, P2544, DOI 10.1200/JCO.2005.02.477; Hirsch FR, 2008, CLIN CANCER RES, V14, P6317, DOI 10.1158/1078-0432.CCR-08-0539; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Miller VA, 2009, P AN M AM SOC CLIN, V27; Miller VA, 2008, J CLIN ONCOL, V26, P1472, DOI 10.1200/JCO.2007.13.0062; Natale RB, 2009, J CLIN ONCOL, V27, P2523, DOI 10.1200/JCO.2008.18.6015; Naumov GN, 2009, CLIN CANCER RES, V15, P3484, DOI 10.1158/1078-0432.CCR-08-2904; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pazdur R, 2004, CANC MANAGEMENT MULT; Reck, 2009, J CLIN ONCOL, V27, P2415, DOI 10.1200/JCO.2009.23.1373; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schicher N, 2009, CLIN CANCER RES, V15, P3495, DOI 10.1158/1078-0432.CCR-08-2407; Shaheen RM, 2001, BRIT J CANCER, V85, P584, DOI 10.1054/bjoc.2001.1936; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Westfall PH, 2001, J STAT PLAN INFER, V99, P25, DOI 10.1016/S0378-3758(01)00077-5; Wu WJ, 2007, MOL CANCER THER, V6, P471, DOI 10.1158/1535-7163.MCT-06-0416	33	317	322	0	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2011	377	9780					1846	1854		10.1016/S0140-6736(11)60545-X	http://dx.doi.org/10.1016/S0140-6736(11)60545-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774UI	21621716	Green Accepted			2022-12-28	WOS:000291411700030
J	Paprotka, T; Delviks-Frankenberry, KA; Cingoz, O; Martinez, A; Kung, HJ; Tepper, CG; Hu, WS; Fivash, MJ; Coffin, JM; Pathak, VK				Paprotka, Tobias; Delviks-Frankenberry, Krista A.; Cingoez, Oya; Martinez, Anthony; Kung, Hsing-Jien; Tepper, Clifford G.; Hu, Wei-Shau; Fivash, Matthew J., Jr.; Coffin, John M.; Pathak, Vinay K.			Recombinant Origin of the Retrovirus XMRV	SCIENCE			English	Article							MURINE LEUKEMIA-VIRUS; CHRONIC-FATIGUE-SYNDROME; PROSTATE-CANCER; MOUSE DNA; IN-VIVO; CONTAMINATION; INFECTION; SEQUENCES; ANDROGEN; BLOOD	The retrovirus XMRV (xenotropic murine leukemia virus-related virus) has been detected in human prostate tumors and in blood samples from patients with chronic fatigue syndrome, but these findings have not been replicated. We hypothesized that an understanding of when and how XMRV first arose might help explain the discrepant results. We studied human prostate cancer cell lines CWR22Rv1 and CWR-R1, which produce XMRV virtually identical to the viruses recently found in patient samples, as well as their progenitor human prostate tumor xenograft (CWR22) that had been passaged in mice. We detected XMRV infection in the two cell lines and in the later passage xenografts, but not in the early passages. In particular, we found that the host mice contained two proviruses, PreXMRV-1 and PreXMRV-2, which share 99.92% identity with XMRV over >3.2-kilobase stretches of their genomes. We conclude that XMRV was not present in the original CWR22 tumor but was generated by recombination of two proviruses during tumor passaging in mice. The probability that an identical recombinant was generated independently is negligible (similar to 10(-12)); our results suggest that the association of XMRV with human disease is due to contamination of human samples with virus originating from this recombination event.	[Paprotka, Tobias; Delviks-Frankenberry, Krista A.; Pathak, Vinay K.] NCI, HIV Drug Resistance Program, Viral Mutat Sect, Frederick, MD 21702 USA; [Hu, Wei-Shau] NCI, HIV Drug Resistance Program, Viral Recombinat Sect, Frederick, MD 21702 USA; [Cingoez, Oya; Coffin, John M.] Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; [Cingoez, Oya; Coffin, John M.] Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA; [Martinez, Anthony; Kung, Hsing-Jien; Tepper, Clifford G.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Kung, Hsing-Jien] Univ Calif Davis, Dept Urol, Sacramento, CA 95817 USA; [Fivash, Matthew J., Jr.] NCI, Data Management Serv Inc, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tufts University; Tufts University; University of California System; University of California Davis; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pathak, VK (corresponding author), NCI, HIV Drug Resistance Program, Viral Mutat Sect, Frederick, MD 21702 USA.	vinay.pathak@nih.gov	Cingöz, Oya/AAN-1739-2021; Tepper, Clifford G/H-6527-2011; Kung, Hsing-Jien/C-7651-2013; Delviks-Frankenberry, Krista A/M-4822-2013	Cingöz, Oya/0000-0002-0096-4948; Delviks-Frankenberry, Krista A/0000-0003-3370-8542; Pathak, Vinay/0000-0003-2441-8412	Center for Cancer Research, National Cancer Institute, NIH; Bench-to-Bedside Award [R37 CA 089441, R01CA150197]; F.M. Kirby Foundation; NATIONAL CANCER INSTITUTE [ZIABC011436, P30CA093373, R37CA089441, ZIABC010504, ZIABC011339, R01CA150197] Funding Source: NIH RePORTER	Center for Cancer Research, National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Bench-to-Bedside Award; F.M. Kirby Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank W. Shao for analysis of MLV diversity, and E. Freed and S. Hughes for helpful discussions. This research was supported in part by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIH. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. This work was also supported in part by a Bench-to-Bedside Award to V.K.P., research grant R37 CA 089441 to J.M.C., and R01CA150197 to H.J.K. J.M.C. was a Research Professor of the American Cancer Society with support from the F.M. Kirby Foundation.	Arnold RS, 2010, UROLOGY, V75, P755, DOI 10.1016/j.urology.2010.01.038; Bogerd HP, 2011, VIROLOGY, V410, P234, DOI 10.1016/j.virol.2010.11.011; Chaipan C, 2011, J VIROL, V85, P4888, DOI 10.1128/JVI.00046-11; Courgnaud V, 2010, P NATL ACAD SCI USA, V107, P15666, DOI 10.1073/pnas.1007944107; Gregory CW, 2001, CANCER RES, V61, P2892; Groom HCT, 2010, P NATL ACAD SCI USA, V107, P5166, DOI 10.1073/pnas.0913650107; Hue S, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-111; Knouf EC, 2009, J VIROL, V83, P7353, DOI 10.1128/JVI.00546-09; Lo SC, 2010, P NATL ACAD SCI USA, V107, P15874, DOI 10.1073/pnas.1006901107; Lombardi VC, 2009, SCIENCE, V326, P585, DOI 10.1126/science.1179052; Nagabhushan M, 1996, CANCER RES, V56, P3042; Oakes B, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-109; Paprotka T, 2010, J VIROL, V84, P5719, DOI 10.1128/JVI.00134-10; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PRETLOW TG, 1993, J NATL CANCER I, V85, P394, DOI 10.1093/jnci/85.5.394; Qiu XX, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-68; Robinson MJ, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-108; Schlaberg R, 2009, P NATL ACAD SCI USA, V106, P16351, DOI 10.1073/pnas.0906922106; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Stieler K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011738; Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; van der Kuyl AC, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2010.00147; Weiss RA, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-124; Zhuang JL, 2006, J VIROL, V80, P6706, DOI 10.1128/JVI.00273-06	25	185	192	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2011	333	6038					97	101		10.1126/science.1205292	http://dx.doi.org/10.1126/science.1205292			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	785UF	21628392	Green Accepted			2022-12-28	WOS:000292255400058
J	Uauy, R				Uauy, Ricardo			The impact of the Brazil experience in Latin America	LANCET			English	Editorial Material							ECONOMIC-GROWTH; HEALTH; EDUCATION		[Uauy, Ricardo] Univ Chile, Inst Nutr, Santiago, Chile; [Uauy, Ricardo] Univ London London Sch Hyg & Trop Med, Dept Nutr & Publ Hlth Intervent Res, London WC1E 7HT, England	Universidad de Chile; University of London; London School of Hygiene & Tropical Medicine	Uauy, R (corresponding author), Univ Chile, Inst Nutr, Santiago, Chile.	Ricardo.uauy@lsthm.ac.uk						Abers R, 1996, LAT AM PERSPECT, V23, P35, DOI 10.1177/0094582X9602300404; Bourne R, 2008, LULA OF BRAZIL: THE STORY SO FAR, P1; Ferreira FHG, 2008, MACROECON DYN, V12, P199, DOI 10.1017/S1365100507070137; HAGEN EE, 1963, J SOC ISSUES, V19, P20, DOI 10.1111/j.1540-4560.1963.tb00428.x; Hall A, 2006, J LAT AM STUD, V38, P689, DOI 10.1017/S0022216X0600157X; Hoddinott J., 2008, CONDITIONAL CASH TRA; Hotez PJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000300; Kohl B, 2010, LAT AM PERSPECT, V37, P107, DOI 10.1177/0094582X10366533; Pelletier DL, 2012, HEALTH POLICY PLANN, V27, P19, DOI 10.1093/heapol/czr011; Rivera JA, 2004, JAMA-J AM MED ASSOC, V291, P2563, DOI 10.1001/jama.291.21.2563; ROSTOW WW, 1959, ECON HIST REV, V12, P1; Ruel MT, 2002, J NUTR, V132, P1180, DOI 10.1093/jn/132.6.1180; VALLA VV, 1994, LAT AM PERSPECT, V21, P104, DOI 10.1177/0094582X9402100307; Victora CG, 2011, LANCET, V377, P1863, DOI 10.1016/S0140-6736(11)60138-4	14	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 11	2011	377	9782					1984	1986		10.1016/S0140-6736(11)60437-6	http://dx.doi.org/10.1016/S0140-6736(11)60437-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	782LR	21561651				2022-12-28	WOS:000292011700007
J	Oldham, ML; Chen, J				Oldham, Michael L.; Chen, Jue			Crystal Structure of the Maltose Transporter in a Pretranslocation Intermediate State	SCIENCE			English	Article							MALTODEXTRIN-BINDING-PROTEIN; BOVINE HEART-MITOCHONDRIA; ABC-TRANSPORTER; ATP-BINDING; ESCHERICHIA-COLI; CASSETTE TRANSPORTER; ALTERNATING ACCESS; ACTIVE-TRANSPORT; MECHANISM; CONFORMATION	Adenosine triphosphate (ATP)-binding cassette (ABC) transporters convert chemical energy from ATP hydrolysis to mechanical work for substrate translocation. They function by alternating between two states, exposing the substrate-binding site to either side of the membrane. A key question that remains to be addressed is how substrates initiate the transport cycle. Using x-ray crystallography, we have captured the maltose transporter in an intermediate step between the inward- and outward-facing states. We show that interactions with substrate-loaded maltose-binding protein in the periplasm induce a partial closure of the MalK dimer in the cytoplasm. ATP binding to this conformation then promotes progression to the outward-facing state. These results, interpreted in light of biochemical and functional studies, provide a structural basis to understand allosteric communication in ABC transporters.	[Oldham, Michael L.; Chen, Jue] Purdue Univ, Howard Hughes Med Inst, Dept Biol Sci, W Lafayette, IN 47907 USA	Howard Hughes Medical Institute; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chen, J (corresponding author), Purdue Univ, Howard Hughes Med Inst, Dept Biol Sci, W Lafayette, IN 47907 USA.	chenjue@purdue.edu			NIH [GM070515]; American Heart Association; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070515, R56GM070515] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Davidson for providing the MBP(G69C/S337C) construct and comments on this manuscript and staff at the Advanced Photon Source beamline 23-ID for assistance with data collection. We are also especially grateful for thoughtful and constructive comments from the anonymous reviewers. This work was supported by an NIH grant (GM070515 to J.C.) and a postdoctoral fellowship from the American Heart Association (to M.L.O). J.C. is an investigator of the Howard Hughes Medical Institute. Coordinates and structure factors have been deposited in the Protein Data Bank under accession nos. 3PV0, 3PUY, and 3PUZ.	ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aller SG, 2009, SCIENCE, V323, P1718, DOI 10.1126/science.1168750; Boudker O, 2007, NATURE, V445, P387, DOI 10.1038/nature05455; Bowler MW, 2007, J BIOL CHEM, V282, P14238, DOI 10.1074/jbc.M700203200; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; Evenas J, 2001, J MOL BIOL, V309, P961, DOI 10.1006/jmbi.2001.4695; Haffke M, 2010, ACTA CRYSTALLOGR D, V66, P979, DOI 10.1107/S0907444910028593; Hall JA, 1997, J BIOL CHEM, V272, P17610, DOI 10.1074/jbc.272.28.17610; Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 2000, J BACTERIOL, V182, P1432, DOI 10.1128/JB.182.5.1432-1436.2000; Hvorup RN, 2007, SCIENCE, V317, P1387, DOI 10.1126/science.1145950; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jones PM, 2009, TRENDS BIOCHEM SCI, V34, P520, DOI 10.1016/j.tibs.2009.06.004; Kadaba NS, 2008, SCIENCE, V321, P250, DOI 10.1126/science.1157987; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Khare D, 2009, MOL CELL, V33, P528, DOI 10.1016/j.molcel.2009.01.035; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Lu G, 2005, P NATL ACAD SCI USA, V102, P17969, DOI 10.1073/pnas.0506039102; Oldham ML, 2007, NATURE, V450, P515, DOI 10.1038/nature06264; Oldham ML, 2008, CURR OPIN STRUC BIOL, V18, P726, DOI 10.1016/j.sbi.2008.09.007; Orelle C, 2008, P NATL ACAD SCI USA, V105, P12837, DOI 10.1073/pnas.0803799105; Orelle C, 2010, P NATL ACAD SCI USA, V107, P20293, DOI 10.1073/pnas.1006544107; Oswald C, 2006, N-S ARCH PHARMACOL, V372, P385, DOI 10.1007/s00210-005-0031-4; Pinkett HW, 2007, SCIENCE, V315, P373, DOI 10.1126/science.1133488; Reyes N, 2009, NATURE, V462, P880, DOI 10.1038/nature08616; Shaffer PL, 2009, SCIENCE, V325, P1010, DOI 10.1126/science.1176088; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Shilton BH, 2008, BBA-BIOMEMBRANES, V1778, P1772, DOI 10.1016/j.bbamem.2007.09.005; Singh SK, 2008, SCIENCE, V322, P1655, DOI 10.1126/science.1166777; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; Tang C, 2007, NATURE, V449, P1078, DOI 10.1038/nature06232; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; Ward A, 2007, P NATL ACAD SCI USA, V104, P19005, DOI 10.1073/pnas.0709388104; Ye JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI 10.1016/j.bbabio.2004.06.003; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zhang YH, 1996, J BIOL CHEM, V271, P17881, DOI 10.1074/jbc.271.30.17881	43	170	172	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 3	2011	332	6034					1202	1205		10.1126/science.1200767	http://dx.doi.org/10.1126/science.1200767			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	772BO	21566157				2022-12-28	WOS:000291205200049
J	Bristow, TF; Bonifacie, M; Derkowski, A; Eiler, JM; Grotzinger, JP				Bristow, Thomas F.; Bonifacie, Magali; Derkowski, Arkadiusz; Eiler, John M.; Grotzinger, John P.			A hydrothermal origin for isotopically anomalous cap dolostone cements from south China	NATURE			English	Article							GAS HYDRATE; NEOPROTEROZOIC SEAWATER; DOUSHANTUO FORMATION; METHANE SEEPS; CARBONATE; EVOLUTION; OXYGEN; FRACTIONATION; TEMPERATURE; EARTH	The release of methane into the atmosphere through destabilization of clathrates is a positive feedback mechanism capable of amplifying global warming trends that may have operated several times in the geological past(1-3). Such methane release is a hypothesized cause or amplifier for one of the most drastic global warming events in Earth history, the end of the Marinoan 'snowball Earth' ice age, similar to 635 Myr ago(4-7). A key piece of evidence supporting this hypothesis is the occurrence of exceptionally depleted carbon isotope signatures (delta(13)C(PDB) down to -48 parts per thousand; ref. 8) in post-glacial cap dolostones (that is, dolostone overlying glacial deposits) from south China; these signatures have been interpreted as products of methane oxidation at the time of deposition(5,6,8). Here we show, on the basis of carbonate clumped isotope thermometry, (87)Sr/(86)Sr isotope ratios, trace element content and clay mineral evidence, that carbonates bearing the (13)C-depleted signatures crystallized more than 1.6 Myr after deposition of the cap dolostone. Our results indicate that highly (13)C-depleted carbonate cements grew from hydrothermal fluids and suggest that their carbon isotope signatures are a consequence of thermogenic methane oxidation at depth. This finding not only negates carbon isotope evidence for methane release during Marinoan deglaciation in south China, but also eliminates the only known occurrence of a Precambrian sedimentary carbonate with highly (13)C-depleted signatures related to methane oxidation in a seep environment. We propose that the capacity to form highly (13)C-depleted seep carbonates, through biogenic anaeorobic oxidation of methane using sulphate, was limited in the Precambrian period by low sulphate concentrations in sea water(9). As a consequence, although clathrate destabilization may or may not have had a role in the exit from the 'snowball' state, it would not have left extreme carbon isotope signals in cap dolostones.	[Bristow, Thomas F.; Bonifacie, Magali; Eiler, John M.; Grotzinger, John P.] CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; [Bonifacie, Magali] Univ Paris Diderot, Equipe Geochim Isotopes Stables, Inst Phys Globe Paris, CNRS,UMR 7154, F-75005 Paris, France; [Derkowski, Arkadiusz] Polish Acad Sci, Inst Geol Sci, PL-31002 Krakow, Poland	California Institute of Technology; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Polish Academy of Sciences; Institute of Geological Sciences of the Polish Academy of Sciences	Bristow, TF (corresponding author), NASA, Ames Res Ctr, Moffett Field, CA 94035 USA.	thomas.f.bristow@nasa.gov	Bonifacie, Magali/P-7737-2019; Bonifacie, Magali/A-5656-2011	Bonifacie, Magali/0000-0002-4797-043X; Bonifacie, Magali/0000-0002-4797-043X	O.K. Earl Postdoctoral fellowship; NSF; INSU	O.K. Earl Postdoctoral fellowship; NSF(National Science Foundation (NSF)); INSU(Centre National de la Recherche Scientifique (CNRS))	We thank G. Jiang for guidance in the field and for providing samples, V. Orphan and W. Fischer for discussion and advice, M. Kennedy for supporting fieldwork and use of analytical equipment, and E. Peterman and K. Morrison for laboratory work. C. Ma and M. Anderson are thanked for analytical assistance and advice. This work was supported by an O.K. Earl Postdoctoral fellowship (to T.F.B.), by the NSF EAR and GEG programmes (to J.M.E.), and by INSU (to M.B.). Part of the work of M.B. is IPGP contribution 3138.	Bechtel A, 1999, CHEM GEOL, V156, P191, DOI 10.1016/S0009-2541(98)00185-5; Boles JR, 2004, AAPG BULL, V88, P947, DOI 10.1306/02090403040; Bristow TF, 2009, P NATL ACAD SCI USA, V106, P13190, DOI 10.1073/pnas.0901080106; Campbell KA, 2006, PALAEOGEOGR PALAEOCL, V232, P362, DOI 10.1016/j.palaeo.2005.06.018; Chen DZ, 2009, CHEM GEOL, V258, P168, DOI 10.1016/j.chemgeo.2008.10.016; Condon D, 2005, SCIENCE, V308, P95, DOI 10.1126/science.1107765; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Eigenbrode JL, 2006, P NATL ACAD SCI USA, V103, P15759, DOI 10.1073/pnas.0607540103; FARVER JR, 1994, EARTH PLANET SC LETT, V121, P575, DOI 10.1016/0012-821X(94)90092-2; FRIEDMAN I, 1977, 444KK US GEOL SURV; Ghosh P, 2006, GEOCHIM COSMOCHIM AC, V70, P1439, DOI 10.1016/j.gca.2005.11.014; Grotzinger JP, 1995, PALAIOS, V10, P578, DOI 10.2307/3515096; Halverson GP, 2007, PALAEOGEOGR PALAEOCL, V256, P103, DOI 10.1016/j.palaeo.2007.02.028; Hesselbo SP, 2000, NATURE, V406, P392, DOI 10.1038/35019044; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; Horita J, 2008, GEOCHIM COSMOCHIM AC, V72, pA391; Huntington KW, 2009, J MASS SPECTROM, V44, P1318, DOI 10.1002/jms.1614; Jacobsen SB, 1999, CHEM GEOL, V161, P37, DOI 10.1016/S0009-2541(99)00080-7; Jiang GQ, 2006, J SEDIMENT RES, V76, P978, DOI 10.2110/jsr.2006.086; Jiang GQ, 2003, NATURE, V426, P822, DOI 10.1038/nature02201; Kah LC, 2004, NATURE, V431, P834, DOI 10.1038/nature02974; Kasting JF, 2005, PRECAMBRIAN RES, V137, P119, DOI 10.1016/j.precamres.2005.03.002; Kennedy M, 2008, NATURE, V453, P642, DOI 10.1038/nature06961; Kennedy MJ, 2001, GEOLOGY, V29, P443, DOI 10.1130/0091-7613(2001)029<0443:APCCAI>2.0.CO;2; Knauth LP, 2009, NATURE, V460, P728, DOI 10.1038/nature08213; MACDONALD GJ, 1990, CLIMATIC CHANGE, V16, P247, DOI 10.1007/BF00144504; Machel HG, 1996, GEOL SOC AM BULL, V108, P1108, DOI 10.1130/0016-7606(1996)108<1108:IEFCCA>2.3.CO;2; Maekawa T, 2004, GEOCHEM J, V38, P129, DOI 10.2343/geochemj.38.129; Meunier, 2005, CLAYS, P471; Orsini L., 1976, J B AFES, V4, P269; Passey BH, 2010, P NATL ACAD SCI USA, V107, P11245, DOI 10.1073/pnas.1001824107; ROSENBAUM J, 1986, GEOCHIM COSMOCHIM AC, V50, P1147, DOI 10.1016/0016-7037(86)90396-0; Sawaki Y, 2010, PRECAMBRIAN RES, V176, P46, DOI 10.1016/j.precamres.2009.10.006; SWART PK, 1991, CHEM GEOL, V86, P89, DOI 10.1016/0168-9622(91)90055-2; Wang JS, 2008, GEOLOGY, V36, P347, DOI 10.1130/G24513A.1; Wegener G, 2009, BIOGEOSCIENCES, V6, P867, DOI 10.5194/bg-6-867-2009; WELHAN JA, 1988, CHEM GEOL, V71, P183, DOI 10.1016/0009-2541(88)90114-3	37	109	113	3	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 2	2011	474	7349					68	U92		10.1038/nature10096	http://dx.doi.org/10.1038/nature10096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	771KV	21613997				2022-12-28	WOS:000291156700038
J	Yeretssian, G; Correa, RG; Doiron, K; Fitzgerald, P; Dillon, CP; Green, DR; Reed, JC; Saleh, M				Yeretssian, Garabet; Correa, Ricardo G.; Doiron, Karine; Fitzgerald, Patrick; Dillon, Christopher P.; Green, Douglas R.; Reed, John C.; Saleh, Maya			Non-apoptotic role of BID in inflammation and innate immunity	NATURE			English	Article							FAMILY-MEMBER; CELL-DEATH; KAPPA-B; PROTEIN; ACTIVATION; NOD1; BCL-2; RECOGNITION; MECHANISM; BINDING	Innate immunity is a fundamental defence response that depends on evolutionarily conserved pattern recognition receptors for sensing infections or danger signals(1,2). Nucleotide-binding and oligomerization domain (NOD) proteins are cytosolic pattern-recognition receptors of paramount importance in the intestine, and their dysregulation is associated with inflammatory bowel disease(3,4). They sense peptidoglycans from commensal microorganisms and pathogens and coordinate signalling events that culminate in the induction of inflammation and anti-microbial responses(2). However, the signalling mechanisms involved in this process are not fully understood. Here, using genome-wide RNA interference, we identify candidate genes that modulate the NOD1 inflammatory response in intestinal epithelial cells. Our results reveal a significant crosstalk between innate immunity and apoptosis and identify BID, a BCL2 family protein, as a critical component of the inflammatory response. Colonocytes depleted of BID or macrophages from Bid(-/-) mice are markedly defective in cytokine production in response to NOD activation. Furthermore, Bid(-/-) mice are unresponsive to local or systemic exposure to NOD agonists or their protective effect in experimental colitis. Mechanistically, BID interacts with NOD1, NOD2 and the I kappa B kinase (IKK) complex, impacting NF-kappa B and extracellular signal-regulated kinase (ERK) signalling. Our results define a novel role of BID in inflammation and immunity independent of its apoptotic function, furthering the mounting evidence of evolutionary conservation between the mechanisms of apoptosis and immunity.	[Yeretssian, Garabet; Doiron, Karine; Saleh, Maya] McGill Univ, Dept Med, Montreal, PQ H3G 0B1, Canada; [Correa, Ricardo G.; Reed, John C.] Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA; [Fitzgerald, Patrick; Dillon, Christopher P.; Green, Douglas R.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA	McGill University; Sanford Burnham Prebys Medical Discovery Institute; St Jude Children's Research Hospital	Saleh, M (corresponding author), McGill Univ, Dept Med, Montreal, PQ H3G 0B1, Canada.	maya.saleh@mcgill.ca	Correa, Ricardo G/G-7613-2012; Dillon, Christopher/P-4457-2014; Green, Douglas R/N-8083-2018	Correa, Ricardo G/0000-0001-6940-7034; Dillon, Christopher/0000-0002-9458-0266; Green, Douglas R/0000-0002-7332-1417; Saleh, Maya/0000-0003-1538-9146	Canadian Institutes for Health Research [CIHR-MOP 82801]; Burroughs Wellcome Fund; McGill University Health Center; SASS Foundation for Medical Research	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Burroughs Wellcome Fund(Burroughs Wellcome Fund); McGill University Health Center; SASS Foundation for Medical Research	We thank A. Strasser for providing Bid<SUP>-/-</SUP> mice, G. Shore for BID antibodies and the McGill University high throughput/high content screening facility. We also thank D. Zhai for BID purification. This work was supported by grants from the Canadian Institutes for Health Research (CIHR-MOP 82801) and the Burroughs Wellcome Fund to M.S. M.S. is a Canadian Institutes for Health Research New Investigator. G.Y. is supported by a PDF-Fellowship from the McGill University Health Center. C.P.D. is supported by a fellowship grant from the SASS Foundation for Medical Research.	Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Bertrand MJM, 2009, IMMUNITY, V30, P789, DOI 10.1016/j.immuni.2009.04.011; Boutros M, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r66; Bruey JM, 2007, CELL, V129, P45, DOI 10.1016/j.cell.2007.01.045; Chen CM, 2004, J BIOL CHEM, V279, P25876, DOI 10.1074/jbc.M400682200; Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Faustin B, 2007, MOL CELL, V25, P713, DOI 10.1016/j.molcel.2007.01.032; Faustin B, 2009, P NATL ACAD SCI USA, V106, P3935, DOI 10.1073/pnas.0809414106; Garrett WS, 2010, CELL, V140, P859, DOI 10.1016/j.cell.2010.01.023; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Hasegawa M, 2008, EMBO J, V27, P373, DOI 10.1038/sj.emboj.7601962; Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Kim JG, 2004, INFECT IMMUN, V72, P1487, DOI 10.1128/IAI.72.3.1487-1495.2004; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Luo W, 2010, CURR CANCER DRUG TAR, V10, P96, DOI 10.2174/156800910790980160; Masumoto J, 2006, J EXP MED, V203, P203, DOI 10.1084/jem.20051229; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Rivals I, 2007, BIOINFORMATICS, V23, P401, DOI 10.1093/bioinformatics/btl633; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Vijay-Kumar M, 2007, INFLAMM BOWEL DIS, V13, P856, DOI 10.1002/ibd.20142; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Watanabe T, 2008, J CLIN INVEST, V118, P545, DOI [10.1172/JC133145, 10.1172/JCI33145]; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Zhai DY, 2005, J BIOL CHEM, V280, P15815, DOI 10.1074/jbc.M411902200; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	36	84	85	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2011	474	7349					96	U126		10.1038/nature09982	http://dx.doi.org/10.1038/nature09982			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	771KV	21552281				2022-12-28	WOS:000291156700045
J	Joye, SB; Leifer, I; MacDonald, IR; Chanton, JP; Meile, CD; Teske, AP; Kostka, JE; Chistoserdova, L; Coffin, R; Hollander, D; Kastner, M; Montoya, JP; Rehder, G; Solomon, E; Treude, T; Villareal, TA				Joye, Samantha B.; Leifer, Ira; MacDonald, Ian R.; Chanton, Jeffery P.; Meile, Christof D.; Teske, Andreas P.; Kostka, Joel E.; Chistoserdova, Ludmila; Coffin, Richard; Hollander, David; Kastner, Miriam; Montoya, Joseph P.; Rehder, Gregor; Solomon, Evan; Treude, Tina; Villareal, Tracy A.			Comment on "A Persistent Oxygen Anomaly Reveals the Fate of Spilled Methane in the Deep Gulf of Mexico"	SCIENCE			English	Editorial Material							HYDROCARBON SEEPS; ATMOSPHERE	Kessler et al. (Reports, 21 January 2011, p. 312) reported that methane released from the 2010 Deepwater Horizon blowout, approximately 40% of the total hydrocarbon discharge, was consumed quantitatively by methanotrophic bacteria in Gulf of Mexico deep waters over a 4-month period. We find the evidence explicitly linking observed oxygen anomalies to methane consumption ambiguous and extension of these observations to hydrate-derived methane climate forcing premature.	[Joye, Samantha B.; Meile, Christof D.] Univ Georgia, Dept Marine Sci, Athens, GA 30602 USA; [Leifer, Ira] Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA; [MacDonald, Ian R.; Chanton, Jeffery P.; Kostka, Joel E.] Florida State Univ, Dept Earth Ocean & Atmospher Sci, Tallahassee, FL 32306 USA; [Teske, Andreas P.] Univ N Carolina, Dept Marine Sci, Chapel Hill, NC 27599 USA; [Chistoserdova, Ludmila] Univ Washington, Dept Chem Engn, Seattle, WA 98918 USA; [Coffin, Richard] USN, Res Lab, Washington, DC 20375 USA; [Hollander, David] Univ S Florida, Coll Marine Sci, St Petersburg, FL 33701 USA; [Kastner, Miriam] Univ Calif San Diego, Scripps Inst Oceanog, San Diego, CA 92093 USA; [Montoya, Joseph P.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; [Rehder, Gregor] Leibniz Inst Balt Sea Res, Rostock, Germany; [Solomon, Evan] Univ Washington, Sch Oceanog, Seattle, WA 98195 USA; [Treude, Tina] Leibniz Inst Marine Sci, D-24105 Kiel, Germany; [Villareal, Tracy A.] Univ Texas Austin, Inst Marine Sci, Port Aransas, TX 78373 USA	University System of Georgia; University of Georgia; University of California System; University of California Santa Barbara; State University System of Florida; Florida State University; University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle; United States Department of Defense; United States Navy; Naval Research Laboratory; State University System of Florida; University of South Florida; University of California System; University of California San Diego; Scripps Institution of Oceanography; University System of Georgia; Georgia Institute of Technology; Leibniz Institut fur Ostseeforschung Warnemunde; University of Washington; University of Washington Seattle; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; University of Texas System; University of Texas Austin	Joye, SB (corresponding author), Univ Georgia, Dept Marine Sci, Athens, GA 30602 USA.	mjoye@uga.edu	Montoya, Joseph/C-3115-2013; Teske, Andreas/AAQ-9577-2021; Villareal, Tracy A/I-9462-2012; Treude, Tina/AAD-5817-2020; Chistoserdova, Ludmila/K-2364-2017	Montoya, Joseph/0000-0001-7197-4660; Villareal, Tracy A/0000-0002-5717-8163; Chistoserdova, Ludmila/0000-0002-5777-0263; Meile, Christof/0000-0002-0825-4596; Joye, Samantha/0000-0003-1610-451X; Treude, Tina/0000-0001-6366-286X	Division Of Ocean Sciences [1043225, 1044939, 1057417] Funding Source: National Science Foundation	Division Of Ocean Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))		Garcia-Pineda O, 2010, DEEP-SEA RES PT II, V57, P1859, DOI 10.1016/j.dsr2.2010.05.005; HOLLANDER D, 2010, AM GEOPH UN FALL M S; Jensen S, 2008, FEMS MICROBIOL ECOL, V66, P320, DOI 10.1111/j.1574-6941.2008.00575.x; JOCHEN A, 2005, 2005032 US DEP INT O; Joye SB, 2011, NAT GEOSCI, V4, P160, DOI [10.1038/ngeo1067, 10.1038/NGEO1067]; Kalyuzhnaya MG, 2008, NAT BIOTECHNOL, V26, P1029, DOI 10.1038/nbt.1488; Kessler JD, 2011, SCIENCE, V331, P312, DOI 10.1126/science.1199697; Kujawinski EB, 2011, ENVIRON SCI TECHNOL, V45, P1298, DOI 10.1021/es103838p; LEHR B, 2010, NOAA OIL BUDGET CALC; Lidstrom ME, 2006, PROKARYOTES: A HANDBOOK ON THE BIOLOGY OF BACTERIA, VOL 2, THIRD EDITION, P618, DOI 10.1007/0-387-30742-7_20; Redmond MC, 2010, APPL ENVIRON MICROB, V76, P6412, DOI 10.1128/AEM.00271-10; Rehder G, 2009, MAR CHEM, V114, P19, DOI 10.1016/j.marchem.2009.03.004; Shakhova N, 2010, SCIENCE, V327, P1246, DOI 10.1126/science.1182221; Solomon EA, 2009, NAT GEOSCI, V2, P561, DOI 10.1038/NGEO574; Valentine DL, 2010, SCIENCE, V330, P208, DOI 10.1126/science.1196830	15	22	22	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2011	332	6033								10.1126/science.1203307	http://dx.doi.org/10.1126/science.1203307			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617058				2022-12-28	WOS:000290996700023
J	De Bono, JS; Logothetis, CJ; Molina, A; Fizazi, K; North, S; Chu, L; Chi, KN; Jones, RJ; Goodman, OB; Saad, F; Staffurth, JN; Mainwaring, P; Harland, S; Flaig, TW; Hutson, TE; Cheng, T; Patterson, H; Hainsworth, JD; Ryan, CJ; Sternberg, CN; Ellard, SL; Flechon, A; Saleh, M; Scholz, M; Efstathiou, E; Zivi, A; Bianchini, D; Loriot, Y; Chieffo, N; Kheoh, T; Haqq, CM; Scher, HI				De Bono, Johann S.; Logothetis, Christopher J.; Molina, Arturo; Fizazi, Karim; North, Scott; Chu, Luis; Chi, Kim N.; Jones, Robert J.; Goodman, Oscar B., Jr.; Saad, Fred; Staffurth, John N.; Mainwaring, Paul; Harland, Stephen; Flaig, Thomas W.; Hutson, Thomas E.; Cheng, Tina; Patterson, Helen; Hainsworth, John D.; Ryan, Charles J.; Sternberg, Cora N.; Ellard, Susan L.; Flechon, Aude; Saleh, Mansoor; Scholz, Mark; Efstathiou, Eleni; Zivi, Andrea; Bianchini, Diletta; Loriot, Yohann; Chieffo, Nicole; Thian Kheoh; Haqq, Christopher M.; Scher, Howard I.		COU-AA-301 Investigators	Abiraterone and Increased Survival in Metastatic Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANDROGEN-DEPRIVATION THERAPY; HUMAN CYTOCHROME P450(17-ALPHA); I CLINICAL-TRIAL; HORMONAL-THERAPY; PLUS PREDNISONE; CASTRATION; ACETATE; CYP17; TESTOSTERONE; DOCETAXEL	BACKGROUND Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS We randomly assigned, in a 2: 1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the pre-planned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group. CONCLUSIONS The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.)	[De Bono, Johann S.; Zivi, Andrea; Bianchini, Diletta] Inst Canc Res, Sutton SM2 5PT, Surrey, England; [De Bono, Johann S.; Zivi, Andrea; Bianchini, Diletta] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England; [Jones, Robert J.] Inst Canc Sci, Glasgow, Lanark, Scotland; [Staffurth, John N.] Cardiff Univ, Velindre Hosp, Cardiff, S Glam, Wales; [Patterson, Helen] Univ Cardiff, Velindre Hosp, Cambridge, England; [Logothetis, Christopher J.; Efstathiou, Eleni] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Molina, Arturo; Chieffo, Nicole; Thian Kheoh; Haqq, Christopher M.] Ortho Biotech Oncol Res & Dev Unit Cougar Biotech, Los Angeles, CA USA; [Fizazi, Karim; Loriot, Yohann] Inst Gustave Roussy, Villejuif, France; [Flechon, Aude] Ctr Leon Berard, F-69373 Lyon, France; [North, Scott] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Chi, Kim N.] Vancouver Canc Ctr, BC Canc Agcy, Vancouver, BC, Canada; [Cheng, Tina] Univ Calgary, Calgary, AB, Canada; [Ellard, Susan L.] Ctr So Interior, BC Canc Agcy, Kelowna, BC, Canada; [Goodman, Oscar B., Jr.] Nevada Canc Inst, Las Vegas, NV USA; [Saad, Fred] Univ Montreal, Montreal, PQ, Canada; [Mainwaring, Paul] Haematol & Oncol Clin Australasia, Milton, Australia; [Harland, Stephen] UCL Canc Inst, London, England; [Flaig, Thomas W.] Univ Colorado, Ctr Canc, Aurora, CO USA; [Hutson, Thomas E.] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA; [Hainsworth, John D.] Sarah Cannon Res Inst, Nashville, TN USA; [Ryan, Charles J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Sternberg, Cora N.] San Camillo Hosp, Rome, Italy; [Scher, Howard I.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Scher, Howard I.] Weill Cornell Med Coll, New York, NY USA; [Sternberg, Cora N.] Forlanini Hosp, Rome, Italy	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of Glasgow; Cardiff University; Velindre Hospital; Cardiff University; Velindre Hospital; University of Texas System; UTMD Anderson Cancer Center; UNICANCER; Gustave Roussy; UNICANCER; Centre Leon Berard; University of Alberta; British Columbia Cancer Agency; University of Calgary; British Columbia Cancer Agency; University of California System; University of California San Diego; Universite de Montreal; University of London; University College London; University of Colorado System; University of Colorado Anschutz Medical Campus; Baylor University Medical Center; Sarah Cannon Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Azienda Ospedaliera San Camillo-Forlanini	De Bono, JS (corresponding author), Inst Canc Res, Downs Rd, Sutton SM2 5PT, Surrey, England.	johann.de-bono@icr.ac.uk	Mulders, Peter F.A./H-8076-2014; Hutson, Thomas/AAS-9639-2020; Loriot, Yohann/W-5572-2019; Sonpavde/L-7107-2019	Hutson, Thomas/0000-0002-4529-4212; Sonpavde/0000-0002-1010-9611; Goodman, Oscar/0000-0002-0882-3621; North, scott/0000-0003-4427-5439; Ellard, Susan/0000-0001-5757-9787; joly, florence/0000-0001-6168-4942; Horvath, Lisa/0000-0001-6842-9223; OUDARD, Stephane/0000-0003-0893-285X; DURAN, IGNACIO/0000-0001-8571-7163; McDermott, Ray/0000-0002-8952-4315; de Bono, Johann S/0000-0002-2034-595X; Jones, Robert/0000-0002-2904-6980	Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology); Medical Research Council of the United Kingdom; Experimental Cancer Medical Centre; National Institute for Health Research Biomedical Research Centre; Prostate Cancer Foundation; Amgen; Astellas; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Enzon; Exelixis; Genentech; GlaxoSmithKline; Medivation; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Supergen; Takeda; Janssen-Cilag; Abraxis; Ortho Biotech; Veridex (a division of Johnson Johnson); Pierre Fabre Laboratories; Bayer; Aragon; Foundation Medicine; Millenium; Veridex; NATIONAL CANCER INSTITUTE [P50CA092629] Funding Source: NIH RePORTER	Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology); Medical Research Council of the United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Experimental Cancer Medical Centre; National Institute for Health Research Biomedical Research Centre(National Institute for Health Research (NIHR)); Prostate Cancer Foundation; Amgen(Amgen); Astellas(Astellas Pharmaceuticals); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Bristol-Myers Squibb(Bristol-Myers Squibb); Dendreon; Enzon; Exelixis; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Medivation; Merck(Merck & Company); Novartis(Novartis); Pfizer(Pfizer); Roche(Roche Holding); Sanofi-Aventis(Sanofi-Aventis); Supergen; Takeda(Takeda Pharmaceutical Company Ltd); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Abraxis; Ortho Biotech; Veridex (a division of Johnson Johnson); Pierre Fabre Laboratories; Bayer(Bayer AG); Aragon; Foundation Medicine; Millenium; Veridex; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology) and grants from the Medical Research Council of the United Kingdom, Experimental Cancer Medical Centre, National Institute for Health Research Biomedical Research Centre, and Prostate Cancer Foundation (to Dr. Scher).; Dr. de Bono reports being an employee of the Institute of Cancer Research, where abiraterone was first designed and synthesized and which has a commercial interest in abiraterone, and receiving consulting fees from Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology), consulting fees and travel support from Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Enzon, Exelixis, Genentech, GlaxoSmithKline, Medivation, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Supergen, and Takeda, and grant support from AstraZeneca; Dr. Logothetis, receiving consulting fees and travel support from Ortho Biotech Oncology Research and Development; Drs. Molina, Haqq, and Kheoh and Ms. Chieffo, being employees of and holding stock options in Johnson & Johnson; Dr. Fizazi, receiving lecture fees from Janssen-Cilag and consulting fees from Ortho Biotech Oncology Research and Development; Dr. North, receiving consulting fees from AstraZeneca, Pfizer, Sanofi-Aventis, Novartis, Abraxis, Ortho Biotech, Amgen, and GlaxoSmithKline and lecture fees from Novartis and Ortho Biotech; Dr. Chu, holding stock in Johnson & Johnson, GlaxoSmithKline, Eli Lilly, Novartis, Rigel Pharmaceuticals, and Sanofi-Aventis; Dr. Jones, receiving grant and travel support from Ortho Biotech Oncology Research and Development; Dr. Goodman, receiving consulting and lecture fees from Veridex (a division of Johnson & Johnson); Dr. Saad, receiving consulting fees from Amgen, Novartis, Sanofi-Aventis, and AstraZeneca and receiving payment for the development of educational presentations from Amgen and Novartis; Dr. Staffurth, receiving consulting fees from Pierre Fabre Laboratories and Ortho Biotech Oncology Research and Development, receiving travel support from Sanofi-Aventis, and holding stock in Johnson & Johnson; Dr. Harland, receiving consulting fees from Sanofi-Aventis and travel support from Ortho Biotech Oncology Research and Development; Dr. Flaig, receiving consulting fees from Sanofi-Aventis and lecture fees from Amgen; Dr. Sternberg, receiving consulting fees and travel support from Ortho Biotech Oncology Research and Development; Dr. Flechon, receiving travel support from Novartis, Bayer, Pfizer, and Ortho Biotech Oncology Research and Development, serving as a board member for Novartis, Sanofi-Aventis, and Ferring, and receiving payment for the development of educational presentations from Novartis, AstraZeneca, Bayer, and Pfizer; Dr. Efstathiou, receiving consulting fees and travel support from Janssen-Cilag; and Dr. Scher, receiving consulting fees from Aragon, Bristol-Myers Squibb, Exelixis, Foundation Medicine, Genentech, and Medivation, consulting fees and travel support from Amgen, Ortho Biotech Oncology Research and Development, Dendreon, Enzon, Millenium, Novartis, Roche, and Sanofi-Aventis, travel support from AstraZeneca, Bristol-Myers Squibb, Exelixis, Genentech, Medivation, and Veridex, and grant support from Bristol-Myers Squibb, Ortho Biotech Services, Medivation, and Veridex, and holding stock in Eli Lilly, Genta, and Johnson & Johnson. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM. org.	Attard G, 2005, BJU INT, V96, P1241, DOI 10.1111/j.1464-410X.2005.05821.x; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Attard G, 2010, J CLIN ONCOL, V28, pE560, DOI 10.1200/JCO.2010.29.5170; Attard G, 2009, CANCER CELL, V16, P458, DOI 10.1016/j.ccr.2009.11.006; Attard G, 2009, J CLIN ONCOL, V27, P3742, DOI 10.1200/JCO.2008.20.0642; Barrie SE, 1997, J STEROID BIOCHEM, V60, P347, DOI 10.1016/S0960-0760(96)00225-7; BENNETT CL, 1994, CANCER INVEST, V12, P336, DOI 10.3109/07357909409023033; Bubley, 2007, J CLIN ONCOL, V25, P1154, DOI 10.1200/JCO.2007.11.1963; Bubley, 2000, J CLIN ONCOL, V18, P2644; Bubley GJ, 1999, J CLIN ONCOL, V17, P3461, DOI 10.1200/JCO.1999.17.11.3461; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Costa-Santos M, 2004, J CLIN ENDOCR METAB, V89, P49, DOI 10.1210/jc.2003-031021; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P1420; Danila DC, 2010, J CLIN ONCOL, V28, P1496, DOI 10.1200/JCO.2009.25.9259; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; de Bono JS, 2009, CLIN CANCER RES, V15, P1506; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; de Bono JS, 2010, ANN ONCOL S8, V21, pLBA5; Esper P, 1997, UROLOGY, V50, P920, DOI 10.1016/S0090-4295(97)00459-7; GELLER J, 1984, J UROLOGY, V132, P693, DOI 10.1016/S0022-5347(17)49829-6; Harris K, 2007, CLIN ONCOL-UK, V19, P523, DOI 10.1016/j.clon.2007.04.007; Hellerstedt BA, 2002, CA-CANCER J CLIN, V52, P154, DOI 10.3322/canjclin.52.3.154; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Jarman M, 1998, J MED CHEM, V41, P5375, DOI 10.1021/jm981017j; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Keating NL, 2010, J NATL CANCER I, V102, P39, DOI 10.1093/jnci/djp404; Lam JS, 2006, J UROLOGY, V175, P27, DOI 10.1016/S0022-5347(05)00034-0; Levine GN, 2010, CA-CANCER J CLIN, V60, P194, DOI 10.3322/caac.20061; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; Michaelson MD, 2008, CA-CANCER J CLIN, V58, P196, DOI 10.3322/CA.2008.0002; Michaelson MD, 2004, CLIN CANCER RES, V10, P2705, DOI 10.1158/1078-0432.CCR-03-0735; Miller WL, 2011, ENDOCR REV, V32, P81, DOI 10.1210/er.2010-0013; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Molina A, 2011, J UROLOGY, V185, P787, DOI 10.1016/j.juro.2010.10.042; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Page ST, 2006, J CLIN ENDOCR METAB, V91, P3850, DOI 10.1210/jc.2006-0968; POTTER GA, 1995, J MED CHEM, V38, P2463, DOI 10.1021/jm00013a022; Reid AHM, 2010, J CLIN ONCOL, V28, P1489, DOI 10.1200/JCO.2009.24.6819; Ryan CJ, 2010, J CLIN ONCOL, V28, P1481, DOI 10.1200/JCO.2009.24.1281; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525	50	3103	3162	6	228	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					1995	2005		10.1056/NEJMoa1014618	http://dx.doi.org/10.1056/NEJMoa1014618			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768QR	21612468	Green Published, Green Accepted			2022-12-28	WOS:000290952000004
J	Thigpen, MC; Whitney, CG; Messonnier, NE; Zell, ER; Lynfield, R; Hadler, JL; Harrison, LH; Farley, MM; Reingold, A; Bennett, NM; Craig, AS; Schaffner, W; Thomas, A; Lewis, MM; Scallan, E; Schuchat, A				Thigpen, Michael C.; Whitney, Cynthia G.; Messonnier, Nancy E.; Zell, Elizabeth R.; Lynfield, Ruth; Hadler, James L.; Harrison, Lee H.; Farley, Monica M.; Reingold, Arthur; Bennett, Nancy M.; Craig, Allen S.; Schaffner, William; Thomas, Ann; Lewis, Melissa M.; Scallan, Elaine; Schuchat, Anne		Emerging Infections Programs Netw	Bacterial Meningitis in the United States, 1998-2007	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCOCCAL CONJUGATE VACCINE; DISEASE; EPIDEMIOLOGY; SURVEILLANCE; LISTERIOSIS; ILLNESS; ADULTS	BACKGROUND The rate of bacterial meningitis declined by 55% in the United States in the early 1990s, when the Haemophilus influenzae type b (Hib) conjugate vaccine for infants was introduced. More recent prevention measures such as the pneumococcal conjugate vaccine and universal screening of pregnant women for group B streptococcus (GBS) have further changed the epidemiology of bacterial meningitis. METHODS We analyzed data on cases of bacterial meningitis reported among residents in eight surveillance areas of the Emerging Infections Programs Network, consisting of approximately 17.4 million persons, during 1998-2007. We defined bacterial meningitis as the presence of H. influenzae, Streptococcus pneumoniae, GBS, Listeria monocytogenes, or Neisseria meningitidis in cerebrospinal fluid or other normally sterile site in association with a clinical diagnosis of meningitis. RESULTS We identified 3188 patients with bacterial meningitis; of 3155 patients for whom outcome data were available, 466 (14.8%) died. The incidence of meningitis changed by -31% (95% confidence interval [CI], -33 to -29) during the surveillance period, from 2.00 cases per 100,000 population (95% CI, 1.85 to 2.15) in 1998-1999 to 1.38 cases per 100,000 population (95% CI 1.27 to 1.50) in 2006-2007. The median age of patients increased from 30.3 years in 1998-1999 to 41.9 years in 2006-2007 (P<0.001 by the Wilcoxon rank-sum test). The case fatality rate did not change significantly: it was 15.7% in 1998-1999 and 14.3% in 2006-2007 (P=0.50). Of the 1670 cases reported during 2003-2007, S. pneumoniae was the predominant infective species (58.0%), followed by GBS (18.1%), N. meningitidis (13.9%), H. influenzae (6.7%), and L. monocytogenes (3.4%). An estimated 4100 cases and 500 deaths from bacterial meningitis occurred annually in the United States during 2003-2007. CONCLUSIONS The rates of bacterial meningitis have decreased since 1998, but the disease still often results in death. With the success of pneumococcal and Hib conjugate vaccines in reducing the risk of meningitis among young children, the burden of bacterial meningitis is now borne more by older adults. (Funded by the Emerging Infections Programs, Centers for Disease Control and Prevention.)	[Thigpen, Michael C.; Whitney, Cynthia G.; Messonnier, Nancy E.; Zell, Elizabeth R.; Lewis, Melissa M.; Scallan, Elaine; Schuchat, Anne] Ctr Dis Control & Prevent, Atlanta, GA USA; [Farley, Monica M.] Georgia Dept Human Resources, Atlanta, GA USA; [Lynfield, Ruth] Minnesota Dept Hlth, Minneapolis, MN USA; [Hadler, James L.] Connecticut Dept Publ Hlth & Addict Serv, Hartford, CT 06106 USA; [Harrison, Lee H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Reingold, Arthur] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Craig, Allen S.; Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA	Centers for Disease Control & Prevention - USA; Minnesota Department of Health (MHD); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Berkeley; University of Rochester; Vanderbilt University	Thigpen, MC (corresponding author), 3150 Rampart Rd, Ft Collins, CO 80521 USA.	mthigpen@cdc.gov	Walter, Elaine Scallan/AAG-4278-2020		Centers for Disease Control and Prevention, Atlanta	Centers for Disease Control and Prevention, Atlanta(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Supported by the Emerging Infections Programs, Centers for Disease Control and Prevention, Atlanta.	Advisory Committee on Immunization Practices, 2009, ADV COMM IMM PRACT S, P59; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P258; Centers for Disease Control and Prevention, ACT BACT COR SURV AB; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P392; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P893; Centers for Disease Control and Prevention (CDC), 2010, ACT BACT COR SURV AB; Cohn AC, 2010, CLIN INFECT DIS, V50, P184, DOI 10.1086/649209; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Flannery B, 2006, ANN INTERN MED, V144, P1, DOI 10.7326/0003-4819-144-1-200601030-00004; Food Safety and Inspection Service, 2000, REV ACT PLAN CONTR L; Food Safety and Inspection Service, 2008, FSIS REG TEST LM RTE; FRASER DW, 1975, AM J EPIDEMIOL, V102, P394, DOI 10.1093/oxfordjournals.aje.a112178; FRASER DW, 1974, AM J EPIDEMIOL, V100, P29, DOI 10.1093/oxfordjournals.aje.a112005; Gottlieb SL, 2006, CLIN INFECT DIS, V42, P29, DOI 10.1086/498113; Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520; Hardnett FP, 2004, CLIN INFECT DIS, V38, pS121, DOI 10.1086/381602; Hsu HE, 2009, NEW ENGL J MED, V360, P244, DOI 10.1056/NEJMoa0800836; Jackson KA, 2010, EPIDEMIOL INFECT, V138, P1503, DOI 10.1017/S0950268810000294; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; National Association of State Public Health Veterinarians Inc. (NASPHV), 2005, MMWR Recomm Rep, V54, P1; Phares CR, 2008, JAMA-J AM MED ASSOC, V299, P2056, DOI 10.1001/jama.299.17.2056; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; Schrag Stephanie, 2002, MMWR Recomm Rep, V51, P1; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; Schuchat A, 2001, EMERG INFECT DIS, V7, P92, DOI 10.3201/eid0701.010114; Tsai CJ, 2008, CLIN INFECT DIS, V46, P1664, DOI 10.1086/587897; Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368; Varma JK, 2007, CLIN INFECT DIS, V44, P521, DOI 10.1086/509920; Voetsch AC, 2007, CLIN INFECT DIS, V44, P513, DOI 10.1086/511006; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823	32	527	569	2	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					2016	2025		10.1056/NEJMoa1005384	http://dx.doi.org/10.1056/NEJMoa1005384			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768QR	21612470				2022-12-28	WOS:000290952000006
J	Moynihan, R				Moynihan, Ray			It's time to rebuild the evidence base	BRITISH MEDICAL JOURNAL			English	Editorial Material							TRIALS		Univ Newcastle, Callaghan, NSW 2308, Australia	University of Newcastle	Moynihan, R (corresponding author), Univ Newcastle, Callaghan, NSW 2308, Australia.	Ray.Moynihan@newcastle.edu.au	Moynihan, Ray/ABC-3010-2020					Bero L, 2007, PLOS MED, V4, P1001, DOI 10.1371/journal.pmed.0040184; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Rattinger G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005826; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Roseman M, 2011, JAMA-J AM MED ASSOC, V305, P1008, DOI 10.1001/jama.2011.257; Smith R, 2005, PLOS MED, V2, P364, DOI 10.1371/journal.pmed.0020138.g001; Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779	7	4	4	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 25	2011	342								d3004	10.1136/bmj.d3004	http://dx.doi.org/10.1136/bmj.d3004			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771KE	21613342				2022-12-28	WOS:000291154800005
J	Brooks, M; Royse, C; Eisen, D; Sparks, P; Bhagwat, K; Royse, A				Brooks, Matthew; Royse, Colin; Eisen, Damon; Sparks, Paul; Bhagwat, Krishna; Royse, Alistair			An accidental mass	LANCET			English	Editorial Material							ASPERGILLUS-ENDOCARDITIS; INVASIVE ASPERGILLOSIS		[Bhagwat, Krishna; Royse, Alistair] Royal Melbourne Hosp, Dept Cardiothorac Surg, Melbourne, Vic 3050, Australia; [Brooks, Matthew; Sparks, Paul] Royal Melbourne Hosp, Dept Cardiol, Melbourne, Vic 3050, Australia; [Royse, Colin] Royal Melbourne Hosp, Dept Anaesthesia & Pain Management, Melbourne, Vic 3050, Australia; [Eisen, Damon] Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic 3050, Australia; [Royse, Colin] Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia	Royal Melbourne Hospital; Royal Melbourne Hospital; Royal Melbourne Hospital; Royal Melbourne Hospital; University of Melbourne	Royse, A (corresponding author), Royal Melbourne Hosp, Dept Cardiothorac Surg, Melbourne, Vic 3050, Australia.	alistair.royse@mh.org.au	Royse, Alistair/A-6046-2008; eisen, damon/AAC-7433-2019	Royse, Alistair/0000-0002-4449-663X; Eisen, Damon/0000-0002-8987-4358; Bhagwat, Krishna/0000-0002-4370-1435; Royse, Colin/0000-0002-2250-8927				DENNING DW, 1990, REV INFECT DIS, V12, P1147; El-Hamamsy I, 2005, ANN THORAC SURG, V80, P359, DOI 10.1016/j.athoracsur.2004.08.070; Hori A, 2002, J HOSP INFECT, V50, P175, DOI 10.1053/jhin.2001.1170; McCormack J, 2011, MED MYCOL, V49, pS30, DOI 10.3109/13693786.2010.498449; Segal BH, 2009, NEW ENGL J MED, V360, P1870, DOI 10.1056/NEJMra0808853	5	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	2011	377	9779					1806	1806		10.1016/S0140-6736(11)60284-5	http://dx.doi.org/10.1016/S0140-6736(11)60284-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771AS	21601711				2022-12-28	WOS:000291130200039
J	Fleury, S				Fleury, Sonia			Brazil's health-care reform: social movements and civil society	LANCET			English	Editorial Material									Getulio Vargas Fdn, Brazilian Sch Publ Adm & Business, BR-22250900 Rio De Janeiro, Brazil	Getulio Vargas Foundation	Fleury, S (corresponding author), Getulio Vargas Fdn, Brazilian Sch Publ Adm & Business, BR-22250900 Rio De Janeiro, Brazil.	Sonia.fleury@fgv.br						Avritzer Leonardo, 2009, PARTICIPACAO DEMOCRA, P151; Cortes Soraya Maria Vargas, 2009, PARTICIPACAO DEMOCRA, P102; DECARVALHO AI, 1997, HLTH DEMOCRACY CEBES, P25; FEDOZZI L., 2009, PARTICIPACAO DEMOCRA, P204; Fleury S, 2009, CIENC SAUDE COLETIVA, V14, P743, DOI 10.1590/S1413-81232009000300010; Le Loup G, 2009, AM J PUBLIC HEALTH, V99, P1; PAIM JS, 2007, BRAZILIAN SANITARY R	7	29	32	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	2011	377	9779					1724	1725		10.1016/S0140-6736(11)60318-8	http://dx.doi.org/10.1016/S0140-6736(11)60318-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771AS	21561650				2022-12-28	WOS:000291130200006
J	Schmoll, HJ				Schmoll, Hans-Joachim			Do we need oncology trials tailored for the elderly or frail?	LANCET			English	Editorial Material							ADVANCED COLORECTAL-CANCER; OXALIPLATIN		[Schmoll, Hans-Joachim] Univ Halle Wittenberg, Dept Internal Med 4, D-06120 Halle, Germany; [Schmoll, Hans-Joachim] Univ Halle Wittenberg, Ctr Cell & Gene Therapy, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Schmoll, HJ (corresponding author), Univ Halle Wittenberg, Dept Internal Med 4, D-06120 Halle, Germany.	hans-joachim.schmoll@uk-halle.de	schmoll, hans-joachim/AAO-5219-2021; Schmoll, Hans-Joachim/AAG-5888-2019	schmoll, hans-joachim/0000-0001-8705-0593; 				Goldberg RM, 2006, J CLIN ONCOL, V24, P4085, DOI 10.1200/JCO.2006.06.9039; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Raftery L, 2008, SEMIN ONCOL, V35, P561, DOI 10.1053/j.seminoncol.2008.08.004; Schmoll HJ, 2007, LANCET, V370, P105, DOI 10.1016/S0140-6736(07)61062-9; Seymour MT, 2011, LANCET, V377, P1749, DOI 10.1016/S0140-6736(11)60399-1; TEBBUTT NC, 2009, J CLIN ONCOL S, V27, P4023	7	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2011	377	9779					1725	1727		10.1016/S0140-6736(11)60654-5	http://dx.doi.org/10.1016/S0140-6736(11)60654-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771AS	21601694				2022-12-28	WOS:000291130200007
J	Dunkle, JA; Wang, LY; Feldman, MB; Pulk, A; Chen, VB; Kapral, GJ; Noeske, J; Richardson, JS; Blanchard, SC; Cate, JHD				Dunkle, Jack A.; Wang, Leyi; Feldman, Michael B.; Pulk, Arto; Chen, Vincent B.; Kapral, Gary J.; Noeske, Jonas; Richardson, Jane S.; Blanchard, Scott C.; Cate, Jamie H. Doudna			Structures of the Bacterial Ribosome in Classical and Hybrid States of tRNA Binding	SCIENCE			English	Article							AMINOACYL-TRANSFER-RNA; CRYSTAL-STRUCTURE; RECYCLING FACTOR; INTERMEDIATE STATES; MESSENGER-RNA; 70S RIBOSOME; TRANSLOCATION; DYNAMICS; SITE; TRANSLATION	During protein synthesis, the ribosome controls the movement of tRNA and mRNA by means of large-scale structural rearrangements. We describe structures of the intact bacterial ribosome from Escherichia coli that reveal how the ribosome binds tRNA in two functionally distinct states, determined to a resolution of similar to 3.2 angstroms by means of x-ray crystallography. One state positions tRNA in the peptidyl-tRNA binding site. The second, a fully rotated state, is stabilized by ribosome recycling factor and binds tRNA in a highly bent conformation in a hybrid peptidyl/exit site. The structures help to explain how the ratchet-like motion of the two ribosomal subunits contributes to the mechanisms of translocation, termination, and ribosome recycling.	[Dunkle, Jack A.; Pulk, Arto; Noeske, Jonas; Cate, Jamie H. Doudna] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Dunkle, Jack A.; Pulk, Arto; Noeske, Jonas; Cate, Jamie H. Doudna] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Wang, Leyi; Feldman, Michael B.; Blanchard, Scott C.] Cornell Univ, Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY 10065 USA; [Feldman, Michael B.] Weill Cornell Rockefeller Univ Sloan Kettering Tr, New York, NY 10065 USA; [Chen, Vincent B.; Kapral, Gary J.; Richardson, Jane S.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; [Cate, Jamie H. Doudna] Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Cornell University; Duke University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Cate, JHD (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	jcate@lbl.gov	Blanchard, Scott C./A-5804-2009; Richardson, Jane/Q-6478-2019; Dunkle, Jack/ABB-9713-2020; Classen, Scott/AAY-8176-2020	Blanchard, Scott C./0000-0003-2717-9365; Richardson, Jane/0000-0002-3311-2944; Dunkle, Jack/0000-0001-6252-0587; Feldman, Michael/0000-0001-7364-5211; Pulk, Arto/0000-0001-8793-3038; Chen, Vincent/0000-0003-2492-979X; Noeske, Jonas/0000-0002-8750-2008	National Institutes of Health [GM65050, GM079238, GM074127-04S1, GM088674, P01-GM63210, GM07739]; National Cancer Institute [CA92584]; National Center for Research Resources [RR-15301]; U.S. Department of Energy [DE-AC03 76SF00098, DE-AC02-06CH11357]; Human Frontiers in Science Program; NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079238, P01GM063210, T32GM007739, R01GM065050, R01GM074127, R01GM088674] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); U.S. Department of Energy(United States Department of Energy (DOE)); Human Frontiers in Science Program(Human Frontier Science Program); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank K. Hamadani for purified RRF; K. Nierhaus for tRNAPhe overexpression plasmids; K. Frankel, S. Classen, and G. Meigs for help with data measurement at the SIBYLS and 8.3.1 beamlines at the Advanced Light Source (ALS); R. Kanagalaghatta, D. Neau, F. Murphy, and I. Kourinov for help with data measurement at ID-24 at the Advanced Photon Source (APS); J. Headd for help with Phenix refinement; and J. Holton for useful crystallographic discussions. We also thank J. Doudna and H. Noller for helpful comments on the manuscript. Atomic coordinates and structure factors are deposited in the Protein Data Bank (accession codes 3R8N and 3R8S for the fully rotated state R<INF>F</INF>, 3R8O and 3R8T for the unrotated state R<INF>0</INF>). This work was funded by the National Institutes of Health (GM65050 to J.H.D.C., GM079238 to S.C.B, and GM074127-04S1, GM088674, and P01-GM63210 project IV to J. S. R.), National Cancer Institute grant CA92584 for the SIBYLS and 8.3.1 beam lines at the ALS, and National Center for Research Resources grant RR-15301 for the Northeastern Collaborative Access Team beam lines at 24-ID at APS, and by the U.S. Department of Energy (DE-AC03 76SF00098 for the SIBYLS and 8.3.1 beamlines at the ALS, and DE-AC02-06CH11357 for the APS). M.B.F. is a trainee in the Weill Cornell/Rockefeller University/SloanKettering Tri-Institutional MD-PhD Program supported by NIH Medical Scientist Training Program grant GM07739. J.N. is supported by a Human Frontiers in Science Program Postdoctoral Fellowship.	Agrawal RK, 2004, P NATL ACAD SCI USA, V101, P8900, DOI 10.1073/pnas.0401904101; Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399; Ben-Shem A, 2010, SCIENCE, V330, P1203, DOI 10.1126/science.1194294; Bokov K, 2009, NATURE, V457, P977, DOI 10.1038/nature07749; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-2; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Connell SR, 2007, MOL CELL, V25, P751, DOI 10.1016/j.molcel.2007.01.027; Cornish PV, 2008, MOL CELL, V30, P578, DOI 10.1016/j.molcel.2008.05.004; Cukras AR, 2005, J MOL BIOL, V349, P47, DOI 10.1016/j.jmb.2005.03.075; Dunkle JA, 2010, ANNU REV BIOPHYS, V39, P227, DOI 10.1146/annurev.biophys.37.032807.125954; Ermolenko DN, 2007, NAT STRUCT MOL BIOL, V14, P493, DOI 10.1038/nsmb1243; Feinberg JS, 2001, P NATL ACAD SCI USA, V98, P11120, DOI 10.1073/pnas.211184098; Feldman MB, 2010, NAT CHEM BIOL, V6, P54, DOI [10.1038/NCHEMBIO.274, 10.1038/nchembio.274]; Fischer N, 2010, NATURE, V466, P329, DOI 10.1038/nature09206; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Frank J, 2007, P NATL ACAD SCI USA, V104, P19671, DOI 10.1073/pnas.0708517104; Gao N, 2005, MOL CELL, V18, P663, DOI 10.1016/j.molcel.2005.05.005; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; Janosi L, 2000, J MOL BIOL, V295, P815, DOI 10.1006/jmbi.1999.3401; Joseph S, 1998, EMBO J, V17, P3478, DOI 10.1093/emboj/17.12.3478; Komoda T, 2006, J BIOL CHEM, V281, P32303, DOI 10.1074/jbc.M607058200; Lancaster L, 2002, CELL, V111, P129, DOI 10.1016/S0092-8674(02)00938-8; Li W, 2007, P NATL ACAD SCI USA, V104, P16540, DOI 10.1073/pnas.0708094104; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Munro JB, 2009, TRENDS BIOCHEM SCI, V34, P390, DOI 10.1016/j.tibs.2009.04.004; Ratje AH, 2010, NATURE, V468, P713, DOI 10.1038/nature09547; Savelsbergh A, 2009, RNA, V15, P772, DOI 10.1261/rna.1592509; Schmeing TM, 2009, SCIENCE, V326, P688, DOI 10.1126/science.1179700; Schmeing TM, 2009, NATURE, V461, P1234, DOI 10.1038/nature08403; Schmeing TM, 2003, RNA, V9, P1345, DOI 10.1261/rna.5120503; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Selmer M, 2006, SCIENCE, V313, P1935, DOI 10.1126/science.1131127; Semenkov YP, 2000, NAT STRUCT BIOL, V7, P1027; Shenvi CL, 2005, RNA, V11, P1898, DOI 10.1261/rna.2192805; Spahn CMT, 2004, EMBO J, V23, P1008, DOI 10.1038/sj.emboj.7600102; Spirin AS, 2009, J BIOL CHEM, V284, P21103, DOI 10.1074/jbc.X109.001552; Stanley RE, 2010, NAT STRUCT MOL BIOL, V17, P289, DOI 10.1038/nsmb.1755; Sternberg SH, 2009, NAT STRUCT MOL BIOL, V16, P861, DOI 10.1038/nsmb.1622; Valle M, 2003, CELL, V114, P123, DOI 10.1016/S0092-8674(03)00476-8; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; Voorhees RM, 2010, SCIENCE, V330, P835, DOI 10.1126/science.1194460; Weixlbaumer A, 2007, NAT STRUCT MOL BIOL, V14, P733, DOI 10.1038/nsmb1282; Zavialov AV, 2003, CELL, V114, P113, DOI 10.1016/S0092-8674(03)00478-1; Zhang W, 2009, SCIENCE, V325, P1014, DOI 10.1126/science.1175275	46	261	267	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2011	332	6032					981	984		10.1126/science.1202692	http://dx.doi.org/10.1126/science.1202692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596992	Green Accepted			2022-12-28	WOS:000290766600048
J	Pankhania, M; Judd, O; Ward, A				Pankhania, Miran; Judd, Owen; Ward, Andy			10-MINUTE CONSULTATION Otorrhoea	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Pankhania, Miran] Milton Keynes Dist Gen Hosp, Dept ENT, Milton Keynes MK6 5LD, Bucks, England; [Judd, Owen] Leicester Royal Infirm, Dept ENT, Leicester LE1 5WW, Leics, England; [Ward, Andy] S Wigston Hlth Ctr, Leicester LE18 4SE, Leics, England	University of Leicester	Pankhania, M (corresponding author), Milton Keynes Dist Gen Hosp, Dept ENT, Milton Keynes MK6 5LD, Bucks, England.	pank@doctors.org.uk	Ward, Andy/AAH-8950-2021	Ward, Andy/0000-0002-4955-1984; Judd, Owen/0000-0003-3112-931X				Beers SL, 2004, PEDIATR EMERG CARE, V20, P250, DOI 10.1097/01.pec.0000121246.99242.f5; Grevers G, 2010, INT J PEDIATR OTORHI, V74, P572, DOI 10.1016/j.ijporl.2010.03.049; McHugh TP, 2007, J EMERG MED, V32, P375, DOI 10.1016/j.jemermed.2006.08.015; Phillips JS, 2007, CLIN OTOLARYNGOL, V32, P330, DOI 10.1111/j.1749-4486.2007.01532.x	4	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 20	2011	342								d2299	10.1136/bmj.d2299	http://dx.doi.org/10.1136/bmj.d2299			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QT	21602234				2022-12-28	WOS:000290952200001
J	He, FL; Hubbell, SP				He, Fangliang; Hubbell, Stephen P.			Species-area relationships always overestimate extinction rates from habitat loss	NATURE			English	Article							DEFORESTATION; PATTERNS	Extinction from habitat loss is the signature conservation problem of the twenty-first century(1). Despite its importance, estimating extinction rates is still highly uncertain because no proven direct methods or reliable data exist for verifying extinctions. The most widely used indirect method is to estimate extinction rates by reversing the species-area accumulation curve, extrapolating backwards to smaller areas to calculate expected species loss. Estimates of extinction rates based on this method are almost always much higher than those actually observed(2-5). This discrepancy gave rise to the concept of an 'extinction debt', referring to species 'committed to extinction' owing to habitat loss and reduced population size but not yet extinct during a non-equilibrium period(6,7). Here we show that the extinction debt as currently defined is largely a sampling artefact due to an unrecognized difference between the underlying sampling problems when constructing a species-area relationship (SAR) and when extrapolating species extinction from habitat loss. The key mathematical result is that the area required to remove the last individual of a species (extinction) is larger, almost always much larger, than the sample area needed to encounter the first individual of a species, irrespective of species distribution and spatial scale. We illustrate these results with data from a global network of large, mapped forest plots and ranges of passerine bird species in the continental USA; and we show that overestimation can be greater than 160%. Although we conclude that extinctions caused by habitat loss require greater loss of habitat than previously thought, our results must not lead to complacency about extinction due to habitat loss, which is a real and growing threat.	[He, Fangliang] Sun Yat Sen Univ, State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China; [He, Fangliang] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510275, Guangdong, Peoples R China; [He, Fangliang] Univ Alberta, Dept Renewable Resources, Edmonton, AB T6G 2H1, Canada; [Hubbell, Stephen P.] Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA 90095 USA; [Hubbell, Stephen P.] Smithsonian Trop Res Inst, Ctr Trop Forest Sci, Unit 0948, APO, AA 34002 USA	Sun Yat Sen University; Sun Yat Sen University; University of Alberta; University of California System; University of California Los Angeles; Smithsonian Institution; Smithsonian Tropical Research Institute	He, FL (corresponding author), Sun Yat Sen Univ, State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China.	fhe@mail.sysu.edu.cn; shubbell@eeb.ucla.edu			Sun Yat-sen University; Natural Sciences and Engineering Research Council (Canada); NASA (National Aeronautics and Space Administration); US National Science Foundation	Sun Yat-sen University; Natural Sciences and Engineering Research Council (Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC)); NASA (National Aeronautics and Space Administration)(National Aeronautics & Space Administration (NASA)); US National Science Foundation(National Science Foundation (NSF))	We acknowledge the work of the principal investigators and their field assistants for collecting the field data on the large plots of the Center for Tropical Forest Science network. We are grateful to P. Gowaty, K. Gaston and M. Rosenzweig for their comments on the paper. We thank R. Condit, R. Perez and S. Agular for Barro Colorado Island, R. Valencia for Yasuni, N. Supardi Noor and R. Kassim for Pasoh, D. Thomas, D. Kenfack and G. Chuyong for Korup, W.-H. Ye for Dinghushan, I.-F. Sun and C.-F. Hseih for Fushan, X.-H. Wang for Tiantong, Z.-Q. Hao for Changbaishan and X.-L. Wang for processing the passerine data. This work was supported by Sun Yat-sen University, the Natural Sciences and Engineering Research Council (Canada), NASA (National Aeronautics and Space Administration) and the US National Science Foundation.	Achard F, 2002, SCIENCE, V297, P999, DOI 10.1126/science.1070656; Arrhenius O, 1921, J ECOL, V9, P95, DOI 10.2307/2255763; Barnosky AD, 2011, NATURE, V471, P51, DOI 10.1038/nature09678; Brooks T, 1996, NATURE, V380, P115, DOI 10.1038/380115a0; Brooks TM, 1999, CONSERV BIOL, V13, P1140, DOI 10.1046/j.1523-1739.1999.98341.x; COLEMAN BD, 1981, MATH BIOSCI, V54, P191, DOI 10.1016/0025-5564(81)90086-9; Condit R, 2000, SCIENCE, V288, P1414, DOI 10.1126/science.288.5470.1414; DIAL R, 1994, NATURE, V370, P104, DOI 10.1038/370104b0; Ehrlich P.R., 1981, EXTINCTION; Green JL, 2003, ECOLOGY, V84, P3090, DOI 10.1890/02-3096; Harte J, 2004, NATURE, V430, DOI 10.1038/nature02718; He FL, 2002, ECOLOGY, V83, P1185, DOI 10.1890/0012-9658(2002)083[1185:SDPDFS]2.0.CO;2; HEYWOOD VH, 1992, TROPICAL DEFORESTATION AND SPECIES EXTINCTION, P91; HEYWOOD VH, 1994, NATURE, V368, P105, DOI 10.1038/368105a0; Kinzig AP, 2000, ECOLOGY, V81, P3305, DOI 10.1890/0012-9658(2000)081[3305:IOEARF]2.0.CO;2; Lovejoy T.E, 1980, GLOBAL 2000 REPORT P, V2, P328; Lugo A.E., 1988, P58; May Robert M., 1995, P1; Millennium Ecosystem Assessment, 2005, EC HUM WELL BEING BI; Myers N, 1979, SINKING ARK NEW LOOK; Myers N., 1983, TROPICAL RAIN FOREST, P325; National Research Council, 1980, RES PRIOR TROP BIOL; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Pimm SL, 2000, NATURE, V403, P843, DOI 10.1038/35002708; PIMM SL, 1995, P NATL ACAD SCI USA, V92, P9343, DOI 10.1073/pnas.92.20.9343; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SIMBERLOFF D, 1992, TROPICAL DEFORESTATION AND SPECIES EXTINCTION, P75; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; TILMAN D, 1994, NATURE, V371, P65, DOI 10.1038/371065a0; WCMC-World Conservation Monitoring Centre, 1992, GLOB BIOD STAT EARTH	30	273	289	11	434	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					368	371		10.1038/nature09985	http://dx.doi.org/10.1038/nature09985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593870				2022-12-28	WOS:000290722400047
J	Venter, WDF; Ndung'u, T; Karim, QA				Venter, W. D. Francois; Ndung'u, Thumbi; Karim, Quarraisha Abdool			Case 15-2011: A 19-Year-Old South African Woman with Headache, Fatigue, and Vaginal Discharge	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	4th Annual Workshop on Advanced Clinical Care - Aids	SEP 30-OCT 01, 2010	Durban, SOUTH AFRICA	Harvard Univ AIDS Res, McCord Hosp, Univ KwaZulu Natal, S African HIV Clin Soc, Dept Hlth KwaZulu Natal			HIV-INFECTION; ANTIRETROVIRAL THERAPY; VIRAL LOAD; TRANSMISSION; PREVENTION; COINFECTIONS; EFFICIENT; WOMEN		[Venter, W. D. Francois] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa; [Venter, W. D. Francois] Univ Witwatersrand, Dept Med, ZA-2001 Johannesburg, South Africa; [Ndung'u, Thumbi] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa; [Karim, Quarraisha Abdool] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Doris Duke Med Res Inst, Ctr AIDS Programme Res South Africa, Durban, South Africa; [Karim, Quarraisha Abdool] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	University of Witwatersrand; University of Witwatersrand; University of Kwazulu Natal; University of Kwazulu Natal; Columbia University	Venter, WDF (corresponding author), Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.		Abdool Karim, Quarraisha/GVS-1160-2022	Abdool Karim, Quarraisha/0000-0002-0985-477X; Ndung'u, Thumbi/0000-0003-2962-3992; Venter, Willem/0000-0002-4157-732X				Abdool Karim Q, 2010, 18 INT AIDS C 2010 V; Barnighausen T, 2008, AIDS, V22, P139, DOI 10.1097/QAD.0b013e3282f2ef43; Boulle A, 2008, B WORLD HEALTH ORGAN, V86, P678, DOI 10.2471/BLT.07.045294; Branson BM, 2010, JAIDS-J ACQ IMM DEF, V55, pS102, DOI 10.1097/QAI.0b013e3181fbca44; Brenchley JM, 2008, CURR OPIN HIV AIDS, V3, P356, DOI 10.1097/COH.0b013e3282f9ae9c; Crepaz N, 2006, AIDS, V20, P143, DOI 10.1097/01.aids.0000196166.48518.a0; *DEP HLTH, 2008, 1 LIN COMPR MAN CONT, P1; GOUWS E, 2010, HIV AIDS S AFRICA, P74; Gregson S, 2002, LANCET, V359, P1896, DOI 10.1016/S0140-6736(02)08780-9; Gregson S, 2002, LANCET, V360, P1102; Janssen RS, 1999, JAMA-J AM MED ASSOC, V281, P1893; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; Karim QA, 2010, HIV AIDS S AFRICA, P285; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Karim SSA, 2009, LANCET, V374, P921, DOI 10.1016/S0140-6736(09)60916-8; Kassutto S, 2006, CLIN INFECT DIS, V42, P1024, DOI 10.1086/500410; Lewis D. A., 2009, Southern African Journal of Epidemiology & Infection, V24, P6; Lewis DA, 2009, 18 ISSTDR CONJ BASHH; Mhlongo S, 2010, SEX TRANSM DIS, V37, P566, DOI 10.1097/OLQ.0b013e3181d877b7; Modjarrad K, 2010, LANCET INFECT DIS, V10, P455, DOI 10.1016/S1473-3099(10)70093-1; Moir S, 2010, BLOOD, V116, P5571, DOI 10.1182/blood-2010-05-285528; National Department of Health, 2010, CLIN GUID MAN HIV AI; National Department of Health, 2009, NAT HIV SYPH ANT SER; O'Farrell N, 2008, SEX TRANSM DIS, V35, P545, DOI 10.1097/OLQ.0b013e31816a4f2e; OFARRELL MJ, 1971, COMP BIOCHEM PHYSIOL, V39, P549, DOI 10.1016/0300-9629(71)90318-5; OFARRELL N, 1994, GENITOURIN MED, V70, P7; Padian NS, 2010, AIDS, V24, P621, DOI 10.1097/QAD.0b013e328337798a; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2009, GUIDELINES USE ANTIR; Pettifor AE, 2007, AIDS, V21, P861, DOI 10.1097/QAD.0b013e3280f00fb3; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rider LG, 2009, NEW ENGL J MED, V360, P1540; Rosenberg ES, M53A CLSI; Shisana O, 2009, S AFRICAN NATL HIV P; Siegfried N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008272.pub2; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; Vanhems P, 1999, J ACQ IMMUN DEF SYND, V21, P99; World Health Organization, 2007, GUID PROV IN HIV TES; World Health Organization, 2009, RAP ADV ANT THER HIV	39	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					1956	1964		10.1056/NEJMcpc1100926	http://dx.doi.org/10.1056/NEJMcpc1100926			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	765PJ	21591948	Green Published			2022-12-28	WOS:000290720700013
J	Adler-Milstein, J; Bates, DW; Jha, AK				Adler-Milstein, Julia; Bates, David W.; Jha, Ashish K.			A Survey of Health Information Exchange Organizations in the United States: Implications for Meaningful Use	ANNALS OF INTERNAL MEDICINE			English	Article								Background: To receive financial incentives for meaningful use of electronic health records, physicians and hospitals will need to engage in health information exchange (HIE). For most providers, joining regional organizations that support HIE is the most viable approach currently available. Objective: To assess the state of HIE in the United States through regional health information organizations (RHIOs). Design: Survey. Setting: All RHIOs in the United States. Participants: 179 U. S.-based RHIOs that facilitated HIE as of December 2009. Measurements: Number of operational RHIOs, the subset of operational RHIOs that supported stage 1 meaningful use, and the subset that supported robust HIE; number of ambulatory practices and hospitals participating in RHIOs; and number of financially viable RHIOs. Results: Of 197 potential RHIOs, 179 (91%) reported their status and 165 (84%) returned completed surveys. Of these, 75 RHIOs were operational, covering approximately 14% of U. S. hospitals and 3% of ambulatory practices. Thirteen RHIOs supported stage 1 meaningful use (covering 3% of hospitals and 0.9% of practices), and none met an expert-derived definition of a comprehensive RHIO. Overall, 50 of 75 RHIOs (67%) did not meet the criteria for financial viability. Limitations: Survey data were self-reported. The sample may not have included all HIE efforts, particularly those of individual providers who set up their own data-exchange agreements. Conclusion: These findings call into question whether RHIOs in their current form can be self-sustaining and effective in helping U. S. physicians and hospitals engage in robust HIE to improve the quality and efficiency of care.	[Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Business, Boston, MA 02163 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Jha, AK (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	ajha@hsph.harvard.edu	Bates, David/AAE-7283-2019		ONC for Health Information Technology at the U.S. Department of Health and Human Services	ONC for Health Information Technology at the U.S. Department of Health and Human Services	Grant Support: By a contract from the ONC for Health Information Technology at the U.S. Department of Health and Human Services.	Adler-Milstein J, 2008, HEALTH AFFAIR, V27, pW60, DOI 10.1377/hlthaff.27.1.w60; Adler-Milstein J, 2009, HEALTH AFFAIR, V28, P483, DOI 10.1377/hlthaff.28.2.483; BLUMENTHAL D, 2010, REQUIREMENTS RECOMME; Blumenthal D, 2010, NEW ENGL J MED, V363, P501, DOI 10.1056/NEJMp1006114; Blumenthal D, 2010, NEW ENGL J MED, V362, P382, DOI 10.1056/NEJMp0912825; Blumenthal D, 2009, NEW ENGL J MED, V360, P1477, DOI 10.1056/NEJMp0901592; Brown BB, 1968, DELPHI PROCESS METHO; *EHEALTH IN, 2009, MAP HLTH INF EXCH AC; Fontaine P, 2010, ARCH INTERN MED, V170, P622, DOI 10.1001/archinternmed.2010.54; Grossman JM, 2006, HEALTH AFFAIR, V25, P1629, DOI 10.1377/hlthaff.25.6.1629; Markle Foundation, 2005, ATT AM REG PERS HLTH; Rudin RS, 2009, AM J PUBLIC HEALTH, V99, P950, DOI 10.2105/AJPH.2008.144873; Tripathi M, 2009, HEALTH AFFAIR, V28, P435, DOI 10.1377/hlthaff.28.2.435; WALKER J, 2005, HLTH AFF MILLWOOD S; Wright A, 2010, J AM MED INFORM ASSN, V17, P66, DOI 10.1197/jamia.M3241	15	85	85	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10					666	+		10.7326/0003-4819-154-10-201105170-00006	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	764HK	21576534				2022-12-28	WOS:000290620300015
J	Lebwohl, M				Lebwohl, Mark			Regular sunscreen use reduces invasive but not overall melanoma in white adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Mt Sinai Sch Med, New York, NY USA	Icahn School of Medicine at Mount Sinai	Lebwohl, M (corresponding author), Mt Sinai Sch Med, New York, NY USA.							Rigel DS, 2010, SEMIN CUTAN MED SURG, V29, P204, DOI 10.1016/j.sder.2010.10.005	1	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-12	10.7326/0003-4819-154-10-201105170-02012	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576530				2022-12-28	WOS:000290620300011
J	Rayman, MP; Stranges, S; Griffin, BA; Pastor-Barriuso, R; Guallar, E				Rayman, Margaret P.; Stranges, Saverio; Griffin, Bruce A.; Pastor-Barriuso, Roberto; Guallar, Eliseo			Effect of Supplementation With High-Selenium Yeast on Plasma Lipids A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; ISCHEMIC-HEART-DISEASE; SERUM SELENIUM; VITAMIN-E; GLUTATHIONE-PEROXIDASE; US ADULTS; PREVENTION; MORTALITY; CANCER; RISK	Background: High selenium status has been linked to elevated blood cholesterol levels in cross-sectional studies. Objective: To investigate the effect of selenium supplementation on plasma lipids. Design: Randomized, placebo-controlled, parallel-group study stratified by age and sex. Participants, research nurses, and persons assessing outcomes were blinded to treatment assignment. (International Standard Randomised Controlled Trial Number Register registration number: ISRCTN25193534) Setting: 4 general practices in the United Kingdom. Participants: 501 volunteers aged 60 to 74 years. Intervention: Participants received selenium, 100 mcg/d (n = 127), 200 mcg/d (n = 127), or 300 mcg/d (n = 126), as high-selenium yeast or a yeast-based placebo (n = 121) for 6 months. Measurements: Total and high-density lipoprotein (HDL) cholesterol concentrations were measured in nonfasting plasma samples stored from participants in the UK PRECISE (United Kingdom PREvention of Cancer by Intervention with SElenium) Pilot Study at baseline (n = 454) and at 6 months (n = 394). Non-HDL cholesterol levels were calculated. Results: Mean plasma selenium concentration was 88.8 ng/g (SD, 19.2) at baseline and increased statistically significantly in the treatment groups. The adjusted difference in change in total cholesterol levels for selenium compared with placebo was -0.22 mmol/L (-8.5 mg/dL) (95% CI, -0.42 to -0.03 mmol/L [-16.2 to -1.2 mg/dL]; P = 0.02) for 100 mcg of selenium per day, -0.25 mmol/L (-9.7 mg/dL) (CI, -0.44 to -0.07 mmol/L [-17.0 to -2.7 mg/dL]; P = 0.008) for 200 mcg of selenium per day, and -0.07 mmol/L (-2.7 mg/dL) (CI, -0.26 to 0.12 mmol/L [-10.1 to 4.6 mg/dL]; P = 0.46) for 300 mcg of selenium per day. Similar reductions were observed for non-HDL cholesterol levels. There was no apparent difference in change in HDL cholesterol levels with 100 and 200 mcg of selenium per day, but the difference was an adjusted 0.06 mmol/L (2.3 mg/dL) (CI, 0.00 to 0.11 mmol/L [0.0 to 4.3 mg/dL]; P = 0.045) with 300 mcg of selenium per day. The total-HDL cholesterol ratio decreased progressively with increasing selenium dose (overall P = 0.01). Limitation: The duration of supplementation was limited, as was the age range of the participants. Conclusion: Selenium supplementation seemed to have modestly beneficial effects on plasma lipid levels in this sample of persons with relatively low selenium status. The clinical significance of the findings is unclear and should not be used to justify the use of selenium supplementation as additional or alternative therapy for dyslipidemia. This is particularly true for persons with higher selenium status, given the limitations of the trial and the potential additional risk in other metabolic dimensions.	[Rayman, Margaret P.] Univ Surrey, Fac Hlth & Med Sci, Guildford GU2 7XH, Surrey, England; Univ Warwick, Sch Med, Hlth Sci Res Inst, Coventry CV4 7AL, W Midlands, England; Carlos III Inst Hlth, Natl Ctr Epidemiol, Madrid, Spain; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	University of Surrey; University of Warwick; Instituto de Salud Carlos III; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Rayman, MP (corresponding author), Univ Surrey, Fac Hlth & Med Sci, Guildford GU2 7XH, Surrey, England.	m.rayman@surrey.ac.uk	Guallar, Eliseo/D-3807-2014; Pastor-Barriuso, Roberto/AAA-6746-2019	Guallar, Eliseo/0000-0002-4471-9565; Pastor-Barriuso, Roberto/0000-0002-7325-3960; Stranges, Saverio/0000-0001-5226-8373	Cancer Research UK (formerly Cancer Research Campaign); Cardiovascular Disease, Diabetes AMP; Metabolism Research Theme, University of Surrey	Cancer Research UK (formerly Cancer Research Campaign)(Cancer Research UK); Cardiovascular Disease, Diabetes AMP; Metabolism Research Theme, University of Surrey	Grant Support: By Cancer Research UK (formerly Cancer Research Campaign) and the Cardiovascular Disease, Diabetes & Metabolism Research Theme, University of Surrey.	Albert PS, 1999, STAT MED, V18, P1707, DOI 10.1002/(SICI)1097-0258(19990715)18:13<1707::AID-SIM138>3.0.CO;2-H; Arnaud J, 2009, J TRACE ELEM MED BIO, V23, P21, DOI 10.1016/j.jtemb.2008.08.001; Bates CJ, 2002, J TRACE ELEM MED BIO, V16, P1, DOI 10.1016/S0946-672X(02)80002-5; Bekaert B, 2008, MOL NUTR FOOD RES, V52, P1324, DOI 10.1002/mnfr.200700353; Bjelakovic G, 2007, JAMA-J AM MED ASSOC, V297, P842, DOI 10.1001/jama.297.8.842; Blankenberg S, 2003, NEW ENGL J MED, V349, P1605, DOI 10.1056/NEJMoa030535; Bleys J, 2008, AM J CLIN NUTR, V88, P416; Bleys J, 2008, ARCH INTERN MED, V168, P404, DOI 10.1001/archinternmed.2007.74; Brigelius-Flohe R, 2003, ANTIOXID REDOX SIGN, V5, P205, DOI 10.1089/152308603764816569; Centers for Disease Control and Prevention, 2020, NAT HLTH NUTR EX SUR; Coudray C, 1997, J AM COLL NUTR, V16, P584; Curran JE, 2005, NAT GENET, V37, P1234, DOI 10.1038/ng1655; Dhingra Sanjiv, 2005, Lipids Health Dis, V4, P28, DOI 10.1186/1476-511X-4-28; Diggle P., 2002, ANAL LONGITUDINAL DA, DOI DOI 10.2307/2983303; Duffield AJ, 1999, AM J CLIN NUTR, V70, P896; Flores-Mateo G, 2006, AM J CLIN NUTR, V84, P762, DOI 10.1093/ajcn/84.4.762; Gamez C, 1997, CLIN CHEM, V43, P693; Gao Y, 2006, CYTOKINE, V33, P246, DOI 10.1016/j.cyto.2006.02.005; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; Halloran P, 1999, ARCH PATHOL LAB MED, V123, P317; JOSSA F, 1991, ATHEROSCLEROSIS, V87, P129, DOI 10.1016/0021-9150(91)90015-U; Klopotek A, 2006, EXP BIOL MED, V231, P1365, DOI 10.1177/153537020623100810; Laclaustra M, 2010, ATHEROSCLEROSIS, V210, P643, DOI 10.1016/j.atherosclerosis.2010.01.005; Lide D. R., 1993, HDB CHEM PHYS; Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864; LUOMA PV, 1984, RES COMMUN CHEM PATH, V46, P469; Mazur A, 1996, BRIT J NUTR, V76, P899, DOI 10.1079/BJN19960096; Moosmann B, 2004, LANCET, V363, P892, DOI 10.1016/S0140-6736(04)15739-5; Neve J, 1996, J Cardiovasc Risk, V3, P42; Raudenbush SW, 2002, HIERARCHICAL LINEAR; Rayman M, 2006, BIOL PSYCHIAT, V59, P147, DOI 10.1016/j.biopsych.2005.06.019; Rayman MP, 2008, AM J CLIN NUTR, V87, P370, DOI 10.1093/ajcn/87.2.370; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SALONEN JT, 1988, ATHEROSCLEROSIS, V70, P155, DOI 10.1016/0021-9150(88)90109-8; SALONEN JT, 1982, LANCET, V2, P175; SATTLER W, 1994, ARCH BIOCHEM BIOPHYS, V309, P214, DOI 10.1006/abbi.1994.1105; Sengupta A, 2008, BIOCHEM BIOPH RES CO, V365, P446, DOI 10.1016/j.bbrc.2007.10.189; Stranges S, 2010, NUTR METAB CARDIOVAS, V20, P754, DOI 10.1016/j.numecd.2010.10.001; Stranges S, 2006, AM J EPIDEMIOL, V163, P694, DOI 10.1093/aje/kwj097; Stranges S, 2007, ANN INTERN MED, V147, P217, DOI 10.7326/0003-4819-147-4-200708210-00175; Stranges S, 2010, J NUTR, V140, P81, DOI 10.3945/jn.109.111252; SUADICANI P, 1992, ATHEROSCLEROSIS, V96, P33, DOI 10.1016/0021-9150(92)90035-F; Touyz RM, 2006, VASC PHARMACOL, V45, P19, DOI 10.1016/j.vph.2005.11.014; Vunta H, 2007, J BIOL CHEM, V282, P17964, DOI 10.1074/jbc.M703075200; WOJCICKI J, 1991, ATHEROSCLEROSIS, V87, P9, DOI 10.1016/0021-9150(91)90227-T; Wolf NM, 2010, BRIT J NUTR, V104, P520, DOI 10.1017/S0007114510000899; Xun PC, 2010, ATHEROSCLEROSIS, V210, P662, DOI 10.1016/j.atherosclerosis.2010.01.021; Yang KC, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-38; YU SY, 1990, BIOL TRACE ELEM RES, V24, P105, DOI 10.1007/BF02917199	49	92	94	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10					656	+		10.7326/0003-4819-154-10-201105170-00005	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-00005			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576533				2022-12-28	WOS:000290620300014
J	Cohen, D				Cohen, Deborah			MEDICAL DEVICES Out of joint: The story of the ASR	BRITISH MEDICAL JOURNAL			English	Editorial Material							ON-METAL BEARINGS; TOTAL HIP REPLACEMENTS; RESURFACING ARTHROPLASTY; WEAR; FAILURE; LUBRICATION; COMPONENT; DIAMETER		BMJ, London WC1H 9JR, England		Cohen, D (corresponding author), BMJ, London WC1H 9JR, England.	dcohen@bmj.com						[Anonymous], 2002, PR NEWSWIRE; [Australian Orthopaedic Association AOA], 2010, NAT JOINT REPL REG A; Australian Orthopaedic Association, 2008, NAT JOINT REPL REG A; Australian Orthopaedic Association, 2007, NAT JOINT REPL REG A; British Orthopaedic Association British Hip Society, 2011, LARG DIAM MET MET BE; BULSTRODE CJK, 1993, BRIT MED J, V306, P732, DOI 10.1136/bmj.306.6880.732; Cohen D, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2748; De Haan R, 2008, J BONE JOINT SURG BR, V90B, P1291, DOI 10.1302/0301-620X.90B10.20533; Della Valle CJ, 2009, CLIN ORTHOP RELAT R, V467, P72, DOI 10.1007/s11999-008-0563-2; Dowson D., 2004, J ARTHROPLASTY S3, V19; FDA, 2011, CONC MET ON MET HIP; *FINSB ORTH, 2006, B FINSB ORTH, V58; Grammatopoulos G, 2009, J BONE JOINT SURG BR, V91B, P1019, DOI 10.1302/0301-620X.91B8.22562; *HAUT AUTH SANT, 2008, COMM EV PROD PREST; Kamali A, 2010, J BONE JOINT SURG BR, V92B, P717, DOI 10.1302/0301-620X.92B5.23320; Kinbrum A, 2008, P I MECH ENG H, V222, P887, DOI 10.1243/09544119JEIM387; Langton DJ, 2008, J BONE JOINT SURG BR, V90B, P1143, DOI 10.1302/0301-620X.90B9.20785; Langton DJ, 2010, J BONE JOINT SURG BR, V92B, P38, DOI 10.1302/0301-620X.92B1.22770; Langton DJ, 2009, J BONE JOINT SURG BR, V91B, P1287, DOI 10.1302/0301-620X.91B10.22308; Langton DJ, 2011, ORTHOP CLIN N AM, V42, P169, DOI 10.1016/j.ocl.2011.01.006; Lavigne M, 2011, J BONE JOINT SURG AM, V93A, P128, DOI 10.2106/JBJS.J.01885; Learmonth ID, 2007, LANCET, V370, P1508, DOI 10.1016/S0140-6736(07)60457-7; Lee Reginald K, 2010, Surg Technol Int, V20, P303; *MCMINN CTR, NO LIGHTS DEB ASR VS; *MHRA, 2001, COMM SAF DEV M 19 JU; MHRA, 2006, COMM SAF DEV M 23 MA; Morlock MM, 2008, J BONE JOINT SURG AM, V90A, P89, DOI 10.2106/JBJS.H.00621; Muirhead-Allwood SK, 1998, BRIT MED J, V316, P644, DOI 10.1136/bmj.316.7132.644; PricewaterhouseCoopers, 2011, MED TECHN INN SCOR; Schmalzried TP, 2000, CLIN ORTHOP RELAT R, P36; Shimmin AJ, 2005, J BONE JOINT SURG BR, V87B, P463, DOI 10.1302/0301-620X.87B4; Smith SL, 2001, P I MECH ENG H, V215, P161, DOI 10.1243/0954411011533724; Smith SL, 2001, P I MECH ENG C-J MEC, V215, P1, DOI 10.1243/0954406011520454; Tanne JH, 2007, BRIT MED J, V335, P1065, DOI 10.1136/bmj.39405.383970.DB; Zuckerman DM, 2011, ARCH INTERN MED 0214; 2010, CLINICA         0726	36	86	86	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 14	2011	342								d2905	10.1136/bmj.d2905	http://dx.doi.org/10.1136/bmj.d2905			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765OV	21572134	Green Published, Bronze			2022-12-28	WOS:000290719100005
J	Slack, JMW				Slack, Jonathan M. W.			Planarian Pluripotency	SCIENCE			English	Editorial Material							HEMATOPOIETIC STEM-CELLS; REGENERATION		Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Slack, JMW (corresponding author), Univ Minnesota, Stem Cell Inst, 2001 6th St SE, Minneapolis, MN 55455 USA.	slack017@umn.edu		Slack, Jonathan/0000-0002-7154-6778				Agata K, 2003, CURR OPIN GENET DEV, V13, P492, DOI 10.1016/j.gde.2003.08.009; Eisenhoffer GT, 2008, CELL STEM CELL, V3, P327, DOI 10.1016/j.stem.2008.07.002; Gurley KA, 2008, SCIENCE, V319, P323, DOI 10.1126/science.1150029; INOUE M, 1988, AM J PATHOL, V132, P49; Jones DL, 2008, NAT REV MOL CELL BIO, V9, P11, DOI 10.1038/nrm2319; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Metcalf D, 2007, STEM CELLS, V25, P2390, DOI 10.1634/stemcells.2007-0544; MOON KA, 2006, SCIENCE, V311, P1880; Newmark PA, 2000, DEV BIOL, V220, P142, DOI 10.1006/dbio.2000.9645; Petersen CP, 2011, SCIENCE, V332, P852, DOI 10.1126/science.1202143; Petersen CP, 2009, CELL, V139, P1056, DOI 10.1016/j.cell.2009.11.035; Reddien PW, 2005, SCIENCE, V310, P1327, DOI 10.1126/science.1116110; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P725, DOI 10.1146/annurev.cellbio.20.010403.095114; Salo E, 2002, J EXP ZOOL, V292, P528, DOI 10.1002/jez.90001; Wagner DE, 2011, SCIENCE, V332, P811, DOI 10.1126/science.1203983; WITHERS HR, 1969, RADIAT RES, V38, P598, DOI 10.2307/3572619	16	3	4	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					799	800		10.1126/science.1206913	http://dx.doi.org/10.1126/science.1206913			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566180				2022-12-28	WOS:000290529900033
J	Goldstraw, P; Ball, D; Jett, JR; Le Chevalier, T; Lim, E; Nicholson, AG; Shepherd, FA				Goldstraw, Peter; Ball, David; Jett, James R.; Le Chevalier, Thierry; Lim, Eric; Nicholson, Andrew G.; Shepherd, Frances A.			Non-small-cell lung cancer	LANCET			English	Article							FORTHCOMING 7TH EDITION; RANDOMIZED PHASE-III; POSITRON-EMISSION-TOMOGRAPHY; TRIALIST ASSOCIATION ANITA; VINORELBINE PLUS CISPLATIN; STAGING PROJECT; TNM CLASSIFICATION; ADJUVANT CHEMOTHERAPY; INTERNATIONAL-ASSOCIATION; RADIATION-THERAPY	In the decade since the last Lancet Seminar on lung cancer there have been advances in many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer (NSCLC). An international panel of experts has been brought together to focus on changes in the epidemiology and pathological classification of NSCLC, the role of CT screening and other techniques that could allow earlier diagnosis and more effective treatment of the disease, and the recently introduced seventh edition of the TNM classification and its relation to other prognostic factors such as biological markers. We also describe advances in treatment that have seen the introduction of a new generation of chemotherapy agents, a proven advantage to adjuvant chemotherapy after complete resection for specific stage groups, new techniques for the planning and administration of radiotherapy, and new surgical approaches to assess and reduce the risks of surgical treatment.	Imperial Coll Sch Med, London, England; [Goldstraw, Peter; Lim, Eric] Royal Brompton & Harefield NHS Fdn Trust, Acad Dept Thorac Surg, London, England; [Nicholson, Andrew G.] Royal Brompton & Harefield NHS Fdn Trust, Dept Histopathol, London, England; [Ball, David] Peter MacCallum Canc Ctr, Div Radiat Oncol, Melbourne, Australia; [Jett, James R.] Mayo Clin, Coll Med, Rochester, MN USA; [Le Chevalier, Thierry] Inst Gustave Roussy, Villejuif, France; [Shepherd, Frances A.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton & Harefield NHS Foundation Trust; Peter Maccallum Cancer Center; Mayo Clinic; UNICANCER; Gustave Roussy; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Goldstraw, P (corresponding author), Royal Brompton Hosp, Sydney St, London SW3 6NP, England.	p.goldstraw@rbht.nhs.uk		Lim, Eric/0000-0002-9078-3226	Eli Lilly; Portaero; Strategen; Abbott Molecular; Roche; AstraZeneca; Merck EMD Serono; Pfizer	Eli Lilly(Eli Lilly); Portaero; Strategen; Abbott Molecular; Roche(Roche Holding); AstraZeneca(AstraZeneca); Merck EMD Serono; Pfizer(Pfizer)	PG has received lecture fees from Eli Lilly and consultancy fees from Portaero. DB has participated in advisory boards for Lilly Oncology and AstraZeneca, has received honoraria from Lilly Oncology, and has received travel expenses from AstraZeneca. JRJ has participated in advisory boards for Genentech and Oncimmune. TLC declares that he has no conflicts of interest. EL has received consultancy fees from Strategen and Abbott Molecular and speakers' fees from Roche. AGN has participated in advisory boards for AstraZeneca, GlaxoSmithKline, and Oncimmune. FAS has received honoraria and consultancy fees from Eli Lilly, AstraZeneca, Roche, Merck EMD Serono, and Pfizer.	Adams K, 2009, THORAX, V64, P757, DOI 10.1136/thx.2008.109868; Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140-6736(09)60737-6; ALBERTI W, 1995, BRIT MED J, V311, P899; Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066; Andrews DW, 2004, LANCET, V363, P1665, DOI 10.1016/S0140-6736(04)16250-8; Arriagada R, 2010, J CLIN ONCOL, V28, P35, DOI 10.1200/JCO.2009.23.2272; Auperin A, 2006, ANN ONCOL, V17, P473, DOI 10.1093/annonc/mdj117; Auperin A, 2010, J CLIN ONCOL, V28, P2181, DOI 10.1200/JCO.2009.26.2543; Azzoli CG, 2009, J CLIN ONCOL, V27, P6251, DOI 10.1200/JCO.2009.23.5622; Bach PB, 2007, JAMA-J AM MED ASSOC, V297, P953, DOI 10.1001/jama.297.9.953; Bang Y, 2010, J CLIN ONCOL S, V28, p6s; Baumann P, 2009, J CLIN ONCOL, V27, P3290, DOI 10.1200/JCO.2008.21.5681; Berghmans T, 2008, J THORAC ONCOL, V3, P6, DOI 10.1097/JTO.0b013e31815e6d6b; Blanchon T, 2007, LUNG CANCER, V58, P50, DOI 10.1016/j.lungcan.2007.05.009; Blomquist T, 2009, CANCER RES, V69, P8629, DOI 10.1158/0008-5472.CAN-09-1568; Borezuk AC, 2009, AM J SURG PATHOL, V33, P462, DOI 10.1097/PAS.0b013e318190157c; Brock J, 2008, CLIN ONCOL-UK, V20, P666, DOI 10.1016/j.clon.2008.06.005; Burdett S, 2005, LUNG CANCER, V47, P81, DOI 10.1016/j.lungcan.2004.09.010; Cappuzzo F, 2010, LANCET ONCOL, V11, P521, DOI 10.1016/S1470-2045(10)70112-1; Chansky K, 2009, J THORAC ONCOL, V4, P792, DOI 10.1097/JTO.0b013e3181a7716e; Ciuleanu T, 2009, LANCET, V374, P1432, DOI 10.1016/S0140-6736(09)61497-5; Coate LE, 2010, J THORAC ONCOL, V5, P723, DOI 10.1097/JTO.0b013e3181d86e8b; Coate LE, 2009, LANCET ONCOL, V10, P1001, DOI 10.1016/S1470-2045(09)70155-X; Darling GE, 2010, AM ASS THOR SURG ANN; Delaney G, 2003, LANCET ONCOL, V4, P120, DOI 10.1016/S1470-2045(03)00984-7; Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247; Din OS, 2008, INT J RADIAT ONCOL, V72, P716, DOI 10.1016/j.ijrobp.2008.01.033; Douillard JY, 2008, INT J RADIAT ONCOL, V72, P695, DOI 10.1016/j.ijrobp.2008.01.044; Douillard JY, 2006, LANCET ONCOL, V7, P719, DOI 10.1016/S1470-2045(06)70804-X; Douillard JY, 2010, J CLIN ONCOL, V28, P744, DOI 10.1200/JCO.2009.24.3030; Fairchild A, 2008, J CLIN ONCOL, V26, P4001, DOI 10.1200/JCO.2007.15.3312; Felip E, 2009, 13 WORLD C LUNG CANC; Finberg KE, 2007, J MOL DIAGN, V9, P320, DOI 10.2353/jmoldx.2007.060182; Fowler JF, 2004, INT J RADIAT ONCOL, V60, P1241, DOI 10.1016/j.ijrobp.2004.07.691; Fowler JF, 2000, INT J RADIAT ONCOL, V46, P516; Gaafar V, 2010, J CLIN ONCOL S15S, V28, p542s; Gilligan D, 2007, LANCET, V369, P1929, DOI 10.1016/S0140-6736(07)60714-4; Girard N, 2009, AM J SURG PATHOL, V33, P1752, DOI 10.1097/PAS.0b013e3181b8cf03; Gohagan JK, 2005, LUNG CANCER, V47, P9, DOI 10.1016/j.lungcan.2004.06.007; Goldstraw P, 2009, IASLC STAGING MANUAL, P113; Goldstraw P, 2009, INT ASS STUDY LUNG C; Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Goldstraw P, 2006, J THORAC ONCOL, V1, P281, DOI 10.1097/01243894-200605000-00002; Gopaldas RR, 2010, ANN THORAC SURG, V89, P1563, DOI 10.1016/j.athoracsur.2010.02.026; Gore EM, 2011, J CLIN ONCOL, V29, P272, DOI 10.1200/JCO.2010.29.1609; Gospodarowicz MK, 2006, PROGNOSTIC FACTORS C; Gridelli C, 2008, J THORAC ONCOL, V3, P430, DOI 10.1097/JTO.0b013e318168c815; Gridelli C, 2010, LUNG CANCER, V68, P319, DOI 10.1016/j.lungcan.2009.11.018; Henschke CI, 2006, NEW ENGL J MED, V355, P1763, DOI 10.1056/NEJMoa060476; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Hurkmans CW, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-1; Infante M, 2009, AM J RESP CRIT CARE, V180, P445, DOI 10.1164/rccm.200901-0076OC; Inoue A, 2009, EJC SUPPL, V7, P6, DOI 10.1016/S1359-6349(09)72038-5; International Union Against Cancer, 2009, TNM CLASS MAL TUM; Johnstone DW, 2002, INT J RADIAT ONCOL, V54, P365, DOI 10.1016/S0360-3016(02)02943-7; Kamal NS, 2010, CLIN CANCER RES, V16, P1206, DOI 10.1158/1078-0432.CCR-09-2204; Kargi A, 2007, APPL IMMUNOHISTO M M, V15, P415, DOI 10.1097/PAI.0b013e31802fab75; Kato H, 2004, NEW ENGL J MED, V350, P1713, DOI 10.1056/NEJMoa032792; Keall PJ, 2004, PHYS MED BIOL, V49, P2053, DOI 10.1088/0031-9155/49/10/015; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; Lally BE, 2006, J CLIN ONCOL, V24, P2998, DOI 10.1200/JCO.2005.04.6110; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Lee JS, 2009, J THORAC ONCOL, V4, pS283; Lim E, 2010, THORAX, V65, P1, DOI 10.1136/thx.2010.145938; Lim E, 2010, THORAX, V65, P847, DOI 10.1136/thx.2009.133181; Loo PS, 2010, J THORAC ONCOL, V5, P442, DOI 10.1097/JTO.0b013e3181d40fac; MacManus M, 2009, RADIOTHER ONCOL, V91, P85, DOI 10.1016/j.radonc.2008.11.008; Makimoto Y, 2005, HISTOPATHOLOGY, V46, P677, DOI 10.1111/j.1365-2559.2005.02126.x; Massion PP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005611; Mazzone PJ, 2008, J THORAC ONCOL, V3, P774, DOI 10.1097/JTO.0b013e31817c7439; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Motoi N, 2008, AM J SURG PATHOL, V32A, P810, DOI 10.1097/PAS.0b013e31815cb162; Nicholson AG, 2010, J THORAC ONCOL, V5, P436, DOI 10.1097/JTO.0b013e3181c6ed9b; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Pastorino U, 2003, LANCET, V362, P593, DOI 10.1016/S0140-6736(03)14188-8; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Pisters KMW, 2010, J CLIN ONCOL, V28, P1843, DOI 10.1200/JCO.2009.26.1685; Postmus PE, 2007, J THORAC ONCOL, V2, P686, DOI 10.1097/JTO.0b013e31811f4703; Qiu J, 2008, J CLIN ONCOL, V26, P5060, DOI 10.1200/JCO.2008.16.2388; Rami-Porta R, 2007, J THORAC ONCOL, V2, P593, DOI 10.1097/JTO.0b013e31807a2f81; Rosell R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001129; Rusch VW, 2007, J THORAC ONCOL, V2, P603, DOI 10.1097/JTO.0b013e31807ec803; Rusch VW, 2009, J THORAC ONCOL, V4, P568, DOI 10.1097/JTO.0b013e3181a0d82e; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Saunders M, 1999, RADIOTHER ONCOL, V52, P137, DOI 10.1016/S0167-8140(99)00087-0; Scagliotti G, 2009, ONCOLOGIST, V14, P253, DOI 10.1634/theoncologist.2008-0232; Scagliotti GV, 2003, JNCI-J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059; Sculier JP, 2008, J THORAC ONCOL, V3, P457, DOI 10.1097/JTO.0b013e31816de2b8; Seve P, 2007, CLIN CANCER RES, V13, P994, DOI 10.1158/1078-0432.CCR-06-1503; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Shepherd FA, 1998, BRIT J CANCER, V78, P683, DOI 10.1038/bjc.1998.560; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2007, J THORAC ONCOL, V2, P1067, DOI 10.1097/JTO.0b013e31815bdc0d; Shepherd FA, 2007, J THORAC ONCOL, V2, pS68, DOI 10.1097/01.JTO.0000269737.05962.a0; Sica G, 2010, AM J SURG PATHOL, V34, P1155, DOI 10.1097/PAS.0b013e3181e4ee32; Simon CJ, 2007, RADIOLOGY, V243, P268, DOI 10.1148/radiol.2431060088; Sobin LH., 2010, TNM CLASSIFICATION M; Spira A, 2007, NAT MED, V13, P361, DOI 10.1038/nm1556; Spitz MR, 2007, JNCI-J NATL CANCER I, V99, P715, DOI 10.1093/jnci/djk153; Stewart LA, 2007, J CLIN ONCOL, V25; Swensen SJ, 2005, RADIOLOGY, V235, P259, DOI 10.1148/radiol.2351041662; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; Timmerman R, 2006, J CLIN ONCOL, V24, P4833, DOI 10.1200/JCO.2006.07.5937; Tournoy KG, 2010, J CLIN ONCOL S, V28, p15s; Travis WD, 2008, J THORAC ONCOL, V3, P1213, DOI 10.1097/JTO.0b013e31818b06e3; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Travis WD, 2010, J THORAC ONCOL, V5, P411, DOI 10.1097/JTO.0b013e3181d57f6e; Travis WD, 2008, J THORAC ONCOL, V3, P1384, DOI 10.1097/JTO.0b013e31818e0d9f; van Klaveren RJ, 2009, NEW ENGL J MED, V361, P2221, DOI 10.1056/NEJMoa0906085; van Meerbeeck JP, 2007, JNCI-J NATL CANCER I, V99, P442, DOI 10.1093/jnci/djk093; Varella-Garcia M, 2010, CANCER PREV RES, V3, P447, DOI 10.1158/1940-6207.CAPR-09-0165; Varlotto JM, 2008, CANCER-AM CANCER SOC, V112, P1547, DOI 10.1002/cncr.23289; Verellen D, 2007, NAT REV CANCER, V7, P949, DOI 10.1038/nrc2288; Waller D, 2004, EUR J CARDIO-THORAC, V26, P173, DOI 10.1016/j.ejcts.2004.03.041; Weder W, 2010, J THORAC CARDIOV SUR, V139, P1424, DOI 10.1016/j.jtcvs.2010.02.039; Wheatley-Price P, 2008, J THORAC ONCOL, V3, P1173, DOI 10.1097/JTO.0b013e318187220f; Wheatley-Price P, 2008, CURR OPIN ONCOL, V20, P162, DOI 10.1097/CCO.0b013e3282f335a3; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; World Health Organization, 2004, TUM LUNG PLEUR THYM; Wu MX, 2003, AM J CLIN PATHOL, V119, P696, DOI 10.1309/XCP6EWPB3BMRKA; Wu YL, 2002, LUNG CANCER-J IASLC, V36, P1, DOI 10.1016/S0169-5002(01)00445-7; Yan TD, 2009, J CLIN ONCOL, V27, P2553, DOI 10.1200/JCO.2008.18.2733; Yee J, 2009, J CLIN ONCOL, V27, P2787, DOI 10.1200/JCO.2008.19.4233; Yoshida J, 2009, J THORAC ONCOL, V4, P959, DOI 10.1097/JTO.0b013e3181a85d5e; Yuan JM, 2009, CANCER RES, V69, P2990, DOI 10.1158/0008-5472.CAN-08-4330; Zheng Z, 2007, NEW ENGL J MED, V356, P800, DOI 10.1056/NEJMoa065411; Zhong L, 2006, J THORAC ONCOL, V1, P513, DOI 10.1097/01243894-200607000-00003; Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924	132	545	580	5	172	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2011	378	9804					1727	1740		10.1016/S0140-6736(10)62101-0	http://dx.doi.org/10.1016/S0140-6736(10)62101-0			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	846LB	21565398				2022-12-28	WOS:000296899800030
J	Schafer, RJ; Moore, T				Schafer, Robert J.; Moore, Tirin			Selective Attention from Voluntary Control of Neurons in Prefrontal Cortex	SCIENCE			English	Article							FRONTAL EYE FIELDS	Animals can learn to voluntarily control neuronal activity within various brain areas through operant conditioning, but the relevance of that control to cognitive functions is unknown. We found that rhesus monkeys can control the activity of neurons within the frontal eye field (FEF), an oculomotor area of the prefrontal cortex. However, operantly driven FEF activity was primarily associated with selective visual attention, and not oculomotor preparation. Attentional effects were untrained and were observed both behaviorally and neurophysiologically. Furthermore, selective attention correlated with voluntary, but not spontaneous, fluctuations in FEF activity. Our results reveal a specific association of voluntarily driven neuronal activity with "top-down" attention and suggest a basis for the use of neurofeedback training to treat disorders of attention.	[Schafer, Robert J.; Moore, Tirin] Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA; [Moore, Tirin] Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Moore, T (corresponding author), Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA.	tirin@stanford.edu		Schafer, Robert/0000-0002-0874-830X	NIH [EY14924]; National Defense Science and Engineering Graduate fellowship; National Research Service Award [F31MH078490]; NATIONAL EYE INSTITUTE [R56EY014924, R01EY014924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH078490] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Defense Science and Engineering Graduate fellowship; National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank D. Aldrich for technical assistance, and E. I. Knudsen and K. V. Shenoy for comments on the manuscript. Supported by NIH grant EY14924, a National Defense Science and Engineering Graduate fellowship, and National Research Service Award F31MH078490 (R.J.S.).	BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Carmena JM, 2003, PLOS BIOL, V1, P193, DOI 10.1371/journal.pbio.0000042; Cerf M, 2010, NATURE, V467, P1104, DOI 10.1038/nature09510; Chapin JK, 1999, NAT NEUROSCI, V2, P664, DOI 10.1038/10223; Fetz EE, 2007, J PHYSIOL-LONDON, V579, P571, DOI 10.1113/jphysiol.2006.127142; FETZ EE, 1969, SCIENCE, V163, P955, DOI 10.1126/science.163.3870.955; FETZ EE, 1975, EXP BRAIN RES, V23, P217; Gevensleben H, 2009, J CHILD PSYCHOL PSYC, V50, P780, DOI 10.1111/j.1469-7610.2008.02033.x; Gregoriou GG, 2009, SCIENCE, V324, P1207, DOI 10.1126/science.1171402; Kobayashi S, 2010, J NEUROPHYSIOL, V103, P1843, DOI 10.1152/jn.00173.2009; Loo SK, 2005, APPL NEUROPSYCHOL, V12, P64, DOI 10.1207/s15324826an1202_2; Moore T, 2006, CURR OPIN NEUROBIOL, V16, P159, DOI 10.1016/j.conb.2006.03.009; Sommer MA, 2000, J NEUROPHYSIOL, V83, P1979, DOI 10.1152/jn.2000.83.4.1979; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Tehovnik EJ, 2000, BRAIN RES REV, V32, P413, DOI 10.1016/S0165-0173(99)00092-2; Thompson KG, 2005, J NEUROSCI, V25, P9479, DOI 10.1523/JNEUROSCI.0741-05.2005	17	107	111	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	2011	332	6037					1568	1571		10.1126/science.1199892	http://dx.doi.org/10.1126/science.1199892			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	782EE	21617042	Green Accepted, Green Submitted			2022-12-28	WOS:000291990000048
J	Fernandez, A; Lynch, M				Fernandez, Ariel; Lynch, Michael			Non-adaptive origins of interactome complexity	NATURE			English	Article							PROTEIN; DYNAMICS; ALGORITHMS; EVOLUTION	The boundaries between prokaryotes, unicellular eukaryotes and multicellular eukaryotes are accompanied by orders-of-magnitude reductions in effective population size, with concurrent amplifications of the effects of random genetic drift and mutation(1). The resultant decline in the efficiency of selection seems to be sufficient to influence a wide range of attributes at the genomic level in a non-adaptive manner(2). A key remaining question concerns the extent to which variation in the power of random genetic drift is capable of influencing phylogenetic diversity at the subcellular and cellular levels(2-4). Should this be the case, population size would have to be considered as a potential determinant of the mechanistic pathways underlying long-term phenotypic evolution. Here we demonstrate a phylogenetically broad inverse relation between the power of drift and the structural integrity of protein subunits. This leads to the hypothesis that the accumulation of mildly deleterious mutations in populations of small size induces secondary selection for protein-protein interactions that stabilize key gene functions. By this means, the complex protein architectures and interactions essential to the genesis of phenotypic diversity may initially emerge by non-adaptive mechanisms.	[Lynch, Michael] Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; [Fernandez, Ariel] Univ Chicago, Dept Comp Sci, Chicago, IL 60637 USA; [Fernandez, Ariel] Rice Univ, Dept Bioengn, Houston, TX 77005 USA	Indiana University System; Indiana University Bloomington; University of Chicago; Rice University	Lynch, M (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	ariel@uchicago.edu; milynch@indiana.edu	Fernandez, Ariel/I-7925-2016	Fernandez, Ariel/0000-0002-5102-4294	National Institutes of Health [R01GM072614, R01GM036827]; Institute of Biophysical Dynamics; Department of Computer Science at The University of Chicago; National Science Foundation [EF-0827411]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072614, R01GM036827] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Institute of Biophysical Dynamics; Department of Computer Science at The University of Chicago; National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	A.F. was supported by National Institutes of Health grant R01GM072614, and by the Institute of Biophysical Dynamics and the Department of Computer Science at The University of Chicago. M.L. was supported by National Institutes of Health grant R01GM036827 and National Science Foundation grant EF-0827411.	BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Fenimore PW, 2004, P NATL ACAD SCI USA, V101, P14408, DOI 10.1073/pnas.0405573101; Fernandez A, 2002, J MOL BIOL, V321, P659, DOI 10.1016/S0022-2836(02)00679-4; Fernandez A, 2010, J PROTEOME RES, V9, P2643, DOI 10.1021/pr100089t; Gabaldon T, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-403; Gray MW, 2010, SCIENCE, V330, P920, DOI 10.1126/science.1198594; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kuriyan J, 2007, NATURE, V450, P983, DOI 10.1038/nature06524; Levy ED, 2008, NATURE, V453, P1262, DOI 10.1038/nature06942; Levy ED, 2006, PLOS COMPUT BIOL, V2, P1395, DOI 10.1371/journal.pcbi.0020155; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lynch M, 2003, SCIENCE, V302, P1401, DOI 10.1126/science.1089370; Lynch M, 2007, ORIGINS GENOME ARCHI; Lynch M, 2007, P NATL ACAD SCI USA, V104, P8597, DOI 10.1073/pnas.0702207104; Moran NA, 1996, P NATL ACAD SCI USA, V93, P2873, DOI 10.1073/pnas.93.7.2873; Ostlund G, 2010, NUCLEIC ACIDS RES, V38, pD196, DOI 10.1093/nar/gkp931; Pietrosemoli N, 2007, J PROTEOME RES, V6, P3519, DOI 10.1021/pr070208k; Rizzo RC, 1999, J AM CHEM SOC, V121, P4827, DOI 10.1021/ja984106u; Rowlinson J. S., 1982, MOL THEORY CAPILLARI; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schutz CN, 2001, PROTEINS, V44, P400, DOI 10.1002/prot.1106; Scott R, 2004, J PHYS A-MATH GEN, V37, P9791, DOI 10.1088/0305-4470/37/41/012; Stoltzfus A, 1999, J MOL EVOL, V49, P169, DOI 10.1007/PL00006540; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Zhou HY, 2010, PROTEINS, V78, P2041, DOI 10.1002/prot.22717	30	90	93	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2011	474	7352					502	U130		10.1038/nature09992	http://dx.doi.org/10.1038/nature09992			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	781NJ	21593762	Green Accepted			2022-12-28	WOS:000291939700047
J	Wang, D; Garcia-Bassets, I; Benner, C; Li, WB; Su, X; Zhou, YM; Qiu, JS; Liu, W; Kaikkonen, MU; Ohgi, KA; Glass, CK; Rosenfeld, MG; Fu, XD				Wang, Dong; Garcia-Bassets, Ivan; Benner, Chris; Li, Wenbo; Su, Xue; Zhou, Yiming; Qiu, Jinsong; Liu, Wen; Kaikkonen, Minna U.; Ohgi, Kenneth A.; Glass, Christopher K.; Rosenfeld, Michael G.; Fu, Xiang-Dong			Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA	NATURE			English	Article							FORKHEAD BOX A1; PROSTATE-CANCER; GENE-EXPRESSION; ANDROGEN RECEPTOR; HISTONE MODIFICATIONS; NUCLEAR RECEPTORS; HUMAN GENOME; IN-VIVO; CHROMATIN; SIGNATURES	Mammalian genomes are populated with thousands of transcriptional enhancers that orchestrate cell-type-specific gene expression programs(1-4), but how those enhancers are exploited to institute alternative, signal-dependent transcriptional responses remains poorly understood. Here we present evidence that cell-lineage-specific factors, such as FoxA1, can simultaneously facilitate and restrict key regulated transcription factors, exemplified by the androgen receptor (AR), to act on structurally and functionally distinct classes of enhancer. Consequently, FoxA1 downregulation, an unfavourable prognostic sign in certain advanced prostate tumours, triggers dramatic reprogramming of the hormonal response by causing a massive switch in AR binding to a distinct cohort of pre-established enhancers. These enhancers are functional, as evidenced by the production of enhancer-templated non-coding RNA (eRNA(5)) based on global nuclear run-on sequencing (GRO-seq) analysis(6), with a unique class apparently requiring no nucleosome remodelling to induce specific enhancer-promoter looping and gene activation. GRO-seq data also suggest that liganded AR induces both transcription initiation and elongation. Together, these findings reveal a large repository of active enhancers that can be dynamically tuned to elicit alternative gene expression programs, which may underlie many sequential gene expression events in development, cell differentiation and disease progression.	[Wang, Dong; Benner, Chris; Qiu, Jinsong; Kaikkonen, Minna U.; Glass, Christopher K.; Fu, Xiang-Dong] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Garcia-Bassets, Ivan; Li, Wenbo; Su, Xue; Liu, Wen; Ohgi, Kenneth A.; Rosenfeld, Michael G.] Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Dept Med, La Jolla, CA 92093 USA; [Garcia-Bassets, Ivan] Univ Calif San Diego, Sch Med, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; [Su, Xue; Liu, Wen] Univ Calif San Diego, Sch Med, Grad Program Biol, La Jolla, CA 92093 USA; [Zhou, Yiming] Digomics LLC, Malden, MA 02148 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Fu, XD (corresponding author), Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ibassets@ucsd.edu; mrosenfeld@ucsd.edu; xdfu@ucsd.edu	Kaikkonen, Minna U/AAK-3612-2020; Wang, Dong/AAH-5611-2020; li, wenbo/GZM-8930-2022; Qiu, Jinsong/K-2325-2013; Glass, Christopher/AAI-3933-2021; Wang, Dong/C-8775-2013; Garcia-Bassets, Ivan/F-5075-2010	Kaikkonen, Minna U/0000-0001-6294-0979; Wang, Dong/0000-0001-7877-7440; Glass, Christopher/0000-0003-4344-3592; Benner, Christopher/0000-0002-4618-0719; Garcia-Bassets, Ivan/0000-0002-6941-9585; Wang, Dong/0000-0002-3656-329X	Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [R01 CA097134, R01 CA097134-10] Funding Source: Medline; NHGRI NIH HHS [R01 HG004659, HG004659, R01 HG004659-03] Funding Source: Medline; NHLBI NIH HHS [R01 HL065445-12, R01 HL065445] Funding Source: Medline; NIDDK NIH HHS [P01 DK074868, R01 DK039949-30, R37 DK039949, R01 DK018477-35, R01 DK091183, DK074868, P01 DK074868-05, DK01847, R37 DK039949-28, R01 DK018477, R01 DK039949, DK37949] Funding Source: Medline; NIGMS NIH HHS [R01 GM049369-17, R01 GM049369, GM049369] Funding Source: Medline; NINDS NIH HHS [R01 NS034934-23, R01 NS034934, NS34934] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097134] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065445] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018477, R01DK091183, R37DK039949, R01DK039949, P01DK074868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034934] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Gao N, 2005, DEVELOPMENT, V132, P3431, DOI 10.1242/dev.01917; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Holmqvist PH, 2005, EXP CELL RES, V304, P593, DOI 10.1016/j.yexcr.2004.12.002; Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Laitinen S, 2002, GENE CHROMOSOME CANC, V35, P66, DOI 10.1002/gcc.10097; Lee HJ, 2008, BIOCHEM BIOPH RES CO, V367, P481, DOI 10.1016/j.bbrc.2007.12.162; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Legrier ME, 2009, INT J CANCER, V124, P1103, DOI 10.1002/ijc.24073; Linhart C, 2008, GENOME RES, V18, P1180, DOI 10.1101/gr.076117.108; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Mirosevich J, 2005, PROSTATE, V62, P339, DOI 10.1002/pros.20131; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thomsen MK, 2010, CANCER RES, V70, P979, DOI 10.1158/0008-5472.CAN-09-2370; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730; Wang H, 2008, CANCER RES, V68, P1625, DOI 10.1158/0008-5472.CAN-07-5915; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	40	620	634	2	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2011	474	7351					390	+		10.1038/nature10006	http://dx.doi.org/10.1038/nature10006			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777TD	21572438	Green Accepted			2022-12-28	WOS:000291647100048
J	Victora, CG; Barreto, ML; Leal, MD; Monteiro, CA; Schmidt, MI; Paim, J; Bastos, FI; Almeida, C; Bahia, L; Travassos, C; Reichenheim, M; Barros, FC				Victora, Cesar G.; Barreto, Mauricio L.; Leal, Maria do Carmo; Monteiro, Carlos A.; Schmidt, Maria Ines; Paim, Jairnilson; Bastos, Francisco I.; Almeida, Celia; Bahia, Ligia; Travassos, Claudia; Reichenheim, Michael; Barros, Fernando C.		Lancet Brazil Series Working Grp	Health conditions and health-policy innovations in Brazil: the way forward	LANCET			English	Article							INFANT-MORTALITY; IMPACT; CARE; RESISTANCE; DISEASES; PROGRAM	Brazil is a large complex country that is undergoing rapid economic, social, and environmental change In this Series of six articles, we have reported important improvements in health status and life expectancy, which can be ascribed largely to progress in social determinants of health and to implementation of a comprehensive national health system with strong social participation. Many challenges remain, however. Socioeconomic and regional disparities are still unacceptably large, reflecting the fact that much progress is still needed to improve basic living conditions for a large proportion of the population. New health problems arise as a result of urbanisation and social and environmental change, and some old health issues remain unabated. Administration of a complex, decentralised public-health system, in which a large share of services is contracted out to the private sector, together with many private insurance providers, inevitably causes conflict and contradiction. The challenge is ultimately political, and we conclude with a call for action that requires continuous engagement by Brazilian society as a whole in securing the right to health for all Brazilian people.	[Victora, Cesar G.] Univ Fed Pelotas, Programa Posgrad Epidemiol, BR-96001970 Pelotas, RS, Brazil; [Barreto, Mauricio L.; Paim, Jairnilson] Univ Fed Bahia, Inst Saude Coletiva, Salvador, BA, Brazil; [Leal, Maria do Carmo; Bastos, Francisco I.; Almeida, Celia] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, Brazil; [Monteiro, Carlos A.] Univ Sao Paulo, Fac Saude Publ, Sao Paulo, Brazil; [Schmidt, Maria Ines] Univ Fed Rio Grande do Sul, Fac Med, Porto Alegre, RS, Brazil; [Bahia, Ligia] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil; [Travassos, Claudia] Fundacao Oswaldo Cruz, Ctr Comunicacao & Informacao Cient & Tecnol, Rio De Janeiro, Brazil; [Reichenheim, Michael] Univ Estado Rio De Janeiro, Inst Social Med, Rio De Janeiro, Brazil; [Barros, Fernando C.] Univ Catolica Pelotas, Pelotas, Brazil	Universidade Federal de Pelotas; Universidade Federal da Bahia; Fundacao Oswaldo Cruz; Universidade de Sao Paulo; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Universidade do Estado do Rio de Janeiro; Universidade Catolica de Pelotas; Universidade Federal de Pelotas	Victora, CG (corresponding author), Univ Fed Pelotas, Programa Posgrad Epidemiol, CP 464, BR-96001970 Pelotas, RS, Brazil.	cvictora@gmail.com	Schmidt, Maria/V-3196-2019; Barreto, Mauricio L/B-1752-2008; Iats, Inct/K-2300-2013; Victora, Cesar G/D-4476-2013; Schmidt, Maria Inês/AGP-6441-2022; Victora, Cesar Gomes/Y-2455-2019; Schmidt, Maria Inês/AGT-5691-2022; Teixeira, Maria Gloria L C/G-4808-2012; Menezes, Paulo/AAM-3529-2021; Monteiro, Carlos Augusto/F-9892-2012; Aquino, Estela M. L./G-2599-2012; Barros, Fernando C/D-4857-2013; Barreto, Sandhi M/D-2855-2014; Menezes, Paulo R/C-9985-2010	Barreto, Mauricio L/0000-0002-0215-4930; Victora, Cesar G/0000-0002-2465-2180; Schmidt, Maria Inês/0000-0002-3837-0731; Victora, Cesar Gomes/0000-0002-2465-2180; Teixeira, Maria Gloria L C/0000-0003-3318-3408; Menezes, Paulo/0000-0001-6330-3314; Monteiro, Carlos Augusto/0000-0002-3777-1533; Aquino, Estela M. L./0000-0002-8204-1249; Barreto, Sandhi M/0000-0001-7383-7811; Menezes, Paulo R/0000-0001-6330-3314; Macinko, James/0000-0001-8055-5441; Rodrigues, Laura Cunha/0000-0001-9008-660X	National Council for Scientific and Technological Development (CNPq) Brazil	National Council for Scientific and Technological Development (CNPq) Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	All authors (apart from LB) received funding from the National Council for Scientific and Technological Development (CNPq) Brazil.	Agencia Nacional de Saude Suplementar, 2010, CAD INF SAUD SUPL; Almeida C, 2001, LANCET, V357, P1692, DOI 10.1016/S0140-6736(00)04825-X; ALMEIDA PF, 2010, CAD SAUDE PUBLICA, V26, P286, DOI DOI 10.1590/S0102-311X2010000200008; Amaral J, 2004, CAD SAUDE PUBLICA, V20, P209; AMARAL JJF, 2006, ATENCAO INTEGRADA DO, P55; Andrade SS, 2006, MEM I OSWALDO CRUZ, V101, P741, DOI 10.1590/S0074-02762006000700006; Aquino EML, 2006, REV SAUDE PUBL, V40, P121, DOI 10.1590/S0034-89102006000400017; Aquino R, 2009, AM J PUBLIC HEALTH, V99, P87, DOI 10.2105/AJPH.2007.127480; Bahia L, 2009, CIENC SAUDE COLETIVA, V14, P753, DOI 10.1590/S1413-81232009000300011; Barriga-Carrasco MD, 2011, LASER PART BEAMS, V29, P81, DOI 10.1017/S0263034610000789; Barros F C, 1986, Health Policy Plan, V1, P19, DOI 10.1093/heapol/1.1.19; Biehl J, 2009, LANCET, V373, P2182, DOI 10.1016/S0140-6736(09)61172-7; Chieffi AL, 2009, CAD SAUDE PUBLICA, V25, P1839, DOI 10.1590/S0102-311X2009000800020; Coimbra Jr CEA, 2004, LOST PARADISES ETHIC, P89; *CONS NAC SECR SAU, 2003, BRAS LEG SUS; *COORD AP PESS NIV, REL CURS REC REC SAU; Cortes Soraya Maria Vargas, 2009, PARTICIPACAO DEMOCRA, P102; Costello A, 2009, LANCET, V373, P1693, DOI [10.1016/S0140-6736(09)60935-1, 10.1016/S0140-6736(09)60929-6]; Cox PM, 2008, NATURE, V453, P212, DOI 10.1038/nature06960; DEALMEIDAFILHO N, 1983, POPUL ENVIRON, V6, P3, DOI 10.1007/BF01255861; Dillon JAR, 2001, SEX TRANSM DIS, V28, P521, DOI 10.1097/00007435-200109000-00008; Diniz SG, 2004, REPROD HEALTH MATTER, V12, P100, DOI 10.1016/S0968-8080(04)23112-3; Gonçalves Maria Jacirema Ferreira, 2004, Rev. salud pública, V6, P156; Fuster V, 2005, LANCET, V366, P1512, DOI 10.1016/S0140-6736(05)67610-6; GADELHA CAG, 2010, HLTH EC IND COMPLEX, P2; GADELHA CAG, COMPLEXO IND SAUDE N; Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2; *GLOB HLTH WORKF A, 2009, GHWA ASKS F DEC; Medeiros CRG, 2010, CIENC SAUDE COLETIVA, V15, P1521, DOI 10.1590/S1413-81232010000700064; Grotto D, 2010, SCI TOTAL ENVIRON, V408, P806, DOI 10.1016/j.scitotenv.2009.10.053; Guanais Frederico C, 2010, BMJ, V341, pc6542, DOI 10.1136/bmj.c6542; Guimarães Reinaldo, 2006, Cad. Saúde Pública, V22, P1775, DOI 10.1590/S0102-311X2006000900002; Haddad AE, 2010, REV SAUDE PUBL, V44, P385, DOI 10.1590/S0034-89102010005000015; Haines A, 2009, LANCET, V374, P2104, DOI 10.1016/S0140-6736(09)61759-1; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Huicho L, 2008, LANCET, V372, P910, DOI 10.1016/S0140-6736(08)61401-4; Hyder Adnan A, 2004, J Coll Physicians Surg Pak, V14, P742; *I BRAS GEOGR EST, 2010, CONT SAT SAUD BRAS 2; LAFERRARA E, 2008, SOAP OPERAS FERTILIT; Macinko J, 2006, J EPIDEMIOL COMMUN H, V60, P13, DOI 10.1136/jech.2005.038323; Macinko J, 2010, HEALTH AFFAIR, V29, P2149, DOI 10.1377/hlthaff.2010.0251; Bosi MLM, 2010, CIENC SAUDE COLETIVA, V15, P2029, DOI 10.1590/S1413-81232010000400017; *MIN SAUD, PART CONTR SOC; Moherdaui F, 1998, SEX TRANSM INFECT, V74, pS38; Monteiro CA, 2010, AM J PUBLIC HEALTH, V100, P975, DOI 10.2105/AJPH.2009.187666; Ocke-Reis Carlos Octavio, 2007, Cien Saude Colet, V12, P1041, DOI 10.1590/S1413-81232007000400025; Santos LMP, 2010, CAD SAUDE PUBLICA, V26, P1667; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Piovesan MF, 2007, CAD SAUDE PUBLICA, V23, P1373, DOI 10.1590/S0102-311X2007000600012; Ramos MC, 2004, INT J STD AIDS, V15, P333, DOI 10.1258/095646204323012832; Reichenheim ME, 2011, LANCET, V377, P1962, DOI 10.1016/S0140-6736(11)60053-6; Rocha R, 2010, HEALTH ECON, V19, P126, DOI 10.1002/hec.1607; Rodrigues AD, 2008, REV SOC BRAS MED TRO, V41, P55; Rohde J, 2008, LANCET, V372, P950, DOI 10.1016/S0140-6736(08)61405-1; Santos LMP, 2008, B WORLD HEALTH ORGAN, V86, P474, DOI 10.2471/BLT.07.043638; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; Schmidt M. I., 2011, Lancet (British edition), V377, P1949, DOI 10.1016/S0140-6736(11)60135-9; *UN OFF DRUGS CRIM, 11 UN SURV CRIM TREN; [UNIFEM UNICEF], 2010, DES RAC GEN ENTR CRI; Victora CG, 2011, LANCET, V377, P1863, DOI 10.1016/S0140-6736(11)60138-4; *WHO, 2001, WORLD HLTH ASS EX BO; WHO, GLOB HLTH ATL; WHO, 2010, TRENDS MAT MORT 1990; *WORLD BANK GROUP, MILL DEV GOALS COUNT	64	259	272	0	65	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2011	377	9782					2042	2053		10.1016/S0140-6736(11)60055-X	http://dx.doi.org/10.1016/S0140-6736(11)60055-X			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	782LR	21561659	Green Published, Green Submitted			2022-12-28	WOS:000292011700039
J	George, TJ; Arnaoutakis, GJ; Merlo, CA; Kemp, CD; Baumgartner, WA; Conte, JV; Shah, AS				George, Timothy J.; Arnaoutakis, George J.; Merlo, Christian A.; Kemp, Clinton D.; Baumgartner, William A.; Conte, John V.; Shah, Ashish S.			Association of Operative Time of Day With Outcomes After Thoracic Organ Transplant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLICATIONS; SURVIVAL; VOLUME; IMPACT	Context Recent emphasis on systems-based approaches to patient safety has led to several studies demonstrating worse outcomes associated with surgery at night. Objective To evaluate whether operative time of day was associated with thoracic organ transplant outcomes, hypothesizing that it would not be associated with increased morbidity or mortality. Design, Setting, and Participants We conducted a retrospective cohort study of adult heart and lung transplant recipients in the United Network for Organ Sharing database from January 2000 through June 2010. Primary stratification was by operative time of day (night, 7 PM-7 AM; day, 7 AM-7 PM). Main Outcome Measures Primary end points were short-term survival, assessed by the Kaplan-Meier method at 30, 90, and 365 days. Secondary end points encompassed common postoperative complications. Risk-adjusted multivariable Cox proportional hazards regression examined mortality. Results A total of 27 118 patients were included in the study population. Of the 16 573 who underwent a heart transplant, 8346 (50.36%) did so during the day and 8227 (49.64%) during the night. Of the 10 545 who underwent a lung transplant, 5179 (49.11%) did so during the day and 5366 (50.89%) during the night. During a median follow-up of 32.2 months (interquartile range, 11.2-61.1 months), 8061 patients (28.99%) died. Survival was similar for organ transplants performed during the day and night. Survival rates at 30 days for heart transplants during the day were 95.0% vs 95.2% during the night (hazard ratio [HR], 1.05; 95% confidence interval, 0.83-1.32; P=.67) and for lung transplants during the day were 96.0% vs 95.5% during the night (HR, 1.22; 95% CI, 0.97-1.55; P=.09). At 90 days, survival rates for heart transplants were 92.6% during the day vs 92.7% during the night (HR, 1.05; 95% CI, 0.88-1.26; P=.59) and for lung transplants during the day were 92.7% vs 91.7% during the night (HR, 1.23; 95% CI, 1.04-1.47; P=.02). At 1 year, survival rates for heart transplants during the day were 88.0% vs 87.7% during the night (HR, 1.05; 95% CI, 0.91-1.21; P=.47) and for lung transplants during the day were 83.8% vs 82.6% during the night (HR, 1.08; 95% CI, 0.96-1.22; P=.19). Among lung transplant recipients, there was a slightly higher rate of airway dehiscence associated with nighttime transplants (57 of 5022 [1.1%] vs 87 of 5224 [1.7%], P=.02). Conclusion Among patients who underwent thoracic organ transplants, there was no significant association between operative time of day and survival up to 1 year after organ transplant. JAMA. 2011;305(21):2193-2199 www.jama.com	[George, Timothy J.; Arnaoutakis, George J.; Kemp, Clinton D.; Baumgartner, William A.; Conte, John V.; Shah, Ashish S.] Johns Hopkins Med Inst, Div Cardiac Surg, Baltimore, MD 21205 USA; [Merlo, Christian A.] Johns Hopkins Med Inst, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Shah, AS (corresponding author), Johns Hopkins Univ Hosp, Div Cardiac Surg, 600 N Wolfe St,Blalock 618, Baltimore, MD 21287 USA.	ashah29@jhmi.edu	Arnaoutakis, George/AAE-8796-2022	Shah, Ashish/0000-0002-1821-9110	Thoratec; Heartware; Medtronic; National Institutes of Health [T32 2T32DK007713-12]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007713] Funding Source: NIH RePORTER	Thoratec; Heartware; Medtronic(Medtronic); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Conte reported that he receives research support from Thoratec, Heartware, and Medtronic; otherwise no other conflicts of interest were reported.; This research was supported by grant T32 2T32DK007713-12 from the National Institutes of Health (Dr George). Dr George is the Hugh R. Sharp Cardiac Surgery Research Fellow. Dr Arnaoutakis is the Irene Piccinini Investigator in Cardiac Surgery.	Fechner G, 2008, TRANSPL P, V40, P1341, DOI 10.1016/j.transproceed.2008.02.072; Glaser R, 2008, JACC-CARDIOVASC INTE, V1, P681, DOI 10.1016/j.jcin.2008.08.020; Grantcharov TP, 2001, BRIT MED J, V323, P1222, DOI 10.1136/bmj.323.7323.1222; Iglehart JK, 2008, NEW ENGL J MED, V359, P2633, DOI 10.1056/NEJMp0808736; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; Komen N, 2009, INT J COLORECTAL DIS, V24, P789, DOI 10.1007/s00384-009-0692-4; Lonze BE, 2010, AM J TRANSPLANT, V10, P1842, DOI 10.1111/j.1600-6143.2010.03177.x; Peberdy MA, 2008, JAMA-J AM MED ASSOC, V299, P785, DOI 10.1001/jama.299.7.785; Ricci WM, 2009, J BONE JOINT SURG AM, V91A, P2067, DOI 10.2106/JBJS.H.00661; Seow YY, 2004, TRANSPLANTATION, V77, P1386, DOI 10.1097/01.TP.0000122230.46091.E2; Taffinder NJ, 1998, LANCET, V352, P1191, DOI 10.1016/S0140-6736(98)00034-8; Weiss ES, 2008, ANN THORAC SURG, V86, P1250, DOI 10.1016/j.athoracsur.2008.06.071; Weiss ES, 2009, ANN THORAC SURG, V88, P1062, DOI 10.1016/j.athoracsur.2009.06.005	13	53	54	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2193	2199		10.1001/jama.2011.726	http://dx.doi.org/10.1001/jama.2011.726			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21632483	Bronze			2022-12-28	WOS:000291106300022
J	Taylor, CC; Clarke, NMP				Taylor, Colm C.; Clarke, N. M. P.			Amputation and intraosseous access in infants	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMPARTMENT SYNDROME; INFUSION		[Taylor, Colm C.; Clarke, N. M. P.] Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton	Clarke, NMP (corresponding author), Southampton Gen Hosp, Tremona Rd, Southampton SO16 6YD, Hants, England.	ortho@soton.ac.uk						Advanced Life Support Group, 2005, ADV PAED LIF SUPP; Atanda Jr A, 2008, AM J ORTHOP, V37, P198; Bailey H, 1944, BRIT MED J, V1944, P181; Committee on Pediatric Emgency Medicine, 1993, AM AC PED REF GUID; Davidoff Jack, 2005, JEMS, V30, P20; FISER DH, 1990, NEW ENGL J MED, V322, P1579; GALPIN RD, 1991, J PEDIATR ORTHOPED, V11, P773, DOI 10.1097/01241398-199111000-00014; GAYLE M, 1994, PEDIATR EMERG CARE, V10, P378; Gunal I, 1996, J PEDIATR SURG, V31, P1491, DOI 10.1016/S0022-3468(96)90162-1; LAFLECHE FR, 1989, ANN EMERG MED, V18, P1099, DOI 10.1016/S0196-0644(89)80937-0; Luck RP, 2010, J EMERG MED, V39, P468, DOI 10.1016/j.jemermed.2009.04.054; MOSCATI R, 1990, AM J EMERG MED, V8, P470, DOI 10.1016/0735-6757(90)90247-W; ONEILL JF, 1945, ANN SURG, V122, P266, DOI 10.1097/00000658-194508000-00011	13	15	15	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 27	2011	342								d2778	10.1136/bmj.d2778	http://dx.doi.org/10.1136/bmj.d2778			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771KI	21622504				2022-12-28	WOS:000291155200001
J	Rebolj, M; Bonde, J; Njor, SH; Lynge, E				Rebolj, Matejka; Bonde, Jesper; Njor, Sisse Helle; Lynge, Elsebeth			Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; LIQUID-BASED CYTOLOGY; INTRAEPITHELIAL NEOPLASIA; CANCER PREVENTION; NATURAL-HISTORY; DNA; WOMEN; RISK; RECRUITMENT; DESIGN	Objective To determine the trade-off between the sensitivity and the specificity for high grade cervical intraepithelial neoplasia at hybrid capture 2 cut-off values above the standard >= 1 relative light units/cut-off level (rlu/co). Design Systematic review. Data sources PubMed. Study selection Randomised controlled trials in primary cervical screening using hybrid capture 2 testing in the intervention arms. Articles published until August 2010 were included if the numbers of women with positive test results and with cervical intraepithelial neoplasia were stratified by hybrid capture 2 cut-off levels. Participants Women in the baseline screening rounds of the trials. Interventions Hybrid capture 2 screening in the baseline round including the diagnostic follow-up as practised in the randomised controlled trials and as reported by hybrid capture 2 cut-off values. Results Owing to heterogeneity in the trials, meta-analysis was not possible. Including cut-off values up to >= 10 rlu/co, 25 observation points were available for analysis. The relative sensitivity for cervical intraepithelial neoplasia grade III or higher at cut-off levels of >= 2, >= 4 or >= 5, and >= 10 rlu/co compared with a cut-off level of >= 1 rlu/covaried by trial, but at their lowest they were 0.97, 0.92, and 0.91, respectively. A similar pattern was observed for cervical intraepithelial neoplasia grade II or higher. The specificity would increase by at least 1%, 2%, and 3%, respectively, so that up to 24%, 39%, and 53%, of positive hybrid capture 2 test results not associated with high grade neoplasia could be avoided. Only two outliers existed to this general pattern. Conclusions Although the data were derived from the baseline screening rounds only, the decrease in the sensitivity for high grade cervical intraepithelial neoplasia using a hybrid capture 2 cut-off level between >= 2 rlu/co and >= 10 rlu/co seemed acceptable given the international recommendations for testing for human papillomavirus DNA in cervical screening, which require 90% or more sensitivity for cervical intraepithelial neoplasia grade II or higher compared with hybrid capture 2 at >= 1 rlu/co. The data suggest that the hybrid capture 2 cut-off level could be increased in primary screening; this seems reasonably safe and is significantly less burdensome for women.	[Rebolj, Matejka; Njor, Sisse Helle] Univ Copenhagen, Dept Publ Hlth, DK-1014 Copenhagen K, Denmark; [Lynge, Elsebeth] Univ Copenhagen, Dept Publ Hlth, Epidemiol, DK-1014 Copenhagen K, Denmark; [Bonde, Jesper] Univ Copenhagen, Hvidovre Hosp, Clin Res Ctr, DK-2650 Hvidovre, Denmark; [Bonde, Jesper] Univ Copenhagen, Hvidovre Hosp, Dept Pathol, DK-2650 Hvidovre, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen	Rebolj, M (corresponding author), Univ Copenhagen, Dept Publ Hlth, Oster Farimagsgade 5, DK-1014 Copenhagen K, Denmark.	mare@sund.ku.dk	Bonde, Jesper H/F-1478-2013; Bonde, Jesper/AAN-5930-2020; Njor, Sisse Helle/S-4486-2017	Njor, Sisse Helle/0000-0003-0429-4176; Bonde, Jesper/0000-0003-4853-6747; Rebolj, Matejka/0000-0001-9597-645X; Lynge, Elsebeth/0000-0003-4785-5236	Olga and Esper Boel's Fund; Aase and Ejnar Danielsen's Fund; Augustinus Fund; Manufacturer Mads Clausen's Fund; Family Hede Nielsen's Fund; Else and Mogens Wedell-Wedellsborg's Fund; Carl and Ellen Hertz's Grant for Danish Medical and Natural Sciences Research; Merchant Sven Hansen and Mrs Ina Hansen's Fund	Olga and Esper Boel's Fund; Aase and Ejnar Danielsen's Fund; Augustinus Fund; Manufacturer Mads Clausen's Fund; Family Hede Nielsen's Fund; Else and Mogens Wedell-Wedellsborg's Fund; Carl and Ellen Hertz's Grant for Danish Medical and Natural Sciences Research; Merchant Sven Hansen and Mrs Ina Hansen's Fund	This work was supported by Olga and Esper Boel's Fund; Aase and Ejnar Danielsen's Fund; Augustinus Fund; Manufacturer Mads Clausen's Fund; Family Hede Nielsen's Fund; Else and Mogens Wedell-Wedellsborg's Fund; Carl and Ellen Hertz's Grant for Danish Medical and Natural Sciences Research; and Merchant Sven Hansen and Mrs Ina Hansen's Fund. None of these had any role in the study design, the collection of data, the analysis, the interpretation of the data, the writing of the paper, and in the decision to submit the paper for publication.	Anttila A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1804; Arbyn M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1284; Bais AG, 2007, INT J CANCER, V120, P1505, DOI 10.1002/ijc.22484; Berkhof J, 2010, INT J CANCER, V127, P2147, DOI 10.1002/ijc.25211; Bos AB, 1997, BRIT J CANCER, V75, P124, DOI 10.1038/bjc.1997.20; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Bulkmans NWJ, 2004, INT J CANCER, V110, P94, DOI 10.1002/ijc.20076; Castle PE, 2009, OBSTET GYNECOL, V113, P18, DOI 10.1097/AOG.0b013e31818f5008; Clavel C, 2001, BRIT J CANCER, V84, P1616, DOI 10.1054/bjoc.2001.1845; Cruickshank M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2546; Cuzick J, 2003, LANCET, V362, P1871, DOI 10.1016/S0140-6736(03)14955-0; Cuzick J, 2008, VACCINE, V26, pK29, DOI 10.1016/j.vaccine.2008.06.019; Davies P, 2006, INT J CANCER, V118, P791, DOI 10.1002/ijc.21611; Denny L, 2005, JAMA-J AM MED ASSOC, V294, P2173, DOI 10.1001/jama.294.17.2173; Dillner J, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1754; Hellsten C, 2008, BJOG-INT J OBSTET GY, V115, P212, DOI 10.1111/j.1471-0528.2007.01609.x; Insinga RP, 2007, MED DECIS MAKING, V27, P414, DOI 10.1177/0272989X07302128; International Agency for Research on Cancer, 2005, IARC HDB CANC PREV, V10; International Agency for Research on Cancer, 2009, 0809 INT AG RES CANC; Kinney W, 2010, AM J CLIN PATHOL, V134, P193, DOI 10.1309/AJCPRI8XPQUEAA3K; Kitchener HC, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13510; Kotaniemi-Talonen L, 2008, INT J CANCER, V123, P2902, DOI 10.1002/ijc.23839; Lynge E, 2009, NAT REV CLIN ONCOL, V6, P699, DOI 10.1038/nrclinonc.2009.167; Mayrand M, 2007, NEW ENGL J MED, V357, P1579, DOI 10.1056/NEJMoa071430; Mayrand MH, 2006, INT J CANCER, V119, P615, DOI 10.1002/ijc.21897; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; Meijer CJLM, 2009, INT J CANCER, V124, P516, DOI 10.1002/ijc.24010; Moy LM, 2010, INT J CANCER, V127, P646, DOI 10.1002/ijc.25071; Naucler P, 2007, NEW ENGL J MED, V357, P1589, DOI 10.1056/NEJMoa073204; Naucler P, 2009, JNCI-J NATL CANCER I, V101, P88, DOI 10.1093/jnci/djn444; Nieminen P, 2004, BJOG-INT J OBSTET GY, V111, P842, DOI 10.1111/j.1471-0528.2004.00210.x; Office for Official Publications of the European Communities, 2008, EUROPEAN GUIDELINES, Vsecond; Ogilvie GS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-111; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Ratnam S, 2011, J CLIN MICROBIOL, V49, P557, DOI 10.1128/JCM.02147-10; Rebolj M, 2011, EUR J CANCER, V47, P255, DOI 10.1016/j.ejca.2010.08.010; Rijkaart DC, 2010, BRIT J CANCER, V103, P939, DOI 10.1038/sj.bjc.6605869; Ronco G, 2008, J NATL CANCER I, V100, P492, DOI 10.1093/jnci/djn065; Ronco G, 2006, JNCI-J NATL CANCER I, V98, P765, DOI 10.1093/jnci/djj209; Ronco G, 2006, LANCET ONCOL, V7, P547, DOI 10.1016/S1470-2045(06)70731-8; Ronco G, 2010, LANCET ONCOL, V11, P249, DOI 10.1016/S1470-2045(09)70360-2; Sankaranarayanan R, 2005, INT J CANCER, V116, P617, DOI 10.1002/ijc.21050; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; Sargent A, 2010, J CLIN MICROBIOL, V48, P554, DOI 10.1128/JCM.00896-09; VANOORTMARSSEN GJ, 1991, BRIT J CANCER, V64, P559, DOI 10.1038/bjc.1991.350; WARDLE J, 1992, J PSYCHOSOM RES, V36, P609, DOI 10.1016/0022-3999(92)90051-3	46	29	31	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 23	2011	342								d2757	10.1136/bmj.d2757	http://dx.doi.org/10.1136/bmj.d2757			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V41KZ	21606136	Green Published, hybrid			2022-12-28	WOS:000209546400001
J	Cairns, JA				Cairns, John A.			CHA(2)DS(2)-VASc had better discrimination than CHADS(2) for predicting risk for thromboembolism in atrial fibrillation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							GUIDELINES; SOCIETY		Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Cairns, JA (corresponding author), Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.		Cairns, John/AAI-8744-2021					Cairns JA, 2011, CAN J CARDIOL, V27, P74, DOI 10.1016/j.cjca.2010.11.007; Camm AJ, 2010, EUR HEART J, V31, P2369, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]; Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432	3	3	6	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-13	10.7326/0003-4819-154-10-201105170-02013	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576531				2022-12-28	WOS:000290620300012
J	Cohen, D; Billingsley, M				Cohen, Deborah; Billingsley, Matthew			MEDICAL DEVICES Europeans are left to their own devices	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Cohen, Deborah; Billingsley, Matthew] BMJ, London WC1H 9JR, England		Cohen, D (corresponding author), BMJ, London WC1H 9JR, England.	dcohen@bmj.com						*AG FRANC SEC SAN, 2010, SIL FILL BREAST IMPL; BYLANDER J, 2011, GRAY SHEET, V37, P1; CAMPBELL B, 2010, REPORT REGISTERS MHR; *EUR COMM, 2011, EXPL INN HEALTHC ROL; *EUR COMM ENT IND, 2009, CLIN EV GUID MAN NOT; European Commission Enterprise and Industry, NOT BOD; FRASER AG, 2011, EUR HEART J; Hazell L, 2006, DRUG SAFETY, V29, P385, DOI 10.2165/00002018-200629050-00003; HENEGHAN C, BMJ OPEN, DOI DOI 10.1136/BMJOPEN-2011-0155; Lyratzopoulos G, 2008, LANCET, V371, P1734, DOI 10.1016/S0140-6736(08)60742-4; Makower J., 2010, FDA IMPACT US MEDICA; MAXWELL A, 2010, CLINICA         0519; PricewaterhouseCoopers, 2011, MED TECHN INN SCOR; RICHWINE L, 2011, REUTERS         0224; SHUREN J, 2011, STATEMENT SUBCOMMITT; SHUREN J, 2011, THEHEART ORG    0218; US Food and Drug Administration, MED DEV PREM APPR; US Food and Drug Administration Web site, MED DEV PREM NOT 510; YEO A, 2011, CLINICA         0106; Zuckerman DM, 2011, ARCH INTERN MED 0214; 2010, DRUGS THER B, V48, P82	21	62	63	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 14	2011	342								d2748	10.1136/bmj.d2748	http://dx.doi.org/10.1136/bmj.d2748			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765OV	21572130	Green Published, Bronze			2022-12-28	WOS:000290719100001
J	Di Mario, C; James, S; Dudek, D; Sabate, M; Degertekin, M				Di Mario, C.; James, S.; Dudek, D.; Sabate, M.; Degertekin, M.			Commentary: The risk of over-regulation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							REVASCULARIZATION		[Di Mario, C.] Royal Brompton Hosp, London SW3 6NP, England; [James, S.] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Dudek, D.] Jagiellonian Univ, Krakow, Poland; [Sabate, M.] Univ Barcelona, Hosp Clin, E-08007 Barcelona, Spain; [Degertekin, M.] Yeditepe Univ Hosp, Istanbul, Turkey	Royal Brompton Hospital; Uppsala University; Jagiellonian University; University of Barcelona; Hospital Clinic de Barcelona; Yeditepe University	Di Mario, C (corresponding author), Royal Brompton Hosp, London SW3 6NP, England.	c.dimario@rbht.nhs.uk	Di Mario, Carlo/K-5185-2018; James, Stefan K/J-4554-2014; Sabate, Manel/AAX-7245-2021	Di Mario, Carlo/0000-0002-4461-2055; Sabate Tenas, Manel/0000-0002-2316-3705				*EUR SOC CARD, EUROOBSERVATIONAL RE; Fraser AG, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2952; GRUNTZIG AR, 1979, NEW ENGL J MED, V301, P61, DOI 10.1056/NEJM197907123010201; James S, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2826; Kedhi E, 2010, LANCET, V375, P201, DOI 10.1016/S0140-6736(09)62127-9; Serruys PW, 2010, NEW ENGL J MED, V363, P136, DOI 10.1056/NEJMoa1004130; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), 2010, Eur Heart J, V31, P2501, DOI 10.1093/eurheartj/ehq277; Windecker S, 2005, NEW ENGL J MED, V353, P653, DOI 10.1056/NEJMoa051175; Windecker S, 2008, LANCET, V372, P1163, DOI 10.1016/S0140-6736(08)61244-1	9	8	8	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 14	2011	342								d3021	10.1136/bmj.d3021	http://dx.doi.org/10.1136/bmj.d3021			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765OV	21572138				2022-12-28	WOS:000290719100009
J	Saijo, K; Collier, JG; Li, AC; Katzenellenbogen, JA; Glass, CK				Saijo, Kaoru; Collier, Jana G.; Li, Andrew C.; Katzenellenbogen, John A.; Glass, Christopher K.			An ADIOL-ER beta-CtBP Transrepression Pathway Negatively Regulates Microglia-Mediated Inflammation	CELL			English	Article							ESTROGEN-RECEPTOR-BETA; T-CELLS; FRACTALKINE RECEPTOR; SELECTIVE LIGANDS; GENE-EXPRESSION; ALPHA; BRAIN; BINDING; ENCEPHALOMYELITIS; TRANSCRIPTION	Microglia and astrocytes play essential roles in the maintenance of homeostasis within the central nervous system, but mechanisms that control the magnitude and duration of responses to infection and injury remain poorly understood. Here, we provide evidence that 5-androsten-3 beta, 17 beta-diol (ADIOL) functions as a selective modulator of estrogen receptor (ER)beta to suppress inflammatory responses of microglia and astrocytes. ADIOL and a subset of synthetic ER beta-specific ligands, but not 17 beta-estradiol, mediate recruitment of CtBP corepressor complexes to AP-1-dependent promoters, thereby repressing genes that amplify inflammatory responses and activate Th17 T cells. Reduction of ADIOL or ER beta expression results in exaggerated inflammatory responses to TLR4 agonists. Conversely, the administration of ADIOL or synthetic ER beta-specific ligands that promote CtBP recruitment prevents experimental autoimmune encephalomyelitis in an ER beta-dependent manner. These findings provide evidence for an ADIOL/ER beta/CtBP-transrepression pathway that regulates inflammatory responses in microglia and can be targeted by selective ER beta modulators.	[Saijo, Kaoru; Collier, Jana G.; Glass, Christopher K.] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Li, Andrew C.; Glass, Christopher K.] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; [Katzenellenbogen, John A.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Illinois System; University of Illinois Urbana-Champaign	Saijo, K (corresponding author), Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ksaijo@ucsd.edu; ckg@ucsd.edu	Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592	NIH [CA52599, HL087391, DK015556]; NATIONAL CANCER INSTITUTE [R01CA052599] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK091183, R01DK015556, R37DK015556] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Benita Katzenellenbogen, Joshua Stender, and Christian Schmedt for the critical reading of this manuscript. We are grateful to Norio Yasui for the preparation of Indazole-Cl; and Mel Simon for retrovirus carrying shRNA against PKA catalytic subunits; the CMMW vivarium for taking care of animals; and Lynn Bautista for help with preparing figures. This work was supported by grants from the NIH (CA52599 to C. K. G., HL087391 to A. C. L., and DK015556 to J.A.K.).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Baker AE, 2004, ENDOCRINOLOGY, V145, P5021, DOI 10.1210/en.2004-0619; Bhaskar K, 2010, NEURON, V68, P19, DOI 10.1016/j.neuron.2010.08.023; Bonetti A, 2009, J NEUROIMMUNOL, V208, P119, DOI 10.1016/j.jneuroim.2009.01.003; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Chang EC, 2008, MOL ENDOCRINOL, V22, P1032, DOI 10.1210/me.2007-0356; De Angelis M, 2005, J MED CHEM, V48, P1132, DOI 10.1021/jm049223g; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Glass CK, 2010, NAT REV IMMUNOL, V10, P365, DOI 10.1038/nri2748; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Gold SM, 2009, J NEUROL SCI, V286, P99, DOI 10.1016/j.jns.2009.05.028; Gold SM, 2009, LAB INVEST, V89, P1076, DOI 10.1038/labinvest.2009.79; Gottfried-Blackmore A, 2008, J STEROID BIOCHEM, V109, P96, DOI 10.1016/j.jsbmb.2007.12.013; Grober OMV, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-36; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Jellinck PH, 2007, J STEROID BIOCHEM, V107, P156, DOI 10.1016/j.jsbmb.2007.04.004; Koga K, 2009, IMMUNITY, V30, P372, DOI 10.1016/j.immuni.2008.12.021; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Krumbholz M, 2005, J EXP MED, V201, P195, DOI 10.1084/jem.20041674; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Laflamme N, 1998, J NEUROBIOL, V36, P357, DOI 10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V; Lin SX, 2006, MOL CELL ENDOCRINOL, V248, P38, DOI 10.1016/j.mce.2005.11.035; Littman DR, 2010, CELL, V140, P845, DOI 10.1016/j.cell.2010.02.021; Lukacik P, 2007, BIOCHEM J, V402, P419, DOI 10.1042/BJ20061319; Mackay F, 2002, NAT REV IMMUNOL, V2, P465, DOI 10.1038/nri844; Malamas MS, 2004, J MED CHEM, V47, P5021, DOI 10.1021/jm049719y; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; MINUTOLO F, 2009, ESTROGEN RECEPTOR BE; Moeller G, 2009, MOL CELL ENDOCRINOL, V301, P7, DOI 10.1016/j.mce.2008.10.040; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Saijo K, 2009, CELL, V137, P47, DOI 10.1016/j.cell.2009.01.038; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; Simard J, 2005, ENDOCR REV, V26, P525, DOI 10.1210/er.2002-0050; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Stossi F, 2009, MOL CELL BIOL, V29, P1749, DOI 10.1128/MCB.01476-08; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Stromnes IM, 2006, NAT PROTOC, V1, P1810, DOI 10.1038/nprot.2006.285; Tiwari-Woodruff S, 2007, P NATL ACAD SCI USA, V104, P14813, DOI 10.1073/pnas.0703783104; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Vegeto E, 2000, EXP GERONTOL, V35, P1309, DOI 10.1016/S0531-5565(00)00161-3; Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001; Wall EA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000202; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wise LH, 1999, ANN HUM GENET, V63, P263, DOI 10.1046/j.1469-1809.1999.6330263.x; Yadav A, 2009, J NEUROIMMUNE PHARM, V4, P430, DOI 10.1007/s11481-009-9174-2	54	223	229	0	22	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 13	2011	145	4					584	595		10.1016/j.cell.2011.03.050	http://dx.doi.org/10.1016/j.cell.2011.03.050			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565615	Bronze, Green Accepted			2022-12-28	WOS:000290560800011
J	Sang, LY; Miller, JJ; Corbit, KC; Giles, RH; Brauer, MJ; Otto, EA; Baye, LM; Wen, XH; Scales, SJ; Kwong, M; Huntzicker, EG; Sfakianos, MK; Sandoval, W; Bazan, JF; Kulkarni, P; Garcia-Gonzalo, FR; Seol, AD; O'Toole, JF; Held, S; Reutter, HM; Lane, WS; Rafiq, MA; Noor, A; Ansar, M; Devi, ARR; Sheffield, VC; Slusarski, DC; Vincent, JB; Doherty, DA; Hildebrandt, F; Reiter, JF; Jackson, PK				Sang, Liyun; Miller, Julie J.; Corbit, Kevin C.; Giles, Rachel H.; Brauer, Matthew J.; Otto, Edgar A.; Baye, Lisa M.; Wen, Xiaohui; Scales, Suzie J.; Kwong, Mandy; Huntzicker, Erik G.; Sfakianos, Mindan K.; Sandoval, Wendy; Bazan, J. Fernando; Kulkarni, Priya; Garcia-Gonzalo, Francesc R.; Seol, Allen D.; O'Toole, John F.; Held, Susanne; Reutter, Heiko M.; Lane, William S.; Rafiq, Muhammad Arshad; Noor, Abdul; Ansar, Muhammad; Devi, Akella Radha Rama; Sheffield, Val C.; Slusarski, Diane C.; Vincent, John B.; Doherty, Daniel A.; Hildebrandt, Friedhelm; Reiter, Jeremy F.; Jackson, Peter K.			Mapping the NPHP-JBTS-MKS Protein Network Reveals Ciliopathy Disease Genes and Pathways	CELL			English	Article							MECKEL-SYNDROME; PRIMARY CILIA; TRANSITION ZONE; INTRAFLAGELLAR TRANSPORT; RETINAL DEGENERATION; KIDNEY-DISEASE; NEPHRONOPHTHISIS; NEPHROCYSTIN; MOUSE; CILIOGENESIS	Nephronophthisis (NPHP), Joubert (JBTS), and Meckel-Gruber (MKS) syndromes are autosomal-recessive ciliopathies presenting with cystic kidneys, retinal degeneration, and cerebellar/neural tube malformation. Whether defects in kidney, retinal, or neural disease primarily involve ciliary, Hedgehog, or cell polarity pathways remains unclear. Using high-confidence proteomics, we identified 850 interactors copurifying with nine NPHP/JBTS/MKS proteins and discovered three connected modules: "NPHP1-4-8" functioning at the apical surface, "NPHP5-6" at centrosomes, and "MKS" linked to Hedgehog signaling. Assays for ciliogenesis and epithelial morphogenesis in 3D renal cultures link renal cystic disease to apical organization defects, whereas ciliary and Hedgehog pathway defects lead to retinal or neural deficits. Using 38 interactors as candidates, linkage and sequencing analysis of 250 patients identified ATXN10 and TCTN2 as new NPHP-JBTS genes, and our Tctn2 mouse knockout shows neural tube and Hedgehog signaling defects. Our study further illustrates the power of linking proteomic networks and human genetics to uncover critical disease pathways.	[Sang, Liyun; Brauer, Matthew J.; Wen, Xiaohui; Scales, Suzie J.; Kwong, Mandy; Huntzicker, Erik G.; Sfakianos, Mindan K.; Sandoval, Wendy; Bazan, J. Fernando; Kulkarni, Priya; Jackson, Peter K.] Genentech Inc, San Francisco, CA 94080 USA; [Miller, Julie J.] Stanford Univ, Dept Chem & Syst Biol, Sch Med, Stanford, CA 94305 USA; [Corbit, Kevin C.; Garcia-Gonzalo, Francesc R.; Seol, Allen D.; Reiter, Jeremy F.] Univ Calif San Francisco, Dept Biochem & Biophys, Cardiovasc Res Inst, San Francisco, CA 94158 USA; [Giles, Rachel H.] Univ Med Ctr Utrecht, Dept Med Oncol, NL-3584 CX Utrecht, Netherlands; [Giles, Rachel H.] Univ Med Ctr Utrecht, Dept Hypertens & Nephrol, NL-3584 CX Utrecht, Netherlands; [Otto, Edgar A.; O'Toole, John F.; Held, Susanne; Hildebrandt, Friedhelm] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Otto, Edgar A.; O'Toole, John F.; Held, Susanne; Hildebrandt, Friedhelm] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; [Baye, Lisa M.; Slusarski, Diane C.] Univ Iowa, Dept Biol, Iowa City, IA 52242 USA; [Sheffield, Val C.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Reutter, Heiko M.] Univ Bonn, Childrens Hosp, Inst Human Genet, D-53111 Bonn, Germany; [Reutter, Heiko M.] Univ Bonn, Childrens Hosp, Dept Neonatol, D-53111 Bonn, Germany; [Lane, William S.] Harvard Univ, Mass Spectrometry & Prote Resource Lab, Ctr Syst Biol, Cambridge, MA 02138 USA; [Rafiq, Muhammad Arshad; Noor, Abdul; Vincent, John B.] Ctr Addict & Mental Hlth, Mol Neuropsychiat & Dev Lab, Neurogenet Sect, Toronto, ON M5T 1R8, Canada; [Ansar, Muhammad] Quaid i Azam Univ, Dept Biochem, Islamabad 45320, Pakistan; [Devi, Akella Radha Rama] Rainbow Childrens Hosp, Hyderabad 500034, Andhra Pradesh, India; [Vincent, John B.] Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada; [Doherty, Daniel A.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Sheffield, Val C.; Hildebrandt, Friedhelm] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Roche Holding; Genentech; Stanford University; University of California System; University of California San Francisco; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Iowa; University of Iowa; University of Bonn; University of Bonn; Harvard University; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Quaid I Azam University; University of Toronto; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute	Jackson, PK (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.	pjackson@gene.com	Scales, Suzie J./H-4507-2019; Noor, Abdul/J-2345-2016; Ansar, Muhammad/F-4808-2015; Ansar, Muhammad/H-5967-2011; Garcia-Gonzalo, Francesc/W-2639-2017	Scales, Suzie J./0000-0003-2544-0283; Ansar, Muhammad/0000-0001-5891-7063; Garcia-Gonzalo, Francesc/0000-0002-9152-2191; Slusarski, Diane/0000-0003-3793-8636; Otto, Edgar/0000-0002-2387-9973; Sheffield, Val/0000-0002-6282-0835; Miller, Julie/0000-0002-1288-593X; Giles, Rachel/0000-0001-9133-2008; Jackson, Peter/0000-0002-1742-2539	NIH [GM07365-33, DK071108, CA112369, R01-AR054396, R01-EY11298, R01-EY017168, DK1068306, DK1069274, DK090917]; Netherlands Organisation for Scientific Research VIDI [016.066.354]; EU [241955]; Cardiovascular Center Interdisciplinary Research Fellowship, University of Iowa; Canadian Institutes of Health Research [MOP-102758, KL2RR025015, R01NS064077]; March of Dimes; Burroughs Wellcome Fund; Packard Foundation; Sandler Family Supporting Foundation; Roy J. Carver Charitable Trust; Carver Endowment for Molecular Ophthalmology, and Research to Prevent Blindness; NATIONAL CANCER INSTITUTE [R01CA112369] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025015] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011298, R01EY017168] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK071108, R01DK068306, RC4DK090917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM095941, T32GM007365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064077] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Netherlands Organisation for Scientific Research VIDI(Netherlands Organization for Scientific Research (NWO)); EU(European Commission); Cardiovascular Center Interdisciplinary Research Fellowship, University of Iowa; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); March of Dimes(March of Dimes); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Packard Foundation(The David & Lucile Packard Foundation); Sandler Family Supporting Foundation; Roy J. Carver Charitable Trust; Carver Endowment for Molecular Ophthalmology, and Research to Prevent Blindness; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors acknowledge expert advice and contributions from Chris Westlake, Guowei Fang, Ben Chih, Andy Peterson, Cecile Chalouni, John S. Beck, Darryl Y. Nishimura, Charles C. Searby, Martin Griebel, John Neveu, Bogdan Budnik, Renee Robinson, Alex Loktev, Jorge Torres, Saikat Mukhopadhyay, Dirk Siepe, and Kevin Wright. We acknowledge the following support: J.J.M., NIH Medical Scientist Training Program Grant GM07365-33; R. H. G., the Netherlands Organisation for Scientific Research VIDI grant 016.066.354 and the EU FP7 "Syscilia" project 241955; L. M. B., the Cardiovascular Center Interdisciplinary Research Fellowship, University of Iowa; J.F.O., NIH grant DK071108; D. C. S., NIH Grant CA112369; J.B.V., Canadian Institutes of Health Research grant MOP-102758; D. A. D., KL2RR025015 and R01NS064077; J.F.R., NIH Grant R01-AR054396, the March of Dimes, the Burroughs Wellcome Fund, the Packard Foundation, and the Sandler Family Supporting Foundation; V. C. S., NIH Grants R01-EY11298, R01-EY017168, the Roy J. Carver Charitable Trust, Carver Endowment for Molecular Ophthalmology, and Research to Prevent Blindness. V. C. S. is an HHMI investigator. F. H. is an HHMI Investigator, a Doris Duke Distinguished Clinical Scientist, and a Frederick G. L. Huetwell Professor. F. H. acknowledges support from the NIH grants (DK1068306, DK1069274, and DK090917). L. S., M. J. B., X. W., S. J. S., M. K., E. G. H., M. K. S., W. S., J. F. B., P. K., and P. K. J. are employees of Genentech, Inc.	Baala L, 2007, AM J HUM GENET, V81, P170, DOI 10.1086/519494; Benzing T, 2001, P NATL ACAD SCI USA, V98, P9784, DOI 10.1073/pnas.171269898; Bialas NJ, 2009, J CELL SCI, V122, P611, DOI 10.1242/jcs.028621; Chang B, 2006, HUM MOL GENET, V15, P1847, DOI 10.1093/hmg/ddl107; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Craige B, 2010, J CELL BIOL, V190, P927, DOI 10.1083/jcb.201006105; Davenport JR, 2007, CURR BIOL, V17, P1586, DOI 10.1016/j.cub.2007.08.034; Delous M, 2009, HUM MOL GENET, V18, P4711, DOI 10.1093/hmg/ddp434; Donaldson JC, 2000, EXP CELL RES, V256, P168, DOI 10.1006/excr.2000.4822; Essner JJ, 2005, DEVELOPMENT, V132, P1247, DOI 10.1242/dev.01663; Fliegauf M, 2006, J AM SOC NEPHROL, V17, P2424, DOI 10.1681/ASN.2005121351; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Hildebrandt F, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000353; Hildebrandt F, 2009, J AM SOC NEPHROL, V20, P23, DOI 10.1681/ASN.2008050456; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Lee JH, 2010, NEUROBIOL DIS, V38, P167, DOI 10.1016/j.nbd.2009.12.022; Lim J, 2006, CELL, V125, P801, DOI 10.1016/j.cell.2006.03.032; Matsuura T, 2000, NAT GENET, V26, P191, DOI 10.1038/79911; Mollet G, 2005, HUM MOL GENET, V14, P645, DOI 10.1093/hmg/ddi061; Mollet G, 2002, NAT GENET, V32, P300, DOI 10.1038/ng996; Mougou-Zerelli S, 2009, HUM MUTAT, V30, P1574, DOI 10.1002/humu.21116; Murga-Zamalloa CA, 2010, MOL VIS, V16, P1373; Nachury MV, 2007, CELL, V129, P1201, DOI 10.1016/j.cell.2007.03.053; Olbrich H, 2003, NAT GENET, V34, P455, DOI 10.1038/ng1216; Oteiza P, 2008, DEVELOPMENT, V135, P2807, DOI 10.1242/dev.022228; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Parisi MA, 2007, EUR J HUM GENET, V15, P511, DOI 10.1038/sj.ejhg.5201648; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Reiter JF, 2006, GENE DEV, V20, P22, DOI 10.1101/gad.1363606; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Salonen R, 1998, J MED GENET, V35, P497, DOI 10.1136/jmg.35.6.497; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; Schafer T, 2008, HUM MOL GENET, V17, P3655, DOI 10.1093/hmg/ddn260; Scholtens D, 2005, BIOINFORMATICS, V21, P3548, DOI 10.1093/bioinformatics/bti567; SCHOLTENS D, 2004, APCOMPLEX ESTIMATE P; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shiba D, 2010, CYTOSKELETON, V67, P112, DOI 10.1002/cm.20428; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Tallila J, 2008, AM J HUM GENET, V82, P1361, DOI 10.1016/j.ajhg.2008.05.004; Torres JZ, 2009, PROTEOMICS, V9, P2888, DOI 10.1002/pmic.200800873; Waragai M, 2006, J NEUROSCI RES, V83, P1170, DOI 10.1002/jnr.20807; Weatherbee SD, 2009, HUM MOL GENET, V18, P4565, DOI 10.1093/hmg/ddp422; Williams CL, 2008, MOL BIOL CELL, V19, P2154, DOI 10.1091/mbc.E07-10-1070; Winkelbauer ME, 2005, J CELL SCI, V118, P5575, DOI 10.1242/jcs.02665; Zaghloul NA, 2009, J CLIN INVEST, V119, P428, DOI 10.1172/JCI37041; Zuo XF, 2009, MOL BIOL CELL, V20, P2522, DOI 10.1091/mbc.E08-07-0772	46	414	440	1	70	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 13	2011	145	4					513	528		10.1016/j.cell.2011.04.019	http://dx.doi.org/10.1016/j.cell.2011.04.019			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565611	Green Accepted, Bronze			2022-12-28	WOS:000290560800006
J	Allen, AE; Dupont, CL; Obornik, M; Horak, A; Nunes-Nesi, A; McCrow, JP; Zheng, H; Johnson, DA; Hu, HH; Fernie, AR; Bowler, C				Allen, Andrew E.; Dupont, Christopher L.; Obornik, Miroslav; Horak, Ales; Nunes-Nesi, Adriano; McCrow, John P.; Zheng, Hong; Johnson, Daniel A.; Hu, Hanhua; Fernie, Alisdair R.; Bowler, Chris			Evolution and metabolic significance of the urea cycle in photosynthetic diatoms	NATURE			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; PHYLOGENETIC ANALYSIS; SEQUENCE ALIGNMENT; TREE; INFERENCE; ACCURATE; INSIGHTS; HISTORY; MRBAYES; GENOME	Diatoms dominate the biomass of phytoplankton in nutrient-rich conditions and form the basis of some of the world's most productive marine food webs(1-4). The diatom nuclear genome contains genes with bacterial and plastid origins as well as genes of the secondary endosymbiotic host (the exosymbiont(5))(1,6-10), yet little is known about the relative contribution of each gene group to diatom metabolism. Here we show that the exosymbiont-derived ornithine-urea cycle, which is similar to that of metazoans but is absent in green algae and plants, facilitates rapid recovery from prolonged nitrogen limitation. RNA-interference-mediated knockdown of a mitochondrial carbamoyl phosphate synthase impairs the response of nitrogen-limited diatoms to nitrogen addition. Metabolomic analyses indicate that intermediates in the ornithine-urea cycle are particularly depleted and that both the tricarboxylic acid cycle and the glutamine synthetase/glutamate synthase cycles are linked directly with the ornithine-urea cycle. Several other depleted metabolites are generated from ornithine-urea cycle intermediates by the products of genes laterally acquired from bacteria. This metabolic coupling of bacterial-and exosymbiont-derived proteins seems to be fundamental to diatom physiology because the compounds affected include the major diatom osmolyte proline(12) and the precursors for long-chain polyamines required for silica precipitation during cell wall formation(11). So far, the ornithine-urea cycle is only known for its essential role in the removal of fixed nitrogen in metazoans. In diatoms, this cycle serves as a distribution and repackaging hub for inorganic carbon and nitrogen and contributes significantly to the metabolic response of diatoms to episodic nitrogen availability. The diatom ornithine-urea cycle therefore represents a key pathway for anaplerotic carbon fixation into nitrogenous compounds that are essential for diatom growth and for the contribution of diatoms to marine productivity.	[Allen, Andrew E.; Dupont, Christopher L.; McCrow, John P.; Zheng, Hong; Johnson, Daniel A.] J Craig Venter Inst, San Diego, CA 92121 USA; [Allen, Andrew E.; Hu, Hanhua; Bowler, Chris] Ecole Normale Super, Inst Biol, Environm & Evolutionary Genom Sect, CNRS,UMR8197,INSERM,U1024, F-75005 Paris, France; [Obornik, Miroslav; Horak, Ales] Biol Ctr ASCR, Inst Parasitol, Ceske Budejovice 37005, Czech Republic; [Obornik, Miroslav; Horak, Ales] Univ S Bohemia, Fac Sci, Ceske Budejovice 37005, Czech Republic; [Nunes-Nesi, Adriano; Fernie, Alisdair R.] Max Planck Insitut Mol Pfanzenphysiol, D-14476 Potsdam, Germany	J. Craig Venter Institute; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences; University of South Bohemia Ceske Budejovice; Max Planck Society	Allen, AE (corresponding author), J Craig Venter Inst, San Diego, CA 92121 USA.	aallen@jcvi.org	Bowler, Chris/AAC-6256-2019; Allen, Andrew E/C-4896-2012; Obornik, Miroslav/G-9350-2014; Nunes-Nesi, Adriano/D-6430-2013; Horak, Ales/H-6723-2012	Allen, Andrew E/0000-0001-5911-6081; Horak, Ales/0000-0002-3364-7383; Nunes-Nesi, Adriano/0000-0002-9581-9355; McCrow, John/0000-0002-7014-5040; Bowler, Chris/0000-0003-3835-6187	National Science Foundation [NSF-OCE-0722374, NSF-OCE-0727997, NSF-MCB-1024913]; JCVI; European Commission; Agence Nationale de la Recherche (France); Czech Science Foundation [206/08/1423]	National Science Foundation(National Science Foundation (NSF)); JCVI; European Commission(European CommissionEuropean Commission Joint Research Centre); Agence Nationale de la Recherche (France)(French National Research Agency (ANR)); Czech Science Foundation(Grant Agency of the Czech Republic)	We thank A. Meichenin and C. Lichtle for assistance with electron microscropy, J. C. Thomas for CPS purification and activity experiments, A. Falciatore for advice on RNAi constructs and A. Main for screening and evaluation of RNAi lines. This study was supported by the National Science Foundation (NSF-OCE-0722374, NSF-OCE-0727997, NSF-MCB-1024913) and JCVI internal funding to A.E.A., the European Commission Diatomics project and Agence Nationale de la Recherche (France) (C.B.) and the Czech Science Foundation (206/08/1423) (M.O.).	Allen AE, 2008, P NATL ACAD SCI USA, V105, P10438, DOI 10.1073/pnas.0711370105; Allen AE, 2006, CURR OPIN PLANT BIOL, V9, P264, DOI 10.1016/j.pbi.2006.03.013; ANDERSON PM, 1980, SCIENCE, V208, P291, DOI 10.1126/science.6245445; Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453; Armbrust EV, 2004, SCIENCE, V306, P79, DOI 10.1126/science.1101156; Ast M, 2009, P NATL ACAD SCI USA, V106, P3621, DOI 10.1073/pnas.0808862106; Benton MJ, 2007, MOL BIOL EVOL, V24, P26, DOI 10.1093/molbev/msl150; Berney C, 2006, P ROY SOC B-BIOL SCI, V273, P1867, DOI 10.1098/rspb.2006.3537; Bowler C, 2008, NATURE, V456, P239, DOI 10.1038/nature07410; Bowler C, 2010, ANNU REV MAR SCI, V2, P333, DOI 10.1146/annurev-marine-120308-081051; De Riso V, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp448; Esteban-Pretel G, 2010, J NUTR, V140, P792, DOI 10.3945/jn.109.119388; Falciatore A, 1999, MAR BIOTECHNOL, V1, P239, DOI 10.1007/PL00011773; Falkowski PG, 2007, NAT REV MICROBIOL, V5, P813, DOI 10.1038/nrmicro1751; Falkowski PG, 2004, SCIENCE, V305, P354, DOI 10.1126/science.1095964; Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; GUPPY M, 1986, TRENDS BIOCHEM SCI, V11, P274, DOI 10.1016/0968-0004(86)90022-8; Hamm Christian, 2007, P311, DOI 10.1016/B978-012370518-1/50015-1; Holden HM, 1999, CELL MOL LIFE SCI, V56, P507, DOI 10.1007/s000180050448; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Krell A, 2007, J PHYCOL, V43, P753, DOI 10.1111/j.1529-8817.2007.00366.x; Kroger N, 2008, ANNU REV GENET, V42, P83, DOI 10.1146/annurev.genet.41.110306.130109; Lartillot N, 2004, MOL BIOL EVOL, V21, P1095, DOI 10.1093/molbev/msh112; Lartillot N, 2009, BIOINFORMATICS, V25, P2286, DOI 10.1093/bioinformatics/btp368; Lawson FS, 1996, MOL BIOL EVOL, V13, P970, DOI 10.1093/oxfordjournals.molbev.a025665; Lee B, 2000, P NATL ACAD SCI USA, V97, P8021, DOI 10.1073/pnas.140082197; Lisec J, 2006, NAT PROTOC, V1, P387, DOI 10.1038/nprot.2006.59; Maheswari U, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r85; MOMMSEN TP, 1989, SCIENCE, V243, P72, DOI 10.1126/science.2563172; Morris SM, 2002, ANNU REV NUTR, V22, P87, DOI 10.1146/annurev.nutr.22.110801.140547; Moustafa A, 2009, SCIENCE, V324, P1724, DOI 10.1126/science.1172983; NELSON DM, 1995, GLOBAL BIOGEOCHEM CY, V9, P359, DOI 10.1029/95GB01070; Nunes-Nesi A, 2010, MOL PLANT, V3, P973, DOI 10.1093/mp/ssq049; Parker MS, 2008, ANNU REV GENET, V42, P619, DOI 10.1146/annurev.genet.42.110807.091417; Quang LS, 2008, BIOINFORMATICS, V24, P2317, DOI 10.1093/bioinformatics/btn445; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Sanderson MJ, 2002, MOL BIOL EVOL, V19, P101, DOI 10.1093/oxfordjournals.molbev.a003974; Sanderson MJ, 1997, MOL BIOL EVOL, V14, P1218, DOI 10.1093/oxfordjournals.molbev.a025731; Schauer N, 2005, FEBS LETT, V579, P1332, DOI 10.1016/j.febslet.2005.01.029; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Siaut M, 2007, GENE, V406, P23, DOI 10.1016/j.gene.2007.05.022; Smetacek V, 1999, PROTIST, V150, P25, DOI 10.1016/S1434-4610(99)70006-4; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Team RC., 2022, LANG ENV STAT COMP; Thorne JL, 1998, MOL BIOL EVOL, V15, P1647, DOI 10.1093/oxfordjournals.molbev.a025892; Young EB, 2003, J PHYCOL, V39, P897, DOI 10.1046/j.1529-8817.2003.03042.x	49	309	320	19	334	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 12	2011	473	7346					203	+		10.1038/nature10074	http://dx.doi.org/10.1038/nature10074			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562560	Green Published			2022-12-28	WOS:000290487200036
J	Zhu, YW; Murali, S; Stoller, MD; Ganesh, KJ; Cai, WW; Ferreira, PJ; Pirkle, A; Wallace, RM; Cychosz, KA; Thommes, M; Su, D; Stach, EA; Ruoff, RS				Zhu, Yanwu; Murali, Shanthi; Stoller, Meryl D.; Ganesh, K. J.; Cai, Weiwei; Ferreira, Paulo J.; Pirkle, Adam; Wallace, Robert M.; Cychosz, Katie A.; Thommes, Matthias; Su, Dong; Stach, Eric A.; Ruoff, Rodney S.			Carbon-Based Supercapacitors Produced by Activation of Graphene	SCIENCE			English	Article							DOUBLE-LAYER CAPACITOR; ELECTROCHEMICAL CAPACITORS; PORE-SIZE; MESOPOROUS CARBONS; GRAPHITE OXIDE; ION SIZE; PERFORMANCE; NANOTUBES; ULTRACAPACITORS; EXFOLIATION	Supercapacitors, also called ultracapacitors or electrochemical capacitors, store electrical charge on high-surface-area conducting materials. Their widespread use is limited by their low energy storage density and relatively high effective series resistance. Using chemical activation of exfoliated graphite oxide, we synthesized a porous carbon with a Brunauer-Emmett-Teller surface area of up to 3100 square meters per gram, a high electrical conductivity, and a low oxygen and hydrogen content. This sp(2)-bonded carbon has a continuous three-dimensional network of highly curved, atom-thick walls that form primarily 0.6- to 5-nanometer-width pores. Two-electrode supercapacitor cells constructed with this carbon yielded high values of gravimetric capacitance and energy density with organic and ionic liquid electrolytes. The processes used to make this carbon are readily scalable to industrial levels.	[Zhu, Yanwu; Murali, Shanthi; Stoller, Meryl D.; Ganesh, K. J.; Cai, Weiwei; Ferreira, Paulo J.; Ruoff, Rodney S.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA; [Zhu, Yanwu; Murali, Shanthi; Stoller, Meryl D.; Ganesh, K. J.; Cai, Weiwei; Ferreira, Paulo J.; Ruoff, Rodney S.] Univ Texas Austin, Mat Sci & Engn Program, Austin, TX 78712 USA; [Pirkle, Adam; Wallace, Robert M.] Univ Texas Dallas, Dept Mat Sci & Engn, Richardson, TX 75080 USA; [Cychosz, Katie A.; Thommes, Matthias] Quantachrome Instruments, Boynton Beach, FL 33426 USA; [Su, Dong; Stach, Eric A.] Brookhaven Natl Lab, Ctr Funct Nanomat, Upton, NY 11973 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Dallas; United States Department of Energy (DOE); Brookhaven National Laboratory	Ruoff, RS (corresponding author), Univ Texas Austin, Dept Mech Engn, 1 Univ Stn C2200, Austin, TX 78712 USA.	r.ruoff@mail.utexas.edu	Stach, Eric A/D-8545-2011; Wallace, Robert M/A-5283-2008; Su, Dong/A-8233-2013; Stach, Eric Andrew/M-6455-2019; Ruoff, Rodney/ABE-6532-2020; Ruoff, Rodney S/B-7605-2009; Zhu, Yanwu/C-8979-2012	Stach, Eric A/0000-0002-3366-2153; Wallace, Robert M/0000-0001-5566-4806; Su, Dong/0000-0002-1921-6683; Stach, Eric Andrew/0000-0002-3366-2153; Ruoff, Rodney/0000-0002-6599-6764; Ruoff, Rodney S/0000-0002-6599-6764; Struckhoff, Katie/0000-0002-2032-7030	NSF [DMR-0907324]; U.S. Department of Energy (DOE) [DE-SC001951]; Institute for Advanced Technology; DOE, Office of Basic Energy Sciences [DE-AC02-98CH10886]; DOE [DE-AC02-98CH10886, DE-AC02-05CH11231]	NSF(National Science Foundation (NSF)); U.S. Department of Energy (DOE)(United States Department of Energy (DOE)); Institute for Advanced Technology; DOE, Office of Basic Energy Sciences(United States Department of Energy (DOE)); DOE(United States Department of Energy (DOE))	We appreciate funding support from NSF under award DMR-0907324, the U.S. Department of Energy (DOE) under award DE-SC001951, and the Institute for Advanced Technology. The research by E.A. and D.S. has been carried out at the Center for Functional Nanomaterials, Brookhaven National Laboratory, which is supported by the DOE, Office of Basic Energy Sciences, under contract DE-AC02-98CH10886. We thank P. Stephens for XRD data collection, which is supported by DOE under contract DE-AC02-98CH10886, and P. Ercius for data collection on the TEAM instrument, supported by DOE contract DE-AC02-05CH11231. We thank M. Nilges for help with EPR. We thank J. Potts for providing graphite oxide samples. We appreciate use of equipment in K. Johnston's lab. R.M.W. and A.P. acknowledge the partial support of the GRC-NRI SWAN Center for the XPS data collection and analysis. R.S.R., Y.Z., M.D.S., and S.M. have filed a U.S. patent application (application no. PCT/US2011/036164) regarding work in this paper.	Ania CO, 2006, CARBON, V44, P3126, DOI 10.1016/j.carbon.2006.07.026; Barborini E, 2002, APPL PHYS LETT, V81, P3359, DOI 10.1063/1.1516635; Barranco V, 2010, J PHYS CHEM C, V114, P10302, DOI 10.1021/jp1021278; BERGER SD, 1988, PHIL MAG LETT, V57, P285, DOI 10.1080/09500838808214715; Brezesinski T, 2010, NAT MATER, V9, P146, DOI [10.1038/NMAT2612, 10.1038/nmat2612]; Burke A, 2007, ELECTROCHIM ACTA, V53, P1083, DOI 10.1016/j.electacta.2007.01.011; Chmiola J, 2006, SCIENCE, V313, P1760, DOI [10.1126/science.1132195, 10.1126/science/1132195]; Fernandez JA, 2008, J POWER SOURCES, V175, P675, DOI 10.1016/j.jpowsour.2007.09.042; Futaba DN, 2006, NAT MATER, V5, P987, DOI 10.1038/nmat1782; Groen JC, 2003, MICROPOR MESOPOR MAT, V60, P1, DOI 10.1016/S1387-1811(03)00339-1; Izadi-Najafabadi A, 2010, ADV MATER, V22, pE235, DOI 10.1002/adma.200904349; Largeot C, 2008, J AM CHEM SOC, V130, P2730, DOI 10.1021/ja7106178; Leiro JA, 2003, J ELECTRON SPECTROSC, V128, P205, DOI 10.1016/S0368-2048(02)00284-0; Lillo-Rodenas MA, 2003, CARBON, V41, P267, DOI 10.1016/S0008-6223(02)00279-8; Liu T, 2003, CARBON, V41, P2440, DOI 10.1016/S0008-6223(03)00245-8; Lv W, 2009, ACS NANO, V3, P3730, DOI 10.1021/nn900933u; Marsh H, 2006, ACTIVATED CARBON, P1; Miller JR, 2008, SCIENCE, V321, P651, DOI 10.1126/science.1158736; Miller JR, 2010, SCIENCE, V329, P1637, DOI 10.1126/science.1194372; Neimark AV, 2009, CARBON, V47, P1617, DOI 10.1016/j.carbon.2009.01.050; Portet C, 2009, PHYS CHEM CHEM PHYS, V11, P4943, DOI 10.1039/b816514a; Ravikovitch PI, 2000, LANGMUIR, V16, P2311, DOI 10.1021/la991011c; Raymundo-Pinero E, 2005, CARBON, V43, P786, DOI 10.1016/j.carbon.2004.11.005; RUDGE A, 1994, J POWER SOURCES, V47, P89, DOI 10.1016/0378-7753(94)80053-7; Segal M, 2009, NAT NANOTECHNOL, V4, P611, DOI 10.1038/nnano.2009.279; Simon P, 2008, NAT MATER, V7, P845, DOI 10.1038/nmat2297; SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603; Stoller MD, 2008, NANO LETT, V8, P3498, DOI 10.1021/nl802558y; Stoller MD, 2010, ENERG ENVIRON SCI, V3, P1294, DOI 10.1039/c0ee00074d; Taberna PL, 2003, J ELECTROCHEM SOC, V150, pA292, DOI 10.1149/1.1543948; Terrones H, 1997, PROG CRYST GROWTH CH, V34, P25, DOI 10.1016/S0960-8974(97)00003-X; Toupin M, 2004, CHEM MATER, V16, P3184, DOI 10.1021/cm049649j; TOWNSEND SJ, 1992, PHYS REV LETT, V69, P921, DOI 10.1103/PhysRevLett.69.921; Vivekchand SRC, 2008, J CHEM SCI, V120, P9, DOI 10.1007/s12039-008-0002-7; Wang Y, 2009, J PHYS CHEM C, V113, P13103, DOI 10.1021/jp902214f; Wu NL, 2002, MATER CHEM PHYS, V75, P6, DOI 10.1016/S0254-0584(02)00022-6; Zhu YW, 2010, ADV MATER, V22, P3906, DOI 10.1002/adma.201001068; Zhu YW, 2010, CARBON, V48, P2118, DOI 10.1016/j.carbon.2010.02.001; Zhu YW, 2010, ACS NANO, V4, P1227, DOI 10.1021/nn901689k	39	4966	5112	148	8613	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 24	2011	332	6037					1537	1541		10.1126/science.1200770	http://dx.doi.org/10.1126/science.1200770			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	782EE	21566159				2022-12-28	WOS:000291990000039
J	Lee, M; Ovbiagele, B				Lee, Meng; Ovbiagele, Bruce			Vascular events after stroke: terutroban fails to PERFORM	LANCET			English	Editorial Material							ACETYLSALICYLIC-ACID; ISCHEMIC-STROKE; ASPIRIN; PREVENTION; RISK; TRIAL; TICLOPIDINE		[Ovbiagele, Bruce] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Lee, Meng] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Chiayi, Dept Neurol, Tao Yuan, Taiwan	University of California System; University of California San Diego; Chang Gung Memorial Hospital; Chang Gung University	Ovbiagele, B (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	ovibes@ucsd.edu						Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bousser MG, 2011, LANCET, V377, P2013, DOI 10.1016/S0140-6736(11)60600-4; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Rodriguez LAG, 2011, NEUROLOGY, V76, P740, DOI 10.1212/WNL.0b013e31820d62b5; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gorelick PB, 2003, JAMA-J AM MED ASSOC, V289, P2947, DOI 10.1001/jama.289.22.2947; Halkes PHA, 2006, LANCET, V367, P1665; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Lovett JK, 2004, NEUROLOGY, V62, P569, DOI 10.1212/01.WNL.0000110311.09970.83; Matias-Guiu J, 2003, STROKE, V34, P840, DOI 10.1161/01.STR.0000063141.24491.50; Shinohara Y, 2010, LANCET NEUROL, V9, P959, DOI 10.1016/S1474-4422(10)70198-8	12	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2011	377	9782					1980	1982		10.1016/S0140-6736(11)60708-3	http://dx.doi.org/10.1016/S0140-6736(11)60708-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	782LR	21616526				2022-12-28	WOS:000292011700005
J	Mishra, SK; Ammon, T; Popowicz, GM; Krajewski, M; Nagel, RJ; Ares, M; Holak, TA; Jentsch, S				Mishra, Shravan Kumar; Ammon, Tim; Popowicz, Grzegorz M.; Krajewski, Marcin; Nagel, Roland J.; Ares, Manuel, Jr.; Holak, Tad A.; Jentsch, Stefan			Role of the ubiquitin-like protein Hub1 in splice-site usage and alternative splicing	NATURE			English	Article							GENE-EXPRESSION; MESSENGER-RNAS; YEAST GENES; MODIFIER; INTRON; SENSITIVITY; DESIGN; SRC1; STEP; UBL5	Alternative splicing of pre-messenger RNAs diversifies gene products in eukaryotes and is guided by factors that enable spliceosomes to recognize particular splice sites. Here we report that alternative splicing of Saccharomyces cerevisiae SRC1 pre-mRNA is promoted by the conserved ubiquitin-like protein Hub1. Structural and biochemical data show that Hub1 binds non-covalently to a conserved element termed HIND, which is present in the spliceosomal protein Snu66 in yeast and mammals, and Prp38 in plants. Hub1 binding mildly alters spliceosomal protein interactions and barely affects general splicing in S. cerevisiae. However, spliceosomes that lack Hub1, or are defective in Hub1-HIND interaction, cannot use certain non-canonical 59 splice sites and are defective in alternative SRC1 splicing. Hub1 confers alternative splicing not only when bound to HIND, but also when experimentally fused to Snu66, Prp38, or even the core splicing factor Prp8. Our study indicates a novel mechanism for splice site utilization that is guided by non-covalent modification of the spliceosome by an unconventional ubiquitin-like modifier.	[Mishra, Shravan Kumar; Ammon, Tim; Jentsch, Stefan] Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany; [Popowicz, Grzegorz M.; Krajewski, Marcin; Holak, Tad A.] Max Planck Inst Biochem, NMR Spect, D-82152 Martinsried, Germany; [Nagel, Roland J.; Ares, Manuel, Jr.] Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA	Max Planck Society; Max Planck Society; University of California System; University of California Santa Cruz	Jentsch, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	Jentsch@biochem.mpg.de	Popowicz, Grzegorz/G-4769-2017	Popowicz, Grzegorz/0000-0003-2818-7498; Ares, Manny/0000-0002-2552-9168; Mishra, Shravan Kumar/0000-0003-3899-0495	Max Planck Society; Deutsche Forschungsgemeinschaft; Fonds der chemischen Industrie; Center for Integrated Protein Science Munich; RUBICON EU Network of Excellence; NIH [GM040478]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040478] Funding Source: NIH RePORTER	Max Planck Society(Max Planck SocietyFoundation CELLEX); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fonds der chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission); Center for Integrated Protein Science Munich; RUBICON EU Network of Excellence; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank U. Cramer and M. Kost for technical assistance, G. Dittmar, C. Guthrie, M. Konarska, K. Matuschewski, O. Nielsen, M. Rosbash and H. Yashiroda for materials, S. Uebel and C. Boulegue for mass spectrometric analysis and help, K. Hofmann for pointing out putative HIND elements in Prp38 proteins of plants, and M. Singh for initiating structural work. S.J. is supported by the Max Planck Society, Deutsche Forschungsgemeinschaft, Fonds der chemischen Industrie, Center for Integrated Protein Science Munich and RUBICON EU Network of Excellence; T.A.H. by the Max Planck Society; M.A. by NIH (GM040478).	ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Benedetti C, 2006, GENETICS, V174, P229, DOI 10.1534/genetics.106.061580; Burckin T, 2005, NAT STRUCT MOL BIOL, V12, P175, DOI 10.1038/nsmb891; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Clark TA, 2002, SCIENCE, V296, P907, DOI 10.1126/science.1069415; Davis CA, 2000, NUCLEIC ACIDS RES, V28, P1700, DOI 10.1093/nar/28.8.1700; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Dittmar GAG, 2002, SCIENCE, V295, P2442, DOI 10.1126/science.1069989; Fabrizio P, 2009, MOL CELL, V36, P593, DOI 10.1016/j.molcel.2009.09.040; Friedmann JS, 2001, GENOMICS, V71, P252, DOI 10.1006/geno.2000.6439; Grund SE, 2008, J CELL BIOL, V182, P897, DOI 10.1083/jcb.200803098; Hagan IM, 2000, PRACT APPROACH SER, V218, P179; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Hochstrasser M, 2009, NATURE, V458, P422, DOI 10.1038/nature07958; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; Janke C, 2004, YEAST, V21, P947, DOI 10.1002/yea.1142; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Keren H, 2010, NAT REV GENET, V11, P345, DOI 10.1038/nrg2776; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kress TL, 2008, MOL CELL, V32, P727, DOI 10.1016/j.molcel.2008.11.013; Kuhn AN, 2003, CURR GENET, V42, P241, DOI 10.1007/s00294-002-0355-2; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LESSER CF, 1993, GENETICS, V133, P851; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; Luders J, 2003, EMBO REP, V4, P1169, DOI 10.1038/sj.embor.7400025; Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553; McNally T, 2003, PROTEIN SCI, V12, P1562, DOI 10.1110/ps.0382803; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Okazaki K, 2000, DNA RES, V7, P27, DOI 10.1093/dnares/7.1.27; Pervushin KV, 1998, J BIOMOL NMR, V12, P345, DOI 10.1023/A:1008268930690; RAMAGE R, 1994, BIOCHEM J, V299, P151, DOI 10.1042/bj2990151; Ramelot Theresa A., 2003, Journal of Structural and Functional Genomics, V4, P25, DOI 10.1023/A:1024674220425; Rodriguez-Navarro S, 2002, YEAST, V19, P43, DOI 10.1002/yea.803; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Steen H, 2004, NAT REV MOL CELL BIO, V5, P699, DOI 10.1038/nrm1468; Stevens SW, 1999, P NATL ACAD SCI USA, V96, P7226, DOI 10.1073/pnas.96.13.7226; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wilkinson CRM, 2004, CURR BIOL, V14, P2283, DOI 10.1016/j.cub.2004.11.058; Yashiroda H, 2004, GENES CELLS, V9, P1189, DOI 10.1111/j.1365-2443.2004.00807.x; Zhu G, 1999, J BIOMOL NMR, V13, P77, DOI 10.1023/A:1008398227519	44	60	62	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	2011	474	7350					173	U205		10.1038/nature10143	http://dx.doi.org/10.1038/nature10143			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	774PE	21614000	Green Accepted			2022-12-28	WOS:000291397800041
J	Feinmann, J				Feinmann, Jane			MEDICAL ERROR Why sorry doesn't need to be the hardest word	BRITISH MEDICAL JOURNAL			English	Editorial Material												jane@janefeinmann.com						BOOTHMAN R, 2009, J HLTH LIFE SCI LAW, V2, P1250; *DEP HLTH, 2003, MAK AM CMOS PROP REF; HM Government, 2010, COAL OUR PROGR GOV; *MED PROT SOC, 2009, ACC HEALTHC SURV; *NAT AUD OFF, 2005, SAF PLAC; *NHS LIT AUTH, 2010, ANN REP 2010 NHSLA	6	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 1	2011	342								d3258	10.1136/bmj.d3258	http://dx.doi.org/10.1136/bmj.d3258			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	774MK	21632662				2022-12-28	WOS:000291390500007
J	Zutic, I; Cerne, J				Zutic, Igor; Cerne, John			Chameleon Magnets	SCIENCE			English	Editorial Material									[Zutic, Igor; Cerne, John] SUNY Buffalo, Dept Phys, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Zutic, I (corresponding author), SUNY Buffalo, Dept Phys, Buffalo, NY 14260 USA.	zigor@buffalo.edu; jcerne@buffalo.edu	Zutic, Igor/S-4933-2018					Acbas G, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.137201; Ahn CH, 2006, REV MOD PHYS, V78, P1185, DOI 10.1103/RevModPhys.78.1185; Calderon MJ, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.235203; Dyakonov M, 2008, SPRINGER SER SOLID-S, V157; Endo M, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3277146; Hsu HS, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3431294; Maekawa S., 2006, CONCEPTS SPIN ELECT; Ohno H, 2000, NATURE, V408, P944, DOI 10.1038/35050040; Petukhov AG, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.257202; Rangaraju N, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.117202; Shinde SR, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.166601; Ueno K, 2008, NAT MATER, V7, P855, DOI 10.1038/nmat2298; Venkatesan M, 2004, NATURE, V430, P630, DOI 10.1038/430630a; Yamada Y, 2011, SCIENCE, V332, P1065, DOI 10.1126/science.1202152; Zutic I, 2004, REV MOD PHYS, V76, P323, DOI 10.1103/RevModPhys.76.323	15	6	6	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2011	332	6033					1040	1041		10.1126/science.1205775	http://dx.doi.org/10.1126/science.1205775			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617063				2022-12-28	WOS:000290996700030
J	Aldridge, RW; Cole, KJ; Hurst, L; McKee, M; Horton, R				Aldridge, Robert W.; Cole, Katie J.; Hurst, Louise; McKee, Martin; Horton, Richard			Lancet UK Policy Matters: better evidence for better health	LANCET			English	Editorial Material							NHS		[Aldridge, Robert W.] UCL, Dept Infect & Populat Hlth, London NW3 2PF, England; [Cole, Katie J.] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London WC1, England; [Hurst, Louise] UCL, Dept Epidemiol & Publ Hlth, London NW3 2PF, England; [McKee, Martin] London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1, England; [Horton, Richard] The Lancet, London, England	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Aldridge, RW (corresponding author), UCL, Dept Infect & Populat Hlth, London NW3 2PF, England.	rob.aldridge@gmail.com	McKee, Marc D/E-2187-2011; McKee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Aldridge, Robert/0000-0003-0542-0816; McKee, Martin/0000-0002-0121-9683	National Institute for Health Research [ACF-2009-18-028] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Acheson D., 1998, INDEPENDENT INQUIRY; Appleby J, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d566; Department of Health, 2010, EQ EXC LIB NHS; Evans D, 2011, J PUBLIC HEALTH-UK, V33, P11, DOI 10.1093/pubmed/fdr007; Greener I, 2006, BRIT MED J, V333, P1168, DOI 10.1136/bmj.39022.486921.94; Healthy People 2020, 2010, FDN HLTH MEAS REP HE; Kay A, 2002, BRIT J GEN PRACT, V52, P141; Levell, 2010, DISTRIBUTIONAL EFFEC; Smith J, 2004, REV EFFECTIVENESS PR; Walshe K, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3843	10	2	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 14	2011	377	9778					1631	1633		10.1016/S0140-6736(11)60652-1	http://dx.doi.org/10.1016/S0140-6736(11)60652-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766JF	21571133				2022-12-28	WOS:000290777700007
J	Holmes, D				Holmes, David			Peter Rothwell: a dedicated flouter of fashion Profile	LANCET			English	Biographical-Item												david.holmes@zoho.com						ROTHWELL P, PUBLICATION LIST	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 14	2011	377	9778					1645	1645		10.1016/S0140-6736(11)60662-4	http://dx.doi.org/10.1016/S0140-6736(11)60662-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766JF	21571136				2022-12-28	WOS:000290777700014
J	Rothwell, PM; Algra, A; Amarenco, P				Rothwell, Peter M.; Algra, Ale; Amarenco, Pierre			Stroke Care 1 Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke	LANCET			English	Article							DENSITY-LIPOPROTEIN-CHOLESTEROL; SYMPTOMATIC CAROTID STENOSIS; PLASMA TRIGLYCERIDE LEVELS; BLOOD-PRESSURE REDUCTION; AGGRESSIVE REDUCTION; CARDIOVASCULAR EVENTS; VASCULAR EVENTS; EARLY RISK; RECURRENT STROKE; MINOR STROKE	Stroke is a major cause of death and disability worldwide. Without improvements in prevention, the burden will increase during the next 20 years because of the ageing population, especially in developing countries. Major advances have occurred in secondary prevention during the past three decades, which demonstrate the broader potential to prevent stroke. We review the main medical treatments that should be considered for most patients with transient ischaemic attack or ischaemic stroke in the acute phase and the long term, and draw attention to recent developments.	[Rothwell, Peter M.] Univ Oxford, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford, England; [Algra, Ale] Rudolf Magnus Inst Neurosci, Dept Neurol, Utrecht Stroke Ctr, NL-3508 TA Utrecht, Netherlands; [Algra, Ale] Univ Med Ctr, Julius Ctr Gen Hlth Sci & Primary Care, Utrecht, Netherlands; [Amarenco, Pierre] Univ Paris 07, INSERM, Grp Hosp Bichat Claude Bernard, Dept Neurol,Rech Clin Atherothrombose,U 698, Paris, France; [Amarenco, Pierre] Univ Paris 07, INSERM, Grp Hosp Bichat Claude Bernard, Stroke Dept,Rech Clin Atherothrombose,U 698, Paris, France	University of Oxford; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Rothwell, PM (corresponding author), John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Level 6,West Wing, Oxford OX3 9DU, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	Boehringer Ingelheim; AstraZeneca; Novartis; Pfizer; Sanofi-Aventis; Otsuka Pharmaceutical	Boehringer Ingelheim(Boehringer Ingelheim); AstraZeneca(AstraZeneca); Novartis(Novartis); Pfizer(Pfizer); Sanofi-Aventis(Sanofi-Aventis); Otsuka Pharmaceutical(Otsuka Pharmaceutical)	This review was independent of any pharmaceutical company or other commercial interest. However, PMR has received honoraria for talks, advisory boards, and clinical trial committees from several pharmaceutical companies, including AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi-Aventis/Bristol-Myers Squibb, and Servier, which manufacture drugs used in secondary prevention of stroke. AA has received honoraria for advisory boards and research funding from Boehringer Ingelheim. PA has received consulting fees from AstraZeneca, Novartis, Pfizer, and Sanofi-Aventis; lecture fees from Otsuka Pharmaceutical and Pfizer, and grant support from Pfizer.	Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690; Albers GW, 2003, LANCET, V362, P1691; Algra A, 1996, J NEUROL NEUROSUR PS, V60, P197, DOI 10.1136/jnnp.60.2.197; Algra A, 1999, J NEUROL NEUROSUR PS, V66, P255, DOI 10.1136/jnnp.66.2.255; Algra A, 2009, STROKE, V40, P1932, DOI 10.1161/STROKEAHA.108.537464; *AM HEART ASS, SS10 LAT BREAK CLIN; *AM HEART ASS, 1997, HEART STROK FACTS ST; Amarenco P, 2008, ATHEROSCLEROSIS, V196, P489, DOI 10.1016/j.atherosclerosis.2007.07.033; Amarenco P, 2007, STROKE, V38, P3198, DOI 10.1161/STROKEAHA.107.493106; Amarenco P, 2009, LANCET NEUROL, V8, P453, DOI 10.1016/S1474-4422(09)70058-4; Amarenco P, 2009, STROKE, V40, P2486, DOI 10.1161/STROKEAHA.108.546135; Amarenco P, 2009, STROKE, V40, P1405, DOI 10.1161/STROKEAHA.108.534107; Amarenco P, 2009, ATHEROSCLEROSIS, V204, P515, DOI 10.1016/j.atherosclerosis.2008.09.008; Amarenco P, 2006, NEW ENGL J MED, V355, P549; ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Bhatt DL, 2006, NEW ENGL J MED, V354, P1706, DOI 10.1056/NEJMoa060989; Blackshear JL, 1996, LANCET, V348, P633; BLOOMFIELD RH, 2001, CIRCULATION, V103, P2828; Bonati LH, 2010, LANCET, V376, P1062, DOI 10.1016/S0140-6736(10)61009-4; Bousser MG, 2009, CEREBROVASC DIS, V27, P608, DOI 10.1159/000216835; Bousser MG, 2009, CEREBROVASC DIS, V27, P509, DOI 10.1159/000212671; BOUSSER MG, LANCET IN PRESS; Bruckert E, 2011, J CARDIOVASC PHARM, V57, P267, DOI 10.1097/FJC.0b013e318202709f; Bruckert E, 2010, ATHEROSCLEROSIS, V210, P353, DOI 10.1016/j.atherosclerosis.2009.12.023; CALLAHAN A, 2007, AM HEART ASS SCI SES; CAMPESE VM, 2007, AM HEART ASS SCI SES; Chandratheva A, 2009, NEUROLOGY, V72, P1941, DOI 10.1212/WNL.0b013e3181a826ad; Chandratheva A, 2010, STROKE, V41, P851, DOI 10.1161/STROKEAHA.109.570010; Chaturvedi S, 2009, NEUROLOGY, V72, P688, DOI 10.1212/01.wnl.0000327339.55844.1a; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; *CLINICALTRIALS, COMBINATION CLOP ASP; *CLINICALTRIALS, PLAT OR INH NEW TIA; Connolly S, 2006, LANCET, V367, P1903, DOI 10.1016/s0140-6736(06)68845-4; Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301; Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; COSTA J, 2005, COCHRANE DB SYST REV, V3; Coull AJ, 2004, STROKE, V35, P1925, DOI 10.1161/01.STR.0000133129.58126.67; Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44; Cuffe RL, 2006, STROKE, V37, P2776, DOI 10.1161/01.STR.0000244761.62073.05; Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Elkind MSV, 2007, LANCET NEUROL, V6, P97, DOI 10.1016/S1474-4422(07)70008-X; Fairhead JF, 2005, NEUROLOGY, V65, P371, DOI 10.1212/01.WNL.0000170368.82460.b4; Flossmann E, 2003, BRAIN, V126, P1940, DOI 10.1093/brain/awg197; Franke CL, 1997, ANN NEUROL, V42, P857; Freeman JV, 2011, ANN INTERN MED, V154, P1, DOI 10.7326/0003-4819-154-1-201101040-00289; Freiberg JJ, 2008, JAMA-J AM MED ASSOC, V300, P2142, DOI 10.1001/jama.2008.621; Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Geraghty OC, 2010, CEREBROVASC DIS, V29, P460, DOI 10.1159/000297961; Giles MF, 2007, LANCET NEUROL, V6, P1063, DOI 10.1016/S1474-4422(07)70274-0; Giles MF, 2007, AGE AGEING, V36, P676, DOI 10.1093/ageing/afm088; Giles MF, 2010, STROKE, V41, P1907, DOI 10.1161/STROKEAHA.110.578971; Giles MF, 2010, STROKE, V41, P667, DOI 10.1161/STROKEAHA.109.571174; Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282; Goldstein LB, 2008, NEUROLOGY, V70, P2364, DOI 10.1212/01.wnl.0000296277.63350.77; Goldstein LB, 2008, STROKE, V39, P2444, DOI 10.1161/STROKEAHA.107.513747; Gorter JW, 1999, NEUROLOGY, V53, P1319, DOI 10.1212/WNL.53.6.1319; Hackam DG, 2007, STROKE, V38, P1881, DOI 10.1161/STROKEAHA.106.475525; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Halkes PHA, 2008, J NEUROL NEUROSUR PS, V79, P1218, DOI 10.1136/jnnp.2008.143875; Halkes PHA, 2007, LANCET NEUROL, V6, P115, DOI 10.1016/S1474-4422(06)70685-8; Halkes PHA, 2006, LANCET, V367, P1665; Hankey GJ, 2011, INT J STROKE, V6, P3, DOI 10.1111/j.1747-4949.2010.00535.x; *INT STROK CTR STR, TRIPL ANT RED DEP IS; Johnston SC, 2007, LANCET, V369, P283, DOI 10.1016/S0140-6736(07)60150-0; Jun M, 2010, LANCET, V375, P1875, DOI 10.1016/S0140-6736(10)60656-3; Kannel WB, 2008, MED CLIN N AM, V92, P17, DOI 10.1016/j.mcna.2007.09.002; Kennedy J, 2007, LANCET NEUROL, V6, P961, DOI 10.1016/S1474-4422(07)70250-8; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Labreuche J, 2010, ATHEROSCLEROSIS, V212, P9, DOI 10.1016/j.atherosclerosis.2010.02.011; Labreuche J, 2009, ATHEROSCLEROSIS, V203, P331, DOI 10.1016/j.atherosclerosis.2008.08.040; Lavallee PC, 2007, LANCET NEUROL, V6, P953, DOI 10.1016/S1474-4422(07)70248-X; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4; Liu LS, 2009, HYPERTENS RES, V32, P1032, DOI 10.1038/hr.2009.139; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lovett JK, 2004, NEUROLOGY, V62, P569, DOI 10.1212/01.WNL.0000110311.09970.83; Luengo-Fernandez R, 2009, LANCET NEUROL, V8, P235, DOI 10.1016/S1474-4422(09)70019-5; Ma RH, 2008, NEUROL RES, V30, P383, DOI 10.1179/174313208X300404; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Markus HS, 2005, CIRCULATION, V111, P2233, DOI 10.1161/01.CIR.0000163561.90680.1C; Merwick A, 2010, LANCET NEUROL, V9, P1060, DOI 10.1016/S1474-4422(10)70240-4; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Morocutti C, 1997, STROKE, V28, P1015, DOI 10.1161/01.STR.28.5.1015; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675; Payne DA, 2004, CIRCULATION, V109, P1476, DOI 10.1161/01.CIR.0000121739.05643.E6; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Potter JF, 2009, LANCET NEUROL, V8, P48, DOI 10.1016/S1474-4422(08)70263-1; Rashid P, 2003, STROKE, V34, P2741, DOI 10.1161/01.STR.0000092488.40085.15; Redgrave JNE, 2007, STROKE, V38, P1482, DOI 10.1161/STROKEAHA.106.477380; Rerkasem K, 2009, STROKE, V40, pE564, DOI 10.1161/STROKEAHA.109.558528; Robinson TG, 2010, LANCET NEUROL, V9, P767, DOI 10.1016/S1474-4422(10)70163-0; Rodgers A, 1996, BRIT MED J, V313, P147, DOI 10.1136/bmj.313.7050.147; Rothwell PM, 2007, LANCET, V370, P1432, DOI 10.1016/S0140-6736(07)61448-2; Rothwell PM, 2010, LANCET, V375, P938, DOI 10.1016/S0140-6736(10)60309-1; Rothwell PM, 2010, LANCET NEUROL, V9, P469, DOI 10.1016/S1474-4422(10)70066-1; Rothwell PM, 2010, LANCET, V375, P895, DOI 10.1016/S0140-6736(10)60308-X; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Rothwell PM, 2005, LANCET, V366, P1773, DOI 10.1016/S0140-6736(05)67702-1; Rothwell PM, 2005, LANCET, V366, P29, DOI 10.1016/S0140-6736(05)66702-5; Rothwell PM, 2005, NEUROLOGY, V64, P817, DOI 10.1212/01.WNL.0000152985.32732.EE; Rothwell PM, 2001, LANCET, V357, P1612, DOI 10.1016/S0140-6736(00)04730-9; Rothwell PM, 2003, STROKE, V34, P2583, DOI 10.1161/01.STR.0000094424.38761.56; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacco RL, 2008, NEW ENGL J MED, V359, P1238, DOI 10.1056/NEJMoa0805002; Saka O, 2009, AGE AGEING, V38, P27, DOI 10.1093/ageing/afn281; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; Sandset EC, 2011, LANCET, V377, P741, DOI 10.1016/S0140-6736(11)60104-9; Schrader J, 2005, STROKE, V36, P1218, DOI 10.1161/01.STR.0000166048.35740.a9; Shinohara Y, 2010, LANCET NEUROL, V9, P959, DOI 10.1016/S1474-4422(10)70198-8; Sillesen H, 2008, STROKE, V39, P3297, DOI 10.1161/STROKEAHA.108.516450; SIRIMARCO G, STROKE IN PRESS; Thijs V, 2008, EUR HEART J, V29, P1086, DOI 10.1093/eurheartj/ehn106; Tikhonoff V, 2009, LANCET NEUROL, V8, P938, DOI 10.1016/S1474-4422(09)70184-X; Toschke AM, 2009, CEREBROVASC DIS, V28, P105, DOI 10.1159/000223434; Turnbull F, 2008, BMJ-BRIT MED J, V336, P1121, DOI 10.1136/bmj.39548.738368.BE; Webb AJS, 2010, LANCET, V375, P906, DOI 10.1016/S0140-6736(10)60235-8; Wong KSL, 2010, LANCET NEUROL, V9, P489, DOI 10.1016/S1474-4422(10)70060-0; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2008, NEW ENGL J MED, V359, P1225, DOI 10.1056/NEJMoa0804593	133	131	136	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	2011	377	9778					1681	1692		10.1016/S0140-6736(11)60516-3	http://dx.doi.org/10.1016/S0140-6736(11)60516-3			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766JF	21571151				2022-12-28	WOS:000290777700033
J	Boyce, N				Boyce, Niall			The first flight of DSM-5	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Boyce, N (corresponding author), The Lancet, London NW1 7BY, England.							*AM PSYCH ASS, 2011, PROP DSM 5 ORG STRUC; American Psychiatric Association, 2000, DSM 4 TR; Bernstein C., 2011, PSYCHIAT NEWS, V46, P7; Tyrer P, 2011, LANCET, V377, P1814, DOI 10.1016/S0140-6736(10)61926-5; World Health Organization, 2016, MHGAP INT GUID MENT	5	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2011	377	9780					1816	1817		10.1016/S0140-6736(11)60743-5	http://dx.doi.org/10.1016/S0140-6736(11)60743-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	774UI	21621711				2022-12-28	WOS:000291411700008
J	Mombouli, JV; Ostroff, SM				Mombouli, Jean-Vivien; Ostroff, Stephen M.			The remaining smallpox stocks: the healthiest outcome	LANCET			English	Editorial Material							MONKEYPOX; CONGO		[Ostroff, Stephen M.] Penn Dept Hlth Harrisburg, Bur Epidemiol, Harrisburg, PA 17120 USA; [Mombouli, Jean-Vivien] Natl Publ Hlth Lab, Brazzaville, Rep Congo		Ostroff, SM (corresponding author), Penn Dept Hlth Harrisburg, Bur Epidemiol, Harrisburg, PA 17120 USA.	sostroff@state.pa.us						Advisory Group of Independent Experts to review the smallpox research programme (AGIES), 2010, ADV GROUP IND EXP RE; [Anonymous], 1999, SMALLP ER DESTR VAR; Damon IK, 2006, NEW ENGL J MED, V355, P962, DOI 10.1056/NEJMc060792; Henderson DA, 1998, EMERG INFECT DIS, V4, P488, DOI 10.3201/eid0403.980340; [Institute of Medicine National Acadamies of Sciences USA], 2009, LIV VAR VIR CONS CON; Khan AS, 2010, SCI REV VARIOLA VIRU; Learned LA, 2005, AM J TROP MED HYG, V73, P428, DOI 10.4269/ajtmh.2005.73.428; Rimoin AW, 2010, P NATL ACAD SCI USA, V107, P16262, DOI 10.1073/pnas.1005769107; WHO, 2007, SMALLP ER DESTR VAR	9	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 7	2012	379	9810					10	12		10.1016/S0140-6736(11)60694-6	http://dx.doi.org/10.1016/S0140-6736(11)60694-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873WC	21601271				2022-12-28	WOS:000298913000011
J	Valouev, A; Johnson, SM; Boyd, SD; Smith, CL; Fire, AZ; Sidow, A				Valouev, Anton; Johnson, Steven M.; Boyd, Scott D.; Smith, Cheryl L.; Fire, Andrew Z.; Sidow, Arend			Determinants of nucleosome organization in primary human cells	NATURE			English	Article							HIGH-RESOLUTION; HUMAN GENOME; SACCHAROMYCES-CEREVISIAE; C. ELEGANS; IN-VIVO; CHROMATIN; DNA; SEQUENCE; YEAST; METHYLATIONS	Nucleosomes are the basic packaging units of chromatin, modulating accessibility of regulatory proteins to DNA and thus influencing eukaryotic gene regulation. Elaborate chromatin remodelling mechanisms have evolved that govern nucleosome organization at promoters, regulatory elements, and other functional regions in the genome(1). Analyses of chromatin landscape have uncovered a variety of mechanisms, including DNA sequence preferences, that can influence nucleosome positions(2-4). To identify major determinants of nucleosome organization in the human genome, we used deep sequencing to map nucleosome positions in three primary human cell types and in vitro. A majority of the genome showed substantial flexibility of nucleosome positions, whereas a small fraction showed reproducibly positioned nucleosomes. Certain sites that position in vitro can anchor the formation of nucleosomal arrays that have cell type-specific spacing in vivo. Our results unveil an interplay of sequence-based nucleosome preferences and non-nucleosomal factors in determining nucleosome organization within mammalian cells.	[Valouev, Anton; Boyd, Scott D.; Smith, Cheryl L.; Fire, Andrew Z.; Sidow, Arend] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Johnson, Steven M.] Brigham Young Univ, Dept Microbiol & Mol Biol, Provo, UT 84602 USA; [Fire, Andrew Z.; Sidow, Arend] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Stanford University; Brigham Young University; Stanford University	Sidow, A (corresponding author), Stanford Univ, Dept Pathol, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	afire@stanford.edu; arend@stanford.edu	Johnson, Steven M/B-3940-2013	Johnson, Steven/0000-0002-7399-8153; Smith, Cheryl/0000-0003-4323-6382; Fire, Andrew/0000-0001-6217-8312	NIGMS [R01GM37706]; NHGRI [U01HG004695, T32HG00044]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000044, U01HG004695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037706] Funding Source: NIH RePORTER	NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the Stanford Genetics/Pathology Sequencing Initiative. We thank G. Narlikar for help with in vitro experiments, Life Technologies, especially J. Briggs, for help with generating sequencing data, P. Lacroute for help with sequence alignment, S. Galli for valuable discussions, L. Gracey for critical reading of the manuscript, and members of the Sidow and Fire labs for valuable feedback and discussions. Work in the Fire lab was partially supported by NIGMS (R01GM37706). A.V. was partially supported by an ENCODE subcontract to A.S. (NHGRI U01HG004695). S.M.J. was partially supported by the Stanford Genome Training program (NHGRI T32HG00044).	Albert I, 2007, NATURE, V446, P572, DOI 10.1038/nature05632; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Field Y, 2009, NAT GENET, V41, P438, DOI 10.1038/ng.324; Fu YT, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000138; Guoping S, 2010, CHROMOSOMA, V119, P73, DOI 10.1007/s00412-009-0235-3; Hughes Amanda, 2009, J Biol, V8, P96, DOI 10.1186/jbiol207; Johnson SM, 2006, GENOME RES, V16, P1505, DOI 10.1101/gr.5560806; Kaplan N, 2009, NATURE, V458, P362, DOI 10.1038/nature07667; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; Lee W, 2007, NAT GENET, V39, P1235, DOI 10.1038/ng2117; Luger K, 1999, METHOD ENZYMOL, V304, P3; Mavrich TN, 2008, GENOME RES, V18, P1073, DOI 10.1101/gr.078261.108; Mavrich TN, 2008, NATURE, V453, P358, DOI 10.1038/nature06929; Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Radman-Livaja M, 2010, DEV BIOL, V339, P258, DOI 10.1016/j.ydbio.2009.06.012; Sasaki S, 2009, SCIENCE, V323, P401, DOI 10.1126/science.1163183; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHLEGEL RA, 1980, BIOCHIM BIOPHYS ACTA, V606, P316, DOI 10.1016/0005-2787(80)90041-6; Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Sha K, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-465; Tillo D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009129; TRIFONOV EN, 1980, P NATL ACAD SCI-BIOL, V77, P3816, DOI 10.1073/pnas.77.7.3816; Valouev A, 2008, NAT METHODS, V5, P829, DOI 10.1038/NMETH.1246; Valouev A, 2008, GENOME RES, V18, P1051, DOI 10.1101/gr.076463.108; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; WIDOM J, 1992, P NATL ACAD SCI USA, V89, P1095, DOI 10.1073/pnas.89.3.1095; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178; Zhang Y, 2009, NAT STRUCT MOL BIOL, V16, P847, DOI 10.1038/nsmb.1636	34	427	433	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	2011	474	7352					516	U148		10.1038/nature10002	http://dx.doi.org/10.1038/nature10002			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	781NJ	21602827	Green Accepted			2022-12-28	WOS:000291939700050
J	Paeschke, K; Capra, JA; Zakian, VA				Paeschke, Katrin; Capra, John A.; Zakian, Virginia A.			DNA Replication through G-Quadruplex Motifs Is Promoted by the Saccharomyces cerevisiae Pif1 DNA Helicase	CELL			English	Article							FALSE DISCOVERY RATE; TELOMERE ELONGATION; FORK PROGRESSION; YEAST; RRM3P; INSTABILITY; SEQUENCES; PROTEIN; GENES; PAUSE	G-quadruplex (G4) DNA structures are extremely stable four-stranded secondary structures held together by noncanonical G-G base pairs. Genome-wide chromatin immunoprecipitation was used to determine the in vivo binding sites of the multifunctional Saccharomyces cerevisiae Pif1 DNA helicase, a potent unwinder of G4 structures in vitro. G4 motifs were a significant subset of the high-confidence Pif1-binding sites. Replication slowed in the vicinity of these motifs, and they were prone to breakage in Pif1-deficient cells, whereas non-G4 Pif1-binding sites did not show this behavior. Introducing many copies of G4 motifs caused slow growth in replication-stressed Pif1-deficient cells, which was relieved by spontaneous mutations that eliminated their ability to form G4 structures, bind Pif1, slow DNA replication, and stimulate DNA breakage. These data suggest that G4 structures form in vivo and that they are resolved by Pif1 to prevent replication fork stalling and DNA breakage.	[Paeschke, Katrin; Zakian, Virginia A.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Capra, John A.] Univ Calif San Francisco, Gladstone Inst, San Francisco, CA 94158 USA	Princeton University; University of California System; University of California San Francisco; The J David Gladstone Institutes	Zakian, VA (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	vzakian@princeton.edu	Capra, Tony/C-7784-2013		NIH [GM26938]; Deutsche Forschungsgemeinschaft; NJCCR; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM026938] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NJCCR; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank B. A. Lenzmeier for strains and advice on the recombination assay and C. Webb, N. Sabouri, M. Bochman, and J. Broach for comments on the manuscript. This work was supported by NIH grant GM26938 (V.A.Z.) and postdoctoral fellowships from Deutsche Forschungsgemeinschaft and NJCCR (K.P.).	Azvolinsky A, 2006, GENE DEV, V20, P3104, DOI 10.1101/gad.1478906; Azvolinsky A, 2009, MOL CELL, V34, P722, DOI 10.1016/j.molcel.2009.05.022; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bochman ML, 2010, DNA REPAIR, V9, P237, DOI 10.1016/j.dnarep.2010.01.008; Boule JB, 2005, NATURE, V438, P57, DOI 10.1038/nature04091; Boule JB, 2007, NUCLEIC ACIDS RES, V35, P5809, DOI 10.1093/nar/gkm613; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; Buck MJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r97; Capra JA, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000861; Cheung I, 2002, NAT GENET, V31, P405, DOI [10.1038/ng928, 10.1038/417405a]; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; FOURY F, 1985, EMBO J, V4, P3525, DOI 10.1002/j.1460-2075.1985.tb04112.x; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gasser R, 1996, J MOL BIOL, V258, P224, DOI 10.1006/jmbi.1996.0245; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; Hershman SG, 2008, NUCLEIC ACIDS RES, V36, P144, DOI 10.1093/nar/gkm986; Huppert JL, 2008, BIOCHIMIE, V90, P1140, DOI 10.1016/j.biochi.2008.01.014; Huppert JL, 2010, FEBS J, V277, P3452, DOI 10.1111/j.1742-4658.2010.07758.x; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; Ivessa AS, 2003, MOL CELL, V12, P1525, DOI 10.1016/S1097-2765(03)00456-8; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lipps HJ, 2009, TRENDS CELL BIOL, V19, P414, DOI 10.1016/j.tcb.2009.05.002; London TBC, 2008, J BIOL CHEM, V283, P36132, DOI 10.1074/jbc.M808152200; Mateyak MK, 2006, CELL CYCLE, V5, P2796, DOI 10.4161/cc.5.23.3524; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Nakken S, 2009, NUCLEIC ACIDS RES, V37, P5749, DOI 10.1093/nar/gkp590; Paeschke K, 2010, FEBS LETT, V584, P3760, DOI 10.1016/j.febslet.2010.07.007; Ribeyre C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000475; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; Sanders CM, 2010, BIOCHEM J, V430, P119, DOI 10.1042/BJ20100612; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SIKORSKI RS, 1989, GENETICS, V122, P19; Storey JD, 2003, ANN STAT, V31, P2013, DOI 10.1214/aos/1074290335; Vega LR, 2007, PLOS GENET, V3, P1065, DOI 10.1371/journal.pgen.0030105; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Zhou JQ, 2000, SCIENCE, V289, P771, DOI 10.1126/science.289.5480.771	37	398	407	2	72	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 27	2011	145	5					678	691		10.1016/j.cell.2011.04.015	http://dx.doi.org/10.1016/j.cell.2011.04.015			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620135	Green Accepted, Bronze			2022-12-28	WOS:000291018600009
J	Pourquie, O				Pourquie, Olivier			Vertebrate Segmentation: From Cyclic Gene Networks to Scoliosis	CELL			English	Review							CAUSES SPONDYLOCOSTAL DYSOSTOSIS; LUNATIC-FRINGE EXPRESSION; PRESOMITIC MESODERM CELLS; SOMITE BOUNDARY FORMATION; NOTCH SIGNALING PATHWAY; AXIAL SKELETAL DEFECTS; RETINOIC-ACID; ZEBRAFISH SOMITOGENESIS; MOUSE EMBRYO; BILATERAL SYMMETRY	One of the most striking features of the human vertebral column is its periodic organization along the anterior-posterior axis. This pattern is established when segments of vertebrates, called somites, bud off at a defined pace from the anterior tip of the embryo's presomitic mesoderm (PSM). To trigger this rhythmic production of somites, three major signaling pathways-Notch, Wnt/beta-catenin, and fibroblast growth factor (FGF)-integrate into a molecular network that generates a traveling wave of gene expression along the embryonic axis, called the "segmentation clock." Recent systems approaches have begun identifying specific signaling circuits within the network that set the pace of the oscillations, synchronize gene expression cycles in neighboring cells, and contribute to the robustness and bilateral symmetry of somite formation. These findings establish a new model for vertebrate segmentation and provide a conceptual framework to explain human diseases of the spine, such as congenital scoliosis.	Univ Strasbourg, IGBMC, INSERM, CNRS,UMR 7104,U964, F-67400 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Pourquie, O (corresponding author), Univ Strasbourg, IGBMC, INSERM, CNRS,UMR 7104,U964, F-67400 Illkirch Graffenstaden, France.	pourquie@igbmc.fr	Pourquié, Olivier/CAJ-5443-2022	Pourquié, Olivier/0000-0001-5189-1227	Association Francaise contre les Myopathies; Chaire d'excellence ANR; ERC; NIH [R02 HD043158]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD043158] Funding Source: NIH RePORTER	Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Chaire d'excellence ANR(French National Research Agency (ANR)); ERC(European Research Council (ERC)European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	I am grateful to A. Aulehla and members of the Pourquie lab for helpful comments. Research in my laboratory is supported by the Association Francaise contre les Myopathies, the Chaire d'excellence ANR, an ERC advanced grant, and an NIH grant R02 HD043158. I apologize to authors whose work was not cited due to space limitations.	Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Ahn Uri Michael, 2002, Am J Orthop (Belle Mead NJ), V31, P387; Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Aulehla A, 1999, DEV BIOL, V207, P49, DOI 10.1006/dbio.1998.9164; Aulehla A, 2008, NAT CELL BIOL, V10, P186, DOI 10.1038/ncb1679; Benazeraf B, 2010, NATURE, V466, P248, DOI 10.1038/nature09151; Bessho Y, 2003, GENE DEV, V17, P1451, DOI 10.1101/gad.1092303; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; Chal J, 2009, COLD SPRING HARB MON, V53, P41; Chen J, 2005, GENESIS, V43, P196, DOI 10.1002/gene.20171; Cole SE, 2002, DEV CELL, V3, P75, DOI 10.1016/S1534-5807(02)00212-5; CONLON RA, 1995, DEVELOPMENT, V121, P1533; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; Cornier AS, 2008, AM J HUM GENET, V82, P1334, DOI 10.1016/j.ajhg.2008.04.014; Cui C, 2009, ANAT REC, V292, P557, DOI 10.1002/ar.20872; Dale JK, 2006, DEV CELL, V10, P355, DOI 10.1016/j.devcel.2006.02.011; Dale JK, 2003, NATURE, V421, P275, DOI 10.1038/nature01244; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Delfini MC, 2005, P NATL ACAD SCI USA, V102, P11343, DOI 10.1073/pnas.0502933102; Dequeant ML, 2008, NAT REV GENET, V9, P370, DOI 10.1038/nrg2320; Dequeant ML, 2006, SCIENCE, V314, P1595, DOI 10.1126/science.1133141; Dequeant ML, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002856; Diez del Corral R, 2003, NEURON, V40, P65; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Dubrulle J, 2004, NATURE, V427, P419, DOI 10.1038/nature02216; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Dunty WC, 2008, DEVELOPMENT, V135, P85, DOI 10.1242/dev.009266; Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795; Echeverri K, 2007, DEV BIOL, V301, P388, DOI 10.1016/j.ydbio.2006.10.003; Fei Q, 2010, SPINE, V35, P983, DOI 10.1097/BRS.0b013e3181bc963c; Feller J, 2008, GENE DEV, V22, P2166, DOI 10.1101/gad.480408; Ferjentsik Z, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000662; Forsberg H, 1998, CURR BIOL, V8, P1027, DOI 10.1016/S0960-9822(07)00424-1; Francois P, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100192; Gibb S, 2009, DEV BIOL, V330, P21, DOI 10.1016/j.ydbio.2009.02.035; Giudicelli F, 2007, PLOS BIOL, V5, P1309, DOI 10.1371/journal.pbio.0050150; Goldbeter A, 2008, J THEOR BIOL, V252, P574, DOI 10.1016/j.jtbi.2008.01.006; Goldbeter A, 2007, DEV DYNAM, V236, P1495, DOI 10.1002/dvdy.21193; Gomez C, 2008, NATURE, V454, P335, DOI 10.1038/nature07020; Gonzalez A, 2010, BIOSYSTEMS, V102, P16, DOI 10.1016/j.biosystems.2010.07.013; Gros J, 2009, SCIENCE, V324, P941, DOI 10.1126/science.1172478; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Hayashi S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005603; Henry CA, 2002, DEVELOPMENT, V129, P3693; Herrgen L, 2010, CURR BIOL, V20, P1244, DOI 10.1016/j.cub.2010.06.034; Hirata H, 2004, NAT GENET, V36, P750, DOI 10.1038/ng1372; Holley SA, 2000, GENE DEV, V14, P1678; Holley SA, 2002, DEVELOPMENT, V129, P1175; Horikawa K, 2006, NATURE, V441, P719, DOI 10.1038/nature04861; Huppert SS, 2005, DEV CELL, V8, P677, DOI 10.1016/j.devcel.2005.02.019; Ishikawa A, 2004, MECH DEVELOP, V121, P1443, DOI 10.1016/j.mod.2004.08.003; Ishimatsu K, 2010, DEVELOPMENT, V137, P1595, DOI 10.1242/dev.046888; Jiang YJ, 2000, NATURE, V408, P475, DOI 10.1038/35044091; Jouve C, 2000, DEVELOPMENT, V127, P1421; Kawakami Y, 2005, NATURE, V435, P165, DOI 10.1038/nature03512; Kawamura A, 2005, DEV CELL, V9, P735, DOI 10.1016/j.devcel.2005.09.021; Kawamura A, 2005, GENE DEV, V19, P1156, DOI 10.1101/gad.1291205; Lewis J, 2003, CURR BIOL, V13, P1398, DOI 10.1016/S0960-9822(03)00534-7; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; MacDonald BT, 2004, DEVELOPMENT, V131, P2543, DOI 10.1242/dev.01126; Mara A, 2007, NAT CELL BIOL, V9, P523, DOI 10.1038/ncb1578; Maroto M, 2005, INT J DEV BIOL, V49, P309, DOI 10.1387/ijdb.041958mm; Martin BL, 2010, GENE DEV, V24, P2778, DOI 10.1101/gad.1962910; Maruhashi M, 2005, DEV DYNAM, V234, P332, DOI 10.1002/dvdy.20546; Masamizu Y, 2006, P NATL ACAD SCI USA, V103, P1313, DOI 10.1073/pnas.0508658103; McGrew MJ, 1998, CURR BIOL, V8, P979, DOI 10.1016/S0960-9822(98)70401-4; Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403; Morales AV, 2002, DEV CELL, V3, P63, DOI 10.1016/S1534-5807(02)00211-3; MORELLI LG, 2004, DEV CELL, V6, P205; Morelli LG, 2009, HFSP J, V3, P55, DOI 10.2976/1.3027088; Morimoto M, 2005, NATURE, V435, P354, DOI 10.1038/nature03591; Morimoto M, 2007, DEVELOPMENT, V134, P1561, DOI 10.1242/dev.000836; Nakayama K, 2008, CURR BIOL, V18, pR332, DOI 10.1016/j.cub.2008.03.013; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 2002, MECH DEVELOP, V110, P165, DOI 10.1016/S0925-4773(01)00561-5; Niwa Y, 2007, DEV CELL, V13, P298, DOI 10.1016/j.devcel.2007.07.013; Oates AC, 2002, DEVELOPMENT, V129, P2929; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Offiah A, 2010, AM J MED GENET A, V152A, P1357, DOI 10.1002/ajmg.a.33361; Oginuma M, 2008, DEVELOPMENT, V135, P2555, DOI 10.1242/dev.019877; Oginuma M, 2010, DEVELOPMENT, V137, P1515, DOI 10.1242/dev.044545; Ozbudak EM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040015; Ozbudak EM, 2010, P NATL ACAD SCI USA, V107, P4224, DOI 10.1073/pnas.0909375107; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Plaster N, 2007, DEV DYNAM, V236, P1891, DOI 10.1002/dvdy.21196; Prince VE, 2001, MECH DEVELOP, V105, P175, DOI 10.1016/S0925-4773(01)00398-7; Pueyo JI, 2008, P NATL ACAD SCI USA, V105, P16614, DOI 10.1073/pnas.0804093105; Raya A, 2004, NATURE, V427, P121, DOI 10.1038/nature02190; Raya Angel, 2008, Birth Defects Research, V84, P81, DOI 10.1002/bdrc.20122; Resende TP, 2010, P NATL ACAD SCI USA, V107, P12907, DOI 10.1073/pnas.1000979107; Riedel-Kruse IH, 2007, SCIENCE, V317, P1911, DOI 10.1126/science.1142538; Romanoff A, 1960, AVIAN EMBRYO STRUCTU, V1; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Sawada A, 2001, DEVELOPMENT, V128, P4873; Schroter C, 2008, DEV DYNAM, V237, P545, DOI 10.1002/dvdy.21458; Schroter C, 2010, CURR BIOL, V20, P1254, DOI 10.1016/j.cub.2010.05.071; Serth K, 2003, GENE DEV, V17, P912, DOI 10.1101/gad.250603; Sewell W, 2009, DEV BIOL, V329, P400, DOI 10.1016/j.ydbio.2009.02.023; Shifley ET, 2008, DEVELOPMENT, V135, P899, DOI 10.1242/dev.006742; Shiratori H, 2006, DEVELOPMENT, V133, P2095, DOI 10.1242/dev.02384; Sirbu IO, 2006, NAT CELL BIOL, V8, P271, DOI 10.1038/ncb1374; Sparrow DB, 2006, AM J HUM GENET, V78, P28, DOI 10.1086/498879; Sparrow DB, 2008, HUM MOL GENET, V17, P3761, DOI 10.1093/hmg/ddn272; Sparrow DB, 2010, EUR J HUM GENET, V18, P674, DOI 10.1038/ejhg.2009.241; Stauber M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007996; Suriben R, 2006, DEV DYNAM, V235, P3177, DOI 10.1002/dvdy.20968; Takahashi J, 2010, DEV BIOL, V342, P134, DOI 10.1016/j.ydbio.2010.03.015; Takahashi Y, 2000, NAT GENET, V25, P390, DOI 10.1038/78062; TAM PPL, 1981, J EMBRYOL EXP MORPH, V65, P103; Turnpenny PD, 2007, DEV DYNAM, V236, P1456, DOI 10.1002/dvdy.21182; Uriu K, 2010, P NATL ACAD SCI USA, V107, P4979, DOI 10.1073/pnas.0907122107; Vermot J, 2005, SCIENCE, V308, P563, DOI 10.1126/science.1108363; Vermot J, 2005, NATURE, V435, P215, DOI 10.1038/nature03488; Vilhais-Neto GC, 2010, NATURE, V463, P953, DOI 10.1038/nature08763; Wahl MB, 2007, DEVELOPMENT, V134, P4033, DOI 10.1242/dev.009167; Whittock NV, 2004, AM J HUM GENET, V74, P1249, DOI 10.1086/421053; Wright D, 2009, DEV DYNAM, V238, P3043, DOI 10.1002/dvdy.22139; Yoon JK, 2000, DEV BIOL, V222, P376, DOI 10.1006/dbio.2000.9717	119	240	246	2	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 27	2011	145	5					650	663		10.1016/j.cell.2011.05.011	http://dx.doi.org/10.1016/j.cell.2011.05.011			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620133	Bronze, Green Accepted			2022-12-28	WOS:000291018600007
J	Yamada, Y; Ueno, K; Fukumura, T; Yuan, HT; Shimotani, H; Iwasa, Y; Gu, L; Tsukimoto, S; Ikuhara, Y; Kawasaki, M				Yamada, Y.; Ueno, K.; Fukumura, T.; Yuan, H. T.; Shimotani, H.; Iwasa, Y.; Gu, L.; Tsukimoto, S.; Ikuhara, Y.; Kawasaki, M.			Electrically Induced Ferromagnetism at Room Temperature in Cobalt-Doped Titanium Dioxide	SCIENCE			English	Article							MAGNETIC SEMICONDUCTORS; SPINTRONICS; OXIDES; FILM	The electric field effect in ferromagnetic semiconductors enables switching of the magnetization, which is a key technology for spintronic applications. We demonstrated electric field-induced ferromagnetism at room temperature in a magnetic oxide semiconductor, (Ti,Co)O(2), by means of electric double-layer gating with high-density electron accumulation (>10(14) per square centimeter). By applying a gate voltage of a few volts, a low-carrier paramagnetic state was transformed into a high-carrier ferromagnetic state, thereby revealing the considerable role of electron carriers in high-temperature ferromagnetism and demonstrating a route to room-temperature semiconductor spintronics.	[Ueno, K.; Fukumura, T.] Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; [Yamada, Y.; Kawasaki, M.] Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan; [Ueno, K.; Gu, L.; Tsukimoto, S.; Ikuhara, Y.; Kawasaki, M.] Tohoku Univ, WPI AIM Res, Sendai, Miyagi 9808577, Japan; [Fukumura, T.] Univ Tokyo, Dept Chem, Tokyo 1130033, Japan; [Yuan, H. T.; Shimotani, H.; Iwasa, Y.; Kawasaki, M.] Univ Tokyo, Quantum Phase Elect Ctr, Tokyo 1138656, Japan; [Yuan, H. T.; Shimotani, H.; Iwasa, Y.; Kawasaki, M.] Univ Tokyo, Dept Appl Phys, Tokyo 1138656, Japan; [Yuan, H. T.; Shimotani, H.; Iwasa, Y.; Kawasaki, M.] Japan Sci & Technol Agcy, CREST, Tokyo 1020075, Japan; [Ikuhara, Y.] Univ Tokyo, Inst Engn Innovat, Tokyo 1138656, Japan; [Ikuhara, Y.] Japan Fine Ceram Ctr, Nanostruct Res Lab, Nagoya, Aichi 4568587, Japan	Japan Science & Technology Agency (JST); Tohoku University; Tohoku University; University of Tokyo; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; Japan Fine Ceramics Center	Fukumura, T (corresponding author), Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan.	fukumura@chem.s.u-tokyo.ac.jp	Yuan, Hongtao/C-9807-2012; Ishida, Mari/AAU-3379-2020; Tsukimoto, Susumu/G-5194-2010; Ikuhara, Yuichi/N-1001-2015; Iwasa, Yoshihiro/C-1719-2009; Ueno, Kazunori/C-3971-2008; Gu, Lin/D-9631-2011; Ikuhara, Yuichi/F-3066-2010; Fukumura, Tomoteru/C-2081-2009; Shimotani, Hidekazu/D-6438-2012; Kawasaki, Masashi/B-5826-2008	Ikuhara, Yuichi/0000-0003-3886-005X; Ueno, Kazunori/0000-0003-2912-7147; Gu, Lin/0000-0002-7504-031X; Fukumura, Tomoteru/0000-0002-8957-3520; Shimotani, Hidekazu/0000-0003-3238-9420; 	Ministry of Education, Culture, Sports, Science and Technology of Japan [21019004]; Funding Program for Next Generation World-Leading Researchers [GR029]; Grants-in-Aid for Scientific Research [22103004, 23656011] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Funding Program for Next Generation World-Leading Researchers(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by Ministry of Education, Culture, Sports, Science and Technology of Japan KAKENHI grant 21019004 and by Funding Program for Next Generation World-Leading Researchers grant GR029.	Ahn CH, 2003, NATURE, V424, P1015, DOI 10.1038/nature01878; Calderon MJ, 2007, ANN PHYS-NEW YORK, V322, P2618, DOI 10.1016/j.aop.2007.01.010; Chiba D, 2003, SCIENCE, V301, P943, DOI 10.1126/science.1086608; Chien C., 2013, HALL EFFECT ITS APPL; Dietl T, 2000, SCIENCE, V287, P1019, DOI 10.1126/science.287.5455.1019; Dietl T, 2010, NAT MATER, V9, P965, DOI [10.1038/nmat2898, 10.1038/NMAT2898]; Endo M, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3277146; Fukumura T, 2003, JPN J APPL PHYS 2, V42, pL105, DOI 10.1143/JJAP.42.L105; Griffin KA, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.157204; Macdonald AH, 2005, NAT MATER, V4, P195, DOI 10.1038/nmat1325; Maruyama T, 2009, NAT NANOTECHNOL, V4, P158, DOI [10.1038/nnano.2008.406, 10.1038/NNANO.2008.406]; Matsumoto Y, 2001, SCIENCE, V291, P854, DOI 10.1126/science.1056186; Ohno H, 2000, NATURE, V408, P944, DOI 10.1038/35050040; PENNYCOOK SJ, 1988, NATURE, V336, P565, DOI 10.1038/336565a0; Toyosaki H, 2004, NAT MATER, V3, P221, DOI 10.1038/nmat1099; Ueno K, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2535777; Ueno K, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3457785; Weisheit M, 2007, SCIENCE, V315, P349, DOI 10.1126/science.1136629; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; Ye JT, 2010, NAT MATER, V9, P125, DOI [10.1038/NMAT2587, 10.1038/nmat2587]; Zutic I, 2004, REV MOD PHYS, V76, P323, DOI 10.1103/RevModPhys.76.323	21	398	409	3	397	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2011	332	6033					1065	1067		10.1126/science.1202152	http://dx.doi.org/10.1126/science.1202152			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769FN	21617071				2022-12-28	WOS:000290996700039
J	Xu, CR; Cole, PA; Meyers, DJ; Kormish, J; Dent, S; Zaret, KS				Xu, Cheng-Ran; Cole, Philip A.; Meyers, David J.; Kormish, Jay; Dent, Sharon; Zaret, Kenneth S.			Chromatin "Prepattern" and Histone Modifiers in a Fate Choice for Liver and Pancreas	SCIENCE			English	Article							TRANSCRIPTION FACTORS; STEM-CELLS; IN-VITRO; GENE; EXPRESSION; ENDODERM; PROMOTER; DISTINCT; ACETYLTRANSFERASE; DIFFERENTIATION	Transcriptionally silent genes can be marked by histone modifications and regulatory proteins that indicate the genes' potential to be activated. Such marks have been identified in pluripotent cells, but it is unknown how such marks occur in descendant, multipotent embryonic cells that have restricted cell fate choices. We isolated mouse embryonic endoderm cells and assessed histone modifications at regulatory elements of silent genes that are activated upon liver or pancreas fate choices. We found that the liver and pancreas elements have distinct chromatin patterns. Furthermore, the histone acetyltransferase P300, recruited via bone morphogenetic protein signaling, and the histone methyltransferase Ezh2 have modulatory roles in the fate choice. These studies reveal a functional "prepattern" of chromatin states within multipotent progenitors and potential targets to modulate cell fate induction.	[Xu, Cheng-Ran; Kormish, Jay; Zaret, Kenneth S.] Univ Penn, Sch Med, Dept Cell & Dev Biol, Inst Regenerat Med,Epigenet Program, Philadelphia, PA 19104 USA; [Cole, Philip A.; Meyers, David J.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Dent, Sharon] Univ Texas MD Anderson Canc Ctr, Dept Mol Carcinogenesis, Smithville, TX 78957 USA	University of Pennsylvania; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center	Zaret, KS (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, Inst Regenerat Med,Epigenet Program, Philadelphia, PA 19104 USA.	zaret@upenn.edu	Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269	FAMRI Foundation; NIH [U54MH084691, RO1 GM067718, R37GM36477, U01DK072503]; Acylin Therapeutics; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK072503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067718, R37GM036477, R01GM062437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U54MH084691] Funding Source: NIH RePORTER	FAMRI Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Acylin Therapeutics; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank T. Jiang, R. Hardy, J. Oesterling, and W. DeMuth for assistance; Z. Zhang, J. Xu, and S. Hua for advice; P. Streeter and K. Kaestner for reagents; J. Epstein, E. Wandzioch, D. Metzger, A. Wecker, A. Hines, and D. Freedman-Cass for comments; and E. Pytko for preparing the manuscript. Supported by the FAMRI Foundation and NIH grant U54MH084691 (P.A.C. and D.J.M.), NIH grant RO1 GM067718 (S.D.), and NIH grants R37GM36477 and U01DK072503 (K.S.Z.). There is a patent on P300i: "Methods and compositions for modulating p300/CBP activity" (pub. WO/2008/157680; international application PCT/US2008/067477 to D.J.M. and P.A.C.). P.A.C. is co-founder, owns equity, and receives consulting fees as science advisor to Acylin Therapeutics, which is attempting the development of clinically useful HAT inhibitors and licenses from Johns Hopkins some of our discoveries related to C646.	Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bort R, 2004, DEVELOPMENT, V131, P797, DOI 10.1242/dev.00965; Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006; Boyer DF, 2006, DEV BIOL, V298, P616, DOI 10.1016/j.ydbio.2006.07.020; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chu GC, 2004, DEVELOPMENT, V131, P3501, DOI 10.1242/dev.01248; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Dahl JA, 2008, NAT PROTOC, V3, P1032, DOI 10.1038/nprot.2008.68; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Deutsch G, 2001, DEVELOPMENT, V128, P871; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; Gadue P, 2009, STEM CELLS, V27, P2103, DOI 10.1002/stem.147; Gao N, 2008, GENE DEV, V22, P3435, DOI 10.1101/gad.1752608; Gerrish K, 2004, MOL ENDOCRINOL, V18, P533, DOI 10.1210/me.2003-0371; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649; Lin WC, 2008, DEV DYNAM, V237, P928, DOI 10.1002/dvdy.21479; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Qiao LP, 2006, J BIOL CHEM, V281, P39915, DOI 10.1074/jbc.M607215200; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Seydel F, 2008, J AUTOIMMUN, V31, P377, DOI 10.1016/j.jaut.2008.08.010; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; van Arensbergen J, 2010, GENOME RES, V20, P722, DOI 10.1101/gr.101709.109; Wandzioch E, 2009, SCIENCE, V324, P1707, DOI 10.1126/science.1174497; Xu J, 2009, GENE DEV, V23, P2824, DOI 10.1101/gad.1861209; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zaret KS, 2008, NAT REV GENET, V9, P329, DOI 10.1038/nrg2318	36	153	158	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2011	332	6032					963	966		10.1126/science.1202845	http://dx.doi.org/10.1126/science.1202845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596989	Green Accepted			2022-12-28	WOS:000290766600043
J	Shekelle, PG; Pronovost, PJ; Wachter, RM; Taylor, SL; Dy, SM; Foy, R; Hempel, S; McDonald, KM; Ovretveit, J; Rubenstein, LV; Adams, AS; Angood, PB; Bates, DW; Bickman, L; Carayon, P; Donaldson, L; Duan, N; Farley, DO; Greenhalgh, T; Haughom, J; Lake, ET; Lilford, R; Lohr, KN; Meyer, GS; Miller, MR; Neuhauser, DV; Ryan, G; Saint, S; Shojania, KG; Shortell, SM; Stevens, DP; Walshe, K				Shekelle, Paul G.; Pronovost, Peter J.; Wachter, Robert M.; Taylor, Stephanie L.; Dy, Sydney M.; Foy, Robbie; Hempel, Susanne; McDonald, Kathryn M.; Ovretveit, John; Rubenstein, Lisa V.; Adams, Alyce S.; Angood, Peter B.; Bates, David W.; Bickman, Leonard; Carayon, Pascale; Donaldson, Liam; Duan, Naihua; Farley, Donna O.; Greenhalgh, Trisha; Haughom, John; Lake, Eileen T.; Lilford, Richard; Lohr, Kathleen N.; Meyer, Gregg S.; Miller, Marlene R.; Neuhauser, Duncan V.; Ryan, Gery; Saint, Sanjay; Shojania, Kaveh G.; Shortell, Stephen M.; Stevens, David P.; Walshe, Kieran			Advancing the Science of Patient Safety	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EVIDENCE-BASED MEDICINE; PHYSICIAN ORDER ENTRY; QUALITY IMPROVEMENT; MEDICATION ERRORS; CARE; ACCOUNTABILITY; INTERVENTION; PUBLICATION	Despite a decade's worth of effort, patient safety has improved slowly, in part because of the limited evidence base for the development and widespread dissemination of successful patient safety practices. The Agency for Healthcare Research and Quality sponsored an international group of experts in patient safety and evaluation methods to develop criteria to improve the design, evaluation, and reporting of practice research in patient safety. This article reports the findings and recommendations of this group, which include greater use of theory and logic models, more detailed descriptions of interventions and their implementation, enhanced explanation of desired and unintended outcomes, and better description and measurement of context and of how context influences interventions. Using these criteria and measuring and reporting contexts will improve the science of patient safety.	RAND Hlth, Santa Monica, CA USA; RAND Hlth, Pittsburgh, PA USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; Johns Hopkins Univ, Baltimore, MD USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Leeds, Leeds, W Yorkshire, England; Stanford Univ, Stanford, CA 94305 USA; Karolinska Inst, Stockholm, Sweden; Kaiser Permanente, Oakland, CA USA; Natl Qual Forum, Washington, DC USA; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Phys Org, Boston, MA USA; Vanderbilt Univ, Nashville, TN USA; Univ Wisconsin, Madison, WI USA; Dept Hlth, London SE1 6TE, England; UCL, London, England; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; PeaceHealth, Bellevue, WA USA; Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Univ Birmingham, Birmingham, W Midlands, England; RTI Int, Res Triangle Pk, NC USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ Michigan, Ann Arbor, MI 48109 USA; [Shojania, Kaveh G.] Univ Toronto, Toronto, ON, Canada; Univ Calif Berkeley, Berkeley, CA 94720 USA; Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA; Univ Manchester, Manchester, Lancs, England	RAND Corporation; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Johns Hopkins University; University of California System; University of California San Francisco; University of Leeds; Stanford University; Karolinska Institutet; Kaiser Permanente; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Vanderbilt University; University of Wisconsin System; University of Wisconsin Madison; University of London; University College London; New York State Psychiatry Institute; University of Pennsylvania; University of Birmingham; Research Triangle Institute; Case Western Reserve University; University of Michigan System; University of Michigan; University of Toronto; University of California System; University of California Berkeley; Dartmouth College; University of Manchester	Shekelle, PG (corresponding author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.	shekelle@rand.org	Saint, Sanjay/AAF-5126-2019; Bates, David/AAE-7283-2019; Chang, Shulan/H-2270-2011; TAYLOR, STEPHANIE/GYV-4768-2022; Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Foy, Robbie/0000-0003-0605-7713; Walshe, Kieran/0000-0002-0696-480X; ovretveit, john/0000-0002-5177-6613; Duan, Naihua/0000-0001-9411-2924; Lilford, Richard/0000-0002-0634-984X; Hempel, Susanne/0000-0003-1597-5110; Taylor, Stephanie/0000-0002-3266-1132; Bickman, Leonard/0000-0002-0746-3791; Lohr, Kathleen/0000-0002-3825-0713	AHRQ [HHSA-290-2009-10001C]	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Grant Support: By the AHRQ (contract HHSA-290-2009-10001C).	Auerbach AD, 2007, NEW ENGL J MED, V357, P608, DOI 10.1056/NEJMsb070738; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bosk CL, 2009, LANCET, V374, P444, DOI 10.1016/S0140-6736(09)61440-9; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; Davidoff F, 2008, ANN INTERN MED, V149, P670, DOI 10.7326/0003-4819-149-9-200811040-00009; Glasziou P, 2010, BMJ-BRIT MED J, V341, pc3852; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; Office of the Inspector General, 2010, ADVERSE EVENTS HOSP; Pronovost P, 2006, QUAL SAF HEALTH CARE, V15, P152, DOI 10.1136/qshc.2006.018432; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Pronovost PJ, 2008, J CRIT CARE, V23, P207, DOI 10.1016/j.jcrc.2007.09.002; Pronovost PJ, 2009, JAMA-J AM MED ASSOC, V302, P890, DOI 10.1001/jama.2009.1177; Pronovost PJ, 2010, BMJ-BRIT MED J, V340, pc309; Shekelle PG, 2010, AHRQ PUBLICATION; Shojania KG, 2010, CAN MED ASSOC J, V182, pE216, DOI 10.1503/cmaj.090578; Shojania KG, 2002, JAMA-J AM MED ASSOC, V288, P508, DOI 10.1001/jama.288.4.508; Smith GCS, 2003, BRIT MED J, V327, P1459, DOI 10.1136/bmj.327.7429.1459; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899; Wachter RM, 2010, HEALTH AFFAIR, V29, P165, DOI 10.1377/hlthaff.2009.0785	23	134	134	2	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10					693	696		10.7326/0003-4819-154-10-201105170-00011	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576538				2022-12-28	WOS:000290620300019
J	Kallmes, DF; Molyneux, AJ				Kallmes, David F.; Molyneux, Andrew J.			Endovascular coils for cerebral aneurysm: HELPS has arrived	LANCET			English	Editorial Material									[Kallmes, David F.] Mayo Clin, Rochester, MN 55905 USA; [Molyneux, Andrew J.] Oxford Radcliffe Hosp, Nuffield Dept Surg Sci, Oxford Neurovasc & Neuroradiol Res Unit, Oxford, England	Mayo Clinic; University of Oxford	Kallmes, DF (corresponding author), Mayo Clin, Rochester, MN 55905 USA.	kallmes.david@mayo.edu						Im SH, 2007, AM J NEURORADIOL, V28, P511; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8; Montori VM, 2005, BMJ-BRIT MED J, V330, P594, DOI 10.1136/bmj.330.7491.594; White PM, 2011, LANCET, V377, P1655, DOI 10.1016/S0140-6736(11)60408-X	5	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 14	2011	377	9778					1627	1628		10.1016/S0140-6736(11)60601-6	http://dx.doi.org/10.1016/S0140-6736(11)60601-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766JF	21571131				2022-12-28	WOS:000290777700004
J	Brady, CA; Jiang, D; Mello, SS; Johnson, TM; Jarvis, LA; Kozak, MM; Broz, DK; Basak, S; Park, EJ; McLaughlin, ME; Karnezis, AN; Attardi, LD				Brady, Colleen A.; Jiang, Dadi; Mello, Stephano S.; Johnson, Thomas M.; Jarvis, Lesley A.; Kozak, Margaret M.; Broz, Daniela Kenzelmann; Basak, Shashwati; Park, Eunice J.; McLaughlin, Margaret E.; Karnezis, Anthony N.; Attardi, Laura D.			Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression	CELL			English	Article							RADIATION-INDUCED APOPTOSIS; P53-DEPENDENT APOPTOSIS; DEFICIENT MUTANT; ONCOGENIC RAS; ONLY PROTEIN; ACTIVATION; DOMAIN; SENESCENCE; BINDING; TARGET	The molecular basis for p53-mediated tumor suppression remains unclear. Here, to elucidate mechanisms of p53 tumor suppression, we use knockin mice expressing an allelic series of p53 transcriptional activation mutants. Microarray analysis reveals that one mutant, p53(25,26), is severely compromised for transactivation of most p53 target genes, and, moreover, p53(25,26) cannot induce G(1)-arrest or apoptosis in response to acute DNA damage. Surprisingly, p(5325,26) retains robust activity in senescence and tumor suppression, indicating that efficient transactivation of the majority of known p53 targets is dispensable for these pathways. In contrast, the transactivation-dead p53(25,26,53,54) mutant cannot induce senescence or inhibit tumorigenesis, like p53 nullizygosity. Thus, p53 transactivation is essential for tumor suppression but, intriguingly, in association with a small set of novel p53 target genes. Together, our studies distinguish the p53 transcriptional programs involved in acute DNA-damage responses and tumor suppression-a critical goal for designing therapeutics that block p53-dependent side effects of chemotherapy without compromising p53 tumor suppression.	[Brady, Colleen A.; Jiang, Dadi; Mello, Stephano S.; Johnson, Thomas M.; Jarvis, Lesley A.; Kozak, Margaret M.; Broz, Daniela Kenzelmann; Basak, Shashwati; Park, Eunice J.; Attardi, Laura D.] Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, Stanford, CA 94305 USA; [Attardi, Laura D.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Kozak, Margaret M.] MIT, Ctr Canc Res, Cambridge, MA 02142 USA; [Karnezis, Anthony N.] Univ Calif San Francisco, Canc Res Inst, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Karnezis, Anthony N.] Univ Calif San Francisco, Dept Pathol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	Stanford University; Stanford University; Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Attardi, LD (corresponding author), Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, Stanford, CA 94305 USA.	attardi@stanford.edu	Mello, Stephano Spano/ABF-9477-2020	Mello, Stephano Spano/0000-0002-2484-086X; Kozak, Margaret/0000-0001-9111-1942	Smith Stanford Graduate Fellowship; Lucille P. Markey Biomedical Research Stanford Graduate Fellowship; National Science Foundation; Gerald Lieberman Dissertation Fellowship; C.A.P.E.S; Swiss National Science Foundation; American Cancer Society; Leukemia and Lymphoma Society; National Institutes of Health [CA140875]; NATIONAL CANCER INSTITUTE [R21CA141087, R01CA140875] Funding Source: NIH RePORTER	Smith Stanford Graduate Fellowship; Lucille P. Markey Biomedical Research Stanford Graduate Fellowship; National Science Foundation(National Science Foundation (NSF)); Gerald Lieberman Dissertation Fellowship; C.A.P.E.S(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); American Cancer Society(American Cancer Society); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Microarray analyses were performed using BRB-ArrayTools developed by Dr. Richard Simon and the BRB-ArrayTools Development Team. We thank T. Jacks for providing the Rosa26CreER<SUP>T2</SUP> mice, S. Lowe for the pWZL-HrasV12 plasmid and Pml antibody, S. Artandi for the 3xHA expression plasmid, and W. Hahn and A. Schinzel and the Dana Farber RNAi facility for the lentiviral shRNA constructs; D. Burkhart, A. Krieg, J. Sage, and L. Sayles for technical assistance; and S. Artandi, A. Brunet, A. Giaccia, and J. Sage for critical reading of the manuscript. This work was supported by a Smith Stanford Graduate Fellowship to C. A. B., a Lucille P. Markey Biomedical Research Stanford Graduate Fellowship to T. M. J., National Science Foundation Graduate Research Fellowships to C. A. B. and T. M. J., a Gerald Lieberman Dissertation Fellowship to C. A. B., a C.A.P.E.S Fellowship to S. S. M., a Swiss National Science Foundation Fellowship to D. K. B., and funding from the American Cancer Society, the Leukemia and Lymphoma Society, and the National Institutes of Health (CA140875) to LD.A.	Attardi LD, 2004, ONCOGENE, V23, P973, DOI 10.1038/sj.onc.1207026; Baptiste-Okoh N, 2008, P NATL ACAD SCI USA, V105, P1937, DOI 10.1073/pnas.0711800105; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Broz DK, 2010, CARCINOGENESIS, V31, P1311, DOI 10.1093/carcin/bgp331; Bugni JM, 2009, ONCOGENE, V28, P734, DOI 10.1038/onc.2008.426; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chi SW, 2005, J BIOL CHEM, V280, P38795, DOI 10.1074/jbc.M508578200; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duxbury MS, 2005, BIOCHEM BIOPH RES CO, V331, P459, DOI 10.1016/j.bbrc.2005.03.199; Efeyan A, 2007, ONCOGENE, V26, P1645, DOI 10.1038/sj.onc.1209972; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gaidarenko O, 2009, ONCOGENE, V28, P4397, DOI 10.1038/onc.2009.290; Gamper AM, 2008, MOL CELL BIOL, V28, P2517, DOI 10.1128/MCB.01461-07; Gao JL, 2010, BIOCHEM BIOPH RES CO, V402, P588, DOI 10.1016/j.bbrc.2010.09.133; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawase T, 2009, CELL, V136, P535, DOI 10.1016/j.cell.2008.12.002; Kennedy AL, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-16; Kodadek T, 2006, CELL, V127, P261, DOI 10.1016/j.cell.2006.10.002; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu J, 2008, NEUROPHARMACOLOGY, V54, P1, DOI 10.1016/j.neuropharm.2007.05.020; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lozano G, 2005, J PATHOL, V205, P206, DOI 10.1002/path.1704; Lu WJ, 2006, CELL DEATH DIFFER, V13, P909, DOI 10.1038/sj.cdd.4401922; Melotte V, 2009, JNCI-J NATL CANCER I, V101, P916, DOI 10.1093/jnci/djp131; MERRITT AJ, 1994, CANCER RES, V54, P614; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Teufel DP, 2007, P NATL ACAD SCI USA, V104, P7009, DOI 10.1073/pnas.0702010104; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; van Ham M, 2003, GENES CELLS, V8, P631, DOI 10.1046/j.1365-2443.2003.00660.x; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	57	374	381	1	50	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 13	2011	145	4					571	583		10.1016/j.cell.2011.03.035	http://dx.doi.org/10.1016/j.cell.2011.03.035			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565614	Green Accepted, Bronze			2022-12-28	WOS:000290560800010
J	Cirimotich, CM; Dong, YM; Clayton, AM; Sandiford, SL; Souza-Neto, JA; Mulenga, M; Dimopoulos, G				Cirimotich, Chris M.; Dong, Yuemei; Clayton, April M.; Sandiford, Simone L.; Souza-Neto, Jayme A.; Mulenga, Musapa; Dimopoulos, George			Natural Microbe-Mediated Refractoriness to Plasmodium Infection in Anopheles gambiae	SCIENCE			English	Article							MALARIA PARASITE INFECTION; GRAM-NEGATIVE BACTERIA; SPOROGONIC DEVELOPMENT; POPULATION-DYNAMICS; NITRIC-OXIDE; MOSQUITO; STEPHENSI; FALCIPARUM; RESISTANCE; IMMUNITY	Malaria parasite transmission depends on the successful transition of Plasmodium through discrete developmental stages in the lumen of the mosquito midgut. Like the human intestinal tract, the mosquito midgut contains a diverse microbial flora, which may compromise the ability of Plasmodium to establish infection. We have identified an Enterobacter bacterium isolated from wild mosquito populations in Zambia that renders the mosquito resistant to infection with the human malaria parasite Plasmodium falciparum by interfering with parasite development before invasion of the midgut epithelium. Phenotypic analyses showed that the anti-Plasmodium mechanism requires small populations of replicating bacteria and is mediated through a mosquito-independent interaction with the malaria parasite. We show that this anti-Plasmodium effect is largely caused by bacterial generation of reactive oxygen species.	[Cirimotich, Chris M.; Dong, Yuemei; Clayton, April M.; Sandiford, Simone L.; Souza-Neto, Jayme A.; Dimopoulos, George] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; [Mulenga, Musapa] Malaria Inst Macha, Choma, Zambia	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Dimopoulos, G (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.	gdimopou@jhsph.edu	Souza-Neto, Jayme A/E-7841-2010	Souza-Neto, Jayme A/0000-0001-9281-894X; Cirimotich, Chris/0000-0002-7636-0542; Dimopoulos, George/0000-0001-6755-8111; Dong, Yuemei/0000-0002-7902-2899	National Institutes of Health/National Institute of Allergy and Infectious Disease [R01AI061576]; Johns Hopkins Malaria Research Institute (JHMRI); Bloomberg Family Foundation; Calvin A. and Helen H. Lang fellowship; NSF; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007417, R01AI061576] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Johns Hopkins Malaria Research Institute (JHMRI); Bloomberg Family Foundation; Calvin A. and Helen H. Lang fellowship; NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work has been supported by the National Institutes of Health/National Institute of Allergy and Infectious Disease R01AI061576 and a Johns Hopkins Malaria Research Institute (JHMRI) Pilot Grant (to G. D.), the Bloomberg Family Foundation, the Calvin A. and Helen H. Lang fellowship (to C. M. C.), a JHMRI postdoctoral fellowship (to J.S.-N.), and a fellowship from the NSF (to A. M. C.). The authors thank the mosquito collection team at the Malaria Institute at Macha, Zambia; the JHMRI Parasitology and Insectary Core facilities; Sanaria Inc.; E. Nelson (Cornell University) for providing mutant bacteria strains; and D. McClellan for editorial services. We performed all experiments according to Johns Hopkins Institutional Animal Care and Use Committee guidelines. Human landing catches were performed according to the approved protocol UNZA REC 011-02-04 with consent of participants. GenBank accession numbers generated for bacterial 16S rDNA sequences are listed in table S1, SOM.	Alavi Y, 2003, INT J PARASITOL, V33, P933, DOI 10.1016/S0020-7519(03)00112-7; Blandin SA, 2009, SCIENCE, V326, P147, DOI 10.1126/science.1175241; Cirimotich CM, 2010, DEV COMP IMMUNOL, V34, P387, DOI 10.1016/j.dci.2009.12.005; Dong YM, 2006, PLOS PATHOG, V2, P513, DOI 10.1371/journal.ppat.0020052; Dong YM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000423; Garver LS, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000335; Gonzalez-Ceron L, 2003, J MED ENTOMOL, V40, P371, DOI 10.1603/0022-2585-40.3.371; Kumar S, 2003, P NATL ACAD SCI USA, V100, P14139, DOI 10.1073/pnas.2036262100; Kumar S, 2010, SCIENCE, V327, P1644, DOI 10.1126/science.1184008; Luckhart S, 1998, P NATL ACAD SCI USA, V95, P5700, DOI 10.1073/pnas.95.10.5700; Mai-Prochnow A, 2008, J BACTERIOL, V190, P5493, DOI 10.1128/JB.00549-08; Meister S, 2005, P NATL ACAD SCI USA, V102, P11420, DOI 10.1073/pnas.0504950102; Meister S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000542; Molina-Cruz A, 2008, J BIOL CHEM, V283, P3217, DOI 10.1074/jbc.M705873200; Niare O, 2002, SCIENCE, V298, P213, DOI 10.1126/science.1073420; Peterson TML, 2007, FREE RADICAL BIO MED, V42, P132, DOI 10.1016/j.freeradbiomed.2006.10.037; Pumpuni CB, 1996, AM J TROP MED HYG, V54, P214, DOI 10.4269/ajtmh.1996.54.214; PUMPUNI CB, 1993, EXP PARASITOL, V77, P195, DOI 10.1006/expr.1993.1076; Riehle MM, 2006, SCIENCE, V312, P577, DOI 10.1126/science.1124153; Terenius O, 2008, J MED ENTOMOL, V45, P172, DOI 10.1603/0022-2585(2008)45[172:SRGSFB]2.0.CO;2; van Dijk K, 2000, APPL ENVIRON MICROB, V66, P5340, DOI 10.1128/AEM.66.12.5340-5347.2000; VAUGHAN JA, 1992, J PARASITOL, V78, P716, DOI 10.2307/3283550; VAUGHAN JA, 1994, AM J TROP MED HYG, V51, P233, DOI 10.4269/ajtmh.1994.51.233	23	389	403	4	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					855	858		10.1126/science.1201618	http://dx.doi.org/10.1126/science.1201618			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566196	Green Accepted			2022-12-28	WOS:000290529900050
J	Barnes, K				Barnes, Katherine			EUROPE'S TICKING TIME BOMB	NATURE			English	News Item							VESUVIUS											Baxter PJ, 2008, J VOLCANOL GEOTH RES, V178, P454, DOI 10.1016/j.jvolgeores.2008.08.015; Mastrolorenzo G, 2006, P NATL ACAD SCI USA, V103, P4366, DOI 10.1073/pnas.0508697103; Mastrolorenzo G, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB006871; Pappalardo L, 2010, EARTH PLANET SC LETT, V296, P133, DOI 10.1016/j.epsl.2010.05.010; Rolandi G, 2010, J VOLCANOL GEOTH RES, V189, P347, DOI 10.1016/j.jvolgeores.2009.08.007; Scaillet B, 2008, NATURE, V455, P216, DOI 10.1038/nature07232	6	8	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 12	2011	473	7346					140	141		10.1038/473140a	http://dx.doi.org/10.1038/473140a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562537	Bronze			2022-12-28	WOS:000290487200012
J	Brown, SC; Brew, S; Madigan, J				Brown, S. C.; Brew, S.; Madigan, J.			RATIONAL IMAGING Investigating suspected subarachnoid haemorrhage in adults	BRITISH MEDICAL JOURNAL			English	Editorial Material							DIGITAL-SUBTRACTION-ANGIOGRAPHY; INTRACRANIAL ANEURYSMS; CT ANGIOGRAPHY; MAGNETIC-RESONANCE; COHORT; DSA		[Brown, S. C.; Brew, S.] Natl Hosp Neurol & Neurosurg, Dept Radiol, London WC1N 3BG, England; [Madigan, J.] Univ London St Georges Hosp, Dept Neuroradiol, London SW17 0QT, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; St Georges University London	Brown, SC (corresponding author), Natl Hosp Neurol & Neurosurg, Dept Radiol, London WC1N 3BG, England.	satsuki@doctors.org.uk						Agid R, 2010, AM J NEURORADIOL, V31, P696, DOI 10.3174/ajnr.A1884; Al-Shahi R, 2006, BMJ-BRIT MED J, V333, P235, DOI 10.1136/bmj.333.7561.235; Brilstra EH, 2000, NEUROLOGY, V55, P1656, DOI 10.1212/WNL.55.11.1656; Chen WH, 2009, SURG NEUROL, V71, P32, DOI 10.1016/j.surneu.2007.08.005; Cloft HJ, 1999, STROKE, V30, P317, DOI 10.1161/01.STR.30.2.317; Cortnum S, 2010, NEUROSURGERY, V66, P900, DOI [10.1227/01.NEU.0000367722.66098.21, 10.1227/01. NEU.0000367722.66098.21]; Cuvinciuc V, 2010, AM J NEURORADIOL, V31, P1355, DOI 10.3174/ajnr.A1986; DONMEZ H, 2010, EUR J RADIOL; Jayaraman MV, 2010, RADIOLOGY, V254, P314, DOI 10.1148/radiol.09091614; Jayaraman MV, 2004, RADIOLOGY, V230, P510, DOI 10.1148/radiol.2302021465; Latchaw RE, 1997, NEUROIMAG CLIN N AM, V7, P693; Li MH, 2009, STROKE, V40, P3127, DOI 10.1161/STROKEAHA.109.553800; Li Q, 2009, RADIOLOGY, V252, P808, DOI 10.1148/radiol.2523081911; LOCKSLEY HB, 1966, J NEUROSURG, V25, P321, DOI 10.3171/jns.1966.25.3.0321; McKinney AM, 2008, AM J NEURORADIOL, V29, P594, DOI 10.3174/ajnr.A0848; Mitchell P, 2001, J NEUROL NEUROSUR PS, V70, P205, DOI 10.1136/jnnp.70.2.205; SUAREZ R, 2006, NEW ENGL J MED, V26, P387; Thiex R, 2010, AM J NEURORADIOL, V31, P230, DOI 10.3174/ajnr.A1803; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; White PM, 2000, RADIOLOGY, V217, P361, DOI 10.1148/radiology.217.2.r00nv06361; White PM, 2001, RADIOLOGY, V219, P739, DOI 10.1148/radiology.219.3.r01ma16739; Yuan Mei-Kang, 2005, J Chin Med Assoc, V68, P131; Zhang LJ, 2010, AM J ROENTGENOL, V194, P23, DOI 10.2214/AJR.08.2290	24	4	4	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 6	2011	342								d2644	10.1136/bmj.d2644	http://dx.doi.org/10.1136/bmj.d2644			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MG	21551185				2022-12-28	WOS:000290482300001
J	Wild, P; Farhan, H; McEwan, DG; Wagner, S; Rogov, VV; Brady, NR; Richter, B; Korac, J; Waidmann, O; Choudhary, C; Dotsch, V; Bumann, D; Dikic, I				Wild, Philipp; Farhan, Hesso; McEwan, David G.; Wagner, Sebastian; Rogov, Vladimir V.; Brady, Nathan R.; Richter, Benjamin; Korac, Jelena; Waidmann, Oliver; Choudhary, Chunaram; Doetsch, Volker; Bumann, Dirk; Dikic, Ivan			Phosphorylation of the Autophagy Receptor Optineurin Restricts Salmonella Growth	SCIENCE			English	Article							UBIQUITIN; TBK1; BINDING; DEGRADATION; P62/SQSTM1; INTEGRITY; BACTERIA; ADAPTER; NDP52	Selective autophagy can be mediated via receptor molecules that link specific cargoes to the autophagosomal membranes decorated by ubiquitin-like microtubule-associated protein light chain 3 (LC3) modifiers. Although several autophagy receptors have been identified, little is known about mechanisms controlling their functions in vivo. In this work, we found that phosphorylation of an autophagy receptor, optineurin, promoted selective autophagy of ubiquitin-coated cytosolic Salmonella enterica. The protein kinase TANK binding kinase 1 (TBK1) phosphorylated optineurin on serine-177, enhancing LC3 binding affinity and autophagic clearance of cytosolic Salmonella. Conversely, ubiquitin-or LC3-binding optineurin mutants and silencing of optineurin or TBK1 impaired Salmonella autophagy, resulting in increased intracellular bacterial proliferation. We propose that phosphorylation of autophagy receptors might be a general mechanism for regulation of cargo-selective autophagy.	[Wild, Philipp; McEwan, David G.; Richter, Benjamin; Waidmann, Oliver; Dikic, Ivan] Goethe Univ Frankfurt, Sch Med, Frankfurt Inst Mol Life Sci, D-60590 Frankfurt, Main, Germany; [Wild, Philipp; McEwan, David G.; Richter, Benjamin; Waidmann, Oliver; Dikic, Ivan] Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Main, Germany; [Farhan, Hesso; Bumann, Dirk] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; [Wagner, Sebastian; Choudhary, Chunaram] Univ Copenhagen, Fac Hlth Sci, Ctr Prot Res, Novo Nordisk Fdn, DK-2200 Copenhagen, Denmark; [Rogov, Vladimir V.; Doetsch, Volker] Goethe Univ Frankfurt, Inst Biophys Chem, D-60439 Frankfurt, Main, Germany; [Rogov, Vladimir V.; Doetsch, Volker] Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance, D-60439 Frankfurt, Main, Germany; [Rogov, Vladimir V.] Inst Prot Res, Pushchino 142290, Russia; [Brady, Nathan R.] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Korac, Jelena; Dikic, Ivan] Univ Split, Sch Med, Dept Immunol & Med Genet, Split 21000, Croatia	Goethe University Frankfurt; Goethe University Frankfurt; University of Basel; Novo Nordisk Foundation; University of Copenhagen; Goethe University Frankfurt; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); University of Split	Dikic, I (corresponding author), Goethe Univ Frankfurt, Sch Med, Frankfurt Inst Mol Life Sci, Theodor Stern Kai 7, D-60590 Frankfurt, Main, Germany.	ivan.dikic@biochem2.de	Choudhary, Chunaram/E-9819-2011; Wild, Philipp S./M-2106-2019; McEwan, David/A-3754-2015; Wagner, Sebastian/B-9056-2012; Farhan, Hesso/C-7997-2012; choudhary, chunaram/ABE-6634-2020; Dikic, Ivan/O-4650-2015; Prlic, Jelena Korac/I-7988-2012; Brady, Nathan/H-2452-2013; McEwan, David/AAY-6264-2020; Prlic, Jelena Korac/AAJ-1029-2021	Choudhary, Chunaram/0000-0002-9863-433X; McEwan, David/0000-0003-0353-6532; Farhan, Hesso/0000-0002-0889-8463; choudhary, chunaram/0000-0002-9863-433X; Dikic, Ivan/0000-0001-8156-9511; Prlic, Jelena Korac/0000-0002-7840-9979; Prlic, Jelena Korac/0000-0002-7840-9979; Brady, Nathan/0000-0002-1901-5996; Dotsch, Volker/0000-0001-5720-212X	Deutsche Forschungsgemeinschaft; Goethe University Frankfurt [EXC115]; Landes-Offensive zur Entwicklung Wissentschaftlich-okonomischer Exzellenz; European Research Council (ERC) under the European Union [250241-LineUb]; Swiss National Fonds [3100A0-121834/1]; Novo Nordisk Foundation; Split, Croatia, government; Danish Council for Independent Research [FSS: 10-085134]; Helmholtz Association; Swiss National Science Foundation [31003A-121834]; Novo Nordisk Foundation Center for Protein Research [PI Chunaram Choudhary] Funding Source: researchfish	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Goethe University Frankfurt; Landes-Offensive zur Entwicklung Wissentschaftlich-okonomischer Exzellenz; European Research Council (ERC) under the European Union(European Research Council (ERC)); Swiss National Fonds(Swiss National Science Foundation (SNSF)); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Split, Croatia, government; Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Helmholtz Association(Helmholtz Association); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novo Nordisk Foundation Center for Protein Research	We thank P. Cohen, S. Mueller, K. Rajalingam, C. Behrends, and the members of Dikic laboratory for constructive comments and critical reading of the manuscript; P. Cohen for OPTN and TBK1 reagents; and V. Kirkin for the initial yeast two-hybrid screens. This work was supported by grants from Deutsche Forschungsgemeinschaft, the Cluster of Excellence "Macromolecular Complexes" of the Goethe University Frankfurt (EXC115), the Landes-Offensive zur Entwicklung Wissentschaftlich-okonomischer Exzellenz-funded Onkogene Signaltransduktion Frankfurt network, and the European Research Council (ERC) under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. (250241-LineUb) to I. D. and partly by Swiss National Fonds (3100A0-121834/1) to D. B. The Center for Protein Research is funded by a generous grant from the Novo Nordisk Foundation. J.K. is supported by a scholarship from the Split, Croatia, government, S. W. by a postdoctoral fellowship from the Danish Council for Independent Research (FSS: 10-085134), N.R.B. by the Initiative and Networking Fund of the Helmholtz Association, and H. F. by Swiss National Science Foundation (31003A-121834).	Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Cemma M, 2011, AUTOPHAGY, V7, P341, DOI 10.4161/auto.7.3.14046; Cherra SJ, 2010, J CELL BIOL, V190, P533, DOI 10.1083/jcb.201002108; Clark K, 2009, J BIOL CHEM, V284, P14136, DOI 10.1074/jbc.M109.000414; Deretic V, 2010, CURR OPIN CELL BIOL, V22, P252, DOI 10.1016/j.ceb.2009.12.009; Ikeda F, 2010, CELL, V143, P677, DOI 10.1016/j.cell.2010.10.026; Jiang HB, 2010, BIOCHEM BIOPH RES CO, V395, P471, DOI 10.1016/j.bbrc.2010.04.030; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020; Knodler LA, 2010, P NATL ACAD SCI USA, V107, P17733, DOI 10.1073/pnas.1006098107; Kraft C, 2010, NAT CELL BIOL, V12, P836, DOI 10.1038/ncb0910-836; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; McEwan DG, 2011, TRENDS CELL BIOL, V21, P195, DOI 10.1016/j.tcb.2010.12.006; Morton S, 2008, FEBS LETT, V582, P997, DOI 10.1016/j.febslet.2008.02.047; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Perrin AJ, 2004, CURR BIOL, V14, P806, DOI 10.1016/j.cub.2004.04.033; Radtke AL, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030029; Stehmeier P, 2009, MOL CELL, V33, P400, DOI 10.1016/j.molcel.2009.01.013; Thurston TLM, 2009, NAT IMMUNOL, V10, P1215, DOI 10.1038/ni.1800; Wagner S, 2008, ONCOGENE, V27, P3739, DOI 10.1038/sj.onc.1211042; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Zheng YT, 2009, J IMMUNOL, V183, P5909, DOI 10.4049/jimmunol.0900441	25	915	944	6	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 8	2011	333	6039					228	233		10.1126/science.1205405	http://dx.doi.org/10.1126/science.1205405			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	789GG	21617041	Green Accepted			2022-12-28	WOS:000292502700052
J	Levi, L; Rechtsman, M; Freedman, B; Schwartz, T; Manela, O; Segev, M				Levi, Liad; Rechtsman, Mikael; Freedman, Barak; Schwartz, Tal; Manela, Ofer; Segev, Mordechai			Disorder-Enhanced Transport in Photonic Quasicrystals	SCIENCE			English	Article							ANDERSON LOCALIZATION; ELECTRONIC TRANSPORT; DISCRETE SOLITONS; LATTICES; WAVE; DYNAMICS; SYSTEMS; LIGHT	Quasicrystals are aperiodic structures with rotational symmetries forbidden to conventional periodic crystals; examples of quasicrystals can be found in aluminum alloys, polymers, and even ancient Islamic art. Here, we present direct experimental observation of disorder-enhanced wave transport in quasicrystals, which contrasts directly with the characteristic suppression of transport by disorder. Our experiments are carried out in photonic quasicrystals, where we find that increasing disorder leads to enhanced expansion of the beam propagating through the medium. By further increasing the disorder, we observe that the beam progresses through a regime of diffusive-like transport until it finally transitions to Anderson localization and the suppression of transport. We study this fundamental phenomenon and elucidate its origins by relating it to the basic properties of quasicrystalline media in the presence of disorder.	[Segev, Mordechai] Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Solid State, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Segev, M (corresponding author), Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel.	msegev@tx.technion.ac.il	Schwartz, Tal/C-1689-2014; Rechtsman, Mikael C./L-8926-2013	Schwartz, Tal/0000-0002-5022-450X; Rechtsman, Mikael C./0000-0002-6909-8355	European Research Council; Israel Ministry of Science; German-Israeli Foundation; Israel Science Foundation; Azrieli Postdoctoral Fellowship	European Research Council(European Research Council (ERC)European Commission); Israel Ministry of Science(Ministry of Science, Technology and Space (MOST), Israel); German-Israeli Foundation(German-Israeli Foundation for Scientific Research and Development); Israel Science Foundation(Israel Science Foundation); Azrieli Postdoctoral Fellowship	This work was supported by an Advanced Grant from the European Research Council, the Israel Ministry of Science, the German-Israeli Foundation, and the Israel Science Foundation. M.R. gratefully acknowledges the generous support of an Azrieli Postdoctoral Fellowship. All authors thank S. Fishman, B. Shapiro, and Y. Krivolapov for useful discussions.	ANDERSON PW, 1958, PHYS REV, V109, P1492, DOI 10.1103/PhysRev.109.1492; Billy J, 2008, NATURE, V453, P891, DOI 10.1038/nature07000; Chabanov AA, 2000, NATURE, V404, P850, DOI 10.1038/35009055; Chan YS, 1998, PHYS REV LETT, V80, P956, DOI 10.1103/PhysRevLett.80.956; DERAEDT H, 1989, PHYS REV LETT, V62, P47, DOI 10.1103/PhysRevLett.62.47; DIVICENZO DP, 1991, QUASICRYSTALS STATE; Fleischer JW, 2003, NATURE, V422, P147, DOI 10.1038/nature01452; Freedman B, 2006, NATURE, V440, P1166, DOI 10.1038/nature04722; Freedman B, 2007, NAT MATER, V6, P776, DOI 10.1038/nmat1981; FUJIWARA T, 1993, PHYS REV LETT, V71, P4166, DOI 10.1103/PhysRevLett.71.4166; FUJIWARA T, 1989, PHYS REV B, V40, P7413, DOI 10.1103/PhysRevB.40.7413; Lahini Y, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.013901; Lahini Y, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.013906; Lederer F, 2008, PHYS REP, V463, P1, DOI 10.1016/j.physrep.2008.04.004; LEE PA, 1985, REV MOD PHYS, V57, P287, DOI 10.1103/RevModPhys.57.287; LEVINE D, 1984, PHYS REV LETT, V53, P2477, DOI 10.1103/PhysRevLett.53.2477; MAYOU D, 1993, PHYS REV LETT, V70, P3915, DOI 10.1103/PhysRevLett.70.3915; Rieth T, 1997, Z PHYS B CON MAT, V104, P99, DOI 10.1007/s002570050424; Roati G, 2008, NATURE, V453, P895, DOI 10.1038/nature07071; Roche S, 1997, PHYS REV LETT, V79, P2518, DOI 10.1103/PhysRevLett.79.2518; Roche S, 1997, J MATH PHYS, V38, P1794, DOI 10.1063/1.531914; Schwartz T, 2007, NATURE, V446, P52, DOI 10.1038/nature05623; SEGEV M, 1994, PHYS REV LETT, V73, P3211, DOI 10.1103/PhysRevLett.73.3211; SHECHTMAN D, 1984, PHYS REV LETT, V53, P1951, DOI 10.1103/PhysRevLett.53.1951; Storzer M, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.063904; Szameit A, 2010, OPT LETT, V35, P1172, DOI 10.1364/OL.35.001172; Wiersma DS, 1997, NATURE, V390, P671, DOI 10.1038/37757	27	138	140	2	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 24	2011	332	6037					1541	1544		10.1126/science.1202977	http://dx.doi.org/10.1126/science.1202977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	782EE	21566156				2022-12-28	WOS:000291990000040
J	Subramanian, SV; Corsi, DJ				Subramanian, S. V.; Corsi, Daniel J.			Can India achieve a balance of sexes at birth?	LANCET			English	Editorial Material									[Subramanian, S. V.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA; [Corsi, Daniel J.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada	Harvard University; Harvard T.H. Chan School of Public Health; McMaster University; Population Health Research Institute	Subramanian, SV (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.	svsubram@hsph.harvard.edu	Corsi, Daniel J/S-4689-2018	Corsi, Daniel J/0000-0001-7063-3354				Almond D, 2008, P NATL ACAD SCI USA, V105, P5681, DOI 10.1073/pnas.0800703105; DASGUPTA M, 2009, IS THERE INCIPIENT T; George SM, 2006, PRENATAL DIAG, V26, P604, DOI 10.1002/pd.1475; *GOV IND MIN HLTH, 2007, ANN REP 2006 IMPL PR; Jha P, 2006, LANCET, V367, P211, DOI 10.1016/S0140-6736(06)67930-0; Jha P, 2011, LANCET, V377, P1921, DOI 10.1016/S0140-6736(11)60649-1; Kishor Sunita, 1995, WOMENS HLTH INDIA RI, P19; NATARAJAN D, 1972, CHANGES SEX RATIO; Registrar General of India, 2011, CENS IND 2011 PROV P; SEN A, 1992, BRIT MED J, V304, P587, DOI 10.1136/bmj.304.6827.587; SINHA K, 2011, TIMES INDIA     0421; Subramanian SV, 2009, J EPIDEMIOL COMMUN H, V63, P245, DOI 10.1136/jech.2008.078477	12	17	17	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 4	2011	377	9781					1893	1894		10.1016/S0140-6736(11)60709-5	http://dx.doi.org/10.1016/S0140-6736(11)60709-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	777LW	21612819				2022-12-28	WOS:000291623200004
J	Ladeveze, S; de Muizon, C; Beck, RMD; Germain, D; Cespedes-Paz, R				Ladeveze, Sandrine; de Muizon, Christian; Beck, Robin M. D.; Germain, Damien; Cespedes-Paz, Ricardo			Earliest evidence of mammalian social behaviour in the basal Tertiary of Bolivia	NATURE			English	Article							SEXUAL-DIMORPHISM; SOUTH-AMERICA; MARSUPIALS; ORGANIZATION; DIDELPHIDAE; DASYURIDAE; PALEOCENE; HISTORY; ORIGIN	The vast majority of Mesozoic and early Cenozoic metatherian mammals (extinct relatives of modern marsupials) are known only from partial jaws or isolated teeth, which give insight into their probable diets and phylogenetic relationships but little else. The few skulls known are generally crushed, incomplete or both(1-4), and associated postcranial material is extremely rare. Here we report the discovery of an exceptionally large number of almost undistorted, nearly complete skulls and skeletons of a stem-metatherian, Pucadelphys andinus, in the early Palaeocene epoch(5) of Tiupampa in Bolivia(6-8). These give an unprecedented glimpse into early metatherian morphology, evolutionary relationships and, especially, ecology. The remains of 35 individuals have been collected, with 22 of these represented by nearly complete skulls and associated postcrania. These individuals were probably buried in a single catastrophic event, and so almost certainly belong to the same population(9). The preservation of multiple adult, sub-adult and juvenile individuals in close proximity (<1 m(2)) is indicative of gregarious social behaviour or at least a high degree of social tolerance and frequent interaction. Such behaviour is unknown in living didelphids, which are highly solitary and have been regarded, perhaps wrongly, as the most generalized living marsupials. The Tiupampan P. andinus population also exhibits strong sexual dimorphism, which, in combination with gregariousness, suggests strong male-male competition and polygyny. Our study shows that social interactions occurred in metatherians as early as the basal Palaeocene and that solitary behaviour may not be plesiomorphic for Metatheria as a whole.	[Ladeveze, Sandrine] Royal Belgian Inst Nat Sci, Dept Palaeontol, B-1000 Brussels, Belgium; [de Muizon, Christian; Germain, Damien] UPMC, MNHN, Dept Hist tERRE, CNRS,UMR7207,CR2P, F-75005 Paris, France; [Beck, Robin M. D.] Amer Museum Nat Hist, Dept Mammal, New York, NY 10024 USA; [Cespedes-Paz, Ricardo] Museo Hist Nat Alcide Orbigny, Cochabamba, Bolivia	Royal Belgian Institute of Natural Sciences; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Sorbonne Universite; American Museum of Natural History (AMNH)	Ladeveze, S (corresponding author), Royal Belgian Inst Nat Sci, Dept Palaeontol, 29 Rue Vautier, B-1000 Brussels, Belgium.	sandrine.ladeveze@naturalsciences.be; muizon@mnhn.fr	germain, damien/I-5906-2012; De Muizon, Christian/P-4335-2017; De Muizon, Christian/Q-7986-2019	De Muizon, Christian/0000-0002-1247-8867; De Muizon, Christian/0000-0002-1247-8867; Beck, Robin/0000-0002-7050-7072; Germain, Damien/0000-0002-7608-2212	National Geographic Society [2908-84]; Institut Francais d'Etudes Andines; Belgian Federal Science Policy Office [MO/36/020]; NSF [DEB-0743039]	National Geographic Society(National Geographic Society); Institut Francais d'Etudes Andines; Belgian Federal Science Policy Office(Belgian Federal Science Policy Office); NSF(National Science Foundation (NSF))	Field expeditions were supported by the National Geographic Society (grants 2908-84) in 1985 and by the 'Institut Francais d'Etudes Andines' in 1997. The specimens collected are the property of the 'Museo de Historia Natural Alcide d'Orbigny' in Cochabamba, Bolivia. Additional financial support was provided by Research Project MO/36/020 of the Belgian Federal Science Policy Office (S. L.), and NSF grant DEB-0743039 (R. M.D.B., in collaboration with R. Voss at the American Museum of Natural History). Photographs are by C. Lemzaouda and P. Loubry, scanning electron microscope photographs are by J. Cillis and the reconstruction in Fig. 1 is by S. Fernandez. We thank E. Westwig for access to the AMNH collections, and O. Lambert, A. Pradel, and T. Soderquist for discussions.	Astua D, 2010, J MAMMAL, V91, P1011, DOI 10.1644/09-MAMM-A-018.1; ATRAMENTOWICZ M, 1986, BIOTROPICA, V18, P136, DOI 10.2307/2388756; Caceres NC, 2007, J NAT HIST, V41, P1979, DOI 10.1080/00222930701520835; Cifelli RL, 1998, CR ACAD SCI II A, V326, P215, DOI 10.1016/S1251-8050(00)89038-2; DE MUIZON C., 2003, PREDATORS POUCHES BI, P42; de Muizon C, ORIGINS EVO IN PRESS; de Muizon Christian, 1998, Geodiversitas, V20, P19; deMuizon C, 1997, NATURE, V389, P486, DOI 10.1038/39029; Fisher DO, 2006, BEHAV ECOL, V17, P164, DOI 10.1093/beheco/arj012; Gelfo JN, 2009, PALAEONTOLOGY, V52, P251, DOI 10.1111/j.1475-4983.2008.00835.x; Head JJ, 2009, NATURE, V457, P715, DOI 10.1038/nature07671; Hershkovitz P, 1997, FIELDIANA ZOOLOGY, V86, P1; Horovitz I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008278; Kraaijeveld K, 2003, P ROY SOC B-BIOL SCI, V270, pS251, DOI 10.1098/rsbl.2003.0082; LAZENBYCOHEN KA, 1988, BEHAV ECOL SOCIOBIOL, V22, P195, DOI 10.1007/BF00300569; Luo ZX, 2003, SCIENCE, V302, P1934, DOI 10.1126/science.1090718; Marshall Larry G., 1995, Memoires du Museum National d'Histoire Naturelle, V165, P21; Marshall LG, 1997, J S AM EARTH SCI, V10, P49, DOI 10.1016/S0895-9811(97)00005-9; MARSHALL LG, 1995, PUCADELPHYS ANDINUS; MORTON SR, 1978, J MAMMAL, V59, P569, DOI 10.2307/1380234; Muizon C., 1992, REV TECNICA YACIMIEN, V12, P575; Oakwood M, 2002, J ZOOL, V257, P237, DOI 10.1017/S0952836902000833; Plavcan JM, 2000, J HUM EVOL, V39, P327, DOI 10.1006/jhev.2000.0423; Rougier GW, 1998, NATURE, V396, P459, DOI 10.1038/24856; RUSSELL EM, 1984, MAMMAL REV, V14, P101, DOI 10.1111/j.1365-2907.1984.tb00343.x; SODERQUIST TR, 1995, J ZOOL, V237, P385, DOI 10.1111/j.1469-7998.1995.tb02769.x; Szalay FS, 1996, J VERTEBR PALEONTOL, V16, P474, DOI 10.1080/02724634.1996.10011335; TYNDALEBISCOE CH, 1976, J MAMMAL, V57, P249, DOI 10.2307/1379686	28	26	26	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 2	2011	474	7349					83	86		10.1038/nature09987	http://dx.doi.org/10.1038/nature09987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	771KV	21552278				2022-12-28	WOS:000291156700042
J	Teutsch, SM; Fielding, JE				Teutsch, Steven M.; Fielding, Jonathan E.			Comparative Effectiveness-Looking Under the Lamppost	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							POPULATION HEALTH		[Teutsch, Steven M.; Fielding, Jonathan E.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA 90012 USA; [Fielding, Jonathan E.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; [Fielding, Jonathan E.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA	Los Angeles County Department of Public Health; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Teutsch, SM (corresponding author), Los Angeles Cty Dept Publ Hlth, 313 N Figueroa,Room 708, Los Angeles, CA 90012 USA.	steutsch@ph.lacounty.gov						[Anonymous], 2009, HLTH GLANC 2009 OECD; BLOW CM, 2011, NY TIMES        0218; Booske BC, 2010, DIFFERENT PERSPECTIV; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; Kindig D, 2010, JAMA-J AM MED ASSOC, V304, P901, DOI 10.1001/jama.2010.1215; Teutsch SM, 2011, HEALTH AFFAIR, V30, P349, DOI 10.1377/hlthaff.2010.0593	6	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2225	2226		10.1001/jama.2011.730	http://dx.doi.org/10.1001/jama.2011.730			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21632487				2022-12-28	WOS:000291106300027
J	Kelly, RP; Foley, MM; Fisher, WS; Feely, RA; Halpern, BS; Waldbusser, GG; Caldwell, MR				Kelly, R. P.; Foley, M. M.; Fisher, W. S.; Feely, R. A.; Halpern, B. S.; Waldbusser, G. G.; Caldwell, M. R.			Mitigating Local Causes of Ocean Acidification with Existing Laws	SCIENCE			English	Editorial Material							CLIMATE-CHANGE; IMPACTS; EUTROPHICATION; SATURATION; COASTAL; WATER		[Kelly, R. P.; Foley, M. M.; Caldwell, M. R.] Stanford Univ, Ctr Ocean Solut, Stanford, CA 94305 USA; [Fisher, W. S.] US EPA, Gulf Ecol Div, Gulf Breeze, FL 32561 USA; [Feely, R. A.] NOAA, Pacific Marine Environm Lab, Seattle, WA 98115 USA; [Halpern, B. S.] Natl Ctr Ecol Anal & Synth, Santa Barbara, CA 93101 USA; [Waldbusser, G. G.] Oregon State Univ, Coll Atmospher & Ocean Sci, Corvallis, OR 97331 USA	Stanford University; United States Environmental Protection Agency; National Oceanic Atmospheric Admin (NOAA) - USA; National Center for Ecological Analysis & Synthesis; Oregon State University	Kelly, RP (corresponding author), Stanford Univ, Ctr Ocean Solut, Stanford, CA 94305 USA.	rpk@stanford.edu	Feely, Richard A./ABI-5740-2020	Waldbusser, George/0000-0002-8334-580X; Kelly, Ryan/0000-0001-5037-2441				[Anonymous], 2009, FED REGISTER, V74, P15; Baron J.S., 2008, PRELIMINARY REV ADAP; Borges AV, 2010, LIMNOL OCEANOGR, V55, P346, DOI 10.4319/lo.2010.55.1.0346; Bradley P.A., 2010, EPA600R10054; Cheung WWL, 2010, GLOBAL CHANGE BIOL, V16, P24, DOI 10.1111/j.1365-2486.2009.01995.x; Cheung WWL, 2009, FISH FISH, V10, P235, DOI 10.1111/j.1467-2979.2008.00315.x; Cooley SR, 2009, ENVIRON RES LETT, V4, DOI 10.1088/1748-9326/4/2/024007; Costanza R, 1998, SCIENCE, V281, P198, DOI 10.1126/science.281.5374.198; Dentener F, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2005GB002672; Doney SC, 2007, P NATL ACAD SCI USA, V104, P14580, DOI 10.1073/pnas.0702218104; Doney SC, 2010, SCIENCE, V328, P1512, DOI 10.1126/science.1185198; Doney SC, 2009, ANNU REV MAR SCI, V1, P169, DOI 10.1146/annurev.marine.010908.163834; Dove MC, 2007, J SHELLFISH RES, V26, P519, DOI 10.2983/0730-8000(2007)26[519:IOEAOS]2.0.CO;2; Feely RA, 2008, SCIENCE, V320, P1490, DOI 10.1126/science.1155676; Feely RA, 2010, ESTUAR COAST SHELF S, V88, P442, DOI 10.1016/j.ecss.2010.05.004; Feely RA, 2009, OCEANOGRAPHY, V22, P36, DOI 10.5670/oceanog.2009.95; Fore LS, 2008, SCIENCE, V322, P1788, DOI 10.1126/science.322.5909.1788a; Green MA, 2009, LIMNOL OCEANOGR, V54, P1037, DOI 10.4319/lo.2009.54.4.1037; Halpern BS, 2008, OCEAN COAST MANAGE, V51, P203, DOI 10.1016/j.ocecoaman.2007.08.002; Kemp WM, 2005, MAR ECOL PROG SER, V303, P1, DOI 10.3354/meps303001; Salisbury J., 2008, EOS T AM GEOPHYS UN, V89, P513, DOI [10.1029/2008EO500001, DOI 10.1029/2008EO500001]; Waldbusser GG, 2011, ESTUAR COAST, V34, P221, DOI 10.1007/s12237-010-9307-0	22	93	97	3	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2011	332	6033					1036	1037		10.1126/science.1203815	http://dx.doi.org/10.1126/science.1203815			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617060				2022-12-28	WOS:000290996700027
J	Teglas, E; Vul, E; Girotto, V; Gonzalez, M; Tenenbaum, JB; Bonatti, LL				Teglas, Erno; Vul, Edward; Girotto, Vittorio; Gonzalez, Michel; Tenenbaum, Joshua B.; Bonatti, Luca L.			Pure Reasoning in 12-Month-Old Infants as Probabilistic Inference	SCIENCE			English	Article							SPEECH STREAM; OBJECT; PERCEPTION; COMPUTATIONS; SEGMENTATION; STATISTICS; SEQUENCES; BELIEFS	Many organisms can predict future events from the statistics of past experience, but humans also excel at making predictions by pure reasoning: integrating multiple sources of information, guided by abstract knowledge, to form rational expectations about novel situations, never directly experienced. Here, we show that this reasoning is surprisingly rich, powerful, and coherent even in preverbal infants. When 12-month-old infants view complex displays of multiple moving objects, they form time-varying expectations about future events that are a systematic and rational function of several stimulus variables. Infants' looking times are consistent with a Bayesian ideal observer embodying abstract principles of object motion. The model explains infants' statistical expectations and classic qualitative findings about object cognition in younger babies, not originally viewed as probabilistic inferences.	[Tenenbaum, Joshua B.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; [Teglas, Erno] Cent European Univ, Cognit Dev Ctr, H-1015 Budapest, Hungary; [Teglas, Erno] Hungarian Acad Sci, H-1015 Budapest, Hungary; [Vul, Edward] Univ Calif San Diego, La Jolla, CA 92093 USA; [Girotto, Vittorio] Univ IUAV Venice, I-30135 Venice, Italy; [Girotto, Vittorio; Gonzalez, Michel] CNRS, F-13331 Marseille, France; [Girotto, Vittorio; Gonzalez, Michel] Aix Marseille Univ, F-13331 Marseille, France; [Bonatti, Luca L.] ICREA, Barcelona 08018, Spain; [Bonatti, Luca L.] Univ Pompeu Fabra, Barcelona 08018, Spain	Massachusetts Institute of Technology (MIT); Central European University; Hungarian Academy of Sciences; University of California System; University of California San Diego; IUAV University Venice; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; ICREA; Pompeu Fabra University	Tenenbaum, JB (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.	lucabonatti@mac.com; jbt@mit.edu	Bonatti, Luca Lorenzo/AAA-2410-2019	Bonatti, Luca Lorenzo/0000-0001-8624-9007; Teglas, Erno/0000-0003-4502-3639	Ministerio de Ciencia E Innovacion [PSI2009-08232PSIC]; James S. McDonnell Foundation; Office of Naval Research [N00014-09-0124, N00014-07-1-0937]; Army Research Office MURI [W911NF-08-1-0242]; Swiss and Global-Fondazione Ca' Foscari; Marie Curie 035975 Disorders and Coherence of the Embodied Self; ICREA Funding Source: Custom	Ministerio de Ciencia E Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); James S. McDonnell Foundation; Office of Naval Research(Office of Naval Research); Army Research Office MURI(MURI); Swiss and Global-Fondazione Ca' Foscari; Marie Curie 035975 Disorders and Coherence of the Embodied Self; ICREA(ICREA)	The research was supported by grants Friuli-Venezia-Giulia "PsyScope XL," Ministerio de Ciencia E Innovacion PSI2009-08232PSIC, the James S. McDonnell Foundation Causal Learning Research Collaborative grant, Office of Naval Research grants N00014-09-0124 and N00014-07-1-0937, Army Research Office MURI W911NF-08-1-0242, the Swiss and Global-Fondazione Ca' Foscari, and Marie Curie 035975 Disorders and Coherence of the Embodied Self. E. T. and L. L. B. designed the experiments and analyzed the data. E. T. ran the experiments. J.B.T. and E. V. conceived the model and the simulations. E. T., E. V., J.B.T., and L. L. B. wrote the paper. All authors discussed the research and revised the text and the analyses. We thank D. Amati, L. Filippin, F. Gandolfo, N. Goodman, A. Isaja, and N. Sebastian for support and suggestions. J. Mehler and the Language, Cognition, and Development Laboratory in Trieste, Italy made the experimental work possible. We are deeply grateful to them.	Aguiar A, 1999, COGNITIVE PSYCHOL, V39, P116, DOI 10.1006/cogp.1999.0717; BAILLARGEON R, 1985, COGNITION, V20, P191, DOI 10.1016/0010-0277(85)90008-3; Baillargeon R., 2009, LEARNING INFANT MIND, P66; Baker CL, 2009, COGNITION, V113, P329, DOI 10.1016/j.cognition.2009.07.005; Brown SD, 2009, COGNITIVE PSYCHOL, V58, P49, DOI 10.1016/j.cogpsych.2008.09.002; Cosmides L, 1996, COGNITION, V58, P1, DOI 10.1016/0010-0277(95)00664-8; Cover T. M., 2006, ELEMENTS INFORM THEO, p[xxiii, 74]; Creel SC, 2004, J EXP PSYCHOL LEARN, V30, P1119, DOI 10.1037/0278-7393.30.5.1119; Fiser J, 2002, J EXP PSYCHOL LEARN, V28, P458, DOI 10.1037//0278-7393.28.3.458; Fodor J. A., 1975, LANGUAGE THOUGHT; Gergely G, 2003, TRENDS COGN SCI, V7, P287, DOI 10.1016/S1364-6613(03)00128-1; GIGERENZER G, 1995, PSYCHOL REV, V102, P684, DOI 10.1037/0033-295X.102.4.684; Girotto V, 2006, NORMS IN HUMAN DEVELOPMENT, P220, DOI 10.1017/CBO9780511489778.010; Griffiths TL, 2006, PSYCHOL SCI, V17, P767, DOI 10.1111/j.1467-9280.2006.01780.x; Hauser MD, 2001, COGNITION, V78, pB53, DOI 10.1016/S0010-0277(00)00132-3; Johnson SP, 2003, CHILD DEV, V74, P94, DOI 10.1111/1467-8624.00523; Johnson-Laird PN, 1999, PSYCHOL REV, V106, P62, DOI 10.1037/0033-295X.106.1.62; KELLMAN PJ, 1983, COGNITIVE PSYCHOL, V15, P483, DOI 10.1016/0010-0285(83)90017-8; KEMP C, 2009, ADV NEURAL INFORM PR, V22, P925; Kersten D, 2004, ANNU REV PSYCHOL, V55, P271, DOI 10.1146/annurev.psych.55.090902.142005; Kovacs AM, 2010, SCIENCE, V330, P1830, DOI 10.1126/science.1190792; LEVY R, 2008, ADV NEURAL INFORM PR, V21, P937; Onishi KH, 2005, SCIENCE, V308, P255, DOI 10.1126/science.1107621; Pena M, 2002, SCIENCE, V298, P604, DOI 10.1126/science.1072901; Russell S, 2009, ARTIFICIAL INTELLIGE; Saffran JR, 1996, J MEM LANG, V35, P606, DOI 10.1006/jmla.1996.0032; SINHA P, 2009, OBJECT CATEGORIZATIO, P301; Spelke Elizabeth, 1986, PSYCHOL FR, V31, P67; SPELKE ES, 1992, PSYCHOL REV, V99, P605, DOI 10.1037/0033-295X.99.4.605; Teglas E, 2007, P NATL ACAD SCI USA, V104, P19156, DOI 10.1073/pnas.0700271104; Tenenbaum JB, 2006, TRENDS COGN SCI, V10, P309, DOI 10.1016/j.tics.2006.05.009; Tenenbaum JB, 2011, SCIENCE, V331, P1279, DOI 10.1126/science.1192788; Toro JM, 2005, PERCEPT PSYCHOPHYS, V67, P867, DOI 10.3758/BF03193539; VUL E, 2009, ADV NEURAL INFORM PR, V22, P1955; Wilcox T, 2003, INFANT BEHAV DEV, V26, P253, DOI 10.1016/S0163-6383(03)00021-3; Woodward AL, 1998, COGNITION, V69, P1, DOI 10.1016/S0010-0277(98)00058-4; WYNN K, 1992, NATURE, V358, P749, DOI 10.1038/358749a0; Xu F, 1996, COGNITIVE PSYCHOL, V30, P111, DOI 10.1006/cogp.1996.0005; Xu F, 2008, P NATL ACAD SCI USA, V105, P5012, DOI 10.1073/pnas.0704450105	39	169	169	4	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2011	332	6033					1054	1059		10.1126/science.1196404	http://dx.doi.org/10.1126/science.1196404			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617069				2022-12-28	WOS:000290996700036
J	Dauphas, N; Pourmand, A				Dauphas, N.; Pourmand, A.			Hf-W-Th evidence for rapid growth of Mars and its status as a planetary embryo	NATURE			English	Article							CORE FORMATION; EARLY DIFFERENTIATION; ISOTOPE GEOCHEMISTRY; TERRESTRIAL PLANETS; OLIGARCHIC GROWTH; GIANT IMPACT; TODGA RESIN; LU-HF; MOON; CHONDRITES	Terrestrial planets are thought to have formed through collisions between large planetary embryos(1) of diameter similar to 1,000-5,000 km. For Earth, the last of these collisions involved an impact by a Mars-size embryo that formed the Moon 50-150 million years (Myr) after the birth of the Solar System(2,3). Although model simulations of the growth of terrestrial planets can reproduce the mass and dynamical parameters of the Earth and Venus, they fall short of explaining the small size of Mars(4,5). One possibility is that Mars was a planetary embryo that escaped collision and merging with other embryos(1). To assess this idea, it is crucial to know Mars' accretion timescale(6), which can be investigated using the Hf-182-W-182 decay system in shergottite-nakhlite-chassignite meteorites(6-10). Nevertheless, this timescale remains poorly constrained owing to a large uncertainty associated with the Hf/W ratio of the Martian mantle(6) and as a result, contradicting timescales have been reported that range between 0 and 15 Myr (refs 6-10). Here we show that Mars accreted very rapidly and reached about half of its present size in only 1.8(-1.0)(+0.9) Myr or less, which is consistent with a stranded planetary embryo origin. We have found a well-defined correlation between the Th/Hf and Hf-176/Hf-177 ratios in chondrites that reflects remobilization of Lu and Th during parent-body processes. Using this relationship, we estimate the Hf/W ratio in Mars' mantle to be 3.51 +/- 0.45. This value is much more precise than previous estimates, which ranged between 2.6 and 5.0 (ref. 6), and lifts the large uncertainty that plagued previous estimates of the age of Mars. Our results also demonstrate that Mars grew before dissipation of the nebular gas when similar to 100-km planetesimals, such as the parent bodies of chondrites, were still being formed. Mars' accretion occurred early enough to allow establishment of a magma ocean powered by decay of Al-26.	[Dauphas, N.; Pourmand, A.] Univ Chicago, Dept Geophys Sci, Origins Lab, Chicago, IL 60637 USA; [Dauphas, N.; Pourmand, A.] Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA; [Pourmand, A.] Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Div Marine Geol & Geophys, Miami, FL 33149 USA	University of Chicago; University of Chicago; University of Miami	Dauphas, N (corresponding author), Univ Chicago, Dept Geophys Sci, Origins Lab, 5734 S Ellis Ave, Chicago, IL 60637 USA.	dauphas@uchicago.edu	Dauphas, Nicolas/E-4568-2011		Packard fellowship; NASA; NSF [NNX09AG59G, EAR-0820807]	Packard fellowship(The David & Lucile Packard Foundation); NASA(National Aeronautics & Space Administration (NASA)); NSF(National Science Foundation (NSF))	Discussions with M. Chaussidon, H. Kobayashi, F. J. Ciesla, D. J. Stevenson, T. W. Dahl, R. Yokochi and G. Coutrot were appreciated. Comments from A. D. Brandon helped to improve the quality of the manuscript. We thank H. Kobayashi for sharing the digital outputs of his model simulations with us. The meteorite samples were provided by the Field Museum, the Smithsonian, the Museum National d'Histoire Naturelle and R. N. Clayton. F. Marcantonio and P. J. Patchett gave us solutions of standards and spikes that were used to calibrate the measurements. This work was supported by a Packard fellowship, NASA and the NSF through grants NNX09AG59G and EAR-0820807 to N.D.	BlichertToft J, 1997, EARTH PLANET SC LETT, V148, P243, DOI 10.1016/S0012-821X(97)00040-X; Bouvier A, 2008, EARTH PLANET SC LETT, V273, P48, DOI 10.1016/j.epsl.2008.06.010; Bouvier A, 2009, EARTH PLANET SC LETT, V280, P285, DOI 10.1016/j.epsl.2009.01.042; Canup RM, 2001, NATURE, V412, P708, DOI 10.1038/35089010; Caro G, 2008, NATURE, V452, P336, DOI 10.1038/nature06760; Chambers J, 2006, ICARUS, V180, P496, DOI 10.1016/j.icarus.2005.10.017; Chu NC, 2002, J ANAL ATOM SPECTROM, V17, P1567, DOI 10.1039/b206707b; Connelly JN, 2006, CHEM GEOL, V233, P126, DOI 10.1016/j.chemgeo.2006.02.020; Dahl TW, 2010, EARTH PLANET SC LETT, V295, P177, DOI 10.1016/j.epsl.2010.03.038; Debaille V, 2007, NATURE, V450, P525, DOI 10.1038/nature06317; Foley CN, 2005, GEOCHIM COSMOCHIM AC, V69, P4557, DOI 10.1016/j.gca.2005.05.009; Goreva JS, 2001, METEORIT PLANET SCI, V36, P63, DOI 10.1111/j.1945-5100.2001.tb01810.x; Halliday AN, 2004, NATURE, V427, P505, DOI 10.1038/nature02275; Horwitz EP, 2005, SOLVENT EXTR ION EXC, V23, P319, DOI 10.1081/SEI-200049898; Jacobsen SB, 2005, ANNU REV EARTH PL SC, V33, P531, DOI 10.1146/annurev.earth.33.092203.122614; Kleine T, 2004, GEOCHIM COSMOCHIM AC, V68, P2935, DOI 10.1016/j.gca.2004.01.009; Kleine T, 2009, GEOCHIM COSMOCHIM AC, V73, P5150, DOI 10.1016/j.gca.2008.11.047; Kobayashi H, 2010, ICARUS, V209, P836, DOI 10.1016/j.icarus.2010.04.021; Lodders K, 1997, ICARUS, V126, P373, DOI 10.1006/icar.1996.5653; Marty B, 2002, EARTH PLANET SC LETT, V196, P251, DOI 10.1016/S0012-821X(01)00612-4; MURRELL MT, 1982, GEOCHIM COSMOCHIM AC, V46, P2453, DOI 10.1016/0016-7037(82)90368-4; PEPIN RO, 1991, ICARUS, V92, P2, DOI 10.1016/0019-1035(91)90036-S; Pourmand A, 2010, TALANTA, V81, P741, DOI 10.1016/j.talanta.2010.01.008; Raymond SN, 2009, ICARUS, V203, P644, DOI 10.1016/j.icarus.2009.05.016; Ricard Y, 2009, EARTH PLANET SC LETT, V284, P144, DOI 10.1016/j.epsl.2009.04.021; Righter K, 2003, GEOCHIM COSMOCHIM AC, V67, P2497, DOI 10.1016/S0016-7037(02)01349-2; Senshu H, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001819; Thommes EW, 2001, ASTR SOC P, V245, P91; Touboul M, 2007, NATURE, V450, P1206, DOI 10.1038/nature06428; Vervoort JD, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2004GC000721; Vervoort JD, 1999, GEOCHIM COSMOCHIM AC, V63, P533, DOI 10.1016/S0016-7037(98)00274-9; Wetherill G.W, 1991, LUNAR PLANETARY I TE, V22, P1495; WILHELMS DE, 1984, NATURE, V309, P138, DOI 10.1038/309138a0; Yin QZ, 2002, NATURE, V418, P949, DOI 10.1038/nature00995	39	297	297	1	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2011	473	7348					489	U227		10.1038/nature10077	http://dx.doi.org/10.1038/nature10077			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21614076				2022-12-28	WOS:000290951300035
J	Gunderson, JG				Gunderson, John G.			Borderline Personality Disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-SERVICE UTILIZATION; PHARMACOTHERAPY; HOSPITALIZATION; COMORBIDITY; TRIAL		McLean Hosp, Psychosocial & Personal Res Program, Belmont, MA 02478 USA	Harvard University; McLean Hospital	Gunderson, JG (corresponding author), McLean Hosp, Psychosocial & Personal Res Program, 115 Mill St, Belmont, MA 02478 USA.	jgunderson@mclean.harvard.edu						Bateman A, 2003, AM J PSYCHIAT, V160, P169, DOI 10.1176/appi.ajp.160.1.169; Bender DS, 2001, AM J PSYCHIAT, V158, P295, DOI 10.1176/appi.ajp.158.2.295; Binks CA, 2007, PHYSCHOL THERAPIES P; Distel MA, 2010, J PERS DISORD, V24, P427, DOI 10.1521/pedi.2010.24.4.427; Donegan NH, 2003, BIOL PSYCHIAT, V54, P1284, DOI 10.1016/S0006-3223(03)00636-X; Montalvo JF, 2006, PSICOTHEMA, V18, P453; Frankenburg FR, 2006, J PERS DISORD, V20, P71, DOI 10.1521/pedi.2006.20.1.71; Gabbard GO, 2001, AM J PSYCHIAT, V158, P1, DOI 10.1176/appi.ajp.158.1.1; Goodman M, 2010, J PERS DISORD, V24, P204, DOI 10.1521/pedi.2010.24.2.204; Grant BF, 2008, J CLIN PSYCHIAT, V69, P533, DOI 10.4088/JCP.v69n0404; Grilo CM, 2007, CAN J PSYCHIAT, V52, P357, DOI 10.1177/070674370705200604; Gross R, 2002, ARCH INTERN MED, V162, P53, DOI 10.1001/archinte.162.1.53; GROVES JE, 1981, NEW ENGL J MED, V305, P259, DOI 10.1056/NEJM198107303050505; Gunderson J.G., 2008, BORDERLINE PERSONALI; Gunderson JG, 2004, J CLIN PSYCHIAT, V65, P1049; Gunderson JG, 2003, PSYCHIATRY, V66, P111, DOI 10.1521/psyc.66.2.111.20614; Gunderson JG, 1997, HARVARD REV PSYCHIAT, V4, P272, DOI 10.3109/10673229709030553; Gunderson JG, 2011, ARCH GEN PSYCHI 0404; Gunderson JG, ARCH GEN PS IN PRESS; Gunderson JG, 2008, J PERS DISORD, V22, P22, DOI 10.1521/pedi.2008.22.1.22; Hoffman PD, 2005, FAM PROCESS, V44, P217, DOI 10.1111/j.1545-5300.2005.00055.x; Ingenhoven T, 2010, J CLIN PSYCHIAT, V71, P14, DOI 10.4088/JCP.08r04526gre; King-Casas B, 2008, SCIENCE, V321, P806, DOI 10.1126/science.1156902; Kupper N, 2005, HYPERTENSION, V45, P80, DOI 10.1161/01.HYP.0000149952.84391.54; Lenzenweger MF, 2007, BIOL PSYCHIAT, V62, P553, DOI 10.1016/j.biopsych.2006.09.019; Lieb K, 2010, BRIT J PSYCHIAT, V196, P4, DOI 10.1192/bjp.bp.108.062984; Linehan, 2007, ARCH GEN PSYCHIAT, V64, P1401; Linehan MM, 2006, ARCH GEN PSYCHIAT, V63, P757, DOI 10.1001/archpsyc.63.7.757; Linehan MM, 1999, COST EFFECTIVENESS P, P291; Massion AO, 2002, ARCH GEN PSYCHIAT, V59, P434, DOI 10.1001/archpsyc.59.5.434; McMain SF, 2010, AM J PSYCHIAT, V167, P1283; McMain SF, 2009, AM J PSYCHIAT, V166, P1365, DOI 10.1176/appi.ajp.2009.09010039; Palmer NB, 2003, AIDS PATIENT CARE ST, V17, P635, DOI 10.1089/108729103771928690; Pascual JC, 2007, PSYCHIAT SERV, V58, P1199, DOI 10.1176/appi.ps.58.9.1199; Rothrock J, 2007, HEADACHE, V47, P22, DOI 10.1111/j.1526-4610.2007.00649.x; Sansone RA, 2010, INT J PSYCHIAT MED, V40, P21, DOI 10.2190/PM.40.1.b; Silbersweig D, 2007, AM J PSYCHIAT, V164, P1832, DOI 10.1176/appi.ajp.2007.06010126; Soeteman DI, 2008, J CLIN PSYCHIAT, V69, P259, DOI 10.4088/JCP.v69n0212; Stanley B, 2010, AM J PSYCHIAT, V167, P24, DOI 10.1176/appi.ajp.2009.09050744; Trestman RL, 2007, J AM ACAD PSYCHIATRY, V35, P490; Tweed R G, 1998, Violence Vict, V13, P217; Vaillant G E, 1992, J Psychother Pract Res, V1, P117; WALDINGER RJ, 1989, PSYCHIATRY, V52, P416, DOI 10.1080/00332747.1989.11024466; Walter M, 2009, ADDICTION, V104, P97, DOI 10.1111/j.1360-0443.2008.02413.x; Weinberg I, 2011, CURR PSYCHIAT REP, V13, P60, DOI 10.1007/s11920-010-0167-x; Weinberg I, 2010, J CLIN PSYCHIAT, V71, P699, DOI 10.4088/JCP.08m04840blu; Winograd G, 2008, J CHILD PSYCHOL PSYC, V49, P933, DOI 10.1111/j.1469-7610.2008.01930.x; Zanarini MC, 2008, J PERS DISORD, V22, P284, DOI 10.1521/pedi.2008.22.3.284; Zanarini MC, 2004, J CLIN PSYCHIAT, V65, P28, DOI 10.4088/jcp.v65n0105; Zimmerman M, 1999, AM J PSYCHIAT, V156, P1570, DOI 10.1176/ajp.156.10.1570; Zimmerman M, 2010, J CLIN PSYCHIAT, V71, P26, DOI 10.4088/JCP.08m04633	51	100	101	1	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					2037	2042		10.1056/NEJMcp1007358	http://dx.doi.org/10.1056/NEJMcp1007358			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QR	21612472				2022-12-28	WOS:000290952000008
J	Jain, A; Liu, RJ; Ramani, B; Arauz, E; Ishitsuka, Y; Ragunathan, K; Park, J; Chen, J; Xiang, YK; Ha, T				Jain, Ankur; Liu, Ruijie; Ramani, Biswarathan; Arauz, Edwin; Ishitsuka, Yuji; Ragunathan, Kaushik; Park, Jeehae; Chen, Jie; Xiang, Yang K.; Ha, Taekjip			Probing cellular protein complexes using single-molecule pull-down	NATURE			English	Article							RESONANCE ENERGY-TRANSFER; LIVING CELLS; ESCHERICHIA-COLI; GENE-EXPRESSION; LIVE CELLS; STOICHIOMETRY; MTOR; FRET; DNA; MICROSCOPY	Proteins perform most cellular functions in macromolecular complexes. The same protein often participates in different complexes to exhibit diverse functionality. Current ensemble approaches of identifying cellular protein interactions cannot reveal physiological permutations of these interactions. Here we describe a single-molecule pull-down (SiMPull) assay that combines the principles of a conventional pull-down assay with single-molecule fluorescence microscopy and enables direct visualization of individual cellular protein complexes. SiMPull can reveal how many proteins and of which kinds are present in the in vivo complex, as we show using protein kinase A. We then demonstrate a wide applicability to various signalling proteins found in the cytosol, membrane and cellular organelles, and to endogenous protein complexes from animal tissue extracts. The pulled-down proteins are functional and are used, without further processing, for single-molecule biochemical studies. SiMPull should provide a rapid, sensitive and robust platform for analysing protein assemblies in biological pathways.	[Jain, Ankur; Ragunathan, Kaushik; Park, Jeehae; Ha, Taekjip] Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; [Jain, Ankur; Ragunathan, Kaushik; Park, Jeehae; Ha, Taekjip] Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA; [Liu, Ruijie; Ramani, Biswarathan; Xiang, Yang K.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; [Arauz, Edwin; Chen, Jie] Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; [Ishitsuka, Yuji; Ha, Taekjip] Univ Illinois, Dept Phys, Urbana, IL 61801 USA; [Ishitsuka, Yuji; Ha, Taekjip] Univ Illinois, Ctr Phys Living Cells, Urbana, IL 61801 USA; [Ishitsuka, Yuji; Ha, Taekjip] Howard Hughes Med Inst, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Howard Hughes Medical Institute	Ha, T (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA.	kevinyx@illinois.edu; tjha@illinois.edu	Diaz, Edwin Arauz/AAI-5457-2021; Ishitsuka, Yuji/J-1921-2014; Ha, Taekjip/B-9506-2009	Ishitsuka, Yuji/0000-0002-6780-7154; Ha, Taekjip/0000-0003-2195-6258; Chen, Jie/0000-0002-7887-3747; liu, ruijie/0000-0002-2468-0579	NIH [AI083025, GM065367, HL082846, AR048914]; NSF [0646550, 0822613]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI083025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065367] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank S. Myong, P. Jena, S. Arslan and R. Vafabakhsh for discussions. The expression vector encoding the YFP-MAVS gene was a gift from D. Lamarre. This work was funded by NIH grants (AI083025, GM065367 to T.H.; HL082846 to Y.K.X.; AR048914 to J.C.). Additional support was provided by NSF grants (0646550, 0822613 to T.H.). T.H. is an investigator with the Howard Hughes Medical Institute.	Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Baril M, 2009, J VIROL, V83, P1299, DOI 10.1128/JVI.01659-08; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Carriba P, 2008, NAT METHODS, V5, P727, DOI 10.1038/nmeth.1229; Chen I, 2005, CURR OPIN BIOTECH, V16, P35, DOI 10.1016/j.copbio.2004.12.003; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; Eyckerman S, 2001, NAT CELL BIOL, V3, P1114, DOI 10.1038/ncb1201-1114; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gingras AC, 2007, NAT REV MOL CELL BIO, V8, P645, DOI 10.1038/nrm2208; Kerppola TK, 2008, ANNU REV BIOPHYS, V37, P465, DOI 10.1146/annurev.biophys.37.032807.125842; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Leake MC, 2008, P NATL ACAD SCI USA, V105, P15376, DOI 10.1073/pnas.0806338105; Leake MC, 2006, NATURE, V443, P355, DOI 10.1038/nature05135; Levene MJ, 2003, SCIENCE, V299, P682, DOI 10.1126/science.1079700; Lopez-Gimenez JF, 2007, MOL PHARMACOL, V71, P1015, DOI 10.1124/mol.106.033035; Maeder CI, 2007, NAT CELL BIOL, V9, P1319, DOI 10.1038/ncb1652; Mashanov GI, 2003, METHODS, V29, P142, DOI 10.1016/S1046-2023(02)00305-5; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; Papin JA, 2005, NAT REV MOL CELL BIO, V6, P99, DOI 10.1038/nrm1570; Park J, 2010, CELL, V142, P544, DOI 10.1016/j.cell.2010.07.016; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Reyes-Lamothe R, 2010, SCIENCE, V328, P498, DOI 10.1126/science.1185757; Roy R, 2008, NAT METHODS, V5, P507, DOI 10.1038/NMETH.1208; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Schulte R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002061; Schwarzenbacher M, 2008, NAT METHODS, V5, P1053, DOI 10.1038/nmeth.1268; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Slaughter BD, 2007, P NATL ACAD SCI USA, V104, P20320, DOI 10.1073/pnas.0710336105; Taniguchi Y, 2010, SCIENCE, V329, P533, DOI 10.1126/science.1188308; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Tunquist BJ, 2008, P NATL ACAD SCI USA, V105, P12557, DOI [10.1073/pnas.0805922105, 10.1073/pnas.0B05922105]; Ulbrich MH, 2008, P NATL ACAD SCI USA, V105, P14163, DOI 10.1073/pnas.0802075105; Ulbrich MH, 2007, NAT METHODS, V4, P319, DOI 10.1038/NMETH1024; Wallrabe H, 2005, CURR OPIN BIOTECH, V16, P19, DOI 10.1016/j.copbio.2004.12.002; Yamada T, 2009, NAT REV MOL CELL BIO, V10, P791, DOI 10.1038/nrm2787; Yip CK, 2010, MOL CELL, V38, P768, DOI 10.1016/j.molcel.2010.05.017; Yu J, 2006, SCIENCE, V311, P1600, DOI 10.1126/science.1119623; Yu Y, 2009, P NATL ACAD SCI USA, V106, P11558, DOI 10.1073/pnas.0903684106; Zamir E, 2010, NAT METHODS, V7, P295, DOI [10.1038/nmeth.1441, 10.1038/NMETH.1441]	42	283	286	1	175	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 26	2011	473	7348					484	U322		10.1038/nature10016	http://dx.doi.org/10.1038/nature10016			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21614075	Green Submitted, Green Accepted			2022-12-28	WOS:000290951300034
J	Lowy, FD				Lowy, Franklin D.			How Staphylococcus aureus Adapts to Its Host	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA	Columbia University	Lowy, FD (corresponding author), Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA.							Diep BA, 2010, P NATL ACAD SCI USA, V107, P5587, DOI 10.1073/pnas.0912403107; Herron-Olson L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001120; Loffler B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000715; Lowder BV, 2009, P NATL ACAD SCI USA, V106, P19545, DOI 10.1073/pnas.0909285106; Pishchany G, 2010, CELL HOST MICROBE, V8, P544, DOI 10.1016/j.chom.2010.11.002	5	36	36	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					1987	1990		10.1056/NEJMp1100251	http://dx.doi.org/10.1056/NEJMp1100251			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QR	21612466				2022-12-28	WOS:000290952000002
J	Chang, CH; Stukel, TA; Flood, AB; Goodman, DC				Chang, Chiang-Hua; Stukel, Therese A.; Flood, Ann Barry; Goodman, David C.			Primary Care Physician Workforce and Medicare Beneficiaries' Health Outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							US PRIMARY-CARE; REGIONAL-VARIATIONS; MORTALITY; STATES; CHALLENGE; QUALITY; REFORM; RATES; LIFE	Context Despite a widespread interest in increasing the numbers of primary care physicians to improve care and to moderate costs, the relationship of the primary care physician workforce to patient-level outcomes remains poorly understood. Objective To measure the association between the adult primary care physician workforce and individual patient outcomes. Design, Setting, and Participants A cross-sectional analysis of the outcomes of a 2007 20% sample of fee-for-service Medicare beneficiaries aged 65 years or older (N=5 132 936), which used 2 measures of adult primary care physicians (general internists and family physicians) across Primary Care Service Areas (N=6542): (1) American Medical Association (AMA) Masterfile nonfederal, office-based physicians per total population and (2) office-based primary care clinical full-time equivalents (FTEs) per Medicare beneficiary derived from Medicare claims. Main Outcome Measures Annual individual-level outcomes (mortality, ambulatory care sensitive condition [ACSC] hospitalizations, and Medicare program spending), adjusted for individual patient characteristics and geographic area variables. Results Marked variation was observed in the primary care physician workforce across areas, but low correlation was observed between the 2 primary care workforce measures (Spearman r=0.056; P<.001). Compared with areas with the lowest quintile of primary care physician measure using AMA Masterfile counts, beneficiaries in the highest quintile had fewer ACSC hospitalizations (74.90 vs 79.61 per 1000 beneficiaries; relative rate [RR], 0.94; 95% confidence interval [CI], 0.93-0.95), lower mortality (5.38 vs 5.47 per 100 beneficiaries; RR, 0.98; 95% CI, 0.97-0.997), and no significant difference in total Medicare spending ($8722 vs $8765 per beneficiary; RR, 1.00; 95% CI, 0.99-1.00). Beneficiaries residing in areas with the highest quintile of primary care clinician FTEs compared with those in the lowest quintile had lower mortality (5.19 vs 5.49 per 100 beneficiaries; RR, 0.95; 95% CI, 0.93-0.96), fewer ACSC hospitalizations (72.53 vs 79.48 per 1000 beneficiaries; RR, 0.91; 95% CI, 0.90-0.92), and higher overall Medicare spending ($8857 vs $8769 per beneficiary; RR, 1.01; 95% CI, 1.004-1.02). Conclusion A higher level of primary care physician workforce, particularly with an FTE measure that may more accurately reflect ambulatory primary care, was generally associated with favorable patient outcomes. JAMA. 2011; 305(20): 2096-2105	[Chang, Chiang-Hua] Ctr Hlth Policy Res, Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA; [Goodman, David C.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pediat, Hanover, NH 03756 USA; [Flood, Ann Barry] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA; [Stukel, Therese A.] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada; [Stukel, Therese A.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada	Dartmouth College; Dartmouth College; Dartmouth College; University of Toronto; University of Toronto	Chang, CH (corresponding author), Ctr Hlth Policy Res, Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, 35 Centerra Pkwy, Lebanon, NH 03766 USA.	chiang-hua.chang@dartmouth.edu	Goodman, David/AAG-7497-2020	Stukel, Therese/0000-0002-2951-1360	Texas Medical Association; Health Action Council, Cincinnati; Richard Stockton College of New Jersey; Iowa Health Business Alliance; Alliance for Academic Internal Medicine; American Medical Association; Connecticut Children's Hospital; Mt Sinai Hospital, New York; World Congress; Rutgers University; Baystate Medical Center; Brigham and Women's Hospital; ESRI Inc; Illinois Hospital Association; National Hospice Workgroup; National Association of Health Data Organizations; St. Peters University Hospital, New Brunswick, New Jersey; Massachusetts Hospital Association; Cooper Health System, Camden, New Jersey; Organizzato dal Laboratorio Management e Sanita Scuola Superiore Sant'Anna di Pisa; Kentucky Academy of Family Physicians; Southern Illinois University Health Policy Institute; Ohio University College of Osteopathic Medicine; Institute for Clinical Quality and Value; Marwood Group; American Society of Clinical Oncologists; OR Manager; Delta Health Alliance; SUNY Upstate University; Intermountain Healthcare; Vermont Department of Banking, Insurance, Securities and Health Care Administration; HealthDialog; Colorado Foundation for Medical Care; Seyferth Blumenthal and Harris; American Medical Forensic Specialists; Robert Wood Johnson Foundation; National Institute on Aging [P01 AG19783]; NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER	Texas Medical Association; Health Action Council, Cincinnati; Richard Stockton College of New Jersey; Iowa Health Business Alliance; Alliance for Academic Internal Medicine; American Medical Association; Connecticut Children's Hospital; Mt Sinai Hospital, New York; World Congress; Rutgers University; Baystate Medical Center; Brigham and Women's Hospital; ESRI Inc; Illinois Hospital Association; National Hospice Workgroup; National Association of Health Data Organizations; St. Peters University Hospital, New Brunswick, New Jersey; Massachusetts Hospital Association; Cooper Health System, Camden, New Jersey; Organizzato dal Laboratorio Management e Sanita Scuola Superiore Sant'Anna di Pisa; Kentucky Academy of Family Physicians; Southern Illinois University Health Policy Institute; Ohio University College of Osteopathic Medicine; Institute for Clinical Quality and Value; Marwood Group; American Society of Clinical Oncologists; OR Manager; Delta Health Alliance; SUNY Upstate University; Intermountain Healthcare; Vermont Department of Banking, Insurance, Securities and Health Care Administration; HealthDialog; Colorado Foundation for Medical Care; Seyferth Blumenthal and Harris; American Medical Forensic Specialists; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Goodman reported speaking fees from Texas Medical Association; Health Action Council, Cincinnati; Richard Stockton College of New Jersey; Iowa Health Business Alliance; Alliance for Academic Internal Medicine; American Medical Association; Connecticut Children's Hospital; Mt Sinai Hospital, New York; World Congress; Rutgers University; Baystate Medical Center; Brigham and Women's Hospital; ESRI Inc; Illinois Hospital Association; National Hospice Workgroup; National Association of Health Data Organizations; St. Peters University Hospital, New Brunswick, New Jersey; Massachusetts Hospital Association; Cooper Health System, Camden, New Jersey; Organizzato dal Laboratorio Management e Sanita Scuola Superiore Sant'Anna di Pisa; Kentucky Academy of Family Physicians; Southern Illinois University Health Policy Institute; Ohio University College of Osteopathic Medicine; Institute for Clinical Quality and Value; The Marwood Group; American Society of Clinical Oncologists; OR Manager; Delta Health Alliance; SUNY Upstate University; and Intermountain Healthcare; and consulting fees from Vermont Department of Banking, Insurance, Securities and Health Care Administration; HealthDialog; Colorado Foundation for Medical Care; Seyferth Blumenthal and Harris; and American Medical Forensic Specialists. Drs Chang, Stukel, and Flood reported no disclosures.; This research was supported in part by the Robert Wood Johnson Foundation and grant P01 AG19783 from the National Institute on Aging.	Billings J, 2003, USING ADM DATA MONIT; Bodenheimer T, 2010, HEALTH AFFAIR, V29, P799, DOI 10.1377/hlthaff.2010.0026; Center for the Evaluative Clinical Sciences at Dartmouth, 1996, QUAL MED CAR US REP; Chernew ME, 2009, HEALTH AFFAIR, V28, P1327, DOI 10.1377/hlthaff.28.5.1327; Collwill JM, 2008, HEALTH AFFAIR, V27, pW232, DOI 10.1377/hlthaff.27.3.w232; Council on Graduate Medical Education, 2010, 20 REP ADV PRIM CAR; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fisher ES, 2003, PERSPECT BIOL MED, V46, P69, DOI 10.1353/pbm.2003.0004; Franks P, 1999, HEALTH SERV RES, V34, P323; Goodman DC, 2006, HEALTH AFFAIR, V25, P521, DOI 10.1377/hlthaff.25.2.521; Goodman DC, 1996, JAMA-J AM MED ASSOC, V276, P1811, DOI 10.1001/jama.276.22.1811; Goodman DC, 2003, HEALTH SERV RES, V38, P287, DOI 10.1111/1475-6773.00116; Goodman DC., 2010, REGIONAL RACIAL VARI; Gottlieb DJ, 2010, HEALTH AFFAIR, V29, P537, DOI 10.1377/hlthaff.2009.0609; GRUMBACH K, 1995, AM J PUBLIC HEALTH, V85, P1402, DOI 10.2105/AJPH.85.10.1402; Guttmann A, 2010, PEDIATRICS, V125, P1119, DOI 10.1542/peds.2009-2821; Krakauer H, 1996, HEALTH SERV RES, V31, P191; Laditka JN, 2005, HEALTH SERV RES, V40, P1148, DOI 10.1111/j.1475-6773.2005.00403.x; Phillips RL, 2004, AM FAM PHYSICIAN, V70, P440; Ricketts TC, 2007, HEALTH SERV RES, V42, P2233, DOI 10.1111/j.1475-6773.2007.00728.x; Rittenhouse DR, 2009, NEW ENGL J MED, V361, P2301, DOI 10.1056/NEJMp0909327; Rittenhouse DR, 2009, JAMA-J AM MED ASSOC, V301, P2038, DOI 10.1001/jama.2009.691; Rosser WW, 2010, NEW ENGL J MED, V362, DOI 10.1056/NEJMp0911519; Salsberg E, 2008, JAMA-J AM MED ASSOC, V300, P1174, DOI 10.1001/jama.300.10.1174; Sandy LG, 2009, HEALTH AFFAIR, V28, P1136, DOI 10.1377/hlthaff.28.4.1136; Shi LY, 2005, SOC SCI MED, V61, P65, DOI 10.1016/j.socscimed.2004.11.056; Shi LY, 2003, J AM BOARD FAM PRACT, V16, P412, DOI 10.3122/jabfm.16.5.412; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; Starfield B, 2005, HLTH AFF MILLWOOD S; Steinbrook R, 2009, NEW ENGL J MED, V360, P2696, DOI 10.1056/NEJMp0903460; Wennberg JE, 2004, BMJ-BRIT MED J, V328, P607, DOI 10.1136/bmj.328.7440.607; Wennberg JE, 2008, TRACKING CARE PATIEN	33	120	121	1	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2011	305	20					2096	2105		10.1001/jama.2011.665	http://dx.doi.org/10.1001/jama.2011.665			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768AC	21610242	Bronze, Green Accepted			2022-12-28	WOS:000290901700023
J	Lakhani, M				Lakhani, Mayur			PERSONAL VIEW Let's talk about dying	BRITISH MEDICAL JOURNAL			English	Editorial Material												MK.Lakhani@GP-C82644.nhs.uk							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 17	2011	342								d3018	10.1136/bmj.d3018	http://dx.doi.org/10.1136/bmj.d3018			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QO	21586451				2022-12-28	WOS:000290951700007
J	Olshansky, B				Olshansky, Brian			Prescription omega-3 fatty acids did not prevent recurrent, symptomatic, paroxysmal or persistent atrial ibrillation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							FATTY-ACIDS		Univ Iowa Hosp, Iowa City, IA USA	University of Iowa	Olshansky, B (corresponding author), Univ Iowa Hosp, Iowa City, IA USA.		Olshansky, Brian/S-3671-2016	Olshansky, Brian/0000-0002-6044-045X				Bianconi L, 2011, EUROPACE, V13, P174, DOI 10.1093/europace/euq386; Hooper L, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003177.PUB2; Lichtenstein AH, 2006, CIRCULATION, V114, P82, DOI 10.1161/CIRCULATIONAHA.106.176158; Rennison JH, 2009, CIRC-ARRHYTHMIA ELEC, V2, P460, DOI 10.1161/CIRCEP.109.880773; Virtanen JK, 2009, CIRCULATION, V120, P2315, DOI 10.1161/CIRCULATIONAHA.109.852657	5	1	1	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10							JC5-9	10.7326/0003-4819-154-10-201105170-02009	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-02009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576527				2022-12-28	WOS:000290620300008
J	Pratt, EJ; Hunt, B; Gadagkar, V; Yamashita, M; Graf, MJ; Balatsky, AV; Davis, JC				Pratt, E. J.; Hunt, B.; Gadagkar, V.; Yamashita, M.; Graf, M. J.; Balatsky, A. V.; Davis, J. C.			Interplay of Rotational, Relaxational, and Shear Dynamics in Solid He-4	SCIENCE			English	Article							SUPERSOLIDITY; TRANSITION; HELIUM	Using a high-sensitivity torsional oscillator (TO) technique, we mapped the rotational and relaxational dynamics of solid helium-4 (He-4) throughout the parameter range of the proposed supersolidity. We found evidence that the same microscopic excitations controlling the torsional oscillator motions are generated independently by thermal and mechanical stimulation. Moreover, a measure for the relaxation times of these excitations diverges smoothly without any indication for a critical temperature or critical velocity of a supersolid transition. Finally, we demonstrated that the combined temperature-velocity dependence of the TO response is indistinguishable from the combined temperature-strain dependence of the solid's shear modulus. This implies that the rotational responses of solid He-4 attributed to supersolidity are associated with generation of the same microscopic excitations as those produced by direct shear strain.	[Pratt, E. J.; Hunt, B.; Gadagkar, V.; Davis, J. C.] Cornell Univ, Dept Phys, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA; [Pratt, E. J.] Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Santa Barbara, CA 93016 USA; [Hunt, B.] MIT, Dept Phys, Cambridge, MA 02139 USA; [Yamashita, M.] Kyoto Univ, Dept Phys, Kyoto 6068502, Japan; [Graf, M. J.; Balatsky, A. V.] Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA; [Graf, M. J.; Balatsky, A. V.] Los Alamos Natl Lab, Ctr Integrated Nanotechnol, Los Alamos, NM 87545 USA; [Davis, J. C.] Brookhaven Natl Lab, Condensed Matter Phys & Mat Sci Dept, Upton, NY 11973 USA; [Davis, J. C.] Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland	Cornell University; University of California System; University of California Santa Barbara; Massachusetts Institute of Technology (MIT); Kyoto University; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Brookhaven National Laboratory; University of St Andrews	Davis, JC (corresponding author), Cornell Univ, Dept Phys, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA.	jcdavis@ccmr.cornell.edu	Hunt, Benjamin/C-3395-2017; YAMASHITA, MINORU/D-6556-2011; Pratt, Ethan/E-8714-2011	Hunt, Benjamin/0000-0002-5008-8042; YAMASHITA, MINORU/0000-0002-3616-6606; 	National Science Foundation [DMR-0806629, NSF PHY05-51164]; U.S. Department of Energy [DE-AC52-06NA25396]; Laboratory Directed Research and Development program; Division Of Materials Research [0806629] Funding Source: National Science Foundation	National Science Foundation(National Science Foundation (NSF)); U.S. Department of Energy(United States Department of Energy (DOE)); Laboratory Directed Research and Development program; Division Of Materials Research(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	We are grateful for discussions and communications with J. Beamish, D. M. Ceperley, M. H. W. Chan, J. Day, A. T. Dorsey, R. B. Hallock, H. Kojima, D. M. Lee, A. J. Leggett, E. Mueller, D. R. Nelson, J. M. Parpia, N. V. Prokof'ev, J. D. Reppy, P. C. E. Stamp, B. Svistunov, and M. Troyer. These studies were supported by the National Science Foundation under grants DMR-0806629 and NSF PHY05-51164 to the Kavli Institute for Theoretical Physics. Work at Los Alamos was supported by U.S. Department of Energy grant DE-AC52-06NA25396 to the Center for Integrated Nanotechnologies and through the Laboratory Directed Research and Development program.	Anderson PW, 2007, NAT PHYS, V3, P160, DOI 10.1038/nphys539; Andreev AF, 2007, JETP LETT+, V85, P585, DOI 10.1134/S0021364007110124; [Anonymous], 1990, SUPERFLUIDITY SUPERC; Aoki Y, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.015301; Balatsky AV, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.094201; Balibar S, 2010, NATURE, V464, P176, DOI 10.1038/nature08913; Biroli G, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.224306; BISHOP DJ, 1978, PHYS REV LETT, V40, P1727, DOI 10.1103/PhysRevLett.40.1727; Boninsegni M, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.035301; Bossy J, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.224507; Choi H, 2010, NAT PHYS, V6, P424, DOI 10.1038/NPHYS1630; Day J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.105304; Day J, 2007, NATURE, V450, P853, DOI 10.1038/nature06383; Day J, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.075302; Graf MJ, 2010, J LOW TEMP PHYS, V158, P550, DOI 10.1007/s10909-009-9958-z; Hunt B, 2009, SCIENCE, V324, P632, DOI 10.1126/science.1169512; Iwasa I, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.104527; Kim E, 2004, SCIENCE, V305, P1941, DOI 10.1126/science.1101501; Kim E, 2004, NATURE, V427, P225, DOI 10.1038/nature02220; Kondo M, 2007, J LOW TEMP PHYS, V148, P695, DOI 10.1007/s10909-007-9471-1; Lin X, 2007, NATURE, V449, P1025, DOI 10.1038/nature06228; Nussinov Z, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.014530; Penzev A, 2007, J LOW TEMP PHYS, V148, P677, DOI 10.1007/s10909-007-9452-4; Penzev A, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.065301; Ray MW, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.235301; Rittner ASC, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.165301; Rittner ASC, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.155301; Rojas X, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.145302; Sasaki S, 2006, SCIENCE, V313, P1098, DOI 10.1126/science.1130879; Shevchenko S. I., 1987, SOV J LOW TEMP PHYS, V13, P115; Svistunov B, 2009, PHYSICA B, V404, P521, DOI 10.1016/j.physb.2008.11.055; Syshchenko O, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.195301; Tam KM, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.215301; Wu JS, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.014515	34	27	27	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					821	824		10.1126/science.1203080	http://dx.doi.org/10.1126/science.1203080			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566187	Green Submitted			2022-12-28	WOS:000290529900040
J	Charlot, M; Grove, EL; Hansen, PR; Olesen, JB; Ahlehoff, O; Selmer, C; Lindhardsen, J; Madsen, JK; Kober, L; Torp-Pedersen, C; Gislason, GH				Charlot, Mette; Grove, Erik L.; Hansen, Peter Riis; Olesen, Jonas B.; Ahlehoff, Ole; Selmer, Christian; Lindhardsen, Jesper; Madsen, Jan Kyst; Kober, Lars; Torp-Pedersen, Christian; Gislason, Gunnar H.			Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study	BRITISH MEDICAL JOURNAL			English	Article							ANTIPLATELET THERAPY; COLLABORATIVE METAANALYSIS; SECONDARY PREVENTION; RANDOMIZED-TRIALS; VASCULAR-DISEASE; CLOPIDOGREL; OMEPRAZOLE; CORONARY; MORTALITY; PHARMACOLOGY	Objective To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction. Design Retrospective nationwide propensity score matched study based on administrative data. Setting All hospitals in Denmark. Participants All aspirin treated patients surviving 30 days after a first myocardial infarction from 1997 to 2006, with follow-up for one year. Patients treated with clopidogrel were excluded. Main outcome measures The risk of the combined end point of cardiovascular death, myocardial infarction, or stroke associated with use of proton pump inhibitors was analysed using Kaplan-Meier analysis, Cox proportional hazard models, and propensity score matched Cox proportional hazard models. Results 3366 of 19 925 (16.9%) aspirin treated patients experienced recurrent myocardial infarction, stroke, or cardiovascular death. The hazard ratio for the combined end point in patients receiving proton pump inhibitors based on the time dependent Cox proportional hazard model was 1.46 (1.33 to 1.61; P<0.001) and for the propensity score matched model based on 8318 patients it was 1.61 (1.45 to 1.79; P<0.001). A sensitivity analysis showed no increase in risk related to use of H(2) receptor blockers (1.04, 0.79 to 1.38; P=0.78). Conclusion In aspirin treated patients with first time myocardial infarction, treatment with proton pump inhibitors was associated with an increased risk of adverse cardiovascular events.	[Charlot, Mette; Hansen, Peter Riis; Olesen, Jonas B.; Ahlehoff, Ole; Selmer, Christian; Lindhardsen, Jesper; Madsen, Jan Kyst; Torp-Pedersen, Christian; Gislason, Gunnar H.] Univ Copenhagen, Dept Cardiol, Gentofte Hosp, DK-2900 Hellerup, Denmark; [Grove, Erik L.] Aarhus Univ, Hosp Skejby, Dept Cardiol, Aarhus, Denmark; [Kober, Lars] Copenhagen Univ Hosp, Rigshosp, Ctr Heart, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; Aarhus University; Rigshospitalet; University of Copenhagen	Charlot, M (corresponding author), Univ Copenhagen, Dept Cardiol, Gentofte Hosp, Post 635,Niels Andersens Vej 65, DK-2900 Hellerup, Denmark.	mc@heart.dk	Gislason, Gunnar/B-7561-2009; Selmer, Christian/H-3314-2019; Hansen, Peter Riis/AAR-7659-2020	Gislason, Gunnar/0000-0002-0548-402X; Selmer, Christian/0000-0002-0534-3163; Hansen, Peter Riis/0000-0002-9056-535X; Kober, Lars/0000-0002-6635-1466; Grove, Erik/0000-0002-1466-0865	Danish Heart Foundation [10-04-R78-A2865-22586]	Danish Heart Foundation	This study was funded by the Danish Heart Foundation (10-04-R78-A2865-22586). The funding source had no influence on the study design, interpretation of results, or decision to submit the article.	Adamopoulos AB, 2009, J CARDIOVASC PHARM, V54, P163, DOI 10.1097/FJC.0b013e3181af6d9c; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bhatt DL, 2008, CIRCULATION, V118, P1894, DOI 10.1161/CIRCULATIONAHA.108.191087; Bhatt DL, 2010, NEW ENGL J MED, V363, P1909, DOI 10.1056/NEJMoa1007964; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; Charlot M, 2010, ANN INTERN MED, V153, P378, DOI 10.7326/0003-4819-153-6-201009210-00005; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Fernandez-Fernandez FJ, 2002, ARCH INTERN MED, V162, P2248, DOI 10.1001/archinte.162.19.2248; Gaist D, 1997, DAN MED BULL, V44, P445; Gilard M, 2006, J THROMB HAEMOST, V4, P2508, DOI 10.1111/j.1538-7836.2006.02162.x; Gilard M, 2008, J AM COLL CARDIOL, V51, P256, DOI 10.1016/j.jacc.2007.06.064; Giraud MN, 1997, ALIMENT PHARM THERAP, V11, P899, DOI 10.1046/j.1365-2036.1997.00216.x; Gislason GH, 2006, EUR HEART J, V27, P1153, DOI 10.1093/eurheartj/ehi705; Ho PM, 2009, JAMA-J AM MED ASSOC, V301, P937, DOI 10.1001/jama.2009.261; HOLLANDER D, 1981, J LAB CLIN MED, V98, P591; Krarup LH, 2007, NEUROEPIDEMIOLOGY, V28, P150, DOI 10.1159/000102143; Lichtenberger LM, 1996, GASTROENTEROLOGY, V111, P990, DOI 10.1016/S0016-5085(96)70066-5; Madsen M, 2003, J CLIN EPIDEMIOL, V56, P124, DOI 10.1016/S0895-4356(02)00591-7; O'Donoghue ML, 2009, LANCET, V374, P989, DOI 10.1016/S0140-6736(09)61525-7; OOSTERHUIS B, 1989, DIGESTION, V44, P9, DOI 10.1159/000200098; Rasmussen S, 2005, MED CARE, V43, P970, DOI 10.1097/01.mlr.0000178195.07110.d3; Robinson M, 2003, DRUGS, V63, P2739, DOI 10.2165/00003495-200363240-00004; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; SHORE PA, 1957, J PHARMACOL EXP THER, V119, P361; Smith SC, 2006, CIRCULATION, V113, P2363, DOI 10.1161/CIRCULATIONAHA.106.174516; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; Wurtz M, HEART, V96, P368; Yasuda H, 2009, INTERNAL MED, V48, P1725, DOI 10.2169/internalmedicine.48.2031; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104; Zuern CS, 2010, THROMB RES, V125, pE51, DOI 10.1016/j.thromres.2009.08.016	30	138	146	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 11	2011	342								d2690	10.1136/bmj.d2690	http://dx.doi.org/10.1136/bmj.d2690			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765OP	21562004	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000290718400002
J	Boyce, N				Boyce, Niall			The art of medicine Gone to earth-the burial grounds of the Royal London Hospital	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Boyce, N (corresponding author), The Lancet, London NW1 7BY, England.	niall.boyce@lancet.com							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 7	2011	377	9777					1564	1565		10.1016/S0140-6736(11)60630-2	http://dx.doi.org/10.1016/S0140-6736(11)60630-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	763IJ	21553717				2022-12-28	WOS:000290549700014
J	Vitari, AC; Leong, KG; Newton, K; Yee, C; O'Rourke, K; Liu, JF; Phu, LL; Vij, R; Ferrando, R; Couto, SS; Mohan, S; Pandita, A; Hongo, JA; Arnott, D; Wertz, IE; Gao, WQ; French, DM; Dixit, VM				Vitari, Alberto C.; Leong, Kevin G.; Newton, Kim; Yee, Cindy; O'Rourke, Karen; Liu, Jinfeng; Phu, Lilian; Vij, Rajesh; Ferrando, Ronald; Couto, Suzana S.; Mohan, Sankar; Pandita, Ajay; Hongo, Jo-Anne; Arnott, David; Wertz, Ingrid E.; Gao, Wei-Qiang; French, Dorothy M.; Dixit, Vishva M.			COP1 is a tumour suppressor that causes degradation of ETS transcription factors	NATURE			English	Article							UBIQUITIN LIGASE; PROSTATE-CANCER; GENE FUSIONS; C-MYC; BURKITTS-LYMPHOMA; REGULATED GENE; MOUSE MODELS; PEA3 GROUP; IN-VIVO; MUTATIONS	The proto-oncogenes ETV1, ETV4 and ETV5 encode transcription factors in the E26 transformation-specific (ETS) family, which includes the most frequently rearranged and overexpressed genes in prostate cancer(1-4). Despite being critical regulators of development, little is known about their post-translational regulation. Here we identify the ubiquitin ligase COP1 (also known as RFWD2) as a tumour suppressor that negatively regulates ETV1, ETV4 and ETV5. ETV1, which is mutated in prostate cancer more often, was degraded after being ubiquitinated by COP1. Truncated ETV1 encoded by prostate cancer translocation TMPRSS2:ETV1 lacks the critical COP1 binding motifs and was 50-fold more stable than wild-type ETV1. Almost all patient translocations render ETV1 insensitive to COP1, implying that this confers a selective advantage to prostate epithelial cells. Indeed, COP1 deficiency in mouse prostate elevated ETV1 and produced increased cell proliferation, hyperplasia, and early prostate intraepithelial neoplasia. Combined loss of COP1 and PTEN enhanced the invasiveness of mouse prostate adenocarcinomas. Finally, rare human prostate cancer samples showed hemizygous loss of the COP1 gene, loss of COP1 protein, and elevated ETV1 protein while lacking a translocation event. These findings identify COP1 as a tumour suppressor whose downregulation promotes prostatic epithelial cell proliferation and tumorigenesis.	[Vitari, Alberto C.; Newton, Kim; O'Rourke, Karen; Dixit, Vishva M.] Genentech Inc, Dept Physiol Chem, San Francisco, CA 94080 USA; [Leong, Kevin G.] Genentech Inc, Dept Res Oncol, San Francisco, CA 94080 USA; [Yee, Cindy; Gao, Wei-Qiang] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; [Liu, Jinfeng] Genentech Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA; [Phu, Lilian; Arnott, David] Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; [Vij, Rajesh; Hongo, Jo-Anne] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA; [Ferrando, Ronald; Couto, Suzana S.; French, Dorothy M.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Mohan, Sankar; Pandita, Ajay] Genentech Inc, Dept Mol Diagnost & Canc Cell Biol, San Francisco, CA 94080 USA; [Wertz, Ingrid E.] Genentech Inc, Dept Early Discovery Biochem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Physiol Chem, 1 DNA Way, San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012; Gao, Wei/GXH-0380-2022	dixit, vishva m/0000-0001-6983-0326; Liu, Jinfeng/0000-0002-0343-8222				ALBERT T, 1994, ONCOGENE, V9, P759; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Baert JL, 2010, ONCOGENE, V29, P1810, DOI 10.1038/onc.2009.471; Bartel FO, 2000, ONCOGENE, V19, P6443, DOI 10.1038/sj.onc.1204038; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Bianchi E, 2003, J BIOL CHEM, V278, P19682, DOI 10.1074/jbc.M212681200; Cai CM, 2007, MOL ENDOCRINOL, V21, P1835, DOI 10.1210/me.2006-0480; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; CLARK HM, 1994, CANCER RES, V54, P3383; Clark JP, 2009, NAT REV UROL, V6, P429, DOI 10.1038/nrurol.2009.127; CUNHA GR, 1978, J EXP ZOOL, V205, P181, DOI 10.1002/jez.1402050203; de Launoit Y, 2006, BBA-REV CANCER, V1766, P79, DOI 10.1016/j.bbcan.2006.02.002; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Gutierrez-Hartmann A, 2007, TRENDS ENDOCRIN MET, V18, P150, DOI 10.1016/j.tem.2007.03.002; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hermans KG, 2008, CANCER RES, V68, P7541, DOI 10.1158/0008-5472.CAN-07-5930; Holm M, 2001, EMBO J, V20, P118, DOI 10.1093/emboj/20.1.118; Jubb Adrian M, 2006, Methods Mol Biol, V326, P255; Kayagaki N, 2007, SCIENCE, V318, P1628, DOI 10.1126/science.1145918; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Kumar-Sinha C, 2008, NAT REV CANCER, V8, P497, DOI 10.1038/nrc2402; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Mehra R, 2007, MODERN PATHOL, V20, P538, DOI 10.1038/modpathol.3800769; Newton K, 2008, CELL, V134, P668, DOI 10.1016/j.cell.2008.07.039; O'Brien C, 2008, CANCER RES, V68, P5380, DOI 10.1158/0008-5472.CAN-08-0234; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Pandita A, 2004, GENE CHROMOSOME CANC, V39, P29, DOI 10.1002/gcc.10300; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Seo HS, 2003, NATURE, V423, P995, DOI 10.1038/nature01696; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yi CL, 2005, TRENDS CELL BIOL, V15, P618, DOI 10.1016/j.tcb.2005.09.007; Yi EC, 2003, RAPID COMMUN MASS SP, V17, P2093, DOI 10.1002/rcm.1150; Yoshimoto M, 2006, CANCER GENET CYTOGEN, V169, P128, DOI 10.1016/j.cancergencyto.2006.04.003	44	129	132	1	32	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 16	2011	474	7351					403	+		10.1038/nature10005	http://dx.doi.org/10.1038/nature10005			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777TD	21572435				2022-12-28	WOS:000291647100051
J	Bousser, MG; Amarenco, P; Chamorro, A; Fisher, M; Ford, I; Fox, KM; Hennerici, MG; Mattle, HP; Rothwell, PM; de Cordoue, A; Fratacci, MD				Bousser, Marie-Germaine; Amarenco, Pierre; Chamorro, Angel; Fisher, Marc; Ford, Ian; Fox, Kim M.; Hennerici, Michael G.; Mattle, Heinrich P.; Rothwell, Peter M.; de Cordouee, Agnes; Fratacci, Marie-Dominique		PERFORM Study Investigators	Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial	LANCET			English	Article							CARDIOVASCULAR EVENTS; CORONARY ANGIOPLASTY; THROMBOXANE; PREVENTION; STROKE; ATTACK; CLOPIDOGREL; DIPYRIDAMOLE; INHIBITION; RESTENOSIS	Background Patients with ischaemic stroke or transient ischaemic attack (TIA) are at high risk of recurrent stroke or other cardiovascular events. We compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in the prevention of cerebral and cardiovascular ischaemic events in patients with a recent non-cardioembolic cerebral ischaemic event. Methods This randomised, double-blind, parallel-group trial was undertaken in 802 centres in 46 countries. Patients who had an ischaemic stroke in the previous 3 months or a TIA in the previous 8 days were randomly allocated with a central interactive response system to 30 mg per day terutroban or 100 mg per day aspirin. Patients and investigators were masked to treatment allocation. The primary efficacy endpoint was a composite of fatal or non-fatal ischaemic stroke, fatal or non-fatal myocardial infarction, or other vascular death (excluding haemorrhagic death). We planned a sequential statistical analysis of non-inferiority (margin 1.05) followed by analysis of superiority. Analysis was by intention to treat. The study was stopped prematurely for futility on the basis of the recommendation of the Data Monitoring Committee. This study is registered, number ISRCTN66157730. Findings 9562 patients were assigned to terutroban (9556 analysed) and 9558 to aspirin (9544 analysed); mean follow-up was 28-3 months (SD 7.7). The primary endpoint occurred in 1091 (11%) patients receiving terutroban and 1062 (11%) receiving aspirin (hazard ratio [HR.] 1.02, 95% CI 0.94-1.12). There was no evidence of a difference between terutroban and aspirin for the secondary or tertiary endpoints. We recorded some increase in minor bleedings with terutroban compared with aspirin (1147 [12%] vs 1045 [11%]; HR 1.11, 95% CI 1.02-1.21), but no significant differences in other safety endpoints. Interpretation The trial did not meet the predefined criteria for non-inferiority, but showed similar rates of the primary endpoint with terutroban and aspirin, without safety advantages for terutroban. In a worldwide perspective, aspirin remains the gold standard antiplatelet drug for secondary stroke prevention in view of its efficacy, tolerance, and cost.	[Bousser, Marie-Germaine] Paris Diderot Univ, Hop Lariboisiere, AP HP, Dept Neurol,INSERM,U740, F-75010 Paris, France; [Amarenco, Pierre] Paris Diderot Univ, Hop Bichat, INSERM, U698, F-75010 Paris, France; [Chamorro, Angel] Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain; [Fisher, Marc] Univ Massachusetts, Sch Med, Worcester, MA USA; [Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Fox, Kim M.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Inst Cardiovasc Med & Sci, London, England; [Hennerici, Michael G.] Heidelberg Univ, Univ Med Mannheim, D-6800 Mannheim, Germany; [Mattle, Heinrich P.] Univ Bern, Inselspital, CH-3010 Bern, Switzerland; [Rothwell, Peter M.] Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England; [de Cordouee, Agnes; Fratacci, Marie-Dominique] Inst Rech Int Servier, F-92415 Courbevoie, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Barcelona; Hospital Clinic de Barcelona; University of Massachusetts System; University of Massachusetts Worcester; University of Glasgow; Imperial College London; Royal Brompton Hospital; Ruprecht Karls University Heidelberg; University of Bern; University of Oxford; Servier; Institut de Recherches Internationales Servier	Bousser, MG (corresponding author), Paris Diderot Univ, Hop Lariboisiere, AP HP, Dept Neurol,INSERM,U740, F-75010 Paris, France.	mg.bousser@lrb.aphp.fr	Macleod, Malcolm Robert/B-2052-2010; Pavel, Kamchatnov/P-6116-2016; Hirt, Lorenz/G-3553-2010; Parati, Eugenio Agostino/AAN-5893-2021; Lueck, Christian Joseph/O-4031-2016; Di Lazzaro, Vincenzo/L-3731-2018; Egido, Jose A/E-3837-2015; Laskov, Vitalii B/H-8548-2013; DIOMEDI, MARINA/K-9047-2016; Chen, Christopher/E-7023-2013; Vanhooren, Geert/H-4433-2011; Sanahuja, Jordi/B-6299-2009; Хабиров, Фарит/AAU-6652-2020; Rothwell, Peter/ABE-5913-2020; Bar, Michal/I-4516-2017; Vécsei, László/B-2066-2010; Hankey, Graeme J/H-4968-2014; de Leeuw, Frank-Erik/E-4795-2012; Ford, Gary A/A-6353-2012; Ford, Ian/ABE-6145-2020; Witte, Otto/P-4127-2018; DIOMEDI, MARINA/AAF-7211-2021; Hamann, Gerhard F./J-6300-2014; Gómez-Escalonilla, Carlos/AAU-1050-2021; Parati, Eugenio A/G-8765-2011; bladin, chris/B-9136-2013; Milanov, Ivan/D-4318-2015; Di Piero, Vittorio/F-6335-2010	Macleod, Malcolm Robert/0000-0001-9187-9839; Pavel, Kamchatnov/0000-0001-6747-3476; Hirt, Lorenz/0000-0002-2921-5000; Parati, Eugenio Agostino/0000-0001-5020-6523; Lueck, Christian Joseph/0000-0003-1537-7612; Di Lazzaro, Vincenzo/0000-0002-9113-5925; Egido, Jose A/0000-0003-1698-9127; Laskov, Vitalii B/0000-0002-2391-5823; DIOMEDI, MARINA/0000-0001-7569-1414; Chen, Christopher/0000-0002-1047-9225; Vanhooren, Geert/0000-0001-6818-9346; Хабиров, Фарит/0000-0002-2572-6970; Rothwell, Peter/0000-0001-9739-9211; Bar, Michal/0000-0002-5049-5844; Vécsei, László/0000-0001-8037-3672; Hankey, Graeme J/0000-0002-6044-7328; Witte, Otto/0000-0003-2101-4105; DIOMEDI, MARINA/0000-0001-7569-1414; Gomez-Sanchez, Jose Carlos/0000-0001-6096-7051; Roine, Risto/0000-0002-3824-3003; Poppert, Holger/0000-0003-2189-7681; Minea, Dan Ioan/0000-0001-6661-2219; Dalkara, Turgay/0000-0003-3943-7819; Milanov, Ivan/0000-0002-4522-4070; Kaste, Markku/0000-0001-6557-6412; Gommans, John/0000-0003-3750-765X; Tyrrell, Pippa/0000-0001-9609-1231; Reyes-Gutierrez, Gerardo-Ali/0000-0002-4667-1446; Di Piero, Vittorio/0000-0002-2631-7562; iudice, alfonso/0000-0003-4661-641X; Boon, Paul/0000-0002-4180-8896; Moulin, thierry/0000-0002-6639-8117; Consoli, Domenico/0000-0002-2050-5538; Dichgans, Martin/0000-0002-0654-387X; Turcani, Peter/0000-0002-4868-6836; Laskov, Vitalii/0000-0003-2870-4547; corsi, fabio massimo/0000-0002-4219-4283; Bogdanov, E.I./0000-0001-9332-8053; Cunha, Luis/0000-0002-0828-3485; Smolanka, Volodymyr/0000-0001-7296-8297; Laska, Ann Charlotte/0000-0002-7330-940X; De Falco, Fabrizio/0000-0001-5065-1678; Teitelbaum, Jeanne/0000-0002-9834-3882	Servier, France; Servier; Sanofi-Aventis; Fondation Bouygues; INSERM; Ministere du travail, de l'emploi et de la sante; Pfizer; Boehringer Ingelheim; Bayer; Biogen	Servier, France(Servier); Servier(Servier); Sanofi-Aventis(Sanofi-Aventis); Fondation Bouygues; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ministere du travail, de l'emploi et de la sante; Pfizer(Pfizer); Boehringer Ingelheim(Boehringer Ingelheim); Bayer(Bayer AG); Biogen(Biogen)	Servier, France.; MGB has received travel and accommodation support for meetings from Servier and Sanofi-Aventis, and research funding and grants from Servier, Sanofi-Aventis, Fondation Bouygues, INSERM, and Ministere du travail, de l'emploi et de la sante. PA has received honoraria for talks, advisory boards, or clinical trial committees from Pfizer, Astra-Zeneca, Bayer, Boehringer Ingelheim, Sanofi-Aventis, Bristol-Myers Squibb, Lundbeck, PAION, Novartis, Merck, EV3, and Servier; and has received research funding from Pfizer, Sanofi-Aventis, Servier and Boehringer Ingelheim. AC has received honoraria for talks, advisory boards, and clinical trial committees from Boehringer Ingelheim, Grupo Ferrer, Sanofi-Aventis, Bristol-Myers Squibb, Pfizer, Service, and Sygnis Bioscience; and has received research funding from Boehringer Ingelheim. MF has received consulting fees, travel fees, and research grants from Servier IF has received research grants, support for attending conferences, and study Executive Committee honoraria from Servier. KMF has received fees, honoraria, and research grants from Servier. MGH has received honoraria for talks, travel support, and advisory board membership from Servier; additionally, he also received similar support from Boehringer Ingelheim, Sanofi-Aventis, Bristol-Myers Squibb, Bayer, Novartis, and Pfizer. HPM has received honoraria for lectures, advisory boards, and clinical trial committees from Bayer, Biogen, Boehringer Ingelheim, Merck, Novartis, Pfizer, Servier, and Teva; and research support from Bayer, Biogen, and Pfizer. PM R has received honoraria for talks, advisory boards, and clinical trial committees from Astra-Zeneca, Bayer, Boehringer Ingelheim, Sanofi-Aventis, Bristol-Myers Squibb, and Servier; and has received research funding from Boehringer Ingelheim. AdC and MDF are employed by Servier.	Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Belhassen L, 2003, J AM COLL CARDIOL, V41, P1198, DOI 10.1016/S0735-1097(03)00048-2; Bousser MG, 2009, CEREBROVASC DIS, V27, P608, DOI 10.1159/000216835; Bousser MG, 2009, CEREBROVASC DIS, V27, P509, DOI 10.1159/000212671; Bousser Marie-Germaine, 2009, Cerebrovasc Dis, V27 Suppl 3, P12, DOI 10.1159/000209261; Cattaneo M, 2010, CIRCULATION, V121, P171, DOI 10.1161/CIRCULATIONAHA.109.853069; Cayatte AJ, 2000, ARTERIOSCL THROM VAS, V20, P1724, DOI 10.1161/01.ATV.20.7.1724; Chamorro Angel, 2009, Cerebrovasc Dis, V27 Suppl 3, P20, DOI 10.1159/000209262; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Egan KM, 2005, CIRCULATION, V111, P334, DOI 10.1161/01.CIR.0000153386.95356.78; Fiessinger JN, 2010, J THROMB HAEMOST, V8, P2369, DOI 10.1111/j.1538-7836.2010.04020.x; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; GONZALEZ JFV, 2005, EUR HEART J, V26, P1557; Hankey GJ, 2010, LANCET NEUROL, V9, P273, DOI 10.1016/S1474-4422(10)70038-7; Sacco RL, 2008, NEW ENGL J MED, V359, P1238, DOI 10.1056/NEJMoa0805002; Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74; Santilli F, 2009, J AM COLL CARDIOL, V53, P667, DOI 10.1016/j.jacc.2008.10.047; SAVAGE MP, 1995, CIRCULATION, V92, P3194, DOI 10.1161/01.CIR.92.11.3194; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; Shi Y, 2008, ACTA PHARMACOL SIN, V29, P185, DOI 10.1111/j.1745-7254.2008.00749.x; Shinohara Y, 2010, LANCET NEUROL, V9, P959, DOI 10.1016/S1474-4422(10)70198-8; Sollier CBD, 2009, CEREBROVASC DIS, V28, P505, DOI 10.1159/000236915; VANDEWERF F, 1994, CIRCULATION, V89, P588	25	149	165	0	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2011	377	9782					2013	2022		10.1016/S0140-6736(11)60600-4	http://dx.doi.org/10.1016/S0140-6736(11)60600-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	782LR	21616527				2022-12-28	WOS:000292011700036
J	Lin, IH; Miller, DS; Bertics, PJ; Murphy, CJ; de Pablo, JJ; Abbott, NL				Lin, I-Hsin; Miller, Daniel S.; Bertics, Paul J.; Murphy, Christopher J.; de Pablo, Juan J.; Abbott, Nicholas L.			Endotoxin-Induced Structural Transformations in Liquid Crystalline Droplets	SCIENCE			English	Article							DEFECTS	The ordering of liquid crystals (LCs) is known to be influenced by surfaces and contaminants. Here, we report that picogram per milliliter concentrations of endotoxin in water trigger ordering transitions in micrometer-size LC droplets. The ordering transitions, which occur at surface concentrations of endotoxin that are less than 10(-5) Langmuir, are not due to adsorbate-induced changes in the interfacial energy of the LC. The sensitivity of the LC to endotoxin was measured to change by six orders of magnitude with the geometry of the LC (droplet versus slab), supporting the hypothesis that interactions of endotoxin with topological defects in the LC mediate the response of the droplets. The LC ordering transitions depend strongly on glycophospholipid structure and provide new designs for responsive soft matter.	[Lin, I-Hsin; Miller, Daniel S.; de Pablo, Juan J.; Abbott, Nicholas L.] Univ Wisconsin, Dept Chem & Biol Engn, Madison, WI 53706 USA; [Bertics, Paul J.] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; [Murphy, Christopher J.] Univ Calif Davis, Sch Med, Dept Ophthalmol & Vis Sci, Davis, CA 95616 USA; [Murphy, Christopher J.] Univ Calif Davis, Sch Vet Med, Dept Vet Surg & Radiol Sci, Davis, CA 95616 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Davis; University of California System; University of California Davis	Abbott, NL (corresponding author), Univ Wisconsin, Dept Chem & Biol Engn, 1415 Engn Dr, Madison, WI 53706 USA.	abbott@engr.wisc.edu	de Pablo, Juan/AAJ-9161-2021; Miller, Daniel S./AAH-3422-2020; Miller, Daniel/G-8578-2013		NSF [DMR-0520527]; Army Research Office [W911NF-07-1-0446, W911NF-06-1-0314]; National Institutes of Health [CA108467, CA105730]; NATIONAL CANCER INSTITUTE [R21CA105730, R01CA108467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI092004] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); Army Research Office; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was primarily supported by NSF through DMR-0520527 (Materials Research Science and Engineering Center), the Army Research Office (W911NF-07-1-0446 and W911NF-06-1-0314), and the National Institutes of Health (CA108467 and CA105730). The technical assistance of B. Carlton is gratefully acknowledged. A patent application based on this work has been filed by the Wisconsin Alumni Research Foundation (P09241US02). N.L.A. and C.J.M. are members of the board of directors of Platypus Technologies LLC, a startup company set up to develop analytic methods based on liquid crystals.	Brake JM, 2003, SCIENCE, V302, P2094, DOI 10.1126/science.1091749; Chen XM, 2008, LANGMUIR, V24, P541, DOI 10.1021/la701844s; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Fernandez-Nieves A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.157801; Gupta JK, 2009, ANGEW CHEM INT EDIT, V48, P1652, DOI 10.1002/anie.200804500; Hu DH, 2000, NATURE, V405, P1030, DOI 10.1038/35016520; Lavrentovich OD, 1998, LIQ CRYST, V24, P117, DOI 10.1080/026782998207640; Lee BW, 2001, SCIENCE, V291, P2576, DOI 10.1126/science.291.5513.2576; McCamley MK, 2007, PROC SPIE, V6441, DOI 10.1117/12.725767; McCamley MK, 2009, J APPL PHYS, V105, DOI 10.1063/1.3148861; Meli MV, 2008, J AM CHEM SOC, V130, P4326, DOI 10.1021/ja077379a; Musevic I, 2006, SCIENCE, V313, P954, DOI 10.1126/science.1129660; Poulin P, 1997, SCIENCE, V275, P1770, DOI 10.1126/science.275.5307.1770; Prischepa OO, 2004, JETP LETT+, V79, P257, DOI 10.1134/1.1759405; Queisser HJ, 1998, SCIENCE, V281, P945, DOI 10.1126/science.281.5379.945; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Ravnik M, 2010, FARADAY DISCUSS, V144, P159, DOI 10.1039/b908676e; Romalis M, 2008, NATURE, V455, P606, DOI 10.1038/455606a; Simon J, 2010, SCIENCE, V327, P60, DOI 10.1126/science.1183226; Sivakumar S, 2009, ADV FUNCT MATER, V19, P2260, DOI 10.1002/adfm.200900399; Skarabot M, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.031705; Volovik G. E., 1983, Soviet Physics - JETP, V58, P1159; Zapotocky M, 1999, SCIENCE, V283, P209, DOI 10.1126/science.283.5399.209	23	279	287	0	188	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2011	332	6035					1297	1300		10.1126/science.1195639	http://dx.doi.org/10.1126/science.1195639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	775EP	21596951	Green Accepted			2022-12-28	WOS:000291441700039
J	Tsukazaki, T; Mori, H; Echizen, Y; Ishitani, R; Fukai, S; Tanaka, T; Perederina, A; Vassylyev, DG; Kohno, T; Maturana, AD; Ito, K; Nureki, O				Tsukazaki, Tomoya; Mori, Hiroyuki; Echizen, Yuka; Ishitani, Ryuichiro; Fukai, Shuya; Tanaka, Takeshi; Perederina, Anna; Vassylyev, Dmitry G.; Kohno, Toshiyuki; Maturana, Andres D.; Ito, Koreaki; Nureki, Osamu			Structure and function of a membrane component SecDF that enhances protein export	NATURE			English	Article							ESCHERICHIA-COLI; PREPROTEIN TRANSLOCASE; CYTOPLASMIC MEMBRANE; CHANNEL; COMPLEX; MACHINERY; MECHANISM; MOVEMENT; DOMAIN	Protein translocation across the bacterial membrane, mediated by the secretory translocon SecYEG and the SecA ATPase(1-4), is enhanced by proton motive force(5,6) and membrane-integrated SecDF(7-9), which associates with SecYEG. The role of SecDF has remained unclear, although it is proposed to function in later stages of translocation as well as in membrane protein biogenesis(4,10-13). Here, we determined the crystal structure of Thermus thermophilus SecDF at 3.3 angstrom resolution, revealing a pseudo-symmetrical, 12-helix transmembrane domain belonging to the RND superfamily and two major periplasmic domains, P1 and P4. Higher-resolution analysis of the periplasmic domains suggested that P1, which binds an unfolded protein, undergoes functionally important conformational changes. In vitro analyses identified an ATP-independent step of protein translocation that requires both SecDF and proton motive force. Electrophysiological analyses revealed that SecDF conducts protons in a manner dependent on pH and the presence of an unfolded protein, with conserved Asp and Arg residues at the transmembrane interface between SecD and SecF playing essential roles in the movements of protons and preproteins. Therefore, we propose that SecDF functions as a membrane-integrated chaperone, powered by proton motive force, to achieve ATP-independent protein translocation.	[Tsukazaki, Tomoya; Echizen, Yuka; Ishitani, Ryuichiro; Nureki, Osamu] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130032, Japan; [Mori, Hiroyuki] Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; [Fukai, Shuya] Univ Tokyo, Synchrotron Radiat Res Org, Div Life Sci, Struct Biol Lab, Tokyo 1130032, Japan; [Fukai, Shuya] Univ Tokyo, Ctr Struct Biol Challenging Prot, Lab Macromol Complexes, Tokyo 1130032, Japan; [Tanaka, Takeshi; Kohno, Toshiyuki] Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; [Perederina, Anna; Vassylyev, Dmitry G.] Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; [Perederina, Anna; Vassylyev, Dmitry G.] Univ Alabama, Sch Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; [Maturana, Andres D.] Nagaoka Univ Technol, Dept Bioengn, Niigata 9402188, Japan; [Ito, Koreaki] Kyoto Sangyo Univ, Kita Ku, Kyoto 6038555, Japan	University of Tokyo; Kyoto University; University of Tokyo; University of Tokyo; Mitsubishi Kagaku Institute of Life Sciences (MITILS); University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Nagaoka University of Technology; Kyoto Sangyo University	Nureki, O (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130032, Japan.	kito@cc.kyoto-su.ac.jp; nureki@ims.u-tokyo.ac.jp	Fukai, Shuya/X-4838-2018; Tsukazaki, Tomoya/N-2299-2019; NUREKI, OSAMU/G-4960-2014	Fukai, Shuya/0000-0002-1241-1443; Tsukazaki, Tomoya/0000-0002-6386-723X; Mori, Hiroyuki/0000-0002-0429-1269	Ministry of Education, Culture, Sports, Science and Technology (MEXT); JST; NIH; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074840] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [22121003, 20247020] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JST(Japan Science & Technology Agency (JST)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Y. Akiyama, R. Suno, Y. Morimoto, T. Minamino, K. Namba, K. Inaba, M. Hattori and H. Nishimasu for suggestions; T. Sakamoto and A. Kurabayashi for assistance with sample preparation; R. Yamasaki, M. Sano, K. Mochizuki, K. Yoshikaie, K. Imayoshi and T. Adachi for technical support; M. Homma and S. Kojima for providing the Vibrio genomic DNA; the beamline staff members at BL41XU of SPring-8 (Hyogo, Japan) and at NW12 of KEK PF-AR (Tsukuba, Japan) for technical help during data collection and M. Ibba for comments on our manuscript. This work was supported by a Grant-in-Aid for Scientific Research (S) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to O.N., by a CREST grant from JST to K.I., by a BIRD grant from JST to H.M. and R.I., by a grant for the National Project on Protein Structural and Functional Analyses to O.N., by NIH grants to D.G.V. and by grants from MEXT to T. Tsukazaki, H.M., R.I., S.F. and K.I.	ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; DRIESSEN AJM, 1991, P NATL ACAD SCI USA, V88, P2471, DOI 10.1073/pnas.88.6.2471; Du Plessis DJF, 2011, BBA-BIOMEMBRANES, V1808, P851, DOI 10.1016/j.bbamem.2010.08.016; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; Hand NJ, 2006, J BACTERIOL, V188, P1251, DOI 10.1128/JB.188.4.1251-1259.2006; Hase CC, 2001, BBA-BIOENERGETICS, V1505, P169, DOI 10.1016/S0005-2728(00)00286-3; Hattori M, 2009, EMBO J, V28, P3602, DOI 10.1038/emboj.2009.288; Inaba K, 2006, CELL, V127, P789, DOI 10.1016/j.cell.2006.10.034; Matsuo E, 1998, J BIOL CHEM, V273, P18835, DOI 10.1074/jbc.273.30.18835; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; Murakami S, 2006, NATURE, V443, P173, DOI 10.1038/nature05076; Nouwen N, 2005, J BACTERIOL, V187, P5857, DOI 10.1128/JB.187.16.5857-5860.2005; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1994, J BACTERIOL, V176, P804, DOI 10.1128/jb.176.3.804-814.1994; SAGARA K, 1994, J BACTERIOL, V176, P4111, DOI 10.1128/JB.176.13.4111-4116.1994; Sasaki M, 2006, SCIENCE, V312, P589, DOI 10.1126/science.1122352; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Seeger MA, 2009, BIOCHEMISTRY-US, V48, P5801, DOI 10.1021/bi900446j; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Tsukazaki T, 2006, ACTA CRYSTALLOGR F, V62, P376, DOI 10.1107/S1744309106007779; Tsukazaki T, 2008, NATURE, V455, P988, DOI 10.1038/nature07421; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Vassylyev DG, 2007, NATURE, V448, P163, DOI 10.1038/nature05931; Zimmer J, 2008, NATURE, V455, P936, DOI 10.1038/nature07335	27	160	172	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 9	2011	474	7350					235	238		10.1038/nature09980	http://dx.doi.org/10.1038/nature09980			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	774PE	21562494	Green Accepted			2022-12-28	WOS:000291397800055
J	Jha, P; Kesler, MA; Kumar, R; Ram, F; Ram, U; Aleksandrowicz, L; Bassani, DG; Chandra, S; Banthia, JK				Jha, Prabhat; Kesler, Maya A.; Kumar, Rajesh; Ram, Faujdar; Ram, Usha; Aleksandrowicz, Lukasz; Bassani, Diego G.; Chandra, Shailaja; Banthia, Jayant K.			Trends in selective abortions of girls in India: analysis of nationally representative birth histories from 1990 to 2005 and census data from 1991 to 2011	LANCET			English	Article							SEX-RATIOS; TECHNOLOGY; POPULATION; MORTALITY	Background India's 2011 census revealed a growing imbalance between the numbers of girls and boys aged 0-6 years, which we postulate is due to increased prenatal sex determination with subsequent selective abortion of female fetuses. We aimed to establish the trends in sex ratio by birth order from 1990 to 2005 with three nationally representative surveys and to quantify the totals of selective abortions of girls with census cohort data. Methods We assessed sex ratios by birth order in 0.25 million births in three rounds of the nationally representative National Family Health Survey covering the period from 1990 to 2005. We estimated totals of selective abortion of girls by assessing the birth cohorts of children aged 0-6 years in the 1991,2001, and 2011 censuses. Our main statistic was the conditional sex ratio of second-order births after a firstborn girl and we used 3-year rolling weighted averages to test for trends, with differences between trends compared by linear regression. Findings The conditional sex ratio for second-order births when the firstborn was a girl fell from 906 per 1000 boys (99% CI 798-1013) in 1990 to 836 (733-939) in 2005; an annual decline of 0.52% (p for trend=0.002). Declines were much greater in mothers with 10 or more years of education than in mothers with no education, and in wealthier households compared with poorer households. By contrast, we did not detect any significant declines in the sex ratio for second-order births if the firstborn was a boy, or for firstborns. Between the 2001 and 2011 censuses, more than twice the number of Indian districts (local administrative areas) showed declines in the child sex ratio as districts with no change or increases. After adjusting for excess mortality rates in girls, our estimates of number of selective abortions of girls rose from 0-2.0 million in the 1980s, to 1.2-4.1 million in the 1990s, and to 3.1-6.0 million in the 2000s. Each 1% decline in child sex ratio at ages 0-6 years implied 1.2-3.6 million more selective abortions of girls. Selective abortions of girls totalled about 4.2-12.1 million from 1980-2010, with a greater rate of increase in the 1990s than in the 2000s. Interpretation Selective abortion of girls, especially for pregnancies after a firstborn girl, has increased substantially in India. Most of India's population now live in states where selective abortion of girls is common.	[Jha, Prabhat; Kesler, Maya A.; Ram, Usha; Aleksandrowicz, Lukasz; Bassani, Diego G.] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Global Hlth Res, Toronto, ON M5B 2C5, Canada; [Jha, Prabhat; Kesler, Maya A.; Ram, Usha; Aleksandrowicz, Lukasz; Bassani, Diego G.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5B 2C5, Canada; [Kumar, Rajesh] Post Grad Inst Med Res & Educ, Sch Publ Hlth, Chandigarh, India; [Ram, Faujdar; Ram, Usha] Int Inst Populat Sci, Mumbai, Maharashtra, India; [Chandra, Shailaja] Govt India, Natl Populat Stabilisat Fund, New Delhi, India; [Banthia, Jayant K.] Govt Maharasthra, Mumbai, Maharashtra, India	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; International Institute for Population Sciences	Jha, P (corresponding author), Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Global Hlth Res, Toronto, ON M5B 2C5, Canada.	prabhat.jha@utoronto.ca	Ram, Usha/AAS-4140-2020; Bassani, Diego/G-2827-2015	Ram, Usha/0000-0001-6722-7347; Bassani, Diego/0000-0001-6704-3820; Aleksandrowicz, Lukasz/0000-0002-3644-1372	Fogarty International Centre of the US National Institutes of Health [R01 TW05991-01]; International Development Research Centre [102172]; Canadian Institute of Health Research (CIHR) [IEG-53506]; Li Ka Shing Knowledge Institute at St Michael's Hospital; University of Toronto; Canada Research Chair programme; FOGARTY INTERNATIONAL CENTER [R01TW005991, R01TW007939] Funding Source: NIH RePORTER	Fogarty International Centre of the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); International Development Research Centre; Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Li Ka Shing Knowledge Institute at St Michael's Hospital; University of Toronto(University of Toronto); Canada Research Chair programme(Canada Research Chairs); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	The Registrar-General of India first established the ongoing national census in 1881, and is presently collaborating with several of the authors on the Million Death Study. External funding is from the Fogarty International Centre of the US National Institutes of Health (grant R01 TW05991-01]), International Development Research Centre (grant 102172), Canadian Institute of Health Research (CIHR; IEG-53506), and the Li Ka Shing Knowledge Institute at St Michael's Hospital and University of Toronto (CGHR support). PJ is supported by the Canada Research Chair programme. The opinions expressed in this report are those of the authors and do not necessarily represent those of the Government of India. We thank Rahim Moineddin and Wilson Suraweera for statistical help, Vicky Hsiao and Brendon Pezzack for graphics, and Daniel Rosenblum and Ansely Wong for comments.	Agarwal Shonali, 2007, J Indian Med Assoc, V105, P132; Almond D, 2008, P NATL ACAD SCI USA, V105, P5681, DOI 10.1073/pnas.0800703105; Almond Jr D., 2009, 15391 NBER; [Anonymous], 2009, WORLD POP PROSP; [Anonymous], 2019, NATL FAMILY HLTH SUR; Bardia A, 2004, NATL MED J INDIA, V17, P207; Bassani DG, 2010, LANCET, V376, P1853, DOI 10.1016/S0140-6736(10)61461-4; BHAT M, 2007, WATERING NEIGHBOURS; COALE AJ, 1991, POPUL DEV REV, V17, P517, DOI 10.2307/1971953; George SM, 2006, PRENATAL DIAG, V26, P604, DOI 10.1002/pd.1475; *GOV IND, 2005, ANN REP IMPL PREC PR; Hatti N, 2004, LUND PAPERS EC HIST, V93; Hesketh T, 2006, P NATL ACAD SCI USA, V103, P13271, DOI 10.1073/pnas.0602203103; International Institute for Population Sciences, 2005, NAT FAM HLTH SURV NF; International Institute for Population Sciences, 1992, NAT FAM HLTH SURV NF; International Institute of Population Sciences, 2010, DISTR LEV HOUS SURV; Jha P, 2006, LANCET, V367, P211, DOI 10.1016/S0140-6736(06)67930-0; Jha P., 2009, CHOOSING HLTH ENTITL; Kulkarni P.M, 2007, ESTIMATION MISSING G; Miller R. G., 1981, SURVIVAL ANAL; Pallikadavath S, 2006, INT FAM PLAN PERSPEC, V32, P120, DOI 10.1363/3212006; *REG GEN IND, 2007, SAMPL REG SYST BAS S; *REG GEN IND, 2011, CENS IND 2011 INSTR; *REG GEN IND, 2001, CENS IND 2001 POST S; Registrar General India, 2009, SAMPL REG SYST STAT; Rodgers JL., 2001, CHANCE MAG, V14, P8, DOI DOI 10.1080/09332480.2001.10542293; Subramanian SV, 2009, J EPIDEMIOL COMMUN H, V63, P245, DOI 10.1136/jech.2008.078477; Teitelbaum M S, 1970, J Biosoc Sci Suppl, V2, P61; World Bank, 2009, WORLD DEV IND; Zhu WX, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1211	30	152	155	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2011	377	9781					1921	1928		10.1016/S0140-6736(11)60649-1	http://dx.doi.org/10.1016/S0140-6736(11)60649-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	777LW	21612820	Green Accepted			2022-12-28	WOS:000291623200028
J	Cotner, JB; Hall, EK				Cotner, James B.; Hall, Edward K.			Comment on "A Bacterium That Can Grow by Using Arsenic Instead of Phosphorus"	SCIENCE			English	Editorial Material									[Cotner, James B.] Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; [Hall, Edward K.] Univ Vienna, Dept Limnol, A-1090 Vienna, Austria	University of Minnesota System; University of Minnesota Twin Cities; University of Vienna	Cotner, JB (corresponding author), Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA.	cotne002@umn.edu	Hall, Ed/C-6013-2014; Cotner, James B/D-8799-2013	Cotner, James B/0000-0001-9792-467X				Cotner JB, 2010, FRONT MICROBIOL, V1, DOI 10.3389/fmicb.2010.00132; DUCKLOW HW, 1992, ADV MICROB ECOL, V12, P113; Makino W, 2003, FUNCT ECOL, V17, P121, DOI 10.1046/j.1365-2435.2003.00712.x; WHITE PA, 1991, MICROBIAL ECOL, V21, P99, DOI 10.1007/BF02539147; Wolfe-Simon F, 2011, SCIENCE, V332, P1163, DOI 10.1126/science.1197258	5	11	11	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2011	332	6034								10.1126/science.1201943	http://dx.doi.org/10.1126/science.1201943			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	772BO	21622705				2022-12-28	WOS:000291205200025
J	Schwartzentruber, DJ; Lawson, DH; Richards, JM; Conry, RM; Miller, DM; Treisman, J; Gailani, F; Riley, L; Conlon, K; Pockaj, B; Kendra, KL; White, RL; Gonzalez, R; Kuzel, TM; Curti, B; Leming, PD; Whitman, ED; Balkissoon, J; Reintgen, DS; Kaufman, H; Marincola, FM; Merino, MJ; Rosenberg, SA; Choyke, P; Vena, D; Hwu, P				Schwartzentruber, Douglas J.; Lawson, David H.; Richards, Jon M.; Conry, Robert M.; Miller, Donald M.; Treisman, Jonathan; Gailani, Fawaz; Riley, Lee; Conlon, Kevin; Pockaj, Barbara; Kendra, Kari L.; White, Richard L.; Gonzalez, Rene; Kuzel, Timothy M.; Curti, Brendan; Leming, Phillip D.; Whitman, Eric D.; Balkissoon, Jai; Reintgen, Douglas S.; Kaufman, Howard; Marincola, Francesco M.; Merino, Maria J.; Rosenberg, Steven A.; Choyke, Peter; Vena, Don; Hwu, Patrick			gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTATIC MELANOMA; CANCER-IMMUNOTHERAPY; DOSE INTERLEUKIN-2; T-CELLS; BLOCKADE	Background Stimulating an immune response against cancer with the use of vaccines remains a challenge. We hypothesized that combining a melanoma vaccine with interleukin-2, an immune activating agent, could improve outcomes. In a previous phase 2 study, patients with metastatic melanoma receiving high-dose interleukin-2 plus the gp100:209-217(210M) peptide vaccine had a higher rate of response than the rate that is expected among patients who are treated with interleukin-2 alone. Methods We conducted a randomized, phase 3 trial involving 185 patients at 21 centers. Eligibility criteria included stage IV or locally advanced stage III cutaneous melanoma, expression of HLA(star)A0201, an absence of brain metastases, and suitability for high-dose interleukin-2 therapy. Patients were randomly assigned to receive interleukin-2 alone (720,000 IU per kilogram of body weight per dose) or gp100: 209-217(210M) plus incomplete Freund's adjuvant (Montanide ISA-51) once per cycle, followed by interleukin-2. The primary end point was clinical response. Secondary end points included toxic effects and progression-free survival. Results The treatment groups were well balanced with respect to baseline characteristics and received a similar amount of interleukin-2 per cycle. The toxic effects were consistent with those expected with interleukin-2 therapy. The vaccine-interleukin-2 group, as compared with the interleukin-2-only group, had a significant improvement in centrally verified overall clinical response (16% vs. 6%, P=0.03), as well as longer progression-free survival (2.2 months; 95% confidence interval [CI], 1.7 to 3.9 vs. 1.6 months; 95% CI, 1.5 to 1.8; P=0.008). The median overall survival was also longer in the vaccine-interleukin-2 group than in the interleukin-2-only group (17.8 months; 95% CI, 11.9 to 25.8 vs. 11.1 months; 95% CI, 8.7 to 16.3; P=0.06). Conclusions In patients with advanced melanoma, the response rate was higher and progression-free survival longer with vaccine and interleukin-2 than with interleukin-2 alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00019682.)	[Schwartzentruber, Douglas J.] Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN 46526 USA; [Lawson, David H.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Conry, Robert M.] Univ Alabama Birmingham, Hlth Serv Fdn, Ctr Comprehens Canc, Birmingham, AL USA; [Miller, Donald M.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA; [Treisman, Jonathan] St Lukes Med Ctr, Milwaukee, WI USA; [Gailani, Fawaz] Kaiser Permanente Med Ctr, Riverside, CA USA; [Balkissoon, Jai] Summit Med Ctr, Oakland, CA USA; [Riley, Lee] St Lukes Hosp, Bethlehem, PA USA; [Merino, Maria J.] Dept Surg Pathol, New Haven, CT 06520 USA; [Rosenberg, Steven A.] Surg Branch, Bethesda, MD USA; [Conlon, Kevin] Canc Therapy Evaluat Program, Bethesda, MD USA; [Choyke, Peter] NCI, Bethesda, MD 20892 USA; [Marincola, Francesco M.] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA; [Marincola, Francesco M.] NIH, Trans NIH Ctr Human Immunol, Bethesda, MD 20892 USA; [Vena, Don] EMMES Corp, Rockville, MD USA; [Pockaj, Barbara] Mayo Clin, Phoenix, AZ USA; [Kendra, Kari L.] Ohio State Univ, Columbus, OH 43210 USA; [White, Richard L.] Carolinas Med Ctr, Charlotte, NC 28203 USA; [Gonzalez, Rene] Univ Colorado, Denver, CO 80202 USA; [Kuzel, Timothy M.] Northwestern Univ, Chicago, IL 60611 USA; [Kaufman, Howard] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [Curti, Brendan] Earle A Chiles Res Inst, Portland, OR USA; [Leming, Phillip D.] Christ Hosp, Cincinnati, OH 45219 USA; [Whitman, Eric D.] Atlantic Melanoma Ctr, Morristown, NJ USA; [Reintgen, Douglas S.] Univ S Florida, Tampa, FL USA; [Hwu, Patrick] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Emory University; University of Alabama System; University of Alabama Birmingham; University of Louisville; Kaiser Permanente; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; Emmes Corporation; Mayo Clinic; Mayo Clinic Phoenix; University System of Ohio; Ohio State University; Carolinas Medical Center; University of Colorado System; University of Colorado Denver; Northwestern University; Rush University; Christ Hospital - Ohio; State University System of Florida; University of South Florida; University of Texas System; UTMD Anderson Cancer Center	Schwartzentruber, DJ (corresponding author), Indiana Univ, Hlth Goshen Ctr Canc Care, 200 High Pk Ave, Goshen, IN 46526 USA.	dschwart@iuhealth.org	gonzález, rene/W-2081-2019		National Cancer Institute; Indiana University Health Goshen, Goshen Hospital and Health Care Foundation, Chiron; Novartis; NATIONAL CANCER INSTITUTE [ZIABC010984] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL002118] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Indiana University Health Goshen, Goshen Hospital and Health Care Foundation, Chiron; Novartis(Novartis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CLINICAL CENTER	Supported by the National Cancer Institute, Indiana University Health Goshen, Goshen Hospital and Health Care Foundation, Chiron, and Novartis.; We thank Juliann Wu, M. S., of EMMES, Rockville, MD, for data management and statistics; Paul Duray, M. D., for review of pathology slides; Lien Ngo, M. S., Surgery Branch, National Cancer Institute (NCI), Bethesda, MD, for performing in vitro studies; personnel at the NCI Cancer Therapy Evaluation Program and Division of Cancer Treatment and Diagnosis for guidance and support for this project; and Jana Risemas for assistance with the preparation of the manuscript.	Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Attia P, 2005, J CLIN ONCOL, V23, P6043, DOI 10.1200/JCO.2005.06.205; Hodi FS, 2010, NEW ENGL J MED, V363, P1290; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Liakou CI, 2008, P NATL ACAD SCI USA, V105, P14987, DOI 10.1073/pnas.0806075105; Lizee G, 2007, CLIN CANCER RES, V13, P5250, DOI 10.1158/1078-0432.CCR-07-1722; Overwijk WW, 2000, CANCER J SCI AM, V6, pS76; Quezada SA, 2010, J EXP MED, V207, P637, DOI 10.1084/jem.20091918; Rosenberg SA, 1999, J IMMUNOL, V163, P1690; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Slingluff CL, 2004, J CLIN ONCOL, V22, P4474, DOI 10.1200/JCO.2004.10.212; Smith FO, 2008, CLIN CANCER RES, V14, P5610, DOI 10.1158/1078-0432.CCR-08-0116; Sosman JA, 2008, J CLIN ONCOL, V26, P2292, DOI 10.1200/JCO.2007.13.3165	16	621	654	3	74	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2119	2127		10.1056/NEJMoa1012863	http://dx.doi.org/10.1056/NEJMoa1012863			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AB	21631324	Green Accepted, Bronze			2022-12-28	WOS:000291200700010
J	Schwartz, AV; Vittinghoff, E; Bauer, DC; Hillier, TA; Strotmeyer, ES; Ensrud, KE; Donaldson, MG; Cauley, JA; Harris, TB; Koster, A; Womack, CR; Palermo, L; Black, DM				Schwartz, Ann V.; Vittinghoff, Eric; Bauer, Douglas C.; Hillier, Teresa A.; Strotmeyer, Elsa S.; Ensrud, Kristine E.; Donaldson, Meghan G.; Cauley, Jane A.; Harris, Tamara B.; Koster, Annemarie; Womack, Catherine R.; Palermo, Lisa; Black, Dennis M.		SOF Res Grp; Osteoporotic Fractures Men MrOS Re; Hlth ABC Res Grp	Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL DENSITY; OSTEOPOROTIC FRACTURES; BODY-COMPOSITION; WOMEN; MEN; PREDICTION; HEALTH; HIP; THIAZOLIDINEDIONES; METAANALYSIS	Context Type 2 diabetes mellitus (DM) is associated with higher bone mineral density (BMD) and paradoxically with increased fracture risk. It is not known if low BMD, central to fracture prediction in older adults, identifies fracture risk in patients with DM. Objective To determine if femoral neck BMD T score and the World Health Organization Fracture Risk Algorithm (FRAX) score are associated with hip and nonspine fracture risk in older adults with type 2 DM. Design, Setting, and Participants Data from 3 prospective observational studies with adjudicated fracture outcomes (Study of Osteoporotic Fractures [December 1998-July 2008]; Osteoporotic Fractures in Men Study [March 2000-March 2009]; and Health, Aging, and Body Composition study [April 1997-June 2007]) were analyzed in older community-dwelling adults (9449 women and 7436 men) in the United States. Main Outcome Measure Self-reported incident fractures, which were verified by radiology reports. Results Of 770 women with DM, 84 experienced a hip fracture and 262 a nonspine fracture during a mean (SD) follow-up of 12.6 (5.3) years. Of 1199 men with DM, 32 experienced a hip fracture and 133 a nonspine fracture during a mean (SD) follow-up of 7.5 (2.0) years. Age-adjusted hazard ratios (HRs) for 1-unit decrease in femoral neck BMD T score in women with DM were 1.88 (95% confidence interval [CI], 1.43-2.48) for hip fracture and 1.52 (95% CI, 1.31-1.75) for nonspine fracture, and in men with DM were 5.71 (95% CI, 3.42-9.53) for hip fracture and 2.17 (95% CI, 1.75-2.69) for nonspine fracture. The FRAX score was also associated with fracture risk in participants with DM (HRs for 1-unit increase in FRAX hip fracture score, 1.05; 95% CI, 1.03-1.07, for women with DM and 1.16; 95% CI, 1.07-1.27, for men with DM; HRs for 1-unit increase in FRAX osteoporotic fracture score, 1.04; 95% CI, 1.02-1.05, for women with DM and 1.09; 95% CI, 1.04-1.14, for men with DM). However, for a given T score and age or for a given FRAX score, participants with DM had a higher fracture risk than those without DM. For a similar fracture risk, participants with DM had a higher T score than participants without DM. For hip fracture, the estimated mean difference in T score for women was 0.59 (95% CI, 0.31-0.87) and for men was 0.38 (95% CI, 0.09-0.66). Conclusions Among older adults with type 2 DM, femoral neck BMD T score and FRAX score were associated with hip and nonspine fracture risk; however, in these patients compared with participants without DM, the fracture risk was higher for a given T score and age or for a given FRAX score. JAMA. 2011;305(21):2184-2192 www.jama.com	[Schwartz, Ann V.; Vittinghoff, Eric; Bauer, Douglas C.; Palermo, Lisa; Black, Dennis M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA; [Bauer, Douglas C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94107 USA; [Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA; [Strotmeyer, Elsa S.; Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Ensrud, Kristine E.] Univ Minnesota, VA Med Ctr, Minneapolis, MN 55455 USA; [Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA; [Donaldson, Meghan G.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA; [Harris, Tamara B.; Koster, Annemarie] NIA, Intramural Res Program, Bethesda, MD 20892 USA; [Koster, Annemarie] Maastricht Univ, Dept Hlth Care Studies, Maastricht, Netherlands; [Womack, Catherine R.] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; California Pacific Medical Center; California Pacific Medical Center Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Maastricht University; University of Tennessee System; University of Tennessee Health Science Center	Schwartz, AV (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 185 Berry St,Lobby 5,Ste 5700, San Francisco, CA 94107 USA.	aschwartz@psg.ucsf.edu	Koster, Annemarie/E-7438-2010; Strotmeyer, Elsa S/F-3015-2014; Newman, Anne B./C-6408-2013	Koster, Annemarie/0000-0003-1583-7391; Newman, Anne B./0000-0002-0106-1150; Strotmeyer, Elsa/0000-0002-4093-6036; Ensrud, Kristine/0000-0002-9069-3036; Cauley, Jane A/0000-0003-0752-4408	Amgen; Novartis; Roche; Merck; National Institutes of Health; National Institute on Aging [R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, R01 AG027576, N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; American Diabetes Association [1-04-JF-46]; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health Roadmap for Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1 RR024140]; National Institute of Nursing Research [R01-NR012459]; National Institutes of Health, National Institute on Aging; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035584, U01AR045654, R01AR035583, U01AR045614, U01AR045632, K24AR051895, U01AR045647, R01AR035582, U01AR045583, U01AR045580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR012459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028050, N01AG062103, U01AG018197, N01AG062101, N01AG062106, R01AG005407, R01AG027576, R01AG027574, R01AG005394, U01AG027810, U01AG042140] Funding Source: NIH RePORTER	Amgen(Amgen); Novartis(Novartis); Roche(Roche Holding); Merck(Merck & Company); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Diabetes Association(American Diabetes Association); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institutes of Health Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Institutes of Health, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Schwartz reported receiving honorarium from Amgen. Dr Bauer reported receiving research support from Amgen and Novartis. Dr Ensrud reported receiving travel support from Merck and Pfizer. Ms Palermo reported that she is a consultant for Nycomed. Dr Black reported receiving research support from Novartis, Roche, Merck, and Amgen. No other authors reported any disclosures.; This study was funded by an investigator-initiated grant from Amgen (Dr Schwartz). The Study of Osteoporotic Fractures is supported by National Institutes of Health funding. The National Institute on Aging provides support under the following grants: R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. The Osteoporotic Fractures in Men study is supported by National Institutes of Health funding and by grant 1-04-JF-46 from the American Diabetes Association (Dr Strotmeyer). The National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, the National Center for Research Resources, and the National Institutes of Health Roadmap for Medical Research provided support under the following grants: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. The Health, Aging, and Body Composition study is supported by contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106 from the National Institute on Aging; grant R01-AG028050 from the National Institute on Aging; grant R01-NR012459 from the National Institute of Nursing Research; and by the Intramural Research Program of the National Institutes of Health, National Institute on Aging.	[Anonymous], 2010, CLIN GUID PREV TREAT; Blank JB, 2005, CONTEMP CLIN TRIALS, V26, P557, DOI 10.1016/j.cct.2005.05.005; Bonds DE, 2006, J CLIN ENDOCR METAB, V91, P3404, DOI 10.1210/jc.2006-0614; Cowie CC, 2009, DIABETES CARE, V32, P287, DOI 10.2337/dc08-1296; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; Dawson-Hughes B, 2008, OSTEOPOROSIS INT, V19, P449, DOI 10.1007/s00198-008-0559-5; Donaldson MG, 2010, J BONE MINER RES, V25, P1506, DOI 10.1002/jbmr.55; Ensrud KE, 2009, ARCH INTERN MED, V169, P2087, DOI 10.1001/archinternmed.2009.404; Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; Kanis JA, 2007, OSTEOPOROSIS INT, V18, P1033, DOI 10.1007/s00198-007-0343-y; Kanis JA, 2005, OSTEOPOROSIS INT, V16, P581, DOI 10.1007/s00198-004-1780-5; Loke YK, 2009, CAN MED ASSOC J, V180, P32, DOI 10.1503/cmaj.080486; Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093; Meier C, 2008, ARCH INTERN MED, V168, P820, DOI 10.1001/archinte.168.8.820; Melton LJ, 2008, J BONE MINER RES, V23, P1334, DOI 10.1359/JBMR.080323; Newman AB, 2003, J AM GERIATR SOC, V51, P323, DOI 10.1046/j.1532-5415.2003.51105.x; Orwoll E, 2005, CONTEMP CLIN TRIALS, V26, P569, DOI 10.1016/j.cct.2005.05.006; Patel S, 2008, CALCIFIED TISSUE INT, V82, P87, DOI 10.1007/s00223-007-9082-5; Schwartz AV, 2002, DIABETES CARE, V25, P1749, DOI 10.2337/diacare.25.10.1749; Schwartz AV, 2001, J CLIN ENDOCR METAB, V86, P32, DOI 10.1210/jc.86.1.32; Strotmeyer ES, 2005, ARCH INTERN MED, V165, P1612, DOI 10.1001/archinte.165.14.1612; Vashishth Deepak, 2007, Curr Osteoporos Rep, V5, P62; Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198-006-0253-4; World Health Organization, FRAX WHO FRACT RISK; Yamamoto M, 2007, CALCIFIED TISSUE INT, V80, P353, DOI 10.1007/s00223-007-9003-7	26	435	468	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2184	2192		10.1001/jama.2011.715	http://dx.doi.org/10.1001/jama.2011.715			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21632482	Bronze, Green Accepted			2022-12-28	WOS:000291106300021
J	Butterworth, B; Varma, S; Laurillard, D				Butterworth, Brian; Varma, Sashank; Laurillard, Diana			Dyscalculia: From Brain to Education	SCIENCE			English	Review							DEVELOPMENTAL DYSCALCULIA; INDIVIDUAL-DIFFERENCES; NUMERICAL CAPACITIES; NUMBER; CHILDREN; DYSLEXIA; REPRESENTATION; DISABILITIES; NEUROSCIENCE; MORPHOMETRY	Recent research in cognitive and developmental neuroscience is providing a new approach to the understanding of dyscalculia that emphasizes a core deficit in understanding sets and their numerosities, which is fundamental to all aspects of elementary school mathematics. The neural bases of numerosity processing have been investigated in structural and functional neuroimaging studies of adults and children, and neural markers of its impairment in dyscalculia have been identified. New interventions to strengthen numerosity processing, including adaptive software, promise effective evidence-based education for dyscalculic learners.	[Butterworth, Brian] UCL, Ctr Educ Neurosci, London, England; [Butterworth, Brian] UCL, Inst Cognit Neurosci, London, England; [Butterworth, Brian] Univ Melbourne, Psychol Sci, Melbourne, Vic 3010, Australia; [Varma, Sashank] Univ Minnesota, Dept Educ Psychol, Minneapolis, MN 55455 USA; [Laurillard, Diana] Univ London, Inst Educ, Ctr Educ Neurosci, London WC1N 3QS, England; [Laurillard, Diana] Univ London, Inst Educ, London Knowledge Lab, London WC1N 3QS, England	University of London; University College London; UCL Institute of Education; University of London; University College London; University of Melbourne; University of Minnesota System; University of Minnesota Twin Cities; University of London; University College London; UCL Institute of Education; University of London; University College London; UCL Institute of Education	Butterworth, B (corresponding author), UCL, Ctr Educ Neurosci, London, England.	b.butterworth@ucl.ac.uk		Laurillard, Diana/0000-0002-8675-5660				Anning A., 1999, PROMOTING CHILDRENS; Ansari D, 2002, TRENDS COGN SCI, V6, P511, DOI 10.1016/S1364-6613(02)02040-5; Ansari D, 2008, NAT REV NEUROSCI, V9, P278, DOI 10.1038/nrn2334; Beddington J, 2008, NATURE, V455, P1057, DOI 10.1038/4551057a; Bird R., 2007, DYSCALCULIA TOOLKIT; Bishop DVM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015112; Briars D.J., 1988, CHILDRENS COUNTING C, P63; BRUNER JS, 1961, HARVARD EDUC REV, V31, P21; Butterworth B., 1999, MATH BRAIN; Butterworth B., 2005, HDB MATH COGNITION, V1st, P455; Butterworth B., 2004, DYSCALCULIA GUIDANCE; Butterworth B, 2006, CAMBRIDGE HANDBOOK OF EXPERTISE AND EXPERT PERFORMANCE, P553; Butterworth B, 2010, ZDM-MATH EDUC, V42, P527, DOI 10.1007/s11858-010-0267-4; Butterworth B, 2010, TRENDS COGN SCI, V14, P534, DOI 10.1016/j.tics.2010.09.007; Cantlon JF, 2006, PLOS BIOL, V4, P844, DOI 10.1371/journal.pbio.0040125; Cappelletti M, 2007, EXP BRAIN RES, V179, P631, DOI 10.1007/s00221-006-0820-0; Castelli F, 2006, P NATL ACAD SCI USA, V103, P4693, DOI 10.1073/pnas.0600444103; CIPOLOTTI L, 2001, HDB NEUROPSYCHOLOGY, V3, P305; Dayan P, 2001, COMPUTATIONAL NEUROS; Deci EL, 2001, REV EDUC RES, V71, P1, DOI 10.3102/00346543071001001; Dehaene S, 2003, COGN NEUROPSYCHOL, V20, P487, DOI 10.1080/02643290244000239; Delazer M, 1997, CORTEX, V33, P697, DOI 10.1016/S0010-9452(08)70727-5; Delazer M, 2005, NEUROIMAGE, V25, P838, DOI 10.1016/j.neuroimage.2004.12.009; Dewey J., 1938, EXPERIENCE ED; Dowker A., 2009, WHAT WORKS CHILDREN; Feigenson L, 2004, TRENDS COGN SCI, V8, P307, DOI 10.1016/j.tics.2004.05.002; Gabrieli JDE, 2009, SCIENCE, V325, P280, DOI 10.1126/science.1171999; Gilmore CK, 2007, NATURE, V447, P589, DOI 10.1038/nature05850; Gilmore CK, 2010, COGNITION, V115, P394, DOI 10.1016/j.cognition.2010.02.002; Goswami U, 2006, NAT REV NEUROSCI, V7, P406, DOI 10.1038/nrn1907; Gross J., 2009, LONG TERM COSTS NUME; GrossTsur V, 1996, DEV MED CHILD NEUROL, V38, P25, DOI 10.1111/j.1469-8749.1996.tb15029.x; Halberda J, 2008, NATURE, V455, P665, DOI 10.1038/nature07246; HITTMAIRDELAZER M, 1994, BRAIN, V117, P715, DOI 10.1093/brain/117.4.715; Holloway ID, 2009, J EXP CHILD PSYCHOL, V103, P17, DOI 10.1016/j.jecp.2008.04.001; Isaacs EB, 2001, BRAIN, V124, P1701, DOI 10.1093/brain/124.9.1701; Ischebeck A, 2009, NEUROIMAGE, V44, P1103, DOI 10.1016/j.neuroimage.2008.10.025; Johnson MH, 2001, NAT REV NEUROSCI, V2, P475, DOI 10.1038/35081509; Kadosh RC, 2007, CURR BIOL, V17, P689, DOI 10.1016/j.cub.2007.02.056; KINSBOURNE M, 1962, BRAIN, V85, P47, DOI 10.1093/brain/85.1.47; KOSC L, 1974, J LEARN DISABIL, V7, P164, DOI 10.1177/002221947400700309; Kovas Y, 2007, MONOGR SOC RES CHILD, V72, P1; Kucian Karin, 2006, Behav Brain Funct, V2, P31; Landerl K, 2004, COGNITION, V93, P99, DOI 10.1016/j.cognition.2003.11.004; Landerl K, 2009, J EXP CHILD PSYCHOL, V103, P309, DOI 10.1016/j.jecp.2009.03.006; Lyytinen H, 2001, DEV NEUROPSYCHOL, V20, P535, DOI 10.1207/S15326942DN2002_5; Monuteaux MC, 2005, J LEARN DISABIL-US, V38, P86, DOI 10.1177/00222194050380010701; Mussolin C, 2010, J COGNITIVE NEUROSCI, V22, P860, DOI 10.1162/jocn.2009.21237; Nieder A, 2009, ANNU REV NEUROSCI, V32, P185, DOI 10.1146/annurev.neuro.051508.135550; Noel MP, 2005, CHILD NEUROPSYCHOL, V11, P413, DOI 10.1080/09297040590951550; OECD, 2010, HIGH COST LOW ED PER; Papert S., 1980, MINDSTORMS CHILDREN; Parsons S., 2005, DOES NUMERACY MATTER; Pesenti M, 2001, NAT NEUROSCI, V4, P103, DOI 10.1038/82831; Piazza M, 2010, COGNITION, V116, P33, DOI 10.1016/j.cognition.2010.03.012; Pinel P, 2001, NEUROIMAGE, V14, P1013, DOI 10.1006/nimg.2001.0913; Price GR, 2007, CURR BIOL, V17, pR1042, DOI 10.1016/j.cub.2007.10.013; Rasanen P, 2009, COGNITIVE DEV, V24, P450, DOI 10.1016/j.cogdev.2009.09.003; Rotzer S, 2008, NEUROIMAGE, V39, P417, DOI 10.1016/j.neuroimage.2007.08.045; Rousselle L, 2007, COGNITION, V102, P361, DOI 10.1016/j.cognition.2006.01.005; Rubinsten O, 2009, TRENDS COGN SCI, V13, P92, DOI 10.1016/j.tics.2008.11.002; Rykhlevskaia E, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.051.2009; Schulte-Korne G, 2007, ANN HUM GENET, V71, P160, DOI 10.1111/j.1469-1809.2006.00312.x; Shalev R. S., 2007, WHY IS MATH SO HARD, P49; Shalev RS, 2005, DEV MED CHILD NEUROL, V47, P121, DOI 10.1017/S0012162205000216; Shalev RS, 2001, PEDIATR NEUROL, V24, P337, DOI 10.1016/S0887-8994(00)00258-7; WHITEHEAD AN, 1948, INTRO MATH; Wilson A. J., 2006, BEHAV BRAIN FUNCT, V1, P1, DOI [DOI 10.1186/1744-9081-2-20, DOI 10.1186/1744-9081-2-1]; Yeo D., 2003, DYSLEXIA HDB; Zamarian L, 2009, NEUROSCI BIOBEHAV R, V33, P909, DOI 10.1016/j.neubiorev.2009.03.005; Zbrodoff W., 2005, HDB MATH COGNITION, P331; Zhou XL, 2007, NEUROIMAGE, V35, P871, DOI 10.1016/j.neuroimage.2006.12.017	72	352	361	14	283	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2011	332	6033					1049	1053		10.1126/science.1201536	http://dx.doi.org/10.1126/science.1201536			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617068	Green Submitted			2022-12-28	WOS:000290996700035
J	Falloon, K; Arroll, B; Elley, CR; Fernando, A				Falloon, Karen; Arroll, Bruce; Elley, C. Raina; Fernando, Antonio, III			The assessment and management of insomnia in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PSYCHIATRIC-DISORDERS; COMPARATIVE METAANALYSIS; BEHAVIORAL TREATMENT; GENERAL-PRACTICE; SLEEP DURATION; OLDER-ADULTS; DEPRESSION; QUESTIONNAIRE; EPIDEMIOLOGY; DIAGNOSIS		[Falloon, Karen; Arroll, Bruce; Elley, C. Raina] Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1142, New Zealand; [Fernando, Antonio, III] Univ Auckland, Dept Psychol Med, Auckland 1142, New Zealand	University of Auckland; University of Auckland	Arroll, B (corresponding author), Univ Auckland, Dept Gen Practice & Primary Hlth Care, Private Bag 92109, Auckland 1142, New Zealand.	b.arroll@auckland.ac.nz						American Sleep Disorders Association, 2005, INT CLASS SLEEP DIS; [Anonymous], INS; Arroll B, 2005, BRIT MED J, V331, P884, DOI 10.1136/bmj.38607.464537.7C; Arroll B, 2010, SLEEPLESS SEATTLE FI; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; CAMPBELL SS, 1994, CHRONOBIOL INT, V11, P126, DOI 10.3109/07420529409055899; Chung F, 2008, ANESTHESIOLOGY, V108, P812, DOI 10.1097/ALN.0b013e31816d83e4; Cooke Jana R, 2011, Handb Clin Neurol, V98, P653, DOI 10.1016/B978-0-444-52006-7.00041-1; Curran HV, 2003, PSYCHOL MED, V33, P1223, DOI 10.1017/S0033291703008213; Edinger JD, 2009, SLEEP, V32, P499, DOI 10.1093/sleep/32.4.499; Edinger JD, 2003, SLEEP, V26, P177, DOI 10.1093/sleep/26.2.177; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Irwin MR, 2006, HEALTH PSYCHOL, V25, P3, DOI 10.1037/0278-6133.25.1.3; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kayumov L, 2001, PSYCHOSOM MED, V63, P40, DOI 10.1097/00006842-200101000-00005; Kroenke K, 2009, PSYCHOSOMATICS, V50, P613, DOI 10.1176/appi.psy.50.6.613; KUPPERMANN M, 1995, J GEN INTERN MED, V10, P25, DOI 10.1007/BF02599573; Mallon L, 2005, DIABETES CARE, V28, P2762, DOI 10.2337/diacare.28.11.2762; Marshall NS, 2004, J SLEEP RES, V13, P177, DOI 10.1111/j.1365-2869.2004.00402.x; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; Morgenthaler T, 2006, SLEEP, V29, P1415; Morin CM, 2006, SLEEP, V29, P1398, DOI 10.1093/sleep/29.11.1398; Morphy H, 2007, SLEEP, V30, P274; National Institute for Health and Clinical Excellence, 2008, CONT POS AIRW PRESS, P139; Panneman MJM, 2003, DRUG AGING, V20, P833, DOI 10.2165/00002512-200320110-00004; Puddifoot S, 2007, INT J PSYCHIAT MED, V37, P371, DOI 10.2190/PM.37.4.b; Rofail LM, 2010, SLEEP, V33, P1106, DOI 10.1093/sleep/33.8.1106; ROSENTHAL NE, 1990, SLEEP, V13, P354; SHAPIRO CM, 1993, BRIT MED J, V306, P1604, DOI 10.1136/bmj.306.6892.1604; Simon GE, 1997, AM J PSYCHIAT, V154, P1417; Smith MT, 2002, AM J PSYCHIAT, V159, P5, DOI 10.1176/appi.ajp.159.1.5; SPIELMAN AJ, 1987, SLEEP, V10, P45; Wennberg P, 1996, REPORTS DEP PSYCHOL, V811, P1; WHO, 2011, ASSIST PROJ ALC SMOK; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	35	9	10	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 27	2011	342								d2899	10.1136/bmj.d2899	http://dx.doi.org/10.1136/bmj.d2899			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771KI	21622505				2022-12-28	WOS:000291155200002
J	Katz, ME; Cramer, BS; Toggweiler, JR; Esmay, G; Liu, CJ; Miller, KG; Rosenthal, Y; Wade, BS; Wright, JD				Katz, Miriam E.; Cramer, Benjamin S.; Toggweiler, J. R.; Esmay, Gar; Liu, Chengjie; Miller, Kenneth G.; Rosenthal, Yair; Wade, Bridget S.; Wright, James D.			Impact of Antarctic Circumpolar Current Development on Late Paleogene Ocean Structure	SCIENCE			English	Article							DRAKE PASSAGE; THERMOHALINE CIRCULATION; NORTH-ATLANTIC; OLIGOCENE; TRANSITION; ISOTOPES; FORAMINIFERA; GREENHOUSE; ICEHOUSE; CLIMATE	Global cooling and the development of continental-scale Antarctic glaciation occurred in the late middle Eocene to early Oligocene (similar to 38 to 28 million years ago), accompanied by deep-ocean reorganization attributed to gradual Antarctic Circumpolar Current (ACC) development. Our benthic foraminiferal stable isotope comparisons show that a large delta(13)C offset developed between mid-depth (similar to 600 meters) and deep (>1000 meters) western North Atlantic waters in the early Oligocene, indicating the development of intermediate-depth delta(13)C and O(2) minima closely linked in the modern ocean to northward incursion of Antarctic Intermediate Water. At the same time, the ocean's coldest waters became restricted to south of the ACC, probably forming a bottom-ocean layer, as in the modern ocean. We show that the modern four-layer ocean structure (surface, intermediate, deep, and bottom waters) developed during the early Oligocene as a consequence of the ACC.	[Katz, Miriam E.] Rensselaer Polytech Inst, Dept Earth & Environm Sci, Troy, NY 12180 USA; [Cramer, Benjamin S.] Theiss Res, Eugene, OR USA; [Toggweiler, J. R.] NOAA, Geophys Fluid Dynam Lab, Princeton, NJ USA; [Esmay, Gar; Miller, Kenneth G.; Rosenthal, Yair; Wright, James D.] Rutgers State Univ, Dept Earth & Planetary Sci, Piscataway, NJ 08854 USA; [Liu, Chengjie] ExxonMobil Explorat, Houston, TX 77210 USA; [Rosenthal, Yair] Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA; [Wade, Bridget S.] Univ Leeds, Sch Earth & Environm, Leeds LS2 9JT, W Yorkshire, England	Rensselaer Polytechnic Institute; National Oceanic Atmospheric Admin (NOAA) - USA; Rutgers State University New Brunswick; Exxon Mobil Corporation; Rutgers State University New Brunswick; University of Leeds	Katz, ME (corresponding author), Rensselaer Polytech Inst, Dept Earth & Environm Sci, Troy, NY 12180 USA.	katzm@rpi.edu	Wright, James/AAF-7180-2019; Wade, Bridget S/F-4987-2014; Toggweiler, J. R./O-5883-2019	Wade, Bridget S/0000-0002-7245-8614; Toggweiler, J. R./0000-0001-6345-5756; Wright, James/0000-0001-5212-9146	NSF [OCE 06-23256, OCE 09-28607, EAR03-07112, EAR05-06720]; Joint Oceanographic Institutions, Inc.; NERC [NE/G014817/1] Funding Source: UKRI; Natural Environment Research Council [NE/G014817/1] Funding Source: researchfish	NSF(National Science Foundation (NSF)); Joint Oceanographic Institutions, Inc.; NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This research was supported by NSF grants OCE 06-23256 (M. E. K., K. G. M., B. S. W., and J.D.W.), OCE 09-28607 (B. S. C. and M. E. K.), EAR03-07112 (K. G. M.), and EAR05-06720 (K. G. M.). This research used samples provided by the ODP, which is sponsored by NSF and participating countries under management of the Joint Oceanographic Institutions, Inc. The authors declare that they have no competing financial interests.	Abelson M, 2008, EARTH PLANET SC LETT, V265, P33, DOI 10.1016/j.epsl.2007.09.021; Aubry MP, 2009, GEOL SOC AM SPEC PAP, V452, P279, DOI 10.1130/2009.2452(18); Barker PF, 2004, EARTH-SCI REV, V66, P143, DOI 10.1016/j.earscirev.2003.10.003; Bemis BE, 1998, PALEOCEANOGRAPHY, V13, P150, DOI 10.1029/98PA00070; COX MD, 1989, J PHYS OCEANOGR, V19, P1730, DOI 10.1175/1520-0485(1989)019<1730:AIMOTW>2.0.CO;2; Cramer BS, 2009, PALEOCEANOGRAPHY, V24, DOI 10.1029/2008PA001683; de Boer AM, 2008, J PHYS OCEANOGR, V38, P435, DOI 10.1175/2007JPO3731.1; DIESTERHAASS L, 2003, GREENHOUSE ICEHOUSE, P397; Exon N. F., 2004, PROC OCEAN DRILL SCI, V189, P1, DOI [DOI 10.2973/ODP.PROC.SR.189.101.2004, 10.2973/odp.proc.sr.189.101.2004]; Haug GH, 1998, NATURE, V393, P673, DOI 10.1038/31447; Katz ME, 2003, MICROPALEONTOLOGY, V49, P1, DOI 10.2113/49.Suppl_2.1; Katz ME, 2008, NAT GEOSCI, V1, P329, DOI 10.1038/ngeo179; Kim ST, 1997, GEOCHIM COSMOCHIM AC, V61, P3461, DOI 10.1016/S0016-7037(97)00169-5; Lear CH, 2008, GEOLOGY, V36, P251, DOI 10.1130/G24584A.1; Lear CH, 2006, GEOLOGY, V34, P985, DOI 10.1130/G22792A.1; Livermore R, 2007, GEOCHEM GEOPHY GEOSY, V8, DOI 10.1029/2005GC001224; Lyle M, 2007, GEOLOGY, V35, P691, DOI 10.1130/G23806A.1; Martin EE, 2000, GEOCHIM COSMOCHIM AC, V64, P835, DOI 10.1016/S0016-7037(99)00376-2; Miller KG, 2005, SCIENCE, V310, P1293, DOI 10.1126/science.1116412; MILLER KG, 1991, J GEOPHYS RES-SOLID, V96, P6829, DOI 10.1029/90JB02015; MILLER KG, 1985, CARBON CYCLE ATMOSPH, P469; Pfuhl HA, 2005, EARTH PLANET SC LETT, V235, P715, DOI 10.1016/j.epsl.2005.04.025; PINET PR, 1985, GEOL SOC AM BULL, V96, P618, DOI 10.1130/0016-7606(1985)96<618:ASOMOC>2.0.CO;2; Raitzsch M, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2007GC001788; Rea D.K., 1995, P ODP SCI RESULTS, V145, P577, DOI [10.2973/odp.proc.ir.145.1993, DOI 10.2973/ODP.PROC.IR.145.1993, 10.2973/odp.proc.sr.145.146.1995, DOI 10.2973/ODP.PROC.SR.145.146.1995]; Scher HD, 2006, SCIENCE, V312, P428, DOI 10.1126/science.1120044; Scher HD, 2004, EARTH PLANET SC LETT, V228, P391, DOI 10.1016/j.epsl.2004.10.016; Scher HD, 2008, PALEOCEANOGRAPHY, V23, DOI 10.1029/2006PA001400; Sijp WP, 2005, J CLIMATE, V18, P1957, DOI 10.1175/JCLI3376.1; Sijp WP, 2004, J PHYS OCEANOGR, V34, P1254, DOI 10.1175/1520-0485(2004)034<1254:EOTDPT>2.0.CO;2; Stickley CE, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2004PA001022; Talley LD, 1996, SOUTH ATLANTIC, P219; Toggweiler JR, 1998, J PHYS OCEANOGR, V28, P1832, DOI 10.1175/1520-0485(1998)028<1832:OTOSLS>2.0.CO;2; Toggweiler JR, 2000, J QUATERNARY SCI, V15, P319, DOI 10.1002/1099-1417(200005)15:4<319::AID-JQS545>3.0.CO;2-C; Via RK, 2006, GEOLOGY, V34, P441, DOI 10.1130/G22545.1; WOLD CN, 1994, PALEOCEANOGRAPHY, V9, P917, DOI 10.1029/94PA01438; Wright JD, 1996, PALEOCEANOGRAPHY, V11, P157, DOI 10.1029/95PA03696; WRIGHT JD, 1993, ANTARCTIC PALEOENVIR, V56, P1	38	100	107	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 27	2011	332	6033					1076	1079		10.1126/science.1202122	http://dx.doi.org/10.1126/science.1202122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769FN	21617074				2022-12-28	WOS:000290996700042
J	Nguitragool, W; Bokhari, AAB; Pillai, AD; Rayavara, K; Sharma, P; Turpin, B; Aravind, L; Desai, SA				Nguitragool, Wang; Bokhari, Abdullah A. B.; Pillai, Ajay D.; Rayavara, Kempaiah; Sharma, Paresh; Turpin, Brad; Aravind, L.; Desai, Sanjay A.			Malaria Parasite clag3 Genes Determine Channel-Mediated Nutrient Uptake by Infected Red Blood Cells	CELL			English	Article							SURFACE ANION CHANNEL; PLASMODIUM-FALCIPARUM; ERYTHROCYTE INVASION; MULTIGENE FAMILY; RHOPTRY PROTEIN; EXPRESSION; CYTOADHERENCE; PERMEABILITY; TRANSPORT; VIRULENCE	Development of malaria parasites within vertebrate erythrocytes requires nutrient uptake at the host cell membrane. The plasmodial surface anion channel (PSAC) mediates this transport and is an antimalarial target, but its molecular basis is unknown. We report a parasite gene family responsible for PSAC activity. We used high-throughput screening for nutrient uptake inhibitors to identify a compound highly specific for channels from the Dd2 line of the human pathogen P. falciparum. Inheritance of this compound's affinity in a Dd2xHB3 genetic cross maps to a single parasite locus on chromosome 3. DNA transfection and in vitro selections indicate that PSAC-inhibitor interactions are encoded by two clag3 genes previously assumed to function in cytoadherence. These genes are conserved in plasmodia, exhibit expression switching, and encode an integral protein on the host membrane, as predicted by functional studies. This protein increases host cell permeability to diverse solutes.	[Nguitragool, Wang; Bokhari, Abdullah A. B.; Pillai, Ajay D.; Rayavara, Kempaiah; Sharma, Paresh; Desai, Sanjay A.] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA; [Turpin, Brad] Natl Instruments Inc, Austin, TX 78730 USA; [Aravind, L.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Desai, SA (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.	sdesai@niaid.nih.gov		Aravind, L/0000-0003-0771-253X; Nguitragool, Wang/0000-0002-5484-7130; Desai, Sanjay/0000-0003-2150-2483	Medicines for Malaria Venture (MMV); National Institutes of Health, National Institute of Allergy and Infectious Diseases, and the National Library of Medicine; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000882] Funding Source: NIH RePORTER	Medicines for Malaria Venture (MMV); National Institutes of Health, National Institute of Allergy and Infectious Diseases, and the National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)NIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank John Adams, Alan Cowman, and Thomas Wellems for providing reagents; Mehreen Baakza, Kent Barbian, Yasmin El-Sayed, Juraj Kabat, Glenn Nardone, Son Nguyen, Norton Peet, Steve Porcella, Jose Riberio, Lattha Souvannaseng, Kurt Wollenberg, and Albert Youn for technical help; and the NIAID Scientific Director's office for providing required temporary laboratory space. We thank Edwin McCleskey and Thomas Wellems for critical reading of the manuscript. S. D. is a named inventor on a provisional patent application describing the PSAC antimalarial target identified in this article. B. T. is an employee and shareholder of National Instruments, Inc., which markets data analysis software used in this study. This research was supported by the Medicines for Malaria Venture (MMV) and the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases, and the National Library of Medicine.	Alkhalil A, 2004, BLOOD, V104, P4279, DOI 10.1182/blood-2004-05-2047; Alkhalil A, 2007, CELL MICROBIOL, V9, P851, DOI 10.1111/j.1462-5822.2006.00834.x; Anantharaman V, 2007, INT REV CYTOL, V262, P1, DOI 10.1016/S0074-7696(07)62001-4; Balu B, 2005, P NATL ACAD SCI USA, V102, P16391, DOI 10.1073/pnas.0504679102; Balu B, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-83; Baumeister S, 2006, MOL MICROBIOL, V60, P493, DOI 10.1111/j.1365-2958.2006.05112.x; Boddey JA, 2010, NATURE, V463, P627, DOI 10.1038/nature08728; Bokhari A, 2008, J MEMBRANE BIOL, V226, P27, DOI 10.1007/s00232-008-9136-2; Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Cohn JV, 2003, MOL BIOCHEM PARASIT, V132, P27, DOI 10.1016/j.molbiopara.2003.08.001; Cortes A, 2007, PLOS PATHOG, V3, P1023, DOI 10.1371/journal.ppat.0030107; CRAIG A, 2000, PARASITOL TODAY REGU, V16, P405; Craig AG, 2000, PARASITOL TODAY, V16, P366, DOI 10.1016/S0169-4758(00)01744-0; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; Decherf G, 2004, BLOOD CELL MOL DIS, V32, P366, DOI 10.1016/j.bcmd.2004.01.008; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; Duranton C, 2004, J GEN PHYSIOL, V123, P417, DOI 10.1085/jgp.200308919; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GINSBURG H, 1985, MOL BIOCHEM PARASIT, V14, P313, DOI 10.1016/0166-6851(85)90059-3; Ginsburg H, 1988, Prog Clin Biol Res, V252, P317; Goel S, 2010, P NATL ACAD SCI USA, V107, P16643, DOI 10.1073/pnas.1002568107; Hill DA, 2007, P NATL ACAD SCI USA, V104, P1063, DOI 10.1073/pnas.0610353104; Holt DC, 1999, INT J PARASITOL, V29, P939, DOI 10.1016/S0020-7519(99)00046-6; HOMEWOOD CA, 1974, NATURE, V252, P718, DOI 10.1038/252718a0; Howitt CA, 2009, MOL MICROBIOL, V73, P1171, DOI 10.1111/j.1365-2958.2009.06846.x; Iriko H, 2008, MOL BIOCHEM PARASIT, V158, P11, DOI 10.1016/j.molbiopara.2007.11.004; Kaneko O, 2005, MOL BIOCHEM PARASIT, V143, P20, DOI 10.1016/j.molbiopara.2005.05.003; Kaneko O, 2001, MOL BIOCHEM PARASIT, V118, P223, DOI 10.1016/S0166-6851(01)00391-7; Kaneko O, 2007, PARASITOL INT, V56, P255, DOI 10.1016/j.parint.2007.05.003; KILEJIAN A, 1991, MOL BIOCHEM PARASIT, V44, P175, DOI 10.1016/0166-6851(91)90003-O; KIRK K, 1994, J BIOL CHEM, V269, P3339; Lavazec C, 2007, MOL MICROBIOL, V64, P1621, DOI 10.1111/j.1365-2958.2007.05767.x; Ling IT, 2004, MOL MICROBIOL, V52, P107, DOI 10.1111/j.1365-2958.2003.03969.x; Lisk G, 2005, EUKARYOT CELL, V4, P2153, DOI 10.1128/EC.4.12.2153-2159.2005; Lisk G, 2008, ANTIMICROB AGENTS CH, V52, P2346, DOI 10.1128/AAC.00057-08; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Pillai AD, 2010, MOL PHARMACOL, V77, P724, DOI 10.1124/mol.109.062711; Richard D, 2010, J BIOL CHEM, V285, P14815, DOI 10.1074/jbc.M109.080770; Rungruang T, 2005, MOL BIOCHEM PARASIT, V140, P13, DOI 10.1016/j.molbiopara.2004.11.017; Russo I, 2010, NATURE, V463, P632, DOI 10.1038/nature08726; Saliba KJ, 1998, J BIOL CHEM, V273, P10190, DOI 10.1074/jbc.273.17.10190; Scherf A, 2008, ANNU REV MICROBIOL, V62, P445, DOI 10.1146/annurev.micro.61.080706.093134; SCHMIDT JA, 1982, J CLIN INVEST, V70, P379, DOI 10.1172/JCI110627; Spielmann T, 2010, TRENDS PARASITOL, V26, P6, DOI 10.1016/j.pt.2009.10.001; Staines HM, 2007, INT J PARASITOL, V37, P475, DOI 10.1016/j.ijpara.2006.12.013; Staines HM, 2000, BBA-BIOMEMBRANES, V1463, P88, DOI 10.1016/S0005-2736(99)00187-X; Trenholme KR, 2000, P NATL ACAD SCI USA, V97, P4029, DOI 10.1073/pnas.040561197; UPSTON JM, 1995, BBA-BIOMEMBRANES, V1236, P249, DOI 10.1016/0005-2736(95)00055-8; Verloo P, 2004, J BIOL CHEM, V279, P10316, DOI 10.1074/jbc.M311540200; Vincensini L, 2008, MOL BIOCHEM PARASIT, V160, P81, DOI 10.1016/j.molbiopara.2008.04.002; Wagner MA, 2003, BIOPHYS J, V84, P116, DOI 10.1016/S0006-3495(03)74836-X; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; WELLEMS TE, 1988, REV BRAS GENET, V11, P813	55	174	178	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 27	2011	145	5					665	677		10.1016/j.cell.2011.05.002	http://dx.doi.org/10.1016/j.cell.2011.05.002			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620134	Green Accepted, Bronze			2022-12-28	WOS:000291018600008
J	Smith, MR; Zietman, AL; Finkelstein, JS; Wu, CL				Smith, Matthew R.; Zietman, Anthony L.; Finkelstein, Joel S.; Wu, Chin-Lee			Case 16-2011: A 67-Year-Old Man with Recurrent Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANDROGEN-DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; PREVENT BONE LOSS; RADICAL PROSTATECTOMY; CARDIOVASCULAR-DISEASE; ADJUVANT RADIOTHERAPY; MEN; RISK; FRACTURE; ASSOCIATION		[Smith, Matthew R.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; [Finkelstein, Joel S.] Massachusetts Gen Hosp, Div Endocrinol, Boston, MA 02114 USA; [Zietman, Anthony L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Wu, Chin-Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Smith, Matthew R.; Finkelstein, Joel S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Zietman, Anthony L.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA; [Wu, Chin-Lee] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Smith, MR (corresponding author), Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA.		Finkelstein, Joel/M-6463-2019		Solvay Pharmaceuticals; AstraZeneca Pharmaceuticals	Solvay Pharmaceuticals(Solvay SA); AstraZeneca Pharmaceuticals(AstraZeneca)	Dr. Finkelstein reports receiving grant support from Solvay Pharmaceuticals and AstraZeneca Pharmaceuticals. Dr. Wu reports having patents pending, together with Massachusetts General Hospital, for testing related to the diagnosis of prostate cancer. No other potential conflict of interest relevant to this article was reported.	Alibhai SMH, 2009, J CLIN ONCOL, V27, P3452, DOI 10.1200/JCO.2008.20.0923; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Bolla M, 2005, LANCET, V366, P572, DOI 10.1016/S0140-6736(05)67101-2; Epstein JI, 2005, SCAND J UROL NEPHROL, V39, P34, DOI 10.1080/03008880510030932; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125; Greenspan SL, 2005, J CLIN ENDOCR METAB, V90, P6410, DOI 10.1210/jc.2005-0183; Greenspan SL, 2007, ANN INTERN MED, V146, P416, DOI 10.7326/0003-4819-146-6-200703200-00006; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; Keating NL, 2006, J CLIN ONCOL, V24, P4448, DOI 10.1200/JCO.2006.06.2497; Lage MJ, 2007, UROLOGY, V70, P1104, DOI 10.1016/j.urology.2007.08.012; Levine GN, 2010, CIRCULATION, V121, P833, DOI 10.1161/CIRCULATIONAHA.109.192695; Messing EM, 1999, NEW ENGL J MED, V341, P1781, DOI 10.1056/NEJM199912093412401; Mittan D, 2002, J CLIN ENDOCR METAB, V87, P3656, DOI 10.1210/jc.87.8.3656; Nair B, 2002, COCHRANE DB SYST REV, V1; Pilepich MV, 1997, J CLIN ONCOL, V15, P1013, DOI 10.1200/JCO.1997.15.3.1013; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Saylor PJ, 2009, J UROLOGY, V181, P1998, DOI 10.1016/j.juro.2009.01.047; Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943; Sharifi N, 2005, JAMA-J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238; Smith MR, 2011, J UROLOGY, V185, P365; Smith MR, 2010, J UROLOGY, V184, P1316, DOI 10.1016/j.juro.2010.06.022; Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003; Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908; Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95; Smith MR, 2004, J CLIN ENDOCR METAB, V89, P3841, DOI 10.1210/jc.2003-032058; Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845; Thompson IM, 2009, J UROLOGY, V181, P956, DOI 10.1016/j.juro.2008.11.032; Wiegel T, 2009, J CLIN ONCOL, V27, P2924, DOI 10.1200/JCO.2008.18.9563	29	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					2044	2051		10.1056/NEJMcpc1011323	http://dx.doi.org/10.1056/NEJMcpc1011323			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768QR	21612474				2022-12-28	WOS:000290952000011
J	Cooley, RB; Rhoads, TW; Arp, DJ; Karplus, PA				Cooley, Richard B.; Rhoads, Timothy W.; Arp, Daniel J.; Karplus, P. Andrew			A Diiron Protein Autogenerates a Valine-Phenylalanine Cross-Link	SCIENCE			English	Article							MONOOXYGENASE; ACTIVATION; METHANE		[Arp, Daniel J.] Oregon State Univ, Dept Bot & Plant Pathol, Corvallis, OR 97331 USA; [Cooley, Richard B.; Rhoads, Timothy W.; Karplus, P. Andrew] Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Arp, DJ (corresponding author), Oregon State Univ, Dept Bot & Plant Pathol, 2082 Cordley Hall, Corvallis, OR 97331 USA.	Dan.J.Arp@oregonstate.edu; karplusp@science.oregonstate.edu	Rhoads, Tim/AAI-2483-2020	Rhoads, Tim/0000-0001-7364-1122; Cooley, Richard/0000-0003-3928-2757; Karplus, Paul/0000-0001-8725-6292	NIH [GM R01-083136]; Oregon Agricultural Experiment Station; National Institute of Environmental Health Sciences Environmental Health Sciences Center [ES00210]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083136] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Oregon Agricultural Experiment Station; National Institute of Environmental Health Sciences Environmental Health Sciences Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by NIH grant GM R01-083136 (P.A.K.), the Oregon Agricultural Experiment Station (D.J.A.), and National Institute of Environmental Health Sciences Environmental Health Sciences Center grant ES00210. We thank J. M. Bollinger and C. Krebs for discussions. Coordinates and structure factors are deposited as Protein Data Bank entry 3QHB.	Andersson CS, 2009, P NATL ACAD SCI USA, V106, P5633, DOI 10.1073/pnas.0812971106; Bergman RG, 2007, NATURE, V446, P391, DOI 10.1038/446391a; Cooley RB, 2010, J MOL BIOL, V404, P232, DOI 10.1016/j.jmb.2010.09.034; Kopp DA, 2002, CURR OPIN CHEM BIOL, V6, P568, DOI 10.1016/S1367-5931(02)00366-6; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; Xie LL, 2001, P NATL ACAD SCI USA, V98, P12863, DOI 10.1073/pnas.231485998	6	9	10	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2011	332	6032					929	929		10.1126/science.1205687	http://dx.doi.org/10.1126/science.1205687			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596985	Green Accepted			2022-12-28	WOS:000290766600033
J	Zhang, ZH; Wippo, CJ; Wal, M; Ward, E; Korber, P; Pugh, BF				Zhang, Zhenhai; Wippo, Christian J.; Wal, Megha; Ward, Elissa; Korber, Philipp; Pugh, B. Franklin			A Packing Mechanism for Nucleosome Organization Reconstituted Across a Eukaryotic Genome	SCIENCE			English	Article							POSITIONS IN-VIVO; SACCHAROMYCES-CEREVISIAE; REMODELING FACTOR; DNA-SEQUENCE; PROMOTER; YEAST; TRANSCRIPTION; POLY(DA-DT); VITRO; ISWI	Near the 5' end of most eukaryotic genes, nucleosomes form highly regular arrays that begin at canonical distances from the transcriptional start site. Determinants of this and other aspects of genomic nucleosome organization have been ascribed to statistical positioning, intrinsically DNA-encoded positioning, or some aspect of transcription initiation. Here, we provide evidence for a different explanation. Biochemical reconstitution of proper nucleosome positioning, spacing, and occupancy levels was achieved across the 5' ends of most yeast genes by adenosine triphosphate-dependent trans-acting factors. These transcription-independent activities override DNA-intrinsic positioning and maintain uniform spacing at the 5' ends of genes even at low nucleosome densities. Thus, an active, nonstatistical nucleosome packing mechanism creates chromatin organizing centers at the 5' ends of genes where important regulatory elements reside.	[Wippo, Christian J.; Korber, Philipp] Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; [Zhang, Zhenhai; Wal, Megha; Ward, Elissa; Pugh, B. Franklin] Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, University Pk, PA 16802 USA	University of Munich; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Korber, P (corresponding author), Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany.	pkorber@lmu.de; bfp2@psu.edu	Korber, Philipp/AAN-7633-2021; Zhang, Zhenhai/GRX-5887-2022; Wal, Megha/J-3607-2019	Korber, Philipp/0000-0001-7526-6549; Zhang, Zhenhai/0000-0002-4310-0525; 	National Institutes of Health [HG004160]; German Research Community [SFB/TR5]; European Community; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004160] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Community(German Research Foundation (DFG)); European Community(European Commission); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank the members of the Penn State Center for Eukaryotic Gene Regulation and of the Molecular Biology Unit of the Adolf-Butenandt-Institut for valuable discussion and support. We are grateful to D. Blaschke for technical assistance and to S. Holmberg for the gift of the S. cerevisiae library. This work was supported by grant HG004160 from the National Institutes of Health to B.F.P.; and by the German Research Community (SFB/TR5) and the Epigenome Network of Excellence in the Sixth Framework Programme of the European Community (NET grant), both to P.K. Sequencing data are available at ArrayExpress under accession number: SRA030538.1.	Albert I, 2007, NATURE, V446, P572, DOI 10.1038/nature05632; Anderson JD, 2001, MOL CELL BIOL, V21, P3830, DOI 10.1128/MCB.21.11.3830-3839.2001; Dion MF, 2007, SCIENCE, V315, P1405, DOI 10.1126/science.1134053; Flaus A, 2003, MOL CELL BIOL, V23, P7767, DOI 10.1128/MCB.23.21.7767-7779.2003; Hartley PD, 2009, CELL, V137, P445, DOI 10.1016/j.cell.2009.02.043; Hughes Amanda, 2009, J Biol, V8, P96, DOI 10.1186/jbiol207; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Kaplan N, 2009, NATURE, V458, P362, DOI 10.1038/nature07667; Korber P, 2004, J BIOL CHEM, V279, P35113, DOI 10.1074/jbc.M405446200; KORNBERG RD, 1988, NUCLEIC ACIDS RES, V16, P6677, DOI 10.1093/nar/16.14.6677; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Luger K, 1999, METHOD ENZYMOL, V304, P3; Mavrich TN, 2008, GENOME RES, V18, P1073, DOI 10.1101/gr.078261.108; Mobius W, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000891; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Rufiange A, 2007, MOL CELL, V27, P393, DOI 10.1016/j.molcel.2007.07.011; Schnitzler GR, 2008, CELL BIOCHEM BIOPHYS, V51, P67, DOI 10.1007/s12013-008-9015-6; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Segal E, 2009, TRENDS GENET, V25, P335, DOI 10.1016/j.tig.2009.06.002; Stein A, 2010, NUCLEIC ACIDS RES, V38, P709, DOI 10.1093/nar/gkp1043; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Vaillant C, 2010, GENOME RES, V20, P59, DOI 10.1101/gr.096644.109; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Weiner A, 2010, GENOME RES, V20, P90, DOI 10.1101/gr.098509.109; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178; Zhang Y, 2009, NAT STRUCT MOL BIOL, V16, P847, DOI 10.1038/nsmb.1636	27	230	231	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 20	2011	332	6032					977	980		10.1126/science.1200508	http://dx.doi.org/10.1126/science.1200508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766FO	21596991	Green Accepted			2022-12-28	WOS:000290766600047
J	Marcocci, C; Kahaly, GJ; Krassas, GE; Bartalena, L; Prummel, M; Stahl, M; Altea, MA; Nardi, M; Pitz, S; Boboridis, K; Sivelli, P; von Arx, G; Mourits, MP; Baldeschi, L; Bencivelli, W; Wiersinga, W				Marcocci, Claudio; Kahaly, George J.; Krassas, Gerasimos E.; Bartalena, Luigi; Prummel, Mark; Stahl, Matthias; Altea, Maria Antonietta; Nardi, Marco; Pitz, Susanne; Boboridis, Kostas; Sivelli, Paolo; von Arx, George; Mourits, Maarten P.; Baldeschi, Lelio; Bencivelli, Walter; Wiersinga, Wilmar		European Grp Graves Orbitopathy	Selenium and the Course of Mild Graves' Orbitopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THYROID-ASSOCIATED OPHTHALMOPATHY; QUALITY-OF-LIFE; GLYCOSAMINOGLYCAN SYNTHESIS; OXIDATIVE STRESS; HUMAN HEALTH; GO-QOL; PENTOXIFYLLINE; DISEASE; FIBROBLASTS; EXPRESSION	Background Oxygen free radicals and cytokines play a pathogenic role in Graves' orbitopathy. Methods We carried out a randomized, double-blind, placebo-controlled trial to determine the effect of selenium (an antioxidant agent) or pentoxifylline (an antiinflammatory agent) in 159 patients with mild Graves' orbitopathy. The patients were given selenium (100 mu g twice daily), pentoxifylline (600 mg twice daily), or placebo (twice daily) orally for 6 months and were then followed for 6 months after treatment was withdrawn. Primary outcomes at 6 months were evaluated by means of an overall ophthalmic assessment, conducted by an ophthalmologist who was unaware of the treatment assignments, and a Graves' orbitopathy-specific quality-of-life questionnaire, completed by the patient. Secondary outcomes were evaluated with the use of a Clinical Activity Score and a diplopia score. Results At the 6-month evaluation, treatment with selenium, but not with pentoxifylline, was associated with an improved quality of life (P<0.001) and less eye involvement (P = 0.01) and slowed the progression of Graves' orbitopathy (P = 0.01), as compared with placebo. The Clinical Activity Score decreased in all groups, but the change was significantly greater in the selenium-treated patients. Exploratory evaluations at 12 months confirmed the results seen at 6 months. Two patients assigned to placebo and one assigned to pentoxifylline required immunosuppressive therapy for deterioration in their condition. No adverse events were evident with selenium, whereas pentoxifylline was associated with frequent gastrointestinal problems. Conclusions Selenium administration significantly improved quality of life, reduced ocular involvement, and slowed progression of the disease in patients with mild Graves' orbitopathy. (Funded by the University of Pisa and the Italian Ministry for Education, University and Research; EUGOGO Netherlands Trial Register number, NTR524.)	[Marcocci, Claudio; Altea, Maria Antonietta] Univ Pisa, Dept Endocrinol & Metab, I-56100 Pisa, Italy; [Nardi, Marco] Univ Pisa, Dept Neurosci, Sect Ophthalmol, I-56100 Pisa, Italy; [Bencivelli, Walter] Univ Pisa, Dept Internal Med, I-56100 Pisa, Italy; [Bartalena, Luigi] Univ Insubria, Dept Clin Med, Varese, Italy; [Sivelli, Paolo] Univ Insubria, Dept Ophthalmol, Varese, Italy; [Kahaly, George J.] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Med, Mainz, Germany; [Pitz, Susanne] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Ophthalmol, Mainz, Germany; [Krassas, Gerasimos E.] Panagia Gen Hosp, Dept Endocrinol, Thessaloniki, Greece; [Boboridis, Kostas] Ahepa Hosp, Univ Dept Ophthalmol, Thessaloniki, Greece; [Prummel, Mark; Wiersinga, Wilmar] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol, NL-1105 AZ Amsterdam, Netherlands; [Mourits, Maarten P.; Baldeschi, Lelio] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands; [Stahl, Matthias] Kantonsspital Olten, Dept Endocrinol & Metab, Olten, Switzerland; [von Arx, George] Interdisziplinares Zentrum Endokrine Orbitopathie, Olten, Switzerland	University of Pisa; University of Pisa; University of Pisa; University of Insubria; University of Insubria; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Aristotle University of Thessaloniki; Ahepa University Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Kantonsspital Olten	Marcocci, C (corresponding author), Univ Pisa, Dept Endocrinol & Metab, Via Paradisa 2, I-56100 Pisa, Italy.	claudio.marcocci@med.unipi.it	BOBORIDIS, KONSTADINOS/A-1853-2011; bencivelli, walter/H-1898-2012; KRASSAS, GERASIMOS/AAJ-3263-2020	BOBORIDIS, KONSTADINOS/0000-0002-0471-0371; nardi, marco/0000-0003-3422-9498	University of Pisa; Italian Ministry for Education, University and Research [PRIN 20074X8RKK]	University of Pisa; Italian Ministry for Education, University and Research(Ministry of Education, Universities and Research (MIUR))	Supported by grants from the University of Pisa (Fondi d'Ateneo per la Ricerca, to Dr. Marcocci) and the Italian Ministry for Education, University and Research (PRIN 20074X8RKK, to Dr. Bartalena).	Abalovich M, 2003, CLIN ENDOCRINOL, V59, P321, DOI 10.1046/j.1365-2265.2003.01850.x; Ademoglu E, 2006, EUR J INTERN MED, V17, P545, DOI 10.1016/j.ejim.2006.04.013; ANAYA JM, 1995, J RHEUMATOL, V22, P595; Bahn RS, 2010, NEW ENGL J MED, V362, P726, DOI 10.1056/NEJMra0905750; BAHN RS, 1987, ENDOCRIN METAB CLIN, V16, P391, DOI 10.1016/S0889-8529(18)30485-7; Balazs C, 1998, HORM METAB RES, V30, P496, DOI 10.1055/s-2007-978919; Balazs C, 1997, J CLIN ENDOCR METAB, V82, P1999, DOI 10.1210/jcem.82.6.9995; Bartalena L, 2000, ENDOCR REV, V21, P168, DOI 10.1210/er.21.2.168; Bartalena L, 2008, EUR J ENDOCRINOL, V158, P273, DOI 10.1530/EJE-07-0666; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bouzas EA, 2000, AM J OPHTHALMOL, V129, P618, DOI 10.1016/S0002-9394(00)00359-7; Burch HB, 1997, EXP EYE RES, V65, P311, DOI 10.1006/exer.1997.0353; Burney P, 2008, ALLERGY, V63, P865, DOI 10.1111/j.1398-9995.2008.01716.x; CHANG CC, 1993, ACTA ENDOCRINOL-COP, V129, P322, DOI 10.1530/acta.0.1290322; Dehina NE, 2009, ACTA MEDICA PORT, V22, P1; DEZUBE BJ, 1993, CANCER IMMUNOL IMMUN, V36, P57, DOI 10.1007/BF01789132; Dickinson AJ, 2001, CLIN ENDOCRINOL, V55, P283, DOI 10.1046/j.1365-2265.2001.01349.x; Gerding MN, 1997, THYROID, V7, P885, DOI 10.1089/thy.1997.7.885; Girolami B, 1999, ARCH INTERN MED, V159, P337, DOI 10.1001/archinte.159.4.337; HEUFELDER AE, 1992, J CLIN ENDOCR METAB, V74, P737, DOI 10.1210/jc.74.4.737; Hoffmann PR, 2008, MOL NUTR FOOD RES, V52, P1273, DOI 10.1002/mnfr.200700330; KRASSAS G, 2010, 12 EUR C END PRAG CZ; Lu R, 1999, THYROID, V9, P297, DOI 10.1089/thy.1999.9.297; Mourits MP, 1997, CLIN ENDOCRINOL, V47, P9, DOI 10.1046/j.1365-2265.1997.2331047.x; Nacamulli D, 2010, CLIN ENDOCRINOL, V73, P535, DOI 10.1111/j.1365-2265.2009.03758.x; Negro Roberto, 2008, Biologics, V2, P265; Okunieff P, 2004, J CLIN ONCOL, V22, P2207, DOI 10.1200/JCO.2004.09.101; PERROS P, 1995, CLIN ENDOCRINOL, V42, P45, DOI 10.1111/j.1365-2265.1995.tb02597.x; Prabhakar BS, 2003, ENDOCR REV, V24, P802, DOI 10.1210/er.2002-0020; Rayman MP, 2008, BRIT J NUTR, V100, P254, DOI 10.1017/S0007114508939830; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Terwee CB, 2001, CLIN ENDOCRINOL, V54, P391, DOI 10.1046/j.1365-2265.2001.01241.x; Terwee CB, 1998, BRIT J OPHTHALMOL, V82, P773, DOI 10.1136/bjo.82.7.773; Vrca VB, 2004, CLIN CHIM ACTA, V341, P55, DOI 10.1016/j.cccn.2003.10.028; Wertenbruch T, 2007, MED CHEM, V3, P281, DOI 10.2174/157340607780620662	35	324	351	1	61	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					1920	1931		10.1056/NEJMoa1012985	http://dx.doi.org/10.1056/NEJMoa1012985			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765PJ	21591944				2022-12-28	WOS:000290720700007
J	Petersen, CP; Reddien, PW				Petersen, Christian P.; Reddien, Peter W.			Polarized notum Activation at Wounds Inhibits Wnt Function to Promote Planarian Head Regeneration	SCIENCE			English	Article							WINGLESS MORPHOGEN GRADIENT; REQUIREMENT; SHAPE	Regeneration requires initiation of programs tailored to the identity of missing parts. Head-versus-tail regeneration in planarians presents a paradigm for study of this phenomenon. After injury, Wnt signaling promotes tail regeneration. We report that wounding elicits expression of the Wnt inhibitor notum preferentially at anterior-facing wounds. This expression asymmetry occurs at essentially any wound, even if the anterior pole is intact. Inhibition of notum with RNA interference (RNAi) causes regeneration of an anterior-facing tail instead of a head, and double-RNAi experiments indicate that notum inhibits Wnt signaling to promote head regeneration. notum expression is itself controlled by Wnt signaling, suggesting that regulation of feedback inhibition controls the binary head-tail regeneration outcome. We conclude that local detection of wound orientation with respect to tissue axes results in distinct signaling environments that initiate appropriate regeneration responses.	[Petersen, Christian P.; Reddien, Peter W.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Reddien, Peter W.] MIT, Dept Biol, Cambridge, MA 02138 USA; [Reddien, Peter W.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute	Reddien, PW (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	reddien@wi.mit.edu	Petersen, Christian P./GZG-4541-2022	Petersen, Christian P./0000-0001-7552-6865; /0000-0002-5569-333X	NIH [R01GM080639]; ACS [RSG-07-180-01-DDC]; Keck Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080639] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS(American Cancer Society); Keck Foundation(W.M. Keck Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Reddien Lab for discussions and S. Lapan for hedgehog constructs. P. W. R. is a Howard Hughes Medical Institute early career scientist. We acknowledge support by NIH R01GM080639, ACS RSG-07-180-01-DDC, the Keck Foundation, and an American Cancer Society postdoctoral fellowship to C. P. P. C. P. P. and P. W. R. are inventors on a pending patent on the use of Notum inhibitors to enhance regeneration.	Adell T, 2009, DEVELOPMENT, V136, P905, DOI 10.1242/dev.033761; Brandman O, 2008, SCIENCE, V322, P390, DOI 10.1126/science.1160617; Gerlitz O, 2002, GENE DEV, V16, P1055, DOI 10.1101/gad.991802; Giraldez AJ, 2002, DEV CELL, V2, P667, DOI 10.1016/S1534-5807(02)00180-6; Goessling W, 2008, DEV BIOL, V320, P161, DOI 10.1016/j.ydbio.2008.05.526; Gurley KA, 2008, SCIENCE, V319, P323, DOI 10.1126/science.1150029; Gurley KA, 2010, DEV BIOL, V347, P24, DOI 10.1016/j.ydbio.2010.08.007; Han C, 2005, DEVELOPMENT, V132, P667, DOI 10.1242/dev.01636; Iglesias M, 2008, DEVELOPMENT, V135, P1215, DOI 10.1242/dev.020289; Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802; Kreuger J, 2004, DEV CELL, V7, P503, DOI 10.1016/j.devcel.2004.08.005; Lin G, 2008, DEV BIOL, V316, P323, DOI 10.1016/j.ydbio.2008.01.032; Morgan TH, 1898, ARCH ENTW MECH ORG, V7, P364; Parker DS, 2008, MOL CELL BIOL, V28, P1815, DOI 10.1128/MCB.01230-07; Petersen CP, 2008, SCIENCE, V319, P327, DOI 10.1126/science.1149943; Petersen CP, 2009, CELL, V139, P1056, DOI 10.1016/j.cell.2009.11.035; Petersen CP, 2009, P NATL ACAD SCI USA, V106, P17061, DOI 10.1073/pnas.0906823106; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P725, DOI 10.1146/annurev.cellbio.20.010403.095114; Rink JC, 2009, SCIENCE, V326, P1406, DOI 10.1126/science.1178712; Stoick-Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123; Torisu Y, 2008, CANCER SCI, V99, P1139, DOI 10.1111/j.1349-7006.2008.00814.x; TRAISTER A, 2007, BIOCHEM J; Yan D, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002493; Yazawa S, 2009, P NATL ACAD SCI USA, V106, P22329, DOI 10.1073/pnas.0907464106; Yokoyama H, 2007, DEV BIOL, V306, P170, DOI 10.1016/j.ydbio.2007.03.014	25	152	163	4	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					852	855		10.1126/science.1202143	http://dx.doi.org/10.1126/science.1202143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566195	Green Accepted, Green Submitted			2022-12-28	WOS:000290529900049
J	Bloom, BR				Bloom, Barry R.			WHO needs change	NATURE			English	Editorial Material									Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Bloom, BR (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	barry_bloom@harvard.edu						Chin CS, 2011, NEW ENGL J MED, V364, P33, DOI 10.1056/NEJMoa1012928; Chow JC., 2010, FOREIGN POLICY  1208; Daar AS, 2007, NATURE, V450, P494, DOI 10.1038/450494a; Institute for Health Metrics and Evaluation, 2010, FIN GLOB HLTH 2010; McNeil Jr D.G., 2010, NY TIMES        1121; Sridhar D, 2011, JAMA-J AM MED ASSOC, V305, P1585, DOI 10.1001/jama.2011.418; WHO, 2010, FUT FIN WHO	7	18	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 12	2011	473	7346					143	145		10.1038/473143a	http://dx.doi.org/10.1038/473143a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	762NT	21562538	Bronze			2022-12-28	WOS:000290487200013
J	Burns, R; Trivedi, NS				Burns, Risa; Trivedi, Neha S.			Update: A 66-Year-Old Man With an Abdominal Aortic Aneurysm	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Trivedi, Neha/0000-0003-1006-1408				Schermerhorn M, 2009, JAMA-J AM MED ASSOC, V302, P2015, DOI 10.1001/jama.2009.1502	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2011	305	18					1899	1899		10.1001/jama.2011.616	http://dx.doi.org/10.1001/jama.2011.616			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761YH	21558520				2022-12-28	WOS:000290438800027
J	Hodgins, DC; Stea, JN; Grant, JE				Hodgins, David C.; Stea, Jonathan N.; Grant, Jon E.			Gambling disorders	LANCET			English	Article							PLACEBO-CONTROLLED TRIAL; PATHOLOGICAL GAMBLERS; DOUBLE-BLIND; TREATMENT-SEEKING; RANDOMIZED-TRIAL; SELF-HELP; MOTIVATIONAL ENHANCEMENT; CLASSIFICATION ACCURACY; CHILDHOOD MALTREATMENT; ALCOHOL DEPENDENCE	Gambling disorders, including pathological gambling and problem gambling, have received increased attention from clinicians and researchers over the past three decades since gambling opportunities have expanded around the world. This Seminar reviews prevalence, causes and associated features, screening and diagnosis, and treatment approaches. Gambling disorders affect 0.2-5.3% of adults worldwide, although measurement and prevalence varies according to the screening instruments and methods used, and availability and accessibility of gambling opportunities. Several distinct treatment approaches have been favourably evaluated, such as cognitive behavioural and brief treatment models and pharmacological interventions. Although promising, family therapy and support from Gamblers Anonymous are less well empirically supported. Gambling disorders are highly comorbid with other mental health and substance use disorders, and a further understanding is needed of both the causes and treatment implications of this disorder.	[Hodgins, David C.; Stea, Jonathan N.] Univ Calgary, Dept Psychol, Calgary, AB T2N 1N4, Canada; [Grant, Jon E.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA	University of Calgary; University of Minnesota System; University of Minnesota Twin Cities	Hodgins, DC (corresponding author), Univ Calgary, Dept Psychol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	dhodgins@ucalgary.ca		Hodgins, David/0000-0003-2737-5200	Alberta Gaming Research Institute; Ontario Problem Gambling Research Institute; New Zealand Ministry of Health; Nova Scotia Research Foundation; Canadian Institutes of Health Research; US National Institute of Mental Health; US National Institute on Drug Abuse; US National Center for Responsible Gaming; Institute for Research on Gambling Disorders; Forest Pharmaceuticals; NATIONAL INSTITUTE ON DRUG ABUSE [RC1DA028279] Funding Source: NIH RePORTER	Alberta Gaming Research Institute; Ontario Problem Gambling Research Institute; New Zealand Ministry of Health; Nova Scotia Research Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); US National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); US National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); US National Center for Responsible Gaming; Institute for Research on Gambling Disorders; Forest Pharmaceuticals; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	DCH receives competitive research funding from the Alberta Gaming Research Institute, the Ontario Problem Gambling Research Institute, the New Zealand Ministry of Health, and the Nova Scotia Research Foundation. He has also received honoraria and travel funds to speak at conferences. JNS receives studentship assistance from the Canadian Institutes of Health Research and the Alberta Gaming Research Institute. JEG receives research grants from the US National Institute of Mental Health, the US National Institute on Drug Abuse, the US National Center for Responsible Gaming and its affiliated Institute for Research on Gambling Disorders, and Forest Pharmaceuticals. He receives yearly compensation from Springer Publishing for acting as Editor-in-Chief of the Journal of Gambling Studies and receives royalties from Oxford University Press, American Psychiatric Publishing, Norton Press, and McGraw Hill.	Abbott MW, 2004, SUBST USE MISUSE, V39, P855, DOI 10.1081/JA-120030891; Abbott MW, 2007, RES MEASUREMENT ISSU, P251; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 2010, DSM 5 DEV PATH GAMBL; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 1999, PATH GAMBL CRIT REV; [Anonymous], 2010, GAMBL AN INT DIR; Bernstein Peter L., 1996, GODS REMARKABLE STOR; Black DW, 2007, J CLIN PSYCHOPHARM, V27, P143, DOI 10.1097/01.jcp.0000264985.25109.25; Black DW, 2006, PSYCHIAT RES, V141, P295, DOI 10.1016/j.psychres.2005.12.005; Blaszczynski A, 2002, ADDICTION, V97, P487, DOI 10.1046/j.1360-0443.2002.00015.x; Brand M, 2005, PSYCHIAT RES, V133, P91, DOI 10.1016/j.psychres.2004.10.003; Carlbring Per, 2010, Cognitive Behaviour Therapy, V39, P92, DOI 10.1080/16506070903190245; Carlbring P, 2008, J CONSULT CLIN PSYCH, V76, P1090, DOI 10.1037/a0013603; Chamberlain SR, 2007, CURR OPIN PSYCHIATR, V20, P255, DOI 10.1097/yco.0b013e3280ba4989; Comings DE, 2001, CLIN GENET, V60, P107, DOI 10.1034/j.1399-0004.2001.600204.x; Cunningham JA, 2005, PSYCHIAT SERV, V56, P1024, DOI 10.1176/appi.ps.56.8.1024-a; Cunningham JA, 2009, SUCHT, V55, P99; Cunningham JA, 2008, PSYCHIAT SERV, V59, P695, DOI 10.1176/appi.ps.59.6.695-a; Dannon PN, 2007, J CLIN PSYCHOPHARM, V27, P620, DOI 10.1097/jcp.0b013e31815a4400; de Ruiter MB, 2009, NEUROPSYCHOPHARMACOL, V34, P1027, DOI 10.1038/npp.2008.175; Diskin KM, 2009, BEHAV RES THER, V47, P382, DOI 10.1016/j.brat.2009.01.018; Eisen SA, 1998, ADDICTION, V93, P1375; Ferris J., 2001, CANADIAN PROBLEM GAM, DOI DOI 10.1007/S10899-010-9224-Y; Fong T, 2008, PHARMACOL BIOCHEM BE, V89, P298, DOI 10.1016/j.pbb.2007.12.025; Fuentes D, 2006, J INT NEUROPSYCH SOC, V12, P907, DOI 10.1017/S1355617706061091; Gebauer L, 2010, CAN J PSYCHIAT, V55, P82, DOI 10.1177/070674371005500204; Gerstein D., 1999, GAMBLING IMPACT BEHA; Gooding P, 2009, BEHAV RES THER, V47, P592, DOI 10.1016/j.brat.2009.04.002; Goudriaan AE, 2006, ADDICTION, V101, P534, DOI 10.1111/j.1360-0443.2006.01380.x; Grant JE, 2006, AM J PSYCHIAT, V163, P303, DOI 10.1176/appi.ajp.163.2.303; Grant JE, 2008, PSYCHOPHARMACOLOGY, V200, P521, DOI 10.1007/s00213-008-1235-3; Grant JE, 2008, J CLIN PSYCHIAT, V69, P783, DOI 10.4088/JCP.v69n0511; Grant JE, 2007, BIOL PSYCHIAT, V62, P652, DOI 10.1016/j.biopsych.2006.11.021; Grant JE, 2010, BRIT J PSYCHIAT, V197, P330, DOI 10.1192/bjp.bp.110.078105; Grant JE, 2009, BRIT J PSYCHIAT, V195, P266, DOI 10.1192/bjp.bp.108.062414; Gupta R, 2009, PROBLEM GAMBLING ADO; Hodgins D, 2007, RES MEASUREMENT ISSU, P372; Hodgins D. C., 1999, J GAMBL STUD, V15, P93, DOI DOI 10.1023/A:1022237807310; Hodgins DC, 2007, J GAMBL STUD, V23, P41, DOI 10.1007/s10899-006-9045-1; Hodgins DC, 2005, J GAMBL STUD, V21, P255, DOI 10.1007/s10899-005-3099-3; Hodgins DC, 2010, PSYCHOL ADDICT BEHAV, V24, P548, DOI 10.1037/a0019946; Hodgins DC, 2009, J CONSULT CLIN PSYCH, V77, P950, DOI 10.1037/a0016318; Hodgins DC, 2000, ADDICTION, V95, P777, DOI 10.1046/j.1360-0443.2000.95577713.x; Hodgins DC, 2004, ADDICT BEHAV, V29, P1685, DOI 10.1016/j.addbeh.2004.03.017; Hodgins DC, 2004, PSYCHOL ADDICT BEHAV, V18, P293, DOI 10.1037/0893-164X.18.3.293; Hodgins DC, 2001, J CONSULT CLIN PSYCH, V69, P50, DOI 10.1037//0022-006X.69.1.50; Hodgins DC, 2008, GUIDE ASSESSMENTS WO, P370; Hollander E, 1998, AM J PSYCHIAT, V155, P1781, DOI 10.1176/ajp.155.12.1781; Kalechstein AD, 2007, J NEUROPSYCH CLIN N, V19, P298, DOI 10.1176/appi.neuropsych.19.3.298; Kalivas PW, 2006, MOL INTERV, V6, P339, DOI 10.1124/mi.6.6.7; Kessler RC, 2008, PSYCHOL MED, V38, P1351, DOI 10.1017/S0033291708002900; Kim SW, 2009, PSYCHIAT RES, V166, P76, DOI 10.1016/j.psychres.2007.11.008; Kim SW, 2001, BIOL PSYCHIAT, V49, P914, DOI 10.1016/S0006-3223(01)01079-4; Ladouceur R, 2009, BEHAV RES THER, V47, P189, DOI 10.1016/j.brat.2008.11.004; LaPlante DA, 2008, CAN J PSYCHIAT, V53, P52, DOI 10.1177/070674370805300108; Lawrence AJ, 2009, PSYCHOPHARMACOLOGY, V207, P163, DOI 10.1007/s00213-009-1645-x; Lawrence AJ, 2009, ADDICTION, V104, P1006, DOI 10.1111/j.1360-0443.2009.02533.x; Lee B.K., 2008, INT GAMBL STUD, V8, P113, DOI [DOI 10.1080/14459790701878137, 10.1080/14459790701878137]; Lesieur H R, 1991, J Gambl Stud, V7, P5, DOI 10.1007/BF01019763; LESIEUR HR, 1987, AM J PSYCHIAT, V144, P1184; Lesieur HR., 1993, J GAMBL STUD, V9, P213, DOI [DOI 10.1007/BF01015919, 10.1007/BF01015919]; Lobo DSS, 2010, BIOL PSYCHOL, V85, P33, DOI 10.1016/j.biopsycho.2010.04.008; Lobo DSS, 2009, ADDICTION, V104, P1454, DOI 10.1111/j.1360-0443.2009.02671.x; Makarchuk K., 2002, ADDICTIVE DISORDERS, V1, P126, DOI DOI 10.1097/00132576-200211000-00003; McElroy SL, 2008, J CLIN PSYCHIAT, V69, P433, DOI 10.4088/JCP.v69n0314; Oei TPS, 2004, PSYCHOL MED, V34, P1279, DOI 10.1017/S0033291704003150; Pallesen S, 2005, ADDICTION, V100, P1412, DOI 10.1111/j.1360-0443.2005.01204.x; Pallesen S, 2007, J CLIN PSYCHOPHARM, V27, P357, DOI 10.1097/jcp.013e3180dcc304d; Parke J, 2007, RES MEASUREMENT ISSU, P217; Petry N., 2005, PATHOLOGICAL GAMBLIN; Petry N. M., 2010, INT GAMBL STUD, V10, P113, DOI DOI 10.1080/14459795.2010.501086; Petry NA, 2008, J CONSULT CLIN PSYCH, V76, P318, DOI 10.1037/0022-006X.76.2.318; Petry NM, 2006, J CONSULT CLIN PSYCH, V74, P555, DOI 10.1037/0022-006X.74.3.555; Petry NM, 2005, PSYCHOL ADDICT BEHAV, V19, P226, DOI 10.1037/0893-164X.19.2.226; Petry NM, 2005, J CLIN PSYCHIAT, V66, P564, DOI 10.4088/JCP.v66n0504; Petry NM, 2003, ADDICTION, V98, P645, DOI 10.1046/j.1360-0443.2003.00336.x; Petry NM, 2001, J ABNORM PSYCHOL, V110, P482, DOI 10.1037/0021-843X.110.3.482; Potenza M N, 2001, Semin Clin Neuropsychiatry, V6, P217, DOI 10.1053/scnp.2001.22929; Potenza MN, 2005, ARCH GEN PSYCHIAT, V62, P1015, DOI 10.1001/archpsyc.62.9.1015; Potenza MN, 2003, AM J PSYCHIAT, V160, P1990, DOI 10.1176/appi.ajp.160.11.1990; Regard M, 2003, COGN BEHAV NEUROL, V16, P47, DOI 10.1097/00146965-200303000-00006; Reuter J, 2005, NAT NEUROSCI, V8, P147, DOI 10.1038/nn1378; Roca M, 2008, COGN BEHAV NEUROL, V21, P1, DOI 10.1097/WNN.0b013e3181684358; Rychtarik RG, 2006, J GAMBL STUD, V22, P165, DOI 10.1007/s10899-006-9008-6; Schreiber L, 2009, AM J ADDICTION, V18, P462, DOI 10.3109/10550490903206007; Shaffer HJ, 2004, PSYCHOL ADDICT BEHAV, V18, P40, DOI 10.1037/0893-164X.18.1.40; Shaffer HJ, 2001, CAN J PUBLIC HEALTH, V92, P168, DOI 10.1007/BF03404298; SHARPE L, 1993, BRIT J PSYCHIAT, V162, P407, DOI 10.1192/bjp.162.3.407; Sharpe L, 2002, CLIN PSYCHOL REV, V22, P1, DOI 10.1016/S0272-7358(00)00087-8; Slutske WS, 2010, ARCH GEN PSYCHIAT, V67, P624, DOI 10.1001/archgenpsychiatry.2010.51; Slutske WS, 2009, TWIN RES HUM GENET, V12, P425, DOI 10.1375/twin.12.5.425; Slutske WS, 2009, TWIN RES HUM GENET, V12, P63, DOI 10.1375/twin.12.1.63; Slutske WS, 2006, AM J PSYCHIAT, V163, P297, DOI 10.1176/appi.ajp.163.2.297; Slutske WS, 2003, J ABNORM PSYCHOL, V112, P263, DOI 10.1037/0021-843X.112.2.263; Slutske WS, 2000, ARCH GEN PSYCHIAT, V57, P666, DOI 10.1001/archpsyc.57.7.666; Sobell LC, 1996, AM J PUBLIC HEALTH, V86, P966, DOI 10.2105/AJPH.86.7.966; Stinchfield R, 2002, ADDICT BEHAV, V27, P1, DOI 10.1016/S0306-4603(00)00158-1; Stinchfield R., 2007, RES MEASUREMENT ISSU, P180; Stinchfield R, 2007, PSYCHOL ADDICT BEHAV, V21, P174, DOI 10.1037/0893-164X.21.2.174; Suurvali H, 2010, J GAMBL STUD, V26, P1, DOI 10.1007/s10899-009-9151-y; Toce-Gerstein M, 2009, J GAMBL STUD, V25, P541, DOI 10.1007/s10899-009-9135-y; Toneatto T, 1999, SUBST USE MISUSE, V34, P1593, DOI 10.3109/10826089909039417; Toneatto T., 2007, RES MEASUREMENT ISSU, P279; Toneatto T, 2009, AM J ADDICTION, V18, P219, DOI 10.1080/10550490902787007; Vachon DD, 2009, PSYCHOL ASSESSMENT, V21, P608, DOI 10.1037/a0016846; Wardle H., 2007, BRIT GAMBLING PREVAL; Weinstock J, 2004, PSYCHOL ASSESSMENT, V16, P72, DOI 10.1037/1040-3590.16.1.72; Wickwire EM, 2008, AM J ADDICTION, V17, P392, DOI 10.1080/10550490802268934; Williams R.J., 2009, INT GAMBL STUD, V9, P101, DOI [https://doi.org/10.1080/14459790902911653, DOI 10.1080/14459790902911653]; Winters KC, 1998, J GAMBL STUD, V14, P213, DOI DOI 10.1023/A:1022084924589; World Health Organization, 1992, INT CLASS DIS ICD 10; Wulfert E, 2006, BEHAV MODIF, V30, P315, DOI 10.1177/0145445503262578; Wulfert E, 2005, J GAMBL STUD, V21, P521, DOI 10.1007/s10899-005-5561-7; Xian H, 2007, TWIN RES HUM GENET, V10, P174, DOI 10.1375/twin.10.1.174; Zack M, 2009, J PSYCHOPHARMACOL, V23, P660, DOI 10.1177/0269881108091072; Zack M, 2007, NEUROPSYCHOPHARMACOL, V32, P1678, DOI 10.1038/sj.npp.1301295; Zack Martin, 2009, Curr Drug Abuse Rev, V2, P11; Zeeb FD, 2009, NEUROPSYCHOPHARMACOL, V34, P2329, DOI 10.1038/npp.2009.62	119	291	296	2	74	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 26	2011	378	9806					1874	1884		10.1016/S0140-6736(10)62185-X	http://dx.doi.org/10.1016/S0140-6736(10)62185-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	857DQ	21600645				2022-12-28	WOS:000297695800032
J	Batista, LFZ; Pech, M; Zhong, FL; Nguyen, HN; Xie, KT; Zaug, AJ; Crary, SM; Choi, J; Sebastiano, V; Cherry, A; Giri, N; Wernig, M; Alter, BP; Cech, TR; Savage, SA; Pera, RAR; Artandi, SE				Batista, Luis F. Z.; Pech, MatthewF.; Zhong, Franklin L.; Nguyen, Ha Nam; Xie, Kathleen T.; Zaug, Arthur J.; Crary, Sharon M.; Choi, Jinkuk; Sebastiano, Vittorio; Cherry, Athena; Giri, Neelam; Wernig, Marius; Alter, Blanche P.; Cech, Thomas R.; Savage, Sharon A.; Pera, Renee A. Reijo; Artandi, Steven E.			Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells	NATURE			English	Article							REVERSE-TRANSCRIPTASE; MOUSE; RNA; LOCALIZATION; ANTICIPATION; ELONGATION; GENERATION; MUTATIONS; LENGTH; LEADS	The differentiation of patient-derived induced pluripotent stem cells (iPSCs) to committed fates such as neurons, muscle and liver is a powerful approach for understanding key parameters of human development and disease(1-6). Whether undifferentiated iPSCs themselves can be used to probe disease mechanisms is uncertain. Dyskeratosis congenita is characterized by defective maintenance of blood, pulmonary tissue and epidermal tissues and is caused by mutations in genes controlling telomere homeostasis(7,8). Short telomeres, a hallmark of dyskeratosis congenita, impair tissue stem cell function in mouse models, indicating that a tissue stem cell defect may underlie the pathophysiology of dyskeratosis congenita(9,10). Here we show that even in the undifferentiated state, iPSCs from dyskeratosis congenita patients harbour the precise biochemical defects characteristic of each form of the disease and that the magnitude of the telomere maintenance defect in iPSCs correlates with clinical severity. In iPSCs from patients with heterozygous mutations in TERT, the telomerase reverse transcriptase, a 50% reduction in telomerase levels blunts the natural telomere elongation that accompanies reprogramming. In contrast, mutation of dyskerin (DKC1) in X-linked dyskeratosis congenita severely impairs telomerase activity by blocking telomerase assembly and disrupts telomere elongation during reprogramming. In iPSCs from a form of dyskeratosis congenita caused by mutations in TCAB1 (also known as WRAP53), telomerase catalytic activity is unperturbed, yet the ability of telomerase to lengthen telomeres is abrogated, because telomerase mislocalizes from Cajal bodies to nucleoli within the iPSCs. Extended culture of DKC1-mutant iPSCs leads to progressive telomere shortening and eventual loss of self-renewal, indicating that a similar process occurs in tissue stem cells in dyskeratosis congenita patients. These findings in iPSCs from dyskeratosis congenita patients reveal that undifferentiated iPSCs accurately recapitulate features of a human stem cell disease and may serve as a cell-culture-based system for the development of targeted therapeutics.	[Batista, Luis F. Z.; Pech, MatthewF.; Zhong, Franklin L.; Choi, Jinkuk; Artandi, Steven E.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Pech, MatthewF.; Zhong, Franklin L.; Choi, Jinkuk; Pera, Renee A. Reijo; Artandi, Steven E.] Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA; [Nguyen, Ha Nam; Sebastiano, Vittorio; Wernig, Marius; Pera, Renee A. Reijo] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Xie, Kathleen T.] Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; [Zaug, Arthur J.; Crary, Sharon M.; Cech, Thomas R.] Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA; [Sebastiano, Vittorio; Cherry, Athena; Wernig, Marius] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Giri, Neelam; Alter, Blanche P.; Savage, Sharon A.] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, NIH,US Dept HHS, Bethesda, MD 20852 USA; [Artandi, Steven E.] Stanford Univ, Sch Med, Glenn Labs Biol Aging, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Stanford University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University	Artandi, SE (corresponding author), Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.	sartandi@stanford.edu	Savage, Sharon/AAB-5160-2019; Savage, Sharon A/B-9747-2015	Savage, Sharon/0000-0001-6006-0740; Savage, Sharon A/0000-0001-6006-0740; Reijo Pera, Renee/0000-0002-6487-1329; Xie, Kathleen/0000-0002-3178-8959; Batista, Luis/0000-0002-7538-3240; Choi, Jinkuk/0000-0002-2449-8291	Howard Hughes Medical Institute Funding Source: Medline; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01 CA125453-05, R01 CA111691-05, T32 CA009302, R01 CA125453, R01 CA111691] Funding Source: Medline; NHLBI NIH HHS [U01 HL100397, RC1 HL100361-01, RC1 HL100361] Funding Source: Medline; NIA NIH HHS [R01 AG033747-02, R01 AG033747] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111691, R01CA125453, T32CA009302, ZIACP010190] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL100397, RC1HL100361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG033747] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agarwal S, 2010, NATURE, V464, P292, DOI 10.1038/nature08792; Allsopp RC, 2003, BLOOD, V102, P517, DOI 10.1182/blood-2002-07-2334; Alter BP, 2007, BLOOD, V110, P1439, DOI 10.1182/blood-2007-02-075598; Alter BP, 2010, BRIT J HAEMATOL, V150, P179, DOI 10.1111/j.1365-2141.2010.08212.x; Armanios M, 2005, P NATL ACAD SCI USA, V102, P15960, DOI 10.1073/pnas.0508124102; Bessler M, 2010, FEBS LETT, V584, P3831, DOI 10.1016/j.febslet.2010.05.019; Byrne J. A., 2009, PLOS ONE, V4, pe7118; Cristofari G, 2006, EMBO J, V25, P565, DOI 10.1038/sj.emboj.7600952; Deb-Rinker P, 2005, J BIOL CHEM, V280, P6257, DOI 10.1074/jbc.C400479200; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lei M, 2005, J BIOL CHEM, V280, P20449, DOI 10.1074/jbc.M502212200; Liu G. H., 2011, NATURE          0223, DOI [10.1038/nature09879, DOI 10.1038/NATURE09879]; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Maehr R, 2009, P NATL ACAD SCI USA, V106, P15768, DOI 10.1073/pnas.0906894106; Marion RM, 2009, CELL STEM CELL, V4, P141, DOI 10.1016/j.stem.2008.12.010; Matera AG, 2007, NAT REV MOL CELL BIO, V8, P209, DOI 10.1038/nrm2124; Middleman EJ, 2006, MOL CELL BIOL, V26, P2146, DOI 10.1128/MCB.26.6.2146-2159.2006; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Mochizuki Y, 2004, P NATL ACAD SCI USA, V101, P10756, DOI 10.1073/pnas.0402560101; Rashid ST, 2010, J CLIN INVEST, V120, P3127, DOI 10.1172/JCI43122; SEABRIGH.M, 1971, LANCET, V2, P971; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Sommer CA, 2009, STEM CELLS, V27, P543, DOI 10.1634/stemcells.2008-1075; Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tomlinson RL, 2008, MOL BIOL CELL, V19, P3793, DOI 10.1091/mbc.E08-02-0184; Tycowski KT, 2009, MOL CELL, V34, P47, DOI 10.1016/j.molcel.2009.02.020; Venteicher AS, 2008, CELL, V132, P945, DOI 10.1016/j.cell.2008.01.019; Venteicher AS, 2009, SCIENCE, V323, P644, DOI 10.1126/science.1165357; Vulliamy T, 2004, NAT GENET, V36, P447, DOI 10.1038/ng1346; Walne AJ, 2009, BRIT J HAEMATOL, V145, P164, DOI 10.1111/j.1365-2141.2009.07598.x; Wang F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454; Wong JMY, 2006, GENE DEV, V20, P2848, DOI 10.1101/gad.1476206; Yoshida Y, 2009, CELL STEM CELL, V5, P237, DOI 10.1016/j.stem.2009.08.001; Zaug AJ, 2010, GENE DEV, V24, P613, DOI 10.1101/gad.1881810; Zhong F, 2011, GENE DEV, V25, P11, DOI 10.1101/gad.2006411	37	181	187	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2011	474	7351					399	+		10.1038/nature10084	http://dx.doi.org/10.1038/nature10084			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777TD	21602826	Green Accepted			2022-12-28	WOS:000291647100050
J	Meijvis, SCA; Hardeman, H; Remmelts, HHF; Heijligenberg, R; Rijkers, GT; van Velzen-Blad, H; Voorn, GP; van de Garde, EMW; Endeman, H; Grutters, JC; Bos, WJW; Biesma, DH				Meijvis, Sabine C. A.; Hardeman, Hans; Remmelts, Hilde H. F.; Heijligenberg, Rik; Rijkers, Ger T.; van Velzen-Blad, Heleen; Voorn, G. Paul; van de Garde, Ewoudt M. W.; Endeman, Henrik; Grutters, Jan C.; Bos, Willem Jan W.; Biesma, Douwe H.			Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; GLUCOCORTICOIDS; INTERLEUKIN-10; HYDROCORTISONE; CORTICOSTEROIDS; GUIDELINES; INCREASES; SEVERITY; EFFICACY; RISK	Background Whether addition of corticosteroids to antibiotic treatment benefits patients with community-acquired pneumonia who are not in intensive care units is unclear. We aimed to assess effect of addition of dexamethasone on length of stay in this group, which might result in earlier resolution of pneumonia through dampening of systemic inflammation. Methods In our double-blind, placebo-controlled trial, we randomly assigned adults aged 18 years or older with confirmed community-acquired pneumonia who presented to emergency departments of two teaching hospitals in the Netherlands to receive intravenous dexamethasone (5 mg once a day) or placebo for 4 days from admission. Patients were ineligible if they were immunocompromised, needed immediate transfer to an intensive-care unit, or were already receiving corticosteroids or immunosuppressive drugs. We randomly allocated patients on a one-to-one basis to treatment groups with a computerised randomisation allocation sequence in blocks of 20. The primary outcome was length of hospital stay in all enrolled patients. This study is registered with ClinicalTrials.gov, number NCT00471640. Findings Between November, 2007, and September, 2010, we enrolled 304 patients and randomly allocated 153 to the placebo group and 151 to the dexamethasone group. 143 (47%) of 304 enrolled patients had pneumonia of pneumonia severity index class 4-5 (79 [52%] patients in the dexamethasone group and 64 [42%] controls). Median length of stay was 6.5 days (IQR 5.0-9.0) in the dexamethasone group compared with 7.5 days (5.3-11.5) in the placebo group (95% CI of difference in medians 0-2 days; p=0.0480). In-hospital mortality and severe adverse events were infrequent and rates did not differ between groups, although 67 (44%) of 151 patients in the dexamethasone group had hyperglycaemia compared with 35 (23%) of 153 controls (p<0.0001). Interpretation Dexamethasone can reduce length of hospital stay when added to antibiotic treatment in non-immunocompromised patients with community-acquired pneumonia.	[Meijvis, Sabine C. A.; Bos, Willem Jan W.; Biesma, Douwe H.] St Antonius Hosp, Dept Internal Med, NL-3430 EM Nieuwegein, Netherlands; [Hardeman, Hans; Grutters, Jan C.] St Antonius Hosp, Dept Pulmonol, NL-3430 EM Nieuwegein, Netherlands; [Rijkers, Ger T.; van Velzen-Blad, Heleen; Voorn, G. Paul] St Antonius Hosp, Dept Med Microbiol & Immunol, NL-3430 EM Nieuwegein, Netherlands; [van de Garde, Ewoudt M. W.] St Antonius Hosp, Dept Clin Pharm, NL-3430 EM Nieuwegein, Netherlands; [Remmelts, Hilde H. F.; Heijligenberg, Rik] Gelderse Vallei Hosp, Dept Internal Med, Ede, Netherlands; [van de Garde, Ewoudt M. W.] Univ Utrecht, Fac Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Endeman, Henrik] Onze Lieve Vrouw Hosp, Dept Intens Care Med, Amsterdam, Netherlands; [Grutters, Jan C.] Univ Med Ctr Utrecht, Div Heart & Lungs, Utrecht, Netherlands; [Remmelts, Hilde H. F.; Biesma, Douwe H.] Univ Med Ctr Utrecht, Dept Internal Med, Utrecht, Netherlands	St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; Gelderse Vallei Hospital; Utrecht University; Onze Lieve Vrouwe Gasthuis Hospital; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Meijvis, SCA (corresponding author), St Antonius Hosp, Dept Internal Med, Koekoekslaan 1,POB 2500, NL-3430 EM Nieuwegein, Netherlands.	s.meijvis@antoniusziekenhuis.nl	Rijkers, Ger/AAW-6143-2020; Rijkers, Ger/R-7236-2019; Biesma, Douwe H./AAV-6343-2020	Rijkers, Ger/0000-0001-6948-6123; Biesma, Douwe H./0000-0001-8334-3057; Bos, Willem Jan W/0000-0002-5062-2567				American Diabetes Association, 2011, Diabetes Care, V34 Suppl 1, pS4, DOI 10.2337/dc11-S004; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; CAMPBELL MJ, 1988, BRIT MED J, V296, P1454, DOI 10.1136/bmj.296.6634.1454; Castellanos Mario R, 2010, Int Arch Med, V3, P16, DOI 10.1186/1755-7682-3-16; Christ-Crain M, 2007, AM J RESP CRIT CARE, V176, P913, DOI 10.1164/rccm.200702-307OC; Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Yandiola PPE, 2009, CHEST, V135, P1572, DOI 10.1378/chest.08-2179; FINE MJ, 1993, AM J MED, V94, P153, DOI 10.1016/0002-9343(93)90177-Q; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Franchimont D, 1999, J CLIN ENDOCR METAB, V84, P2834, DOI 10.1210/jc.84.8.2834; Fushimi T, 1997, INT ARCH ALLERGY IMM, V112, P13, DOI 10.1159/000237425; Garcia-Vidal C, 2007, EUR RESPIR J, V30, P951, DOI 10.1183/09031936.00027607; Garnacho-Montero J, 2010, SCAND J INFECT DIS, V42, P185, DOI 10.3109/00365540903418522; Gil-Prieto R, 2011, VACCINE, V29, P412, DOI 10.1016/j.vaccine.2010.11.025; Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Keh D, 2003, AM J RESP CRIT CARE, V167, P512, DOI 10.1164/rccm.200205-446OC; MARIK P, 1993, CHEST, V104, P389, DOI 10.1378/chest.104.2.389; MELBY JC, 1977, ANNU REV PHARMACOL, V17, P511, DOI 10.1146/annurev.pa.17.040177.002455; Mikami K, 2007, LUNG, V185, P249, DOI 10.1007/s00408-007-9020-3; MIKE V, 1982, STAT MED RES METHODS; Monton C, 1999, EUR RESPIR J, V14, P218, DOI 10.1034/j.1399-3003.1999.14a37.x; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; Salluh JIF, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2010.03.004; Schouten J A, 2005, Ned Tijdschr Geneeskd, V149, P2495; Snijders D, 2010, AM J RESP CRIT CARE, V181, P975, DOI 10.1164/rccm.200905-0808OC; vanderPoll T, 1996, J CLIN ENDOCR METAB, V81, P3604, DOI 10.1210/jc.81.10.3604; Visser J, 1998, BLOOD, V91, P4255, DOI 10.1182/blood.V91.11.4255.411a03_4255_4264; Voelker R, 2010, JAMA-J AM MED ASSOC, V303, P2345, DOI 10.1001/jama.2010.790	32	213	230	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2011	377	9782					2023	2030		10.1016/S0140-6736(11)60607-7	http://dx.doi.org/10.1016/S0140-6736(11)60607-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	782LR	21636122				2022-12-28	WOS:000292011700037
J	Khurana, KK; Jia, XZ; Kivelson, MG; Nimmo, F; Schubert, G; Russell, CT				Khurana, Krishan K.; Jia, Xianzhe; Kivelson, Margaret G.; Nimmo, Francis; Schubert, Gerald; Russell, Christopher T.			Evidence of a Global Magma Ocean in Io's Interior	SCIENCE			English	Article							VISCOELASTIC MODELS; GALILEO SPACECRAFT; SUBSURFACE OCEANS; HEAT-FLOW; PLASMA; FIELD; ATMOSPHERE; EUROPA; ROCKS	Extensive volcanism and high-temperature lavas hint at a global magma reservoir in Io, but no direct evidence has been available. We exploited Jupiter's rotating magnetic field as a sounding signal and show that the magnetometer data collected by the Galileo spacecraft near Io provide evidence of electromagnetic induction from a global conducting layer. We demonstrate that a completely solid mantle provides insufficient response to explain the magnetometer observations, but a global subsurface magma layer with a thickness of over 50 kilometers and a rock melt fraction of 20% or more is fully consistent with the observations. We also place a stronger upper limit of about 110 nanoteslas (surface equatorial field) on the dynamo dipolar field generated inside Io.	[Khurana, Krishan K.; Kivelson, Margaret G.; Schubert, Gerald; Russell, Christopher T.] Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; [Jia, Xianzhe; Kivelson, Margaret G.] Univ Michigan, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48109 USA; [Nimmo, Francis] Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA	University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; University of California System; University of California Santa Cruz	Khurana, KK (corresponding author), Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA.	kkhurana@igpp.ucla.edu	Kivelson, Margaret G/I-9019-2012; Russell, Christopher T/E-7745-2012; Jia, Xianzhe/C-5171-2012	Kivelson, Margaret G/0000-0003-3859-8581; Russell, Christopher T/0000-0003-1639-8298; Jia, Xianzhe/0000-0002-8685-1484; Khurana, Krishan/0000-0002-2856-1171	NASA [NNX08AT48G]; NSF [AST-0909206]	NASA(National Aeronautics & Space Administration (NASA)); NSF(National Science Foundation (NSF))	The work at the University of California at Los Angeles was supported by NASA grant NNX08AT48G and NSF Planetary Astronomy grant AST-0909206. The field and plasma data used in this work are available online on the Planetary Data System at http://ppi.pds.nasa.gov/search/?s=GALILEO%20ORBITER.	Anderson JD, 2001, J GEOPHYS RES-PLANET, V106, P32963, DOI 10.1029/2000JE001367; Feaga LM, 2009, ICARUS, V201, P570, DOI 10.1016/j.icarus.2009.01.029; FISCHER HJ, 1990, ICARUS, V83, P39, DOI 10.1016/0019-1035(90)90005-T; Frank LA, 2000, J GEOPHYS RES-SPACE, V105, P25363, DOI 10.1029/1999JA000460; Frank LA, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2002JA009240; Frank LA, 2001, J GEOPHYS RES-SPACE, V106, P26209, DOI 10.1029/2000JA002503; Gurnett DA, 2001, J GEOPHYS RES-SPACE, V106, P26225, DOI 10.1029/2000JA002509; Jia XZ, 2009, J GEOPHYS RES-SPACE, V114, DOI 10.1029/2009JA014375; Jia XZ, 2008, J GEOPHYS RES-SPACE, V113, DOI 10.1029/2007JA012748; Johnson RE, 2004, ASTROPHYS J, V609, pL99, DOI 10.1086/422912; Johnson RE, 2004, CAMB PLANET, P485; Keszthelyi L, 1997, ICARUS, V130, P437, DOI 10.1006/icar.1997.5837; Keszthelyi L, 2004, ICARUS, V169, P271, DOI 10.1016/j.icarus.2004.01.005; Keszthelyi L, 1999, ICARUS, V141, P415, DOI 10.1006/icar.1999.6179; Keszthelyi L, 2007, ICARUS, V192, P491, DOI 10.1016/j.icarus.2007.07.008; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; Kivelson MG, 2002, ICARUS, V157, P507, DOI 10.1006/icar.2002.6834; Lellouch E, 2005, SPACE SCI REV, V116, P211, DOI 10.1007/s11214-005-1957-z; Linker JA, 1998, J GEOPHYS RES-PLANET, V103, P19867, DOI 10.1029/98JE00632; Maumus J, 2005, GEOCHIM COSMOCHIM AC, V69, P4703, DOI 10.1016/j.gca.2005.05.010; MCGRATH MA, 1989, J GEOPHYS RES, V94, P2677, DOI 10.1029/JA094iA03p02677; Moore WB, 2001, ICARUS, V154, P548, DOI 10.1006/icar.2001.6739; Moore WB, 2007, S-P B ASTRON PLANET, P89, DOI 10.1007/978-3-540-48841-5_5; MULLER WF, 1995, PLANET SPACE SCI, V43, P469, DOI 10.1016/0032-0633(94)00181-P; Neubauer FM, 1998, J GEOPHYS RES-PLANET, V103, P19843, DOI 10.1029/97JE03370; OLHOEFT GR, 1989, PHYS PROPERTIES ROCK, P257; Parkinson W. D., 1983, INTRO GEOMAGNETISM; Partzsch GM, 2000, TECTONOPHYSICS, V317, P189, DOI 10.1016/S0040-1951(99)00320-0; Rathbun JA, 2004, ICARUS, V169, P127, DOI 10.1016/j.icarus.2003.10.021; ROSS MN, 1985, ICARUS, V64, P391, DOI 10.1016/0019-1035(85)90063-6; ROSS MN, 1990, ICARUS, V85, P309, DOI 10.1016/0019-1035(90)90119-T; Saur J, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2001JA005067; Schilling FR, 1997, PHYS EARTH PLANET IN, V103, P17, DOI 10.1016/S0031-9201(97)00011-3; SEGATZ M, 1988, ICARUS, V75, P187, DOI 10.1016/0019-1035(88)90001-2; Sinha MC, 1997, PHILOS T R SOC A, V355, P233, DOI 10.1098/rsta.1997.0008; Sohl F, 2002, ICARUS, V157, P104, DOI 10.1006/icar.2002.6828; Spencer JR, 1996, ANNU REV EARTH PL SC, V24, P125, DOI 10.1146/annurev.earth.24.1.125; Spencer JR, 2005, ICARUS, V176, P283, DOI 10.1016/j.icarus.2005.01.019; VEEDER GJ, 1994, J GEOPHYS RES-PLANET, V99, P17095, DOI 10.1029/94JE00637; Wong MC, 2000, ICARUS, V146, P60, DOI 10.1006/icar.2000.6362; Zimmer C, 2000, ICARUS, V147, P329, DOI 10.1006/icar.2000.6456	41	83	84	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2011	332	6034					1186	1189		10.1126/science.1201425	http://dx.doi.org/10.1126/science.1201425			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	772BO	21566160				2022-12-28	WOS:000291205200045
J	Schoepp-Cothenet, B; Nitschke, W; Barge, LM; Ponce, A; Russell, MJ; Tsapin, AI				Schoepp-Cothenet, B.; Nitschke, W.; Barge, L. M.; Ponce, A.; Russell, M. J.; Tsapin, A. I.			Comment on "A Bacterium That Can Grow by Using Arsenic Instead of Phosphorus"	SCIENCE			English	Editorial Material									[Schoepp-Cothenet, B.; Nitschke, W.] CNRS, IFR88, F-13402 Marseille, France; [Barge, L. M.; Ponce, A.; Russell, M. J.; Tsapin, A. I.] CALTECH, Jet Prop Lab, NASA, Pasadena, CA 91109 USA	Centre National de la Recherche Scientifique (CNRS); California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Nitschke, W (corresponding author), CNRS, IFR88, F-13402 Marseille, France.	nitschke@ifr88.cnrs-mrs.fr	Nitschke, Wolfgang/C-4812-2012; Schoepp-Cothenet, Barbara/AAH-8911-2021	Schoepp-Cothenet, Barbara/0000-0002-6820-4478; Nitschke, Wolfgang/0000-0003-2084-3032				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BAER CD, 1981, INORG CHEM, V20, P905, DOI 10.1021/ic50217a052; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; Lebrun E, 2003, MOL BIOL EVOL, V20, P686, DOI 10.1093/molbev/msg071; Schink B, 2000, NATURE, V406, P37, DOI 10.1038/35017644; Schoepp-Cothenet B, 2009, SCIENCE, V323, DOI 10.1126/science.1164967; Wolfe-Simon F, 2011, SCIENCE, V332, P1163, DOI 10.1126/science.1197258	7	4	4	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2011	332	6034								10.1126/science.1201438	http://dx.doi.org/10.1126/science.1201438			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	772BO	21622707				2022-12-28	WOS:000291205200023
J	Ginsburg, PB				Ginsburg, Paul B.			Spending to Save - ACOs and the Medicare Shared Savings Program	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ginsburg, Paul B.] Ctr Studying Hlth Syst Change, Washington, DC 20024 USA; [Ginsburg, Paul B.] Natl Inst Hlth Care Reform, Washington, DC USA	National Institutes of Health (NIH) - USA	Ginsburg, PB (corresponding author), Ctr Studying Hlth Syst Change, Washington, DC 20024 USA.							CMS HHS, 2011, FED REGISTER, V76, P19528; *CTR MED MED SERV, 2011, SUMM PROP RUL PROV A; Haywood TT, 2011, NEW ENGL J MED, V364, DOI 10.1056/NEJMp1100950	3	21	21	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2085	2086		10.1056/NEJMp1103604	http://dx.doi.org/10.1056/NEJMp1103604			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	772AB	21612463				2022-12-28	WOS:000291200700003
J	Hotez, PJ; Mistry, N; Rubinstein, J; Sachs, JD				Hotez, Peter J.; Mistry, Neeraj; Rubinstein, Joanna; Sachs, Jeffrey D.			Integrating Neglected Tropical Diseases into AIDS, Tuberculosis, and Malaria Control	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMPACT		[Hotez, Peter J.; Mistry, Neeraj] Sabin Vaccine Inst, Washington, DC 20006 USA; [Hotez, Peter J.] Baylor Coll Med, Houston, TX 77030 USA; [Hotez, Peter J.] Texas Childrens Hosp, Houston, TX 77030 USA; [Rubinstein, Joanna; Sachs, Jeffrey D.] Columbia Univ, Earth Inst, New York, NY USA	Baylor College of Medicine; Baylor College of Medicine; Columbia University	Hotez, PJ (corresponding author), Sabin Vaccine Inst, Washington, DC 20006 USA.			Hotez, Peter/0000-0001-8770-1042				Brooker S, 2007, AM J TROP MED HYG, V77, P88, DOI 10.4269/ajtmh.2007.77.88; Kirwan P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-277; Kjetland EF, 2006, AIDS, V20, P593, DOI 10.1097/01.aids.0000210614.45212.0a; Linehan M, 2011, AM J TROP MED HYG, V84, P5, DOI 10.4269/ajtmh.2011.10-0411; Walson JL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006419.pub3	5	42	43	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2086	2089		10.1056/NEJMp1014637	http://dx.doi.org/10.1056/NEJMp1014637			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	772AB	21631320				2022-12-28	WOS:000291200700004
J	Liu, M; Yin, XB; Ulin-Avila, E; Geng, BS; Zentgraf, T; Ju, L; Wang, F; Zhang, X				Liu, Ming; Yin, Xiaobo; Ulin-Avila, Erick; Geng, Baisong; Zentgraf, Thomas; Ju, Long; Wang, Feng; Zhang, Xiang			A graphene-based broadband optical modulator	NATURE			English	Article							QUANTUM-WELL STRUCTURES; SUSPENDED GRAPHENE; LARGE-AREA; SILICON; FILMS; TRANSISTORS; ELECTROABSORPTION; ELECTRONICS; GATE	Integrated optical modulators with high modulation speed, small footprint and large optical bandwidth are poised to be the enabling devices for on-chip optical interconnects(1,2). Semiconductor modulators have therefore been heavily researched over the past few years. However, the device footprint of silicon-based modulators is of the order of millimetres, owing to its weak electro-optical properties(3). Germanium and compound semiconductors, on the other hand, face the major challenge of integration with existing silicon electronics and photonics platforms(4-6). Integrating silicon modulators with high-quality-factor optical resonators increases the modulation strength, but these devices suffer from intrinsic narrow bandwidth and require sophisticated optical design; they also have stringent fabrication requirements and limited temperature tolerances(7). Finding a complementary metal-oxide-semiconductor (CMOS)-compatible material with adequate modulation speed and strength has therefore become a task of not only scientific interest, but also industrial importance. Here we experimentally demonstrate a broadband, high-speed, waveguide-integrated electroabsorption modulator based on monolayer graphene. By electrically tuning the Fermi level of the graphene sheet, we demonstrate modulation of the guided light at frequencies over 1 GHz, together with a broad operation spectrum that ranges from 1.35 to 1.6 mm under ambient conditions. The high modulation efficiency of graphene results in an active device area of merely 25 mu m(2), which is among the smallest to date. This graphene-based optical modulation mechanism, with combined advantages of compact footprint, low operation voltage and ultrafast modulation speed across a broad range of wavelengths, can enable novel architectures for on-chip optical communications.	[Liu, Ming; Yin, Xiaobo; Ulin-Avila, Erick; Zentgraf, Thomas; Zhang, Xiang] Univ Calif Berkeley, NSF Nanoscale Sci & Engn Ctr NSEC, Berkeley, CA 94720 USA; [Geng, Baisong; Ju, Long; Wang, Feng] Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; [Wang, Feng; Zhang, Xiang] Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA	National Science Foundation (NSF); University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Zhang, X (corresponding author), Univ Calif Berkeley, NSF Nanoscale Sci & Engn Ctr NSEC, 3112 Etcheverry Hall, Berkeley, CA 94720 USA.	fengwang76@berkeley.edu; xiang@berkeley.edu	Zhang, Xiang/F-6905-2011; Yin, Xiaobo/A-4142-2011; wang, Feng/I-5727-2015; ulin-avila, erick/M-3278-2014; Zentgraf, Thomas/G-8848-2013	wang, Feng/0000-0001-8369-6194; Zentgraf, Thomas/0000-0002-8662-1101; Liu, Ming/0000-0001-9849-1845; Ulin-Avila, Erick/0000-0003-4098-529X; Zhang, Xiang/0000-0002-3272-894X	National Science Foundation Nano-scale Science and Engineering Center (NSF-NSEC) for Scalable and Integrated Nano Manufacturing (SINAM) [CMMI-0751621]; US Department of Energy, Basic Energy Sciences Energy Frontier Research Center (DoE-LMI-EFRC) [DOE DE-AC02-05CH11231]; Div Of Civil, Mechanical, & Manufact Inn [0751621] Funding Source: National Science Foundation	National Science Foundation Nano-scale Science and Engineering Center (NSF-NSEC) for Scalable and Integrated Nano Manufacturing (SINAM)(National Science Foundation (NSF)); US Department of Energy, Basic Energy Sciences Energy Frontier Research Center (DoE-LMI-EFRC)(United States Department of Energy (DOE)); Div Of Civil, Mechanical, & Manufact Inn(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG))	This work was supported by the National Science Foundation Nano-scale Science and Engineering Center (NSF-NSEC) for Scalable and Integrated Nano Manufacturing (SINAM) (grant no. CMMI-0751621) and by the US Department of Energy, Basic Energy Sciences Energy Frontier Research Center (DoE-LMI-EFRC) under award DOE DE-AC02-05CH11231. M.L. thanks Y. Rao for discussions.	Avouris P, 2007, NAT NANOTECHNOL, V2, P605, DOI 10.1038/nnano.2007.300; Bae S, 2010, NAT NANOTECHNOL, V5, P574, DOI [10.1038/nnano.2010.132, 10.1038/NNANO.2010.132]; Bolotin KI, 2008, SOLID STATE COMMUN, V146, P351, DOI 10.1016/j.ssc.2008.02.024; Bonaccorso F, 2010, NAT PHOTONICS, V4, P611, DOI [10.1038/NPHOTON.2010.186, 10.1038/nphoton.2010.186]; Du X, 2008, NAT NANOTECHNOL, V3, P491, DOI 10.1038/nnano.2008.199; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Jablan M, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.245435; Kampfrath T, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.187403; Kim KS, 2009, NATURE, V457, P706, DOI 10.1038/nature07719; Kuo YH, 2005, NATURE, V437, P1334, DOI 10.1038/nature04204; Li XS, 2009, SCIENCE, V324, P1312, DOI 10.1126/science.1171245; Li ZQ, 2008, NAT PHYS, V4, P532, DOI 10.1038/nphys989; Liao L, 2010, NATURE, V467, P305, DOI 10.1038/nature09405; Liu AS, 2004, NATURE, V427, P615, DOI 10.1038/nature02310; Liu J, 2008, NAT PHOTONICS, V2, P433, DOI 10.1038/nphoton.2008.99; Mak KF, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.196405; MILLER DAB, 1984, PHYS REV LETT, V53, P2173, DOI 10.1103/PhysRevLett.53.2173; Miller DAB, 2010, NAT PHOTONICS, V4, P3, DOI 10.1038/nphoton.2009.240; Nair RR, 2008, SCIENCE, V320, P1308, DOI 10.1126/science.1156965; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Reed GT, 2010, NAT PHOTONICS, V4, P518, DOI [10.1038/nphoton.2010.179, 10.1038/NPHOTON.2010.179]; Reina A, 2009, NANO LETT, V9, P30, DOI 10.1021/nl801827v; Rogers JA, 2010, SCIENCE, V327, P1603, DOI 10.1126/science.1182383; Schwierz F, 2010, NAT NANOTECHNOL, V5, P487, DOI [10.1038/NNANO.2010.89, 10.1038/nnano.2010.89]; Wang F, 2008, SCIENCE, V320, P206, DOI 10.1126/science.1152793; Xia FN, 2009, NAT NANOTECHNOL, V4, P839, DOI [10.1038/nnano.2009.292, 10.1038/NNANO.2009.292]; Xu QF, 2005, NATURE, V435, P325, DOI 10.1038/nature03569; Zhang YB, 2009, NAT PHYS, V5, P722, DOI 10.1038/NPHYS1365; Zhou SY, 2006, NAT PHYS, V2, P595, DOI 10.1038/nphys393	30	2509	2595	74	1692	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2011	474	7349					64	67		10.1038/nature10067	http://dx.doi.org/10.1038/nature10067			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	771KV	21552277				2022-12-28	WOS:000291156700037
J	Haran, B; Poliakoff, M				Haran, Brady; Poliakoff, Martyn			The Periodic Table of Videos	SCIENCE			English	Editorial Material									[Haran, Brady; Poliakoff, Martyn] Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England	University of Nottingham	Poliakoff, M (corresponding author), Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England.	martyn.poliakoff@nottingham.ac.uk			Engineering and Physical Sciences Research Council [EP/D501229/1, EP/H027424/1] Funding Source: researchfish; EPSRC [EP/D501229/1, EP/H027424/1] Funding Source: UKRI	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Ball P., 2010, CHEM WORLD, V7, P40; Fleming DG, 2011, SCIENCE, V331, P448, DOI 10.1126/science.1199421; Haran B, 2011, NAT CHEM, V3, P180, DOI 10.1038/nchem.990; Moore M., 2008, TELEGRAPH       0715; Ritter SK, 2008, CHEM ENG NEWS, V86, P42	5	17	18	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2011	332	6033					1046	1047		10.1126/science.1196980	http://dx.doi.org/10.1126/science.1196980			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769FN	21617067	Bronze			2022-12-28	WOS:000290996700034
J	Robock, A				Robock, Alan			Nuclear winter is a real and present danger	NATURE			English	Editorial Material							CONSEQUENCES		Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Robock, A (corresponding author), Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA.	robock@envsci.rutgers.edu	Robock, Alan/B-6385-2016	Robock, Alan/0000-0002-6319-5656				Badash L, 2009, TRANSFORMATIONS-STUD, P1; Robock A, 2007, ATMOS CHEM PHYS, V7, P2003, DOI 10.5194/acp-7-2003-2007; Robock A, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008235; SAGAN C, 1984, FOREIGN AFF, V62, P257; THOMPSON SL, 1986, FOREIGN AFF, V64, P981, DOI 10.2307/20042777; TURCO RP, 1983, SCIENCE, V222, P1283, DOI 10.1126/science.222.4630.1283	6	4	5	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 19	2011	473	7347					275	276		10.1038/473275a	http://dx.doi.org/10.1038/473275a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	765QA	21593838	Bronze			2022-12-28	WOS:000290722400013
J	Galmiche, JP; Hatlebakk, J; Attwood, S; Ell, C; Fiocca, R; Eklund, S; Langstrom, G; Lind, T; Lundell, L				Galmiche, Jean-Paul; Hatlebakk, Jan; Attwood, Stephen; Ell, Christian; Fiocca, Roberto; Eklund, Stefan; Langstrom, Goran; Lind, Tore; Lundell, Lars		LOTUS Trial Collaborators	Laparoscopic Antireflux Surgery vs Esomeprazole Treatment for Chronic GERD The LOTUS Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GASTROESOPHAGEAL-REFLUX DISEASE; PROTON-PUMP INHIBITORS; LANSOPRAZOLE 30 MG; NISSEN FUNDOPLICATION; EROSIVE ESOPHAGITIS; HIP FRACTURE; ACID CONTROL; FOLLOW-UP; OMEPRAZOLE; THERAPY	Context Gastroesophageal reflux disease (GERD) is a chronic, relapsing disease with symptoms that have negative effects on daily life. Two treatment options are long-term medication or surgery. Objective To evaluate optimized esomeprazole therapy vs standardized laparoscopic antireflux surgery (LARS) in patients with GERD. Design, Setting, and Participants The LOTUS trial, a 5-year exploratory randomized, open, parallel-group trial conducted in academic hospitals in 11 European countries between October 2001 and April 2009 among 554 patients with well-established chronic GERD who initially responded to acid suppression. A total of 372 patients (esomeprazole, n=192; LARS, n=180) completed 5-year follow-up. Interventions Two hundred sixty-six patients were randomly assigned to receive esomeprazole, 20 to 40 mg/d, allowing for dose adjustments; 288 were randomly assigned to undergo LARS, of whom 248 actually underwent the operation. Main Outcome Measure Time to treatment failure (for LARS, defined as need for acid suppressive therapy; for esomeprazole, inadequate symptom control after dose adjustment), expressed as estimated remission rates and analyzed using the Kaplan-Meier method. Results Estimated remission rates at 5 years were 92% (95% confidence interval [CI], 89%-96%) in the esomeprazole group and 85% (95% CI, 81%-90%) in the LARS group (log-rank P=.048). The difference between groups was no longer statistically significant following best-case scenario modeling of the effects of study dropout. The prevalence and severity of symptoms at 5 years in the esomeprazole and LARS groups, respectively, were 16% and 8% for heartburn (P=.14), 13% and 2% for acid regurgitation (P<.001), 5% and 11% for dysphagia (P<.001), 28% and 40% for bloating (P<.001), and 40% and 57% for flatulence (P<.001). Mortality during the study was low (4 deaths in the esomeprazole group and 1 death in the LARS group) and not attributed to treatment, and the percentages of patients reporting serious adverse events were similar in the esomeprazole group (24.1%) and in the LARS group (28.6%). Conclusion This multicenter clinical trial demonstrated that with contemporary antireflux therapy for GERD, either by drug-induced acid suppression with esomeprazole or by LARS, most patients achieve and remain in remission at 5 years.	[Galmiche, Jean-Paul] Univ Nantes, Dept Gastroenterol & Hepatol, CIC INSERM, F-44093 Nantes, France; [Hatlebakk, Jan] Univ Bergen, Haukeland Univ Hosp, Inst Med, Bergen, Norway; [Attwood, Stephen] N Tyneside Gen Hosp, Dept Surg, N Shields, Tyne & Wear, England; [Ell, Christian] Dr Horst Schmidt Hosp, Dept Gastroenterol, Wiesbaden, Germany; [Fiocca, Roberto] Univ Genoa, Dept Surg & Morphol Sci, Anat Pathol Div, Genoa, Italy; [Eklund, Stefan; Langstrom, Goran; Lind, Tore] AstraZeneca Res & Dev, Molndal, Sweden; [Lundell, Lars] Karolinska Univ Hosp, Dept Surg, Huddinge, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; University of Bergen; Haukeland University Hospital; University of Genoa; AstraZeneca; Karolinska Institutet; Karolinska University Hospital	Galmiche, JP (corresponding author), Univ Nantes, Dept Gastroenterol & Hepatol, CIC INSERM, Pl Alexis Ricordeau, F-44093 Nantes, France.	jeanpaul.galmiche@chu-nantes.fr	Gooszen, H.G./H-8036-2014; Fiocca, Roberto/K-9705-2016	Fiocca, Roberto/0000-0002-8856-6185; ROSATI, Riccardo/0000-0002-2608-5749; Naver, Lars Peter Skat/0000-0003-0113-9576; Piessevaux, Hubert/0000-0003-1193-0601	AstraZeneca; Given Imaging; Mauna Kea Technology; Fujinon; Erbe; Hitachi; Karolinska University Hospital; AstraZeneca Research and Development, Molndal, Sweden	AstraZeneca(AstraZeneca); Given Imaging; Mauna Kea Technology; Fujinon; Erbe; Hitachi; Karolinska University Hospital(Karolinska Institutet); AstraZeneca Research and Development, Molndal, Sweden(AstraZeneca)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Galmiche reported that he is a consultant for several biomedical companies (AstraZeneca, Janssen-Cilag, Given Imaging, Xenoport, and Norgine) and that his institution receives grants for research from AstraZeneca, Given Imaging, and Mauna Kea Technology. He has prepared educational presentations for Shire Movetis. Dr Attwood reported that he has received honoraria for speaking at meetings sponsored by AstraZeneca. Dr Ell reported that he receives grants for research from several biomedical companies (AstraZeneca, Fujinon, Erbe, and Hitachi). Dr Fiocca reported that he has received travel and related expenses for attending study-associated meetings and his institution received a grant from AstraZeneca for central histological analyses. Drs Eklund, Langstrom, and Lind reported that they are employees of AstraZeneca. Dr Lundell reported that he receives consultancy and lecture fees from several biomedical companies including AstraZeneca and that his institution (Karolinska University Hospital) receives grants for research on his behalf.; The study was funded in total by AstraZeneca Research and Development, Molndal, Sweden.	ANVARI M, 1995, BRIT J SURG, V82, P938, DOI 10.1002/bjs.1800820728; Attwood SEA, 2008, WORLD J SURG, V32, P995, DOI 10.1007/s00268-007-9409-4; Camilleri M, 2005, CLIN GASTROENTEROL H, V3, P543, DOI 10.1016/S1542-3565(05)00153-9; Castell DO, 2002, AM J GASTROENTEROL, V97, P575; Edwards SJ, 2006, ALIMENT PHARM THER, V24, P743, DOI 10.1111/j.1365-2036.2006.03074.x; Ell C, 2010, GASTROENTEROLOGY, V138, pS654; Fiocca R, 2010, AM J GASTROENTEROL, V105, P1015, DOI 10.1038/ajg.2009.631; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Gralnek IM, 2006, CLIN GASTROENTEROL H, V4, P1452, DOI 10.1016/j.cgh.2006.09.013; Grant AM, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2664; Hatlebakk J, 2010, GUT, V59, pA87; Hatlebakk JG, 1998, ALIMENT PHARM THERAP, V12, P1235; Kulig M, 2003, ALIMENT PHARM THER, V18, P767, DOI 10.1046/j.1365-2036.2003.01770.x; Lodato F, 2010, BEST PRACT RES CL GA, V24, P193, DOI 10.1016/j.bpg.2009.11.004; Lundell L, 2008, GUT, V57, P1207, DOI 10.1136/gut.2008.148833; Lundell L, 2009, CLIN GASTROENTEROL H, V7, P1292, DOI 10.1016/j.cgh.2009.05.021; Luostarinen MES, 1999, SCAND J GASTROENTERO, V34, P117; Mahon D, 2005, BRIT J SURG, V92, P695, DOI 10.1002/bjs.4934; McQuaid KR, 2005, CLIN GASTROENTEROL H, V3, P553, DOI 10.1016/S1542-3565(05)00023-6; Mehta S, 2006, J GASTROINTEST SURG, V10, P1312, DOI 10.1016/j.gassur.2006.07.010; Miner P, 2003, AM J GASTROENTEROL, V98, P2616, DOI 10.1016/j.amjgastroenterol.2003.09.053; Moayyedi P, 2008, AM J GASTROENTEROL, V103, P2428, DOI 10.1111/j.1572-0241.2008.02031.x; Oelschlager BK, 2008, AM J GASTROENTEROL, V103, P280, DOI 10.1111/j.1572-0241.2007.01606.x; Peters MJ, 2009, AM J GASTROENTEROL, V104, P1548, DOI 10.1038/ajg.2009.176; Rohss K, 2004, EUR J CLIN PHARMACOL, V60, P531, DOI 10.1007/s00228-004-0804-6; Spechler SJ, 2001, JAMA-J AM MED ASSOC, V285, P2331, DOI 10.1001/jama.285.18.2331; Targownik LE, 2010, GASTROENTEROLOGY, V138, P896, DOI 10.1053/j.gastro.2009.11.014; Wahlqvist P, 2006, ALIMENT PHARM THERAP, V24, P259, DOI 10.1111/j.1365-2036.2006.02996.x; Yang YX, 2006, JAMA-J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947; Zaninotto G, 2010, BRIT J SURG, V97, P139, DOI 10.1002/bjs.6863	30	275	285	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2011	305	19					1969	1977		10.1001/jama.2011.626	http://dx.doi.org/10.1001/jama.2011.626			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764WO	21586712				2022-12-28	WOS:000290665500020
J	Weatherall, DJ				Weatherall, D. J.			Hydroxycarbamide for sickle-cell anaemia in infancy	LANCET			English	Editorial Material							FETAL-HEMOGLOBIN PRODUCTION; HYDROXYUREA; CHILDREN; TRIAL		Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	Weatherall, DJ (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	liz.rose@imm.ox.ac.uk						CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Christianson A., 2006, GLOBAL REPORT BIRTH; Ferster A, 2001, BLOOD, V97, P3628, DOI 10.1182/blood.V97.11.3628; Herrick J.B., 1910, ARCH INTERN MED, V6, P517; LETVIN NL, 1984, NEW ENGL J MED, V310, P869, DOI 10.1056/NEJM198404053101401; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; Saunthararajah Y, 2009, DISORDERS OF HEMOGLOBIN: GENETICS, PATHOPHYSIOLOGY, AND CLINICAL MANAGEMENT, 2ND EDITION, P745; SHERIDAN BL, 1976, BRIT J HAEMATOL, V32, P487, DOI 10.1111/j.1365-2141.1976.tb00952.x; Thompson BW, 2010, PEDIATR BLOOD CANCER, V54, P250, DOI 10.1002/pbc.22269; Wang WC, 2001, J PEDIATR-US, V139, P790, DOI 10.1067/mpd.2001.119590; Wang WC, 2011, LANCET, V377, P1663, DOI 10.1016/S0140-6736(11)60355-3; Weatherall D.J., 2001, THALASSAEMIA SYNDROM, Vfourth; Weatherall DJ, 2010, BLOOD, V115, P4331, DOI 10.1182/blood-2010-01-251348; Williams TN, 2009, LANCET, V374, P1364, DOI 10.1016/S0140-6736(09)61374-X	15	2	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 14	2011	377	9778					1628	1630		10.1016/S0140-6736(11)60511-4	http://dx.doi.org/10.1016/S0140-6736(11)60511-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766JF	21571132				2022-12-28	WOS:000290777700005
J	Gosselin, D; Rivest, S				Gosselin, David; Rivest, Serge			Estrogen Receptor Transrepresses Brain Inflammation	CELL			English	Editorial Material							DEHYDROEPIANDROSTERONE; MICROGLIA		[Rivest, Serge] Univ Laval, Lab Endocrinol & Genom, CHUQ Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Mol Med, Fac Med, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Rivest, S (corresponding author), Univ Laval, Lab Endocrinol & Genom, CHUQ Res Ctr, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	serge.rivest@crchul.ulaval.ca		Rivest, Serge/0000-0002-6082-770X				Du CG, 2001, J IMMUNOL, V167, P7094, DOI 10.4049/jimmunol.167.12.7094; Jellinck PH, 2007, J STEROID BIOCHEM, V107, P156, DOI 10.1016/j.jsbmb.2007.04.004; Orton SM, 2006, LANCET NEUROL, V5, P932, DOI 10.1016/S1474-4422(06)70581-6; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Soucy G, 2005, J IMMUNOL, V174, P6391, DOI 10.4049/jimmunol.174.10.6391; Stossi F, 2009, MOL CELL BIOL, V29, P1749, DOI 10.1128/MCB.01476-08; Tiwari-Woodruff S, 2009, J NEUROL SCI, V286, P81, DOI 10.1016/j.jns.2009.04.023; Yong VW, 2009, NEURON, V64, P55, DOI 10.1016/j.neuron.2009.09.035	9	16	16	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 13	2011	145	4					495	497		10.1016/j.cell.2011.04.018	http://dx.doi.org/10.1016/j.cell.2011.04.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	763MF	21565607	Bronze			2022-12-28	WOS:000290560800002
J	Watanabe, T; Tomizawa, S; Mitsuya, K; Totoki, Y; Yamamoto, Y; Kuramochi-Miyagawa, S; Iida, N; Hoki, Y; Murphy, PJ; Toyoda, A; Gotoh, K; Hiura, H; Arima, T; Fujiyama, A; Sado, T; Shibata, T; Nakano, T; Lin, HF; Ichiyanagi, K; Soloway, PD; Sasaki, H				Watanabe, Toshiaki; Tomizawa, Shin-ichi; Mitsuya, Kohzoh; Totoki, Yasushi; Yamamoto, Yasuhiro; Kuramochi-Miyagawa, Satomi; Iida, Naoko; Hoki, Yuko; Murphy, Patrick J.; Toyoda, Atsushi; Gotoh, Kengo; Hiura, Hitoshi; Arima, Takahiro; Fujiyama, Asao; Sado, Takashi; Shibata, Tatsuhiro; Nakano, Toru; Lin, Haifan; Ichiyanagi, Kenji; Soloway, Paul D.; Sasaki, Hiroyuki			Role for piRNAs and Noncoding RNA in de Novo DNA Methylation of the Imprinted Mouse Rasgrf1 Locus	SCIENCE			English	Article							GERM-CELL DEVELOPMENT; MAMMALIAN DEVELOPMENT; DROSOPHILA; TRANSCRIPTION; FAMILY; GENES; PIWI; MILI	Genomic imprinting causes parental origin-specific monoallelic gene expression through differential DNA methylation established in the parental germ line. However, the mechanisms underlying how specific sequences are selectively methylated are not fully understood. We have found that the components of the PIWI-interacting RNA (piRNA) pathway are required for de novo methylation of the differentially methylated region (DMR) of the imprinted mouse Rasgrf1 locus, but not other paternally imprinted loci. A retrotransposon sequence within a noncoding RNA spanning the DMR was targeted by piRNAs generated from a different locus. A direct repeat in the DMR, which is required for the methylation and imprinting of Rasgrf1, served as a promoter for this RNA. We propose a model in which piRNAs and a target RNA direct the sequence-specific methylation of Rasgrf1.	[Watanabe, Toshiaki; Tomizawa, Shin-ichi; Yamamoto, Yasuhiro; Iida, Naoko; Hoki, Yuko; Sado, Takashi; Ichiyanagi, Kenji; Sasaki, Hiroyuki] Res Org Informat & Syst, Natl Inst Genet, Div Human Genet, Mishima, Shizuoka 4118540, Japan; [Watanabe, Toshiaki; Tomizawa, Shin-ichi; Yamamoto, Yasuhiro; Iida, Naoko; Hoki, Yuko; Sado, Takashi; Ichiyanagi, Kenji; Sasaki, Hiroyuki] Res Org Informat & Syst, Natl Inst Genet, Dept Integrated Genet, Mishima, Shizuoka 4118540, Japan; [Watanabe, Toshiaki; Lin, Haifan] Yale Univ, Sch Med, New Haven, CT 06520 USA; [Tomizawa, Shin-ichi] Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB22 3AT, England; [Mitsuya, Kohzoh] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, Ctr Pregnancy & Newborn Res, San Antonio, TX 78229 USA; [Totoki, Yasushi; Shibata, Tatsuhiro] Natl Canc Ctr, Res Inst, Div Canc Genom, Chuo Ku, Tokyo 1040045, Japan; [Yamamoto, Yasuhiro; Hoki, Yuko; Sado, Takashi; Ichiyanagi, Kenji; Sasaki, Hiroyuki] Kyushu Univ, Med Inst Bioregulat, Div Epigenom, Higashi Ku, Fukuoka 8128582, Japan; [Kuramochi-Miyagawa, Satomi; Gotoh, Kengo; Nakano, Toru] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; [Iida, Naoko] Res Org Informat & Syst, Natl Inst Genet, Dept Mol Genet, Div Mutagenesis, Mishima, Shizuoka 4118540, Japan; [Murphy, Patrick J.; Soloway, Paul D.] Cornell Univ, Coll Agr & Life Sci, Div Nutr Sci, Ithaca, NY 14853 USA; [Toyoda, Atsushi; Fujiyama, Asao] Res Org Informat & Syst, Natl Inst Genet, Ctr Genet Resource Informat, Comparat Genom Lab, Mishima, Shizuoka 4118540, Japan; [Hiura, Hitoshi; Arima, Takahiro] Tohoku Univ, Grad Sch Med, Environm & Genome Res Ctr, Dept Informat Genet,Aoba Ku, Sendai, Miyagi 9808575, Japan; [Fujiyama, Asao] Natl Inst Informat, Principle Informat Res Div, Chiyoda Ku, Tokyo 1018430, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Yale University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Texas System; University of Texas Health San Antonio; National Cancer Center - Japan; Kyushu University; Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Cornell University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Tohoku University; Research Organization of Information & Systems (ROIS); National Institute of Informatics (NII) - Japan	Watanabe, T (corresponding author), Res Org Informat & Syst, Natl Inst Genet, Div Human Genet, Mishima, Shizuoka 4118540, Japan.	toshwatatoshiakiwatanabe@gmail.com; hsasaki@bioreg.kyushu-u.ac.jp	Ichiyanagi, Kenji/J-2141-2015; Soloway, Paul/T-8243-2019; Mitsuya, Kohzoh/F-4437-2010; Shibata, Tatsuhiro/AAO-1278-2021; Sado, Takashi/AAI-1689-2019; Tomizawa, Shinichi/AAT-7149-2020; Shibata, Tatsuhiro/ABA-8234-2020	Tomizawa, Shinichi/0000-0002-8291-6623; Sado, Takashi/0000-0002-1232-0250; Mitsuya, Kohzoh/0000-0002-0950-5406; Soloway, Paul/0000-0003-1967-0437; Ichiyanagi, Kenji/0000-0002-6831-6525	Ministry of Education, Culture, Sports, Science, and Technology of Japan; NATIONAL CANCER INSTITUTE [R01CA098597] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23013003, 23659768, 23390385, 19061001] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank M. Kaneda, S. Chuma, V. Shteyn, and J. Peng for comments on the manuscript and H. Horiike, H. Furuumi, T. Ichiyanagi, Y. Amakawa, H. Chiba, and Y. Li for sample preparation. The accession number for the small RNA sequences is GSE20327. This work was supported in part by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan to H. S. and K.M.	Aravin AA, 2008, MOL CELL, V31, P785, DOI 10.1016/j.molcel.2008.09.003; Aravin AA, 2007, SCIENCE, V316, P744, DOI 10.1126/science.1142612; Bartolomei MS, 2009, GENE DEV, V23, P2124, DOI 10.1101/gad.1841409; Brennecke J, 2007, CELL, V128, P1089, DOI 10.1016/j.cell.2007.01.043; Buhler M, 2006, CELL, V125, P873, DOI 10.1016/j.cell.2006.04.025; Carmell MA, 2007, DEV CELL, V12, P503, DOI 10.1016/j.devcel.2007.03.001; Chotalia M, 2009, GENE DEV, V23, P105, DOI 10.1101/gad.495809; de la Puente A, 2002, GENE, V291, P287, DOI 10.1016/S0378-1119(02)00601-7; Drake NM, 2009, MAMM GENOME, V20, P654, DOI 10.1007/s00335-009-9192-7; Gunawardane LS, 2007, SCIENCE, V315, P1587, DOI 10.1126/science.1140494; Hirasawa R, 2008, GENE DEV, V22, P1607, DOI 10.1101/gad.1667008; Irvine DV, 2006, SCIENCE, V313, P1134, DOI 10.1126/science.1128813; Kato Y, 2007, HUM MOL GENET, V16, P2272, DOI 10.1093/hmg/ddm179; Koerner MV, 2009, DEVELOPMENT, V136, P1771, DOI 10.1242/dev.030403; Kuramochi-Miyagawa S, 2008, GENE DEV, V22, P908, DOI 10.1101/gad.1640708; Lindroth AM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000145; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Malone CD, 2009, CELL, V137, P522, DOI 10.1016/j.cell.2009.03.040; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; Pane A, 2007, DEV CELL, V12, P851, DOI 10.1016/j.devcel.2007.03.022; Pearsall RS, 1999, GENOMICS, V55, P194, DOI 10.1006/geno.1998.5660; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Saito K, 2009, NATURE, V461, P1296, DOI 10.1038/nature08501; Sasaki H, 2008, NAT REV GENET, V9, P129, DOI 10.1038/nrg2295; Schaefer CB, 2007, SCIENCE, V316, P398, DOI 10.1126/science.1137544; Tomizawa S, 2011, DEVELOPMENT, V138, P811, DOI 10.1242/dev.061416; Watanabe T, 2011, DEV CELL, V20, P364, DOI 10.1016/j.devcel.2011.01.005; Wierzbicki AT, 2009, NAT GENET, V41, P630, DOI 10.1038/ng.365; Yoon BJ, 2002, NAT GENET, V30, P92, DOI 10.1038/ng795	29	281	294	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2011	332	6031					848	852		10.1126/science.1203919	http://dx.doi.org/10.1126/science.1203919			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566194	Green Accepted			2022-12-28	WOS:000290529900048
J	Klinakis, A; Lobry, C; Abdel-Wahab, O; Oh, P; Haeno, H; Buonamici, S; van De Walle, I; Cathelin, S; Trimarchi, T; Araldi, E; Liu, C; Ibrahim, S; Beran, M; Zavadil, J; Efstratiadis, A; Taghon, T; Michor, F; Levine, RL; Aifantis, I				Klinakis, Apostolos; Lobry, Camille; Abdel-Wahab, Omar; Oh, Philmo; Haeno, Hiroshi; Buonamici, Silvia; van De Walle, Inge; Cathelin, Severine; Trimarchi, Thomas; Araldi, Elisa; Liu, Cynthia; Ibrahim, Sherif; Beran, Miroslav; Zavadil, Jiri; Efstratiadis, Argiris; Taghon, Tom; Michor, Franziska; Levine, Ross L.; Aifantis, Iannis			A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia	NATURE			English	Article							T-CELL DEVELOPMENT; MICE; DIFFERENTIATION; SPECIFICATION; ACTIVATION; EXPRESSION; PROGENITOR; COMPLEX	Notch signalling is a central regulator of differentiation in a variety of organisms and tissue types(1). Its activity is controlled by the multisubunit gamma-secretase (gamma SE) complex(2). Although Notch signalling can play both oncogenic and tumour-suppressor roles in solid tumours, in the haematopoietic system it is exclusively oncogenic, notably in T-cell acute lymphoblastic leukaemia, a disease characterized by Notch1-activating mutations(3). Here we identify novel somatic-inactivating Notch pathway mutations in a fraction of patients with chronic myelomonocytic leukaemia (CMML). Inactivation of Notch signalling in mouse haematopoietic stem cells (HSCs) results in an aberrant accumulation of granulocyte/monocyte progenitors (GMPs), extramedullary haematopoieisis and the induction of CMML-like disease. Transcriptome analysis revealed that Notch signalling regulates an extensive myelomonocytic-specific gene signature, through the direct suppression of gene transcription by the Notch target Hes1. Our studies identify a novel role for Notch signalling during early haematopoietic stem cell differentiation and suggest that the Notch pathway can play both tumour-promoting and -suppressive roles within the same tissue.	[Lobry, Camille; Oh, Philmo; Buonamici, Silvia; Cathelin, Severine; Trimarchi, Thomas; Araldi, Elisa; Liu, Cynthia; Ibrahim, Sherif; Aifantis, Iannis] NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; [Lobry, Camille; Oh, Philmo; Buonamici, Silvia; Cathelin, Severine; Trimarchi, Thomas; Araldi, Elisa; Liu, Cynthia; Ibrahim, Sherif; Aifantis, Iannis] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Klinakis, Apostolos; Efstratiadis, Argiris] Acad Athens, Biomed Res Fdn, Athens, Greece; [Abdel-Wahab, Omar; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program, New York, NY 10016 USA; [Abdel-Wahab, Omar; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10016 USA; [Haeno, Hiroshi; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Haeno, Hiroshi; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [van De Walle, Inge; Taghon, Tom] Univ Ghent, State Univ Ghent Hosp, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium; [Beran, Miroslav] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Zavadil, Jiri] NYU Canc Inst, Dept Pathol, New York, NY 10016 USA; [Zavadil, Jiri] NYU Langone Med Ctr, Ctr Hlth Informat & Bioinformat, New York, NY 10016 USA; [Buonamici, Silvia] Novartis Inst Biomed Res, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; New York University; New York University; Academy of Athens; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Ghent University; Ghent University Hospital; University of Texas System; UTMD Anderson Cancer Center; New York University; NYU Langone Medical Center; Novartis	Aifantis, I (corresponding author), NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA.	aklinakis@bioacademy.gr; iannis.aifantis@nyumc.org	Zavadil, Jiri/ABG-1780-2020; levine, ross/AAE-7658-2019; Taghon, Tom/M-9111-2018; Araldi, Elisa/AAZ-5946-2021; lobry, camille/A-6188-2015	Zavadil, Jiri/0000-0003-0640-5562; lobry, camille/0000-0003-0550-4921; Abdel-Wahab, Omar/0000-0002-3907-6171; Araldi, Elisa/0000-0002-6596-6784; Taghon, Tom/0000-0002-5781-0288; Van de Walle, Inge/0000-0002-7631-399X	National Institutes of Health [RO1CA133379, RO1CA105129, R21CA141399, RO1CA149655, R01CA1328234, U54CA143798]; Leukemia & Lymphoma Society; American Cancer Society; Irma T. Hirschl Trust; Dana Foundation; Mallinckrodt Foundation; Alex's Lemonade Stand Foundation; Fund for Scientific Research Flanders (Fonds Wetenschappelijk Onderzoek); National Cancer Institute [1P01CA97403]; EU; Institute for the Promotion of Innovation by Science and Technology in Flanders (Agentschap voor Innovatie door Wetenschap en Technologie); Hope Street Kids Foundations; New York University; Fonds Wetenschappelijk Onderzoek; Memorial Sloan Kettering Cancer Center; American Society of Hematology; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R21CA141399, U54CA143798, P01CA097403, R01CA149655, R01CA105129, R01CA133379] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); American Cancer Society(American Cancer Society); Irma T. Hirschl Trust; Dana Foundation; Mallinckrodt Foundation; Alex's Lemonade Stand Foundation; Fund for Scientific Research Flanders (Fonds Wetenschappelijk Onderzoek)(FWO); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EU(European Commission); Institute for the Promotion of Innovation by Science and Technology in Flanders (Agentschap voor Innovatie door Wetenschap en Technologie)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Hope Street Kids Foundations; New York University; Fonds Wetenschappelijk Onderzoek(FWO); Memorial Sloan Kettering Cancer Center; American Society of Hematology; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank G. Fishel, F. Radtke and R. Kopan for donating mouse strains; P. Lopez and the New York University Flow Facility for cell sorting; and A. Heguy and the Geoffrey Beene Translational Core laboratory for assistance with DNA resequencing. The New York University Cancer Institute Genomics Facility helped with micro-array processing. This work was supported by the National Institutes of Health (RO1CA133379, RO1CA105129, R21CA141399, RO1CA149655 to I.A.; R01CA1328234 to R.L.L. and F.M.; U54CA143798 to F.M.), the Leukemia & Lymphoma Society (to I.A.), the American Cancer Society (to I.A.), the Irma T. Hirschl Trust, the Dana Foundation, The Mallinckrodt Foundation, the Alex's Lemonade Stand Foundation (to I.A.), and the Fund for Scientific Research Flanders (Fonds Wetenschappelijk Onderzoek) and its Odysseus Research Program (to T.T.). A.E. was supported by the National Cancer Institute (1P01CA97403, Project 2) and a gift from the Berrie Foundation. A.K. was supported by an EU Marie Curie International Re-integration Grant. I.v.D.W. was supported by the Institute for the Promotion of Innovation by Science and Technology in Flanders (Agentschap voor Innovatie door Wetenschap en Technologie). S.C. was supported by the Hope Street Kids Foundations and P.O. by the New York University Medical Scientist Training Program. T.T. was supported by the Fonds Wetenschappelijk Onderzoek). O.A.W. was supported by the Clinical Scholars Program at Memorial Sloan Kettering Cancer Center and by the American Society of Hematology. R.L.L. is an Early Career Award recipient of the Howard Hughes Medical Institute and is the Geoffrey Beene Junior Chair at Memorial Sloan Kettering Cancer Center. I.A. is a Howard Hughes Medical Institute Early Career Scientist.	Aifantis I, 1999, J EXP MED, V190, P141, DOI 10.1084/jem.190.1.141; Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Buonamici S, 2009, NATURE, V459, P1000, DOI 10.1038/nature08020; Challen GA, 2010, CELL STEM CELL, V6, P265, DOI 10.1016/j.stem.2010.02.002; De Strooper B, 2005, CELL, V122, P318, DOI 10.1016/j.cell.2005.07.021; Demehri S, 2008, PLOS BIOL, V6, P992, DOI 10.1371/journal.pbio.0060123; Dumortier A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009258; Emanuel PD, 2008, LEUKEMIA, V22, P1335, DOI 10.1038/leu.2008.162; GRABHER C, 2006, NAT REV CANCER, V6, P1; Hurlbut GD, 2007, CURR OPIN CELL BIOL, V19, P166, DOI 10.1016/j.ceb.2007.02.012; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Leighton PA, 2001, NATURE, V410, P174, DOI 10.1038/35065539; Mercher T, 2008, CELL STEM CELL, V3, P314, DOI 10.1016/j.stem.2008.07.010; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Ng SYM, 2009, IMMUNITY, V30, P493, DOI 10.1016/j.immuni.2009.01.014; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Robert-Moreno A, 2008, EMBO J, V27, P1886, DOI 10.1038/emboj.2008.113; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Rothenberg EV, 2005, ANNU REV IMMUNOL, V23, P601, DOI 10.1146/annurev.immunol.23.021704.115737; Saito T, 2003, IMMUNITY, V18, P675, DOI 10.1016/S1074-7613(03)00111-0; Santaguida M, 2009, CANCER CELL, V15, P341, DOI 10.1016/j.ccr.2009.02.016; Stadtfeld M, 2005, DEVELOPMENT, V132, P203, DOI 10.1242/dev.01558; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taghon TN, 2005, GENE DEV, V19, P965, DOI 10.1101/gad.1298305; Taghon T, 2009, BLOOD, V113, P3254, DOI 10.1182/blood-2008-07-168906; Tefferi A, 2010, LEUKEMIA, V24, P1128, DOI 10.1038/leu.2010.69; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Van de Walle I, 2009, BLOOD, V113, P2988, DOI 10.1182/blood-2008-06-164871; Yang XD, 2004, DEV BIOL, V269, P81, DOI 10.1016/j.ydbio.2004.01.014; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	32	285	296	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 12	2011	473	7346					230	+		10.1038/nature09999	http://dx.doi.org/10.1038/nature09999			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	762NT	21562564	Green Accepted			2022-12-28	WOS:000290487200042
J	Chang, HJ				Chang, Huan J.			Lower Extremity Purpura	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SCURVY					tina.chang@jama-archives.org						Chisholm C, 2010, ARCH DERMATOL, V146, P1167, DOI 10.1001/archdermatol.2010.280-a; De Luna RH, 2003, AM J HEMATOL, V74, P85, DOI 10.1002/ajh.10354; Des Roches A, 2006, ALLERGY, V61, P1487, DOI 10.1111/j.1398-9995.2006.01200.x; Hampl JS, 2004, AM J PUBLIC HEALTH, V94, P870, DOI 10.2105/AJPH.94.5.870; Leger D, 2008, CAN FAM PHYSICIAN, V54, P1403; Shidfar F, 2005, East Mediterr Health J, V11, P87; Velandia B, 2008, J GEN INTERN MED, V23, P1281, DOI 10.1007/s11606-008-0577-1	7	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2011	305	18					1911	1912		10.1001/jama.2011.567	http://dx.doi.org/10.1001/jama.2011.567			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761YH	21558527				2022-12-28	WOS:000290438800034
J	Sculier, JP; Meert, AP; Berghmans, T				Sculier, Jean-Paul; Meert, Anne-Pascal; Berghmans, Thieny			Salvage with erlotinib plus bevacizumab: not in NSCLC	LANCET			English	Editorial Material							CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; FACTOR RECEPTOR; CHEMOTHERAPY; DOCETAXEL; BLOCKADE; THERAPY; TRIAL		[Sculier, Jean-Paul] Univ Libre Bruxelles, Ctr Tumeurs, Inst Jules Bordet, Intens Care Serv, B-1000 Brussels, Belgium	Institut Jules Bordet; Universite Libre de Bruxelles	Sculier, JP (corresponding author), Univ Libre Bruxelles, Ctr Tumeurs, Inst Jules Bordet, Intens Care Serv, B-1000 Brussels, Belgium.	sculier@bordet.be						Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Herbst RS, 2011, LANCET, V377, P1846, DOI 10.1016/S0140-6736(11)60545-X; Naumov GN, 2009, CLIN CANCER RES, V15, P3484, DOI 10.1158/1078-0432.CCR-08-2904; Sculier JP, 2009, EUR RESPIR J, V33, P915, DOI 10.1183/09031936.00132008; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Wu WJ, 2007, MOL CANCER THER, V6, P471, DOI 10.1158/1535-7163.MCT-06-0416	7	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2011	377	9780					1810	1812		10.1016/S0140-6736(11)60740-X	http://dx.doi.org/10.1016/S0140-6736(11)60740-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774UI	21621709				2022-12-28	WOS:000291411700005
J	Knox, K; Carrigan, D; Simmons, G; Teque, F; Zhou, YC; Hackett, J; Qiu, XX; Luk, KC; Schochetman, G; Knox, A; Kogelnik, AM; Levy, JA				Knox, Konstance; Carrigan, Donald; Simmons, Graham; Teque, Fernando; Zhou, Yanchen; Hackett, John, Jr.; Qiu, Xiaoxing; Luk, Ka-Cheung; Schochetman, Gerald; Knox, Allyn; Kogelnik, Andreas M.; Levy, Jay A.			No Evidence of Murine-Like Gammaretroviruses in CFS Patients Previously Identified as XMRV-Infected	SCIENCE			English	Article							CHRONIC-FATIGUE-SYNDROME; VIRUS-RELATED VIRUS; AIDS-ASSOCIATED RETROVIRUS; VIRAL GENOME; HUMAN-SERUM; MOUSE DNA; CONTAMINATION; INACTIVATION; SEQUENCES; BLOOD	Members of the gammaretroviruses-such as murine leukemia viruses (MLVs), most notably XMRV [xenotropic murine leukemia virus (X-MLV)-related virus-have been reported to be present in the blood of patients with chronic fatigue syndrome (CFS). We evaluated blood samples from 61 patients with CFS from a single clinical practice, 43 of whom had previously been identified as XMRV-positive. Our analysis included polymerase chain reaction and reverse transcription polymerase chain reaction procedures for detection of viral nucleic acids and assays for detection of infectious virus and virus-specific antibodies. We found no evidence of XMRV or other MLVs in these blood samples. In addition, we found that these gammaretroviruses were strongly (X-MLV) or partially (XMRV) susceptible to inactivation by sera from CFS patients and healthy controls, which suggested that establishment of a successful MLV infection in humans would be unlikely. Consistent with previous reports, we detected MLV sequences in commercial laboratory reagents. Our results indicate that previous evidence linking XMRV and MLVs to CFS is likely attributable to laboratory contamination.	[Teque, Fernando; Levy, Jay A.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA; [Knox, Konstance; Carrigan, Donald; Knox, Allyn] Wisconsin Viral Res Grp, Milwaukee, WI 53226 USA; [Knox, Konstance; Carrigan, Donald; Kogelnik, Andreas M.] Open Med Inst, Mountain View, CA 94040 USA; [Simmons, Graham; Zhou, Yanchen] Blood Syst Res Inst, San Francisco, CA 94118 USA; [Simmons, Graham; Zhou, Yanchen] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Hackett, John, Jr.; Qiu, Xiaoxing; Luk, Ka-Cheung; Schochetman, Gerald] Abbott Labs, Abbott Pk, IL 60064 USA	University of California System; University of California San Francisco; Vitalant; Vitalant Research Institute; University of California System; University of California San Francisco; Abbott Laboratories	Levy, JA (corresponding author), Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA.	jay.levy@ucsf.edu	Simmons, Graham/G-3523-2012	Simmons, Graham/0000-0002-9615-7023				Baliji S, 2010, J VIROL, V84, P12841, DOI 10.1128/JVI.01863-10; BANAPOUR B, 1986, VIROLOGY, V152, P268, DOI 10.1016/0042-6822(86)90392-2; Erlwein O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008519; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Groom HCT, 2010, P NATL ACAD SCI USA, V107, P5166, DOI 10.1073/pnas.0913650107; Groom HCT, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-10; Henrich TJ, 2010, J INFECT DIS, V202, P1478, DOI 10.1086/657168; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; Hong P, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-224; Hue S, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-111; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; Levy J A, 1978, Curr Top Microbiol Immunol, V79, P111; LEVY JA, 1973, SCIENCE, V182, P1151, DOI 10.1126/science.182.4117.1151; Lo SC, 2010, P NATL ACAD SCI USA, V107, P15874, DOI 10.1073/pnas.1006901107; Lombardi VC, 2009, SCIENCE, V326, P585, DOI 10.1126/science.1179052; Oakes B, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-109; Paprotka T, 2010, J VIROL, V84, P5719, DOI 10.1128/JVI.00134-10; Qiu XX, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-68; Robinson MJ, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-108; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; Sato E, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-110; Simmons G, 2011, TRANSFUSION, V51, P643, DOI 10.1111/j.1537-2995.2011.03063.x; Switzer WM, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-57; Takefman DM, 2002, J VIROL, V76, P1999, DOI 10.1128/JVI.76.4.1999-2002.2002; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025; van Kuppeveld FJM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1018; VARNIER OE, 1984, VIROLOGY, V132, P79, DOI 10.1016/0042-6822(84)90093-X; VARNIER OE, 1983, J GEN VIROL, V64, P425, DOI 10.1099/0022-1317-64-2-425; Weiss RA, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-124	30	86	88	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 1	2011	333	6038					94	97		10.1126/science.1204963	http://dx.doi.org/10.1126/science.1204963			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	785UF	21628393				2022-12-28	WOS:000292255400057
J	Peter, IS; Davidson, EH				Peter, Isabelle S.; Davidson, Eric H.			A gene regulatory network controlling the embryonic specification of endoderm	NATURE			English	Article							SEA-URCHIN EMBRYO; NUCLEAR BETA-CATENIN; STRONGYLOCENTROTUS-PURPURATUS; CELL FATES; EXPRESSION; IDENTIFICATION; BLASTOMERES; LINEAGES; FAMILY	Specification of endoderm is the prerequisite for gut formation in the embryogenesis of bilaterian organisms. Modern lineage labelling studies(1-3) have shown that in the sea urchin embryo model system, descendants of the veg1 and veg2 cell lineages produce the endoderm, and that the veg2 lineage also gives rise to mesodermal cell types. It is known that Wnt/beta-catenin signalling is required for endoderm specification(4-6) and Delta/Notch signalling is required for mesoderm specification(7-9). Some directcis-regulatory targets of these signals have been found(10,11) and various phenomenological patterns of gene expression have been observed in the pre-gastrular endomesoderm. However, no comprehensive, causal explanation of endoderm specification has been conceived for sea urchins, nor for any other deuterostome. Here we propose a model, on the basis of the underlying genomic control system, that provides such an explanation, built at several levels of biological organization. The hardwired core of the control system consists of the cis-regulatory apparatus of endodermal regulatory genes, which determine the relationship between the inputs to which these genes are exposed and their outputs. The architecture of the network circuitry controlling the dynamic process of endoderm specification then explains, at the system level, a sequence of developmental logic operations, which generate the biological process. The control system initiates non-interacting endodermal and mesodermal gene regulatory networks in veg2-derived cells and extinguishes the endodermal gene regulatory network in mesodermal precursors. It also generates a cross-regulatory network that specifies future anterior endoderm in veg2 descendants and institutes a distinct network specifying posterior endoderm in veg1-derived cells. The network model provides an explanatory framework that relates endoderm specification to the genomic regulatory code.	[Peter, Isabelle S.; Davidson, Eric H.] CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Davidson, EH (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	ipeter@caltech.edu; davidson@caltech.edu		Peter, Isabelle/0000-0003-3685-3147	Swiss National Science Foundation; National Institutes of Health [HD37105]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD037105] Funding Source: NIH RePORTER	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We acknowledge technical assistance from J. Yun, who executed much of the perturbation analysis matrix, and from A. Puszynska and E. Erkenbrack, who contributed to whole-mount in situ hybridization results. We are grateful to E. Rothenberg for a detailed critique of the manuscript. I. S. P. was the recipient of a fellowship from the Swiss National Science Foundation in the initial stages of this work. The research was supported by National Institutes of Health grant HD37105 to E.H.D.	Byrum CA, 2009, DEV DYNAM, V238, P1649, DOI 10.1002/dvdy.21978; CAMERON RA, 1991, DEVELOPMENT, V113, P1085; Croce JC, 2010, DEVELOPMENT, V137, P83, DOI 10.1242/dev.044149; Davidson EH, 2010, NATURE, V468, P911, DOI 10.1038/nature09645; De-Leon SBT, 2010, P NATL ACAD SCI USA, V107, P10103, DOI 10.1073/pnas.1004824107; Howard-Ashby M, 2006, DEV BIOL, V300, P90, DOI 10.1016/j.ydbio.2006.08.033; Howard-Ashby M, 2006, DEV BIOL, V300, P74, DOI 10.1016/j.ydbio.2006.08.039; Livi CB, 2007, GENE EXPR PATTERNS, V7, P1, DOI 10.1016/j.modgep.2006.04.009; Logan CY, 1999, DEVELOPMENT, V126, P345; Logan CY, 1997, DEVELOPMENT, V124, P2213; Longabaugh WJR, 2009, BBA-GENE REGUL MECH, V1789, P363, DOI 10.1016/j.bbagrm.2008.07.014; Materna SC, 2006, DEV BIOL, V300, P108, DOI 10.1016/j.ydbio.2006.08.032; Materna SC, 2008, NAT PROTOC, V3, P1876, DOI 10.1038/nprot.2008.187; Minokawa T, 2005, DEV BIOL, V288, P545, DOI 10.1016/j.ydbio.2005.09.047; Oliveri P, 2008, P NATL ACAD SCI USA, V105, P5955, DOI 10.1073/pnas.0711220105; Peter IS, 2010, DEV BIOL, V340, P188, DOI 10.1016/j.ydbio.2009.10.037; Peter IS, 2009, FEBS LETT, V583, P3948, DOI 10.1016/j.febslet.2009.11.060; Ransick A, 2004, METHOD CELL BIOL, V74, P601; Ransick A, 1998, DEV BIOL, V195, P38, DOI 10.1006/dbio.1997.8814; Ransick A, 2006, DEV BIOL, V297, P587, DOI 10.1016/j.ydbio.2006.05.037; Rast JP, 2000, DEV BIOL, V228, P270, DOI 10.1006/dbio.2000.9941; Revilla-I-Domingo R, 2007, P NATL ACAD SCI USA, V104, P12383, DOI 10.1073/pnas.0705324104; Rizzo F, 2006, DEV BIOL, V300, P35, DOI 10.1016/j.ydbio.2006.08.012; Sherwood DR, 1999, DEVELOPMENT, V126, P1703; Smith J, 2008, DEV BIOL, V313, P863, DOI 10.1016/j.ydbio.2007.10.042; Smith J, 2007, SCIENCE, V318, P794, DOI 10.1126/science.1146524; Sweet HC, 2002, DEVELOPMENT, V129, P1945; Sweet HC, 1999, DEVELOPMENT, V126, P5255; Tu Q, 2006, DEV BIOL, V300, P49, DOI 10.1016/j.ydbio.2006.09.031; Wikramanayake AH, 2004, GENESIS, V39, P194, DOI 10.1002/gene.20045	30	158	160	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 30	2011	474	7353					635	U110		10.1038/nature10100	http://dx.doi.org/10.1038/nature10100			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	785CF	21623371	Green Accepted			2022-12-28	WOS:000292204300038
J	Voineagu, I; Wang, XC; Johnston, P; Lowe, JK; Tian, Y; Horvath, S; Mill, J; Cantor, RM; Blencowe, BJ; Geschwind, DH				Voineagu, Irina; Wang, Xinchen; Johnston, Patrick; Lowe, Jennifer K.; Tian, Yuan; Horvath, Steve; Mill, Jonathan; Cantor, Rita M.; Blencowe, Benjamin J.; Geschwind, Daniel H.			Transcriptomic analysis of autistic brain reveals convergent molecular pathology	NATURE			English	Article							COMMON GENETIC-VARIANTS; SPECTRUM DISORDERS; NETWORK ANALYSIS; CANDIDATE GENE; COPY NUMBER; ASSOCIATION; EXPRESSION; PATHWAYS; PACKAGE; DISEASE	Autism spectrum disorder (ASD) is a common, highly heritable neurodevelopmental condition characterized by marked genetic heterogeneity(1-3). Thus, a fundamental question is whether autism represents an aetiologically heterogeneous disorder in which the myriad genetic or environmental risk factors perturb common underlying molecular pathways in the brain(4). Here, we demonstrate consistent differences in transcriptome organization between autistic and normal brain by gene co-expression network analysis. Remarkably, regional patterns of gene expression that typically distinguish frontal and temporal cortex are significantly attenuated in the ASD brain, suggesting abnormalities in cortical patterning. We further identify discrete modules of co-expressed genes associated with autism: a neuronal module enriched for known autism susceptibility genes, including the neuronal specific splicing factor A2BP1 (also known as FOX1), and a module enriched for immune genes and glial markers. Using high-throughput RNA sequencing we demonstrate dysregulated splicing of A2BP1-dependent alternative exons in the ASD brain. Moreover, using a published autism genome-wide association study (GWAS) data set, we show that the neuronal module is enriched for genetically associated variants, providing independent support for the causal involvement of these genes in autism. In contrast, the immune-glial module showed no enrichment for autism GWAS signals, indicating a non-genetic aetiology for this process. Collectively, our results provide strong evidence for convergent molecular abnormalities in ASD, and implicate transcriptional and splicing dysregulation as underlying mechanisms of neuronal dysfunction in this disorder.	[Voineagu, Irina; Lowe, Jennifer K.; Tian, Yuan; Geschwind, Daniel H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet & Neurobehav Genet, Los Angeles, CA 90095 USA; [Voineagu, Irina; Lowe, Jennifer K.; Tian, Yuan; Geschwind, Daniel H.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst, Los Angeles, CA 90095 USA; [Wang, Xinchen; Blencowe, Benjamin J.] Univ Toronto, Donnelly Ctr, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; [Johnston, Patrick; Mill, Jonathan] Kings Coll London, Inst Psychiat, London SE5 8AF, England; [Horvath, Steve; Cantor, Rita M.; Geschwind, Daniel H.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Toronto; University of London; King's College London; University of California System; University of California Los Angeles	Geschwind, DH (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Program Neurogenet & Neurobehav Genet, Los Angeles, CA 90095 USA.	dhg@mednet.ucla.edu	Mill, Jonathan/B-5678-2014; Mill, Jonathan S/B-3276-2010	Mill, Jonathan/0000-0003-1115-3224; Mill, Jonathan S/0000-0003-1115-3224; Wang, Xinchen/0000-0002-5198-6581; Voineagu, Irina/0000-0003-4162-3872	CIHR Funding Source: Medline; NIMH NIH HHS [R37 MH060233-12, R37 MH060233, R37 MH060233-11, R01 MH081754-03, R01 MH081754, R37MH060233, R01 MH081754-04, R01 MH094714, R01 MH081754-02, 5R01MH081754-03, R01 MH081754-01, R01 MH081754-05] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH081754, R37MH060233, R01MH094714] Funding Source: NIH RePORTER; Medical Research Council [G9817803B] Funding Source: researchfish	CIHR(Canadian Institutes of Health Research (CIHR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Abrahams BS, 2008, NAT REV GENET, V9, P341, DOI 10.1038/nrg2346; Alarcon M, 2008, AM J HUM GENET, V82, P150, DOI 10.1016/j.ajhg.2007.09.005; Albright AV, 2004, J NEUROIMMUNOL, V157, P27, DOI 10.1016/j.jneuroim.2004.09.007; Amaral DG, 2008, TRENDS NEUROSCI, V31, P137, DOI 10.1016/j.tins.2007.12.005; Babatz TD, 2009, AUTISM RES, V2, P359, DOI 10.1002/aur.107; Boulanger LM, 2009, NEURON, V64, P93, DOI 10.1016/j.neuron.2009.09.001; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Castermans D, 2010, HUM MOL GENET, V19, P1368, DOI 10.1093/hmg/ddq013; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Cooper GM, 2008, BLOOD, V112, P1022, DOI 10.1182/blood-2008-01-134247; Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933; Garbett K, 2008, NEUROBIOL DIS, V30, P303, DOI 10.1016/j.nbd.2008.01.012; Geschwind DH, 2008, CELL, V135, P391, DOI 10.1016/j.cell.2008.10.016; Han JL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000074; Johnson MB, 2009, NEURON, V62, P494, DOI 10.1016/j.neuron.2009.03.027; Langfelder P, 2008, BIOINFORMATICS, V24, P719, DOI 10.1093/bioinformatics/btm563; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee JA, 2009, GENE DEV, V23, P2284, DOI 10.1101/gad.1837009; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Martin CL, 2007, AM J MED GENET B, V144B, P869, DOI 10.1002/ajmg.b.30530; Miller JA, 2010, P NATL ACAD SCI USA, V107, P12698, DOI 10.1073/pnas.0914257107; Morgan JT, 2010, BIOL PSYCHIAT, V68, P368, DOI 10.1016/j.biopsych.2010.05.024; Moy SS, 2009, BEHAV BRAIN RES, V205, P123, DOI 10.1016/j.bbr.2009.06.021; Oldham MC, 2008, NAT NEUROSCI, V11, P1271, DOI 10.1038/nn.2207; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Pinto D, 2010, NATURE, V466, P368, DOI 10.1038/nature09146; Plaisier CL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000642; Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659; Underwood JG, 2005, MOL CELL BIOL, V25, P10005, DOI 10.1128/MCB.25.22.10005-10016.2005; Wang K, 2007, AM J HUM GENET, V81, P1278, DOI 10.1086/522374; Wang K, 2009, NATURE, V459, P528, DOI 10.1038/nature07999; Wintle RF, 2011, AUTISM RES, V4, P89, DOI 10.1002/aur.173; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128; Zhang CL, 2008, GENE DEV, V22, P2550, DOI 10.1101/gad.1703108; Zhang KL, 2010, NUCLEIC ACIDS RES, V38, pW90, DOI 10.1093/nar/gkq324; Zhao XZ, 2006, BIOL PSYCHIAT, V59, P747, DOI 10.1016/j.biopsych.2005.10.023; Zikopoulos B, 2010, J NEUROSCI, V30, P14595, DOI 10.1523/JNEUROSCI.2257-10.2010	37	1181	1205	6	255	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	2011	474	7351					380	+		10.1038/nature10110	http://dx.doi.org/10.1038/nature10110			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777TD	21614001	Green Accepted, Green Submitted			2022-12-28	WOS:000291647100046
J	Csabai, I; Szathmary, E				Csabai, Istvan; Szathmary, Eors			Comment on "A Bacterium That Can Grow by Using Arsenic Instead of Phosphorus"	SCIENCE			English	Editorial Material									[Csabai, Istvan] Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; [Csabai, Istvan] Eotvos Lorand Univ, Dept Phys Complex Syst, Budapest, Hungary; [Szathmary, Eors] Eotvos Lorand Univ, Dept Plant Taxon & Ecol, Budapest, Hungary; [Szathmary, Eors] Coll Budapest, Inst Adv Study, Budapest, Hungary	Johns Hopkins University; Eotvos Lorand University; Eotvos Lorand University	Csabai, I (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA.	csabai@pha.jhu.edu	Ponce, Adrian/P-3487-2019; Szathmary, Eors/AAS-1202-2021; Csabai, Istvan/F-6045-2011	Ponce, Adrian/0000-0001-7657-1617; Szathmary, Eors/0000-0001-5227-2997; Csabai, Istvan/0000-0001-9232-9898				Ganti T., 2003, PRINCIPLES LIFE; Wolfe-Simon F, 2011, SCIENCE, V332, P1163, DOI 10.1126/science.1197258	2	2	2	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2011	332	6034								10.1126/science.1201399	http://dx.doi.org/10.1126/science.1201399			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	772BO	21622708				2022-12-28	WOS:000291205200021
J	Foster, PL				Foster, Patricia L.			Comment on "A Bacterium That Can Grow by Using Arsenic Instead of Phosphorus"	SCIENCE			English	Editorial Material									Indiana Univ, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Foster, PL (corresponding author), Indiana Univ, Bloomington, IN 47405 USA.	plfoster@indiana.edu		Foster, Patricia/0000-0002-7236-4378	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065175] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM065175-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Fagerbakke KM, 1996, AQUAT MICROB ECOL, V10, P15, DOI 10.3354/ame010015; WILLSKY GR, 1980, J BACTERIOL, V144, P366, DOI 10.1128/JB.144.1.366-374.1980; Wolfe-Simon F, 2011, SCIENCE, V332, P1163, DOI 10.1126/science.1197258	3	3	3	3	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2011	332	6034								10.1126/science.1201551	http://dx.doi.org/10.1126/science.1201551			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	772BO	21622713				2022-12-28	WOS:000291205200028
J	Ekland, EH; Akabas, MH; Fidock, DA				Ekland, Eric H.; Akabas, Myles H.; Fidock, David A.			Taking Charge: Feeding Malaria via Anion Channels	CELL			English	Editorial Material							PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; PARASITE	The human malaria parasite Plasmodium falciparum increases red blood cell membrane permeability during infection to allow for import of nutrients and other solutes. Nguitragool et al. (2011) have now identified parasite-encoded CLAG3 proteins as key components of the import channel located on the erythrocyte membrane.	[Ekland, Eric H.; Fidock, David A.] Columbia Univ Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA; [Fidock, David A.] Columbia Univ Coll Phys & Surg, Dept Med, Div Infect Dis, New York, NY 10032 USA; [Akabas, Myles H.] Yeshiva Univ, Dept Phys & Biophys, Albert Einstein Coll Med, Bronx, NY 10461 USA	Columbia University; Columbia University; Yeshiva University; Albert Einstein College of Medicine	Fidock, DA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol & Immunol, 630 W 168th St, New York, NY 10032 USA.	df2260@columbia.edu		Fidock, David/0000-0001-6753-8938; Akabas, Myles/0000-0001-8781-7846				Bouyer G, 2007, P NATL ACAD SCI USA, V104, P11044, DOI 10.1073/pnas.0704582104; Comeaux CA, 2011, MOL MICROBIOL, V80, P378, DOI 10.1111/j.1365-2958.2011.07572.x; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; GINSBURG H, 1983, MOL BIOCHEM PARASIT, V8, P177, DOI 10.1016/0166-6851(83)90008-7; Nguitragool W, 2011, CELL, V145, P665, DOI 10.1016/j.cell.2011.05.002; Planells-Cases R, 2009, BBA-MOL BASIS DIS, V1792, P173, DOI 10.1016/j.bbadis.2009.02.002; Pongs O, 2010, PHYSIOL REV, V90, P755, DOI 10.1152/physrev.00020.2009; Staines HM, 2007, INT J PARASITOL, V37, P475, DOI 10.1016/j.ijpara.2006.12.013; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; Vincensini L, 2008, MOL BIOCHEM PARASIT, V160, P81, DOI 10.1016/j.molbiopara.2008.04.002	10	6	6	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 27	2011	145	5					645	647		10.1016/j.cell.2011.05.012	http://dx.doi.org/10.1016/j.cell.2011.05.012			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	769MR	21620131	Bronze			2022-12-28	WOS:000291018600005
J	Carter, PJ; Taylor, BJ; Williams, SM; Taylor, RW				Carter, Philippa J.; Taylor, Barry J.; Williams, Sheila M.; Taylor, Rachael W.			Longitudinal analysis of sleep in relation to BMI and body fat in children: the FLAME study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MASS INDEX; RISK-FACTORS; CHILDHOOD OVERWEIGHT; CIRCADIAN-RHYTHMS; DURATION; OBESITY; ADOLESCENTS; AGE; ACCELEROMETERS; ASSOCIATION	Objectives To determine whether reduced sleep is associated with differences in body composition and the risk of becoming overweight in young children. Design Longitudinal study with repeated annual measurements. Setting Dunedin, New Zealand. Participants 244 children recruited from a birth cohort and followed from age 3 to 7. Main outcome measures Body mass index (BMI), fat mass (kg), and fat free mass (kg) measured with bioelectrical impedance; dual energy x ray absorptiometry; physical activity and sleep duration measured with accelerometry; dietary intake (fruit and vegetables, non-core foods), television viewing, and family factors (maternal BMI and education, birth weight, smoking during pregnancy) measured with questionnaire. Results After adjustment for multiple confounders, each additional hour of sleep at ages 3-5 was associated with a reduction in BMI of 0.48 (95% confidence interval 0.01 to 0.96) and a reduced risk of being overweight (BMI >= 85th centile) of 0.39 (0.24 to 0.63) at age 7. Further adjustment for BMI at age 3 strengthened these relations. These differences in BMI were explained by differences in fat mass index (-0.43, -0.82 to -0.03) more than by differences in fat free mass index (-0.21, -0.41 to -0.00). Conclusions Young children who do not get enough sleep are at increased risk of becoming overweight, even after adjustment for initial weight status and multiple confounding factors. This weight gain is a result of increased fat deposition in both sexes rather than additional accumulation of fat free mass.	[Carter, Philippa J.; Taylor, Barry J.] Univ Otago, Dept Womens & Childrens Hlth, Dunedin, New Zealand; [Williams, Sheila M.] Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; [Taylor, Rachael W.] Univ Otago, Dept Med & Surg Sci, Edgar Natl Ctr Diabet & Obes Res, Dunedin, New Zealand	University of Otago; University of Otago; University of Otago	Taylor, RW (corresponding author), Dept Human Nutr, POB 56, Dunedin 9054, New Zealand.	rachael.taylor@otago.ac.nz	Williams, Sheila/L-4028-2019; Taylor, Barry j/G-1410-2010	Taylor, Barry/0000-0002-6450-8677	University of Otago; Child Health Research Foundation; New Zealand Heart Foundation; Bequest-AAW Jones Trust	University of Otago; Child Health Research Foundation; New Zealand Heart Foundation; Bequest-AAW Jones Trust	This study was funded by the University of Otago, the Child Health Research Foundation, the New Zealand Heart Foundation, and the Dean's Bequest-AAW Jones Trust. The funders had no role in study design; or in the collection, analysis, and interpretation of data; or in the writing of the report or the decision to submit the article for publication.	Acebo C, 1999, SLEEP, V22, P95, DOI 10.1093/sleep/22.1.95; Agras WS, 2004, J PEDIATR-US, V145, P20, DOI 10.1016/j.jpeds.2004.03.023; Balding DJ, 2004, APPL LONGITUDINAL AN; Bayer O, 2009, SLEEP, V32, P1183, DOI 10.1093/sleep/32.9.1183; Cappuccio FP, 2008, SLEEP, V31, P619, DOI 10.1093/sleep/31.5.619; Chen XL, 2008, OBESITY, V16, P265, DOI 10.1038/oby.2007.63; Cliff DP, 2009, J SCI MED SPORT, V12, P557, DOI 10.1016/j.jsams.2008.10.008; Crabtree VM, 2009, CHILD ADOL PSYCH CL, V18, P799, DOI 10.1016/j.chc.2009.04.013; Dollman I, 2007, ACTA PAEDIATR, V96, P1011, DOI 10.1111/j.1651-2227.2007.00278.x; Gangwisch JE, 2009, OBES REV, V10, P37, DOI 10.1111/j.1467-789X.2009.00663.x; Guo, 2002, VITAL HLTH STAT, V11, DOI DOI 10.1016/J.BBRC.2015.06.114; Hart CN, 2008, BEHAV SLEEP MED, V6, P251, DOI 10.1080/15402000802371379; Hitze B, 2009, EUR J CLIN NUTR, V63, P739, DOI 10.1038/ejcn.2008.41; Horlick M, 2002, AM J CLIN NUTR, V76, P991, DOI 10.1093/ajcn/76.5.991; Iglowstein I, 2003, PEDIATRICS, V111, P302, DOI 10.1542/peds.111.2.302; Keith SW, 2006, INT J OBESITY, V30, P1585, DOI 10.1038/sj.ijo.0803326; Landhuis CE, 2008, PEDIATRICS, V122, P955, DOI 10.1542/peds.2007-3521; Littner M, 2003, SLEEP, V26, P337, DOI 10.1093/sleep/26.3.337; Lumeng JC, 2007, PEDIATRICS, V120, P1020, DOI 10.1542/peds.2006-3295; Marshall NS, 2008, SLEEP MED REV, V12, P289, DOI 10.1016/j.smrv.2008.03.001; Ministry of Health, 2008, PORTR HLTH KEY RES 2; Must A, 2009, INT J OBESITY, V33, pS82, DOI 10.1038/ijo.2009.23; Nixon GM, 2008, SLEEP, V31, P71, DOI 10.1093/sleep/31.1.71; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; Padez C, 2009, AM J HUM BIOL, V21, P371, DOI 10.1002/ajhb.20884; Patel SR, 2009, OBES REV, V10, P61, DOI 10.1111/j.1467-789X.2009.00664.x; Patel SR, 2008, OBESITY, V16, P643, DOI 10.1038/oby.2007.118; Pfeiffer KA, 2006, MED SCI SPORT EXER, V38, P152, DOI 10.1249/01.mss.0000183219.44127.e7; Puyau MR, 2004, MED SCI SPORT EXER, V36, P1625, DOI 10.1249/01.MSS.0000139898.30804.60; Reilly JJ, 2005, BMJ-BRIT MED J, V330, P1357, DOI 10.1136/bmj.38470.670903.E0; Roche A., 1996, HUMAN BODY COMPOSITI, P167; Rose G., 1992, STRATEGY PREVENTIVE; Sadeh A, 2002, SLEEP MED REV, V6, P113, DOI 10.1053/smrv.2001.0182; Sadeh A, 2008, J PEDIATR PSYCHOL, V33, P406, DOI 10.1093/jpepsy/jsn018; Sadeh A, 2009, SLEEP, V32, P1602, DOI 10.1093/sleep/32.12.1602; Sazonov E, 2004, PHYSIOL MEAS, V25, P1291, DOI 10.1088/0967-3334/25/5/018; Snell EK, 2007, CHILD DEV, V78, P309, DOI 10.1111/j.1467-8624.2007.00999.x; Sugimori H, 2004, PEDIATR INT, V46, P302, DOI 10.1111/j.1442-200x.2004.01895.x; Sundblom E, 2008, INT J OBESITY, V32, P1525, DOI 10.1038/ijo.2008.104; Swartz AM, 2000, MED SCI SPORT EXER, V32, pS450, DOI 10.1097/00005768-200009001-00003; Taveras EM, 2008, ARCH PEDIAT ADOL MED, V162, P305, DOI 10.1001/archpedi.162.4.305; Taylor RW, 2007, AM J CLIN NUTR, V86, P735, DOI 10.1093/ajcn/86.3.735; Taylor RW, 2009, MED SCI SPORT EXER, V41, P96, DOI 10.1249/MSS.0b013e3181849d81; Taylor RW, 2002, AM J CLIN NUTR, V76, P1416, DOI 10.1093/ajcn/76.6.1416; Touchette E, 2008, SLEEP, V31, P1507, DOI 10.1093/sleep/31.11.1507; von Kries R, 2002, INT J OBESITY, V26, P710, DOI 10.1038/sj.ijo.0801980; Wells JCK, 1999, AM J CLIN NUTR, V69, P904; Yu YX, 2007, SLEEP, V30, P1688, DOI 10.1093/sleep/30.12.1688	48	124	131	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 26	2011	342								d2712	10.1136/bmj.d2712	http://dx.doi.org/10.1136/bmj.d2712			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771KG	21622518	hybrid, Green Published			2022-12-28	WOS:000291155000002
J	Van Roy, P; Briggs, DEG				Van Roy, Peter; Briggs, Derek E. G.			A giant Ordovician anomalocaridid	NATURE			English	Article							GREAT-APPENDAGE ARTHROPOD; BURGESS SHALE; DINOCARIDA; GREENLAND; EVOLUTION; OPABINIA	Anomalocaridids, giant lightly sclerotized invertebrate predators, occur in a number of exceptionally preserved early and middle Cambrian (542-501 million years ago) biotas and have come to symbolize the unfamiliar morphologies displayed by stem organisms in faunas of the Burgess Shale type. They are characterized by a pair of anterior, segmented appendages, a circlet of plates around the mouth, and an elongate segmented trunk lacking true tergites with a pair of flexible lateral lobes per segment(1,2). Disarticulated body parts, such as the anterior appendages and oral circlet, had been assigned to a range of taxonomic groups-but the discovery of complete specimens from the middle Cambrian Burgess Shale showed that these disparate elements all belong to a single kind of animal(3). Phylogenetic analyses support a position of anomalocaridids in the arthropod stem, as a sister group to the euarthropods(4-6). The anomalocaridids were the largest animals in Cambrian communities. The youngest unequivocal examples occur in the middle Cambrian Marjum Formation of Utah(7) but an arthropod retaining some anomalocaridid characteristics is present in the Devonian of Germany(5). Here we report the post-Cambrian occurrence of anomalocaridids, from the Early Ordovician (488-472 million years ago) Fezouata Biota(8) in southeastern Morocco, including specimens larger than any in Cambrian biotas. These giant animals were an important element of some marine communities for about 30 million years longer than previously realized. The Moroccan specimens confirm the presence of a dorsal array of flexible blades attached to a transverse rachis on the trunk segments; these blades probably functioned as gills.	[Van Roy, Peter; Briggs, Derek E. G.] Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; [Van Roy, Peter] Univ Ghent, Dept Geol & Soil Sci, Res Unit Palaeontol, B-9000 Ghent, Belgium; [Briggs, Derek E. G.] Yale Univ, Yale Peabody Museum Nat Hist, New Haven, CT 06520 USA	Yale University; Ghent University; Yale University	Briggs, DEG (corresponding author), Yale Univ, Dept Geol & Geophys, POB 208109, New Haven, CT 06520 USA.	derek.briggs@yale.edu		Van Roy, Peter/0000-0001-5330-8402	National Geographic Society; Yale University	National Geographic Society(National Geographic Society); Yale University	S. Butts (Yale Peabody Museum of Natural History) provided access to specimens. M. Ben Said Ben Moula originally discovered the specimens and made them available for study; he, together with J. P. Botting-Muir and L. A. Botting-Muir, P. J. Orr, C. Upton and J. Vinther also assisted with fieldwork, and B. Tahiri arranged logistical support. J. W. Hagadorn shared information on anomalocaridid size and R. R. Gaines discussed aspects of the taphonomy. E. Champion helped with the preparation of figures. This research was supported by a National Geographic Society Research and Exploration grant and by Yale University.	BERGSTROM J, 1987, LETHAIA, V20, P187, DOI 10.1111/j.1502-3931.1987.tb00777.x; BERGSTROM J, 1986, LETHAIA, V19, P241, DOI 10.1111/j.1502-3931.1986.tb00738.x; Braddy SJ, 2008, BIOL LETTERS, V4, P106, DOI 10.1098/rsbl.2007.0491; BRIGGS DEG, 1984, U KANSAS PALEONTOLOG, V111, P1; BUDD G, 1993, NATURE, V364, P709, DOI 10.1038/364709a0; Budd G. E., LETHAIA IN PRESS; CHEN JY, 1994, SCIENCE, V264, P1304, DOI 10.1126/science.264.5163.1304; Chen JY, 2004, LETHAIA, V37, P3, DOI 10.1080/00241160410004764; Collins D, 1996, J PALEONTOL, V70, P280, DOI 10.1017/S0022336000023362; Daley AC, 2010, PALAEONTOLOGY, V53, P721, DOI 10.1111/j.1475-4983.2010.00955.x; Daley AC, 2010, J PALEONTOL, V84, P352, DOI 10.1666/09-136R1.1; Daley AC, 2009, SCIENCE, V323, P1597, DOI 10.1126/science.1169514; DZIK J, 1988, LETHAIA, V21, P29, DOI 10.1111/j.1502-3931.1988.tb01749.x; Fortey RA, 2009, MEM ASSOC AUSTRALAS, V37, P9; Hahn G., 1986, Geologica et Palaeontologica, V20, P125; HOU XG, 1995, GFF, V117, P163, DOI 10.1080/11035899509546213; Hou XG, 2006, GEOL J, V41, P259, DOI 10.1002/gj.1050; Kuhl G, 2009, SCIENCE, V323, P771, DOI 10.1126/science.1166586; Masiak Monika, 1994, Acta Palaeontologica Polonica, V39, P329; Ponomarenko AG, 2010, PALEONTOL J+, V44, P503, DOI 10.1134/S0031030110050047; ROLFE W. D. IAN, 1962, BREVIORA MUS COMP ZOOL [HARVARD], V160, P1; Servais T, 2010, PALAEOGEOGR PALAEOCL, V294, P99, DOI 10.1016/j.palaeo.2010.05.031; Van Roy P, 2006, ACTA PALAEONTOL POL, V51, P239; Van Roy P, 2010, NATURE, V465, P215, DOI 10.1038/nature09038; Vinther J, 2008, NATURE, V451, P185, DOI 10.1038/nature06474; Walcott Charles D., 1912, Smithsonian Institution Miscellaneous Collection, V57; Walcott Charles D., 1911, Smithsonian Institution Miscellaneous Collection, V57; Walcott Charles Doolittle, 1911, Smithsonian Institution Miscellaneous Collection, V57; Whiteaves J. F., 1892, CANADIAN RECORD SCI, V5, P205; WHITTINGTON HB, 1985, PHILOS T R SOC B, V309, P569, DOI 10.1098/rstb.1985.0096	30	65	66	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	2011	473	7348					510	513		10.1038/nature09920	http://dx.doi.org/10.1038/nature09920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	768QM	21614078				2022-12-28	WOS:000290951300040
J	Libby, P; Ridker, PM; Hansson, GK				Libby, Peter; Ridker, Paul M.; Hansson, Goran K.			Progress and challenges in translating the biology of atherosclerosis	NATURE			English	Review							LOW-DENSITY-LIPOPROTEIN; ACUTE CORONARY SYNDROME; ESTER TRANSFER PROTEIN; T-CELLS; CARDIOVASCULAR EVENTS; STATIN THERAPY; NICOTINIC-ACID; RISK-FACTORS; HEART; CHOLESTEROL	Atherosclerosis is a chronic disease of the arterial wall, and a leading cause of death and loss of productive life years worldwide. Research into the disease has led to many compelling hypotheses about the pathophysiology of atherosclerotic lesion formation and of complications such as myocardial infarction and stroke. Yet, despite these advances, we still lack definitive evidence to show that processes such as lipoprotein oxidation, inflammation and immunity have a crucial involvement in human atherosclerosis. Experimental atherosclerosis in animals furnishes an important research tool, but extrapolation to humans requires care. Understanding how to combine experimental and clinical science will provide further insight into atherosclerosis and could lead to new clinical applications.	[Libby, Peter; Ridker, Paul M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc,Dept Med, Boston, MA 02115 USA; [Ridker, Paul M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med,Div Prevent Med,Dept Med, Boston, MA 02115 USA; [Hansson, Goran K.] Karolinska Univ Hosp, Karolinska Inst, Dept Med, SE-17176 Stockholm, Sweden; [Hansson, Goran K.] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, SE-17176 Stockholm, Sweden	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Libby, P (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc,Dept Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	plibby@rics.bwh.harvard.edu	Hansson, Goran K/B-7423-2012; Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X; Hansson, Goran/0000-0003-4148-5190; Venkatasubramanian, Siddharth/0000-0002-5860-0768				Ait-Oufella H, 2006, NAT MED, V12, P178, DOI 10.1038/nm1343; Ait-Oufella H, 2010, J EXP MED, V207, P1579, DOI 10.1084/jem.20100155; Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Andersson J, 2010, CLIN IMMUNOL, V134, P33, DOI 10.1016/j.clim.2009.07.002; Asztalos BF, 2005, J LIPID RES, V46, P2246, DOI 10.1194/jlr.M500187-JLR200; Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; Barter PJ, 2006, J AM COLL CARDIOL, V47, P492, DOI 10.1016/j.jacc.2005.09.042; Bentzon JF, 2010, CURR OPIN LIPIDOL, V21, P434, DOI 10.1097/MOL.0b013e32833ded6a; Berliner JA, 2005, NEW ENGL J MED, V353, P9, DOI 10.1056/NEJMp058118; Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010; Brewer HB, 2004, ARTERIOSCL THROM VAS, V24, P387, DOI 10.1161/01.ATV.0000121505.88326.d2; Brown BG, 2008, AM J CARDIOL, V101, p58B, DOI 10.1016/j.amjcard.2008.02.039; Brown MS, 2006, SCIENCE, V311, P1721, DOI 10.1126/science.1125884; Brown MS, 1996, SCIENCE, V272, P629, DOI 10.1126/science.272.5262.629; Caligiuri G, 2002, J CLIN INVEST, V109, P745, DOI 10.1172/JCI200207272; Cannon CP, 2010, NEW ENGL J MED, V363, P2406, DOI 10.1056/NEJMoa1009744; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Chapman MJ, 2010, EUR HEART J, V31, P149, DOI 10.1093/eurheartj/ehp399; Cheng XA, 2011, ATHEROSCLEROSIS, V215, P471, DOI 10.1016/j.atherosclerosis.2010.12.034; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Duffy D, 2009, NAT REV CARDIOL, V6, P455, DOI 10.1038/nrcardio.2009.94; Eriksson P, 1998, ARTERIOSCL THROM VAS, V18, P20, DOI 10.1161/01.ATV.18.1.20; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Hansson GK, 2009, SEMIN IMMUNOPATHOL, V31, P95, DOI 10.1007/s00281-009-0151-x; Harismendy O, 2011, NATURE, V470, P264, DOI 10.1038/nature09753; Hartvigsen K, 2009, J LIPID RES, V50, pS388, DOI 10.1194/jlr.R800100-JLR200; Hermansson A, 2010, J EXP MED, V207, P1081, DOI 10.1084/jem.20092243; Jahangiri A, 2009, ARTERIOSCL THROM VAS, V29, P261, DOI 10.1161/ATVBAHA.108.178681; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Jones PH, 2005, AM J CARDIOL, V95, P120, DOI 10.1016/j.amjcard.2004.08.076; Jun M, 2010, LANCET, V375, P1875, DOI 10.1016/S0140-6736(10)60656-3; Kathiresan S, 2008, NAT GENET, V40, P189, DOI 10.1038/ng.75; Kawakami A, 2008, CIRC RES, V103, P1402, DOI 10.1161/CIRCRESAHA.108.178426; Keech A, 2005, LANCET, V366, P1849, DOI 10.1016/S0140-6736(05)67667-2; Libby P, 2005, J AM COLL CARDIOL, V46, P1225, DOI 10.1016/j.jacc.2005.07.006; Libby P, 2010, J NUCL MED, V51, p33S, DOI 10.2967/jnumed.109.069633; Libby P, 2009, J LIPID RES, V50, pS352, DOI 10.1194/jlr.R800099-JLR200; Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900; Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Madhur M. S., 2011, ARTERIOSCLER TH 0407, P7, DOI [10.1161/ATVBAHA.111.227629, DOI 10.1161/ATVBAHA.111.2276292011]; Majesky MW, 2007, ARTERIOSCL THROM VAS, V27, P1248, DOI 10.1161/ATVBAHA.107.141069; Maron R, 2002, CIRCULATION, V106, P1708, DOI 10.1161/01.CIR.0000029750.99462.30; Morgan TM, 2007, JAMA-J AM MED ASSOC, V297, P1551, DOI 10.1001/jama.297.14.1551; Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482; Navab Mohamad, 2003, Curr Opin Investig Drugs, V4, P1100; Nissen SE, 2006, JAMA-J AM MED ASSOC, V295, P1556, DOI 10.1001/jama.295.13.jpc60002; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Nussenblatt RB, 2010, ANN NY ACAD SCI, V1200, pE1, DOI 10.1111/j.1749-6632.2010.05682.x; PALINSKI W, 1995, P NATL ACAD SCI USA, V92, P821, DOI 10.1073/pnas.92.3.821; Parmar KM, 2006, J CLIN INVEST, V116, P49, DOI 10.1172/JCI24787; Paynter NP, 2010, JAMA-J AM MED ASSOC, V303, P631, DOI 10.1001/jama.2010.119; Raes G, 2005, J IMMUNOL, V174, P6561, DOI 10.4049/jimmunol.174.11.6561; Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2009, J THROMB HAEMOST, V7, P332, DOI 10.1111/j.1538-7836.2009.03404.x; Ridker PM, 2009, LANCET, V373, P1175, DOI 10.1016/S0140-6736(09)60447-5; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Robertson AKL, 2003, J CLIN INVEST, V112, P1342, DOI 10.1172/JCI200318607; Robins SJ, 2001, JAMA-J AM MED ASSOC, V285, P1585, DOI 10.1001/jama.285.12.1585; Rye KA, 2009, J LIPID RES, V50, pS195, DOI 10.1194/jlr.R800034-JLR200; Sarwar N, 2007, CIRCULATION, V115, P450, DOI 10.1161/CIRCULATIONAHA.106.637793; Schunkert H, 2008, CIRCULATION, V117, P1675, DOI 10.1161/CIRCULATIONAHA.107.730614; Serruys PW, 2008, CIRCULATION, V118, P1172, DOI 10.1161/CIRCULATIONAHA.108.771899; Siscovick DS, 2003, CIRCULATION, V107, P2632, DOI 10.1161/01.CIR.0000074779.11379.62; Staels B, 2010, LANCET, V375, P1847, DOI 10.1016/S0140-6736(10)60758-1; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; Steinberg D, 2010, ARTERIOSCL THROM VAS, V30, P2311, DOI 10.1161/ATVBAHA.108.179697; Steinberg D, 2009, J LIPID RES, V50, pS376, DOI 10.1194/jlr.R800087-JLR200; Steinberg Daniel, 2007, CHOLESTEROL WARS SKE; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890; Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Taggart AKP, 2005, J BIOL CHEM, V280, P26649, DOI 10.1074/jbc.C500213200; Taleb S, 2010, CURR OPIN LIPIDOL, V21, P404, DOI 10.1097/MOL.0b013e32833dc7f9; Taleb S, 2009, J EXP MED, V206, P2067, DOI 10.1084/jem.20090545; Tall AR, 2008, CELL METAB, V7, P365, DOI 10.1016/j.cmet.2008.03.001; Tardif JC, 2008, LANCET, V371, P1761, DOI 10.1016/S0140-6736(08)60763-1; Tardif JC, 2007, JAMA-J AM MED ASSOC, V297, P1675, DOI 10.1001/jama.297.15.jpc70004; Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656; Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206; van Es T, 2009, BIOCHEM BIOPH RES CO, V388, P261, DOI 10.1016/j.bbrc.2009.07.152; Wang CY, 2008, TRENDS MOL MED, V14, P37, DOI 10.1016/j.molmed.2007.11.004; [No title captured]; [No title captured]	96	2505	2630	21	763	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 19	2011	473	7347					317	325		10.1038/nature10146	http://dx.doi.org/10.1038/nature10146			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765QA	21593864				2022-12-28	WOS:000290722400038
J	McCartney, M				McCartney, Margaret			MEDICINE AND THE MEDIA What GPs know about asthma	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358					0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 18	2011	342								d2972	10.1136/bmj.d2972	http://dx.doi.org/10.1136/bmj.d2972			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QQ	21593089				2022-12-28	WOS:000290951900005
J	Blankenship, RE; Tiede, DM; Barber, J; Brudvig, GW; Fleming, G; Ghirardi, M; Gunner, MR; Junge, W; Kramer, DM; Melis, A; Moore, TA; Moser, CC; Nocera, DG; Nozik, AJ; Ort, DR; Parson, WW; Prince, RC; Sayre, RT				Blankenship, Robert E.; Tiede, David M.; Barber, James; Brudvig, Gary W.; Fleming, Graham; Ghirardi, Maria; Gunner, M. R.; Junge, Wolfgang; Kramer, David M.; Melis, Anastasios; Moore, Thomas A.; Moser, Christopher C.; Nocera, Daniel G.; Nozik, Arthur J.; Ort, Donald R.; Parson, William W.; Prince, Roger C.; Sayre, Richard T.			Comparing Photosynthetic and Photovoltaic Efficiencies and Recognizing the Potential for Improvement	SCIENCE			English	Review							CO2 CONCENTRATING MECHANISMS; SOLAR-ENERGY; QUANTUM YIELD; CARBON; CONVERSION; CYCLE; HYDROGENASES; MICROALGAE; RUBISCO; PLANTS	Comparing photosynthetic and photovoltaic efficiencies is not a simple issue. Although both processes harvest the energy in sunlight, they operate in distinctly different ways and produce different types of products: biomass or chemical fuels in the case of natural photosynthesis and nonstored electrical current in the case of photovoltaics. In order to find common ground for evaluating energy-conversion efficiency, we compare natural photosynthesis with present technologies for photovoltaic-driven electrolysis of water to produce hydrogen. Photovoltaic-driven electrolysis is the more efficient process when measured on an annual basis, yet short-term yields for photosynthetic conversion under optimal conditions come within a factor of 2 or 3 of the photovoltaic benchmark. We consider opportunities in which the frontiers of synthetic biology might be used to enhance natural photosynthesis for improved solar energy conversion efficiency.	[Blankenship, Robert E.] Washington Univ, Dept Biol, St Louis, MO 63130 USA; [Blankenship, Robert E.] Washington Univ, Dept Chem, St Louis, MO 63130 USA; [Tiede, David M.] Argonne Natl Lab, Chem Sci & Engn Div, Argonne, IL 60439 USA; [Barber, James] Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England; [Barber, James] Politecn Torino, Dept Mat Sci & Engn, I-10129 Turin, Italy; [Brudvig, Gary W.] Yale Univ, Dept Chem, New Haven, CT 06520 USA; [Fleming, Graham] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Fleming, Graham] Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA; [Ghirardi, Maria] Natl Renewable Energy Lab, Biosci Ctr, Golden, CO 80401 USA; [Gunner, M. R.] CUNY, Dept Phys, New York, NY 10031 USA; [Junge, Wolfgang] Univ Osnabruck, Div Biophys, D-49069 Osnabruck, Germany; [Kramer, David M.] Michigan State Univ, Biochem & Mol Biol & DOE Plant Res Lab, E Lansing, MI 48824 USA; [Melis, Anastasios] Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; [Moore, Thomas A.] Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; [Moser, Christopher C.] Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; [Nocera, Daniel G.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Nozik, Arthur J.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Ort, Donald R.] Univ Illinois, USDA, ARS, Photosynth Res Unit, Urbana, IL 61801 USA; [Parson, William W.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA; [Prince, Roger C.] ExxonMobil Biomed Sci, Annandale, NJ 08801 USA; [Sayre, Richard T.] Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Washington University (WUSTL); Washington University (WUSTL); United States Department of Energy (DOE); Argonne National Laboratory; Imperial College London; Polytechnic University of Turin; Yale University; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); National Renewable Energy Laboratory - USA; City University of New York (CUNY) System; University Osnabruck; Michigan State University; United States Department of Energy (DOE); University of California System; University of California Berkeley; Arizona State University; Arizona State University-Tempe; University of Pennsylvania; Massachusetts Institute of Technology (MIT); University of Colorado System; University of Colorado Boulder; United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign; University of Washington; University of Washington Seattle; Exxon Mobil Corporation; Donald Danforth Plant Science Center	Blankenship, RE (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.	blankenship@wustl.edu; tiede@anl.gov	Tiede, David M/AFT-6713-2022; Nozik, Arthur J./P-2641-2016; Nozik, Arthur J/A-1481-2012; Moser, Christopher C/O-6559-2014; Junge, Wolfgang/F-6289-2012; Kramer, David/B-9588-2016	Nozik, Arthur J./0000-0001-7176-7645; Moser, Christopher C/0000-0003-4814-8568; Sayre, Richard/0000-0002-3153-7084; Kramer, David/0000-0003-2181-6888	Council on Chemical and Biochemical Sciences of the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences	Council on Chemical and Biochemical Sciences of the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE))	This article evolved from presentations and discussions at the workshop "What is the Efficiency of Photosynthesis?" held in May 2009 in Albuquerque, New Mexico, sponsored by the Council on Chemical and Biochemical Sciences of the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences. The authors thank the members of the Council for their encouragement and assistance in developing this workshop. In addition, the authors are indebted to the agencies responsible for funding their individual research efforts, without which this work would not have been possible.	*A S T M, 2008, G17303 ASTM; [Anonymous], 2002, PHOTOSYNTHETICA; Anten NPR, 2005, ANN BOT-LONDON, V95, P495, DOI 10.1093/aob/mci048; Badger MR, 2003, J EXP BOT, V54, P609, DOI 10.1093/jxb/erg076; Baker NR, 2008, ANNU REV PLANT BIOL, V59, P89, DOI 10.1146/annurev.arplant.59.032607.092759; Bar-Even A, 2010, P NATL ACAD SCI USA, V107, P8889, DOI 10.1073/pnas.0907176107; Barber J, 2009, CHEM SOC REV, V38, P185, DOI 10.1039/b802262n; BLANKENSHIP RE, 1995, ANOXYGENIC PHOTOSYNT; BOLTON JR, 1979, ANNU REV ENERGY, V4, P353, DOI 10.1146/annurev.eg.04.110179.002033; Buchmann N, 1998, AGR FOREST METEOROL, V89, P45, DOI 10.1016/S0168-1923(97)00059-2; CHEN M, TRENDS PLANT SCI; Chen M, 2010, SCIENCE, V329, P1318, DOI 10.1126/science.1191127; *COMM AM FUT, 2009, AM EN FUT TECHN TRAN; Davis SC, 2009, TRENDS PLANT SCI, V14, P140, DOI 10.1016/j.tplants.2008.12.006; Dempsey JL, 2009, ACCOUNTS CHEM RES, V42, P1995, DOI 10.1021/ar900253e; DUYSENS L. N. M., 1958, BROOKHAVEN SYMPOSIA IN BIOL, V11, P10; EMERSON R, 1958, ANNU REV PLANT PHYS, V9, P1, DOI 10.1146/annurev.pp.09.060158.000245; Engel GS, 2007, NATURE, V446, P782, DOI 10.1038/nature05678; Foyer CH, 2009, ANNU REV PLANT BIOL, V60, P455, DOI 10.1146/annurev.arplant.043008.091948; Genovese J, 2009, CURRENT 2009 STATE O; Ghirardi ML, 2007, ANNU REV PLANT BIOL, V58, P71, DOI 10.1146/annurev.arplant.58.032806.103848; Giordano M, 2005, ANNU REV PLANT BIOL, V56, P99, DOI 10.1146/annurev.arplant.56.032604.144052; Green B. R, 2003, LIGH HARVESTING ANTE; Green M. A., 2003, 3 GENERATION PHOTOVO; Green MA, 2010, PROG PHOTOVOLTAICS, V18, P144, DOI 10.1002/pip.974; Gust D, 2008, MRS BULL, V33, P383, DOI 10.1557/mrs2008.78; Hanna MC, 2006, J APPL PHYS, V100, DOI 10.1063/1.2356795; Hibberd JM, 2010, ANNU REV PLANT BIOL, V61, P181, DOI 10.1146/annurev-arplant-042809-112238; Hoffert MI, 2002, SCIENCE, V298, P981, DOI 10.1126/science.1072357; Ihara M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1677, DOI 10.1562/2006-05-07-RA-893; Janssen M, 2003, BIOTECHNOL BIOENG, V81, P193, DOI 10.1002/bit.10468; JELLISON GE, 1982, J APPL PHYS, V53, P3745, DOI 10.1063/1.331113; Kan JJ, 2011, ENVIRON SCI TECHNOL, V45, P1139, DOI 10.1021/es102645v; Kebeish R, 2007, NAT BIOTECHNOL, V25, P593, DOI 10.1038/nbt1299; Knox RS, 2007, BBA-BIOENERGETICS, V1767, P1189, DOI 10.1016/j.bbabio.2007.07.004; Kung H., 2005, BASIC RES NEEDS SOLA; Lewis NS, 2006, P NATL ACAD SCI USA, V103, P15729, DOI 10.1073/pnas.0603395103; Long SP, 2006, PLANT CELL ENVIRON, V29, P315, DOI 10.1111/j.1365-3040.2005.01493.x; Melis A, 2009, PLANT SCI, V177, P272, DOI 10.1016/j.plantsci.2009.06.005; Mitra M, 2008, OPT EXPRESS, V16, P21807, DOI 10.1364/OE.16.021807; Miyashita H, 1996, NATURE, V383, P402, DOI 10.1038/383402a0; Mussgnug JH, 2007, PLANT BIOTECHNOL J, V5, P802, DOI 10.1111/j.1467-7652.2007.00285.x; Nevin KP, 2010, MBIO, V1, DOI 10.1128/mBio.00103-10; Ort DR, 2011, PLANT PHYSIOL, V155, P79, DOI 10.1104/pp.110.165886; Raines CA, 2003, PHOTOSYNTH RES, V75, P1, DOI 10.1023/A:1022421515027; Reda T, 2008, P NATL ACAD SCI USA, V105, P10654, DOI 10.1073/pnas.0801290105; Sakamoto W, 2006, ANNU REV PLANT BIOL, V57, P599, DOI 10.1146/annurev.arplant.57.032905.105401; Savage DF, 2008, ACS CHEM BIOL, V3, P13, DOI 10.1021/cb700259j; Sayre R, 2010, BIOSCIENCE, V60, P722, DOI 10.1525/bio.2010.60.9.9; Sherwani AF, 2010, RENEW SUST ENERG REV, V14, P540, DOI 10.1016/j.rser.2009.08.003; SHOCKLEY W, 1961, J APPL PHYS, V32, P510, DOI 10.1063/1.1736034; Skillman JB, 2008, J EXP BOT, V59, P1647, DOI 10.1093/jxb/ern029; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Thauer RK, 2007, SCIENCE, V318, P1732, DOI 10.1126/science.1152209; TOPIC M, 2006, 2006 IEEE 4 WORLD C, V2, P2141; TOPIC M, 2006, 2006 IEEE 4 WORLD C, V1, P2141; Utschig LM, 2011, J PHYS CHEM LETT, V2, P236, DOI 10.1021/jz101728v; Vignais PM, 2007, CHEM REV, V107, P4206, DOI 10.1021/cr050196r; Walker DA, 2009, J APPL PHYCOL, V21, P509, DOI 10.1007/s10811-009-9446-5; Wijffels RH, 2010, SCIENCE, V329, P796, DOI 10.1126/science.1189003; WRAIGHT CA, 1974, BIOCHIM BIOPHYS ACTA, V333, P246, DOI 10.1016/0005-2728(74)90009-7; Zarzycki J, 2009, P NATL ACAD SCI USA, V106, P21317, DOI 10.1073/pnas.0908356106; Zhu XG, 2004, PLANT CELL ENVIRON, V27, P155, DOI 10.1046/j.1365-3040.2004.01142.x; Zhu XG, 2010, ANNU REV PLANT BIOL, V61, P235, DOI 10.1146/annurev-arplant-042809-112206	64	1080	1107	43	1257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2011	332	6031					805	809		10.1126/science.1200165	http://dx.doi.org/10.1126/science.1200165			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566184	Green Published			2022-12-28	WOS:000290529900037
J	Der, BS; Kuhlman, B				Der, Bryan S.; Kuhlman, Brian			From Computational Design to a Protein That Binds	SCIENCE			English	Editorial Material							RECOGNITION; DISPLAY; PAIR		[Der, Bryan S.; Kuhlman, Brian] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Der, BS (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	bder@email.unc.edu; bkuhlman@email.unc.edu						Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Fleishman SJ, 2011, SCIENCE, V332, P816, DOI 10.1126/science.1202617; Gai SA, 2007, CURR OPIN STRUC BIOL, V17, P467, DOI 10.1016/j.sbi.2007.08.012; Huang PS, 2007, PROTEIN SCI, V16, P2770, DOI 10.1110/ps.073125207; Jha RK, 2010, J MOL BIOL, V400, P257, DOI 10.1016/j.jmb.2010.05.006; Karanicolas J, 2011, MOL CELL, V42, P250, DOI 10.1016/j.molcel.2011.03.010; Karanicolas J, 2009, CURR OPIN STRUC BIOL, V19, P458, DOI 10.1016/j.sbi.2009.07.005; Leaver-Fay A, 2011, METHOD ENZYMOL, P545, DOI [10.1016/S0076-6879(11)87019-9, 10.1016/B978-0-12-381270-4.00019-6]; Mandell DJ, 2009, NAT CHEM BIOL, V5, P797, DOI 10.1038/nchembio.251; Liu S, 2007, P NATL ACAD SCI USA, V104, P5330, DOI 10.1073/pnas.0606198104; Sidhu SS, 2007, CURR OPIN STRUC BIOL, V17, P481, DOI 10.1016/j.sbi.2007.08.007; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513	13	9	9	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	2011	332	6031					801	802		10.1126/science.1207082	http://dx.doi.org/10.1126/science.1207082			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	763CD	21566181				2022-12-28	WOS:000290529900034
J	Goodman, WK				Goodman, Wayne K.			Electroconvulsive Therapy in the Spotlight	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Goodman, Wayne K.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Goodman, Wayne K.] Mt Sinai Sch Med, Friedman Brain Inst, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Goodman, WK (corresponding author), Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.							Committee on Electroconvulsive Therapy, 2001, PRACT EL THER REC TR; Food and Drug Administration, 2011, M DISC CLASS EL THER; Fraser LM, 2008, J ECT, V24, P10, DOI 10.1097/YCT.0b013e3181616c26; Piolino P, 2009, NEUROPSYCHOLOGIA, V47, P2314, DOI 10.1016/j.neuropsychologia.2009.01.020; Weiner RD, 2000, ARCH GEN PSYCHIAT, V57, P591, DOI 10.1001/archpsyc.57.6.591	5	19	19	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					1785	1787		10.1056/NEJMp1101096	http://dx.doi.org/10.1056/NEJMp1101096			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561344				2022-12-28	WOS:000290483000002
